data_2lmn_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lmn _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.0 t . . . . . 0 N--CA 1.465 0.283 0 CA-C-O 121.426 0.632 . . . . 0.0 111.591 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -106.5 -172.35 2.07 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.96 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 48.5 p-80 -146.8 170.92 16.02 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -147.69 178.75 8.22 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.603 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -138.7 129.45 26.36 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.801 0.334 . . . . 0.0 110.467 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.4 mt -112.48 114.61 27.39 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . 0.438 ' O ' ' CG2' ' A' ' 18' ' ' VAL . 6.2 m -127.55 121.16 56.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.119 0 CA-C-O 121.345 0.593 . . . . 0.0 111.433 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -116.88 107.9 15.17 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 177.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.4 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.8 p90 -126.68 126.81 44.15 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.94 125.62 53.84 Favored 'General case' 0 C--O 1.24 0.577 0 CA-C-O 121.275 0.56 . . . . 0.0 111.624 -178.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -155.47 82.0 1.04 Allowed 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.162 -2.162 . . . . 0.0 105.162 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -34.84 120.64 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 114.922 -1.035 . . . . 0.0 113.612 -176.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 26' ' ' SER . 60.7 t -100.94 125.13 54.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 177.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -31.71 83.27 0.0 OUTLIER Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.324 0.39 . . . . 0.0 113.033 -177.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.599 ' N ' ' O ' ' A' ' 24' ' ' VAL . 69.5 m -87.02 -179.23 6.45 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 28' ' ' LYS . 11.8 m120 -75.71 178.53 6.03 Favored 'General case' 0 C--N 1.314 -0.966 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.094 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.519 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 99.1 mttt -45.34 -110.77 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.879 0.847 . . . . 0.0 112.066 178.689 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.32 93.71 1.65 Allowed Glycine 0 N--CA 1.467 0.734 0 CA-C-O 118.428 -1.206 . . . . 0.0 110.181 178.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.57 160.11 14.73 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 116.688 -2.005 . . . . 0.0 108.699 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -155.39 117.81 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 113.986 -1.461 . . . . 0.0 109.464 -173.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.453 ' C ' ' SD ' ' G' ' 35' ' ' MET . 96.9 mt -126.33 129.37 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-O 120.812 0.339 . . . . 0.0 110.686 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.49 121.67 2.73 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.9 mt -138.96 139.07 37.84 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.938 0.875 . . . . 0.0 111.463 179.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.438 ' C ' ' SD ' ' A' ' 35' ' ' MET . 6.8 tmm? -136.15 131.42 34.66 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.288 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.0 t -121.52 73.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -105.5 100.7 1.75 Allowed Glycine 0 N--CA 1.442 -0.933 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -177.66 170.44 42.84 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.468 0.428 0 CA-C-O 120.889 0.376 . . . . 0.0 110.795 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.461 0.172 . . . . 0.0 110.799 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -132.41 104.95 6.98 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.585 0.231 . . . . 0.0 110.793 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' B' ' 15' ' ' GLN . 52.7 m170 -126.33 167.08 15.99 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.6 mm-40 -155.27 178.39 10.27 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.663 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -171.08 115.72 0.43 Allowed 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.113 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.429 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 8.2 tt -128.42 122.62 31.77 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.127 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 28.6 m -137.76 131.98 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 N-CA-C 113.129 0.788 . . . . 0.0 113.129 -179.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -110.09 115.68 30.19 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.598 ' CE1' ' CD1' ' C' ' 20' ' ' PHE . 74.2 t80 -121.76 123.5 41.97 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.56 124.76 36.77 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 113.04 0.756 . . . . 0.0 113.04 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.451 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 42.8 tp10 -153.99 129.49 9.91 Favored 'General case' 0 C--O 1.221 -0.415 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.344 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.529 ' OD2' ' NZ ' ' C' ' 28' ' ' LYS . 8.8 t0 -152.41 134.99 15.31 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.055 -178.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' B' ' 25' ' ' GLY . 2.1 p -110.73 111.68 37.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.898 -1.047 . . . . 0.0 108.928 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 32.74 90.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.349 0 C-N-CA 121.586 -0.34 . . . . 0.0 113.328 177.524 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.569 ' CB ' ' HZ3' ' C' ' 28' ' ' LYS . 54.8 p -100.31 150.52 22.49 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 117.626 0.713 . . . . 0.0 109.083 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.532 ' CG ' ' H ' ' B' ' 28' ' ' LYS . 11.6 t30 -42.02 173.94 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.852 0.834 . . . . 0.0 113.207 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.532 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 57.7 tttt -76.3 111.15 11.43 Favored 'General case' 0 CA--C 1.548 0.893 0 N-CA-C 115.563 1.69 . . . . 0.0 115.563 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.36 93.41 0.03 OUTLIER Glycine 0 N--CA 1.478 1.454 0 C-N-CA 119.123 -1.513 . . . . 0.0 115.695 171.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.442 ' C ' ' CG1' ' B' ' 31' ' ' ILE . . . -123.3 152.47 41.38 Favored 'General case' 0 C--O 1.245 0.836 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 173.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.442 ' CG1' ' C ' ' B' ' 30' ' ' ALA . 0.2 OUTLIER -152.8 135.31 6.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 C-N-CA 118.215 -1.394 . . . . 0.0 111.899 -171.762 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 16.5 tt -146.29 137.44 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.332 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.48 128.89 6.48 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.527 ' H ' HD21 ' C' ' 34' ' ' LEU . 48.9 mt -139.33 128.98 24.55 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 122.227 -0.573 . . . . 0.0 111.94 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.43 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 61.8 ttp -130.93 127.33 38.23 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.247 177.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' B' ' 37' ' ' GLY . 15.4 m -133.83 76.4 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 119.936 -0.706 . . . . 0.0 112.779 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -33.6 -95.67 0.01 OUTLIER Glycine 0 CA--C 1.53 1.0 0 N-CA-C 111.521 -0.632 . . . . 0.0 111.521 178.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.47 -168.75 35.43 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.64 134.78 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 120.985 0.421 . . . . 0.0 110.412 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.668 179.837 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -108.44 132.09 54.13 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.551 0.215 . . . . 0.0 110.457 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -95.92 134.77 38.52 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 121.014 0.435 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.429 ' CG1' ' HE2' ' B' ' 14' ' ' HIS . 53.4 t -127.71 136.15 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.11 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -130.16 125.48 35.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.792 0.33 . . . . 0.0 111.013 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.497 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 45.1 t-80 -145.2 166.79 24.44 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.497 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 99.7 mm-40 -153.16 176.83 11.49 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.807 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 69.0 tttt -170.17 104.31 0.3 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.598 178.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 11.2 mp -118.5 118.59 32.12 Favored 'General case' 0 C--O 1.237 0.432 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -131.73 131.5 62.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.603 ' CD1' ' CZ ' ' D' ' 19' ' ' PHE . 52.3 m-85 -113.69 116.51 29.55 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.382 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE1' ' B' ' 20' ' ' PHE . 51.9 t80 -125.94 122.14 35.12 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 118.625 0.648 . . . . 0.0 109.548 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.29 130.12 30.37 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 113.769 1.025 . . . . 0.0 113.769 -178.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.451 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 71.3 mt-10 -155.17 114.98 3.72 Favored 'General case' 0 C--N 1.352 0.682 0 CA-C-N 113.661 -1.608 . . . . 0.0 108.806 178.104 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.423 ' O ' ' O ' ' D' ' 26' ' ' SER . 65.6 t0 -147.54 122.51 10.05 Favored 'General case' 0 N--CA 1.476 0.862 0 O-C-N 121.739 -0.6 . . . . 0.0 111.419 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 14.5 t -98.53 -112.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.056 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.434 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 39.68 -90.94 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.103 -179.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.631 ' O ' ' O ' ' C' ' 27' ' ' ASN . 2.0 m 171.15 170.11 0.08 Allowed 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.631 ' O ' ' O ' ' C' ' 26' ' ' SER . 65.8 t30 -17.56 158.61 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 O-C-N 124.616 1.198 . . . . 0.0 113.696 177.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.569 ' HZ3' ' CB ' ' B' ' 26' ' ' SER . 50.5 tttt -161.26 110.63 1.61 Allowed 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.521 174.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.69 92.64 0.29 Allowed Glycine 0 C--O 1.224 -0.488 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 173.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.16 150.5 47.98 Favored 'General case' 0 CA--C 1.476 -1.885 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 174.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.36 114.49 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 C-N-CA 117.672 -1.611 . . . . 0.0 110.996 -173.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.401 HD13 HG23 ' C' ' 32' ' ' ILE . 9.2 mt -108.84 124.04 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.147 178.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.43 100.62 0.6 Allowed Glycine 0 N--CA 1.474 1.186 0 N-CA-C 108.521 -1.831 . . . . 0.0 108.521 177.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.527 HD21 ' H ' ' B' ' 34' ' ' LEU . 1.6 mt -134.32 142.27 47.19 Favored 'General case' 0 C--O 1.243 0.722 0 CA-C-O 122.886 1.327 . . . . 0.0 113.859 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.544 ' SD ' ' CE ' ' D' ' 35' ' ' MET . 41.9 ttp -127.51 118.8 24.7 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 112.771 -2.013 . . . . 0.0 108.127 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.448 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.1 OUTLIER -116.33 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-N 114.173 -1.376 . . . . 0.0 107.864 179.067 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -39.86 -101.48 0.01 OUTLIER Glycine 0 C--N 1.366 2.238 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.88 -145.83 11.32 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.4 m -128.32 158.85 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 120.664 0.269 . . . . 0.0 110.306 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.467 179.984 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 N--CA 1.465 0.281 0 CA-C-O 121.348 0.594 . . . . 0.0 110.757 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -132.97 134.85 45.05 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.666 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 73.3 m80 -149.04 167.03 26.93 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 121.266 0.555 . . . . 0.0 110.039 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -155.76 171.23 20.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.326 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -158.62 114.1 2.62 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.926 -0.31 . . . . 0.0 111.107 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mt -118.55 119.13 33.59 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -131.31 129.54 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.603 ' CZ ' ' CD1' ' C' ' 19' ' ' PHE . 19.8 m-85 -118.97 123.63 45.04 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -131.26 119.83 22.35 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.747 0.308 . . . . 0.0 111.633 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.08 122.45 28.35 Favored 'General case' 0 N--CA 1.476 0.835 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.136 178.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -84.9 157.01 20.99 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.403 ' HA ' ' NZ ' ' F' ' 28' ' ' LYS . 1.2 t0 -88.72 -174.12 4.4 Favored 'General case' 0 C--N 1.348 0.525 0 CA-C-O 121.213 0.53 . . . . 0.0 110.897 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.413 ' O ' ' O ' ' D' ' 25' ' ' GLY . 20.7 t 62.64 104.45 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' D' ' 24' ' ' VAL . . . 64.71 100.0 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 117.618 -2.23 . . . . 0.0 107.686 -178.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.423 ' O ' ' O ' ' C' ' 23' ' ' ASP . 78.6 p -52.44 171.93 0.05 OUTLIER 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 118.037 0.918 . . . . 0.0 108.617 -176.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.449 ' O ' ' O ' ' D' ' 28' ' ' LYS . 27.4 m-20 -81.84 178.51 8.27 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.694 -0.802 . . . . 0.0 112.115 -175.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' D' ' 27' ' ' ASN . 44.2 tttp -38.6 -106.51 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.294 -1.321 . . . . 0.0 112.533 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.47 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . 86.29 -100.04 2.48 Favored Glycine 0 CA--C 1.456 -3.637 0 N-CA-C 106.218 -2.753 . . . . 0.0 106.218 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.795 ' H ' ' HB2' ' E' ' 30' ' ' ALA . . . 67.55 -163.86 0.21 Allowed 'General case' 0 N--CA 1.419 -2.001 1 N-CA-C 98.449 -4.648 . . . . 0.0 98.449 -176.36 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.552 ' N ' ' CD1' ' D' ' 31' ' ' ILE . 0.0 OUTLIER -115.79 110.94 33.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 CA-C-N 123.941 3.064 . . . . 0.0 110.397 177.258 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.446 ' C ' ' SD ' ' J' ' 35' ' ' MET . 13.7 tt -122.57 127.56 75.04 Favored 'Isoleucine or valine' 0 C--N 1.353 0.744 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.96 179.351 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.36 101.22 0.77 Allowed Glycine 0 N--CA 1.457 0.092 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 5.0 mp -120.34 125.81 48.96 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 122.32 1.057 . . . . 0.0 110.923 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.617 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 37.3 ttp -120.29 119.26 32.63 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 113.928 -1.487 . . . . 0.0 107.839 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.51 74.06 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.698 -178.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . -48.35 111.45 0.89 Allowed Glycine 0 C--N 1.351 1.392 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 37' ' ' GLY . . . -59.77 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 74.7 t -120.95 133.73 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.688 -179.93 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -109.23 132.86 53.72 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.58 151.0 42.79 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.684 0.278 . . . . 0.0 110.629 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 66.2 t -125.86 131.2 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.947 0.403 . . . . 0.0 110.609 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 16.9 t60 -138.93 130.75 27.69 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.532 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 27.1 m80 -148.15 168.24 22.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.751 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.606 ' NE2' HE21 ' F' ' 15' ' ' GLN . 75.1 mt-30 -154.83 165.97 34.97 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.427 178.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -148.6 117.73 6.81 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.192 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.27 122.72 34.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.238 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -127.56 125.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.074 0.464 . . . . 0.0 111.0 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -117.74 113.81 22.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.542 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 55.0 t80 -123.46 116.72 23.69 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 134.74 15.52 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 118.974 -1.09 . . . . 0.0 113.664 -178.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -102.6 117.28 34.33 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 176.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' E' ' 23' ' ' ASP . 7.1 p-10 -131.06 113.26 13.72 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 114.395 1.257 . . . . 0.0 114.395 -177.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.631 ' O ' ' N ' ' E' ' 26' ' ' SER . 40.3 t -127.23 122.29 59.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 175.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.467 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . -28.97 83.8 0.0 OUTLIER Glycine 0 N--CA 1.484 1.883 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.631 ' N ' ' O ' ' E' ' 24' ' ' VAL . 6.3 p -88.24 -179.75 6.2 Favored 'General case' 0 N--CA 1.441 -0.885 0 CA-C-O 123.102 1.43 . . . . 0.0 113.734 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.406 ' CG ' ' H ' ' E' ' 28' ' ' LYS . 60.3 t30 -77.04 179.35 6.31 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-N 111.446 -2.616 . . . . 0.0 110.836 176.063 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.406 ' H ' ' CG ' ' E' ' 27' ' ' ASN . 82.9 tttt 42.88 110.98 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 114.697 1.369 . . . . 0.0 114.697 176.444 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.43 93.99 1.68 Allowed Glycine 0 N--CA 1.47 0.905 0 N-CA-C 108.035 -2.026 . . . . 0.0 108.035 174.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.795 ' HB2' ' H ' ' D' ' 30' ' ' ALA . . . -100.5 166.79 10.75 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -156.44 121.79 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.051 0 C-N-CA 117.916 -1.514 . . . . 0.0 112.306 -173.087 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -111.15 123.74 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.877 178.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.8 109.78 1.7 Allowed Glycine 0 CA--C 1.512 -0.139 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 41.5 tp -133.24 126.74 32.2 Favored 'General case' 0 C--O 1.243 0.745 0 CA-C-O 121.848 0.832 . . . . 0.0 111.454 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.541 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 57.9 ttp -115.62 124.3 50.58 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.059 177.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -129.68 71.58 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.332 -179.885 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -32.46 -101.0 0.01 OUTLIER Glycine 0 C--N 1.364 2.106 0 N-CA-C 111.678 -0.569 . . . . 0.0 111.678 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.18 159.2 30.21 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.94 161.38 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.697 0.284 . . . . 0.0 110.424 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.509 179.501 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 77.0 t . . . . . 0 N--CA 1.464 0.27 0 CA-C-O 121.144 0.497 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -161.11 109.84 1.58 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.243 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -153.63 174.58 14.29 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.606 HE21 ' NE2' ' E' ' 15' ' ' GLN . 95.0 mt-30 -145.56 172.89 12.59 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.326 -0.549 . . . . 0.0 110.605 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.79 112.32 7.83 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.012 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 tt -125.2 122.4 36.9 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.418 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -129.32 130.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.536 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 53.0 p90 -131.5 127.47 37.36 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.816 0.341 . . . . 0.0 110.292 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -142.04 126.87 18.16 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.422 0.629 . . . . 0.0 110.057 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -161.3 161.9 30.77 Favored 'General case' 0 C--N 1.32 -0.683 0 C-N-CA 120.08 -0.648 . . . . 0.0 111.082 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 95.6 mt-10 -116.82 107.99 15.3 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.275 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 49.1 t0 . . . . . 0 N--CA 1.467 0.401 0 CA-C-O 121.265 0.555 . . . . 0.0 111.951 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.546 ' O ' ' N ' ' F' ' 30' ' ' ALA . 22.6 tttt . . . . . 0 CA--C 1.527 0.086 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.88 91.65 0.08 OUTLIER Glycine 0 N--CA 1.467 0.761 0 C-N-CA 117.056 -2.497 . . . . 0.0 109.034 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.546 ' N ' ' O ' ' F' ' 28' ' ' LYS . . . -171.53 162.01 6.4 Favored 'General case' 0 C--N 1.295 -1.786 1 N-CA-C 98.752 -4.536 . . . . 0.0 98.752 178.569 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.463 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.0 OUTLIER -152.11 131.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 115.778 -2.369 . . . . 0.0 113.243 -175.262 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 76.0 mt -106.12 113.49 42.99 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 114.13 -1.395 . . . . 0.0 109.615 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.08 96.46 1.53 Allowed Glycine 0 CA--C 1.502 -0.75 0 N-CA-C 106.217 -2.753 . . . . 0.0 106.217 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.428 ' O ' ' CG ' ' F' ' 34' ' ' LEU . 1.4 pp -118.39 122.2 42.23 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 111.478 0.177 . . . . 0.0 111.478 -177.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.501 ' SD ' ' CA ' ' L' ' 33' ' ' GLY . 58.1 ttp -118.71 115.71 25.07 Favored 'General case' 0 CA--C 1.5 -0.96 0 C-N-CA 119.094 -1.042 . . . . 0.0 108.64 176.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' F' ' 37' ' ' GLY . 3.1 m -123.34 71.44 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -24.97 -103.29 0.0 OUTLIER Glycine 0 C--N 1.36 1.863 0 O-C-N 123.515 0.509 . . . . 0.0 112.432 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.04 163.27 7.45 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -144.34 143.32 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.79 0.328 . . . . 0.0 110.612 179.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.428 179.921 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -118.64 138.27 52.72 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.801 0.334 . . . . 0.0 110.496 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -76.2 158.62 31.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.289 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 56.8 t -118.27 132.93 66.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.147 0.499 . . . . 0.0 110.225 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -104.77 -168.78 1.52 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.395 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.45 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 3.4 m80 -76.57 165.28 25.0 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.456 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 6.3 tp-100 -161.67 175.18 12.3 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.456 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 64.2 tttp -161.63 131.82 4.91 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.102 179.522 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -123.54 125.66 45.28 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.397 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 63.2 t -125.19 126.45 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.857 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.41 ' CZ ' HD12 ' J' ' 34' ' ' LEU . 5.7 t80 -114.49 109.08 17.73 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -118.34 115.66 25.15 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.94 121.38 44.49 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.96 0.41 . . . . 0.0 110.632 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -154.81 118.34 4.54 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -58.23 121.27 10.33 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.279 -178.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.2 m -88.25 124.15 41.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.99 84.53 0.01 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 121.461 -0.4 . . . . 0.0 112.192 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' G' ' 24' ' ' VAL . 60.7 m -93.52 178.6 5.65 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.03 178.73 0.17 Allowed 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.127 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.95 110.94 1.3 Allowed 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.101 -0.64 . . . . 0.0 111.009 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . 0.736 ' H ' HD21 ' H' ' 27' ' ' ASN . . . 71.16 93.11 0.08 OUTLIER Glycine 0 N--CA 1.463 0.485 0 C-N-CA 119.501 -1.333 . . . . 0.0 112.21 176.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.67 160.27 17.42 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 119.784 1.792 . . . . 0.0 109.195 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.04 123.67 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.017 -177.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.429 HD12 HG22 ' G' ' 32' ' ' ILE . 96.6 mt -133.96 128.29 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 O-C-N 121.942 -0.474 . . . . 0.0 111.249 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.04 121.59 3.43 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 54.6 tp -142.5 135.13 28.05 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.384 0.611 . . . . 0.0 112.254 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.453 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 66.3 ttp -127.3 139.01 53.18 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' G' ' 37' ' ' GLY . 22.5 t -133.55 78.36 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -179.31 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -33.85 -94.11 0.01 OUTLIER Glycine 0 C--N 1.345 1.045 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 177.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.99 -164.32 37.87 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -126.53 158.1 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.482 -179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.613 -179.197 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -104.53 131.66 51.67 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -141.3 144.47 34.64 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.608 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . 0.428 ' CG1' ' CE1' ' I' ' 13' ' ' HIS . 18.9 m -125.62 131.84 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -127.1 115.71 19.56 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-O 120.854 0.359 . . . . 0.0 110.956 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.405 ' CD2' ' N ' ' H' ' 14' ' ' HIS . 5.1 p80 -158.99 171.42 20.06 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.39 0.614 . . . . 0.0 110.587 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mm-40 -150.35 173.89 13.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.417 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -148.17 121.26 8.86 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -123.0 127.61 49.06 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.81 0.338 . . . . 0.0 111.851 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -122.05 125.64 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -122.27 115.17 21.87 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -126.86 121.66 32.47 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.49 127.13 51.92 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.613 -0.435 . . . . 0.0 112.001 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.404 ' HG3' ' H ' ' I' ' 24' ' ' VAL . 43.0 tt0 -158.29 103.34 1.8 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.918 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -80.17 134.7 36.17 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-O 120.952 0.406 . . . . 0.0 110.825 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.403 ' O ' ' N ' ' H' ' 26' ' ' SER . 88.9 t -103.68 113.73 41.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -178.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -30.6 88.64 0.01 OUTLIER Glycine 0 CA--C 1.537 1.459 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.775 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' H' ' 27' ' ' ASN . 11.7 p -129.78 -178.54 4.75 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.736 HD21 ' H ' ' G' ' 29' ' ' GLY . 1.4 p-10 -40.16 174.82 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 113.486 0.921 . . . . 0.0 113.486 -174.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -74.8 111.15 9.71 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 116.18 1.919 . . . . 0.0 116.18 -178.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.32 93.54 0.07 OUTLIER Glycine 0 N--CA 1.467 0.733 0 C-N-CA 119.893 -1.146 . . . . 0.0 115.484 171.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.76 157.68 18.9 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 103.348 -2.834 . . . . 0.0 103.348 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.44 119.46 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.714 -174.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.403 ' C ' ' SD ' ' B' ' 35' ' ' MET . 27.7 mm -124.55 124.26 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.414 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.1 126.65 5.49 Favored Glycine 0 N--CA 1.469 0.873 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.4 tt -147.76 134.59 20.1 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.929 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.1 tmm? -128.62 127.09 41.55 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.851 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.436 ' O ' ' O ' ' H' ' 37' ' ' GLY . 10.5 t -122.92 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.294 0.85 . . . . 0.0 113.294 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -35.6 -93.8 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 177.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.1 -171.03 33.88 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.47 141.9 36.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 110.122 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.676 -179.995 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.465 0.283 0 CA-C-O 120.675 0.274 . . . . 0.0 111.056 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.428 ' CE1' ' CG1' ' H' ' 12' ' ' VAL . 0.5 OUTLIER -116.22 170.19 8.71 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.93 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -72.89 169.81 16.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -137.36 172.77 12.49 Favored 'General case' 0 C--N 1.318 -0.768 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.415 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -150.19 128.96 12.42 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.1 0.476 . . . . 0.0 111.663 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.6 tt -133.62 124.47 26.87 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -123.71 128.83 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.862 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.402 ' CE1' HD22 ' K' ' 34' ' ' LEU . 10.3 t80 -122.39 118.99 29.73 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.912 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -135.16 121.63 20.53 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.802 0.334 . . . . 0.0 111.062 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.18 123.49 38.35 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -162.6 126.52 3.02 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 115.354 -0.839 . . . . 0.0 108.815 178.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -102.27 114.03 27.84 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.404 ' H ' ' HG3' ' H' ' 22' ' ' GLU . 4.0 p -79.86 131.63 33.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.754 177.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.63 82.62 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 C-N-CA 119.725 -1.226 . . . . 0.0 112.392 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' I' ' 27' ' ' ASN . 75.1 m -60.04 -174.11 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 115.194 -0.503 . . . . 0.0 109.858 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' I' ' 26' ' ' SER . 17.9 m-20 98.53 -175.3 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 O-C-N 124.218 0.949 . . . . 0.0 109.975 -176.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' I' ' 27' ' ' ASN . 82.4 tttt 38.71 110.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -177.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 95.85 1.74 Allowed Glycine 0 CA--C 1.484 -1.885 0 N-CA-C 107.98 -2.048 . . . . 0.0 107.98 176.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 164.89 16.92 Favored 'General case' 0 N--CA 1.426 -1.662 0 C-N-CA 118.001 -1.48 . . . . 0.0 107.272 -179.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.56 117.31 4.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 119.376 -0.929 . . . . 0.0 108.827 -174.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 tt -125.51 124.16 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.834 178.18 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.33 96.62 0.73 Allowed Glycine 0 C--N 1.331 0.275 0 N-CA-C 107.72 -2.152 . . . . 0.0 107.72 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 8.7 tt -130.32 134.1 46.94 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 122.392 1.092 . . . . 0.0 112.183 -178.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 tmm? -128.26 125.74 39.49 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.618 -1.174 . . . . 0.0 110.344 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.69 76.95 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.34 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 38' ' ' GLY . . . -71.9 106.36 1.9 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -49.27 179.38 0.01 OUTLIER Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 -179.29 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -124.58 138.78 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.938 -1.03 . . . . 0.0 110.365 179.688 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -110.06 138.58 46.24 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.692 0.282 . . . . 0.0 110.298 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -127.56 145.19 50.94 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.952 0.406 . . . . 0.0 110.768 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.86 152.71 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.778 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 31.0 m80 -132.57 146.98 52.33 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.52 ' CE1' ' O ' ' J' ' 15' ' ' GLN . 5.9 t-80 -154.52 157.84 38.95 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.52 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 82.3 mt-30 -148.97 178.06 9.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-O 121.538 0.685 . . . . 0.0 111.653 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -165.34 114.03 1.02 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.151 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -120.86 122.29 39.95 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.155 0.502 . . . . 0.0 111.04 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -114.02 121.82 66.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -125.04 108.37 11.76 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.9 0.381 . . . . 0.0 110.236 -177.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -130.17 127.83 40.51 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.629 0.728 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.67 128.57 31.28 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.842 178.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -142.39 111.24 6.3 Favored 'General case' 0 N--CA 1.462 0.142 0 C-N-CA 119.621 -0.831 . . . . 0.0 111.249 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -85.73 105.02 15.96 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.671 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.68 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 10.5 t -110.12 -131.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.123 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.68 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . 29.03 -82.24 0.0 OUTLIER Glycine 0 CA--C 1.529 0.914 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.869 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.636 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.2 p 169.65 177.76 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.34 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.744 HD21 ' H ' ' K' ' 29' ' ' GLY . 31.7 m120 -28.08 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 114.183 -1.371 . . . . 0.0 112.838 173.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.535 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 29.5 tttt 144.63 104.31 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 123.02 1.39 . . . . 0.0 112.005 177.347 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.16 93.54 0.01 OUTLIER Glycine 0 C--O 1.219 -0.825 0 CA-C-N 112.248 -2.251 . . . . 0.0 111.373 174.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.2 152.81 47.68 Favored 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 120.78 2.29 . . . . 0.0 106.526 176.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.432 ' HB ' ' SD ' ' D' ' 35' ' ' MET . 0.0 OUTLIER -137.97 121.86 21.61 Favored 'Isoleucine or valine' 0 C--O 1.248 1.022 0 C-N-CA 119.218 -0.993 . . . . 0.0 112.384 -174.895 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -104.42 109.44 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.406 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . 0.617 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -109.72 102.46 1.59 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 106.37 -2.692 . . . . 0.0 106.37 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.41 HD12 ' CZ ' ' G' ' 19' ' ' PHE . 5.1 tt -144.35 140.51 29.13 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 122.406 1.098 . . . . 0.0 111.775 -175.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.446 ' SD ' ' C ' ' D' ' 32' ' ' ILE . 61.0 ttp -133.69 130.21 37.85 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.08 -179.142 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -122.78 79.47 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.78 -178.336 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.19 104.54 0.48 Allowed Glycine 0 C--N 1.342 0.907 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.74 167.06 54.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -139.28 160.66 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.727 0.299 . . . . 0.0 110.584 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 C--O 1.221 -0.419 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.846 179.734 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -84.33 138.07 33.09 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.867 0.365 . . . . 0.0 111.068 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' L' ' 11' ' ' GLU . 72.3 mm-40 -137.6 131.98 32.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.628 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 m -138.09 135.56 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.906 0.384 . . . . 0.0 111.123 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 9.7 m80 -134.28 127.51 31.96 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.571 ' NE2' ' CG ' ' L' ' 13' ' ' HIS . 80.5 m80 -116.43 163.17 16.44 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.646 0.736 . . . . 0.0 110.36 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.52 ' N ' ' OE1' ' L' ' 15' ' ' GLN . 50.9 tt0 -163.27 172.31 14.89 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.412 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' K' ' 15' ' ' GLN . 55.4 tttp -164.81 114.88 1.14 Allowed 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 28.6 tp -118.8 121.65 40.54 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.76 127.83 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -131.0 125.7 34.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.23 0.538 . . . . 0.0 112.262 -178.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -133.06 125.79 30.39 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.993 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 127.43 35.36 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.182 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -149.29 137.73 20.88 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.048 -0.661 . . . . 0.0 112.023 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 20.6 p-10 -123.23 120.53 33.42 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 120.986 0.422 . . . . 0.0 110.029 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 84.3 t -60.62 121.1 7.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.519 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.31 -90.97 0.53 Allowed Glycine 0 CA--C 1.527 0.817 0 C-N-CA 121.368 -0.444 . . . . 0.0 112.464 177.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.587 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.8 p -141.37 171.22 14.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 121.196 0.522 . . . . 0.0 110.348 -178.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.587 ' O ' ' O ' ' K' ' 26' ' ' SER . 3.3 p30 -29.01 170.5 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.179 -1.373 . . . . 0.0 113.983 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -148.35 111.3 4.84 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.141 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.744 ' H ' HD21 ' J' ' 27' ' ' ASN . . . -54.53 91.58 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 121.244 -0.503 . . . . 0.0 112.211 179.208 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.63 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -166.38 158.17 13.56 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.8 123.61 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 118.721 -1.192 . . . . 0.0 111.829 -179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.448 ' C ' ' SD ' ' E' ' 35' ' ' MET . 1.0 OUTLIER -102.09 118.41 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.077 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . 0.541 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -112.74 94.88 0.75 Allowed Glycine 0 CA--C 1.51 -0.26 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 179.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.412 HD12 ' N ' ' K' ' 35' ' ' MET . 41.0 tp -129.38 130.77 46.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-O 122.218 1.009 . . . . 0.0 111.968 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.412 ' N ' HD12 ' K' ' 34' ' ' LEU . 7.9 tmm? -116.71 114.73 24.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.893 175.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 m -116.56 79.86 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -66.8 103.24 0.87 Allowed Glycine 0 C--N 1.35 1.36 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -87.39 -178.55 48.38 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.48 142.9 30.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.951 0.405 . . . . 0.0 110.29 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.761 -179.768 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -101.7 130.06 48.0 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.5 tt0 -123.52 138.75 54.5 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 120.96 0.41 . . . . 0.0 110.748 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.53 156.04 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.187 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.7 ' CG ' ' H ' ' L' ' 14' ' ' HIS . 41.8 t-80 -91.29 -177.5 4.88 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 120.784 0.326 . . . . 0.0 110.727 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.7 ' H ' ' CG ' ' L' ' 13' ' ' HIS . 99.2 m-70 -75.52 171.73 13.77 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.53 ' NE2' ' O ' ' L' ' 14' ' ' HIS . 51.5 mm-40 -139.2 -179.78 6.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.62 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.95 124.38 15.72 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.685 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 58.0 tp -125.44 121.22 33.19 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.381 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -129.41 129.35 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.461 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 54.7 p90 -139.45 130.85 26.92 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.785 0.326 . . . . 0.0 111.123 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 84.8 t80 -142.55 131.99 23.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.019 179.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.16 146.43 35.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.814 0.34 . . . . 0.0 110.58 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' K' ' 23' ' ' ASP . 84.6 tt0 -78.52 142.76 37.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.145 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -76.73 121.72 23.7 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 121.225 0.536 . . . . 0.0 110.766 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' L' ' 25' ' ' GLY . 19.5 t -102.75 122.88 55.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.115 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.452 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -30.56 -86.47 0.01 OUTLIER Glycine 0 N--CA 1.478 1.442 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 30.7 t -90.21 -179.97 5.77 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 177.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -58.8 162.89 3.7 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 117.866 -1.534 . . . . 0.0 110.456 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 59.6 tttt -58.3 111.64 1.28 Allowed 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.85 -98.28 0.01 OUTLIER Glycine 0 C--N 1.319 -0.416 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.63 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -72.72 174.57 7.45 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 178.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.468 HG13 ' H ' ' L' ' 32' ' ' ILE . 7.5 tt -171.17 165.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 C-N-CA 115.033 -2.667 . . . . 0.0 115.448 -172.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.468 ' H ' HG13 ' L' ' 31' ' ' ILE . 16.3 tt -99.31 122.02 50.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.761 0 CA-C-N 113.284 -1.78 . . . . 0.0 108.154 177.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . 0.501 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -110.52 94.37 0.79 Allowed Glycine 0 CA--C 1.507 -0.436 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 51.3 tp -119.03 118.76 32.33 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 11.3 tmm? -105.16 119.22 38.5 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.497 ' O ' ' C ' ' L' ' 37' ' ' GLY . 2.7 m -129.03 75.04 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.927 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.497 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -16.95 -101.76 0.0 OUTLIER Glycine 0 C--N 1.359 1.856 0 O-C-N 123.158 0.286 . . . . 0.0 112.707 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.0 173.87 37.68 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.271 -0.731 . . . . 0.0 111.271 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -122.65 138.45 52.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.885 0.374 . . . . 0.0 110.51 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.813 -179.659 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 18.5 p-80 -143.71 164.44 30.44 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.934 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.1 p-80 -87.78 169.98 11.61 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-O 121.395 0.617 . . . . 0.0 110.375 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.448 ' CG ' ' H ' ' A' ' 16' ' ' LYS . 51.5 tt0 -153.28 175.32 13.21 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.301 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.448 ' H ' ' CG ' ' A' ' 15' ' ' GLN . 99.5 mttt -137.68 133.65 34.48 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.819 0.343 . . . . 0.0 110.831 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -129.16 121.52 27.91 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -132.74 131.3 59.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -111.21 116.79 31.66 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.535 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 55.5 p90 -129.84 125.92 36.81 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.75 126.3 32.15 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.083 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' A' ' 22' ' ' GLU . 55.4 mp0 -141.32 163.94 31.59 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 33.7 t70 -79.2 113.67 17.52 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -178.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.502 ' O ' ' N ' ' A' ' 26' ' ' SER . 3.5 p -127.11 121.66 58.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 176.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -29.31 84.04 0.0 OUTLIER Glycine 0 CA--C 1.537 1.412 0 CA-C-O 118.833 -0.982 . . . . 0.0 113.834 178.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 24' ' ' VAL . 10.0 p -97.62 171.82 8.11 Favored 'General case' 0 C--N 1.347 0.468 0 CA-C-N 119.686 1.743 . . . . 0.0 107.311 177.002 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 p30 -60.13 177.53 0.25 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 118.418 -1.313 . . . . 0.0 110.227 178.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -61.76 110.61 1.57 Allowed 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.505 174.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.639 ' H ' ' CB ' ' B' ' 27' ' ' ASN . . . 70.86 93.82 0.07 OUTLIER Glycine 0 N--CA 1.467 0.714 0 C-N-CA 117.541 -2.266 . . . . 0.0 111.716 174.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.52 158.57 17.43 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 121.283 2.542 . . . . 0.0 111.225 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.98 120.38 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 113.433 -1.712 . . . . 0.0 110.566 -175.532 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.7 mt -130.6 125.3 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 O-C-N 121.52 -0.738 . . . . 0.0 110.438 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.575 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -132.15 119.12 2.43 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 80.8 mt -122.23 129.97 52.74 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.071 0.462 . . . . 0.0 110.895 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.402 ' HE2' ' H ' ' H' ' 33' ' ' GLY . 0.0 OUTLIER -126.53 120.49 29.78 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.18 179.995 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -104.94 77.74 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 120.22 -0.592 . . . . 0.0 112.239 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -92.27 101.0 2.73 Favored Glycine 0 C--N 1.342 0.893 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.64 155.87 27.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 28.4 m . . . . . 0 N--CA 1.464 0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.415 179.701 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 26.5 m . . . . . 0 N--CA 1.464 0.239 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.437 ' C ' ' CG ' ' B' ' 14' ' ' HIS . 80.6 t60 -138.7 138.9 38.16 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.644 0.259 . . . . 0.0 110.533 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.587 ' CE1' ' CE1' ' C' ' 14' ' ' HIS . 19.6 m-70 -150.76 170.24 19.71 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.278 0.561 . . . . 0.0 109.983 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -153.14 173.04 16.01 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.49 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -153.9 118.66 4.97 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -116.31 120.95 40.54 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 45.5 t -126.07 121.79 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.157 0.504 . . . . 0.0 110.641 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.438 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 6.4 m-85 -113.52 113.16 24.73 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.709 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -118.17 106.17 12.57 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 175.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.99 125.93 52.12 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.523 ' N ' ' OE1' ' B' ' 22' ' ' GLU . 57.0 mp0 -142.41 178.88 7.29 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 177.208 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.499 ' OD1' ' NZ ' ' D' ' 28' ' ' LYS . 14.1 m-20 -38.09 121.92 0.99 Allowed 'General case' 0 N--CA 1.475 0.811 0 CA-C-N 119.244 0.929 . . . . 0.0 110.644 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.619 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 97.3 t -58.55 -120.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.648 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.021 -178.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.619 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -79.67 -90.28 0.45 Allowed Glycine 0 CA--C 1.523 0.577 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.996 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 77.6 p -155.01 -172.07 4.06 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.835 0.826 . . . . 0.0 110.403 -179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.639 ' CB ' ' H ' ' A' ' 29' ' ' GLY . 8.9 t-20 57.72 -171.72 0.1 Allowed 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 114.201 -1.363 . . . . 0.0 111.671 178.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.591 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 72.2 mmtt -56.96 -111.3 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.709 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.92 94.47 1.57 Allowed Glycine 0 N--CA 1.461 0.314 0 CA-C-N 115.265 -0.88 . . . . 0.0 114.39 -177.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.33 163.97 15.79 Favored 'General case' 0 C--N 1.35 0.605 0 C-N-CA 116.821 -1.952 . . . . 0.0 106.673 177.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.26 128.76 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 C-N-CA 119.111 -1.036 . . . . 0.0 111.739 -172.779 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 99.0 mt -133.23 133.61 58.02 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.325 0.583 . . . . 0.0 110.922 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.01 127.11 4.63 Favored Glycine 0 N--CA 1.47 0.952 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.9 tt -133.79 127.87 33.59 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.294 0.547 . . . . 0.0 111.038 -178.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.548 ' SD ' ' CA ' ' H' ' 33' ' ' GLY . 20.7 ttt -130.24 123.82 31.04 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.421 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 t -124.33 76.02 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.801 178.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.32 101.54 2.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -134.72 163.54 24.72 Favored Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.86 136.97 56.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.506 -179.813 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -106.9 135.97 47.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.921 0.391 . . . . 0.0 110.644 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -67.77 135.63 52.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.795 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 58.5 t -124.89 133.65 68.92 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.05 0.452 . . . . 0.0 111.075 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 p-80 -147.52 145.51 29.12 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.574 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.587 ' CE1' ' CE1' ' B' ' 14' ' ' HIS . 10.2 p-80 -153.76 168.05 27.58 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.361 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -148.75 176.85 10.02 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.248 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -147.23 127.74 14.11 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.296 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.7 mp -130.51 127.28 38.83 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-O 121.1 0.476 . . . . 0.0 111.372 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.8 t -127.4 126.01 66.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.089 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.403 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 57.2 m-85 -111.45 116.11 30.36 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.198 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 50.4 t80 -127.88 117.68 22.24 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.6 130.67 49.43 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.326 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -155.57 101.1 2.15 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.979 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -68.7 133.98 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.977 0.418 . . . . 0.0 110.206 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.34 113.02 20.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.621 0.724 . . . . 0.0 111.178 -179.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 52.97 -91.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.473 -1.24 . . . . 0.0 115.288 177.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.582 ' HG ' ' N ' ' C' ' 27' ' ' ASN . 47.3 t -153.78 -175.57 5.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 122.678 1.228 . . . . 0.0 113.102 -175.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.582 ' N ' ' HG ' ' C' ' 26' ' ' SER . 24.7 m120 52.73 179.93 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 112.433 -2.167 . . . . 0.0 115.129 178.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 75.2 mttt 53.4 110.6 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 CA-C-N 112.536 -2.12 . . . . 0.0 113.967 -177.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.77 95.97 1.85 Allowed Glycine 0 N--CA 1.488 2.127 0 CA-C-O 117.828 -1.54 . . . . 0.0 110.366 175.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.54 160.09 15.59 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 121.354 2.577 . . . . 0.0 109.833 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -148.53 124.97 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.102 -176.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.44 ' O ' ' SD ' ' J' ' 35' ' ' MET . 14.3 tt -130.18 128.92 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 121.195 0.522 . . . . 0.0 110.459 177.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.445 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -112.77 117.62 4.36 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 29.3 mt -124.69 119.66 29.61 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -176.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.461 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 5.3 ttm -122.4 117.58 26.35 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 177.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.52 74.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.998 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.313 -178.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 38' ' ' GLY . . . -61.0 110.98 3.4 Favored Glycine 0 C--N 1.354 1.535 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . -53.9 -167.47 0.02 OUTLIER Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.71 161.82 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.068 0.461 . . . . 0.0 111.221 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 68.6 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.889 -1.053 . . . . 0.0 110.594 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 30.9 m . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CB ' ' E' ' 13' ' ' HIS . 5.7 t60 -89.21 122.38 32.44 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.013 178.567 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 47.5 p-80 -156.15 169.04 25.43 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.056 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -145.04 177.97 8.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -152.59 119.77 5.88 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.185 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -119.68 120.35 36.37 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.855 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -125.7 125.87 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.802 0.334 . . . . 0.0 110.962 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.403 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 72.3 m-85 -115.75 115.82 26.97 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.069 179.011 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 53.9 t80 -127.5 121.15 29.96 Favored 'General case' 0 C--O 1.239 0.5 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 178.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.15 135.58 37.49 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.298 0.571 . . . . 0.0 112.297 -179.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -136.92 96.48 3.31 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.048 178.379 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.425 ' O ' ' CG2' ' E' ' 24' ' ' VAL . 89.8 m-20 -85.89 134.89 33.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.416 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 8.1 p -88.27 112.75 24.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.457 0.646 . . . . 0.0 109.403 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.472 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -45.45 92.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.597 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.346 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.472 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 163.92 -169.6 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.641 0 CA-C-O 121.727 0.775 . . . . 0.0 110.163 -178.562 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -50.64 179.77 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.499 ' NZ ' ' OD1' ' B' ' 23' ' ' ASP . 67.2 tttt 60.49 112.38 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 112.248 -2.251 . . . . 0.0 115.881 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.0 96.16 2.18 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.091 -2.804 . . . . 0.0 106.091 170.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.421 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . -79.31 162.77 25.4 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 123.47 3.635 . . . . 0.0 105.805 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.421 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 1.1 mt -147.21 126.47 4.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 C-N-CA 117.679 -1.608 . . . . 0.0 111.348 -174.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 52.6 mt -123.91 116.95 49.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 177.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.28 103.59 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 105.878 -2.889 . . . . 0.0 105.878 176.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.438 ' CD2' ' CZ ' ' B' ' 19' ' ' PHE . 12.7 tp -116.54 124.36 49.68 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 114.077 1.139 . . . . 0.0 114.077 -175.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.437 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 8.0 ttm -126.54 110.47 13.28 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 174.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.25 79.89 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.151 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.02 103.13 1.32 Allowed Glycine 0 C--N 1.349 1.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 112.506 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.59 178.93 38.46 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 178.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 60.7 t -141.88 157.95 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.946 0.403 . . . . 0.0 111.011 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.52 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 77.1 t80 -85.28 138.96 31.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.883 0.373 . . . . 0.0 110.528 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -55.4 143.05 30.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.689 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.64 135.75 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.487 ' CB ' ' O ' ' D' ' 13' ' ' HIS . 6.4 p80 -155.66 162.07 40.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.041 0.448 . . . . 0.0 111.296 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 69.0 m80 -139.82 168.19 20.39 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.854 0.835 . . . . 0.0 110.287 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -153.17 165.34 35.97 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 114.678 -1.146 . . . . 0.0 108.826 178.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -157.24 116.88 3.4 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.627 0.251 . . . . 0.0 110.334 179.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 32.6 tp -117.14 113.79 22.77 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.47 128.7 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -127.27 120.49 28.77 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.924 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -127.84 118.49 23.77 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 130.04 46.65 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.129 0.49 . . . . 0.0 111.326 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -113.27 102.62 10.53 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 64.4 t0 -79.9 123.17 27.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.174 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.425 ' CG2' ' O ' ' D' ' 23' ' ' ASP . 93.0 t -96.5 121.65 47.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 42.7 -87.03 0.01 OUTLIER Glycine 0 CA--C 1.533 1.17 0 CA-C-N 115.127 -0.942 . . . . 0.0 114.688 178.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 11.1 p -165.38 -178.36 4.95 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-O 122.235 1.017 . . . . 0.0 112.044 -175.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.602 ' CG ' ' H ' ' E' ' 28' ' ' LYS . 7.0 t-20 51.36 -179.13 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 116.105 1.891 . . . . 0.0 116.105 177.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.602 ' H ' ' CG ' ' E' ' 27' ' ' ASN . 27.2 tttt 53.76 110.97 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 112.178 -2.283 . . . . 0.0 114.223 -175.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -87.13 96.44 2.17 Favored Glycine 0 C--N 1.337 0.6 0 CA-C-N 111.973 -2.376 . . . . 0.0 110.909 175.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.412 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -78.83 166.24 22.65 Favored 'General case' 0 C--O 1.241 0.624 0 CA-C-N 122.765 3.282 . . . . 0.0 103.553 177.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.412 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 1.1 mt -147.57 127.39 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 116.687 -2.005 . . . . 0.0 112.903 -172.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 15.7 tt -135.4 119.88 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-O 121.472 0.653 . . . . 0.0 109.49 176.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.68 110.3 2.78 Favored Glycine 0 CA--C 1.508 -0.356 0 N-CA-C 107.492 -2.243 . . . . 0.0 107.492 178.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.57 123.24 43.44 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 122.259 1.028 . . . . 0.0 111.775 -178.2 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.424 ' CE ' ' O ' ' L' ' 31' ' ' ILE . 9.5 tpt -111.47 110.77 21.38 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 113.709 -1.587 . . . . 0.0 107.467 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -119.66 80.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-O 121.035 0.445 . . . . 0.0 109.94 -178.043 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.08 102.17 0.08 OUTLIER Glycine 0 C--N 1.341 0.833 0 CA-C-N 116.247 -0.433 . . . . 0.0 112.044 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.96 150.61 22.7 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.6 t -126.56 136.71 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 88.8 t . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.374 179.819 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m . . . . . 0 N--CA 1.467 0.379 0 CA-C-O 120.99 0.424 . . . . 0.0 110.785 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.468 ' CB ' ' CE1' ' E' ' 13' ' ' HIS . 44.4 p-80 -87.68 163.21 16.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.312 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 53.2 m80 -147.33 172.15 14.33 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -144.12 178.06 8.15 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.847 -179.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.9 121.9 0.57 Allowed 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.738 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.69 125.19 35.4 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.401 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 86.9 t -134.1 129.4 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.923 0.392 . . . . 0.0 111.237 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -122.55 125.66 46.17 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.049 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -136.07 132.63 36.42 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.13 0.491 . . . . 0.0 110.024 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.27 149.46 31.91 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.099 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -74.17 152.74 39.75 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.729 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 t0 . . . . . 0 N--CA 1.462 0.137 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.121 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.423 ' CG ' ' H ' ' F' ' 29' ' ' GLY . 28.6 pttt . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.85 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.618 ' O ' ' O ' ' F' ' 30' ' ' ALA . . . -120.01 -100.1 1.81 Allowed Glycine 0 C--N 1.343 0.943 0 N-CA-C 108.299 -1.921 . . . . 0.0 108.299 173.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.618 ' O ' ' O ' ' F' ' 29' ' ' GLY . . . 54.83 151.97 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 105.412 -2.07 . . . . 0.0 105.412 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.426 ' HB ' ' O ' ' F' ' 30' ' ' ALA . 2.7 tp -165.8 132.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 C-N-CA 115.002 -2.679 . . . . 0.0 114.192 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 97.0 mt -111.69 112.98 42.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 113.631 -1.622 . . . . 0.0 108.418 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -97.13 101.74 2.63 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 105.382 -3.087 . . . . 0.0 105.382 176.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -104.73 108.69 20.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -176.189 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.47 ' SD ' ' C ' ' L' ' 32' ' ' ILE . 0.9 OUTLIER -109.42 107.34 17.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 176.102 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -136.01 80.59 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.984 -179.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.49 -101.66 0.09 OUTLIER Glycine 0 C--N 1.344 1.004 0 C-N-CA 120.976 -0.631 . . . . 0.0 111.99 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.74 -159.71 31.64 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.1 m -135.19 161.72 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 120.626 0.251 . . . . 0.0 110.529 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.204 179.612 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -126.77 142.69 51.47 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.37 143.72 42.11 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.057 0.456 . . . . 0.0 111.019 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 p -130.49 134.99 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.187 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -122.79 127.25 48.88 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 120.95 0.405 . . . . 0.0 110.445 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 70.8 t60 -157.62 165.41 35.58 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-O 121.16 0.505 . . . . 0.0 110.183 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 83.6 mt-30 -151.28 174.76 12.91 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.018 178.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -171.57 114.04 0.36 Allowed 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.082 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 64.7 mt -131.16 124.1 29.97 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.331 0.586 . . . . 0.0 110.306 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 30.9 m -128.12 129.83 69.53 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.135 -179.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.434 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 15.4 m-85 -110.53 113.03 25.34 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.466 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 45.6 p90 -123.95 124.13 41.93 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.27 131.13 38.07 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -145.6 167.22 23.59 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 177.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 58.6 t0 -90.14 111.78 23.03 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.015 -0.674 . . . . 0.0 112.186 -178.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.611 ' O ' ' N ' ' G' ' 26' ' ' SER . 3.6 p -113.17 131.04 65.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.127 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.29 81.96 0.0 OUTLIER Glycine 0 CA--C 1.532 1.11 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.782 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.611 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.1 m -96.58 176.2 6.11 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.504 ' O ' ' O ' ' G' ' 28' ' ' LYS . 53.3 p30 -62.2 -177.73 0.14 Allowed 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.504 ' O ' ' O ' ' G' ' 27' ' ' ASN . 98.4 mttt -48.85 -109.2 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-O 121.682 0.753 . . . . 0.0 110.64 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.65 96.53 2.1 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.42 161.32 23.77 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 115.49 -2.484 . . . . 0.0 109.609 -177.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -154.33 116.27 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.868 -175.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -143.09 137.76 26.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.502 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -158.8 164.33 33.6 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.466 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 3.3 tp -169.57 163.28 10.21 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.13 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.575 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 53.5 ttp -131.93 134.12 45.3 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.601 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 21.1 t -117.48 65.03 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.514 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -55.12 -106.76 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.25 -166.12 13.97 Favored Glycine 0 N--CA 1.465 0.629 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -132.58 159.22 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.025 0.44 . . . . 0.0 110.852 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.669 -179.805 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -107.41 128.95 54.93 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.869 0.366 . . . . 0.0 110.354 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -145.76 135.4 23.29 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.612 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -140.44 134.93 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 77.6 m80 -118.69 118.74 32.44 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.416 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.528 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 5.8 m-70 -135.56 164.29 28.17 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.507 0.67 . . . . 0.0 109.856 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.416 ' CG ' ' N ' ' H' ' 16' ' ' LYS . 52.5 tt0 -161.86 170.51 19.34 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.437 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . 0.416 ' N ' ' CG ' ' H' ' 15' ' ' GLN . 68.7 mttm -155.94 115.79 3.64 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.722 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 76.6 mt -114.76 115.27 26.77 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -125.09 124.6 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -113.01 108.76 17.79 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.522 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 24.6 t80 -127.06 129.52 48.16 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.164 0.438 . . . . 0.0 110.635 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.47 150.4 26.57 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 118.346 -1.342 . . . . 0.0 114.56 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -132.53 173.04 11.73 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 114.367 -1.288 . . . . 0.0 109.582 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.406 ' C ' ' OD1' ' H' ' 23' ' ' ASP . 64.5 t0 -148.51 116.53 6.4 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 113.253 0.835 . . . . 0.0 113.253 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 3.2 p -121.49 122.33 66.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 177.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.24 83.79 0.01 OUTLIER Glycine 0 N--CA 1.472 1.052 0 CA-C-O 121.588 0.549 . . . . 0.0 112.245 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -45.35 170.28 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 113.864 1.061 . . . . 0.0 113.864 179.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.472 ' O ' ' O ' ' H' ' 28' ' ' LYS . 19.5 m120 -135.61 177.04 8.13 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 113.444 -1.707 . . . . 0.0 107.738 173.773 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.472 ' O ' ' O ' ' H' ' 27' ' ' ASN . 65.2 mttm -21.28 -102.86 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . -158.85 100.27 0.19 Allowed Glycine 0 C--N 1.349 1.256 0 CA-C-O 118.365 -1.241 . . . . 0.0 110.788 177.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.82 157.14 31.19 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-N 120.869 2.334 . . . . 0.0 109.125 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -142.91 118.5 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.473 -176.547 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.53 ' O ' ' SD ' ' B' ' 35' ' ' MET . 86.1 mt -127.7 126.17 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.406 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.548 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -131.88 110.33 0.95 Allowed Glycine 0 N--CA 1.477 1.398 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.76 137.96 31.97 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 121.582 -0.952 . . . . 0.0 112.476 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 40.8 ttp -127.3 139.33 52.96 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.835 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.447 ' O ' ' O ' ' H' ' 37' ' ' GLY . 2.5 p -153.48 75.15 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.943 178.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -37.25 -95.5 0.01 OUTLIER Glycine 0 C--N 1.343 0.928 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 178.376 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -165.22 38.58 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 t -90.44 134.67 28.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.969 0.414 . . . . 0.0 110.764 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.218 -0.587 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.312 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 CA--C 1.531 0.237 0 CA-C-O 120.873 0.368 . . . . 0.0 111.001 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.449 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 25.0 m-70 -119.87 138.92 53.11 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.605 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.449 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 25.8 m-70 -144.74 168.79 19.37 Favored 'General case' 0 CA--C 1.511 -0.552 0 CA-C-O 121.499 0.666 . . . . 0.0 110.483 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -149.42 177.99 9.2 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.84 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . 0.479 ' HZ2' ' CG1' ' I' ' 18' ' ' VAL . 65.5 tttm -171.36 107.01 0.24 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.862 179.191 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 mt -120.07 115.54 23.91 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . 0.479 ' CG1' ' HZ2' ' I' ' 16' ' ' LYS . 2.2 m -134.43 127.61 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.23 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.42 ' CD2' ' CE2' ' J' ' 19' ' ' PHE . 12.6 m-30 -110.35 118.8 37.27 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.251 178.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.522 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 53.3 t80 -125.65 118.05 24.83 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.43 135.49 33.66 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -177.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.548 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 82.9 tt0 -115.92 100.18 7.8 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.155 -1.794 . . . . 0.0 106.155 176.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.548 ' CB ' ' O ' ' I' ' 22' ' ' GLU . 53.2 t0 121.61 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 O-C-N 124.817 1.323 . . . . 0.0 108.246 -176.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.537 ' H ' ' CG ' ' I' ' 23' ' ' ASP . 19.8 m -106.14 112.02 37.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.798 0.809 . . . . 0.0 108.929 -178.501 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' I' ' 24' ' ' VAL . . . 33.65 -92.16 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -177.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.64 ' O ' ' O ' ' I' ' 27' ' ' ASN . 41.4 t -130.46 168.24 17.33 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.64 ' O ' ' O ' ' I' ' 26' ' ' SER . 98.2 m-20 38.43 179.13 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 O-C-N 124.096 0.873 . . . . 0.0 111.628 176.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.54 ' HD2' ' H ' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -92.65 -120.75 0.08 Allowed 'General case' 0 N--CA 1.471 0.585 0 O-C-N 120.906 -1.121 . . . . 0.0 109.134 178.919 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.415 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -69.08 88.11 0.23 Allowed Glycine 0 CA--C 1.484 -1.903 0 N-CA-C 104.824 -3.31 . . . . 0.0 104.824 171.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.47 162.79 35.65 Favored 'General case' 0 CA--C 1.464 -2.331 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.91 -175.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -137.74 113.21 10.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.004 -179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.461 ' C ' ' SD ' ' C' ' 35' ' ' MET . 1.6 tt -107.03 114.1 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 179.179 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.427 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -116.65 97.52 0.76 Allowed Glycine 0 CA--C 1.508 -0.377 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -123.17 131.55 53.72 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-O 122.379 1.085 . . . . 0.0 110.579 179.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 25.6 ttt -116.19 117.38 29.88 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.577 -1.647 . . . . 0.0 110.29 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.7 71.3 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.51 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.19 105.58 3.21 Favored Glycine 0 C--N 1.365 2.157 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 176.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.08 165.17 53.27 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.745 -0.741 . . . . 0.0 111.694 -178.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t -143.75 136.9 24.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.68 0.276 . . . . 0.0 110.351 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.098 -0.953 . . . . 0.0 110.324 179.699 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -81.92 142.81 32.13 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.957 0.408 . . . . 0.0 110.926 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -63.04 142.12 58.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.705 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -134.85 144.29 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 3.5 m80 -139.13 138.55 37.11 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.377 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.475 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 79.6 t60 -139.73 166.92 23.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.475 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 85.5 mt-30 -148.61 172.0 15.25 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.612 179.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 47.6 mtpt -156.93 112.07 2.83 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.603 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -123.82 120.53 32.89 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.437 0.16 . . . . 0.0 110.661 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -137.31 130.86 44.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 119.921 -0.712 . . . . 0.0 112.014 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.42 ' CE2' ' CD2' ' I' ' 19' ' ' PHE . 18.0 m-85 -111.04 119.78 40.18 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 114.741 -1.118 . . . . 0.0 108.75 178.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -131.31 122.08 25.79 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.67 145.04 31.54 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -131.41 160.31 35.46 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.911 -1.041 . . . . 0.0 108.897 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -121.77 120.63 35.17 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.428 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 14.3 t -62.87 -120.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.94 177.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.428 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . -75.3 -90.26 0.21 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.203 -177.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 53.4 m -140.97 171.23 14.36 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 122.067 0.937 . . . . 0.0 111.024 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' J' ' 28' ' ' LYS . 38.8 t-20 -28.66 151.1 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 113.627 -1.624 . . . . 0.0 115.168 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.533 ' N ' ' OD1' ' J' ' 27' ' ' ASN . 97.9 mttt -163.75 110.7 1.13 Allowed 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 112.594 -2.094 . . . . 0.0 107.594 177.231 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.65 93.82 0.32 Allowed Glycine 0 N--CA 1.476 1.303 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.538 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.16 157.73 20.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 105.85 -1.907 . . . . 0.0 105.85 177.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.55 111.24 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 119.715 -0.794 . . . . 0.0 110.329 -173.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.437 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.2 tt -104.54 118.57 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.113 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.773 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.61 106.51 0.89 Allowed Glycine 0 C--O 1.241 0.567 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.434 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 5.3 mp -129.71 132.06 46.52 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-O 122.15 0.976 . . . . 0.0 111.217 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.44 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 23.2 ttt -102.04 114.91 29.44 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 113.383 -1.735 . . . . 0.0 108.143 178.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -136.46 70.45 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.446 -177.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.72 -101.12 1.99 Allowed Glycine 0 C--N 1.358 1.756 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 177.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.61 154.71 26.21 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -142.79 139.17 28.11 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-O 121.128 0.489 . . . . 0.0 110.726 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.589 179.641 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.62 139.03 45.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.76 0.314 . . . . 0.0 110.913 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.542 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 95.0 mt-10 -139.47 153.53 47.55 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.619 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 54.6 t -121.71 131.16 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 116.312 -0.403 . . . . 0.0 109.968 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -161.51 162.63 30.4 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.716 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.488 ' HE2' ' CG2' ' L' ' 12' ' ' VAL . 89.4 m-70 -152.45 168.01 26.89 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.947 179.389 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 -158.04 178.83 9.77 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.11 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.1 tttt -160.14 126.58 4.27 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.123 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -116.86 119.11 34.37 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.38 125.69 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.866 0.365 . . . . 0.0 111.395 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -116.91 119.69 36.14 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.116 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.405 ' CE1' ' OE2' ' K' ' 22' ' ' GLU . 37.8 t80 -127.92 119.72 26.16 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.367 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.43 132.98 34.21 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.47 ' OE1' ' OE2' ' L' ' 22' ' ' GLU . 57.7 mm-40 -102.83 167.86 9.6 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.459 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 2.9 p30 -152.35 133.7 14.44 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 119.11 -1.036 . . . . 0.0 113.788 -178.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.5 ' O ' ' N ' ' K' ' 26' ' ' SER . 7.7 p -88.69 113.29 25.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 104.222 -2.51 . . . . 0.0 104.222 174.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.46 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -45.39 91.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.621 0 C-N-CA 119.722 -1.228 . . . . 0.0 113.503 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.6 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.6 t 161.17 160.69 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.127 0.489 . . . . 0.0 110.159 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.623 ' O ' ' HB2' ' K' ' 28' ' ' LYS . 82.3 m-20 -29.76 175.91 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.245 173.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.623 ' HB2' ' O ' ' K' ' 27' ' ' ASN . 2.9 tptm 147.56 100.85 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 C-N-CA 127.032 2.133 . . . . 0.0 110.299 176.02 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -51.22 -100.17 0.01 OUTLIER Glycine 0 C--O 1.21 -1.397 0 CA-C-O 124.465 2.147 . . . . 0.0 114.385 175.133 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 70.74 143.87 0.06 Allowed 'General case' 0 C--O 1.245 0.826 0 CA-C-N 111.354 -2.423 . . . . 0.0 107.203 177.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.475 HG22 HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -147.88 123.09 2.35 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.795 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.493 ' CG2' ' O ' ' K' ' 32' ' ' ILE . 0.8 OUTLIER -108.97 115.12 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.692 178.816 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 91.35 0.58 Allowed Glycine 0 C--O 1.24 0.485 0 N-CA-C 107.333 -2.307 . . . . 0.0 107.333 176.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 92.2 mt -114.75 118.75 34.47 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.331 0.586 . . . . 0.0 109.862 -179.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 2.5 ttt -107.7 115.04 29.43 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.742 -178.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.11 68.35 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.763 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.03 -100.99 0.01 OUTLIER Glycine 0 C--N 1.349 1.262 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.86 160.2 14.39 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.9 m -136.76 159.74 37.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.794 0.33 . . . . 0.0 110.219 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.325 -0.457 0 CA-C-O 118.089 -0.958 . . . . 0.0 110.765 -179.77 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.351 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -104.38 132.33 50.75 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -71.9 132.42 44.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.354 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . 0.488 ' CG2' ' HE2' ' K' ' 14' ' ' HIS . 21.8 m -143.13 156.2 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 122.011 0.91 . . . . 0.0 112.543 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.542 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 3.9 m80 -151.16 118.33 5.94 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.729 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -153.88 172.82 16.8 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.273 0.559 . . . . 0.0 110.418 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -145.67 173.86 11.7 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.728 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -159.82 120.92 3.14 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.93 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 tt -122.51 119.73 31.77 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -129.07 132.89 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -135.64 130.32 34.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.935 0.398 . . . . 0.0 110.715 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.2 t80 -137.31 127.62 26.38 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.0 148.21 36.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.265 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.47 ' OE2' ' OE1' ' K' ' 22' ' ' GLU . 78.1 mt-10 -81.73 149.17 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.464 0.649 . . . . 0.0 110.722 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.411 ' O ' ' O ' ' L' ' 22' ' ' GLU . 99.3 m-20 54.17 114.42 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.869 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 67.3 t -95.12 130.61 43.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 CA-C-N 114.519 -1.219 . . . . 0.0 109.879 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 49.56 82.74 0.03 OUTLIER Glycine 0 CA--C 1.525 0.698 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.183 178.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' L' ' 27' ' ' ASN . 5.8 p 176.96 -167.52 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' L' ' 26' ' ' SER . 14.5 m120 -38.92 179.91 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -175.485 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.44 ' HG2' ' N ' ' L' ' 29' ' ' GLY . 85.1 tttt 77.42 -111.42 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.668 -1.151 . . . . 0.0 112.128 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.477 ' O ' ' CB ' ' L' ' 30' ' ' ALA . . . 83.93 -94.59 1.83 Allowed Glycine 0 CA--C 1.503 -0.682 0 N-CA-C 107.892 -2.083 . . . . 0.0 107.892 -174.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.495 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . 77.17 169.77 0.23 Allowed 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.424 ' O ' ' CE ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -138.83 109.19 4.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 116.81 -1.956 . . . . 0.0 111.224 179.23 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' L' ' 32' ' ' ILE . 7.4 tt -102.7 115.88 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-N 113.34 -1.755 . . . . 0.0 107.961 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 110.18 2.24 Favored Glycine 0 C--N 1.334 0.464 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 -179.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.38 111.8 22.03 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.582 -0.809 . . . . 0.0 110.086 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 2.7 tpp -93.65 104.97 17.05 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' L' ' 37' ' ' GLY . 0.7 OUTLIER -131.09 71.36 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.954 0 O-C-N 122.051 -0.405 . . . . 0.0 109.922 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -35.49 -100.66 0.01 OUTLIER Glycine 0 C--N 1.346 1.085 0 C-N-CA 121.815 -0.231 . . . . 0.0 112.717 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.27 174.91 19.16 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 159.2 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.979 0.419 . . . . 0.0 110.709 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.184 179.897 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 121.307 0.575 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.488 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 69.7 m80 -116.44 172.5 7.17 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.813 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.683 ' CD2' ' H ' ' A' ' 15' ' ' GLN . 12.3 t-80 -80.45 165.55 22.09 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 109.622 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.683 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 1.2 pm0 -161.01 179.03 8.78 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.315 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -144.24 128.22 17.48 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.713 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 78.5 mt -124.03 124.19 42.01 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.24 131.45 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.333 0.587 . . . . 0.0 111.852 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -118.44 112.11 19.53 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.533 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 51.1 p90 -125.44 128.27 47.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -177.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.27 115.85 28.06 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.219 0.533 . . . . 0.0 110.166 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.465 ' O ' ' C ' ' A' ' 23' ' ' ASP . 84.7 tt0 -163.89 96.52 0.82 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.465 ' C ' ' O ' ' A' ' 22' ' ' GLU . 0.1 OUTLIER -25.89 115.46 0.06 Allowed 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 -177.097 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' A' ' 26' ' ' SER . 2.1 p -87.27 130.64 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.75 82.29 0.0 OUTLIER Glycine 0 CA--C 1.525 0.712 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.618 -177.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' A' ' 24' ' ' VAL . 80.2 p -98.47 174.95 6.21 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.123 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.07 178.89 0.16 Allowed 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 119.396 -0.922 . . . . 0.0 108.635 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.68 110.78 1.22 Allowed 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.73 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 94.2 0.11 Allowed Glycine 0 N--CA 1.469 0.843 0 C-N-CA 119.702 -1.237 . . . . 0.0 111.284 177.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.32 160.23 14.87 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-N 119.707 1.753 . . . . 0.0 107.497 177.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.425 HD13 HG21 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -152.6 113.03 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.175 -175.308 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.47 ' O ' ' SD ' ' G' ' 35' ' ' MET . 97.6 mt -128.86 128.04 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-O 121.435 0.636 . . . . 0.0 111.671 -179.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' G' ' 35' ' ' MET . . . -123.5 127.03 6.43 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.043 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -130.18 130.05 44.21 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.799 0.3 . . . . 0.0 111.021 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.674 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 19.8 ttp -130.63 128.08 40.24 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.096 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 54.4 t -115.64 72.15 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.88 98.82 0.81 Allowed Glycine 0 CA--C 1.529 0.924 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 176.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.76 172.45 40.48 Favored Glycine 0 CA--C 1.523 0.547 0 C-N-CA 120.485 -0.864 . . . . 0.0 111.564 -179.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 N--CA 1.471 0.587 0 CA-C-O 120.781 0.324 . . . . 0.0 110.765 179.986 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.466 0.366 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.464 ' O ' ' CB ' ' C' ' 13' ' ' HIS . 4.8 m-70 -105.67 117.76 34.84 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.789 0.328 . . . . 0.0 110.909 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.476 ' ND1' ' CD2' ' A' ' 14' ' ' HIS . 52.5 t-80 -157.21 159.51 37.76 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.437 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 74.4 mt-30 -159.98 179.07 9.09 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.832 179.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -157.71 126.12 5.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.754 0.311 . . . . 0.0 110.762 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 tp -120.76 123.25 42.21 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.312 0.577 . . . . 0.0 110.297 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -117.93 121.37 67.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.601 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.434 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 13.5 t80 -128.05 116.26 19.73 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 -178.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.543 ' CG ' ' CZ ' ' C' ' 20' ' ' PHE . 38.8 p90 -150.2 160.22 43.85 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.41 138.85 38.59 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.896 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -125.4 175.1 7.72 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.467 ' CG ' ' H ' ' C' ' 27' ' ' ASN . 50.5 t0 -142.98 99.33 3.44 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.139 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.47 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 1.6 t -118.21 -151.17 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.47 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -38.9 -75.88 0.09 OUTLIER Glycine 0 N--CA 1.47 0.937 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.601 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.707 ' HG ' ' HZ1' ' C' ' 28' ' ' LYS . 31.1 t 60.15 173.13 0.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.73 -1.235 . . . . 0.0 113.568 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.498 ' ND2' ' HG ' ' A' ' 26' ' ' SER . 18.9 p30 -101.38 -178.98 3.89 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 113.395 -1.73 . . . . 0.0 112.567 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.494 ' O ' ' O ' ' B' ' 27' ' ' ASN . 87.3 tttt -34.15 -102.66 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.118 177.115 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -137.13 100.8 0.32 Allowed Glycine 0 CA--C 1.485 -1.829 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.5 157.72 31.45 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.349 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -148.58 120.87 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.583 -178.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.501 ' O ' ' SD ' ' H' ' 35' ' ' MET . 86.8 mt -133.98 128.68 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.362 -178.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.505 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -120.81 109.5 1.56 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.976 -1.65 . . . . 0.0 108.976 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 8.7 tt -117.08 123.32 46.53 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 117.072 0.436 . . . . 0.0 111.099 -179.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.599 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 32.1 ttp -124.79 117.37 24.01 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.299 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 37' ' ' GLY . 34.5 m -136.54 73.01 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -47.4 -95.35 0.01 OUTLIER Glycine 0 C--N 1.337 0.604 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 175.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.13 176.67 40.45 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -140.96 144.48 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-O 121.031 0.443 . . . . 0.0 111.215 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 85.0 t . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.309 179.842 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.156 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -105.73 131.56 52.94 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.709 0.29 . . . . 0.0 110.595 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -74.3 133.14 42.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.068 179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.16 166.68 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 CA-C-O 120.832 0.349 . . . . 0.0 110.887 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.464 ' CB ' ' O ' ' B' ' 13' ' ' HIS . 0.0 OUTLIER -169.28 164.76 10.92 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.271 178.749 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.495 ' CG ' ' OE1' ' D' ' 15' ' ' GLN . 88.6 m-70 -105.52 -179.91 4.08 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' C' ' 16' ' ' LYS . 44.9 tt0 -88.69 169.19 11.88 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.433 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' C' ' 15' ' ' GLN . 99.2 mttt -123.5 133.92 53.95 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 29.1 mt -122.3 119.35 30.86 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.026 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 6.2 p -124.77 123.23 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -123.41 119.17 29.25 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.571 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.543 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 49.7 p90 -142.86 130.26 21.11 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-O 122.574 1.178 . . . . 0.0 112.953 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.94 121.74 38.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.397 179.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.496 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 97.2 mt-10 -99.01 101.08 12.35 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.498 ' OD1' ' NZ ' ' E' ' 28' ' ' LYS . 15.7 t0 83.68 133.56 0.05 Allowed 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.508 ' O ' ' N ' ' C' ' 26' ' ' SER . 34.8 t -83.41 -110.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -42.85 92.19 0.01 OUTLIER Glycine 0 C--N 1.317 -0.473 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.527 ' O ' ' O ' ' C' ' 27' ' ' ASN . 42.3 p -101.11 165.22 11.42 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 122.49 1.138 . . . . 0.0 110.784 -176.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.613 ' ND2' ' HZ2' ' C' ' 28' ' ' LYS . 0.1 OUTLIER 49.05 169.15 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 112.009 -2.36 . . . . 0.0 109.114 -176.235 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.712 ' H ' ' CE ' ' C' ' 28' ' ' LYS . 0.0 OUTLIER -79.08 110.7 14.57 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.641 -0.824 . . . . 0.0 108.824 175.634 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 57.25 91.51 0.01 OUTLIER Glycine 0 C--O 1.219 -0.829 0 C-N-CA 118.342 -1.885 . . . . 0.0 109.877 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.66 152.22 50.16 Favored 'General case' 0 CA--C 1.476 -1.903 0 CA-C-N 121.428 2.614 . . . . 0.0 105.016 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.405 ' O ' ' CE ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -144.48 109.66 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.185 -173.028 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -114.9 118.44 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.05 -178.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.21 108.51 2.48 Favored Glycine 0 N--CA 1.46 0.298 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 5.8 mt -114.76 112.72 23.25 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 120.916 0.388 . . . . 0.0 110.331 -178.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.5 ttt -112.42 104.06 12.18 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.59 72.24 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.994 -177.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -42.97 -97.43 0.01 OUTLIER Glycine 0 C--N 1.349 1.27 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.12 -173.12 42.95 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -141.52 154.22 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.019 0.438 . . . . 0.0 111.133 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.087 -0.959 . . . . 0.0 110.218 179.56 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 m . . . . . 0 N--CA 1.465 0.28 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 70.0 m80 -82.15 112.95 19.65 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.168 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' D' ' 13' ' ' HIS . 3.4 m-70 -145.72 159.94 42.44 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG ' ' C' ' 14' ' ' HIS . 0.0 OUTLIER -159.23 174.18 15.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.26 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -153.32 129.09 10.14 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.886 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 36.7 tp -123.28 118.33 27.32 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -122.39 126.19 73.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.941 0.4 . . . . 0.0 110.687 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -123.25 112.33 17.52 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -131.57 133.42 45.0 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.79 131.79 29.59 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.886 0.374 . . . . 0.0 111.725 179.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -127.88 143.52 51.11 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.991 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -131.3 111.97 12.35 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.969 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.494 ' O ' ' N ' ' D' ' 26' ' ' SER . 12.6 m -138.01 -122.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 120.424 -0.51 . . . . 0.0 109.915 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.438 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . 28.37 -84.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.536 -0.756 . . . . 0.0 113.097 -178.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.3 m 170.28 178.77 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.518 0.675 . . . . 0.0 110.574 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' D' ' 26' ' ' SER . 12.4 m120 -28.73 -179.21 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 113.041 -1.891 . . . . 0.0 114.248 176.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 85.4 mttt 128.26 105.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 125.867 1.667 . . . . 0.0 112.137 176.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.6 94.87 0.05 OUTLIER Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.43 154.25 38.0 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 176.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.04 112.29 2.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.732 -171.629 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.436 HD11 HG21 ' D' ' 32' ' ' ILE . 2.1 mt -107.93 114.01 45.3 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.409 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.38 100.65 1.66 Allowed Glycine 0 CA--C 1.498 -1.007 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 176.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.434 ' CD2' ' CZ ' ' B' ' 19' ' ' PHE . 13.6 tp -112.99 121.08 43.56 Favored 'General case' 0 CA--C 1.503 -0.852 0 CA-C-N 115.298 -0.451 . . . . 0.0 110.934 -177.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 43.3 ttp -128.97 107.25 9.46 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -123.61 72.14 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.675 -179.927 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.15 -100.52 0.01 OUTLIER Glycine 0 C--N 1.36 1.892 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.891 179.144 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 157.13 -157.24 27.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -132.36 147.95 31.99 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.462 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.32 -179.731 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -114.76 134.31 55.21 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.768 0.318 . . . . 0.0 110.491 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -98.37 137.47 37.04 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.28 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 22.6 m -131.74 160.34 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 121.332 0.587 . . . . 0.0 111.141 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 27.6 m80 -124.01 120.51 32.65 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.606 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.467 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -150.66 162.91 39.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.927 0.87 . . . . 0.0 111.473 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.467 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 50.2 tt0 -157.99 168.6 26.67 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.375 -1.284 . . . . 0.0 110.063 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -143.57 126.79 16.59 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.837 179.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 tt -118.98 115.68 24.86 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -120.23 125.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.734 0.302 . . . . 0.0 110.36 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -124.16 113.4 18.28 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.482 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -125.72 125.13 42.51 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.212 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.23 119.63 19.01 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.232 0.539 . . . . 0.0 110.327 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.402 ' C ' ' OD1' ' E' ' 23' ' ' ASP . 97.8 mt-10 -129.16 128.35 43.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' E' ' 22' ' ' GLU . 1.2 m-20 -141.89 112.1 6.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.264 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' E' ' 26' ' ' SER . 13.2 m -103.24 -122.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 C-N-CA 120.326 -0.55 . . . . 0.0 111.057 -178.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.05 -84.92 0.01 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.834 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' E' ' 27' ' ' ASN . 3.0 p 170.88 170.54 0.07 Allowed 'General case' 0 CA--C 1.511 -0.55 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' E' ' 26' ' ' SER . 27.6 t-20 -18.17 157.47 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.975 0 O-C-N 124.792 1.308 . . . . 0.0 113.475 179.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.498 ' NZ ' ' OD1' ' C' ' 23' ' ' ASP . 84.8 tttt -162.55 111.35 1.38 Allowed 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.552 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.17 92.36 0.25 Allowed Glycine 0 N--CA 1.479 1.528 0 O-C-N 121.931 -0.481 . . . . 0.0 113.194 177.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.5 161.97 21.58 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 175.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.4 HG23 HD12 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -145.68 132.21 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 118.903 -1.119 . . . . 0.0 113.647 -175.561 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.46 ' O ' ' CE ' ' K' ' 35' ' ' MET . 0.2 OUTLIER -109.71 116.48 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.306 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.67 105.36 2.23 Favored Glycine 0 N--CA 1.466 0.669 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 16.4 mt -115.83 115.0 25.49 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 117.561 0.68 . . . . 0.0 112.155 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.717 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 11.4 ttp -114.07 106.66 14.66 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 176.074 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.91 73.81 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.331 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.17 111.57 2.66 Favored Glycine 0 C--N 1.354 1.577 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 178.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.5 -157.08 0.04 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.15 142.81 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.975 0.417 . . . . 0.0 110.49 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.772 179.827 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t . . . . . 0 N--CA 1.468 0.43 0 CA-C-O 121.115 0.483 . . . . 0.0 110.397 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -130.02 128.53 42.18 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.923 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.519 ' CE1' ' O ' ' F' ' 15' ' ' GLN . 56.9 t-80 -151.99 168.5 25.02 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.519 ' O ' ' CE1' ' F' ' 14' ' ' HIS . 84.7 mt-30 -150.52 173.47 14.05 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.41 179.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.41 127.01 14.21 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.39 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -128.73 127.57 42.33 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.554 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -127.56 128.3 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -123.36 120.74 33.92 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.678 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 78.8 t80 -141.13 121.88 14.35 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -159.59 154.71 25.04 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 119.785 -0.766 . . . . 0.0 112.578 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -96.94 124.16 40.84 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 60.3 t0 . . . . . 0 CA--C 1.536 0.407 0 C-N-CA 119.652 -0.819 . . . . 0.0 113.033 -178.198 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.489 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 75.1 tttt . . . . . 0 CA--C 1.544 0.717 0 CA-C-O 124.085 1.897 . . . . 0.0 112.226 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.489 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -109.29 -100.33 2.63 Favored Glycine 0 CA--C 1.484 -1.881 0 C-N-CA 130.168 3.747 . . . . 0.0 109.753 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' E' ' 28' ' ' LYS . . . -58.11 172.85 0.39 Allowed 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 -178.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.39 134.42 34.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.147 -1.421 . . . . 0.0 111.479 -172.131 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.495 ' CG2' ' O ' ' F' ' 32' ' ' ILE . 5.2 tt -110.12 117.24 54.29 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 114.001 -1.454 . . . . 0.0 108.452 -179.266 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.77 102.87 2.42 Favored Glycine 0 C--N 1.322 -0.249 0 N-CA-C 108.027 -2.029 . . . . 0.0 108.027 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.2 pp -107.44 115.73 30.67 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 117.039 0.42 . . . . 0.0 110.518 -179.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 18.3 ttp -119.46 110.5 16.99 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 m -132.87 79.92 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.16 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -64.65 103.5 0.77 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.0 -146.15 19.15 Favored Glycine 0 N--CA 1.465 0.61 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -113.86 133.58 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 32.9 m . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.761 -179.67 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -121.92 147.84 45.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.745 0.307 . . . . 0.0 110.707 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -68.51 156.96 36.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.069 179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . 0.477 ' O ' ' ND1' ' H' ' 13' ' ' HIS . 78.0 t -115.63 131.6 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.061 0.458 . . . . 0.0 110.315 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -89.15 179.45 6.13 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.972 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -74.69 164.45 26.57 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 91.7 mt-30 -155.63 -179.84 8.5 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.442 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.428 ' HZ3' ' CG2' ' G' ' 18' ' ' VAL . 65.2 tttm -161.32 119.26 2.35 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.682 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 35.7 tp -118.83 126.12 51.11 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 121.299 0.571 . . . . 0.0 110.478 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . 0.428 ' CG2' ' HZ3' ' G' ' 16' ' ' LYS . 47.9 t -125.72 125.9 69.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.901 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.452 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 0.1 OUTLIER -114.76 119.47 36.77 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.937 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -142.92 147.96 36.14 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 119.674 -0.81 . . . . 0.0 112.369 -178.041 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.32 132.22 35.37 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.285 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -135.48 167.33 21.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.53 ' OD2' ' N ' ' H' ' 24' ' ' VAL . 34.8 m-20 -85.94 -151.19 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.168 -178.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' G' ' 23' ' ' ASP . 14.0 t 27.09 103.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.77 -94.69 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.827 177.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -64.03 -178.81 0.36 Allowed 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -80.95 173.49 12.56 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.12 0.486 . . . . 0.0 111.302 177.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -44.91 110.79 0.26 Allowed 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.947 176.365 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.26 94.73 0.52 Allowed Glycine 0 N--CA 1.472 1.084 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.324 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -118.34 151.61 37.39 Favored 'General case' 0 CA--C 1.504 -0.808 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.196 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.19 108.81 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 CA-C-N 113.182 -1.826 . . . . 0.0 109.594 -171.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.76 123.46 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.89 0.376 . . . . 0.0 111.237 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . 0.674 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -130.33 111.23 1.11 Allowed Glycine 0 N--CA 1.465 0.573 0 N-CA-C 108.794 -1.723 . . . . 0.0 108.794 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.89 130.41 52.82 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.916 0.388 . . . . 0.0 111.656 -178.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' A' ' 33' ' ' GLY . 28.1 ttt -130.46 128.52 41.43 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' G' ' 37' ' ' GLY . 3.7 t -111.42 65.9 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -178.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -55.25 -105.55 0.01 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 178.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -105.06 174.59 21.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 30.0 m -135.23 158.13 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.11 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -86.65 131.01 34.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.918 0.389 . . . . 0.0 110.103 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -136.06 142.81 44.41 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.908 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -126.06 134.31 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.456 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' O ' ' G' ' 12' ' ' VAL . 75.4 m80 -87.08 175.35 8.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.124 0.488 . . . . 0.0 110.792 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.547 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 25.4 m-70 -77.9 173.28 12.32 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.45 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -142.75 175.44 9.82 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.128 179.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -151.58 125.87 9.36 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.151 -179.184 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 58.1 mt -121.17 120.51 35.43 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -127.8 130.52 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -178.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.44 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 5.9 m-85 -117.73 120.06 36.81 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.615 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 29.0 t80 -130.78 122.6 27.46 Favored 'General case' 0 N--CA 1.476 0.834 0 O-C-N 122.231 -0.293 . . . . 0.0 110.626 -179.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.77 130.0 48.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -137.94 106.74 5.93 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.426 ' OD2' ' NZ ' ' J' ' 28' ' ' LYS . 35.7 t70 -114.51 114.11 25.34 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.53 ' N ' ' OD2' ' G' ' 23' ' ' ASP . 1.2 p -128.79 122.26 56.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.051 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 30.49 82.79 0.01 OUTLIER Glycine 0 CA--C 1.537 1.442 0 CA-C-O 119.473 -0.626 . . . . 0.0 114.593 175.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.677 ' HG ' ' HZ3' ' I' ' 28' ' ' LYS . 1.0 OUTLIER -140.14 170.62 15.49 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 118.71 1.255 . . . . 0.0 111.108 179.107 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' H' ' 26' ' ' SER . 5.5 m-20 -31.04 173.14 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 113.671 -1.604 . . . . 0.0 114.812 -177.206 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -87.84 111.41 21.38 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.267 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . 69.61 93.6 0.06 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 118.124 -1.989 . . . . 0.0 115.526 172.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.42 155.51 22.09 Favored 'General case' 0 C--O 1.248 0.985 0 CA-C-N 120.627 2.214 . . . . 0.0 106.698 175.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -148.31 119.27 1.37 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 118.921 -1.112 . . . . 0.0 111.684 -173.055 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.9 mt -129.87 128.32 64.98 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.034 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.599 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -132.23 127.54 4.94 Favored Glycine 0 N--CA 1.465 0.63 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.4 tt -135.08 130.96 36.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.565 0.698 . . . . 0.0 110.736 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 19.3 ttt -130.37 128.99 42.53 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.652 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.52 79.54 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.77 105.12 1.15 Allowed Glycine 0 C--N 1.339 0.707 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 178.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.74 -171.27 50.34 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -132.37 161.78 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-O 120.993 0.425 . . . . 0.0 110.909 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 34.3 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.658 179.766 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.464 0.25 0 N-CA-C 110.075 -0.342 . . . . 0.0 110.075 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.513 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 16.5 p-80 -164.27 161.08 21.72 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.554 -0.459 . . . . 0.0 111.229 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.547 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 0.8 OUTLIER -122.92 166.76 14.52 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.951 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -142.25 175.64 9.6 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.65 179.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -166.49 113.7 0.86 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.771 -179.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mp -112.56 124.24 52.09 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -127.91 128.75 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-O 121.17 0.51 . . . . 0.0 112.095 -179.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.437 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 32.1 m-85 -118.75 118.98 33.07 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.573 178.251 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.615 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 58.8 t80 -126.57 116.95 21.85 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.48 129.63 52.21 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.18 0.514 . . . . 0.0 111.771 -179.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -143.83 144.29 31.71 Favored 'General case' 0 C--N 1.34 0.193 0 CA-C-N 115.366 -0.833 . . . . 0.0 109.036 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.605 ' O ' ' O ' ' I' ' 24' ' ' VAL . 0.9 OUTLIER -175.04 129.55 0.3 Allowed 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.062 -0.655 . . . . 0.0 110.773 179.724 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.605 ' O ' ' O ' ' I' ' 23' ' ' ASP . 61.6 t -29.34 -113.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 O-C-N 124.425 1.078 . . . . 0.0 112.66 178.156 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.541 ' N ' ' CG1' ' I' ' 24' ' ' VAL . . . -170.77 90.55 0.09 OUTLIER Glycine 0 CA--C 1.53 0.981 0 CA-C-N 115.272 -0.877 . . . . 0.0 112.117 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.525 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t 161.99 160.45 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.921 0.867 . . . . 0.0 111.128 176.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.525 ' O ' ' O ' ' I' ' 26' ' ' SER . 29.2 m120 -30.16 179.07 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 113.084 -1.871 . . . . 0.0 116.027 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.677 ' HZ3' ' HG ' ' H' ' 26' ' ' SER . 86.4 tttt 127.81 103.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 112.2 -2.273 . . . . 0.0 111.203 174.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.487 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -59.86 99.54 0.16 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.248 -1.307 . . . . 0.0 110.735 174.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.439 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -118.08 141.4 48.51 Favored 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 102.529 -3.137 . . . . 0.0 102.529 174.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.439 ' CG1' ' C ' ' I' ' 30' ' ' ALA . 2.1 mt -146.06 114.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 C-N-CA 118.181 -1.408 . . . . 0.0 112.515 -169.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.4 HG22 HD12 ' I' ' 32' ' ' ILE . 1.3 mt -114.62 119.74 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 177.355 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.16 106.56 1.44 Allowed Glycine 0 N--CA 1.461 0.311 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.452 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 54.4 tp -116.23 120.93 40.53 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 5.6 tpp -117.1 102.02 8.96 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 174.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.473 ' O ' ' CG1' ' I' ' 36' ' ' VAL . 4.2 p -131.81 74.89 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.114 -177.298 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.28 -96.92 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.995 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 163.31 -167.76 37.72 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.65 150.58 3.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.768 0.318 . . . . 0.0 110.387 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.854 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -83.64 141.89 31.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.955 0.407 . . . . 0.0 110.065 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -66.35 135.63 54.64 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.477 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.581 ' CG1' ' H ' ' J' ' 13' ' ' HIS . 27.4 t -145.77 178.8 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.119 179.434 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.581 ' H ' ' CG1' ' J' ' 12' ' ' VAL . 92.2 m-70 -50.82 125.28 12.96 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.069 0.461 . . . . 0.0 112.146 -177.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.499 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 18.0 t-80 -145.38 163.43 34.6 Favored 'General case' 0 C--N 1.341 0.239 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.499 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 89.6 mt-30 -148.54 177.6 9.34 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.088 0.47 . . . . 0.0 111.364 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -170.26 116.28 0.51 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.819 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -114.23 125.27 53.72 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.495 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -126.78 121.05 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 120.78 0.324 . . . . 0.0 111.241 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -118.43 116.22 26.26 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.416 ' CZ ' ' CD1' ' K' ' 20' ' ' PHE . 1.1 t80 -131.38 129.66 41.62 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 120.922 0.391 . . . . 0.0 110.553 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.41 134.65 41.88 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.458 0.647 . . . . 0.0 112.421 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 mt-10 -144.3 102.87 3.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.029 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -152.22 177.3 10.68 Favored 'General case' 0 CA--C 1.515 -0.394 0 O-C-N 122.096 -0.378 . . . . 0.0 110.392 -178.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -91.96 102.99 14.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 122.176 0.989 . . . . 0.0 108.379 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' K' ' 26' ' ' SER . . . -35.9 95.59 0.01 OUTLIER Glycine 0 CA--C 1.526 0.763 0 CA-C-N 113.269 -1.787 . . . . 0.0 115.653 -179.087 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.4 t 170.24 176.18 0.05 Allowed 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 121.627 0.727 . . . . 0.0 110.678 175.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' J' ' 26' ' ' SER . 52.2 t30 -28.96 179.5 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 115.886 1.81 . . . . 0.0 115.886 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.536 ' H ' ' CG ' ' J' ' 27' ' ' ASN . 61.8 tttp 128.26 105.11 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 112.715 -2.039 . . . . 0.0 112.719 175.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.02 95.07 0.05 OUTLIER Glycine 0 N--CA 1.465 0.59 0 CA-C-N 113.934 -1.484 . . . . 0.0 113.031 174.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.51 142.33 46.99 Favored 'General case' 0 CA--C 1.496 -1.117 0 CA-C-N 119.884 1.842 . . . . 0.0 106.201 174.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.11 110.93 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 CA-C-N 114.454 -1.248 . . . . 0.0 111.837 -171.41 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.529 ' O ' ' SD ' ' E' ' 35' ' ' MET . 0.2 OUTLIER -114.68 118.9 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 177.783 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -114.15 106.68 1.75 Allowed Glycine 0 CA--C 1.496 -1.115 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 177.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.44 ' CD2' ' CZ ' ' H' ' 19' ' ' PHE . 37.1 tp -115.37 118.87 34.44 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 113.292 0.849 . . . . 0.0 113.292 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -117.29 107.63 14.63 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' J' ' 37' ' ' GLY . 0.0 OUTLIER -119.37 80.29 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.3 -94.42 0.01 OUTLIER Glycine 0 C--N 1.352 1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.714 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.62 -178.14 18.74 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 111.031 -0.827 . . . . 0.0 111.031 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -114.63 134.93 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.444 179.95 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -103.96 135.44 45.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.655 0.264 . . . . 0.0 110.377 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.471 ' N ' ' OE1' ' L' ' 11' ' ' GLU . 94.9 mt-10 -137.48 156.52 48.06 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.607 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.6 m -134.48 163.2 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.657 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 t60 -159.37 128.37 5.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.314 -179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -152.67 167.52 28.65 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.688 0.756 . . . . 0.0 110.002 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -156.51 175.92 13.39 Favored 'General case' 0 C--N 1.307 -1.239 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.762 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -148.73 120.37 8.03 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 23.1 mt -112.51 116.05 29.63 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.6 p -133.31 134.47 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 CA-C-O 121.42 0.629 . . . . 0.0 112.308 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -125.76 126.94 45.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.227 179.087 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.416 ' CD1' ' CZ ' ' J' ' 20' ' ' PHE . 8.2 t80 -136.51 128.96 30.26 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.171 0.51 . . . . 0.0 111.818 -179.315 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.78 129.53 47.19 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.772 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.417 ' HG2' ' N ' ' K' ' 23' ' ' ASP . 75.7 tt0 -88.44 170.1 11.2 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.453 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.417 ' N ' ' HG2' ' K' ' 22' ' ' GLU . 48.0 t0 -39.33 115.46 0.5 Allowed 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 121.007 0.432 . . . . 0.0 110.821 -178.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' K' ' 25' ' ' GLY . 10.4 p -129.84 117.16 40.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . -27.92 -90.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.381 0 CA-C-O 121.524 0.513 . . . . 0.0 111.825 178.161 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.637 ' O ' ' O ' ' K' ' 27' ' ' ASN . 26.7 p -140.97 170.73 15.18 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.121 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.637 ' O ' ' O ' ' K' ' 26' ' ' SER . 56.8 p30 -28.29 169.75 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -149.4 111.45 4.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.685 178.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.71 91.6 0.02 OUTLIER Glycine 0 N--CA 1.464 0.521 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.59 151.69 43.37 Favored 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 106.314 -1.735 . . . . 0.0 106.314 176.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -135.83 115.44 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.579 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.53 ' O ' ' SD ' ' F' ' 35' ' ' MET . 0.8 OUTLIER -115.59 116.91 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 178.362 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . 0.717 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -109.56 106.0 2.13 Favored Glycine 0 N--CA 1.464 0.547 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 178.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.437 ' CD1' ' CZ ' ' I' ' 19' ' ' PHE . 21.5 mt -110.44 111.98 23.6 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 117.047 0.423 . . . . 0.0 111.659 -177.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.46 ' CE ' ' O ' ' E' ' 32' ' ' ILE . 11.4 tpt -107.59 103.1 12.32 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 176.624 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -129.58 73.83 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.146 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.445 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.38 -101.5 0.01 OUTLIER Glycine 0 C--N 1.359 1.828 0 CA-C-N 116.388 -0.369 . . . . 0.0 112.844 -179.215 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.92 -155.69 26.57 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 30.0 m -126.54 160.54 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.762 0.315 . . . . 0.0 110.548 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.501 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -148.22 160.68 42.69 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.655 0.264 . . . . 0.0 110.334 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . 0.471 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 78.5 mm-40 -75.78 157.0 34.02 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.733 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 96.1 t -92.86 131.06 40.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.123 0 CA-C-O 121.061 0.458 . . . . 0.0 110.216 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.5 ' NE2' ' OXT' ' L' ' 40' ' ' VAL . 45.1 t-80 -144.25 134.21 23.98 Favored 'General case' 0 N--CA 1.461 0.113 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.954 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 46.8 t-80 -154.99 170.83 20.84 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.478 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 96.2 mt-30 -148.3 178.56 8.47 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.646 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -164.3 122.48 1.79 Allowed 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.11 0.481 . . . . 0.0 111.204 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 59.1 tp -120.75 121.57 38.5 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.977 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.91 131.65 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.156 0.503 . . . . 0.0 110.501 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.534 ' CD1' ' O ' ' L' ' 19' ' ' PHE . 41.1 p90 -135.14 125.63 26.72 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.217 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -140.08 142.57 36.1 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 121.776 0.798 . . . . 0.0 110.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.39 143.63 24.06 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.343 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.405 ' O ' ' O ' ' L' ' 23' ' ' ASP . 78.5 tt0 -76.12 153.1 36.52 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.585 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.405 ' O ' ' O ' ' L' ' 22' ' ' GLU . 59.4 m-20 -58.62 -134.4 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -177.09 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' L' ' 26' ' ' SER . 3.8 t 84.69 110.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.6 -92.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.807 ' O ' ' O ' ' L' ' 27' ' ' ASN . 34.1 p -161.18 163.98 30.82 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.698 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.807 ' O ' ' O ' ' L' ' 26' ' ' SER . 83.2 m-20 -9.98 -178.62 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 177.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' L' ' 29' ' ' GLY . 82.6 tttt -128.08 110.41 12.46 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.052 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' L' ' 28' ' ' LYS . . . -54.15 -95.26 0.01 OUTLIER Glycine 0 C--N 1.334 0.451 0 C-N-CA 117.113 -2.47 . . . . 0.0 111.305 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.405 ' O ' ' C ' ' L' ' 29' ' ' GLY . . . 71.65 163.32 0.26 Allowed 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 103.663 -2.717 . . . . 0.0 103.663 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.564 ' N ' ' CD1' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -138.2 100.6 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 122.957 2.617 . . . . 0.0 108.838 175.181 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.501 ' O ' ' CG2' ' L' ' 32' ' ' ILE . 4.6 tt -102.01 112.67 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 CA-C-N 113.356 -1.747 . . . . 0.0 106.628 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -99.97 102.39 2.5 Favored Glycine 0 CA--C 1.5 -0.889 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 43.6 tp -107.23 115.93 31.04 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.912 -0.315 . . . . 0.0 111.233 -178.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 17.6 tpp -112.64 104.22 12.28 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 176.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 10.5 m -135.84 79.59 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -66.1 103.68 0.9 Allowed Glycine 0 C--N 1.344 0.986 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 -162.04 38.0 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -125.58 153.12 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 121.044 0.449 . . . . 0.0 110.839 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . 0.5 ' OXT' ' NE2' ' L' ' 13' ' ' HIS . 31.3 m . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.73 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.501 ' O ' ' CG ' ' A' ' 13' ' ' HIS . 48.9 t . . . . . 0 C--O 1.231 0.13 0 N-CA-C 109.182 -0.674 . . . . 0.0 109.182 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 12' ' ' VAL . 97.3 m-70 -155.57 110.4 2.95 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.218 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 6.1 p-80 -151.12 166.33 31.13 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 97.9 mm-40 -152.51 179.22 8.78 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.394 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -149.48 110.9 4.45 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.918 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 77.3 mt -138.12 127.8 25.15 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 121.575 0.702 . . . . 0.0 112.076 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.4 m -129.16 127.78 66.08 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.233 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.515 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 11.2 t80 -121.18 121.8 38.6 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.502 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.2 p90 -137.1 128.19 27.74 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.407 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.66 126.67 52.44 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.979 0.418 . . . . 0.0 111.122 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -153.21 108.81 3.27 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -57.21 121.55 10.35 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.489 -177.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 26' ' ' SER . 26.9 m -88.63 124.03 41.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.84 84.71 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 CA-C-N 116.08 -0.509 . . . . 0.0 112.388 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.524 ' N ' ' O ' ' A' ' 24' ' ' VAL . 11.8 p -91.85 179.16 5.69 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 m120 -60.31 178.97 0.17 Allowed 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 120.166 -0.613 . . . . 0.0 111.258 -179.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.4 110.89 1.2 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.718 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.804 ' H ' HD22 ' B' ' 27' ' ' ASN . . . 71.93 94.09 0.08 OUTLIER Glycine 0 N--CA 1.465 0.587 0 CA-C-O 118.511 -1.161 . . . . 0.0 111.783 177.332 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 153.78 25.87 Favored 'General case' 0 C--O 1.241 0.646 0 C-N-CA 117.607 -1.637 . . . . 0.0 107.602 177.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.406 HD13 HG23 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -148.2 109.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 CA-C-N 113.783 -1.553 . . . . 0.0 110.023 -171.945 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -131.07 126.96 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.245 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.47 119.57 2.12 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 mt -136.15 150.31 49.01 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-O 121.398 0.618 . . . . 0.0 111.762 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 18.6 ttt -149.53 139.8 22.25 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.992 -0.443 . . . . 0.0 111.865 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 5.6 p -152.28 79.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.385 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.69 104.78 1.67 Allowed Glycine 0 CA--C 1.527 0.814 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.138 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.38 176.17 23.84 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.88 -0.488 . . . . 0.0 111.88 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.7 t . . . . . 0 N--CA 1.465 0.316 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.931 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 N--CA 1.464 0.259 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -135.69 137.55 41.88 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 111.262 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 72.7 t60 -155.44 169.88 23.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.549 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 47.1 tt0 -163.4 169.74 18.51 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.251 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . 0.403 ' N ' ' HG2' ' B' ' 15' ' ' GLN . 98.0 mttt -151.3 108.69 3.61 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 178.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.5 mt -126.08 120.77 31.08 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.119 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -123.26 130.35 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.567 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 2.0 t80 -129.39 122.88 30.34 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.305 -178.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -131.88 133.29 44.44 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 120.892 0.377 . . . . 0.0 110.453 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.48 126.19 32.41 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.882 0.372 . . . . 0.0 110.779 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -155.03 158.9 39.83 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -147.43 112.68 5.54 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 65.4 t -123.73 124.94 70.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.498 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.55 82.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 114.63 0.612 . . . . 0.0 114.63 174.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.551 ' O ' ' O ' ' B' ' 27' ' ' ASN . 32.2 p -140.06 170.71 15.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 118.338 1.069 . . . . 0.0 109.615 179.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.804 HD22 ' H ' ' A' ' 29' ' ' GLY . 48.1 t30 -30.88 173.25 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -175.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.5 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 88.3 tttt -88.95 111.16 21.79 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.167 -0.924 . . . . 0.0 112.079 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.404 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 60.31 92.96 0.01 OUTLIER Glycine 0 N--CA 1.465 0.583 0 C-N-CA 118.66 -1.733 . . . . 0.0 112.631 174.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.17 155.06 36.58 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 119.486 1.643 . . . . 0.0 110.172 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.85 120.17 9.04 Favored 'Isoleucine or valine' 0 C--O 1.244 0.774 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.622 -176.731 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 14.9 mm -131.87 133.11 61.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.189 -177.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.584 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -143.43 146.23 16.74 Favored Glycine 0 N--CA 1.468 0.802 0 C-N-CA 120.349 -0.929 . . . . 0.0 111.726 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.416 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 3.3 tt -156.45 135.62 12.05 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 119.781 -0.767 . . . . 0.0 112.235 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.405 ' CE ' ' SD ' ' C' ' 35' ' ' MET . 11.4 ttm -119.54 126.56 51.55 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.932 179.41 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.515 ' O ' ' C ' ' B' ' 37' ' ' GLY . 11.6 t -129.08 83.55 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.593 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' B' ' 36' ' ' VAL . . . -12.42 -95.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.068 0 O-C-N 123.642 0.589 . . . . 0.0 113.041 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.06 -179.14 40.38 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -138.5 162.41 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 120.826 0.346 . . . . 0.0 110.818 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 117.908 -1.044 . . . . 0.0 110.319 179.849 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -108.04 143.12 37.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.932 0.396 . . . . 0.0 110.587 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -64.77 153.55 39.55 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -131.46 157.3 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.144 0.497 . . . . 0.0 111.5 -179.028 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -138.78 127.73 23.79 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.12 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.579 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 38.6 t60 -148.2 168.08 23.43 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 121.375 0.607 . . . . 0.0 110.322 -178.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.579 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 47.1 tt0 -160.42 165.65 30.69 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.997 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -153.95 115.62 4.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.111 0.482 . . . . 0.0 110.71 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 49.9 tp -129.23 122.31 29.42 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -121.92 128.71 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.015 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -125.15 121.32 33.87 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.414 ' CD1' ' C ' ' C' ' 20' ' ' PHE . 25.3 t80 -131.96 126.97 35.34 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.5 136.34 39.32 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.292 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -140.5 146.32 38.01 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.094 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -129.09 111.95 13.49 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.676 179.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.659 ' CG2' ' H ' ' C' ' 25' ' ' GLY . 7.0 p -137.68 -122.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.169 -178.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.659 ' H ' ' CG2' ' C' ' 24' ' ' VAL . . . 28.72 -84.31 0.0 OUTLIER Glycine 0 N--CA 1.47 0.907 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.822 -177.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.5 t 170.54 176.88 0.06 Allowed 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 117.484 0.642 . . . . 0.0 110.332 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' C' ' 26' ' ' SER . 59.8 t30 -28.53 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.536 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 86.2 tttt 128.23 104.75 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 113.847 -1.524 . . . . 0.0 112.115 176.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.29 96.68 0.08 OUTLIER Glycine 0 CA--C 1.501 -0.827 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 173.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -117.19 150.67 38.35 Favored 'General case' 0 CA--C 1.481 -1.686 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -145.62 116.23 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 C-N-CA 118.938 -1.105 . . . . 0.0 109.634 -172.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.404 HG23 HD13 ' C' ' 32' ' ' ILE . 0.2 OUTLIER -109.78 117.12 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.816 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.79 98.26 0.73 Allowed Glycine 0 N--CA 1.469 0.891 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.431 ' O ' ' HA ' ' D' ' 34' ' ' LEU . 4.6 mp -132.49 148.37 52.39 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 122.853 1.311 . . . . 0.0 113.192 -178.613 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.405 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 15.8 ttm -135.15 120.31 18.84 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.484 -1.234 . . . . 0.0 108.352 177.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.484 ' O ' ' C ' ' C' ' 37' ' ' GLY . 0.2 OUTLIER -129.95 75.13 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.206 -179.527 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.484 ' C ' ' O ' ' C' ' 36' ' ' VAL . . . -16.88 -101.43 0.0 OUTLIER Glycine 0 C--N 1.367 2.299 0 O-C-N 123.418 0.448 . . . . 0.0 112.366 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.46 -158.69 31.71 Favored Glycine 0 CA--C 1.522 0.479 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 54.8 t -120.01 135.46 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.555 -179.96 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.467 0.406 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' E' ' 13' ' ' HIS . 73.9 m80 -106.53 136.52 46.16 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 120.883 0.373 . . . . 0.0 111.589 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.568 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 44.5 t-80 -149.77 167.54 26.23 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.191 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.568 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 51.6 tt0 -169.73 165.74 9.9 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.409 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . 0.442 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.0 mttt -146.39 112.59 5.82 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.677 177.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -124.54 125.43 44.18 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.779 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 96.1 t -123.95 124.82 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.306 0.574 . . . . 0.0 111.378 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -109.83 107.72 17.79 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 8.8 t80 -129.07 122.81 30.75 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 119.643 1.111 . . . . 0.0 111.263 -178.384 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.62 132.51 33.14 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -130.02 106.27 8.52 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.004 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.79 112.0 24.04 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' D' ' 26' ' ' SER . 4.7 t -131.83 -122.16 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.634 . . . . 0.0 110.251 -178.142 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 30.16 -84.33 0.0 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.757 -177.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.684 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.8 p 170.56 178.85 0.05 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.684 ' O ' ' O ' ' D' ' 26' ' ' SER . 70.2 m-80 -28.2 171.13 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 O-C-N 124.731 1.269 . . . . 0.0 112.57 178.018 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 79.0 tttt 141.42 103.31 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 124.145 0.978 . . . . 0.0 108.468 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.514 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -43.69 -98.25 0.01 OUTLIER Glycine 0 C--N 1.344 0.994 0 C-N-CA 118.816 -1.659 . . . . 0.0 111.313 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.431 ' CB ' ' O ' ' D' ' 29' ' ' GLY . . . 83.56 142.21 0.06 Allowed 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 101.928 -3.36 . . . . 0.0 101.928 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -146.98 116.24 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 117.904 -1.518 . . . . 0.0 108.974 -177.071 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -106.95 112.41 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -179.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.59 101.24 0.96 Allowed Glycine 0 C--O 1.236 0.249 0 N-CA-C 108.139 -1.984 . . . . 0.0 108.139 179.255 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.515 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 8.8 tt -143.51 144.02 31.8 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 122.411 1.1 . . . . 0.0 113.329 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 14.5 ttm -125.19 125.47 43.7 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-N 114.669 -1.15 . . . . 0.0 109.017 177.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 p -137.5 71.89 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.042 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.64 111.74 3.48 Favored Glycine 0 C--N 1.366 2.212 0 N-CA-C 111.837 -0.505 . . . . 0.0 111.837 -179.04 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' E' ' 38' ' ' GLY . . . -101.48 146.22 17.15 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.4 ' O ' ' C ' ' D' ' 40' ' ' VAL . 21.3 t -137.51 165.51 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.564 0.221 . . . . 0.0 110.674 -179.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.4 ' C ' ' O ' ' D' ' 39' ' ' VAL . 98.4 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.974 -1.012 . . . . 0.0 111.585 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -83.98 140.04 32.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.633 0.254 . . . . 0.0 110.436 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -142.38 153.74 44.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.87 0.366 . . . . 0.0 110.744 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -121.93 134.64 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' D' ' 13' ' ' HIS . 0.2 OUTLIER -76.74 156.98 32.03 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.083 0.468 . . . . 0.0 110.694 -179.214 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.494 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 3.6 m170 -88.42 174.71 7.97 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.521 ' OE1' ' NE2' ' F' ' 15' ' ' GLN . 89.1 mt-30 -124.83 173.64 8.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -136.81 115.16 11.77 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.254 0.55 . . . . 0.0 111.814 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 35.2 mt -119.55 119.6 34.27 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -127.25 126.29 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-O 120.76 0.314 . . . . 0.0 111.198 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -121.14 122.37 39.86 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 79.8 t80 -134.51 121.61 21.24 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.813 0.34 . . . . 0.0 111.115 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.05 127.78 23.36 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 121.07 0.462 . . . . 0.0 111.032 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -135.32 139.68 44.5 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.444 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' C ' ' E' ' 24' ' ' VAL . 18.9 p-10 159.47 113.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 O-C-N 124.204 0.94 . . . . 0.0 108.997 -178.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.476 ' C ' ' O ' ' E' ' 23' ' ' ASP . 70.7 t -37.46 132.4 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -178.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.49 85.64 1.48 Allowed Glycine 0 CA--C 1.523 0.531 0 N-CA-C 116.756 1.462 . . . . 0.0 116.756 -173.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.532 ' O ' ' O ' ' E' ' 27' ' ' ASN . 92.8 p -145.75 151.97 38.82 Favored 'General case' 0 CA--C 1.508 -0.665 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 172.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.532 ' O ' ' O ' ' E' ' 26' ' ' SER . 9.1 t-20 -21.49 155.86 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.506 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 86.1 tttt -164.45 110.97 1.03 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 170.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.55 92.57 0.23 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 120.106 -1.045 . . . . 0.0 113.734 179.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.426 ' HA ' ' O ' ' D' ' 29' ' ' GLY . . . -168.39 150.09 5.07 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.42 125.28 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 118.05 -1.46 . . . . 0.0 113.434 -177.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.432 ' C ' ' SD ' ' K' ' 35' ' ' MET . 2.0 mt -107.65 116.44 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . 0.477 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -116.18 100.01 0.9 Allowed Glycine 0 C--O 1.234 0.146 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.567 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 7.7 tt -143.91 137.14 27.64 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 122.26 1.029 . . . . 0.0 112.951 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.51 ' SD ' ' CG2' ' K' ' 31' ' ' ILE . 23.3 ttm -117.6 128.37 54.87 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.495 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -124.81 74.28 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.387 179.834 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.464 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -20.98 -101.38 0.0 OUTLIER Glycine 0 C--N 1.355 1.637 0 O-C-N 123.208 0.317 . . . . 0.0 112.817 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . 140.9 -174.95 22.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 56.3 t -121.24 135.63 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.4 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.433 -179.934 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.893 0.378 . . . . 0.0 110.753 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -150.35 102.38 3.06 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -151.19 174.42 13.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.521 ' NE2' ' OE1' ' E' ' 15' ' ' GLN . 88.3 mt-30 -141.36 175.0 10.01 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.979 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -130.13 114.84 16.22 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.943 0.402 . . . . 0.0 110.135 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -120.03 116.92 26.69 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.259 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 49.7 t -129.95 131.39 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.459 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 55.2 p90 -142.63 133.09 24.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.266 0.555 . . . . 0.0 111.659 -179.391 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -138.1 120.39 15.83 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.34 144.83 31.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.167 0.508 . . . . 0.0 111.376 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -101.1 106.22 17.47 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.988 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 61.8 t0 . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 121.388 0.613 . . . . 0.0 112.029 -179.76 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.436 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 88.2 tttt . . . . . 0 CA--C 1.538 0.495 0 CA-C-O 121.619 0.723 . . . . 0.0 112.775 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' F' ' 30' ' ' ALA . . . -139.9 -100.57 0.46 Allowed Glycine 0 CA--C 1.482 -2.018 0 CA-C-O 123.622 1.679 . . . . 0.0 111.48 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.442 ' O ' ' C ' ' F' ' 29' ' ' GLY . . . -58.33 175.73 0.22 Allowed 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 110.164 -3.018 . . . . 0.0 103.358 173.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.5 mt -131.43 116.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 116.538 -2.065 . . . . 0.0 109.774 -177.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.477 ' C ' ' SD ' ' L' ' 35' ' ' MET . 16.5 tt -103.33 116.96 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 CA-C-N 113.084 -1.871 . . . . 0.0 110.074 -177.539 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -105.71 86.34 0.48 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 106.7 -2.56 . . . . 0.0 106.7 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 35.2 tp -116.72 119.02 34.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 35.2 mmm -123.04 135.44 54.44 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.057 -0.657 . . . . 0.0 112.28 -177.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 m -124.99 81.14 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.515 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.58 102.07 0.35 Allowed Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -153.52 178.09 30.7 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -124.94 137.16 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.247 0.546 . . . . 0.0 110.192 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.819 -1.086 . . . . 0.0 110.398 -179.442 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -106.39 131.79 53.18 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.921 0.391 . . . . 0.0 110.617 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -89.22 158.15 17.98 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.431 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -122.43 133.85 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.134 0.493 . . . . 0.0 110.705 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -134.44 -178.49 5.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.623 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -77.56 167.62 21.32 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -157.49 169.59 24.36 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.995 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.27 130.08 10.1 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.676 0.274 . . . . 0.0 110.732 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 90.2 mt -125.05 115.59 20.77 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.659 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 14.3 m -133.87 129.14 54.42 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 121.45 0.643 . . . . 0.0 112.134 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.427 ' CE1' ' CD1' ' I' ' 34' ' ' LEU . 8.8 m-85 -111.79 116.77 31.25 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.445 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.494 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 55.1 p90 -133.96 130.72 38.08 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.775 -179.236 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . 0.429 ' O ' ' OD1' ' H' ' 23' ' ' ASP . . . -121.35 125.43 46.97 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-O 121.122 0.487 . . . . 0.0 110.985 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . 0.499 ' CA ' ' OD2' ' H' ' 23' ' ' ASP . 96.0 mt-10 -146.64 150.31 35.19 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 106.43 -1.693 . . . . 0.0 106.43 178.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' NZ ' ' I' ' 28' ' ' LYS . 78.2 m-20 -78.11 111.61 14.21 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 112.754 -177.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.577 ' O ' ' N ' ' G' ' 26' ' ' SER . 52.9 t -114.06 130.85 67.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 176.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.48 81.94 0.0 OUTLIER Glycine 0 CA--C 1.535 1.308 0 CA-C-O 119.561 -0.577 . . . . 0.0 113.532 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.577 ' N ' ' O ' ' G' ' 24' ' ' VAL . 4.7 t -98.62 172.36 7.54 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 176.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -58.73 162.4 4.02 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 118.567 -1.253 . . . . 0.0 109.726 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -58.68 111.3 1.21 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 118.789 -0.624 . . . . 0.0 111.562 175.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.24 93.29 0.08 OUTLIER Glycine 0 N--CA 1.471 0.976 0 C-N-CA 118.311 -1.9 . . . . 0.0 111.947 175.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.75 159.2 17.85 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 120.319 2.06 . . . . 0.0 111.556 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.01 123.2 1.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.154 -178.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' A' ' 35' ' ' MET . 96.8 mt -133.5 128.71 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.952 -0.468 . . . . 0.0 111.308 -179.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . 0.445 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -132.85 117.56 1.99 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.434 -1.067 . . . . 0.0 110.434 179.295 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 84.1 mt -134.86 142.54 46.64 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.95 0.405 . . . . 0.0 110.576 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -141.09 137.55 32.91 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.212 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.3 t -119.03 82.72 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.68 97.99 2.34 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.95 165.03 38.61 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.23 159.08 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.738 0.304 . . . . 0.0 110.226 179.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.542 -179.924 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -117.21 139.5 50.71 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.642 0.258 . . . . 0.0 110.596 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . 0.48 ' N ' ' CD ' ' H' ' 11' ' ' GLU . 0.9 OUTLIER -128.02 132.24 49.13 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -140.02 157.21 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -139.5 105.61 5.23 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.929 0.395 . . . . 0.0 111.34 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.416 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 17.2 m-70 -118.86 166.46 12.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -151.14 176.68 10.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.996 178.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -170.97 113.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.164 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -113.41 119.81 38.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.98 127.16 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 121.061 0.458 . . . . 0.0 111.683 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.513 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 18.1 m-85 -117.24 118.28 31.85 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.056 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -126.44 119.59 27.6 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.82 119.58 33.11 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.145 0.498 . . . . 0.0 111.626 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -163.48 89.27 0.6 Allowed 'General case' 0 C--N 1.341 0.234 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.723 ' H ' ' HZ1' ' J' ' 28' ' ' LYS . 5.0 m-20 -128.2 119.28 24.91 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -177.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.637 ' O ' ' O ' ' H' ' 23' ' ' ASP . 3.1 t -38.04 -124.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 124.105 0.878 . . . . 0.0 112.021 176.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -130.38 83.93 0.31 Allowed Glycine 0 CA--C 1.533 1.187 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 12.5 p -67.37 -173.06 0.26 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -78.92 169.69 17.82 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 118.332 -1.347 . . . . 0.0 110.506 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -47.09 110.21 0.28 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.95 95.61 0.28 Allowed Glycine 0 N--CA 1.468 0.827 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.582 171.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.455 ' C ' ' CG1' ' H' ' 31' ' ' ILE . . . -119.29 147.45 44.27 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 101.117 -3.661 . . . . 0.0 101.117 171.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.455 ' CG1' ' C ' ' H' ' 30' ' ' ALA . 1.2 mt -149.01 126.12 2.51 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 C-N-CA 117.918 -1.513 . . . . 0.0 111.752 -170.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 44.2 mm -121.3 123.36 69.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.73 123.58 5.11 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.43 ' H ' HD23 ' I' ' 34' ' ' LEU . 29.0 tp -135.12 128.75 32.74 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 122.286 -0.538 . . . . 0.0 110.453 -179.252 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.584 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 2.6 ttp -123.34 116.94 24.13 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.031 -178.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' H' ' 37' ' ' GLY . 14.2 t -133.42 83.19 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -22.75 -94.05 0.01 OUTLIER Glycine 0 C--N 1.349 1.273 0 N-CA-C 112.159 -0.376 . . . . 0.0 112.159 177.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.65 -177.23 42.12 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 50.4 t -127.58 136.12 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-O 120.962 0.411 . . . . 0.0 110.245 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 34.8 t . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.451 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.401 ' C ' ' CD2' ' I' ' 13' ' ' HIS . 3.8 m . . . . . 0 N--CA 1.466 0.363 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.434 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 30.9 m-70 -141.79 145.13 34.38 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.752 0.311 . . . . 0.0 111.413 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.434 ' ND1' ' C ' ' I' ' 13' ' ' HIS . 42.6 m80 -148.18 159.18 44.22 Favored 'General case' 0 CA--C 1.514 -0.427 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.372 178.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -153.94 166.06 34.15 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.283 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -162.53 123.86 2.59 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 123.023 0.202 . . . . 0.0 110.566 179.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 10.6 mp -115.22 115.63 27.02 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -126.56 123.68 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 CA-C-O 120.983 0.421 . . . . 0.0 111.307 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 9.8 m-85 -119.21 116.43 26.27 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 115.815 -0.629 . . . . 0.0 109.742 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -128.59 126.85 41.12 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.76 135.33 26.11 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.382 0.61 . . . . 0.0 111.961 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -141.57 142.58 33.49 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.081 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.442 ' O ' ' CG2' ' J' ' 24' ' ' VAL . 64.9 t0 -85.78 123.35 31.05 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 121.47 0.652 . . . . 0.0 111.69 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' I' ' 26' ' ' SER . 2.9 t -93.2 121.81 44.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.06 -88.22 0.01 OUTLIER Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.891 -1.283 . . . . 0.0 109.891 -177.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' I' ' 24' ' ' VAL . 52.9 p -141.0 170.28 16.03 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 118.127 0.964 . . . . 0.0 109.477 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -29.17 169.44 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 114.138 -1.392 . . . . 0.0 114.027 -179.252 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.609 ' NZ ' ' OD1' ' G' ' 23' ' ' ASP . 35.8 tttt -150.27 111.18 4.32 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 114.372 -1.286 . . . . 0.0 108.936 172.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.96 92.07 0.02 OUTLIER Glycine 0 N--CA 1.464 0.535 0 C-N-CA 118.913 -1.613 . . . . 0.0 109.082 176.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -138.32 148.07 44.22 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.9 116.18 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-N 114.057 -1.429 . . . . 0.0 110.387 -174.125 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -106.99 114.76 46.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.68 93.87 0.57 Allowed Glycine 0 N--CA 1.462 0.415 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.43 HD23 ' H ' ' H' ' 34' ' ' LEU . 7.4 mt -127.61 135.26 50.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 122.484 1.135 . . . . 0.0 111.554 -178.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 42.9 ttp -125.62 120.7 31.47 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.402 177.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.99 73.57 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.784 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -21.1 -101.72 0.0 OUTLIER Glycine 0 C--N 1.367 2.301 0 O-C-N 123.508 0.505 . . . . 0.0 112.378 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.66 -153.71 23.65 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.655 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 5.0 p -134.59 141.43 43.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-O 120.879 0.371 . . . . 0.0 110.105 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' H' ' 40' ' ' VAL . 2.6 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.062 -0.97 . . . . 0.0 110.218 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' K' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.489 2.197 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -142.22 163.14 33.66 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-O 120.778 0.323 . . . . 0.0 110.289 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -153.3 154.21 34.14 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.162 0.506 . . . . 0.0 111.212 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.43 ' C ' ' ND1' ' J' ' 13' ' ' HIS . 2.4 p -140.56 151.37 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.799 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.43 ' ND1' ' C ' ' J' ' 12' ' ' VAL . 1.6 m80 -127.34 130.79 50.09 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.479 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -126.6 156.57 40.7 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-O 121.494 0.664 . . . . 0.0 109.529 178.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mt-30 -150.68 173.79 13.76 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.775 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -175.25 123.92 0.23 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.842 179.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 4.7 mp -125.48 122.25 36.08 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.43 137.22 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.197 0.522 . . . . 0.0 112.135 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -121.62 129.65 52.96 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.863 179.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -129.65 122.19 28.5 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.136 0.426 . . . . 0.0 110.245 178.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.96 126.87 35.09 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 121.382 0.61 . . . . 0.0 111.427 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -126.77 109.33 11.9 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.229 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.562 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 0.0 OUTLIER -104.68 112.3 25.33 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 120.068 -0.653 . . . . 0.0 112.127 -178.607 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.571 ' O ' ' N ' ' J' ' 26' ' ' SER . 2.7 m -82.37 132.87 30.42 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.381 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.26 -85.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.415 0 N-CA-C 107.484 -2.246 . . . . 0.0 107.484 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.571 ' N ' ' O ' ' J' ' 24' ' ' VAL . 10.9 t -140.98 169.62 17.26 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 118.373 1.086 . . . . 0.0 110.298 174.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' N ' ' L' ' 30' ' ' ALA . 1.0 OUTLIER -30.27 172.81 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 N-CA-C 115.165 1.542 . . . . 0.0 115.165 178.394 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.723 ' HZ1' ' H ' ' H' ' 23' ' ' ASP . 87.0 tttt -97.54 112.25 24.18 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 117.671 -1.157 . . . . 0.0 110.197 171.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -61.42 91.49 0.06 OUTLIER Glycine 0 N--CA 1.49 2.271 0 CA-C-N 123.453 2.842 . . . . 0.0 108.343 175.052 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.555 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -148.85 153.42 38.04 Favored 'General case' 0 CA--C 1.482 -1.655 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.35 115.95 4.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 C-N-CA 118.716 -1.194 . . . . 0.0 109.439 -174.632 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.419 HD12 HG21 ' J' ' 32' ' ' ILE . 1.7 mt -105.52 117.01 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.563 -178.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 101.1 1.02 Allowed Glycine 0 CA--C 1.503 -0.71 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 tt -142.02 135.4 29.22 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 118.932 -1.107 . . . . 0.0 112.788 -177.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 60.9 ttp -127.82 124.0 36.54 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.807 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.3 75.36 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.751 0 CA-C-N 114.52 -1.218 . . . . 0.0 107.734 178.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -89.75 103.17 2.98 Favored Glycine 0 C--N 1.356 1.665 0 N-CA-C 111.784 -0.526 . . . . 0.0 111.784 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.82 152.14 20.9 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 30.6 m -135.08 157.38 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 8.3 p . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.176 -0.916 . . . . 0.0 110.5 -179.63 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' J' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -135.48 154.84 51.29 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 121.159 0.504 . . . . 0.0 111.179 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -137.3 131.77 32.73 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.34 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 11.2 m -145.0 136.63 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.348 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -118.4 127.15 53.4 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.742 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -124.02 158.27 32.53 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.556 0.693 . . . . 0.0 110.179 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.481 ' O ' ' O ' ' L' ' 15' ' ' GLN . 50.9 tt0 -166.17 170.23 13.55 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.776 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . 0.446 ' HZ2' ' CD2' ' L' ' 14' ' ' HIS . 66.3 mttm -163.82 125.5 2.37 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.556 179.356 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . 0.929 ' O ' ' C ' ' L' ' 17' ' ' LEU . 17.9 tp -118.05 118.39 31.8 Favored 'General case' 0 N--CA 1.503 2.224 0 CA-C-O 123.339 1.543 . . . . 0.0 112.124 178.479 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 5.3 p -134.07 123.96 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.352 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -109.23 127.17 54.03 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.464 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -117.36 114.3 23.35 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 178.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 131.31 47.51 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.208 0.528 . . . . 0.0 111.569 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.406 ' O ' ' O ' ' K' ' 23' ' ' ASP . 74.5 mm-40 -83.33 158.26 22.25 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.257 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.55 ' O ' ' O ' ' K' ' 24' ' ' VAL . 48.8 p-10 -60.99 -133.88 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.201 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.55 ' O ' ' O ' ' K' ' 23' ' ' ASP . 24.7 t 26.72 111.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 123.942 0.776 . . . . 0.0 112.356 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.43 82.74 0.14 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 120.206 -0.997 . . . . 0.0 113.183 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.491 ' O ' ' OG ' ' J' ' 26' ' ' SER . 30.2 p -139.05 170.2 16.41 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-N 117.759 0.779 . . . . 0.0 109.334 177.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 50.62 -178.75 0.02 OUTLIER 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.765 179.078 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt 55.37 -106.61 0.33 Allowed 'General case' 0 C--O 1.233 0.208 0 CA-C-O 121.204 0.526 . . . . 0.0 111.918 177.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.6 91.54 1.83 Allowed Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.515 ' CB ' ' O ' ' J' ' 28' ' ' LYS . . . -82.19 174.2 11.4 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 104.707 -2.331 . . . . 0.0 104.707 177.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.51 ' CG2' ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -156.4 119.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 116.768 -1.973 . . . . 0.0 111.224 -175.431 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -103.72 113.09 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 176.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.1 88.98 0.52 Allowed Glycine 0 CA--C 1.504 -0.603 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 177.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.513 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 9.3 tt -127.66 134.54 49.62 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 122.004 0.907 . . . . 0.0 111.834 -177.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.477 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 65.8 ttp -123.34 127.56 48.68 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 115.079 -0.964 . . . . 0.0 112.593 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.5 72.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 114.427 -1.26 . . . . 0.0 107.887 177.703 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.03 101.86 2.33 Favored Glycine 0 C--N 1.353 1.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -145.16 163.52 28.08 Favored Glycine 0 N--CA 1.46 0.242 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -124.06 135.58 63.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.905 0.383 . . . . 0.0 110.125 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.466 179.967 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -112.95 152.92 28.81 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.507 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.51 136.8 49.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.856 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.97 132.77 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.999 0.428 . . . . 0.0 110.503 -179.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 23.3 p-80 -160.91 147.71 15.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.487 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.446 ' CD2' ' HZ2' ' K' ' 16' ' ' LYS . 11.0 t60 -95.16 177.54 5.83 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.508 ' HG3' ' H ' ' L' ' 16' ' ' LYS . 45.6 tp60 -114.84 174.98 5.7 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.932 -179.564 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . 0.508 ' H ' ' HG3' ' L' ' 15' ' ' GLN . 88.9 mttt -88.9 -174.96 4.7 Favored 'General case' 0 C--O 1.176 -2.765 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . 0.929 ' C ' ' O ' ' K' ' 17' ' ' LEU . 38.3 mt -141.48 161.28 38.29 Favored 'General case' 0 C--N 1.31 -1.12 0 O-C-N 119.922 -1.736 . . . . 0.0 110.289 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 10.8 m -84.54 -144.05 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 117.723 2.49 . . . . 0.0 117.723 -171.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.492 ' N ' ' CD1' ' L' ' 19' ' ' PHE . 9.6 m-85 -124.22 147.62 47.91 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 113.506 -1.679 . . . . 0.0 111.143 -178.066 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -137.48 132.19 32.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.263 -0.881 . . . . 0.0 108.945 178.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.3 159.37 38.78 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.277 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -85.7 157.97 20.17 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -53.16 122.88 10.34 Favored 'General case' 0 CA--C 1.52 -0.185 0 C-N-CA 119.899 -0.721 . . . . 0.0 109.243 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 3.5 t -92.68 121.79 43.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.575 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.16 -87.01 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 79.4 p -89.07 -177.7 5.5 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.417 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 63.9 t30 -60.27 179.55 0.14 Allowed 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.713 -177.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.417 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 11.6 tptt -57.26 110.72 0.89 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 122.005 0.907 . . . . 0.0 112.998 -176.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.27 -98.14 0.04 OUTLIER Glycine 0 CA--C 1.496 -1.149 0 CA-C-N 113.801 -1.545 . . . . 0.0 111.155 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.683 ' N ' ' ND2' ' J' ' 27' ' ' ASN . . . -61.2 165.16 4.64 Favored 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 -178.612 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -141.51 125.32 16.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 117.692 -1.603 . . . . 0.0 112.441 -176.238 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.407 HG21 HD13 ' L' ' 32' ' ' ILE . 4.3 mt -101.16 117.66 46.74 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.632 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 177.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.55 98.19 0.61 Allowed Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . 0.496 ' CD2' ' C ' ' L' ' 34' ' ' LEU . 1.0 OUTLIER -128.82 139.58 52.1 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.557 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 66.4 ttp -118.33 124.15 47.08 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.588 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -123.42 80.07 0.67 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.648 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.93 102.48 0.12 Allowed Glycine 0 C--N 1.349 1.295 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.68 -173.21 29.37 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.56 142.87 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.842 0.353 . . . . 0.0 110.599 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.995 -1.002 . . . . 0.0 111.015 -179.795 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.466 0.355 0 CA-C-O 120.868 0.366 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 77.7 m80 -142.98 165.13 28.2 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.344 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m80 -135.69 178.55 6.96 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 109.61 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -98.12 179.18 4.85 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.022 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -104.56 140.95 37.24 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.195 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -124.12 120.12 31.42 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.079 0.466 . . . . 0.0 110.726 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.06 128.19 52.53 Favored 'Isoleucine or valine' 0 C--O 1.231 0.098 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.11 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.623 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 11.7 m-85 -112.88 118.83 35.98 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.07 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.549 ' CE2' ' CD1' ' B' ' 20' ' ' PHE . 55.7 t80 -127.71 113.08 15.56 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.51 129.26 56.41 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.118 0.485 . . . . 0.0 110.98 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 tt0 -156.72 158.69 37.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 179.284 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -81.11 111.29 17.42 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.718 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.628 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.0 t -114.27 131.18 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.839 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 177.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.83 81.94 0.0 OUTLIER Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.576 -0.345 . . . . 0.0 112.409 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.628 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.1 p -94.64 177.31 5.96 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.686 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' A' ' 28' ' ' LYS . 98.5 m-20 -61.58 179.6 0.23 Allowed 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.584 -0.846 . . . . 0.0 108.763 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.8 mttm -52.12 -111.87 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.761 0.791 . . . . 0.0 111.406 178.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.41 93.33 1.63 Allowed Glycine 0 N--CA 1.467 0.707 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 177.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.55 160.9 14.05 Favored 'General case' 0 CA--C 1.509 -0.605 0 C-N-CA 116.582 -2.047 . . . . 0.0 111.627 -177.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.457 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.0 OUTLIER -152.51 117.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.112 0 CA-C-N 111.819 -2.446 . . . . 0.0 109.184 -174.334 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.87 118.54 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.709 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.64 108.71 0.98 Allowed Glycine 0 N--CA 1.464 0.56 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 48.5 tp -131.69 133.01 44.4 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 117.194 0.497 . . . . 0.0 111.07 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 13.4 ttt -139.38 134.66 32.77 Favored 'General case' 0 C--N 1.328 -0.36 0 O-C-N 122.234 -0.291 . . . . 0.0 110.788 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.7 t -146.06 81.29 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.51 100.22 2.43 Favored Glycine 0 C--N 1.338 0.66 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.226 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.24 176.48 47.86 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 N--CA 1.466 0.369 0 CA-C-O 120.82 0.343 . . . . 0.0 110.356 179.214 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . 0.401 ' CG1' ' N ' ' B' ' 13' ' ' HIS . 93.4 t . . . . . 0 N--CA 1.469 0.478 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.401 ' N ' ' CG1' ' B' ' 12' ' ' VAL . 28.3 t60 -166.77 104.78 0.59 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.218 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 47.6 m170 -120.0 165.77 14.25 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.401 ' CG ' ' H ' ' B' ' 16' ' ' LYS . 50.6 tt0 -162.85 173.23 14.01 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.331 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . 0.401 ' H ' ' CG ' ' B' ' 15' ' ' GLN . 97.6 mttt -149.85 116.29 5.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.939 0.399 . . . . 0.0 110.742 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 60.6 mt -116.57 114.42 24.11 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.302 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.52 123.66 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-O 121.214 0.531 . . . . 0.0 110.945 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -117.47 118.52 32.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.963 179.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.549 ' CD1' ' CE2' ' A' ' 20' ' ' PHE . 33.1 t80 -138.37 125.67 21.69 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 122.22 -0.3 . . . . 0.0 110.326 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 131.32 46.89 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.155 0.503 . . . . 0.0 111.965 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -157.67 91.3 1.13 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.588 ' H ' ' CG ' ' C' ' 23' ' ' ASP . 10.7 t0 -121.6 113.1 19.3 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -176.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' B' ' 26' ' ' SER . 12.0 p -60.41 132.37 25.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.252 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.94 83.72 0.04 OUTLIER Glycine 0 CA--C 1.526 0.751 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.694 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.484 ' OG ' ' NZ ' ' C' ' 28' ' ' LYS . 11.8 p -87.62 -179.1 6.25 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.583 0.706 . . . . 0.0 109.627 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.425 ' O ' ' O ' ' B' ' 28' ' ' LYS . 28.3 t-20 -75.63 175.96 8.1 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.544 177.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' B' ' 27' ' ' ASN . 97.6 mttt 42.49 107.9 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 114.9 1.445 . . . . 0.0 114.9 176.121 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.2 100.04 1.98 Allowed Glycine 0 N--CA 1.479 1.565 0 CA-C-N 114.273 -1.33 . . . . 0.0 110.717 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 161.35 31.15 Favored 'General case' 0 C--O 1.248 1.016 0 CA-C-O 122.772 1.272 . . . . 0.0 110.772 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.457 ' O ' ' HA ' ' A' ' 31' ' ' ILE . 0.0 OUTLIER -143.02 122.74 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 112.939 -1.937 . . . . 0.0 110.378 -172.929 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.452 ' C ' ' SD ' ' H' ' 35' ' ' MET . 44.3 pt -136.08 135.29 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-O 121.847 0.832 . . . . 0.0 112.129 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -141.11 137.88 8.46 Favored Glycine 0 CA--C 1.531 1.033 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.142 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 tt -146.93 139.74 25.12 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 120.196 -0.601 . . . . 0.0 111.158 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 24.1 ttm -128.32 126.19 40.27 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-O 121.397 0.618 . . . . 0.0 112.133 -179.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.43 79.6 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.021 177.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' B' ' 38' ' ' GLY . . . -50.91 104.13 0.12 Allowed Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.769 -179.045 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 44.99 179.74 0.01 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 p -148.36 149.77 14.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 C--O 1.218 -0.559 0 CA-C-O 118.176 -0.916 . . . . 0.0 111.078 -179.681 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 141.44 47.83 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.417 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -142.58 159.34 42.43 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.418 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 55.3 t -121.27 133.56 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.423 ' O ' ' O ' ' D' ' 13' ' ' HIS . 97.6 m-70 -148.08 123.63 10.42 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.822 0.344 . . . . 0.0 111.179 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.529 ' ND1' ' O ' ' D' ' 14' ' ' HIS . 26.1 t60 -141.45 164.65 29.66 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.409 ' HG2' ' N ' ' C' ' 16' ' ' LYS . 51.8 tt0 -169.39 170.36 8.45 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.845 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . 0.409 ' N ' ' HG2' ' C' ' 15' ' ' GLN . 68.2 mttm -142.59 118.79 10.77 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.238 178.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -120.11 121.39 38.73 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.06 123.25 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.048 0.452 . . . . 0.0 111.739 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.441 ' CZ ' ' CD2' ' F' ' 34' ' ' LEU . 6.6 m-85 -113.65 116.78 30.0 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.544 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 33.6 t80 -132.24 118.65 19.78 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 118.227 0.467 . . . . 0.0 110.203 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.9 37.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 120.857 0.361 . . . . 0.0 110.884 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -173.2 102.97 0.13 Allowed 'General case' 0 CA--C 1.522 -0.134 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.706 ' H ' ' NZ ' ' E' ' 28' ' ' LYS . 1.1 m-20 -115.15 113.66 24.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 121.095 0.474 . . . . 0.0 111.417 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 91.4 t -64.76 131.5 30.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.84 84.02 0.31 Allowed Glycine 0 CA--C 1.525 0.696 0 C-N-CA 119.195 -1.479 . . . . 0.0 110.726 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.536 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 1.7 m -59.87 -174.27 0.02 OUTLIER 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.536 ' CB ' ' O ' ' C' ' 26' ' ' SER . 6.1 t-20 99.85 -174.62 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.928 0 O-C-N 124.342 1.026 . . . . 0.0 111.202 -177.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.529 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 81.9 tttt 37.44 108.93 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.987 -177.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.426 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -85.79 96.84 2.13 Favored Glycine 0 CA--C 1.504 -0.622 0 CA-C-N 114.325 -1.307 . . . . 0.0 112.056 177.387 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.8 164.7 19.36 Favored 'General case' 0 C--O 1.244 0.808 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.461 ' CG2' ' SD ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -145.83 121.3 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 117.961 -1.496 . . . . 0.0 111.702 -174.804 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 1.1 mt -114.54 120.63 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.898 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.98 98.88 0.65 Allowed Glycine 0 N--CA 1.472 1.04 0 N-CA-C 106.939 -2.464 . . . . 0.0 106.939 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 tt -129.93 129.28 43.64 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 119.05 -1.06 . . . . 0.0 113.749 -175.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 96.6 mmm -107.39 118.08 35.77 Favored 'General case' 0 CA--C 1.503 -0.859 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.267 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.02 72.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.723 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 175.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.14 112.31 4.6 Favored Glycine 0 C--N 1.36 1.882 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.47 157.39 51.88 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -138.72 161.51 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.103 -0.951 . . . . 0.0 110.508 179.968 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t . . . . . 0 C--O 1.232 0.173 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.423 ' O ' ' O ' ' C' ' 13' ' ' HIS . 3.4 m-70 -87.31 161.48 17.92 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.336 0.589 . . . . 0.0 111.354 -178.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.529 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.8 p-80 -93.93 178.83 5.54 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.327 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -127.7 179.04 5.74 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.502 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -137.23 127.1 25.66 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.248 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.3 mp -126.43 129.17 48.21 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.223 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -126.81 125.01 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.027 0.441 . . . . 0.0 111.488 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -110.57 112.57 24.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.51 ' CE1' ' CE2' ' C' ' 20' ' ' PHE . 27.5 t80 -126.72 123.32 37.21 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 118.542 0.61 . . . . 0.0 109.947 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.17 142.63 28.63 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -142.97 145.17 32.72 Favored 'General case' 0 C--N 1.343 0.302 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.653 178.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.515 ' O ' ' O ' ' E' ' 24' ' ' VAL . 14.0 m-20 -112.64 124.67 53.07 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.898 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' E' ' 26' ' ' SER . 5.7 t -95.34 -112.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 113.124 0.787 . . . . 0.0 113.124 -176.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.94 -91.12 0.01 OUTLIER Glycine 0 N--CA 1.469 0.864 0 N-CA-C 112.386 -0.286 . . . . 0.0 112.386 -176.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.609 ' O ' ' O ' ' D' ' 27' ' ' ASN . 21.5 p -151.54 171.87 16.91 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.666 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 18.6 m120 -19.29 156.7 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 O-C-N 124.253 0.971 . . . . 0.0 113.164 -178.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 56.5 tttt -162.45 110.68 1.36 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 121.406 -0.809 . . . . 0.0 110.461 173.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.426 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -68.62 92.83 0.29 Allowed Glycine 0 C--O 1.215 -1.036 0 CA-C-O 117.861 -1.522 . . . . 0.0 110.77 175.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.43 ' O ' HG13 ' E' ' 31' ' ' ILE . . . -129.04 151.61 49.54 Favored 'General case' 0 CA--C 1.482 -1.652 0 N-CA-C 103.028 -2.953 . . . . 0.0 103.028 173.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -147.75 118.25 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.339 -172.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.5 tt -119.0 113.42 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.483 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.07 128.22 5.57 Favored Glycine 0 C--O 1.241 0.536 0 C-N-CA 121.09 -0.576 . . . . 0.0 111.811 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.623 ' CD2' ' CZ ' ' A' ' 19' ' ' PHE . 4.0 mp -141.5 142.57 33.58 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-O 122.249 1.023 . . . . 0.0 111.277 178.659 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.428 ' SD ' ' HB ' ' J' ' 31' ' ' ILE . 29.3 tpp -100.87 113.6 26.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 113.574 -1.648 . . . . 0.0 108.448 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.55 74.0 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.302 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.113 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.96 111.21 1.82 Allowed Glycine 0 C--N 1.358 1.793 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.17 -170.28 0.15 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m -133.85 160.62 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.815 0.34 . . . . 0.0 110.791 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.562 179.845 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -101.47 129.12 47.46 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.993 0.425 . . . . 0.0 110.539 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.88 138.86 28.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.84 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.1 t -126.36 132.77 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.904 0.383 . . . . 0.0 110.329 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 t-80 -143.95 112.57 6.55 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.564 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -128.81 173.01 10.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -151.1 175.93 11.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.709 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -167.85 108.25 0.57 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.05 0.452 . . . . 0.0 110.686 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.0 tt -124.84 127.35 47.02 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.707 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.13 128.84 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -119.61 119.97 35.33 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -128.18 121.96 30.73 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-O 120.909 0.385 . . . . 0.0 110.273 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.5 133.33 43.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.994 0.426 . . . . 0.0 111.52 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -137.74 123.78 20.28 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.554 -0.458 . . . . 0.0 109.831 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -84.77 114.82 22.34 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.062 0.458 . . . . 0.0 111.181 -178.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' E' ' 26' ' ' SER . 53.8 t -95.78 130.81 43.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.68 -85.07 0.01 OUTLIER Glycine 0 CA--C 1.535 1.289 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' E' ' 24' ' ' VAL . 12.6 t -153.0 174.29 14.35 Favored 'General case' 0 C--N 1.347 0.46 0 CA-C-N 118.897 1.348 . . . . 0.0 112.995 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.666 ' ND2' ' H ' ' D' ' 27' ' ' ASN . 12.9 p-10 -19.01 160.24 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 116.761 2.134 . . . . 0.0 116.761 178.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.706 ' NZ ' ' H ' ' C' ' 23' ' ' ASP . 80.9 tttt -170.14 105.55 0.31 Allowed 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 174.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' F' ' 30' ' ' ALA . . . -49.99 -97.84 0.01 OUTLIER Glycine 0 N--CA 1.469 0.9 0 C-N-CA 118.664 -1.731 . . . . 0.0 111.299 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 74.07 143.71 0.07 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.43 HG13 ' O ' ' D' ' 30' ' ' ALA . 0.0 OUTLIER -150.78 118.11 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.08 -178.471 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 4.5 tt -117.44 128.31 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 CA-C-O 121.329 0.585 . . . . 0.0 111.255 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 99.7 0.7 Allowed Glycine 0 N--CA 1.451 -0.331 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 178.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 37.6 tp -115.58 116.39 28.06 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.551 ' CE ' ' SD ' ' F' ' 35' ' ' MET . 0.4 OUTLIER -91.76 111.63 23.24 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.976 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' O ' ' E' ' 36' ' ' VAL . 2.0 t -138.4 66.56 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -54.84 -103.53 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.44 169.01 34.51 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -140.67 140.85 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.064 -0.969 . . . . 0.0 110.357 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.463 0.211 0 CA-C-O 121.199 0.523 . . . . 0.0 109.851 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.508 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -151.26 130.05 12.4 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.417 -179.868 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.402 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 80.6 m80 -155.82 178.29 10.43 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -139.72 177.87 7.64 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.248 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -155.12 115.9 3.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.336 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.44 128.01 42.07 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.17 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 99.8 t -129.63 130.94 67.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.7 p90 -132.32 128.52 37.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.887 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.6 t80 -138.82 125.37 20.63 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.46 146.3 30.51 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.681 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -124.15 95.68 4.64 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 178.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 5.8 t70 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.909 -178.673 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 33.1 tttm . . . . . 0 N--CA 1.498 1.937 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.64 -99.88 0.01 OUTLIER Glycine 0 C--N 1.348 1.214 0 CA-C-O 124.622 2.235 . . . . 0.0 114.143 174.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.589 ' HA ' ' O ' ' E' ' 29' ' ' GLY . . . 70.18 143.36 0.05 Allowed 'General case' 0 CA--C 1.503 -0.839 0 CA-C-N 108.575 -3.812 . . . . 0.0 107.208 177.062 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.422 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.0 OUTLIER -160.06 125.05 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 122.538 2.427 . . . . 0.0 113.399 -179.711 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 87.7 mt -107.78 117.74 54.05 Favored 'Isoleucine or valine' 0 C--N 1.355 0.83 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.951 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.53 91.06 0.55 Allowed Glycine 0 N--CA 1.452 -0.245 0 N-CA-C 109.061 -1.615 . . . . 0.0 109.061 177.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.441 ' CD2' ' CZ ' ' C' ' 19' ' ' PHE . 3.1 tp -114.22 116.18 28.63 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.628 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 2.2 mtp -88.34 114.26 24.78 Favored 'General case' 0 CA--C 1.48 -1.735 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 p -139.63 74.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 105.775 -1.935 . . . . 0.0 105.775 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.32 104.85 2.64 Favored Glycine 0 C--N 1.356 1.667 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.03 -179.43 26.37 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -134.76 138.07 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.692 0.282 . . . . 0.0 111.03 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 N--CA 1.469 0.52 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.538 179.584 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -119.51 142.59 48.16 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -152.43 123.56 7.59 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.416 0.626 . . . . 0.0 111.578 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -150.21 146.29 16.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.498 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -151.93 140.97 21.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.077 0.465 . . . . 0.0 110.815 179.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -134.64 163.74 29.07 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -150.53 171.34 17.24 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.528 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -156.2 128.98 7.84 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.15 124.6 44.26 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 110.218 179.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 5.4 p -121.67 120.46 61.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -117.12 103.16 9.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -122.37 121.5 36.84 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.93 123.75 48.86 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.862 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -158.3 155.53 28.99 Favored 'General case' 0 CA--C 1.528 0.122 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -88.25 120.9 30.05 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.116 0.484 . . . . 0.0 112.289 -178.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.569 ' O ' ' N ' ' G' ' 26' ' ' SER . 88.1 t -100.97 124.03 54.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.63 83.49 0.0 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-O 120.052 -0.305 . . . . 0.0 112.985 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.569 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.1 m -97.46 174.78 6.5 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.269 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 22.8 p30 -59.22 164.38 3.21 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.196 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -57.23 111.53 1.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.779 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . 0.402 ' H ' ' HE3' ' H' ' 28' ' ' LYS . . . 72.38 93.49 0.09 OUTLIER Glycine 0 N--CA 1.466 0.681 0 C-N-CA 119.678 -1.249 . . . . 0.0 111.315 177.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.55 157.51 19.56 Favored 'General case' 0 CA--C 1.51 -0.595 0 C-N-CA 118.426 -1.31 . . . . 0.0 108.847 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -153.04 117.35 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.776 -173.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.485 ' O ' ' SD ' ' A' ' 35' ' ' MET . 18.0 tt -135.58 129.47 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.064 179.543 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.88 116.9 1.96 Allowed Glycine 0 N--CA 1.466 0.639 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 76.5 mt -137.33 148.77 46.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 121.681 0.753 . . . . 0.0 112.289 -178.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 ttt -139.3 135.8 34.19 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.196 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' G' ' 37' ' ' GLY . 9.5 t -141.53 81.27 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' G' ' 36' ' ' VAL . . . -26.89 -94.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 O-C-N 123.337 0.398 . . . . 0.0 112.773 178.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.13 -157.84 30.5 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 71.8 t -98.86 133.49 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.847 0.356 . . . . 0.0 110.24 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.731 -179.395 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -145.0 159.5 42.84 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.788 0.327 . . . . 0.0 110.522 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . 0.536 ' CD ' ' HE2' ' H' ' 13' ' ' HIS . 82.5 tt0 -134.73 145.54 48.56 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.835 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.48 133.17 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 116.793 -0.185 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.536 ' HE2' ' CD ' ' H' ' 11' ' ' GLU . 80.9 m-70 -137.31 143.58 42.18 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.837 0.351 . . . . 0.0 111.307 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.506 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 86.3 t60 -146.92 162.08 39.43 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.448 0.642 . . . . 0.0 110.307 178.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.506 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 42.4 tt0 -156.72 174.62 15.21 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -162.71 125.47 2.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.892 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 tt -125.62 121.79 34.55 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.982 0.42 . . . . 0.0 110.533 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 56.6 t -120.36 126.16 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.876 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 29.5 t80 -121.93 111.91 17.66 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -130.38 126.23 36.55 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.34 128.64 51.27 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.238 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.24 149.1 40.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.643 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.51 ' O ' ' NZ ' ' J' ' 28' ' ' LYS . 53.2 t0 -155.79 121.1 4.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.575 ' CG2' ' N ' ' H' ' 25' ' ' GLY . 2.6 p -133.87 -112.01 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.575 ' N ' ' CG2' ' H' ' 24' ' ' VAL . . . 32.86 -90.26 0.01 OUTLIER Glycine 0 CA--C 1.53 1.016 0 CA-C-N 115.97 -0.559 . . . . 0.0 112.362 -178.085 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.661 ' O ' ' O ' ' H' ' 27' ' ' ASN . 1.6 t 171.61 178.72 0.07 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 117.622 0.711 . . . . 0.0 109.984 -179.519 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.661 ' O ' ' O ' ' H' ' 26' ' ' SER . 9.4 t-20 -28.57 179.59 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 O-C-N 125.07 1.481 . . . . 0.0 114.259 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.555 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 87.0 tttt 128.43 105.18 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 124.359 1.064 . . . . 0.0 111.763 178.356 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.86 96.27 0.05 OUTLIER Glycine 0 N--CA 1.47 0.948 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.08 146.6 47.04 Favored 'General case' 0 C--O 1.253 1.288 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 177.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -140.04 119.61 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.281 0 CA-C-N 113.02 -1.9 . . . . 0.0 110.697 -171.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -126.96 122.73 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.767 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.17 118.64 2.18 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -137.3 129.97 30.1 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.456 0.646 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.452 ' SD ' ' C ' ' B' ' 32' ' ' ILE . 13.2 ttt -124.47 124.91 43.33 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.247 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.427 ' O ' ' C ' ' H' ' 37' ' ' GLY . 34.5 m -136.08 81.24 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -29.14 -93.47 0.01 OUTLIER Glycine 0 CA--C 1.529 0.925 0 CA-C-N 116.488 -0.324 . . . . 0.0 112.489 178.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.09 -161.86 28.66 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.7 m -120.51 134.79 62.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 120.657 0.265 . . . . 0.0 110.39 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.442 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.468 0.473 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.54 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 49.3 p-80 -155.86 161.62 40.57 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.147 -0.621 . . . . 0.0 112.303 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 7.2 m-70 -141.37 162.78 34.66 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.45 179.097 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -150.54 175.36 11.97 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.858 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -155.26 130.53 9.61 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.989 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.4 mt -124.39 118.74 27.39 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -123.62 128.44 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.56 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.648 ' CD2' ' CZ ' ' J' ' 19' ' ' PHE . 27.7 t80 -128.01 116.23 19.72 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -127.89 130.32 48.33 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-O 120.703 0.287 . . . . 0.0 110.941 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.14 125.78 32.09 Favored 'General case' 0 C--O 1.243 0.718 0 CA-C-O 121.444 0.64 . . . . 0.0 112.067 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -145.08 158.34 43.85 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.553 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.545 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.9 p-10 -173.96 121.88 0.31 Allowed 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 -179.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' I' ' 26' ' ' SER . 11.5 t -124.0 -111.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.222 -178.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.18 -90.75 0.01 OUTLIER Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -177.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.563 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.7 p 171.39 169.37 0.09 Allowed 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 177.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.563 ' O ' ' O ' ' I' ' 26' ' ' SER . 21.3 t-20 -19.49 155.8 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 179.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.542 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 73.5 tttt -170.69 106.57 0.28 Allowed 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.676 173.718 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.66 93.16 0.01 OUTLIER Glycine 0 C--O 1.227 -0.335 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 174.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -142.04 145.38 34.32 Favored 'General case' 0 CA--C 1.486 -1.504 0 CA-C-N 119.167 1.483 . . . . 0.0 107.889 177.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.8 117.28 10.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.349 -177.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' I' ' 32' ' ' ILE . 0.4 OUTLIER -107.82 116.63 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.68 100.61 0.8 Allowed Glycine 0 CA--C 1.496 -1.133 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 5.3 tt -130.49 125.33 34.09 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 118.824 -1.151 . . . . 0.0 110.252 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.461 ' SD ' ' CG2' ' C' ' 31' ' ' ILE . 28.3 ttm -115.56 117.11 29.42 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.176 -1.375 . . . . 0.0 109.01 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.97 75.29 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.681 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.431 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -29.63 -97.29 0.01 OUTLIER Glycine 0 C--N 1.354 1.543 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.843 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.75 -164.54 28.5 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.82 146.91 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 110.027 -0.361 . . . . 0.0 110.027 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.73 -179.79 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.173 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -105.21 129.45 53.58 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 120.901 0.382 . . . . 0.0 110.615 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -127.95 127.14 42.77 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.228 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 t -141.64 134.18 28.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -149.61 133.54 17.04 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.479 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 1.5 t-80 -151.64 159.2 44.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.633 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 49.6 tt0 -160.58 169.5 22.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.419 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -151.08 128.79 11.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 14.2 tp -126.33 114.55 18.39 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 64.6 t -119.51 126.76 75.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.981 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.648 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 1.5 t80 -120.19 119.35 32.97 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.51 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 56.4 t80 -132.84 126.36 32.08 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.611 0.243 . . . . 0.0 110.849 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.84 26.58 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 119.848 -0.741 . . . . 0.0 112.47 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -125.58 143.89 50.82 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.151 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -130.04 110.85 11.96 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 177.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.554 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 14.0 t -139.39 -123.51 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.589 -178.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.554 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . 27.5 -83.92 0.0 OUTLIER Glycine 0 C--N 1.342 0.879 0 CA-C-N 114.947 -1.024 . . . . 0.0 112.406 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.635 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.2 p 170.48 170.42 0.07 Allowed 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 178.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.635 ' O ' ' O ' ' J' ' 26' ' ' SER . 76.3 m-20 -18.37 157.58 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 O-C-N 124.375 1.047 . . . . 0.0 113.064 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.574 ' O ' ' O ' ' K' ' 29' ' ' GLY . 81.0 tttt -161.79 110.9 1.52 Allowed 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.573 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -67.45 92.49 0.22 Allowed Glycine 0 C--N 1.32 -0.333 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.06 149.17 22.84 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 177.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.472 ' CD1' ' N ' ' J' ' 31' ' ' ILE . 0.0 OUTLIER -144.81 122.56 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 C-N-CA 119.201 -1.0 . . . . 0.0 111.505 -176.946 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 4.2 mt -108.94 119.56 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-N 114.975 -1.012 . . . . 0.0 109.826 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.42 112.91 2.48 Favored Glycine 0 C--N 1.336 0.567 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 177.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -143.72 135.0 25.85 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.126 0.965 . . . . 0.0 113.015 -177.586 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 98.7 mmm -112.63 111.19 21.82 Favored 'General case' 0 CA--C 1.504 -0.79 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.032 177.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.25 62.39 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.34 -111.49 0.13 Allowed Glycine 0 C--N 1.356 1.642 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.771 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.35 142.83 7.04 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 11.6 p -142.08 151.82 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 m . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.402 179.806 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -113.48 132.28 55.72 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.718 0.294 . . . . 0.0 110.442 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -129.9 127.71 40.72 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.918 0.389 . . . . 0.0 110.936 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.55 132.74 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -150.64 131.84 14.48 Favored 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.054 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' CE1' ' J' ' 14' ' ' HIS . 50.3 t-80 -152.93 165.01 36.85 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.174 0.511 . . . . 0.0 109.842 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 80.8 mt-30 -156.88 179.85 8.89 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.325 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -170.3 120.08 0.59 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.327 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 31.4 tp -119.98 123.99 44.85 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.549 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 65.0 t -130.03 121.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.551 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -118.67 120.62 37.96 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.51 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 48.6 t80 -129.01 121.26 27.56 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.998 0.428 . . . . 0.0 111.592 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.19 129.36 41.61 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.494 178.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -124.49 143.2 50.79 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 121.417 0.627 . . . . 0.0 112.323 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -131.55 123.7 28.51 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.974 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.435 ' CG1' ' N ' ' K' ' 25' ' ' GLY . 57.7 t -96.15 -112.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.667 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.435 ' N ' ' CG1' ' K' ' 24' ' ' VAL . . . -46.96 -91.04 0.01 OUTLIER Glycine 0 CA--C 1.526 0.765 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.456 -176.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.605 ' O ' ' O ' ' K' ' 27' ' ' ASN . 34.9 p -152.98 -172.63 4.31 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 117.611 0.705 . . . . 0.0 110.444 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.605 ' O ' ' O ' ' K' ' 26' ' ' SER . 54.7 t30 -19.86 158.05 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.65 0 O-C-N 124.997 1.436 . . . . 0.0 113.724 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.454 ' O ' ' HA ' ' L' ' 30' ' ' ALA . 87.1 tttt -161.6 111.08 1.57 Allowed 'General case' 0 C--O 1.213 -0.823 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.839 176.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.574 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -67.92 92.39 0.24 Allowed Glycine 0 N--CA 1.475 1.276 0 CA-C-O 119.376 -0.68 . . . . 0.0 113.553 177.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.87 152.82 27.28 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 103.523 -2.769 . . . . 0.0 103.523 174.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.436 ' HB ' ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -149.62 116.16 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.857 0 C-N-CA 116.714 -1.994 . . . . 0.0 113.407 -171.844 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.428 ' C ' ' CE ' ' E' ' 35' ' ' MET . 62.7 mt -104.55 118.3 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.91 177.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . 0.413 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.06 104.19 1.32 Allowed Glycine 0 C--O 1.237 0.319 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 177.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.578 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 8.4 tt -139.54 132.7 29.71 Favored 'General case' 0 C--O 1.243 0.734 0 CA-C-O 122.835 1.302 . . . . 0.0 112.876 -177.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CG ' ' L' ' 35' ' ' MET . 95.9 mmm -107.17 118.43 36.69 Favored 'General case' 0 CA--C 1.505 -0.767 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.53 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.46 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -124.24 74.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.911 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.46 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -17.43 -101.93 0.0 OUTLIER Glycine 0 C--N 1.359 1.855 0 O-C-N 123.868 0.73 . . . . 0.0 113.031 -179.249 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.17 -161.9 30.28 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 74.4 t -124.08 138.39 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-O 120.751 0.31 . . . . 0.0 110.611 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.436 179.495 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -82.23 134.68 35.3 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.856 0.36 . . . . 0.0 110.48 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.42 143.68 33.83 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.519 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 50.4 t -121.68 132.92 69.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.063 0.459 . . . . 0.0 110.222 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 21.3 p-80 -164.12 110.43 1.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.479 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -144.85 169.04 18.8 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -151.72 175.64 12.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.126 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -153.34 123.89 7.18 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.346 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 64.4 mt -120.6 114.8 22.25 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -128.5 130.39 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.966 0.412 . . . . 0.0 110.54 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.506 ' CD1' ' O ' ' L' ' 19' ' ' PHE . 55.4 p90 -138.19 127.69 24.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -134.28 127.3 31.53 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.217 0.532 . . . . 0.0 110.746 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.61 134.48 32.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.771 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -110.19 109.77 20.38 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.644 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 42.7 t0 -99.16 133.84 42.87 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.188 0.518 . . . . 0.0 109.961 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' L' ' 26' ' ' SER . 90.5 t -107.02 112.97 42.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.394 -179.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 35.3 -91.22 0.01 OUTLIER Glycine 0 CA--C 1.528 0.88 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.873 -179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.448 ' N ' ' O ' ' L' ' 24' ' ' VAL . 13.4 p -62.49 -177.83 0.16 Allowed 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 117.571 0.685 . . . . 0.0 110.342 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -79.52 176.63 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.855 -1.066 . . . . 0.0 113.697 -177.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 35.7 tttp -48.51 111.1 0.41 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 113.835 -1.53 . . . . 0.0 112.947 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.41 -97.91 0.04 OUTLIER Glycine 0 CA--C 1.501 -0.808 0 CA-C-N 114.542 -1.208 . . . . 0.0 110.606 -178.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' K' ' 28' ' ' LYS . . . -60.84 170.87 1.34 Allowed 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 119.882 1.841 . . . . 0.0 106.135 -178.121 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -139.87 118.88 12.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 117.799 -1.56 . . . . 0.0 110.629 -172.71 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.541 ' C ' ' SD ' ' F' ' 35' ' ' MET . 67.2 mt -108.92 123.74 65.01 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 CA-C-N 114.398 -1.274 . . . . 0.0 109.09 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . 0.628 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -101.66 89.26 0.76 Allowed Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 105.477 -3.049 . . . . 0.0 105.477 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -108.57 112.89 25.48 Favored 'General case' 0 CA--C 1.502 -0.897 0 CA-C-O 120.684 0.278 . . . . 0.0 110.27 -177.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.505 ' CG ' ' SD ' ' K' ' 35' ' ' MET . 93.9 mmm -105.48 110.4 22.73 Favored 'General case' 0 CA--C 1.503 -0.846 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.169 179.428 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.7 79.42 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.5 103.68 0.52 Allowed Glycine 0 C--N 1.346 1.098 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.6 -161.06 36.9 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.7 m -133.15 160.91 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 120.966 0.412 . . . . 0.0 110.607 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 14.1 m . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.37 179.794 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 N--CA 1.464 0.264 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -93.6 135.5 34.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.761 0.315 . . . . 0.0 110.648 -179.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.554 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 75.2 t60 -152.21 164.09 38.08 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 44.9 tt0 -169.04 168.75 9.92 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.419 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.418 ' N ' ' CG ' ' A' ' 15' ' ' GLN . 66.5 mttm -153.75 123.72 6.86 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -119.59 114.12 21.75 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.179 0.514 . . . . 0.0 110.466 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 70.5 t -120.34 115.44 47.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.147 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.535 ' CD2' ' CE2' ' B' ' 19' ' ' PHE . 23.7 t80 -115.65 110.45 19.19 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 50.0 p90 -125.74 124.29 40.71 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.43 120.68 43.1 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.817 0.341 . . . . 0.0 110.357 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -159.65 115.32 2.46 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -74.89 121.85 22.5 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.96 0.409 . . . . 0.0 111.697 -178.553 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 26' ' ' SER . 13.9 t -84.48 124.6 39.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.06 84.3 0.01 OUTLIER Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.989 -178.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 24' ' ' VAL . 20.7 p -91.41 -179.76 5.47 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 178.175 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.43 179.13 0.17 Allowed 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 119.656 -0.817 . . . . 0.0 110.722 -179.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -59.5 111.11 1.28 Allowed 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.66 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.23 93.81 0.09 OUTLIER Glycine 0 N--CA 1.464 0.501 0 C-N-CA 120.169 -1.015 . . . . 0.0 112.214 177.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.24 156.14 21.92 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 176.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.432 HG22 HD11 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -151.86 119.67 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.0 -173.248 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.455 ' C ' ' SD ' ' G' ' 35' ' ' MET . 5.9 tp -149.59 131.58 5.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.154 179.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.415 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.67 128.86 5.82 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -129.65 129.63 44.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.314 0.578 . . . . 0.0 110.606 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.517 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 27.9 ttt -130.81 129.23 42.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.552 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.6 t -84.46 75.99 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.979 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -90.51 103.36 3.02 Favored Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 178.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.45 179.95 52.43 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 N--CA 1.467 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.492 -179.886 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 N--CA 1.465 0.303 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.458 ' H ' ' HA ' ' C' ' 12' ' ' VAL . 61.7 t-80 -122.46 118.73 29.02 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.861 0.363 . . . . 0.0 110.198 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.489 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 80.8 t60 -132.8 163.83 28.18 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.489 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 1.6 pt20 -169.93 177.6 4.3 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.981 179.174 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -156.28 125.96 6.33 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -122.23 121.2 36.27 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 7.1 p -134.18 130.79 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.535 ' CE2' ' CD2' ' A' ' 19' ' ' PHE . 18.2 t80 -115.29 117.58 30.85 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -129.14 129.22 44.86 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.716 0.293 . . . . 0.0 111.423 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.8 123.37 37.21 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 120.616 -0.433 . . . . 0.0 111.652 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 41.0 tp10 -164.74 105.1 0.82 Allowed 'General case' 0 C--N 1.343 0.283 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.553 ' O ' ' O ' ' B' ' 24' ' ' VAL . 42.6 t0 -104.67 112.1 25.06 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.553 ' O ' ' O ' ' B' ' 23' ' ' ASP . 2.1 t -50.27 -133.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.745 178.042 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -95.35 -84.95 1.68 Allowed Glycine 0 CA--C 1.536 1.403 0 CA-C-N 115.933 -0.576 . . . . 0.0 113.276 -178.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 35.0 t 68.51 178.83 0.24 Allowed 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -177.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -89.88 168.27 12.18 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 118.456 -1.298 . . . . 0.0 112.513 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 45.9 pttt -40.92 110.57 0.16 Allowed 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 177.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.427 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 80.0 94.54 0.37 Allowed Glycine 0 N--CA 1.476 1.329 0 N-CA-C 116.892 1.517 . . . . 0.0 116.892 171.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.25 152.91 37.08 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 171.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.36 117.72 2.27 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.721 -174.308 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -127.05 131.57 70.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.029 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.31 119.59 3.45 Favored Glycine 0 N--CA 1.475 1.239 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 59.3 tp -127.45 126.24 41.97 Favored 'General case' 0 N--CA 1.47 0.527 0 O-C-N 122.287 -0.537 . . . . 0.0 110.885 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.518 ' SD ' ' O ' ' H' ' 32' ' ' ILE . 11.9 ttt -139.6 137.75 35.59 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.348 0.594 . . . . 0.0 111.481 179.525 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 24.4 t -122.51 73.88 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.845 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' B' ' 38' ' ' GLY . . . -62.85 111.95 4.52 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 178.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -26.66 148.53 0.01 OUTLIER Glycine 0 N--CA 1.469 0.871 0 CA-C-O 121.107 0.282 . . . . 0.0 112.676 -178.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 68.1 t -115.29 135.58 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 m . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.381 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -114.22 138.59 50.27 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.781 0.324 . . . . 0.0 110.592 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -110.75 131.28 55.18 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.146 0.498 . . . . 0.0 110.538 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.458 ' HA ' ' H ' ' B' ' 13' ' ' HIS . 28.3 m -136.11 164.17 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.473 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.733 ' CG ' ' H ' ' C' ' 14' ' ' HIS . 76.0 t60 -103.15 -173.48 2.32 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.733 ' H ' ' CG ' ' C' ' 13' ' ' HIS . 2.3 m170 -77.2 174.13 11.08 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.89 174.83 10.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.414 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -151.51 133.37 14.98 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.937 0.398 . . . . 0.0 111.731 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.409 ' CD2' ' C ' ' C' ' 17' ' ' LEU . 6.6 tt -127.62 123.2 35.06 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.578 178.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.5 t -128.04 129.52 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 CA-C-O 120.912 0.387 . . . . 0.0 111.648 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -121.7 115.21 22.3 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -127.45 125.79 41.18 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.92 0.39 . . . . 0.0 111.083 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.2 129.52 46.58 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.87 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 80.5 tt0 -155.97 158.39 37.82 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.938 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -142.8 120.65 11.97 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.57 0.224 . . . . 0.0 110.624 179.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -129.88 -112.19 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-O 121.308 0.575 . . . . 0.0 110.13 -179.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 35.07 -90.68 0.01 OUTLIER Glycine 0 CA--C 1.531 1.054 0 CA-C-N 115.337 -0.847 . . . . 0.0 114.084 -178.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.0 OUTLIER 175.28 -167.21 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 118.396 1.098 . . . . 0.0 110.793 -178.582 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' C' ' 26' ' ' SER . 51.4 p-10 -36.47 -179.62 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.164 -1.38 . . . . 0.0 113.641 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.494 ' HB3' ' O ' ' C' ' 27' ' ' ASN . 74.8 tttt 98.55 113.88 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.958 1.703 . . . . 0.0 113.182 179.047 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.88 93.64 0.49 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 172.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.2 163.07 12.88 Favored 'General case' 0 CA--C 1.498 -1.047 0 CA-C-N 120.74 2.27 . . . . 0.0 106.461 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.72 117.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 118.337 -1.345 . . . . 0.0 110.417 -174.113 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.485 ' C ' ' SD ' ' I' ' 35' ' ' MET . 13.5 tt -129.13 132.84 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 CA-C-O 121.736 0.779 . . . . 0.0 110.747 178.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -119.71 119.34 4.22 Favored Glycine 0 N--CA 1.465 0.612 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.494 ' CD2' ' CZ ' ' A' ' 19' ' ' PHE . 32.6 tp -118.67 121.86 41.14 Favored 'General case' 0 CA--C 1.512 -0.516 0 C-N-CA 120.986 -0.285 . . . . 0.0 111.743 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.522 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 7.9 ttm -122.05 108.98 14.0 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 173.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 m -128.75 72.37 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 120.543 -0.463 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.0 110.81 3.11 Favored Glycine 0 C--N 1.362 1.993 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.13 160.07 53.93 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -139.06 161.43 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.871 0.367 . . . . 0.0 111.051 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.398 179.64 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 70.0 t . . . . . 0 N--CA 1.468 0.459 0 CA-C-O 121.026 0.441 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.447 ' CE1' ' CG2' ' C' ' 12' ' ' VAL . 32.5 m-70 -138.39 97.83 3.46 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.167 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.504 ' HE2' ' CG1' ' E' ' 12' ' ' VAL . 38.6 m170 -119.98 161.93 20.07 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.41 0.624 . . . . 0.0 109.583 179.467 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.429 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 43.9 tt0 -154.32 170.33 21.56 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.804 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . 0.429 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.3 mttt -152.95 129.33 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.364 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -123.23 124.24 42.57 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.715 0.293 . . . . 0.0 110.643 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -123.63 126.77 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.085 0.469 . . . . 0.0 110.508 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.44 ' CZ ' ' CD2' ' F' ' 34' ' ' LEU . 7.7 t80 -124.69 110.55 14.51 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -123.13 129.85 51.99 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.522 0.677 . . . . 0.0 111.778 -178.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.93 122.19 26.5 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.497 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 79.6 mm-40 -115.86 120.33 38.87 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -151.51 112.0 4.17 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 -179.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.695 ' O ' ' N ' ' D' ' 26' ' ' SER . 52.1 t -111.96 131.07 64.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 102.572 -3.121 . . . . 0.0 102.572 174.125 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.663 ' N ' ' HZ1' ' F' ' 28' ' ' LYS . . . -37.59 81.67 0.0 OUTLIER Glycine 0 CA--C 1.534 1.256 0 C-N-CA 120.172 -1.014 . . . . 0.0 112.569 -176.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.695 ' N ' ' O ' ' D' ' 24' ' ' VAL . 26.8 m -88.48 -179.58 6.1 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-O 122.566 1.174 . . . . 0.0 111.612 178.356 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.416 ' CG ' ' H ' ' D' ' 28' ' ' LYS . 48.6 t30 -76.61 -177.13 4.07 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.921 175.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.416 ' H ' ' CG ' ' D' ' 27' ' ' ASN . 35.1 tttt 44.96 111.62 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 117.959 2.577 . . . . 0.0 117.959 177.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.465 ' CA ' ' O ' ' E' ' 29' ' ' GLY . . . -82.64 94.66 1.74 Allowed Glycine 0 CA--C 1.499 -0.957 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 173.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.24 167.36 12.38 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.42 118.29 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.623 -174.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 14.4 tt -130.13 130.88 66.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-O 121.828 0.823 . . . . 0.0 111.942 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.8 104.27 2.35 Favored Glycine 0 CA--C 1.509 -0.338 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 177.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.478 ' CD2' ' CZ ' ' B' ' 19' ' ' PHE . 16.6 tp -111.33 117.85 34.26 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 117.376 0.588 . . . . 0.0 111.945 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 17.7 tpp -121.08 108.01 13.31 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 176.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -121.04 76.51 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.951 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.04 103.31 2.85 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.16 174.33 41.96 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -135.4 160.62 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 121.047 0.451 . . . . 0.0 110.755 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.177 -0.916 . . . . 0.0 110.366 179.578 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -120.26 143.78 48.12 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.815 0.34 . . . . 0.0 110.332 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -73.23 135.15 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.84 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.504 ' CG1' ' HE2' ' D' ' 14' ' ' HIS . 8.4 t -146.74 135.62 16.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.108 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -132.54 131.7 41.83 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.638 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 24.2 t60 -152.08 163.6 38.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 121.922 0.868 . . . . 0.0 110.446 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.638 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 53.5 tt0 -159.55 167.11 29.35 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.496 178.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . 0.501 ' CG ' ' HE2' ' E' ' 14' ' ' HIS . 99.2 mttt -151.44 130.11 12.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 179.432 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.5 mt -115.52 116.18 27.74 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.52 115.34 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.099 -179.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -117.03 124.43 49.29 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 116.78 -0.191 . . . . 0.0 110.756 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -129.94 119.09 22.68 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.65 121.13 22.7 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.231 0.539 . . . . 0.0 111.425 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 35.0 tt0 -88.52 165.63 14.73 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.7 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.563 ' O ' ' O ' ' E' ' 24' ' ' VAL . 46.0 t0 -145.4 -122.27 0.08 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.002 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.563 ' O ' ' O ' ' E' ' 23' ' ' ASP . 2.9 t 22.22 121.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 -178.707 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.08 -85.0 0.09 OUTLIER Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 177.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.492 ' H ' ' CE ' ' F' ' 28' ' ' LYS . 1.7 p 162.39 160.8 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 177.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.455 ' O ' ' O ' ' E' ' 26' ' ' SER . 69.6 m-80 -29.78 159.42 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.694 178.087 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.447 ' HD2' ' H ' ' D' ' 26' ' ' SER . 76.1 tttt -179.73 105.84 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 174.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.465 ' O ' ' CA ' ' D' ' 29' ' ' GLY . . . -58.65 93.54 0.05 OUTLIER Glycine 0 C--O 1.211 -1.323 0 CA-C-O 118.16 -1.356 . . . . 0.0 111.708 173.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -155.9 149.37 24.82 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 103.1 -2.926 . . . . 0.0 103.1 173.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.05 124.3 6.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 C-N-CA 117.984 -1.486 . . . . 0.0 112.133 -168.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.437 ' CG2' ' O ' ' E' ' 32' ' ' ILE . 0.7 OUTLIER -120.91 111.29 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 CA-C-N 114.529 -1.214 . . . . 0.0 107.761 179.541 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.57 110.24 3.62 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 mt -117.97 112.76 20.72 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -176.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' K' ' 32' ' ' ILE . 6.2 ttm -115.29 107.91 15.87 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 175.419 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.16 80.97 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.23 102.64 0.5 Allowed Glycine 0 C--N 1.346 1.116 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -86.67 -160.22 34.35 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.31 160.47 33.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.185 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.5 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.689 -179.993 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.408 ' CG2' ' N ' ' F' ' 13' ' ' HIS . 1.5 p . . . . . 0 N--CA 1.464 0.27 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.568 ' ND1' ' ND1' ' E' ' 14' ' ' HIS . 15.2 t-80 -125.02 155.27 39.98 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 120.912 0.387 . . . . 0.0 110.595 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.558 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 89.9 m-70 -80.42 178.28 8.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -125.93 -179.88 4.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.364 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -133.62 137.58 45.5 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.161 0.505 . . . . 0.0 110.993 -179.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 33.1 mt -122.03 115.17 22.02 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.276 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 28.5 m -134.04 127.64 51.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.341 0.591 . . . . 0.0 110.092 178.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.495 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 50.0 p90 -138.69 131.52 29.39 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.575 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -129.79 122.27 28.45 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.6 146.24 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.422 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -115.78 125.9 53.33 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.217 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 . . . . . 0 CA--C 1.532 0.286 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.978 178.536 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.663 ' HZ1' ' N ' ' D' ' 25' ' ' GLY . 30.6 tttt . . . . . 0 CA--C 1.544 0.723 0 CA-C-O 122.882 1.325 . . . . 0.0 112.476 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.535 ' H ' ' CG ' ' F' ' 28' ' ' LYS . . . -90.6 -99.85 1.18 Allowed Glycine 0 CA--C 1.484 -1.883 0 C-N-CA 127.568 2.509 . . . . 0.0 111.76 -179.509 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.66 166.46 3.24 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 105.838 -1.912 . . . . 0.0 105.838 -177.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -132.61 135.71 57.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.34 -171.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 61.4 mt -114.87 117.24 55.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 CA-C-N 115.198 -0.91 . . . . 0.0 112.646 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.69 92.58 1.23 Allowed Glycine 0 CA--C 1.51 -0.244 0 N-CA-C 104.51 -3.436 . . . . 0.0 104.51 173.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.44 ' CD2' ' CZ ' ' D' ' 19' ' ' PHE . 8.4 tp -110.3 116.77 32.07 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.346 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.403 ' HG3' ' CA ' ' L' ' 33' ' ' GLY . 96.4 mmm -119.58 111.98 18.75 Favored 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 176.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -127.36 80.22 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 34.47 -103.27 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 CA-C-N 116.436 -0.347 . . . . 0.0 112.308 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.97 -150.17 10.95 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.8 t -120.02 135.77 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.997 0.427 . . . . 0.0 110.803 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.13 -0.938 . . . . 0.0 110.281 179.559 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . 0.409 ' O ' ' OE2' ' H' ' 11' ' ' GLU . 99.1 m-85 -99.19 133.77 43.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.136 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -139.67 145.6 38.62 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.301 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 62.2 t -125.34 132.63 70.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.225 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -88.31 172.11 9.67 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.919 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.537 ' CD2' ' N ' ' G' ' 14' ' ' HIS . 3.6 m170 -89.05 170.52 10.58 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.626 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.406 ' HG2' ' N ' ' G' ' 16' ' ' LYS . 54.8 tt0 -147.57 171.81 14.99 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.859 179.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.406 ' N ' ' HG2' ' G' ' 15' ' ' GLN . 98.9 mttt -150.8 125.0 9.38 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 121.227 -0.189 . . . . 0.0 111.101 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 77.9 mt -118.28 122.42 42.87 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -138.66 132.42 40.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 121.774 0.797 . . . . 0.0 113.101 -178.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.452 ' CZ ' ' CD1' ' J' ' 34' ' ' LEU . 6.9 m-85 -113.14 111.72 22.59 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 175.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -130.62 121.06 24.92 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 131.03 41.07 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-O 121.373 0.606 . . . . 0.0 112.038 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' G' ' 23' ' ' ASP . 83.8 tt0 -156.05 152.95 28.68 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 177.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.475 ' O ' ' C ' ' G' ' 24' ' ' VAL . 22.2 t70 -59.48 -120.41 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.534 -178.612 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.475 ' C ' ' O ' ' G' ' 23' ' ' ASP . 22.7 m -27.2 121.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 122.179 0.192 . . . . 0.0 111.001 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.15 -85.6 0.1 Allowed Glycine 0 CA--C 1.526 0.775 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.225 -177.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.697 ' O ' ' O ' ' G' ' 27' ' ' ASN . 62.5 m -152.73 -170.81 3.74 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -175.591 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.697 ' O ' ' O ' ' G' ' 26' ' ' SER . 12.7 t-20 -19.34 159.59 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.103 0 O-C-N 124.629 1.206 . . . . 0.0 114.016 -176.35 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -159.82 110.64 1.94 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.236 -176.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . 0.551 ' O ' ' CB ' ' H' ' 30' ' ' ALA . . . -69.51 96.09 0.48 Allowed Glycine 0 CA--C 1.455 -3.683 0 CA-C-O 123.686 1.715 . . . . 0.0 110.511 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . 0.522 ' O ' ' C ' ' G' ' 29' ' ' GLY . . . -81.6 -139.99 0.04 OUTLIER 'General case' 0 N--CA 1.395 -3.215 1 N-CA-C 94.424 -6.139 . . . . 0.0 94.424 171.171 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.693 ' N ' ' CD1' ' G' ' 31' ' ' ILE . 1.0 OUTLIER -85.18 111.31 20.5 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.298 0 CA-C-N 125.186 3.63 . . . . 0.0 109.443 179.928 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.517 ' O ' ' SD ' ' A' ' 35' ' ' MET . 39.1 mm -136.73 129.34 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 120.304 -0.558 . . . . 0.0 112.035 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . 0.516 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -131.34 130.76 6.13 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 34.2 tp -156.19 135.33 12.09 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.801 0.81 . . . . 0.0 112.99 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.455 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 63.7 ttp -121.93 143.94 49.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.363 178.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 25.5 t -120.03 75.86 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.5 101.12 2.58 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 177.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.6 167.33 22.13 Favored Glycine 0 N--CA 1.467 0.741 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 81.8 t -131.3 138.27 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.752 0.31 . . . . 0.0 110.301 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.9 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.347 179.472 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -118.61 140.48 49.84 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' O ' ' G' ' 10' ' ' TYR . 80.9 mm-40 -132.36 135.9 46.47 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.711 0.767 . . . . 0.0 111.978 -178.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 58.0 t -128.47 134.33 64.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.094 -0.957 . . . . 0.0 108.654 179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 -137.86 101.11 4.36 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.95 -0.3 . . . . 0.0 110.754 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 11.1 m170 -115.5 154.67 28.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 80.5 mt-30 -155.91 174.31 15.51 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.468 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -156.96 112.17 2.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.712 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -111.42 111.4 22.41 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.69 125.32 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-O 121.86 0.838 . . . . 0.0 111.732 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.604 ' CG ' ' CE2' ' I' ' 19' ' ' PHE . 6.0 m-85 -113.17 116.81 30.41 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 114.182 -1.372 . . . . 0.0 108.666 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -128.67 126.56 40.38 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.13 130.24 35.14 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 121.19 0.519 . . . . 0.0 111.394 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' H' ' 23' ' ' ASP . 84.9 tt0 -149.96 91.12 1.75 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 178.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' H' ' 22' ' ' GLU . 1.1 m-20 62.74 115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 -176.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.53 ' C ' ' HZ2' ' I' ' 28' ' ' LYS . 48.9 t -118.84 123.75 72.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.471 -174.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.55 ' C ' ' HZ2' ' I' ' 28' ' ' LYS . . . 35.91 83.69 0.01 OUTLIER Glycine 0 N--CA 1.47 0.905 0 C-N-CA 121.482 -0.39 . . . . 0.0 113.255 177.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.627 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 5.4 t -58.9 170.92 0.74 Allowed 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 121.18 0.514 . . . . 0.0 110.389 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.527 ' ND2' ' O ' ' H' ' 26' ' ' SER . 68.7 m-20 103.26 177.43 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 113.259 -1.791 . . . . 0.0 107.298 -177.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' H' ' 27' ' ' ASN . 98.7 mttt -23.69 -102.87 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 O-C-N 123.567 0.542 . . . . 0.0 111.981 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -141.25 100.46 0.26 Allowed Glycine 0 N--CA 1.472 1.059 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 177.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.551 ' CB ' ' O ' ' G' ' 29' ' ' GLY . . . -66.59 158.48 29.72 Favored 'General case' 0 C--O 1.248 1.013 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.016 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.446 HD11 HG23 ' H' ' 31' ' ' ILE . 0.1 OUTLIER -154.55 132.15 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.544 -175.796 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' B' ' 35' ' ' MET . 41.5 pt -130.42 127.07 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.499 0.666 . . . . 0.0 112.226 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.53 97.89 0.66 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 4.4 mp -129.44 149.8 51.07 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.924 0.868 . . . . 0.0 111.974 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.406 ' CE ' ' SD ' ' G' ' 35' ' ' MET . 20.7 ttp -141.03 134.69 30.17 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.482 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 4.1 t -126.42 79.01 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.53 105.07 0.8 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 177.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.94 173.05 0.64 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.99 161.88 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.965 0.412 . . . . 0.0 110.66 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.9 m . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.831 179.951 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 N--CA 1.468 0.452 0 CA-C-O 120.188 0.042 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -135.75 132.31 36.65 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.505 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.625 ' NE2' ' CG ' ' J' ' 13' ' ' HIS . 75.7 m80 -122.91 159.69 27.71 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 178.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -157.51 177.52 11.32 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.629 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -170.05 114.16 0.49 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 tt -117.67 118.49 32.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.071 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -141.72 136.76 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 119.967 -0.693 . . . . 0.0 111.896 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.604 ' CE2' ' CG ' ' H' ' 19' ' ' PHE . 26.8 m-85 -123.92 128.5 49.52 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 115.393 -0.822 . . . . 0.0 110.224 179.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.587 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.2 t80 -133.26 124.86 28.12 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.09 133.21 44.07 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.488 0.921 . . . . 0.0 113.488 -178.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -143.35 167.75 21.42 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' I' ' 24' ' ' VAL . 3.6 m-20 -142.32 -102.14 0.13 Allowed 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.519 ' O ' ' O ' ' I' ' 23' ' ' ASP . 10.9 t 46.98 159.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 122.263 1.03 . . . . 0.0 112.655 -176.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.443 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 107.88 -76.35 0.22 Allowed Glycine 0 CA--C 1.541 1.712 0 CA-C-N 114.139 -1.391 . . . . 0.0 112.529 -175.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.9 ' O ' ' O ' ' I' ' 27' ' ' ASN . 0.4 OUTLIER 170.89 -169.48 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.403 0 CA-C-N 119.502 1.651 . . . . 0.0 109.354 -176.43 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.9 ' O ' ' O ' ' I' ' 26' ' ' SER . 62.1 t30 -17.01 -179.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.06 0 O-C-N 125.287 1.617 . . . . 0.0 113.537 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.659 ' CG ' ' O ' ' I' ' 27' ' ' ASN . 26.8 mmtt 139.89 -110.52 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -175.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.42 ' CA ' ' O ' ' J' ' 29' ' ' GLY . . . 49.27 91.28 0.01 OUTLIER Glycine 0 CA--C 1.482 -2.022 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -171.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.447 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -103.06 170.75 7.78 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 111.509 -2.346 . . . . 0.0 106.63 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.447 ' CG1' ' C ' ' I' ' 30' ' ' ALA . 0.3 OUTLIER -145.78 110.03 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 C-N-CA 118.299 -1.361 . . . . 0.0 109.423 -175.899 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.508 ' C ' ' SD ' ' C' ' 35' ' ' MET . 58.7 mt -103.6 115.72 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.516 -178.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.522 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.61 92.65 0.54 Allowed Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 107.509 -2.237 . . . . 0.0 107.509 176.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.445 HD13 ' N ' ' I' ' 35' ' ' MET . 22.6 tp -129.22 122.4 29.63 Favored 'General case' 0 C--O 1.244 0.785 0 CA-C-O 123.276 1.512 . . . . 0.0 110.798 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 24.7 ttp -106.61 120.42 41.91 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 112.596 -2.093 . . . . 0.0 108.548 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -135.49 72.23 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.392 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -104.13 101.62 2.01 Favored Glycine 0 C--N 1.36 1.914 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 178.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.35 178.91 24.56 Favored Glycine 0 N--CA 1.463 0.485 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 8.4 p -141.43 152.34 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.878 0.371 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.5 179.856 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.452 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -120.45 147.2 45.41 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -122.95 161.65 23.78 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.185 0.517 . . . . 0.0 110.441 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -143.77 151.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.591 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.655 ' CG ' ' H ' ' J' ' 14' ' ' HIS . 25.2 t-80 -92.45 -173.92 3.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.853 0.359 . . . . 0.0 110.219 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.655 ' H ' ' CG ' ' J' ' 13' ' ' HIS . 0.5 OUTLIER -86.01 175.19 8.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.336 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -126.16 166.26 17.38 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -148.57 122.89 9.63 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.756 0.312 . . . . 0.0 111.591 -179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 3.4 mp -123.9 121.14 34.54 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 94.5 t -129.72 128.66 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-O 121.149 0.499 . . . . 0.0 112.086 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 m-85 -115.53 119.83 37.48 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.587 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 29.0 t80 -130.99 120.35 23.37 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.616 0.644 . . . . 0.0 109.727 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.34 134.44 34.24 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -110.45 122.96 48.98 Favored 'General case' 0 C--N 1.346 0.43 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.311 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.508 ' HB3' ' H ' ' K' ' 24' ' ' VAL . 8.8 t70 -84.28 122.66 29.2 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.017 0.437 . . . . 0.0 110.911 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' J' ' 26' ' ' SER . 72.1 t -99.66 122.52 51.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.748 -179.06 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 39.17 -86.06 0.01 OUTLIER Glycine 0 C--N 1.337 0.619 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.301 177.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.653 ' O ' ' O ' ' J' ' 27' ' ' ASN . 87.9 p -161.25 174.17 13.98 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.653 ' O ' ' O ' ' J' ' 26' ' ' SER . 74.9 m-20 -9.39 159.4 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 116.369 1.989 . . . . 0.0 116.369 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt 179.86 104.83 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 112.566 -2.106 . . . . 0.0 106.618 175.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.42 ' O ' ' CA ' ' I' ' 29' ' ' GLY . . . -60.51 95.03 0.08 OUTLIER Glycine 0 C--O 1.22 -0.722 0 CA-C-O 118.724 -1.042 . . . . 0.0 113.924 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.401 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -127.37 149.01 50.25 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 102.215 -3.254 . . . . 0.0 102.215 172.414 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.401 ' CG1' ' C ' ' J' ' 30' ' ' ALA . 0.2 OUTLIER -148.48 118.64 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 C-N-CA 118.011 -1.476 . . . . 0.0 111.222 -172.296 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.427 HD11 HG21 ' J' ' 32' ' ' ILE . 2.0 mt -108.12 112.48 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.384 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.07 101.94 1.32 Allowed Glycine 0 C--O 1.239 0.455 0 N-CA-C 106.579 -2.608 . . . . 0.0 106.579 176.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.452 ' CD1' ' CZ ' ' G' ' 19' ' ' PHE . 0.2 OUTLIER -142.16 135.17 28.73 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 122.205 1.002 . . . . 0.0 112.391 -176.634 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 49.0 ttp -123.3 127.61 48.79 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.979 179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.86 69.08 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.306 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.725 178.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.2 -100.83 0.01 OUTLIER Glycine 0 C--N 1.36 1.89 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.07 150.91 20.43 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 75.6 t -134.52 137.31 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 p . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.401 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -109.51 142.54 40.4 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.58 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -130.59 144.13 51.21 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.671 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.05 133.79 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.803 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -134.4 124.27 25.43 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.019 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.578 ' CD2' ' N ' ' K' ' 15' ' ' GLN . 33.0 t60 -156.48 166.87 32.17 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-O 121.409 0.623 . . . . 0.0 109.921 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.578 ' N ' ' CD2' ' K' ' 14' ' ' HIS . 79.6 mt-30 -153.91 173.49 15.88 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.359 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 79.1 tttt -153.78 113.3 3.8 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.125 178.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 tt -116.01 121.74 43.15 Favored 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -126.61 129.37 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -125.05 123.82 40.62 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -134.39 122.54 22.71 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.676 0.274 . . . . 0.0 111.266 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.49 131.42 31.81 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 121.246 0.546 . . . . 0.0 111.85 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -110.27 128.17 55.39 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.748 179.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.447 ' OD2' ' O ' ' L' ' 22' ' ' GLU . 89.0 m-20 -100.48 115.65 30.57 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.552 ' O ' ' N ' ' K' ' 26' ' ' SER . 53.3 t -95.37 130.29 44.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.03 -85.31 0.01 OUTLIER Glycine 0 CA--C 1.529 0.917 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.552 ' N ' ' O ' ' K' ' 24' ' ' VAL . 29.4 p -141.16 170.76 15.12 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.945 0.878 . . . . 0.0 111.516 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.515 ' O ' ' O ' ' K' ' 26' ' ' SER . 2.3 p30 -28.83 169.72 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.184 -1.825 . . . . 0.0 114.294 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -149.85 111.38 4.48 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.101 175.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.413 ' H ' ' HA ' ' J' ' 27' ' ' ASN . . . -60.11 91.91 0.05 OUTLIER Glycine 0 N--CA 1.476 1.337 0 CA-C-O 119.603 -0.554 . . . . 0.0 113.643 176.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.12 153.97 51.02 Favored 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 102.961 -2.977 . . . . 0.0 102.961 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.09 111.68 2.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 C-N-CA 118.221 -1.392 . . . . 0.0 111.713 -172.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' E' ' 35' ' ' MET . 0.1 OUTLIER -106.83 111.12 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.661 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.79 97.64 1.05 Allowed Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 94.2 mt -130.24 142.3 50.57 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 122.024 0.916 . . . . 0.0 113.196 -176.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 40.7 ttp -129.67 117.91 21.08 Favored 'General case' 0 CA--C 1.501 -0.939 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.266 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' K' ' 37' ' ' GLY . 0.2 OUTLIER -115.19 65.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.666 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -36.69 -106.87 0.01 OUTLIER Glycine 0 C--N 1.352 1.471 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.569 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.73 144.98 0.07 OUTLIER Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -178.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -146.38 143.57 20.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.782 -179.579 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -111.87 137.2 50.15 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.703 0.287 . . . . 0.0 110.271 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -53.98 152.48 5.72 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.18 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 28.5 m -113.77 133.27 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.549 0.69 . . . . 0.0 111.663 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -150.07 138.59 20.66 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.804 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.553 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 68.0 t60 -157.31 175.5 13.93 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.553 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 87.9 mt-30 -142.86 176.44 9.07 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.952 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -166.23 113.47 0.88 Allowed 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.268 0.556 . . . . 0.0 111.024 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -121.56 125.97 48.02 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.607 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.6 t -134.43 133.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -141.78 133.4 26.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.124 0.488 . . . . 0.0 111.41 -179.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -134.49 128.56 33.64 Favored 'General case' 0 C--O 1.231 0.088 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.74 148.5 25.48 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.566 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.447 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 98.5 mt-10 -91.26 152.57 20.45 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.484 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -141.55 123.32 15.24 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.459 0.647 . . . . 0.0 112.036 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.533 ' O ' ' N ' ' L' ' 26' ' ' SER . 94.7 t -94.58 121.04 44.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.0 -88.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.082 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.533 ' N ' ' O ' ' L' ' 24' ' ' VAL . 11.9 p -90.97 179.72 5.68 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -61.1 170.44 1.63 Allowed 'General case' 0 C--N 1.314 -0.945 0 C-N-CA 118.491 -1.284 . . . . 0.0 109.612 -179.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -53.88 111.94 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.198 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.45 92.23 0.5 Allowed Glycine 0 N--CA 1.47 0.923 0 C-N-CA 118.64 -1.743 . . . . 0.0 110.058 176.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -174.83 163.29 3.35 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 102.386 -3.19 . . . . 0.0 102.386 178.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.86 120.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 116.927 -1.909 . . . . 0.0 113.207 -177.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 mt -102.78 111.72 33.57 Favored 'Isoleucine or valine' 0 C--N 1.343 0.325 0 CA-C-N 113.466 -1.697 . . . . 0.0 107.372 177.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . 0.403 ' CA ' ' HG3' ' F' ' 35' ' ' MET . . . -110.06 83.94 0.35 Allowed Glycine 0 CA--C 1.493 -1.318 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 177.305 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . 0.452 ' CD2' ' C ' ' L' ' 34' ' ' LEU . 7.3 tt -122.27 117.08 25.28 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 65.4 ttp -106.05 130.27 53.99 Favored 'General case' 0 CA--C 1.505 -0.784 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.333 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.2 79.97 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.18 103.24 0.76 Allowed Glycine 0 C--N 1.348 1.224 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.96 152.98 21.24 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -132.14 157.81 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.751 -179.599 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.2 m . . . . . 0 N--CA 1.466 0.347 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -138.24 163.19 32.38 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.944 0.402 . . . . 0.0 110.866 -178.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.629 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -82.11 170.82 15.05 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.551 -179.844 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -148.89 174.76 11.9 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.01 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -153.4 124.54 7.46 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.074 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.0 mt -121.12 114.26 21.19 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.1 t -131.26 129.34 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 CA-C-O 121.403 0.621 . . . . 0.0 112.354 -178.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.595 ' CG ' ' CE1' ' B' ' 19' ' ' PHE . 3.5 m-85 -108.85 111.63 23.45 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 50.1 p90 -131.59 126.32 34.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 118.797 0.726 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.12 133.14 42.51 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-O 121.461 0.648 . . . . 0.0 112.405 -178.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.496 ' OE1' ' N ' ' A' ' 22' ' ' GLU . 36.5 mp0 -142.97 156.52 44.88 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.457 ' O ' ' CG1' ' B' ' 24' ' ' VAL . 34.5 t70 -87.89 111.72 21.74 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 120.165 -0.614 . . . . 0.0 112.387 -178.445 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.598 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.5 t -113.8 131.2 66.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.093 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.96 81.97 0.0 OUTLIER Glycine 0 CA--C 1.53 1.022 0 O-C-N 123.315 0.384 . . . . 0.0 112.427 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.598 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.4 p -91.19 -179.3 5.39 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.538 ' O ' ' O ' ' A' ' 28' ' ' LYS . 58.8 t30 -62.64 -178.03 0.18 Allowed 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.538 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.2 mttt -48.48 -110.51 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.746 0.784 . . . . 0.0 110.604 -179.355 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -84.2 94.97 1.88 Allowed Glycine 0 N--CA 1.459 0.23 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 176.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.07 161.32 16.61 Favored 'General case' 0 C--N 1.351 0.636 0 C-N-CA 115.473 -2.491 . . . . 0.0 110.776 -177.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.415 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.7 OUTLIER -153.4 121.7 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 CA-C-N 112.545 -2.116 . . . . 0.0 110.667 -172.596 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' G' ' 35' ' ' MET . 78.6 mt -129.2 120.16 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 120.381 -0.527 . . . . 0.0 110.72 178.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.62 122.31 3.54 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 16.0 tp -127.75 141.96 51.44 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 117.241 0.52 . . . . 0.0 111.355 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.591 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 13.3 ttt -131.32 129.29 41.25 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.315 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 16.4 t -131.4 71.66 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 N-CA-C 112.315 0.487 . . . . 0.0 112.315 178.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -125.75 96.51 0.49 Allowed Glycine 0 C--N 1.344 1.024 0 N-CA-C 108.799 -1.72 . . . . 0.0 108.799 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.86 172.25 42.56 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.466 0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 110.761 179.834 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p . . . . . 0 N--CA 1.464 0.239 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.458 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 47.1 t-80 -142.18 105.98 4.71 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.659 0.266 . . . . 0.0 110.923 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -160.45 178.77 9.22 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-O 121.109 0.481 . . . . 0.0 110.283 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -133.44 -179.14 5.33 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.97 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -146.74 132.38 18.84 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.879 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.9 tp -125.39 115.9 21.02 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 120.701 -0.4 . . . . 0.0 112.01 -177.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 74.9 t -125.39 123.8 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 120.866 0.365 . . . . 0.0 110.912 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.595 ' CE1' ' CG ' ' A' ' 19' ' ' PHE . 13.3 m-85 -116.83 118.98 33.97 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.73 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.7 t80 -134.11 125.4 27.91 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.99 133.71 33.98 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -178.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -153.15 176.76 11.57 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -153.35 134.69 14.22 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.913 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.457 ' CG1' ' O ' ' A' ' 23' ' ' ASP . 2.8 p -109.09 112.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.005 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 33.09 88.57 0.01 OUTLIER Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -177.288 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -46.96 170.86 0.01 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.17 -1.015 . . . . 0.0 113.232 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.507 ' H ' ' HD2' ' C' ' 28' ' ' LYS . 78.3 m-20 -129.67 -179.94 5.47 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 114.316 -1.311 . . . . 0.0 108.62 176.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.498 ' O ' ' O ' ' B' ' 27' ' ' ASN . 98.1 mttt -26.71 -103.3 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 179.42 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.85 98.43 0.18 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.82 158.72 32.96 Favored 'General case' 0 C--O 1.25 1.088 0 C-N-CA 117.086 -1.846 . . . . 0.0 111.26 177.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 31' ' ' ILE . 0.1 OUTLIER -153.68 112.99 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.556 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.491 ' O ' ' SD ' ' H' ' 35' ' ' MET . 42.7 pt -136.02 150.36 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.255 -177.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.462 ' CA ' ' O ' ' C' ' 33' ' ' GLY . . . -166.18 150.29 17.4 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 119.835 -1.174 . . . . 0.0 112.332 -179.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 6.0 mt -139.17 143.43 38.14 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 120.9 0.381 . . . . 0.0 110.586 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.63 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 5.2 ttt -120.22 122.09 40.16 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.2 t -138.14 71.83 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.12 95.85 0.41 Allowed Glycine 0 C--N 1.343 0.969 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 177.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.33 179.44 18.69 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -179.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -123.75 136.12 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.982 0.42 . . . . 0.0 110.284 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.186 179.812 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -147.79 163.82 35.56 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . 0.515 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 56.7 mp0 -127.04 150.25 49.53 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.663 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.49 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 32.6 m -131.27 156.16 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.949 179.661 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 10.0 m-70 -150.98 150.43 30.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.995 -178.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 2.4 t60 -154.55 158.14 39.35 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.508 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 78.2 mt-30 -152.08 179.27 8.63 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 120.289 -0.565 . . . . 0.0 111.432 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -165.45 117.53 1.14 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.836 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.3 mt -115.81 114.78 25.22 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.79 140.92 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 119.426 -0.91 . . . . 0.0 113.163 -178.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.552 ' CE1' ' CD1' ' F' ' 34' ' ' LEU . 65.1 m-85 -124.28 125.11 43.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.541 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.0 t80 -130.61 117.21 19.19 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.24 136.15 46.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 120.559 -0.456 . . . . 0.0 111.641 -178.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -125.97 121.04 31.93 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.418 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' D' ' 24' ' ' VAL . 41.0 t0 -90.63 123.05 33.95 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.127 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.3 t -142.32 -111.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' C' ' 26' ' ' SER . . . -29.8 91.56 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 CA-C-N 116.145 -0.479 . . . . 0.0 112.747 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.545 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 12.8 p -61.18 179.15 0.21 Allowed 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 105.596 -2.001 . . . . 0.0 105.596 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.545 ' CB ' ' O ' ' C' ' 26' ' ' SER . 3.1 m120 91.17 -170.81 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -177.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.507 ' HD2' ' H ' ' B' ' 27' ' ' ASN . 84.3 tttt 40.59 -106.29 0.06 Allowed 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 114.803 1.408 . . . . 0.0 114.803 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.6 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . 92.95 91.91 1.51 Allowed Glycine 0 CA--C 1.497 -1.07 0 N-CA-C 107.483 -2.247 . . . . 0.0 107.483 -171.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.475 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -83.5 172.47 12.37 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.512 -176.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.475 ' CG1' ' C ' ' C' ' 30' ' ' ALA . 0.1 OUTLIER -152.72 124.19 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 C-N-CA 117.7 -1.6 . . . . 0.0 110.157 -175.909 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.7 tt -122.42 131.73 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.462 ' O ' ' CA ' ' B' ' 33' ' ' GLY . . . -122.44 109.13 1.36 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 179.131 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.406 ' H ' HD23 ' D' ' 34' ' ' LEU . 1.0 OUTLIER -137.07 126.57 25.12 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.45 -1.029 . . . . 0.0 112.258 -178.402 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.666 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 14.2 ttp -110.58 121.8 46.2 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 114.388 -1.278 . . . . 0.0 109.945 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -139.87 70.46 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.732 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.53 -100.48 0.62 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.44 155.27 25.49 Favored Glycine 0 CA--C 1.521 0.434 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -136.06 162.09 36.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.761 0.315 . . . . 0.0 110.213 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.8 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.721 -179.699 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.467 0.385 0 N-CA-C 110.787 -0.079 . . . . 0.0 110.787 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 73.9 m-70 -128.62 102.04 6.42 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.534 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 6.7 m170 -95.23 158.15 15.59 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 121.904 0.859 . . . . 0.0 111.162 -179.179 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.534 ' NE2' ' O ' ' D' ' 14' ' ' HIS . 99.7 mm-40 -152.61 171.34 18.31 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 114.023 -1.444 . . . . 0.0 107.905 178.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -174.1 128.67 0.37 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 121.014 -0.275 . . . . 0.0 110.275 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 8.8 mt -120.74 119.46 32.83 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 120.451 -0.5 . . . . 0.0 111.103 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -128.99 119.47 49.43 Favored 'Isoleucine or valine' 0 C--N 1.341 0.201 0 C-N-CA 120.636 -0.426 . . . . 0.0 111.359 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -113.03 116.66 30.28 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' OE2' ' D' ' 22' ' ' GLU . 9.0 t80 -129.5 119.4 23.66 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.13 0.423 . . . . 0.0 110.152 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.76 127.58 43.84 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 78.6 mm-40 -121.49 112.31 18.36 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 179.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 24' ' ' VAL . 19.9 t0 -84.35 97.34 9.41 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.622 ' O ' ' N ' ' D' ' 26' ' ' SER . 14.0 t -103.61 168.73 2.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.607 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.497 ' C ' ' HG ' ' D' ' 26' ' ' SER . . . 39.36 -78.31 0.0 OUTLIER Glycine 0 CA--C 1.527 0.783 0 CA-C-O 119.448 -0.64 . . . . 0.0 112.631 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.622 ' N ' ' O ' ' D' ' 24' ' ' VAL . 1.4 p 170.98 -170.83 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 117.895 0.848 . . . . 0.0 111.552 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.592 ' O ' ' O ' ' D' ' 26' ' ' SER . 20.5 m-80 -18.68 -172.11 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -179.126 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.687 ' N ' ' HZ1' ' E' ' 28' ' ' LYS . 86.0 tttt 127.2 104.46 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 111.217 -2.719 . . . . 0.0 110.48 177.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.6 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -59.9 96.28 0.08 OUTLIER Glycine 0 CA--C 1.491 -1.438 0 CA-C-O 118.337 -1.257 . . . . 0.0 110.559 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.464 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . -117.61 150.36 39.15 Favored 'General case' 0 CA--C 1.467 -2.224 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 174.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.464 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 0.3 OUTLIER -150.51 122.03 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 118.049 -1.461 . . . . 0.0 110.278 -171.973 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.4 HD11 HG23 ' D' ' 32' ' ' ILE . 0.1 OUTLIER -105.87 119.01 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 114.187 -1.369 . . . . 0.0 110.375 -179.091 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.86 101.55 0.69 Allowed Glycine 0 N--CA 1.464 0.554 0 N-CA-C 108.093 -2.003 . . . . 0.0 108.093 178.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.406 HD23 ' H ' ' C' ' 34' ' ' LEU . 16.8 mt -139.09 152.03 47.19 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.378 -0.929 . . . . 0.0 112.326 -176.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.591 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 35.2 ttp -126.36 118.16 24.46 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 176.639 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 40.1 t -127.06 70.22 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.57 -102.62 2.75 Favored Glycine 0 C--N 1.36 1.884 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.73 170.21 34.72 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -140.29 140.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.854 0.359 . . . . 0.0 110.232 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.43 -179.824 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.434 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -146.26 162.09 38.86 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.897 0.379 . . . . 0.0 110.458 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . 0.533 ' OE1' ' N ' ' E' ' 11' ' ' GLU . 56.1 mp0 -130.91 144.16 51.26 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.587 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -115.65 131.63 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' D' ' 13' ' ' HIS . 85.9 m-70 -109.99 160.56 16.32 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 118.532 0.605 . . . . 0.0 111.949 -178.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.539 ' CE1' ' O ' ' D' ' 13' ' ' HIS . 98.0 m-70 -152.14 174.44 13.72 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.279 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mm-40 -119.75 -171.02 2.05 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -97.77 175.72 6.07 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 122.504 1.145 . . . . 0.0 113.945 -176.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.1 tt -120.81 121.47 38.24 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 113.407 -1.724 . . . . 0.0 106.986 178.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.57 138.66 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-O 121.524 0.678 . . . . 0.0 112.616 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -124.21 124.51 42.62 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.578 -1.192 . . . . 0.0 109.007 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -131.2 122.55 26.77 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.86 127.87 42.72 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 120.861 0.362 . . . . 0.0 111.025 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 80.1 tt0 -92.91 144.48 25.23 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.814 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.612 ' O ' ' O ' ' E' ' 24' ' ' VAL . 41.5 p-10 -71.21 -122.34 0.0 OUTLIER 'General case' 0 C--O 1.218 -0.562 0 CA-C-N 116.304 -0.407 . . . . 0.0 109.982 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.612 ' O ' ' O ' ' E' ' 23' ' ' ASP . 87.3 t 19.84 122.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.58 -84.19 0.09 OUTLIER Glycine 0 CA--C 1.522 0.514 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.69 177.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.529 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.4 p 154.18 -179.23 0.0 OUTLIER 'General case' 0 C--N 1.345 0.382 0 CA-C-O 122.58 1.181 . . . . 0.0 111.006 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.426 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 1.8 m-20 -52.63 -178.94 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 112.44 -2.163 . . . . 0.0 112.643 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.687 ' HZ1' ' N ' ' D' ' 28' ' ' LYS . 0.0 OUTLIER 60.66 113.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 123.017 1.389 . . . . 0.0 114.385 -179.521 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -88.26 96.22 2.17 Favored Glycine 0 C--O 1.224 -0.522 0 CA-C-N 111.687 -2.506 . . . . 0.0 112.727 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -63.95 175.44 1.19 Allowed 'General case' 0 C--O 1.24 0.596 0 CA-C-N 119.882 1.841 . . . . 0.0 107.461 -178.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.428 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.1 OUTLIER -152.39 129.65 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.421 0 C-N-CA 116.736 -1.986 . . . . 0.0 114.606 -172.451 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.423 HD11 HG23 ' E' ' 32' ' ' ILE . 1.8 mt -107.67 121.04 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.072 177.237 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.3 104.59 0.82 Allowed Glycine 0 C--N 1.332 0.332 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.415 HD11 ' N ' ' E' ' 35' ' ' MET . 3.4 tp -150.31 135.3 17.73 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.461 1.124 . . . . 0.0 112.584 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.585 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 33.8 ttp -102.26 126.3 49.22 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.762 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.39 70.94 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.9 114.08 5.88 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.05 -139.49 0.14 Allowed Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -119.01 136.7 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 120.755 0.312 . . . . 0.0 110.527 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 20.6 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.408 179.824 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.52 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 58.3 t . . . . . 0 N--CA 1.468 0.466 0 CA-C-O 120.841 0.353 . . . . 0.0 110.44 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.52 ' CG ' ' O ' ' F' ' 12' ' ' VAL . 78.9 m80 -161.28 99.39 1.18 Allowed 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.817 179.59 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 92.1 m-70 -153.74 163.99 39.08 Favored 'General case' 0 N--CA 1.447 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 109.9 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -158.27 177.43 11.28 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.792 179.022 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -142.53 139.83 31.58 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 121.16 0.505 . . . . 0.0 110.574 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 39.5 mt -113.33 127.94 56.3 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.17 138.26 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.535 0.683 . . . . 0.0 111.694 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.0 p90 -132.47 131.03 41.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.765 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -136.44 130.15 32.22 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.99 144.31 25.75 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.633 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.405 ' HB2' ' H ' ' E' ' 23' ' ' ASP . 73.0 mm-40 -99.27 161.27 13.71 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 59.9 m-20 . . . . . 0 N--CA 1.465 0.292 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.531 -179.213 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 23.8 tttm . . . . . 0 CA--C 1.536 0.418 0 CA-C-O 121.588 0.708 . . . . 0.0 111.89 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 45.82 91.36 0.01 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 114.632 -1.167 . . . . 0.0 114.577 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.429 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -103.15 176.41 5.16 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 100.204 -3.998 . . . . 0.0 100.204 172.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.429 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.1 OUTLIER -149.76 122.38 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 C-N-CA 115.986 -2.285 . . . . 0.0 112.566 -175.053 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -104.81 111.38 34.1 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.441 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.304 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.01 89.98 0.56 Allowed Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 107.102 -2.399 . . . . 0.0 107.102 175.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.552 ' CD1' ' CE1' ' C' ' 19' ' ' PHE . 9.2 tt -126.86 127.84 45.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 39.5 ttp -106.04 129.47 54.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.59 -178.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.55 78.48 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.05 104.35 1.32 Allowed Glycine 0 C--N 1.344 1.019 0 N-CA-C 111.269 -0.732 . . . . 0.0 111.269 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.64 -164.84 33.99 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 63.1 t -120.54 135.65 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.887 0.375 . . . . 0.0 110.178 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 37.9 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.574 179.952 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.83 138.84 49.73 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.719 0.295 . . . . 0.0 110.564 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' G' ' 11' ' ' GLU . 57.8 mp0 -76.92 134.1 39.04 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . 0.493 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 21.9 m -137.7 165.82 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.857 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 64.6 m80 -154.99 135.14 13.09 Favored 'General case' 0 C--O 1.222 -0.371 0 C-N-CA 120.241 -0.584 . . . . 0.0 111.169 179.133 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -156.74 165.7 35.48 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 96.3 mm-40 -150.59 177.47 10.0 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.865 179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -158.61 129.68 6.32 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.056 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -133.86 128.93 35.66 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 121.097 0.475 . . . . 0.0 110.421 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.17 130.76 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.38 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.435 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 2.6 t80 -116.65 114.31 23.89 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 54.5 p90 -124.19 121.14 34.3 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.68 125.3 50.44 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.112 0.482 . . . . 0.0 111.222 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -161.44 166.51 27.14 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' ND2' ' H' ' 27' ' ' ASN . 63.3 t0 -79.0 114.84 18.28 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.075 -0.65 . . . . 0.0 111.077 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.0 p -88.57 130.83 37.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.82 82.43 0.0 OUTLIER Glycine 0 CA--C 1.531 1.058 0 CA-C-N 116.055 -0.52 . . . . 0.0 112.803 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.535 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.3 m -132.23 162.47 30.88 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 178.23 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.531 ' O ' ' O ' ' G' ' 26' ' ' SER . 80.6 m-20 -38.74 175.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.241 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -73.62 111.15 8.49 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.38 93.97 0.19 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.31 162.06 13.2 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.433 HG23 HD13 ' G' ' 31' ' ' ILE . 0.0 OUTLIER -146.72 104.02 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -174.631 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.508 ' O ' ' SD ' ' B' ' 35' ' ' MET . 85.5 mt -126.89 127.93 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.242 0.544 . . . . 0.0 111.126 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . 0.591 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -133.15 113.22 1.2 Allowed Glycine 0 CA--C 1.517 0.158 0 N-CA-C 108.934 -1.666 . . . . 0.0 108.934 178.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -136.69 147.87 47.05 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 122.221 1.01 . . . . 0.0 112.726 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 49.4 ttp -131.24 132.04 44.35 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.734 -1.575 . . . . 0.0 109.591 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.1 t -99.86 72.01 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.22 -96.45 0.01 OUTLIER Glycine 0 N--CA 1.438 -1.17 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.26 -172.11 33.47 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.43 ' O ' ' OXT' ' G' ' 40' ' ' VAL . 2.7 p -139.2 142.92 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . 0.43 ' OXT' ' O ' ' G' ' 39' ' ' VAL . 53.7 t . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.014 -0.993 . . . . 0.0 110.069 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.49 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -115.21 140.62 48.94 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.671 0.272 . . . . 0.0 110.476 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -81.23 142.33 33.27 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.452 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 m -121.76 131.82 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -118.93 140.62 49.69 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.733 0.301 . . . . 0.0 111.599 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.47 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 45.1 m-70 -142.31 160.61 39.92 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.345 0.593 . . . . 0.0 109.812 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.47 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 98.5 mm-40 -149.1 172.45 14.78 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.128 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -159.48 117.37 2.74 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.062 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -119.26 119.91 35.45 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -125.5 126.73 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.837 0.351 . . . . 0.0 110.534 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -123.06 118.77 28.5 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 -179.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 72.1 t80 -131.23 127.91 38.83 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.756 0.312 . . . . 0.0 111.288 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.7 123.96 30.47 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-O 120.886 0.374 . . . . 0.0 111.557 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -165.64 140.87 4.95 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 45.4 p30 -100.13 140.53 34.23 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.453 0.644 . . . . 0.0 112.509 -178.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.408 ' O ' ' C ' ' H' ' 25' ' ' GLY . 92.5 t -108.4 111.12 34.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' H' ' 24' ' ' VAL . . . 33.63 90.97 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 -177.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -46.45 152.74 0.42 Allowed 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.169 -1.015 . . . . 0.0 113.538 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.537 ' O ' ' O ' ' H' ' 28' ' ' LYS . 16.8 p30 -128.19 -179.97 5.29 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 114.189 -1.369 . . . . 0.0 107.823 174.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.537 ' O ' ' O ' ' H' ' 27' ' ' ASN . 84.4 tttt -27.51 -102.71 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.727 0.694 . . . . 0.0 111.885 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . 0.413 ' CA ' ' O ' ' I' ' 29' ' ' GLY . . . -149.96 100.36 0.21 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 175.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.56 155.45 35.7 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 117.064 -1.854 . . . . 0.0 108.336 177.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.41 HD11 HG22 ' H' ' 31' ' ' ILE . 2.2 mt -144.45 108.17 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -128.35 129.71 69.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.63 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.68 119.5 3.68 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 108.314 -1.915 . . . . 0.0 108.314 177.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 95.1 mt -135.31 129.45 33.51 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -177.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.491 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 24.0 ttp -129.55 131.87 46.69 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.338 178.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.43 ' O ' ' O ' ' H' ' 37' ' ' GLY . 2.4 p -149.47 75.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 119.999 -0.68 . . . . 0.0 112.325 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.74 -95.56 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 178.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -165.08 37.72 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.77 141.78 41.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.893 0.377 . . . . 0.0 110.353 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 27.9 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.645 -179.996 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.636 ' CE1' ' ND1' ' J' ' 13' ' ' HIS . 14.9 p-80 -156.24 156.19 33.67 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.767 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' I' ' 15' ' ' GLN . 11.1 m170 -133.37 161.19 35.2 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.696 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' I' ' 14' ' ' HIS . 43.6 mm-40 -142.59 171.71 13.68 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.521 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -159.51 120.49 3.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.103 178.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 tt -125.3 124.38 41.5 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 120.803 0.335 . . . . 0.0 110.48 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.59 125.32 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.408 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.493 ' CD1' ' CZ ' ' J' ' 19' ' ' PHE . 12.2 t80 -118.97 113.24 20.68 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.552 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 47.6 t80 -126.45 116.82 21.73 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 121.076 0.465 . . . . 0.0 111.058 -178.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.71 126.71 47.02 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.244 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -146.65 103.86 3.69 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.077 0.465 . . . . 0.0 110.818 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.401 ' CB ' ' HZ2' ' K' ' 28' ' ' LYS . 99.4 m-20 -95.31 122.82 38.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.496 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.427 ' CG2' ' H ' ' I' ' 25' ' ' GLY . 3.6 m -143.5 -111.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.854 -178.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.427 ' H ' ' CG2' ' I' ' 24' ' ' VAL . . . 27.39 -90.2 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.433 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.826 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.1 p 171.54 171.0 0.09 Allowed 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.826 ' O ' ' O ' ' I' ' 26' ' ' SER . 44.5 p-10 -9.51 179.27 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 O-C-N 125.869 1.981 . . . . 0.0 115.745 178.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.564 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 85.8 tttt 129.64 104.69 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 114.052 1.13 . . . . 0.0 114.052 175.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.413 ' O ' ' CA ' ' H' ' 29' ' ' GLY . . . -58.46 96.81 0.07 OUTLIER Glycine 0 C--O 1.225 -0.422 0 N-CA-C 106.711 -2.556 . . . . 0.0 106.711 171.133 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.43 ' C ' ' CD1' ' I' ' 31' ' ' ILE . . . -120.88 146.04 47.01 Favored 'General case' 0 CA--C 1.48 -1.729 0 N-CA-C 105.112 -2.181 . . . . 0.0 105.112 178.144 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.43 ' CD1' ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -137.84 108.04 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 C-N-CA 119.343 -0.943 . . . . 0.0 111.088 -173.854 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.419 HD13 HG21 ' I' ' 32' ' ' ILE . 96.7 mt -111.65 112.5 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 175.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.666 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.05 108.74 1.69 Allowed Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 177.029 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.427 ' HG ' ' N ' ' I' ' 35' ' ' MET . 0.9 OUTLIER -142.39 144.0 32.94 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-O 122.673 1.225 . . . . 0.0 113.352 -177.082 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.427 ' N ' ' HG ' ' I' ' 34' ' ' LEU . 12.7 tmm? -127.42 117.95 23.14 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 113.196 -1.82 . . . . 0.0 109.626 177.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 15.7 m -121.91 73.94 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.822 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.36 103.48 2.99 Favored Glycine 0 C--N 1.36 1.883 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 175.88 43.96 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -144.94 151.45 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 120.891 0.376 . . . . 0.0 110.774 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.567 179.651 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.447 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -111.1 132.55 54.18 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.781 0.324 . . . . 0.0 110.266 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' K' ' 11' ' ' GLU . 17.1 pt-20 -158.56 138.26 11.93 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.053 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -150.23 153.4 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.636 ' ND1' ' CE1' ' I' ' 13' ' ' HIS . 50.5 m-70 -144.21 116.05 8.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 118.966 0.803 . . . . 0.0 110.966 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.64 ' NE2' ' CG ' ' K' ' 13' ' ' HIS . 44.3 m80 -122.0 159.88 26.06 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.386 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 63.2 mt-30 -158.12 177.06 11.72 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.412 178.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 43.5 tttp -169.43 123.32 0.79 Allowed 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.427 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 8.8 tt -121.21 121.87 38.73 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.634 0.254 . . . . 0.0 110.328 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 79.2 t -124.28 127.48 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.493 ' CZ ' ' CD1' ' I' ' 19' ' ' PHE . 5.4 t80 -126.53 121.35 32.04 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.907 0.384 . . . . 0.0 110.72 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.552 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 50.7 t80 -128.93 127.18 41.24 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.003 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.34 137.53 30.61 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -142.58 106.0 4.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.131 -0.941 . . . . 0.0 109.272 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -96.59 108.91 21.59 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.049 -179.075 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 2.1 p -46.1 140.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.256 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.598 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -86.12 84.85 1.56 Allowed Glycine 0 CA--C 1.531 1.091 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.423 -178.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.59 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.3 t 162.36 160.41 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 CA-C-O 121.212 0.53 . . . . 0.0 110.12 176.203 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.59 ' O ' ' O ' ' J' ' 26' ' ' SER . 7.2 t-20 -29.99 178.99 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.544 ' H ' ' CG ' ' J' ' 27' ' ' ASN . 42.6 tttp 128.45 104.85 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 113.052 -1.886 . . . . 0.0 112.899 175.189 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.84 95.43 0.05 OUTLIER Glycine 0 N--CA 1.462 0.429 0 CA-C-N 113.057 -1.883 . . . . 0.0 112.782 173.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.21 141.06 35.97 Favored 'General case' 0 CA--C 1.49 -1.364 0 CA-C-N 120.751 2.275 . . . . 0.0 107.353 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.449 ' CD1' ' N ' ' J' ' 31' ' ' ILE . 0.0 OUTLIER -137.73 106.94 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.894 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.447 HG22 HD11 ' J' ' 32' ' ' ILE . 0.1 OUTLIER -109.75 110.84 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.018 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . 0.591 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -123.78 98.82 0.6 Allowed Glycine 0 N--CA 1.463 0.436 0 N-CA-C 107.312 -2.315 . . . . 0.0 107.312 178.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.435 ' CD2' ' CE1' ' G' ' 19' ' ' PHE . 5.5 mp -131.07 140.75 50.09 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-O 122.134 0.969 . . . . 0.0 111.786 -177.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 11.5 tmm? -124.18 121.44 35.11 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.513 179.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' J' ' 37' ' ' GLY . 0.1 OUTLIER -110.43 73.74 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.178 -178.75 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -24.9 -101.18 0.01 OUTLIER Glycine 0 C--N 1.355 1.62 0 CA-C-N 116.198 -0.456 . . . . 0.0 112.851 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 131.24 -174.54 19.94 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -133.7 160.44 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 110.357 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.548 -179.934 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.74 133.35 51.55 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 110.267 -0.271 . . . . 0.0 110.267 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' J' ' 11' ' ' GLU . 81.4 tt0 -156.18 141.18 17.27 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-O 120.944 0.402 . . . . 0.0 110.711 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.34 154.57 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.64 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 22.3 m-70 -125.64 144.56 50.54 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 118.608 0.64 . . . . 0.0 110.725 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.546 ' CG ' ' H ' ' K' ' 15' ' ' GLN . 30.9 t-80 -86.71 -178.25 6.31 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.499 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.546 ' H ' ' CG ' ' K' ' 14' ' ' HIS . 86.5 mt-30 -84.85 172.69 11.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.148 -178.522 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -146.25 133.01 19.99 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 114.825 -1.08 . . . . 0.0 108.575 179.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -131.42 131.57 43.7 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.225 0.536 . . . . 0.0 112.274 -178.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.6 t -126.77 127.7 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.836 178.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -128.86 128.2 43.39 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.561 0.22 . . . . 0.0 110.795 -178.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.435 ' CE2' ' CD2' ' L' ' 20' ' ' PHE . 8.8 t80 -135.76 123.43 22.33 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-O 120.906 0.384 . . . . 0.0 110.517 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.51 129.33 44.39 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.113 0.483 . . . . 0.0 111.312 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.094 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.421 ' H ' ' HB3' ' L' ' 22' ' ' GLU . 26.3 t70 -91.85 134.25 34.93 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.429 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.598 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 44.0 t -109.19 112.46 40.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.27 -91.29 0.01 OUTLIER Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.21 -0.905 . . . . 0.0 112.783 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.504 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.8 m -162.86 -161.11 0.68 Allowed 'General case' 0 N--CA 1.447 -0.615 0 CA-C-O 122.579 1.181 . . . . 0.0 112.867 -179.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.597 ' CG ' ' H ' ' K' ' 28' ' ' LYS . 4.4 t-20 30.08 -173.28 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 111.874 -2.421 . . . . 0.0 115.401 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.597 ' H ' ' CG ' ' K' ' 27' ' ' ASN . 82.3 tttt 103.56 110.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 127.136 2.174 . . . . 0.0 109.184 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.521 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -60.16 -95.16 0.01 OUTLIER Glycine 0 CA--C 1.535 1.3 0 C-N-CA 115.212 -3.375 . . . . 0.0 110.535 175.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 69.63 151.21 0.09 Allowed 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 174.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.487 ' O ' ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -149.25 117.88 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-N 120.974 1.716 . . . . 0.0 111.508 178.075 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 4.6 mt -105.38 111.85 36.44 Favored 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 175.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . 0.585 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.84 96.77 0.75 Allowed Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 106.315 -2.714 . . . . 0.0 106.315 177.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -120.93 120.37 35.29 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-O 122.304 1.05 . . . . 0.0 110.201 -177.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -109.53 114.08 27.42 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.412 -1.722 . . . . 0.0 107.965 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.18 78.38 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.829 -177.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.48 105.43 0.97 Allowed Glycine 0 C--N 1.352 1.472 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.71 -144.01 4.35 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -106.79 134.7 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 20.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.021 -0.99 . . . . 0.0 111.073 -179.579 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.542 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -84.52 139.9 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.723 0.297 . . . . 0.0 110.855 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -121.52 131.03 53.91 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.971 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.98 156.79 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.179 0.514 . . . . 0.0 111.252 -179.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -158.19 163.21 37.74 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.787 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 41.9 m80 -136.74 169.8 17.13 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -148.08 176.29 10.32 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.174 0.512 . . . . 0.0 111.304 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 ttpt -170.59 111.46 0.39 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.983 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 72.0 mt -121.22 111.37 17.3 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 70.4 t -126.64 129.95 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.7 p90 -136.94 125.28 23.3 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.299 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.435 ' CD2' ' CE2' ' K' ' 20' ' ' PHE . 79.4 t80 -136.8 131.57 33.5 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 121.123 0.487 . . . . 0.0 110.297 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.74 143.75 35.15 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.393 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.421 ' HB3' ' H ' ' K' ' 23' ' ' ASP . 51.8 tp10 -78.21 140.96 38.92 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -58.86 130.46 47.05 Favored 'General case' 0 CA--C 1.518 -0.275 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.451 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.443 ' O ' ' C ' ' L' ' 25' ' ' GLY . 14.7 p -116.12 114.84 47.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.279 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.443 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -28.28 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.47 0.927 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -88.45 -177.4 5.61 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 60.3 m-20 -60.29 179.62 0.14 Allowed 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.477 -176.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.421 ' HZ2' HD12 ' L' ' 32' ' ' ILE 0.251 69.1 tttt -57.45 111.36 1.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 -177.015 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -68.62 -97.71 0.04 OUTLIER Glycine 0 CA--C 1.499 -0.932 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.521 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -60.9 170.78 1.4 Allowed 'General case' 0 CA--C 1.511 -0.552 0 CA-C-N 120.844 2.322 . . . . 0.0 105.805 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.454 ' N ' ' CD1' ' L' ' 31' ' ' ILE . 0.1 OUTLIER -134.17 121.79 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 115.811 -2.356 . . . . 0.0 114.086 -174.327 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.421 HD12 ' HZ2' ' L' ' 28' ' ' LYS . 97.3 mt -106.41 116.07 49.36 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 176.261 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -106.29 96.73 1.17 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 105.71 -2.956 . . . . 0.0 105.71 176.708 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 1.2 pp -110.23 112.09 23.84 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.751 -0.725 . . . . 0.0 110.298 -177.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.454 ' C ' ' SD ' ' L' ' 35' ' ' MET . 8.6 tmm? -109.69 110.85 22.01 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 178.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' C ' ' L' ' 37' ' ' GLY . 3.3 m -126.93 77.42 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.681 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 22.29 -110.69 0.01 OUTLIER Glycine 0 C--N 1.356 1.654 0 O-C-N 123.106 0.254 . . . . 0.0 113.017 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.79 140.85 8.9 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -134.89 159.24 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.886 0.375 . . . . 0.0 110.46 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.128 -0.939 . . . . 0.0 110.764 -179.885 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 m . . . . . 0 N--CA 1.465 0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 111.846 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.493 ' HE2' HE21 ' A' ' 15' ' ' GLN . 5.4 p80 -97.15 -175.58 3.28 Favored 'General case' 0 CA--C 1.527 0.086 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.838 178.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.5 p-80 -89.85 164.98 14.39 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.44 0.638 . . . . 0.0 110.619 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.493 HE21 ' HE2' ' A' ' 13' ' ' HIS . 83.0 mt-30 -155.99 -178.2 7.13 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.684 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -135.29 111.69 9.82 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.372 -0.232 . . . . 0.0 110.372 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -117.81 127.8 54.24 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 120.792 0.33 . . . . 0.0 110.515 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.8 m -133.04 128.39 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-O 121.149 0.5 . . . . 0.0 111.125 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 75.0 t80 -122.69 116.13 23.27 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -147.08 153.84 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.343 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.0 133.81 43.62 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.209 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -167.49 92.21 0.38 Allowed 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 62.5 t0 -70.11 121.82 18.24 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -177.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.422 ' O ' ' C ' ' A' ' 25' ' ' GLY . 26.1 m -105.98 121.72 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.637 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . 30.8 82.8 0.01 OUTLIER Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.847 -0.418 . . . . 0.0 112.255 178.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.519 ' OG ' ' ND2' ' B' ' 27' ' ' ASN . 19.9 p -95.8 175.65 6.43 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 118.059 0.93 . . . . 0.0 109.182 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' LYS . 20.1 p30 -61.93 -177.67 0.13 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 176.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.548 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.6 mttm -50.41 -110.85 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.846 0.832 . . . . 0.0 109.842 178.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.66 94.66 1.82 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 176.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.452 ' CB ' HD22 ' A' ' 27' ' ' ASN . . . -92.54 160.65 14.94 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 115.599 -2.441 . . . . 0.0 109.703 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.411 HD12 HG23 ' A' ' 31' ' ' ILE . 0.3 OUTLIER -154.31 119.68 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 114.0 -1.455 . . . . 0.0 109.878 -173.729 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.51 ' O ' ' SD ' ' G' ' 35' ' ' MET . 96.5 mt -119.44 112.45 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.103 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.21 106.64 1.45 Allowed Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 178.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.7 tp -149.11 147.19 28.19 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 118.124 0.962 . . . . 0.0 113.028 -178.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.511 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 53.5 ttp -141.43 146.35 36.42 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.2 t -128.89 79.61 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.949 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.99 97.85 2.06 Favored Glycine 0 C--N 1.338 0.681 0 N-CA-C 109.599 -1.401 . . . . 0.0 109.599 177.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.13 167.81 39.68 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.541 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.465 0.293 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.405 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.465 0.28 0 CA-C-O 120.747 0.308 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -117.09 160.1 21.53 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.1 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 16.3 p-80 -77.34 171.94 14.08 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -149.48 176.0 11.0 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . 0.558 ' NZ ' ' CG2' ' B' ' 18' ' ' VAL . 62.4 tttm -140.3 123.3 16.59 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.233 0.54 . . . . 0.0 111.407 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.1 mt -118.37 124.08 46.86 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.093 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . 0.558 ' CG2' ' NZ ' ' B' ' 16' ' ' LYS . 93.7 t -119.56 121.45 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 C-N-CA 120.711 -0.395 . . . . 0.0 110.998 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 11.8 t80 -115.2 112.22 22.16 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -132.59 125.76 31.21 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.18 0.514 . . . . 0.0 112.238 -177.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.66 126.28 49.85 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -153.96 159.75 41.81 Favored 'General case' 0 C--N 1.348 0.512 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -121.46 123.06 41.15 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.535 0.607 . . . . 0.0 111.885 -178.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.17 120.88 55.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.18 84.11 0.01 OUTLIER Glycine 0 N--CA 1.471 0.986 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.445 179.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 4.3 p -45.88 167.61 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.519 ' ND2' ' OG ' ' A' ' 26' ' ' SER . 2.2 p30 -137.82 178.87 6.78 Favored 'General case' 0 C--O 1.203 -1.383 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 171.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.499 ' O ' ' O ' ' B' ' 27' ' ' ASN . 61.2 mttp -19.85 -103.13 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 CA-C-N 120.219 1.372 . . . . 0.0 113.338 176.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -142.62 99.94 0.24 Allowed Glycine 0 N--CA 1.485 1.962 0 N-CA-C 107.831 -2.108 . . . . 0.0 107.831 174.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.449 ' H ' ' CE ' ' C' ' 28' ' ' LYS . . . -70.6 156.55 39.3 Favored 'General case' 0 C--O 1.245 0.836 0 C-N-CA 117.064 -1.854 . . . . 0.0 109.399 177.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.25 115.49 2.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.481 ' O ' ' SD ' ' H' ' 35' ' ' MET . 82.9 mt -121.13 119.62 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -177.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.51 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -125.37 117.15 2.87 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 177.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 9.6 tt -148.8 154.67 39.87 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.532 -178.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 17.6 ttp -147.83 141.57 25.66 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 120.16 -0.616 . . . . 0.0 112.458 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' B' ' 37' ' ' GLY . 38.2 t -131.78 83.28 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.307 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.472 ' C ' ' O ' ' B' ' 36' ' ' VAL . . . -23.45 -93.71 0.01 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.818 -0.513 . . . . 0.0 111.818 177.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.88 179.16 40.33 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -143.95 153.09 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.937 0.398 . . . . 0.0 110.821 -179.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.46 179.722 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -111.51 146.95 36.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 110.378 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -55.84 146.19 22.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.16 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.513 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 32.9 m -129.28 156.31 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.513 ' CD2' ' O ' ' C' ' 12' ' ' VAL . 48.2 m80 -158.01 151.71 23.75 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.405 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -87.39 -179.67 6.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -88.2 174.91 7.94 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.958 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -123.85 138.77 54.44 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -141.62 131.65 24.62 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 120.422 -0.511 . . . . 0.0 111.764 -179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -126.55 130.42 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.307 0.575 . . . . 0.0 109.706 178.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -117.34 118.52 32.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.135 -178.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -130.35 114.9 16.18 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 118.147 0.43 . . . . 0.0 110.017 179.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.03 126.74 51.54 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.645 -0.422 . . . . 0.0 111.549 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -157.73 155.7 30.36 Favored 'General case' 0 C--O 1.226 -0.158 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.524 ' O ' ' NZ ' ' E' ' 28' ' ' LYS . 7.2 t0 -175.21 108.58 0.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 119.794 -0.762 . . . . 0.0 112.251 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 m -46.46 141.05 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 176.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -86.34 82.82 1.63 Allowed Glycine 0 N--CA 1.463 0.468 0 C-N-CA 118.471 -1.823 . . . . 0.0 110.159 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 50.7 p -100.48 -163.97 1.07 Allowed 'General case' 0 N--CA 1.439 -0.991 0 CA-C-O 122.432 1.11 . . . . 0.0 110.077 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.489 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 61.8 t30 -63.31 179.5 0.42 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.266 -1.788 . . . . 0.0 109.344 175.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.489 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 41.5 tttt 55.35 111.08 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 118.424 2.75 . . . . 0.0 118.424 178.075 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -81.63 96.43 1.77 Allowed Glycine 0 CA--C 1.497 -1.088 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 171.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 163.67 22.1 Favored 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 116.22 -2.192 . . . . 0.0 108.278 -177.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.86 108.06 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.013 -174.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.484 ' C ' ' SD ' ' I' ' 35' ' ' MET . 2.0 mt -106.78 117.9 53.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.96 94.25 0.51 Allowed Glycine 0 CA--C 1.523 0.577 0 N-CA-C 107.912 -2.075 . . . . 0.0 107.912 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 22.7 tp -124.77 137.03 54.34 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.345 1.069 . . . . 0.0 112.048 -178.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' D' ' 35' ' ' MET . 11.3 mmm -110.97 116.38 31.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.835 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 m -142.88 63.45 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 C-N-CA 121.11 -0.236 . . . . 0.0 110.507 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.09 -110.31 0.79 Allowed Glycine 0 C--N 1.363 2.053 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.56 -175.2 34.03 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.92 158.69 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.602 -179.728 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p . . . . . 0 N--CA 1.466 0.365 0 CA-C-O 121.04 0.448 . . . . 0.0 111.54 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.448 ' NE2' ' OE2' ' E' ' 11' ' ' GLU . 86.8 m-70 -123.66 125.19 44.36 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.801 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.58 ' CG ' ' N ' ' D' ' 15' ' ' GLN . 82.5 t60 -136.94 166.84 22.71 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.163 0.506 . . . . 0.0 110.144 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.58 ' N ' ' CG ' ' D' ' 14' ' ' HIS . 51.9 tt0 -161.61 173.23 15.04 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.438 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 65.1 tttp -160.92 110.12 1.65 Allowed 'General case' 0 C--O 1.235 0.307 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.95 179.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -122.0 115.82 23.21 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.911 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.4 t -114.35 115.61 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -114.27 109.05 17.77 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -178.164 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -136.47 130.89 33.28 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.444 0.64 . . . . 0.0 111.621 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . 0.427 ' CB ' ' CD1' ' F' ' 32' ' ' ILE . . . -144.83 145.09 31.47 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.352 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -132.67 102.96 5.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.751 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -79.26 112.54 16.59 Favored 'General case' 0 C--O 1.231 0.119 0 C-N-CA 118.099 -1.44 . . . . 0.0 107.631 179.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 89.6 t -60.92 130.38 24.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.694 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -68.74 86.35 0.21 Allowed Glycine 0 CA--C 1.538 1.489 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.618 177.517 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.4 OUTLIER 162.18 161.3 0.02 OUTLIER 'General case' 0 C--N 1.345 0.393 0 CA-C-N 119.267 1.533 . . . . 0.0 112.786 176.801 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.462 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 87.1 m-20 -34.07 -179.65 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 112.056 -2.338 . . . . 0.0 116.25 179.119 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' E' ' 29' ' ' GLY . 86.7 tttt 98.92 114.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 128.095 2.558 . . . . 0.0 113.576 176.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.447 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -73.39 92.1 0.66 Allowed Glycine 0 N--CA 1.473 1.132 0 CA-C-O 116.284 -2.398 . . . . 0.0 113.159 173.478 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.87 157.09 35.01 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 123.271 3.536 . . . . 0.0 109.197 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.415 ' HB ' ' SD ' ' J' ' 35' ' ' MET . 0.0 OUTLIER -145.01 126.1 8.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.892 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.725 -177.216 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.518 ' C ' ' SD ' ' J' ' 35' ' ' MET . 2.1 mt -110.49 110.48 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . 0.408 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -109.21 95.57 0.91 Allowed Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 178.35 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.07 120.97 35.87 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-O 121.578 0.704 . . . . 0.0 110.461 -178.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' C' ' 35' ' ' MET . 26.9 ttt -102.02 114.04 27.8 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 176.725 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.51 80.64 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.247 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.437 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.22 102.46 0.86 Allowed Glycine 0 C--N 1.353 1.475 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.88 -167.06 38.9 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 40' ' ' VAL . 53.9 t -123.07 136.89 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 39' ' ' VAL . 18.0 m . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.47 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -111.61 133.13 54.07 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.855 0.359 . . . . 0.0 110.95 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . 0.448 ' OE2' ' NE2' ' D' ' 13' ' ' HIS . 39.1 tp10 -120.51 127.39 52.14 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.8 t -134.13 134.36 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 O-C-N 123.322 0.389 . . . . 0.0 110.466 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 58.0 m80 -119.47 133.64 55.59 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 120.884 0.373 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.494 ' ND1' ' O ' ' F' ' 14' ' ' HIS . 85.2 t60 -143.3 165.41 27.55 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 178.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.474 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 81.8 mt-30 -154.94 179.16 9.39 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.359 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.35 108.13 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.692 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -126.99 121.93 33.06 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.025 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 77.4 t -125.88 127.53 71.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.746 0.307 . . . . 0.0 110.881 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -126.47 120.53 29.94 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.514 179.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -133.9 127.36 32.34 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.027 0.442 . . . . 0.0 110.263 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.29 128.42 41.51 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.341 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -110.56 167.69 10.02 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.345 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' E' ' 24' ' ' VAL . 14.3 t0 -173.11 -125.28 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.389 -177.144 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.519 ' N ' ' OD1' ' E' ' 23' ' ' ASP . 7.9 t 31.61 115.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -90.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 106.001 -2.84 . . . . 0.0 106.001 179.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.544 ' O ' ' O ' ' E' ' 27' ' ' ASN . 27.9 p -152.03 155.0 37.1 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 119.224 1.512 . . . . 0.0 109.067 172.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.544 ' O ' ' O ' ' E' ' 26' ' ' SER . 17.0 m120 -20.01 157.83 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 176.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.524 ' NZ ' ' O ' ' C' ' 23' ' ' ASP . 75.4 tttt -162.88 110.89 1.28 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.09 170.41 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.595 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -68.53 92.12 0.27 Allowed Glycine 0 C--O 1.218 -0.852 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 174.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.41 150.56 33.73 Favored 'General case' 0 CA--C 1.464 -2.345 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 175.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -151.24 117.24 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 C-N-CA 118.679 -1.208 . . . . 0.0 110.042 -172.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.56 112.99 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . 0.438 ' H ' ' HE3' ' J' ' 35' ' ' MET . . . -109.28 85.9 0.42 Allowed Glycine 0 CA--C 1.499 -0.963 0 N-CA-C 104.884 -3.286 . . . . 0.0 104.884 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.549 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 6.4 tt -130.31 134.05 46.91 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.787 0.803 . . . . 0.0 111.717 -177.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.7 ttm -122.91 125.34 45.15 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.484 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -124.32 81.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.687 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . 34.42 -101.66 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.681 -0.567 . . . . 0.0 111.681 178.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.94 -172.21 33.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.784 -0.927 . . . . 0.0 110.784 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.06 161.2 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.893 0.378 . . . . 0.0 110.595 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 8.8 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.362 179.788 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p . . . . . 0 CA--C 1.52 -0.183 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.671 ' CG ' ' H ' ' F' ' 14' ' ' HIS . 46.4 t-80 -111.62 175.18 5.53 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.671 ' H ' ' CG ' ' F' ' 13' ' ' HIS . 98.1 m-70 -70.2 177.05 3.47 Favored 'General case' 0 N--CA 1.44 -0.936 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' E' ' 15' ' ' GLN . 57.7 mm-40 -133.26 179.19 6.35 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.278 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -151.29 106.06 3.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.21 0.528 . . . . 0.0 110.695 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 tt -127.81 121.58 30.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.182 179.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.51 129.93 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.532 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -120.1 128.1 53.15 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.577 179.133 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -142.37 130.14 21.62 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.973 0.416 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.53 141.02 26.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.474 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 74.4 tt0 -92.51 115.46 28.11 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.462 0.126 0 CA-C-O 121.169 0.509 . . . . 0.0 111.317 -178.801 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 43.9 tttm . . . . . 0 N--CA 1.463 0.178 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.79 -99.33 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 177.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.37 170.95 15.69 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 103.356 -2.831 . . . . 0.0 103.356 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.94 117.13 12.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 118.043 -1.463 . . . . 0.0 111.398 -172.473 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.427 ' CD1' ' CB ' ' D' ' 21' ' ' ALA . 12.9 tt -103.86 123.2 57.41 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.261 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.19 102.75 1.04 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 tt -122.95 113.36 18.99 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.443 ' SD ' ' O ' ' K' ' 32' ' ' ILE . 28.3 ttt -95.39 121.88 37.53 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.606 -178.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -138.3 80.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.614 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 40.57 -103.25 0.03 OUTLIER Glycine 0 C--N 1.346 1.11 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.214 177.154 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -147.84 7.77 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 40' ' ' VAL . 55.9 t -121.41 136.39 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.874 0.368 . . . . 0.0 110.766 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 39' ' ' VAL . 2.3 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.592 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -108.15 137.93 45.29 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.482 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -125.33 145.67 49.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.077 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 7.4 m -119.78 134.79 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.134 0.492 . . . . 0.0 110.851 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -142.63 140.26 31.56 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.01 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -88.74 169.13 11.9 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.332 0.587 . . . . 0.0 110.532 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -151.4 177.67 10.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.486 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -137.58 129.11 28.27 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.665 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.5 tp -123.8 125.84 45.41 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -131.39 127.71 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.601 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 9.5 m-85 -113.58 117.5 31.81 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 176.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.518 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 39.9 p90 -130.37 118.02 20.61 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 121.034 -0.266 . . . . 0.0 111.558 -179.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . 0.484 ' O ' ' OE1' ' H' ' 22' ' ' GLU . . . -117.96 117.4 29.13 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 -144.75 175.0 10.5 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 123.729 0.643 . . . . 0.0 109.815 -179.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -64.85 113.55 3.9 Favored 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 112.025 0.379 . . . . 0.0 112.025 -178.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.42 ' H ' ' HA2' ' H' ' 25' ' ' GLY . 60.1 t -127.22 121.54 57.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' G' ' 24' ' ' VAL . . . -29.22 -85.87 0.01 OUTLIER Glycine 0 CA--C 1.535 1.317 0 CA-C-O 121.607 0.559 . . . . 0.0 113.481 179.044 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.6 t 65.7 176.2 0.22 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 -178.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -88.06 177.31 6.96 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.98 176.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -56.73 110.41 0.79 Allowed 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 118.612 -0.709 . . . . 0.0 111.895 175.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . 0.53 ' H ' ' CB ' ' H' ' 27' ' ' ASN . . . 72.12 94.51 0.08 OUTLIER Glycine 0 N--CA 1.469 0.897 0 C-N-CA 118.165 -1.969 . . . . 0.0 112.391 174.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.87 156.13 19.02 Favored 'General case' 0 CA--C 1.507 -0.679 0 CA-C-N 120.004 1.902 . . . . 0.0 107.885 178.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.44 HG23 HD12 ' G' ' 31' ' ' ILE . 0.4 OUTLIER -152.53 106.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.347 -0.842 . . . . 0.0 108.835 -173.187 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.447 ' C ' ' SD ' ' A' ' 35' ' ' MET . 50.3 mm -124.56 130.57 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.103 -178.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . 0.511 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -135.57 125.5 3.65 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 179.247 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.4 tp -144.82 136.85 25.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.258 0.529 . . . . 0.0 111.857 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.51 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 11.4 ttt -133.66 144.71 49.36 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.401 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.4 t -102.51 72.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.46 100.71 1.38 Allowed Glycine 0 C--N 1.341 0.837 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 177.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.93 170.96 41.62 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.423 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 5.6 p -135.8 143.33 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.52 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 80.5 t . . . . . 0 C--O 1.218 -0.565 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.565 -179.372 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -82.46 145.46 29.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.732 0.301 . . . . 0.0 110.593 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.03 137.09 47.69 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-O 121.194 0.521 . . . . 0.0 110.751 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.1 t -121.75 134.03 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.546 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 t-80 -142.49 103.46 4.25 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.197 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.434 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 33.4 p-80 -152.23 168.7 24.5 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.484 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -150.58 171.96 16.27 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.151 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -134.45 118.39 17.32 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.245 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -118.57 121.33 39.96 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 62.3 t -124.43 126.28 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.976 0.417 . . . . 0.0 110.421 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.511 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 2.5 m-85 -119.16 108.91 15.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -117.17 115.62 25.68 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 177.372 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.1 130.09 46.04 Favored 'General case' 0 C--O 1.242 0.671 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -177.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.566 ' O ' ' O ' ' H' ' 23' ' ' ASP . 52.4 mp0 -142.29 141.9 32.48 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.825 -1.534 . . . . 0.0 107.194 176.79 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.566 ' O ' ' O ' ' H' ' 22' ' ' GLU . 7.6 t0 -54.79 -130.63 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' H' ' 23' ' ' ASP . 32.7 m 28.49 111.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 178.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.42 ' HA2' ' H ' ' G' ' 24' ' ' VAL . . . -160.86 -91.24 0.08 OUTLIER Glycine 0 CA--C 1.521 0.428 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 177.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.81 -163.2 0.99 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 119.551 1.676 . . . . 0.0 109.487 176.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.53 ' CB ' ' H ' ' G' ' 29' ' ' GLY . 66.5 t30 -61.8 177.62 0.41 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.777 177.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.522 ' H ' ' CG ' ' H' ' 27' ' ' ASN . 60.1 tttm -47.51 111.06 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.291 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 92.43 -95.71 2.05 Favored Glycine 0 C--O 1.207 -1.591 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.217 -176.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.444 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . 70.44 145.37 0.06 Allowed 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 103.141 -2.911 . . . . 0.0 103.141 -176.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 5.2 tt -163.34 124.61 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 115.783 -2.367 . . . . 0.0 112.266 -177.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.9 mt -120.22 122.94 69.61 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 113.947 -1.478 . . . . 0.0 109.951 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.28 117.08 2.46 Favored Glycine 0 N--CA 1.47 0.9 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.73 141.97 51.74 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.277 0.561 . . . . 0.0 111.127 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.51 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 23.2 ttt -140.39 126.58 19.8 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.127 0.489 . . . . 0.0 111.303 -178.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 11.8 t -122.68 74.06 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.024 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.42 101.49 2.32 Favored Glycine 0 C--N 1.344 1.023 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.65 159.13 31.78 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 120.245 -0.979 . . . . 0.0 111.722 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -125.9 134.64 66.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.885 -1.055 . . . . 0.0 110.552 -179.903 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.466 0.374 0 CA-C-O 120.884 0.373 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 48.2 m-70 -144.07 104.43 4.13 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.855 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.434 ' O ' ' CB ' ' H' ' 14' ' ' HIS . 5.3 m170 -130.82 169.03 16.27 Favored 'General case' 0 C--O 1.221 -0.442 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 81.2 mt-30 -155.31 172.14 18.69 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 178.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -145.09 125.1 13.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.717 0.294 . . . . 0.0 111.279 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 37.9 tp -125.82 117.46 23.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 120.806 0.336 . . . . 0.0 110.35 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -122.59 127.96 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.934 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -121.91 117.25 26.0 Favored 'General case' 0 N--CA 1.47 0.575 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.411 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 42.0 t80 -126.24 123.76 38.88 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.32 132.07 42.59 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.813 0.339 . . . . 0.0 111.412 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -155.93 157.33 36.09 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.767 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.405 ' HB2' ' HZ1' ' K' ' 28' ' ' LYS . 7.1 t70 -111.6 101.83 10.2 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 121.415 0.626 . . . . 0.0 110.655 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.9 p -90.01 159.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.068 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 49.64 -80.28 0.01 OUTLIER Glycine 0 CA--C 1.531 1.073 0 CA-C-O 119.382 -0.677 . . . . 0.0 112.955 -179.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.621 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.4 p 170.84 -179.53 0.05 OUTLIER 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 118.445 1.122 . . . . 0.0 110.577 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.621 ' O ' ' O ' ' I' ' 26' ' ' SER . 42.0 p-10 -28.31 -179.82 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 -177.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.445 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 83.9 mttt 128.77 103.38 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 111.828 -2.442 . . . . 0.0 108.571 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -59.25 100.32 0.18 Allowed Glycine 0 CA--C 1.486 -1.756 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.665 177.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' H' ' 29' ' ' GLY . . . -112.47 144.67 41.54 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 103.869 -2.641 . . . . 0.0 103.869 177.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 mt -137.98 107.21 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 C-N-CA 118.251 -1.38 . . . . 0.0 110.472 -174.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -117.66 130.75 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 120.981 0.42 . . . . 0.0 110.115 179.094 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -134.18 134.01 7.17 Favored Glycine 0 CA--C 1.503 -0.673 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 177.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.429 ' H ' ' HG ' ' J' ' 34' ' ' LEU . 3.8 tt -145.89 131.21 18.56 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.799 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.484 ' SD ' ' C ' ' C' ' 32' ' ' ILE . 8.7 ttt -112.91 119.75 39.04 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.263 -1.335 . . . . 0.0 108.395 179.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.1 OUTLIER -118.53 72.38 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.645 -179.504 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -31.15 -100.25 0.01 OUTLIER Glycine 0 C--N 1.369 2.373 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -175.89 40.73 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.1 t -134.37 152.48 33.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.497 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . 0.436 ' O ' ' CE2' ' K' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.367 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -123.15 119.37 30.05 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -137.36 134.2 35.71 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.589 0.233 . . . . 0.0 110.388 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.449 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -126.01 132.81 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.953 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' K' ' 13' ' ' HIS . 66.4 m80 -119.64 140.65 50.29 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.418 -0.216 . . . . 0.0 110.418 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 59.5 t60 -151.83 167.78 27.2 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 121.204 0.526 . . . . 0.0 109.77 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.6 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 66.7 tp60 -158.32 164.31 36.51 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.613 178.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . 0.407 ' N ' ' HG3' ' J' ' 15' ' ' GLN . 50.3 tttp -157.99 116.29 3.08 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.977 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . 0.429 ' CD2' ' C ' ' J' ' 17' ' ' LEU . 7.2 tt -131.35 123.26 27.89 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.51 127.91 57.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.33 0.586 . . . . 0.0 111.636 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 6.1 m-30 -109.17 119.2 38.8 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 115.079 -0.964 . . . . 0.0 108.648 178.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD2' ' K' ' 20' ' ' PHE . 34.6 t80 -124.58 113.7 18.41 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 134.23 47.81 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.491 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -134.75 105.99 6.71 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.676 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -85.41 114.24 22.31 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' J' ' 25' ' ' GLY . 4.6 p -122.56 122.9 67.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 24' ' ' VAL . . . 34.61 84.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.141 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -177.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.461 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 6.0 m -46.2 152.05 0.45 Allowed 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 113.722 -1.239 . . . . 0.0 114.066 -177.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' J' ' 28' ' ' LYS . 65.9 m-80 -138.02 178.0 7.45 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.881 172.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.748 ' HZ2' ' H ' ' J' ' 29' ' ' GLY . 0.9 OUTLIER -20.43 -104.12 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.413 1.264 . . . . 0.0 114.413 177.668 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.748 ' H ' ' HZ2' ' J' ' 28' ' ' LYS . . . -167.45 96.88 0.13 Allowed Glycine 0 C--N 1.361 1.919 0 CA-C-O 117.472 -1.738 . . . . 0.0 110.745 176.179 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.2 167.44 14.25 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 123.128 3.464 . . . . 0.0 106.884 177.164 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -145.14 123.79 5.53 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.328 0 CA-C-N 121.128 1.786 . . . . 0.0 111.943 -176.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -122.33 122.52 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . 0.413 ' O ' ' HA2' ' I' ' 33' ' ' GLY . . . -131.17 100.97 0.47 Allowed Glycine 0 N--CA 1.476 1.302 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.601 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 6.0 mp -131.78 138.54 48.61 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-O 122.696 1.236 . . . . 0.0 113.906 -176.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.518 ' SD ' ' C ' ' D' ' 32' ' ' ILE . 4.9 ttm -116.66 119.57 35.91 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 113.799 -1.546 . . . . 0.0 109.66 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.61 77.03 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.074 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.738 -179.169 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -84.57 103.97 2.69 Favored Glycine 0 C--N 1.355 1.596 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 179.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.46 170.9 55.14 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 65.6 t -131.47 136.02 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.947 0.403 . . . . 0.0 110.536 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.517 179.817 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . 0.436 ' CE2' ' O ' ' J' ' 9' ' ' GLY . 93.3 m-85 -112.68 133.95 54.45 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' L' ' 10' ' ' TYR . 79.7 mm-40 -137.43 139.23 40.53 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.96 0.409 . . . . 0.0 110.792 -179.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 58.1 t -127.63 132.54 69.02 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' J' ' 13' ' ' HIS . 22.1 m170 -79.26 149.1 31.95 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.86 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 24.5 p-80 -78.84 178.08 8.21 Favored 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -117.87 175.88 5.46 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.574 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -145.14 118.52 9.01 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 120.911 0.386 . . . . 0.0 111.205 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 34.1 mt -124.77 118.8 27.21 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.37 138.15 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.644 0.735 . . . . 0.0 112.633 -178.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -124.21 127.67 48.06 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.288 179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.418 ' CD2' ' CE2' ' J' ' 20' ' ' PHE . 71.5 t80 -133.09 121.07 22.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.56 133.69 31.14 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.476 0.655 . . . . 0.0 112.665 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 96.4 mt-10 -117.69 124.66 49.07 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.211 178.327 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' K' ' 22' ' ' GLU . 14.5 m-20 -140.15 111.89 7.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' K' ' 26' ' ' SER . 6.3 m -129.55 -122.48 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 31.63 -84.25 0.0 OUTLIER Glycine 0 N--CA 1.474 1.183 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 -179.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.623 ' O ' ' O ' ' K' ' 27' ' ' ASN . 3.9 p 170.93 170.64 0.07 Allowed 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.209 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.623 ' O ' ' O ' ' K' ' 26' ' ' SER . 93.6 m-20 -18.75 157.48 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.554 1.159 . . . . 0.0 113.849 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' K' ' 29' ' ' GLY . 88.1 tttt -170.47 104.95 0.28 Allowed 'General case' 0 C--O 1.215 -0.729 0 CA-C-O 117.709 -1.139 . . . . 0.0 109.01 176.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -50.65 -99.08 0.01 OUTLIER Glycine 0 C--O 1.214 -1.126 0 C-N-CA 116.6 -2.714 . . . . 0.0 110.994 178.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 70.74 141.91 0.05 Allowed 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 102.616 -3.105 . . . . 0.0 102.616 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -147.95 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 122.298 2.317 . . . . 0.0 111.214 -176.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.443 ' O ' ' SD ' ' F' ' 35' ' ' MET . 10.6 mt -106.61 113.4 43.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 175.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.7 115.2 2.29 Favored Glycine 0 C--N 1.317 -0.519 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.511 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 0.8 OUTLIER -150.42 143.27 24.69 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 122.732 1.253 . . . . 0.0 112.631 -178.526 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 29.4 ttm -117.67 122.21 42.93 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 113.664 -1.607 . . . . 0.0 109.308 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -116.2 79.76 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.23 103.91 0.4 Allowed Glycine 0 C--N 1.351 1.377 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.48 -163.11 15.38 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.1 136.27 54.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 120.833 0.349 . . . . 0.0 110.623 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 86.6 t . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.455 179.868 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' L' L ' 10' ' ' TYR . . . . . 0.402 ' O ' ' OE2' ' K' ' 11' ' ' GLU . 94.9 m-85 -108.48 137.52 46.3 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.901 0.381 . . . . 0.0 110.928 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -96.34 158.89 15.23 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 179.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.16 133.14 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.823 0.344 . . . . 0.0 110.562 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 65.6 t60 -160.24 117.53 2.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.173 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.474 ' ND1' ' O ' ' L' ' 13' ' ' HIS . 80.1 m-70 -151.51 174.55 13.27 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -146.08 170.59 16.36 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -148.89 117.85 6.72 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.662 0.268 . . . . 0.0 110.303 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 7.2 tt -126.48 115.89 20.26 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.215 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 m -136.62 137.2 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-O 121.005 0.431 . . . . 0.0 110.426 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -134.28 133.81 41.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.237 0.541 . . . . 0.0 111.275 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -135.56 124.74 24.51 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.722 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -150.37 146.45 26.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.329 -0.548 . . . . 0.0 111.594 -179.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -104.17 102.15 11.88 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -91.87 113.64 25.96 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.562 ' O ' ' N ' ' L' ' 26' ' ' SER . 85.2 t -65.95 131.26 31.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.439 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -54.53 84.51 0.01 OUTLIER Glycine 0 CA--C 1.528 0.892 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.271 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.562 ' N ' ' O ' ' L' ' 24' ' ' VAL . 1.4 p 159.82 178.88 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.473 ' O ' ' O ' ' L' ' 26' ' ' SER . 21.2 p30 -41.92 177.64 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.053 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.552 ' NZ ' ' O ' ' L' ' 30' ' ' ALA . 8.6 tptp -75.2 110.57 9.64 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.708 -1.133 . . . . 0.0 112.31 178.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -51.29 -99.87 0.01 OUTLIER Glycine 0 C--N 1.317 -0.513 0 CA-C-O 119.054 -0.859 . . . . 0.0 111.607 179.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.552 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . . . -80.48 163.91 23.41 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 104.75 -2.315 . . . . 0.0 104.75 -178.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.28 128.85 49.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 116.487 -2.085 . . . . 0.0 113.038 -174.155 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 2.0 pt -117.52 114.94 47.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.232 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.8 90.64 0.56 Allowed Glycine 0 N--CA 1.463 0.47 0 N-CA-C 106.029 -2.828 . . . . 0.0 106.029 176.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . 0.451 ' N ' ' CD1' ' L' ' 34' ' ' LEU . 9.1 mp -116.16 134.59 54.76 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.747 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 77.7 mmm -119.62 119.47 33.84 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.683 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' L' ' 37' ' ' GLY . 1.2 m -125.64 76.54 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 115.043 -0.981 . . . . 0.0 108.657 178.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -37.12 105.71 0.04 OUTLIER Glycine 0 C--N 1.356 1.646 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.86 172.15 6.81 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.933 -0.467 . . . . 0.0 111.933 -177.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 14.9 p -133.57 144.07 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 115.457 -0.371 . . . . 0.0 110.362 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.558 179.797 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.465 0.284 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -107.24 119.41 39.33 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.687 0.28 . . . . 0.0 111.032 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -100.27 165.88 11.25 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -156.23 174.14 15.83 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.887 178.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttp -175.8 115.76 0.14 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.377 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 97.0 mt -124.89 115.69 21.03 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.119 0.485 . . . . 0.0 110.439 179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.2 m -122.14 126.92 75.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.355 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.467 ' CZ ' ' CD1' ' C' ' 34' ' ' LEU . 0.6 OUTLIER -117.85 113.52 21.9 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.418 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 t80 -122.87 116.42 23.61 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.79 119.87 38.11 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.22 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -174.79 108.57 0.11 Allowed 'General case' 0 CA--C 1.528 0.098 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -74.09 114.6 12.61 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.98 -0.688 . . . . 0.0 109.782 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.9 m -121.46 123.54 69.85 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.769 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.4 82.09 0.01 OUTLIER Glycine 0 CA--C 1.53 0.971 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.259 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.616 ' O ' ' O ' ' A' ' 27' ' ' ASN . 58.4 m -140.5 170.68 15.34 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 117.923 0.862 . . . . 0.0 108.942 177.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.616 ' O ' ' O ' ' A' ' 26' ' ' SER . 70.9 m-80 -30.94 174.4 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.707 0 O-C-N 124.29 0.994 . . . . 0.0 113.261 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.61 110.84 21.67 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.592 176.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 52.09 91.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.719 0 C-N-CA 119.922 -1.132 . . . . 0.0 110.436 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.65 166.77 10.22 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 118.906 1.353 . . . . 0.0 110.518 179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.05 107.32 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.389 -178.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 93.6 mt -128.21 130.09 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 121.442 0.639 . . . . 0.0 112.291 -177.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.433 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -128.13 110.88 1.2 Allowed Glycine 0 CA--C 1.521 0.439 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.03 124.55 52.88 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 120.908 0.385 . . . . 0.0 110.395 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.55 ' SD ' ' CA ' ' G' ' 33' ' ' GLY . 25.7 ttt -130.73 126.32 36.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.893 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.1 t -98.12 65.39 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 112.983 0.735 . . . . 0.0 112.983 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.2 -106.19 0.06 OUTLIER Glycine 0 N--CA 1.44 -1.075 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -95.44 178.16 35.26 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.468 0.438 0 CA-C-O 120.92 0.39 . . . . 0.0 110.275 179.739 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 N--CA 1.466 0.367 0 CA-C-O 121.165 0.507 . . . . 0.0 111.344 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.612 ' CG ' ' H ' ' B' ' 14' ' ' HIS . 15.3 t-80 -122.86 -164.26 1.18 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.036 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.612 ' H ' ' CG ' ' B' ' 13' ' ' HIS . 19.9 t-80 -71.59 168.05 18.46 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.586 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 79.0 mt-30 -152.3 177.47 10.53 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.156 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -158.43 128.63 6.02 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 120.554 -0.458 . . . . 0.0 111.672 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.44 119.55 29.51 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -129.21 131.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 121.068 0.461 . . . . 0.0 111.52 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.435 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 7.9 t80 -122.64 115.55 22.3 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 53.3 t80 -125.59 122.33 36.17 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 110.4 -0.222 . . . . 0.0 110.4 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.52 125.77 45.49 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -163.48 130.23 3.34 Favored 'General case' 0 C--O 1.222 -0.364 0 CA-C-N 115.018 -0.992 . . . . 0.0 108.472 178.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' NZ ' ' D' ' 28' ' ' LYS . 66.1 t0 -142.6 113.14 7.31 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 m -59.32 131.59 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.13 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 176.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.36 84.33 0.1 Allowed Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.357 -0.925 . . . . 0.0 113.313 -178.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 6.3 p -87.77 180.0 6.38 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.757 0.789 . . . . 0.0 109.438 176.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.487 ' O ' ' O ' ' B' ' 28' ' ' LYS . 51.1 p30 -76.69 179.22 6.17 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.342 -1.299 . . . . 0.0 109.578 175.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 27' ' ' ASN . 68.4 mttm 43.93 110.53 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 115.019 1.489 . . . . 0.0 115.019 175.773 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.76 97.79 1.51 Allowed Glycine 0 CA--C 1.485 -1.827 0 CA-C-N 113.562 -1.654 . . . . 0.0 110.866 -176.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -75.62 164.75 25.99 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 122.462 1.125 . . . . 0.0 109.658 -175.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -137.57 114.04 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 CA-C-N 112.63 -2.077 . . . . 0.0 110.504 -170.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' I' ' 35' ' ' MET . 96.4 mt -132.83 128.12 56.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 CA-C-O 121.64 0.733 . . . . 0.0 112.805 -177.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.491 ' CA ' ' SD ' ' I' ' 35' ' ' MET . . . -129.74 128.8 5.79 Favored Glycine 0 N--CA 1.471 0.999 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 179.304 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -129.25 126.13 38.4 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.149 0.5 . . . . 0.0 111.761 -178.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 7.2 tpp -120.86 117.81 28.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.428 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.37 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.66 104.63 2.1 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.505 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.44 -171.81 0.65 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.2 m -133.77 163.06 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.896 0.379 . . . . 0.0 110.47 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.342 179.727 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.439 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -116.2 138.53 51.2 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.767 0.318 . . . . 0.0 110.644 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -120.72 128.49 52.99 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.34 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -130.04 134.63 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.496 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.0 t-80 -136.62 127.36 27.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.843 0.354 . . . . 0.0 110.61 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.496 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 79.9 m-70 -152.16 164.74 36.69 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -156.83 171.01 21.16 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.092 178.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -158.13 113.95 2.74 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -114.46 122.38 46.43 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.45 124.52 62.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.658 -0.246 . . . . 0.0 110.431 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.569 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 1.1 t80 -120.46 111.98 18.39 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.054 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.4 t80 -119.84 121.92 40.15 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.681 0.277 . . . . 0.0 110.828 -178.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.74 128.92 49.51 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 121.331 0.586 . . . . 0.0 112.065 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -150.37 149.8 30.56 Favored 'General case' 0 C--O 1.226 -0.157 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.959 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -163.77 121.23 1.8 Allowed 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.63 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.439 ' CG2' ' H ' ' C' ' 25' ' ' GLY . 4.2 m -128.02 -112.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.803 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.439 ' H ' ' CG2' ' C' ' 24' ' ' VAL . . . 34.26 -90.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 115.725 -0.671 . . . . 0.0 112.315 -178.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.619 ' O ' ' O ' ' C' ' 27' ' ' ASN . 0.3 OUTLIER 172.0 -170.82 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.6 179.65 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.619 ' O ' ' O ' ' C' ' 26' ' ' SER . 14.3 m120 -20.31 -175.2 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 117.327 2.343 . . . . 0.0 117.327 177.665 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 82.6 tttt 111.64 110.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 CA-C-N 111.81 -2.45 . . . . 0.0 114.477 176.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.74 92.48 0.07 OUTLIER Glycine 0 C--O 1.218 -0.87 0 CA-C-N 112.305 -2.225 . . . . 0.0 112.714 171.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.67 156.8 40.47 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 122.902 3.351 . . . . 0.0 107.984 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.412 ' CD1' ' N ' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -138.73 129.07 33.51 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.189 -176.021 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 13.0 tt -133.84 122.97 43.96 Favored 'Isoleucine or valine' 0 C--N 1.348 0.525 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.523 177.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.52 115.36 3.61 Favored Glycine 0 CA--C 1.499 -0.936 0 N-CA-C 107.602 -2.199 . . . . 0.0 107.602 178.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.467 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 52.6 mt -116.26 111.4 20.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.117 0.484 . . . . 0.0 111.56 -176.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 24.6 tpp -109.48 103.16 12.01 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 177.126 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -121.35 70.74 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.727 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.239 -178.734 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -38.2 -100.79 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 178.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.85 -163.79 31.73 Favored Glycine 0 CA--C 1.521 0.456 0 N-CA-C 110.535 -1.026 . . . . 0.0 110.535 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 68.5 t -119.19 134.06 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.005 -0.997 . . . . 0.0 110.632 -179.641 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . 0.477 ' C ' ' ND1' ' D' ' 13' ' ' HIS . 9.8 p . . . . . 0 N--CA 1.467 0.385 0 CA-C-O 121.142 0.496 . . . . 0.0 110.702 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' C ' ' D' ' 12' ' ' VAL . 14.7 m80 -142.56 108.99 5.3 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.555 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.44 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 31.6 m-70 -126.55 167.08 16.13 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -151.39 171.86 16.83 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.581 179.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -155.24 121.16 5.11 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.139 179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -119.92 122.83 42.11 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.33 125.1 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.016 0.436 . . . . 0.0 110.678 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -118.73 117.55 29.22 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -128.26 122.3 31.38 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 112.059 0.392 . . . . 0.0 112.059 -177.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.79 121.3 29.84 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-O 121.112 0.482 . . . . 0.0 109.978 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -97.85 175.29 6.21 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.212 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -72.63 122.08 20.83 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.26 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 28.7 m -87.56 123.33 40.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.914 179.107 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -42.88 -86.09 0.01 OUTLIER Glycine 0 CA--C 1.532 1.152 0 C-N-CA 121.393 -0.432 . . . . 0.0 112.443 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.738 ' O ' ' O ' ' D' ' 27' ' ' ASN . 13.2 p -152.84 -171.61 3.99 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -178.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.738 ' O ' ' O ' ' D' ' 26' ' ' SER . 81.5 m-20 -20.15 172.24 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 114.783 1.401 . . . . 0.0 114.783 -179.05 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.556 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 83.2 tttt 132.02 105.65 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 124.95 1.3 . . . . 0.0 107.701 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -49.89 -97.72 0.01 OUTLIER Glycine 0 N--CA 1.473 1.135 0 C-N-CA 118.112 -1.994 . . . . 0.0 110.269 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.451 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . 72.54 145.01 0.07 Allowed 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.451 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 0.3 OUTLIER -149.42 116.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.202 -175.026 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -111.57 111.41 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.741 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.91 97.53 1.61 Allowed Glycine 0 CA--C 1.509 -0.289 0 N-CA-C 105.024 -3.23 . . . . 0.0 105.024 175.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.435 ' CD2' ' CZ ' ' B' ' 19' ' ' PHE . 62.8 tp -110.94 118.67 36.71 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -175.149 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -122.16 108.84 13.78 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 176.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -124.43 70.04 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -49.41 -100.6 0.01 OUTLIER Glycine 0 C--N 1.347 1.142 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.266 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 111.23 159.19 15.67 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -124.15 136.34 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.972 0.415 . . . . 0.0 110.664 -179.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 91.6 t . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.058 -0.973 . . . . 0.0 110.414 179.63 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -104.87 134.95 47.14 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -140.8 146.57 37.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.997 0.427 . . . . 0.0 110.956 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 4.2 m -131.55 155.84 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.748 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -156.75 162.37 39.77 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 121.312 0.577 . . . . 0.0 112.302 -179.025 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.59 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 36.4 t60 -154.96 164.75 38.45 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-O 121.411 0.624 . . . . 0.0 110.635 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.59 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 82.6 mt-30 -149.85 170.03 19.72 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.465 0.65 . . . . 0.0 110.892 178.608 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.19 128.79 3.17 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.096 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 52.5 tp -125.36 124.36 41.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.2 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.73 123.61 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -124.54 120.24 31.39 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.239 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -129.13 120.53 26.02 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 120.31 16.94 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.213 0.53 . . . . 0.0 110.948 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -143.09 128.3 18.71 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.476 179.538 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -154.14 120.4 5.4 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.455 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 14.1 t -107.5 -112.76 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.007 0.432 . . . . 0.0 110.327 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.7 -90.63 0.01 OUTLIER Glycine 0 N--CA 1.469 0.878 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.397 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.602 ' O ' ' O ' ' E' ' 27' ' ' ASN . 2.7 t 171.34 170.1 0.08 Allowed 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.602 ' O ' ' O ' ' E' ' 26' ' ' SER . 60.3 t30 -17.67 158.34 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.533 ' O ' ' CB ' ' F' ' 30' ' ' ALA . 75.2 tttt -161.73 111.41 1.57 Allowed 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.406 175.456 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.77 92.29 0.23 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-O 119.156 -0.802 . . . . 0.0 113.178 176.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.24 154.08 22.82 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.47 126.05 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 117.49 -1.684 . . . . 0.0 114.123 -175.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.522 ' O ' ' SD ' ' L' ' 35' ' ' MET . 0.8 OUTLIER -114.39 116.39 52.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 114.731 -1.122 . . . . 0.0 108.202 176.505 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.95 102.13 2.76 Favored Glycine 0 CA--C 1.501 -0.811 0 N-CA-C 104.192 -3.563 . . . . 0.0 104.192 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.569 ' CD1' ' CZ ' ' C' ' 19' ' ' PHE . 6.7 tt -107.14 105.54 15.59 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 121.045 0.45 . . . . 0.0 111.366 -174.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.9 ttt -123.82 112.51 17.38 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.5 80.38 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.01 102.76 0.26 Allowed Glycine 0 C--N 1.351 1.397 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.54 -151.55 23.62 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.0 p -130.84 140.82 47.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 43.1 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.755 -179.828 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p . . . . . 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.753 . . . . 0.0 111.507 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.444 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 33.0 p-80 -161.64 157.08 24.02 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.188 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 97.0 m-70 -156.4 168.29 27.8 Favored 'General case' 0 CA--C 1.511 -0.537 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.101 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -151.01 173.26 14.52 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 119.951 -0.7 . . . . 0.0 110.716 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -147.66 129.09 14.89 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.447 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 50.8 mt -120.33 115.48 23.63 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -127.31 129.5 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.82 0.343 . . . . 0.0 110.129 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.524 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.3 p90 -143.34 126.23 16.2 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.069 0.462 . . . . 0.0 111.543 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -127.29 128.11 45.44 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.18 149.64 28.22 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 119.89 -0.724 . . . . 0.0 112.286 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -80.09 126.56 31.23 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 57.8 t0 . . . . . 0 N--CA 1.471 0.601 0 CA-C-O 121.868 0.842 . . . . 0.0 113.266 -177.483 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.446 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 80.1 tttt . . . . . 0 CA--C 1.542 0.664 0 CA-C-O 123.537 1.637 . . . . 0.0 111.859 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.446 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -114.33 -100.45 2.36 Favored Glycine 0 CA--C 1.483 -1.944 0 CA-C-N 111.218 -2.719 . . . . 0.0 113.305 -179.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.533 ' CB ' ' O ' ' E' ' 28' ' ' LYS . . . -60.41 177.04 0.3 Allowed 'General case' 0 CA--C 1.474 -1.957 0 CA-C-N 110.82 -2.69 . . . . 0.0 104.933 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 tp -158.41 144.76 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 C-N-CA 114.998 -2.681 . . . . 0.0 114.638 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 pt -102.14 112.34 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-N 112.807 -1.997 . . . . 0.0 107.965 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -80.38 97.12 1.67 Allowed Glycine 0 CA--C 1.497 -1.061 0 N-CA-C 103.496 -3.842 . . . . 0.0 103.496 175.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.416 ' CD1' ' C ' ' F' ' 34' ' ' LEU . 0.3 OUTLIER -100.01 111.09 23.39 Favored 'General case' 0 CA--C 1.497 -1.089 0 CA-C-N 117.412 0.606 . . . . 0.0 111.445 -176.676 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.622 ' SD ' ' O ' ' L' ' 32' ' ' ILE . 24.2 mtp -135.33 114.94 12.71 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-O 122.754 1.264 . . . . 0.0 107.766 176.463 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.516 ' O ' ' CG1' ' F' ' 36' ' ' VAL . 5.5 p -133.0 78.63 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 CA-C-N 112.566 -2.106 . . . . 0.0 108.373 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 51.87 -104.08 0.14 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -175.13 46.7 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.531 ' C ' HD22 ' L' ' 27' ' ' ASN . 66.6 t -131.42 137.72 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 120.814 0.34 . . . . 0.0 111.16 -179.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 61.5 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.119 -0.943 . . . . 0.0 110.335 179.289 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.457 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -98.71 130.29 45.19 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.859 0.361 . . . . 0.0 110.345 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -71.02 147.61 48.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.744 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 t -124.95 134.03 67.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.8 t60 -144.27 136.9 26.85 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.382 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 27.6 m170 -112.78 178.69 4.2 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -102.33 178.11 4.68 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.407 -179.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -97.02 137.63 35.81 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.655 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -123.97 128.14 48.96 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.375 0.607 . . . . 0.0 111.378 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.49 128.85 61.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.562 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -108.85 113.27 26.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 176.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 52.7 p90 -124.99 123.96 40.98 Favored 'General case' 0 CA--C 1.521 -0.14 0 CA-C-O 120.892 0.377 . . . . 0.0 110.932 -178.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.09 120.84 40.37 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -159.27 141.63 13.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -66.29 112.12 3.83 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' G' ' 26' ' ' SER . 54.2 t -111.86 130.85 64.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.96 81.85 0.0 OUTLIER Glycine 0 CA--C 1.532 1.126 0 CA-C-N 114.97 -1.014 . . . . 0.0 113.376 177.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.516 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.6 m -131.41 179.46 6.02 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 119.172 1.486 . . . . 0.0 109.562 178.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.465 ' O ' ' O ' ' G' ' 26' ' ' SER . 15.0 m120 -40.18 174.37 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.186 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -77.41 110.64 12.34 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.381 175.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . 0.403 ' H ' ' HE2' ' H' ' 28' ' ' LYS . . . 65.36 94.39 0.03 OUTLIER Glycine 0 N--CA 1.466 0.648 0 C-N-CA 118.292 -1.909 . . . . 0.0 110.361 177.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 161.37 13.65 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 120.18 1.99 . . . . 0.0 109.386 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.98 112.77 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.758 -172.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' A' ' 35' ' ' MET . 94.8 mt -121.45 117.26 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-O 120.662 0.268 . . . . 0.0 110.89 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . 0.55 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -125.7 116.39 2.62 Favored Glycine 0 N--CA 1.47 0.911 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 179.401 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.401 HD11 ' H ' ' G' ' 35' ' ' MET . 56.4 tp -144.15 140.57 29.45 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-O 121.384 0.611 . . . . 0.0 112.198 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.433 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 40.0 ttp -130.64 137.73 49.75 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.466 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' G' ' 37' ' ' GLY . 4.8 t -125.82 69.77 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 CA-C-N 116.328 -0.396 . . . . 0.0 112.038 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -43.77 -101.68 0.01 OUTLIER Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.12 174.28 40.21 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 13.3 p -145.03 149.56 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.183 0.516 . . . . 0.0 111.329 -179.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.969 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -82.44 130.11 35.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.012 0.434 . . . . 0.0 110.392 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -115.34 163.51 15.59 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.761 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' H' ' 13' ' ' HIS . 71.5 t -118.66 158.78 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.869 0.842 . . . . 0.0 110.902 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.629 ' CD2' HE21 ' H' ' 15' ' ' GLN . 32.5 p-80 -98.65 154.24 18.09 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -178.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.566 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 58.4 t60 -87.93 167.4 13.77 Favored 'General case' 0 N--CA 1.442 -0.862 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 178.139 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.629 HE21 ' CD2' ' H' ' 13' ' ' HIS . 84.5 mt-30 -150.66 167.2 28.05 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 119.906 -0.717 . . . . 0.0 111.381 178.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . 0.428 ' CG ' ' HE2' ' H' ' 14' ' ' HIS . 98.1 mttt -153.11 115.26 4.37 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.389 -179.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 24.6 tp -122.64 121.86 37.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.737 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.09 123.43 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-O 121.106 0.479 . . . . 0.0 112.146 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -110.2 114.31 27.69 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 177.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.597 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 48.4 t80 -127.63 123.74 36.33 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 118.473 0.579 . . . . 0.0 110.407 -178.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.59 128.67 44.68 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 120.924 0.392 . . . . 0.0 111.918 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -144.87 153.22 41.36 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -105.28 103.7 13.29 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' H' ' 26' ' ' SER . 22.5 t -90.23 153.68 3.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 48.71 -80.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.75 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.7 OUTLIER 171.46 -170.71 0.03 OUTLIER 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 117.371 0.586 . . . . 0.0 109.578 -179.787 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.75 ' O ' ' O ' ' H' ' 26' ' ' SER . 4.9 m120 -18.67 -172.42 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 116.322 1.971 . . . . 0.0 116.322 -178.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.546 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 62.9 tttm 127.02 104.51 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.984 0 CA-C-N 113.644 -1.617 . . . . 0.0 111.307 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.98 96.86 0.07 OUTLIER Glycine 0 N--CA 1.47 0.954 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.153 176.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.99 148.12 43.94 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.1 124.92 5.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.263 -173.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -122.81 117.53 52.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.83 179.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.02 122.72 5.09 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 178.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 7.8 tt -151.44 140.38 21.01 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.557 -0.966 . . . . 0.0 111.582 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 43.0 ttp -131.74 130.17 41.58 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.298 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' H' ' 37' ' ' GLY . 11.6 t -123.77 73.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -48.2 -95.07 0.01 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 177.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.76 177.42 16.71 Favored Glycine 0 C--N 1.336 0.571 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.56 134.57 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.641 -179.739 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m . . . . . 0 N--CA 1.463 0.195 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.458 ' ND1' ' O ' ' H' ' 12' ' ' VAL . 2.0 m80 -107.06 -172.56 2.1 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.958 0.409 . . . . 0.0 110.884 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.598 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 20.9 p-80 -135.91 176.53 8.6 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -133.18 177.73 7.44 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.588 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -138.69 115.9 11.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.039 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 39.0 mt -114.27 117.38 30.95 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -126.62 125.8 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.208 0.528 . . . . 0.0 111.614 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.447 ' CZ ' ' CD2' ' L' ' 34' ' ' LEU . 6.9 m-85 -113.25 115.09 27.65 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 177.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.597 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 25.8 t80 -129.27 122.96 30.71 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.482 0.583 . . . . 0.0 110.237 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.15 131.31 34.53 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.539 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -137.9 132.49 32.53 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -96.69 101.38 12.98 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.59 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.615 ' O ' ' N ' ' I' ' 26' ' ' SER . 53.6 t -91.27 158.46 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 48.9 -80.46 0.01 OUTLIER Glycine 0 CA--C 1.527 0.805 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.427 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.615 ' N ' ' O ' ' I' ' 24' ' ' VAL . 2.4 p 171.16 171.21 0.08 Allowed 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.397 0.618 . . . . 0.0 110.052 -179.481 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.589 ' O ' ' O ' ' I' ' 26' ' ' SER . 23.0 p30 -16.13 158.41 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.335 -1.757 . . . . 0.0 115.5 -176.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.556 ' O ' ' O ' ' J' ' 29' ' ' GLY . 63.5 tttp -161.17 111.03 1.66 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.497 176.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.73 92.8 0.2 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 150.71 52.03 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -151.57 123.43 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 C-N-CA 118.711 -1.196 . . . . 0.0 110.943 -174.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 97.3 mt -116.69 116.21 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.279 178.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.65 98.03 1.03 Allowed Glycine 0 N--CA 1.462 0.381 0 N-CA-C 105.888 -2.885 . . . . 0.0 105.888 175.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -122.61 129.07 51.48 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.68 0.752 . . . . 0.0 112.334 -176.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 78.9 mtp -108.91 112.78 25.19 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.434 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.48 ' H ' ' HG2' ' J' ' 35' ' ' MET . 0.2 OUTLIER -123.54 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 177.454 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.6 111.2 3.22 Favored Glycine 0 C--N 1.364 2.107 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.0 179.38 1.56 Allowed Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.39 156.24 41.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.365 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.571 -179.701 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -82.54 140.84 33.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.659 0.266 . . . . 0.0 110.314 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -141.74 159.92 41.23 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.931 0.396 . . . . 0.0 110.874 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' J' ' 13' ' ' HIS . 25.8 t -120.57 161.22 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.469 ' N ' ' CG1' ' J' ' 12' ' ' VAL . 28.9 p-80 -71.48 150.54 44.77 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -176.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.598 ' NE2' ' CG ' ' I' ' 14' ' ' HIS . 43.8 p-80 -152.86 172.87 16.09 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 113.918 -1.492 . . . . 0.0 107.167 179.326 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -144.36 174.12 11.19 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.59 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -148.73 112.47 5.09 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.333 -0.849 . . . . 0.0 109.974 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -117.52 121.21 40.38 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.91 123.28 58.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.937 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.643 ' CE1' ' CE2' ' K' ' 19' ' ' PHE . 94.9 m-85 -115.87 117.09 29.24 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -123.22 111.24 16.23 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.54 132.93 46.97 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -120.84 87.89 2.84 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.216 -0.902 . . . . 0.0 108.862 177.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.522 ' C ' ' HZ3' ' K' ' 28' ' ' LYS . 20.9 m-20 -68.33 -102.42 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 114.602 -1.181 . . . . 0.0 108.53 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' J' ' 23' ' ' ASP . 34.5 t 46.43 157.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 122.661 1.22 . . . . 0.0 114.254 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.414 ' N ' ' CG1' ' J' ' 24' ' ' VAL . . . 91.67 -80.25 1.26 Allowed Glycine 0 CA--C 1.527 0.843 0 CA-C-N 113.219 -1.809 . . . . 0.0 110.46 -176.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.606 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.8 p 170.28 170.48 0.06 Allowed 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 118.092 0.946 . . . . 0.0 109.729 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.606 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.8 t-20 -17.66 157.75 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.699 0 O-C-N 124.953 1.408 . . . . 0.0 114.02 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.553 ' O ' ' O ' ' K' ' 29' ' ' GLY . 61.3 tttt -161.6 110.55 1.53 Allowed 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 173.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.556 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -68.13 93.06 0.27 Allowed Glycine 0 C--O 1.216 -1.0 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.75 177.049 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.472 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -143.28 143.25 31.64 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 103.061 -2.94 . . . . 0.0 103.061 173.404 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.472 ' CG1' ' C ' ' J' ' 30' ' ' ALA . 0.2 OUTLIER -152.37 111.76 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 118.424 -1.31 . . . . 0.0 108.929 -171.546 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.476 ' CG2' ' O ' ' J' ' 32' ' ' ILE . 0.1 OUTLIER -111.6 111.92 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.046 0.451 . . . . 0.0 109.86 -179.491 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.16 94.56 0.75 Allowed Glycine 0 C--O 1.239 0.447 0 N-CA-C 107.398 -2.281 . . . . 0.0 107.398 176.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 9.7 mp -117.33 127.15 53.77 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 122.279 1.038 . . . . 0.0 111.307 -179.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.48 ' HG2' ' H ' ' I' ' 36' ' ' VAL . 0.1 OUTLIER -101.57 118.59 37.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.521 178.315 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 98.2 t -133.9 76.55 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.49 104.58 2.07 Favored Glycine 0 C--N 1.352 1.443 0 CA-C-N 115.353 -0.839 . . . . 0.0 111.849 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.61 -176.76 40.0 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.6 m -134.4 162.5 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.682 0.277 . . . . 0.0 110.509 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 95.0 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.886 -179.76 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -111.53 145.79 38.46 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.706 0.288 . . . . 0.0 110.655 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -53.78 148.85 9.39 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.879 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -134.04 156.59 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 121.891 0.853 . . . . 0.0 111.996 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -170.17 83.42 0.11 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.074 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -154.98 169.0 25.1 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 65.5 mt-30 -149.9 178.31 9.03 Favored 'General case' 0 C--N 1.312 -1.047 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.004 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -126.66 109.45 12.1 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.717 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 55.8 mt -111.23 113.04 25.25 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.9 t -126.24 114.13 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 O-C-N 122.015 -0.428 . . . . 0.0 111.091 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.718 ' O ' ' C ' ' L' ' 19' ' ' PHE . 76.0 m-85 -116.86 105.31 12.22 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 177.139 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.436 ' HA ' ' O ' ' L' ' 19' ' ' PHE . 91.0 t80 -128.3 125.99 39.91 Favored 'General case' 0 N--CA 1.482 1.151 0 O-C-N 124.287 0.992 . . . . 0.0 112.219 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.422 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -147.36 156.32 42.79 Favored 'General case' 0 C--N 1.353 0.732 0 C-N-CA 118.502 -1.279 . . . . 0.0 114.236 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -127.3 137.27 52.79 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -165.5 135.43 3.55 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 118.868 -1.133 . . . . 0.0 113.725 -176.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.42 ' O ' ' CG1' ' K' ' 24' ' ' VAL . 13.1 p -70.83 112.74 5.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -50.59 92.47 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.526 -1.215 . . . . 0.0 114.546 -175.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.451 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.5 t 162.35 160.5 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.766 0 CA-C-O 121.801 0.81 . . . . 0.0 110.134 176.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.451 ' O ' ' O ' ' K' ' 26' ' ' SER . 31.4 m120 -29.7 159.8 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 113.785 -1.552 . . . . 0.0 113.207 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.522 ' HZ3' ' C ' ' J' ' 23' ' ' ASP . 75.6 tttt 179.48 104.01 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.228 175.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -65.62 94.7 0.2 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.923 -0.932 . . . . 0.0 113.781 177.624 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.429 ' O ' ' CG2' ' K' ' 31' ' ' ILE . . . -168.01 147.08 4.67 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.429 ' CG2' ' O ' ' K' ' 30' ' ' ALA . 0.1 OUTLIER -160.37 130.02 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.54 0 C-N-CA 118.283 -1.367 . . . . 0.0 113.575 -176.311 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 12.8 tt -108.51 113.85 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 175.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.35 121.69 4.88 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 20.1 tp -140.66 136.99 33.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.781 0.801 . . . . 0.0 110.214 179.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.7 ttm -112.03 124.09 51.67 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 m -124.06 79.38 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -69.4 103.3 1.07 Allowed Glycine 0 C--N 1.35 1.308 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.48 146.9 17.38 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -127.12 136.78 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 120.734 0.302 . . . . 0.0 110.223 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.422 179.76 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -90.22 128.05 36.29 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.754 0.312 . . . . 0.0 110.81 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -140.06 160.83 39.06 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 109.935 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . 0.438 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 49.6 t -118.63 130.17 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.553 0.692 . . . . 0.0 110.372 179.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.438 ' CD2' ' O ' ' L' ' 12' ' ' VAL . 88.6 m-70 -156.86 110.44 2.63 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.583 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.519 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 35.3 t-80 -156.85 175.67 13.77 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.039 0.447 . . . . 0.0 109.881 -179.054 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.519 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 77.8 mt-30 -142.4 -179.97 6.59 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.216 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -164.66 114.48 1.16 Allowed 'General case' 0 C--O 1.234 0.261 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.7 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 17.5 mt -116.02 121.25 41.68 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -112.36 133.1 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 118.802 0.728 . . . . 0.0 110.966 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.718 ' C ' ' O ' ' K' ' 19' ' ' PHE . 63.6 m-85 -42.37 141.56 0.95 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 -172.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.567 ' N ' ' O ' ' K' ' 19' ' ' PHE . 50.5 p90 -99.93 -169.47 1.74 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-N 108.638 -3.892 . . . . 0.0 110.363 179.298 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' L' ' 20' ' ' PHE . . . -23.47 135.24 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -173.282 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -70.46 159.38 34.35 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 113.04 -1.891 . . . . 0.0 109.239 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -50.52 114.05 1.04 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.106 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 25' ' ' GLY . 3.5 m -127.82 121.22 55.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.812 -178.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -27.84 -87.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.956 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -67.2 -173.01 0.24 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-O 121.222 0.534 . . . . 0.0 109.992 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.531 HD22 ' C ' ' F' ' 39' ' ' VAL . 72.4 m-20 -78.73 175.88 10.04 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.025 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 32.2 tttm -49.12 111.21 0.45 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 114.219 -1.355 . . . . 0.0 113.967 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.47 -97.86 0.05 OUTLIER Glycine 0 C--O 1.223 -0.593 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.95 172.23 1.03 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 120.265 2.033 . . . . 0.0 106.544 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.9 141.26 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 117.236 -1.786 . . . . 0.0 114.375 -173.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.622 ' O ' ' SD ' ' F' ' 35' ' ' MET . 88.4 mt -109.14 114.66 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 CA-C-N 114.061 -1.427 . . . . 0.0 110.131 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.92 91.25 0.56 Allowed Glycine 0 CA--C 1.517 0.179 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 177.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . 0.447 ' CD2' ' CZ ' ' I' ' 19' ' ' PHE . 18.9 tp -117.72 120.65 38.61 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.205 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 42.2 ttp -97.08 119.19 35.11 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.084 179.067 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' L' ' 37' ' ' GLY . 1.4 m -130.25 71.01 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -29.8 -102.67 0.01 OUTLIER Glycine 0 C--N 1.358 1.802 0 O-C-N 122.935 0.147 . . . . 0.0 112.892 -178.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.61 163.07 35.86 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -136.81 162.64 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.913 0.387 . . . . 0.0 110.661 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.635 -179.414 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.465 0.302 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -131.25 138.83 49.49 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.161 0.505 . . . . 0.0 111.295 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.588 ' CD2' ' H ' ' A' ' 15' ' ' GLN . 10.5 t-80 -156.85 165.85 35.04 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.588 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 51.2 tt0 -169.52 169.93 8.52 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.537 179.265 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -152.27 115.12 4.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.983 178.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 35.3 tp -121.37 121.6 37.99 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 109.945 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 35.5 m -122.85 122.68 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 CA-C-O 121.351 0.596 . . . . 0.0 111.246 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.461 ' CD1' ' CE1' ' B' ' 19' ' ' PHE . 15.6 t80 -123.64 106.41 10.52 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 178.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -134.39 145.94 49.4 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.01 117.76 13.16 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.122 -0.945 . . . . 0.0 108.512 177.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -130.76 157.65 42.27 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.408 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 47.5 t0 -98.42 112.69 24.62 Favored 'General case' 0 N--CA 1.462 0.158 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.518 ' O ' ' C ' ' A' ' 25' ' ' GLY . 2.1 p -147.72 113.49 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 103.595 -2.742 . . . . 0.0 103.595 172.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.518 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -19.87 87.17 0.01 OUTLIER Glycine 0 N--CA 1.476 1.303 0 CA-C-O 119.282 -0.732 . . . . 0.0 112.522 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.483 ' N ' ' O ' ' A' ' 24' ' ' VAL . 40.9 t -67.97 -179.72 1.28 Allowed 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 119.219 1.509 . . . . 0.0 108.046 178.044 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 53.2 p30 -87.31 174.93 8.26 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt 35.85 -108.45 0.05 OUTLIER 'General case' 0 CA--C 1.538 0.514 0 CA-C-O 122.28 1.038 . . . . 0.0 113.574 173.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.412 ' O ' ' C ' ' A' ' 30' ' ' ALA . . . 90.59 -102.04 2.87 Favored Glycine 1 CA--C 1.427 -5.457 0 CA-C-N 113.157 -1.838 . . . . 0.0 108.635 -177.384 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.412 ' C ' ' O ' ' A' ' 29' ' ' GLY . . . 56.63 -146.95 0.54 Allowed 'General case' 0 N--CA 1.405 -2.7 0 C-N-CA 113.497 -3.281 . . . . 0.0 109.7 173.251 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.666 ' CD1' ' H ' ' A' ' 31' ' ' ILE 0.252 0.0 OUTLIER -89.89 113.65 26.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 CA-C-N 113.259 -1.791 . . . . 0.0 113.688 -179.788 . . . . . . . . 4 4 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' G' ' 35' ' ' MET . 87.1 mt -130.03 120.17 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 O-C-N 120.103 -1.623 . . . . 0.0 109.922 178.395 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.609 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.68 113.63 1.53 Allowed Glycine 0 CA--C 1.52 0.375 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -133.29 134.9 44.47 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.99 0.424 . . . . 0.0 110.72 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 5.9 ttm -125.44 129.62 50.21 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.738 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.92 70.8 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 120.656 -0.417 . . . . 0.0 111.473 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -114.66 100.65 1.02 Allowed Glycine 0 C--N 1.341 0.811 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 177.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.65 41.6 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.554 -1.018 . . . . 0.0 110.554 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 120.76 0.314 . . . . 0.0 110.383 -179.893 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 33.5 t . . . . . 0 N--CA 1.465 0.304 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.674 ' HE2' HE21 ' B' ' 15' ' ' GLN . 86.0 t60 -157.87 101.47 1.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.628 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 55.7 m170 -110.2 167.44 10.19 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.674 HE21 ' HE2' ' B' ' 13' ' ' HIS . 87.8 mt-30 -152.43 176.7 11.38 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.231 179.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -171.46 111.95 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.638 178.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 64.1 mt -120.98 120.33 35.11 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.5 t -120.79 121.6 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 120.889 -0.325 . . . . 0.0 111.432 -179.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.461 ' CE1' ' CD1' ' A' ' 19' ' ' PHE . 12.0 t80 -120.7 110.54 16.51 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -119.32 117.11 27.67 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.22 119.92 34.61 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -177.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' B' ' 23' ' ' ASP . 95.3 mt-10 -153.05 89.82 1.4 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 115.162 -0.926 . . . . 0.0 108.754 176.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.458 ' C ' ' O ' ' B' ' 22' ' ' GLU . 49.5 t0 8.2 113.63 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 114.039 1.125 . . . . 0.0 114.039 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 85.4 t -58.56 131.2 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.205 0.526 . . . . 0.0 110.367 178.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.34 84.67 0.13 Allowed Glycine 0 CA--C 1.529 0.927 0 CA-C-N 115.415 -0.811 . . . . 0.0 113.768 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.517 ' O ' ' O ' ' B' ' 27' ' ' ASN . 39.0 m -132.24 162.67 30.38 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 118.284 1.042 . . . . 0.0 110.003 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.517 ' O ' ' O ' ' B' ' 26' ' ' SER . 65.5 t30 -38.44 177.72 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.632 179.384 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.509 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 98.7 mttt -73.31 111.87 8.84 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.22 92.5 0.08 OUTLIER Glycine 0 N--CA 1.464 0.567 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 -178.092 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.58 152.66 49.72 Favored 'General case' 0 CA--C 1.487 -1.465 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 174.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.449 ' N ' ' CD1' ' B' ' 31' ' ' ILE . 0.0 OUTLIER -139.89 117.44 10.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -173.989 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.524 ' O ' ' SD ' ' I' ' 35' ' ' MET . 81.6 mt -122.13 126.63 74.62 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.733 -177.014 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.1 118.53 3.59 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 42.3 tp -126.53 118.45 24.92 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.292 0.568 . . . . 0.0 110.557 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.8 tpt -106.4 115.52 30.35 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' B' ' 37' ' ' GLY . 8.8 t -112.65 74.16 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.782 -0.19 . . . . 0.0 110.823 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.442 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -40.07 -95.84 0.01 OUTLIER Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -170.68 40.02 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m -135.72 161.9 37.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.896 0.379 . . . . 0.0 110.344 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.572 179.969 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -86.88 144.87 26.8 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.379 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . 0.542 ' CD ' ' HE2' ' C' ' 13' ' ' HIS . 84.6 tt0 -142.32 136.25 29.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.957 0.408 . . . . 0.0 110.55 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 5.6 m -126.23 131.56 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.008 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.542 ' HE2' ' CD ' ' C' ' 11' ' ' GLU . 82.1 m-70 -114.75 127.18 55.6 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.162 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CG ' ' D' ' 13' ' ' HIS . 4.0 m-70 -119.04 164.08 16.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 79.7 mt-30 -156.68 170.42 22.46 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 121.234 0.54 . . . . 0.0 110.818 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -168.0 113.83 0.68 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.362 178.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 tp -128.15 123.64 34.89 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 35.6 m -124.87 126.68 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.524 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 47.3 t80 -123.78 111.04 15.65 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.929 -178.562 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -114.56 119.35 36.5 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 120.428 0.156 . . . . 0.0 110.767 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.82 115.97 27.85 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.8 mt-10 -150.7 169.4 21.69 Favored 'General case' 0 C--N 1.347 0.473 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.707 -179.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.475 ' HB3' ' HZ3' ' E' ' 28' ' ' LYS . 74.8 m-20 -155.45 121.2 5.03 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.582 ' CG1' ' H ' ' C' ' 25' ' ' GLY . 3.5 p -136.73 -112.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.311 -177.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.582 ' H ' ' CG1' ' C' ' 24' ' ' VAL . . . 30.38 -89.21 0.01 OUTLIER Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.434 -177.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.4 t 171.54 177.73 0.07 Allowed 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 117.817 0.808 . . . . 0.0 109.687 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' C' ' 26' ' ' SER . 42.4 t30 -28.46 178.07 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.722 0 O-C-N 124.766 1.291 . . . . 0.0 113.818 -179.189 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.577 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 88.8 mttt 127.66 104.91 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 C-N-CA 125.564 1.545 . . . . 0.0 111.616 175.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.37 96.64 0.07 OUTLIER Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 174.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -122.54 145.69 48.1 Favored 'General case' 0 CA--C 1.479 -1.77 0 N-CA-C 104.519 -2.4 . . . . 0.0 104.519 176.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.417 ' CG1' ' C ' ' C' ' 30' ' ' ALA . 2.0 mt -142.8 108.4 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.548 0 CA-C-N 113.851 -1.522 . . . . 0.0 108.801 -172.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 14.9 tt -120.17 128.06 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 CA-C-O 121.054 0.454 . . . . 0.0 110.176 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.407 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -133.67 122.6 3.1 Favored Glycine 0 CA--C 1.508 -0.387 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.472 ' CD1' ' N ' ' C' ' 34' ' ' LEU . 0.0 OUTLIER -136.96 147.44 46.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 122.085 0.945 . . . . 0.0 111.837 -179.084 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.509 ' SD ' ' O ' ' I' ' 32' ' ' ILE . 5.1 tpt -111.56 117.42 32.92 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.54 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 26.2 t -130.96 66.33 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 -179.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -123.83 102.48 0.73 Allowed Glycine 0 C--N 1.358 1.772 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.83 -170.31 12.66 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 -179.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.2 t -119.47 135.03 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.703 -179.475 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 121.008 0.432 . . . . 0.0 110.485 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.701 ' CG ' ' H ' ' D' ' 14' ' ' HIS . 51.6 t60 -93.14 -169.93 2.28 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.572 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.701 ' H ' ' CG ' ' D' ' 13' ' ' HIS . 52.9 m80 -73.85 170.61 14.99 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.353 0.597 . . . . 0.0 110.146 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -148.93 173.58 13.17 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.177 179.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -147.26 114.63 6.29 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 120.898 0.38 . . . . 0.0 111.409 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -122.36 116.16 23.55 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.04 131.13 72.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.38 0.609 . . . . 0.0 110.654 -179.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.524 ' CE2' ' CD1' ' C' ' 19' ' ' PHE . 28.1 t80 -131.62 110.75 11.16 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -118.71 126.45 51.93 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.817 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.3 126.25 45.73 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.602 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -149.52 111.56 4.61 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.496 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -90.35 134.04 34.59 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.591 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.09 112.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.278 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -46.53 91.77 0.01 OUTLIER Glycine 0 CA--C 1.536 1.367 0 CA-C-O 119.125 -0.819 . . . . 0.0 114.276 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 1.4 t 161.98 161.08 0.02 OUTLIER 'General case' 0 C--O 1.212 -0.89 0 CA-C-N 118.472 1.136 . . . . 0.0 112.303 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.466 ' O ' ' O ' ' D' ' 26' ' ' SER . 73.7 m-80 -33.48 -179.26 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 112.998 -1.91 . . . . 0.0 116.118 178.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.466 ' O ' ' O ' ' E' ' 29' ' ' GLY . 87.1 tttt 99.64 113.8 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 128.398 2.679 . . . . 0.0 115.73 177.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.29 92.53 0.58 Allowed Glycine 0 C--N 1.348 1.238 0 CA-C-N 111.868 -2.423 . . . . 0.0 114.474 173.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.99 151.54 49.02 Favored 'General case' 0 CA--C 1.501 -0.911 0 CA-C-N 121.369 2.584 . . . . 0.0 106.725 173.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.03 116.84 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.56 -173.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.25 124.92 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.81 99.19 0.53 Allowed Glycine 0 N--CA 1.464 0.534 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 177.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' E' ' 34' ' ' LEU . 40.7 tp -126.3 130.23 50.43 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 122.75 1.262 . . . . 0.0 112.69 -179.07 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -104.54 110.92 23.4 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 113.688 -1.596 . . . . 0.0 107.302 176.372 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.463 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -126.68 71.38 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.758 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -34.27 -100.46 0.01 OUTLIER Glycine 0 C--N 1.357 1.696 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.33 -168.06 40.65 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.2 160.58 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.955 0.407 . . . . 0.0 110.933 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.711 -179.978 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -114.47 139.17 49.75 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -113.67 141.26 47.45 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.941 0.4 . . . . 0.0 110.802 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 19.1 m -134.29 158.07 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.95 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.49 ' ND1' ' CE1' ' D' ' 14' ' ' HIS . 12.1 m170 -86.75 178.31 7.05 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.1 OUTLIER -77.08 172.23 13.55 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -179.359 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.493 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 44.2 tt0 -148.2 170.17 18.44 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.113 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . 0.493 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 99.1 mttt -144.16 117.28 8.92 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.123 0.487 . . . . 0.0 111.165 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.2 tt -119.21 114.95 23.23 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 t -124.06 120.46 59.53 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.601 0.715 . . . . 0.0 111.743 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.569 ' O ' ' N ' ' F' ' 20' ' ' PHE . 10.2 m-85 -126.39 104.54 8.23 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 48.1 t80 -121.97 129.6 52.63 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 122.975 0.172 . . . . 0.0 111.092 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . 0.587 ' O ' ' C ' ' F' ' 21' ' ' ALA . . . -133.82 135.39 43.75 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-O 123.362 1.553 . . . . 0.0 113.332 178.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -145.14 105.37 4.06 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.976 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.431 ' O ' ' OD2' ' F' ' 23' ' ' ASP . 4.2 t0 -83.04 122.63 28.58 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 63.4 t -72.8 120.42 21.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.353 0.597 . . . . 0.0 111.863 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.9 -90.25 0.04 OUTLIER Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.016 -0.993 . . . . 0.0 114.633 176.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.638 ' O ' ' O ' ' E' ' 27' ' ' ASN . 9.7 p -171.14 -178.61 2.47 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-O 121.153 0.502 . . . . 0.0 110.992 -176.423 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.638 ' O ' ' O ' ' E' ' 26' ' ' SER . 92.1 m-20 20.62 -179.81 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 117.12 2.267 . . . . 0.0 117.12 178.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.512 ' CB ' ' O ' ' E' ' 27' ' ' ASN . 78.2 tttt 128.68 106.13 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 112.381 -2.19 . . . . 0.0 110.002 -177.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -55.32 93.6 0.02 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.054 176.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.73 144.64 18.07 Favored 'General case' 0 CA--C 1.477 -1.843 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 174.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -154.55 125.66 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 117.946 -1.502 . . . . 0.0 111.177 -173.029 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -109.51 117.42 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.768 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . 0.458 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -109.63 97.86 1.07 Allowed Glycine 0 C--O 1.231 -0.074 0 N-CA-C 106.28 -2.728 . . . . 0.0 106.28 176.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.424 ' O ' ' HA ' ' F' ' 34' ' ' LEU . 6.9 tt -138.87 128.68 24.95 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-O 123.01 1.386 . . . . 0.0 113.427 -176.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 97.3 mmm -106.98 120.27 41.62 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 114.097 -1.41 . . . . 0.0 110.489 179.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.1 OUTLIER -116.39 72.31 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 176.968 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -27.71 -101.03 0.01 OUTLIER Glycine 0 C--N 1.366 2.218 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.32 -176.71 25.67 Favored Glycine 0 N--CA 1.461 0.365 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -129.22 160.18 40.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.28 -0.46 . . . . 0.0 109.995 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.903 -1.046 . . . . 0.0 110.565 179.859 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.465 ' CG2' ' N ' ' F' ' 13' ' ' HIS . 2.7 p . . . . . 0 CA--C 1.53 0.187 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.465 ' N ' ' CG2' ' F' ' 12' ' ' VAL . 17.5 m-70 -95.02 97.99 10.35 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.586 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.569 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 82.9 t60 -156.36 167.74 29.49 Favored 'General case' 0 N--CA 1.446 -0.672 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.569 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 12.0 pt20 -167.33 177.83 5.86 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.104 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -121.55 123.97 43.26 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.664 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 mt -122.94 121.21 35.59 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 111.653 0.242 . . . . 0.0 111.653 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.89 133.11 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 177.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.54 ' O ' ' O ' ' F' ' 20' ' ' PHE . 98.0 m-85 -114.24 136.58 52.8 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -177.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.569 ' N ' ' O ' ' E' ' 19' ' ' PHE . 42.0 p90 -20.58 -157.29 0.0 OUTLIER 'General case' 0 C--O 1.195 -1.792 0 N-CA-C 118.991 2.96 . . . . 0.0 118.991 -175.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . 0.587 ' C ' ' O ' ' E' ' 21' ' ' ALA . . . 175.54 -168.56 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 122.213 1.006 . . . . 0.0 111.54 -173.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -170.97 167.27 7.35 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 114.473 -1.24 . . . . 0.0 107.964 -177.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.431 ' OD2' ' O ' ' E' ' 23' ' ' ASP . 23.6 m-20 . . . . . 0 N--CA 1.475 0.803 0 CA-C-N 119.05 0.841 . . . . 0.0 111.823 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.401 ' HZ2' ' HA ' ' F' ' 31' ' ' ILE . 44.6 tttm . . . . . 0 N--CA 1.473 0.68 0 CA-C-O 121.224 0.535 . . . . 0.0 111.531 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -50.27 -99.42 0.01 OUTLIER Glycine 0 CA--C 1.506 -0.488 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.553 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.76 173.39 12.65 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.401 ' HA ' ' HZ2' ' F' ' 28' ' ' LYS . 0.2 OUTLIER -136.7 118.41 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 116.302 -2.159 . . . . 0.0 114.101 -170.38 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' L' ' 35' ' ' MET . 59.4 mt -98.83 112.1 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.054 177.229 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -109.72 89.68 0.56 Allowed Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 105.831 -2.907 . . . . 0.0 105.831 177.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.507 ' C ' ' CD2' ' F' ' 34' ' ' LEU . 0.8 OUTLIER -141.29 147.65 38.53 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 120.714 -0.394 . . . . 0.0 109.952 -177.894 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.508 ' SD ' ' O ' ' L' ' 32' ' ' ILE . 3.6 ttp -137.05 133.95 36.0 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.943 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -114.28 80.32 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.909 -179.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 50.82 -102.66 0.07 OUTLIER Glycine 0 C--N 1.342 0.862 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.763 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.44 -156.49 15.49 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 90.9 t -122.96 136.22 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.833 0.349 . . . . 0.0 110.959 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 m . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.482 179.683 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -100.93 127.56 47.36 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -88.68 156.89 18.75 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . 0.488 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 3.4 m -132.85 154.69 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.164 0.507 . . . . 0.0 110.601 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 96.2 m-70 -158.2 167.11 30.71 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.153 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -122.53 179.1 4.71 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 98.7 mt-30 -96.85 176.6 5.92 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.376 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -113.96 144.04 43.73 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.098 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.3 mt -119.07 126.83 52.6 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.048 0.452 . . . . 0.0 110.786 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 25.9 m -133.44 119.96 36.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 121.18 0.514 . . . . 0.0 110.658 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.451 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 2.4 m-85 -113.07 119.63 38.51 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.26 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.528 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 48.5 p90 -122.2 121.78 37.65 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.071 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.94 122.47 42.31 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 120.55 -0.46 . . . . 0.0 111.812 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -166.73 89.17 0.36 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.628 ' H ' ' NZ ' ' I' ' 28' ' ' LYS . 90.8 m-20 -85.71 102.78 13.91 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.993 0.425 . . . . 0.0 112.131 -177.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.412 ' O ' ' O ' ' G' ' 23' ' ' ASP . 18.3 m -56.78 -160.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.489 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -77.59 80.51 1.3 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-O 119.524 -0.598 . . . . 0.0 112.947 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.416 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 30.9 t -94.4 176.55 6.26 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 118.76 1.28 . . . . 0.0 107.879 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -60.14 178.24 0.2 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 119.166 -1.013 . . . . 0.0 111.096 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -60.77 110.71 1.39 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.064 -0.517 . . . . 0.0 112.318 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.87 94.25 0.08 OUTLIER Glycine 0 N--CA 1.465 0.61 0 C-N-CA 118.381 -1.866 . . . . 0.0 112.601 174.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.43 158.72 16.46 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-N 119.935 1.867 . . . . 0.0 106.464 177.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.585 ' N ' ' CD1' ' G' ' 31' ' ' ILE . 0.2 OUTLIER -150.31 114.72 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.382 -174.427 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 97.3 mt -125.27 124.98 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.224 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.02 123.12 3.92 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 tp -131.03 133.7 45.99 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 117.211 0.505 . . . . 0.0 111.32 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.609 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 63.4 ttp -130.82 134.91 47.25 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.421 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.52 79.78 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.79 104.64 1.27 Allowed Glycine 0 C--N 1.342 0.905 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 44.05 -167.2 0.02 OUTLIER Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.24 160.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 120.855 0.36 . . . . 0.0 110.65 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.515 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -80.91 136.12 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.781 0.324 . . . . 0.0 110.624 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -52.64 137.63 30.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.466 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -127.41 132.87 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.159 0.504 . . . . 0.0 110.744 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.51 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 34.5 m170 -126.99 111.38 14.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.106 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.448 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 84.0 t60 -114.05 162.15 16.82 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.448 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 83.3 mt-30 -156.72 177.9 10.96 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.136 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -167.73 111.23 0.65 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.824 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -116.96 120.92 39.91 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 66.7 t -124.0 123.34 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 121.343 0.592 . . . . 0.0 110.786 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.481 ' CD2' ' CE1' ' I' ' 19' ' ' PHE . 11.5 m-85 -117.02 115.49 25.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.132 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -143.13 132.2 23.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.967 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 138.84 41.06 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.105 0.955 . . . . 0.0 112.777 -178.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -131.01 105.91 8.04 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 105.861 -1.903 . . . . 0.0 105.861 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -77.95 117.25 19.1 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -175.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.556 ' O ' ' N ' ' H' ' 26' ' ' SER . 55.0 t -102.46 125.94 56.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.6 83.05 0.0 OUTLIER Glycine 0 CA--C 1.537 1.443 0 CA-C-O 119.536 -0.591 . . . . 0.0 113.291 178.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.556 ' N ' ' O ' ' H' ' 24' ' ' VAL . 17.4 p -94.15 176.8 6.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 177.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' O ' ' G' ' 26' ' ' SER . 28.1 m120 -60.11 178.22 0.2 Allowed 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.247 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -60.63 110.66 1.35 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.03 94.17 0.08 OUTLIER Glycine 0 N--CA 1.469 0.869 0 C-N-CA 118.741 -1.695 . . . . 0.0 114.815 173.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.19 157.57 17.47 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 102.659 -3.089 . . . . 0.0 102.659 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.86 121.61 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 118.146 -1.421 . . . . 0.0 112.207 -171.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 93.0 mt -132.57 127.47 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.381 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.74 128.6 5.55 Favored Glycine 0 N--CA 1.472 1.097 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.786 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 mp -132.6 130.66 40.53 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.284 0.564 . . . . 0.0 111.458 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.3 tmm? -129.67 127.32 40.29 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.454 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' H' ' 37' ' ' GLY . 66.9 t -107.41 86.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -179.009 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.493 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -15.48 -93.38 0.01 OUTLIER Glycine 0 C--N 1.346 1.084 0 O-C-N 123.859 0.724 . . . . 0.0 112.288 177.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.44 -176.13 42.32 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.62 162.23 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 120.715 0.293 . . . . 0.0 110.501 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.403 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.361 179.791 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.469 0.514 0 N-CA-C 111.541 0.2 . . . . 0.0 111.541 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.536 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 53.3 m-70 -68.43 145.1 54.4 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -177.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 47.8 m-70 -154.66 169.28 24.25 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.382 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -159.99 168.3 25.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.033 178.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -154.64 131.54 10.83 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.51 0.195 . . . . 0.0 110.539 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -127.72 119.91 26.82 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 70.7 t -126.24 129.53 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 120.629 -0.428 . . . . 0.0 112.151 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.481 ' CE1' ' CD2' ' H' ' 19' ' ' PHE . 61.2 m-85 -123.22 121.75 36.68 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.924 179.169 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.419 ' CE2' ' CG ' ' J' ' 20' ' ' PHE . 7.5 m-85 -131.67 130.69 42.37 Favored 'General case' 0 N--CA 1.476 0.867 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 135.17 39.23 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -137.76 150.28 47.12 Favored 'General case' 0 C--N 1.352 0.692 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.247 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.435 ' OD2' ' O ' ' J' ' 26' ' ' SER . 13.4 t70 -116.95 114.53 23.96 Favored 'General case' 0 N--CA 1.481 1.115 0 O-C-N 122.21 -0.306 . . . . 0.0 111.36 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.458 ' O ' ' N ' ' I' ' 26' ' ' SER . 14.7 t -81.59 130.93 34.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.8 -85.8 0.01 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.529 ' O ' ' O ' ' I' ' 27' ' ' ASN . 26.1 p -153.62 -172.86 4.37 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-O 121.639 0.733 . . . . 0.0 111.224 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.734 ' H ' ' HZ2' ' K' ' 28' ' ' LYS . 64.8 t30 -19.71 159.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 113.303 -1.771 . . . . 0.0 115.156 178.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.628 ' NZ ' ' H ' ' G' ' 23' ' ' ASP . 74.1 tttt -161.21 110.83 1.64 Allowed 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 114.744 -1.116 . . . . 0.0 109.376 175.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.33 93.23 0.23 Allowed Glycine 0 CA--C 1.508 -0.369 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 177.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.73 147.05 51.3 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 176.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.68 113.97 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.942 -175.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.509 ' O ' ' SD ' ' C' ' 35' ' ' MET . 0.1 OUTLIER -110.76 124.56 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.522 179.471 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.35 102.84 1.39 Allowed Glycine 0 N--CA 1.46 0.292 0 N-CA-C 108.446 -1.862 . . . . 0.0 108.446 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.451 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 23.1 tp -119.0 126.68 52.29 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 117.277 0.538 . . . . 0.0 111.817 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.524 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 12.2 ptm -131.9 110.87 11.1 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 174.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.18 72.02 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.652 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.57 179.554 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.61 102.81 2.33 Favored Glycine 0 C--N 1.36 1.869 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.62 157.36 22.07 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.4 t -124.28 136.56 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.913 0.387 . . . . 0.0 110.53 -179.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.377 179.78 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.426 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -83.38 138.48 33.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.797 0.332 . . . . 0.0 110.478 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -152.34 137.54 17.43 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.408 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -93.03 126.93 45.4 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.694 0 CA-C-O 121.319 0.58 . . . . 0.0 109.847 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.545 ' O ' ' CD2' ' J' ' 14' ' ' HIS . 18.3 t60 -164.92 111.76 0.99 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.233 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' K' ' 13' ' ' HIS . 86.2 m-70 -154.55 177.23 11.43 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -133.82 177.58 7.61 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.731 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -137.54 131.77 32.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 mt -117.89 121.7 41.41 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.673 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 67.8 t -122.47 121.21 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-O 120.948 0.404 . . . . 0.0 110.961 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.418 ' CE1' ' CD2' ' L' ' 34' ' ' LEU . 96.9 m-85 -113.39 114.49 26.68 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 178.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 19.2 t80 -129.03 123.34 32.09 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.988 0.423 . . . . 0.0 111.634 -177.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.94 124.12 32.31 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.05 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.4 tt0 -103.52 156.81 17.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.131 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.467 ' CG ' ' H ' ' J' ' 24' ' ' VAL . 35.2 t70 -78.13 -113.89 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.341 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' J' ' 26' ' ' SER . 4.1 t 73.45 124.45 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.57 -87.09 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -177.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.678 ' O ' ' O ' ' J' ' 27' ' ' ASN . 0.5 OUTLIER 170.79 176.17 0.06 Allowed 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.702 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.678 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.4 m120 -28.3 170.42 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.13 0 O-C-N 124.319 1.012 . . . . 0.0 112.074 177.446 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.561 ' O ' ' N ' ' J' ' 30' ' ' ALA . 37.4 pttt -148.73 111.55 4.82 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.161 -0.962 . . . . 0.0 112.208 177.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.44 91.35 0.01 OUTLIER Glycine 0 CA--C 1.505 -0.566 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 176.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -137.85 153.71 49.56 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 103.328 -2.842 . . . . 0.0 103.328 177.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.41 111.67 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 C-N-CA 118.265 -1.374 . . . . 0.0 109.968 -174.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.467 ' CG2' ' O ' ' J' ' 32' ' ' ILE . 6.7 tt -112.71 116.63 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.293 -0.867 . . . . 0.0 108.731 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.07 103.69 2.33 Favored Glycine 0 N--CA 1.46 0.284 0 N-CA-C 107.596 -2.202 . . . . 0.0 107.596 178.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.437 ' CD1' ' CE1' ' H' ' 19' ' ' PHE . 24.2 mt -114.39 114.0 25.28 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 121.606 0.717 . . . . 0.0 110.247 -177.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -116.59 118.65 33.21 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.506 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.44 ' O ' ' C ' ' J' ' 37' ' ' GLY . 1.1 t -131.15 75.95 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.025 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.2 -97.56 0.01 OUTLIER Glycine 0 C--N 1.362 2.025 0 N-CA-C 112.097 -0.401 . . . . 0.0 112.097 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.97 -163.85 30.23 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 82.9 t -121.95 135.32 62.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.039 -0.982 . . . . 0.0 110.554 -179.649 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.1 137.88 50.77 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 120.89 0.376 . . . . 0.0 110.514 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.77 162.28 35.12 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.4 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 m -110.7 133.22 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.557 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 0.4 OUTLIER -76.12 -166.01 0.55 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.259 -178.546 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 7.6 p-80 -138.23 178.45 7.12 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.607 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -99.27 175.1 5.99 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.486 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -147.42 124.95 11.69 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -117.55 124.05 47.74 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 44.9 t -127.94 126.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-O 120.832 0.349 . . . . 0.0 111.575 -179.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -115.62 116.09 27.53 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.594 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.7 t80 -125.19 122.73 37.88 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.68 26.4 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.159 1.17 . . . . 0.0 114.159 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' L' ' 22' ' ' GLU . 70.3 mm-40 -90.46 152.41 20.97 Favored 'General case' 0 C--O 1.232 0.158 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 177.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.561 ' OD2' ' N ' ' L' ' 28' ' ' LYS . 28.0 t0 -148.43 116.29 6.36 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.028 0.442 . . . . 0.0 111.739 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 2.5 p -146.81 112.14 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.044 -179.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.32 91.32 0.01 OUTLIER Glycine 0 N--CA 1.472 1.064 0 CA-C-O 121.509 0.505 . . . . 0.0 112.63 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -45.15 153.86 0.18 Allowed 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 122.597 1.189 . . . . 0.0 112.511 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.514 ' O ' ' C ' ' K' ' 28' ' ' LYS . 33.9 m120 -156.85 178.58 10.19 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 112.631 -2.077 . . . . 0.0 108.483 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.734 ' HZ2' ' H ' ' I' ' 27' ' ' ASN . 0.1 OUTLIER 2.91 -104.33 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.411 0 C-N-CA 123.562 0.745 . . . . 0.0 112.05 179.816 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 141.09 95.33 0.25 Allowed Glycine 0 N--CA 1.48 1.602 0 CA-C-N 118.986 0.812 . . . . 0.0 111.924 178.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.4 169.85 0.41 Allowed 'General case' 0 C--N 1.345 0.399 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.036 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -148.53 111.97 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 118.996 -1.082 . . . . 0.0 109.035 -179.028 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -111.99 122.08 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.465 -177.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.45 108.99 2.54 Favored Glycine 0 N--CA 1.468 0.829 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 mt -122.09 114.96 21.63 Favored 'General case' 0 CA--C 1.501 -0.913 0 CA-C-N 117.332 0.566 . . . . 0.0 110.821 -177.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.458 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 33.6 ttp -120.86 114.31 21.41 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 176.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -130.19 73.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 107.672 -1.232 . . . . 0.0 107.672 178.632 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.35 -101.6 0.01 OUTLIER Glycine 0 C--N 1.364 2.121 0 O-C-N 123.59 0.556 . . . . 0.0 112.482 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.35 -170.97 38.11 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -125.13 137.19 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.848 -179.788 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -100.77 132.7 46.04 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -151.32 147.39 26.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.965 0.412 . . . . 0.0 111.055 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.5 t -123.13 129.32 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.471 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 56.5 p-80 -170.74 111.88 0.39 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.053 0.454 . . . . 0.0 110.973 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 96.6 m-70 -155.8 177.81 10.98 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -115.58 173.8 6.35 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.302 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 50.3 mtpt -151.25 109.54 3.76 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.959 0.409 . . . . 0.0 110.455 179.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 57.6 tp -123.66 118.51 27.44 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -130.26 133.06 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.875 0.369 . . . . 0.0 110.086 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.469 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -136.86 129.73 30.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.271 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -138.8 132.05 30.0 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.496 0.665 . . . . 0.0 110.455 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.83 138.88 42.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.498 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 95.0 mt-10 -98.4 114.73 27.19 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -102.68 121.64 42.83 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.26 0.552 . . . . 0.0 111.838 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 25.3 t -104.91 -111.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.34 -91.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' L' ' 27' ' ' ASN . 45.9 m -141.01 170.68 15.28 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' L' ' 26' ' ' SER . 93.8 m-20 -29.0 170.13 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.828 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.561 ' N ' ' OD2' ' K' ' 23' ' ' ASP . 87.8 tttt -148.35 109.99 4.46 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 176.08 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -50.84 -95.8 0.01 OUTLIER Glycine 0 C--N 1.334 0.445 0 C-N-CA 118.549 -1.786 . . . . 0.0 112.545 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.473 ' O ' ' C ' ' L' ' 29' ' ' GLY . . . 72.57 156.11 0.17 Allowed 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 100.409 -3.923 . . . . 0.0 100.409 -176.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.41 HG12 ' C ' ' L' ' 30' ' ' ALA . 0.0 OUTLIER -144.77 107.67 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 CA-C-N 124.081 3.128 . . . . 0.0 109.237 179.781 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.508 ' O ' ' SD ' ' F' ' 35' ' ' MET . 1.4 tt -102.53 112.46 35.93 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 CA-C-N 113.956 -1.475 . . . . 0.0 109.975 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.1 96.69 1.0 Allowed Glycine 0 N--CA 1.46 0.286 0 N-CA-C 107.296 -2.321 . . . . 0.0 107.296 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . 0.418 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 3.4 pp -120.62 125.88 48.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.91 0.386 . . . . 0.0 110.948 -177.745 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 65.6 ttp -125.6 121.77 34.52 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-O 121.431 0.634 . . . . 0.0 109.877 179.112 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 m -124.26 77.05 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.65 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -35.64 104.81 0.03 OUTLIER Glycine 0 C--N 1.349 1.289 0 N-CA-C 111.751 -0.539 . . . . 0.0 111.751 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.05 -177.28 42.51 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 8.5 p -140.86 151.12 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 121.081 0.467 . . . . 0.0 111.066 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 47.3 t . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.292 179.7 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 99.5 m-85 -114.81 144.69 43.1 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.834 0.35 . . . . 0.0 110.502 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -55.83 140.59 41.83 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.0 t -118.55 131.54 71.04 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.426 0.632 . . . . 0.0 111.591 -179.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -106.5 -172.35 2.07 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.96 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 48.5 p-80 -146.8 170.92 16.02 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -147.69 178.75 8.22 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.603 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -138.7 129.45 26.36 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.801 0.334 . . . . 0.0 110.467 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.4 mt -112.48 114.61 27.39 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . 0.438 ' O ' ' CG2' ' A' ' 18' ' ' VAL . 6.2 m -127.55 121.16 56.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.119 0 CA-C-O 121.345 0.593 . . . . 0.0 111.433 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -116.88 107.9 15.17 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 177.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.4 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.8 p90 -126.68 126.81 44.15 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.94 125.62 53.84 Favored 'General case' 0 C--O 1.24 0.577 0 CA-C-O 121.275 0.56 . . . . 0.0 111.624 -178.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -155.47 82.0 1.04 Allowed 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.162 -2.162 . . . . 0.0 105.162 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -34.84 120.64 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 114.922 -1.035 . . . . 0.0 113.612 -176.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 26' ' ' SER . 60.7 t -100.94 125.13 54.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 177.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -31.71 83.27 0.0 OUTLIER Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.324 0.39 . . . . 0.0 113.033 -177.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.599 ' N ' ' O ' ' A' ' 24' ' ' VAL . 69.5 m -87.02 -179.23 6.45 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 28' ' ' LYS . 11.8 m120 -75.71 178.53 6.03 Favored 'General case' 0 C--N 1.314 -0.966 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.094 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.519 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 99.1 mttt -45.34 -110.77 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.879 0.847 . . . . 0.0 112.066 178.689 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.32 93.71 1.65 Allowed Glycine 0 N--CA 1.467 0.734 0 CA-C-O 118.428 -1.206 . . . . 0.0 110.181 178.104 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.57 160.11 14.73 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 116.688 -2.005 . . . . 0.0 108.699 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -155.39 117.81 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 113.986 -1.461 . . . . 0.0 109.464 -173.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.453 ' C ' ' SD ' ' G' ' 35' ' ' MET . 96.9 mt -126.33 129.37 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-O 120.812 0.339 . . . . 0.0 110.686 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.49 121.67 2.73 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.9 mt -138.96 139.07 37.84 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.938 0.875 . . . . 0.0 111.463 179.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.438 ' C ' ' SD ' ' A' ' 35' ' ' MET . 6.8 tmm? -136.15 131.42 34.66 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.288 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.0 t -121.52 73.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -105.5 100.7 1.75 Allowed Glycine 0 N--CA 1.442 -0.933 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 178.315 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -177.66 170.44 42.84 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m -134.33 161.46 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.889 0.376 . . . . 0.0 110.795 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.407 179.728 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -111.59 136.95 50.08 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.701 0.286 . . . . 0.0 110.672 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -111.72 129.65 56.04 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.021 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t -142.19 138.39 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.799 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -132.41 104.95 6.98 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.585 0.231 . . . . 0.0 110.793 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' B' ' 15' ' ' GLN . 52.7 m170 -126.33 167.08 15.99 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.6 mm-40 -155.27 178.39 10.27 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.663 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -171.08 115.72 0.43 Allowed 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.113 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.429 ' CD2' ' C ' ' B' ' 17' ' ' LEU . 8.2 tt -128.42 122.62 31.77 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.127 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 28.6 m -137.76 131.98 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 N-CA-C 113.129 0.788 . . . . 0.0 113.129 -179.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -110.09 115.68 30.19 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.598 ' CE1' ' CD1' ' C' ' 20' ' ' PHE . 74.2 t80 -121.76 123.5 41.97 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.56 124.76 36.77 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 113.04 0.756 . . . . 0.0 113.04 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.451 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 42.8 tp10 -153.99 129.49 9.91 Favored 'General case' 0 C--O 1.221 -0.415 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.344 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.529 ' OD2' ' NZ ' ' C' ' 28' ' ' LYS . 8.8 t0 -152.41 134.99 15.31 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.055 -178.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' B' ' 25' ' ' GLY . 2.1 p -110.73 111.68 37.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.898 -1.047 . . . . 0.0 108.928 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 32.74 90.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.349 0 C-N-CA 121.586 -0.34 . . . . 0.0 113.328 177.524 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.569 ' CB ' ' HZ3' ' C' ' 28' ' ' LYS . 54.8 p -100.31 150.52 22.49 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 117.626 0.713 . . . . 0.0 109.083 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.532 ' CG ' ' H ' ' B' ' 28' ' ' LYS . 11.6 t30 -42.02 173.94 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.852 0.834 . . . . 0.0 113.207 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.532 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 57.7 tttt -76.3 111.15 11.43 Favored 'General case' 0 CA--C 1.548 0.893 0 N-CA-C 115.563 1.69 . . . . 0.0 115.563 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.36 93.41 0.03 OUTLIER Glycine 0 N--CA 1.478 1.454 0 C-N-CA 119.123 -1.513 . . . . 0.0 115.695 171.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.442 ' C ' ' CG1' ' B' ' 31' ' ' ILE . . . -123.3 152.47 41.38 Favored 'General case' 0 C--O 1.245 0.836 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 173.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.442 ' CG1' ' C ' ' B' ' 30' ' ' ALA . 0.2 OUTLIER -152.8 135.31 6.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 C-N-CA 118.215 -1.394 . . . . 0.0 111.899 -171.762 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 16.5 tt -146.29 137.44 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.332 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.48 128.89 6.48 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.527 ' H ' HD21 ' C' ' 34' ' ' LEU . 48.9 mt -139.33 128.98 24.55 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 122.227 -0.573 . . . . 0.0 111.94 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.43 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 61.8 ttp -130.93 127.33 38.23 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.247 177.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' B' ' 37' ' ' GLY . 15.4 m -133.83 76.4 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 119.936 -0.706 . . . . 0.0 112.779 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -33.6 -95.67 0.01 OUTLIER Glycine 0 CA--C 1.53 1.0 0 N-CA-C 111.521 -0.632 . . . . 0.0 111.521 178.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.47 -168.75 35.43 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.64 134.78 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 120.985 0.421 . . . . 0.0 110.412 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.668 179.837 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -108.44 132.09 54.13 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.551 0.215 . . . . 0.0 110.457 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -95.92 134.77 38.52 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 121.014 0.435 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.429 ' CG1' ' HE2' ' B' ' 14' ' ' HIS . 53.4 t -127.71 136.15 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.11 -179.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -130.16 125.48 35.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.792 0.33 . . . . 0.0 111.013 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.497 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 45.1 t-80 -145.2 166.79 24.44 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.497 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 99.7 mm-40 -153.16 176.83 11.49 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.807 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 69.0 tttt -170.17 104.31 0.3 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.598 178.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 11.2 mp -118.5 118.59 32.12 Favored 'General case' 0 C--O 1.237 0.432 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -131.73 131.5 62.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.603 ' CD1' ' CZ ' ' D' ' 19' ' ' PHE . 52.3 m-85 -113.69 116.51 29.55 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.382 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE1' ' B' ' 20' ' ' PHE . 51.9 t80 -125.94 122.14 35.12 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 118.625 0.648 . . . . 0.0 109.548 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.29 130.12 30.37 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 113.769 1.025 . . . . 0.0 113.769 -178.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.451 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 71.3 mt-10 -155.17 114.98 3.72 Favored 'General case' 0 C--N 1.352 0.682 0 CA-C-N 113.661 -1.608 . . . . 0.0 108.806 178.104 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.423 ' O ' ' O ' ' D' ' 26' ' ' SER . 65.6 t0 -147.54 122.51 10.05 Favored 'General case' 0 N--CA 1.476 0.862 0 O-C-N 121.739 -0.6 . . . . 0.0 111.419 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 14.5 t -98.53 -112.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.056 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.434 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 39.68 -90.94 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.103 -179.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.631 ' O ' ' O ' ' C' ' 27' ' ' ASN . 2.0 m 171.15 170.11 0.08 Allowed 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.631 ' O ' ' O ' ' C' ' 26' ' ' SER . 65.8 t30 -17.56 158.61 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 O-C-N 124.616 1.198 . . . . 0.0 113.696 177.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.569 ' HZ3' ' CB ' ' B' ' 26' ' ' SER . 50.5 tttt -161.26 110.63 1.61 Allowed 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.521 174.491 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.69 92.64 0.29 Allowed Glycine 0 C--O 1.224 -0.488 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 173.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.16 150.5 47.98 Favored 'General case' 0 CA--C 1.476 -1.885 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 174.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.36 114.49 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 C-N-CA 117.672 -1.611 . . . . 0.0 110.996 -173.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.401 HD13 HG23 ' C' ' 32' ' ' ILE . 9.2 mt -108.84 124.04 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.147 178.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.43 100.62 0.6 Allowed Glycine 0 N--CA 1.474 1.186 0 N-CA-C 108.521 -1.831 . . . . 0.0 108.521 177.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.527 HD21 ' H ' ' B' ' 34' ' ' LEU . 1.6 mt -134.32 142.27 47.19 Favored 'General case' 0 C--O 1.243 0.722 0 CA-C-O 122.886 1.327 . . . . 0.0 113.859 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.544 ' SD ' ' CE ' ' D' ' 35' ' ' MET . 41.9 ttp -127.51 118.8 24.7 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 112.771 -2.013 . . . . 0.0 108.127 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.448 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.1 OUTLIER -116.33 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-N 114.173 -1.376 . . . . 0.0 107.864 179.067 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -39.86 -101.48 0.01 OUTLIER Glycine 0 C--N 1.366 2.238 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.88 -145.83 11.32 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.4 m -128.32 158.85 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 120.664 0.269 . . . . 0.0 110.306 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.467 179.984 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -83.37 137.61 33.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.799 0.333 . . . . 0.0 110.522 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -120.9 133.65 55.29 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.426 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 33.7 m -129.03 133.13 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 121.348 0.594 . . . . 0.0 110.757 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -132.97 134.85 45.05 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.666 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 73.3 m80 -149.04 167.03 26.93 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 121.266 0.555 . . . . 0.0 110.039 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -155.76 171.23 20.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.326 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -158.62 114.1 2.62 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.926 -0.31 . . . . 0.0 111.107 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mt -118.55 119.13 33.59 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.444 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -131.31 129.54 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.603 ' CZ ' ' CD1' ' C' ' 19' ' ' PHE . 19.8 m-85 -118.97 123.63 45.04 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -131.26 119.83 22.35 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.747 0.308 . . . . 0.0 111.633 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.08 122.45 28.35 Favored 'General case' 0 N--CA 1.476 0.835 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.136 178.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -84.9 157.01 20.99 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.403 ' HA ' ' NZ ' ' F' ' 28' ' ' LYS . 1.2 t0 -88.72 -174.12 4.4 Favored 'General case' 0 C--N 1.348 0.525 0 CA-C-O 121.213 0.53 . . . . 0.0 110.897 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.413 ' O ' ' O ' ' D' ' 25' ' ' GLY . 20.7 t 62.64 104.45 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' D' ' 24' ' ' VAL . . . 64.71 100.0 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 117.618 -2.23 . . . . 0.0 107.686 -178.664 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.423 ' O ' ' O ' ' C' ' 23' ' ' ASP . 78.6 p -52.44 171.93 0.05 OUTLIER 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 118.037 0.918 . . . . 0.0 108.617 -176.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.449 ' O ' ' O ' ' D' ' 28' ' ' LYS . 27.4 m-20 -81.84 178.51 8.27 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.694 -0.802 . . . . 0.0 112.115 -175.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' D' ' 27' ' ' ASN . 44.2 tttp -38.6 -106.51 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.294 -1.321 . . . . 0.0 112.533 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.47 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . 86.29 -100.04 2.48 Favored Glycine 0 CA--C 1.456 -3.637 0 N-CA-C 106.218 -2.753 . . . . 0.0 106.218 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.795 ' H ' ' HB2' ' E' ' 30' ' ' ALA . . . 67.55 -163.86 0.21 Allowed 'General case' 0 N--CA 1.419 -2.001 1 N-CA-C 98.449 -4.648 . . . . 0.0 98.449 -176.36 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.552 ' N ' ' CD1' ' D' ' 31' ' ' ILE . 0.0 OUTLIER -115.79 110.94 33.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 CA-C-N 123.941 3.064 . . . . 0.0 110.397 177.258 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.446 ' C ' ' SD ' ' J' ' 35' ' ' MET . 13.7 tt -122.57 127.56 75.04 Favored 'Isoleucine or valine' 0 C--N 1.353 0.744 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.96 179.351 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.36 101.22 0.77 Allowed Glycine 0 N--CA 1.457 0.092 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 5.0 mp -120.34 125.81 48.96 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 122.32 1.057 . . . . 0.0 110.923 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.617 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 37.3 ttp -120.29 119.26 32.63 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 113.928 -1.487 . . . . 0.0 107.839 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.51 74.06 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.698 -178.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . -48.35 111.45 0.89 Allowed Glycine 0 C--N 1.351 1.392 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 37' ' ' GLY . . . -59.77 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 74.7 t -120.95 133.73 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.688 -179.93 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -109.23 132.86 53.72 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.58 151.0 42.79 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.684 0.278 . . . . 0.0 110.629 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 66.2 t -125.86 131.2 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.947 0.403 . . . . 0.0 110.609 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 16.9 t60 -138.93 130.75 27.69 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.532 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 27.1 m80 -148.15 168.24 22.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.751 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.606 ' NE2' HE21 ' F' ' 15' ' ' GLN . 75.1 mt-30 -154.83 165.97 34.97 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.427 178.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -148.6 117.73 6.81 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.192 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.27 122.72 34.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.238 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -127.56 125.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.074 0.464 . . . . 0.0 111.0 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -117.74 113.81 22.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.542 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 55.0 t80 -123.46 116.72 23.69 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 134.74 15.52 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 118.974 -1.09 . . . . 0.0 113.664 -178.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -102.6 117.28 34.33 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 176.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' E' ' 23' ' ' ASP . 7.1 p-10 -131.06 113.26 13.72 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 114.395 1.257 . . . . 0.0 114.395 -177.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.631 ' O ' ' N ' ' E' ' 26' ' ' SER . 40.3 t -127.23 122.29 59.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 175.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.467 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . -28.97 83.8 0.0 OUTLIER Glycine 0 N--CA 1.484 1.883 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.631 ' N ' ' O ' ' E' ' 24' ' ' VAL . 6.3 p -88.24 -179.75 6.2 Favored 'General case' 0 N--CA 1.441 -0.885 0 CA-C-O 123.102 1.43 . . . . 0.0 113.734 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.406 ' CG ' ' H ' ' E' ' 28' ' ' LYS . 60.3 t30 -77.04 179.35 6.31 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-N 111.446 -2.616 . . . . 0.0 110.836 176.063 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.406 ' H ' ' CG ' ' E' ' 27' ' ' ASN . 82.9 tttt 42.88 110.98 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 114.697 1.369 . . . . 0.0 114.697 176.444 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.43 93.99 1.68 Allowed Glycine 0 N--CA 1.47 0.905 0 N-CA-C 108.035 -2.026 . . . . 0.0 108.035 174.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.795 ' HB2' ' H ' ' D' ' 30' ' ' ALA . . . -100.5 166.79 10.75 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -156.44 121.79 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.051 0 C-N-CA 117.916 -1.514 . . . . 0.0 112.306 -173.087 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -111.15 123.74 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.877 178.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.8 109.78 1.7 Allowed Glycine 0 CA--C 1.512 -0.139 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 41.5 tp -133.24 126.74 32.2 Favored 'General case' 0 C--O 1.243 0.745 0 CA-C-O 121.848 0.832 . . . . 0.0 111.454 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.541 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 57.9 ttp -115.62 124.3 50.58 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.059 177.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -129.68 71.58 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.332 -179.885 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -32.46 -101.0 0.01 OUTLIER Glycine 0 C--N 1.364 2.106 0 N-CA-C 111.678 -0.569 . . . . 0.0 111.678 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.18 159.2 30.21 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.94 161.38 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.697 0.284 . . . . 0.0 110.424 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.509 179.501 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -109.28 140.11 43.35 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.685 0.278 . . . . 0.0 110.623 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -54.87 142.28 30.06 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 77.0 t -100.56 130.44 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-O 121.144 0.497 . . . . 0.0 110.72 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -161.11 109.84 1.58 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.243 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -153.63 174.58 14.29 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.606 HE21 ' NE2' ' E' ' 15' ' ' GLN . 95.0 mt-30 -145.56 172.89 12.59 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.326 -0.549 . . . . 0.0 110.605 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.79 112.32 7.83 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.012 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 tt -125.2 122.4 36.9 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.418 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 69.2 t -129.32 130.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.536 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 53.0 p90 -131.5 127.47 37.36 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.816 0.341 . . . . 0.0 110.292 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -142.04 126.87 18.16 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.422 0.629 . . . . 0.0 110.057 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -161.3 161.9 30.77 Favored 'General case' 0 C--N 1.32 -0.683 0 C-N-CA 120.08 -0.648 . . . . 0.0 111.082 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 95.6 mt-10 -116.82 107.99 15.3 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.275 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 49.1 t0 -108.73 114.14 27.69 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.265 0.555 . . . . 0.0 111.951 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.588 ' O ' ' N ' ' F' ' 26' ' ' SER . 83.1 t -96.11 130.97 44.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 177.387 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.88 -85.5 0.01 OUTLIER Glycine 0 CA--C 1.529 0.915 0 N-CA-C 109.604 -1.399 . . . . 0.0 109.604 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.588 ' N ' ' O ' ' F' ' 24' ' ' VAL . 58.3 p -132.35 162.84 30.07 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 117.946 0.873 . . . . 0.0 109.258 177.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.449 ' O ' ' O ' ' F' ' 26' ' ' SER . 53.1 p30 -38.6 174.88 0.0 OUTLIER 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.683 -1.144 . . . . 0.0 113.387 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.546 ' O ' ' N ' ' F' ' 30' ' ' ALA . 22.6 tttt -74.63 112.47 10.85 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.807 175.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.88 91.65 0.08 OUTLIER Glycine 0 N--CA 1.467 0.761 0 C-N-CA 117.056 -2.497 . . . . 0.0 109.034 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.546 ' N ' ' O ' ' F' ' 28' ' ' LYS . . . -171.53 162.01 6.4 Favored 'General case' 0 C--N 1.295 -1.786 1 N-CA-C 98.752 -4.536 . . . . 0.0 98.752 178.569 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.463 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.0 OUTLIER -152.11 131.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 115.778 -2.369 . . . . 0.0 113.243 -175.262 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 76.0 mt -106.12 113.49 42.99 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 114.13 -1.395 . . . . 0.0 109.615 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.08 96.46 1.53 Allowed Glycine 0 CA--C 1.502 -0.75 0 N-CA-C 106.217 -2.753 . . . . 0.0 106.217 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.428 ' O ' ' CG ' ' F' ' 34' ' ' LEU . 1.4 pp -118.39 122.2 42.23 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 111.478 0.177 . . . . 0.0 111.478 -177.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.501 ' SD ' ' CA ' ' L' ' 33' ' ' GLY . 58.1 ttp -118.71 115.71 25.07 Favored 'General case' 0 CA--C 1.5 -0.96 0 C-N-CA 119.094 -1.042 . . . . 0.0 108.64 176.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' F' ' 37' ' ' GLY . 3.1 m -123.34 71.44 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.469 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -24.97 -103.29 0.0 OUTLIER Glycine 0 C--N 1.36 1.863 0 O-C-N 123.515 0.509 . . . . 0.0 112.432 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.04 163.27 7.45 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -144.34 143.32 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.79 0.328 . . . . 0.0 110.612 179.303 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.428 179.921 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -118.64 138.27 52.72 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.801 0.334 . . . . 0.0 110.496 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -76.2 158.62 31.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.289 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 56.8 t -118.27 132.93 66.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.147 0.499 . . . . 0.0 110.225 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -104.77 -168.78 1.52 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.395 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.45 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 3.4 m80 -76.57 165.28 25.0 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.456 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 6.3 tp-100 -161.67 175.18 12.3 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.456 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 64.2 tttp -161.63 131.82 4.91 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.102 179.522 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -123.54 125.66 45.28 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.397 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 63.2 t -125.19 126.45 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.857 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.41 ' CZ ' HD12 ' J' ' 34' ' ' LEU . 5.7 t80 -114.49 109.08 17.73 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -118.34 115.66 25.15 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.94 121.38 44.49 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.96 0.41 . . . . 0.0 110.632 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -154.81 118.34 4.54 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -58.23 121.27 10.33 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.279 -178.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.2 m -88.25 124.15 41.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.99 84.53 0.01 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 121.461 -0.4 . . . . 0.0 112.192 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' G' ' 24' ' ' VAL . 60.7 m -93.52 178.6 5.65 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.03 178.73 0.17 Allowed 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.127 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.95 110.94 1.3 Allowed 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.101 -0.64 . . . . 0.0 111.009 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.736 ' H ' HD21 ' H' ' 27' ' ' ASN . . . 71.16 93.11 0.08 OUTLIER Glycine 0 N--CA 1.463 0.485 0 C-N-CA 119.501 -1.333 . . . . 0.0 112.21 176.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.67 160.27 17.42 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 119.784 1.792 . . . . 0.0 109.195 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.04 123.67 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.017 -177.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.429 HD12 HG22 ' G' ' 32' ' ' ILE . 96.6 mt -133.96 128.29 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 O-C-N 121.942 -0.474 . . . . 0.0 111.249 179.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.04 121.59 3.43 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 54.6 tp -142.5 135.13 28.05 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.384 0.611 . . . . 0.0 112.254 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.453 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 66.3 ttp -127.3 139.01 53.18 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' G' ' 37' ' ' GLY . 22.5 t -133.55 78.36 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -179.31 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -33.85 -94.11 0.01 OUTLIER Glycine 0 C--N 1.345 1.045 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 177.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.99 -164.32 37.87 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -126.53 158.1 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.482 -179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.613 -179.197 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -104.53 131.66 51.67 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -141.3 144.47 34.64 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.608 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . 0.428 ' CG1' ' CE1' ' I' ' 13' ' ' HIS . 18.9 m -125.62 131.84 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -127.1 115.71 19.56 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-O 120.854 0.359 . . . . 0.0 110.956 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.405 ' CD2' ' N ' ' H' ' 14' ' ' HIS . 5.1 p80 -158.99 171.42 20.06 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.39 0.614 . . . . 0.0 110.587 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mm-40 -150.35 173.89 13.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.417 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -148.17 121.26 8.86 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -123.0 127.61 49.06 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.81 0.338 . . . . 0.0 111.851 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -122.05 125.64 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -122.27 115.17 21.87 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -178.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -126.86 121.66 32.47 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.49 127.13 51.92 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.613 -0.435 . . . . 0.0 112.001 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.404 ' HG3' ' H ' ' I' ' 24' ' ' VAL . 43.0 tt0 -158.29 103.34 1.8 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.918 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 78.4 m-20 -80.17 134.7 36.17 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-O 120.952 0.406 . . . . 0.0 110.825 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.403 ' O ' ' N ' ' H' ' 26' ' ' SER . 88.9 t -103.68 113.73 41.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -178.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -30.6 88.64 0.01 OUTLIER Glycine 0 CA--C 1.537 1.459 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.775 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' H' ' 27' ' ' ASN . 11.7 p -129.78 -178.54 4.75 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.736 HD21 ' H ' ' G' ' 29' ' ' GLY . 1.4 p-10 -40.16 174.82 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 113.486 0.921 . . . . 0.0 113.486 -174.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -74.8 111.15 9.71 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 116.18 1.919 . . . . 0.0 116.18 -178.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.32 93.54 0.07 OUTLIER Glycine 0 N--CA 1.467 0.733 0 C-N-CA 119.893 -1.146 . . . . 0.0 115.484 171.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.76 157.68 18.9 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 103.348 -2.834 . . . . 0.0 103.348 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.44 119.46 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.714 -174.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.403 ' C ' ' SD ' ' B' ' 35' ' ' MET . 27.7 mm -124.55 124.26 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.414 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.1 126.65 5.49 Favored Glycine 0 N--CA 1.469 0.873 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.4 tt -147.76 134.59 20.1 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.929 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.1 tmm? -128.62 127.09 41.55 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.851 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.436 ' O ' ' O ' ' H' ' 37' ' ' GLY . 10.5 t -122.92 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.294 0.85 . . . . 0.0 113.294 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -35.6 -93.8 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 177.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.1 -171.03 33.88 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.47 141.9 36.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 110.122 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.676 -179.995 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -87.1 135.01 33.45 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.593 0.235 . . . . 0.0 110.404 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -80.22 149.39 30.46 Favored 'General case' 0 C--N 1.332 -0.153 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 15.4 t -132.11 162.42 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.056 -178.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.428 ' CE1' ' CG1' ' H' ' 12' ' ' VAL . 0.5 OUTLIER -116.22 170.19 8.71 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.93 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -72.89 169.81 16.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -137.36 172.77 12.49 Favored 'General case' 0 C--N 1.318 -0.768 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.415 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -150.19 128.96 12.42 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.1 0.476 . . . . 0.0 111.663 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.6 tt -133.62 124.47 26.87 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -123.71 128.83 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.862 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.402 ' CE1' HD22 ' K' ' 34' ' ' LEU . 10.3 t80 -122.39 118.99 29.73 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.912 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -135.16 121.63 20.53 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.802 0.334 . . . . 0.0 111.062 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.18 123.49 38.35 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -162.6 126.52 3.02 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 115.354 -0.839 . . . . 0.0 108.815 178.195 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -102.27 114.03 27.84 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.404 ' H ' ' HG3' ' H' ' 22' ' ' GLU . 4.0 p -79.86 131.63 33.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.754 177.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.63 82.62 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 C-N-CA 119.725 -1.226 . . . . 0.0 112.392 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' I' ' 27' ' ' ASN . 75.1 m -60.04 -174.11 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 115.194 -0.503 . . . . 0.0 109.858 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' I' ' 26' ' ' SER . 17.9 m-20 98.53 -175.3 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 O-C-N 124.218 0.949 . . . . 0.0 109.975 -176.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' I' ' 27' ' ' ASN . 82.4 tttt 38.71 110.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -177.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 95.85 1.74 Allowed Glycine 0 CA--C 1.484 -1.885 0 N-CA-C 107.98 -2.048 . . . . 0.0 107.98 176.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 164.89 16.92 Favored 'General case' 0 N--CA 1.426 -1.662 0 C-N-CA 118.001 -1.48 . . . . 0.0 107.272 -179.024 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.56 117.31 4.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 119.376 -0.929 . . . . 0.0 108.827 -174.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 tt -125.51 124.16 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.834 178.18 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.33 96.62 0.73 Allowed Glycine 0 C--N 1.331 0.275 0 N-CA-C 107.72 -2.152 . . . . 0.0 107.72 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 8.7 tt -130.32 134.1 46.94 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 122.392 1.092 . . . . 0.0 112.183 -178.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 tmm? -128.26 125.74 39.49 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.618 -1.174 . . . . 0.0 110.344 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -130.69 76.95 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.34 179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 38' ' ' GLY . . . -71.9 106.36 1.9 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -49.27 179.38 0.01 OUTLIER Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 -179.29 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -124.58 138.78 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.938 -1.03 . . . . 0.0 110.365 179.688 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -110.06 138.58 46.24 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.692 0.282 . . . . 0.0 110.298 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -127.56 145.19 50.94 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.952 0.406 . . . . 0.0 110.768 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.86 152.71 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.778 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 31.0 m80 -132.57 146.98 52.33 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.52 ' CE1' ' O ' ' J' ' 15' ' ' GLN . 5.9 t-80 -154.52 157.84 38.95 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.52 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 82.3 mt-30 -148.97 178.06 9.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-O 121.538 0.685 . . . . 0.0 111.653 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -165.34 114.03 1.02 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.151 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -120.86 122.29 39.95 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.155 0.502 . . . . 0.0 111.04 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -114.02 121.82 66.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -125.04 108.37 11.76 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.9 0.381 . . . . 0.0 110.236 -177.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -130.17 127.83 40.51 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.629 0.728 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.67 128.57 31.28 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.842 178.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -142.39 111.24 6.3 Favored 'General case' 0 N--CA 1.462 0.142 0 C-N-CA 119.621 -0.831 . . . . 0.0 111.249 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -85.73 105.02 15.96 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.671 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.68 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 10.5 t -110.12 -131.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.123 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.68 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . 29.03 -82.24 0.0 OUTLIER Glycine 0 CA--C 1.529 0.914 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.869 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.636 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.2 p 169.65 177.76 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.34 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.744 HD21 ' H ' ' K' ' 29' ' ' GLY . 31.7 m120 -28.08 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 114.183 -1.371 . . . . 0.0 112.838 173.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.535 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 29.5 tttt 144.63 104.31 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 123.02 1.39 . . . . 0.0 112.005 177.347 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.16 93.54 0.01 OUTLIER Glycine 0 C--O 1.219 -0.825 0 CA-C-N 112.248 -2.251 . . . . 0.0 111.373 174.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.2 152.81 47.68 Favored 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 120.78 2.29 . . . . 0.0 106.526 176.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.432 ' HB ' ' SD ' ' D' ' 35' ' ' MET . 0.0 OUTLIER -137.97 121.86 21.61 Favored 'Isoleucine or valine' 0 C--O 1.248 1.022 0 C-N-CA 119.218 -0.993 . . . . 0.0 112.384 -174.895 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -104.42 109.44 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.406 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . 0.617 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -109.72 102.46 1.59 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 106.37 -2.692 . . . . 0.0 106.37 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.41 HD12 ' CZ ' ' G' ' 19' ' ' PHE . 5.1 tt -144.35 140.51 29.13 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 122.406 1.098 . . . . 0.0 111.775 -175.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.446 ' SD ' ' C ' ' D' ' 32' ' ' ILE . 61.0 ttp -133.69 130.21 37.85 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.08 -179.142 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -122.78 79.47 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.78 -178.336 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.19 104.54 0.48 Allowed Glycine 0 C--N 1.342 0.907 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.74 167.06 54.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -139.28 160.66 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.727 0.299 . . . . 0.0 110.584 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 C--O 1.221 -0.419 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.846 179.734 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -84.33 138.07 33.09 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.867 0.365 . . . . 0.0 111.068 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' L' ' 11' ' ' GLU . 72.3 mm-40 -137.6 131.98 32.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.628 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 m -138.09 135.56 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.906 0.384 . . . . 0.0 111.123 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 9.7 m80 -134.28 127.51 31.96 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.571 ' NE2' ' CG ' ' L' ' 13' ' ' HIS . 80.5 m80 -116.43 163.17 16.44 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.646 0.736 . . . . 0.0 110.36 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.52 ' N ' ' OE1' ' L' ' 15' ' ' GLN . 50.9 tt0 -163.27 172.31 14.89 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.412 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' K' ' 15' ' ' GLN . 55.4 tttp -164.81 114.88 1.14 Allowed 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 28.6 tp -118.8 121.65 40.54 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.76 127.83 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -131.0 125.7 34.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.23 0.538 . . . . 0.0 112.262 -178.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -133.06 125.79 30.39 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.993 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 127.43 35.36 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.182 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -149.29 137.73 20.88 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.048 -0.661 . . . . 0.0 112.023 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 20.6 p-10 -123.23 120.53 33.42 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 120.986 0.422 . . . . 0.0 110.029 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 84.3 t -60.62 121.1 7.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.519 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.31 -90.97 0.53 Allowed Glycine 0 CA--C 1.527 0.817 0 C-N-CA 121.368 -0.444 . . . . 0.0 112.464 177.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.587 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.8 p -141.37 171.22 14.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 121.196 0.522 . . . . 0.0 110.348 -178.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.587 ' O ' ' O ' ' K' ' 26' ' ' SER . 3.3 p30 -29.01 170.5 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.179 -1.373 . . . . 0.0 113.983 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -148.35 111.3 4.84 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.141 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.744 ' H ' HD21 ' J' ' 27' ' ' ASN . . . -54.53 91.58 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 121.244 -0.503 . . . . 0.0 112.211 179.208 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.63 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -166.38 158.17 13.56 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.8 123.61 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 118.721 -1.192 . . . . 0.0 111.829 -179.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.448 ' C ' ' SD ' ' E' ' 35' ' ' MET . 1.0 OUTLIER -102.09 118.41 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.077 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . 0.541 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -112.74 94.88 0.75 Allowed Glycine 0 CA--C 1.51 -0.26 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 179.181 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.412 HD12 ' N ' ' K' ' 35' ' ' MET . 41.0 tp -129.38 130.77 46.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-O 122.218 1.009 . . . . 0.0 111.968 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.412 ' N ' HD12 ' K' ' 34' ' ' LEU . 7.9 tmm? -116.71 114.73 24.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.893 175.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 m -116.56 79.86 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -66.8 103.24 0.87 Allowed Glycine 0 C--N 1.35 1.36 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -87.39 -178.55 48.38 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.48 142.9 30.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.951 0.405 . . . . 0.0 110.29 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.761 -179.768 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -101.7 130.06 48.0 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.5 tt0 -123.52 138.75 54.5 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 120.96 0.41 . . . . 0.0 110.748 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.53 156.04 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.187 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.7 ' CG ' ' H ' ' L' ' 14' ' ' HIS . 41.8 t-80 -91.29 -177.5 4.88 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 120.784 0.326 . . . . 0.0 110.727 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.7 ' H ' ' CG ' ' L' ' 13' ' ' HIS . 99.2 m-70 -75.52 171.73 13.77 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.53 ' NE2' ' O ' ' L' ' 14' ' ' HIS . 51.5 mm-40 -139.2 -179.78 6.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.62 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.95 124.38 15.72 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.685 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 58.0 tp -125.44 121.22 33.19 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.381 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -129.41 129.35 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.461 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 54.7 p90 -139.45 130.85 26.92 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.785 0.326 . . . . 0.0 111.123 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 84.8 t80 -142.55 131.99 23.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.019 179.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.16 146.43 35.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.814 0.34 . . . . 0.0 110.58 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' K' ' 23' ' ' ASP . 84.6 tt0 -78.52 142.76 37.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.145 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -76.73 121.72 23.7 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 121.225 0.536 . . . . 0.0 110.766 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' L' ' 25' ' ' GLY . 19.5 t -102.75 122.88 55.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.115 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.452 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -30.56 -86.47 0.01 OUTLIER Glycine 0 N--CA 1.478 1.442 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 30.7 t -90.21 -179.97 5.77 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 177.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -58.8 162.89 3.7 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 117.866 -1.534 . . . . 0.0 110.456 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 59.6 tttt -58.3 111.64 1.28 Allowed 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.85 -98.28 0.01 OUTLIER Glycine 0 C--N 1.319 -0.416 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.63 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -72.72 174.57 7.45 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 178.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.468 HG13 ' H ' ' L' ' 32' ' ' ILE . 7.5 tt -171.17 165.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 C-N-CA 115.033 -2.667 . . . . 0.0 115.448 -172.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.468 ' H ' HG13 ' L' ' 31' ' ' ILE . 16.3 tt -99.31 122.02 50.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.761 0 CA-C-N 113.284 -1.78 . . . . 0.0 108.154 177.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . 0.501 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -110.52 94.37 0.79 Allowed Glycine 0 CA--C 1.507 -0.436 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 51.3 tp -119.03 118.76 32.33 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 11.3 tmm? -105.16 119.22 38.5 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.497 ' O ' ' C ' ' L' ' 37' ' ' GLY . 2.7 m -129.03 75.04 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.927 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.497 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -16.95 -101.76 0.0 OUTLIER Glycine 0 C--N 1.359 1.856 0 O-C-N 123.158 0.286 . . . . 0.0 112.707 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.0 173.87 37.68 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.271 -0.731 . . . . 0.0 111.271 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -122.65 138.45 52.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.885 0.374 . . . . 0.0 110.51 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.813 -179.659 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -109.86 141.64 42.27 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.924 0.393 . . . . 0.0 110.937 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.469 ' N ' ' CD ' ' A' ' 11' ' ' GLU . 2.0 pm0 -117.58 147.99 42.31 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.074 179.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m -113.8 133.79 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 110.613 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 18.5 p-80 -143.71 164.44 30.44 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.934 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.1 p-80 -87.78 169.98 11.61 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-O 121.395 0.617 . . . . 0.0 110.375 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.448 ' CG ' ' H ' ' A' ' 16' ' ' LYS . 51.5 tt0 -153.28 175.32 13.21 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.301 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.448 ' H ' ' CG ' ' A' ' 15' ' ' GLN . 99.5 mttt -137.68 133.65 34.48 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.819 0.343 . . . . 0.0 110.831 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -129.16 121.52 27.91 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -132.74 131.3 59.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -111.21 116.79 31.66 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.535 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 55.5 p90 -129.84 125.92 36.81 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.75 126.3 32.15 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.083 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' A' ' 22' ' ' GLU . 55.4 mp0 -141.32 163.94 31.59 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 33.7 t70 -79.2 113.67 17.52 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -178.538 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.502 ' O ' ' N ' ' A' ' 26' ' ' SER . 3.5 p -127.11 121.66 58.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 176.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -29.31 84.04 0.0 OUTLIER Glycine 0 CA--C 1.537 1.412 0 CA-C-O 118.833 -0.982 . . . . 0.0 113.834 178.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 24' ' ' VAL . 10.0 p -97.62 171.82 8.11 Favored 'General case' 0 C--N 1.347 0.468 0 CA-C-N 119.686 1.743 . . . . 0.0 107.311 177.002 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 p30 -60.13 177.53 0.25 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 118.418 -1.313 . . . . 0.0 110.227 178.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -61.76 110.61 1.57 Allowed 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.505 174.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.639 ' H ' ' CB ' ' B' ' 27' ' ' ASN . . . 70.86 93.82 0.07 OUTLIER Glycine 0 N--CA 1.467 0.714 0 C-N-CA 117.541 -2.266 . . . . 0.0 111.716 174.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.52 158.57 17.43 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 121.283 2.542 . . . . 0.0 111.225 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.98 120.38 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 113.433 -1.712 . . . . 0.0 110.566 -175.532 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.7 mt -130.6 125.3 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 O-C-N 121.52 -0.738 . . . . 0.0 110.438 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.575 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -132.15 119.12 2.43 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 80.8 mt -122.23 129.97 52.74 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.071 0.462 . . . . 0.0 110.895 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.402 ' HE2' ' H ' ' H' ' 33' ' ' GLY . 0.0 OUTLIER -126.53 120.49 29.78 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.18 179.995 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -104.94 77.74 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 120.22 -0.592 . . . . 0.0 112.239 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -92.27 101.0 2.73 Favored Glycine 0 C--N 1.342 0.893 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.64 155.87 27.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 28.4 m -136.93 161.51 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.415 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.6 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.616 -179.909 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 72.0 t80 -138.81 159.05 43.07 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -60.39 132.17 53.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.121 0.486 . . . . 0.0 110.965 -179.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 26.5 m -139.56 162.88 26.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.631 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.437 ' C ' ' CG ' ' B' ' 14' ' ' HIS . 80.6 t60 -138.7 138.9 38.16 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.644 0.259 . . . . 0.0 110.533 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.587 ' CE1' ' CE1' ' C' ' 14' ' ' HIS . 19.6 m-70 -150.76 170.24 19.71 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.278 0.561 . . . . 0.0 109.983 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -153.14 173.04 16.01 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.49 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -153.9 118.66 4.97 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -116.31 120.95 40.54 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 45.5 t -126.07 121.79 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.157 0.504 . . . . 0.0 110.641 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.438 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 6.4 m-85 -113.52 113.16 24.73 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.709 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -118.17 106.17 12.57 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 175.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.99 125.93 52.12 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.523 ' N ' ' OE1' ' B' ' 22' ' ' GLU . 57.0 mp0 -142.41 178.88 7.29 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 177.208 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.499 ' OD1' ' NZ ' ' D' ' 28' ' ' LYS . 14.1 m-20 -38.09 121.92 0.99 Allowed 'General case' 0 N--CA 1.475 0.811 0 CA-C-N 119.244 0.929 . . . . 0.0 110.644 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.619 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 97.3 t -58.55 -120.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.648 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.021 -178.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.619 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -79.67 -90.28 0.45 Allowed Glycine 0 CA--C 1.523 0.577 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.996 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 77.6 p -155.01 -172.07 4.06 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.835 0.826 . . . . 0.0 110.403 -179.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.639 ' CB ' ' H ' ' A' ' 29' ' ' GLY . 8.9 t-20 57.72 -171.72 0.1 Allowed 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 114.201 -1.363 . . . . 0.0 111.671 178.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.591 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 72.2 mmtt -56.96 -111.3 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.709 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.92 94.47 1.57 Allowed Glycine 0 N--CA 1.461 0.314 0 CA-C-N 115.265 -0.88 . . . . 0.0 114.39 -177.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.33 163.97 15.79 Favored 'General case' 0 C--N 1.35 0.605 0 C-N-CA 116.821 -1.952 . . . . 0.0 106.673 177.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.26 128.76 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 C-N-CA 119.111 -1.036 . . . . 0.0 111.739 -172.779 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 99.0 mt -133.23 133.61 58.02 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.325 0.583 . . . . 0.0 110.922 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.01 127.11 4.63 Favored Glycine 0 N--CA 1.47 0.952 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.238 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.9 tt -133.79 127.87 33.59 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.294 0.547 . . . . 0.0 111.038 -178.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.548 ' SD ' ' CA ' ' H' ' 33' ' ' GLY . 20.7 ttt -130.24 123.82 31.04 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.421 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 t -124.33 76.02 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.801 178.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.32 101.54 2.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -134.72 163.54 24.72 Favored Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.86 136.97 56.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.506 -179.813 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -106.9 135.97 47.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.921 0.391 . . . . 0.0 110.644 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -67.77 135.63 52.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.795 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 58.5 t -124.89 133.65 68.92 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.05 0.452 . . . . 0.0 111.075 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 p-80 -147.52 145.51 29.12 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.574 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.587 ' CE1' ' CE1' ' B' ' 14' ' ' HIS . 10.2 p-80 -153.76 168.05 27.58 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.361 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -148.75 176.85 10.02 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.248 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -147.23 127.74 14.11 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.296 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.7 mp -130.51 127.28 38.83 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-O 121.1 0.476 . . . . 0.0 111.372 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.8 t -127.4 126.01 66.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.089 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.403 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 57.2 m-85 -111.45 116.11 30.36 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.198 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 50.4 t80 -127.88 117.68 22.24 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.6 130.67 49.43 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.326 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -155.57 101.1 2.15 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.979 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -68.7 133.98 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.977 0.418 . . . . 0.0 110.206 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.34 113.02 20.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.621 0.724 . . . . 0.0 111.178 -179.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 52.97 -91.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.473 -1.24 . . . . 0.0 115.288 177.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.582 ' HG ' ' N ' ' C' ' 27' ' ' ASN . 47.3 t -153.78 -175.57 5.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 122.678 1.228 . . . . 0.0 113.102 -175.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.582 ' N ' ' HG ' ' C' ' 26' ' ' SER . 24.7 m120 52.73 179.93 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 112.433 -2.167 . . . . 0.0 115.129 178.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 75.2 mttt 53.4 110.6 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 CA-C-N 112.536 -2.12 . . . . 0.0 113.967 -177.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.77 95.97 1.85 Allowed Glycine 0 N--CA 1.488 2.127 0 CA-C-O 117.828 -1.54 . . . . 0.0 110.366 175.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.54 160.09 15.59 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 121.354 2.577 . . . . 0.0 109.833 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -148.53 124.97 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.102 -176.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.44 ' O ' ' SD ' ' J' ' 35' ' ' MET . 14.3 tt -130.18 128.92 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 121.195 0.522 . . . . 0.0 110.459 177.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.445 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -112.77 117.62 4.36 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 29.3 mt -124.69 119.66 29.61 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -176.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.461 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 5.3 ttm -122.4 117.58 26.35 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 177.312 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.52 74.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.998 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.313 -178.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 38' ' ' GLY . . . -61.0 110.98 3.4 Favored Glycine 0 C--N 1.354 1.535 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . -53.9 -167.47 0.02 OUTLIER Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.71 161.82 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.068 0.461 . . . . 0.0 111.221 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 68.6 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.889 -1.053 . . . . 0.0 110.594 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -82.31 145.78 29.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.994 0.426 . . . . 0.0 110.547 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -65.49 167.17 9.18 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.378 -179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 30.9 m -131.18 171.44 17.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -177.683 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CB ' ' E' ' 13' ' ' HIS . 5.7 t60 -89.21 122.38 32.44 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.013 178.567 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 47.5 p-80 -156.15 169.04 25.43 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.056 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -145.04 177.97 8.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -152.59 119.77 5.88 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.185 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -119.68 120.35 36.37 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.855 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -125.7 125.87 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.802 0.334 . . . . 0.0 110.962 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.403 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 72.3 m-85 -115.75 115.82 26.97 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.069 179.011 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 53.9 t80 -127.5 121.15 29.96 Favored 'General case' 0 C--O 1.239 0.5 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 178.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.15 135.58 37.49 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.298 0.571 . . . . 0.0 112.297 -179.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -136.92 96.48 3.31 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.048 178.379 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.425 ' O ' ' CG2' ' E' ' 24' ' ' VAL . 89.8 m-20 -85.89 134.89 33.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.416 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 8.1 p -88.27 112.75 24.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.457 0.646 . . . . 0.0 109.403 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.472 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -45.45 92.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.597 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.346 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.472 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 163.92 -169.6 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.641 0 CA-C-O 121.727 0.775 . . . . 0.0 110.163 -178.562 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -50.64 179.77 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.499 ' NZ ' ' OD1' ' B' ' 23' ' ' ASP . 67.2 tttt 60.49 112.38 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 112.248 -2.251 . . . . 0.0 115.881 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.0 96.16 2.18 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.091 -2.804 . . . . 0.0 106.091 170.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.421 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . -79.31 162.77 25.4 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 123.47 3.635 . . . . 0.0 105.805 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.421 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 1.1 mt -147.21 126.47 4.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 C-N-CA 117.679 -1.608 . . . . 0.0 111.348 -174.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 52.6 mt -123.91 116.95 49.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 177.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.28 103.59 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 105.878 -2.889 . . . . 0.0 105.878 176.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.438 ' CD2' ' CZ ' ' B' ' 19' ' ' PHE . 12.7 tp -116.54 124.36 49.68 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 114.077 1.139 . . . . 0.0 114.077 -175.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.437 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 8.0 ttm -126.54 110.47 13.28 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 174.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.25 79.89 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.151 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.02 103.13 1.32 Allowed Glycine 0 C--N 1.349 1.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 112.506 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.59 178.93 38.46 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 178.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 60.7 t -141.88 157.95 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.946 0.403 . . . . 0.0 111.011 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.52 179.916 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 77.1 t80 -85.28 138.96 31.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.883 0.373 . . . . 0.0 110.528 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -55.4 143.05 30.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.689 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.64 135.75 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.487 ' CB ' ' O ' ' D' ' 13' ' ' HIS . 6.4 p80 -155.66 162.07 40.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.041 0.448 . . . . 0.0 111.296 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 69.0 m80 -139.82 168.19 20.39 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.854 0.835 . . . . 0.0 110.287 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 51.8 tt0 -153.17 165.34 35.97 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 114.678 -1.146 . . . . 0.0 108.826 178.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -157.24 116.88 3.4 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.627 0.251 . . . . 0.0 110.334 179.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 32.6 tp -117.14 113.79 22.77 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.47 128.7 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -127.27 120.49 28.77 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.924 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -127.84 118.49 23.77 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.68 130.04 46.65 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.129 0.49 . . . . 0.0 111.326 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -113.27 102.62 10.53 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 64.4 t0 -79.9 123.17 27.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.174 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.425 ' CG2' ' O ' ' D' ' 23' ' ' ASP . 93.0 t -96.5 121.65 47.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.195 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 42.7 -87.03 0.01 OUTLIER Glycine 0 CA--C 1.533 1.17 0 CA-C-N 115.127 -0.942 . . . . 0.0 114.688 178.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 11.1 p -165.38 -178.36 4.95 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-O 122.235 1.017 . . . . 0.0 112.044 -175.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.602 ' CG ' ' H ' ' E' ' 28' ' ' LYS . 7.0 t-20 51.36 -179.13 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 116.105 1.891 . . . . 0.0 116.105 177.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.602 ' H ' ' CG ' ' E' ' 27' ' ' ASN . 27.2 tttt 53.76 110.97 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 112.178 -2.283 . . . . 0.0 114.223 -175.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -87.13 96.44 2.17 Favored Glycine 0 C--N 1.337 0.6 0 CA-C-N 111.973 -2.376 . . . . 0.0 110.909 175.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.412 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -78.83 166.24 22.65 Favored 'General case' 0 C--O 1.241 0.624 0 CA-C-N 122.765 3.282 . . . . 0.0 103.553 177.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.412 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 1.1 mt -147.57 127.39 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 116.687 -2.005 . . . . 0.0 112.903 -172.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 15.7 tt -135.4 119.88 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-O 121.472 0.653 . . . . 0.0 109.49 176.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.68 110.3 2.78 Favored Glycine 0 CA--C 1.508 -0.356 0 N-CA-C 107.492 -2.243 . . . . 0.0 107.492 178.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.57 123.24 43.44 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 122.259 1.028 . . . . 0.0 111.775 -178.2 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.424 ' CE ' ' O ' ' L' ' 31' ' ' ILE . 9.5 tpt -111.47 110.77 21.38 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 113.709 -1.587 . . . . 0.0 107.467 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -119.66 80.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-O 121.035 0.445 . . . . 0.0 109.94 -178.043 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.08 102.17 0.08 OUTLIER Glycine 0 C--N 1.341 0.833 0 CA-C-N 116.247 -0.433 . . . . 0.0 112.044 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.96 150.61 22.7 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.6 t -126.56 136.71 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 88.8 t . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.374 179.819 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 31.5 p90 -147.72 159.48 43.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.686 0.279 . . . . 0.0 110.415 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -153.78 147.21 24.94 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.198 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m -140.23 -172.01 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 120.99 0.424 . . . . 0.0 110.785 -179.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.468 ' CB ' ' CE1' ' E' ' 13' ' ' HIS . 44.4 p-80 -87.68 163.21 16.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.312 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 53.2 m80 -147.33 172.15 14.33 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -144.12 178.06 8.15 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.847 -179.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.9 121.9 0.57 Allowed 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.738 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.69 125.19 35.4 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.401 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 86.9 t -134.1 129.4 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.923 0.392 . . . . 0.0 111.237 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -122.55 125.66 46.17 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.049 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -136.07 132.63 36.42 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.13 0.491 . . . . 0.0 110.024 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.27 149.46 31.91 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.099 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -74.17 152.74 39.75 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.729 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 t0 78.13 -141.02 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.137 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.121 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 59.4 t -108.02 106.85 21.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.74 -95.27 0.01 OUTLIER Glycine 0 CA--C 1.528 0.893 0 CA-C-N 114.672 -1.149 . . . . 0.0 111.848 -179.041 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 41.6 t -48.08 150.61 1.14 Allowed 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 178.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.622 ' O ' ' O ' ' F' ' 28' ' ' LYS . 94.0 m-20 -127.4 179.74 5.32 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 175.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.622 ' O ' ' O ' ' F' ' 27' ' ' ASN . 28.6 pttt -28.87 -103.95 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.85 177.016 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.618 ' O ' ' O ' ' F' ' 30' ' ' ALA . . . -120.01 -100.1 1.81 Allowed Glycine 0 C--N 1.343 0.943 0 N-CA-C 108.299 -1.921 . . . . 0.0 108.299 173.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.618 ' O ' ' O ' ' F' ' 29' ' ' GLY . . . 54.83 151.97 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 105.412 -2.07 . . . . 0.0 105.412 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.426 ' HB ' ' O ' ' F' ' 30' ' ' ALA . 2.7 tp -165.8 132.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 C-N-CA 115.002 -2.679 . . . . 0.0 114.192 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 97.0 mt -111.69 112.98 42.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 113.631 -1.622 . . . . 0.0 108.418 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -97.13 101.74 2.63 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 105.382 -3.087 . . . . 0.0 105.382 176.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -104.73 108.69 20.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -176.189 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.47 ' SD ' ' C ' ' L' ' 32' ' ' ILE . 0.9 OUTLIER -109.42 107.34 17.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 176.102 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -136.01 80.59 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.984 -179.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.49 -101.66 0.09 OUTLIER Glycine 0 C--N 1.344 1.004 0 C-N-CA 120.976 -0.631 . . . . 0.0 111.99 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.74 -159.71 31.64 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.1 m -135.19 161.72 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 120.626 0.251 . . . . 0.0 110.529 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.204 179.612 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -126.77 142.69 51.47 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.37 143.72 42.11 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.057 0.456 . . . . 0.0 111.019 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 p -130.49 134.99 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.187 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -122.79 127.25 48.88 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 120.95 0.405 . . . . 0.0 110.445 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 70.8 t60 -157.62 165.41 35.58 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-O 121.16 0.505 . . . . 0.0 110.183 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 83.6 mt-30 -151.28 174.76 12.91 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.018 178.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -171.57 114.04 0.36 Allowed 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.082 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 64.7 mt -131.16 124.1 29.97 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.331 0.586 . . . . 0.0 110.306 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 30.9 m -128.12 129.83 69.53 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.135 -179.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.434 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 15.4 m-85 -110.53 113.03 25.34 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.466 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 45.6 p90 -123.95 124.13 41.93 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.27 131.13 38.07 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -145.6 167.22 23.59 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 177.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 58.6 t0 -90.14 111.78 23.03 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.015 -0.674 . . . . 0.0 112.186 -178.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.611 ' O ' ' N ' ' G' ' 26' ' ' SER . 3.6 p -113.17 131.04 65.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.127 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.29 81.96 0.0 OUTLIER Glycine 0 CA--C 1.532 1.11 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.782 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.611 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.1 m -96.58 176.2 6.11 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.504 ' O ' ' O ' ' G' ' 28' ' ' LYS . 53.3 p30 -62.2 -177.73 0.14 Allowed 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.504 ' O ' ' O ' ' G' ' 27' ' ' ASN . 98.4 mttt -48.85 -109.2 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-O 121.682 0.753 . . . . 0.0 110.64 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.65 96.53 2.1 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.42 161.32 23.77 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 115.49 -2.484 . . . . 0.0 109.609 -177.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -154.33 116.27 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.868 -175.066 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -143.09 137.76 26.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.502 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -158.8 164.33 33.6 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.466 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 3.3 tp -169.57 163.28 10.21 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.13 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.575 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 53.5 ttp -131.93 134.12 45.3 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.601 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 21.1 t -117.48 65.03 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.514 179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -55.12 -106.76 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.25 -166.12 13.97 Favored Glycine 0 N--CA 1.465 0.629 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -132.58 159.22 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.025 0.44 . . . . 0.0 110.852 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.669 -179.805 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -107.41 128.95 54.93 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.869 0.366 . . . . 0.0 110.354 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -145.76 135.4 23.29 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.612 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -140.44 134.93 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 77.6 m80 -118.69 118.74 32.44 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.416 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.528 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 5.8 m-70 -135.56 164.29 28.17 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.507 0.67 . . . . 0.0 109.856 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.416 ' CG ' ' N ' ' H' ' 16' ' ' LYS . 52.5 tt0 -161.86 170.51 19.34 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.437 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . 0.416 ' N ' ' CG ' ' H' ' 15' ' ' GLN . 68.7 mttm -155.94 115.79 3.64 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.722 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 76.6 mt -114.76 115.27 26.77 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -125.09 124.6 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -113.01 108.76 17.79 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.522 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 24.6 t80 -127.06 129.52 48.16 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.164 0.438 . . . . 0.0 110.635 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.47 150.4 26.57 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 118.346 -1.342 . . . . 0.0 114.56 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -132.53 173.04 11.73 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 114.367 -1.288 . . . . 0.0 109.582 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.406 ' C ' ' OD1' ' H' ' 23' ' ' ASP . 64.5 t0 -148.51 116.53 6.4 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 113.253 0.835 . . . . 0.0 113.253 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 3.2 p -121.49 122.33 66.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 177.412 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.24 83.79 0.01 OUTLIER Glycine 0 N--CA 1.472 1.052 0 CA-C-O 121.588 0.549 . . . . 0.0 112.245 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -45.35 170.28 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 113.864 1.061 . . . . 0.0 113.864 179.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.472 ' O ' ' O ' ' H' ' 28' ' ' LYS . 19.5 m120 -135.61 177.04 8.13 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 113.444 -1.707 . . . . 0.0 107.738 173.773 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.472 ' O ' ' O ' ' H' ' 27' ' ' ASN . 65.2 mttm -21.28 -102.86 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . -158.85 100.27 0.19 Allowed Glycine 0 C--N 1.349 1.256 0 CA-C-O 118.365 -1.241 . . . . 0.0 110.788 177.042 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.82 157.14 31.19 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-N 120.869 2.334 . . . . 0.0 109.125 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -142.91 118.5 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.473 -176.547 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.53 ' O ' ' SD ' ' B' ' 35' ' ' MET . 86.1 mt -127.7 126.17 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.406 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.548 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -131.88 110.33 0.95 Allowed Glycine 0 N--CA 1.477 1.398 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.76 137.96 31.97 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 121.582 -0.952 . . . . 0.0 112.476 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 40.8 ttp -127.3 139.33 52.96 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.835 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.447 ' O ' ' O ' ' H' ' 37' ' ' GLY . 2.5 p -153.48 75.15 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.943 178.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -37.25 -95.5 0.01 OUTLIER Glycine 0 C--N 1.343 0.928 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 178.376 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -165.22 38.58 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 t -90.44 134.67 28.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.969 0.414 . . . . 0.0 110.764 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.218 -0.587 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.312 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -136.67 149.41 47.92 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.656 0.265 . . . . 0.0 110.299 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -56.37 133.18 52.74 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 120.96 0.41 . . . . 0.0 110.961 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -150.32 151.02 13.06 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.001 -179.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.449 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 25.0 m-70 -119.87 138.92 53.11 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.605 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.449 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 25.8 m-70 -144.74 168.79 19.37 Favored 'General case' 0 CA--C 1.511 -0.552 0 CA-C-O 121.499 0.666 . . . . 0.0 110.483 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -149.42 177.99 9.2 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.84 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . 0.479 ' HZ2' ' CG1' ' I' ' 18' ' ' VAL . 65.5 tttm -171.36 107.01 0.24 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.862 179.191 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 mt -120.07 115.54 23.91 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . 0.479 ' CG1' ' HZ2' ' I' ' 16' ' ' LYS . 2.2 m -134.43 127.61 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.23 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.42 ' CD2' ' CE2' ' J' ' 19' ' ' PHE . 12.6 m-30 -110.35 118.8 37.27 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.251 178.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.522 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 53.3 t80 -125.65 118.05 24.83 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.43 135.49 33.66 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -177.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.548 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 82.9 tt0 -115.92 100.18 7.8 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.155 -1.794 . . . . 0.0 106.155 176.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.548 ' CB ' ' O ' ' I' ' 22' ' ' GLU . 53.2 t0 121.61 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 O-C-N 124.817 1.323 . . . . 0.0 108.246 -176.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.537 ' H ' ' CG ' ' I' ' 23' ' ' ASP . 19.8 m -106.14 112.02 37.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.798 0.809 . . . . 0.0 108.929 -178.501 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' I' ' 24' ' ' VAL . . . 33.65 -92.16 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -177.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.64 ' O ' ' O ' ' I' ' 27' ' ' ASN . 41.4 t -130.46 168.24 17.33 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.64 ' O ' ' O ' ' I' ' 26' ' ' SER . 98.2 m-20 38.43 179.13 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 O-C-N 124.096 0.873 . . . . 0.0 111.628 176.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.54 ' HD2' ' H ' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -92.65 -120.75 0.08 Allowed 'General case' 0 N--CA 1.471 0.585 0 O-C-N 120.906 -1.121 . . . . 0.0 109.134 178.919 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.415 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -69.08 88.11 0.23 Allowed Glycine 0 CA--C 1.484 -1.903 0 N-CA-C 104.824 -3.31 . . . . 0.0 104.824 171.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.47 162.79 35.65 Favored 'General case' 0 CA--C 1.464 -2.331 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.91 -175.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -137.74 113.21 10.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.004 -179.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.461 ' C ' ' SD ' ' C' ' 35' ' ' MET . 1.6 tt -107.03 114.1 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 179.179 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.427 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -116.65 97.52 0.76 Allowed Glycine 0 CA--C 1.508 -0.377 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -123.17 131.55 53.72 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-O 122.379 1.085 . . . . 0.0 110.579 179.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 25.6 ttt -116.19 117.38 29.88 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.577 -1.647 . . . . 0.0 110.29 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.7 71.3 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.51 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.19 105.58 3.21 Favored Glycine 0 C--N 1.365 2.157 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 176.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.08 165.17 53.27 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.745 -0.741 . . . . 0.0 111.694 -178.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t -143.75 136.9 24.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.68 0.276 . . . . 0.0 110.351 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.098 -0.953 . . . . 0.0 110.324 179.699 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -81.92 142.81 32.13 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.957 0.408 . . . . 0.0 110.926 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -63.04 142.12 58.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.705 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -134.85 144.29 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 3.5 m80 -139.13 138.55 37.11 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.377 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.475 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 79.6 t60 -139.73 166.92 23.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.475 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 85.5 mt-30 -148.61 172.0 15.25 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.612 179.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 47.6 mtpt -156.93 112.07 2.83 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.603 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -123.82 120.53 32.89 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.437 0.16 . . . . 0.0 110.661 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -137.31 130.86 44.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 119.921 -0.712 . . . . 0.0 112.014 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.42 ' CE2' ' CD2' ' I' ' 19' ' ' PHE . 18.0 m-85 -111.04 119.78 40.18 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 114.741 -1.118 . . . . 0.0 108.75 178.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -131.31 122.08 25.79 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.67 145.04 31.54 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -131.41 160.31 35.46 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.911 -1.041 . . . . 0.0 108.897 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -121.77 120.63 35.17 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.428 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 14.3 t -62.87 -120.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.94 177.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.428 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . -75.3 -90.26 0.21 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.203 -177.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 53.4 m -140.97 171.23 14.36 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 122.067 0.937 . . . . 0.0 111.024 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' J' ' 28' ' ' LYS . 38.8 t-20 -28.66 151.1 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 113.627 -1.624 . . . . 0.0 115.168 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.533 ' N ' ' OD1' ' J' ' 27' ' ' ASN . 97.9 mttt -163.75 110.7 1.13 Allowed 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 112.594 -2.094 . . . . 0.0 107.594 177.231 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.65 93.82 0.32 Allowed Glycine 0 N--CA 1.476 1.303 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.538 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.16 157.73 20.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 105.85 -1.907 . . . . 0.0 105.85 177.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.55 111.24 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 119.715 -0.794 . . . . 0.0 110.329 -173.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.437 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.2 tt -104.54 118.57 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.113 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.773 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.61 106.51 0.89 Allowed Glycine 0 C--O 1.241 0.567 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.434 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 5.3 mp -129.71 132.06 46.52 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-O 122.15 0.976 . . . . 0.0 111.217 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.44 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 23.2 ttt -102.04 114.91 29.44 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 113.383 -1.735 . . . . 0.0 108.143 178.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -136.46 70.45 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.446 -177.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.72 -101.12 1.99 Allowed Glycine 0 C--N 1.358 1.756 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 177.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.61 154.71 26.21 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -142.79 139.17 28.11 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-O 121.128 0.489 . . . . 0.0 110.726 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.589 179.641 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.62 139.03 45.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.76 0.314 . . . . 0.0 110.913 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.542 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 95.0 mt-10 -139.47 153.53 47.55 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.619 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 54.6 t -121.71 131.16 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 116.312 -0.403 . . . . 0.0 109.968 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -161.51 162.63 30.4 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.716 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.488 ' HE2' ' CG2' ' L' ' 12' ' ' VAL . 89.4 m-70 -152.45 168.01 26.89 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.947 179.389 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 -158.04 178.83 9.77 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.11 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.1 tttt -160.14 126.58 4.27 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.123 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -116.86 119.11 34.37 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.38 125.69 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.866 0.365 . . . . 0.0 111.395 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -116.91 119.69 36.14 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.116 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.405 ' CE1' ' OE2' ' K' ' 22' ' ' GLU . 37.8 t80 -127.92 119.72 26.16 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.367 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.43 132.98 34.21 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.47 ' OE1' ' OE2' ' L' ' 22' ' ' GLU . 57.7 mm-40 -102.83 167.86 9.6 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.459 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 2.9 p30 -152.35 133.7 14.44 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 119.11 -1.036 . . . . 0.0 113.788 -178.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.5 ' O ' ' N ' ' K' ' 26' ' ' SER . 7.7 p -88.69 113.29 25.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 104.222 -2.51 . . . . 0.0 104.222 174.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.46 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -45.39 91.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.621 0 C-N-CA 119.722 -1.228 . . . . 0.0 113.503 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.6 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.6 t 161.17 160.69 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.127 0.489 . . . . 0.0 110.159 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.623 ' O ' ' HB2' ' K' ' 28' ' ' LYS . 82.3 m-20 -29.76 175.91 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.245 173.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.623 ' HB2' ' O ' ' K' ' 27' ' ' ASN . 2.9 tptm 147.56 100.85 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 C-N-CA 127.032 2.133 . . . . 0.0 110.299 176.02 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -51.22 -100.17 0.01 OUTLIER Glycine 0 C--O 1.21 -1.397 0 CA-C-O 124.465 2.147 . . . . 0.0 114.385 175.133 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 70.74 143.87 0.06 Allowed 'General case' 0 C--O 1.245 0.826 0 CA-C-N 111.354 -2.423 . . . . 0.0 107.203 177.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.475 HG22 HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -147.88 123.09 2.35 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.795 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.493 ' CG2' ' O ' ' K' ' 32' ' ' ILE . 0.8 OUTLIER -108.97 115.12 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.692 178.816 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 91.35 0.58 Allowed Glycine 0 C--O 1.24 0.485 0 N-CA-C 107.333 -2.307 . . . . 0.0 107.333 176.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 92.2 mt -114.75 118.75 34.47 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.331 0.586 . . . . 0.0 109.862 -179.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 2.5 ttt -107.7 115.04 29.43 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.742 -178.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.11 68.35 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.763 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.03 -100.99 0.01 OUTLIER Glycine 0 C--N 1.349 1.262 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.86 160.2 14.39 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.9 m -136.76 159.74 37.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.794 0.33 . . . . 0.0 110.219 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.325 -0.457 0 CA-C-O 118.089 -0.958 . . . . 0.0 110.765 -179.77 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.351 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -104.38 132.33 50.75 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -71.9 132.42 44.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.354 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . 0.488 ' CG2' ' HE2' ' K' ' 14' ' ' HIS . 21.8 m -143.13 156.2 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 122.011 0.91 . . . . 0.0 112.543 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.542 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 3.9 m80 -151.16 118.33 5.94 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.729 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -153.88 172.82 16.8 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.273 0.559 . . . . 0.0 110.418 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -145.67 173.86 11.7 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.728 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -159.82 120.92 3.14 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.93 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 tt -122.51 119.73 31.77 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -129.07 132.89 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -135.64 130.32 34.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.935 0.398 . . . . 0.0 110.715 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.2 t80 -137.31 127.62 26.38 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.0 148.21 36.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.265 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.47 ' OE2' ' OE1' ' K' ' 22' ' ' GLU . 78.1 mt-10 -81.73 149.17 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.464 0.649 . . . . 0.0 110.722 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.411 ' O ' ' O ' ' L' ' 22' ' ' GLU . 99.3 m-20 54.17 114.42 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.869 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 67.3 t -95.12 130.61 43.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 CA-C-N 114.519 -1.219 . . . . 0.0 109.879 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 49.56 82.74 0.03 OUTLIER Glycine 0 CA--C 1.525 0.698 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.183 178.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' L' ' 27' ' ' ASN . 5.8 p 176.96 -167.52 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' L' ' 26' ' ' SER . 14.5 m120 -38.92 179.91 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -175.485 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.44 ' HG2' ' N ' ' L' ' 29' ' ' GLY . 85.1 tttt 77.42 -111.42 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.668 -1.151 . . . . 0.0 112.128 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.477 ' O ' ' CB ' ' L' ' 30' ' ' ALA . . . 83.93 -94.59 1.83 Allowed Glycine 0 CA--C 1.503 -0.682 0 N-CA-C 107.892 -2.083 . . . . 0.0 107.892 -174.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.495 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . 77.17 169.77 0.23 Allowed 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.424 ' O ' ' CE ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -138.83 109.19 4.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 116.81 -1.956 . . . . 0.0 111.224 179.23 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' L' ' 32' ' ' ILE . 7.4 tt -102.7 115.88 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-N 113.34 -1.755 . . . . 0.0 107.961 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 110.18 2.24 Favored Glycine 0 C--N 1.334 0.464 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 -179.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.38 111.8 22.03 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.582 -0.809 . . . . 0.0 110.086 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 2.7 tpp -93.65 104.97 17.05 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' L' ' 37' ' ' GLY . 0.7 OUTLIER -131.09 71.36 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.954 0 O-C-N 122.051 -0.405 . . . . 0.0 109.922 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -35.49 -100.66 0.01 OUTLIER Glycine 0 C--N 1.346 1.085 0 C-N-CA 121.815 -0.231 . . . . 0.0 112.717 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.27 174.91 19.16 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 159.2 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.979 0.419 . . . . 0.0 110.709 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.184 179.897 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -81.86 137.03 35.32 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.828 0.346 . . . . 0.0 110.547 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -122.48 143.02 49.97 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.94 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t -121.48 132.35 70.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 121.307 0.575 . . . . 0.0 110.859 -179.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.488 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 69.7 m80 -116.44 172.5 7.17 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.813 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.683 ' CD2' ' H ' ' A' ' 15' ' ' GLN . 12.3 t-80 -80.45 165.55 22.09 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 109.622 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.683 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 1.2 pm0 -161.01 179.03 8.78 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.315 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -144.24 128.22 17.48 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.713 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 78.5 mt -124.03 124.19 42.01 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.24 131.45 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.333 0.587 . . . . 0.0 111.852 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -118.44 112.11 19.53 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.533 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 51.1 p90 -125.44 128.27 47.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -177.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.27 115.85 28.06 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.219 0.533 . . . . 0.0 110.166 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.465 ' O ' ' C ' ' A' ' 23' ' ' ASP . 84.7 tt0 -163.89 96.52 0.82 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.465 ' C ' ' O ' ' A' ' 22' ' ' GLU . 0.1 OUTLIER -25.89 115.46 0.06 Allowed 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 -177.097 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' A' ' 26' ' ' SER . 2.1 p -87.27 130.64 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.75 82.29 0.0 OUTLIER Glycine 0 CA--C 1.525 0.712 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.618 -177.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' A' ' 24' ' ' VAL . 80.2 p -98.47 174.95 6.21 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.123 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.07 178.89 0.16 Allowed 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 119.396 -0.922 . . . . 0.0 108.635 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.68 110.78 1.22 Allowed 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.73 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 94.2 0.11 Allowed Glycine 0 N--CA 1.469 0.843 0 C-N-CA 119.702 -1.237 . . . . 0.0 111.284 177.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.32 160.23 14.87 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-N 119.707 1.753 . . . . 0.0 107.497 177.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.425 HD13 HG21 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -152.6 113.03 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.175 -175.308 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.47 ' O ' ' SD ' ' G' ' 35' ' ' MET . 97.6 mt -128.86 128.04 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-O 121.435 0.636 . . . . 0.0 111.671 -179.362 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' G' ' 35' ' ' MET . . . -123.5 127.03 6.43 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.043 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -130.18 130.05 44.21 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.799 0.3 . . . . 0.0 111.021 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.674 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 19.8 ttp -130.63 128.08 40.24 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.096 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 54.4 t -115.64 72.15 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.88 98.82 0.81 Allowed Glycine 0 CA--C 1.529 0.924 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 176.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.76 172.45 40.48 Favored Glycine 0 CA--C 1.523 0.547 0 C-N-CA 120.485 -0.864 . . . . 0.0 111.564 -179.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m -132.47 161.24 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-O 120.781 0.324 . . . . 0.0 110.765 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 N--CA 1.467 0.385 0 CA-C-O 118.073 -0.965 . . . . 0.0 110.217 179.369 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -104.83 139.17 39.98 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.123 0.487 . . . . 0.0 110.597 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' C' ' 11' ' ' GLU . 18.6 pt-20 -64.19 142.97 58.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.181 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -132.88 137.36 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.16 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.464 ' O ' ' CB ' ' C' ' 13' ' ' HIS . 4.8 m-70 -105.67 117.76 34.84 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.789 0.328 . . . . 0.0 110.909 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.476 ' ND1' ' CD2' ' A' ' 14' ' ' HIS . 52.5 t-80 -157.21 159.51 37.76 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.437 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 74.4 mt-30 -159.98 179.07 9.09 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.832 179.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -157.71 126.12 5.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.754 0.311 . . . . 0.0 110.762 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 tp -120.76 123.25 42.21 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.312 0.577 . . . . 0.0 110.297 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -117.93 121.37 67.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.601 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.434 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 13.5 t80 -128.05 116.26 19.73 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 -178.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.543 ' CG ' ' CZ ' ' C' ' 20' ' ' PHE . 38.8 p90 -150.2 160.22 43.85 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.41 138.85 38.59 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.896 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -125.4 175.1 7.72 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.467 ' CG ' ' H ' ' C' ' 27' ' ' ASN . 50.5 t0 -142.98 99.33 3.44 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.139 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.47 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 1.6 t -118.21 -151.17 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.47 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -38.9 -75.88 0.09 OUTLIER Glycine 0 N--CA 1.47 0.937 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.601 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.707 ' HG ' ' HZ1' ' C' ' 28' ' ' LYS . 31.1 t 60.15 173.13 0.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.73 -1.235 . . . . 0.0 113.568 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.498 ' ND2' ' HG ' ' A' ' 26' ' ' SER . 18.9 p30 -101.38 -178.98 3.89 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 113.395 -1.73 . . . . 0.0 112.567 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.494 ' O ' ' O ' ' B' ' 27' ' ' ASN . 87.3 tttt -34.15 -102.66 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.118 177.115 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -137.13 100.8 0.32 Allowed Glycine 0 CA--C 1.485 -1.829 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.5 157.72 31.45 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.349 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -148.58 120.87 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.583 -178.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.501 ' O ' ' SD ' ' H' ' 35' ' ' MET . 86.8 mt -133.98 128.68 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.362 -178.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.505 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -120.81 109.5 1.56 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.976 -1.65 . . . . 0.0 108.976 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 8.7 tt -117.08 123.32 46.53 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 117.072 0.436 . . . . 0.0 111.099 -179.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.599 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 32.1 ttp -124.79 117.37 24.01 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.299 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 37' ' ' GLY . 34.5 m -136.54 73.01 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -47.4 -95.35 0.01 OUTLIER Glycine 0 C--N 1.337 0.604 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 175.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.13 176.67 40.45 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -140.96 144.48 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-O 121.031 0.443 . . . . 0.0 111.215 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 85.0 t . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.309 179.842 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.156 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -105.73 131.56 52.94 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.709 0.29 . . . . 0.0 110.595 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 11' ' ' GLU . 97.5 mt-10 -74.3 133.14 42.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.068 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.16 166.68 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 CA-C-O 120.832 0.349 . . . . 0.0 110.887 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.493 ' ND1' ' OE1' ' D' ' 11' ' ' GLU . 0.0 OUTLIER -169.28 164.76 10.92 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.271 178.749 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.495 ' CG ' ' OE1' ' D' ' 15' ' ' GLN . 88.6 m-70 -105.52 -179.91 4.08 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' C' ' 16' ' ' LYS . 44.9 tt0 -88.69 169.19 11.88 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.433 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' C' ' 15' ' ' GLN . 99.2 mttt -123.5 133.92 53.95 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 29.1 mt -122.3 119.35 30.86 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.026 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 6.2 p -124.77 123.23 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -123.41 119.17 29.25 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.571 -176.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.543 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 49.7 p90 -142.86 130.26 21.11 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-O 122.574 1.178 . . . . 0.0 112.953 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.94 121.74 38.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.397 179.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.496 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 97.2 mt-10 -99.01 101.08 12.35 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.498 ' OD1' ' NZ ' ' E' ' 28' ' ' LYS . 15.7 t0 83.68 133.56 0.05 Allowed 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.508 ' O ' ' N ' ' C' ' 26' ' ' SER . 34.8 t -83.41 -110.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -42.85 92.19 0.01 OUTLIER Glycine 0 C--N 1.317 -0.473 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.527 ' O ' ' O ' ' C' ' 27' ' ' ASN . 42.3 p -101.11 165.22 11.42 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 122.49 1.138 . . . . 0.0 110.784 -176.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.613 ' ND2' ' HZ2' ' C' ' 28' ' ' LYS . 0.1 OUTLIER 49.05 169.15 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 112.009 -2.36 . . . . 0.0 109.114 -176.235 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.712 ' H ' ' CE ' ' C' ' 28' ' ' LYS . 0.0 OUTLIER -79.08 110.7 14.57 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.641 -0.824 . . . . 0.0 108.824 175.634 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 57.25 91.51 0.01 OUTLIER Glycine 0 C--O 1.219 -0.829 0 C-N-CA 118.342 -1.885 . . . . 0.0 109.877 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.66 152.22 50.16 Favored 'General case' 0 CA--C 1.476 -1.903 0 CA-C-N 121.428 2.614 . . . . 0.0 105.016 175.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.405 ' O ' ' CE ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -144.48 109.66 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.185 -173.028 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -114.9 118.44 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.05 -178.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.21 108.51 2.48 Favored Glycine 0 N--CA 1.46 0.298 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 5.8 mt -114.76 112.72 23.25 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 120.916 0.388 . . . . 0.0 110.331 -178.428 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.5 ttt -112.42 104.06 12.18 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.59 72.24 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.994 -177.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -42.97 -97.43 0.01 OUTLIER Glycine 0 C--N 1.349 1.27 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.12 -173.12 42.95 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -141.52 154.22 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.019 0.438 . . . . 0.0 111.133 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.087 -0.959 . . . . 0.0 110.218 179.56 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.129 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . 0.528 ' CD2' ' N ' ' E' ' 9' ' ' GLY . 96.5 m-85 -109.2 133.39 53.08 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.954 0.407 . . . . 0.0 110.336 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.493 ' OE1' ' ND1' ' C' ' 13' ' ' HIS . 80.9 mm-40 -77.17 133.91 38.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.415 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 m -142.19 174.86 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.126 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 70.0 m80 -82.15 112.95 19.65 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.168 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' D' ' 13' ' ' HIS . 3.4 m-70 -145.72 159.94 42.44 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG ' ' C' ' 14' ' ' HIS . 0.0 OUTLIER -159.23 174.18 15.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.26 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -153.32 129.09 10.14 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.886 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 36.7 tp -123.28 118.33 27.32 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -122.39 126.19 73.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.941 0.4 . . . . 0.0 110.687 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -123.25 112.33 17.52 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -131.57 133.42 45.0 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.79 131.79 29.59 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.886 0.374 . . . . 0.0 111.725 179.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -127.88 143.52 51.11 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.991 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -131.3 111.97 12.35 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.969 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.494 ' O ' ' N ' ' D' ' 26' ' ' SER . 12.6 m -138.01 -122.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 120.424 -0.51 . . . . 0.0 109.915 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.438 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . 28.37 -84.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.536 -0.756 . . . . 0.0 113.097 -178.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.3 m 170.28 178.77 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.518 0.675 . . . . 0.0 110.574 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' D' ' 26' ' ' SER . 12.4 m120 -28.73 -179.21 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 113.041 -1.891 . . . . 0.0 114.248 176.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 85.4 mttt 128.26 105.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 125.867 1.667 . . . . 0.0 112.137 176.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.6 94.87 0.05 OUTLIER Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.43 154.25 38.0 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 176.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.04 112.29 2.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.732 -171.629 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.436 HD11 HG21 ' D' ' 32' ' ' ILE . 2.1 mt -107.93 114.01 45.3 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.409 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.38 100.65 1.66 Allowed Glycine 0 CA--C 1.498 -1.007 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 176.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.434 ' CD2' ' CZ ' ' B' ' 19' ' ' PHE . 13.6 tp -112.99 121.08 43.56 Favored 'General case' 0 CA--C 1.503 -0.852 0 CA-C-N 115.298 -0.451 . . . . 0.0 110.934 -177.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 43.3 ttp -128.97 107.25 9.46 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -123.61 72.14 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.675 -179.927 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.15 -100.52 0.01 OUTLIER Glycine 0 C--N 1.36 1.892 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.891 179.144 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 157.13 -157.24 27.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -132.36 147.95 31.99 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.462 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.32 -179.731 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . 0.528 ' N ' ' CD2' ' D' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -114.76 134.31 55.21 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.768 0.318 . . . . 0.0 110.491 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -98.37 137.47 37.04 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.28 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 22.6 m -131.74 160.34 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 121.332 0.587 . . . . 0.0 111.141 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 27.6 m80 -124.01 120.51 32.65 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.606 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.467 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -150.66 162.91 39.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.927 0.87 . . . . 0.0 111.473 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.467 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 50.2 tt0 -157.99 168.6 26.67 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.375 -1.284 . . . . 0.0 110.063 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -143.57 126.79 16.59 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.837 179.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 tt -118.98 115.68 24.86 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -120.23 125.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.734 0.302 . . . . 0.0 110.36 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -124.16 113.4 18.28 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.482 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -125.72 125.13 42.51 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.212 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.23 119.63 19.01 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.232 0.539 . . . . 0.0 110.327 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.402 ' C ' ' OD1' ' E' ' 23' ' ' ASP . 97.8 mt-10 -129.16 128.35 43.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.402 ' OD1' ' C ' ' E' ' 22' ' ' GLU . 1.2 m-20 -141.89 112.1 6.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.264 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' E' ' 26' ' ' SER . 13.2 m -103.24 -122.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 C-N-CA 120.326 -0.55 . . . . 0.0 111.057 -178.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.05 -84.92 0.01 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.834 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' E' ' 27' ' ' ASN . 3.0 p 170.88 170.54 0.07 Allowed 'General case' 0 CA--C 1.511 -0.55 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' E' ' 26' ' ' SER . 27.6 t-20 -18.17 157.47 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.975 0 O-C-N 124.792 1.308 . . . . 0.0 113.475 179.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.498 ' NZ ' ' OD1' ' C' ' 23' ' ' ASP . 84.8 tttt -162.55 111.35 1.38 Allowed 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.552 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.17 92.36 0.25 Allowed Glycine 0 N--CA 1.479 1.528 0 O-C-N 121.931 -0.481 . . . . 0.0 113.194 177.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.5 161.97 21.58 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 175.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.4 HG23 HD12 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -145.68 132.21 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 118.903 -1.119 . . . . 0.0 113.647 -175.561 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.46 ' O ' ' CE ' ' K' ' 35' ' ' MET . 0.2 OUTLIER -109.71 116.48 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.306 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.67 105.36 2.23 Favored Glycine 0 N--CA 1.466 0.669 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 16.4 mt -115.83 115.0 25.49 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 117.561 0.68 . . . . 0.0 112.155 -177.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.717 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 11.4 ttp -114.07 106.66 14.66 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 176.074 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.91 73.81 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.331 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.17 111.57 2.66 Favored Glycine 0 C--N 1.354 1.577 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 178.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.5 -157.08 0.04 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.15 142.81 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.975 0.417 . . . . 0.0 110.49 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.772 179.827 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.464 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -107.02 134.91 49.46 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.566 0.222 . . . . 0.0 110.622 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.525 ' N ' ' OE1' ' F' ' 11' ' ' GLU . 56.7 mp0 -105.12 143.38 33.38 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.209 -0.45 . . . . 0.0 109.903 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t -120.76 135.26 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-O 121.115 0.483 . . . . 0.0 110.397 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -130.02 128.53 42.18 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.923 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.519 ' CE1' ' O ' ' F' ' 15' ' ' GLN . 56.9 t-80 -151.99 168.5 25.02 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.519 ' O ' ' CE1' ' F' ' 14' ' ' HIS . 84.7 mt-30 -150.52 173.47 14.05 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.41 179.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.41 127.01 14.21 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.39 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -128.73 127.57 42.33 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.554 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -127.56 128.3 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -123.36 120.74 33.92 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.678 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 78.8 t80 -141.13 121.88 14.35 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -159.59 154.71 25.04 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 119.785 -0.766 . . . . 0.0 112.578 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -96.94 124.16 40.84 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.558 ' OD1' ' N ' ' F' ' 24' ' ' VAL . 60.3 t0 -169.66 139.0 1.95 Allowed 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 119.652 -0.819 . . . . 0.0 113.033 -178.198 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.572 ' O ' ' O ' ' F' ' 26' ' ' SER . 24.2 t -108.07 111.7 37.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.23 -92.04 0.01 OUTLIER Glycine 0 CA--C 1.539 1.535 0 CA-C-O 119.026 -0.874 . . . . 0.0 111.732 -177.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.572 ' O ' ' O ' ' F' ' 24' ' ' VAL . 13.7 p -63.79 -177.56 0.25 Allowed 'General case' 0 CA--C 1.503 -0.848 0 N-CA-C 104.403 -2.443 . . . . 0.0 104.403 177.404 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.439 ' O ' ' O ' ' F' ' 28' ' ' LYS . 64.3 t30 -80.59 174.13 11.91 Favored 'General case' 0 C--N 1.318 -0.798 0 C-N-CA 114.894 -2.722 . . . . 0.0 108.25 178.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.489 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 75.1 tttt -43.7 -105.91 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 124.085 1.897 . . . . 0.0 112.226 174.243 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.489 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -109.29 -100.33 2.63 Favored Glycine 0 CA--C 1.484 -1.881 0 C-N-CA 130.168 3.747 . . . . 0.0 109.753 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' E' ' 28' ' ' LYS . . . -58.11 172.85 0.39 Allowed 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 -178.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.39 134.42 34.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.147 -1.421 . . . . 0.0 111.479 -172.131 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.495 ' CG2' ' O ' ' F' ' 32' ' ' ILE . 5.2 tt -110.12 117.24 54.29 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 114.001 -1.454 . . . . 0.0 108.452 -179.266 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.77 102.87 2.42 Favored Glycine 0 C--N 1.322 -0.249 0 N-CA-C 108.027 -2.029 . . . . 0.0 108.027 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.2 pp -107.44 115.73 30.67 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 117.039 0.42 . . . . 0.0 110.518 -179.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 18.3 ttp -119.46 110.5 16.99 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 m -132.87 79.92 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.16 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -64.65 103.5 0.77 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.0 -146.15 19.15 Favored Glycine 0 N--CA 1.465 0.61 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -113.86 133.58 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 32.9 m . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.761 -179.67 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -121.92 147.84 45.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.745 0.307 . . . . 0.0 110.707 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -68.51 156.96 36.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.069 179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . 0.477 ' O ' ' ND1' ' H' ' 13' ' ' HIS . 78.0 t -115.63 131.6 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.061 0.458 . . . . 0.0 110.315 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -89.15 179.45 6.13 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.972 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -74.69 164.45 26.57 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 91.7 mt-30 -155.63 -179.84 8.5 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.442 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.428 ' HZ3' ' CG2' ' G' ' 18' ' ' VAL . 65.2 tttm -161.32 119.26 2.35 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.682 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 35.7 tp -118.83 126.12 51.11 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 121.299 0.571 . . . . 0.0 110.478 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . 0.428 ' CG2' ' HZ3' ' G' ' 16' ' ' LYS . 47.9 t -125.72 125.9 69.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.901 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.452 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 0.1 OUTLIER -114.76 119.47 36.77 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.937 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -142.92 147.96 36.14 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 119.674 -0.81 . . . . 0.0 112.369 -178.041 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.32 132.22 35.37 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.285 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -135.48 167.33 21.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.53 ' OD2' ' N ' ' H' ' 24' ' ' VAL . 34.8 m-20 -85.94 -151.19 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.168 -178.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' G' ' 23' ' ' ASP . 14.0 t 27.09 103.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.77 -94.69 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.827 177.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -64.03 -178.81 0.36 Allowed 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -80.95 173.49 12.56 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.12 0.486 . . . . 0.0 111.302 177.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -44.91 110.79 0.26 Allowed 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.947 176.365 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.26 94.73 0.52 Allowed Glycine 0 N--CA 1.472 1.084 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.324 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -118.34 151.61 37.39 Favored 'General case' 0 CA--C 1.504 -0.808 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.196 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.19 108.81 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 CA-C-N 113.182 -1.826 . . . . 0.0 109.594 -171.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.76 123.46 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.89 0.376 . . . . 0.0 111.237 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . 0.674 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -130.33 111.23 1.11 Allowed Glycine 0 N--CA 1.465 0.573 0 N-CA-C 108.794 -1.723 . . . . 0.0 108.794 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.89 130.41 52.82 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.916 0.388 . . . . 0.0 111.656 -178.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' A' ' 33' ' ' GLY . 28.1 ttt -130.46 128.52 41.43 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' G' ' 37' ' ' GLY . 3.7 t -111.42 65.9 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -178.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.451 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -55.25 -105.55 0.01 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 178.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -105.06 174.59 21.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 30.0 m -135.23 158.13 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.11 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -86.65 131.01 34.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.918 0.389 . . . . 0.0 110.103 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -136.06 142.81 44.41 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.908 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -126.06 134.31 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.456 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' O ' ' G' ' 12' ' ' VAL . 75.4 m80 -87.08 175.35 8.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.124 0.488 . . . . 0.0 110.792 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.547 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 25.4 m-70 -77.9 173.28 12.32 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.45 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -142.75 175.44 9.82 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.128 179.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -151.58 125.87 9.36 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.151 -179.184 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 58.1 mt -121.17 120.51 35.43 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -127.8 130.52 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -178.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.44 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 5.9 m-85 -117.73 120.06 36.81 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.615 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 29.0 t80 -130.78 122.6 27.46 Favored 'General case' 0 N--CA 1.476 0.834 0 O-C-N 122.231 -0.293 . . . . 0.0 110.626 -179.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.77 130.0 48.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -137.94 106.74 5.93 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.426 ' OD2' ' NZ ' ' J' ' 28' ' ' LYS . 35.7 t70 -114.51 114.11 25.34 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.53 ' N ' ' OD2' ' G' ' 23' ' ' ASP . 1.2 p -128.79 122.26 56.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.051 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 30.49 82.79 0.01 OUTLIER Glycine 0 CA--C 1.537 1.442 0 CA-C-O 119.473 -0.626 . . . . 0.0 114.593 175.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.677 ' HG ' ' HZ3' ' I' ' 28' ' ' LYS . 1.0 OUTLIER -140.14 170.62 15.49 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 118.71 1.255 . . . . 0.0 111.108 179.107 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' H' ' 26' ' ' SER . 5.5 m-20 -31.04 173.14 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 113.671 -1.604 . . . . 0.0 114.812 -177.206 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -87.84 111.41 21.38 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.267 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.487 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . 69.61 93.6 0.06 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 118.124 -1.989 . . . . 0.0 115.526 172.442 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.42 155.51 22.09 Favored 'General case' 0 C--O 1.248 0.985 0 CA-C-N 120.627 2.214 . . . . 0.0 106.698 175.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -148.31 119.27 1.37 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 118.921 -1.112 . . . . 0.0 111.684 -173.055 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.9 mt -129.87 128.32 64.98 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.034 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.599 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -132.23 127.54 4.94 Favored Glycine 0 N--CA 1.465 0.63 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.4 tt -135.08 130.96 36.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.565 0.698 . . . . 0.0 110.736 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 19.3 ttt -130.37 128.99 42.53 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.652 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.52 79.54 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.77 105.12 1.15 Allowed Glycine 0 C--N 1.339 0.707 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 178.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.74 -171.27 50.34 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -132.37 161.78 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-O 120.993 0.425 . . . . 0.0 110.909 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 34.3 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.658 179.766 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -109.94 132.15 54.42 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.8 0.333 . . . . 0.0 110.72 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -73.79 131.92 42.06 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.563 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.61 131.17 47.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.075 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.513 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 16.5 p-80 -164.27 161.08 21.72 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.554 -0.459 . . . . 0.0 111.229 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.547 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 0.8 OUTLIER -122.92 166.76 14.52 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.951 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 86.6 mt-30 -142.25 175.64 9.6 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.65 179.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -166.49 113.7 0.86 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.771 -179.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 mp -112.56 124.24 52.09 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -127.91 128.75 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-O 121.17 0.51 . . . . 0.0 112.095 -179.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.437 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 32.1 m-85 -118.75 118.98 33.07 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.573 178.251 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.615 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 58.8 t80 -126.57 116.95 21.85 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.48 129.63 52.21 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.18 0.514 . . . . 0.0 111.771 -179.108 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -143.83 144.29 31.71 Favored 'General case' 0 C--N 1.34 0.193 0 CA-C-N 115.366 -0.833 . . . . 0.0 109.036 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.605 ' O ' ' O ' ' I' ' 24' ' ' VAL . 0.9 OUTLIER -175.04 129.55 0.3 Allowed 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.062 -0.655 . . . . 0.0 110.773 179.724 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.605 ' O ' ' O ' ' I' ' 23' ' ' ASP . 61.6 t -29.34 -113.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 O-C-N 124.425 1.078 . . . . 0.0 112.66 178.156 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.541 ' N ' ' CG1' ' I' ' 24' ' ' VAL . . . -170.77 90.55 0.09 OUTLIER Glycine 0 CA--C 1.53 0.981 0 CA-C-N 115.272 -0.877 . . . . 0.0 112.117 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.525 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t 161.99 160.45 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.921 0.867 . . . . 0.0 111.128 176.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.525 ' O ' ' O ' ' I' ' 26' ' ' SER . 29.2 m120 -30.16 179.07 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 113.084 -1.871 . . . . 0.0 116.027 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.677 ' HZ3' ' HG ' ' H' ' 26' ' ' SER . 86.4 tttt 127.81 103.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 112.2 -2.273 . . . . 0.0 111.203 174.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.487 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -59.86 99.54 0.16 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.248 -1.307 . . . . 0.0 110.735 174.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.439 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -118.08 141.4 48.51 Favored 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 102.529 -3.137 . . . . 0.0 102.529 174.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.439 ' CG1' ' C ' ' I' ' 30' ' ' ALA . 2.1 mt -146.06 114.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 C-N-CA 118.181 -1.408 . . . . 0.0 112.515 -169.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.4 HG22 HD12 ' I' ' 32' ' ' ILE . 1.3 mt -114.62 119.74 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 177.355 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.16 106.56 1.44 Allowed Glycine 0 N--CA 1.461 0.311 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.452 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 54.4 tp -116.23 120.93 40.53 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 5.6 tpp -117.1 102.02 8.96 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 174.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.473 ' O ' ' CG1' ' I' ' 36' ' ' VAL . 4.2 p -131.81 74.89 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.114 -177.298 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.28 -96.92 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.995 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 163.31 -167.76 37.72 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.65 150.58 3.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.768 0.318 . . . . 0.0 110.387 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.854 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -83.64 141.89 31.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.955 0.407 . . . . 0.0 110.065 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -66.35 135.63 54.64 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.477 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.581 ' CG1' ' H ' ' J' ' 13' ' ' HIS . 27.4 t -145.77 178.8 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.119 179.434 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.581 ' H ' ' CG1' ' J' ' 12' ' ' VAL . 92.2 m-70 -50.82 125.28 12.96 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.069 0.461 . . . . 0.0 112.146 -177.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.499 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 18.0 t-80 -145.38 163.43 34.6 Favored 'General case' 0 C--N 1.341 0.239 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.499 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 89.6 mt-30 -148.54 177.6 9.34 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.088 0.47 . . . . 0.0 111.364 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -170.26 116.28 0.51 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.819 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -114.23 125.27 53.72 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.495 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -126.78 121.05 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 120.78 0.324 . . . . 0.0 111.241 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -118.43 116.22 26.26 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.416 ' CZ ' ' CD1' ' K' ' 20' ' ' PHE . 1.1 t80 -131.38 129.66 41.62 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 120.922 0.391 . . . . 0.0 110.553 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.41 134.65 41.88 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.458 0.647 . . . . 0.0 112.421 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 mt-10 -144.3 102.87 3.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.029 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -152.22 177.3 10.68 Favored 'General case' 0 CA--C 1.515 -0.394 0 O-C-N 122.096 -0.378 . . . . 0.0 110.392 -178.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -91.96 102.99 14.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 122.176 0.989 . . . . 0.0 108.379 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' K' ' 26' ' ' SER . . . -35.9 95.59 0.01 OUTLIER Glycine 0 CA--C 1.526 0.763 0 CA-C-N 113.269 -1.787 . . . . 0.0 115.653 -179.087 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.4 t 170.24 176.18 0.05 Allowed 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 121.627 0.727 . . . . 0.0 110.678 175.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' J' ' 26' ' ' SER . 52.2 t30 -28.96 179.5 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 115.886 1.81 . . . . 0.0 115.886 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.536 ' H ' ' CG ' ' J' ' 27' ' ' ASN . 61.8 tttp 128.26 105.11 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 112.715 -2.039 . . . . 0.0 112.719 175.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.02 95.07 0.05 OUTLIER Glycine 0 N--CA 1.465 0.59 0 CA-C-N 113.934 -1.484 . . . . 0.0 113.031 174.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.51 142.33 46.99 Favored 'General case' 0 CA--C 1.496 -1.117 0 CA-C-N 119.884 1.842 . . . . 0.0 106.201 174.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.11 110.93 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 CA-C-N 114.454 -1.248 . . . . 0.0 111.837 -171.41 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.529 ' O ' ' SD ' ' E' ' 35' ' ' MET . 0.2 OUTLIER -114.68 118.9 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 177.783 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -114.15 106.68 1.75 Allowed Glycine 0 CA--C 1.496 -1.115 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 177.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.44 ' CD2' ' CZ ' ' H' ' 19' ' ' PHE . 37.1 tp -115.37 118.87 34.44 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 113.292 0.849 . . . . 0.0 113.292 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -117.29 107.63 14.63 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' J' ' 37' ' ' GLY . 0.0 OUTLIER -119.37 80.29 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.3 -94.42 0.01 OUTLIER Glycine 0 C--N 1.352 1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.714 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.62 -178.14 18.74 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 111.031 -0.827 . . . . 0.0 111.031 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -114.63 134.93 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.444 179.95 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -103.96 135.44 45.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.655 0.264 . . . . 0.0 110.377 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.471 ' N ' ' OE1' ' L' ' 11' ' ' GLU . 94.9 mt-10 -137.48 156.52 48.06 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.607 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.6 m -134.48 163.2 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.657 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 t60 -159.37 128.37 5.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.314 -179.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -152.67 167.52 28.65 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.688 0.756 . . . . 0.0 110.002 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -156.51 175.92 13.39 Favored 'General case' 0 C--N 1.307 -1.239 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.762 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -148.73 120.37 8.03 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 23.1 mt -112.51 116.05 29.63 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.6 p -133.31 134.47 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 CA-C-O 121.42 0.629 . . . . 0.0 112.308 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -125.76 126.94 45.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.227 179.087 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.416 ' CD1' ' CZ ' ' J' ' 20' ' ' PHE . 8.2 t80 -136.51 128.96 30.26 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.171 0.51 . . . . 0.0 111.818 -179.315 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.78 129.53 47.19 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.772 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.417 ' HG2' ' N ' ' K' ' 23' ' ' ASP . 75.7 tt0 -88.44 170.1 11.2 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.453 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.417 ' N ' ' HG2' ' K' ' 22' ' ' GLU . 48.0 t0 -39.33 115.46 0.5 Allowed 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 121.007 0.432 . . . . 0.0 110.821 -178.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' K' ' 25' ' ' GLY . 10.4 p -129.84 117.16 40.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.867 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . -27.92 -90.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.381 0 CA-C-O 121.524 0.513 . . . . 0.0 111.825 178.161 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.637 ' O ' ' O ' ' K' ' 27' ' ' ASN . 26.7 p -140.97 170.73 15.18 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.121 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.637 ' O ' ' O ' ' K' ' 26' ' ' SER . 56.8 p30 -28.29 169.75 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -149.4 111.45 4.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.685 178.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.71 91.6 0.02 OUTLIER Glycine 0 N--CA 1.464 0.521 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.59 151.69 43.37 Favored 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 106.314 -1.735 . . . . 0.0 106.314 176.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -135.83 115.44 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.579 -178.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.53 ' O ' ' SD ' ' F' ' 35' ' ' MET . 0.8 OUTLIER -115.59 116.91 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 178.362 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . 0.717 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -109.56 106.0 2.13 Favored Glycine 0 N--CA 1.464 0.547 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 178.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.437 ' CD1' ' CZ ' ' I' ' 19' ' ' PHE . 21.5 mt -110.44 111.98 23.6 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 117.047 0.423 . . . . 0.0 111.659 -177.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.46 ' CE ' ' O ' ' E' ' 32' ' ' ILE . 11.4 tpt -107.59 103.1 12.32 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 176.624 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -129.58 73.83 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.146 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.445 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.38 -101.5 0.01 OUTLIER Glycine 0 C--N 1.359 1.828 0 CA-C-N 116.388 -0.369 . . . . 0.0 112.844 -179.215 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.92 -155.69 26.57 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 30.0 m -126.54 160.54 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.762 0.315 . . . . 0.0 110.548 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.501 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -148.22 160.68 42.69 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.655 0.264 . . . . 0.0 110.334 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . 0.471 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 78.5 mm-40 -75.78 157.0 34.02 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.733 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 96.1 t -92.86 131.06 40.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.123 0 CA-C-O 121.061 0.458 . . . . 0.0 110.216 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.5 ' NE2' ' OXT' ' L' ' 40' ' ' VAL . 45.1 t-80 -144.25 134.21 23.98 Favored 'General case' 0 N--CA 1.461 0.113 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.954 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 46.8 t-80 -154.99 170.83 20.84 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.478 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 96.2 mt-30 -148.3 178.56 8.47 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.646 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -164.3 122.48 1.79 Allowed 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.11 0.481 . . . . 0.0 111.204 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 59.1 tp -120.75 121.57 38.5 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.977 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.91 131.65 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.156 0.503 . . . . 0.0 110.501 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.534 ' CD1' ' O ' ' L' ' 19' ' ' PHE . 41.1 p90 -135.14 125.63 26.72 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.217 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -140.08 142.57 36.1 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 121.776 0.798 . . . . 0.0 110.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.39 143.63 24.06 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.343 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.405 ' O ' ' O ' ' L' ' 23' ' ' ASP . 78.5 tt0 -76.12 153.1 36.52 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.585 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.405 ' O ' ' O ' ' L' ' 22' ' ' GLU . 59.4 m-20 -58.62 -134.4 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -177.09 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.488 ' O ' ' N ' ' L' ' 26' ' ' SER . 3.8 t 84.69 110.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.6 -92.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.807 ' O ' ' O ' ' L' ' 27' ' ' ASN . 34.1 p -161.18 163.98 30.82 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.698 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.807 ' O ' ' O ' ' L' ' 26' ' ' SER . 83.2 m-20 -9.98 -178.62 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 177.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' L' ' 29' ' ' GLY . 82.6 tttt -128.08 110.41 12.46 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.052 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' L' ' 28' ' ' LYS . . . -54.15 -95.26 0.01 OUTLIER Glycine 0 C--N 1.334 0.451 0 C-N-CA 117.113 -2.47 . . . . 0.0 111.305 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.405 ' O ' ' C ' ' L' ' 29' ' ' GLY . . . 71.65 163.32 0.26 Allowed 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 103.663 -2.717 . . . . 0.0 103.663 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.564 ' N ' ' CD1' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -138.2 100.6 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 122.957 2.617 . . . . 0.0 108.838 175.181 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.501 ' O ' ' CG2' ' L' ' 32' ' ' ILE . 4.6 tt -102.01 112.67 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 CA-C-N 113.356 -1.747 . . . . 0.0 106.628 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -99.97 102.39 2.5 Favored Glycine 0 CA--C 1.5 -0.889 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 43.6 tp -107.23 115.93 31.04 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.912 -0.315 . . . . 0.0 111.233 -178.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 17.6 tpp -112.64 104.22 12.28 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 176.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 10.5 m -135.84 79.59 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -66.1 103.68 0.9 Allowed Glycine 0 C--N 1.344 0.986 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 -162.04 38.0 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -125.58 153.12 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 121.044 0.449 . . . . 0.0 110.839 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.5 ' OXT' ' NE2' ' L' ' 13' ' ' HIS . 31.3 m . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.73 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -90.95 138.35 31.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.806 0.336 . . . . 0.0 110.504 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -122.83 136.34 54.83 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.344 0.592 . . . . 0.0 111.273 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.501 ' O ' ' CG ' ' A' ' 13' ' ' HIS . 48.9 t -142.55 158.96 19.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.182 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 12' ' ' VAL . 97.3 m-70 -155.57 110.4 2.95 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.218 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 6.1 p-80 -151.12 166.33 31.13 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 97.9 mm-40 -152.51 179.22 8.78 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.394 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -149.48 110.9 4.45 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.918 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 77.3 mt -138.12 127.8 25.15 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 121.575 0.702 . . . . 0.0 112.076 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.4 m -129.16 127.78 66.08 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.233 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.515 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 11.2 t80 -121.18 121.8 38.6 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.502 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.2 p90 -137.1 128.19 27.74 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.407 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.66 126.67 52.44 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.979 0.418 . . . . 0.0 111.122 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -153.21 108.81 3.27 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -57.21 121.55 10.35 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.489 -177.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 26' ' ' SER . 26.9 m -88.63 124.03 41.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.84 84.71 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 CA-C-N 116.08 -0.509 . . . . 0.0 112.388 179.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.524 ' N ' ' O ' ' A' ' 24' ' ' VAL . 11.8 p -91.85 179.16 5.69 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 m120 -60.31 178.97 0.17 Allowed 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 120.166 -0.613 . . . . 0.0 111.258 -179.424 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.4 110.89 1.2 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.718 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.804 ' H ' HD22 ' B' ' 27' ' ' ASN . . . 71.93 94.09 0.08 OUTLIER Glycine 0 N--CA 1.465 0.587 0 CA-C-O 118.511 -1.161 . . . . 0.0 111.783 177.332 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 153.78 25.87 Favored 'General case' 0 C--O 1.241 0.646 0 C-N-CA 117.607 -1.637 . . . . 0.0 107.602 177.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.406 HD13 HG23 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -148.2 109.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 CA-C-N 113.783 -1.553 . . . . 0.0 110.023 -171.945 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -131.07 126.96 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.245 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.47 119.57 2.12 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 mt -136.15 150.31 49.01 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-O 121.398 0.618 . . . . 0.0 111.762 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 18.6 ttt -149.53 139.8 22.25 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.992 -0.443 . . . . 0.0 111.865 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 5.6 p -152.28 79.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.385 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.69 104.78 1.67 Allowed Glycine 0 CA--C 1.527 0.814 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.138 -179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.38 176.17 23.84 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.88 -0.488 . . . . 0.0 111.88 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.7 t -131.95 138.25 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 63.9 t . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.473 -179.92 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -113.29 143.71 43.97 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 121.015 0.436 . . . . 0.0 110.764 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -119.24 131.65 55.82 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.114 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 34.4 m -136.33 158.65 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.903 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -135.69 137.55 41.88 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 111.262 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 72.7 t60 -155.44 169.88 23.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.549 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 47.1 tt0 -163.4 169.74 18.51 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.251 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . 0.403 ' N ' ' HG2' ' B' ' 15' ' ' GLN . 98.0 mttt -151.3 108.69 3.61 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 178.97 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.5 mt -126.08 120.77 31.08 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.119 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -123.26 130.35 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.567 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 2.0 t80 -129.39 122.88 30.34 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.305 -178.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -131.88 133.29 44.44 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 120.892 0.377 . . . . 0.0 110.453 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.48 126.19 32.41 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.882 0.372 . . . . 0.0 110.779 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -155.03 158.9 39.83 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -147.43 112.68 5.54 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 65.4 t -123.73 124.94 70.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.498 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.55 82.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 114.63 0.612 . . . . 0.0 114.63 174.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.551 ' O ' ' O ' ' B' ' 27' ' ' ASN . 32.2 p -140.06 170.71 15.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 118.338 1.069 . . . . 0.0 109.615 179.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.804 HD22 ' H ' ' A' ' 29' ' ' GLY . 48.1 t30 -30.88 173.25 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -175.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.5 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 88.3 tttt -88.95 111.16 21.79 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.167 -0.924 . . . . 0.0 112.079 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.404 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 60.31 92.96 0.01 OUTLIER Glycine 0 N--CA 1.465 0.583 0 C-N-CA 118.66 -1.733 . . . . 0.0 112.631 174.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.17 155.06 36.58 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 119.486 1.643 . . . . 0.0 110.172 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.85 120.17 9.04 Favored 'Isoleucine or valine' 0 C--O 1.244 0.774 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.622 -176.731 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 14.9 mm -131.87 133.11 61.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.189 -177.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.584 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -143.43 146.23 16.74 Favored Glycine 0 N--CA 1.468 0.802 0 C-N-CA 120.349 -0.929 . . . . 0.0 111.726 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.416 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 3.3 tt -156.45 135.62 12.05 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 119.781 -0.767 . . . . 0.0 112.235 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.405 ' CE ' ' SD ' ' C' ' 35' ' ' MET . 11.4 ttm -119.54 126.56 51.55 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.932 179.41 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.515 ' O ' ' C ' ' B' ' 37' ' ' GLY . 11.6 t -129.08 83.55 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.593 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' B' ' 36' ' ' VAL . . . -12.42 -95.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.068 0 O-C-N 123.642 0.589 . . . . 0.0 113.041 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.06 -179.14 40.38 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -138.5 162.41 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 120.826 0.346 . . . . 0.0 110.818 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 117.908 -1.044 . . . . 0.0 110.319 179.849 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -108.04 143.12 37.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.932 0.396 . . . . 0.0 110.587 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -64.77 153.55 39.55 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -131.46 157.3 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.144 0.497 . . . . 0.0 111.5 -179.028 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -138.78 127.73 23.79 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.12 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.579 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 38.6 t60 -148.2 168.08 23.43 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 121.375 0.607 . . . . 0.0 110.322 -178.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.579 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 47.1 tt0 -160.42 165.65 30.69 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.997 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -153.95 115.62 4.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.111 0.482 . . . . 0.0 110.71 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 49.9 tp -129.23 122.31 29.42 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -121.92 128.71 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.015 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -125.15 121.32 33.87 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.414 ' CD1' ' C ' ' C' ' 20' ' ' PHE . 25.3 t80 -131.96 126.97 35.34 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.5 136.34 39.32 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.292 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -140.5 146.32 38.01 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.094 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -129.09 111.95 13.49 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.676 179.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.659 ' CG2' ' H ' ' C' ' 25' ' ' GLY . 7.0 p -137.68 -122.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.169 -178.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.659 ' H ' ' CG2' ' C' ' 24' ' ' VAL . . . 28.72 -84.31 0.0 OUTLIER Glycine 0 N--CA 1.47 0.907 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.822 -177.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.5 t 170.54 176.88 0.06 Allowed 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 117.484 0.642 . . . . 0.0 110.332 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' C' ' 26' ' ' SER . 59.8 t30 -28.53 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.536 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 86.2 tttt 128.23 104.75 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 113.847 -1.524 . . . . 0.0 112.115 176.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.29 96.68 0.08 OUTLIER Glycine 0 CA--C 1.501 -0.827 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 173.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -117.19 150.67 38.35 Favored 'General case' 0 CA--C 1.481 -1.686 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -145.62 116.23 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 C-N-CA 118.938 -1.105 . . . . 0.0 109.634 -172.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.404 HG23 HD13 ' C' ' 32' ' ' ILE . 0.2 OUTLIER -109.78 117.12 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.816 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.79 98.26 0.73 Allowed Glycine 0 N--CA 1.469 0.891 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.431 ' O ' ' HA ' ' D' ' 34' ' ' LEU . 4.6 mp -132.49 148.37 52.39 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 122.853 1.311 . . . . 0.0 113.192 -178.613 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.405 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 15.8 ttm -135.15 120.31 18.84 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.484 -1.234 . . . . 0.0 108.352 177.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.484 ' O ' ' C ' ' C' ' 37' ' ' GLY . 0.2 OUTLIER -129.95 75.13 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.206 -179.527 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.484 ' C ' ' O ' ' C' ' 36' ' ' VAL . . . -16.88 -101.43 0.0 OUTLIER Glycine 0 C--N 1.367 2.299 0 O-C-N 123.418 0.448 . . . . 0.0 112.366 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.46 -158.69 31.71 Favored Glycine 0 CA--C 1.522 0.479 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 54.8 t -120.01 135.46 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.555 -179.96 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . 0.625 ' CD2' ' CE1' ' E' ' 10' ' ' TYR . 96.6 m-85 -106.59 135.25 48.44 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.789 0.328 . . . . 0.0 110.373 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -146.26 161.43 40.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.577 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 m -100.89 131.54 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.115 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' E' ' 13' ' ' HIS . 73.9 m80 -106.53 136.52 46.16 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 120.883 0.373 . . . . 0.0 111.589 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.568 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 44.5 t-80 -149.77 167.54 26.23 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.191 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.568 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 51.6 tt0 -169.73 165.74 9.9 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.409 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . 0.442 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.0 mttt -146.39 112.59 5.82 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.677 177.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -124.54 125.43 44.18 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.779 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 96.1 t -123.95 124.82 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.306 0.574 . . . . 0.0 111.378 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -109.83 107.72 17.79 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 8.8 t80 -129.07 122.81 30.75 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 119.643 1.111 . . . . 0.0 111.263 -178.384 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.62 132.51 33.14 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -130.02 106.27 8.52 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.004 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.79 112.0 24.04 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' D' ' 26' ' ' SER . 4.7 t -131.83 -122.16 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.634 . . . . 0.0 110.251 -178.142 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 30.16 -84.33 0.0 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.757 -177.834 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.684 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.8 p 170.56 178.85 0.05 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.684 ' O ' ' O ' ' D' ' 26' ' ' SER . 70.2 m-80 -28.2 171.13 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 O-C-N 124.731 1.269 . . . . 0.0 112.57 178.018 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 79.0 tttt 141.42 103.31 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 124.145 0.978 . . . . 0.0 108.468 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.514 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -43.69 -98.25 0.01 OUTLIER Glycine 0 C--N 1.344 0.994 0 C-N-CA 118.816 -1.659 . . . . 0.0 111.313 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.431 ' CB ' ' O ' ' D' ' 29' ' ' GLY . . . 83.56 142.21 0.06 Allowed 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 101.928 -3.36 . . . . 0.0 101.928 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -146.98 116.24 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 117.904 -1.518 . . . . 0.0 108.974 -177.071 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -106.95 112.41 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -179.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.59 101.24 0.96 Allowed Glycine 0 C--O 1.236 0.249 0 N-CA-C 108.139 -1.984 . . . . 0.0 108.139 179.255 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.515 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 8.8 tt -143.51 144.02 31.8 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 122.411 1.1 . . . . 0.0 113.329 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 14.5 ttm -125.19 125.47 43.7 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-N 114.669 -1.15 . . . . 0.0 109.017 177.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 p -137.5 71.89 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.042 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.64 111.74 3.48 Favored Glycine 0 C--N 1.366 2.212 0 N-CA-C 111.837 -0.505 . . . . 0.0 111.837 -179.04 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' E' ' 38' ' ' GLY . . . -101.48 146.22 17.15 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.4 ' O ' ' C ' ' D' ' 40' ' ' VAL . 21.3 t -137.51 165.51 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.564 0.221 . . . . 0.0 110.674 -179.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.4 ' C ' ' O ' ' D' ' 39' ' ' VAL . 98.4 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.974 -1.012 . . . . 0.0 111.585 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . 0.625 ' CE1' ' CD2' ' D' ' 10' ' ' TYR . 74.2 m-85 -83.98 140.04 32.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.633 0.254 . . . . 0.0 110.436 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -142.38 153.74 44.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.87 0.366 . . . . 0.0 110.744 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -121.93 134.64 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' D' ' 13' ' ' HIS . 0.2 OUTLIER -76.74 156.98 32.03 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.083 0.468 . . . . 0.0 110.694 -179.214 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.494 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 3.6 m170 -88.42 174.71 7.97 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.521 ' OE1' ' NE2' ' F' ' 15' ' ' GLN . 89.1 mt-30 -124.83 173.64 8.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -136.81 115.16 11.77 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.254 0.55 . . . . 0.0 111.814 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 35.2 mt -119.55 119.6 34.27 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -127.25 126.29 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-O 120.76 0.314 . . . . 0.0 111.198 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -121.14 122.37 39.86 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 79.8 t80 -134.51 121.61 21.24 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.813 0.34 . . . . 0.0 111.115 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.05 127.78 23.36 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 121.07 0.462 . . . . 0.0 111.032 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -135.32 139.68 44.5 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.444 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' C ' ' E' ' 24' ' ' VAL . 18.9 p-10 159.47 113.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 O-C-N 124.204 0.94 . . . . 0.0 108.997 -178.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.476 ' C ' ' O ' ' E' ' 23' ' ' ASP . 70.7 t -37.46 132.4 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -178.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.49 85.64 1.48 Allowed Glycine 0 CA--C 1.523 0.531 0 N-CA-C 116.756 1.462 . . . . 0.0 116.756 -173.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.532 ' O ' ' O ' ' E' ' 27' ' ' ASN . 92.8 p -145.75 151.97 38.82 Favored 'General case' 0 CA--C 1.508 -0.665 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 172.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.532 ' O ' ' O ' ' E' ' 26' ' ' SER . 9.1 t-20 -21.49 155.86 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.506 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 86.1 tttt -164.45 110.97 1.03 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 170.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.55 92.57 0.23 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 120.106 -1.045 . . . . 0.0 113.734 179.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.426 ' HA ' ' O ' ' D' ' 29' ' ' GLY . . . -168.39 150.09 5.07 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.42 125.28 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 118.05 -1.46 . . . . 0.0 113.434 -177.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.432 ' C ' ' SD ' ' K' ' 35' ' ' MET . 2.0 mt -107.65 116.44 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . 0.477 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -116.18 100.01 0.9 Allowed Glycine 0 C--O 1.234 0.146 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.567 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 7.7 tt -143.91 137.14 27.64 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 122.26 1.029 . . . . 0.0 112.951 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.51 ' SD ' ' CG2' ' K' ' 31' ' ' ILE . 23.3 ttm -117.6 128.37 54.87 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.495 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -124.81 74.28 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.387 179.834 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.464 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -20.98 -101.38 0.0 OUTLIER Glycine 0 C--N 1.355 1.637 0 O-C-N 123.208 0.317 . . . . 0.0 112.817 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . 140.9 -174.95 22.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 56.3 t -121.24 135.63 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.4 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.433 -179.934 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 87.5 m-85 -117.68 136.71 53.15 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.088 0.47 . . . . 0.0 110.946 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -109.84 128.46 55.34 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.063 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t -128.13 133.81 66.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.893 0.378 . . . . 0.0 110.753 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -150.35 102.38 3.06 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -151.19 174.42 13.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.521 ' NE2' ' OE1' ' E' ' 15' ' ' GLN . 88.3 mt-30 -141.36 175.0 10.01 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.979 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -130.13 114.84 16.22 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.943 0.402 . . . . 0.0 110.135 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -120.03 116.92 26.69 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.259 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 49.7 t -129.95 131.39 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.459 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 55.2 p90 -142.63 133.09 24.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.266 0.555 . . . . 0.0 111.659 -179.391 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -138.1 120.39 15.83 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.34 144.83 31.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.167 0.508 . . . . 0.0 111.376 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -101.1 106.22 17.47 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.988 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.424 ' OD1' ' O ' ' F' ' 26' ' ' SER . 61.8 t0 -146.66 118.57 8.17 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.388 0.613 . . . . 0.0 112.029 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' F' ' 26' ' ' SER . 3.1 m -97.74 125.36 50.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.173 -0.922 . . . . 0.0 111.051 178.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.8 -86.41 0.01 OUTLIER Glycine 0 N--CA 1.473 1.161 0 C-N-CA 121.521 -0.371 . . . . 0.0 113.503 177.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.455 ' N ' ' O ' ' F' ' 24' ' ' VAL . 72.9 m -63.8 -173.72 0.08 Allowed 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 -177.498 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.544 ' O ' ' O ' ' F' ' 28' ' ' LYS . 88.2 m-20 -78.89 177.87 8.41 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 118.038 -1.465 . . . . 0.0 108.763 -176.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.544 ' O ' ' O ' ' F' ' 27' ' ' ASN . 88.2 tttt -38.04 -103.51 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.619 0.723 . . . . 0.0 112.775 -176.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' F' ' 30' ' ' ALA . . . -139.9 -100.57 0.46 Allowed Glycine 0 CA--C 1.482 -2.018 0 CA-C-O 123.622 1.679 . . . . 0.0 111.48 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.442 ' O ' ' C ' ' F' ' 29' ' ' GLY . . . -58.33 175.73 0.22 Allowed 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 110.164 -3.018 . . . . 0.0 103.358 173.843 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.5 mt -131.43 116.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 116.538 -2.065 . . . . 0.0 109.774 -177.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.477 ' C ' ' SD ' ' L' ' 35' ' ' MET . 16.5 tt -103.33 116.96 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 CA-C-N 113.084 -1.871 . . . . 0.0 110.074 -177.539 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -105.71 86.34 0.48 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 106.7 -2.56 . . . . 0.0 106.7 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 35.2 tp -116.72 119.02 34.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 35.2 mmm -123.04 135.44 54.44 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.057 -0.657 . . . . 0.0 112.28 -177.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 m -124.99 81.14 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.515 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.58 102.07 0.35 Allowed Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -153.52 178.09 30.7 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -124.94 137.16 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.247 0.546 . . . . 0.0 110.192 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.819 -1.086 . . . . 0.0 110.398 -179.442 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -106.39 131.79 53.18 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.921 0.391 . . . . 0.0 110.617 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -89.22 158.15 17.98 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.431 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -122.43 133.85 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.134 0.493 . . . . 0.0 110.705 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -134.44 -178.49 5.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.623 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -77.56 167.62 21.32 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -157.49 169.59 24.36 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.995 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.27 130.08 10.1 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.676 0.274 . . . . 0.0 110.732 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 90.2 mt -125.05 115.59 20.77 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.659 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 14.3 m -133.87 129.14 54.42 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 121.45 0.643 . . . . 0.0 112.134 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.427 ' CE1' ' CD1' ' I' ' 34' ' ' LEU . 8.8 m-85 -111.79 116.77 31.25 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.445 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.494 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 55.1 p90 -133.96 130.72 38.08 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.775 -179.236 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . 0.429 ' O ' ' OD1' ' H' ' 23' ' ' ASP . . . -121.35 125.43 46.97 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-O 121.122 0.487 . . . . 0.0 110.985 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.499 ' CA ' ' OD2' ' H' ' 23' ' ' ASP . 96.0 mt-10 -146.64 150.31 35.19 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 106.43 -1.693 . . . . 0.0 106.43 178.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' NZ ' ' I' ' 28' ' ' LYS . 78.2 m-20 -78.11 111.61 14.21 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 112.754 -177.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.577 ' O ' ' N ' ' G' ' 26' ' ' SER . 52.9 t -114.06 130.85 67.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 176.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.48 81.94 0.0 OUTLIER Glycine 0 CA--C 1.535 1.308 0 CA-C-O 119.561 -0.577 . . . . 0.0 113.532 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.577 ' N ' ' O ' ' G' ' 24' ' ' VAL . 4.7 t -98.62 172.36 7.54 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 176.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -58.73 162.4 4.02 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 118.567 -1.253 . . . . 0.0 109.726 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -58.68 111.3 1.21 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 118.789 -0.624 . . . . 0.0 111.562 175.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.24 93.29 0.08 OUTLIER Glycine 0 N--CA 1.471 0.976 0 C-N-CA 118.311 -1.9 . . . . 0.0 111.947 175.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.75 159.2 17.85 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 120.319 2.06 . . . . 0.0 111.556 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.01 123.2 1.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.154 -178.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' A' ' 35' ' ' MET . 96.8 mt -133.5 128.71 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.952 -0.468 . . . . 0.0 111.308 -179.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . 0.445 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -132.85 117.56 1.99 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.434 -1.067 . . . . 0.0 110.434 179.295 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 84.1 mt -134.86 142.54 46.64 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.95 0.405 . . . . 0.0 110.576 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -141.09 137.55 32.91 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.212 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.3 t -119.03 82.72 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.68 97.99 2.34 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.95 165.03 38.61 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.23 159.08 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.738 0.304 . . . . 0.0 110.226 179.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.542 -179.924 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -117.21 139.5 50.71 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.642 0.258 . . . . 0.0 110.596 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.48 ' N ' ' CD ' ' H' ' 11' ' ' GLU . 0.9 OUTLIER -128.02 132.24 49.13 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -140.02 157.21 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -139.5 105.61 5.23 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.929 0.395 . . . . 0.0 111.34 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.416 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 17.2 m-70 -118.86 166.46 12.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -151.14 176.68 10.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.996 178.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -170.97 113.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.164 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -113.41 119.81 38.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.98 127.16 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 121.061 0.458 . . . . 0.0 111.683 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.513 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 18.1 m-85 -117.24 118.28 31.85 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.056 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -126.44 119.59 27.6 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.82 119.58 33.11 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.145 0.498 . . . . 0.0 111.626 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -163.48 89.27 0.6 Allowed 'General case' 0 C--N 1.341 0.234 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.723 ' H ' ' HZ1' ' J' ' 28' ' ' LYS . 5.0 m-20 -128.2 119.28 24.91 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -177.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.637 ' O ' ' O ' ' H' ' 23' ' ' ASP . 3.1 t -38.04 -124.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 124.105 0.878 . . . . 0.0 112.021 176.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -130.38 83.93 0.31 Allowed Glycine 0 CA--C 1.533 1.187 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 12.5 p -67.37 -173.06 0.26 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -78.92 169.69 17.82 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 118.332 -1.347 . . . . 0.0 110.506 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -47.09 110.21 0.28 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.95 95.61 0.28 Allowed Glycine 0 N--CA 1.468 0.827 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.582 171.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.455 ' C ' ' CG1' ' H' ' 31' ' ' ILE . . . -119.29 147.45 44.27 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 101.117 -3.661 . . . . 0.0 101.117 171.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.455 ' CG1' ' C ' ' H' ' 30' ' ' ALA . 1.2 mt -149.01 126.12 2.51 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 C-N-CA 117.918 -1.513 . . . . 0.0 111.752 -170.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 44.2 mm -121.3 123.36 69.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.73 123.58 5.11 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.43 ' H ' HD23 ' I' ' 34' ' ' LEU . 29.0 tp -135.12 128.75 32.74 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 122.286 -0.538 . . . . 0.0 110.453 -179.252 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.584 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 2.6 ttp -123.34 116.94 24.13 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.031 -178.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' H' ' 37' ' ' GLY . 14.2 t -133.42 83.19 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -22.75 -94.05 0.01 OUTLIER Glycine 0 C--N 1.349 1.273 0 N-CA-C 112.159 -0.376 . . . . 0.0 112.159 177.734 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.65 -177.23 42.12 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 50.4 t -127.58 136.12 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-O 120.962 0.411 . . . . 0.0 110.245 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 34.8 t . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.451 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . 0.421 ' O ' ' N ' ' J' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -95.34 128.36 42.12 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.472 ' O ' ' CB ' ' J' ' 11' ' ' GLU . 22.4 pt-20 -164.32 146.93 9.01 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.222 -0.591 . . . . 0.0 111.5 -179.627 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.401 ' C ' ' CD2' ' I' ' 13' ' ' HIS . 3.8 m -133.07 162.85 39.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.359 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.434 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 30.9 m-70 -141.79 145.13 34.38 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.752 0.311 . . . . 0.0 111.413 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.434 ' ND1' ' C ' ' I' ' 13' ' ' HIS . 42.6 m80 -148.18 159.18 44.22 Favored 'General case' 0 CA--C 1.514 -0.427 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.372 178.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -153.94 166.06 34.15 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.283 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -162.53 123.86 2.59 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 123.023 0.202 . . . . 0.0 110.566 179.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 10.6 mp -115.22 115.63 27.02 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -126.56 123.68 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 CA-C-O 120.983 0.421 . . . . 0.0 111.307 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 9.8 m-85 -119.21 116.43 26.27 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 115.815 -0.629 . . . . 0.0 109.742 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -128.59 126.85 41.12 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.76 135.33 26.11 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.382 0.61 . . . . 0.0 111.961 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -141.57 142.58 33.49 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.081 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.442 ' O ' ' CG2' ' J' ' 24' ' ' VAL . 64.9 t0 -85.78 123.35 31.05 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 121.47 0.652 . . . . 0.0 111.69 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' I' ' 26' ' ' SER . 2.9 t -93.2 121.81 44.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.06 -88.22 0.01 OUTLIER Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.891 -1.283 . . . . 0.0 109.891 -177.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' I' ' 24' ' ' VAL . 52.9 p -141.0 170.28 16.03 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 118.127 0.964 . . . . 0.0 109.477 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -29.17 169.44 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 114.138 -1.392 . . . . 0.0 114.027 -179.252 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.609 ' NZ ' ' OD1' ' G' ' 23' ' ' ASP . 35.8 tttt -150.27 111.18 4.32 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 114.372 -1.286 . . . . 0.0 108.936 172.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.96 92.07 0.02 OUTLIER Glycine 0 N--CA 1.464 0.535 0 C-N-CA 118.913 -1.613 . . . . 0.0 109.082 176.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -138.32 148.07 44.22 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.9 116.18 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-N 114.057 -1.429 . . . . 0.0 110.387 -174.125 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -106.99 114.76 46.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.68 93.87 0.57 Allowed Glycine 0 N--CA 1.462 0.415 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.43 HD23 ' H ' ' H' ' 34' ' ' LEU . 7.4 mt -127.61 135.26 50.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 122.484 1.135 . . . . 0.0 111.554 -178.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 42.9 ttp -125.62 120.7 31.47 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.402 177.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.99 73.57 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.784 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -21.1 -101.72 0.0 OUTLIER Glycine 0 C--N 1.367 2.301 0 O-C-N 123.508 0.505 . . . . 0.0 112.378 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.66 -153.71 23.65 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.655 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 5.0 p -134.59 141.43 43.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-O 120.879 0.371 . . . . 0.0 110.105 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' H' ' 40' ' ' VAL . 2.6 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.062 -0.97 . . . . 0.0 110.218 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' K' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.489 2.197 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -142.22 163.14 33.66 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-O 120.778 0.323 . . . . 0.0 110.289 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.472 ' CB ' ' O ' ' I' ' 11' ' ' GLU . 17.3 pt-20 -153.3 154.21 34.14 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.162 0.506 . . . . 0.0 111.212 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.43 ' C ' ' ND1' ' J' ' 13' ' ' HIS . 2.4 p -140.56 151.37 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.799 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.43 ' ND1' ' C ' ' J' ' 12' ' ' VAL . 1.6 m80 -127.34 130.79 50.09 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.479 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -126.6 156.57 40.7 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-O 121.494 0.664 . . . . 0.0 109.529 178.444 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mt-30 -150.68 173.79 13.76 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.775 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -175.25 123.92 0.23 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.842 179.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 4.7 mp -125.48 122.25 36.08 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.43 137.22 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.197 0.522 . . . . 0.0 112.135 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -121.62 129.65 52.96 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.863 179.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -129.65 122.19 28.5 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.136 0.426 . . . . 0.0 110.245 178.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.96 126.87 35.09 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 121.382 0.61 . . . . 0.0 111.427 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -126.77 109.33 11.9 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.229 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.562 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 0.0 OUTLIER -104.68 112.3 25.33 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 120.068 -0.653 . . . . 0.0 112.127 -178.607 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.571 ' O ' ' N ' ' J' ' 26' ' ' SER . 2.7 m -82.37 132.87 30.42 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.381 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.26 -85.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.415 0 N-CA-C 107.484 -2.246 . . . . 0.0 107.484 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.571 ' N ' ' O ' ' J' ' 24' ' ' VAL . 10.9 t -140.98 169.62 17.26 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 118.373 1.086 . . . . 0.0 110.298 174.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' N ' ' L' ' 30' ' ' ALA . 1.0 OUTLIER -30.27 172.81 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 N-CA-C 115.165 1.542 . . . . 0.0 115.165 178.394 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.723 ' HZ1' ' H ' ' H' ' 23' ' ' ASP . 87.0 tttt -97.54 112.25 24.18 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 117.671 -1.157 . . . . 0.0 110.197 171.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -61.42 91.49 0.06 OUTLIER Glycine 0 N--CA 1.49 2.271 0 CA-C-N 123.453 2.842 . . . . 0.0 108.343 175.052 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.555 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -148.85 153.42 38.04 Favored 'General case' 0 CA--C 1.482 -1.655 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.35 115.95 4.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 C-N-CA 118.716 -1.194 . . . . 0.0 109.439 -174.632 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.419 HD12 HG21 ' J' ' 32' ' ' ILE . 1.7 mt -105.52 117.01 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.563 -178.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 101.1 1.02 Allowed Glycine 0 CA--C 1.503 -0.71 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 tt -142.02 135.4 29.22 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 118.932 -1.107 . . . . 0.0 112.788 -177.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 60.9 ttp -127.82 124.0 36.54 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.807 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.3 75.36 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.751 0 CA-C-N 114.52 -1.218 . . . . 0.0 107.734 178.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -89.75 103.17 2.98 Favored Glycine 0 C--N 1.356 1.665 0 N-CA-C 111.784 -0.526 . . . . 0.0 111.784 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.82 152.14 20.9 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 30.6 m -135.08 157.38 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 8.3 p . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.176 -0.916 . . . . 0.0 110.5 -179.63 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' J' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -135.48 154.84 51.29 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 121.159 0.504 . . . . 0.0 111.179 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -137.3 131.77 32.73 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.34 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 11.2 m -145.0 136.63 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.348 179.339 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -118.4 127.15 53.4 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.742 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -124.02 158.27 32.53 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.556 0.693 . . . . 0.0 110.179 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.481 ' O ' ' O ' ' L' ' 15' ' ' GLN . 50.9 tt0 -166.17 170.23 13.55 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.776 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . 0.446 ' HZ2' ' CD2' ' L' ' 14' ' ' HIS . 66.3 mttm -163.82 125.5 2.37 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.556 179.356 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . 0.929 ' O ' ' C ' ' L' ' 17' ' ' LEU . 17.9 tp -118.05 118.39 31.8 Favored 'General case' 0 N--CA 1.503 2.224 0 CA-C-O 123.339 1.543 . . . . 0.0 112.124 178.479 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 5.3 p -134.07 123.96 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.352 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -109.23 127.17 54.03 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.464 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -117.36 114.3 23.35 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 178.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 131.31 47.51 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.208 0.528 . . . . 0.0 111.569 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.406 ' O ' ' O ' ' K' ' 23' ' ' ASP . 74.5 mm-40 -83.33 158.26 22.25 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.257 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.55 ' O ' ' O ' ' K' ' 24' ' ' VAL . 48.8 p-10 -60.99 -133.88 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.201 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.55 ' O ' ' O ' ' K' ' 23' ' ' ASP . 24.7 t 26.72 111.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 123.942 0.776 . . . . 0.0 112.356 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.43 82.74 0.14 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 120.206 -0.997 . . . . 0.0 113.183 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.491 ' O ' ' OG ' ' J' ' 26' ' ' SER . 30.2 p -139.05 170.2 16.41 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-N 117.759 0.779 . . . . 0.0 109.334 177.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 50.62 -178.75 0.02 OUTLIER 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.765 179.078 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt 55.37 -106.61 0.33 Allowed 'General case' 0 C--O 1.233 0.208 0 CA-C-O 121.204 0.526 . . . . 0.0 111.918 177.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 96.6 91.54 1.83 Allowed Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.515 ' CB ' ' O ' ' J' ' 28' ' ' LYS . . . -82.19 174.2 11.4 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 104.707 -2.331 . . . . 0.0 104.707 177.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.51 ' CG2' ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -156.4 119.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 116.768 -1.973 . . . . 0.0 111.224 -175.431 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -103.72 113.09 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 176.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.1 88.98 0.52 Allowed Glycine 0 CA--C 1.504 -0.603 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 177.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.513 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 9.3 tt -127.66 134.54 49.62 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 122.004 0.907 . . . . 0.0 111.834 -177.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.477 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 65.8 ttp -123.34 127.56 48.68 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 115.079 -0.964 . . . . 0.0 112.593 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.5 72.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 114.427 -1.26 . . . . 0.0 107.887 177.703 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.03 101.86 2.33 Favored Glycine 0 C--N 1.353 1.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -145.16 163.52 28.08 Favored Glycine 0 N--CA 1.46 0.242 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -124.06 135.58 63.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.905 0.383 . . . . 0.0 110.125 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.466 179.967 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -112.95 152.92 28.81 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.507 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.51 136.8 49.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.856 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.97 132.77 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.999 0.428 . . . . 0.0 110.503 -179.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 23.3 p-80 -160.91 147.71 15.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.487 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.446 ' CD2' ' HZ2' ' K' ' 16' ' ' LYS . 11.0 t60 -95.16 177.54 5.83 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.508 ' HG3' ' H ' ' L' ' 16' ' ' LYS . 45.6 tp60 -114.84 174.98 5.7 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.932 -179.564 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . 0.508 ' H ' ' HG3' ' L' ' 15' ' ' GLN . 88.9 mttt -88.9 -174.96 4.7 Favored 'General case' 0 C--O 1.176 -2.765 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . 0.929 ' C ' ' O ' ' K' ' 17' ' ' LEU . 38.3 mt -141.48 161.28 38.29 Favored 'General case' 0 C--N 1.31 -1.12 0 O-C-N 119.922 -1.736 . . . . 0.0 110.289 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 10.8 m -84.54 -144.05 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 117.723 2.49 . . . . 0.0 117.723 -171.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.492 ' N ' ' CD1' ' L' ' 19' ' ' PHE . 9.6 m-85 -124.22 147.62 47.91 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 113.506 -1.679 . . . . 0.0 111.143 -178.066 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -137.48 132.19 32.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.263 -0.881 . . . . 0.0 108.945 178.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.3 159.37 38.78 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.277 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -85.7 157.97 20.17 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -53.16 122.88 10.34 Favored 'General case' 0 CA--C 1.52 -0.185 0 C-N-CA 119.899 -0.721 . . . . 0.0 109.243 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 3.5 t -92.68 121.79 43.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.575 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.16 -87.01 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 79.4 p -89.07 -177.7 5.5 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.417 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 63.9 t30 -60.27 179.55 0.14 Allowed 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.713 -177.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.417 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 11.6 tptt -57.26 110.72 0.89 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 122.005 0.907 . . . . 0.0 112.998 -176.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.27 -98.14 0.04 OUTLIER Glycine 0 CA--C 1.496 -1.149 0 CA-C-N 113.801 -1.545 . . . . 0.0 111.155 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.683 ' N ' ' ND2' ' J' ' 27' ' ' ASN . . . -61.2 165.16 4.64 Favored 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 -178.612 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -141.51 125.32 16.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 117.692 -1.603 . . . . 0.0 112.441 -176.238 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.407 HG21 HD13 ' L' ' 32' ' ' ILE . 4.3 mt -101.16 117.66 46.74 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.632 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 177.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.55 98.19 0.61 Allowed Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . 0.496 ' CD2' ' C ' ' L' ' 34' ' ' LEU . 1.0 OUTLIER -128.82 139.58 52.1 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.557 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 66.4 ttp -118.33 124.15 47.08 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.588 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -123.42 80.07 0.67 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.648 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.93 102.48 0.12 Allowed Glycine 0 C--N 1.349 1.295 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.247 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.68 -173.21 29.37 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.56 142.87 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.842 0.353 . . . . 0.0 110.599 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.995 -1.002 . . . . 0.0 111.015 -179.795 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -84.03 140.09 32.09 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.813 0.339 . . . . 0.0 110.212 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -65.76 145.32 56.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.013 -179.326 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -139.35 141.11 36.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.09 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 77.7 m80 -142.98 165.13 28.2 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.344 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m80 -135.69 178.55 6.96 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 109.61 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -98.12 179.18 4.85 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.022 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -104.56 140.95 37.24 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.195 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -124.12 120.12 31.42 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.079 0.466 . . . . 0.0 110.726 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.06 128.19 52.53 Favored 'Isoleucine or valine' 0 C--O 1.231 0.098 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.11 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.623 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 11.7 m-85 -112.88 118.83 35.98 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.07 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.549 ' CE2' ' CD1' ' B' ' 20' ' ' PHE . 55.7 t80 -127.71 113.08 15.56 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.51 129.26 56.41 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.118 0.485 . . . . 0.0 110.98 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 tt0 -156.72 158.69 37.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 179.284 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -81.11 111.29 17.42 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.718 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.628 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.0 t -114.27 131.18 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.839 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 177.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.83 81.94 0.0 OUTLIER Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.576 -0.345 . . . . 0.0 112.409 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.628 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.1 p -94.64 177.31 5.96 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.686 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' A' ' 28' ' ' LYS . 98.5 m-20 -61.58 179.6 0.23 Allowed 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.584 -0.846 . . . . 0.0 108.763 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.8 mttm -52.12 -111.87 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.761 0.791 . . . . 0.0 111.406 178.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.41 93.33 1.63 Allowed Glycine 0 N--CA 1.467 0.707 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 177.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.55 160.9 14.05 Favored 'General case' 0 CA--C 1.509 -0.605 0 C-N-CA 116.582 -2.047 . . . . 0.0 111.627 -177.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.457 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.0 OUTLIER -152.51 117.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.112 0 CA-C-N 111.819 -2.446 . . . . 0.0 109.184 -174.334 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.87 118.54 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.709 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.64 108.71 0.98 Allowed Glycine 0 N--CA 1.464 0.56 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 48.5 tp -131.69 133.01 44.4 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 117.194 0.497 . . . . 0.0 111.07 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 13.4 ttt -139.38 134.66 32.77 Favored 'General case' 0 C--N 1.328 -0.36 0 O-C-N 122.234 -0.291 . . . . 0.0 110.788 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.7 t -146.06 81.29 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.51 100.22 2.43 Favored Glycine 0 C--N 1.338 0.66 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.226 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.24 176.48 47.86 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m -131.72 158.57 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 120.82 0.343 . . . . 0.0 110.356 179.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.3 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.636 -179.706 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . 0.563 ' CE1' ' CD1' ' D' ' 10' ' ' TYR . 95.7 m-85 -83.06 144.1 30.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.736 0.303 . . . . 0.0 110.489 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -133.99 156.33 48.37 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.68 -179.613 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . 0.401 ' CG1' ' N ' ' B' ' 13' ' ' HIS . 93.4 t -133.17 159.94 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.894 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.401 ' N ' ' CG1' ' B' ' 12' ' ' VAL . 28.3 t60 -166.77 104.78 0.59 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.218 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 47.6 m170 -120.0 165.77 14.25 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.401 ' CG ' ' H ' ' B' ' 16' ' ' LYS . 50.6 tt0 -162.85 173.23 14.01 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.331 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . 0.401 ' H ' ' CG ' ' B' ' 15' ' ' GLN . 97.6 mttt -149.85 116.29 5.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.939 0.399 . . . . 0.0 110.742 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 60.6 mt -116.57 114.42 24.11 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.302 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.52 123.66 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-O 121.214 0.531 . . . . 0.0 110.945 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -117.47 118.52 32.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.963 179.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.549 ' CD1' ' CE2' ' A' ' 20' ' ' PHE . 33.1 t80 -138.37 125.67 21.69 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 122.22 -0.3 . . . . 0.0 110.326 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 131.32 46.89 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.155 0.503 . . . . 0.0 111.965 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -157.67 91.3 1.13 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.588 ' H ' ' CG ' ' C' ' 23' ' ' ASP . 10.7 t0 -121.6 113.1 19.3 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -176.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' B' ' 26' ' ' SER . 12.0 p -60.41 132.37 25.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.252 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.94 83.72 0.04 OUTLIER Glycine 0 CA--C 1.526 0.751 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.694 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.484 ' OG ' ' NZ ' ' C' ' 28' ' ' LYS . 11.8 p -87.62 -179.1 6.25 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.583 0.706 . . . . 0.0 109.627 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.425 ' O ' ' O ' ' B' ' 28' ' ' LYS . 28.3 t-20 -75.63 175.96 8.1 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.544 177.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' B' ' 27' ' ' ASN . 97.6 mttt 42.49 107.9 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 114.9 1.445 . . . . 0.0 114.9 176.121 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.2 100.04 1.98 Allowed Glycine 0 N--CA 1.479 1.565 0 CA-C-N 114.273 -1.33 . . . . 0.0 110.717 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 161.35 31.15 Favored 'General case' 0 C--O 1.248 1.016 0 CA-C-O 122.772 1.272 . . . . 0.0 110.772 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.457 ' O ' ' HA ' ' A' ' 31' ' ' ILE . 0.0 OUTLIER -143.02 122.74 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 112.939 -1.937 . . . . 0.0 110.378 -172.929 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.452 ' C ' ' SD ' ' H' ' 35' ' ' MET . 44.3 pt -136.08 135.29 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-O 121.847 0.832 . . . . 0.0 112.129 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -141.11 137.88 8.46 Favored Glycine 0 CA--C 1.531 1.033 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.142 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 tt -146.93 139.74 25.12 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 120.196 -0.601 . . . . 0.0 111.158 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 24.1 ttm -128.32 126.19 40.27 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-O 121.397 0.618 . . . . 0.0 112.133 -179.346 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.43 79.6 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.021 177.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' B' ' 38' ' ' GLY . . . -50.91 104.13 0.12 Allowed Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.769 -179.045 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 44.99 179.74 0.01 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 p -148.36 149.77 14.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 C--O 1.218 -0.559 0 CA-C-O 118.176 -0.916 . . . . 0.0 111.078 -179.681 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 141.44 47.83 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.417 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -142.58 159.34 42.43 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.418 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 55.3 t -121.27 133.56 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.423 ' O ' ' O ' ' D' ' 13' ' ' HIS . 97.6 m-70 -148.08 123.63 10.42 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.822 0.344 . . . . 0.0 111.179 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.529 ' ND1' ' O ' ' D' ' 14' ' ' HIS . 26.1 t60 -141.45 164.65 29.66 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.409 ' HG2' ' N ' ' C' ' 16' ' ' LYS . 51.8 tt0 -169.39 170.36 8.45 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.845 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . 0.409 ' N ' ' HG2' ' C' ' 15' ' ' GLN . 68.2 mttm -142.59 118.79 10.77 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.238 178.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -120.11 121.39 38.73 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.06 123.25 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.048 0.452 . . . . 0.0 111.739 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.441 ' CZ ' ' CD2' ' F' ' 34' ' ' LEU . 6.6 m-85 -113.65 116.78 30.0 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.544 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 33.6 t80 -132.24 118.65 19.78 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 118.227 0.467 . . . . 0.0 110.203 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.9 37.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 120.857 0.361 . . . . 0.0 110.884 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -173.2 102.97 0.13 Allowed 'General case' 0 CA--C 1.522 -0.134 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.706 ' H ' ' NZ ' ' E' ' 28' ' ' LYS . 1.1 m-20 -115.15 113.66 24.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 121.095 0.474 . . . . 0.0 111.417 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 91.4 t -64.76 131.5 30.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.84 84.02 0.31 Allowed Glycine 0 CA--C 1.525 0.696 0 C-N-CA 119.195 -1.479 . . . . 0.0 110.726 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.536 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 1.7 m -59.87 -174.27 0.02 OUTLIER 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.536 ' CB ' ' O ' ' C' ' 26' ' ' SER . 6.1 t-20 99.85 -174.62 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.928 0 O-C-N 124.342 1.026 . . . . 0.0 111.202 -177.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.529 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 81.9 tttt 37.44 108.93 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.987 -177.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.426 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -85.79 96.84 2.13 Favored Glycine 0 CA--C 1.504 -0.622 0 CA-C-N 114.325 -1.307 . . . . 0.0 112.056 177.387 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.8 164.7 19.36 Favored 'General case' 0 C--O 1.244 0.808 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.461 ' CG2' ' SD ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -145.83 121.3 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 117.961 -1.496 . . . . 0.0 111.702 -174.804 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 1.1 mt -114.54 120.63 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.898 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.98 98.88 0.65 Allowed Glycine 0 N--CA 1.472 1.04 0 N-CA-C 106.939 -2.464 . . . . 0.0 106.939 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 tt -129.93 129.28 43.64 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 119.05 -1.06 . . . . 0.0 113.749 -175.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 96.6 mmm -107.39 118.08 35.77 Favored 'General case' 0 CA--C 1.503 -0.859 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.267 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.02 72.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.723 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 175.83 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.14 112.31 4.6 Favored Glycine 0 C--N 1.36 1.882 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.47 157.39 51.88 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -138.72 161.51 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.103 -0.951 . . . . 0.0 110.508 179.968 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . 0.563 ' CD1' ' CE1' ' B' ' 10' ' ' TYR . 87.3 m-85 -108.42 142.12 39.27 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.736 0.303 . . . . 0.0 110.322 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' D' ' 11' ' ' GLU . 2.1 pm0 -143.92 169.42 17.84 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.646 -179.479 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t -83.12 130.68 35.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.423 ' O ' ' O ' ' C' ' 13' ' ' HIS . 3.4 m-70 -87.31 161.48 17.92 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.336 0.589 . . . . 0.0 111.354 -178.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.529 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.8 p-80 -93.93 178.83 5.54 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.327 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -127.7 179.04 5.74 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.502 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -137.23 127.1 25.66 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.248 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.3 mp -126.43 129.17 48.21 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.223 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -126.81 125.01 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.027 0.441 . . . . 0.0 111.488 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 4.9 m-85 -110.57 112.57 24.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.51 ' CE1' ' CE2' ' C' ' 20' ' ' PHE . 27.5 t80 -126.72 123.32 37.21 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 118.542 0.61 . . . . 0.0 109.947 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.17 142.63 28.63 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -142.97 145.17 32.72 Favored 'General case' 0 C--N 1.343 0.302 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.653 178.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.515 ' O ' ' O ' ' E' ' 24' ' ' VAL . 14.0 m-20 -112.64 124.67 53.07 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.898 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' E' ' 26' ' ' SER . 5.7 t -95.34 -112.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 113.124 0.787 . . . . 0.0 113.124 -176.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.94 -91.12 0.01 OUTLIER Glycine 0 N--CA 1.469 0.864 0 N-CA-C 112.386 -0.286 . . . . 0.0 112.386 -176.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.609 ' O ' ' O ' ' D' ' 27' ' ' ASN . 21.5 p -151.54 171.87 16.91 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.666 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 18.6 m120 -19.29 156.7 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 O-C-N 124.253 0.971 . . . . 0.0 113.164 -178.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 56.5 tttt -162.45 110.68 1.36 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 121.406 -0.809 . . . . 0.0 110.461 173.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.426 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -68.62 92.83 0.29 Allowed Glycine 0 C--O 1.215 -1.036 0 CA-C-O 117.861 -1.522 . . . . 0.0 110.77 175.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.43 ' O ' HG13 ' E' ' 31' ' ' ILE . . . -129.04 151.61 49.54 Favored 'General case' 0 CA--C 1.482 -1.652 0 N-CA-C 103.028 -2.953 . . . . 0.0 103.028 173.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -147.75 118.25 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.339 -172.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 18.5 tt -119.0 113.42 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.483 178.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.07 128.22 5.57 Favored Glycine 0 C--O 1.241 0.536 0 C-N-CA 121.09 -0.576 . . . . 0.0 111.811 -178.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.623 ' CD2' ' CZ ' ' A' ' 19' ' ' PHE . 4.0 mp -141.5 142.57 33.58 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-O 122.249 1.023 . . . . 0.0 111.277 178.659 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.428 ' SD ' ' HB ' ' J' ' 31' ' ' ILE . 29.3 tpp -100.87 113.6 26.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 113.574 -1.648 . . . . 0.0 108.448 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.55 74.0 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.302 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.113 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.96 111.21 1.82 Allowed Glycine 0 C--N 1.358 1.793 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.17 -170.28 0.15 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m -133.85 160.62 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.815 0.34 . . . . 0.0 110.791 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.562 179.845 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -101.47 129.12 47.46 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.993 0.425 . . . . 0.0 110.539 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.88 138.86 28.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.84 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.1 t -126.36 132.77 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.904 0.383 . . . . 0.0 110.329 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 t-80 -143.95 112.57 6.55 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.564 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -128.81 173.01 10.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -151.1 175.93 11.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.709 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -167.85 108.25 0.57 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.05 0.452 . . . . 0.0 110.686 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.0 tt -124.84 127.35 47.02 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.707 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.13 128.84 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -119.61 119.97 35.33 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -128.18 121.96 30.73 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-O 120.909 0.385 . . . . 0.0 110.273 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.5 133.33 43.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.994 0.426 . . . . 0.0 111.52 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -137.74 123.78 20.28 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.554 -0.458 . . . . 0.0 109.831 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -84.77 114.82 22.34 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.062 0.458 . . . . 0.0 111.181 -178.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' E' ' 26' ' ' SER . 53.8 t -95.78 130.81 43.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.68 -85.07 0.01 OUTLIER Glycine 0 CA--C 1.535 1.289 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' E' ' 24' ' ' VAL . 12.6 t -153.0 174.29 14.35 Favored 'General case' 0 C--N 1.347 0.46 0 CA-C-N 118.897 1.348 . . . . 0.0 112.995 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.666 ' ND2' ' H ' ' D' ' 27' ' ' ASN . 12.9 p-10 -19.01 160.24 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 116.761 2.134 . . . . 0.0 116.761 178.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.706 ' NZ ' ' H ' ' C' ' 23' ' ' ASP . 80.9 tttt -170.14 105.55 0.31 Allowed 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 174.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.589 ' O ' ' HA ' ' F' ' 30' ' ' ALA . . . -49.99 -97.84 0.01 OUTLIER Glycine 0 N--CA 1.469 0.9 0 C-N-CA 118.664 -1.731 . . . . 0.0 111.299 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . 74.07 143.71 0.07 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.43 HG13 ' O ' ' D' ' 30' ' ' ALA . 0.0 OUTLIER -150.78 118.11 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.08 -178.471 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 4.5 tt -117.44 128.31 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 CA-C-O 121.329 0.585 . . . . 0.0 111.255 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 99.7 0.7 Allowed Glycine 0 N--CA 1.451 -0.331 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 178.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 37.6 tp -115.58 116.39 28.06 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.551 ' CE ' ' SD ' ' F' ' 35' ' ' MET . 0.4 OUTLIER -91.76 111.63 23.24 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.976 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' O ' ' E' ' 36' ' ' VAL . 2.0 t -138.4 66.56 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -54.84 -103.53 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.44 169.01 34.51 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -140.67 140.85 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.064 -0.969 . . . . 0.0 110.357 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -84.3 139.92 31.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.04 0.448 . . . . 0.0 110.887 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -60.7 149.85 34.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.911 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.14 131.44 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.851 179.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.508 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -151.26 130.05 12.4 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.417 -179.868 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.402 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 80.6 m80 -155.82 178.29 10.43 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -139.72 177.87 7.64 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.248 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -155.12 115.9 3.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.336 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.44 128.01 42.07 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.17 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 99.8 t -129.63 130.94 67.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.7 p90 -132.32 128.52 37.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.887 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.6 t80 -138.82 125.37 20.63 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.46 146.3 30.51 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.681 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -124.15 95.68 4.64 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 178.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -108.3 114.57 28.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.909 -178.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' F' ' 26' ' ' SER . 43.9 t -63.49 130.92 28.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 107.141 -1.429 . . . . 0.0 107.141 178.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.32 84.37 0.01 OUTLIER Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.352 -0.928 . . . . 0.0 112.866 -176.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.559 ' O ' ' O ' ' F' ' 27' ' ' ASN . 2.8 p 170.68 175.59 0.06 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 114.902 -0.649 . . . . 0.0 109.486 176.304 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.611 ' CG ' ' H ' ' F' ' 28' ' ' LYS . 65.0 t30 -29.15 179.29 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 115.587 1.699 . . . . 0.0 115.587 178.695 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.611 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 33.1 tttm 129.07 102.33 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.937 0 C-N-CA 128.826 2.85 . . . . 0.0 108.455 174.697 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.64 -99.88 0.01 OUTLIER Glycine 0 C--N 1.348 1.214 0 CA-C-O 124.622 2.235 . . . . 0.0 114.143 174.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.589 ' HA ' ' O ' ' E' ' 29' ' ' GLY . . . 70.18 143.36 0.05 Allowed 'General case' 0 CA--C 1.503 -0.839 0 CA-C-N 108.575 -3.812 . . . . 0.0 107.208 177.062 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.422 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.0 OUTLIER -160.06 125.05 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 122.538 2.427 . . . . 0.0 113.399 -179.711 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 87.7 mt -107.78 117.74 54.05 Favored 'Isoleucine or valine' 0 C--N 1.355 0.83 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.951 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.53 91.06 0.55 Allowed Glycine 0 N--CA 1.452 -0.245 0 N-CA-C 109.061 -1.615 . . . . 0.0 109.061 177.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.441 ' CD2' ' CZ ' ' C' ' 19' ' ' PHE . 3.1 tp -114.22 116.18 28.63 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.628 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 2.2 mtp -88.34 114.26 24.78 Favored 'General case' 0 CA--C 1.48 -1.735 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 p -139.63 74.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 105.775 -1.935 . . . . 0.0 105.775 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.32 104.85 2.64 Favored Glycine 0 C--N 1.356 1.667 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.03 -179.43 26.37 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -134.76 138.07 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.692 0.282 . . . . 0.0 111.03 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 N--CA 1.469 0.52 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.538 179.584 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -119.51 142.59 48.16 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -152.43 123.56 7.59 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.416 0.626 . . . . 0.0 111.578 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -150.21 146.29 16.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.498 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -151.93 140.97 21.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.077 0.465 . . . . 0.0 110.815 179.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -134.64 163.74 29.07 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -150.53 171.34 17.24 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.528 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -156.2 128.98 7.84 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 5.8 mp -122.15 124.6 44.26 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 110.218 179.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 5.4 p -121.67 120.46 61.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -117.12 103.16 9.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -122.37 121.5 36.84 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.93 123.75 48.86 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.862 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -158.3 155.53 28.99 Favored 'General case' 0 CA--C 1.528 0.122 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -88.25 120.9 30.05 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.116 0.484 . . . . 0.0 112.289 -178.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.569 ' O ' ' N ' ' G' ' 26' ' ' SER . 88.1 t -100.97 124.03 54.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.63 83.49 0.0 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-O 120.052 -0.305 . . . . 0.0 112.985 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.569 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.1 m -97.46 174.78 6.5 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.269 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 22.8 p30 -59.22 164.38 3.21 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.196 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -57.23 111.53 1.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.779 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.402 ' H ' ' HE3' ' H' ' 28' ' ' LYS . . . 72.38 93.49 0.09 OUTLIER Glycine 0 N--CA 1.466 0.681 0 C-N-CA 119.678 -1.249 . . . . 0.0 111.315 177.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.55 157.51 19.56 Favored 'General case' 0 CA--C 1.51 -0.595 0 C-N-CA 118.426 -1.31 . . . . 0.0 108.847 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -153.04 117.35 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.776 -173.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.485 ' O ' ' SD ' ' A' ' 35' ' ' MET . 18.0 tt -135.58 129.47 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.064 179.543 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.88 116.9 1.96 Allowed Glycine 0 N--CA 1.466 0.639 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 76.5 mt -137.33 148.77 46.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 121.681 0.753 . . . . 0.0 112.289 -178.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 ttt -139.3 135.8 34.19 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.196 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' G' ' 37' ' ' GLY . 9.5 t -141.53 81.27 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' G' ' 36' ' ' VAL . . . -26.89 -94.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 O-C-N 123.337 0.398 . . . . 0.0 112.773 178.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.13 -157.84 30.5 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 71.8 t -98.86 133.49 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.847 0.356 . . . . 0.0 110.24 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.731 -179.395 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -145.0 159.5 42.84 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.788 0.327 . . . . 0.0 110.522 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.536 ' CD ' ' HE2' ' H' ' 13' ' ' HIS . 82.5 tt0 -134.73 145.54 48.56 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.835 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.48 133.17 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 116.793 -0.185 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.536 ' HE2' ' CD ' ' H' ' 11' ' ' GLU . 80.9 m-70 -137.31 143.58 42.18 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.837 0.351 . . . . 0.0 111.307 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.506 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 86.3 t60 -146.92 162.08 39.43 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.448 0.642 . . . . 0.0 110.307 178.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.506 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 42.4 tt0 -156.72 174.62 15.21 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -162.71 125.47 2.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.892 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 tt -125.62 121.79 34.55 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.982 0.42 . . . . 0.0 110.533 179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 56.6 t -120.36 126.16 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.876 179.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 29.5 t80 -121.93 111.91 17.66 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -130.38 126.23 36.55 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.34 128.64 51.27 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.238 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.24 149.1 40.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.643 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.51 ' O ' ' NZ ' ' J' ' 28' ' ' LYS . 53.2 t0 -155.79 121.1 4.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.575 ' CG2' ' N ' ' H' ' 25' ' ' GLY . 2.6 p -133.87 -112.01 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.575 ' N ' ' CG2' ' H' ' 24' ' ' VAL . . . 32.86 -90.26 0.01 OUTLIER Glycine 0 CA--C 1.53 1.016 0 CA-C-N 115.97 -0.559 . . . . 0.0 112.362 -178.085 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.661 ' O ' ' O ' ' H' ' 27' ' ' ASN . 1.6 t 171.61 178.72 0.07 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 117.622 0.711 . . . . 0.0 109.984 -179.519 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.661 ' O ' ' O ' ' H' ' 26' ' ' SER . 9.4 t-20 -28.57 179.59 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 O-C-N 125.07 1.481 . . . . 0.0 114.259 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.555 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 87.0 tttt 128.43 105.18 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 124.359 1.064 . . . . 0.0 111.763 178.356 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.86 96.27 0.05 OUTLIER Glycine 0 N--CA 1.47 0.948 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.08 146.6 47.04 Favored 'General case' 0 C--O 1.253 1.288 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 177.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -140.04 119.61 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.281 0 CA-C-N 113.02 -1.9 . . . . 0.0 110.697 -171.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -126.96 122.73 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.767 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.17 118.64 2.18 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -137.3 129.97 30.1 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.456 0.646 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.452 ' SD ' ' C ' ' B' ' 32' ' ' ILE . 13.2 ttt -124.47 124.91 43.33 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.247 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.427 ' O ' ' C ' ' H' ' 37' ' ' GLY . 34.5 m -136.08 81.24 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -29.14 -93.47 0.01 OUTLIER Glycine 0 CA--C 1.529 0.925 0 CA-C-N 116.488 -0.324 . . . . 0.0 112.489 178.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.09 -161.86 28.66 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.7 m -120.51 134.79 62.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 120.657 0.265 . . . . 0.0 110.39 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.442 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . 0.52 ' CD1' ' OE2' ' J' ' 11' ' ' GLU . 89.5 m-85 -108.41 145.21 34.93 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.69 0.281 . . . . 0.0 110.322 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -122.63 147.12 46.8 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.905 0.383 . . . . 0.0 110.694 -179.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m -119.03 133.13 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.98 -0.554 . . . . 0.0 109.647 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.54 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 49.3 p-80 -155.86 161.62 40.57 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.147 -0.621 . . . . 0.0 112.303 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 7.2 m-70 -141.37 162.78 34.66 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.45 179.097 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -150.54 175.36 11.97 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.858 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -155.26 130.53 9.61 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.989 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.4 mt -124.39 118.74 27.39 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -123.62 128.44 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.56 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.648 ' CD2' ' CZ ' ' J' ' 19' ' ' PHE . 27.7 t80 -128.01 116.23 19.72 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -127.89 130.32 48.33 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-O 120.703 0.287 . . . . 0.0 110.941 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.14 125.78 32.09 Favored 'General case' 0 C--O 1.243 0.718 0 CA-C-O 121.444 0.64 . . . . 0.0 112.067 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -145.08 158.34 43.85 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.553 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.545 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.9 p-10 -173.96 121.88 0.31 Allowed 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 -179.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' I' ' 26' ' ' SER . 11.5 t -124.0 -111.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.222 -178.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.18 -90.75 0.01 OUTLIER Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -177.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.563 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.7 p 171.39 169.37 0.09 Allowed 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 177.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.563 ' O ' ' O ' ' I' ' 26' ' ' SER . 21.3 t-20 -19.49 155.8 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 179.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.542 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 73.5 tttt -170.69 106.57 0.28 Allowed 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.676 173.718 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.66 93.16 0.01 OUTLIER Glycine 0 C--O 1.227 -0.335 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 174.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -142.04 145.38 34.32 Favored 'General case' 0 CA--C 1.486 -1.504 0 CA-C-N 119.167 1.483 . . . . 0.0 107.889 177.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.8 117.28 10.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.349 -177.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' I' ' 32' ' ' ILE . 0.4 OUTLIER -107.82 116.63 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.68 100.61 0.8 Allowed Glycine 0 CA--C 1.496 -1.133 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 5.3 tt -130.49 125.33 34.09 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 118.824 -1.151 . . . . 0.0 110.252 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.461 ' SD ' ' CG2' ' C' ' 31' ' ' ILE . 28.3 ttm -115.56 117.11 29.42 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.176 -1.375 . . . . 0.0 109.01 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.97 75.29 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.681 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.431 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -29.63 -97.29 0.01 OUTLIER Glycine 0 C--N 1.354 1.543 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.843 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.75 -164.54 28.5 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.82 146.91 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 110.027 -0.361 . . . . 0.0 110.027 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.73 -179.79 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.173 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -105.21 129.45 53.58 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 120.901 0.382 . . . . 0.0 110.615 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.52 ' OE2' ' CD1' ' I' ' 10' ' ' TYR . 97.6 mt-10 -127.95 127.14 42.77 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.228 179.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 t -141.64 134.18 28.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -149.61 133.54 17.04 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.479 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 1.5 t-80 -151.64 159.2 44.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.633 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 49.6 tt0 -160.58 169.5 22.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.419 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -151.08 128.79 11.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 14.2 tp -126.33 114.55 18.39 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 64.6 t -119.51 126.76 75.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.981 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.648 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 1.5 t80 -120.19 119.35 32.97 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.51 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 56.4 t80 -132.84 126.36 32.08 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.611 0.243 . . . . 0.0 110.849 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.84 26.58 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 119.848 -0.741 . . . . 0.0 112.47 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -125.58 143.89 50.82 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.151 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -130.04 110.85 11.96 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 177.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.554 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 14.0 t -139.39 -123.51 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.589 -178.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.554 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . 27.5 -83.92 0.0 OUTLIER Glycine 0 C--N 1.342 0.879 0 CA-C-N 114.947 -1.024 . . . . 0.0 112.406 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.635 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.2 p 170.48 170.42 0.07 Allowed 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 178.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.635 ' O ' ' O ' ' J' ' 26' ' ' SER . 76.3 m-20 -18.37 157.58 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 O-C-N 124.375 1.047 . . . . 0.0 113.064 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.574 ' O ' ' O ' ' K' ' 29' ' ' GLY . 81.0 tttt -161.79 110.9 1.52 Allowed 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.573 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -67.45 92.49 0.22 Allowed Glycine 0 C--N 1.32 -0.333 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.06 149.17 22.84 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 177.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.472 ' CD1' ' N ' ' J' ' 31' ' ' ILE . 0.0 OUTLIER -144.81 122.56 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 C-N-CA 119.201 -1.0 . . . . 0.0 111.505 -176.946 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 4.2 mt -108.94 119.56 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-N 114.975 -1.012 . . . . 0.0 109.826 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.42 112.91 2.48 Favored Glycine 0 C--N 1.336 0.567 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 177.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -143.72 135.0 25.85 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.126 0.965 . . . . 0.0 113.015 -177.586 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 98.7 mmm -112.63 111.19 21.82 Favored 'General case' 0 CA--C 1.504 -0.79 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.032 177.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.25 62.39 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.34 -111.49 0.13 Allowed Glycine 0 C--N 1.356 1.642 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.771 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.35 142.83 7.04 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 11.6 p -142.08 151.82 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 m . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.402 179.806 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -113.48 132.28 55.72 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.718 0.294 . . . . 0.0 110.442 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -129.9 127.71 40.72 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.918 0.389 . . . . 0.0 110.936 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.55 132.74 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -150.64 131.84 14.48 Favored 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.054 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' CE1' ' J' ' 14' ' ' HIS . 50.3 t-80 -152.93 165.01 36.85 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.174 0.511 . . . . 0.0 109.842 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 80.8 mt-30 -156.88 179.85 8.89 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.325 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -170.3 120.08 0.59 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.327 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 31.4 tp -119.98 123.99 44.85 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.549 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 65.0 t -130.03 121.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.551 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -118.67 120.62 37.96 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.51 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 48.6 t80 -129.01 121.26 27.56 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.998 0.428 . . . . 0.0 111.592 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.19 129.36 41.61 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.494 178.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -124.49 143.2 50.79 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 121.417 0.627 . . . . 0.0 112.323 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -131.55 123.7 28.51 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.974 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.435 ' CG1' ' N ' ' K' ' 25' ' ' GLY . 57.7 t -96.15 -112.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.667 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.435 ' N ' ' CG1' ' K' ' 24' ' ' VAL . . . -46.96 -91.04 0.01 OUTLIER Glycine 0 CA--C 1.526 0.765 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.456 -176.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.605 ' O ' ' O ' ' K' ' 27' ' ' ASN . 34.9 p -152.98 -172.63 4.31 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 117.611 0.705 . . . . 0.0 110.444 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.605 ' O ' ' O ' ' K' ' 26' ' ' SER . 54.7 t30 -19.86 158.05 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.65 0 O-C-N 124.997 1.436 . . . . 0.0 113.724 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.454 ' O ' ' HA ' ' L' ' 30' ' ' ALA . 87.1 tttt -161.6 111.08 1.57 Allowed 'General case' 0 C--O 1.213 -0.823 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.839 176.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.574 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -67.92 92.39 0.24 Allowed Glycine 0 N--CA 1.475 1.276 0 CA-C-O 119.376 -0.68 . . . . 0.0 113.553 177.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -156.87 152.82 27.28 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 103.523 -2.769 . . . . 0.0 103.523 174.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.436 ' HB ' ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -149.62 116.16 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.857 0 C-N-CA 116.714 -1.994 . . . . 0.0 113.407 -171.844 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.428 ' C ' ' CE ' ' E' ' 35' ' ' MET . 62.7 mt -104.55 118.3 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.91 177.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . 0.413 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.06 104.19 1.32 Allowed Glycine 0 C--O 1.237 0.319 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 177.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.578 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 8.4 tt -139.54 132.7 29.71 Favored 'General case' 0 C--O 1.243 0.734 0 CA-C-O 122.835 1.302 . . . . 0.0 112.876 -177.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CG ' ' L' ' 35' ' ' MET . 95.9 mmm -107.17 118.43 36.69 Favored 'General case' 0 CA--C 1.505 -0.767 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.53 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.46 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -124.24 74.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.911 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.46 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -17.43 -101.93 0.0 OUTLIER Glycine 0 C--N 1.359 1.855 0 O-C-N 123.868 0.73 . . . . 0.0 113.031 -179.249 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.17 -161.9 30.28 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 74.4 t -124.08 138.39 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-O 120.751 0.31 . . . . 0.0 110.611 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.436 179.495 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -82.23 134.68 35.3 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.856 0.36 . . . . 0.0 110.48 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.42 143.68 33.83 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.519 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 50.4 t -121.68 132.92 69.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.063 0.459 . . . . 0.0 110.222 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 21.3 p-80 -164.12 110.43 1.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.479 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -144.85 169.04 18.8 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -151.72 175.64 12.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.126 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -153.34 123.89 7.18 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.346 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 64.4 mt -120.6 114.8 22.25 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -128.5 130.39 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.966 0.412 . . . . 0.0 110.54 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.506 ' CD1' ' O ' ' L' ' 19' ' ' PHE . 55.4 p90 -138.19 127.69 24.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -134.28 127.3 31.53 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.217 0.532 . . . . 0.0 110.746 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.61 134.48 32.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.771 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -110.19 109.77 20.38 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.644 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 42.7 t0 -99.16 133.84 42.87 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.188 0.518 . . . . 0.0 109.961 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' L' ' 26' ' ' SER . 90.5 t -107.02 112.97 42.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.394 -179.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 35.3 -91.22 0.01 OUTLIER Glycine 0 CA--C 1.528 0.88 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.873 -179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.448 ' N ' ' O ' ' L' ' 24' ' ' VAL . 13.4 p -62.49 -177.83 0.16 Allowed 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 117.571 0.685 . . . . 0.0 110.342 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -79.52 176.63 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.855 -1.066 . . . . 0.0 113.697 -177.166 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 35.7 tttp -48.51 111.1 0.41 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 113.835 -1.53 . . . . 0.0 112.947 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.41 -97.91 0.04 OUTLIER Glycine 0 CA--C 1.501 -0.808 0 CA-C-N 114.542 -1.208 . . . . 0.0 110.606 -178.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' K' ' 28' ' ' LYS . . . -60.84 170.87 1.34 Allowed 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 119.882 1.841 . . . . 0.0 106.135 -178.121 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -139.87 118.88 12.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 117.799 -1.56 . . . . 0.0 110.629 -172.71 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.541 ' C ' ' SD ' ' F' ' 35' ' ' MET . 67.2 mt -108.92 123.74 65.01 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 CA-C-N 114.398 -1.274 . . . . 0.0 109.09 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . 0.628 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -101.66 89.26 0.76 Allowed Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 105.477 -3.049 . . . . 0.0 105.477 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -108.57 112.89 25.48 Favored 'General case' 0 CA--C 1.502 -0.897 0 CA-C-O 120.684 0.278 . . . . 0.0 110.27 -177.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.505 ' CG ' ' SD ' ' K' ' 35' ' ' MET . 93.9 mmm -105.48 110.4 22.73 Favored 'General case' 0 CA--C 1.503 -0.846 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.169 179.428 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 m -128.7 79.42 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.5 103.68 0.52 Allowed Glycine 0 C--N 1.346 1.098 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.6 -161.06 36.9 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.7 m -133.15 160.91 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 120.966 0.412 . . . . 0.0 110.607 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 14.1 m . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.37 179.794 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -100.4 133.7 44.44 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.495 ' N ' ' OE1' ' A' ' 11' ' ' GLU . 54.6 mp0 -95.18 164.0 13.05 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.034 0.445 . . . . 0.0 110.643 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.31 131.6 56.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -93.6 135.5 34.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.761 0.315 . . . . 0.0 110.648 -179.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.554 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 75.2 t60 -152.21 164.09 38.08 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 44.9 tt0 -169.04 168.75 9.92 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.419 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.418 ' N ' ' CG ' ' A' ' 15' ' ' GLN . 66.5 mttm -153.75 123.72 6.86 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -119.59 114.12 21.75 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.179 0.514 . . . . 0.0 110.466 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 70.5 t -120.34 115.44 47.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.147 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.535 ' CD2' ' CE2' ' B' ' 19' ' ' PHE . 23.7 t80 -115.65 110.45 19.19 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 50.0 p90 -125.74 124.29 40.71 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.43 120.68 43.1 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.817 0.341 . . . . 0.0 110.357 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -159.65 115.32 2.46 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -74.89 121.85 22.5 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.96 0.409 . . . . 0.0 111.697 -178.553 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 26' ' ' SER . 13.9 t -84.48 124.6 39.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.06 84.3 0.01 OUTLIER Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.989 -178.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 24' ' ' VAL . 20.7 p -91.41 -179.76 5.47 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 178.175 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.43 179.13 0.17 Allowed 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 119.656 -0.817 . . . . 0.0 110.722 -179.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -59.5 111.11 1.28 Allowed 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.66 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.23 93.81 0.09 OUTLIER Glycine 0 N--CA 1.464 0.501 0 C-N-CA 120.169 -1.015 . . . . 0.0 112.214 177.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.24 156.14 21.92 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 176.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.432 HG22 HD11 ' A' ' 31' ' ' ILE . 0.2 OUTLIER -151.86 119.67 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.0 -173.248 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.455 ' C ' ' SD ' ' G' ' 35' ' ' MET . 5.9 tp -149.59 131.58 5.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.154 179.416 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.415 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.67 128.86 5.82 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -129.65 129.63 44.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.314 0.578 . . . . 0.0 110.606 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.517 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 27.9 ttt -130.81 129.23 42.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.552 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.6 t -84.46 75.99 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.979 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -90.51 103.36 3.02 Favored Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 178.731 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.45 179.95 52.43 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.57 163.7 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.492 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 46.9 t . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.488 179.798 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -98.14 127.17 43.93 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -67.33 127.4 32.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.267 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 70.8 t -134.06 136.67 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.039 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.458 ' H ' ' HA ' ' C' ' 12' ' ' VAL . 61.7 t-80 -122.46 118.73 29.02 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.861 0.363 . . . . 0.0 110.198 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.489 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 80.8 t60 -132.8 163.83 28.18 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.489 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 1.6 pt20 -169.93 177.6 4.3 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.981 179.174 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -156.28 125.96 6.33 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -122.23 121.2 36.27 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 7.1 p -134.18 130.79 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.535 ' CE2' ' CD2' ' A' ' 19' ' ' PHE . 18.2 t80 -115.29 117.58 30.85 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -129.14 129.22 44.86 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.716 0.293 . . . . 0.0 111.423 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.8 123.37 37.21 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 120.616 -0.433 . . . . 0.0 111.652 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 41.0 tp10 -164.74 105.1 0.82 Allowed 'General case' 0 C--N 1.343 0.283 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.553 ' O ' ' O ' ' B' ' 24' ' ' VAL . 42.6 t0 -104.67 112.1 25.06 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.553 ' O ' ' O ' ' B' ' 23' ' ' ASP . 2.1 t -50.27 -133.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.745 178.042 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -95.35 -84.95 1.68 Allowed Glycine 0 CA--C 1.536 1.403 0 CA-C-N 115.933 -0.576 . . . . 0.0 113.276 -178.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 35.0 t 68.51 178.83 0.24 Allowed 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -177.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -89.88 168.27 12.18 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 118.456 -1.298 . . . . 0.0 112.513 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 45.9 pttt -40.92 110.57 0.16 Allowed 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 177.101 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.427 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 80.0 94.54 0.37 Allowed Glycine 0 N--CA 1.476 1.329 0 N-CA-C 116.892 1.517 . . . . 0.0 116.892 171.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.25 152.91 37.08 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 171.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.36 117.72 2.27 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.721 -174.308 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -127.05 131.57 70.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.029 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.31 119.59 3.45 Favored Glycine 0 N--CA 1.475 1.239 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 59.3 tp -127.45 126.24 41.97 Favored 'General case' 0 N--CA 1.47 0.527 0 O-C-N 122.287 -0.537 . . . . 0.0 110.885 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.518 ' SD ' ' O ' ' H' ' 32' ' ' ILE . 11.9 ttt -139.6 137.75 35.59 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.348 0.594 . . . . 0.0 111.481 179.525 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 24.4 t -122.51 73.88 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.845 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' B' ' 38' ' ' GLY . . . -62.85 111.95 4.52 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 178.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -26.66 148.53 0.01 OUTLIER Glycine 0 N--CA 1.469 0.871 0 CA-C-O 121.107 0.282 . . . . 0.0 112.676 -178.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 68.1 t -115.29 135.58 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 m . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.381 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -114.22 138.59 50.27 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.781 0.324 . . . . 0.0 110.592 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.448 ' OE2' ' O ' ' D' ' 10' ' ' TYR . 80.0 mm-40 -110.75 131.28 55.18 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.146 0.498 . . . . 0.0 110.538 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.458 ' HA ' ' H ' ' B' ' 13' ' ' HIS . 28.3 m -136.11 164.17 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.473 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.733 ' CG ' ' H ' ' C' ' 14' ' ' HIS . 76.0 t60 -103.15 -173.48 2.32 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.733 ' H ' ' CG ' ' C' ' 13' ' ' HIS . 2.3 m170 -77.2 174.13 11.08 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.89 174.83 10.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.414 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -151.51 133.37 14.98 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.937 0.398 . . . . 0.0 111.731 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.409 ' CD2' ' C ' ' C' ' 17' ' ' LEU . 6.6 tt -127.62 123.2 35.06 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.578 178.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.5 t -128.04 129.52 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 CA-C-O 120.912 0.387 . . . . 0.0 111.648 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -121.7 115.21 22.3 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -127.45 125.79 41.18 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.92 0.39 . . . . 0.0 111.083 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.2 129.52 46.58 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.87 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 80.5 tt0 -155.97 158.39 37.82 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.938 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -142.8 120.65 11.97 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.57 0.224 . . . . 0.0 110.624 179.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -129.88 -112.19 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-O 121.308 0.575 . . . . 0.0 110.13 -179.235 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.428 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 35.07 -90.68 0.01 OUTLIER Glycine 0 CA--C 1.531 1.054 0 CA-C-N 115.337 -0.847 . . . . 0.0 114.084 -178.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.0 OUTLIER 175.28 -167.21 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 118.396 1.098 . . . . 0.0 110.793 -178.582 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' C' ' 26' ' ' SER . 51.4 p-10 -36.47 -179.62 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.164 -1.38 . . . . 0.0 113.641 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.494 ' HB3' ' O ' ' C' ' 27' ' ' ASN . 74.8 tttt 98.55 113.88 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.958 1.703 . . . . 0.0 113.182 179.047 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.88 93.64 0.49 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 172.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.2 163.07 12.88 Favored 'General case' 0 CA--C 1.498 -1.047 0 CA-C-N 120.74 2.27 . . . . 0.0 106.461 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -149.72 117.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 118.337 -1.345 . . . . 0.0 110.417 -174.113 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.485 ' C ' ' SD ' ' I' ' 35' ' ' MET . 13.5 tt -129.13 132.84 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 CA-C-O 121.736 0.779 . . . . 0.0 110.747 178.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -119.71 119.34 4.22 Favored Glycine 0 N--CA 1.465 0.612 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.494 ' CD2' ' CZ ' ' A' ' 19' ' ' PHE . 32.6 tp -118.67 121.86 41.14 Favored 'General case' 0 CA--C 1.512 -0.516 0 C-N-CA 120.986 -0.285 . . . . 0.0 111.743 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.522 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 7.9 ttm -122.05 108.98 14.0 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 173.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 m -128.75 72.37 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 120.543 -0.463 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.0 110.81 3.11 Favored Glycine 0 C--N 1.362 1.993 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.13 160.07 53.93 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -139.06 161.43 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.871 0.367 . . . . 0.0 111.051 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.398 179.64 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . 0.448 ' O ' ' OE2' ' C' ' 11' ' ' GLU . 95.7 m-85 -106.83 129.66 54.64 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.499 ' OE2' ' NE2' ' D' ' 13' ' ' HIS . 9.9 pt-20 -155.06 159.23 40.12 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 70.0 t -114.52 131.7 65.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.026 0.441 . . . . 0.0 110.935 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.499 ' NE2' ' OE2' ' D' ' 11' ' ' GLU . 32.5 m-70 -138.39 97.83 3.46 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.167 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.504 ' HE2' ' CG1' ' E' ' 12' ' ' VAL . 38.6 m170 -119.98 161.93 20.07 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.41 0.624 . . . . 0.0 109.583 179.467 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.429 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 43.9 tt0 -154.32 170.33 21.56 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.804 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . 0.429 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.3 mttt -152.95 129.33 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.364 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -123.23 124.24 42.57 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.715 0.293 . . . . 0.0 110.643 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -123.63 126.77 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.085 0.469 . . . . 0.0 110.508 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.44 ' CZ ' ' CD2' ' F' ' 34' ' ' LEU . 7.7 t80 -124.69 110.55 14.51 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -123.13 129.85 51.99 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.522 0.677 . . . . 0.0 111.778 -178.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.93 122.19 26.5 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.497 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 79.6 mm-40 -115.86 120.33 38.87 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -151.51 112.0 4.17 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 -179.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.695 ' O ' ' N ' ' D' ' 26' ' ' SER . 52.1 t -111.96 131.07 64.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 102.572 -3.121 . . . . 0.0 102.572 174.125 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.663 ' N ' ' HZ1' ' F' ' 28' ' ' LYS . . . -37.59 81.67 0.0 OUTLIER Glycine 0 CA--C 1.534 1.256 0 C-N-CA 120.172 -1.014 . . . . 0.0 112.569 -176.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.695 ' N ' ' O ' ' D' ' 24' ' ' VAL . 26.8 m -88.48 -179.58 6.1 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-O 122.566 1.174 . . . . 0.0 111.612 178.356 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.416 ' CG ' ' H ' ' D' ' 28' ' ' LYS . 48.6 t30 -76.61 -177.13 4.07 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.921 175.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.416 ' H ' ' CG ' ' D' ' 27' ' ' ASN . 35.1 tttt 44.96 111.62 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 117.959 2.577 . . . . 0.0 117.959 177.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.465 ' CA ' ' O ' ' E' ' 29' ' ' GLY . . . -82.64 94.66 1.74 Allowed Glycine 0 CA--C 1.499 -0.957 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 173.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.24 167.36 12.38 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.42 118.29 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.623 -174.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 14.4 tt -130.13 130.88 66.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-O 121.828 0.823 . . . . 0.0 111.942 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.8 104.27 2.35 Favored Glycine 0 CA--C 1.509 -0.338 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 177.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.478 ' CD2' ' CZ ' ' B' ' 19' ' ' PHE . 16.6 tp -111.33 117.85 34.26 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 117.376 0.588 . . . . 0.0 111.945 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 17.7 tpp -121.08 108.01 13.31 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 176.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -121.04 76.51 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.951 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.04 103.31 2.85 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.16 174.33 41.96 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -135.4 160.62 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 121.047 0.451 . . . . 0.0 110.755 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.177 -0.916 . . . . 0.0 110.366 179.578 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -120.26 143.78 48.12 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.815 0.34 . . . . 0.0 110.332 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.523 ' OE1' ' CE1' ' F' ' 10' ' ' TYR . 82.5 tt0 -73.23 135.15 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.84 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.504 ' CG1' ' HE2' ' D' ' 14' ' ' HIS . 8.4 t -146.74 135.62 16.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.108 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -132.54 131.7 41.83 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.638 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 24.2 t60 -152.08 163.6 38.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 121.922 0.868 . . . . 0.0 110.446 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.638 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 53.5 tt0 -159.55 167.11 29.35 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.496 178.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . 0.501 ' CG ' ' HE2' ' E' ' 14' ' ' HIS . 99.2 mttt -151.44 130.11 12.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 179.432 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.5 mt -115.52 116.18 27.74 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.52 115.34 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.099 -179.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -117.03 124.43 49.29 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 116.78 -0.191 . . . . 0.0 110.756 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -129.94 119.09 22.68 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.65 121.13 22.7 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.231 0.539 . . . . 0.0 111.425 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 35.0 tt0 -88.52 165.63 14.73 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.7 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.563 ' O ' ' O ' ' E' ' 24' ' ' VAL . 46.0 t0 -145.4 -122.27 0.08 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.002 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.563 ' O ' ' O ' ' E' ' 23' ' ' ASP . 2.9 t 22.22 121.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 -178.707 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.08 -85.0 0.09 OUTLIER Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 177.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.492 ' H ' ' CE ' ' F' ' 28' ' ' LYS . 1.7 p 162.39 160.8 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 177.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.455 ' O ' ' O ' ' E' ' 26' ' ' SER . 69.6 m-80 -29.78 159.42 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.694 178.087 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.447 ' HD2' ' H ' ' D' ' 26' ' ' SER . 76.1 tttt -179.73 105.84 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 174.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.465 ' O ' ' CA ' ' D' ' 29' ' ' GLY . . . -58.65 93.54 0.05 OUTLIER Glycine 0 C--O 1.211 -1.323 0 CA-C-O 118.16 -1.356 . . . . 0.0 111.708 173.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -155.9 149.37 24.82 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 103.1 -2.926 . . . . 0.0 103.1 173.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -145.05 124.3 6.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 C-N-CA 117.984 -1.486 . . . . 0.0 112.133 -168.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.437 ' CG2' ' O ' ' E' ' 32' ' ' ILE . 0.7 OUTLIER -120.91 111.29 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 CA-C-N 114.529 -1.214 . . . . 0.0 107.761 179.541 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.57 110.24 3.62 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 mt -117.97 112.76 20.72 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -176.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' K' ' 32' ' ' ILE . 6.2 ttm -115.29 107.91 15.87 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 175.419 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.16 80.97 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.23 102.64 0.5 Allowed Glycine 0 C--N 1.346 1.116 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -86.67 -160.22 34.35 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.31 160.47 33.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.185 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.5 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.689 -179.993 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.43 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . 0.523 ' CE1' ' OE1' ' E' ' 11' ' ' GLU . 41.8 t80 -78.89 125.42 29.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.073 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' E' ' 11' ' ' GLU . 78.6 mm-40 -118.54 132.48 56.21 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.158 0.504 . . . . 0.0 110.988 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.408 ' CG2' ' N ' ' F' ' 13' ' ' HIS . 1.5 p -147.82 160.23 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.434 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.568 ' ND1' ' ND1' ' E' ' 14' ' ' HIS . 15.2 t-80 -125.02 155.27 39.98 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 120.912 0.387 . . . . 0.0 110.595 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.558 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 89.9 m-70 -80.42 178.28 8.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -125.93 -179.88 4.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.364 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -133.62 137.58 45.5 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.161 0.505 . . . . 0.0 110.993 -179.599 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 33.1 mt -122.03 115.17 22.02 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.276 -179.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 28.5 m -134.04 127.64 51.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.341 0.591 . . . . 0.0 110.092 178.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.495 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 50.0 p90 -138.69 131.52 29.39 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.575 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -129.79 122.27 28.45 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.6 146.24 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.422 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -115.78 125.9 53.33 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.217 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -168.12 113.45 0.66 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.978 178.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.498 ' O ' ' N ' ' F' ' 26' ' ' SER . 95.6 t -81.1 132.44 31.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.978 178.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.16 -85.58 0.01 OUTLIER Glycine 0 CA--C 1.523 0.558 0 C-N-CA 119.338 -1.41 . . . . 0.0 111.702 178.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' F' ' 27' ' ' ASN . 62.3 m -140.38 171.4 14.2 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -178.332 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' F' ' 26' ' ' SER . 25.0 m120 -29.66 169.98 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 122.79 1.281 . . . . 0.0 114.23 -174.444 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.663 ' HZ1' ' N ' ' D' ' 25' ' ' GLY . 30.6 tttt -98.54 -111.17 0.17 Allowed 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 113.881 -1.509 . . . . 0.0 112.476 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.535 ' H ' ' CG ' ' F' ' 28' ' ' LYS . . . -90.6 -99.85 1.18 Allowed Glycine 0 CA--C 1.484 -1.883 0 C-N-CA 127.568 2.509 . . . . 0.0 111.76 -179.509 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.66 166.46 3.24 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 105.838 -1.912 . . . . 0.0 105.838 -177.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -132.61 135.71 57.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.34 -171.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 61.4 mt -114.87 117.24 55.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 CA-C-N 115.198 -0.91 . . . . 0.0 112.646 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.69 92.58 1.23 Allowed Glycine 0 CA--C 1.51 -0.244 0 N-CA-C 104.51 -3.436 . . . . 0.0 104.51 173.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.44 ' CD2' ' CZ ' ' D' ' 19' ' ' PHE . 8.4 tp -110.3 116.77 32.07 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.346 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.403 ' HG3' ' CA ' ' L' ' 33' ' ' GLY . 96.4 mmm -119.58 111.98 18.75 Favored 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 176.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -127.36 80.22 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.075 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 34.47 -103.27 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 CA-C-N 116.436 -0.347 . . . . 0.0 112.308 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.97 -150.17 10.95 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.8 t -120.02 135.77 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.997 0.427 . . . . 0.0 110.803 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.13 -0.938 . . . . 0.0 110.281 179.559 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . 0.409 ' O ' ' OE2' ' H' ' 11' ' ' GLU . 99.1 m-85 -99.19 133.77 43.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.136 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -139.67 145.6 38.62 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.301 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 62.2 t -125.34 132.63 70.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.225 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -88.31 172.11 9.67 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.919 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.537 ' CD2' ' N ' ' G' ' 14' ' ' HIS . 3.6 m170 -89.05 170.52 10.58 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.626 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.406 ' HG2' ' N ' ' G' ' 16' ' ' LYS . 54.8 tt0 -147.57 171.81 14.99 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.859 179.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.406 ' N ' ' HG2' ' G' ' 15' ' ' GLN . 98.9 mttt -150.8 125.0 9.38 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 121.227 -0.189 . . . . 0.0 111.101 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 77.9 mt -118.28 122.42 42.87 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -138.66 132.42 40.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 121.774 0.797 . . . . 0.0 113.101 -178.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.452 ' CZ ' ' CD1' ' J' ' 34' ' ' LEU . 6.9 m-85 -113.14 111.72 22.59 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 175.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -130.62 121.06 24.92 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 131.03 41.07 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-O 121.373 0.606 . . . . 0.0 112.038 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' G' ' 23' ' ' ASP . 83.8 tt0 -156.05 152.95 28.68 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 177.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.475 ' O ' ' C ' ' G' ' 24' ' ' VAL . 22.2 t70 -59.48 -120.41 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.534 -178.612 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.475 ' C ' ' O ' ' G' ' 23' ' ' ASP . 22.7 m -27.2 121.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 122.179 0.192 . . . . 0.0 111.001 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.15 -85.6 0.1 Allowed Glycine 0 CA--C 1.526 0.775 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.225 -177.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.697 ' O ' ' O ' ' G' ' 27' ' ' ASN . 62.5 m -152.73 -170.81 3.74 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -175.591 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.697 ' O ' ' O ' ' G' ' 26' ' ' SER . 12.7 t-20 -19.34 159.59 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.103 0 O-C-N 124.629 1.206 . . . . 0.0 114.016 -176.35 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -159.82 110.64 1.94 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.236 -176.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.551 ' O ' ' CB ' ' H' ' 30' ' ' ALA . . . -69.51 96.09 0.48 Allowed Glycine 0 CA--C 1.455 -3.683 0 CA-C-O 123.686 1.715 . . . . 0.0 110.511 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . 0.522 ' O ' ' C ' ' G' ' 29' ' ' GLY . . . -81.6 -139.99 0.04 OUTLIER 'General case' 0 N--CA 1.395 -3.215 1 N-CA-C 94.424 -6.139 . . . . 0.0 94.424 171.171 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.693 ' N ' ' CD1' ' G' ' 31' ' ' ILE . 1.0 OUTLIER -85.18 111.31 20.5 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.298 0 CA-C-N 125.186 3.63 . . . . 0.0 109.443 179.928 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.517 ' O ' ' SD ' ' A' ' 35' ' ' MET . 39.1 mm -136.73 129.34 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 120.304 -0.558 . . . . 0.0 112.035 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . 0.516 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -131.34 130.76 6.13 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 34.2 tp -156.19 135.33 12.09 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.801 0.81 . . . . 0.0 112.99 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.455 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 63.7 ttp -121.93 143.94 49.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.363 178.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 25.5 t -120.03 75.86 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.5 101.12 2.58 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 177.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.6 167.33 22.13 Favored Glycine 0 N--CA 1.467 0.741 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 81.8 t -131.3 138.27 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.752 0.31 . . . . 0.0 110.301 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.9 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.347 179.472 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -118.61 140.48 49.84 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' O ' ' G' ' 10' ' ' TYR . 80.9 mm-40 -132.36 135.9 46.47 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.711 0.767 . . . . 0.0 111.978 -178.926 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 58.0 t -128.47 134.33 64.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.094 -0.957 . . . . 0.0 108.654 179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 -137.86 101.11 4.36 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.95 -0.3 . . . . 0.0 110.754 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 11.1 m170 -115.5 154.67 28.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 80.5 mt-30 -155.91 174.31 15.51 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.468 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -156.96 112.17 2.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.712 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -111.42 111.4 22.41 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.69 125.32 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-O 121.86 0.838 . . . . 0.0 111.732 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.604 ' CG ' ' CE2' ' I' ' 19' ' ' PHE . 6.0 m-85 -113.17 116.81 30.41 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 114.182 -1.372 . . . . 0.0 108.666 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -128.67 126.56 40.38 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.13 130.24 35.14 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 121.19 0.519 . . . . 0.0 111.394 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' H' ' 23' ' ' ASP . 84.9 tt0 -149.96 91.12 1.75 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 178.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' H' ' 22' ' ' GLU . 1.1 m-20 62.74 115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 -176.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.53 ' C ' ' HZ2' ' I' ' 28' ' ' LYS . 48.9 t -118.84 123.75 72.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.471 -174.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.55 ' C ' ' HZ2' ' I' ' 28' ' ' LYS . . . 35.91 83.69 0.01 OUTLIER Glycine 0 N--CA 1.47 0.905 0 C-N-CA 121.482 -0.39 . . . . 0.0 113.255 177.128 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.627 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 5.4 t -58.9 170.92 0.74 Allowed 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 121.18 0.514 . . . . 0.0 110.389 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.527 ' ND2' ' O ' ' H' ' 26' ' ' SER . 68.7 m-20 103.26 177.43 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 113.259 -1.791 . . . . 0.0 107.298 -177.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' H' ' 27' ' ' ASN . 98.7 mttt -23.69 -102.87 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 O-C-N 123.567 0.542 . . . . 0.0 111.981 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -141.25 100.46 0.26 Allowed Glycine 0 N--CA 1.472 1.059 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 177.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.551 ' CB ' ' O ' ' G' ' 29' ' ' GLY . . . -66.59 158.48 29.72 Favored 'General case' 0 C--O 1.248 1.013 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.016 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.446 HD11 HG23 ' H' ' 31' ' ' ILE . 0.1 OUTLIER -154.55 132.15 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.544 -175.796 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' B' ' 35' ' ' MET . 41.5 pt -130.42 127.07 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.499 0.666 . . . . 0.0 112.226 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.53 97.89 0.66 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 4.4 mp -129.44 149.8 51.07 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.924 0.868 . . . . 0.0 111.974 -178.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.406 ' CE ' ' SD ' ' G' ' 35' ' ' MET . 20.7 ttp -141.03 134.69 30.17 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.482 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 4.1 t -126.42 79.01 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.53 105.07 0.8 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 177.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.94 173.05 0.64 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.99 161.88 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.965 0.412 . . . . 0.0 110.66 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.9 m . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.831 179.951 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -110.2 151.74 26.93 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.692 0.282 . . . . 0.0 110.337 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.478 ' O ' ' O ' ' J' ' 11' ' ' GLU . 83.1 tt0 -50.0 134.95 21.05 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.27 151.01 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.97 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -135.75 132.31 36.65 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.505 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.625 ' NE2' ' CG ' ' J' ' 13' ' ' HIS . 75.7 m80 -122.91 159.69 27.71 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 178.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -157.51 177.52 11.32 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.629 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -170.05 114.16 0.49 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 tt -117.67 118.49 32.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.071 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -141.72 136.76 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 119.967 -0.693 . . . . 0.0 111.896 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.604 ' CE2' ' CG ' ' H' ' 19' ' ' PHE . 26.8 m-85 -123.92 128.5 49.52 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 115.393 -0.822 . . . . 0.0 110.224 179.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.587 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.2 t80 -133.26 124.86 28.12 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.09 133.21 44.07 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.488 0.921 . . . . 0.0 113.488 -178.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -143.35 167.75 21.42 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' I' ' 24' ' ' VAL . 3.6 m-20 -142.32 -102.14 0.13 Allowed 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.519 ' O ' ' O ' ' I' ' 23' ' ' ASP . 10.9 t 46.98 159.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 122.263 1.03 . . . . 0.0 112.655 -176.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.443 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 107.88 -76.35 0.22 Allowed Glycine 0 CA--C 1.541 1.712 0 CA-C-N 114.139 -1.391 . . . . 0.0 112.529 -175.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.9 ' O ' ' O ' ' I' ' 27' ' ' ASN . 0.4 OUTLIER 170.89 -169.48 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.403 0 CA-C-N 119.502 1.651 . . . . 0.0 109.354 -176.43 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.9 ' O ' ' O ' ' I' ' 26' ' ' SER . 62.1 t30 -17.01 -179.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.06 0 O-C-N 125.287 1.617 . . . . 0.0 113.537 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.659 ' CG ' ' O ' ' I' ' 27' ' ' ASN . 26.8 mmtt 139.89 -110.52 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -175.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.42 ' CA ' ' O ' ' J' ' 29' ' ' GLY . . . 49.27 91.28 0.01 OUTLIER Glycine 0 CA--C 1.482 -2.022 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -171.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.447 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -103.06 170.75 7.78 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 111.509 -2.346 . . . . 0.0 106.63 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.447 ' CG1' ' C ' ' I' ' 30' ' ' ALA . 0.3 OUTLIER -145.78 110.03 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 C-N-CA 118.299 -1.361 . . . . 0.0 109.423 -175.899 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.508 ' C ' ' SD ' ' C' ' 35' ' ' MET . 58.7 mt -103.6 115.72 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.516 -178.654 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.522 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.61 92.65 0.54 Allowed Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 107.509 -2.237 . . . . 0.0 107.509 176.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.445 HD13 ' N ' ' I' ' 35' ' ' MET . 22.6 tp -129.22 122.4 29.63 Favored 'General case' 0 C--O 1.244 0.785 0 CA-C-O 123.276 1.512 . . . . 0.0 110.798 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 24.7 ttp -106.61 120.42 41.91 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 112.596 -2.093 . . . . 0.0 108.548 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -135.49 72.23 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.392 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -104.13 101.62 2.01 Favored Glycine 0 C--N 1.36 1.914 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 178.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.35 178.91 24.56 Favored Glycine 0 N--CA 1.463 0.485 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 8.4 p -141.43 152.34 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.878 0.371 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.5 179.856 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.452 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . 0.471 ' CD1' ' OE1' ' I' ' 11' ' ' GLU . 66.8 m-85 -120.45 147.2 45.41 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.478 ' O ' ' O ' ' I' ' 11' ' ' GLU . 95.6 mt-10 -122.95 161.65 23.78 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.185 0.517 . . . . 0.0 110.441 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -143.77 151.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.591 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.655 ' CG ' ' H ' ' J' ' 14' ' ' HIS . 25.2 t-80 -92.45 -173.92 3.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.853 0.359 . . . . 0.0 110.219 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.655 ' H ' ' CG ' ' J' ' 13' ' ' HIS . 0.5 OUTLIER -86.01 175.19 8.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.336 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -126.16 166.26 17.38 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -148.57 122.89 9.63 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.756 0.312 . . . . 0.0 111.591 -179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 3.4 mp -123.9 121.14 34.54 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 94.5 t -129.72 128.66 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-O 121.149 0.499 . . . . 0.0 112.086 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 m-85 -115.53 119.83 37.48 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 178.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.587 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 29.0 t80 -130.99 120.35 23.37 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.616 0.644 . . . . 0.0 109.727 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.34 134.44 34.24 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -110.45 122.96 48.98 Favored 'General case' 0 C--N 1.346 0.43 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.311 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.508 ' HB3' ' H ' ' K' ' 24' ' ' VAL . 8.8 t70 -84.28 122.66 29.2 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.017 0.437 . . . . 0.0 110.911 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' J' ' 26' ' ' SER . 72.1 t -99.66 122.52 51.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.748 -179.06 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 39.17 -86.06 0.01 OUTLIER Glycine 0 C--N 1.337 0.619 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.301 177.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.653 ' O ' ' O ' ' J' ' 27' ' ' ASN . 87.9 p -161.25 174.17 13.98 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.653 ' O ' ' O ' ' J' ' 26' ' ' SER . 74.9 m-20 -9.39 159.4 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 116.369 1.989 . . . . 0.0 116.369 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt 179.86 104.83 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 112.566 -2.106 . . . . 0.0 106.618 175.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.42 ' O ' ' CA ' ' I' ' 29' ' ' GLY . . . -60.51 95.03 0.08 OUTLIER Glycine 0 C--O 1.22 -0.722 0 CA-C-O 118.724 -1.042 . . . . 0.0 113.924 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.401 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -127.37 149.01 50.25 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 102.215 -3.254 . . . . 0.0 102.215 172.414 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.401 ' CG1' ' C ' ' J' ' 30' ' ' ALA . 0.2 OUTLIER -148.48 118.64 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 C-N-CA 118.011 -1.476 . . . . 0.0 111.222 -172.296 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.427 HD11 HG21 ' J' ' 32' ' ' ILE . 2.0 mt -108.12 112.48 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.384 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.07 101.94 1.32 Allowed Glycine 0 C--O 1.239 0.455 0 N-CA-C 106.579 -2.608 . . . . 0.0 106.579 176.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.452 ' CD1' ' CZ ' ' G' ' 19' ' ' PHE . 0.2 OUTLIER -142.16 135.17 28.73 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 122.205 1.002 . . . . 0.0 112.391 -176.634 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 49.0 ttp -123.3 127.61 48.79 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.979 179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.86 69.08 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.306 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.725 178.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.2 -100.83 0.01 OUTLIER Glycine 0 C--N 1.36 1.89 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.07 150.91 20.43 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 75.6 t -134.52 137.31 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 p . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.401 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -109.51 142.54 40.4 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.58 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -130.59 144.13 51.21 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.671 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.05 133.79 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.803 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -134.4 124.27 25.43 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.019 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.578 ' CD2' ' N ' ' K' ' 15' ' ' GLN . 33.0 t60 -156.48 166.87 32.17 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-O 121.409 0.623 . . . . 0.0 109.921 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.578 ' N ' ' CD2' ' K' ' 14' ' ' HIS . 79.6 mt-30 -153.91 173.49 15.88 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.359 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 79.1 tttt -153.78 113.3 3.8 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.125 178.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 tt -116.01 121.74 43.15 Favored 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -126.61 129.37 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -125.05 123.82 40.62 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -134.39 122.54 22.71 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.676 0.274 . . . . 0.0 111.266 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.49 131.42 31.81 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 121.246 0.546 . . . . 0.0 111.85 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -110.27 128.17 55.39 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.748 179.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.447 ' OD2' ' O ' ' L' ' 22' ' ' GLU . 89.0 m-20 -100.48 115.65 30.57 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.552 ' O ' ' N ' ' K' ' 26' ' ' SER . 53.3 t -95.37 130.29 44.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.03 -85.31 0.01 OUTLIER Glycine 0 CA--C 1.529 0.917 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.552 ' N ' ' O ' ' K' ' 24' ' ' VAL . 29.4 p -141.16 170.76 15.12 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.945 0.878 . . . . 0.0 111.516 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.515 ' O ' ' O ' ' K' ' 26' ' ' SER . 2.3 p30 -28.83 169.72 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.184 -1.825 . . . . 0.0 114.294 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -149.85 111.38 4.48 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.101 175.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.413 ' H ' ' HA ' ' J' ' 27' ' ' ASN . . . -60.11 91.91 0.05 OUTLIER Glycine 0 N--CA 1.476 1.337 0 CA-C-O 119.603 -0.554 . . . . 0.0 113.643 176.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.12 153.97 51.02 Favored 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 102.961 -2.977 . . . . 0.0 102.961 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.09 111.68 2.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 C-N-CA 118.221 -1.392 . . . . 0.0 111.713 -172.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' E' ' 35' ' ' MET . 0.1 OUTLIER -106.83 111.12 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.661 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.79 97.64 1.05 Allowed Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 94.2 mt -130.24 142.3 50.57 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 122.024 0.916 . . . . 0.0 113.196 -176.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 40.7 ttp -129.67 117.91 21.08 Favored 'General case' 0 CA--C 1.501 -0.939 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.266 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' K' ' 37' ' ' GLY . 0.2 OUTLIER -115.19 65.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.666 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -36.69 -106.87 0.01 OUTLIER Glycine 0 C--N 1.352 1.471 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.569 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.73 144.98 0.07 OUTLIER Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -178.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -146.38 143.57 20.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.782 -179.579 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -111.87 137.2 50.15 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.703 0.287 . . . . 0.0 110.271 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -53.98 152.48 5.72 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.18 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 28.5 m -113.77 133.27 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.549 0.69 . . . . 0.0 111.663 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -150.07 138.59 20.66 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.804 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.553 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 68.0 t60 -157.31 175.5 13.93 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.553 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 87.9 mt-30 -142.86 176.44 9.07 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.952 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -166.23 113.47 0.88 Allowed 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.268 0.556 . . . . 0.0 111.024 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -121.56 125.97 48.02 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.607 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.6 t -134.43 133.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -141.78 133.4 26.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.124 0.488 . . . . 0.0 111.41 -179.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -134.49 128.56 33.64 Favored 'General case' 0 C--O 1.231 0.088 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.243 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.74 148.5 25.48 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.566 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.447 ' O ' ' OD2' ' K' ' 23' ' ' ASP . 98.5 mt-10 -91.26 152.57 20.45 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.484 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -141.55 123.32 15.24 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.459 0.647 . . . . 0.0 112.036 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.533 ' O ' ' N ' ' L' ' 26' ' ' SER . 94.7 t -94.58 121.04 44.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.0 -88.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.082 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.533 ' N ' ' O ' ' L' ' 24' ' ' VAL . 11.9 p -90.97 179.72 5.68 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -61.1 170.44 1.63 Allowed 'General case' 0 C--N 1.314 -0.945 0 C-N-CA 118.491 -1.284 . . . . 0.0 109.612 -179.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -53.88 111.94 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.198 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.45 92.23 0.5 Allowed Glycine 0 N--CA 1.47 0.923 0 C-N-CA 118.64 -1.743 . . . . 0.0 110.058 176.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -174.83 163.29 3.35 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 102.386 -3.19 . . . . 0.0 102.386 178.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -143.86 120.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 116.927 -1.909 . . . . 0.0 113.207 -177.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 mt -102.78 111.72 33.57 Favored 'Isoleucine or valine' 0 C--N 1.343 0.325 0 CA-C-N 113.466 -1.697 . . . . 0.0 107.372 177.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . 0.403 ' CA ' ' HG3' ' F' ' 35' ' ' MET . . . -110.06 83.94 0.35 Allowed Glycine 0 CA--C 1.493 -1.318 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 177.305 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . 0.452 ' CD2' ' C ' ' L' ' 34' ' ' LEU . 7.3 tt -122.27 117.08 25.28 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 65.4 ttp -106.05 130.27 53.99 Favored 'General case' 0 CA--C 1.505 -0.784 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.333 -179.683 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.2 79.97 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.18 103.24 0.76 Allowed Glycine 0 C--N 1.348 1.224 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.96 152.98 21.24 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -132.14 157.81 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.751 -179.599 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.396 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -112.69 147.02 37.67 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.756 0.312 . . . . 0.0 110.433 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.0 mt-10 -113.33 143.54 44.27 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.981 0.419 . . . . 0.0 110.748 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.2 m -130.65 154.91 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.778 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -138.24 163.19 32.38 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.944 0.402 . . . . 0.0 110.866 -178.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.629 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -82.11 170.82 15.05 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.551 -179.844 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -148.89 174.76 11.9 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.01 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -153.4 124.54 7.46 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.074 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.0 mt -121.12 114.26 21.19 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.1 t -131.26 129.34 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 CA-C-O 121.403 0.621 . . . . 0.0 112.354 -178.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.595 ' CG ' ' CE1' ' B' ' 19' ' ' PHE . 3.5 m-85 -108.85 111.63 23.45 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 50.1 p90 -131.59 126.32 34.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 118.797 0.726 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.12 133.14 42.51 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-O 121.461 0.648 . . . . 0.0 112.405 -178.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.496 ' OE1' ' N ' ' A' ' 22' ' ' GLU . 36.5 mp0 -142.97 156.52 44.88 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.457 ' O ' ' CG1' ' B' ' 24' ' ' VAL . 34.5 t70 -87.89 111.72 21.74 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 120.165 -0.614 . . . . 0.0 112.387 -178.445 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.598 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.5 t -113.8 131.2 66.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.093 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.96 81.97 0.0 OUTLIER Glycine 0 CA--C 1.53 1.022 0 O-C-N 123.315 0.384 . . . . 0.0 112.427 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.598 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.4 p -91.19 -179.3 5.39 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.538 ' O ' ' O ' ' A' ' 28' ' ' LYS . 58.8 t30 -62.64 -178.03 0.18 Allowed 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.538 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.2 mttt -48.48 -110.51 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.746 0.784 . . . . 0.0 110.604 -179.355 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -84.2 94.97 1.88 Allowed Glycine 0 N--CA 1.459 0.23 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 176.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.07 161.32 16.61 Favored 'General case' 0 C--N 1.351 0.636 0 C-N-CA 115.473 -2.491 . . . . 0.0 110.776 -177.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.415 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.7 OUTLIER -153.4 121.7 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 CA-C-N 112.545 -2.116 . . . . 0.0 110.667 -172.596 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' G' ' 35' ' ' MET . 78.6 mt -129.2 120.16 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 120.381 -0.527 . . . . 0.0 110.72 178.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.62 122.31 3.54 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 16.0 tp -127.75 141.96 51.44 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 117.241 0.52 . . . . 0.0 111.355 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.591 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 13.3 ttt -131.32 129.29 41.25 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.315 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 16.4 t -131.4 71.66 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 N-CA-C 112.315 0.487 . . . . 0.0 112.315 178.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -125.75 96.51 0.49 Allowed Glycine 0 C--N 1.344 1.024 0 N-CA-C 108.799 -1.72 . . . . 0.0 108.799 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.86 172.25 42.56 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -133.99 159.22 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 110.761 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.923 -1.037 . . . . 0.0 110.297 179.769 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.177 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -109.53 134.69 51.6 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.693 0.282 . . . . 0.0 110.47 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.527 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 56.9 mp0 -121.09 128.08 52.25 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.44 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p -144.46 138.42 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.971 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.458 ' O ' ' ND1' ' C' ' 13' ' ' HIS . 47.1 t-80 -142.18 105.98 4.71 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.659 0.266 . . . . 0.0 110.923 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -160.45 178.77 9.22 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-O 121.109 0.481 . . . . 0.0 110.283 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -133.44 -179.14 5.33 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.97 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -146.74 132.38 18.84 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.879 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.9 tp -125.39 115.9 21.02 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 120.701 -0.4 . . . . 0.0 112.01 -177.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 74.9 t -125.39 123.8 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 120.866 0.365 . . . . 0.0 110.912 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.595 ' CE1' ' CG ' ' A' ' 19' ' ' PHE . 13.3 m-85 -116.83 118.98 33.97 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.73 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.7 t80 -134.11 125.4 27.91 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.99 133.71 33.98 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -178.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -153.15 176.76 11.57 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -153.35 134.69 14.22 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.913 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.457 ' CG1' ' O ' ' A' ' 23' ' ' ASP . 2.8 p -109.09 112.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.005 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 33.09 88.57 0.01 OUTLIER Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -177.288 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -46.96 170.86 0.01 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.17 -1.015 . . . . 0.0 113.232 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.507 ' H ' ' HD2' ' C' ' 28' ' ' LYS . 78.3 m-20 -129.67 -179.94 5.47 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 114.316 -1.311 . . . . 0.0 108.62 176.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.498 ' O ' ' O ' ' B' ' 27' ' ' ASN . 98.1 mttt -26.71 -103.3 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 179.42 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.85 98.43 0.18 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.82 158.72 32.96 Favored 'General case' 0 C--O 1.25 1.088 0 C-N-CA 117.086 -1.846 . . . . 0.0 111.26 177.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.415 ' O ' ' HA ' ' A' ' 31' ' ' ILE . 0.1 OUTLIER -153.68 112.99 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.556 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.491 ' O ' ' SD ' ' H' ' 35' ' ' MET . 42.7 pt -136.02 150.36 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.255 -177.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.462 ' CA ' ' O ' ' C' ' 33' ' ' GLY . . . -166.18 150.29 17.4 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 119.835 -1.174 . . . . 0.0 112.332 -179.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 6.0 mt -139.17 143.43 38.14 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 120.9 0.381 . . . . 0.0 110.586 179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.63 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 5.2 ttt -120.22 122.09 40.16 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.2 t -138.14 71.83 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.12 95.85 0.41 Allowed Glycine 0 C--N 1.343 0.969 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 177.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.33 179.44 18.69 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -179.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -123.75 136.12 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.982 0.42 . . . . 0.0 110.284 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.186 179.812 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -147.79 163.82 35.56 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.515 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 56.7 mp0 -127.04 150.25 49.53 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.663 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.49 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 32.6 m -131.27 156.16 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.949 179.661 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 10.0 m-70 -150.98 150.43 30.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.995 -178.961 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 2.4 t60 -154.55 158.14 39.35 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.508 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 78.2 mt-30 -152.08 179.27 8.63 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 120.289 -0.565 . . . . 0.0 111.432 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -165.45 117.53 1.14 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.836 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.3 mt -115.81 114.78 25.22 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.79 140.92 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 119.426 -0.91 . . . . 0.0 113.163 -178.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.552 ' CE1' ' CD1' ' F' ' 34' ' ' LEU . 65.1 m-85 -124.28 125.11 43.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.541 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.0 t80 -130.61 117.21 19.19 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.24 136.15 46.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 120.559 -0.456 . . . . 0.0 111.641 -178.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -125.97 121.04 31.93 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.418 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' D' ' 24' ' ' VAL . 41.0 t0 -90.63 123.05 33.95 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.127 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.3 t -142.32 -111.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' C' ' 26' ' ' SER . . . -29.8 91.56 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 CA-C-N 116.145 -0.479 . . . . 0.0 112.747 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.545 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 12.8 p -61.18 179.15 0.21 Allowed 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 105.596 -2.001 . . . . 0.0 105.596 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.545 ' CB ' ' O ' ' C' ' 26' ' ' SER . 3.1 m120 91.17 -170.81 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -177.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.507 ' HD2' ' H ' ' B' ' 27' ' ' ASN . 84.3 tttt 40.59 -106.29 0.06 Allowed 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 114.803 1.408 . . . . 0.0 114.803 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.6 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . 92.95 91.91 1.51 Allowed Glycine 0 CA--C 1.497 -1.07 0 N-CA-C 107.483 -2.247 . . . . 0.0 107.483 -171.691 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.475 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -83.5 172.47 12.37 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.512 -176.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.475 ' CG1' ' C ' ' C' ' 30' ' ' ALA . 0.1 OUTLIER -152.72 124.19 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 C-N-CA 117.7 -1.6 . . . . 0.0 110.157 -175.909 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.7 tt -122.42 131.73 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.462 ' O ' ' CA ' ' B' ' 33' ' ' GLY . . . -122.44 109.13 1.36 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 179.131 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.406 ' H ' HD23 ' D' ' 34' ' ' LEU . 1.0 OUTLIER -137.07 126.57 25.12 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.45 -1.029 . . . . 0.0 112.258 -178.402 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.666 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 14.2 ttp -110.58 121.8 46.2 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 114.388 -1.278 . . . . 0.0 109.945 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -139.87 70.46 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.732 179.847 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.53 -100.48 0.62 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.44 155.27 25.49 Favored Glycine 0 CA--C 1.521 0.434 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -136.06 162.09 36.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.761 0.315 . . . . 0.0 110.213 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.8 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.721 -179.699 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -116.09 138.64 51.06 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 120.837 0.351 . . . . 0.0 110.407 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -64.09 128.86 37.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.197 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m -137.84 137.42 44.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.787 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 73.9 m-70 -128.62 102.04 6.42 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.534 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 6.7 m170 -95.23 158.15 15.59 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 121.904 0.859 . . . . 0.0 111.162 -179.179 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.534 ' NE2' ' O ' ' D' ' 14' ' ' HIS . 99.7 mm-40 -152.61 171.34 18.31 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 114.023 -1.444 . . . . 0.0 107.905 178.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -174.1 128.67 0.37 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 121.014 -0.275 . . . . 0.0 110.275 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 8.8 mt -120.74 119.46 32.83 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 120.451 -0.5 . . . . 0.0 111.103 -179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -128.99 119.47 49.43 Favored 'Isoleucine or valine' 0 C--N 1.341 0.201 0 C-N-CA 120.636 -0.426 . . . . 0.0 111.359 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -113.03 116.66 30.28 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' OE2' ' D' ' 22' ' ' GLU . 9.0 t80 -129.5 119.4 23.66 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.13 0.423 . . . . 0.0 110.152 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.76 127.58 43.84 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 78.6 mm-40 -121.49 112.31 18.36 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 179.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 24' ' ' VAL . 19.9 t0 -84.35 97.34 9.41 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.622 ' O ' ' N ' ' D' ' 26' ' ' SER . 14.0 t -103.61 168.73 2.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.607 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.497 ' C ' ' HG ' ' D' ' 26' ' ' SER . . . 39.36 -78.31 0.0 OUTLIER Glycine 0 CA--C 1.527 0.783 0 CA-C-O 119.448 -0.64 . . . . 0.0 112.631 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.622 ' N ' ' O ' ' D' ' 24' ' ' VAL . 1.4 p 170.98 -170.83 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 117.895 0.848 . . . . 0.0 111.552 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.592 ' O ' ' O ' ' D' ' 26' ' ' SER . 20.5 m-80 -18.68 -172.11 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -179.126 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.687 ' N ' ' HZ1' ' E' ' 28' ' ' LYS . 86.0 tttt 127.2 104.46 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 111.217 -2.719 . . . . 0.0 110.48 177.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.6 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -59.9 96.28 0.08 OUTLIER Glycine 0 CA--C 1.491 -1.438 0 CA-C-O 118.337 -1.257 . . . . 0.0 110.559 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.464 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . -117.61 150.36 39.15 Favored 'General case' 0 CA--C 1.467 -2.224 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 174.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.464 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 0.3 OUTLIER -150.51 122.03 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 118.049 -1.461 . . . . 0.0 110.278 -171.973 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.4 HD11 HG23 ' D' ' 32' ' ' ILE . 0.1 OUTLIER -105.87 119.01 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 114.187 -1.369 . . . . 0.0 110.375 -179.091 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.86 101.55 0.69 Allowed Glycine 0 N--CA 1.464 0.554 0 N-CA-C 108.093 -2.003 . . . . 0.0 108.093 178.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.406 HD23 ' H ' ' C' ' 34' ' ' LEU . 16.8 mt -139.09 152.03 47.19 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.378 -0.929 . . . . 0.0 112.326 -176.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.591 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 35.2 ttp -126.36 118.16 24.46 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 176.639 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 40.1 t -127.06 70.22 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.57 -102.62 2.75 Favored Glycine 0 C--N 1.36 1.884 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 77.73 170.21 34.72 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -140.29 140.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.854 0.359 . . . . 0.0 110.232 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.43 -179.824 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.434 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -146.26 162.09 38.86 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.897 0.379 . . . . 0.0 110.458 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.533 ' OE1' ' N ' ' E' ' 11' ' ' GLU . 56.1 mp0 -130.91 144.16 51.26 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.587 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 46.9 t -115.65 131.63 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' D' ' 13' ' ' HIS . 85.9 m-70 -109.99 160.56 16.32 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 118.532 0.605 . . . . 0.0 111.949 -178.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.539 ' CE1' ' O ' ' D' ' 13' ' ' HIS . 98.0 m-70 -152.14 174.44 13.72 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.279 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mm-40 -119.75 -171.02 2.05 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -97.77 175.72 6.07 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 122.504 1.145 . . . . 0.0 113.945 -176.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.1 tt -120.81 121.47 38.24 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 113.407 -1.724 . . . . 0.0 106.986 178.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.57 138.66 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-O 121.524 0.678 . . . . 0.0 112.616 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -124.21 124.51 42.62 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.578 -1.192 . . . . 0.0 109.007 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -131.2 122.55 26.77 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.86 127.87 42.72 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 120.861 0.362 . . . . 0.0 111.025 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 80.1 tt0 -92.91 144.48 25.23 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.814 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.612 ' O ' ' O ' ' E' ' 24' ' ' VAL . 41.5 p-10 -71.21 -122.34 0.0 OUTLIER 'General case' 0 C--O 1.218 -0.562 0 CA-C-N 116.304 -0.407 . . . . 0.0 109.982 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.612 ' O ' ' O ' ' E' ' 23' ' ' ASP . 87.3 t 19.84 122.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.58 -84.19 0.09 OUTLIER Glycine 0 CA--C 1.522 0.514 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.69 177.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.529 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.4 p 154.18 -179.23 0.0 OUTLIER 'General case' 0 C--N 1.345 0.382 0 CA-C-O 122.58 1.181 . . . . 0.0 111.006 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.426 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 1.8 m-20 -52.63 -178.94 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 112.44 -2.163 . . . . 0.0 112.643 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.687 ' HZ1' ' N ' ' D' ' 28' ' ' LYS . 0.0 OUTLIER 60.66 113.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 123.017 1.389 . . . . 0.0 114.385 -179.521 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -88.26 96.22 2.17 Favored Glycine 0 C--O 1.224 -0.522 0 CA-C-N 111.687 -2.506 . . . . 0.0 112.727 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -63.95 175.44 1.19 Allowed 'General case' 0 C--O 1.24 0.596 0 CA-C-N 119.882 1.841 . . . . 0.0 107.461 -178.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.428 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.1 OUTLIER -152.39 129.65 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.421 0 C-N-CA 116.736 -1.986 . . . . 0.0 114.606 -172.451 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.423 HD11 HG23 ' E' ' 32' ' ' ILE . 1.8 mt -107.67 121.04 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.072 177.237 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.3 104.59 0.82 Allowed Glycine 0 C--N 1.332 0.332 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.415 HD11 ' N ' ' E' ' 35' ' ' MET . 3.4 tp -150.31 135.3 17.73 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.461 1.124 . . . . 0.0 112.584 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.585 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 33.8 ttp -102.26 126.3 49.22 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.762 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.39 70.94 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.9 114.08 5.88 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.05 -139.49 0.14 Allowed Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -119.01 136.7 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 120.755 0.312 . . . . 0.0 110.527 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 20.6 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.408 179.824 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -111.33 133.2 53.83 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-O 120.856 0.36 . . . . 0.0 110.401 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -121.8 138.58 54.32 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.365 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.52 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 58.3 t -123.73 131.32 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.44 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.52 ' CG ' ' O ' ' F' ' 12' ' ' VAL . 78.9 m80 -161.28 99.39 1.18 Allowed 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.817 179.59 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 92.1 m-70 -153.74 163.99 39.08 Favored 'General case' 0 N--CA 1.447 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 109.9 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -158.27 177.43 11.28 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.792 179.022 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -142.53 139.83 31.58 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 121.16 0.505 . . . . 0.0 110.574 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 39.5 mt -113.33 127.94 56.3 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.17 138.26 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.535 0.683 . . . . 0.0 111.694 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.0 p90 -132.47 131.03 41.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.765 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -136.44 130.15 32.22 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.99 144.31 25.75 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.633 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.405 ' HB2' ' H ' ' E' ' 23' ' ' ASP . 73.0 mm-40 -99.27 161.27 13.71 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.491 ' O ' ' O ' ' F' ' 24' ' ' VAL . 59.9 m-20 -145.29 -132.32 0.08 Allowed 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.531 -179.213 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' F' ' 23' ' ' ASP . 2.8 t 25.81 112.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -178.835 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.17 -91.57 0.1 OUTLIER Glycine 0 CA--C 1.525 0.695 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 177.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.495 ' O ' ' O ' ' F' ' 27' ' ' ASN . 50.4 m -141.3 170.26 16.05 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.444 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.542 ' OD1' ' N ' ' F' ' 28' ' ' LYS . 56.8 t-20 -29.19 155.89 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.744 0 O-C-N 123.73 0.643 . . . . 0.0 111.727 179.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.542 ' N ' ' OD1' ' F' ' 27' ' ' ASN . 23.8 tttm -151.67 -110.45 0.05 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.588 0.708 . . . . 0.0 111.89 176.126 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 45.82 91.36 0.01 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 114.632 -1.167 . . . . 0.0 114.577 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.429 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -103.15 176.41 5.16 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 100.204 -3.998 . . . . 0.0 100.204 172.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.429 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.1 OUTLIER -149.76 122.38 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 C-N-CA 115.986 -2.285 . . . . 0.0 112.566 -175.053 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -104.81 111.38 34.1 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.441 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.304 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.01 89.98 0.56 Allowed Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 107.102 -2.399 . . . . 0.0 107.102 175.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.552 ' CD1' ' CE1' ' C' ' 19' ' ' PHE . 9.2 tt -126.86 127.84 45.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 39.5 ttp -106.04 129.47 54.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.59 -178.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.55 78.48 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.08 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.05 104.35 1.32 Allowed Glycine 0 C--N 1.344 1.019 0 N-CA-C 111.269 -0.732 . . . . 0.0 111.269 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.64 -164.84 33.99 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 63.1 t -120.54 135.65 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.887 0.375 . . . . 0.0 110.178 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 37.9 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.574 179.952 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.83 138.84 49.73 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.719 0.295 . . . . 0.0 110.564 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' G' ' 11' ' ' GLU . 57.8 mp0 -76.92 134.1 39.04 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . 0.493 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 21.9 m -137.7 165.82 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.857 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 64.6 m80 -154.99 135.14 13.09 Favored 'General case' 0 C--O 1.222 -0.371 0 C-N-CA 120.241 -0.584 . . . . 0.0 111.169 179.133 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -156.74 165.7 35.48 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 96.3 mm-40 -150.59 177.47 10.0 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.865 179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -158.61 129.68 6.32 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.056 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -133.86 128.93 35.66 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 121.097 0.475 . . . . 0.0 110.421 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.17 130.76 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.38 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.435 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 2.6 t80 -116.65 114.31 23.89 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.532 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 54.5 p90 -124.19 121.14 34.3 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.68 125.3 50.44 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.112 0.482 . . . . 0.0 111.222 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -161.44 166.51 27.14 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' ND2' ' H' ' 27' ' ' ASN . 63.3 t0 -79.0 114.84 18.28 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.075 -0.65 . . . . 0.0 111.077 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.0 p -88.57 130.83 37.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.82 82.43 0.0 OUTLIER Glycine 0 CA--C 1.531 1.058 0 CA-C-N 116.055 -0.52 . . . . 0.0 112.803 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.535 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.3 m -132.23 162.47 30.88 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 178.23 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.531 ' O ' ' O ' ' G' ' 26' ' ' SER . 80.6 m-20 -38.74 175.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.241 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -73.62 111.15 8.49 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.38 93.97 0.19 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.31 162.06 13.2 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.433 HG23 HD13 ' G' ' 31' ' ' ILE . 0.0 OUTLIER -146.72 104.02 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -174.631 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.508 ' O ' ' SD ' ' B' ' 35' ' ' MET . 85.5 mt -126.89 127.93 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.242 0.544 . . . . 0.0 111.126 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . 0.591 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -133.15 113.22 1.2 Allowed Glycine 0 CA--C 1.517 0.158 0 N-CA-C 108.934 -1.666 . . . . 0.0 108.934 178.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -136.69 147.87 47.05 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 122.221 1.01 . . . . 0.0 112.726 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 49.4 ttp -131.24 132.04 44.35 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.734 -1.575 . . . . 0.0 109.591 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.1 t -99.86 72.01 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.22 -96.45 0.01 OUTLIER Glycine 0 N--CA 1.438 -1.17 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.26 -172.11 33.47 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.43 ' O ' ' OXT' ' G' ' 40' ' ' VAL . 2.7 p -139.2 142.92 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.43 ' OXT' ' O ' ' G' ' 39' ' ' VAL . 53.7 t . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.014 -0.993 . . . . 0.0 110.069 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.49 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -115.21 140.62 48.94 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.671 0.272 . . . . 0.0 110.476 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -81.23 142.33 33.27 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.452 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 m -121.76 131.82 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -118.93 140.62 49.69 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.733 0.301 . . . . 0.0 111.599 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.47 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 45.1 m-70 -142.31 160.61 39.92 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.345 0.593 . . . . 0.0 109.812 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.47 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 98.5 mm-40 -149.1 172.45 14.78 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.128 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -159.48 117.37 2.74 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.062 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -119.26 119.91 35.45 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -125.5 126.73 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.837 0.351 . . . . 0.0 110.534 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -123.06 118.77 28.5 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 -179.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 72.1 t80 -131.23 127.91 38.83 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.756 0.312 . . . . 0.0 111.288 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.7 123.96 30.47 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-O 120.886 0.374 . . . . 0.0 111.557 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -165.64 140.87 4.95 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 45.4 p30 -100.13 140.53 34.23 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.453 0.644 . . . . 0.0 112.509 -178.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.408 ' O ' ' C ' ' H' ' 25' ' ' GLY . 92.5 t -108.4 111.12 34.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' H' ' 24' ' ' VAL . . . 33.63 90.97 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 -177.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -46.45 152.74 0.42 Allowed 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.169 -1.015 . . . . 0.0 113.538 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.537 ' O ' ' O ' ' H' ' 28' ' ' LYS . 16.8 p30 -128.19 -179.97 5.29 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 114.189 -1.369 . . . . 0.0 107.823 174.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.537 ' O ' ' O ' ' H' ' 27' ' ' ASN . 84.4 tttt -27.51 -102.71 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.727 0.694 . . . . 0.0 111.885 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.413 ' CA ' ' O ' ' I' ' 29' ' ' GLY . . . -149.96 100.36 0.21 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 175.271 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.56 155.45 35.7 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 117.064 -1.854 . . . . 0.0 108.336 177.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.41 HD11 HG22 ' H' ' 31' ' ' ILE . 2.2 mt -144.45 108.17 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -128.35 129.71 69.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.63 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.68 119.5 3.68 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 108.314 -1.915 . . . . 0.0 108.314 177.645 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 95.1 mt -135.31 129.45 33.51 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -177.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.491 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 24.0 ttp -129.55 131.87 46.69 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.338 178.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.43 ' O ' ' O ' ' H' ' 37' ' ' GLY . 2.4 p -149.47 75.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 119.999 -0.68 . . . . 0.0 112.325 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.74 -95.56 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 178.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -165.08 37.72 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.77 141.78 41.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.893 0.377 . . . . 0.0 110.353 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 27.9 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.645 -179.996 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -113.96 139.5 49.18 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -86.47 163.81 17.33 Favored 'General case' 0 N--CA 1.463 0.177 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -99.3 132.79 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.636 ' CE1' ' ND1' ' J' ' 13' ' ' HIS . 14.9 p-80 -156.24 156.19 33.67 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.767 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' I' ' 15' ' ' GLN . 11.1 m170 -133.37 161.19 35.2 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.696 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' I' ' 14' ' ' HIS . 43.6 mm-40 -142.59 171.71 13.68 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.521 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -159.51 120.49 3.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.103 178.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 tt -125.3 124.38 41.5 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 120.803 0.335 . . . . 0.0 110.48 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.59 125.32 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.408 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.493 ' CD1' ' CZ ' ' J' ' 19' ' ' PHE . 12.2 t80 -118.97 113.24 20.68 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.552 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 47.6 t80 -126.45 116.82 21.73 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 121.076 0.465 . . . . 0.0 111.058 -178.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.71 126.71 47.02 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.244 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -146.65 103.86 3.69 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.077 0.465 . . . . 0.0 110.818 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.401 ' CB ' ' HZ2' ' K' ' 28' ' ' LYS . 99.4 m-20 -95.31 122.82 38.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.496 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.427 ' CG2' ' H ' ' I' ' 25' ' ' GLY . 3.6 m -143.5 -111.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.854 -178.699 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.427 ' H ' ' CG2' ' I' ' 24' ' ' VAL . . . 27.39 -90.2 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.433 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.826 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.1 p 171.54 171.0 0.09 Allowed 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.826 ' O ' ' O ' ' I' ' 26' ' ' SER . 44.5 p-10 -9.51 179.27 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 O-C-N 125.869 1.981 . . . . 0.0 115.745 178.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.564 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 85.8 tttt 129.64 104.69 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 114.052 1.13 . . . . 0.0 114.052 175.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.413 ' O ' ' CA ' ' H' ' 29' ' ' GLY . . . -58.46 96.81 0.07 OUTLIER Glycine 0 C--O 1.225 -0.422 0 N-CA-C 106.711 -2.556 . . . . 0.0 106.711 171.133 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.43 ' C ' ' CD1' ' I' ' 31' ' ' ILE . . . -120.88 146.04 47.01 Favored 'General case' 0 CA--C 1.48 -1.729 0 N-CA-C 105.112 -2.181 . . . . 0.0 105.112 178.144 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.43 ' CD1' ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -137.84 108.04 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 C-N-CA 119.343 -0.943 . . . . 0.0 111.088 -173.854 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.419 HD13 HG21 ' I' ' 32' ' ' ILE . 96.7 mt -111.65 112.5 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 175.779 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.666 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.05 108.74 1.69 Allowed Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 177.029 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.427 ' HG ' ' N ' ' I' ' 35' ' ' MET . 0.9 OUTLIER -142.39 144.0 32.94 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-O 122.673 1.225 . . . . 0.0 113.352 -177.082 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.427 ' N ' ' HG ' ' I' ' 34' ' ' LEU . 12.7 tmm? -127.42 117.95 23.14 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 113.196 -1.82 . . . . 0.0 109.626 177.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 15.7 m -121.91 73.94 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.822 179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.36 103.48 2.99 Favored Glycine 0 C--N 1.36 1.883 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 175.88 43.96 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -144.94 151.45 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 120.891 0.376 . . . . 0.0 110.774 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.567 179.651 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.447 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -111.1 132.55 54.18 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.781 0.324 . . . . 0.0 110.266 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' K' ' 11' ' ' GLU . 17.1 pt-20 -158.56 138.26 11.93 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.053 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -150.23 153.4 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.636 ' ND1' ' CE1' ' I' ' 13' ' ' HIS . 50.5 m-70 -144.21 116.05 8.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 118.966 0.803 . . . . 0.0 110.966 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.64 ' NE2' ' CG ' ' K' ' 13' ' ' HIS . 44.3 m80 -122.0 159.88 26.06 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.386 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 63.2 mt-30 -158.12 177.06 11.72 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.412 178.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 43.5 tttp -169.43 123.32 0.79 Allowed 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.427 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 8.8 tt -121.21 121.87 38.73 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.634 0.254 . . . . 0.0 110.328 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 79.2 t -124.28 127.48 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.493 ' CZ ' ' CD1' ' I' ' 19' ' ' PHE . 5.4 t80 -126.53 121.35 32.04 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.907 0.384 . . . . 0.0 110.72 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.552 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 50.7 t80 -128.93 127.18 41.24 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.003 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.34 137.53 30.61 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -142.58 106.0 4.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.131 -0.941 . . . . 0.0 109.272 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -96.59 108.91 21.59 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.049 -179.075 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 2.1 p -46.1 140.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.256 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.598 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -86.12 84.85 1.56 Allowed Glycine 0 CA--C 1.531 1.091 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.423 -178.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.59 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.3 t 162.36 160.41 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 CA-C-O 121.212 0.53 . . . . 0.0 110.12 176.203 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.59 ' O ' ' O ' ' J' ' 26' ' ' SER . 7.2 t-20 -29.99 178.99 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.544 ' H ' ' CG ' ' J' ' 27' ' ' ASN . 42.6 tttp 128.45 104.85 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 113.052 -1.886 . . . . 0.0 112.899 175.189 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.84 95.43 0.05 OUTLIER Glycine 0 N--CA 1.462 0.429 0 CA-C-N 113.057 -1.883 . . . . 0.0 112.782 173.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.21 141.06 35.97 Favored 'General case' 0 CA--C 1.49 -1.364 0 CA-C-N 120.751 2.275 . . . . 0.0 107.353 174.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.449 ' CD1' ' N ' ' J' ' 31' ' ' ILE . 0.0 OUTLIER -137.73 106.94 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.894 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.447 HG22 HD11 ' J' ' 32' ' ' ILE . 0.1 OUTLIER -109.75 110.84 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.018 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . 0.591 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -123.78 98.82 0.6 Allowed Glycine 0 N--CA 1.463 0.436 0 N-CA-C 107.312 -2.315 . . . . 0.0 107.312 178.893 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.435 ' CD2' ' CE1' ' G' ' 19' ' ' PHE . 5.5 mp -131.07 140.75 50.09 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-O 122.134 0.969 . . . . 0.0 111.786 -177.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 11.5 tmm? -124.18 121.44 35.11 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.513 179.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' J' ' 37' ' ' GLY . 0.1 OUTLIER -110.43 73.74 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.178 -178.75 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -24.9 -101.18 0.01 OUTLIER Glycine 0 C--N 1.355 1.62 0 CA-C-N 116.198 -0.456 . . . . 0.0 112.851 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 131.24 -174.54 19.94 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -133.7 160.44 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 110.357 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.548 -179.934 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.74 133.35 51.55 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 110.267 -0.271 . . . . 0.0 110.267 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' J' ' 11' ' ' GLU . 81.4 tt0 -156.18 141.18 17.27 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-O 120.944 0.402 . . . . 0.0 110.711 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.34 154.57 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.64 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 22.3 m-70 -125.64 144.56 50.54 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 118.608 0.64 . . . . 0.0 110.725 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.546 ' CG ' ' H ' ' K' ' 15' ' ' GLN . 30.9 t-80 -86.71 -178.25 6.31 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.499 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.546 ' H ' ' CG ' ' K' ' 14' ' ' HIS . 86.5 mt-30 -84.85 172.69 11.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.148 -178.522 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -146.25 133.01 19.99 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 114.825 -1.08 . . . . 0.0 108.575 179.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -131.42 131.57 43.7 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.225 0.536 . . . . 0.0 112.274 -178.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.6 t -126.77 127.7 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.836 178.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -128.86 128.2 43.39 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.561 0.22 . . . . 0.0 110.795 -178.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.435 ' CE2' ' CD2' ' L' ' 20' ' ' PHE . 8.8 t80 -135.76 123.43 22.33 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-O 120.906 0.384 . . . . 0.0 110.517 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.51 129.33 44.39 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.113 0.483 . . . . 0.0 111.312 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.094 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.421 ' H ' ' HB3' ' L' ' 22' ' ' GLU . 26.3 t70 -91.85 134.25 34.93 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.429 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.598 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 44.0 t -109.19 112.46 40.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.27 -91.29 0.01 OUTLIER Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.21 -0.905 . . . . 0.0 112.783 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.504 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.8 m -162.86 -161.11 0.68 Allowed 'General case' 0 N--CA 1.447 -0.615 0 CA-C-O 122.579 1.181 . . . . 0.0 112.867 -179.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.597 ' CG ' ' H ' ' K' ' 28' ' ' LYS . 4.4 t-20 30.08 -173.28 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 111.874 -2.421 . . . . 0.0 115.401 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.597 ' H ' ' CG ' ' K' ' 27' ' ' ASN . 82.3 tttt 103.56 110.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 127.136 2.174 . . . . 0.0 109.184 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.521 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -60.16 -95.16 0.01 OUTLIER Glycine 0 CA--C 1.535 1.3 0 C-N-CA 115.212 -3.375 . . . . 0.0 110.535 175.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 69.63 151.21 0.09 Allowed 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 174.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.487 ' O ' ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -149.25 117.88 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-N 120.974 1.716 . . . . 0.0 111.508 178.075 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 4.6 mt -105.38 111.85 36.44 Favored 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 175.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . 0.585 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.84 96.77 0.75 Allowed Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 106.315 -2.714 . . . . 0.0 106.315 177.242 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -120.93 120.37 35.29 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-O 122.304 1.05 . . . . 0.0 110.201 -177.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -109.53 114.08 27.42 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.412 -1.722 . . . . 0.0 107.965 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.18 78.38 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.829 -177.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.48 105.43 0.97 Allowed Glycine 0 C--N 1.352 1.472 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.71 -144.01 4.35 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -106.79 134.7 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 20.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.021 -0.99 . . . . 0.0 111.073 -179.579 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.542 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -84.52 139.9 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.723 0.297 . . . . 0.0 110.855 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -121.52 131.03 53.91 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.971 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.98 156.79 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.179 0.514 . . . . 0.0 111.252 -179.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -158.19 163.21 37.74 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.787 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 41.9 m80 -136.74 169.8 17.13 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -148.08 176.29 10.32 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.174 0.512 . . . . 0.0 111.304 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 ttpt -170.59 111.46 0.39 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.983 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 72.0 mt -121.22 111.37 17.3 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 70.4 t -126.64 129.95 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.7 p90 -136.94 125.28 23.3 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.299 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.435 ' CD2' ' CE2' ' K' ' 20' ' ' PHE . 79.4 t80 -136.8 131.57 33.5 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 121.123 0.487 . . . . 0.0 110.297 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.74 143.75 35.15 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.393 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.421 ' HB3' ' H ' ' K' ' 23' ' ' ASP . 51.8 tp10 -78.21 140.96 38.92 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -58.86 130.46 47.05 Favored 'General case' 0 CA--C 1.518 -0.275 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.451 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.443 ' O ' ' C ' ' L' ' 25' ' ' GLY . 14.7 p -116.12 114.84 47.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.279 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.443 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -28.28 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.47 0.927 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -88.45 -177.4 5.61 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 60.3 m-20 -60.29 179.62 0.14 Allowed 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.477 -176.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.421 ' HZ2' HD12 ' L' ' 32' ' ' ILE 0.251 69.1 tttt -57.45 111.36 1.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 -177.015 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -68.62 -97.71 0.04 OUTLIER Glycine 0 CA--C 1.499 -0.932 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.521 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -60.9 170.78 1.4 Allowed 'General case' 0 CA--C 1.511 -0.552 0 CA-C-N 120.844 2.322 . . . . 0.0 105.805 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.454 ' N ' ' CD1' ' L' ' 31' ' ' ILE . 0.1 OUTLIER -134.17 121.79 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 115.811 -2.356 . . . . 0.0 114.086 -174.327 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.421 HD12 ' HZ2' ' L' ' 28' ' ' LYS . 97.3 mt -106.41 116.07 49.36 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 176.261 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -106.29 96.73 1.17 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 105.71 -2.956 . . . . 0.0 105.71 176.708 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 1.2 pp -110.23 112.09 23.84 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.751 -0.725 . . . . 0.0 110.298 -177.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.454 ' C ' ' SD ' ' L' ' 35' ' ' MET . 8.6 tmm? -109.69 110.85 22.01 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 178.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' C ' ' L' ' 37' ' ' GLY . 3.3 m -126.93 77.42 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.681 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 22.29 -110.69 0.01 OUTLIER Glycine 0 C--N 1.356 1.654 0 O-C-N 123.106 0.254 . . . . 0.0 113.017 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.79 140.85 8.9 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -134.89 159.24 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.886 0.375 . . . . 0.0 110.46 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.128 -0.939 . . . . 0.0 110.764 -179.885 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -113.72 138.38 50.31 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.995 0.426 . . . . 0.0 110.914 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 52.4 tp10 -113.45 133.8 55.0 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 m -133.15 135.03 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 111.846 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.493 ' HE2' HE21 ' A' ' 15' ' ' GLN . 5.4 p80 -97.15 -175.58 3.28 Favored 'General case' 0 CA--C 1.527 0.086 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.838 178.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.5 p-80 -89.85 164.98 14.39 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.44 0.638 . . . . 0.0 110.619 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.493 HE21 ' HE2' ' A' ' 13' ' ' HIS . 83.0 mt-30 -155.99 -178.2 7.13 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.684 179.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -135.29 111.69 9.82 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.372 -0.232 . . . . 0.0 110.372 179.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -117.81 127.8 54.24 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 120.792 0.33 . . . . 0.0 110.515 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 5.8 m -133.04 128.39 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-O 121.149 0.5 . . . . 0.0 111.125 179.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 75.0 t80 -122.69 116.13 23.27 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -147.08 153.84 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.343 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.0 133.81 43.62 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.209 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -167.49 92.21 0.38 Allowed 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 62.5 t0 -70.11 121.82 18.24 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -177.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.422 ' O ' ' C ' ' A' ' 25' ' ' GLY . 26.1 m -105.98 121.72 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.637 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . 30.8 82.8 0.01 OUTLIER Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.847 -0.418 . . . . 0.0 112.255 178.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.519 ' OG ' ' ND2' ' B' ' 27' ' ' ASN . 19.9 p -95.8 175.65 6.43 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 118.059 0.93 . . . . 0.0 109.182 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' LYS . 20.1 p30 -61.93 -177.67 0.13 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 176.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.548 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.6 mttm -50.41 -110.85 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.846 0.832 . . . . 0.0 109.842 178.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.66 94.66 1.82 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 176.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.452 ' CB ' HD22 ' A' ' 27' ' ' ASN . . . -92.54 160.65 14.94 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 115.599 -2.441 . . . . 0.0 109.703 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.411 HD12 HG23 ' A' ' 31' ' ' ILE . 0.3 OUTLIER -154.31 119.68 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 114.0 -1.455 . . . . 0.0 109.878 -173.729 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.51 ' O ' ' SD ' ' G' ' 35' ' ' MET . 96.5 mt -119.44 112.45 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.103 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.21 106.64 1.45 Allowed Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 178.335 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 34.7 tp -149.11 147.19 28.19 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 118.124 0.962 . . . . 0.0 113.028 -178.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.511 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 53.5 ttp -141.43 146.35 36.42 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.2 t -128.89 79.61 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.949 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.99 97.85 2.06 Favored Glycine 0 C--N 1.338 0.681 0 N-CA-C 109.599 -1.401 . . . . 0.0 109.599 177.483 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.13 167.81 39.68 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.541 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.37 137.42 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.742 -179.821 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -116.15 138.92 50.85 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.736 0.303 . . . . 0.0 110.434 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -56.37 136.14 53.71 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.899 0.38 . . . . 0.0 110.543 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -137.22 153.13 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.446 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -117.09 160.1 21.53 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.1 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 16.3 p-80 -77.34 171.94 14.08 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -149.48 176.0 11.0 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . 0.558 ' NZ ' ' CG2' ' B' ' 18' ' ' VAL . 62.4 tttm -140.3 123.3 16.59 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.233 0.54 . . . . 0.0 111.407 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.1 mt -118.37 124.08 46.86 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.093 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . 0.558 ' CG2' ' NZ ' ' B' ' 16' ' ' LYS . 93.7 t -119.56 121.45 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 C-N-CA 120.711 -0.395 . . . . 0.0 110.998 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 11.8 t80 -115.2 112.22 22.16 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -132.59 125.76 31.21 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.18 0.514 . . . . 0.0 112.238 -177.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.66 126.28 49.85 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -153.96 159.75 41.81 Favored 'General case' 0 C--N 1.348 0.512 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -121.46 123.06 41.15 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.535 0.607 . . . . 0.0 111.885 -178.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.17 120.88 55.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.18 84.11 0.01 OUTLIER Glycine 0 N--CA 1.471 0.986 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.445 179.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 4.3 p -45.88 167.61 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.519 ' ND2' ' OG ' ' A' ' 26' ' ' SER . 2.2 p30 -137.82 178.87 6.78 Favored 'General case' 0 C--O 1.203 -1.383 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 171.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.499 ' O ' ' O ' ' B' ' 27' ' ' ASN . 61.2 mttp -19.85 -103.13 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 CA-C-N 120.219 1.372 . . . . 0.0 113.338 176.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -142.62 99.94 0.24 Allowed Glycine 0 N--CA 1.485 1.962 0 N-CA-C 107.831 -2.108 . . . . 0.0 107.831 174.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.449 ' H ' ' CE ' ' C' ' 28' ' ' LYS . . . -70.6 156.55 39.3 Favored 'General case' 0 C--O 1.245 0.836 0 C-N-CA 117.064 -1.854 . . . . 0.0 109.399 177.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.25 115.49 2.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.481 ' O ' ' SD ' ' H' ' 35' ' ' MET . 82.9 mt -121.13 119.62 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -177.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.51 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -125.37 117.15 2.87 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 177.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 9.6 tt -148.8 154.67 39.87 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.532 -178.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 17.6 ttp -147.83 141.57 25.66 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 120.16 -0.616 . . . . 0.0 112.458 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' B' ' 37' ' ' GLY . 38.2 t -131.78 83.28 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.307 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.472 ' C ' ' O ' ' B' ' 36' ' ' VAL . . . -23.45 -93.71 0.01 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.818 -0.513 . . . . 0.0 111.818 177.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.88 179.16 40.33 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 8.3 p -143.95 153.09 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.937 0.398 . . . . 0.0 110.821 -179.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.46 179.722 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -111.51 146.95 36.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 110.378 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -55.84 146.19 22.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.16 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.513 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 32.9 m -129.28 156.31 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.513 ' CD2' ' O ' ' C' ' 12' ' ' VAL . 48.2 m80 -158.01 151.71 23.75 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.405 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -87.39 -179.67 6.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 13.1 pt20 -88.2 174.91 7.94 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.958 -179.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -123.85 138.77 54.44 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -141.62 131.65 24.62 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 120.422 -0.511 . . . . 0.0 111.764 -179.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -126.55 130.42 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.307 0.575 . . . . 0.0 109.706 178.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -117.34 118.52 32.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.135 -178.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -130.35 114.9 16.18 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 118.147 0.43 . . . . 0.0 110.017 179.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.03 126.74 51.54 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.645 -0.422 . . . . 0.0 111.549 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -157.73 155.7 30.36 Favored 'General case' 0 C--O 1.226 -0.158 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.524 ' O ' ' NZ ' ' E' ' 28' ' ' LYS . 7.2 t0 -175.21 108.58 0.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 119.794 -0.762 . . . . 0.0 112.251 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 m -46.46 141.05 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 176.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -86.34 82.82 1.63 Allowed Glycine 0 N--CA 1.463 0.468 0 C-N-CA 118.471 -1.823 . . . . 0.0 110.159 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 50.7 p -100.48 -163.97 1.07 Allowed 'General case' 0 N--CA 1.439 -0.991 0 CA-C-O 122.432 1.11 . . . . 0.0 110.077 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.489 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 61.8 t30 -63.31 179.5 0.42 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.266 -1.788 . . . . 0.0 109.344 175.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.489 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 41.5 tttt 55.35 111.08 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 118.424 2.75 . . . . 0.0 118.424 178.075 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -81.63 96.43 1.77 Allowed Glycine 0 CA--C 1.497 -1.088 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 171.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 163.67 22.1 Favored 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 116.22 -2.192 . . . . 0.0 108.278 -177.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.86 108.06 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.013 -174.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.484 ' C ' ' SD ' ' I' ' 35' ' ' MET . 2.0 mt -106.78 117.9 53.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.96 94.25 0.51 Allowed Glycine 0 CA--C 1.523 0.577 0 N-CA-C 107.912 -2.075 . . . . 0.0 107.912 177.522 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 22.7 tp -124.77 137.03 54.34 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.345 1.069 . . . . 0.0 112.048 -178.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' D' ' 35' ' ' MET . 11.3 mmm -110.97 116.38 31.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.835 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 m -142.88 63.45 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 C-N-CA 121.11 -0.236 . . . . 0.0 110.507 -179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.09 -110.31 0.79 Allowed Glycine 0 C--N 1.363 2.053 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.56 -175.2 34.03 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.92 158.69 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.602 -179.728 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -111.39 130.12 55.8 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.771 0.32 . . . . 0.0 110.307 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 34.6 tp10 -136.98 135.91 38.05 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.398 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -141.76 148.22 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 121.04 0.448 . . . . 0.0 111.54 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.448 ' NE2' ' OE2' ' E' ' 11' ' ' GLU . 86.8 m-70 -123.66 125.19 44.36 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.801 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.58 ' CG ' ' N ' ' D' ' 15' ' ' GLN . 82.5 t60 -136.94 166.84 22.71 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.163 0.506 . . . . 0.0 110.144 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.58 ' N ' ' CG ' ' D' ' 14' ' ' HIS . 51.9 tt0 -161.61 173.23 15.04 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.438 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 65.1 tttp -160.92 110.12 1.65 Allowed 'General case' 0 C--O 1.235 0.307 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.95 179.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -122.0 115.82 23.21 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.911 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.4 t -114.35 115.61 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -114.27 109.05 17.77 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -178.164 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -136.47 130.89 33.28 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.444 0.64 . . . . 0.0 111.621 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . 0.427 ' CB ' ' CD1' ' F' ' 32' ' ' ILE . . . -144.83 145.09 31.47 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.352 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -132.67 102.96 5.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.751 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -79.26 112.54 16.59 Favored 'General case' 0 C--O 1.231 0.119 0 C-N-CA 118.099 -1.44 . . . . 0.0 107.631 179.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 89.6 t -60.92 130.38 24.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.694 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -68.74 86.35 0.21 Allowed Glycine 0 CA--C 1.538 1.489 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.618 177.517 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.4 OUTLIER 162.18 161.3 0.02 OUTLIER 'General case' 0 C--N 1.345 0.393 0 CA-C-N 119.267 1.533 . . . . 0.0 112.786 176.801 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.462 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 87.1 m-20 -34.07 -179.65 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 112.056 -2.338 . . . . 0.0 116.25 179.119 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' E' ' 29' ' ' GLY . 86.7 tttt 98.92 114.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 128.095 2.558 . . . . 0.0 113.576 176.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.447 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -73.39 92.1 0.66 Allowed Glycine 0 N--CA 1.473 1.132 0 CA-C-O 116.284 -2.398 . . . . 0.0 113.159 173.478 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.87 157.09 35.01 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 123.271 3.536 . . . . 0.0 109.197 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.415 ' HB ' ' SD ' ' J' ' 35' ' ' MET . 0.0 OUTLIER -145.01 126.1 8.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.892 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.725 -177.216 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.518 ' C ' ' SD ' ' J' ' 35' ' ' MET . 2.1 mt -110.49 110.48 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . 0.408 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -109.21 95.57 0.91 Allowed Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 178.35 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -122.07 120.97 35.87 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-O 121.578 0.704 . . . . 0.0 110.461 -178.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' C' ' 35' ' ' MET . 26.9 ttt -102.02 114.04 27.8 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 176.725 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.51 80.64 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.247 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.437 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.22 102.46 0.86 Allowed Glycine 0 C--N 1.353 1.475 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.88 -167.06 38.9 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 40' ' ' VAL . 53.9 t -123.07 136.89 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 39' ' ' VAL . 18.0 m . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.47 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -111.61 133.13 54.07 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.855 0.359 . . . . 0.0 110.95 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.496 ' O ' ' O ' ' F' ' 11' ' ' GLU . 39.1 tp10 -120.51 127.39 52.14 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.8 t -134.13 134.36 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 O-C-N 123.322 0.389 . . . . 0.0 110.466 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 58.0 m80 -119.47 133.64 55.59 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 120.884 0.373 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.494 ' ND1' ' O ' ' F' ' 14' ' ' HIS . 85.2 t60 -143.3 165.41 27.55 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 178.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.474 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 81.8 mt-30 -154.94 179.16 9.39 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.359 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.35 108.13 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.692 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -126.99 121.93 33.06 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.025 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 77.4 t -125.88 127.53 71.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.746 0.307 . . . . 0.0 110.881 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -126.47 120.53 29.94 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.514 179.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -133.9 127.36 32.34 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.027 0.442 . . . . 0.0 110.263 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.29 128.42 41.51 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.341 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -110.56 167.69 10.02 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.345 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' E' ' 24' ' ' VAL . 14.3 t0 -173.11 -125.28 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.389 -177.144 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.519 ' N ' ' OD1' ' E' ' 23' ' ' ASP . 7.9 t 31.61 115.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -90.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 106.001 -2.84 . . . . 0.0 106.001 179.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.544 ' O ' ' O ' ' E' ' 27' ' ' ASN . 27.9 p -152.03 155.0 37.1 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 119.224 1.512 . . . . 0.0 109.067 172.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.544 ' O ' ' O ' ' E' ' 26' ' ' SER . 17.0 m120 -20.01 157.83 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 176.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.524 ' NZ ' ' O ' ' C' ' 23' ' ' ASP . 75.4 tttt -162.88 110.89 1.28 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.09 170.41 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.595 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -68.53 92.12 0.27 Allowed Glycine 0 C--O 1.218 -0.852 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 174.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.41 150.56 33.73 Favored 'General case' 0 CA--C 1.464 -2.345 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 175.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -151.24 117.24 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 C-N-CA 118.679 -1.208 . . . . 0.0 110.042 -172.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.56 112.99 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . 0.438 ' H ' ' HE3' ' J' ' 35' ' ' MET . . . -109.28 85.9 0.42 Allowed Glycine 0 CA--C 1.499 -0.963 0 N-CA-C 104.884 -3.286 . . . . 0.0 104.884 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.549 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 6.4 tt -130.31 134.05 46.91 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.787 0.803 . . . . 0.0 111.717 -177.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.7 ttm -122.91 125.34 45.15 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.484 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -124.32 81.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.687 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . 34.42 -101.66 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.681 -0.567 . . . . 0.0 111.681 178.231 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.94 -172.21 33.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.784 -0.927 . . . . 0.0 110.784 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.06 161.2 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.893 0.378 . . . . 0.0 110.595 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 8.8 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.362 179.788 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -82.23 139.25 34.35 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.496 ' O ' ' O ' ' E' ' 11' ' ' GLU . 97.6 mt-10 -124.88 167.03 15.23 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-O 121.302 0.572 . . . . 0.0 110.79 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -147.3 156.72 10.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.719 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.671 ' CG ' ' H ' ' F' ' 14' ' ' HIS . 46.4 t-80 -111.62 175.18 5.53 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.671 ' H ' ' CG ' ' F' ' 13' ' ' HIS . 98.1 m-70 -70.2 177.05 3.47 Favored 'General case' 0 N--CA 1.44 -0.936 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' E' ' 15' ' ' GLN . 57.7 mm-40 -133.26 179.19 6.35 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.278 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -151.29 106.06 3.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.21 0.528 . . . . 0.0 110.695 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 tt -127.81 121.58 30.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.182 179.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.51 129.93 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.532 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -120.1 128.1 53.15 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.577 179.133 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -142.37 130.14 21.62 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.973 0.416 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.53 141.02 26.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.474 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 74.4 tt0 -92.51 115.46 28.11 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -73.87 134.32 43.25 Favored 'General case' 0 N--CA 1.462 0.126 0 CA-C-O 121.169 0.509 . . . . 0.0 111.317 -178.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.514 ' O ' ' N ' ' F' ' 26' ' ' SER . 62.4 t -89.4 112.75 24.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.223 179.391 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.538 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . -46.05 92.16 0.01 OUTLIER Glycine 0 CA--C 1.533 1.213 0 N-CA-C 110.209 -1.157 . . . . 0.0 110.209 177.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' F' ' 27' ' ' ASN . 68.0 m 121.04 172.43 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 -178.76 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' F' ' 26' ' ' SER . 15.4 p30 -41.21 176.37 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 121.127 0.489 . . . . 0.0 111.476 -179.006 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 43.9 tttm -75.33 110.44 9.68 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.79 -99.33 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 177.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.37 170.95 15.69 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 103.356 -2.831 . . . . 0.0 103.356 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.94 117.13 12.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 118.043 -1.463 . . . . 0.0 111.398 -172.473 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.427 ' CD1' ' CB ' ' D' ' 21' ' ' ALA . 12.9 tt -103.86 123.2 57.41 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.261 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.19 102.75 1.04 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 tt -122.95 113.36 18.99 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.443 ' SD ' ' O ' ' K' ' 32' ' ' ILE . 28.3 ttt -95.39 121.88 37.53 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.606 -178.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -138.3 80.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.614 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 40.57 -103.25 0.03 OUTLIER Glycine 0 C--N 1.346 1.11 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.214 177.154 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -147.84 7.77 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 40' ' ' VAL . 55.9 t -121.41 136.39 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.874 0.368 . . . . 0.0 110.766 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 39' ' ' VAL . 2.3 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.592 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -108.15 137.93 45.29 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.482 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -125.33 145.67 49.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.077 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 7.4 m -119.78 134.79 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.134 0.492 . . . . 0.0 110.851 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -142.63 140.26 31.56 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.01 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -88.74 169.13 11.9 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.332 0.587 . . . . 0.0 110.532 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -151.4 177.67 10.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.486 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -137.58 129.11 28.27 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.665 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.5 tp -123.8 125.84 45.41 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -131.39 127.71 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.601 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 9.5 m-85 -113.58 117.5 31.81 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 176.595 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.518 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 39.9 p90 -130.37 118.02 20.61 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 121.034 -0.266 . . . . 0.0 111.558 -179.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . 0.484 ' O ' ' OE1' ' H' ' 22' ' ' GLU . . . -117.96 117.4 29.13 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 68.4 tt0 -144.75 175.0 10.5 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 123.729 0.643 . . . . 0.0 109.815 -179.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 15.8 t0 -64.85 113.55 3.9 Favored 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 112.025 0.379 . . . . 0.0 112.025 -178.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.42 ' H ' ' HA2' ' H' ' 25' ' ' GLY . 60.1 t -127.22 121.54 57.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' G' ' 24' ' ' VAL . . . -29.22 -85.87 0.01 OUTLIER Glycine 0 CA--C 1.535 1.317 0 CA-C-O 121.607 0.559 . . . . 0.0 113.481 179.044 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.6 t 65.7 176.2 0.22 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 -178.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -88.06 177.31 6.96 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.98 176.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -56.73 110.41 0.79 Allowed 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 118.612 -0.709 . . . . 0.0 111.895 175.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.53 ' H ' ' CB ' ' H' ' 27' ' ' ASN . . . 72.12 94.51 0.08 OUTLIER Glycine 0 N--CA 1.469 0.897 0 C-N-CA 118.165 -1.969 . . . . 0.0 112.391 174.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.87 156.13 19.02 Favored 'General case' 0 CA--C 1.507 -0.679 0 CA-C-N 120.004 1.902 . . . . 0.0 107.885 178.066 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.44 HG23 HD12 ' G' ' 31' ' ' ILE . 0.4 OUTLIER -152.53 106.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.347 -0.842 . . . . 0.0 108.835 -173.187 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.447 ' C ' ' SD ' ' A' ' 35' ' ' MET . 50.3 mm -124.56 130.57 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.103 -178.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . 0.511 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -135.57 125.5 3.65 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 179.247 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.4 tp -144.82 136.85 25.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.258 0.529 . . . . 0.0 111.857 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.51 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 11.4 ttt -133.66 144.71 49.36 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.401 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.4 t -102.51 72.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.46 100.71 1.38 Allowed Glycine 0 C--N 1.341 0.837 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 177.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.93 170.96 41.62 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.423 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 5.6 p -135.8 143.33 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.52 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 80.5 t . . . . . 0 C--O 1.218 -0.565 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.565 -179.372 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -82.46 145.46 29.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.732 0.301 . . . . 0.0 110.593 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.03 137.09 47.69 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-O 121.194 0.521 . . . . 0.0 110.751 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.1 t -121.75 134.03 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.546 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 t-80 -142.49 103.46 4.25 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.197 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.434 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 33.4 p-80 -152.23 168.7 24.5 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.484 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -150.58 171.96 16.27 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.151 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -134.45 118.39 17.32 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.245 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -118.57 121.33 39.96 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 62.3 t -124.43 126.28 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.976 0.417 . . . . 0.0 110.421 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.511 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 2.5 m-85 -119.16 108.91 15.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -117.17 115.62 25.68 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 177.372 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.1 130.09 46.04 Favored 'General case' 0 C--O 1.242 0.671 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -177.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.566 ' O ' ' O ' ' H' ' 23' ' ' ASP . 52.4 mp0 -142.29 141.9 32.48 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.825 -1.534 . . . . 0.0 107.194 176.79 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.566 ' O ' ' O ' ' H' ' 22' ' ' GLU . 7.6 t0 -54.79 -130.63 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' H' ' 23' ' ' ASP . 32.7 m 28.49 111.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 178.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.42 ' HA2' ' H ' ' G' ' 24' ' ' VAL . . . -160.86 -91.24 0.08 OUTLIER Glycine 0 CA--C 1.521 0.428 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 177.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -101.81 -163.2 0.99 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 119.551 1.676 . . . . 0.0 109.487 176.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.53 ' CB ' ' H ' ' G' ' 29' ' ' GLY . 66.5 t30 -61.8 177.62 0.41 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.777 177.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.522 ' H ' ' CG ' ' H' ' 27' ' ' ASN . 60.1 tttm -47.51 111.06 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.291 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 92.43 -95.71 2.05 Favored Glycine 0 C--O 1.207 -1.591 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.217 -176.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.444 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . 70.44 145.37 0.06 Allowed 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 103.141 -2.911 . . . . 0.0 103.141 -176.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 5.2 tt -163.34 124.61 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 115.783 -2.367 . . . . 0.0 112.266 -177.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.9 mt -120.22 122.94 69.61 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 113.947 -1.478 . . . . 0.0 109.951 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.28 117.08 2.46 Favored Glycine 0 N--CA 1.47 0.9 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.73 141.97 51.74 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.277 0.561 . . . . 0.0 111.127 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.51 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 23.2 ttt -140.39 126.58 19.8 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.127 0.489 . . . . 0.0 111.303 -178.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 11.8 t -122.68 74.06 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.024 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.42 101.49 2.32 Favored Glycine 0 C--N 1.344 1.023 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.65 159.13 31.78 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 120.245 -0.979 . . . . 0.0 111.722 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -125.9 134.64 66.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.885 -1.055 . . . . 0.0 110.552 -179.903 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -113.4 135.94 53.32 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.958 0.408 . . . . 0.0 110.644 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 81.1 mm-40 -122.0 129.49 52.5 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.066 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m -143.5 140.22 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-O 120.884 0.373 . . . . 0.0 110.721 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 48.2 m-70 -144.07 104.43 4.13 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.855 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.434 ' O ' ' CB ' ' H' ' 14' ' ' HIS . 5.3 m170 -130.82 169.03 16.27 Favored 'General case' 0 C--O 1.221 -0.442 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 81.2 mt-30 -155.31 172.14 18.69 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 178.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -145.09 125.1 13.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.717 0.294 . . . . 0.0 111.279 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 37.9 tp -125.82 117.46 23.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 120.806 0.336 . . . . 0.0 110.35 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -122.59 127.96 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.934 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -121.91 117.25 26.0 Favored 'General case' 0 N--CA 1.47 0.575 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.411 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 42.0 t80 -126.24 123.76 38.88 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.32 132.07 42.59 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.813 0.339 . . . . 0.0 111.412 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -155.93 157.33 36.09 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.767 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.405 ' HB2' ' HZ1' ' K' ' 28' ' ' LYS . 7.1 t70 -111.6 101.83 10.2 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 121.415 0.626 . . . . 0.0 110.655 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.9 p -90.01 159.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.068 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 49.64 -80.28 0.01 OUTLIER Glycine 0 CA--C 1.531 1.073 0 CA-C-O 119.382 -0.677 . . . . 0.0 112.955 -179.126 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.621 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.4 p 170.84 -179.53 0.05 OUTLIER 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 118.445 1.122 . . . . 0.0 110.577 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.621 ' O ' ' O ' ' I' ' 26' ' ' SER . 42.0 p-10 -28.31 -179.82 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 -177.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.445 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 83.9 mttt 128.77 103.38 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 111.828 -2.442 . . . . 0.0 108.571 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -59.25 100.32 0.18 Allowed Glycine 0 CA--C 1.486 -1.756 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.665 177.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' H' ' 29' ' ' GLY . . . -112.47 144.67 41.54 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 103.869 -2.641 . . . . 0.0 103.869 177.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 mt -137.98 107.21 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 C-N-CA 118.251 -1.38 . . . . 0.0 110.472 -174.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -117.66 130.75 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 120.981 0.42 . . . . 0.0 110.115 179.094 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -134.18 134.01 7.17 Favored Glycine 0 CA--C 1.503 -0.673 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 177.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.429 ' H ' ' HG ' ' J' ' 34' ' ' LEU . 3.8 tt -145.89 131.21 18.56 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.799 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.484 ' SD ' ' C ' ' C' ' 32' ' ' ILE . 8.7 ttt -112.91 119.75 39.04 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.263 -1.335 . . . . 0.0 108.395 179.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.1 OUTLIER -118.53 72.38 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.645 -179.504 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -31.15 -100.25 0.01 OUTLIER Glycine 0 C--N 1.369 2.373 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -175.89 40.73 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.1 t -134.37 152.48 33.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.497 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . 0.436 ' O ' ' CE2' ' K' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.367 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -123.15 119.37 30.05 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -137.36 134.2 35.71 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.589 0.233 . . . . 0.0 110.388 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.449 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -126.01 132.81 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.953 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' K' ' 13' ' ' HIS . 66.4 m80 -119.64 140.65 50.29 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.418 -0.216 . . . . 0.0 110.418 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 59.5 t60 -151.83 167.78 27.2 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 121.204 0.526 . . . . 0.0 109.77 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.6 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 66.7 tp60 -158.32 164.31 36.51 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.613 178.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . 0.407 ' N ' ' HG3' ' J' ' 15' ' ' GLN . 50.3 tttp -157.99 116.29 3.08 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.977 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . 0.429 ' CD2' ' C ' ' J' ' 17' ' ' LEU . 7.2 tt -131.35 123.26 27.89 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.51 127.91 57.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.33 0.586 . . . . 0.0 111.636 179.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 6.1 m-30 -109.17 119.2 38.8 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 115.079 -0.964 . . . . 0.0 108.648 178.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD2' ' K' ' 20' ' ' PHE . 34.6 t80 -124.58 113.7 18.41 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 134.23 47.81 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.491 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -134.75 105.99 6.71 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.676 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -85.41 114.24 22.31 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' J' ' 25' ' ' GLY . 4.6 p -122.56 122.9 67.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 24' ' ' VAL . . . 34.61 84.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.141 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -177.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.461 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 6.0 m -46.2 152.05 0.45 Allowed 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 113.722 -1.239 . . . . 0.0 114.066 -177.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' J' ' 28' ' ' LYS . 65.9 m-80 -138.02 178.0 7.45 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.881 172.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.748 ' HZ2' ' H ' ' J' ' 29' ' ' GLY . 0.9 OUTLIER -20.43 -104.12 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.413 1.264 . . . . 0.0 114.413 177.668 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.748 ' H ' ' HZ2' ' J' ' 28' ' ' LYS . . . -167.45 96.88 0.13 Allowed Glycine 0 C--N 1.361 1.919 0 CA-C-O 117.472 -1.738 . . . . 0.0 110.745 176.179 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.2 167.44 14.25 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 123.128 3.464 . . . . 0.0 106.884 177.164 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -145.14 123.79 5.53 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.328 0 CA-C-N 121.128 1.786 . . . . 0.0 111.943 -176.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -122.33 122.52 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . 0.413 ' O ' ' HA2' ' I' ' 33' ' ' GLY . . . -131.17 100.97 0.47 Allowed Glycine 0 N--CA 1.476 1.302 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.601 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 6.0 mp -131.78 138.54 48.61 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-O 122.696 1.236 . . . . 0.0 113.906 -176.763 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.518 ' SD ' ' C ' ' D' ' 32' ' ' ILE . 4.9 ttm -116.66 119.57 35.91 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 113.799 -1.546 . . . . 0.0 109.66 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.61 77.03 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.074 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.738 -179.169 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -84.57 103.97 2.69 Favored Glycine 0 C--N 1.355 1.596 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 179.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.46 170.9 55.14 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 65.6 t -131.47 136.02 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.947 0.403 . . . . 0.0 110.536 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.517 179.817 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . 0.436 ' CE2' ' O ' ' J' ' 9' ' ' GLY . 93.3 m-85 -112.68 133.95 54.45 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' L' ' 10' ' ' TYR . 79.7 mm-40 -137.43 139.23 40.53 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.96 0.409 . . . . 0.0 110.792 -179.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 58.1 t -127.63 132.54 69.02 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' J' ' 13' ' ' HIS . 22.1 m170 -79.26 149.1 31.95 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.86 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 24.5 p-80 -78.84 178.08 8.21 Favored 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -117.87 175.88 5.46 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.574 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -145.14 118.52 9.01 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 120.911 0.386 . . . . 0.0 111.205 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 34.1 mt -124.77 118.8 27.21 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.37 138.15 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.644 0.735 . . . . 0.0 112.633 -178.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -124.21 127.67 48.06 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.288 179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.418 ' CD2' ' CE2' ' J' ' 20' ' ' PHE . 71.5 t80 -133.09 121.07 22.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.56 133.69 31.14 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.476 0.655 . . . . 0.0 112.665 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 96.4 mt-10 -117.69 124.66 49.07 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.211 178.327 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' K' ' 22' ' ' GLU . 14.5 m-20 -140.15 111.89 7.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' K' ' 26' ' ' SER . 6.3 m -129.55 -122.48 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 31.63 -84.25 0.0 OUTLIER Glycine 0 N--CA 1.474 1.183 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 -179.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.623 ' O ' ' O ' ' K' ' 27' ' ' ASN . 3.9 p 170.93 170.64 0.07 Allowed 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.209 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.623 ' O ' ' O ' ' K' ' 26' ' ' SER . 93.6 m-20 -18.75 157.48 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.554 1.159 . . . . 0.0 113.849 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' K' ' 29' ' ' GLY . 88.1 tttt -170.47 104.95 0.28 Allowed 'General case' 0 C--O 1.215 -0.729 0 CA-C-O 117.709 -1.139 . . . . 0.0 109.01 176.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -50.65 -99.08 0.01 OUTLIER Glycine 0 C--O 1.214 -1.126 0 C-N-CA 116.6 -2.714 . . . . 0.0 110.994 178.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 70.74 141.91 0.05 Allowed 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 102.616 -3.105 . . . . 0.0 102.616 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -147.95 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 122.298 2.317 . . . . 0.0 111.214 -176.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.443 ' O ' ' SD ' ' F' ' 35' ' ' MET . 10.6 mt -106.61 113.4 43.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 175.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.7 115.2 2.29 Favored Glycine 0 C--N 1.317 -0.519 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.511 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 0.8 OUTLIER -150.42 143.27 24.69 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 122.732 1.253 . . . . 0.0 112.631 -178.526 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 29.4 ttm -117.67 122.21 42.93 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 113.664 -1.607 . . . . 0.0 109.308 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -116.2 79.76 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.23 103.91 0.4 Allowed Glycine 0 C--N 1.351 1.377 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.48 -163.11 15.38 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.1 136.27 54.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 120.833 0.349 . . . . 0.0 110.623 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 86.6 t . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.455 179.868 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . 0.402 ' O ' ' OE2' ' K' ' 11' ' ' GLU . 94.9 m-85 -108.48 137.52 46.3 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.901 0.381 . . . . 0.0 110.928 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -96.34 158.89 15.23 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 179.34 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.16 133.14 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.823 0.344 . . . . 0.0 110.562 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 65.6 t60 -160.24 117.53 2.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.173 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.474 ' ND1' ' O ' ' L' ' 13' ' ' HIS . 80.1 m-70 -151.51 174.55 13.27 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -146.08 170.59 16.36 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -148.89 117.85 6.72 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.662 0.268 . . . . 0.0 110.303 -179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 7.2 tt -126.48 115.89 20.26 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.215 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 m -136.62 137.2 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-O 121.005 0.431 . . . . 0.0 110.426 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -134.28 133.81 41.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.237 0.541 . . . . 0.0 111.275 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -135.56 124.74 24.51 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.722 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -150.37 146.45 26.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.329 -0.548 . . . . 0.0 111.594 -179.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -104.17 102.15 11.88 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -91.87 113.64 25.96 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.562 ' O ' ' N ' ' L' ' 26' ' ' SER . 85.2 t -65.95 131.26 31.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.439 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -54.53 84.51 0.01 OUTLIER Glycine 0 CA--C 1.528 0.892 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.271 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.562 ' N ' ' O ' ' L' ' 24' ' ' VAL . 1.4 p 159.82 178.88 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.473 ' O ' ' O ' ' L' ' 26' ' ' SER . 21.2 p30 -41.92 177.64 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.053 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.552 ' NZ ' ' O ' ' L' ' 30' ' ' ALA . 8.6 tptp -75.2 110.57 9.64 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.708 -1.133 . . . . 0.0 112.31 178.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -51.29 -99.87 0.01 OUTLIER Glycine 0 C--N 1.317 -0.513 0 CA-C-O 119.054 -0.859 . . . . 0.0 111.607 179.714 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.552 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . . . -80.48 163.91 23.41 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 104.75 -2.315 . . . . 0.0 104.75 -178.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -135.28 128.85 49.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 116.487 -2.085 . . . . 0.0 113.038 -174.155 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 2.0 pt -117.52 114.94 47.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.232 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.8 90.64 0.56 Allowed Glycine 0 N--CA 1.463 0.47 0 N-CA-C 106.029 -2.828 . . . . 0.0 106.029 176.492 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . 0.451 ' N ' ' CD1' ' L' ' 34' ' ' LEU . 9.1 mp -116.16 134.59 54.76 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.747 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 77.7 mmm -119.62 119.47 33.84 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.683 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' L' ' 37' ' ' GLY . 1.2 m -125.64 76.54 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 115.043 -0.981 . . . . 0.0 108.657 178.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -37.12 105.71 0.04 OUTLIER Glycine 0 C--N 1.356 1.646 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.86 172.15 6.81 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.933 -0.467 . . . . 0.0 111.933 -177.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 14.9 p -133.57 144.07 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 115.457 -0.371 . . . . 0.0 110.362 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.558 179.797 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -148.36 159.47 43.98 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.8 tp10 -134.52 127.32 31.13 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 121.242 0.544 . . . . 0.0 110.866 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m -139.3 163.78 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -107.24 119.41 39.33 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.687 0.28 . . . . 0.0 111.032 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -100.27 165.88 11.25 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -156.23 174.14 15.83 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.887 178.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttp -175.8 115.76 0.14 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.377 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 97.0 mt -124.89 115.69 21.03 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.119 0.485 . . . . 0.0 110.439 179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.2 m -122.14 126.92 75.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.355 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.467 ' CZ ' ' CD1' ' C' ' 34' ' ' LEU . 0.6 OUTLIER -117.85 113.52 21.9 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.418 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 t80 -122.87 116.42 23.61 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.79 119.87 38.11 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.22 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -174.79 108.57 0.11 Allowed 'General case' 0 CA--C 1.528 0.098 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -74.09 114.6 12.61 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.98 -0.688 . . . . 0.0 109.782 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.9 m -121.46 123.54 69.85 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.769 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.4 82.09 0.01 OUTLIER Glycine 0 CA--C 1.53 0.971 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.259 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.616 ' O ' ' O ' ' A' ' 27' ' ' ASN . 58.4 m -140.5 170.68 15.34 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 117.923 0.862 . . . . 0.0 108.942 177.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.616 ' O ' ' O ' ' A' ' 26' ' ' SER . 70.9 m-80 -30.94 174.4 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.707 0 O-C-N 124.29 0.994 . . . . 0.0 113.261 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.61 110.84 21.67 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.592 176.416 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 52.09 91.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.719 0 C-N-CA 119.922 -1.132 . . . . 0.0 110.436 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.65 166.77 10.22 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 118.906 1.353 . . . . 0.0 110.518 179.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.05 107.32 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.389 -178.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 93.6 mt -128.21 130.09 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 121.442 0.639 . . . . 0.0 112.291 -177.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.433 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -128.13 110.88 1.2 Allowed Glycine 0 CA--C 1.521 0.439 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.03 124.55 52.88 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 120.908 0.385 . . . . 0.0 110.395 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.55 ' SD ' ' CA ' ' G' ' 33' ' ' GLY . 25.7 ttt -130.73 126.32 36.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.893 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.1 t -98.12 65.39 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 112.983 0.735 . . . . 0.0 112.983 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.2 -106.19 0.06 OUTLIER Glycine 0 N--CA 1.44 -1.075 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -95.44 178.16 35.26 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -135.14 140.53 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 120.92 0.39 . . . . 0.0 110.275 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.935 -179.401 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -103.49 130.17 50.81 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.652 0.263 . . . . 0.0 110.481 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -76.85 136.08 38.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.559 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m -135.53 166.04 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 121.165 0.507 . . . . 0.0 111.344 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.612 ' CG ' ' H ' ' B' ' 14' ' ' HIS . 15.3 t-80 -122.86 -164.26 1.18 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.036 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.612 ' H ' ' CG ' ' B' ' 13' ' ' HIS . 19.9 t-80 -71.59 168.05 18.46 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.586 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 79.0 mt-30 -152.3 177.47 10.53 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.156 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -158.43 128.63 6.02 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 120.554 -0.458 . . . . 0.0 111.672 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.44 119.55 29.51 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -129.21 131.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 121.068 0.461 . . . . 0.0 111.52 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.435 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 7.9 t80 -122.64 115.55 22.3 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 53.3 t80 -125.59 122.33 36.17 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 110.4 -0.222 . . . . 0.0 110.4 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.52 125.77 45.49 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -163.48 130.23 3.34 Favored 'General case' 0 C--O 1.222 -0.364 0 CA-C-N 115.018 -0.992 . . . . 0.0 108.472 178.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' NZ ' ' D' ' 28' ' ' LYS . 66.1 t0 -142.6 113.14 7.31 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 m -59.32 131.59 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.13 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 176.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.36 84.33 0.1 Allowed Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.357 -0.925 . . . . 0.0 113.313 -178.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 6.3 p -87.77 180.0 6.38 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.757 0.789 . . . . 0.0 109.438 176.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.487 ' O ' ' O ' ' B' ' 28' ' ' LYS . 51.1 p30 -76.69 179.22 6.17 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.342 -1.299 . . . . 0.0 109.578 175.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 27' ' ' ASN . 68.4 mttm 43.93 110.53 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 115.019 1.489 . . . . 0.0 115.019 175.773 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.76 97.79 1.51 Allowed Glycine 0 CA--C 1.485 -1.827 0 CA-C-N 113.562 -1.654 . . . . 0.0 110.866 -176.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -75.62 164.75 25.99 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 122.462 1.125 . . . . 0.0 109.658 -175.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -137.57 114.04 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 CA-C-N 112.63 -2.077 . . . . 0.0 110.504 -170.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' I' ' 35' ' ' MET . 96.4 mt -132.83 128.12 56.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 CA-C-O 121.64 0.733 . . . . 0.0 112.805 -177.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.491 ' CA ' ' SD ' ' I' ' 35' ' ' MET . . . -129.74 128.8 5.79 Favored Glycine 0 N--CA 1.471 0.999 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 179.304 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -129.25 126.13 38.4 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.149 0.5 . . . . 0.0 111.761 -178.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 7.2 tpp -120.86 117.81 28.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.428 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.37 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.66 104.63 2.1 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.505 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.44 -171.81 0.65 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.2 m -133.77 163.06 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.896 0.379 . . . . 0.0 110.47 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.342 179.727 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.439 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -116.2 138.53 51.2 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.767 0.318 . . . . 0.0 110.644 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -120.72 128.49 52.99 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.34 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -130.04 134.63 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.496 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.0 t-80 -136.62 127.36 27.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.843 0.354 . . . . 0.0 110.61 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.496 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 79.9 m-70 -152.16 164.74 36.69 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -156.83 171.01 21.16 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.092 178.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -158.13 113.95 2.74 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -114.46 122.38 46.43 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.45 124.52 62.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.658 -0.246 . . . . 0.0 110.431 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.569 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 1.1 t80 -120.46 111.98 18.39 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.054 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.4 t80 -119.84 121.92 40.15 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.681 0.277 . . . . 0.0 110.828 -178.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.74 128.92 49.51 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 121.331 0.586 . . . . 0.0 112.065 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -150.37 149.8 30.56 Favored 'General case' 0 C--O 1.226 -0.157 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.959 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -163.77 121.23 1.8 Allowed 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.63 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.439 ' CG2' ' H ' ' C' ' 25' ' ' GLY . 4.2 m -128.02 -112.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.803 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.439 ' H ' ' CG2' ' C' ' 24' ' ' VAL . . . 34.26 -90.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 115.725 -0.671 . . . . 0.0 112.315 -178.271 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.619 ' O ' ' O ' ' C' ' 27' ' ' ASN . 0.3 OUTLIER 172.0 -170.82 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.6 179.65 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.619 ' O ' ' O ' ' C' ' 26' ' ' SER . 14.3 m120 -20.31 -175.2 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 117.327 2.343 . . . . 0.0 117.327 177.665 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 82.6 tttt 111.64 110.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 CA-C-N 111.81 -2.45 . . . . 0.0 114.477 176.061 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.74 92.48 0.07 OUTLIER Glycine 0 C--O 1.218 -0.87 0 CA-C-N 112.305 -2.225 . . . . 0.0 112.714 171.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.67 156.8 40.47 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 122.902 3.351 . . . . 0.0 107.984 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.412 ' CD1' ' N ' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -138.73 129.07 33.51 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.189 -176.021 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 13.0 tt -133.84 122.97 43.96 Favored 'Isoleucine or valine' 0 C--N 1.348 0.525 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.523 177.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.52 115.36 3.61 Favored Glycine 0 CA--C 1.499 -0.936 0 N-CA-C 107.602 -2.199 . . . . 0.0 107.602 178.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.467 ' CD1' ' CZ ' ' A' ' 19' ' ' PHE . 52.6 mt -116.26 111.4 20.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.117 0.484 . . . . 0.0 111.56 -176.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 24.6 tpp -109.48 103.16 12.01 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 177.126 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -121.35 70.74 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.727 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.239 -178.734 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -38.2 -100.79 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 178.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.85 -163.79 31.73 Favored Glycine 0 CA--C 1.521 0.456 0 N-CA-C 110.535 -1.026 . . . . 0.0 110.535 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 68.5 t -119.19 134.06 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.005 -0.997 . . . . 0.0 110.632 -179.641 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -82.55 137.69 34.5 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.734 0.302 . . . . 0.0 110.461 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -115.75 141.28 48.3 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.392 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . 0.477 ' C ' ' ND1' ' D' ' 13' ' ' HIS . 9.8 p -130.17 135.59 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-O 121.142 0.496 . . . . 0.0 110.702 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' C ' ' D' ' 12' ' ' VAL . 14.7 m80 -142.56 108.99 5.3 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.555 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.44 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 31.6 m-70 -126.55 167.08 16.13 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -151.39 171.86 16.83 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.581 179.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -155.24 121.16 5.11 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.139 179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -119.92 122.83 42.11 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.33 125.1 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.016 0.436 . . . . 0.0 110.678 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -118.73 117.55 29.22 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.446 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -128.26 122.3 31.38 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 112.059 0.392 . . . . 0.0 112.059 -177.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.79 121.3 29.84 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-O 121.112 0.482 . . . . 0.0 109.978 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -97.85 175.29 6.21 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.212 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -72.63 122.08 20.83 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.26 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 28.7 m -87.56 123.33 40.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.914 179.107 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -42.88 -86.09 0.01 OUTLIER Glycine 0 CA--C 1.532 1.152 0 C-N-CA 121.393 -0.432 . . . . 0.0 112.443 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.738 ' O ' ' O ' ' D' ' 27' ' ' ASN . 13.2 p -152.84 -171.61 3.99 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -178.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.738 ' O ' ' O ' ' D' ' 26' ' ' SER . 81.5 m-20 -20.15 172.24 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 114.783 1.401 . . . . 0.0 114.783 -179.05 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.556 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 83.2 tttt 132.02 105.65 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 124.95 1.3 . . . . 0.0 107.701 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -49.89 -97.72 0.01 OUTLIER Glycine 0 N--CA 1.473 1.135 0 C-N-CA 118.112 -1.994 . . . . 0.0 110.269 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.451 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . 72.54 145.01 0.07 Allowed 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.451 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 0.3 OUTLIER -149.42 116.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.202 -175.026 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -111.57 111.41 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.741 -179.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.91 97.53 1.61 Allowed Glycine 0 CA--C 1.509 -0.289 0 N-CA-C 105.024 -3.23 . . . . 0.0 105.024 175.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.435 ' CD2' ' CZ ' ' B' ' 19' ' ' PHE . 62.8 tp -110.94 118.67 36.71 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -175.149 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -122.16 108.84 13.78 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 176.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -124.43 70.04 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -49.41 -100.6 0.01 OUTLIER Glycine 0 C--N 1.347 1.142 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.266 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 111.23 159.19 15.67 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -124.15 136.34 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.972 0.415 . . . . 0.0 110.664 -179.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 91.6 t . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.058 -0.973 . . . . 0.0 110.414 179.63 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -104.87 134.95 47.14 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -140.8 146.57 37.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.997 0.427 . . . . 0.0 110.956 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 4.2 m -131.55 155.84 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.748 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -156.75 162.37 39.77 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 121.312 0.577 . . . . 0.0 112.302 -179.025 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.59 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 36.4 t60 -154.96 164.75 38.45 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-O 121.411 0.624 . . . . 0.0 110.635 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.59 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 82.6 mt-30 -149.85 170.03 19.72 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.465 0.65 . . . . 0.0 110.892 178.608 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.19 128.79 3.17 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.096 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 52.5 tp -125.36 124.36 41.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.2 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.73 123.61 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -124.54 120.24 31.39 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.239 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -129.13 120.53 26.02 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 120.31 16.94 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.213 0.53 . . . . 0.0 110.948 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -143.09 128.3 18.71 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.476 179.538 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -154.14 120.4 5.4 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.455 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 14.1 t -107.5 -112.76 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.007 0.432 . . . . 0.0 110.327 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.7 -90.63 0.01 OUTLIER Glycine 0 N--CA 1.469 0.878 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.397 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.602 ' O ' ' O ' ' E' ' 27' ' ' ASN . 2.7 t 171.34 170.1 0.08 Allowed 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.602 ' O ' ' O ' ' E' ' 26' ' ' SER . 60.3 t30 -17.67 158.34 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.533 ' O ' ' CB ' ' F' ' 30' ' ' ALA . 75.2 tttt -161.73 111.41 1.57 Allowed 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.406 175.456 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.77 92.29 0.23 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-O 119.156 -0.802 . . . . 0.0 113.178 176.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.24 154.08 22.82 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.512 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.47 126.05 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 117.49 -1.684 . . . . 0.0 114.123 -175.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.522 ' O ' ' SD ' ' L' ' 35' ' ' MET . 0.8 OUTLIER -114.39 116.39 52.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 114.731 -1.122 . . . . 0.0 108.202 176.505 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.95 102.13 2.76 Favored Glycine 0 CA--C 1.501 -0.811 0 N-CA-C 104.192 -3.563 . . . . 0.0 104.192 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.569 ' CD1' ' CZ ' ' C' ' 19' ' ' PHE . 6.7 tt -107.14 105.54 15.59 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 121.045 0.45 . . . . 0.0 111.366 -174.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.9 ttt -123.82 112.51 17.38 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.5 80.38 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.01 102.76 0.26 Allowed Glycine 0 C--N 1.351 1.397 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.54 -151.55 23.62 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.0 p -130.84 140.82 47.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 43.1 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.755 -179.828 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -116.19 139.34 50.45 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.74 0.305 . . . . 0.0 110.711 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -56.81 135.79 55.55 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.345 -0.389 . . . . 0.0 109.997 179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p -141.81 148.11 21.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.753 . . . . 0.0 111.507 -178.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.444 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 33.0 p-80 -161.64 157.08 24.02 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.188 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 97.0 m-70 -156.4 168.29 27.8 Favored 'General case' 0 CA--C 1.511 -0.537 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.101 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -151.01 173.26 14.52 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 119.951 -0.7 . . . . 0.0 110.716 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -147.66 129.09 14.89 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.447 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 50.8 mt -120.33 115.48 23.63 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.306 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -127.31 129.5 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.82 0.343 . . . . 0.0 110.129 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.524 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.3 p90 -143.34 126.23 16.2 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.069 0.462 . . . . 0.0 111.543 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -127.29 128.11 45.44 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.18 149.64 28.22 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 119.89 -0.724 . . . . 0.0 112.286 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -80.09 126.56 31.23 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -91.32 113.71 26.05 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 121.868 0.842 . . . . 0.0 113.266 -177.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.571 ' O ' ' O ' ' F' ' 26' ' ' SER . 78.4 t -128.54 120.8 53.63 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 177.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.482 ' C ' ' O ' ' F' ' 24' ' ' VAL . . . -27.67 -88.95 0.01 OUTLIER Glycine 0 N--CA 1.486 2.017 0 CA-C-N 119.358 0.981 . . . . 0.0 111.65 -177.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.571 ' O ' ' O ' ' F' ' 24' ' ' VAL . 69.3 m -70.31 -173.55 0.72 Allowed 'General case' 0 CA--C 1.502 -0.899 0 N-CA-C 103.251 -2.87 . . . . 0.0 103.251 175.018 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.478 ' O ' ' O ' ' F' ' 28' ' ' LYS . 16.6 t30 -79.91 176.19 9.96 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 115.677 -2.409 . . . . 0.0 107.941 175.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.478 ' O ' ' O ' ' F' ' 27' ' ' ASN . 80.1 tttt -44.45 -105.83 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.664 0 CA-C-O 123.537 1.637 . . . . 0.0 111.859 174.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.446 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -114.33 -100.45 2.36 Favored Glycine 0 CA--C 1.483 -1.944 0 CA-C-N 111.218 -2.719 . . . . 0.0 113.305 -179.664 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.533 ' CB ' ' O ' ' E' ' 28' ' ' LYS . . . -60.41 177.04 0.3 Allowed 'General case' 0 CA--C 1.474 -1.957 0 CA-C-N 110.82 -2.69 . . . . 0.0 104.933 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 tp -158.41 144.76 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 C-N-CA 114.998 -2.681 . . . . 0.0 114.638 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 pt -102.14 112.34 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-N 112.807 -1.997 . . . . 0.0 107.965 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -80.38 97.12 1.67 Allowed Glycine 0 CA--C 1.497 -1.061 0 N-CA-C 103.496 -3.842 . . . . 0.0 103.496 175.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.416 ' CD1' ' C ' ' F' ' 34' ' ' LEU . 0.3 OUTLIER -100.01 111.09 23.39 Favored 'General case' 0 CA--C 1.497 -1.089 0 CA-C-N 117.412 0.606 . . . . 0.0 111.445 -176.676 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.622 ' SD ' ' O ' ' L' ' 32' ' ' ILE . 24.2 mtp -135.33 114.94 12.71 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-O 122.754 1.264 . . . . 0.0 107.766 176.463 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.516 ' O ' ' CG1' ' F' ' 36' ' ' VAL . 5.5 p -133.0 78.63 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 CA-C-N 112.566 -2.106 . . . . 0.0 108.373 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 51.87 -104.08 0.14 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -175.13 46.7 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.531 ' C ' HD22 ' L' ' 27' ' ' ASN . 66.6 t -131.42 137.72 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 120.814 0.34 . . . . 0.0 111.16 -179.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 61.5 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.119 -0.943 . . . . 0.0 110.335 179.289 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.457 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -98.71 130.29 45.19 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.859 0.361 . . . . 0.0 110.345 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -71.02 147.61 48.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.744 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 t -124.95 134.03 67.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.8 t60 -144.27 136.9 26.85 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.382 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 27.6 m170 -112.78 178.69 4.2 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -102.33 178.11 4.68 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.407 -179.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -97.02 137.63 35.81 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.655 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -123.97 128.14 48.96 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.375 0.607 . . . . 0.0 111.378 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.49 128.85 61.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.562 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -108.85 113.27 26.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 176.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.519 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 52.7 p90 -124.99 123.96 40.98 Favored 'General case' 0 CA--C 1.521 -0.14 0 CA-C-O 120.892 0.377 . . . . 0.0 110.932 -178.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.09 120.84 40.37 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -159.27 141.63 13.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -66.29 112.12 3.83 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' G' ' 26' ' ' SER . 54.2 t -111.86 130.85 64.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.96 81.85 0.0 OUTLIER Glycine 0 CA--C 1.532 1.126 0 CA-C-N 114.97 -1.014 . . . . 0.0 113.376 177.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.516 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.6 m -131.41 179.46 6.02 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 119.172 1.486 . . . . 0.0 109.562 178.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.465 ' O ' ' O ' ' G' ' 26' ' ' SER . 15.0 m120 -40.18 174.37 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.186 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -77.41 110.64 12.34 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.381 175.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.403 ' H ' ' HE2' ' H' ' 28' ' ' LYS . . . 65.36 94.39 0.03 OUTLIER Glycine 0 N--CA 1.466 0.648 0 C-N-CA 118.292 -1.909 . . . . 0.0 110.361 177.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 161.37 13.65 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 120.18 1.99 . . . . 0.0 109.386 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.98 112.77 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.758 -172.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' A' ' 35' ' ' MET . 94.8 mt -121.45 117.26 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-O 120.662 0.268 . . . . 0.0 110.89 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . 0.55 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -125.7 116.39 2.62 Favored Glycine 0 N--CA 1.47 0.911 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 179.401 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.401 HD11 ' H ' ' G' ' 35' ' ' MET . 56.4 tp -144.15 140.57 29.45 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-O 121.384 0.611 . . . . 0.0 112.198 -179.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.433 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 40.0 ttp -130.64 137.73 49.75 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.466 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' G' ' 37' ' ' GLY . 4.8 t -125.82 69.77 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 CA-C-N 116.328 -0.396 . . . . 0.0 112.038 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -43.77 -101.68 0.01 OUTLIER Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.12 174.28 40.21 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 13.3 p -145.03 149.56 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.183 0.516 . . . . 0.0 111.329 -179.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.969 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -82.44 130.11 35.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.012 0.434 . . . . 0.0 110.392 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -115.34 163.51 15.59 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.761 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' H' ' 13' ' ' HIS . 71.5 t -118.66 158.78 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.869 0.842 . . . . 0.0 110.902 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.629 ' CD2' HE21 ' H' ' 15' ' ' GLN . 32.5 p-80 -98.65 154.24 18.09 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -178.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.566 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 58.4 t60 -87.93 167.4 13.77 Favored 'General case' 0 N--CA 1.442 -0.862 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 178.139 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.629 HE21 ' CD2' ' H' ' 13' ' ' HIS . 84.5 mt-30 -150.66 167.2 28.05 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 119.906 -0.717 . . . . 0.0 111.381 178.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . 0.428 ' CG ' ' HE2' ' H' ' 14' ' ' HIS . 98.1 mttt -153.11 115.26 4.37 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.389 -179.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 24.6 tp -122.64 121.86 37.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.737 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.09 123.43 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-O 121.106 0.479 . . . . 0.0 112.146 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -110.2 114.31 27.69 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 177.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.597 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 48.4 t80 -127.63 123.74 36.33 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 118.473 0.579 . . . . 0.0 110.407 -178.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.59 128.67 44.68 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 120.924 0.392 . . . . 0.0 111.918 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -144.87 153.22 41.36 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -105.28 103.7 13.29 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' H' ' 26' ' ' SER . 22.5 t -90.23 153.68 3.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 48.71 -80.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.75 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.7 OUTLIER 171.46 -170.71 0.03 OUTLIER 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 117.371 0.586 . . . . 0.0 109.578 -179.787 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.75 ' O ' ' O ' ' H' ' 26' ' ' SER . 4.9 m120 -18.67 -172.42 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 116.322 1.971 . . . . 0.0 116.322 -178.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.546 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 62.9 tttm 127.02 104.51 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.984 0 CA-C-N 113.644 -1.617 . . . . 0.0 111.307 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.98 96.86 0.07 OUTLIER Glycine 0 N--CA 1.47 0.954 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.153 176.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.99 148.12 43.94 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.1 124.92 5.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.263 -173.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -122.81 117.53 52.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.83 179.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.02 122.72 5.09 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 178.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 7.8 tt -151.44 140.38 21.01 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.557 -0.966 . . . . 0.0 111.582 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 43.0 ttp -131.74 130.17 41.58 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.298 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' H' ' 37' ' ' GLY . 11.6 t -123.77 73.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -48.2 -95.07 0.01 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 177.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.76 177.42 16.71 Favored Glycine 0 C--N 1.336 0.571 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.56 134.57 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.641 -179.739 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -102.6 132.4 48.72 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -94.17 132.54 38.6 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 121.0 0.429 . . . . 0.0 110.437 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m -138.95 159.28 29.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.267 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.458 ' ND1' ' O ' ' H' ' 12' ' ' VAL . 2.0 m80 -107.06 -172.56 2.1 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.958 0.409 . . . . 0.0 110.884 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.598 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 20.9 p-80 -135.91 176.53 8.6 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -133.18 177.73 7.44 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.588 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -138.69 115.9 11.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.039 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 39.0 mt -114.27 117.38 30.95 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -126.62 125.8 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.208 0.528 . . . . 0.0 111.614 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.447 ' CZ ' ' CD2' ' L' ' 34' ' ' LEU . 6.9 m-85 -113.25 115.09 27.65 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 177.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.597 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 25.8 t80 -129.27 122.96 30.71 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.482 0.583 . . . . 0.0 110.237 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.15 131.31 34.53 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.539 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -137.9 132.49 32.53 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -96.69 101.38 12.98 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.59 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.615 ' O ' ' N ' ' I' ' 26' ' ' SER . 53.6 t -91.27 158.46 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 48.9 -80.46 0.01 OUTLIER Glycine 0 CA--C 1.527 0.805 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.427 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.615 ' N ' ' O ' ' I' ' 24' ' ' VAL . 2.4 p 171.16 171.21 0.08 Allowed 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.397 0.618 . . . . 0.0 110.052 -179.481 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.589 ' O ' ' O ' ' I' ' 26' ' ' SER . 23.0 p30 -16.13 158.41 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.335 -1.757 . . . . 0.0 115.5 -176.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.556 ' O ' ' O ' ' J' ' 29' ' ' GLY . 63.5 tttp -161.17 111.03 1.66 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.497 176.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.73 92.8 0.2 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 150.71 52.03 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -151.57 123.43 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 C-N-CA 118.711 -1.196 . . . . 0.0 110.943 -174.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 97.3 mt -116.69 116.21 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.279 178.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.65 98.03 1.03 Allowed Glycine 0 N--CA 1.462 0.381 0 N-CA-C 105.888 -2.885 . . . . 0.0 105.888 175.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -122.61 129.07 51.48 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.68 0.752 . . . . 0.0 112.334 -176.015 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 78.9 mtp -108.91 112.78 25.19 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.434 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.48 ' H ' ' HG2' ' J' ' 35' ' ' MET . 0.2 OUTLIER -123.54 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 177.454 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.6 111.2 3.22 Favored Glycine 0 C--N 1.364 2.107 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.0 179.38 1.56 Allowed Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.39 156.24 41.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.365 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.571 -179.701 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -82.54 140.84 33.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.659 0.266 . . . . 0.0 110.314 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -141.74 159.92 41.23 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.931 0.396 . . . . 0.0 110.874 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' J' ' 13' ' ' HIS . 25.8 t -120.57 161.22 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.469 ' N ' ' CG1' ' J' ' 12' ' ' VAL . 28.9 p-80 -71.48 150.54 44.77 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -176.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.598 ' NE2' ' CG ' ' I' ' 14' ' ' HIS . 43.8 p-80 -152.86 172.87 16.09 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 113.918 -1.492 . . . . 0.0 107.167 179.326 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -144.36 174.12 11.19 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.59 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -148.73 112.47 5.09 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.333 -0.849 . . . . 0.0 109.974 -179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -117.52 121.21 40.38 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.91 123.28 58.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.937 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.643 ' CE1' ' CE2' ' K' ' 19' ' ' PHE . 94.9 m-85 -115.87 117.09 29.24 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -123.22 111.24 16.23 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.54 132.93 46.97 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -120.84 87.89 2.84 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.216 -0.902 . . . . 0.0 108.862 177.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.522 ' C ' ' HZ3' ' K' ' 28' ' ' LYS . 20.9 m-20 -68.33 -102.42 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 114.602 -1.181 . . . . 0.0 108.53 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' J' ' 23' ' ' ASP . 34.5 t 46.43 157.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 122.661 1.22 . . . . 0.0 114.254 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.414 ' N ' ' CG1' ' J' ' 24' ' ' VAL . . . 91.67 -80.25 1.26 Allowed Glycine 0 CA--C 1.527 0.843 0 CA-C-N 113.219 -1.809 . . . . 0.0 110.46 -176.786 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.606 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.8 p 170.28 170.48 0.06 Allowed 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 118.092 0.946 . . . . 0.0 109.729 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.606 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.8 t-20 -17.66 157.75 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.699 0 O-C-N 124.953 1.408 . . . . 0.0 114.02 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.553 ' O ' ' O ' ' K' ' 29' ' ' GLY . 61.3 tttt -161.6 110.55 1.53 Allowed 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 173.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.556 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -68.13 93.06 0.27 Allowed Glycine 0 C--O 1.216 -1.0 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.75 177.049 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.472 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -143.28 143.25 31.64 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 103.061 -2.94 . . . . 0.0 103.061 173.404 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.472 ' CG1' ' C ' ' J' ' 30' ' ' ALA . 0.2 OUTLIER -152.37 111.76 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 118.424 -1.31 . . . . 0.0 108.929 -171.546 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.476 ' CG2' ' O ' ' J' ' 32' ' ' ILE . 0.1 OUTLIER -111.6 111.92 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.046 0.451 . . . . 0.0 109.86 -179.491 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.16 94.56 0.75 Allowed Glycine 0 C--O 1.239 0.447 0 N-CA-C 107.398 -2.281 . . . . 0.0 107.398 176.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 9.7 mp -117.33 127.15 53.77 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 122.279 1.038 . . . . 0.0 111.307 -179.216 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.48 ' HG2' ' H ' ' I' ' 36' ' ' VAL . 0.1 OUTLIER -101.57 118.59 37.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.521 178.315 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 98.2 t -133.9 76.55 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.49 104.58 2.07 Favored Glycine 0 C--N 1.352 1.443 0 CA-C-N 115.353 -0.839 . . . . 0.0 111.849 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.61 -176.76 40.0 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.6 m -134.4 162.5 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.682 0.277 . . . . 0.0 110.509 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 95.0 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.886 -179.76 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -111.53 145.79 38.46 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.706 0.288 . . . . 0.0 110.655 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -53.78 148.85 9.39 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.879 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -134.04 156.59 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 121.891 0.853 . . . . 0.0 111.996 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -170.17 83.42 0.11 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.074 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -154.98 169.0 25.1 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 65.5 mt-30 -149.9 178.31 9.03 Favored 'General case' 0 C--N 1.312 -1.047 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.004 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -126.66 109.45 12.1 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.717 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 55.8 mt -111.23 113.04 25.25 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.9 t -126.24 114.13 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 O-C-N 122.015 -0.428 . . . . 0.0 111.091 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.718 ' O ' ' C ' ' L' ' 19' ' ' PHE . 76.0 m-85 -116.86 105.31 12.22 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 177.139 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.436 ' HA ' ' O ' ' L' ' 19' ' ' PHE . 91.0 t80 -128.3 125.99 39.91 Favored 'General case' 0 N--CA 1.482 1.151 0 O-C-N 124.287 0.992 . . . . 0.0 112.219 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.422 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -147.36 156.32 42.79 Favored 'General case' 0 C--N 1.353 0.732 0 C-N-CA 118.502 -1.279 . . . . 0.0 114.236 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -127.3 137.27 52.79 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 11.4 p-10 -165.5 135.43 3.55 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 118.868 -1.133 . . . . 0.0 113.725 -176.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.42 ' O ' ' CG1' ' K' ' 24' ' ' VAL . 13.1 p -70.83 112.74 5.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -50.59 92.47 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.526 -1.215 . . . . 0.0 114.546 -175.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.451 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.5 t 162.35 160.5 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.766 0 CA-C-O 121.801 0.81 . . . . 0.0 110.134 176.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.451 ' O ' ' O ' ' K' ' 26' ' ' SER . 31.4 m120 -29.7 159.8 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 113.785 -1.552 . . . . 0.0 113.207 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.522 ' HZ3' ' C ' ' J' ' 23' ' ' ASP . 75.6 tttt 179.48 104.01 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.228 175.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -65.62 94.7 0.2 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.923 -0.932 . . . . 0.0 113.781 177.624 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.429 ' O ' ' CG2' ' K' ' 31' ' ' ILE . . . -168.01 147.08 4.67 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.429 ' CG2' ' O ' ' K' ' 30' ' ' ALA . 0.1 OUTLIER -160.37 130.02 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.54 0 C-N-CA 118.283 -1.367 . . . . 0.0 113.575 -176.311 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 12.8 tt -108.51 113.85 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 175.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.35 121.69 4.88 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 20.1 tp -140.66 136.99 33.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.781 0.801 . . . . 0.0 110.214 179.121 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.7 ttm -112.03 124.09 51.67 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 m -124.06 79.38 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -69.4 103.3 1.07 Allowed Glycine 0 C--N 1.35 1.308 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.48 146.9 17.38 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -127.12 136.78 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 120.734 0.302 . . . . 0.0 110.223 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 16.0 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.422 179.76 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -90.22 128.05 36.29 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.754 0.312 . . . . 0.0 110.81 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -140.06 160.83 39.06 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 109.935 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . 0.438 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 49.6 t -118.63 130.17 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.553 0.692 . . . . 0.0 110.372 179.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.438 ' CD2' ' O ' ' L' ' 12' ' ' VAL . 88.6 m-70 -156.86 110.44 2.63 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.583 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.519 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 35.3 t-80 -156.85 175.67 13.77 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.039 0.447 . . . . 0.0 109.881 -179.054 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.519 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 77.8 mt-30 -142.4 -179.97 6.59 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.216 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -164.66 114.48 1.16 Allowed 'General case' 0 C--O 1.234 0.261 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.7 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 17.5 mt -116.02 121.25 41.68 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -112.36 133.1 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 118.802 0.728 . . . . 0.0 110.966 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.718 ' C ' ' O ' ' K' ' 19' ' ' PHE . 63.6 m-85 -42.37 141.56 0.95 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 -172.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.567 ' N ' ' O ' ' K' ' 19' ' ' PHE . 50.5 p90 -99.93 -169.47 1.74 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-N 108.638 -3.892 . . . . 0.0 110.363 179.298 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.45 ' C ' ' O ' ' L' ' 20' ' ' PHE . . . -23.47 135.24 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -173.282 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -70.46 159.38 34.35 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 113.04 -1.891 . . . . 0.0 109.239 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -50.52 114.05 1.04 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.106 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 25' ' ' GLY . 3.5 m -127.82 121.22 55.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.812 -178.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -27.84 -87.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.956 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -67.2 -173.01 0.24 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-O 121.222 0.534 . . . . 0.0 109.992 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.531 HD22 ' C ' ' F' ' 39' ' ' VAL . 72.4 m-20 -78.73 175.88 10.04 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.025 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 32.2 tttm -49.12 111.21 0.45 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 114.219 -1.355 . . . . 0.0 113.967 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.47 -97.86 0.05 OUTLIER Glycine 0 C--O 1.223 -0.593 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.95 172.23 1.03 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 120.265 2.033 . . . . 0.0 106.544 -179.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.9 141.26 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 117.236 -1.786 . . . . 0.0 114.375 -173.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.622 ' O ' ' SD ' ' F' ' 35' ' ' MET . 88.4 mt -109.14 114.66 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 CA-C-N 114.061 -1.427 . . . . 0.0 110.131 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.92 91.25 0.56 Allowed Glycine 0 CA--C 1.517 0.179 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 177.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . 0.447 ' CD2' ' CZ ' ' I' ' 19' ' ' PHE . 18.9 tp -117.72 120.65 38.61 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.205 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 42.2 ttp -97.08 119.19 35.11 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.084 179.067 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' L' ' 37' ' ' GLY . 1.4 m -130.25 71.01 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -29.8 -102.67 0.01 OUTLIER Glycine 0 C--N 1.358 1.802 0 O-C-N 122.935 0.147 . . . . 0.0 112.892 -178.729 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.61 163.07 35.86 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -136.81 162.64 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.913 0.387 . . . . 0.0 110.661 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.635 -179.414 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.58 128.89 49.05 Favored 'General case' 0 N--CA 1.463 0.194 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.513 ' CD ' ' HE2' ' A' ' 13' ' ' HIS . 81.6 tt0 -156.09 143.23 19.07 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.529 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p -136.49 143.29 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.663 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.513 ' HE2' ' CD ' ' A' ' 11' ' ' GLU . 98.7 m-70 -131.25 138.83 49.49 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.161 0.505 . . . . 0.0 111.295 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.588 ' CD2' ' H ' ' A' ' 15' ' ' GLN . 10.5 t-80 -156.85 165.85 35.04 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.588 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 51.2 tt0 -169.52 169.93 8.52 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.537 179.265 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -152.27 115.12 4.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.983 178.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 35.3 tp -121.37 121.6 37.99 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 109.945 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 35.5 m -122.85 122.68 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 CA-C-O 121.351 0.596 . . . . 0.0 111.246 -179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.461 ' CD1' ' CE1' ' B' ' 19' ' ' PHE . 15.6 t80 -123.64 106.41 10.52 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 178.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -134.39 145.94 49.4 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.01 117.76 13.16 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.122 -0.945 . . . . 0.0 108.512 177.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -130.76 157.65 42.27 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.408 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 47.5 t0 -98.42 112.69 24.62 Favored 'General case' 0 N--CA 1.462 0.158 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.518 ' O ' ' C ' ' A' ' 25' ' ' GLY . 2.1 p -147.72 113.49 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 103.595 -2.742 . . . . 0.0 103.595 172.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -19.87 87.17 0.01 OUTLIER Glycine 0 N--CA 1.476 1.303 0 CA-C-O 119.282 -0.732 . . . . 0.0 112.522 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.483 ' N ' ' O ' ' A' ' 24' ' ' VAL . 40.9 t -67.97 -179.72 1.28 Allowed 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 119.219 1.509 . . . . 0.0 108.046 178.044 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 53.2 p30 -87.31 174.93 8.26 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt 35.85 -108.45 0.05 OUTLIER 'General case' 0 CA--C 1.538 0.514 0 CA-C-O 122.28 1.038 . . . . 0.0 113.574 173.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.412 ' O ' ' C ' ' A' ' 30' ' ' ALA . . . 90.59 -102.04 2.87 Favored Glycine 1 CA--C 1.427 -5.457 0 CA-C-N 113.157 -1.838 . . . . 0.0 108.635 -177.384 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.412 ' C ' ' O ' ' A' ' 29' ' ' GLY . . . 56.63 -146.95 0.54 Allowed 'General case' 0 N--CA 1.405 -2.7 0 C-N-CA 113.497 -3.281 . . . . 0.0 109.7 173.251 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.666 ' CD1' ' H ' ' A' ' 31' ' ' ILE 0.252 0.0 OUTLIER -89.89 113.65 26.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 CA-C-N 113.259 -1.791 . . . . 0.0 113.688 -179.788 . . . . . . . . 4 4 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' G' ' 35' ' ' MET . 87.1 mt -130.03 120.17 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 O-C-N 120.103 -1.623 . . . . 0.0 109.922 178.395 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.609 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.68 113.63 1.53 Allowed Glycine 0 CA--C 1.52 0.375 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -133.29 134.9 44.47 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.99 0.424 . . . . 0.0 110.72 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 5.9 ttm -125.44 129.62 50.21 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.738 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.92 70.8 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 120.656 -0.417 . . . . 0.0 111.473 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -114.66 100.65 1.02 Allowed Glycine 0 C--N 1.341 0.811 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 177.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.65 41.6 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.554 -1.018 . . . . 0.0 110.554 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -120.04 136.21 57.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.76 0.314 . . . . 0.0 110.383 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.7 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.139 -0.934 . . . . 0.0 110.663 -179.895 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 56.3 p90 -143.08 157.41 44.55 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.874 0.369 . . . . 0.0 110.653 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -144.45 150.41 37.61 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.252 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 33.5 t -130.77 159.78 42.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.039 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.674 ' HE2' HE21 ' B' ' 15' ' ' GLN . 86.0 t60 -157.87 101.47 1.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.628 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 55.7 m170 -110.2 167.44 10.19 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.674 HE21 ' HE2' ' B' ' 13' ' ' HIS . 87.8 mt-30 -152.43 176.7 11.38 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.231 179.347 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -171.46 111.95 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.638 178.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 64.1 mt -120.98 120.33 35.11 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.5 t -120.79 121.6 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 120.889 -0.325 . . . . 0.0 111.432 -179.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.461 ' CE1' ' CD1' ' A' ' 19' ' ' PHE . 12.0 t80 -120.7 110.54 16.51 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -119.32 117.11 27.67 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.22 119.92 34.61 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -177.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' B' ' 23' ' ' ASP . 95.3 mt-10 -153.05 89.82 1.4 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 115.162 -0.926 . . . . 0.0 108.754 176.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.458 ' C ' ' O ' ' B' ' 22' ' ' GLU . 49.5 t0 8.2 113.63 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 114.039 1.125 . . . . 0.0 114.039 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 85.4 t -58.56 131.2 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.205 0.526 . . . . 0.0 110.367 178.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.34 84.67 0.13 Allowed Glycine 0 CA--C 1.529 0.927 0 CA-C-N 115.415 -0.811 . . . . 0.0 113.768 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.517 ' O ' ' O ' ' B' ' 27' ' ' ASN . 39.0 m -132.24 162.67 30.38 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 118.284 1.042 . . . . 0.0 110.003 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.517 ' O ' ' O ' ' B' ' 26' ' ' SER . 65.5 t30 -38.44 177.72 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.632 179.384 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.509 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 98.7 mttt -73.31 111.87 8.84 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.22 92.5 0.08 OUTLIER Glycine 0 N--CA 1.464 0.567 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 -178.092 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.58 152.66 49.72 Favored 'General case' 0 CA--C 1.487 -1.465 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 174.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.449 ' N ' ' CD1' ' B' ' 31' ' ' ILE . 0.0 OUTLIER -139.89 117.44 10.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -173.989 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.524 ' O ' ' SD ' ' I' ' 35' ' ' MET . 81.6 mt -122.13 126.63 74.62 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.733 -177.014 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.1 118.53 3.59 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 42.3 tp -126.53 118.45 24.92 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.292 0.568 . . . . 0.0 110.557 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.8 tpt -106.4 115.52 30.35 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.487 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' B' ' 37' ' ' GLY . 8.8 t -112.65 74.16 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.782 -0.19 . . . . 0.0 110.823 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.442 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -40.07 -95.84 0.01 OUTLIER Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -170.68 40.02 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m -135.72 161.9 37.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.896 0.379 . . . . 0.0 110.344 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.572 179.969 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -86.88 144.87 26.8 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.379 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.542 ' CD ' ' HE2' ' C' ' 13' ' ' HIS . 84.6 tt0 -142.32 136.25 29.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.957 0.408 . . . . 0.0 110.55 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 5.6 m -126.23 131.56 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.008 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.542 ' HE2' ' CD ' ' C' ' 11' ' ' GLU . 82.1 m-70 -114.75 127.18 55.6 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.162 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CG ' ' D' ' 13' ' ' HIS . 4.0 m-70 -119.04 164.08 16.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 79.7 mt-30 -156.68 170.42 22.46 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 121.234 0.54 . . . . 0.0 110.818 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -168.0 113.83 0.68 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.362 178.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 tp -128.15 123.64 34.89 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 35.6 m -124.87 126.68 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.524 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 47.3 t80 -123.78 111.04 15.65 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.929 -178.562 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -114.56 119.35 36.5 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 120.428 0.156 . . . . 0.0 110.767 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.82 115.97 27.85 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.8 mt-10 -150.7 169.4 21.69 Favored 'General case' 0 C--N 1.347 0.473 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.707 -179.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.475 ' HB3' ' HZ3' ' E' ' 28' ' ' LYS . 74.8 m-20 -155.45 121.2 5.03 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.582 ' CG1' ' H ' ' C' ' 25' ' ' GLY . 3.5 p -136.73 -112.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.311 -177.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.582 ' H ' ' CG1' ' C' ' 24' ' ' VAL . . . 30.38 -89.21 0.01 OUTLIER Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.434 -177.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.4 t 171.54 177.73 0.07 Allowed 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 117.817 0.808 . . . . 0.0 109.687 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' C' ' 26' ' ' SER . 42.4 t30 -28.46 178.07 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.722 0 O-C-N 124.766 1.291 . . . . 0.0 113.818 -179.189 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.577 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 88.8 mttt 127.66 104.91 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 C-N-CA 125.564 1.545 . . . . 0.0 111.616 175.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.37 96.64 0.07 OUTLIER Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 174.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -122.54 145.69 48.1 Favored 'General case' 0 CA--C 1.479 -1.77 0 N-CA-C 104.519 -2.4 . . . . 0.0 104.519 176.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.417 ' CG1' ' C ' ' C' ' 30' ' ' ALA . 2.0 mt -142.8 108.4 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.548 0 CA-C-N 113.851 -1.522 . . . . 0.0 108.801 -172.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 14.9 tt -120.17 128.06 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 CA-C-O 121.054 0.454 . . . . 0.0 110.176 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.407 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -133.67 122.6 3.1 Favored Glycine 0 CA--C 1.508 -0.387 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.472 ' CD1' ' N ' ' C' ' 34' ' ' LEU . 0.0 OUTLIER -136.96 147.44 46.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 122.085 0.945 . . . . 0.0 111.837 -179.084 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.509 ' SD ' ' O ' ' I' ' 32' ' ' ILE . 5.1 tpt -111.56 117.42 32.92 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.54 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 26.2 t -130.96 66.33 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 -179.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -123.83 102.48 0.73 Allowed Glycine 0 C--N 1.358 1.772 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.83 -170.31 12.66 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 -179.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.2 t -119.47 135.03 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.703 -179.475 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -125.68 143.66 50.94 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.889 0.376 . . . . 0.0 110.557 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' C' ' 11' ' ' GLU . 95.0 mt-10 -63.41 152.46 38.16 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.683 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 32.5 m -134.36 156.87 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 121.008 0.432 . . . . 0.0 110.485 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.701 ' CG ' ' H ' ' D' ' 14' ' ' HIS . 51.6 t60 -93.14 -169.93 2.28 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.572 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.701 ' H ' ' CG ' ' D' ' 13' ' ' HIS . 52.9 m80 -73.85 170.61 14.99 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.353 0.597 . . . . 0.0 110.146 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -148.93 173.58 13.17 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.177 179.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -147.26 114.63 6.29 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 120.898 0.38 . . . . 0.0 111.409 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -122.36 116.16 23.55 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.04 131.13 72.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.38 0.609 . . . . 0.0 110.654 -179.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.524 ' CE2' ' CD1' ' C' ' 19' ' ' PHE . 28.1 t80 -131.62 110.75 11.16 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -118.71 126.45 51.93 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.817 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.3 126.25 45.73 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.602 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -149.52 111.56 4.61 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.496 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -90.35 134.04 34.59 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.591 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.09 112.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.278 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.49 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -46.53 91.77 0.01 OUTLIER Glycine 0 CA--C 1.536 1.367 0 CA-C-O 119.125 -0.819 . . . . 0.0 114.276 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 1.4 t 161.98 161.08 0.02 OUTLIER 'General case' 0 C--O 1.212 -0.89 0 CA-C-N 118.472 1.136 . . . . 0.0 112.303 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.466 ' O ' ' O ' ' D' ' 26' ' ' SER . 73.7 m-80 -33.48 -179.26 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 112.998 -1.91 . . . . 0.0 116.118 178.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.466 ' O ' ' O ' ' E' ' 29' ' ' GLY . 87.1 tttt 99.64 113.8 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 128.398 2.679 . . . . 0.0 115.73 177.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.29 92.53 0.58 Allowed Glycine 0 C--N 1.348 1.238 0 CA-C-N 111.868 -2.423 . . . . 0.0 114.474 173.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.99 151.54 49.02 Favored 'General case' 0 CA--C 1.501 -0.911 0 CA-C-N 121.369 2.584 . . . . 0.0 106.725 173.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.03 116.84 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.56 -173.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.25 124.92 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.81 99.19 0.53 Allowed Glycine 0 N--CA 1.464 0.534 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 177.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' E' ' 34' ' ' LEU . 40.7 tp -126.3 130.23 50.43 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 122.75 1.262 . . . . 0.0 112.69 -179.07 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -104.54 110.92 23.4 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 113.688 -1.596 . . . . 0.0 107.302 176.372 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.463 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -126.68 71.38 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.758 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -34.27 -100.46 0.01 OUTLIER Glycine 0 C--N 1.357 1.696 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.33 -168.06 40.65 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.2 160.58 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.955 0.407 . . . . 0.0 110.933 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.711 -179.978 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -114.47 139.17 49.75 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -113.67 141.26 47.45 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.941 0.4 . . . . 0.0 110.802 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 19.1 m -134.29 158.07 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.95 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.49 ' ND1' ' CE1' ' D' ' 14' ' ' HIS . 12.1 m170 -86.75 178.31 7.05 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.1 OUTLIER -77.08 172.23 13.55 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -179.359 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.493 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 44.2 tt0 -148.2 170.17 18.44 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.113 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . 0.493 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 99.1 mttt -144.16 117.28 8.92 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.123 0.487 . . . . 0.0 111.165 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.2 tt -119.21 114.95 23.23 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 t -124.06 120.46 59.53 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.601 0.715 . . . . 0.0 111.743 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.569 ' O ' ' N ' ' F' ' 20' ' ' PHE . 10.2 m-85 -126.39 104.54 8.23 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 48.1 t80 -121.97 129.6 52.63 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 122.975 0.172 . . . . 0.0 111.092 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . 0.587 ' O ' ' C ' ' F' ' 21' ' ' ALA . . . -133.82 135.39 43.75 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-O 123.362 1.553 . . . . 0.0 113.332 178.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -145.14 105.37 4.06 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.976 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.431 ' O ' ' OD2' ' F' ' 23' ' ' ASP . 4.2 t0 -83.04 122.63 28.58 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.977 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 63.4 t -72.8 120.42 21.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.353 0.597 . . . . 0.0 111.863 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.9 -90.25 0.04 OUTLIER Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.016 -0.993 . . . . 0.0 114.633 176.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.638 ' O ' ' O ' ' E' ' 27' ' ' ASN . 9.7 p -171.14 -178.61 2.47 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-O 121.153 0.502 . . . . 0.0 110.992 -176.423 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.638 ' O ' ' O ' ' E' ' 26' ' ' SER . 92.1 m-20 20.62 -179.81 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 117.12 2.267 . . . . 0.0 117.12 178.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.512 ' CB ' ' O ' ' E' ' 27' ' ' ASN . 78.2 tttt 128.68 106.13 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 112.381 -2.19 . . . . 0.0 110.002 -177.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -55.32 93.6 0.02 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.054 176.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.73 144.64 18.07 Favored 'General case' 0 CA--C 1.477 -1.843 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 174.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -154.55 125.66 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 117.946 -1.502 . . . . 0.0 111.177 -173.029 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -109.51 117.42 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.768 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . 0.458 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -109.63 97.86 1.07 Allowed Glycine 0 C--O 1.231 -0.074 0 N-CA-C 106.28 -2.728 . . . . 0.0 106.28 176.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.424 ' O ' ' HA ' ' F' ' 34' ' ' LEU . 6.9 tt -138.87 128.68 24.95 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-O 123.01 1.386 . . . . 0.0 113.427 -176.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 97.3 mmm -106.98 120.27 41.62 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 114.097 -1.41 . . . . 0.0 110.489 179.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.1 OUTLIER -116.39 72.31 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 176.968 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -27.71 -101.03 0.01 OUTLIER Glycine 0 C--N 1.366 2.218 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.32 -176.71 25.67 Favored Glycine 0 N--CA 1.461 0.365 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -129.22 160.18 40.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.28 -0.46 . . . . 0.0 109.995 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.903 -1.046 . . . . 0.0 110.565 179.859 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -96.19 134.65 39.01 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.824 0.345 . . . . 0.0 110.465 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -85.34 136.11 33.61 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.336 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.465 ' CG2' ' N ' ' F' ' 13' ' ' HIS . 2.7 p -143.28 161.52 17.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.964 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.465 ' N ' ' CG2' ' F' ' 12' ' ' VAL . 17.5 m-70 -95.02 97.99 10.35 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.586 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.569 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 82.9 t60 -156.36 167.74 29.49 Favored 'General case' 0 N--CA 1.446 -0.672 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.569 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 12.0 pt20 -167.33 177.83 5.86 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.104 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -121.55 123.97 43.26 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.664 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 mt -122.94 121.21 35.59 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 111.653 0.242 . . . . 0.0 111.653 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.89 133.11 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 177.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.54 ' O ' ' O ' ' F' ' 20' ' ' PHE . 98.0 m-85 -114.24 136.58 52.8 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -177.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.569 ' N ' ' O ' ' E' ' 19' ' ' PHE . 42.0 p90 -20.58 -157.29 0.0 OUTLIER 'General case' 0 C--O 1.195 -1.792 0 N-CA-C 118.991 2.96 . . . . 0.0 118.991 -175.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . 0.587 ' C ' ' O ' ' E' ' 21' ' ' ALA . . . 175.54 -168.56 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 122.213 1.006 . . . . 0.0 111.54 -173.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -170.97 167.27 7.35 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 114.473 -1.24 . . . . 0.0 107.964 -177.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.431 ' OD2' ' O ' ' E' ' 23' ' ' ASP . 23.6 m-20 -92.84 113.98 26.41 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 119.05 0.841 . . . . 0.0 111.823 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 p -31.2 123.9 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-N 115.194 -0.912 . . . . 0.0 112.743 177.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.87 -85.1 0.1 OUTLIER Glycine 0 CA--C 1.526 0.738 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.79 177.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.775 ' O ' ' O ' ' F' ' 27' ' ' ASN . 10.5 m -172.11 173.7 4.25 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 178.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.775 ' O ' ' O ' ' F' ' 26' ' ' SER . 9.0 t-20 19.8 -178.34 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.071 0 O-C-N 125.374 1.671 . . . . 0.0 114.982 178.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.54 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 44.6 tttm -108.49 110.36 21.84 Favored 'General case' 0 N--CA 1.473 0.68 0 CA-C-O 121.224 0.535 . . . . 0.0 111.531 179.018 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -50.27 -99.42 0.01 OUTLIER Glycine 0 CA--C 1.506 -0.488 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.553 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.76 173.39 12.65 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.401 ' HA ' ' HZ2' ' F' ' 28' ' ' LYS . 0.2 OUTLIER -136.7 118.41 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 116.302 -2.159 . . . . 0.0 114.101 -170.38 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' L' ' 35' ' ' MET . 59.4 mt -98.83 112.1 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.054 177.229 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -109.72 89.68 0.56 Allowed Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 105.831 -2.907 . . . . 0.0 105.831 177.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.507 ' C ' ' CD2' ' F' ' 34' ' ' LEU . 0.8 OUTLIER -141.29 147.65 38.53 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 120.714 -0.394 . . . . 0.0 109.952 -177.894 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.508 ' SD ' ' O ' ' L' ' 32' ' ' ILE . 3.6 ttp -137.05 133.95 36.0 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.943 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -114.28 80.32 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.909 -179.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 50.82 -102.66 0.07 OUTLIER Glycine 0 C--N 1.342 0.862 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.763 178.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.44 -156.49 15.49 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 90.9 t -122.96 136.22 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.833 0.349 . . . . 0.0 110.959 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 m . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.482 179.683 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -100.93 127.56 47.36 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -88.68 156.89 18.75 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . 0.488 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 3.4 m -132.85 154.69 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.164 0.507 . . . . 0.0 110.601 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 96.2 m-70 -158.2 167.11 30.71 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.153 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -122.53 179.1 4.71 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 98.7 mt-30 -96.85 176.6 5.92 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.376 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -113.96 144.04 43.73 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.098 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.3 mt -119.07 126.83 52.6 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.048 0.452 . . . . 0.0 110.786 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 25.9 m -133.44 119.96 36.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 121.18 0.514 . . . . 0.0 110.658 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.451 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 2.4 m-85 -113.07 119.63 38.51 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.26 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.528 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 48.5 p90 -122.2 121.78 37.65 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.071 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.94 122.47 42.31 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 120.55 -0.46 . . . . 0.0 111.812 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -166.73 89.17 0.36 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.628 ' H ' ' NZ ' ' I' ' 28' ' ' LYS . 90.8 m-20 -85.71 102.78 13.91 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.993 0.425 . . . . 0.0 112.131 -177.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.412 ' O ' ' O ' ' G' ' 23' ' ' ASP . 18.3 m -56.78 -160.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.489 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -77.59 80.51 1.3 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-O 119.524 -0.598 . . . . 0.0 112.947 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.416 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 30.9 t -94.4 176.55 6.26 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 118.76 1.28 . . . . 0.0 107.879 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -60.14 178.24 0.2 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 119.166 -1.013 . . . . 0.0 111.096 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -60.77 110.71 1.39 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.064 -0.517 . . . . 0.0 112.318 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.87 94.25 0.08 OUTLIER Glycine 0 N--CA 1.465 0.61 0 C-N-CA 118.381 -1.866 . . . . 0.0 112.601 174.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.43 158.72 16.46 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-N 119.935 1.867 . . . . 0.0 106.464 177.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.585 ' N ' ' CD1' ' G' ' 31' ' ' ILE . 0.2 OUTLIER -150.31 114.72 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.382 -174.427 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 97.3 mt -125.27 124.98 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.224 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.02 123.12 3.92 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 tp -131.03 133.7 45.99 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 117.211 0.505 . . . . 0.0 111.32 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.609 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 63.4 ttp -130.82 134.91 47.25 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.421 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.52 79.78 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.79 104.64 1.27 Allowed Glycine 0 C--N 1.342 0.905 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 44.05 -167.2 0.02 OUTLIER Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.24 160.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 120.855 0.36 . . . . 0.0 110.65 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.515 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -80.91 136.12 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.781 0.324 . . . . 0.0 110.624 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -52.64 137.63 30.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.466 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -127.41 132.87 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.159 0.504 . . . . 0.0 110.744 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.51 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 34.5 m170 -126.99 111.38 14.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.106 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.448 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 84.0 t60 -114.05 162.15 16.82 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.448 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 83.3 mt-30 -156.72 177.9 10.96 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.136 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -167.73 111.23 0.65 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.824 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -116.96 120.92 39.91 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 66.7 t -124.0 123.34 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 121.343 0.592 . . . . 0.0 110.786 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.481 ' CD2' ' CE1' ' I' ' 19' ' ' PHE . 11.5 m-85 -117.02 115.49 25.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.132 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -143.13 132.2 23.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.967 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 138.84 41.06 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.105 0.955 . . . . 0.0 112.777 -178.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -131.01 105.91 8.04 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 105.861 -1.903 . . . . 0.0 105.861 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -77.95 117.25 19.1 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -175.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.556 ' O ' ' N ' ' H' ' 26' ' ' SER . 55.0 t -102.46 125.94 56.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.6 83.05 0.0 OUTLIER Glycine 0 CA--C 1.537 1.443 0 CA-C-O 119.536 -0.591 . . . . 0.0 113.291 178.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.556 ' N ' ' O ' ' H' ' 24' ' ' VAL . 17.4 p -94.15 176.8 6.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 177.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' O ' ' G' ' 26' ' ' SER . 28.1 m120 -60.11 178.22 0.2 Allowed 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.247 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -60.63 110.66 1.35 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.03 94.17 0.08 OUTLIER Glycine 0 N--CA 1.469 0.869 0 C-N-CA 118.741 -1.695 . . . . 0.0 114.815 173.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.19 157.57 17.47 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 102.659 -3.089 . . . . 0.0 102.659 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.86 121.61 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 118.146 -1.421 . . . . 0.0 112.207 -171.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 93.0 mt -132.57 127.47 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.381 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.74 128.6 5.55 Favored Glycine 0 N--CA 1.472 1.097 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.786 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 mp -132.6 130.66 40.53 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.284 0.564 . . . . 0.0 111.458 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.3 tmm? -129.67 127.32 40.29 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.454 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' H' ' 37' ' ' GLY . 66.9 t -107.41 86.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -179.009 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.493 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -15.48 -93.38 0.01 OUTLIER Glycine 0 C--N 1.346 1.084 0 O-C-N 123.859 0.724 . . . . 0.0 112.288 177.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.44 -176.13 42.32 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.62 162.23 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 120.715 0.293 . . . . 0.0 110.501 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.403 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.361 179.791 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 46.0 p90 -143.09 147.99 35.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.913 0.387 . . . . 0.0 110.571 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -143.35 131.02 21.3 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 35.7 m -145.18 164.52 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.541 -177.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.536 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 53.3 m-70 -68.43 145.1 54.4 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -177.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 47.8 m-70 -154.66 169.28 24.25 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.382 179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 54.8 tt0 -159.99 168.3 25.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.033 178.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -154.64 131.54 10.83 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.51 0.195 . . . . 0.0 110.539 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -127.72 119.91 26.82 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 70.7 t -126.24 129.53 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 120.629 -0.428 . . . . 0.0 112.151 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.481 ' CE1' ' CD2' ' H' ' 19' ' ' PHE . 61.2 m-85 -123.22 121.75 36.68 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.924 179.169 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.419 ' CE2' ' CG ' ' J' ' 20' ' ' PHE . 7.5 m-85 -131.67 130.69 42.37 Favored 'General case' 0 N--CA 1.476 0.867 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 135.17 39.23 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -137.76 150.28 47.12 Favored 'General case' 0 C--N 1.352 0.692 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.247 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.435 ' OD2' ' O ' ' J' ' 26' ' ' SER . 13.4 t70 -116.95 114.53 23.96 Favored 'General case' 0 N--CA 1.481 1.115 0 O-C-N 122.21 -0.306 . . . . 0.0 111.36 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.458 ' O ' ' N ' ' I' ' 26' ' ' SER . 14.7 t -81.59 130.93 34.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.8 -85.8 0.01 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.529 ' O ' ' O ' ' I' ' 27' ' ' ASN . 26.1 p -153.62 -172.86 4.37 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-O 121.639 0.733 . . . . 0.0 111.224 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.734 ' H ' ' HZ2' ' K' ' 28' ' ' LYS . 64.8 t30 -19.71 159.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 113.303 -1.771 . . . . 0.0 115.156 178.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.628 ' NZ ' ' H ' ' G' ' 23' ' ' ASP . 74.1 tttt -161.21 110.83 1.64 Allowed 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 114.744 -1.116 . . . . 0.0 109.376 175.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.33 93.23 0.23 Allowed Glycine 0 CA--C 1.508 -0.369 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 177.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.73 147.05 51.3 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 176.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.68 113.97 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.942 -175.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.509 ' O ' ' SD ' ' C' ' 35' ' ' MET . 0.1 OUTLIER -110.76 124.56 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.522 179.471 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.35 102.84 1.39 Allowed Glycine 0 N--CA 1.46 0.292 0 N-CA-C 108.446 -1.862 . . . . 0.0 108.446 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.451 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 23.1 tp -119.0 126.68 52.29 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 117.277 0.538 . . . . 0.0 111.817 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.524 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 12.2 ptm -131.9 110.87 11.1 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 174.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.18 72.02 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.652 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.57 179.554 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.61 102.81 2.33 Favored Glycine 0 C--N 1.36 1.869 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.62 157.36 22.07 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.4 t -124.28 136.56 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.913 0.387 . . . . 0.0 110.53 -179.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.377 179.78 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.426 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -83.38 138.48 33.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.797 0.332 . . . . 0.0 110.478 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -152.34 137.54 17.43 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.408 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -93.03 126.93 45.4 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.694 0 CA-C-O 121.319 0.58 . . . . 0.0 109.847 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.545 ' O ' ' CD2' ' J' ' 14' ' ' HIS . 18.3 t60 -164.92 111.76 0.99 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.233 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' K' ' 13' ' ' HIS . 86.2 m-70 -154.55 177.23 11.43 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -133.82 177.58 7.61 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.731 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -137.54 131.77 32.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 mt -117.89 121.7 41.41 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.673 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 67.8 t -122.47 121.21 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-O 120.948 0.404 . . . . 0.0 110.961 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.418 ' CE1' ' CD2' ' L' ' 34' ' ' LEU . 96.9 m-85 -113.39 114.49 26.68 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 178.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 19.2 t80 -129.03 123.34 32.09 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.988 0.423 . . . . 0.0 111.634 -177.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.94 124.12 32.31 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.05 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.4 tt0 -103.52 156.81 17.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.131 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.467 ' CG ' ' H ' ' J' ' 24' ' ' VAL . 35.2 t70 -78.13 -113.89 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.341 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' J' ' 26' ' ' SER . 4.1 t 73.45 124.45 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.57 -87.09 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -177.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.678 ' O ' ' O ' ' J' ' 27' ' ' ASN . 0.5 OUTLIER 170.79 176.17 0.06 Allowed 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.702 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.678 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.4 m120 -28.3 170.42 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.13 0 O-C-N 124.319 1.012 . . . . 0.0 112.074 177.446 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.561 ' O ' ' N ' ' J' ' 30' ' ' ALA . 37.4 pttt -148.73 111.55 4.82 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.161 -0.962 . . . . 0.0 112.208 177.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.44 91.35 0.01 OUTLIER Glycine 0 CA--C 1.505 -0.566 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 176.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -137.85 153.71 49.56 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 103.328 -2.842 . . . . 0.0 103.328 177.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.41 111.67 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 C-N-CA 118.265 -1.374 . . . . 0.0 109.968 -174.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.467 ' CG2' ' O ' ' J' ' 32' ' ' ILE . 6.7 tt -112.71 116.63 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.293 -0.867 . . . . 0.0 108.731 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.07 103.69 2.33 Favored Glycine 0 N--CA 1.46 0.284 0 N-CA-C 107.596 -2.202 . . . . 0.0 107.596 178.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.437 ' CD1' ' CE1' ' H' ' 19' ' ' PHE . 24.2 mt -114.39 114.0 25.28 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 121.606 0.717 . . . . 0.0 110.247 -177.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -116.59 118.65 33.21 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.506 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.44 ' O ' ' C ' ' J' ' 37' ' ' GLY . 1.1 t -131.15 75.95 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.025 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.2 -97.56 0.01 OUTLIER Glycine 0 C--N 1.362 2.025 0 N-CA-C 112.097 -0.401 . . . . 0.0 112.097 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.97 -163.85 30.23 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 82.9 t -121.95 135.32 62.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.039 -0.982 . . . . 0.0 110.554 -179.649 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.1 137.88 50.77 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 120.89 0.376 . . . . 0.0 110.514 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.77 162.28 35.12 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.4 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 6.0 m -110.7 133.22 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.557 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 0.4 OUTLIER -76.12 -166.01 0.55 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.259 -178.546 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 7.6 p-80 -138.23 178.45 7.12 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.607 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -99.27 175.1 5.99 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.486 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -147.42 124.95 11.69 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -117.55 124.05 47.74 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 44.9 t -127.94 126.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-O 120.832 0.349 . . . . 0.0 111.575 -179.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -115.62 116.09 27.53 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.594 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.7 t80 -125.19 122.73 37.88 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.68 26.4 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.159 1.17 . . . . 0.0 114.159 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' L' ' 22' ' ' GLU . 70.3 mm-40 -90.46 152.41 20.97 Favored 'General case' 0 C--O 1.232 0.158 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 177.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.561 ' OD2' ' N ' ' L' ' 28' ' ' LYS . 28.0 t0 -148.43 116.29 6.36 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.028 0.442 . . . . 0.0 111.739 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 2.5 p -146.81 112.14 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.044 -179.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.32 91.32 0.01 OUTLIER Glycine 0 N--CA 1.472 1.064 0 CA-C-O 121.509 0.505 . . . . 0.0 112.63 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -45.15 153.86 0.18 Allowed 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 122.597 1.189 . . . . 0.0 112.511 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.514 ' O ' ' C ' ' K' ' 28' ' ' LYS . 33.9 m120 -156.85 178.58 10.19 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 112.631 -2.077 . . . . 0.0 108.483 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.734 ' HZ2' ' H ' ' I' ' 27' ' ' ASN . 0.1 OUTLIER 2.91 -104.33 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.411 0 C-N-CA 123.562 0.745 . . . . 0.0 112.05 179.816 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 141.09 95.33 0.25 Allowed Glycine 0 N--CA 1.48 1.602 0 CA-C-N 118.986 0.812 . . . . 0.0 111.924 178.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.4 169.85 0.41 Allowed 'General case' 0 C--N 1.345 0.399 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.036 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -148.53 111.97 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 118.996 -1.082 . . . . 0.0 109.035 -179.028 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -111.99 122.08 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.465 -177.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.45 108.99 2.54 Favored Glycine 0 N--CA 1.468 0.829 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 mt -122.09 114.96 21.63 Favored 'General case' 0 CA--C 1.501 -0.913 0 CA-C-N 117.332 0.566 . . . . 0.0 110.821 -177.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.458 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 33.6 ttp -120.86 114.31 21.41 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 176.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -130.19 73.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 107.672 -1.232 . . . . 0.0 107.672 178.632 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.35 -101.6 0.01 OUTLIER Glycine 0 C--N 1.364 2.121 0 O-C-N 123.59 0.556 . . . . 0.0 112.482 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.35 -170.97 38.11 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -125.13 137.19 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.848 -179.788 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -100.77 132.7 46.04 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -151.32 147.39 26.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.965 0.412 . . . . 0.0 111.055 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.5 t -123.13 129.32 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.471 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 56.5 p-80 -170.74 111.88 0.39 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.053 0.454 . . . . 0.0 110.973 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 96.6 m-70 -155.8 177.81 10.98 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -115.58 173.8 6.35 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.302 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 50.3 mtpt -151.25 109.54 3.76 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.959 0.409 . . . . 0.0 110.455 179.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 57.6 tp -123.66 118.51 27.44 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -130.26 133.06 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.875 0.369 . . . . 0.0 110.086 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.469 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -136.86 129.73 30.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.271 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -138.8 132.05 30.0 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.496 0.665 . . . . 0.0 110.455 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.83 138.88 42.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.498 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 95.0 mt-10 -98.4 114.73 27.19 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -102.68 121.64 42.83 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.26 0.552 . . . . 0.0 111.838 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 25.3 t -104.91 -111.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.34 -91.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' L' ' 27' ' ' ASN . 45.9 m -141.01 170.68 15.28 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' L' ' 26' ' ' SER . 93.8 m-20 -29.0 170.13 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.828 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.561 ' N ' ' OD2' ' K' ' 23' ' ' ASP . 87.8 tttt -148.35 109.99 4.46 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 176.08 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -50.84 -95.8 0.01 OUTLIER Glycine 0 C--N 1.334 0.445 0 C-N-CA 118.549 -1.786 . . . . 0.0 112.545 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.473 ' O ' ' C ' ' L' ' 29' ' ' GLY . . . 72.57 156.11 0.17 Allowed 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 100.409 -3.923 . . . . 0.0 100.409 -176.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.41 HG12 ' C ' ' L' ' 30' ' ' ALA . 0.0 OUTLIER -144.77 107.67 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 CA-C-N 124.081 3.128 . . . . 0.0 109.237 179.781 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.508 ' O ' ' SD ' ' F' ' 35' ' ' MET . 1.4 tt -102.53 112.46 35.93 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 CA-C-N 113.956 -1.475 . . . . 0.0 109.975 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.1 96.69 1.0 Allowed Glycine 0 N--CA 1.46 0.286 0 N-CA-C 107.296 -2.321 . . . . 0.0 107.296 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . 0.418 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 3.4 pp -120.62 125.88 48.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.91 0.386 . . . . 0.0 110.948 -177.745 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 65.6 ttp -125.6 121.77 34.52 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-O 121.431 0.634 . . . . 0.0 109.877 179.112 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 m -124.26 77.05 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.65 179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -35.64 104.81 0.03 OUTLIER Glycine 0 C--N 1.349 1.289 0 N-CA-C 111.751 -0.539 . . . . 0.0 111.751 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.05 -177.28 42.51 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 8.5 p -140.86 151.12 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 121.081 0.467 . . . . 0.0 111.066 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 47.3 t . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.292 179.7 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.0 t . . . . . 0 N--CA 1.465 0.283 0 CA-C-O 121.426 0.632 . . . . 0.0 111.591 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -106.5 -172.35 2.07 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.96 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 48.5 p-80 -146.8 170.92 16.02 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -147.69 178.75 8.22 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.603 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -138.7 129.45 26.36 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.801 0.334 . . . . 0.0 110.467 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.4 mt -112.48 114.61 27.39 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.592 HG23 ' O ' ' A' ' 18' ' ' VAL . 6.2 m -127.55 121.16 56.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.119 0 CA-C-O 121.345 0.593 . . . . 0.0 111.433 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.501 ' CE1' HD21 ' D' ' 34' ' ' LEU . 0.9 OUTLIER -116.88 107.9 15.17 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 177.283 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.4 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.8 p90 -126.68 126.81 44.15 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.94 125.62 53.84 Favored 'General case' 0 C--O 1.24 0.577 0 CA-C-O 121.275 0.56 . . . . 0.0 111.624 -178.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -155.47 82.0 1.04 Allowed 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.162 -2.162 . . . . 0.0 105.162 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -34.84 120.64 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 114.922 -1.035 . . . . 0.0 113.612 -176.315 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 26' ' ' SER . 60.7 t -100.94 125.13 54.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 177.56 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -31.71 83.27 0.0 OUTLIER Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.324 0.39 . . . . 0.0 113.033 -177.28 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.599 ' N ' ' O ' ' A' ' 24' ' ' VAL . 69.5 m -87.02 -179.23 6.45 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 28' ' ' LYS . 87.7 m-20 -75.71 178.53 6.03 Favored 'General case' 0 C--N 1.314 -0.966 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.094 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.507 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.1 mttt -45.34 -110.77 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.879 0.847 . . . . 0.0 112.066 178.689 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.32 93.71 1.65 Allowed Glycine 0 N--CA 1.467 0.734 0 CA-C-O 118.428 -1.206 . . . . 0.0 110.181 178.104 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.57 160.11 14.73 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 116.688 -2.005 . . . . 0.0 108.699 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.648 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.4 OUTLIER -155.39 117.81 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 113.986 -1.461 . . . . 0.0 109.464 -173.987 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.453 ' C ' ' SD ' ' G' ' 35' ' ' MET . 96.9 mt -126.33 129.37 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-O 120.812 0.339 . . . . 0.0 110.686 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.49 121.67 2.73 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.9 mt -138.96 139.07 37.84 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.938 0.875 . . . . 0.0 111.463 179.284 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.438 ' C ' ' SD ' ' A' ' 35' ' ' MET . 6.8 tmm? -136.15 131.42 34.66 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.288 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.0 t -121.52 73.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.415 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -105.5 100.7 1.75 Allowed Glycine 0 N--CA 1.442 -0.933 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 178.315 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -177.66 170.44 42.84 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.468 0.428 0 CA-C-O 120.889 0.376 . . . . 0.0 110.795 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.461 0.172 . . . . 0.0 110.799 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -132.41 104.95 6.98 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.585 0.231 . . . . 0.0 110.793 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' B' ' 15' ' ' GLN . 52.7 m170 -126.33 167.08 15.99 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.6 mm-40 -155.27 178.39 10.27 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.663 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -171.08 115.72 0.43 Allowed 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.113 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.679 HD23 ' C ' ' B' ' 17' ' ' LEU . 8.2 tt -128.42 122.62 31.77 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.127 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.41 ' N ' HD23 ' B' ' 17' ' ' LEU . 28.6 m -137.76 131.98 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 N-CA-C 113.129 0.788 . . . . 0.0 113.129 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.548 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 2.8 m-85 -110.09 115.68 30.19 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.198 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.598 ' CE1' ' CD1' ' C' ' 20' ' ' PHE . 74.2 t80 -121.76 123.5 41.97 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.56 124.76 36.77 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 113.04 0.756 . . . . 0.0 113.04 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.451 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 42.8 tp10 -153.99 129.49 9.91 Favored 'General case' 0 C--O 1.221 -0.415 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.344 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.529 ' OD2' ' NZ ' ' C' ' 28' ' ' LYS . 8.8 t0 -152.41 134.99 15.31 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.055 -178.829 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' B' ' 25' ' ' GLY . 2.1 p -110.73 111.68 37.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.898 -1.047 . . . . 0.0 108.928 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 32.74 90.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.349 0 C-N-CA 121.586 -0.34 . . . . 0.0 113.328 177.524 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.51 ' OG ' ' CE ' ' C' ' 28' ' ' LYS . 54.8 p -100.31 150.52 22.49 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 117.626 0.713 . . . . 0.0 109.083 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.491 ' CG ' ' H ' ' B' ' 28' ' ' LYS . 25.6 t-20 -42.02 173.94 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.852 0.834 . . . . 0.0 113.207 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.491 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 57.7 tttt -76.3 111.15 11.43 Favored 'General case' 0 CA--C 1.548 0.893 0 N-CA-C 115.563 1.69 . . . . 0.0 115.563 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.36 93.41 0.03 OUTLIER Glycine 0 N--CA 1.478 1.454 0 C-N-CA 119.123 -1.513 . . . . 0.0 115.695 171.915 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.442 ' C ' ' CG1' ' B' ' 31' ' ' ILE . . . -123.3 152.47 41.38 Favored 'General case' 0 C--O 1.245 0.836 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 173.816 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.648 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.2 OUTLIER -152.8 135.31 6.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 C-N-CA 118.215 -1.394 . . . . 0.0 111.899 -171.762 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 16.5 tt -146.29 137.44 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.332 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.48 128.89 6.48 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.541 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.441 ' HB2' HD22 ' C' ' 34' ' ' LEU . 48.9 mt -139.33 128.98 24.55 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 122.227 -0.573 . . . . 0.0 111.94 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.43 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 61.8 ttp -130.93 127.33 38.23 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.247 177.467 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' B' ' 37' ' ' GLY . 15.4 m -133.83 76.4 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 119.936 -0.706 . . . . 0.0 112.779 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.437 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -33.6 -95.67 0.01 OUTLIER Glycine 0 CA--C 1.53 1.0 0 N-CA-C 111.521 -0.632 . . . . 0.0 111.521 178.11 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.47 -168.75 35.43 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.64 134.78 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 120.985 0.421 . . . . 0.0 110.412 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.668 179.837 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -108.44 132.09 54.13 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.551 0.215 . . . . 0.0 110.457 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -95.92 134.77 38.52 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 121.014 0.435 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -127.71 136.15 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.11 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -130.16 125.48 35.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.792 0.33 . . . . 0.0 111.013 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.497 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 45.1 t-80 -145.2 166.79 24.44 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.464 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.497 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 99.7 mm-40 -153.16 176.83 11.49 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.807 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.66 ' C ' HD12 ' C' ' 17' ' ' LEU . 69.0 tttt -170.17 104.31 0.3 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.598 178.389 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.66 HD12 ' C ' ' C' ' 16' ' ' LYS . 11.2 mp -118.5 118.59 32.12 Favored 'General case' 0 C--O 1.237 0.432 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.321 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -131.73 131.5 62.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.895 ' CZ ' HD23 ' E' ' 34' ' ' LEU . 52.3 m-85 -113.69 116.51 29.55 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.382 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE1' ' B' ' 20' ' ' PHE . 51.9 t80 -125.94 122.14 35.12 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 118.625 0.648 . . . . 0.0 109.548 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 21' ' ' ALA . . . . . 0.527 ' HB1' ' HB3' ' D' ' 27' ' ' ASN . . . -137.29 130.12 30.37 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 113.769 1.025 . . . . 0.0 113.769 -178.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.451 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 71.3 mt-10 -155.17 114.98 3.72 Favored 'General case' 0 C--N 1.352 0.682 0 CA-C-N 113.661 -1.608 . . . . 0.0 108.806 178.104 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.423 ' O ' ' O ' ' D' ' 26' ' ' SER . 65.6 t0 -147.54 122.51 10.05 Favored 'General case' 0 N--CA 1.476 0.862 0 O-C-N 121.739 -0.6 . . . . 0.0 111.419 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 14.5 t -98.53 -112.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.056 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 39.68 -90.94 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.103 -179.09 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.631 ' O ' ' O ' ' C' ' 27' ' ' ASN . 2.0 m 171.15 170.11 0.08 Allowed 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.436 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.631 ' O ' ' O ' ' C' ' 26' ' ' SER . 65.8 t30 -17.56 158.61 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 O-C-N 124.616 1.198 . . . . 0.0 113.696 177.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.529 ' NZ ' ' OD2' ' B' ' 23' ' ' ASP . 50.5 tttt -161.26 110.63 1.61 Allowed 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.521 174.491 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.69 92.64 0.29 Allowed Glycine 0 C--O 1.224 -0.488 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 173.421 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.16 150.5 47.98 Favored 'General case' 0 CA--C 1.476 -1.885 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 174.297 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.42 HD13 HG21 ' C' ' 31' ' ' ILE . 0.1 OUTLIER -147.36 114.49 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 C-N-CA 117.672 -1.611 . . . . 0.0 110.996 -173.931 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 9.2 mt -108.84 124.04 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.147 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.859 ' O ' HD23 ' C' ' 34' ' ' LEU . . . -125.43 100.62 0.6 Allowed Glycine 0 N--CA 1.474 1.186 0 N-CA-C 108.521 -1.831 . . . . 0.0 108.521 177.633 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.859 HD23 ' O ' ' C' ' 33' ' ' GLY . 1.6 mt -134.32 142.27 47.19 Favored 'General case' 0 C--O 1.243 0.722 0 CA-C-O 122.886 1.327 . . . . 0.0 113.859 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.544 ' SD ' ' CE ' ' D' ' 35' ' ' MET . 41.9 ttp -127.51 118.8 24.7 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 112.771 -2.013 . . . . 0.0 108.127 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.448 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.1 OUTLIER -116.33 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-N 114.173 -1.376 . . . . 0.0 107.864 179.067 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -39.86 -101.48 0.01 OUTLIER Glycine 0 C--N 1.366 2.238 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.88 -145.83 11.32 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.4 m -128.32 158.85 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 120.664 0.269 . . . . 0.0 110.306 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.467 179.984 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 N--CA 1.465 0.281 0 CA-C-O 121.348 0.594 . . . . 0.0 110.757 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -132.97 134.85 45.05 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.666 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 73.3 m80 -149.04 167.03 26.93 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 121.266 0.555 . . . . 0.0 110.039 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -155.76 171.23 20.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.326 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -158.62 114.1 2.62 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.926 -0.31 . . . . 0.0 111.107 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mt -118.55 119.13 33.59 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.444 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -131.31 129.54 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.603 ' CZ ' ' CD1' ' C' ' 19' ' ' PHE . 19.8 m-85 -118.97 123.63 45.04 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -131.26 119.83 22.35 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.747 0.308 . . . . 0.0 111.633 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.08 122.45 28.35 Favored 'General case' 0 N--CA 1.476 0.835 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.136 178.624 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -84.9 157.01 20.99 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.416 ' HA ' ' NZ ' ' F' ' 28' ' ' LYS . 1.2 t0 -88.72 -174.12 4.4 Favored 'General case' 0 C--N 1.348 0.525 0 CA-C-O 121.213 0.53 . . . . 0.0 110.897 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.413 ' O ' ' O ' ' D' ' 25' ' ' GLY . 20.7 t 62.64 104.45 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' D' ' 24' ' ' VAL . . . 64.71 100.0 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 117.618 -2.23 . . . . 0.0 107.686 -178.664 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.423 ' O ' ' O ' ' C' ' 23' ' ' ASP . 78.6 p -52.44 171.93 0.05 OUTLIER 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 118.037 0.918 . . . . 0.0 108.617 -176.024 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.527 ' HB3' ' HB1' ' C' ' 21' ' ' ALA . 6.8 m120 -81.84 178.51 8.27 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.694 -0.802 . . . . 0.0 112.115 -175.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' D' ' 27' ' ' ASN . 44.2 tttp -38.6 -106.51 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.294 -1.321 . . . . 0.0 112.533 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.673 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . 86.29 -100.04 2.48 Favored Glycine 0 CA--C 1.456 -3.637 0 N-CA-C 106.218 -2.753 . . . . 0.0 106.218 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.918 ' C ' HD13 ' D' ' 31' ' ' ILE . . . 67.55 -163.86 0.21 Allowed 'General case' 0 N--CA 1.419 -2.001 1 N-CA-C 98.449 -4.648 . . . . 0.0 98.449 -176.36 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.918 HD13 ' C ' ' D' ' 30' ' ' ALA . 0.0 OUTLIER -115.79 110.94 33.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 CA-C-N 123.941 3.064 . . . . 0.0 110.397 177.258 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.446 ' C ' ' SD ' ' J' ' 35' ' ' MET . 13.7 tt -122.57 127.56 75.04 Favored 'Isoleucine or valine' 0 C--N 1.353 0.744 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.96 179.351 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.544 ' O ' HD12 ' D' ' 34' ' ' LEU . . . -121.36 101.22 0.77 Allowed Glycine 0 N--CA 1.457 0.092 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.544 HD12 ' O ' ' D' ' 33' ' ' GLY . 5.0 mp -120.34 125.81 48.96 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 122.32 1.057 . . . . 0.0 110.923 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.617 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 37.3 ttp -120.29 119.26 32.63 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 113.928 -1.487 . . . . 0.0 107.839 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.51 74.06 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.698 -178.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . -48.35 111.45 0.89 Allowed Glycine 0 C--N 1.351 1.392 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 37' ' ' GLY . . . -59.77 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 74.7 t -120.95 133.73 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.688 -179.93 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -109.23 132.86 53.72 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.58 151.0 42.79 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.684 0.278 . . . . 0.0 110.629 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 66.2 t -125.86 131.2 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.947 0.403 . . . . 0.0 110.609 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 16.9 t60 -138.93 130.75 27.69 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.532 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 27.1 m80 -148.15 168.24 22.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.751 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 -154.83 165.97 34.97 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.427 178.051 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -148.6 117.73 6.81 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.192 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.27 122.72 34.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.238 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -127.56 125.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.074 0.464 . . . . 0.0 111.0 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -117.74 113.81 22.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.542 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 55.0 t80 -123.46 116.72 23.69 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.141 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 134.74 15.52 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 118.974 -1.09 . . . . 0.0 113.664 -178.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -102.6 117.28 34.33 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 176.275 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.498 ' OD1' ' N ' ' E' ' 23' ' ' ASP . 7.1 p-10 -131.06 113.26 13.72 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 114.395 1.257 . . . . 0.0 114.395 -177.483 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.631 ' O ' ' N ' ' E' ' 26' ' ' SER . 40.3 t -127.23 122.29 59.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 175.35 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.467 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . -28.97 83.8 0.0 OUTLIER Glycine 0 N--CA 1.484 1.883 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.631 ' N ' ' O ' ' E' ' 24' ' ' VAL . 6.3 p -88.24 -179.75 6.2 Favored 'General case' 0 N--CA 1.441 -0.885 0 CA-C-O 123.102 1.43 . . . . 0.0 113.734 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -77.04 179.35 6.31 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-N 111.446 -2.616 . . . . 0.0 110.836 176.063 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.478 ' HE2' ' HB2' ' E' ' 30' ' ' ALA . 82.9 tttt 42.88 110.98 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 114.697 1.369 . . . . 0.0 114.697 176.444 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.43 93.99 1.68 Allowed Glycine 0 N--CA 1.47 0.905 0 N-CA-C 108.035 -2.026 . . . . 0.0 108.035 174.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.659 ' HB1' ' H ' ' D' ' 30' ' ' ALA . . . -100.5 166.79 10.75 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.475 HG22 ' HE1' ' L' ' 35' ' ' MET . 0.0 OUTLIER -156.44 121.79 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.051 0 C-N-CA 117.916 -1.514 . . . . 0.0 112.306 -173.087 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -111.15 123.74 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.877 178.188 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.8 109.78 1.7 Allowed Glycine 0 CA--C 1.512 -0.139 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.895 HD23 ' CZ ' ' C' ' 19' ' ' PHE . 41.5 tp -133.24 126.74 32.2 Favored 'General case' 0 C--O 1.243 0.745 0 CA-C-O 121.848 0.832 . . . . 0.0 111.454 -179.64 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.541 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 57.9 ttp -115.62 124.3 50.58 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.059 177.196 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -129.68 71.58 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.332 -179.885 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -32.46 -101.0 0.01 OUTLIER Glycine 0 C--N 1.364 2.106 0 N-CA-C 111.678 -0.569 . . . . 0.0 111.678 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.18 159.2 30.21 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.94 161.38 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.697 0.284 . . . . 0.0 110.424 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.509 179.501 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 77.0 t . . . . . 0 N--CA 1.464 0.27 0 CA-C-O 121.144 0.497 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -161.11 109.84 1.58 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.243 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -153.63 174.58 14.29 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -145.56 172.89 12.59 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.326 -0.549 . . . . 0.0 110.605 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.79 112.32 7.83 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.012 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.583 HD23 ' C ' ' F' ' 17' ' ' LEU . 8.4 tt -125.2 122.4 36.9 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.418 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 18' ' ' VAL . . . . . 0.415 ' N ' HD23 ' F' ' 17' ' ' LEU . 69.2 t -129.32 130.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.536 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 53.0 p90 -131.5 127.47 37.36 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.816 0.341 . . . . 0.0 110.292 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -142.04 126.87 18.16 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.422 0.629 . . . . 0.0 110.057 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -161.3 161.9 30.77 Favored 'General case' 0 C--N 1.32 -0.683 0 C-N-CA 120.08 -0.648 . . . . 0.0 111.082 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 95.6 mt-10 -116.82 107.99 15.3 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.275 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 49.1 t0 . . . . . 0 N--CA 1.467 0.401 0 CA-C-O 121.265 0.555 . . . . 0.0 111.951 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.546 ' O ' ' N ' ' F' ' 30' ' ' ALA . 22.6 tttt . . . . . 0 CA--C 1.527 0.086 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.88 91.65 0.08 OUTLIER Glycine 0 N--CA 1.467 0.761 0 C-N-CA 117.056 -2.497 . . . . 0.0 109.034 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.546 ' N ' ' O ' ' F' ' 28' ' ' LYS . . . -171.53 162.01 6.4 Favored 'General case' 0 C--N 1.295 -1.786 1 N-CA-C 98.752 -4.536 . . . . 0.0 98.752 178.569 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.463 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.0 OUTLIER -152.11 131.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 115.778 -2.369 . . . . 0.0 113.243 -175.262 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.55 HG22 HD23 ' F' ' 34' ' ' LEU . 76.0 mt -106.12 113.49 42.99 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 114.13 -1.395 . . . . 0.0 109.615 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.08 96.46 1.53 Allowed Glycine 0 CA--C 1.502 -0.75 0 N-CA-C 106.217 -2.753 . . . . 0.0 106.217 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.55 HD23 HG22 ' F' ' 32' ' ' ILE . 1.4 pp -118.39 122.2 42.23 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 111.478 0.177 . . . . 0.0 111.478 -177.141 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.784 ' SD ' HG23 ' L' ' 31' ' ' ILE . 58.1 ttp -118.71 115.71 25.07 Favored 'General case' 0 CA--C 1.5 -0.96 0 C-N-CA 119.094 -1.042 . . . . 0.0 108.64 176.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' F' ' 37' ' ' GLY . 3.1 m -123.34 71.44 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -24.97 -103.29 0.0 OUTLIER Glycine 0 C--N 1.36 1.863 0 O-C-N 123.515 0.509 . . . . 0.0 112.432 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.04 163.27 7.45 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -144.34 143.32 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.79 0.328 . . . . 0.0 110.612 179.303 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.428 179.921 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -118.64 138.27 52.72 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.801 0.334 . . . . 0.0 110.496 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -76.2 158.62 31.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.289 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 56.8 t -118.27 132.93 66.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.147 0.499 . . . . 0.0 110.225 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -104.77 -168.78 1.52 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.395 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.45 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 3.4 m80 -76.57 165.28 25.0 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.449 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 34.8 tp60 -161.67 175.18 12.3 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.449 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 64.2 tttp -161.63 131.82 4.91 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.102 179.522 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -123.54 125.66 45.28 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.397 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 63.2 t -125.19 126.45 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.857 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.853 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 5.7 t80 -114.49 109.08 17.73 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -118.34 115.66 25.15 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.94 121.38 44.49 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.96 0.41 . . . . 0.0 110.632 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -154.81 118.34 4.54 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -58.23 121.27 10.33 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.279 -178.574 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.2 m -88.25 124.15 41.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.99 84.53 0.01 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 121.461 -0.4 . . . . 0.0 112.192 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' G' ' 24' ' ' VAL . 60.7 m -93.52 178.6 5.65 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.03 178.73 0.17 Allowed 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.127 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.95 110.94 1.3 Allowed 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.101 -0.64 . . . . 0.0 111.009 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.848 ' H ' HD22 ' H' ' 27' ' ' ASN . . . 71.16 93.11 0.08 OUTLIER Glycine 0 N--CA 1.463 0.485 0 C-N-CA 119.501 -1.333 . . . . 0.0 112.21 176.186 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.67 160.27 17.42 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 119.784 1.792 . . . . 0.0 109.195 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.426 HG22 HD12 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -145.04 123.67 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.017 -177.107 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -133.96 128.29 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 O-C-N 121.942 -0.474 . . . . 0.0 111.249 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.04 121.59 3.43 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 54.6 tp -142.5 135.13 28.05 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.384 0.611 . . . . 0.0 112.254 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.453 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 66.3 ttp -127.3 139.01 53.18 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.502 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' G' ' 37' ' ' GLY . 22.5 t -133.55 78.36 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -179.31 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.433 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -33.85 -94.11 0.01 OUTLIER Glycine 0 C--N 1.345 1.045 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 177.005 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.99 -164.32 37.87 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -126.53 158.1 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.482 -179.746 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.613 -179.197 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -104.53 131.66 51.67 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -141.3 144.47 34.64 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.608 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.449 ' O ' HG23 ' H' ' 12' ' ' VAL . 18.9 m -125.62 131.84 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.501 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -127.1 115.71 19.56 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-O 120.854 0.359 . . . . 0.0 110.956 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 16.5 p-80 -158.99 171.42 20.06 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.39 0.614 . . . . 0.0 110.587 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mm-40 -150.35 173.89 13.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.417 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -148.17 121.26 8.86 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.652 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -123.0 127.61 49.06 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.81 0.338 . . . . 0.0 111.851 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -122.05 125.64 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.502 ' HZ ' HD13 ' J' ' 34' ' ' LEU . 2.7 t80 -122.27 115.17 21.87 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -126.86 121.66 32.47 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.49 127.13 51.92 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.613 -0.435 . . . . 0.0 112.001 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.461 ' HG3' ' H ' ' I' ' 24' ' ' VAL . 43.0 tt0 -158.29 103.34 1.8 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.918 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.464 ' HB3' ' HZ1' ' J' ' 28' ' ' LYS . 78.4 m-20 -80.17 134.7 36.17 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-O 120.952 0.406 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.403 ' O ' ' N ' ' H' ' 26' ' ' SER . 88.9 t -103.68 113.73 41.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -178.422 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -30.6 88.64 0.01 OUTLIER Glycine 0 CA--C 1.537 1.459 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.775 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' H' ' 27' ' ' ASN . 11.7 p -129.78 -178.54 4.75 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.739 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.848 HD22 ' H ' ' G' ' 29' ' ' GLY . 1.4 p-10 -40.16 174.82 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 113.486 0.921 . . . . 0.0 113.486 -174.245 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -74.8 111.15 9.71 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 116.18 1.919 . . . . 0.0 116.18 -178.065 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.472 ' H ' ' HG3' ' I' ' 28' ' ' LYS . . . 70.32 93.54 0.07 OUTLIER Glycine 0 N--CA 1.467 0.733 0 C-N-CA 119.893 -1.146 . . . . 0.0 115.484 171.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.76 157.68 18.9 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 103.348 -2.834 . . . . 0.0 103.348 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.437 HD13 ' HA3' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -144.44 119.46 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.714 -174.545 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.403 ' C ' ' SD ' ' B' ' 35' ' ' MET . 27.7 mm -124.55 124.26 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.414 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.1 126.65 5.49 Favored Glycine 0 N--CA 1.469 0.873 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.4 tt -147.76 134.59 20.1 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.929 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.1 tmm? -128.62 127.09 41.55 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.851 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.436 ' O ' ' O ' ' H' ' 37' ' ' GLY . 10.5 t -122.92 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.294 0.85 . . . . 0.0 113.294 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -35.6 -93.8 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 177.785 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.1 -171.03 33.88 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.47 141.9 36.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 110.122 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.676 -179.995 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.443 HG12 ' N ' ' I' ' 13' ' ' HIS . 15.4 t . . . . . 0 N--CA 1.465 0.283 0 CA-C-O 120.675 0.274 . . . . 0.0 111.056 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.443 ' N ' HG12 ' I' ' 12' ' ' VAL . 0.5 OUTLIER -116.22 170.19 8.71 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.93 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -72.89 169.81 16.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -137.36 172.77 12.49 Favored 'General case' 0 C--N 1.318 -0.768 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.415 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -150.19 128.96 12.42 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.1 0.476 . . . . 0.0 111.663 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.6 tt -133.62 124.47 26.87 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -123.71 128.83 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.862 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.648 ' CD2' HD22 ' L' ' 34' ' ' LEU . 10.3 t80 -122.39 118.99 29.73 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.912 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -135.16 121.63 20.53 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.802 0.334 . . . . 0.0 111.062 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.18 123.49 38.35 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -162.6 126.52 3.02 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 115.354 -0.839 . . . . 0.0 108.815 178.195 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -102.27 114.03 27.84 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.461 ' H ' ' HG3' ' H' ' 22' ' ' GLU . 4.0 p -79.86 131.63 33.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.754 177.453 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.63 82.62 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 C-N-CA 119.725 -1.226 . . . . 0.0 112.392 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' I' ' 27' ' ' ASN . 75.1 m -60.04 -174.11 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 115.194 -0.503 . . . . 0.0 109.858 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' I' ' 26' ' ' SER . 17.9 m-20 98.53 -175.3 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 O-C-N 124.218 0.949 . . . . 0.0 109.975 -176.562 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' I' ' 27' ' ' ASN . 82.4 tttt 38.71 110.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -177.723 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 95.85 1.74 Allowed Glycine 0 CA--C 1.484 -1.885 0 N-CA-C 107.98 -2.048 . . . . 0.0 107.98 176.292 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 164.89 16.92 Favored 'General case' 0 N--CA 1.426 -1.662 0 C-N-CA 118.001 -1.48 . . . . 0.0 107.272 -179.024 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.719 HG23 ' CG1' ' J' ' 31' ' ' ILE . 0.2 OUTLIER -142.56 117.31 4.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 119.376 -0.929 . . . . 0.0 108.827 -174.497 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 tt -125.51 124.16 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.834 178.18 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.33 96.62 0.73 Allowed Glycine 0 C--N 1.331 0.275 0 N-CA-C 107.72 -2.152 . . . . 0.0 107.72 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.513 HD21 HG13 ' I' ' 36' ' ' VAL . 8.7 tt -130.32 134.1 46.94 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 122.392 1.092 . . . . 0.0 112.183 -178.475 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 tmm? -128.26 125.74 39.49 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.618 -1.174 . . . . 0.0 110.344 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.513 HG13 HD21 ' I' ' 34' ' ' LEU . 0.1 OUTLIER -130.69 76.95 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.34 179.678 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 38' ' ' GLY . . . -71.9 106.36 1.9 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -49.27 179.38 0.01 OUTLIER Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 -179.29 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -124.58 138.78 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.938 -1.03 . . . . 0.0 110.365 179.688 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -110.06 138.58 46.24 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.692 0.282 . . . . 0.0 110.298 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -127.56 145.19 50.94 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.952 0.406 . . . . 0.0 110.768 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.86 152.71 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.778 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 31.0 m80 -132.57 146.98 52.33 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.52 ' CE1' ' O ' ' J' ' 15' ' ' GLN . 5.9 t-80 -154.52 157.84 38.95 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.52 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 82.3 mt-30 -148.97 178.06 9.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-O 121.538 0.685 . . . . 0.0 111.653 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -165.34 114.03 1.02 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.151 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -120.86 122.29 39.95 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.155 0.502 . . . . 0.0 111.04 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -114.02 121.82 66.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.468 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.677 ' CZ ' HD23 ' L' ' 34' ' ' LEU . 1.0 OUTLIER -125.04 108.37 11.76 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.9 0.381 . . . . 0.0 110.236 -177.124 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -130.17 127.83 40.51 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.629 0.728 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.67 128.57 31.28 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.842 178.51 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -142.39 111.24 6.3 Favored 'General case' 0 N--CA 1.462 0.142 0 C-N-CA 119.621 -0.831 . . . . 0.0 111.249 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -85.73 105.02 15.96 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.671 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.759 HG12 ' H ' ' J' ' 25' ' ' GLY . 10.5 t -110.12 -131.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.123 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.759 ' H ' HG12 ' J' ' 24' ' ' VAL . . . 29.03 -82.24 0.0 OUTLIER Glycine 0 CA--C 1.529 0.914 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.869 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.636 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.2 p 169.65 177.76 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.34 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.636 ' O ' ' O ' ' J' ' 26' ' ' SER . 77.6 m-20 -28.08 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 114.183 -1.371 . . . . 0.0 112.838 173.611 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.535 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 29.5 tttt 144.63 104.31 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 123.02 1.39 . . . . 0.0 112.005 177.347 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.16 93.54 0.01 OUTLIER Glycine 0 C--O 1.219 -0.825 0 CA-C-N 112.248 -2.251 . . . . 0.0 111.373 174.004 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.2 152.81 47.68 Favored 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 120.78 2.29 . . . . 0.0 106.526 176.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.719 ' CG1' HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -137.97 121.86 21.61 Favored 'Isoleucine or valine' 0 C--O 1.248 1.022 0 C-N-CA 119.218 -0.993 . . . . 0.0 112.384 -174.895 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -104.42 109.44 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.406 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.617 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -109.72 102.46 1.59 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 106.37 -2.692 . . . . 0.0 106.37 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.853 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 5.1 tt -144.35 140.51 29.13 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 122.406 1.098 . . . . 0.0 111.775 -175.388 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.525 ' N ' HD23 ' J' ' 34' ' ' LEU . 61.0 ttp -133.69 130.21 37.85 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.08 -179.142 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.471 HG13 HG23 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -122.78 79.47 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.78 -178.336 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.19 104.54 0.48 Allowed Glycine 0 C--N 1.342 0.907 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.74 167.06 54.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -139.28 160.66 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.727 0.299 . . . . 0.0 110.584 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.442 HG23 ' H ' ' J' ' 40' ' ' VAL . 15.9 t . . . . . 0 C--O 1.221 -0.419 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.846 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -84.33 138.07 33.09 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.867 0.365 . . . . 0.0 111.068 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' L' ' 11' ' ' GLU . 72.3 mm-40 -137.6 131.98 32.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.628 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 m -138.09 135.56 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.906 0.384 . . . . 0.0 111.123 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 9.7 m80 -134.28 127.51 31.96 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.571 ' NE2' ' CG ' ' L' ' 13' ' ' HIS . 80.5 m80 -116.43 163.17 16.44 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.646 0.736 . . . . 0.0 110.36 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.52 ' N ' ' OE1' ' L' ' 15' ' ' GLN . 50.9 tt0 -163.27 172.31 14.89 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.412 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' K' ' 15' ' ' GLN . 55.4 tttp -164.81 114.88 1.14 Allowed 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 28.6 tp -118.8 121.65 40.54 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.76 127.83 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -131.0 125.7 34.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.23 0.538 . . . . 0.0 112.262 -178.361 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -133.06 125.79 30.39 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.993 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 127.43 35.36 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.182 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -149.29 137.73 20.88 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.048 -0.661 . . . . 0.0 112.023 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.45 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 20.6 p-10 -123.23 120.53 33.42 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 120.986 0.422 . . . . 0.0 110.029 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.554 HG21 HG13 ' J' ' 24' ' ' VAL . 84.3 t -60.62 121.1 7.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.519 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.31 -90.97 0.53 Allowed Glycine 0 CA--C 1.527 0.817 0 C-N-CA 121.368 -0.444 . . . . 0.0 112.464 177.391 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.587 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.8 p -141.37 171.22 14.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 121.196 0.522 . . . . 0.0 110.348 -178.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.587 ' O ' ' O ' ' K' ' 26' ' ' SER . 3.3 p30 -29.01 170.5 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.179 -1.373 . . . . 0.0 113.983 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.662 ' O ' ' HB3' ' L' ' 30' ' ' ALA . 80.0 tttt -148.35 111.3 4.84 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.141 178.713 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.514 ' HA2' ' HB2' ' L' ' 30' ' ' ALA . . . -54.53 91.58 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 121.244 -0.503 . . . . 0.0 112.211 179.208 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.746 ' H ' ' HB1' ' L' ' 30' ' ' ALA . . . -166.38 158.17 13.56 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.504 ' CG1' HG22 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -145.8 123.61 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 118.721 -1.192 . . . . 0.0 111.829 -179.209 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.448 ' C ' ' SD ' ' E' ' 35' ' ' MET . 1.0 OUTLIER -102.09 118.41 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.077 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.541 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -112.74 94.88 0.75 Allowed Glycine 0 CA--C 1.51 -0.26 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 179.181 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.636 HD12 ' O ' ' J' ' 34' ' ' LEU . 41.0 tp -129.38 130.77 46.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-O 122.218 1.009 . . . . 0.0 111.968 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.48 ' H ' HD12 ' K' ' 34' ' ' LEU . 7.9 tmm? -116.71 114.73 24.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.893 175.73 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.405 HG12 ' CG2' ' J' ' 36' ' ' VAL . 2.2 m -116.56 79.86 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.708 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.419 ' HA3' HD13 ' E' ' 31' ' ' ILE . . . -66.8 103.24 0.87 Allowed Glycine 0 C--N 1.35 1.36 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -87.39 -178.55 48.38 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.48 142.9 30.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.951 0.405 . . . . 0.0 110.29 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.761 -179.768 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -101.7 130.06 48.0 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.5 tt0 -123.52 138.75 54.5 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 120.96 0.41 . . . . 0.0 110.748 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.413 HG22 ' O ' ' L' ' 13' ' ' HIS . 2.4 p -139.53 156.04 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.187 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.661 ' CG ' ' H ' ' L' ' 14' ' ' HIS . 41.8 t-80 -91.29 -177.5 4.88 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 120.784 0.326 . . . . 0.0 110.727 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.661 ' H ' ' CG ' ' L' ' 13' ' ' HIS . 99.2 m-70 -75.52 171.73 13.77 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.53 ' NE2' ' O ' ' L' ' 14' ' ' HIS . 51.5 mm-40 -139.2 -179.78 6.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.62 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.95 124.38 15.72 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.685 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 58.0 tp -125.44 121.22 33.19 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.381 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -129.41 129.35 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.461 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 54.7 p90 -139.45 130.85 26.92 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.785 0.326 . . . . 0.0 111.123 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 84.8 t80 -142.55 131.99 23.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.019 179.252 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.16 146.43 35.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.814 0.34 . . . . 0.0 110.58 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' K' ' 23' ' ' ASP . 84.6 tt0 -78.52 142.76 37.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.145 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -76.73 121.72 23.7 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 121.225 0.536 . . . . 0.0 110.766 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' L' ' 25' ' ' GLY . 19.5 t -102.75 122.88 55.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.115 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.452 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -30.56 -86.47 0.01 OUTLIER Glycine 0 N--CA 1.478 1.442 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 30.7 t -90.21 -179.97 5.77 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 177.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -58.8 162.89 3.7 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 117.866 -1.534 . . . . 0.0 110.456 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.565 ' HB3' HD12 ' L' ' 31' ' ' ILE . 59.6 tttt -58.3 111.64 1.28 Allowed 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 179.11 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.85 -98.28 0.01 OUTLIER Glycine 0 C--N 1.319 -0.416 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.746 ' HB1' ' H ' ' K' ' 30' ' ' ALA . . . -72.72 174.57 7.45 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 178.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.784 HG23 ' SD ' ' F' ' 35' ' ' MET . 7.5 tt -171.17 165.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 C-N-CA 115.033 -2.667 . . . . 0.0 115.448 -172.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.544 ' O ' HG23 ' L' ' 32' ' ' ILE . 16.3 tt -99.31 122.02 50.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.761 0 CA-C-N 113.284 -1.78 . . . . 0.0 108.154 177.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 33' ' ' GLY . . . . . 0.501 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -110.52 94.37 0.79 Allowed Glycine 0 CA--C 1.507 -0.436 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.677 HD23 ' CZ ' ' J' ' 19' ' ' PHE . 51.3 tp -119.03 118.76 32.33 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.475 ' HE1' HG22 ' E' ' 31' ' ' ILE . 11.3 tmm? -105.16 119.22 38.5 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.202 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.497 ' O ' ' C ' ' L' ' 37' ' ' GLY . 2.7 m -129.03 75.04 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.927 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.497 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -16.95 -101.76 0.0 OUTLIER Glycine 0 C--N 1.359 1.856 0 O-C-N 123.158 0.286 . . . . 0.0 112.707 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.0 173.87 37.68 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.271 -0.731 . . . . 0.0 111.271 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -122.65 138.45 52.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.885 0.374 . . . . 0.0 110.51 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.813 -179.659 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 18.5 p-80 -143.71 164.44 30.44 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.934 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.1 p-80 -87.78 169.98 11.61 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-O 121.395 0.617 . . . . 0.0 110.375 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HG2' ' N ' ' A' ' 16' ' ' LYS . 51.5 tt0 -153.28 175.32 13.21 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.301 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.442 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 99.5 mttt -137.68 133.65 34.48 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.819 0.343 . . . . 0.0 110.831 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -129.16 121.52 27.91 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -132.74 131.3 59.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.75 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 14.7 m-85 -111.21 116.79 31.66 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.772 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.535 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 55.5 p90 -129.84 125.92 36.81 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.75 126.3 32.15 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.083 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' A' ' 22' ' ' GLU . 55.4 mp0 -141.32 163.94 31.59 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 33.7 t70 -79.2 113.67 17.52 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -178.538 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.502 ' O ' ' N ' ' A' ' 26' ' ' SER . 3.5 p -127.11 121.66 58.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 176.359 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -29.31 84.04 0.0 OUTLIER Glycine 0 CA--C 1.537 1.412 0 CA-C-O 118.833 -0.982 . . . . 0.0 113.834 178.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 24' ' ' VAL . 10.0 p -97.62 171.82 8.11 Favored 'General case' 0 C--N 1.347 0.468 0 CA-C-N 119.686 1.743 . . . . 0.0 107.311 177.002 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 p30 -60.13 177.53 0.25 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 118.418 -1.313 . . . . 0.0 110.227 178.461 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -61.76 110.61 1.57 Allowed 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.505 174.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.655 ' H ' ' CB ' ' B' ' 27' ' ' ASN . . . 70.86 93.82 0.07 OUTLIER Glycine 0 N--CA 1.467 0.714 0 C-N-CA 117.541 -2.266 . . . . 0.0 111.716 174.284 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.52 158.57 17.43 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 121.283 2.542 . . . . 0.0 111.225 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.603 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -143.98 120.38 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 113.433 -1.712 . . . . 0.0 110.566 -175.532 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.7 mt -130.6 125.3 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 O-C-N 121.52 -0.738 . . . . 0.0 110.438 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.575 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -132.15 119.12 2.43 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 80.8 mt -122.23 129.97 52.74 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.071 0.462 . . . . 0.0 110.895 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.53 120.49 29.78 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.18 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -104.94 77.74 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 120.22 -0.592 . . . . 0.0 112.239 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.542 ' CA ' HG21 ' G' ' 31' ' ' ILE . . . -92.27 101.0 2.73 Favored Glycine 0 C--N 1.342 0.893 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.14 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.64 155.87 27.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 28.4 m . . . . . 0 N--CA 1.464 0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.415 179.701 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 26.5 m . . . . . 0 N--CA 1.464 0.239 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.437 ' C ' ' CG ' ' B' ' 14' ' ' HIS . 80.6 t60 -138.7 138.9 38.16 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.644 0.259 . . . . 0.0 110.533 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.437 ' CG ' ' C ' ' B' ' 13' ' ' HIS . 19.6 m-70 -150.76 170.24 19.71 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.278 0.561 . . . . 0.0 109.983 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -153.14 173.04 16.01 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.49 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -153.9 118.66 4.97 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -116.31 120.95 40.54 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 45.5 t -126.07 121.79 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.157 0.504 . . . . 0.0 110.641 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.906 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 6.4 m-85 -113.52 113.16 24.73 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.709 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -118.17 106.17 12.57 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 175.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.99 125.93 52.12 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.523 ' N ' ' OE1' ' B' ' 22' ' ' GLU . 57.0 mp0 -142.41 178.88 7.29 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 177.208 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.499 ' OD1' ' NZ ' ' D' ' 28' ' ' LYS . 14.1 m-20 -38.09 121.92 0.99 Allowed 'General case' 0 N--CA 1.475 0.811 0 CA-C-N 119.244 0.929 . . . . 0.0 110.644 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.805 HG12 ' H ' ' B' ' 25' ' ' GLY . 97.3 t -58.55 -120.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.648 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.021 -178.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.805 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -79.67 -90.28 0.45 Allowed Glycine 0 CA--C 1.523 0.577 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.996 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.419 ' HB3' ' H ' ' A' ' 26' ' ' SER . 77.6 p -155.01 -172.07 4.06 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.835 0.826 . . . . 0.0 110.403 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.655 ' CB ' ' H ' ' A' ' 29' ' ' GLY . 8.9 t-20 57.72 -171.72 0.1 Allowed 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 114.201 -1.363 . . . . 0.0 111.671 178.354 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.566 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 72.2 mmtt -56.96 -111.3 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.709 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.92 94.47 1.57 Allowed Glycine 0 N--CA 1.461 0.314 0 CA-C-N 115.265 -0.88 . . . . 0.0 114.39 -177.439 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.33 163.97 15.79 Favored 'General case' 0 C--N 1.35 0.605 0 C-N-CA 116.821 -1.952 . . . . 0.0 106.673 177.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.46 HD13 ' HA3' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -150.26 128.76 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 C-N-CA 119.111 -1.036 . . . . 0.0 111.739 -172.779 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 99.0 mt -133.23 133.61 58.02 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.325 0.583 . . . . 0.0 110.922 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.01 127.11 4.63 Favored Glycine 0 N--CA 1.47 0.952 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.238 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.41 HD21 ' CG2' ' B' ' 36' ' ' VAL . 7.9 tt -133.79 127.87 33.59 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.294 0.547 . . . . 0.0 111.038 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.548 ' SD ' ' CA ' ' H' ' 33' ' ' GLY . 20.7 ttt -130.24 123.82 31.04 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.421 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.41 ' CG2' HD21 ' B' ' 34' ' ' LEU . 2.6 t -124.33 76.02 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.801 178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.32 101.54 2.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -134.72 163.54 24.72 Favored Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.86 136.97 56.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.506 -179.813 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -106.9 135.97 47.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.921 0.391 . . . . 0.0 110.644 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -67.77 135.63 52.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.795 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.572 HG13 ' O ' ' D' ' 12' ' ' VAL . 58.5 t -124.89 133.65 68.92 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.05 0.452 . . . . 0.0 111.075 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 p-80 -147.52 145.51 29.12 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.574 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 17.4 p80 -153.76 168.05 27.58 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.361 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -148.75 176.85 10.02 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.248 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -147.23 127.74 14.11 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.296 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.7 mp -130.51 127.28 38.83 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-O 121.1 0.476 . . . . 0.0 111.372 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.8 t -127.4 126.01 66.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.089 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.403 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 57.2 m-85 -111.45 116.11 30.36 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.198 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 50.4 t80 -127.88 117.68 22.24 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.6 130.67 49.43 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.326 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -155.57 101.1 2.15 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.979 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -68.7 133.98 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.977 0.418 . . . . 0.0 110.206 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.34 113.02 20.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.621 0.724 . . . . 0.0 111.178 -179.07 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.431 ' O ' HG11 ' D' ' 24' ' ' VAL . . . 52.97 -91.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.473 -1.24 . . . . 0.0 115.288 177.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.515 ' OG ' ' N ' ' C' ' 27' ' ' ASN . 47.3 t -153.78 -175.57 5.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 122.678 1.228 . . . . 0.0 113.102 -175.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.515 ' N ' ' OG ' ' C' ' 26' ' ' SER . 24.7 m120 52.73 179.93 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 112.433 -2.167 . . . . 0.0 115.129 178.716 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 75.2 mttt 53.4 110.6 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 CA-C-N 112.536 -2.12 . . . . 0.0 113.967 -177.557 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.77 95.97 1.85 Allowed Glycine 0 N--CA 1.488 2.127 0 CA-C-O 117.828 -1.54 . . . . 0.0 110.366 175.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.52 ' HB1' HG21 ' B' ' 24' ' ' VAL . . . -91.54 160.09 15.59 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 121.354 2.577 . . . . 0.0 109.833 -179.044 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.592 ' CG2' HD12 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -148.53 124.97 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.102 -176.421 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.44 ' O ' ' SD ' ' J' ' 35' ' ' MET . 14.3 tt -130.18 128.92 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 121.195 0.522 . . . . 0.0 110.459 177.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.445 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -112.77 117.62 4.36 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.75 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 29.3 mt -124.69 119.66 29.61 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -176.211 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.461 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 5.3 ttm -122.4 117.58 26.35 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 177.312 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.52 74.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.998 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.313 -178.375 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 38' ' ' GLY . . . -61.0 110.98 3.4 Favored Glycine 0 C--N 1.354 1.535 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . -53.9 -167.47 0.02 OUTLIER Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.71 161.82 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.068 0.461 . . . . 0.0 111.221 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 68.6 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.889 -1.053 . . . . 0.0 110.594 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.572 ' O ' HG13 ' C' ' 12' ' ' VAL . 30.9 m . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CB ' ' E' ' 13' ' ' HIS . 5.7 t60 -89.21 122.38 32.44 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.013 178.567 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 47.5 p-80 -156.15 169.04 25.43 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.056 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -145.04 177.97 8.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -152.59 119.77 5.88 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.185 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -119.68 120.35 36.37 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.855 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -125.7 125.87 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.802 0.334 . . . . 0.0 110.962 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.403 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 72.3 m-85 -115.75 115.82 26.97 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.069 179.011 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 53.9 t80 -127.5 121.15 29.96 Favored 'General case' 0 C--O 1.239 0.5 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 178.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.15 135.58 37.49 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.298 0.571 . . . . 0.0 112.297 -179.026 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -136.92 96.48 3.31 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.048 178.379 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.425 ' O ' ' CG2' ' E' ' 24' ' ' VAL . 89.8 m-20 -85.89 134.89 33.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.416 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.5 ' O ' HG13 ' D' ' 24' ' ' VAL . 8.1 p -88.27 112.75 24.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.457 0.646 . . . . 0.0 109.403 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.472 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -45.45 92.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.597 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.346 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.472 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 163.92 -169.6 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.641 0 CA-C-O 121.727 0.775 . . . . 0.0 110.163 -178.562 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -50.64 179.77 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.314 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.727 ' HE2' ' HB2' ' D' ' 30' ' ' ALA . 67.2 tttt 60.49 112.38 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 112.248 -2.251 . . . . 0.0 115.881 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.0 96.16 2.18 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.091 -2.804 . . . . 0.0 106.091 170.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.727 ' HB2' ' HE2' ' D' ' 28' ' ' LYS . . . -79.31 162.77 25.4 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 123.47 3.635 . . . . 0.0 105.805 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.592 HD12 ' CG2' ' C' ' 31' ' ' ILE . 1.1 mt -147.21 126.47 4.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 C-N-CA 117.679 -1.608 . . . . 0.0 111.348 -174.541 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 52.6 mt -123.91 116.95 49.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 177.648 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.28 103.59 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 105.878 -2.889 . . . . 0.0 105.878 176.028 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.906 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 12.7 tp -116.54 124.36 49.68 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 114.077 1.139 . . . . 0.0 114.077 -175.172 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.437 ' N ' HD12 ' D' ' 34' ' ' LEU . 8.0 ttm -126.54 110.47 13.28 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 174.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.596 HG13 HD11 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -126.25 79.89 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.151 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.02 103.13 1.32 Allowed Glycine 0 C--N 1.349 1.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 112.506 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.59 178.93 38.46 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 178.584 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.51 HG12 ' N ' ' D' ' 40' ' ' VAL . 60.7 t -141.88 157.95 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.946 0.403 . . . . 0.0 111.011 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.51 ' N ' HG12 ' D' ' 39' ' ' VAL . 19.4 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.52 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 77.1 t80 -85.28 138.96 31.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.883 0.373 . . . . 0.0 110.528 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -55.4 143.05 30.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.689 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.64 135.75 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.487 ' CB ' ' O ' ' D' ' 13' ' ' HIS . 12.0 p-80 -155.66 162.07 40.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.041 0.448 . . . . 0.0 111.296 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 69.0 m80 -139.82 168.19 20.39 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.854 0.835 . . . . 0.0 110.287 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.412 ' HG2' ' N ' ' E' ' 16' ' ' LYS . 51.8 tt0 -153.17 165.34 35.97 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 114.678 -1.146 . . . . 0.0 108.826 178.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.412 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 98.0 mttt -157.24 116.88 3.4 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.627 0.251 . . . . 0.0 110.334 179.392 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 32.6 tp -117.14 113.79 22.77 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.47 128.7 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' E' ' 21' ' ' ALA . 41.1 t80 -127.27 120.49 28.77 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.924 -179.786 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -127.84 118.49 23.77 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.422 ' HB2' ' CZ ' ' E' ' 19' ' ' PHE . . . -128.68 130.04 46.65 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.129 0.49 . . . . 0.0 111.326 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -113.27 102.62 10.53 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 64.4 t0 -79.9 123.17 27.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.174 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.437 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 93.0 t -96.5 121.65 47.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.195 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 42.7 -87.03 0.01 OUTLIER Glycine 0 CA--C 1.533 1.17 0 CA-C-N 115.127 -0.942 . . . . 0.0 114.688 178.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 11.1 p -165.38 -178.36 4.95 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-O 122.235 1.017 . . . . 0.0 112.044 -175.524 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.6 ' CG ' ' H ' ' E' ' 28' ' ' LYS . 7.0 t-20 51.36 -179.13 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 116.105 1.891 . . . . 0.0 116.105 177.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.6 ' H ' ' CG ' ' E' ' 27' ' ' ASN . 27.2 tttt 53.76 110.97 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 112.178 -2.283 . . . . 0.0 114.223 -175.648 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.456 ' HA2' ' H ' ' F' ' 30' ' ' ALA . . . -87.13 96.44 2.17 Favored Glycine 0 C--N 1.337 0.6 0 CA-C-N 111.973 -2.376 . . . . 0.0 110.909 175.04 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.412 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -78.83 166.24 22.65 Favored 'General case' 0 C--O 1.241 0.624 0 CA-C-N 122.765 3.282 . . . . 0.0 103.553 177.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.435 HG21 HD13 ' E' ' 31' ' ' ILE . 1.1 mt -147.57 127.39 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 116.687 -2.005 . . . . 0.0 112.903 -172.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.49 ' O ' HG23 ' E' ' 32' ' ' ILE . 15.7 tt -135.4 119.88 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-O 121.472 0.653 . . . . 0.0 109.49 176.141 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.68 110.3 2.78 Favored Glycine 0 CA--C 1.508 -0.356 0 N-CA-C 107.492 -2.243 . . . . 0.0 107.492 178.356 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.57 123.24 43.44 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 122.259 1.028 . . . . 0.0 111.775 -178.2 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.432 ' HE2' ' N ' ' K' ' 32' ' ' ILE . 9.5 tpt -111.47 110.77 21.38 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 113.709 -1.587 . . . . 0.0 107.467 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.404 HG13 HG23 ' D' ' 36' ' ' VAL . 0.2 OUTLIER -119.66 80.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-O 121.035 0.445 . . . . 0.0 109.94 -178.043 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.08 102.17 0.08 OUTLIER Glycine 0 C--N 1.341 0.833 0 CA-C-N 116.247 -0.433 . . . . 0.0 112.044 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.96 150.61 22.7 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.6 t -126.56 136.71 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 88.8 t . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.374 179.819 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m . . . . . 0 N--CA 1.467 0.379 0 CA-C-O 120.99 0.424 . . . . 0.0 110.785 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.414 ' HB3' ' CE1' ' E' ' 13' ' ' HIS . 44.4 p-80 -87.68 163.21 16.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.312 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 53.2 m80 -147.33 172.15 14.33 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -144.12 178.06 8.15 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.847 -179.482 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.9 121.9 0.57 Allowed 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.738 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.69 125.19 35.4 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.401 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 86.9 t -134.1 129.4 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.923 0.392 . . . . 0.0 111.237 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -122.55 125.66 46.17 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.049 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -136.07 132.63 36.42 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.13 0.491 . . . . 0.0 110.024 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.27 149.46 31.91 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.099 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -74.17 152.74 39.75 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.729 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 t0 . . . . . 0 N--CA 1.462 0.137 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.121 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 28.6 pttt . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.618 ' O ' ' O ' ' F' ' 30' ' ' ALA . . . -120.01 -100.1 1.81 Allowed Glycine 0 C--N 1.343 0.943 0 N-CA-C 108.299 -1.921 . . . . 0.0 108.299 173.541 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.618 ' O ' ' O ' ' F' ' 29' ' ' GLY . . . 54.83 151.97 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 105.412 -2.07 . . . . 0.0 105.412 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.447 ' HB ' ' O ' ' F' ' 30' ' ' ALA . 2.7 tp -165.8 132.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 C-N-CA 115.002 -2.679 . . . . 0.0 114.192 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 97.0 mt -111.69 112.98 42.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 113.631 -1.622 . . . . 0.0 108.418 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 33' ' ' GLY . . . . . 0.437 ' H ' ' HE2' ' L' ' 35' ' ' MET . . . -97.13 101.74 2.63 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 105.382 -3.087 . . . . 0.0 105.382 176.045 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.473 HD12 ' O ' ' F' ' 34' ' ' LEU . 0.4 OUTLIER -104.73 108.69 20.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -176.189 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.47 ' SD ' ' C ' ' L' ' 32' ' ' ILE . 0.9 OUTLIER -109.42 107.34 17.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 176.102 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -136.01 80.59 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.984 -179.329 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.49 -101.66 0.09 OUTLIER Glycine 0 C--N 1.344 1.004 0 C-N-CA 120.976 -0.631 . . . . 0.0 111.99 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.74 -159.71 31.64 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.1 m -135.19 161.72 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 120.626 0.251 . . . . 0.0 110.529 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.204 179.612 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -126.77 142.69 51.47 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.37 143.72 42.11 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.057 0.456 . . . . 0.0 111.019 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.413 ' O ' HG13 ' G' ' 12' ' ' VAL . 12.4 p -130.49 134.99 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.187 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -122.79 127.25 48.88 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 120.95 0.405 . . . . 0.0 110.445 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 70.8 t60 -157.62 165.41 35.58 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-O 121.16 0.505 . . . . 0.0 110.183 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 83.6 mt-30 -151.28 174.76 12.91 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.018 178.891 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -171.57 114.04 0.36 Allowed 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.082 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 64.7 mt -131.16 124.1 29.97 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.331 0.586 . . . . 0.0 110.306 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.46 ' O ' HG23 ' G' ' 18' ' ' VAL . 30.9 m -128.12 129.83 69.53 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.135 -179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.551 ' CE2' HD21 ' J' ' 34' ' ' LEU . 15.4 m-85 -110.53 113.03 25.34 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.466 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 45.6 p90 -123.95 124.13 41.93 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.27 131.13 38.07 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -145.6 167.22 23.59 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 177.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 58.6 t0 -90.14 111.78 23.03 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.015 -0.674 . . . . 0.0 112.186 -178.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.611 ' O ' ' N ' ' G' ' 26' ' ' SER . 3.6 p -113.17 131.04 65.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.127 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.29 81.96 0.0 OUTLIER Glycine 0 CA--C 1.532 1.11 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.782 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.611 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.1 m -96.58 176.2 6.11 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.504 ' O ' ' O ' ' G' ' 28' ' ' LYS . 53.3 p30 -62.2 -177.73 0.14 Allowed 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.137 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.504 ' O ' ' O ' ' G' ' 27' ' ' ASN . 98.4 mttt -48.85 -109.2 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-O 121.682 0.753 . . . . 0.0 110.64 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.65 96.53 2.1 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.42 161.32 23.77 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 115.49 -2.484 . . . . 0.0 109.609 -177.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.627 ' CG2' HD12 ' H' ' 31' ' ' ILE . 0.1 OUTLIER -154.33 116.27 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.868 -175.066 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -143.09 137.76 26.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.502 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -158.8 164.33 33.6 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.466 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 3.3 tp -169.57 163.28 10.21 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.13 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.575 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 53.5 ttp -131.93 134.12 45.3 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.601 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.406 ' HB ' HG23 ' H' ' 36' ' ' VAL . 21.1 t -117.48 65.03 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.514 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.603 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -55.12 -106.76 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.25 -166.12 13.97 Favored Glycine 0 N--CA 1.465 0.629 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -132.58 159.22 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.025 0.44 . . . . 0.0 110.852 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.669 -179.805 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -107.41 128.95 54.93 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.869 0.366 . . . . 0.0 110.354 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -145.76 135.4 23.29 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.612 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -140.44 134.93 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 77.6 m80 -118.69 118.74 32.44 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.416 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.528 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 5.8 m-70 -135.56 164.29 28.17 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.507 0.67 . . . . 0.0 109.856 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.43 HE21 ' HB2' ' H' ' 15' ' ' GLN . 6.4 tt0 -161.86 170.51 19.34 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.437 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 16' ' ' LYS . . . . . 0.416 ' N ' ' CG ' ' H' ' 15' ' ' GLN . 68.7 mttm -155.94 115.79 3.64 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.722 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.687 HD12 HD22 ' I' ' 17' ' ' LEU . 76.6 mt -114.76 115.27 26.77 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -125.09 124.6 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.396 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -113.01 108.76 17.79 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.522 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 24.6 t80 -127.06 129.52 48.16 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.164 0.438 . . . . 0.0 110.635 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.47 150.4 26.57 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 118.346 -1.342 . . . . 0.0 114.56 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -132.53 173.04 11.73 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 114.367 -1.288 . . . . 0.0 109.582 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.406 ' OD1' ' C ' ' H' ' 23' ' ' ASP . 64.5 t0 -148.51 116.53 6.4 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 113.253 0.835 . . . . 0.0 113.253 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 3.2 p -121.49 122.33 66.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 177.412 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.24 83.79 0.01 OUTLIER Glycine 0 N--CA 1.472 1.052 0 CA-C-O 121.588 0.549 . . . . 0.0 112.245 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -45.35 170.28 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 113.864 1.061 . . . . 0.0 113.864 179.197 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.472 ' O ' ' O ' ' H' ' 28' ' ' LYS . 19.5 m120 -135.61 177.04 8.13 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 113.444 -1.707 . . . . 0.0 107.738 173.773 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.472 ' O ' ' O ' ' H' ' 27' ' ' ASN . 65.2 mttm -21.28 -102.86 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . -158.85 100.27 0.19 Allowed Glycine 0 C--N 1.349 1.256 0 CA-C-O 118.365 -1.241 . . . . 0.0 110.788 177.042 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.82 157.14 31.19 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-N 120.869 2.334 . . . . 0.0 109.125 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.637 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.5 OUTLIER -142.91 118.5 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.473 -176.547 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.53 ' O ' ' SD ' ' B' ' 35' ' ' MET . 86.1 mt -127.7 126.17 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.406 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.548 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -131.88 110.33 0.95 Allowed Glycine 0 N--CA 1.477 1.398 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.76 137.96 31.97 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 121.582 -0.952 . . . . 0.0 112.476 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 40.8 ttp -127.3 139.33 52.96 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.835 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.614 ' O ' HG22 ' H' ' 36' ' ' VAL . 2.5 p -153.48 75.15 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.943 178.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.46 ' HA3' HD13 ' B' ' 31' ' ' ILE . . . -37.25 -95.5 0.01 OUTLIER Glycine 0 C--N 1.343 0.928 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 178.376 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -165.22 38.58 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 t -90.44 134.67 28.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.969 0.414 . . . . 0.0 110.764 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.218 -0.587 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.312 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.488 HG21 ' NE2' ' I' ' 14' ' ' HIS . 2.5 p . . . . . 0 CA--C 1.531 0.237 0 CA-C-O 120.873 0.368 . . . . 0.0 111.001 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.519 ' CD2' ' HB2' ' H' ' 13' ' ' HIS . 27.3 m80 -119.87 138.92 53.11 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.605 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.488 ' NE2' HG21 ' I' ' 12' ' ' VAL . 25.8 m-70 -144.74 168.79 19.37 Favored 'General case' 0 CA--C 1.511 -0.552 0 CA-C-O 121.499 0.666 . . . . 0.0 110.483 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -149.42 177.99 9.2 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.84 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -171.36 107.01 0.24 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.862 179.191 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.687 HD22 HD12 ' H' ' 17' ' ' LEU . 9.2 mt -120.07 115.54 23.91 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.407 ' O ' HG23 ' I' ' 18' ' ' VAL . 2.2 m -134.43 127.61 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.23 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.42 ' CD2' ' CE2' ' J' ' 19' ' ' PHE . 12.6 m-30 -110.35 118.8 37.27 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.251 178.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.522 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 53.3 t80 -125.65 118.05 24.83 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.664 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 0.454 ' HB1' ' O ' ' I' ' 25' ' ' GLY . . . -139.43 135.49 33.66 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -177.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.548 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 82.9 tt0 -115.92 100.18 7.8 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.155 -1.794 . . . . 0.0 106.155 176.05 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.548 ' CB ' ' O ' ' I' ' 22' ' ' GLU . 53.2 t0 121.61 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 O-C-N 124.817 1.323 . . . . 0.0 108.246 -176.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.586 HG13 ' NZ ' ' K' ' 28' ' ' LYS . 19.8 m -106.14 112.02 37.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.798 0.809 . . . . 0.0 108.929 -178.501 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.454 ' O ' ' HB1' ' I' ' 21' ' ' ALA . . . 33.65 -92.16 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -177.206 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.64 ' O ' ' O ' ' I' ' 27' ' ' ASN . 41.4 t -130.46 168.24 17.33 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.64 ' O ' ' O ' ' I' ' 26' ' ' SER . 98.2 m-20 38.43 179.13 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 O-C-N 124.096 0.873 . . . . 0.0 111.628 176.354 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.619 ' H ' ' HD2' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -92.65 -120.75 0.08 Allowed 'General case' 0 N--CA 1.471 0.585 0 O-C-N 120.906 -1.121 . . . . 0.0 109.134 178.919 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.461 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -69.08 88.11 0.23 Allowed Glycine 0 CA--C 1.484 -1.903 0 N-CA-C 104.824 -3.31 . . . . 0.0 104.824 171.354 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.47 162.79 35.65 Favored 'General case' 0 CA--C 1.464 -2.331 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.91 -175.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.637 ' CG1' HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -137.74 113.21 10.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.004 -179.404 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.601 ' CG2' HD11 ' J' ' 34' ' ' LEU . 1.6 tt -107.03 114.1 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 179.179 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.427 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -116.65 97.52 0.76 Allowed Glycine 0 CA--C 1.508 -0.377 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -123.17 131.55 53.72 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-O 122.379 1.085 . . . . 0.0 110.579 179.576 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 25.6 ttt -116.19 117.38 29.88 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.577 -1.647 . . . . 0.0 110.29 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.7 71.3 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.51 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.19 105.58 3.21 Favored Glycine 0 C--N 1.365 2.157 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 176.721 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.08 165.17 53.27 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.745 -0.741 . . . . 0.0 111.694 -178.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t -143.75 136.9 24.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.68 0.276 . . . . 0.0 110.351 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.098 -0.953 . . . . 0.0 110.324 179.699 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -81.92 142.81 32.13 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.957 0.408 . . . . 0.0 110.926 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -63.04 142.12 58.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.705 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -134.85 144.29 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 3.5 m80 -139.13 138.55 37.11 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.377 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.475 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 79.6 t60 -139.73 166.92 23.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.475 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 85.5 mt-30 -148.61 172.0 15.25 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.612 179.655 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 47.6 mtpt -156.93 112.07 2.83 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.603 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' J' ' 17' ' ' LEU . 5.3 mp -123.82 120.53 32.89 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.437 0.16 . . . . 0.0 110.661 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -137.31 130.86 44.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 119.921 -0.712 . . . . 0.0 112.014 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.42 ' CE2' ' CD2' ' I' ' 19' ' ' PHE . 18.0 m-85 -111.04 119.78 40.18 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 114.741 -1.118 . . . . 0.0 108.75 178.789 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -131.31 122.08 25.79 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.67 145.04 31.54 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -131.41 160.31 35.46 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.911 -1.041 . . . . 0.0 108.897 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -121.77 120.63 35.17 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.524 HG12 ' N ' ' J' ' 25' ' ' GLY . 14.3 t -62.87 -120.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.94 177.794 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.524 ' N ' HG12 ' J' ' 24' ' ' VAL . . . -75.3 -90.26 0.21 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.203 -177.494 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 53.4 m -140.97 171.23 14.36 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 122.067 0.937 . . . . 0.0 111.024 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' J' ' 28' ' ' LYS . 38.8 t-20 -28.66 151.1 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 113.627 -1.624 . . . . 0.0 115.168 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.533 ' N ' ' OD1' ' J' ' 27' ' ' ASN . 97.9 mttt -163.75 110.7 1.13 Allowed 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 112.594 -2.094 . . . . 0.0 107.594 177.231 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.65 93.82 0.32 Allowed Glycine 0 N--CA 1.476 1.303 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.538 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.507 ' HB2' ' O ' ' I' ' 28' ' ' LYS . . . -112.16 157.73 20.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 105.85 -1.907 . . . . 0.0 105.85 177.122 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.646 HG23 ' CG1' ' K' ' 31' ' ' ILE . 0.0 OUTLIER -146.55 111.24 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 119.715 -0.794 . . . . 0.0 110.329 -173.729 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.437 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.2 tt -104.54 118.57 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.113 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.773 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.61 106.51 0.89 Allowed Glycine 0 C--O 1.241 0.567 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.601 HD11 ' CG2' ' I' ' 32' ' ' ILE . 5.3 mp -129.71 132.06 46.52 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-O 122.15 0.976 . . . . 0.0 111.217 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.44 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 23.2 ttt -102.04 114.91 29.44 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 113.383 -1.735 . . . . 0.0 108.143 178.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -136.46 70.45 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.446 -177.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.72 -101.12 1.99 Allowed Glycine 0 C--N 1.358 1.756 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 177.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.61 154.71 26.21 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -142.79 139.17 28.11 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-O 121.128 0.489 . . . . 0.0 110.726 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.589 179.641 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.62 139.03 45.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.76 0.314 . . . . 0.0 110.913 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.542 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 95.0 mt-10 -139.47 153.53 47.55 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.619 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.454 HG22 ' H ' ' L' ' 12' ' ' VAL . 54.6 t -121.71 131.16 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 116.312 -0.403 . . . . 0.0 109.968 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -161.51 162.63 30.4 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.716 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -152.45 168.01 26.89 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.947 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 -158.04 178.83 9.77 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.11 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.1 tttt -160.14 126.58 4.27 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.123 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -116.86 119.11 34.37 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.043 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.38 125.69 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.866 0.365 . . . . 0.0 111.395 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -116.91 119.69 36.14 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.116 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.405 ' CE1' ' OE2' ' K' ' 22' ' ' GLU . 37.8 t80 -127.92 119.72 26.16 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.367 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.43 132.98 34.21 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.47 ' OE1' ' OE2' ' L' ' 22' ' ' GLU . 57.7 mm-40 -102.83 167.86 9.6 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.763 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' K' ' 23' ' ' ASP . 2.9 p30 -152.35 133.7 14.44 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 119.11 -1.036 . . . . 0.0 113.788 -178.524 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.555 ' O ' HG13 ' K' ' 24' ' ' VAL . 7.7 p -88.69 113.29 25.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 104.222 -2.51 . . . . 0.0 104.222 174.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.46 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -45.39 91.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.621 0 C-N-CA 119.722 -1.228 . . . . 0.0 113.503 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.6 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.6 t 161.17 160.69 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.127 0.489 . . . . 0.0 110.159 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' K' ' 28' ' ' LYS . 82.3 m-20 -29.76 175.91 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.245 173.227 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.66 ' HB2' ' O ' ' K' ' 27' ' ' ASN . 2.9 tptm 147.56 100.85 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 C-N-CA 127.032 2.133 . . . . 0.0 110.299 176.02 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -51.22 -100.17 0.01 OUTLIER Glycine 0 C--O 1.21 -1.397 0 CA-C-O 124.465 2.147 . . . . 0.0 114.385 175.133 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.81 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 70.74 143.87 0.06 Allowed 'General case' 0 C--O 1.245 0.826 0 CA-C-N 111.354 -2.423 . . . . 0.0 107.203 177.407 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.81 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -147.88 123.09 2.35 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.795 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.493 ' O ' ' CG2' ' K' ' 32' ' ' ILE . 0.8 OUTLIER -108.97 115.12 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.692 178.816 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 91.35 0.58 Allowed Glycine 0 C--O 1.24 0.485 0 N-CA-C 107.333 -2.307 . . . . 0.0 107.333 176.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.4 HD12 ' CE2' ' I' ' 19' ' ' PHE . 92.2 mt -114.75 118.75 34.47 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.331 0.586 . . . . 0.0 109.862 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 2.5 ttt -107.7 115.04 29.43 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.742 -178.788 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.11 68.35 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.763 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.415 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -62.03 -100.99 0.01 OUTLIER Glycine 0 C--N 1.349 1.262 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.86 160.2 14.39 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.9 m -136.76 159.74 37.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.794 0.33 . . . . 0.0 110.219 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.325 -0.457 0 CA-C-O 118.089 -0.958 . . . . 0.0 110.765 -179.77 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.351 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -104.38 132.33 50.75 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -71.9 132.42 44.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.354 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.454 ' H ' HG22 ' K' ' 12' ' ' VAL . 21.8 m -143.13 156.2 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 122.011 0.91 . . . . 0.0 112.543 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.542 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 3.9 m80 -151.16 118.33 5.94 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.729 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -153.88 172.82 16.8 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.273 0.559 . . . . 0.0 110.418 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -145.67 173.86 11.7 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.728 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -159.82 120.92 3.14 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.93 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 tt -122.51 119.73 31.77 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -129.07 132.89 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -135.64 130.32 34.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.935 0.398 . . . . 0.0 110.715 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.2 t80 -137.31 127.62 26.38 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.568 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.0 148.21 36.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.265 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.47 ' OE2' ' OE1' ' K' ' 22' ' ' GLU . 78.1 mt-10 -81.73 149.17 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.464 0.649 . . . . 0.0 110.722 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.411 ' O ' ' O ' ' L' ' 22' ' ' GLU . 99.3 m-20 54.17 114.42 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.869 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 67.3 t -95.12 130.61 43.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 CA-C-N 114.519 -1.219 . . . . 0.0 109.879 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 49.56 82.74 0.03 OUTLIER Glycine 0 CA--C 1.525 0.698 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.183 178.151 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' L' ' 27' ' ' ASN . 5.8 p 176.96 -167.52 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' L' ' 26' ' ' SER . 90.4 m-20 -38.92 179.91 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -175.485 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.468 ' NZ ' ' O ' ' K' ' 22' ' ' GLU . 85.1 tttt 77.42 -111.42 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.668 -1.151 . . . . 0.0 112.128 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.646 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 83.93 -94.59 1.83 Allowed Glycine 0 CA--C 1.503 -0.682 0 N-CA-C 107.892 -2.083 . . . . 0.0 107.892 -174.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.646 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 77.17 169.77 0.23 Allowed 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.617 HD13 ' C ' ' L' ' 30' ' ' ALA . 0.0 OUTLIER -138.83 109.19 4.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 116.81 -1.956 . . . . 0.0 111.224 179.23 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' L' ' 32' ' ' ILE . 7.4 tt -102.7 115.88 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-N 113.34 -1.755 . . . . 0.0 107.961 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 110.18 2.24 Favored Glycine 0 C--N 1.334 0.464 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 -179.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.38 111.8 22.03 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.582 -0.809 . . . . 0.0 110.086 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.437 ' HE2' ' H ' ' F' ' 33' ' ' GLY . 2.7 tpp -93.65 104.97 17.05 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.817 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' L' ' 37' ' ' GLY . 0.7 OUTLIER -131.09 71.36 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.954 0 O-C-N 122.051 -0.405 . . . . 0.0 109.922 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -35.49 -100.66 0.01 OUTLIER Glycine 0 C--N 1.346 1.085 0 C-N-CA 121.815 -0.231 . . . . 0.0 112.717 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.27 174.91 19.16 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 159.2 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.979 0.419 . . . . 0.0 110.709 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.184 179.897 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 121.307 0.575 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.491 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 69.7 m80 -116.44 172.5 7.17 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.813 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.51 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 34.9 t60 -80.45 165.55 22.09 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 109.622 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.51 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 0.1 OUTLIER -161.01 179.03 8.78 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.315 179.428 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -144.24 128.22 17.48 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.713 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 78.5 mt -124.03 124.19 42.01 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.24 131.45 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.333 0.587 . . . . 0.0 111.852 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.912 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 0.2 OUTLIER -118.44 112.11 19.53 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.937 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.533 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 51.1 p90 -125.44 128.27 47.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -177.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.27 115.85 28.06 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.219 0.533 . . . . 0.0 110.166 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.465 ' O ' ' C ' ' A' ' 23' ' ' ASP . 84.7 tt0 -163.89 96.52 0.82 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.465 ' C ' ' O ' ' A' ' 22' ' ' GLU . 0.1 OUTLIER -25.89 115.46 0.06 Allowed 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 -177.097 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' A' ' 26' ' ' SER . 2.1 p -87.27 130.64 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.75 82.29 0.0 OUTLIER Glycine 0 CA--C 1.525 0.712 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.618 -177.249 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' A' ' 24' ' ' VAL . 80.2 p -98.47 174.95 6.21 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.123 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.07 178.89 0.16 Allowed 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 119.396 -0.922 . . . . 0.0 108.635 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.68 110.78 1.22 Allowed 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.73 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 94.2 0.11 Allowed Glycine 0 N--CA 1.469 0.843 0 C-N-CA 119.702 -1.237 . . . . 0.0 111.284 177.516 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.402 ' HB2' ' OG ' ' A' ' 26' ' ' SER . . . -103.32 160.23 14.87 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-N 119.707 1.753 . . . . 0.0 107.497 177.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.579 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.2 OUTLIER -152.6 113.03 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.175 -175.308 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.47 ' O ' ' SD ' ' G' ' 35' ' ' MET . 97.6 mt -128.86 128.04 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-O 121.435 0.636 . . . . 0.0 111.671 -179.362 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' G' ' 35' ' ' MET . . . -123.5 127.03 6.43 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.043 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -130.18 130.05 44.21 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.799 0.3 . . . . 0.0 111.021 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.674 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 19.8 ttp -130.63 128.08 40.24 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.096 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.449 HG12 ' O ' ' A' ' 36' ' ' VAL . 54.4 t -115.64 72.15 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.88 98.82 0.81 Allowed Glycine 0 CA--C 1.529 0.924 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 176.717 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.76 172.45 40.48 Favored Glycine 0 CA--C 1.523 0.547 0 C-N-CA 120.485 -0.864 . . . . 0.0 111.564 -179.272 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 N--CA 1.471 0.587 0 CA-C-O 120.781 0.324 . . . . 0.0 110.765 179.986 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.466 0.366 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.464 ' O ' ' CB ' ' C' ' 13' ' ' HIS . 4.8 m-70 -105.67 117.76 34.84 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.789 0.328 . . . . 0.0 110.909 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.437 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 52.5 t-80 -157.21 159.51 37.76 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.437 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 74.4 mt-30 -159.98 179.07 9.09 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.832 179.342 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -157.71 126.12 5.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.754 0.311 . . . . 0.0 110.762 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 tp -120.76 123.25 42.21 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.312 0.577 . . . . 0.0 110.297 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.48 HG22 ' CG1' ' C' ' 18' ' ' VAL . 56.0 t -117.93 121.37 67.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.601 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.901 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 13.5 t80 -128.05 116.26 19.73 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 -178.908 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.543 ' CG ' ' CZ ' ' C' ' 20' ' ' PHE . 38.8 p90 -150.2 160.22 43.85 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.41 138.85 38.59 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.896 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -125.4 175.1 7.72 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.487 ' CG ' ' H ' ' C' ' 27' ' ' ASN . 50.5 t0 -142.98 99.33 3.44 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.139 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.656 HG12 ' H ' ' B' ' 25' ' ' GLY . 1.6 t -118.21 -151.17 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.656 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -38.9 -75.88 0.09 OUTLIER Glycine 0 N--CA 1.47 0.937 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.601 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.592 ' HG ' ' H ' ' B' ' 27' ' ' ASN . 31.1 t 60.15 173.13 0.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.73 -1.235 . . . . 0.0 113.568 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.592 ' H ' ' HG ' ' B' ' 26' ' ' SER . 18.9 p30 -101.38 -178.98 3.89 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 113.395 -1.73 . . . . 0.0 112.567 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.494 ' O ' ' O ' ' B' ' 27' ' ' ASN . 87.3 tttt -34.15 -102.66 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.118 177.115 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -137.13 100.8 0.32 Allowed Glycine 0 CA--C 1.485 -1.829 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.5 157.72 31.45 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.349 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.754 HG23 HG13 ' C' ' 31' ' ' ILE . 0.6 OUTLIER -148.58 120.87 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.583 -178.796 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.501 ' O ' ' SD ' ' H' ' 35' ' ' MET . 86.8 mt -133.98 128.68 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.362 -178.065 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.505 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -120.81 109.5 1.56 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.976 -1.65 . . . . 0.0 108.976 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 8.7 tt -117.08 123.32 46.53 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 117.072 0.436 . . . . 0.0 111.099 -179.051 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.599 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 32.1 ttp -124.79 117.37 24.01 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.299 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 37' ' ' GLY . 34.5 m -136.54 73.01 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -47.4 -95.35 0.01 OUTLIER Glycine 0 C--N 1.337 0.604 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 175.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.13 176.67 40.45 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -140.96 144.48 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-O 121.031 0.443 . . . . 0.0 111.215 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 85.0 t . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.309 179.842 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.156 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -105.73 131.56 52.94 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.709 0.29 . . . . 0.0 110.595 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -74.3 133.14 42.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.068 179.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.16 166.68 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 CA-C-O 120.832 0.349 . . . . 0.0 110.887 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.464 ' CB ' ' O ' ' B' ' 13' ' ' HIS . 0.0 OUTLIER -169.28 164.76 10.92 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.271 178.749 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.495 ' CG ' ' OE1' ' D' ' 15' ' ' GLN . 54.1 m80 -105.52 -179.91 4.08 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' C' ' 16' ' ' LYS . 13.6 tt0 -88.69 169.19 11.88 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.433 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' C' ' 15' ' ' GLN . 99.2 mttt -123.5 133.92 53.95 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 29.1 mt -122.3 119.35 30.86 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.026 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 18' ' ' VAL . . . . . 0.48 ' CG1' HG22 ' B' ' 18' ' ' VAL . 6.2 p -124.77 123.23 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.067 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.707 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 3.6 t80 -123.41 119.17 29.25 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.571 -176.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.543 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 49.7 p90 -142.86 130.26 21.11 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-O 122.574 1.178 . . . . 0.0 112.953 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.94 121.74 38.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.397 179.683 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.496 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 97.2 mt-10 -99.01 101.08 12.35 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.498 ' OD1' ' NZ ' ' E' ' 28' ' ' LYS . 15.7 t0 83.68 133.56 0.05 Allowed 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.508 ' O ' ' N ' ' C' ' 26' ' ' SER . 34.8 t -83.41 -110.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.718 ' HA2' ' HB3' ' D' ' 30' ' ' ALA . . . -42.85 92.19 0.01 OUTLIER Glycine 0 C--N 1.317 -0.473 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.527 ' O ' ' O ' ' C' ' 27' ' ' ASN . 42.3 p -101.11 165.22 11.42 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 122.49 1.138 . . . . 0.0 110.784 -176.33 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.646 ' CG ' ' HZ2' ' C' ' 28' ' ' LYS . 0.1 OUTLIER 49.05 169.15 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 112.009 -2.36 . . . . 0.0 109.114 -176.235 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.787 ' CE ' ' H ' ' C' ' 28' ' ' LYS . 0.0 OUTLIER -79.08 110.7 14.57 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.641 -0.824 . . . . 0.0 108.824 175.634 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 57.25 91.51 0.01 OUTLIER Glycine 0 C--O 1.219 -0.829 0 C-N-CA 118.342 -1.885 . . . . 0.0 109.877 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.421 ' HB2' ' OD1' ' C' ' 27' ' ' ASN . . . -136.66 152.22 50.16 Favored 'General case' 0 CA--C 1.476 -1.903 0 CA-C-N 121.428 2.614 . . . . 0.0 105.016 175.673 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.754 HG13 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -144.48 109.66 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.185 -173.028 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.488 HG12 HD21 ' C' ' 34' ' ' LEU . 0.8 OUTLIER -114.9 118.44 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.05 -178.918 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.21 108.51 2.48 Favored Glycine 0 N--CA 1.46 0.298 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.912 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 5.8 mt -114.76 112.72 23.25 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 120.916 0.388 . . . . 0.0 110.331 -178.428 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.5 ttt -112.42 104.06 12.18 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.59 72.24 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.994 -177.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -42.97 -97.43 0.01 OUTLIER Glycine 0 C--N 1.349 1.27 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.12 -173.12 42.95 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -141.52 154.22 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.019 0.438 . . . . 0.0 111.133 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.087 -0.959 . . . . 0.0 110.218 179.56 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.439 ' HB ' ' H ' ' E' ' 12' ' ' VAL . 23.0 m . . . . . 0 N--CA 1.465 0.28 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 96.5 m-70 -82.15 112.95 19.65 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.168 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.624 ' CE1' HG23 ' E' ' 12' ' ' VAL . 3.4 m-70 -145.72 159.94 42.44 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.865 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG ' ' C' ' 14' ' ' HIS . 0.0 OUTLIER -159.23 174.18 15.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.26 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -153.32 129.09 10.14 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.886 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 36.7 tp -123.28 118.33 27.32 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -122.39 126.19 73.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.941 0.4 . . . . 0.0 110.687 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -123.25 112.33 17.52 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.369 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -131.57 133.42 45.0 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.79 131.79 29.59 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.886 0.374 . . . . 0.0 111.725 179.29 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -127.88 143.52 51.11 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.991 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -131.3 111.97 12.35 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.969 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.494 ' O ' ' N ' ' D' ' 26' ' ' SER . 12.6 m -138.01 -122.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 120.424 -0.51 . . . . 0.0 109.915 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.418 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . 28.37 -84.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.536 -0.756 . . . . 0.0 113.097 -178.401 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.3 m 170.28 178.77 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.518 0.675 . . . . 0.0 110.574 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' D' ' 26' ' ' SER . 12.4 m120 -28.73 -179.21 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 113.041 -1.891 . . . . 0.0 114.248 176.85 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 85.4 mttt 128.26 105.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 125.867 1.667 . . . . 0.0 112.137 176.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.6 94.87 0.05 OUTLIER Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.718 ' HB3' ' HA2' ' C' ' 25' ' ' GLY . . . -122.43 154.25 38.0 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 176.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.504 HD12 ' CG2' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.04 112.29 2.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.732 -171.629 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.41 ' O ' HG22 ' D' ' 32' ' ' ILE . 2.1 mt -107.93 114.01 45.3 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.409 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.408 ' CA ' ' HG3' ' J' ' 35' ' ' MET . . . -106.38 100.65 1.66 Allowed Glycine 0 CA--C 1.498 -1.007 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 176.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.901 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 13.6 tp -112.99 121.08 43.56 Favored 'General case' 0 CA--C 1.503 -0.852 0 CA-C-N 115.298 -0.451 . . . . 0.0 110.934 -177.865 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 43.3 ttp -128.97 107.25 9.46 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -123.61 72.14 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.675 -179.927 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.15 -100.52 0.01 OUTLIER Glycine 0 C--N 1.36 1.892 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.891 179.144 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 157.13 -157.24 27.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -132.36 147.95 31.99 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.462 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.32 -179.731 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -114.76 134.31 55.21 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.768 0.318 . . . . 0.0 110.491 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -98.37 137.47 37.04 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.28 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.624 HG23 ' CE1' ' D' ' 14' ' ' HIS . 22.6 m -131.74 160.34 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 121.332 0.587 . . . . 0.0 111.141 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 27.6 m80 -124.01 120.51 32.65 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.606 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.467 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -150.66 162.91 39.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.927 0.87 . . . . 0.0 111.473 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.467 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 50.2 tt0 -157.99 168.6 26.67 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.375 -1.284 . . . . 0.0 110.063 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -143.57 126.79 16.59 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.837 179.126 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 tt -118.98 115.68 24.86 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -120.23 125.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.734 0.302 . . . . 0.0 110.36 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -124.16 113.4 18.28 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.482 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -125.72 125.13 42.51 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.212 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.434 ' HB3' ' CB ' ' F' ' 21' ' ' ALA . . . -134.23 119.63 19.01 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.232 0.539 . . . . 0.0 110.327 179.096 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.402 ' C ' ' OD1' ' E' ' 23' ' ' ASP . 97.8 mt-10 -129.16 128.35 43.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.459 ' HB3' ' HZ2' ' F' ' 28' ' ' LYS . 1.2 m-20 -141.89 112.1 6.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.264 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' E' ' 26' ' ' SER . 13.2 m -103.24 -122.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 C-N-CA 120.326 -0.55 . . . . 0.0 111.057 -178.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.05 -84.92 0.01 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.834 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' E' ' 27' ' ' ASN . 3.0 p 170.88 170.54 0.07 Allowed 'General case' 0 CA--C 1.511 -0.55 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' E' ' 26' ' ' SER . 27.6 t-20 -18.17 157.47 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.975 0 O-C-N 124.792 1.308 . . . . 0.0 113.475 179.7 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.722 ' O ' ' HB2' ' F' ' 30' ' ' ALA . 84.8 tttt -162.55 111.35 1.38 Allowed 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.552 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.17 92.36 0.25 Allowed Glycine 0 N--CA 1.479 1.528 0 O-C-N 121.931 -0.481 . . . . 0.0 113.194 177.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.5 161.97 21.58 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 175.623 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.466 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.68 132.21 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 118.903 -1.119 . . . . 0.0 113.647 -175.561 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.571 HG23 HD21 ' E' ' 34' ' ' LEU . 0.2 OUTLIER -109.71 116.48 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.306 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.67 105.36 2.23 Favored Glycine 0 N--CA 1.466 0.669 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.707 HD13 ' CZ ' ' C' ' 19' ' ' PHE . 16.4 mt -115.83 115.0 25.49 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 117.561 0.68 . . . . 0.0 112.155 -177.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.717 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 11.4 ttp -114.07 106.66 14.66 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 176.074 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.91 73.81 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.331 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.17 111.57 2.66 Favored Glycine 0 C--N 1.354 1.577 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 178.603 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.5 -157.08 0.04 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.15 142.81 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.975 0.417 . . . . 0.0 110.49 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.772 179.827 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t . . . . . 0 N--CA 1.468 0.43 0 CA-C-O 121.115 0.483 . . . . 0.0 110.397 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -130.02 128.53 42.18 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.923 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.448 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 78.8 t60 -151.99 168.5 25.02 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.448 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 33.8 mt-30 -150.52 173.47 14.05 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.41 179.454 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.41 127.01 14.21 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.39 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -128.73 127.57 42.33 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.554 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -127.56 128.3 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -123.36 120.74 33.92 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.678 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 78.8 t80 -141.13 121.88 14.35 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.434 ' CB ' ' HB3' ' E' ' 21' ' ' ALA . . . -159.59 154.71 25.04 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 119.785 -0.766 . . . . 0.0 112.578 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -96.94 124.16 40.84 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.547 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 60.3 t0 . . . . . 0 CA--C 1.536 0.407 0 C-N-CA 119.652 -0.819 . . . . 0.0 113.033 -178.198 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.509 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 75.1 tttt . . . . . 0 CA--C 1.544 0.717 0 CA-C-O 124.085 1.897 . . . . 0.0 112.226 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.509 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -109.29 -100.33 2.63 Favored Glycine 0 CA--C 1.484 -1.881 0 C-N-CA 130.168 3.747 . . . . 0.0 109.753 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.722 ' HB2' ' O ' ' E' ' 28' ' ' LYS . . . -58.11 172.85 0.39 Allowed 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 -178.865 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.448 HD13 ' HA3' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -140.39 134.42 34.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.147 -1.421 . . . . 0.0 111.479 -172.131 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.495 ' CG2' ' O ' ' F' ' 32' ' ' ILE . 5.2 tt -110.12 117.24 54.29 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 114.001 -1.454 . . . . 0.0 108.452 -179.266 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.77 102.87 2.42 Favored Glycine 0 C--N 1.322 -0.249 0 N-CA-C 108.027 -2.029 . . . . 0.0 108.027 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.504 ' O ' HD12 ' F' ' 34' ' ' LEU . 2.2 pp -107.44 115.73 30.67 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 117.039 0.42 . . . . 0.0 110.518 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 18.3 ttp -119.46 110.5 16.99 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 m -132.87 79.92 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.16 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -64.65 103.5 0.77 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.0 -146.15 19.15 Favored Glycine 0 N--CA 1.465 0.61 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -113.86 133.58 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 32.9 m . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.761 -179.67 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -121.92 147.84 45.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.745 0.307 . . . . 0.0 110.707 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -68.51 156.96 36.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.069 179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 78.0 t -115.63 131.6 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.061 0.458 . . . . 0.0 110.315 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -89.15 179.45 6.13 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.972 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -74.69 164.45 26.57 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 91.7 mt-30 -155.63 -179.84 8.5 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.442 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.414 ' NZ ' ' CG2' ' G' ' 18' ' ' VAL . 65.2 tttm -161.32 119.26 2.35 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.682 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 35.7 tp -118.83 126.12 51.11 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 121.299 0.571 . . . . 0.0 110.478 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.414 ' CG2' ' NZ ' ' G' ' 16' ' ' LYS . 47.9 t -125.72 125.9 69.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.901 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.923 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 0.1 OUTLIER -114.76 119.47 36.77 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.937 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -142.92 147.96 36.14 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 119.674 -0.81 . . . . 0.0 112.369 -178.041 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.32 132.22 35.37 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.285 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -135.48 167.33 21.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.53 ' OD2' ' N ' ' H' ' 24' ' ' VAL . 34.8 m-20 -85.94 -151.19 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.168 -178.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' G' ' 23' ' ' ASP . 14.0 t 27.09 103.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.77 -94.69 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.827 177.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -64.03 -178.81 0.36 Allowed 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -80.95 173.49 12.56 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.12 0.486 . . . . 0.0 111.302 177.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -44.91 110.79 0.26 Allowed 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.947 176.365 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.26 94.73 0.52 Allowed Glycine 0 N--CA 1.472 1.084 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.324 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -118.34 151.61 37.39 Favored 'General case' 0 CA--C 1.504 -0.808 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.196 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.19 108.81 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 CA-C-N 113.182 -1.826 . . . . 0.0 109.594 -171.338 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.76 123.46 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.89 0.376 . . . . 0.0 111.237 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.674 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -130.33 111.23 1.11 Allowed Glycine 0 N--CA 1.465 0.573 0 N-CA-C 108.794 -1.723 . . . . 0.0 108.794 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.89 130.41 52.82 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.916 0.388 . . . . 0.0 111.656 -178.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' A' ' 33' ' ' GLY . 28.1 ttt -130.46 128.52 41.43 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' G' ' 37' ' ' GLY . 3.7 t -111.42 65.9 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -178.209 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.509 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -55.25 -105.55 0.01 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 178.151 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -105.06 174.59 21.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 30.0 m -135.23 158.13 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.11 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -86.65 131.01 34.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.918 0.389 . . . . 0.0 110.103 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -136.06 142.81 44.41 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.908 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -126.06 134.31 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.456 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 75.4 m80 -87.08 175.35 8.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.124 0.488 . . . . 0.0 110.792 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.547 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 25.4 m-70 -77.9 173.28 12.32 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.45 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -142.75 175.44 9.82 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.128 179.623 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -151.58 125.87 9.36 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.151 -179.184 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 58.1 mt -121.17 120.51 35.43 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -127.8 130.52 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -178.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.744 ' CZ ' HD22 ' J' ' 34' ' ' LEU . 5.9 m-85 -117.73 120.06 36.81 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.615 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 29.0 t80 -130.78 122.6 27.46 Favored 'General case' 0 N--CA 1.476 0.834 0 O-C-N 122.231 -0.293 . . . . 0.0 110.626 -179.129 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.77 130.0 48.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -137.94 106.74 5.93 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -114.51 114.11 25.34 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.53 ' N ' ' OD2' ' G' ' 23' ' ' ASP . 1.2 p -128.79 122.26 56.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.051 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 30.49 82.79 0.01 OUTLIER Glycine 0 CA--C 1.537 1.442 0 CA-C-O 119.473 -0.626 . . . . 0.0 114.593 175.66 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.542 ' O ' ' O ' ' H' ' 27' ' ' ASN . 1.0 OUTLIER -140.14 170.62 15.49 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 118.71 1.255 . . . . 0.0 111.108 179.107 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' H' ' 26' ' ' SER . 5.5 m-20 -31.04 173.14 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 113.671 -1.604 . . . . 0.0 114.812 -177.206 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -87.84 111.41 21.38 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.267 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . 69.61 93.6 0.06 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 118.124 -1.989 . . . . 0.0 115.526 172.442 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.42 155.51 22.09 Favored 'General case' 0 C--O 1.248 0.985 0 CA-C-N 120.627 2.214 . . . . 0.0 106.698 175.327 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.759 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -148.31 119.27 1.37 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 118.921 -1.112 . . . . 0.0 111.684 -173.055 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.9 mt -129.87 128.32 64.98 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.034 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.599 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -132.23 127.54 4.94 Favored Glycine 0 N--CA 1.465 0.63 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.454 ' O ' HD12 ' I' ' 34' ' ' LEU . 8.4 tt -135.08 130.96 36.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.565 0.698 . . . . 0.0 110.736 -179.48 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 19.3 ttt -130.37 128.99 42.53 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.652 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.52 79.54 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.549 ' CA ' HG21 ' B' ' 31' ' ' ILE . . . -65.77 105.12 1.15 Allowed Glycine 0 C--N 1.339 0.707 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.74 -171.27 50.34 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -132.37 161.78 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-O 120.993 0.425 . . . . 0.0 110.909 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 34.3 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.658 179.766 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.464 0.25 0 N-CA-C 110.075 -0.342 . . . . 0.0 110.075 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.513 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 16.5 p-80 -164.27 161.08 21.72 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.554 -0.459 . . . . 0.0 111.229 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.547 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 0.8 OUTLIER -122.92 166.76 14.52 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.951 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -142.25 175.64 9.6 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.65 179.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.528 ' C ' HD12 ' I' ' 17' ' ' LEU . 87.4 tttt -166.49 113.7 0.86 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.771 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.528 HD12 ' C ' ' I' ' 16' ' ' LYS . 8.0 mp -112.56 124.24 52.09 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.162 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -127.91 128.75 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-O 121.17 0.51 . . . . 0.0 112.095 -179.382 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.834 ' CZ ' HD13 ' K' ' 34' ' ' LEU . 32.1 m-85 -118.75 118.98 33.07 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.573 178.251 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.615 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 58.8 t80 -126.57 116.95 21.85 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.48 129.63 52.21 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.18 0.514 . . . . 0.0 111.771 -179.108 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -143.83 144.29 31.71 Favored 'General case' 0 C--N 1.34 0.193 0 CA-C-N 115.366 -0.833 . . . . 0.0 109.036 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.605 ' O ' ' O ' ' I' ' 24' ' ' VAL . 0.9 OUTLIER -175.04 129.55 0.3 Allowed 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.062 -0.655 . . . . 0.0 110.773 179.724 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.757 HG12 ' N ' ' I' ' 25' ' ' GLY . 61.6 t -29.34 -113.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 O-C-N 124.425 1.078 . . . . 0.0 112.66 178.156 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.757 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -170.77 90.55 0.09 OUTLIER Glycine 0 CA--C 1.53 0.981 0 CA-C-N 115.272 -0.877 . . . . 0.0 112.117 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.525 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t 161.99 160.45 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.921 0.867 . . . . 0.0 111.128 176.729 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.525 ' O ' ' O ' ' I' ' 26' ' ' SER . 81.8 m-20 -30.16 179.07 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 113.084 -1.871 . . . . 0.0 116.027 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.508 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 86.4 tttt 127.81 103.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 112.2 -2.273 . . . . 0.0 111.203 174.085 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.514 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -59.86 99.54 0.16 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.248 -1.307 . . . . 0.0 110.735 174.708 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.439 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -118.08 141.4 48.51 Favored 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 102.529 -3.137 . . . . 0.0 102.529 174.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.759 HD12 ' CG2' ' H' ' 31' ' ' ILE . 2.1 mt -146.06 114.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 C-N-CA 118.181 -1.408 . . . . 0.0 112.515 -169.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 1.3 mt -114.62 119.74 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.16 106.56 1.44 Allowed Glycine 0 N--CA 1.461 0.311 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.923 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 54.4 tp -116.23 120.93 40.53 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 5.6 tpp -117.1 102.02 8.96 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 174.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.705 ' O ' HG13 ' I' ' 36' ' ' VAL . 4.2 p -131.81 74.89 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.114 -177.298 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.28 -96.92 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.995 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 163.31 -167.76 37.72 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.65 150.58 3.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.768 0.318 . . . . 0.0 110.387 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.854 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -83.64 141.89 31.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.955 0.407 . . . . 0.0 110.065 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -66.35 135.63 54.64 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.477 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.814 HG12 ' H ' ' J' ' 13' ' ' HIS . 27.4 t -145.77 178.8 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.119 179.434 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.814 ' H ' HG12 ' J' ' 12' ' ' VAL . 92.2 m-70 -50.82 125.28 12.96 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.069 0.461 . . . . 0.0 112.146 -177.422 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.499 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 18.0 t-80 -145.38 163.43 34.6 Favored 'General case' 0 C--N 1.341 0.239 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.499 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 89.6 mt-30 -148.54 177.6 9.34 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.088 0.47 . . . . 0.0 111.364 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.419 ' C ' HD22 ' J' ' 17' ' ' LEU . 88.9 tttt -170.26 116.28 0.51 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.819 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.419 HD22 ' C ' ' J' ' 16' ' ' LYS . 1.4 mm? -114.23 125.27 53.72 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.495 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -126.78 121.05 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 120.78 0.324 . . . . 0.0 111.241 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.673 ' CZ ' HD22 ' L' ' 34' ' ' LEU . 95.4 m-85 -118.43 116.22 26.26 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.416 ' CZ ' ' CD1' ' K' ' 20' ' ' PHE . 1.1 t80 -131.38 129.66 41.62 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 120.922 0.391 . . . . 0.0 110.553 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.41 134.65 41.88 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.458 0.647 . . . . 0.0 112.421 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 mt-10 -144.3 102.87 3.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.029 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -152.22 177.3 10.68 Favored 'General case' 0 CA--C 1.515 -0.394 0 O-C-N 122.096 -0.378 . . . . 0.0 110.392 -178.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -91.96 102.99 14.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 122.176 0.989 . . . . 0.0 108.379 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' K' ' 26' ' ' SER . . . -35.9 95.59 0.01 OUTLIER Glycine 0 CA--C 1.526 0.763 0 CA-C-N 113.269 -1.787 . . . . 0.0 115.653 -179.087 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.4 t 170.24 176.18 0.05 Allowed 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 121.627 0.727 . . . . 0.0 110.678 175.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' J' ' 26' ' ' SER . 52.2 t30 -28.96 179.5 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 115.886 1.81 . . . . 0.0 115.886 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.505 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 61.8 tttp 128.26 105.11 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 112.715 -2.039 . . . . 0.0 112.719 175.329 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.02 95.07 0.05 OUTLIER Glycine 0 N--CA 1.465 0.59 0 CA-C-N 113.934 -1.484 . . . . 0.0 113.031 174.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.51 142.33 46.99 Favored 'General case' 0 CA--C 1.496 -1.117 0 CA-C-N 119.884 1.842 . . . . 0.0 106.201 174.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.46 HG23 ' CG1' ' K' ' 31' ' ' ILE . 0.0 OUTLIER -143.11 110.93 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 CA-C-N 114.454 -1.248 . . . . 0.0 111.837 -171.41 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.529 ' O ' ' SD ' ' E' ' 35' ' ' MET . 0.2 OUTLIER -114.68 118.9 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 177.783 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -114.15 106.68 1.75 Allowed Glycine 0 CA--C 1.496 -1.115 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 177.507 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.744 HD22 ' CZ ' ' H' ' 19' ' ' PHE . 37.1 tp -115.37 118.87 34.44 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 113.292 0.849 . . . . 0.0 113.292 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.408 ' HG3' ' CA ' ' D' ' 33' ' ' GLY . 0.0 OUTLIER -117.29 107.63 14.63 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.639 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.524 HG22 HD11 ' J' ' 34' ' ' LEU . 0.0 OUTLIER -119.37 80.29 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.3 -94.42 0.01 OUTLIER Glycine 0 C--N 1.352 1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.714 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.62 -178.14 18.74 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 111.031 -0.827 . . . . 0.0 111.031 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -114.63 134.93 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.444 179.95 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -103.96 135.44 45.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.655 0.264 . . . . 0.0 110.377 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.471 ' N ' ' OE1' ' L' ' 11' ' ' GLU . 94.9 mt-10 -137.48 156.52 48.06 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.607 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.6 m -134.48 163.2 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.657 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 t60 -159.37 128.37 5.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.314 -179.567 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -152.67 167.52 28.65 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.688 0.756 . . . . 0.0 110.002 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -156.51 175.92 13.39 Favored 'General case' 0 C--N 1.307 -1.239 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.762 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -148.73 120.37 8.03 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 23.1 mt -112.51 116.05 29.63 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.6 p -133.31 134.47 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 CA-C-O 121.42 0.629 . . . . 0.0 112.308 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -125.76 126.94 45.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.227 179.087 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.416 ' CD1' ' CZ ' ' J' ' 20' ' ' PHE . 8.2 t80 -136.51 128.96 30.26 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.171 0.51 . . . . 0.0 111.818 -179.315 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.78 129.53 47.19 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.772 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.446 ' HG2' ' N ' ' K' ' 23' ' ' ASP . 75.7 tt0 -88.44 170.1 11.2 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.453 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.503 ' OD1' HG21 ' L' ' 24' ' ' VAL . 48.0 t0 -39.33 115.46 0.5 Allowed 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 121.007 0.432 . . . . 0.0 110.821 -178.601 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.556 HG13 ' O ' ' K' ' 24' ' ' VAL . 10.4 p -129.84 117.16 40.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.867 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . -27.92 -90.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.381 0 CA-C-O 121.524 0.513 . . . . 0.0 111.825 178.161 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.637 ' O ' ' O ' ' K' ' 27' ' ' ASN . 26.7 p -140.97 170.73 15.18 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.121 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.637 ' O ' ' O ' ' K' ' 26' ' ' SER . 56.8 p30 -28.29 169.75 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -149.4 111.45 4.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.685 178.068 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.71 91.6 0.02 OUTLIER Glycine 0 N--CA 1.464 0.521 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.59 151.69 43.37 Favored 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 106.314 -1.735 . . . . 0.0 106.314 176.685 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.46 ' CG1' HG23 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -135.83 115.44 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.579 -178.724 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.545 HG23 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -115.59 116.91 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 178.362 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.717 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -109.56 106.0 2.13 Favored Glycine 0 N--CA 1.464 0.547 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 178.581 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.834 HD13 ' CZ ' ' I' ' 19' ' ' PHE . 21.5 mt -110.44 111.98 23.6 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 117.047 0.423 . . . . 0.0 111.659 -177.55 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.46 ' CE ' ' O ' ' E' ' 32' ' ' ILE . 11.4 tpt -107.59 103.1 12.32 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 176.624 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -129.58 73.83 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.146 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.445 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.38 -101.5 0.01 OUTLIER Glycine 0 C--N 1.359 1.828 0 CA-C-N 116.388 -0.369 . . . . 0.0 112.844 -179.215 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.92 -155.69 26.57 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 30.0 m -126.54 160.54 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.762 0.315 . . . . 0.0 110.548 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.501 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -148.22 160.68 42.69 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.655 0.264 . . . . 0.0 110.334 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 11' ' ' GLU . . . . . 0.471 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 78.5 mm-40 -75.78 157.0 34.02 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.733 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 96.1 t -92.86 131.06 40.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.123 0 CA-C-O 121.061 0.458 . . . . 0.0 110.216 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.5 ' NE2' ' OXT' ' L' ' 40' ' ' VAL . 45.1 t-80 -144.25 134.21 23.98 Favored 'General case' 0 N--CA 1.461 0.113 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.954 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 46.8 t-80 -154.99 170.83 20.84 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.466 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.478 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 96.2 mt-30 -148.3 178.56 8.47 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.646 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -164.3 122.48 1.79 Allowed 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.11 0.481 . . . . 0.0 111.204 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 59.1 tp -120.75 121.57 38.5 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.977 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.91 131.65 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.156 0.503 . . . . 0.0 110.501 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.534 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 41.1 p90 -135.14 125.63 26.72 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.217 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -140.08 142.57 36.1 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 121.776 0.798 . . . . 0.0 110.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.39 143.63 24.06 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.343 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.405 ' O ' ' O ' ' L' ' 23' ' ' ASP . 78.5 tt0 -76.12 153.1 36.52 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.585 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.535 ' C ' HG23 ' L' ' 24' ' ' VAL . 59.4 m-20 -58.62 -134.4 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -177.09 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.535 HG23 ' C ' ' L' ' 23' ' ' ASP . 3.8 t 84.69 110.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.6 -92.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.124 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.807 ' O ' ' O ' ' L' ' 27' ' ' ASN . 34.1 p -161.18 163.98 30.82 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.698 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.807 ' O ' ' O ' ' L' ' 26' ' ' SER . 83.2 m-20 -9.98 -178.62 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 177.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' L' ' 29' ' ' GLY . 82.6 tttt -128.08 110.41 12.46 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.052 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' L' ' 28' ' ' LYS . . . -54.15 -95.26 0.01 OUTLIER Glycine 0 C--N 1.334 0.451 0 C-N-CA 117.113 -2.47 . . . . 0.0 111.305 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.793 ' C ' HD13 ' L' ' 31' ' ' ILE . . . 71.65 163.32 0.26 Allowed 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 103.663 -2.717 . . . . 0.0 103.663 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.798 HD13 ' N ' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -138.2 100.6 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 122.957 2.617 . . . . 0.0 108.838 175.181 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.501 ' CG2' ' O ' ' L' ' 32' ' ' ILE . 4.6 tt -102.01 112.67 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 CA-C-N 113.356 -1.747 . . . . 0.0 106.628 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -99.97 102.39 2.5 Favored Glycine 0 CA--C 1.5 -0.889 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.673 HD22 ' CZ ' ' J' ' 19' ' ' PHE . 43.6 tp -107.23 115.93 31.04 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.912 -0.315 . . . . 0.0 111.233 -178.369 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 17.6 tpp -112.64 104.22 12.28 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 176.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.426 ' CG1' HG23 ' K' ' 36' ' ' VAL . 10.5 m -135.84 79.59 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.448 ' HA3' HD13 ' F' ' 31' ' ' ILE . . . -66.1 103.68 0.9 Allowed Glycine 0 C--N 1.344 0.986 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.398 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 -162.04 38.0 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -125.58 153.12 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 121.044 0.449 . . . . 0.0 110.839 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 40' ' ' VAL . . . . . 0.5 ' OXT' ' NE2' ' L' ' 13' ' ' HIS . 31.3 m . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.73 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.501 ' O ' ' CG ' ' A' ' 13' ' ' HIS . 48.9 t . . . . . 0 C--O 1.231 0.13 0 N-CA-C 109.182 -0.674 . . . . 0.0 109.182 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 12' ' ' VAL . 97.3 m-70 -155.57 110.4 2.95 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.218 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 6.1 p-80 -151.12 166.33 31.13 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 97.9 mm-40 -152.51 179.22 8.78 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.394 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -149.48 110.9 4.45 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.918 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 77.3 mt -138.12 127.8 25.15 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 121.575 0.702 . . . . 0.0 112.076 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 18' ' ' VAL . 17.4 m -129.16 127.78 66.08 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.233 178.683 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.515 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 11.2 t80 -121.18 121.8 38.6 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.502 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.2 p90 -137.1 128.19 27.74 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.407 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.66 126.67 52.44 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.979 0.418 . . . . 0.0 111.122 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -153.21 108.81 3.27 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.41 ' HB3' ' HZ1' ' C' ' 28' ' ' LYS . 1.6 m-20 -57.21 121.55 10.35 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.489 -177.727 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 26' ' ' SER . 26.9 m -88.63 124.03 41.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.413 ' HA2' ' H ' ' B' ' 27' ' ' ASN . . . -44.84 84.71 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 CA-C-N 116.08 -0.509 . . . . 0.0 112.388 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.524 ' N ' ' O ' ' A' ' 24' ' ' VAL . 11.8 p -91.85 179.16 5.69 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 m120 -60.31 178.97 0.17 Allowed 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 120.166 -0.613 . . . . 0.0 111.258 -179.424 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.4 110.89 1.2 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.718 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.934 ' H ' HD21 ' B' ' 27' ' ' ASN . . . 71.93 94.09 0.08 OUTLIER Glycine 0 N--CA 1.465 0.587 0 CA-C-O 118.511 -1.161 . . . . 0.0 111.783 177.332 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 153.78 25.87 Favored 'General case' 0 C--O 1.241 0.646 0 C-N-CA 117.607 -1.637 . . . . 0.0 107.602 177.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.481 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.2 OUTLIER -148.2 109.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 CA-C-N 113.783 -1.553 . . . . 0.0 110.023 -171.945 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -131.07 126.96 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.245 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.47 119.57 2.12 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 mt -136.15 150.31 49.01 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-O 121.398 0.618 . . . . 0.0 111.762 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 18.6 ttt -149.53 139.8 22.25 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.992 -0.443 . . . . 0.0 111.865 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 36' ' ' VAL . 5.6 p -152.28 79.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.385 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.64 ' HA3' HD12 ' H' ' 31' ' ' ILE . . . -73.69 104.78 1.67 Allowed Glycine 0 CA--C 1.527 0.814 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.138 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.38 176.17 23.84 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.88 -0.488 . . . . 0.0 111.88 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.7 t . . . . . 0 N--CA 1.465 0.316 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.931 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 N--CA 1.464 0.259 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -135.69 137.55 41.88 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 111.262 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 72.7 t60 -155.44 169.88 23.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.549 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 47.1 tt0 -163.4 169.74 18.51 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.251 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.43 ' N ' ' HG2' ' B' ' 15' ' ' GLN . 98.0 mttt -151.3 108.69 3.61 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 178.97 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.5 mt -126.08 120.77 31.08 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.119 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -123.26 130.35 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.567 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 2.0 t80 -129.39 122.88 30.34 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.305 -178.837 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -131.88 133.29 44.44 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 120.892 0.377 . . . . 0.0 110.453 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.48 126.19 32.41 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.882 0.372 . . . . 0.0 110.779 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -155.03 158.9 39.83 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -147.43 112.68 5.54 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 65.4 t -123.73 124.94 70.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.498 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.55 82.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 114.63 0.612 . . . . 0.0 114.63 174.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.551 ' O ' ' O ' ' B' ' 27' ' ' ASN . 32.2 p -140.06 170.71 15.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 118.338 1.069 . . . . 0.0 109.615 179.372 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.934 HD21 ' H ' ' A' ' 29' ' ' GLY . 48.1 t30 -30.88 173.25 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -175.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.494 ' N ' ' CG ' ' B' ' 27' ' ' ASN . 88.3 tttt -88.95 111.16 21.79 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.167 -0.924 . . . . 0.0 112.079 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.512 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 60.31 92.96 0.01 OUTLIER Glycine 0 N--CA 1.465 0.583 0 C-N-CA 118.66 -1.733 . . . . 0.0 112.631 174.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.17 155.06 36.58 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 119.486 1.643 . . . . 0.0 110.172 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.411 HG21 ' CA ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -141.85 120.17 9.04 Favored 'Isoleucine or valine' 0 C--O 1.244 0.774 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.622 -176.731 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 14.9 mm -131.87 133.11 61.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.189 -177.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.584 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -143.43 146.23 16.74 Favored Glycine 0 N--CA 1.468 0.802 0 C-N-CA 120.349 -0.929 . . . . 0.0 111.726 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.455 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 3.3 tt -156.45 135.62 12.05 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 119.781 -0.767 . . . . 0.0 112.235 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.8 ' SD ' HG22 ' H' ' 31' ' ' ILE . 11.4 ttm -119.54 126.56 51.55 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.932 179.41 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.515 ' O ' ' C ' ' B' ' 37' ' ' GLY . 11.6 t -129.08 83.55 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.593 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' B' ' 36' ' ' VAL . . . -12.42 -95.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.068 0 O-C-N 123.642 0.589 . . . . 0.0 113.041 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.06 -179.14 40.38 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -138.5 162.41 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 120.826 0.346 . . . . 0.0 110.818 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 117.908 -1.044 . . . . 0.0 110.319 179.849 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -108.04 143.12 37.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.932 0.396 . . . . 0.0 110.587 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -64.77 153.55 39.55 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -131.46 157.3 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.144 0.497 . . . . 0.0 111.5 -179.028 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -138.78 127.73 23.79 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.12 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.579 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 38.6 t60 -148.2 168.08 23.43 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 121.375 0.607 . . . . 0.0 110.322 -178.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.579 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 47.1 tt0 -160.42 165.65 30.69 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.997 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -153.95 115.62 4.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.111 0.482 . . . . 0.0 110.71 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 49.9 tp -129.23 122.31 29.42 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -121.92 128.71 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.015 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.447 ' HE2' HD22 ' E' ' 34' ' ' LEU . 1.7 t80 -125.15 121.32 33.87 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.414 ' C ' ' CD1' ' C' ' 20' ' ' PHE . 25.3 t80 -131.96 126.97 35.34 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.5 136.34 39.32 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.292 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -140.5 146.32 38.01 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.094 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -129.09 111.95 13.49 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.676 179.293 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.842 HG22 ' H ' ' C' ' 25' ' ' GLY . 7.0 p -137.68 -122.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.169 -178.317 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.842 ' H ' HG22 ' C' ' 24' ' ' VAL . . . 28.72 -84.31 0.0 OUTLIER Glycine 0 N--CA 1.47 0.907 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.822 -177.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.5 t 170.54 176.88 0.06 Allowed 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 117.484 0.642 . . . . 0.0 110.332 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' C' ' 26' ' ' SER . 59.8 t30 -28.53 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.536 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 86.2 tttt 128.23 104.75 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 113.847 -1.524 . . . . 0.0 112.115 176.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.29 96.68 0.08 OUTLIER Glycine 0 CA--C 1.501 -0.827 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 173.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -117.19 150.67 38.35 Favored 'General case' 0 CA--C 1.481 -1.686 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.436 HG23 HD12 ' D' ' 31' ' ' ILE . 0.2 OUTLIER -145.62 116.23 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 C-N-CA 118.938 -1.105 . . . . 0.0 109.634 -172.716 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -109.78 117.12 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.79 98.26 0.73 Allowed Glycine 0 N--CA 1.469 0.891 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.562 ' HB2' HD12 ' D' ' 34' ' ' LEU . 4.6 mp -132.49 148.37 52.39 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 122.853 1.311 . . . . 0.0 113.192 -178.613 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.405 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 15.8 ttm -135.15 120.31 18.84 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.484 -1.234 . . . . 0.0 108.352 177.682 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.484 ' O ' ' C ' ' C' ' 37' ' ' GLY . 0.2 OUTLIER -129.95 75.13 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.206 -179.527 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.484 ' C ' ' O ' ' C' ' 36' ' ' VAL . . . -16.88 -101.43 0.0 OUTLIER Glycine 0 C--N 1.367 2.299 0 O-C-N 123.418 0.448 . . . . 0.0 112.366 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.46 -158.69 31.71 Favored Glycine 0 CA--C 1.522 0.479 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 54.8 t -120.01 135.46 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.555 -179.96 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.467 0.406 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' E' ' 13' ' ' HIS . 73.9 m80 -106.53 136.52 46.16 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 120.883 0.373 . . . . 0.0 111.589 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.568 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 44.5 t-80 -149.77 167.54 26.23 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.191 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.568 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 51.6 tt0 -169.73 165.74 9.9 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.409 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.442 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.0 mttt -146.39 112.59 5.82 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.677 177.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -124.54 125.43 44.18 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.779 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 96.1 t -123.95 124.82 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.306 0.574 . . . . 0.0 111.378 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.405 ' CZ ' HD23 ' F' ' 34' ' ' LEU . 0.2 OUTLIER -109.83 107.72 17.79 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 178.985 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 8.8 t80 -129.07 122.81 30.75 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 119.643 1.111 . . . . 0.0 111.263 -178.384 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.62 132.51 33.14 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -130.02 106.27 8.52 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.004 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.79 112.0 24.04 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' D' ' 26' ' ' SER . 4.7 t -131.83 -122.16 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.634 . . . . 0.0 110.251 -178.142 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.418 ' N ' HG12 ' D' ' 24' ' ' VAL . . . 30.16 -84.33 0.0 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.757 -177.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.684 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.8 p 170.56 178.85 0.05 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.684 ' O ' ' O ' ' D' ' 26' ' ' SER . 70.2 m-80 -28.2 171.13 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 O-C-N 124.731 1.269 . . . . 0.0 112.57 178.018 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 79.0 tttt 141.42 103.31 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 124.145 0.978 . . . . 0.0 108.468 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.552 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . -43.69 -98.25 0.01 OUTLIER Glycine 0 C--N 1.344 0.994 0 C-N-CA 118.816 -1.659 . . . . 0.0 111.313 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' D' ' 29' ' ' GLY . . . 83.56 142.21 0.06 Allowed 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 101.928 -3.36 . . . . 0.0 101.928 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.704 HG22 ' SD ' ' J' ' 35' ' ' MET . 0.3 OUTLIER -146.98 116.24 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 117.904 -1.518 . . . . 0.0 108.974 -177.071 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.453 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.1 OUTLIER -106.95 112.41 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -179.704 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.59 101.24 0.96 Allowed Glycine 0 C--O 1.236 0.249 0 N-CA-C 108.139 -1.984 . . . . 0.0 108.139 179.255 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.581 HD23 ' N ' ' D' ' 35' ' ' MET . 8.8 tt -143.51 144.02 31.8 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 122.411 1.1 . . . . 0.0 113.329 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.581 ' N ' HD23 ' D' ' 34' ' ' LEU . 14.5 ttm -125.19 125.47 43.7 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-N 114.669 -1.15 . . . . 0.0 109.017 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.421 HG22 ' O ' ' D' ' 36' ' ' VAL . 2.2 p -137.5 71.89 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.042 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.391 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.64 111.74 3.48 Favored Glycine 0 C--N 1.366 2.212 0 N-CA-C 111.837 -0.505 . . . . 0.0 111.837 -179.04 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' E' ' 38' ' ' GLY . . . -101.48 146.22 17.15 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.556 HG12 ' N ' ' D' ' 40' ' ' VAL . 21.3 t -137.51 165.51 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.564 0.221 . . . . 0.0 110.674 -179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.556 ' N ' HG12 ' D' ' 39' ' ' VAL . 98.4 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.974 -1.012 . . . . 0.0 111.585 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -83.98 140.04 32.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.633 0.254 . . . . 0.0 110.436 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -142.38 153.74 44.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.87 0.366 . . . . 0.0 110.744 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -121.93 134.64 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' D' ' 13' ' ' HIS . 0.2 OUTLIER -76.74 156.98 32.03 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.083 0.468 . . . . 0.0 110.694 -179.214 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.494 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 3.6 m170 -88.42 174.71 7.97 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.521 ' OE1' ' NE2' ' F' ' 15' ' ' GLN . 89.1 mt-30 -124.83 173.64 8.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.352 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -136.81 115.16 11.77 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.254 0.55 . . . . 0.0 111.814 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 35.2 mt -119.55 119.6 34.27 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -127.25 126.29 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-O 120.76 0.314 . . . . 0.0 111.198 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -121.14 122.37 39.86 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 79.8 t80 -134.51 121.61 21.24 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.813 0.34 . . . . 0.0 111.115 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.05 127.78 23.36 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 121.07 0.462 . . . . 0.0 111.032 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.403 ' O ' ' HB3' ' E' ' 23' ' ' ASP . 16.7 pt-20 -135.32 139.68 44.5 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.444 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' C ' ' E' ' 24' ' ' VAL . 18.9 p-10 159.47 113.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 O-C-N 124.204 0.94 . . . . 0.0 108.997 -178.073 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.476 ' C ' ' O ' ' E' ' 23' ' ' ASP . 70.7 t -37.46 132.4 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -178.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.49 85.64 1.48 Allowed Glycine 0 CA--C 1.523 0.531 0 N-CA-C 116.756 1.462 . . . . 0.0 116.756 -173.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.532 ' O ' ' O ' ' E' ' 27' ' ' ASN . 92.8 p -145.75 151.97 38.82 Favored 'General case' 0 CA--C 1.508 -0.665 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 172.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.532 ' O ' ' O ' ' E' ' 26' ' ' SER . 37.8 t30 -21.49 155.86 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.453 ' HD3' ' HB2' ' F' ' 30' ' ' ALA . 86.1 tttt -164.45 110.97 1.03 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 170.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.41 ' O ' ' HA2' ' D' ' 29' ' ' GLY . . . -67.55 92.57 0.23 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 120.106 -1.045 . . . . 0.0 113.734 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' D' ' 29' ' ' GLY . . . -168.39 150.09 5.07 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.699 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.1 OUTLIER -146.42 125.28 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 118.05 -1.46 . . . . 0.0 113.434 -177.562 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.432 ' C ' ' SD ' ' K' ' 35' ' ' MET . 2.0 mt -107.65 116.44 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 33' ' ' GLY . . . . . 0.477 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -116.18 100.01 0.9 Allowed Glycine 0 C--O 1.234 0.146 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.639 HD23 ' N ' ' E' ' 35' ' ' MET . 7.7 tt -143.91 137.14 27.64 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 122.26 1.029 . . . . 0.0 112.951 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.736 ' SD ' HG22 ' K' ' 31' ' ' ILE . 23.3 ttm -117.6 128.37 54.87 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.495 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -124.81 74.28 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.387 179.834 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.464 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -20.98 -101.38 0.0 OUTLIER Glycine 0 C--N 1.355 1.637 0 O-C-N 123.208 0.317 . . . . 0.0 112.817 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . 140.9 -174.95 22.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 56.3 t -121.24 135.63 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.4 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.433 -179.934 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.893 0.378 . . . . 0.0 110.753 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -150.35 102.38 3.06 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -151.19 174.42 13.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.521 ' NE2' ' OE1' ' E' ' 15' ' ' GLN . 88.3 mt-30 -141.36 175.0 10.01 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.979 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -130.13 114.84 16.22 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.943 0.402 . . . . 0.0 110.135 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -120.03 116.92 26.69 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.259 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 49.7 t -129.95 131.39 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.459 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 55.2 p90 -142.63 133.09 24.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.266 0.555 . . . . 0.0 111.659 -179.391 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -138.1 120.39 15.83 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.14 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.34 144.83 31.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.167 0.508 . . . . 0.0 111.376 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -101.1 106.22 17.47 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.988 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 61.8 t0 . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 121.388 0.613 . . . . 0.0 112.029 -179.76 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.444 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 88.2 tttt . . . . . 0 CA--C 1.538 0.495 0 CA-C-O 121.619 0.723 . . . . 0.0 112.775 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.444 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -139.9 -100.57 0.46 Allowed Glycine 0 CA--C 1.482 -2.018 0 CA-C-O 123.622 1.679 . . . . 0.0 111.48 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.453 ' HB2' ' HD3' ' E' ' 28' ' ' LYS . . . -58.33 175.73 0.22 Allowed 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 110.164 -3.018 . . . . 0.0 103.358 173.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.5 mt -131.43 116.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 116.538 -2.065 . . . . 0.0 109.774 -177.332 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.655 ' O ' HG23 ' F' ' 32' ' ' ILE . 16.5 tt -103.33 116.96 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 CA-C-N 113.084 -1.871 . . . . 0.0 110.074 -177.539 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -105.71 86.34 0.48 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 106.7 -2.56 . . . . 0.0 106.7 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.452 HD11 ' CG2' ' E' ' 36' ' ' VAL . 35.2 tp -116.72 119.02 34.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 35.2 mmm -123.04 135.44 54.44 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.057 -0.657 . . . . 0.0 112.28 -177.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 m -124.99 81.14 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.515 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.58 102.07 0.35 Allowed Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -153.52 178.09 30.7 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -124.94 137.16 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.247 0.546 . . . . 0.0 110.192 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.43 ' HB ' HE22 ' F' ' 15' ' ' GLN . 27.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.819 -1.086 . . . . 0.0 110.398 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -106.39 131.79 53.18 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.921 0.391 . . . . 0.0 110.617 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -89.22 158.15 17.98 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.431 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -122.43 133.85 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.134 0.493 . . . . 0.0 110.705 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -134.44 -178.49 5.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.623 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -77.56 167.62 21.32 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -157.49 169.59 24.36 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.995 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.27 130.08 10.1 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.676 0.274 . . . . 0.0 110.732 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 90.2 mt -125.05 115.59 20.77 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.659 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.482 ' O ' HG23 ' G' ' 18' ' ' VAL . 14.3 m -133.87 129.14 54.42 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 121.45 0.643 . . . . 0.0 112.134 -178.712 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.521 ' CE2' HD11 ' J' ' 34' ' ' LEU . 8.8 m-85 -111.79 116.77 31.25 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.445 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.494 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 55.1 p90 -133.96 130.72 38.08 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.775 -179.236 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 21' ' ' ALA . . . . . 0.429 ' O ' ' OD1' ' H' ' 23' ' ' ASP . . . -121.35 125.43 46.97 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-O 121.122 0.487 . . . . 0.0 110.985 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.499 ' CA ' ' OD2' ' H' ' 23' ' ' ASP . 96.0 mt-10 -146.64 150.31 35.19 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 106.43 -1.693 . . . . 0.0 106.43 178.336 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' NZ ' ' I' ' 28' ' ' LYS . 78.2 m-20 -78.11 111.61 14.21 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 112.754 -177.491 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.577 ' O ' ' N ' ' G' ' 26' ' ' SER . 52.9 t -114.06 130.85 67.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 176.464 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.48 81.94 0.0 OUTLIER Glycine 0 CA--C 1.535 1.308 0 CA-C-O 119.561 -0.577 . . . . 0.0 113.532 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.577 ' N ' ' O ' ' G' ' 24' ' ' VAL . 4.7 t -98.62 172.36 7.54 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 176.744 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 -58.73 162.4 4.02 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 118.567 -1.253 . . . . 0.0 109.726 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -58.68 111.3 1.21 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 118.789 -0.624 . . . . 0.0 111.562 175.999 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.24 93.29 0.08 OUTLIER Glycine 0 N--CA 1.471 0.976 0 C-N-CA 118.311 -1.9 . . . . 0.0 111.947 175.185 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.75 159.2 17.85 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 120.319 2.06 . . . . 0.0 111.556 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.01 123.2 1.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.154 -178.292 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' A' ' 35' ' ' MET . 96.8 mt -133.5 128.71 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.952 -0.468 . . . . 0.0 111.308 -179.319 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.445 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -132.85 117.56 1.99 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.434 -1.067 . . . . 0.0 110.434 179.295 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 84.1 mt -134.86 142.54 46.64 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.95 0.405 . . . . 0.0 110.576 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -141.09 137.55 32.91 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.212 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.3 t -119.03 82.72 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.481 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -87.68 97.99 2.34 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.12 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.95 165.03 38.61 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.23 159.08 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.738 0.304 . . . . 0.0 110.226 179.381 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.542 -179.924 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -117.21 139.5 50.71 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.642 0.258 . . . . 0.0 110.596 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 11' ' ' GLU . . . . . 0.48 ' CD ' ' N ' ' H' ' 11' ' ' GLU . 0.9 OUTLIER -128.02 132.24 49.13 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -140.02 157.21 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -139.5 105.61 5.23 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.929 0.395 . . . . 0.0 111.34 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.416 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 17.2 m-70 -118.86 166.46 12.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -151.14 176.68 10.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.996 178.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -170.97 113.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.164 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -113.41 119.81 38.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.98 127.16 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 121.061 0.458 . . . . 0.0 111.683 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.558 ' CZ ' HD11 ' K' ' 34' ' ' LEU . 18.1 m-85 -117.24 118.28 31.85 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.056 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -126.44 119.59 27.6 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.82 119.58 33.11 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.145 0.498 . . . . 0.0 111.626 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -163.48 89.27 0.6 Allowed 'General case' 0 C--N 1.341 0.234 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.41 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.711 ' H ' ' HZ2' ' J' ' 28' ' ' LYS . 5.0 m-20 -128.2 119.28 24.91 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -177.21 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.637 ' O ' ' O ' ' H' ' 23' ' ' ASP . 3.1 t -38.04 -124.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 124.105 0.878 . . . . 0.0 112.021 176.653 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.401 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -130.38 83.93 0.31 Allowed Glycine 0 CA--C 1.533 1.187 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 12.5 p -67.37 -173.06 0.26 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -78.92 169.69 17.82 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 118.332 -1.347 . . . . 0.0 110.506 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -47.09 110.21 0.28 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.95 95.61 0.28 Allowed Glycine 0 N--CA 1.468 0.827 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.582 171.701 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.455 ' C ' ' CG1' ' H' ' 31' ' ' ILE . . . -119.29 147.45 44.27 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 101.117 -3.661 . . . . 0.0 101.117 171.548 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.8 HG22 ' SD ' ' B' ' 35' ' ' MET . 1.2 mt -149.01 126.12 2.51 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 C-N-CA 117.918 -1.513 . . . . 0.0 111.752 -170.82 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 44.2 mm -121.3 123.36 69.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.73 123.58 5.11 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.518 ' CB ' HD22 ' I' ' 34' ' ' LEU . 29.0 tp -135.12 128.75 32.74 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 122.286 -0.538 . . . . 0.0 110.453 -179.252 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.584 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 2.6 ttp -123.34 116.94 24.13 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.031 -178.782 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' H' ' 37' ' ' GLY . 14.2 t -133.42 83.19 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -22.75 -94.05 0.01 OUTLIER Glycine 0 C--N 1.349 1.273 0 N-CA-C 112.159 -0.376 . . . . 0.0 112.159 177.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.65 -177.23 42.12 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 50.4 t -127.58 136.12 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-O 120.962 0.411 . . . . 0.0 110.245 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 34.8 t . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.451 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 m . . . . . 0 N--CA 1.466 0.363 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.434 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 34.0 m80 -141.79 145.13 34.38 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.752 0.311 . . . . 0.0 111.413 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.434 ' ND1' ' C ' ' I' ' 13' ' ' HIS . 42.6 m80 -148.18 159.18 44.22 Favored 'General case' 0 CA--C 1.514 -0.427 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.372 178.665 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -153.94 166.06 34.15 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.283 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.504 ' C ' HD12 ' I' ' 17' ' ' LEU . 96.2 mttt -162.53 123.86 2.59 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 123.023 0.202 . . . . 0.0 110.566 179.12 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.504 HD12 ' C ' ' I' ' 16' ' ' LYS . 10.6 mp -115.22 115.63 27.02 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -126.56 123.68 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 CA-C-O 120.983 0.421 . . . . 0.0 111.307 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.754 ' CZ ' HD12 ' L' ' 34' ' ' LEU . 9.8 m-85 -119.21 116.43 26.27 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 115.815 -0.629 . . . . 0.0 109.742 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -128.59 126.85 41.12 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.76 135.33 26.11 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.382 0.61 . . . . 0.0 111.961 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -141.57 142.58 33.49 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.081 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.442 ' O ' ' CG2' ' J' ' 24' ' ' VAL . 64.9 t0 -85.78 123.35 31.05 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 121.47 0.652 . . . . 0.0 111.69 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' I' ' 26' ' ' SER . 2.9 t -93.2 121.81 44.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.06 -88.22 0.01 OUTLIER Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.891 -1.283 . . . . 0.0 109.891 -177.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' I' ' 24' ' ' VAL . 52.9 p -141.0 170.28 16.03 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 118.127 0.964 . . . . 0.0 109.477 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -29.17 169.44 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 114.138 -1.392 . . . . 0.0 114.027 -179.252 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.609 ' NZ ' ' OD1' ' G' ' 23' ' ' ASP . 35.8 tttt -150.27 111.18 4.32 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 114.372 -1.286 . . . . 0.0 108.936 172.856 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.96 92.07 0.02 OUTLIER Glycine 0 N--CA 1.464 0.535 0 C-N-CA 118.913 -1.613 . . . . 0.0 109.082 176.619 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -138.32 148.07 44.22 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.407 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.693 HG13 HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -146.9 116.18 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-N 114.057 -1.429 . . . . 0.0 110.387 -174.125 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.412 HD13 HG21 ' I' ' 32' ' ' ILE . 0.3 OUTLIER -106.99 114.76 46.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.542 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.533 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -118.68 93.87 0.57 Allowed Glycine 0 N--CA 1.462 0.415 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 179.304 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.533 HD23 ' O ' ' I' ' 33' ' ' GLY . 7.4 mt -127.61 135.26 50.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 122.484 1.135 . . . . 0.0 111.554 -178.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 42.9 ttp -125.62 120.7 31.47 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.402 177.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.99 73.57 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.784 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -21.1 -101.72 0.0 OUTLIER Glycine 0 C--N 1.367 2.301 0 O-C-N 123.508 0.505 . . . . 0.0 112.378 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.66 -153.71 23.65 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.655 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 5.0 p -134.59 141.43 43.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-O 120.879 0.371 . . . . 0.0 110.105 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' H' ' 40' ' ' VAL . 2.6 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.062 -0.97 . . . . 0.0 110.218 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 9' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' K' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.489 2.197 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -142.22 163.14 33.66 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-O 120.778 0.323 . . . . 0.0 110.289 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -153.3 154.21 34.14 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.162 0.506 . . . . 0.0 111.212 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.431 HG23 HG23 ' K' ' 12' ' ' VAL . 2.4 p -140.56 151.37 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.799 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.43 ' ND1' ' C ' ' J' ' 12' ' ' VAL . 1.6 m80 -127.34 130.79 50.09 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.479 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -126.6 156.57 40.7 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-O 121.494 0.664 . . . . 0.0 109.529 178.444 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mt-30 -150.68 173.79 13.76 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.775 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -175.25 123.92 0.23 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.842 179.133 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.456 HD13 HE21 ' K' ' 15' ' ' GLN . 4.7 mp -125.48 122.25 36.08 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.753 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.43 137.22 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.197 0.522 . . . . 0.0 112.135 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.493 ' CZ ' HD13 ' L' ' 34' ' ' LEU . 73.7 m-85 -121.62 129.65 52.96 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.863 179.106 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -129.65 122.19 28.5 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.136 0.426 . . . . 0.0 110.245 178.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.96 126.87 35.09 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 121.382 0.61 . . . . 0.0 111.427 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -126.77 109.33 11.9 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.229 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.562 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 0.0 OUTLIER -104.68 112.3 25.33 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 120.068 -0.653 . . . . 0.0 112.127 -178.607 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.571 ' O ' ' N ' ' J' ' 26' ' ' SER . 2.7 m -82.37 132.87 30.42 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.381 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.254 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.26 -85.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.415 0 N-CA-C 107.484 -2.246 . . . . 0.0 107.484 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.571 ' N ' ' O ' ' J' ' 24' ' ' VAL . 10.9 t -140.98 169.62 17.26 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 118.373 1.086 . . . . 0.0 110.298 174.251 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' N ' ' L' ' 30' ' ' ALA . 1.0 OUTLIER -30.27 172.81 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 N-CA-C 115.165 1.542 . . . . 0.0 115.165 178.394 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.718 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 87.0 tttt -97.54 112.25 24.18 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 117.671 -1.157 . . . . 0.0 110.197 171.176 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.494 ' H ' ' HB2' ' I' ' 27' ' ' ASN . . . -61.42 91.49 0.06 OUTLIER Glycine 0 N--CA 1.49 2.271 0 CA-C-N 123.453 2.842 . . . . 0.0 108.343 175.052 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.555 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -148.85 153.42 38.04 Favored 'General case' 0 CA--C 1.482 -1.655 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.546 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -142.35 115.95 4.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 C-N-CA 118.716 -1.194 . . . . 0.0 109.439 -174.632 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.438 HG22 ' O ' ' J' ' 32' ' ' ILE . 1.7 mt -105.52 117.01 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.563 -178.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 101.1 1.02 Allowed Glycine 0 CA--C 1.503 -0.71 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.521 HD11 ' CE2' ' G' ' 19' ' ' PHE . 5.1 tt -142.02 135.4 29.22 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 118.932 -1.107 . . . . 0.0 112.788 -177.039 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.704 ' SD ' HG22 ' D' ' 31' ' ' ILE . 60.9 ttp -127.82 124.0 36.54 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.807 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.464 HG23 HG13 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -124.3 75.36 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.751 0 CA-C-N 114.52 -1.218 . . . . 0.0 107.734 178.415 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -89.75 103.17 2.98 Favored Glycine 0 C--N 1.356 1.665 0 N-CA-C 111.784 -0.526 . . . . 0.0 111.784 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.82 152.14 20.9 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 30.6 m -135.08 157.38 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 8.3 p . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.176 -0.916 . . . . 0.0 110.5 -179.63 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' K' K ' 9' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' J' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -135.48 154.84 51.29 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 121.159 0.504 . . . . 0.0 111.179 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -137.3 131.77 32.73 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.34 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.431 HG23 HG23 ' J' ' 12' ' ' VAL . 11.2 m -145.0 136.63 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.348 179.339 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -118.4 127.15 53.4 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.742 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -124.02 158.27 32.53 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.556 0.693 . . . . 0.0 110.179 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.481 ' O ' ' O ' ' L' ' 15' ' ' GLN . 50.9 tt0 -166.17 170.23 13.55 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.776 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.406 ' CG ' ' O ' ' K' ' 15' ' ' GLN . 66.3 mttm -163.82 125.5 2.37 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.556 179.356 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.929 ' O ' ' C ' ' L' ' 17' ' ' LEU . 17.9 tp -118.05 118.39 31.8 Favored 'General case' 0 N--CA 1.503 2.224 0 CA-C-O 123.339 1.543 . . . . 0.0 112.124 178.479 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.517 HG13 ' O ' ' K' ' 18' ' ' VAL . 5.3 p -134.07 123.96 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.352 -179.466 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -109.23 127.17 54.03 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.464 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -117.36 114.3 23.35 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 178.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 131.31 47.51 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.208 0.528 . . . . 0.0 111.569 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.406 ' O ' ' O ' ' K' ' 23' ' ' ASP . 74.5 mm-40 -83.33 158.26 22.25 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.257 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.55 ' O ' ' O ' ' K' ' 24' ' ' VAL . 48.8 p-10 -60.99 -133.88 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.201 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.55 ' O ' ' O ' ' K' ' 23' ' ' ASP . 24.7 t 26.72 111.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 123.942 0.776 . . . . 0.0 112.356 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.43 82.74 0.14 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 120.206 -0.997 . . . . 0.0 113.183 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 30.2 p -139.05 170.2 16.41 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-N 117.759 0.779 . . . . 0.0 109.334 177.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 50.62 -178.75 0.02 OUTLIER 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.765 179.078 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt 55.37 -106.61 0.33 Allowed 'General case' 0 C--O 1.233 0.208 0 CA-C-O 121.204 0.526 . . . . 0.0 111.918 177.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.433 ' H ' ' HB2' ' J' ' 27' ' ' ASN . . . 96.6 91.54 1.83 Allowed Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -177.584 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' J' ' 28' ' ' LYS . . . -82.19 174.2 11.4 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 104.707 -2.331 . . . . 0.0 104.707 177.8 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.736 HG22 ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -156.4 119.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 116.768 -1.973 . . . . 0.0 111.224 -175.431 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.453 HG22 ' O ' ' K' ' 32' ' ' ILE . 0.9 OUTLIER -103.72 113.09 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 176.687 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.1 88.98 0.52 Allowed Glycine 0 CA--C 1.504 -0.603 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 177.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.58 HD23 ' N ' ' K' ' 35' ' ' MET . 9.3 tt -127.66 134.54 49.62 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 122.004 0.907 . . . . 0.0 111.834 -177.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.58 ' N ' HD23 ' K' ' 34' ' ' LEU . 65.8 ttp -123.34 127.56 48.68 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 115.079 -0.964 . . . . 0.0 112.593 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.464 HG13 HG23 ' J' ' 36' ' ' VAL . 0.0 OUTLIER -132.5 72.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 114.427 -1.26 . . . . 0.0 107.887 177.703 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.03 101.86 2.33 Favored Glycine 0 C--N 1.353 1.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -145.16 163.52 28.08 Favored Glycine 0 N--CA 1.46 0.242 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -124.06 135.58 63.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.905 0.383 . . . . 0.0 110.125 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.466 179.967 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -112.95 152.92 28.81 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.507 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.51 136.8 49.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.856 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.97 132.77 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.999 0.428 . . . . 0.0 110.503 -179.485 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 23.3 p-80 -160.91 147.71 15.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.487 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -95.16 177.54 5.83 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.497 ' HG3' ' H ' ' L' ' 16' ' ' LYS . 45.6 tp60 -114.84 174.98 5.7 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.932 -179.564 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 16' ' ' LYS . . . . . 0.497 ' H ' ' HG3' ' L' ' 15' ' ' GLN . 88.9 mttt -88.9 -174.96 4.7 Favored 'General case' 0 C--O 1.176 -2.765 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.929 ' C ' ' O ' ' K' ' 17' ' ' LEU . 38.3 mt -141.48 161.28 38.29 Favored 'General case' 0 C--N 1.31 -1.12 0 O-C-N 119.922 -1.736 . . . . 0.0 110.289 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 18' ' ' VAL . . . . . 0.452 HG23 ' N ' ' L' ' 19' ' ' PHE . 10.8 m -84.54 -144.05 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 117.723 2.49 . . . . 0.0 117.723 -171.208 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.492 ' CD1' ' N ' ' L' ' 19' ' ' PHE . 9.6 m-85 -124.22 147.62 47.91 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 113.506 -1.679 . . . . 0.0 111.143 -178.066 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -137.48 132.19 32.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.263 -0.881 . . . . 0.0 108.945 178.537 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.3 159.37 38.78 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.277 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -85.7 157.97 20.17 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -53.16 122.88 10.34 Favored 'General case' 0 CA--C 1.52 -0.185 0 C-N-CA 119.899 -0.721 . . . . 0.0 109.243 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 3.5 t -92.68 121.79 43.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.575 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.16 -87.01 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.093 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 79.4 p -89.07 -177.7 5.5 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 63.9 t30 -60.27 179.55 0.14 Allowed 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.713 -177.334 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 11.6 tptt -57.26 110.72 0.89 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 122.005 0.907 . . . . 0.0 112.998 -176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.27 -98.14 0.04 OUTLIER Glycine 0 CA--C 1.496 -1.149 0 CA-C-N 113.801 -1.545 . . . . 0.0 111.155 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.683 ' N ' ' ND2' ' J' ' 27' ' ' ASN . . . -61.2 165.16 4.64 Favored 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 -178.612 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.504 HD12 ' O ' ' K' ' 30' ' ' ALA . 0.8 OUTLIER -141.51 125.32 16.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 117.692 -1.603 . . . . 0.0 112.441 -176.238 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 4.3 mt -101.16 117.66 46.74 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.632 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 177.81 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.55 98.19 0.61 Allowed Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.97 HD21 HG13 ' L' ' 36' ' ' VAL . 1.0 OUTLIER -128.82 139.58 52.1 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.557 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 66.4 ttp -118.33 124.15 47.08 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.588 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.97 HG13 HD21 ' L' ' 34' ' ' LEU . 0.9 OUTLIER -123.42 80.07 0.67 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.648 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.93 102.48 0.12 Allowed Glycine 0 C--N 1.349 1.295 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.247 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.68 -173.21 29.37 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.56 142.87 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.842 0.353 . . . . 0.0 110.599 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.995 -1.002 . . . . 0.0 111.015 -179.795 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.466 0.355 0 CA-C-O 120.868 0.366 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 77.7 m80 -142.98 165.13 28.2 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.344 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m80 -135.69 178.55 6.96 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 109.61 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -98.12 179.18 4.85 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.022 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -104.56 140.95 37.24 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.195 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -124.12 120.12 31.42 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.079 0.466 . . . . 0.0 110.726 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 18' ' ' VAL . 5.6 m -134.06 128.19 52.53 Favored 'Isoleucine or valine' 0 C--O 1.231 0.098 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.11 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.623 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 11.7 m-85 -112.88 118.83 35.98 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.07 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.549 ' CE2' ' CD1' ' B' ' 20' ' ' PHE . 55.7 t80 -127.71 113.08 15.56 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.51 129.26 56.41 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.118 0.485 . . . . 0.0 110.98 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 tt0 -156.72 158.69 37.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 179.284 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -81.11 111.29 17.42 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.718 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.628 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.0 t -114.27 131.18 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.839 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 177.639 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.83 81.94 0.0 OUTLIER Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.576 -0.345 . . . . 0.0 112.409 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.628 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.1 p -94.64 177.31 5.96 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.686 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' A' ' 28' ' ' LYS . 98.5 m-20 -61.58 179.6 0.23 Allowed 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.584 -0.846 . . . . 0.0 108.763 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.8 mttm -52.12 -111.87 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.761 0.791 . . . . 0.0 111.406 178.668 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.41 93.33 1.63 Allowed Glycine 0 N--CA 1.467 0.707 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 177.113 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.55 160.9 14.05 Favored 'General case' 0 CA--C 1.509 -0.605 0 C-N-CA 116.582 -2.047 . . . . 0.0 111.627 -177.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.0 OUTLIER -152.51 117.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.112 0 CA-C-N 111.819 -2.446 . . . . 0.0 109.184 -174.334 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.87 118.54 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.709 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.64 108.71 0.98 Allowed Glycine 0 N--CA 1.464 0.56 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 48.5 tp -131.69 133.01 44.4 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 117.194 0.497 . . . . 0.0 111.07 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 13.4 ttt -139.38 134.66 32.77 Favored 'General case' 0 C--N 1.328 -0.36 0 O-C-N 122.234 -0.291 . . . . 0.0 110.788 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.7 t -146.06 81.29 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.487 ' HA3' HD12 ' H' ' 31' ' ' ILE . . . -85.51 100.22 2.43 Favored Glycine 0 C--N 1.338 0.66 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.226 178.315 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.24 176.48 47.86 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 N--CA 1.466 0.369 0 CA-C-O 120.82 0.343 . . . . 0.0 110.356 179.214 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.509 HG12 ' N ' ' B' ' 13' ' ' HIS . 93.4 t . . . . . 0 N--CA 1.469 0.478 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.509 ' N ' HG12 ' B' ' 12' ' ' VAL . 28.3 t60 -166.77 104.78 0.59 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.218 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.9 m-70 -120.0 165.77 14.25 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.605 HE21 HD21 ' B' ' 17' ' ' LEU . 50.6 tt0 -162.85 173.23 14.01 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.331 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.41 ' N ' ' HG2' ' B' ' 15' ' ' GLN . 97.6 mttt -149.85 116.29 5.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.939 0.399 . . . . 0.0 110.742 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.605 HD21 HE21 ' B' ' 15' ' ' GLN . 60.6 mt -116.57 114.42 24.11 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.302 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.52 123.66 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-O 121.214 0.531 . . . . 0.0 110.945 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.646 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 4.4 m-85 -117.47 118.52 32.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.963 179.197 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.549 ' CD1' ' CE2' ' A' ' 20' ' ' PHE . 33.1 t80 -138.37 125.67 21.69 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 122.22 -0.3 . . . . 0.0 110.326 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 131.32 46.89 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.155 0.503 . . . . 0.0 111.965 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -157.67 91.3 1.13 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.619 ' H ' ' CG ' ' C' ' 23' ' ' ASP . 10.7 t0 -121.6 113.1 19.3 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -176.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' B' ' 26' ' ' SER . 12.0 p -60.41 132.37 25.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.252 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.94 83.72 0.04 OUTLIER Glycine 0 CA--C 1.526 0.751 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.694 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.425 ' N ' ' O ' ' B' ' 24' ' ' VAL . 11.8 p -87.62 -179.1 6.25 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.583 0.706 . . . . 0.0 109.627 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.425 ' O ' ' O ' ' B' ' 28' ' ' LYS . 28.3 t-20 -75.63 175.96 8.1 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.544 177.203 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' B' ' 27' ' ' ASN . 97.6 mttt 42.49 107.9 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 114.9 1.445 . . . . 0.0 114.9 176.121 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.2 100.04 1.98 Allowed Glycine 0 N--CA 1.479 1.565 0 CA-C-N 114.273 -1.33 . . . . 0.0 110.717 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 161.35 31.15 Favored 'General case' 0 C--O 1.248 1.016 0 CA-C-O 122.772 1.272 . . . . 0.0 110.772 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.514 ' CG2' HD12 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.02 122.74 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 112.939 -1.937 . . . . 0.0 110.378 -172.929 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.452 ' C ' ' SD ' ' H' ' 35' ' ' MET . 44.3 pt -136.08 135.29 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-O 121.847 0.832 . . . . 0.0 112.129 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -141.11 137.88 8.46 Favored Glycine 0 CA--C 1.531 1.033 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.142 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 tt -146.93 139.74 25.12 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 120.196 -0.601 . . . . 0.0 111.158 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 24.1 ttm -128.32 126.19 40.27 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-O 121.397 0.618 . . . . 0.0 112.133 -179.346 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.43 79.6 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.021 177.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.533 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -50.91 104.13 0.12 Allowed Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.769 -179.045 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 44.99 179.74 0.01 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 p -148.36 149.77 14.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.439 ' OXT' HG22 ' B' ' 40' ' ' VAL . 6.0 p . . . . . 0 C--O 1.218 -0.559 0 CA-C-O 118.176 -0.916 . . . . 0.0 111.078 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 141.44 47.83 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.417 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -142.58 159.34 42.43 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.418 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.463 HG13 ' CD2' ' D' ' 13' ' ' HIS . 55.3 t -121.27 133.56 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.489 ' H ' ' H ' ' D' ' 13' ' ' HIS . 97.6 m-70 -148.08 123.63 10.42 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.822 0.344 . . . . 0.0 111.179 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.529 ' ND1' ' O ' ' D' ' 14' ' ' HIS . 26.1 t60 -141.45 164.65 29.66 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.437 ' HG2' ' N ' ' C' ' 16' ' ' LYS . 51.8 tt0 -169.39 170.36 8.45 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.845 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.437 ' N ' ' HG2' ' C' ' 15' ' ' GLN . 68.2 mttm -142.59 118.79 10.77 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.238 178.821 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -120.11 121.39 38.73 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.06 123.25 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.048 0.452 . . . . 0.0 111.739 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.953 ' CZ ' HD22 ' F' ' 34' ' ' LEU . 6.6 m-85 -113.65 116.78 30.0 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.408 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.544 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 33.6 t80 -132.24 118.65 19.78 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 118.227 0.467 . . . . 0.0 110.203 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.9 37.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 120.857 0.361 . . . . 0.0 110.884 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -173.2 102.97 0.13 Allowed 'General case' 0 CA--C 1.522 -0.134 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.912 ' H ' ' HZ2' ' E' ' 28' ' ' LYS . 1.1 m-20 -115.15 113.66 24.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 121.095 0.474 . . . . 0.0 111.417 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 91.4 t -64.76 131.5 30.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.84 84.02 0.31 Allowed Glycine 0 CA--C 1.525 0.696 0 C-N-CA 119.195 -1.479 . . . . 0.0 110.726 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.536 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 1.7 m -59.87 -174.27 0.02 OUTLIER 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.536 ' CB ' ' O ' ' C' ' 26' ' ' SER . 6.1 t-20 99.85 -174.62 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.928 0 O-C-N 124.342 1.026 . . . . 0.0 111.202 -177.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.52 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 81.9 tttt 37.44 108.93 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.987 -177.077 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.426 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -85.79 96.84 2.13 Favored Glycine 0 CA--C 1.504 -0.622 0 CA-C-N 114.325 -1.307 . . . . 0.0 112.056 177.387 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.8 164.7 19.36 Favored 'General case' 0 C--O 1.244 0.808 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.689 HG23 HG13 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.83 121.3 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 117.961 -1.496 . . . . 0.0 111.702 -174.804 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 1.1 mt -114.54 120.63 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.898 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.98 98.88 0.65 Allowed Glycine 0 N--CA 1.472 1.04 0 N-CA-C 106.939 -2.464 . . . . 0.0 106.939 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.467 HD21 HG13 ' C' ' 36' ' ' VAL . 5.1 tt -129.93 129.28 43.64 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 119.05 -1.06 . . . . 0.0 113.749 -175.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.435 ' CG ' ' HA3' ' I' ' 33' ' ' GLY . 96.6 mmm -107.39 118.08 35.77 Favored 'General case' 0 CA--C 1.503 -0.859 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.267 179.261 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.467 HG13 HD21 ' C' ' 34' ' ' LEU . 0.0 OUTLIER -131.02 72.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.723 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 175.83 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.14 112.31 4.6 Favored Glycine 0 C--N 1.36 1.882 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.47 157.39 51.88 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -138.72 161.51 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.103 -0.951 . . . . 0.0 110.508 179.968 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t . . . . . 0 C--O 1.232 0.173 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.489 ' H ' ' H ' ' C' ' 13' ' ' HIS . 3.4 m-70 -87.31 161.48 17.92 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.336 0.589 . . . . 0.0 111.354 -178.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.529 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.8 p-80 -93.93 178.83 5.54 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.327 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -127.7 179.04 5.74 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.502 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -137.23 127.1 25.66 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.248 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.3 mp -126.43 129.17 48.21 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.223 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -126.81 125.01 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.027 0.441 . . . . 0.0 111.488 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.756 ' CZ ' HD23 ' F' ' 34' ' ' LEU . 4.9 m-85 -110.57 112.57 24.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.039 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.51 ' CE1' ' CE2' ' C' ' 20' ' ' PHE . 27.5 t80 -126.72 123.32 37.21 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 118.542 0.61 . . . . 0.0 109.947 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.17 142.63 28.63 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -142.97 145.17 32.72 Favored 'General case' 0 C--N 1.343 0.302 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.653 178.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.515 ' O ' ' O ' ' E' ' 24' ' ' VAL . 14.0 m-20 -112.64 124.67 53.07 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.898 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' E' ' 26' ' ' SER . 5.7 t -95.34 -112.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 113.124 0.787 . . . . 0.0 113.124 -176.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.94 -91.12 0.01 OUTLIER Glycine 0 N--CA 1.469 0.864 0 N-CA-C 112.386 -0.286 . . . . 0.0 112.386 -176.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.609 ' O ' ' O ' ' D' ' 27' ' ' ASN . 21.5 p -151.54 171.87 16.91 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.692 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 90.6 m-20 -19.29 156.7 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 O-C-N 124.253 0.971 . . . . 0.0 113.164 -178.313 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.497 ' H ' ' H ' ' E' ' 29' ' ' GLY . 56.5 tttt -162.45 110.68 1.36 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 121.406 -0.809 . . . . 0.0 110.461 173.548 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.426 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -68.62 92.83 0.29 Allowed Glycine 0 C--O 1.215 -1.036 0 CA-C-O 117.861 -1.522 . . . . 0.0 110.77 175.425 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.463 ' O ' HG13 ' E' ' 31' ' ' ILE . . . -129.04 151.61 49.54 Favored 'General case' 0 CA--C 1.482 -1.652 0 N-CA-C 103.028 -2.953 . . . . 0.0 103.028 173.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.689 HG13 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -147.75 118.25 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.339 -172.909 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.532 ' O ' HG23 ' D' ' 32' ' ' ILE . 18.5 tt -119.0 113.42 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.483 178.459 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.705 ' C ' HD12 ' D' ' 34' ' ' LEU . . . -130.07 128.22 5.57 Favored Glycine 0 C--O 1.241 0.536 0 C-N-CA 121.09 -0.576 . . . . 0.0 111.811 -178.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.705 HD12 ' C ' ' D' ' 33' ' ' GLY . 4.0 mp -141.5 142.57 33.58 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-O 122.249 1.023 . . . . 0.0 111.277 178.659 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.46 ' SD ' ' HB ' ' J' ' 31' ' ' ILE . 29.3 tpp -100.87 113.6 26.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 113.574 -1.648 . . . . 0.0 108.448 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.617 ' CG2' HD11 ' E' ' 34' ' ' LEU . 0.0 OUTLIER -126.55 74.0 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.302 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.113 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.96 111.21 1.82 Allowed Glycine 0 C--N 1.358 1.793 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.17 -170.28 0.15 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m -133.85 160.62 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.815 0.34 . . . . 0.0 110.791 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.562 179.845 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -101.47 129.12 47.46 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.993 0.425 . . . . 0.0 110.539 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.88 138.86 28.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.84 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.1 t -126.36 132.77 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.904 0.383 . . . . 0.0 110.329 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 t-80 -143.95 112.57 6.55 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.564 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -128.81 173.01 10.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -151.1 175.93 11.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.709 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -167.85 108.25 0.57 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.05 0.452 . . . . 0.0 110.686 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.0 tt -124.84 127.35 47.02 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.707 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.13 128.84 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -119.61 119.97 35.33 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -128.18 121.96 30.73 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-O 120.909 0.385 . . . . 0.0 110.273 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.5 133.33 43.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.994 0.426 . . . . 0.0 111.52 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -137.74 123.78 20.28 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.554 -0.458 . . . . 0.0 109.831 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -84.77 114.82 22.34 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.062 0.458 . . . . 0.0 111.181 -178.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' E' ' 26' ' ' SER . 53.8 t -95.78 130.81 43.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.68 -85.07 0.01 OUTLIER Glycine 0 CA--C 1.535 1.289 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' E' ' 24' ' ' VAL . 12.6 t -153.0 174.29 14.35 Favored 'General case' 0 C--N 1.347 0.46 0 CA-C-N 118.897 1.348 . . . . 0.0 112.995 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.692 ' ND2' ' H ' ' D' ' 27' ' ' ASN . 12.9 p-10 -19.01 160.24 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 116.761 2.134 . . . . 0.0 116.761 178.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.912 ' HZ2' ' H ' ' C' ' 23' ' ' ASP . 80.9 tttt -170.14 105.55 0.31 Allowed 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 174.676 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.677 ' O ' ' HA ' ' F' ' 30' ' ' ALA . . . -49.99 -97.84 0.01 OUTLIER Glycine 0 N--CA 1.469 0.9 0 C-N-CA 118.664 -1.731 . . . . 0.0 111.299 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.561 ' HB3' ' O ' ' E' ' 29' ' ' GLY . . . 74.07 143.71 0.07 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.599 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -150.78 118.11 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.08 -178.471 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 4.5 tt -117.44 128.31 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 CA-C-O 121.329 0.585 . . . . 0.0 111.255 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 99.7 0.7 Allowed Glycine 0 N--CA 1.451 -0.331 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 178.405 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.646 HD13 ' CZ ' ' B' ' 19' ' ' PHE . 37.6 tp -115.58 116.39 28.06 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.551 ' CE ' ' SD ' ' F' ' 35' ' ' MET . 0.4 OUTLIER -91.76 111.63 23.24 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.976 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.71 ' O ' HG12 ' E' ' 36' ' ' VAL . 2.0 t -138.4 66.56 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -54.84 -103.53 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.44 169.01 34.51 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -140.67 140.85 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.064 -0.969 . . . . 0.0 110.357 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.463 0.211 0 CA-C-O 121.199 0.523 . . . . 0.0 109.851 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.508 ' ND1' ' N ' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -151.26 130.05 12.4 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.417 -179.868 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.402 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 80.6 m80 -155.82 178.29 10.43 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -139.72 177.87 7.64 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.248 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -155.12 115.9 3.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.336 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.44 128.01 42.07 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.17 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 99.8 t -129.63 130.94 67.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.508 ' O ' ' CD2' ' F' ' 19' ' ' PHE . 54.7 p90 -132.32 128.52 37.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.887 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.6 t80 -138.82 125.37 20.63 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.46 146.3 30.51 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.681 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -124.15 95.68 4.64 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 178.173 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 5.8 t70 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.909 -178.673 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 33.1 tttm . . . . . 0 N--CA 1.498 1.937 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.64 -99.88 0.01 OUTLIER Glycine 0 C--N 1.348 1.214 0 CA-C-O 124.622 2.235 . . . . 0.0 114.143 174.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.677 ' HA ' ' O ' ' E' ' 29' ' ' GLY . . . 70.18 143.36 0.05 Allowed 'General case' 0 CA--C 1.503 -0.839 0 CA-C-N 108.575 -3.812 . . . . 0.0 107.208 177.062 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.513 HG13 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -160.06 125.05 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 122.538 2.427 . . . . 0.0 113.399 -179.711 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 87.7 mt -107.78 117.74 54.05 Favored 'Isoleucine or valine' 0 C--N 1.355 0.83 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.951 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.53 91.06 0.55 Allowed Glycine 0 N--CA 1.452 -0.245 0 N-CA-C 109.061 -1.615 . . . . 0.0 109.061 177.261 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.953 HD22 ' CZ ' ' C' ' 19' ' ' PHE . 3.1 tp -114.22 116.18 28.63 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.628 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 2.2 mtp -88.34 114.26 24.78 Favored 'General case' 0 CA--C 1.48 -1.735 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.407 HG22 ' O ' ' F' ' 36' ' ' VAL . 2.2 p -139.63 74.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 105.775 -1.935 . . . . 0.0 105.775 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.32 104.85 2.64 Favored Glycine 0 C--N 1.356 1.667 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.03 -179.43 26.37 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -134.76 138.07 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.692 0.282 . . . . 0.0 111.03 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 N--CA 1.469 0.52 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.538 179.584 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -119.51 142.59 48.16 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -152.43 123.56 7.59 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.416 0.626 . . . . 0.0 111.578 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -150.21 146.29 16.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.498 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -151.93 140.97 21.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.077 0.465 . . . . 0.0 110.815 179.596 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -134.64 163.74 29.07 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -150.53 171.34 17.24 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.528 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -156.2 128.98 7.84 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.46 HD13 HE21 ' H' ' 15' ' ' GLN . 5.8 mp -122.15 124.6 44.26 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 110.218 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.436 HG13 ' O ' ' G' ' 18' ' ' VAL . 5.4 p -121.67 120.46 61.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.189 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.586 ' CZ ' HD13 ' I' ' 34' ' ' LEU . 3.9 t80 -117.12 103.16 9.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -122.37 121.5 36.84 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.93 123.75 48.86 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.862 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -158.3 155.53 28.99 Favored 'General case' 0 CA--C 1.528 0.122 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -88.25 120.9 30.05 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.116 0.484 . . . . 0.0 112.289 -178.54 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.569 ' O ' ' N ' ' G' ' 26' ' ' SER . 88.1 t -100.97 124.03 54.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.63 83.49 0.0 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-O 120.052 -0.305 . . . . 0.0 112.985 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.569 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.1 m -97.46 174.78 6.5 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.269 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 22.8 p30 -59.22 164.38 3.21 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.196 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -57.23 111.53 1.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.779 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.462 ' H ' ' HE3' ' H' ' 28' ' ' LYS . . . 72.38 93.49 0.09 OUTLIER Glycine 0 N--CA 1.466 0.681 0 C-N-CA 119.678 -1.249 . . . . 0.0 111.315 177.854 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.55 157.51 19.56 Favored 'General case' 0 CA--C 1.51 -0.595 0 C-N-CA 118.426 -1.31 . . . . 0.0 108.847 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.514 HG22 HD12 ' H' ' 31' ' ' ILE . 0.1 OUTLIER -153.04 117.35 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.776 -173.434 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.485 ' O ' ' SD ' ' A' ' 35' ' ' MET . 18.0 tt -135.58 129.47 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.064 179.543 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.88 116.9 1.96 Allowed Glycine 0 N--CA 1.466 0.639 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 76.5 mt -137.33 148.77 46.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 121.681 0.753 . . . . 0.0 112.289 -178.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 ttt -139.3 135.8 34.19 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.196 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' G' ' 37' ' ' GLY . 9.5 t -141.53 81.27 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' G' ' 36' ' ' VAL . . . -26.89 -94.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 O-C-N 123.337 0.398 . . . . 0.0 112.773 178.551 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.13 -157.84 30.5 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 71.8 t -98.86 133.49 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.847 0.356 . . . . 0.0 110.24 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.731 -179.395 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -145.0 159.5 42.84 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.788 0.327 . . . . 0.0 110.522 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 11' ' ' GLU . . . . . 0.481 ' CD ' ' NE2' ' H' ' 13' ' ' HIS . 82.5 tt0 -134.73 145.54 48.56 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.835 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.48 133.17 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 116.793 -0.185 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.481 ' NE2' ' CD ' ' H' ' 11' ' ' GLU . 80.9 m-70 -137.31 143.58 42.18 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.837 0.351 . . . . 0.0 111.307 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.506 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 86.3 t60 -146.92 162.08 39.43 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.448 0.642 . . . . 0.0 110.307 178.709 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.506 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 42.4 tt0 -156.72 174.62 15.21 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -162.71 125.47 2.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.892 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.561 ' C ' HD23 ' H' ' 17' ' ' LEU . 6.6 tt -125.62 121.79 34.55 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.982 0.42 . . . . 0.0 110.533 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.498 ' N ' HD23 ' H' ' 17' ' ' LEU . 56.6 t -120.36 126.16 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.876 179.206 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 29.5 t80 -121.93 111.91 17.66 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -130.38 126.23 36.55 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.34 128.64 51.27 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.238 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.24 149.1 40.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.643 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.51 ' O ' ' NZ ' ' J' ' 28' ' ' LYS . 53.2 t0 -155.79 121.1 4.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.849 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.802 HG22 ' N ' ' H' ' 25' ' ' GLY . 2.6 p -133.87 -112.01 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.587 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.802 ' N ' HG22 ' H' ' 24' ' ' VAL . . . 32.86 -90.26 0.01 OUTLIER Glycine 0 CA--C 1.53 1.016 0 CA-C-N 115.97 -0.559 . . . . 0.0 112.362 -178.085 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.661 ' O ' ' O ' ' H' ' 27' ' ' ASN . 1.6 t 171.61 178.72 0.07 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 117.622 0.711 . . . . 0.0 109.984 -179.519 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.661 ' O ' ' O ' ' H' ' 26' ' ' SER . 9.4 t-20 -28.57 179.59 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 O-C-N 125.07 1.481 . . . . 0.0 114.259 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.555 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 87.0 tttt 128.43 105.18 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 124.359 1.064 . . . . 0.0 111.763 178.356 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.86 96.27 0.05 OUTLIER Glycine 0 N--CA 1.47 0.948 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.08 146.6 47.04 Favored 'General case' 0 C--O 1.253 1.288 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 177.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.599 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.1 OUTLIER -140.04 119.61 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.281 0 CA-C-N 113.02 -1.9 . . . . 0.0 110.697 -171.855 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -126.96 122.73 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.767 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.17 118.64 2.18 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -137.3 129.97 30.1 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.456 0.646 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.452 ' SD ' ' C ' ' B' ' 32' ' ' ILE . 13.2 ttt -124.47 124.91 43.33 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.247 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.556 HG23 ' O ' ' H' ' 36' ' ' VAL . 34.5 m -136.08 81.24 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -29.14 -93.47 0.01 OUTLIER Glycine 0 CA--C 1.529 0.925 0 CA-C-N 116.488 -0.324 . . . . 0.0 112.489 178.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.09 -161.86 28.66 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.407 ' O ' HG23 ' I' ' 39' ' ' VAL . 27.7 m -120.51 134.79 62.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 120.657 0.265 . . . . 0.0 110.39 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.442 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.468 0.473 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.54 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 49.3 p-80 -155.86 161.62 40.57 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.147 -0.621 . . . . 0.0 112.303 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 7.2 m-70 -141.37 162.78 34.66 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.45 179.097 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -150.54 175.36 11.97 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.858 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -155.26 130.53 9.61 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.989 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.4 mt -124.39 118.74 27.39 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -123.62 128.44 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.56 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.648 ' CD2' ' CZ ' ' J' ' 19' ' ' PHE . 27.7 t80 -128.01 116.23 19.72 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -127.89 130.32 48.33 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-O 120.703 0.287 . . . . 0.0 110.941 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.14 125.78 32.09 Favored 'General case' 0 C--O 1.243 0.718 0 CA-C-O 121.444 0.64 . . . . 0.0 112.067 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -145.08 158.34 43.85 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.553 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.545 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.9 p-10 -173.96 121.88 0.31 Allowed 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 -179.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' I' ' 26' ' ' SER . 11.5 t -124.0 -111.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.222 -178.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.18 -90.75 0.01 OUTLIER Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -177.227 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.563 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.7 p 171.39 169.37 0.09 Allowed 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 177.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.563 ' O ' ' O ' ' I' ' 26' ' ' SER . 21.3 t-20 -19.49 155.8 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 179.552 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.542 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 73.5 tttt -170.69 106.57 0.28 Allowed 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.676 173.718 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.66 93.16 0.01 OUTLIER Glycine 0 C--O 1.227 -0.335 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 174.577 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -142.04 145.38 34.32 Favored 'General case' 0 CA--C 1.486 -1.504 0 CA-C-N 119.167 1.483 . . . . 0.0 107.889 177.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.599 ' CG1' HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -139.8 117.28 10.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.349 -177.964 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' I' ' 32' ' ' ILE . 0.4 OUTLIER -107.82 116.63 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.435 ' HA3' ' CG ' ' C' ' 35' ' ' MET . . . -119.68 100.61 0.8 Allowed Glycine 0 CA--C 1.496 -1.133 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.057 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.586 HD13 ' CZ ' ' G' ' 19' ' ' PHE . 5.3 tt -130.49 125.33 34.09 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 118.824 -1.151 . . . . 0.0 110.252 -179.449 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.679 ' SD ' HG22 ' C' ' 31' ' ' ILE . 28.3 ttm -115.56 117.11 29.42 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.176 -1.375 . . . . 0.0 109.01 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.97 75.29 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.681 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.431 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -29.63 -97.29 0.01 OUTLIER Glycine 0 C--N 1.354 1.543 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.843 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.75 -164.54 28.5 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.407 HG23 ' O ' ' H' ' 39' ' ' VAL . 2.6 p -133.82 146.91 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 110.027 -0.361 . . . . 0.0 110.027 179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.73 -179.79 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.173 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -105.21 129.45 53.58 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 120.901 0.382 . . . . 0.0 110.615 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -127.95 127.14 42.77 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.228 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 t -141.64 134.18 28.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -149.61 133.54 17.04 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.479 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 1.5 t-80 -151.64 159.2 44.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.455 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.633 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 49.6 tt0 -160.58 169.5 22.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.419 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -151.08 128.79 11.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 14.2 tp -126.33 114.55 18.39 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 64.6 t -119.51 126.76 75.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.981 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.648 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 1.5 t80 -120.19 119.35 32.97 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.51 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 56.4 t80 -132.84 126.36 32.08 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.611 0.243 . . . . 0.0 110.849 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.84 26.58 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 119.848 -0.741 . . . . 0.0 112.47 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -125.58 143.89 50.82 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.151 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -130.04 110.85 11.96 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 177.391 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.584 HG12 ' N ' ' J' ' 25' ' ' GLY . 14.0 t -139.39 -123.51 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.589 -178.551 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.584 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 27.5 -83.92 0.0 OUTLIER Glycine 0 C--N 1.342 0.879 0 CA-C-N 114.947 -1.024 . . . . 0.0 112.406 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.635 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.2 p 170.48 170.42 0.07 Allowed 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 178.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.635 ' O ' ' O ' ' J' ' 26' ' ' SER . 76.3 m-20 -18.37 157.58 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 O-C-N 124.375 1.047 . . . . 0.0 113.064 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.576 ' HB3' ' HB2' ' K' ' 30' ' ' ALA . 81.0 tttt -161.79 110.9 1.52 Allowed 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.573 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.471 ' H ' ' CG ' ' I' ' 27' ' ' ASN . . . -67.45 92.49 0.22 Allowed Glycine 0 C--N 1.32 -0.333 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.609 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -157.06 149.17 22.84 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 177.614 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.658 ' N ' HD13 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -144.81 122.56 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 C-N-CA 119.201 -1.0 . . . . 0.0 111.505 -176.946 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 4.2 mt -108.94 119.56 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-N 114.975 -1.012 . . . . 0.0 109.826 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.42 112.91 2.48 Favored Glycine 0 C--N 1.336 0.567 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 177.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.435 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 0.1 OUTLIER -143.72 135.0 25.85 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.126 0.965 . . . . 0.0 113.015 -177.586 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.586 ' CE ' HG22 ' D' ' 31' ' ' ILE . 98.7 mmm -112.63 111.19 21.82 Favored 'General case' 0 CA--C 1.504 -0.79 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.032 177.15 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.25 62.39 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.34 -111.49 0.13 Allowed Glycine 0 C--N 1.356 1.642 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.771 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.35 142.83 7.04 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 11.6 p -142.08 151.82 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 m . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.402 179.806 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -113.48 132.28 55.72 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.718 0.294 . . . . 0.0 110.442 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -129.9 127.71 40.72 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.918 0.389 . . . . 0.0 110.936 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.55 132.74 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.729 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -150.64 131.84 14.48 Favored 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.054 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' CE1' ' J' ' 14' ' ' HIS . 50.3 t-80 -152.93 165.01 36.85 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.174 0.511 . . . . 0.0 109.842 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 80.8 mt-30 -156.88 179.85 8.89 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.325 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -170.3 120.08 0.59 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.327 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 31.4 tp -119.98 123.99 44.85 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.549 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 65.0 t -130.03 121.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.551 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -118.67 120.62 37.96 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.51 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 48.6 t80 -129.01 121.26 27.56 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.998 0.428 . . . . 0.0 111.592 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.19 129.36 41.61 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.494 178.577 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -124.49 143.2 50.79 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 121.417 0.627 . . . . 0.0 112.323 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -131.55 123.7 28.51 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.974 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.64 HG12 ' N ' ' K' ' 25' ' ' GLY . 57.7 t -96.15 -112.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.667 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.64 ' N ' HG12 ' K' ' 24' ' ' VAL . . . -46.96 -91.04 0.01 OUTLIER Glycine 0 CA--C 1.526 0.765 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.456 -176.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.605 ' O ' ' O ' ' K' ' 27' ' ' ASN . 34.9 p -152.98 -172.63 4.31 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 117.611 0.705 . . . . 0.0 110.444 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.605 ' O ' ' O ' ' K' ' 26' ' ' SER . 54.7 t30 -19.86 158.05 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.65 0 O-C-N 124.997 1.436 . . . . 0.0 113.724 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' L' ' 30' ' ' ALA . 87.1 tttt -161.6 111.08 1.57 Allowed 'General case' 0 C--O 1.213 -0.823 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.839 176.112 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.574 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -67.92 92.39 0.24 Allowed Glycine 0 N--CA 1.475 1.276 0 CA-C-O 119.376 -0.68 . . . . 0.0 113.553 177.004 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.576 ' HB2' ' HB3' ' J' ' 28' ' ' LYS . . . -156.87 152.82 27.28 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 103.523 -2.769 . . . . 0.0 103.523 174.289 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.496 ' HB ' ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -149.62 116.16 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.857 0 C-N-CA 116.714 -1.994 . . . . 0.0 113.407 -171.844 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.428 ' C ' ' CE ' ' E' ' 35' ' ' MET . 62.7 mt -104.55 118.3 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.91 177.445 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.413 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.06 104.19 1.32 Allowed Glycine 0 C--O 1.237 0.319 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 177.537 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.578 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 8.4 tt -139.54 132.7 29.71 Favored 'General case' 0 C--O 1.243 0.734 0 CA-C-O 122.835 1.302 . . . . 0.0 112.876 -177.487 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CG ' ' L' ' 35' ' ' MET . 95.9 mmm -107.17 118.43 36.69 Favored 'General case' 0 CA--C 1.505 -0.767 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.53 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.569 HG13 HD21 ' K' ' 34' ' ' LEU . 0.0 OUTLIER -124.24 74.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.911 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.46 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -17.43 -101.93 0.0 OUTLIER Glycine 0 C--N 1.359 1.855 0 O-C-N 123.868 0.73 . . . . 0.0 113.031 -179.249 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.17 -161.9 30.28 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 74.4 t -124.08 138.39 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-O 120.751 0.31 . . . . 0.0 110.611 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 40' ' ' VAL . . . . . 0.413 ' O ' HG13 ' K' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.436 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -82.23 134.68 35.3 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.856 0.36 . . . . 0.0 110.48 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.42 143.68 33.83 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.519 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 50.4 t -121.68 132.92 69.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.063 0.459 . . . . 0.0 110.222 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 21.3 p-80 -164.12 110.43 1.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.479 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -144.85 169.04 18.8 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -151.72 175.64 12.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.126 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -153.34 123.89 7.18 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.346 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 64.4 mt -120.6 114.8 22.25 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -128.5 130.39 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.966 0.412 . . . . 0.0 110.54 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.506 ' CD1' ' O ' ' L' ' 19' ' ' PHE . 55.4 p90 -138.19 127.69 24.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -134.28 127.3 31.53 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.217 0.532 . . . . 0.0 110.746 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.61 134.48 32.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.771 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -110.19 109.77 20.38 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.644 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 42.7 t0 -99.16 133.84 42.87 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.188 0.518 . . . . 0.0 109.961 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' L' ' 26' ' ' SER . 90.5 t -107.02 112.97 42.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.394 -179.393 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 35.3 -91.22 0.01 OUTLIER Glycine 0 CA--C 1.528 0.88 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.873 -179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.448 ' N ' ' O ' ' L' ' 24' ' ' VAL . 13.4 p -62.49 -177.83 0.16 Allowed 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 117.571 0.685 . . . . 0.0 110.342 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -79.52 176.63 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.855 -1.066 . . . . 0.0 113.697 -177.166 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 35.7 tttp -48.51 111.1 0.41 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 113.835 -1.53 . . . . 0.0 112.947 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.41 -97.91 0.04 OUTLIER Glycine 0 CA--C 1.501 -0.808 0 CA-C-N 114.542 -1.208 . . . . 0.0 110.606 -178.492 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' K' ' 28' ' ' LYS . . . -60.84 170.87 1.34 Allowed 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 119.882 1.841 . . . . 0.0 106.135 -178.121 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -139.87 118.88 12.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 117.799 -1.56 . . . . 0.0 110.629 -172.71 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.541 ' C ' ' SD ' ' F' ' 35' ' ' MET . 67.2 mt -108.92 123.74 65.01 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 CA-C-N 114.398 -1.274 . . . . 0.0 109.09 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 33' ' ' GLY . . . . . 0.628 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -101.66 89.26 0.76 Allowed Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 105.477 -3.049 . . . . 0.0 105.477 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -108.57 112.89 25.48 Favored 'General case' 0 CA--C 1.502 -0.897 0 CA-C-O 120.684 0.278 . . . . 0.0 110.27 -177.835 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.505 ' CG ' ' SD ' ' K' ' 35' ' ' MET . 93.9 mmm -105.48 110.4 22.73 Favored 'General case' 0 CA--C 1.503 -0.846 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.169 179.428 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.487 HG13 HG23 ' K' ' 36' ' ' VAL . 2.9 m -128.7 79.42 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.263 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.5 103.68 0.52 Allowed Glycine 0 C--N 1.346 1.098 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.6 -161.06 36.9 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.7 m -133.15 160.91 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 120.966 0.412 . . . . 0.0 110.607 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 14.1 m . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.37 179.794 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 N--CA 1.464 0.264 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -93.6 135.5 34.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.761 0.315 . . . . 0.0 110.648 -179.043 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.554 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 75.2 t60 -152.21 164.09 38.08 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 44.9 tt0 -169.04 168.75 9.92 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.419 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.429 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 66.5 mttm -153.75 123.72 6.86 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -119.59 114.12 21.75 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.179 0.514 . . . . 0.0 110.466 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 70.5 t -120.34 115.44 47.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.147 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.961 ' CZ ' HD22 ' C' ' 34' ' ' LEU . 23.7 t80 -115.65 110.45 19.19 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.252 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 50.0 p90 -125.74 124.29 40.71 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.43 120.68 43.1 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.817 0.341 . . . . 0.0 110.357 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -159.65 115.32 2.46 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -74.89 121.85 22.5 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.96 0.409 . . . . 0.0 111.697 -178.553 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 26' ' ' SER . 13.9 t -84.48 124.6 39.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.06 84.3 0.01 OUTLIER Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.989 -178.109 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 24' ' ' VAL . 20.7 p -91.41 -179.76 5.47 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 178.175 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.43 179.13 0.17 Allowed 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 119.656 -0.817 . . . . 0.0 110.722 -179.087 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -59.5 111.11 1.28 Allowed 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.66 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.23 93.81 0.09 OUTLIER Glycine 0 N--CA 1.464 0.501 0 C-N-CA 120.169 -1.015 . . . . 0.0 112.214 177.602 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.24 156.14 21.92 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 176.549 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.609 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.2 OUTLIER -151.86 119.67 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.0 -173.248 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.455 ' C ' ' SD ' ' G' ' 35' ' ' MET . 5.9 tp -149.59 131.58 5.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.154 179.416 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.415 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.67 128.86 5.82 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -129.65 129.63 44.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.314 0.578 . . . . 0.0 110.606 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.517 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 27.9 ttt -130.81 129.23 42.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.552 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.6 t -84.46 75.99 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.979 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.412 ' CA ' HG21 ' G' ' 31' ' ' ILE . . . -90.51 103.36 3.02 Favored Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 178.731 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.45 179.95 52.43 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 N--CA 1.467 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.492 -179.886 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 N--CA 1.465 0.303 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.487 ' H ' ' HA ' ' C' ' 12' ' ' VAL . 61.7 t-80 -122.46 118.73 29.02 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.861 0.363 . . . . 0.0 110.198 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.489 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 80.8 t60 -132.8 163.83 28.18 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.489 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 1.6 pt20 -169.93 177.6 4.3 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.981 179.174 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -156.28 125.96 6.33 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.438 ' N ' HD12 ' B' ' 17' ' ' LEU . 5.0 mp -122.23 121.2 36.27 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.162 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 7.1 p -134.18 130.79 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.916 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 18.2 t80 -115.29 117.58 30.85 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -129.14 129.22 44.86 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.716 0.293 . . . . 0.0 111.423 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.8 123.37 37.21 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 120.616 -0.433 . . . . 0.0 111.652 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 41.0 tp10 -164.74 105.1 0.82 Allowed 'General case' 0 C--N 1.343 0.283 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.553 ' O ' ' O ' ' B' ' 24' ' ' VAL . 42.6 t0 -104.67 112.1 25.06 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.553 ' O ' ' O ' ' B' ' 23' ' ' ASP . 2.1 t -50.27 -133.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.745 178.042 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -95.35 -84.95 1.68 Allowed Glycine 0 CA--C 1.536 1.403 0 CA-C-N 115.933 -0.576 . . . . 0.0 113.276 -178.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 35.0 t 68.51 178.83 0.24 Allowed 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -177.538 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -89.88 168.27 12.18 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 118.456 -1.298 . . . . 0.0 112.513 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 45.9 pttt -40.92 110.57 0.16 Allowed 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 177.101 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.546 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 80.0 94.54 0.37 Allowed Glycine 0 N--CA 1.476 1.329 0 N-CA-C 116.892 1.517 . . . . 0.0 116.892 171.156 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.25 152.91 37.08 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 171.611 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.609 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.0 OUTLIER -145.36 117.72 2.27 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.721 -174.308 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -127.05 131.57 70.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.029 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.31 119.59 3.45 Favored Glycine 0 N--CA 1.475 1.239 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 59.3 tp -127.45 126.24 41.97 Favored 'General case' 0 N--CA 1.47 0.527 0 O-C-N 122.287 -0.537 . . . . 0.0 110.885 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.518 ' SD ' ' O ' ' H' ' 32' ' ' ILE . 11.9 ttt -139.6 137.75 35.59 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.348 0.594 . . . . 0.0 111.481 179.525 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 24.4 t -122.51 73.88 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.845 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.657 ' CA ' HG21 ' H' ' 31' ' ' ILE . . . -62.85 111.95 4.52 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 178.351 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -26.66 148.53 0.01 OUTLIER Glycine 0 N--CA 1.469 0.871 0 CA-C-O 121.107 0.282 . . . . 0.0 112.676 -178.704 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 68.1 t -115.29 135.58 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 m . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.381 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -114.22 138.59 50.27 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.781 0.324 . . . . 0.0 110.592 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -110.75 131.28 55.18 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.146 0.498 . . . . 0.0 110.538 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.487 ' HA ' ' H ' ' B' ' 13' ' ' HIS . 28.3 m -136.11 164.17 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.473 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.699 ' CG ' ' H ' ' C' ' 14' ' ' HIS . 24.2 t-80 -103.15 -173.48 2.32 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.699 ' H ' ' CG ' ' C' ' 13' ' ' HIS . 2.3 m170 -77.2 174.13 11.08 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.89 174.83 10.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.414 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -151.51 133.37 14.98 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.937 0.398 . . . . 0.0 111.731 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.63 ' C ' HD23 ' C' ' 17' ' ' LEU . 6.6 tt -127.62 123.2 35.06 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.578 178.752 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 18' ' ' VAL . . . . . 0.607 ' N ' HD23 ' C' ' 17' ' ' LEU . 57.5 t -128.04 129.52 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 CA-C-O 120.912 0.387 . . . . 0.0 111.648 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.737 ' CE1' HD13 ' E' ' 34' ' ' LEU . 2.5 t80 -121.7 115.21 22.3 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -127.45 125.79 41.18 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.92 0.39 . . . . 0.0 111.083 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.2 129.52 46.58 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.87 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 80.5 tt0 -155.97 158.39 37.82 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.938 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -142.8 120.65 11.97 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.57 0.224 . . . . 0.0 110.624 179.656 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -129.88 -112.19 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-O 121.308 0.575 . . . . 0.0 110.13 -179.235 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 35.07 -90.68 0.01 OUTLIER Glycine 0 CA--C 1.531 1.054 0 CA-C-N 115.337 -0.847 . . . . 0.0 114.084 -178.159 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.0 OUTLIER 175.28 -167.21 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 118.396 1.098 . . . . 0.0 110.793 -178.582 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' C' ' 26' ' ' SER . 51.4 p-10 -36.47 -179.62 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.164 -1.38 . . . . 0.0 113.641 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.546 ' HG3' ' H ' ' B' ' 29' ' ' GLY . 74.8 tttt 98.55 113.88 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.958 1.703 . . . . 0.0 113.182 179.047 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.88 93.64 0.49 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 172.649 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.2 163.07 12.88 Favored 'General case' 0 CA--C 1.498 -1.047 0 CA-C-N 120.74 2.27 . . . . 0.0 106.461 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.579 HD12 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -149.72 117.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 118.337 -1.345 . . . . 0.0 110.417 -174.113 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.485 ' C ' ' SD ' ' I' ' 35' ' ' MET . 13.5 tt -129.13 132.84 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 CA-C-O 121.736 0.779 . . . . 0.0 110.747 178.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -119.71 119.34 4.22 Favored Glycine 0 N--CA 1.465 0.612 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.961 HD22 ' CZ ' ' A' ' 19' ' ' PHE . 32.6 tp -118.67 121.86 41.14 Favored 'General case' 0 CA--C 1.512 -0.516 0 C-N-CA 120.986 -0.285 . . . . 0.0 111.743 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.522 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 7.9 ttm -122.05 108.98 14.0 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 173.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 m -128.75 72.37 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 120.543 -0.463 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.0 110.81 3.11 Favored Glycine 0 C--N 1.362 1.993 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.13 160.07 53.93 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -139.06 161.43 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.871 0.367 . . . . 0.0 111.051 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.414 ' O ' HG22 ' C' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.398 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 70.0 t . . . . . 0 N--CA 1.468 0.459 0 CA-C-O 121.026 0.441 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m80 -138.39 97.83 3.46 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.167 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 m170 -119.98 161.93 20.07 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.41 0.624 . . . . 0.0 109.583 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.429 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 43.9 tt0 -154.32 170.33 21.56 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.804 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.429 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.3 mttt -152.95 129.33 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.364 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -123.23 124.24 42.57 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.715 0.293 . . . . 0.0 110.643 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -123.63 126.77 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.085 0.469 . . . . 0.0 110.508 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.854 ' CZ ' HD22 ' F' ' 34' ' ' LEU . 7.7 t80 -124.69 110.55 14.51 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -123.13 129.85 51.99 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.522 0.677 . . . . 0.0 111.778 -178.787 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.93 122.19 26.5 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.497 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 79.6 mm-40 -115.86 120.33 38.87 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -151.51 112.0 4.17 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 -179.444 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.695 ' O ' ' N ' ' D' ' 26' ' ' SER . 52.1 t -111.96 131.07 64.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 102.572 -3.121 . . . . 0.0 102.572 174.125 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.624 ' H ' ' HZ1' ' F' ' 28' ' ' LYS . . . -37.59 81.67 0.0 OUTLIER Glycine 0 CA--C 1.534 1.256 0 C-N-CA 120.172 -1.014 . . . . 0.0 112.569 -176.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.695 ' N ' ' O ' ' D' ' 24' ' ' VAL . 26.8 m -88.48 -179.58 6.1 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-O 122.566 1.174 . . . . 0.0 111.612 178.356 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -76.61 -177.13 4.07 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.921 175.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 35.1 tttt 44.96 111.62 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 117.959 2.577 . . . . 0.0 117.959 177.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.483 ' HA2' ' HB2' ' E' ' 30' ' ' ALA . . . -82.64 94.66 1.74 Allowed Glycine 0 CA--C 1.499 -0.957 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 173.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.24 167.36 12.38 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.721 HG23 HG13 ' E' ' 31' ' ' ILE . 0.2 OUTLIER -146.42 118.29 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.623 -174.976 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.422 HD12 ' CG2' ' C' ' 32' ' ' ILE . 14.4 tt -130.13 130.88 66.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-O 121.828 0.823 . . . . 0.0 111.942 179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.8 104.27 2.35 Favored Glycine 0 CA--C 1.509 -0.338 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 177.544 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.916 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 16.6 tp -111.33 117.85 34.26 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 117.376 0.588 . . . . 0.0 111.945 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.55 ' SD ' HG22 ' J' ' 31' ' ' ILE . 17.7 tpp -121.08 108.01 13.31 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 176.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.6 HG22 HD11 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -121.04 76.51 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.951 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.778 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.04 103.31 2.85 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.16 174.33 41.96 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -135.4 160.62 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 121.047 0.451 . . . . 0.0 110.755 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.177 -0.916 . . . . 0.0 110.366 179.578 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -120.26 143.78 48.12 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.815 0.34 . . . . 0.0 110.332 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -73.23 135.15 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.84 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 8.4 t -146.74 135.62 16.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.108 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -132.54 131.7 41.83 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.638 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 24.2 t60 -152.08 163.6 38.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 121.922 0.868 . . . . 0.0 110.446 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.638 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 53.5 tt0 -159.55 167.11 29.35 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.496 178.69 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.401 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 99.2 mttt -151.44 130.11 12.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 179.432 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.5 HD12 ' CD2' ' F' ' 17' ' ' LEU . 12.5 mt -115.52 116.18 27.74 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.425 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.52 115.34 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.099 -179.667 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -117.03 124.43 49.29 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 116.78 -0.191 . . . . 0.0 110.756 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -129.94 119.09 22.68 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.65 121.13 22.7 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.231 0.539 . . . . 0.0 111.425 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 35.0 tt0 -88.52 165.63 14.73 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.7 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.563 ' O ' ' O ' ' E' ' 24' ' ' VAL . 46.0 t0 -145.4 -122.27 0.08 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.002 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.563 ' O ' ' O ' ' E' ' 23' ' ' ASP . 2.9 t 22.22 121.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 -178.707 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.08 -85.0 0.09 OUTLIER Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 177.897 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.509 ' H ' ' CE ' ' F' ' 28' ' ' LYS . 1.7 p 162.39 160.8 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 177.353 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.455 ' O ' ' O ' ' E' ' 26' ' ' SER . 69.6 m-80 -29.78 159.42 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.694 178.087 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.476 ' HD2' ' H ' ' D' ' 26' ' ' SER . 76.1 tttt -179.73 105.84 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 174.528 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.465 ' O ' ' CA ' ' D' ' 29' ' ' GLY . . . -58.65 93.54 0.05 OUTLIER Glycine 0 C--O 1.211 -1.323 0 CA-C-O 118.16 -1.356 . . . . 0.0 111.708 173.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.483 ' HB2' ' HA2' ' D' ' 29' ' ' GLY . . . -155.9 149.37 24.82 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 103.1 -2.926 . . . . 0.0 103.1 173.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.721 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.05 124.3 6.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 C-N-CA 117.984 -1.486 . . . . 0.0 112.133 -168.983 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.461 HG12 HD21 ' E' ' 34' ' ' LEU . 0.7 OUTLIER -120.91 111.29 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 CA-C-N 114.529 -1.214 . . . . 0.0 107.761 179.541 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.57 110.24 3.62 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.737 HD13 ' CE1' ' C' ' 19' ' ' PHE . 2.9 mt -117.97 112.76 20.72 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -176.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' K' ' 32' ' ' ILE . 6.2 ttm -115.29 107.91 15.87 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 175.419 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.16 80.97 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.23 102.64 0.5 Allowed Glycine 0 C--N 1.346 1.116 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -86.67 -160.22 34.35 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.31 160.47 33.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.185 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.5 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.689 -179.993 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.408 ' CG2' ' N ' ' F' ' 13' ' ' HIS . 1.5 p . . . . . 0 N--CA 1.464 0.27 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.536 ' ND1' ' ND1' ' E' ' 14' ' ' HIS . 15.2 t-80 -125.02 155.27 39.98 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 120.912 0.387 . . . . 0.0 110.595 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.558 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 89.9 m-70 -80.42 178.28 8.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -125.93 -179.88 4.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.364 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -133.62 137.58 45.5 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.161 0.505 . . . . 0.0 110.993 -179.599 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.5 ' CD2' HD12 ' E' ' 17' ' ' LEU . 33.1 mt -122.03 115.17 22.02 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.276 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 28.5 m -134.04 127.64 51.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.341 0.591 . . . . 0.0 110.092 178.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.495 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 50.0 p90 -138.69 131.52 29.39 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.575 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -129.79 122.27 28.45 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.252 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.6 146.24 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.422 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -115.78 125.9 53.33 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.217 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 . . . . . 0 CA--C 1.532 0.286 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.978 178.536 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.624 ' HZ1' ' H ' ' D' ' 25' ' ' GLY . 30.6 tttt . . . . . 0 CA--C 1.544 0.723 0 CA-C-O 122.882 1.325 . . . . 0.0 112.476 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.516 ' H ' ' CG ' ' F' ' 28' ' ' LYS . . . -90.6 -99.85 1.18 Allowed Glycine 0 CA--C 1.484 -1.883 0 C-N-CA 127.568 2.509 . . . . 0.0 111.76 -179.509 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.66 166.46 3.24 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 105.838 -1.912 . . . . 0.0 105.838 -177.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -132.61 135.71 57.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.34 -171.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 61.4 mt -114.87 117.24 55.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 CA-C-N 115.198 -0.91 . . . . 0.0 112.646 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.69 92.58 1.23 Allowed Glycine 0 CA--C 1.51 -0.244 0 N-CA-C 104.51 -3.436 . . . . 0.0 104.51 173.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.854 HD22 ' CZ ' ' D' ' 19' ' ' PHE . 8.4 tp -110.3 116.77 32.07 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.346 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.466 ' HG3' ' CA ' ' L' ' 33' ' ' GLY . 96.4 mmm -119.58 111.98 18.75 Favored 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 176.122 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.491 HG13 HD11 ' F' ' 34' ' ' LEU . 0.1 OUTLIER -127.36 80.22 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.075 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 34.47 -103.27 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 CA-C-N 116.436 -0.347 . . . . 0.0 112.308 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.97 -150.17 10.95 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.8 t -120.02 135.77 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.997 0.427 . . . . 0.0 110.803 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.13 -0.938 . . . . 0.0 110.281 179.559 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' G' G ' 10' ' ' TYR . . . . . 0.409 ' O ' ' OE2' ' H' ' 11' ' ' GLU . 99.1 m-85 -99.19 133.77 43.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.136 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -139.67 145.6 38.62 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.301 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 62.2 t -125.34 132.63 70.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.225 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -88.31 172.11 9.67 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.919 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.537 ' CD2' ' N ' ' G' ' 14' ' ' HIS . 3.6 m170 -89.05 170.52 10.58 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.626 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.431 ' HG2' ' N ' ' G' ' 16' ' ' LYS . 54.8 tt0 -147.57 171.81 14.99 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.859 179.24 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.431 ' N ' ' HG2' ' G' ' 15' ' ' GLN . 98.9 mttt -150.8 125.0 9.38 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 121.227 -0.189 . . . . 0.0 111.101 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 77.9 mt -118.28 122.42 42.87 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -138.66 132.42 40.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 121.774 0.797 . . . . 0.0 113.101 -178.437 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.637 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 6.9 m-85 -113.14 111.72 22.59 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 175.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -130.62 121.06 24.92 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 131.03 41.07 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-O 121.373 0.606 . . . . 0.0 112.038 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' G' ' 23' ' ' ASP . 83.8 tt0 -156.05 152.95 28.68 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 177.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.475 ' O ' ' C ' ' G' ' 24' ' ' VAL . 22.2 t70 -59.48 -120.41 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.534 -178.612 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.475 ' C ' ' O ' ' G' ' 23' ' ' ASP . 22.7 m -27.2 121.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 122.179 0.192 . . . . 0.0 111.001 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.15 -85.6 0.1 Allowed Glycine 0 CA--C 1.526 0.775 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.225 -177.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.697 ' O ' ' O ' ' G' ' 27' ' ' ASN . 62.5 m -152.73 -170.81 3.74 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -175.591 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.697 ' O ' ' O ' ' G' ' 26' ' ' SER . 12.7 t-20 -19.34 159.59 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.103 0 O-C-N 124.629 1.206 . . . . 0.0 114.016 -176.35 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -159.82 110.64 1.94 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.236 -176.264 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 1.058 ' O ' ' HB1' ' H' ' 30' ' ' ALA . . . -69.51 96.09 0.48 Allowed Glycine 0 CA--C 1.455 -3.683 0 CA-C-O 123.686 1.715 . . . . 0.0 110.511 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.522 ' O ' ' C ' ' G' ' 29' ' ' GLY . . . -81.6 -139.99 0.04 OUTLIER 'General case' 0 N--CA 1.395 -3.215 1 N-CA-C 94.424 -6.139 . . . . 0.0 94.424 171.171 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.693 ' CD1' ' N ' ' G' ' 31' ' ' ILE . 1.0 OUTLIER -85.18 111.31 20.5 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.298 0 CA-C-N 125.186 3.63 . . . . 0.0 109.443 179.928 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.517 ' O ' ' SD ' ' A' ' 35' ' ' MET . 39.1 mm -136.73 129.34 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 120.304 -0.558 . . . . 0.0 112.035 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.516 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -131.34 130.76 6.13 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.64 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 34.2 tp -156.19 135.33 12.09 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.801 0.81 . . . . 0.0 112.99 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.455 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 63.7 ttp -121.93 143.94 49.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.363 178.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 25.5 t -120.03 75.86 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.482 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -96.5 101.12 2.58 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.6 167.33 22.13 Favored Glycine 0 N--CA 1.467 0.741 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.16 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 81.8 t -131.3 138.27 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.752 0.31 . . . . 0.0 110.301 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.9 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.347 179.472 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -118.61 140.48 49.84 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' O ' ' G' ' 10' ' ' TYR . 80.9 mm-40 -132.36 135.9 46.47 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.711 0.767 . . . . 0.0 111.978 -178.926 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 58.0 t -128.47 134.33 64.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.094 -0.957 . . . . 0.0 108.654 179.326 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 -137.86 101.11 4.36 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.95 -0.3 . . . . 0.0 110.754 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 11.1 m170 -115.5 154.67 28.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.725 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 80.5 mt-30 -155.91 174.31 15.51 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.468 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -156.96 112.17 2.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.712 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.507 HD12 ' N ' ' H' ' 17' ' ' LEU . 6.5 mp -111.42 111.4 22.41 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.69 125.32 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-O 121.86 0.838 . . . . 0.0 111.732 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.604 ' CG ' ' CE2' ' I' ' 19' ' ' PHE . 6.0 m-85 -113.17 116.81 30.41 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 114.182 -1.372 . . . . 0.0 108.666 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -128.67 126.56 40.38 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.434 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.13 130.24 35.14 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 121.19 0.519 . . . . 0.0 111.394 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' H' ' 23' ' ' ASP . 84.9 tt0 -149.96 91.12 1.75 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 178.057 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' H' ' 22' ' ' GLU . 1.1 m-20 62.74 115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 -176.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.598 ' C ' ' HZ3' ' I' ' 28' ' ' LYS . 48.9 t -118.84 123.75 72.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.471 -174.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.505 ' C ' ' HZ3' ' I' ' 28' ' ' LYS . . . 35.91 83.69 0.01 OUTLIER Glycine 0 N--CA 1.47 0.905 0 C-N-CA 121.482 -0.39 . . . . 0.0 113.255 177.128 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.627 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 5.4 t -58.9 170.92 0.74 Allowed 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 121.18 0.514 . . . . 0.0 110.389 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.512 ' O ' ' O ' ' H' ' 28' ' ' LYS . 19.6 m120 103.26 177.43 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 113.259 -1.791 . . . . 0.0 107.298 -177.334 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' H' ' 27' ' ' ASN . 98.7 mttt -23.69 -102.87 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 O-C-N 123.567 0.542 . . . . 0.0 111.981 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -141.25 100.46 0.26 Allowed Glycine 0 N--CA 1.472 1.059 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 177.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 1.058 ' HB1' ' O ' ' G' ' 29' ' ' GLY . . . -66.59 158.48 29.72 Favored 'General case' 0 C--O 1.248 1.013 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.016 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.657 HG21 ' CA ' ' B' ' 37' ' ' GLY . 0.1 OUTLIER -154.55 132.15 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.544 -175.796 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' B' ' 35' ' ' MET . 41.5 pt -130.42 127.07 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.499 0.666 . . . . 0.0 112.226 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.53 97.89 0.66 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.507 ' O ' HD12 ' I' ' 34' ' ' LEU . 4.4 mp -129.44 149.8 51.07 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.924 0.868 . . . . 0.0 111.974 -178.31 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.406 ' CE ' ' SD ' ' G' ' 35' ' ' MET . 20.7 ttp -141.03 134.69 30.17 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.482 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 4.1 t -126.42 79.01 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' B' ' 31' ' ' ILE . . . -61.53 105.07 0.8 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 177.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.94 173.05 0.64 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.99 161.88 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.965 0.412 . . . . 0.0 110.66 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.9 m . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.831 179.951 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 N--CA 1.468 0.452 0 CA-C-O 120.188 0.042 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -135.75 132.31 36.65 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.505 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.625 ' NE2' ' CG ' ' J' ' 13' ' ' HIS . 75.7 m80 -122.91 159.69 27.71 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 178.37 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -157.51 177.52 11.32 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.629 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -170.05 114.16 0.49 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.462 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 tt -117.67 118.49 32.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.071 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -141.72 136.76 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 119.967 -0.693 . . . . 0.0 111.896 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.604 ' CE2' ' CG ' ' H' ' 19' ' ' PHE . 26.8 m-85 -123.92 128.5 49.52 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 115.393 -0.822 . . . . 0.0 110.224 179.473 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.587 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.2 t80 -133.26 124.86 28.12 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.09 133.21 44.07 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.488 0.921 . . . . 0.0 113.488 -178.524 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -143.35 167.75 21.42 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' I' ' 24' ' ' VAL . 3.6 m-20 -142.32 -102.14 0.13 Allowed 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.519 ' O ' ' O ' ' I' ' 23' ' ' ASP . 10.9 t 46.98 159.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 122.263 1.03 . . . . 0.0 112.655 -176.402 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.497 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 107.88 -76.35 0.22 Allowed Glycine 0 CA--C 1.541 1.712 0 CA-C-N 114.139 -1.391 . . . . 0.0 112.529 -175.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.9 ' O ' ' O ' ' I' ' 27' ' ' ASN . 0.4 OUTLIER 170.89 -169.48 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.403 0 CA-C-N 119.502 1.651 . . . . 0.0 109.354 -176.43 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.9 ' O ' ' O ' ' I' ' 26' ' ' SER . 62.1 t30 -17.01 -179.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.06 0 O-C-N 125.287 1.617 . . . . 0.0 113.537 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.659 ' CG ' ' O ' ' I' ' 27' ' ' ASN . 26.8 mmtt 139.89 -110.52 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -175.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.42 ' CA ' ' O ' ' J' ' 29' ' ' GLY . . . 49.27 91.28 0.01 OUTLIER Glycine 0 CA--C 1.482 -2.022 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -171.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.447 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -103.06 170.75 7.78 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 111.509 -2.346 . . . . 0.0 106.63 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.481 HD12 ' CG2' ' H' ' 31' ' ' ILE . 0.3 OUTLIER -145.78 110.03 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 C-N-CA 118.299 -1.361 . . . . 0.0 109.423 -175.899 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.517 HG12 HD11 ' H' ' 32' ' ' ILE . 58.7 mt -103.6 115.72 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.516 -178.654 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.522 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.61 92.65 0.54 Allowed Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 107.509 -2.237 . . . . 0.0 107.509 176.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.61 HD23 ' HZ ' ' G' ' 19' ' ' PHE . 22.6 tp -129.22 122.4 29.63 Favored 'General case' 0 C--O 1.244 0.785 0 CA-C-O 123.276 1.512 . . . . 0.0 110.798 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 24.7 ttp -106.61 120.42 41.91 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 112.596 -2.093 . . . . 0.0 108.548 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -135.49 72.23 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.392 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -104.13 101.62 2.01 Favored Glycine 0 C--N 1.36 1.914 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 178.272 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.35 178.91 24.56 Favored Glycine 0 N--CA 1.463 0.485 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 8.4 p -141.43 152.34 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.878 0.371 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.5 179.856 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.452 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -120.45 147.2 45.41 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -122.95 161.65 23.78 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.185 0.517 . . . . 0.0 110.441 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -143.77 151.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.591 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.625 ' CG ' ' NE2' ' I' ' 14' ' ' HIS . 25.2 t-80 -92.45 -173.92 3.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.853 0.359 . . . . 0.0 110.219 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.621 ' H ' ' CG ' ' J' ' 13' ' ' HIS . 0.5 OUTLIER -86.01 175.19 8.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.336 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.408 ' HG2' ' N ' ' J' ' 16' ' ' LYS . 48.3 tt0 -126.16 166.26 17.38 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.408 ' N ' ' HG2' ' J' ' 15' ' ' GLN . 99.5 mttt -148.57 122.89 9.63 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.756 0.312 . . . . 0.0 111.591 -179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 3.4 mp -123.9 121.14 34.54 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.32 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 94.5 t -129.72 128.66 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-O 121.149 0.499 . . . . 0.0 112.086 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.453 ' CZ ' HD13 ' L' ' 34' ' ' LEU . 46.5 m-85 -115.53 119.83 37.48 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 178.106 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.587 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 29.0 t80 -130.99 120.35 23.37 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.616 0.644 . . . . 0.0 109.727 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.34 134.44 34.24 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -110.45 122.96 48.98 Favored 'General case' 0 C--N 1.346 0.43 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.311 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.549 ' HB3' ' H ' ' K' ' 24' ' ' VAL . 8.8 t70 -84.28 122.66 29.2 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.017 0.437 . . . . 0.0 110.911 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' J' ' 26' ' ' SER . 72.1 t -99.66 122.52 51.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.748 -179.06 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 39.17 -86.06 0.01 OUTLIER Glycine 0 C--N 1.337 0.619 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.301 177.08 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.653 ' O ' ' O ' ' J' ' 27' ' ' ASN . 87.9 p -161.25 174.17 13.98 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.653 ' O ' ' O ' ' J' ' 26' ' ' SER . 74.9 m-20 -9.39 159.4 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 116.369 1.989 . . . . 0.0 116.369 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt 179.86 104.83 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 112.566 -2.106 . . . . 0.0 106.618 175.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.42 ' O ' ' CA ' ' I' ' 29' ' ' GLY . . . -60.51 95.03 0.08 OUTLIER Glycine 0 C--O 1.22 -0.722 0 CA-C-O 118.724 -1.042 . . . . 0.0 113.924 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.401 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -127.37 149.01 50.25 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 102.215 -3.254 . . . . 0.0 102.215 172.414 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.55 HG22 ' SD ' ' D' ' 35' ' ' MET . 0.2 OUTLIER -148.48 118.64 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 C-N-CA 118.011 -1.476 . . . . 0.0 111.222 -172.296 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.649 ' CG2' HD21 ' K' ' 34' ' ' LEU . 2.0 mt -108.12 112.48 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.384 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.07 101.94 1.32 Allowed Glycine 0 C--O 1.239 0.455 0 N-CA-C 106.579 -2.608 . . . . 0.0 106.579 176.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.637 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 0.2 OUTLIER -142.16 135.17 28.73 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 122.205 1.002 . . . . 0.0 112.391 -176.634 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 49.0 ttp -123.3 127.61 48.79 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.979 179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.86 69.08 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.306 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.725 178.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.2 -100.83 0.01 OUTLIER Glycine 0 C--N 1.36 1.89 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.07 150.91 20.43 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 75.6 t -134.52 137.31 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 p . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.401 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -109.51 142.54 40.4 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.58 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -130.59 144.13 51.21 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.671 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.05 133.79 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.803 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -134.4 124.27 25.43 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.019 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.553 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 62.4 t-80 -156.48 166.87 32.17 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-O 121.409 0.623 . . . . 0.0 109.921 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.553 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 79.6 mt-30 -153.91 173.49 15.88 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.359 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 79.1 tttt -153.78 113.3 3.8 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.125 178.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 tt -116.01 121.74 43.15 Favored 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -126.61 129.37 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -125.05 123.82 40.62 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -134.39 122.54 22.71 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.676 0.274 . . . . 0.0 111.266 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.49 131.42 31.81 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 121.246 0.546 . . . . 0.0 111.85 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -110.27 128.17 55.39 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.748 179.378 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.462 ' H ' ' HB2' ' L' ' 22' ' ' GLU . 89.0 m-20 -100.48 115.65 30.57 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.552 ' O ' ' N ' ' K' ' 26' ' ' SER . 53.3 t -95.37 130.29 44.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.03 -85.31 0.01 OUTLIER Glycine 0 CA--C 1.529 0.917 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.552 ' N ' ' O ' ' K' ' 24' ' ' VAL . 29.4 p -141.16 170.76 15.12 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.945 0.878 . . . . 0.0 111.516 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.515 ' O ' ' O ' ' K' ' 26' ' ' SER . 2.3 p30 -28.83 169.72 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.184 -1.825 . . . . 0.0 114.294 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.541 ' O ' ' HB2' ' L' ' 30' ' ' ALA . 88.6 tttt -149.85 111.38 4.48 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.101 175.579 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.11 91.91 0.05 OUTLIER Glycine 0 N--CA 1.476 1.337 0 CA-C-O 119.603 -0.554 . . . . 0.0 113.643 176.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.12 153.97 51.02 Favored 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 102.961 -2.977 . . . . 0.0 102.961 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.504 HG23 ' CG1' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -142.09 111.68 2.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 C-N-CA 118.221 -1.392 . . . . 0.0 111.713 -172.965 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.49 ' O ' HG22 ' K' ' 32' ' ' ILE . 0.1 OUTLIER -106.83 111.12 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.661 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.79 97.64 1.05 Allowed Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.649 HD21 ' CG2' ' J' ' 32' ' ' ILE . 94.2 mt -130.24 142.3 50.57 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 122.024 0.916 . . . . 0.0 113.196 -176.451 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 40.7 ttp -129.67 117.91 21.08 Favored 'General case' 0 CA--C 1.501 -0.939 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.266 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' K' ' 37' ' ' GLY . 0.2 OUTLIER -115.19 65.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.666 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -36.69 -106.87 0.01 OUTLIER Glycine 0 C--N 1.352 1.471 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.569 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.73 144.98 0.07 OUTLIER Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -178.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -146.38 143.57 20.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.782 -179.579 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -111.87 137.2 50.15 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.703 0.287 . . . . 0.0 110.271 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -53.98 152.48 5.72 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.18 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 28.5 m -113.77 133.27 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.549 0.69 . . . . 0.0 111.663 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -150.07 138.59 20.66 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.804 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.517 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 18.8 t-80 -157.31 175.5 13.93 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.517 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 87.9 mt-30 -142.86 176.44 9.07 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.952 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -166.23 113.47 0.88 Allowed 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.268 0.556 . . . . 0.0 111.024 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -121.56 125.97 48.02 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.607 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.6 t -134.43 133.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -141.78 133.4 26.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.124 0.488 . . . . 0.0 111.41 -179.575 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -134.49 128.56 33.64 Favored 'General case' 0 C--O 1.231 0.088 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.243 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.74 148.5 25.48 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.566 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.462 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 98.5 mt-10 -91.26 152.57 20.45 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.484 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -141.55 123.32 15.24 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.459 0.647 . . . . 0.0 112.036 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.533 ' O ' ' N ' ' L' ' 26' ' ' SER . 94.7 t -94.58 121.04 44.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.0 -88.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.082 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.533 ' N ' ' O ' ' L' ' 24' ' ' VAL . 11.9 p -90.97 179.72 5.68 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 88.0 m-20 -61.1 170.44 1.63 Allowed 'General case' 0 C--N 1.314 -0.945 0 C-N-CA 118.491 -1.284 . . . . 0.0 109.612 -179.448 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -53.88 111.94 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.198 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.474 ' H ' ' HB3' ' K' ' 27' ' ' ASN . . . -71.45 92.23 0.5 Allowed Glycine 0 N--CA 1.47 0.923 0 C-N-CA 118.64 -1.743 . . . . 0.0 110.058 176.028 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.541 ' HB2' ' O ' ' K' ' 28' ' ' LYS . . . -174.83 163.29 3.35 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 102.386 -3.19 . . . . 0.0 102.386 178.103 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.504 ' CG1' HG23 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -143.86 120.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 116.927 -1.909 . . . . 0.0 113.207 -177.464 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.435 HG22 ' O ' ' L' ' 32' ' ' ILE . 3.4 mt -102.78 111.72 33.57 Favored 'Isoleucine or valine' 0 C--N 1.343 0.325 0 CA-C-N 113.466 -1.697 . . . . 0.0 107.372 177.437 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 33' ' ' GLY . . . . . 0.466 ' CA ' ' HG3' ' F' ' 35' ' ' MET . . . -110.06 83.94 0.35 Allowed Glycine 0 CA--C 1.493 -1.318 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 177.305 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.692 HD21 HG13 ' L' ' 36' ' ' VAL . 7.3 tt -122.27 117.08 25.28 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.499 ' N ' HD23 ' L' ' 34' ' ' LEU . 65.4 ttp -106.05 130.27 53.99 Favored 'General case' 0 CA--C 1.505 -0.784 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.333 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.692 HG13 HD21 ' L' ' 34' ' ' LEU . 0.0 OUTLIER -132.2 79.97 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.629 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.18 103.24 0.76 Allowed Glycine 0 C--N 1.348 1.224 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.96 152.98 21.24 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -132.14 157.81 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.751 -179.599 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.2 m . . . . . 0 N--CA 1.466 0.347 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -138.24 163.19 32.38 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.944 0.402 . . . . 0.0 110.866 -178.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.629 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -82.11 170.82 15.05 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.551 -179.844 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -148.89 174.76 11.9 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.01 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -153.4 124.54 7.46 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.074 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.0 mt -121.12 114.26 21.19 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.1 t -131.26 129.34 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 CA-C-O 121.403 0.621 . . . . 0.0 112.354 -178.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.595 ' CG ' ' CE1' ' B' ' 19' ' ' PHE . 3.5 m-85 -108.85 111.63 23.45 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 50.1 p90 -131.59 126.32 34.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 118.797 0.726 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.12 133.14 42.51 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-O 121.461 0.648 . . . . 0.0 112.405 -178.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.496 ' N ' ' OE1' ' A' ' 22' ' ' GLU . 36.5 mp0 -142.97 156.52 44.88 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.457 ' O ' ' CG1' ' B' ' 24' ' ' VAL . 34.5 t70 -87.89 111.72 21.74 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 120.165 -0.614 . . . . 0.0 112.387 -178.445 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.598 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.5 t -113.8 131.2 66.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.093 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.96 81.97 0.0 OUTLIER Glycine 0 CA--C 1.53 1.022 0 O-C-N 123.315 0.384 . . . . 0.0 112.427 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.598 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.4 p -91.19 -179.3 5.39 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.538 ' O ' ' O ' ' A' ' 28' ' ' LYS . 58.8 t30 -62.64 -178.03 0.18 Allowed 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.783 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.538 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.2 mttt -48.48 -110.51 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.746 0.784 . . . . 0.0 110.604 -179.355 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -84.2 94.97 1.88 Allowed Glycine 0 N--CA 1.459 0.23 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 176.59 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.07 161.32 16.61 Favored 'General case' 0 C--N 1.351 0.636 0 C-N-CA 115.473 -2.491 . . . . 0.0 110.776 -177.105 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.458 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.7 OUTLIER -153.4 121.7 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 CA-C-N 112.545 -2.116 . . . . 0.0 110.667 -172.596 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' G' ' 35' ' ' MET . 78.6 mt -129.2 120.16 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 120.381 -0.527 . . . . 0.0 110.72 178.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.62 122.31 3.54 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 16.0 tp -127.75 141.96 51.44 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 117.241 0.52 . . . . 0.0 111.355 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.57 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 13.3 ttt -131.32 129.29 41.25 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.315 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 16.4 t -131.4 71.66 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 N-CA-C 112.315 0.487 . . . . 0.0 112.315 178.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.549 ' O ' HD12 ' G' ' 31' ' ' ILE . . . -125.75 96.51 0.49 Allowed Glycine 0 C--N 1.344 1.024 0 N-CA-C 108.799 -1.72 . . . . 0.0 108.799 177.386 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.86 172.25 42.56 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.466 0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 110.761 179.834 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p . . . . . 0 N--CA 1.464 0.239 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 -142.18 105.98 4.71 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.659 0.266 . . . . 0.0 110.923 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -160.45 178.77 9.22 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-O 121.109 0.481 . . . . 0.0 110.283 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -133.44 -179.14 5.33 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.97 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -146.74 132.38 18.84 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.879 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.9 tp -125.39 115.9 21.02 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 120.701 -0.4 . . . . 0.0 112.01 -177.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 74.9 t -125.39 123.8 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 120.866 0.365 . . . . 0.0 110.912 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.595 ' CE1' ' CG ' ' A' ' 19' ' ' PHE . 13.3 m-85 -116.83 118.98 33.97 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.73 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.7 t80 -134.11 125.4 27.91 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.99 133.71 33.98 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -178.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -153.15 176.76 11.57 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.46 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -153.35 134.69 14.22 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.913 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.457 ' CG1' ' O ' ' A' ' 23' ' ' ASP . 2.8 p -109.09 112.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.005 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 33.09 88.57 0.01 OUTLIER Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -177.288 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -46.96 170.86 0.01 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.17 -1.015 . . . . 0.0 113.232 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.559 ' H ' ' HD2' ' C' ' 28' ' ' LYS . 78.3 m-20 -129.67 -179.94 5.47 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 114.316 -1.311 . . . . 0.0 108.62 176.546 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.498 ' O ' ' O ' ' B' ' 27' ' ' ASN . 98.1 mttt -26.71 -103.3 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 179.42 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.85 98.43 0.18 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.091 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.42 ' H ' ' HE3' ' C' ' 28' ' ' LYS . . . -74.82 158.72 32.96 Favored 'General case' 0 C--O 1.25 1.088 0 C-N-CA 117.086 -1.846 . . . . 0.0 111.26 177.727 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.458 ' O ' ' HA ' ' A' ' 31' ' ' ILE . 0.1 OUTLIER -153.68 112.99 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.556 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.491 ' O ' ' SD ' ' H' ' 35' ' ' MET . 42.7 pt -136.02 150.36 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.255 -177.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.506 ' O ' HD23 ' B' ' 34' ' ' LEU . . . -166.18 150.29 17.4 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 119.835 -1.174 . . . . 0.0 112.332 -179.641 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.628 HD12 HD11 ' C' ' 34' ' ' LEU . 6.0 mt -139.17 143.43 38.14 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 120.9 0.381 . . . . 0.0 110.586 179.81 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.63 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 5.2 ttt -120.22 122.09 40.16 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.2 t -138.14 71.83 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.814 ' O ' HG21 ' H' ' 31' ' ' ILE . . . -128.12 95.85 0.41 Allowed Glycine 0 C--N 1.343 0.969 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 177.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.33 179.44 18.69 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -179.039 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -123.75 136.12 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.982 0.42 . . . . 0.0 110.284 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.186 179.812 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -147.79 163.82 35.56 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 11' ' ' GLU . . . . . 0.515 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 56.7 mp0 -127.04 150.25 49.53 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.663 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.49 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 32.6 m -131.27 156.16 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.949 179.661 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.49 ' CD2' ' C ' ' C' ' 12' ' ' VAL . 10.0 m-70 -150.98 150.43 30.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.995 -178.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 2.4 t60 -154.55 158.14 39.35 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.508 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 78.2 mt-30 -152.08 179.27 8.63 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 120.289 -0.565 . . . . 0.0 111.432 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -165.45 117.53 1.14 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.836 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.3 mt -115.81 114.78 25.22 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.79 140.92 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 119.426 -0.91 . . . . 0.0 113.163 -178.546 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.552 ' CE1' ' CD1' ' F' ' 34' ' ' LEU . 65.1 m-85 -124.28 125.11 43.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.541 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.0 t80 -130.61 117.21 19.19 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.027 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.24 136.15 46.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 120.559 -0.456 . . . . 0.0 111.641 -178.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -125.97 121.04 31.93 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.418 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' D' ' 24' ' ' VAL . 41.0 t0 -90.63 123.05 33.95 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.127 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.3 t -142.32 -111.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' C' ' 26' ' ' SER . . . -29.8 91.56 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 CA-C-N 116.145 -0.479 . . . . 0.0 112.747 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.545 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 12.8 p -61.18 179.15 0.21 Allowed 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 105.596 -2.001 . . . . 0.0 105.596 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.545 ' CB ' ' O ' ' C' ' 26' ' ' SER . 3.1 m120 91.17 -170.81 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -177.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.559 ' HD2' ' H ' ' B' ' 27' ' ' ASN . 84.3 tttt 40.59 -106.29 0.06 Allowed 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 114.803 1.408 . . . . 0.0 114.803 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.6 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . 92.95 91.91 1.51 Allowed Glycine 0 CA--C 1.497 -1.07 0 N-CA-C 107.483 -2.247 . . . . 0.0 107.483 -171.691 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.475 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -83.5 172.47 12.37 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.512 -176.48 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.475 ' CG1' ' C ' ' C' ' 30' ' ' ALA . 0.1 OUTLIER -152.72 124.19 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 C-N-CA 117.7 -1.6 . . . . 0.0 110.157 -175.909 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.7 tt -122.42 131.73 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.462 ' O ' ' CA ' ' B' ' 33' ' ' GLY . . . -122.44 109.13 1.36 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 179.131 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.764 ' H ' HD23 ' D' ' 34' ' ' LEU . 1.0 OUTLIER -137.07 126.57 25.12 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.45 -1.029 . . . . 0.0 112.258 -178.402 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.666 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 14.2 ttp -110.58 121.8 46.2 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 114.388 -1.278 . . . . 0.0 109.945 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.463 HG13 ' CD2' ' C' ' 34' ' ' LEU . 0.2 OUTLIER -139.87 70.46 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.732 179.847 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.53 -100.48 0.62 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.44 155.27 25.49 Favored Glycine 0 CA--C 1.521 0.434 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -136.06 162.09 36.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.761 0.315 . . . . 0.0 110.213 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.8 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.721 -179.699 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.467 0.385 0 N-CA-C 110.787 -0.079 . . . . 0.0 110.787 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.539 ' O ' ' CE1' ' E' ' 14' ' ' HIS . 78.2 m80 -128.62 102.04 6.42 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 m170 -95.23 158.15 15.59 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 121.904 0.859 . . . . 0.0 111.162 -179.179 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 29.6 mm100 -152.61 171.34 18.31 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 114.023 -1.444 . . . . 0.0 107.905 178.342 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -174.1 128.67 0.37 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 121.014 -0.275 . . . . 0.0 110.275 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.474 HD21 HG11 ' F' ' 36' ' ' VAL . 8.8 mt -120.74 119.46 32.83 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 120.451 -0.5 . . . . 0.0 111.103 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -128.99 119.47 49.43 Favored 'Isoleucine or valine' 0 C--N 1.341 0.201 0 C-N-CA 120.636 -0.426 . . . . 0.0 111.359 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -113.03 116.66 30.28 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' OE2' ' D' ' 22' ' ' GLU . 9.0 t80 -129.5 119.4 23.66 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.13 0.423 . . . . 0.0 110.152 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.76 127.58 43.84 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 78.6 mm-40 -121.49 112.31 18.36 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 179.214 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 24' ' ' VAL . 19.9 t0 -84.35 97.34 9.41 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.622 ' O ' ' N ' ' D' ' 26' ' ' SER . 14.0 t -103.61 168.73 2.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.607 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.495 ' N ' ' CG1' ' D' ' 24' ' ' VAL . . . 39.36 -78.31 0.0 OUTLIER Glycine 0 CA--C 1.527 0.783 0 CA-C-O 119.448 -0.64 . . . . 0.0 112.631 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.622 ' N ' ' O ' ' D' ' 24' ' ' VAL . 1.4 p 170.98 -170.83 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 117.895 0.848 . . . . 0.0 111.552 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.592 ' O ' ' O ' ' D' ' 26' ' ' SER . 20.5 m-80 -18.68 -172.11 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -179.126 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.554 ' H ' ' HD3' ' E' ' 28' ' ' LYS . 86.0 tttt 127.2 104.46 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 111.217 -2.719 . . . . 0.0 110.48 177.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.6 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -59.9 96.28 0.08 OUTLIER Glycine 0 CA--C 1.491 -1.438 0 CA-C-O 118.337 -1.257 . . . . 0.0 110.559 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.464 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . -117.61 150.36 39.15 Favored 'General case' 0 CA--C 1.467 -2.224 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 174.707 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.464 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 0.3 OUTLIER -150.51 122.03 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 118.049 -1.461 . . . . 0.0 110.278 -171.973 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.415 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.1 OUTLIER -105.87 119.01 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 114.187 -1.369 . . . . 0.0 110.375 -179.091 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.623 ' O ' HD23 ' D' ' 34' ' ' LEU . . . -123.86 101.55 0.69 Allowed Glycine 0 N--CA 1.464 0.554 0 N-CA-C 108.093 -2.003 . . . . 0.0 108.093 178.598 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.764 HD23 ' H ' ' C' ' 34' ' ' LEU . 16.8 mt -139.09 152.03 47.19 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.378 -0.929 . . . . 0.0 112.326 -176.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.591 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 35.2 ttp -126.36 118.16 24.46 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 176.639 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 40.1 t -127.06 70.22 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.57 -102.62 2.75 Favored Glycine 0 C--N 1.36 1.884 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.422 ' H ' HG21 ' J' ' 31' ' ' ILE . . . 77.73 170.21 34.72 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -140.29 140.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.854 0.359 . . . . 0.0 110.232 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.43 -179.824 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.434 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -146.26 162.09 38.86 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.897 0.379 . . . . 0.0 110.458 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 11' ' ' GLU . . . . . 0.533 ' N ' ' OE1' ' E' ' 11' ' ' GLU . 56.1 mp0 -130.91 144.16 51.26 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.587 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.52 HG13 ' H ' ' D' ' 13' ' ' HIS . 46.9 t -115.65 131.63 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 179.524 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' D' ' 13' ' ' HIS . 85.9 m-70 -109.99 160.56 16.32 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 118.532 0.605 . . . . 0.0 111.949 -178.634 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.539 ' CE1' ' O ' ' D' ' 13' ' ' HIS . 98.0 m-70 -152.14 174.44 13.72 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.279 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mm-40 -119.75 -171.02 2.05 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -97.77 175.72 6.07 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 122.504 1.145 . . . . 0.0 113.945 -176.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.1 tt -120.81 121.47 38.24 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 113.407 -1.724 . . . . 0.0 106.986 178.001 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.57 138.66 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-O 121.524 0.678 . . . . 0.0 112.616 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -124.21 124.51 42.62 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.578 -1.192 . . . . 0.0 109.007 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -131.2 122.55 26.77 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.86 127.87 42.72 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 120.861 0.362 . . . . 0.0 111.025 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 80.1 tt0 -92.91 144.48 25.23 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.814 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.612 ' O ' ' O ' ' E' ' 24' ' ' VAL . 41.5 p-10 -71.21 -122.34 0.0 OUTLIER 'General case' 0 C--O 1.218 -0.562 0 CA-C-N 116.304 -0.407 . . . . 0.0 109.982 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.612 ' O ' ' O ' ' E' ' 23' ' ' ASP . 87.3 t 19.84 122.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.58 -84.19 0.09 OUTLIER Glycine 0 CA--C 1.522 0.514 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.69 177.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.529 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.4 p 154.18 -179.23 0.0 OUTLIER 'General case' 0 C--N 1.345 0.382 0 CA-C-O 122.58 1.181 . . . . 0.0 111.006 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.426 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 1.8 m-20 -52.63 -178.94 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 112.44 -2.163 . . . . 0.0 112.643 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.554 ' HD3' ' H ' ' D' ' 28' ' ' LYS . 0.0 OUTLIER 60.66 113.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 123.017 1.389 . . . . 0.0 114.385 -179.521 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -88.26 96.22 2.17 Favored Glycine 0 C--O 1.224 -0.522 0 CA-C-N 111.687 -2.506 . . . . 0.0 112.727 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -63.95 175.44 1.19 Allowed 'General case' 0 C--O 1.24 0.596 0 CA-C-N 119.882 1.841 . . . . 0.0 107.461 -178.548 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.428 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.1 OUTLIER -152.39 129.65 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.421 0 C-N-CA 116.736 -1.986 . . . . 0.0 114.606 -172.451 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mt -107.67 121.04 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.072 177.237 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.3 104.59 0.82 Allowed Glycine 0 C--N 1.332 0.332 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.775 HD12 ' N ' ' E' ' 35' ' ' MET . 3.4 tp -150.31 135.3 17.73 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.461 1.124 . . . . 0.0 112.584 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.775 ' N ' HD12 ' E' ' 34' ' ' LEU . 33.8 ttp -102.26 126.3 49.22 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.762 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.39 70.94 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.9 114.08 5.88 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.05 -139.49 0.14 Allowed Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -119.01 136.7 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 120.755 0.312 . . . . 0.0 110.527 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 20.6 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.408 179.824 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.52 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 58.3 t . . . . . 0 N--CA 1.468 0.466 0 CA-C-O 120.841 0.353 . . . . 0.0 110.44 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.52 ' CG ' ' O ' ' F' ' 12' ' ' VAL . 78.9 m80 -161.28 99.39 1.18 Allowed 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.817 179.59 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -153.74 163.99 39.08 Favored 'General case' 0 N--CA 1.447 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 109.9 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -158.27 177.43 11.28 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.792 179.022 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -142.53 139.83 31.58 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 121.16 0.505 . . . . 0.0 110.574 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 39.5 mt -113.33 127.94 56.3 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.17 138.26 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.535 0.683 . . . . 0.0 111.694 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.0 p90 -132.47 131.03 41.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.765 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -136.44 130.15 32.22 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.99 144.31 25.75 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.633 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.467 ' HB2' ' H ' ' E' ' 23' ' ' ASP . 73.0 mm-40 -99.27 161.27 13.71 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 59.9 m-20 . . . . . 0 N--CA 1.465 0.292 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.531 -179.213 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 23.8 tttm . . . . . 0 CA--C 1.536 0.418 0 CA-C-O 121.588 0.708 . . . . 0.0 111.89 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 45.82 91.36 0.01 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 114.632 -1.167 . . . . 0.0 114.577 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.429 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -103.15 176.41 5.16 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 100.204 -3.998 . . . . 0.0 100.204 172.2 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.459 HG22 ' SD ' ' L' ' 35' ' ' MET . 0.1 OUTLIER -149.76 122.38 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 C-N-CA 115.986 -2.285 . . . . 0.0 112.566 -175.053 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -104.81 111.38 34.1 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.441 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.304 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.01 89.98 0.56 Allowed Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 107.102 -2.399 . . . . 0.0 107.102 175.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.659 HD21 HG13 ' F' ' 36' ' ' VAL . 9.2 tt -126.86 127.84 45.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 39.5 ttp -106.04 129.47 54.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.59 -178.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.659 HG13 HD21 ' F' ' 34' ' ' LEU . 0.0 OUTLIER -132.55 78.48 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.08 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.05 104.35 1.32 Allowed Glycine 0 C--N 1.344 1.019 0 N-CA-C 111.269 -0.732 . . . . 0.0 111.269 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.64 -164.84 33.99 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 63.1 t -120.54 135.65 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.887 0.375 . . . . 0.0 110.178 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 37.9 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.574 179.952 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.83 138.84 49.73 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.719 0.295 . . . . 0.0 110.564 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 11' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' G' ' 11' ' ' GLU . 57.8 mp0 -76.92 134.1 39.04 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.493 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 21.9 m -137.7 165.82 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.857 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 64.6 m80 -154.99 135.14 13.09 Favored 'General case' 0 C--O 1.222 -0.371 0 C-N-CA 120.241 -0.584 . . . . 0.0 111.169 179.133 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -156.74 165.7 35.48 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 96.3 mm-40 -150.59 177.47 10.0 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.865 179.595 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -158.61 129.68 6.32 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.056 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -133.86 128.93 35.66 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 121.097 0.475 . . . . 0.0 110.421 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.17 130.76 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.38 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.435 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 2.6 t80 -116.65 114.31 23.89 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.532 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 54.5 p90 -124.19 121.14 34.3 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.68 125.3 50.44 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.112 0.482 . . . . 0.0 111.222 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -161.44 166.51 27.14 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' ND2' ' H' ' 27' ' ' ASN . 63.3 t0 -79.0 114.84 18.28 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.075 -0.65 . . . . 0.0 111.077 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.0 p -88.57 130.83 37.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.82 82.43 0.0 OUTLIER Glycine 0 CA--C 1.531 1.058 0 CA-C-N 116.055 -0.52 . . . . 0.0 112.803 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.535 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.3 m -132.23 162.47 30.88 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 178.23 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.531 ' O ' ' O ' ' G' ' 26' ' ' SER . 80.6 m-20 -38.74 175.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.241 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -73.62 111.15 8.49 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.38 93.97 0.19 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.31 162.06 13.2 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.045 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -146.72 104.02 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -174.631 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.508 ' O ' ' SD ' ' B' ' 35' ' ' MET . 85.5 mt -126.89 127.93 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.242 0.544 . . . . 0.0 111.126 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.57 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -133.15 113.22 1.2 Allowed Glycine 0 CA--C 1.517 0.158 0 N-CA-C 108.934 -1.666 . . . . 0.0 108.934 178.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -136.69 147.87 47.05 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 122.221 1.01 . . . . 0.0 112.726 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 49.4 ttp -131.24 132.04 44.35 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.734 -1.575 . . . . 0.0 109.591 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.1 t -99.86 72.01 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.22 -96.45 0.01 OUTLIER Glycine 0 N--CA 1.438 -1.17 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.26 -172.11 33.47 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.43 ' O ' ' OXT' ' G' ' 40' ' ' VAL . 2.7 p -139.2 142.92 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 40' ' ' VAL . . . . . 0.47 ' O ' HG12 ' G' ' 40' ' ' VAL . 53.7 t . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.014 -0.993 . . . . 0.0 110.069 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.49 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -115.21 140.62 48.94 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.671 0.272 . . . . 0.0 110.476 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -81.23 142.33 33.27 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.452 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.421 ' O ' HG23 ' H' ' 12' ' ' VAL . 6.2 m -121.76 131.82 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.415 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -118.93 140.62 49.69 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.733 0.301 . . . . 0.0 111.599 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.47 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 45.1 m-70 -142.31 160.61 39.92 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.345 0.593 . . . . 0.0 109.812 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.47 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 98.5 mm-40 -149.1 172.45 14.78 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.128 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -159.48 117.37 2.74 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.062 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -119.26 119.91 35.45 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -125.5 126.73 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.837 0.351 . . . . 0.0 110.534 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.647 ' CE1' HD11 ' K' ' 34' ' ' LEU . 1.4 t80 -123.06 118.77 28.5 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 72.1 t80 -131.23 127.91 38.83 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.756 0.312 . . . . 0.0 111.288 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.7 123.96 30.47 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-O 120.886 0.374 . . . . 0.0 111.557 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -165.64 140.87 4.95 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 45.4 p30 -100.13 140.53 34.23 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.453 0.644 . . . . 0.0 112.509 -178.435 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.408 ' O ' ' C ' ' H' ' 25' ' ' GLY . 92.5 t -108.4 111.12 34.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' H' ' 24' ' ' VAL . . . 33.63 90.97 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 -177.532 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -46.45 152.74 0.42 Allowed 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.169 -1.015 . . . . 0.0 113.538 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.537 ' O ' ' O ' ' H' ' 28' ' ' LYS . 16.8 p30 -128.19 -179.97 5.29 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 114.189 -1.369 . . . . 0.0 107.823 174.54 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.537 ' O ' ' O ' ' H' ' 27' ' ' ASN . 84.4 tttt -27.51 -102.71 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.727 0.694 . . . . 0.0 111.885 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.413 ' CA ' ' O ' ' I' ' 29' ' ' GLY . . . -149.96 100.36 0.21 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 175.271 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.415 ' H ' ' CE ' ' I' ' 28' ' ' LYS . . . -65.56 155.45 35.7 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 117.064 -1.854 . . . . 0.0 108.336 177.063 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.814 HG21 ' O ' ' B' ' 37' ' ' GLY . 2.2 mt -144.45 108.17 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -128.35 129.71 69.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.419 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.63 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.68 119.5 3.68 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 108.314 -1.915 . . . . 0.0 108.314 177.645 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.752 ' HB2' HD12 ' I' ' 34' ' ' LEU . 95.1 mt -135.31 129.45 33.51 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -177.083 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.491 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 24.0 ttp -129.55 131.87 46.69 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.338 178.759 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.631 ' CG1' HG12 ' I' ' 36' ' ' VAL . 2.4 p -149.47 75.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 119.999 -0.68 . . . . 0.0 112.325 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.74 -95.56 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 178.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -165.08 37.72 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.77 141.78 41.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.893 0.377 . . . . 0.0 110.353 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 27.9 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.645 -179.996 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.574 ' CE1' ' HD1' ' J' ' 13' ' ' HIS . 32.9 p80 -156.24 156.19 33.67 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.767 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' I' ' 15' ' ' GLN . 16.2 m-70 -133.37 161.19 35.2 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.696 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' I' ' 14' ' ' HIS . 43.6 mm-40 -142.59 171.71 13.68 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.521 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -159.51 120.49 3.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.103 178.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 tt -125.3 124.38 41.5 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 120.803 0.335 . . . . 0.0 110.48 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.59 125.32 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.408 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.541 ' CZ ' HD13 ' K' ' 34' ' ' LEU . 12.2 t80 -118.97 113.24 20.68 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.552 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 47.6 t80 -126.45 116.82 21.73 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 121.076 0.465 . . . . 0.0 111.058 -178.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.71 126.71 47.02 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.244 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -146.65 103.86 3.69 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.077 0.465 . . . . 0.0 110.818 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.434 ' O ' HG12 ' J' ' 24' ' ' VAL . 99.4 m-20 -95.31 122.82 38.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.496 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.48 HG23 ' H ' ' I' ' 25' ' ' GLY . 3.6 m -143.5 -111.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.854 -178.699 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.48 ' H ' HG23 ' I' ' 24' ' ' VAL . . . 27.39 -90.2 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.433 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.826 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.1 p 171.54 171.0 0.09 Allowed 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.826 ' O ' ' O ' ' I' ' 26' ' ' SER . 44.5 p-10 -9.51 179.27 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 O-C-N 125.869 1.981 . . . . 0.0 115.745 178.09 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.564 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 85.8 tttt 129.64 104.69 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 114.052 1.13 . . . . 0.0 114.052 175.658 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.413 ' O ' ' CA ' ' H' ' 29' ' ' GLY . . . -58.46 96.81 0.07 OUTLIER Glycine 0 C--O 1.225 -0.422 0 N-CA-C 106.711 -2.556 . . . . 0.0 106.711 171.133 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.891 ' C ' HD13 ' I' ' 31' ' ' ILE . . . -120.88 146.04 47.01 Favored 'General case' 0 CA--C 1.48 -1.729 0 N-CA-C 105.112 -2.181 . . . . 0.0 105.112 178.144 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.891 HD13 ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -137.84 108.04 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 C-N-CA 119.343 -0.943 . . . . 0.0 111.088 -173.854 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -111.65 112.5 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 175.779 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.666 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.05 108.74 1.69 Allowed Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 177.029 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.752 HD12 ' HB2' ' H' ' 34' ' ' LEU . 0.9 OUTLIER -142.39 144.0 32.94 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-O 122.673 1.225 . . . . 0.0 113.352 -177.082 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.445 ' N ' ' HG ' ' I' ' 34' ' ' LEU . 12.7 tmm? -127.42 117.95 23.14 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 113.196 -1.82 . . . . 0.0 109.626 177.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.747 HG13 HD21 ' I' ' 34' ' ' LEU . 15.7 m -121.91 73.94 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.822 179.235 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.36 103.48 2.99 Favored Glycine 0 C--N 1.36 1.883 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 175.88 43.96 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -144.94 151.45 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 120.891 0.376 . . . . 0.0 110.774 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.412 ' O ' HG13 ' I' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.567 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.447 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -111.1 132.55 54.18 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.781 0.324 . . . . 0.0 110.266 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' K' ' 11' ' ' GLU . 17.1 pt-20 -158.56 138.26 11.93 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.053 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -150.23 153.4 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.574 ' HD1' ' CE1' ' I' ' 13' ' ' HIS . 50.5 m-70 -144.21 116.05 8.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 118.966 0.803 . . . . 0.0 110.966 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.64 ' NE2' ' CG ' ' K' ' 13' ' ' HIS . 44.3 m80 -122.0 159.88 26.06 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.386 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.408 HE21 ' HG3' ' I' ' 15' ' ' GLN . 63.2 mt-30 -158.12 177.06 11.72 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.412 178.615 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 43.5 tttp -169.43 123.32 0.79 Allowed 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.427 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 8.8 tt -121.21 121.87 38.73 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.634 0.254 . . . . 0.0 110.328 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 79.2 t -124.28 127.48 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.493 ' CZ ' ' CD1' ' I' ' 19' ' ' PHE . 5.4 t80 -126.53 121.35 32.04 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.907 0.384 . . . . 0.0 110.72 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.552 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 50.7 t80 -128.93 127.18 41.24 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.003 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.34 137.53 30.61 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -142.58 106.0 4.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.131 -0.941 . . . . 0.0 109.272 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.448 ' OD1' HD11 ' L' ' 32' ' ' ILE . 10.3 m-20 -96.59 108.91 21.59 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.049 -179.075 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.434 HG12 ' O ' ' I' ' 23' ' ' ASP . 2.1 p -46.1 140.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.256 178.633 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.626 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -86.12 84.85 1.56 Allowed Glycine 0 CA--C 1.531 1.091 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.423 -178.631 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.59 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.3 t 162.36 160.41 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 CA-C-O 121.212 0.53 . . . . 0.0 110.12 176.203 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.59 ' O ' ' O ' ' J' ' 26' ' ' SER . 7.2 t-20 -29.99 178.99 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.517 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 42.6 tttp 128.45 104.85 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 113.052 -1.886 . . . . 0.0 112.899 175.189 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.84 95.43 0.05 OUTLIER Glycine 0 N--CA 1.462 0.429 0 CA-C-N 113.057 -1.883 . . . . 0.0 112.782 173.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.739 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -140.21 141.06 35.97 Favored 'General case' 0 CA--C 1.49 -1.364 0 CA-C-N 120.751 2.275 . . . . 0.0 107.353 174.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.739 HD13 ' C ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -137.73 106.94 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.894 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.468 HG22 ' O ' ' J' ' 32' ' ' ILE . 0.1 OUTLIER -109.75 110.84 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.018 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.591 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -123.78 98.82 0.6 Allowed Glycine 0 N--CA 1.463 0.436 0 N-CA-C 107.312 -2.315 . . . . 0.0 107.312 178.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.667 HD23 HD22 ' I' ' 34' ' ' LEU . 5.5 mp -131.07 140.75 50.09 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-O 122.134 0.969 . . . . 0.0 111.786 -177.706 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.416 ' SD ' HG22 ' D' ' 31' ' ' ILE . 11.5 tmm? -124.18 121.44 35.11 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.513 179.172 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' J' ' 37' ' ' GLY . 0.1 OUTLIER -110.43 73.74 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.178 -178.75 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -24.9 -101.18 0.01 OUTLIER Glycine 0 C--N 1.355 1.62 0 CA-C-N 116.198 -0.456 . . . . 0.0 112.851 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 131.24 -174.54 19.94 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -133.7 160.44 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 110.357 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.548 -179.934 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.74 133.35 51.55 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 110.267 -0.271 . . . . 0.0 110.267 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' J' ' 11' ' ' GLU . 81.4 tt0 -156.18 141.18 17.27 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-O 120.944 0.402 . . . . 0.0 110.711 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.34 154.57 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.64 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 22.3 m-70 -125.64 144.56 50.54 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 118.608 0.64 . . . . 0.0 110.725 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.522 ' CG ' ' H ' ' K' ' 15' ' ' GLN . 30.9 t-80 -86.71 -178.25 6.31 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.499 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.522 ' H ' ' CG ' ' K' ' 14' ' ' HIS . 86.5 mt-30 -84.85 172.69 11.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.148 -178.522 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -146.25 133.01 19.99 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 114.825 -1.08 . . . . 0.0 108.575 179.023 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -131.42 131.57 43.7 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.225 0.536 . . . . 0.0 112.274 -178.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.6 t -126.77 127.7 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.836 178.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -128.86 128.2 43.39 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.561 0.22 . . . . 0.0 110.795 -178.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.435 ' CE2' ' CD2' ' L' ' 20' ' ' PHE . 8.8 t80 -135.76 123.43 22.33 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-O 120.906 0.384 . . . . 0.0 110.517 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.51 129.33 44.39 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.113 0.483 . . . . 0.0 111.312 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.094 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.492 ' H ' ' HB3' ' L' ' 22' ' ' GLU . 26.3 t70 -91.85 134.25 34.93 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.429 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.626 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 44.0 t -109.19 112.46 40.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.27 -91.29 0.01 OUTLIER Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.21 -0.905 . . . . 0.0 112.783 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.504 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.8 m -162.86 -161.11 0.68 Allowed 'General case' 0 N--CA 1.447 -0.615 0 CA-C-O 122.579 1.181 . . . . 0.0 112.867 -179.406 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.572 ' CG ' ' H ' ' K' ' 28' ' ' LYS . 4.4 t-20 30.08 -173.28 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 111.874 -2.421 . . . . 0.0 115.401 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.572 ' H ' ' CG ' ' K' ' 27' ' ' ASN . 82.3 tttt 103.56 110.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 127.136 2.174 . . . . 0.0 109.184 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -60.16 -95.16 0.01 OUTLIER Glycine 0 CA--C 1.535 1.3 0 C-N-CA 115.212 -3.375 . . . . 0.0 110.535 175.519 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.521 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 69.63 151.21 0.09 Allowed 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 174.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.521 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -149.25 117.88 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-N 120.974 1.716 . . . . 0.0 111.508 178.075 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.413 ' N ' ' HE1' ' F' ' 35' ' ' MET . 4.6 mt -105.38 111.85 36.44 Favored 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 175.691 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.585 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.84 96.77 0.75 Allowed Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 106.315 -2.714 . . . . 0.0 106.315 177.242 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.647 HD11 ' CE1' ' H' ' 19' ' ' PHE . 0.3 OUTLIER -120.93 120.37 35.29 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-O 122.304 1.05 . . . . 0.0 110.201 -177.971 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -109.53 114.08 27.42 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.412 -1.722 . . . . 0.0 107.965 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.18 78.38 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.829 -177.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.48 105.43 0.97 Allowed Glycine 0 C--N 1.352 1.472 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.71 -144.01 4.35 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -106.79 134.7 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 20.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.021 -0.99 . . . . 0.0 111.073 -179.579 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.542 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -84.52 139.9 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.723 0.297 . . . . 0.0 110.855 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -121.52 131.03 53.91 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.971 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.98 156.79 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.179 0.514 . . . . 0.0 111.252 -179.704 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -158.19 163.21 37.74 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.787 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 41.9 m80 -136.74 169.8 17.13 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -148.08 176.29 10.32 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.174 0.512 . . . . 0.0 111.304 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 ttpt -170.59 111.46 0.39 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.983 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 72.0 mt -121.22 111.37 17.3 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.478 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 70.4 t -126.64 129.95 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.7 p90 -136.94 125.28 23.3 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.299 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.435 ' CD2' ' CE2' ' K' ' 20' ' ' PHE . 79.4 t80 -136.8 131.57 33.5 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 121.123 0.487 . . . . 0.0 110.297 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.74 143.75 35.15 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.393 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.492 ' HB3' ' H ' ' K' ' 23' ' ' ASP . 51.8 tp10 -78.21 140.96 38.92 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -58.86 130.46 47.05 Favored 'General case' 0 CA--C 1.518 -0.275 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.451 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.602 ' O ' HG13 ' L' ' 24' ' ' VAL . 14.7 p -116.12 114.84 47.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.279 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.443 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -28.28 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.47 0.927 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -88.45 -177.4 5.61 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 60.3 m-20 -60.29 179.62 0.14 Allowed 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.477 -176.491 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.551 ' HZ3' HG13 ' L' ' 32' ' ' ILE 0.251 69.1 tttt -57.45 111.36 1.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 -177.015 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -68.62 -97.71 0.04 OUTLIER Glycine 0 CA--C 1.499 -0.932 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.586 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -60.9 170.78 1.4 Allowed 'General case' 0 CA--C 1.511 -0.552 0 CA-C-N 120.844 2.322 . . . . 0.0 105.805 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.649 HD12 ' N ' ' L' ' 31' ' ' ILE . 0.1 OUTLIER -134.17 121.79 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 115.811 -2.356 . . . . 0.0 114.086 -174.327 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.551 HG13 ' HZ3' ' L' ' 28' ' ' LYS . 97.3 mt -106.41 116.07 49.36 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 176.261 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -106.29 96.73 1.17 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 105.71 -2.956 . . . . 0.0 105.71 176.708 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.456 HD23 HG22 ' L' ' 32' ' ' ILE . 1.2 pp -110.23 112.09 23.84 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.751 -0.725 . . . . 0.0 110.298 -177.493 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.459 ' SD ' HG22 ' F' ' 31' ' ' ILE . 8.6 tmm? -109.69 110.85 22.01 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 178.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' C ' ' L' ' 37' ' ' GLY . 3.3 m -126.93 77.42 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.681 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 22.29 -110.69 0.01 OUTLIER Glycine 0 C--N 1.356 1.654 0 O-C-N 123.106 0.254 . . . . 0.0 113.017 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.79 140.85 8.9 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -134.89 159.24 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.886 0.375 . . . . 0.0 110.46 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.128 -0.939 . . . . 0.0 110.764 -179.885 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 m . . . . . 0 N--CA 1.465 0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 111.846 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 5.4 p80 -97.15 -175.58 3.28 Favored 'General case' 0 CA--C 1.527 0.086 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.838 178.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.5 p-80 -89.85 164.98 14.39 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.44 0.638 . . . . 0.0 110.619 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 83.0 mt-30 -155.99 -178.2 7.13 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.684 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.611 ' C ' HD22 ' A' ' 17' ' ' LEU . 99.6 mttt -135.29 111.69 9.82 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.372 -0.232 . . . . 0.0 110.372 179.269 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.611 HD22 ' C ' ' A' ' 16' ' ' LYS . 4.3 mm? -117.81 127.8 54.24 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 120.792 0.33 . . . . 0.0 110.515 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 18' ' ' VAL . 5.8 m -133.04 128.39 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-O 121.149 0.5 . . . . 0.0 111.125 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.519 ' CZ ' HD23 ' C' ' 34' ' ' LEU . 75.0 t80 -122.69 116.13 23.27 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -147.08 153.84 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.343 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.0 133.81 43.62 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.209 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -167.49 92.21 0.38 Allowed 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 62.5 t0 -70.11 121.82 18.24 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -177.581 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.565 ' O ' HG23 ' A' ' 24' ' ' VAL . 26.1 m -105.98 121.72 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.637 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . 30.8 82.8 0.01 OUTLIER Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.847 -0.418 . . . . 0.0 112.255 178.398 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.9 p -95.8 175.65 6.43 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 118.059 0.93 . . . . 0.0 109.182 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' LYS . 20.1 p30 -61.93 -177.67 0.13 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 176.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.548 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.6 mttm -50.41 -110.85 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.846 0.832 . . . . 0.0 109.842 178.615 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.66 94.66 1.82 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 176.39 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.479 ' CB ' HD21 ' A' ' 27' ' ' ASN . . . -92.54 160.65 14.94 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 115.599 -2.441 . . . . 0.0 109.703 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.537 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.3 OUTLIER -154.31 119.68 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 114.0 -1.455 . . . . 0.0 109.878 -173.729 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.51 ' O ' ' SD ' ' G' ' 35' ' ' MET . 96.5 mt -119.44 112.45 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.103 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.21 106.64 1.45 Allowed Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 178.335 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.407 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 34.7 tp -149.11 147.19 28.19 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 118.124 0.962 . . . . 0.0 113.028 -178.417 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.511 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 53.5 ttp -141.43 146.35 36.42 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.2 t -128.89 79.61 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.949 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.51 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -96.99 97.85 2.06 Favored Glycine 0 C--N 1.338 0.681 0 N-CA-C 109.599 -1.401 . . . . 0.0 109.599 177.483 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.13 167.81 39.68 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.541 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.465 0.293 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.405 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.465 0.28 0 CA-C-O 120.747 0.308 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -117.09 160.1 21.53 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.1 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 16.3 p-80 -77.34 171.94 14.08 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.432 ' H ' ' HA ' ' C' ' 15' ' ' GLN . 54.0 tt0 -149.48 176.0 11.0 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.578 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.558 ' NZ ' ' CG2' ' B' ' 18' ' ' VAL . 62.4 tttm -140.3 123.3 16.59 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.233 0.54 . . . . 0.0 111.407 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.1 mt -118.37 124.08 46.86 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.093 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.558 ' CG2' ' NZ ' ' B' ' 16' ' ' LYS . 93.7 t -119.56 121.45 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 C-N-CA 120.711 -0.395 . . . . 0.0 110.998 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 11.8 t80 -115.2 112.22 22.16 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -132.59 125.76 31.21 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.18 0.514 . . . . 0.0 112.238 -177.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.66 126.28 49.85 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -153.96 159.75 41.81 Favored 'General case' 0 C--N 1.348 0.512 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.061 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -121.46 123.06 41.15 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.535 0.607 . . . . 0.0 111.885 -178.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.17 120.88 55.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.18 84.11 0.01 OUTLIER Glycine 0 N--CA 1.471 0.986 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.445 179.328 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 4.3 p -45.88 167.61 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.499 ' O ' ' O ' ' B' ' 28' ' ' LYS . 1.3 p-10 -137.82 178.87 6.78 Favored 'General case' 0 C--O 1.203 -1.383 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 171.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.499 ' O ' ' O ' ' B' ' 27' ' ' ASN . 61.2 mttp -19.85 -103.13 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 CA-C-N 120.219 1.372 . . . . 0.0 113.338 176.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -142.62 99.94 0.24 Allowed Glycine 0 N--CA 1.485 1.962 0 N-CA-C 107.831 -2.108 . . . . 0.0 107.831 174.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.511 ' H ' ' CE ' ' C' ' 28' ' ' LYS . . . -70.6 156.55 39.3 Favored 'General case' 0 C--O 1.245 0.836 0 C-N-CA 117.064 -1.854 . . . . 0.0 109.399 177.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.537 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.2 OUTLIER -144.25 115.49 2.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.814 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.481 ' O ' ' SD ' ' H' ' 35' ' ' MET . 82.9 mt -121.13 119.62 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -177.118 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.51 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -125.37 117.15 2.87 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 177.801 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.72 ' O ' HD12 ' C' ' 34' ' ' LEU . 9.6 tt -148.8 154.67 39.87 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.532 -178.487 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 17.6 ttp -147.83 141.57 25.66 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 120.16 -0.616 . . . . 0.0 112.458 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' B' ' 37' ' ' GLY . 38.2 t -131.78 83.28 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.307 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.682 ' HA2' HG21 ' H' ' 31' ' ' ILE . . . -23.45 -93.71 0.01 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.818 -0.513 . . . . 0.0 111.818 177.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.88 179.16 40.33 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.404 HG22 ' N ' ' B' ' 40' ' ' VAL . 8.3 p -143.95 153.09 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.937 0.398 . . . . 0.0 110.821 -179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.404 ' N ' HG22 ' B' ' 39' ' ' VAL . 7.2 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.46 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -111.51 146.95 36.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 110.378 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -55.84 146.19 22.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.16 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.513 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 32.9 m -129.28 156.31 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.513 ' CD2' ' O ' ' C' ' 12' ' ' VAL . 48.2 m80 -158.01 151.71 23.75 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.405 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -87.39 -179.67 6.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.432 ' HA ' ' H ' ' B' ' 15' ' ' GLN . 13.1 pt20 -88.2 174.91 7.94 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.958 -179.374 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -123.85 138.77 54.44 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -141.62 131.65 24.62 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 120.422 -0.511 . . . . 0.0 111.764 -179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -126.55 130.42 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.307 0.575 . . . . 0.0 109.706 178.362 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.523 ' CE2' HD12 ' F' ' 34' ' ' LEU . 21.2 t80 -117.34 118.52 32.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.135 -178.579 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -130.35 114.9 16.18 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 118.147 0.43 . . . . 0.0 110.017 179.2 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.03 126.74 51.54 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.645 -0.422 . . . . 0.0 111.549 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -157.73 155.7 30.36 Favored 'General case' 0 C--O 1.226 -0.158 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.524 ' O ' ' NZ ' ' E' ' 28' ' ' LYS . 7.2 t0 -175.21 108.58 0.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 119.794 -0.762 . . . . 0.0 112.251 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 m -46.46 141.05 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 176.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -86.34 82.82 1.63 Allowed Glycine 0 N--CA 1.463 0.468 0 C-N-CA 118.471 -1.823 . . . . 0.0 110.159 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 50.7 p -100.48 -163.97 1.07 Allowed 'General case' 0 N--CA 1.439 -0.991 0 CA-C-O 122.432 1.11 . . . . 0.0 110.077 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.433 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 61.8 t30 -63.31 179.5 0.42 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.266 -1.788 . . . . 0.0 109.344 175.282 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.511 ' CE ' ' H ' ' B' ' 30' ' ' ALA . 41.5 tttt 55.35 111.08 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 118.424 2.75 . . . . 0.0 118.424 178.075 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -81.63 96.43 1.77 Allowed Glycine 0 CA--C 1.497 -1.088 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 171.759 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 163.67 22.1 Favored 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 116.22 -2.192 . . . . 0.0 108.278 -177.092 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.622 HG23 ' CG1' ' D' ' 31' ' ' ILE . 0.0 OUTLIER -139.86 108.06 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.013 -174.85 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.484 ' C ' ' SD ' ' I' ' 35' ' ' MET . 2.0 mt -106.78 117.9 53.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.406 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -122.96 94.25 0.51 Allowed Glycine 0 CA--C 1.523 0.577 0 N-CA-C 107.912 -2.075 . . . . 0.0 107.912 177.522 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.72 HD12 ' O ' ' B' ' 34' ' ' LEU . 22.7 tp -124.77 137.03 54.34 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.345 1.069 . . . . 0.0 112.048 -178.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' D' ' 35' ' ' MET . 11.3 mmm -110.97 116.38 31.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.835 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.498 HG13 HD11 ' C' ' 34' ' ' LEU . 2.6 m -142.88 63.45 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 C-N-CA 121.11 -0.236 . . . . 0.0 110.507 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.09 -110.31 0.79 Allowed Glycine 0 C--N 1.363 2.053 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.56 -175.2 34.03 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.92 158.69 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.602 -179.728 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p . . . . . 0 N--CA 1.466 0.365 0 CA-C-O 121.04 0.448 . . . . 0.0 111.54 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.448 ' NE2' ' OE2' ' E' ' 11' ' ' GLU . 86.8 m-70 -123.66 125.19 44.36 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.801 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.58 ' CG ' ' N ' ' D' ' 15' ' ' GLN . 82.5 t60 -136.94 166.84 22.71 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.163 0.506 . . . . 0.0 110.144 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.58 ' N ' ' CG ' ' D' ' 14' ' ' HIS . 51.9 tt0 -161.61 173.23 15.04 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.438 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.408 ' N ' ' HG2' ' D' ' 15' ' ' GLN . 65.1 tttp -160.92 110.12 1.65 Allowed 'General case' 0 C--O 1.235 0.307 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.95 179.136 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -122.0 115.82 23.21 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.911 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.4 t -114.35 115.61 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.572 ' CE1' HD13 ' F' ' 34' ' ' LEU . 0.8 OUTLIER -114.27 109.05 17.77 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -178.164 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -136.47 130.89 33.28 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.444 0.64 . . . . 0.0 111.621 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 21' ' ' ALA . . . . . 0.427 ' CB ' ' CD1' ' F' ' 32' ' ' ILE . . . -144.83 145.09 31.47 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.352 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -132.67 102.96 5.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.751 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -79.26 112.54 16.59 Favored 'General case' 0 C--O 1.231 0.119 0 C-N-CA 118.099 -1.44 . . . . 0.0 107.631 179.228 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 89.6 t -60.92 130.38 24.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.694 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -68.74 86.35 0.21 Allowed Glycine 0 CA--C 1.538 1.489 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.618 177.517 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.4 OUTLIER 162.18 161.3 0.02 OUTLIER 'General case' 0 C--N 1.345 0.393 0 CA-C-N 119.267 1.533 . . . . 0.0 112.786 176.801 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.462 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 87.1 m-20 -34.07 -179.65 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 112.056 -2.338 . . . . 0.0 116.25 179.119 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' E' ' 29' ' ' GLY . 86.7 tttt 98.92 114.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 128.095 2.558 . . . . 0.0 113.576 176.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.447 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -73.39 92.1 0.66 Allowed Glycine 0 N--CA 1.473 1.132 0 CA-C-O 116.284 -2.398 . . . . 0.0 113.159 173.478 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.87 157.09 35.01 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 123.271 3.536 . . . . 0.0 109.197 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.622 ' CG1' HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -145.01 126.1 8.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.892 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.725 -177.216 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.518 ' C ' ' SD ' ' J' ' 35' ' ' MET . 2.1 mt -110.49 110.48 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.408 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -109.21 95.57 0.91 Allowed Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 178.35 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.49 HD13 ' O ' ' C' ' 34' ' ' LEU . 0.0 OUTLIER -122.07 120.97 35.87 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-O 121.578 0.704 . . . . 0.0 110.461 -178.395 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' C' ' 35' ' ' MET . 26.9 ttt -102.02 114.04 27.8 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 176.725 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.475 HG22 HD12 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -126.51 80.64 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.247 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.437 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.22 102.46 0.86 Allowed Glycine 0 C--N 1.353 1.475 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.88 -167.06 38.9 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 40' ' ' VAL . 53.9 t -123.07 136.89 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 39' ' ' VAL . 18.0 m . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.47 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -111.61 133.13 54.07 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.855 0.359 . . . . 0.0 110.95 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 11' ' ' GLU . . . . . 0.448 ' OE2' ' NE2' ' D' ' 13' ' ' HIS . 39.1 tp10 -120.51 127.39 52.14 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.8 t -134.13 134.36 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 O-C-N 123.322 0.389 . . . . 0.0 110.466 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 83.6 m-70 -119.47 133.64 55.59 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 120.884 0.373 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.474 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 85.2 t60 -143.3 165.41 27.55 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 178.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.474 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 81.8 mt-30 -154.94 179.16 9.39 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.359 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.35 108.13 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.692 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -126.99 121.93 33.06 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.025 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 77.4 t -125.88 127.53 71.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.746 0.307 . . . . 0.0 110.881 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -126.47 120.53 29.94 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.514 179.369 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -133.9 127.36 32.34 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.027 0.442 . . . . 0.0 110.263 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.29 128.42 41.51 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.341 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -110.56 167.69 10.02 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.345 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' E' ' 24' ' ' VAL . 14.3 t0 -173.11 -125.28 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.389 -177.144 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.519 ' N ' ' OD1' ' E' ' 23' ' ' ASP . 7.9 t 31.61 115.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -90.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 106.001 -2.84 . . . . 0.0 106.001 179.266 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.544 ' O ' ' O ' ' E' ' 27' ' ' ASN . 27.9 p -152.03 155.0 37.1 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 119.224 1.512 . . . . 0.0 109.067 172.687 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.544 ' O ' ' O ' ' E' ' 26' ' ' SER . 88.7 m-20 -20.01 157.83 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 176.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.663 ' HB3' ' HB2' ' F' ' 30' ' ' ALA . 75.4 tttt -162.88 110.89 1.28 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.09 170.41 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.595 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -68.53 92.12 0.27 Allowed Glycine 0 C--O 1.218 -0.852 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 174.42 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.41 150.56 33.73 Favored 'General case' 0 CA--C 1.464 -2.345 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 175.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.426 ' HA ' ' O ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -151.24 117.24 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 C-N-CA 118.679 -1.208 . . . . 0.0 110.042 -172.948 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.56 112.99 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 33' ' ' GLY . . . . . 0.44 ' H ' ' HE1' ' J' ' 35' ' ' MET . . . -109.28 85.9 0.42 Allowed Glycine 0 CA--C 1.499 -0.963 0 N-CA-C 104.884 -3.286 . . . . 0.0 104.884 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.549 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 6.4 tt -130.31 134.05 46.91 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.787 0.803 . . . . 0.0 111.717 -177.496 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.7 ttm -122.91 125.34 45.15 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.484 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.58 ' CG2' HD21 ' F' ' 34' ' ' LEU . 0.0 OUTLIER -124.32 81.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.687 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.497 ' HA2' HD13 ' K' ' 31' ' ' ILE . . . 34.42 -101.66 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.681 -0.567 . . . . 0.0 111.681 178.231 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.94 -172.21 33.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.784 -0.927 . . . . 0.0 110.784 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.06 161.2 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.893 0.378 . . . . 0.0 110.595 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 8.8 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.362 179.788 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.401 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.3 p . . . . . 0 CA--C 1.52 -0.183 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.645 ' CG ' ' N ' ' F' ' 14' ' ' HIS . 46.4 t-80 -111.62 175.18 5.53 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.645 ' N ' ' CG ' ' F' ' 13' ' ' HIS . 98.1 m-70 -70.2 177.05 3.47 Favored 'General case' 0 N--CA 1.44 -0.936 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' E' ' 15' ' ' GLN . 57.7 mm-40 -133.26 179.19 6.35 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.278 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -151.29 106.06 3.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.21 0.528 . . . . 0.0 110.695 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 tt -127.81 121.58 30.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.182 179.412 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.51 129.93 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.532 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -120.1 128.1 53.15 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.577 179.133 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -142.37 130.14 21.62 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.973 0.416 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.53 141.02 26.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.474 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 74.4 tt0 -92.51 115.46 28.11 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.462 0.126 0 CA-C-O 121.169 0.509 . . . . 0.0 111.317 -178.801 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 43.9 tttm . . . . . 0 N--CA 1.463 0.178 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.79 -99.33 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 177.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' E' ' 28' ' ' LYS . . . -80.37 170.95 15.69 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 103.356 -2.831 . . . . 0.0 103.356 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' E' ' 31' ' ' ILE . 0.0 OUTLIER -138.94 117.13 12.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 118.043 -1.463 . . . . 0.0 111.398 -172.473 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.476 ' O ' HG23 ' F' ' 32' ' ' ILE . 12.9 tt -103.86 123.2 57.41 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.261 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.19 102.75 1.04 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.58 HD21 ' CG2' ' E' ' 36' ' ' VAL . 3.4 tt -122.95 113.36 18.99 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.351 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.473 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.3 ttt -95.39 121.88 37.53 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.606 -178.735 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.561 HG13 ' CD2' ' F' ' 34' ' ' LEU . 0.5 OUTLIER -138.3 80.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.614 -178.749 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 40.57 -103.25 0.03 OUTLIER Glycine 0 C--N 1.346 1.11 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.214 177.154 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -147.84 7.77 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 40' ' ' VAL . 55.9 t -121.41 136.39 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.874 0.368 . . . . 0.0 110.766 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 39' ' ' VAL . 2.3 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.592 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -108.15 137.93 45.29 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.482 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -125.33 145.67 49.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.077 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 7.4 m -119.78 134.79 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.134 0.492 . . . . 0.0 110.851 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -142.63 140.26 31.56 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.01 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -88.74 169.13 11.9 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.332 0.587 . . . . 0.0 110.532 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -151.4 177.67 10.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.486 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -137.58 129.11 28.27 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.665 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.5 tp -123.8 125.84 45.41 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -131.39 127.71 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.715 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.601 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 9.5 m-85 -113.58 117.5 31.81 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 176.595 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.518 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 39.9 p90 -130.37 118.02 20.61 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 121.034 -0.266 . . . . 0.0 111.558 -179.138 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 21' ' ' ALA . . . . . 0.484 ' O ' ' OE1' ' H' ' 22' ' ' GLU . . . -117.96 117.4 29.13 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.701 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.432 ' HG2' ' H ' ' G' ' 23' ' ' ASP . 68.4 tt0 -144.75 175.0 10.5 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 123.729 0.643 . . . . 0.0 109.815 -179.536 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.432 ' H ' ' HG2' ' G' ' 22' ' ' GLU . 15.8 t0 -64.85 113.55 3.9 Favored 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 112.025 0.379 . . . . 0.0 112.025 -178.274 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.442 ' H ' ' HA2' ' H' ' 25' ' ' GLY . 60.1 t -127.22 121.54 57.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.506 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' G' ' 24' ' ' VAL . . . -29.22 -85.87 0.01 OUTLIER Glycine 0 CA--C 1.535 1.317 0 CA-C-O 121.607 0.559 . . . . 0.0 113.481 179.044 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.6 t 65.7 176.2 0.22 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 -178.75 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -88.06 177.31 6.96 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.98 176.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -56.73 110.41 0.79 Allowed 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 118.612 -0.709 . . . . 0.0 111.895 175.209 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.507 ' H ' ' CB ' ' H' ' 27' ' ' ASN . . . 72.12 94.51 0.08 OUTLIER Glycine 0 N--CA 1.469 0.897 0 C-N-CA 118.165 -1.969 . . . . 0.0 112.391 174.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.87 156.13 19.02 Favored 'General case' 0 CA--C 1.507 -0.679 0 CA-C-N 120.004 1.902 . . . . 0.0 107.885 178.066 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.51 HG21 ' HA3' ' A' ' 37' ' ' GLY . 0.4 OUTLIER -152.53 106.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.347 -0.842 . . . . 0.0 108.835 -173.187 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.447 ' C ' ' SD ' ' A' ' 35' ' ' MET . 50.3 mm -124.56 130.57 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.103 -178.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.511 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -135.57 125.5 3.65 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 179.247 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.4 tp -144.82 136.85 25.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.258 0.529 . . . . 0.0 111.857 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.51 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 11.4 ttt -133.66 144.71 49.36 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.401 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.4 t -102.51 72.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.463 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -109.46 100.71 1.38 Allowed Glycine 0 C--N 1.341 0.837 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 177.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.93 170.96 41.62 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.423 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.449 HG22 HG23 ' G' ' 40' ' ' VAL . 5.6 p -135.8 143.33 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.52 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 40' ' ' VAL . . . . . 0.449 HG23 HG22 ' G' ' 39' ' ' VAL . 80.5 t . . . . . 0 C--O 1.218 -0.565 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.565 -179.372 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -82.46 145.46 29.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.732 0.301 . . . . 0.0 110.593 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.03 137.09 47.69 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-O 121.194 0.521 . . . . 0.0 110.751 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.1 t -121.75 134.03 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.546 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 t-80 -142.49 103.46 4.25 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.197 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.434 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 33.4 p-80 -152.23 168.7 24.5 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.484 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -150.58 171.96 16.27 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.151 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -134.45 118.39 17.32 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.245 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -118.57 121.33 39.96 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 62.3 t -124.43 126.28 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.976 0.417 . . . . 0.0 110.421 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.511 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 2.5 m-85 -119.16 108.91 15.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -117.17 115.62 25.68 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 177.372 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 21' ' ' ALA . . . . . 0.607 ' HB2' HD12 ' J' ' 32' ' ' ILE . . . -129.1 130.09 46.04 Favored 'General case' 0 C--O 1.242 0.671 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -177.519 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.566 ' O ' ' O ' ' H' ' 23' ' ' ASP . 52.4 mp0 -142.29 141.9 32.48 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.825 -1.534 . . . . 0.0 107.194 176.79 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.566 ' O ' ' O ' ' H' ' 22' ' ' GLU . 7.6 t0 -54.79 -130.63 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' H' ' 23' ' ' ASP . 32.7 m 28.49 111.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 178.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.442 ' HA2' ' H ' ' G' ' 24' ' ' VAL . . . -160.86 -91.24 0.08 OUTLIER Glycine 0 CA--C 1.521 0.428 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 177.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.473 ' HB2' ' HB2' ' H' ' 30' ' ' ALA . 0.1 OUTLIER -101.81 -163.2 0.99 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 119.551 1.676 . . . . 0.0 109.487 176.603 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.507 ' CB ' ' H ' ' G' ' 29' ' ' GLY . 66.5 t30 -61.8 177.62 0.41 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.777 177.566 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.489 ' H ' ' CG ' ' H' ' 27' ' ' ASN . 60.1 tttm -47.51 111.06 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.291 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 92.43 -95.71 2.05 Favored Glycine 0 C--O 1.207 -1.591 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.217 -176.649 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.605 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . 70.44 145.37 0.06 Allowed 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 103.141 -2.911 . . . . 0.0 103.141 -176.411 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.682 HG21 ' HA2' ' B' ' 37' ' ' GLY . 5.2 tt -163.34 124.61 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 115.783 -2.367 . . . . 0.0 112.266 -177.206 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.9 mt -120.22 122.94 69.61 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 113.947 -1.478 . . . . 0.0 109.951 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.28 117.08 2.46 Favored Glycine 0 N--CA 1.47 0.9 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.73 141.97 51.74 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.277 0.561 . . . . 0.0 111.127 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.51 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 23.2 ttt -140.39 126.58 19.8 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.127 0.489 . . . . 0.0 111.303 -178.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 11.8 t -122.68 74.06 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.024 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.42 101.49 2.32 Favored Glycine 0 C--N 1.344 1.023 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.65 159.13 31.78 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 120.245 -0.979 . . . . 0.0 111.722 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -125.9 134.64 66.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.885 -1.055 . . . . 0.0 110.552 -179.903 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.466 0.374 0 CA-C-O 120.884 0.373 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 48.2 m-70 -144.07 104.43 4.13 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.855 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.434 ' O ' ' CB ' ' H' ' 14' ' ' HIS . 7.2 m-70 -130.82 169.03 16.27 Favored 'General case' 0 C--O 1.221 -0.442 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 81.2 mt-30 -155.31 172.14 18.69 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 178.342 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -145.09 125.1 13.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.717 0.294 . . . . 0.0 111.279 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 37.9 tp -125.82 117.46 23.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 120.806 0.336 . . . . 0.0 110.35 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -122.59 127.96 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.934 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.478 ' CD2' HD23 ' L' ' 34' ' ' LEU . 1.1 m-85 -121.91 117.25 26.0 Favored 'General case' 0 N--CA 1.47 0.575 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.357 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.411 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 42.0 t80 -126.24 123.76 38.88 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.32 132.07 42.59 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.813 0.339 . . . . 0.0 111.412 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -155.93 157.33 36.09 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.767 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.505 ' HB2' ' HZ1' ' K' ' 28' ' ' LYS . 7.1 t70 -111.6 101.83 10.2 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 121.415 0.626 . . . . 0.0 110.655 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.9 p -90.01 159.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.068 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 49.64 -80.28 0.01 OUTLIER Glycine 0 CA--C 1.531 1.073 0 CA-C-O 119.382 -0.677 . . . . 0.0 112.955 -179.126 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.621 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.4 p 170.84 -179.53 0.05 OUTLIER 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 118.445 1.122 . . . . 0.0 110.577 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.621 ' O ' ' O ' ' I' ' 26' ' ' SER . 42.0 p-10 -28.31 -179.82 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 -177.596 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.445 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 83.9 mttt 128.77 103.38 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 111.828 -2.442 . . . . 0.0 108.571 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -59.25 100.32 0.18 Allowed Glycine 0 CA--C 1.486 -1.756 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.665 177.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' H' ' 29' ' ' GLY . . . -112.47 144.67 41.54 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 103.869 -2.641 . . . . 0.0 103.869 177.717 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.555 HD12 HD12 ' H' ' 31' ' ' ILE . 1.1 mt -137.98 107.21 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 C-N-CA 118.251 -1.38 . . . . 0.0 110.472 -174.137 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -117.66 130.75 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 120.981 0.42 . . . . 0.0 110.115 179.094 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -134.18 134.01 7.17 Favored Glycine 0 CA--C 1.503 -0.673 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 177.78 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.496 ' H ' ' HG ' ' J' ' 34' ' ' LEU . 3.8 tt -145.89 131.21 18.56 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.799 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.484 ' SD ' ' C ' ' C' ' 32' ' ' ILE . 8.7 ttt -112.91 119.75 39.04 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.263 -1.335 . . . . 0.0 108.395 179.117 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.1 OUTLIER -118.53 72.38 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.645 -179.504 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -31.15 -100.25 0.01 OUTLIER Glycine 0 C--N 1.369 2.373 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -175.89 40.73 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.1 t -134.37 152.48 33.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.497 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' J' J ' 9' ' ' GLY . . . . . 0.436 ' O ' ' CE2' ' K' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.367 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -123.15 119.37 30.05 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -137.36 134.2 35.71 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.589 0.233 . . . . 0.0 110.388 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.449 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -126.01 132.81 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.953 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' K' ' 13' ' ' HIS . 66.4 m80 -119.64 140.65 50.29 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.418 -0.216 . . . . 0.0 110.418 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 59.5 t60 -151.83 167.78 27.2 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 121.204 0.526 . . . . 0.0 109.77 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.6 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 66.7 tp60 -158.32 164.31 36.51 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.613 178.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.415 ' N ' ' HG3' ' J' ' 15' ' ' GLN . 50.3 tttp -157.99 116.29 3.08 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.977 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.657 HD23 ' C ' ' J' ' 17' ' ' LEU . 7.2 tt -131.35 123.26 27.89 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 18' ' ' VAL . . . . . 0.545 ' N ' HD23 ' J' ' 17' ' ' LEU . 2.7 p -132.51 127.91 57.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.33 0.586 . . . . 0.0 111.636 179.327 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.6 ' CE1' HD21 ' J' ' 17' ' ' LEU . 6.1 m-30 -109.17 119.2 38.8 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 115.079 -0.964 . . . . 0.0 108.648 178.113 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD2' ' K' ' 20' ' ' PHE . 34.6 t80 -124.58 113.7 18.41 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 134.23 47.81 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.491 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -134.75 105.99 6.71 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.676 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -85.41 114.24 22.31 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' J' ' 25' ' ' GLY . 4.6 p -122.56 122.9 67.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 24' ' ' VAL . . . 34.61 84.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.141 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -177.634 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.461 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 6.0 m -46.2 152.05 0.45 Allowed 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 113.722 -1.239 . . . . 0.0 114.066 -177.508 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' J' ' 28' ' ' LYS . 65.9 m-80 -138.02 178.0 7.45 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.881 172.779 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.888 ' HZ3' ' H ' ' J' ' 29' ' ' GLY . 0.9 OUTLIER -20.43 -104.12 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.413 1.264 . . . . 0.0 114.413 177.668 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.888 ' H ' ' HZ3' ' J' ' 28' ' ' LYS . . . -167.45 96.88 0.13 Allowed Glycine 0 C--N 1.361 1.919 0 CA-C-O 117.472 -1.738 . . . . 0.0 110.745 176.179 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.562 ' HB2' ' OD1' ' H' ' 23' ' ' ASP . . . -68.2 167.44 14.25 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 123.128 3.464 . . . . 0.0 106.884 177.164 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.55 HD12 HG23 ' I' ' 31' ' ' ILE . 0.3 OUTLIER -145.14 123.79 5.53 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.328 0 CA-C-N 121.128 1.786 . . . . 0.0 111.943 -176.924 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.607 HD12 ' HB2' ' H' ' 21' ' ' ALA . 0.1 OUTLIER -122.33 122.52 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.891 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.565 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -131.17 100.97 0.47 Allowed Glycine 0 N--CA 1.476 1.302 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.601 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 6.0 mp -131.78 138.54 48.61 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-O 122.696 1.236 . . . . 0.0 113.906 -176.763 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.518 ' SD ' ' C ' ' D' ' 32' ' ' ILE . 4.9 ttm -116.66 119.57 35.91 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 113.799 -1.546 . . . . 0.0 109.66 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.61 77.03 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.074 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.738 -179.169 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -84.57 103.97 2.69 Favored Glycine 0 C--N 1.355 1.596 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 179.295 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.46 170.9 55.14 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 65.6 t -131.47 136.02 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.947 0.403 . . . . 0.0 110.536 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.517 179.817 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' K' K ' 10' ' ' TYR . . . . . 0.436 ' CE2' ' O ' ' J' ' 9' ' ' GLY . 93.3 m-85 -112.68 133.95 54.45 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' L' ' 10' ' ' TYR . 79.7 mm-40 -137.43 139.23 40.53 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.96 0.409 . . . . 0.0 110.792 -179.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 58.1 t -127.63 132.54 69.02 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' J' ' 13' ' ' HIS . 22.1 m170 -79.26 149.1 31.95 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.86 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 24.5 p-80 -78.84 178.08 8.21 Favored 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -117.87 175.88 5.46 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.574 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -145.14 118.52 9.01 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 120.911 0.386 . . . . 0.0 111.205 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.441 HD12 HE21 ' L' ' 15' ' ' GLN . 34.1 mt -124.77 118.8 27.21 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.37 138.15 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.644 0.735 . . . . 0.0 112.633 -178.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -124.21 127.67 48.06 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.288 179.236 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.418 ' CD2' ' CE2' ' J' ' 20' ' ' PHE . 71.5 t80 -133.09 121.07 22.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.56 133.69 31.14 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.476 0.655 . . . . 0.0 112.665 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 96.4 mt-10 -117.69 124.66 49.07 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.211 178.327 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' K' ' 22' ' ' GLU . 14.5 m-20 -140.15 111.89 7.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' K' ' 26' ' ' SER . 6.3 m -129.55 -122.48 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 31.63 -84.25 0.0 OUTLIER Glycine 0 N--CA 1.474 1.183 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 -179.737 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.623 ' O ' ' O ' ' K' ' 27' ' ' ASN . 3.9 p 170.93 170.64 0.07 Allowed 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.209 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.623 ' O ' ' O ' ' K' ' 26' ' ' SER . 93.6 m-20 -18.75 157.48 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.554 1.159 . . . . 0.0 113.849 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' K' ' 29' ' ' GLY . 88.1 tttt -170.47 104.95 0.28 Allowed 'General case' 0 C--O 1.215 -0.729 0 CA-C-O 117.709 -1.139 . . . . 0.0 109.01 176.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -50.65 -99.08 0.01 OUTLIER Glycine 0 C--O 1.214 -1.126 0 C-N-CA 116.6 -2.714 . . . . 0.0 110.994 178.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 70.74 141.91 0.05 Allowed 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 102.616 -3.105 . . . . 0.0 102.616 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.497 HD13 ' HA2' ' E' ' 37' ' ' GLY . 0.2 OUTLIER -147.95 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 122.298 2.317 . . . . 0.0 111.214 -176.903 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.57 HG22 HD11 ' L' ' 34' ' ' LEU . 10.6 mt -106.61 113.4 43.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 175.762 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.7 115.2 2.29 Favored Glycine 0 C--N 1.317 -0.519 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 1.037 HD21 HG13 ' K' ' 36' ' ' VAL . 0.8 OUTLIER -150.42 143.27 24.69 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 122.732 1.253 . . . . 0.0 112.631 -178.526 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 29.4 ttm -117.67 122.21 42.93 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 113.664 -1.607 . . . . 0.0 109.308 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 1.037 HG13 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -116.2 79.76 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.131 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.23 103.91 0.4 Allowed Glycine 0 C--N 1.351 1.377 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.48 -163.11 15.38 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.1 136.27 54.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 120.833 0.349 . . . . 0.0 110.623 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 86.6 t . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.455 179.868 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' L' L ' 10' ' ' TYR . . . . . 0.402 ' O ' ' OE2' ' K' ' 11' ' ' GLU . 94.9 m-85 -108.48 137.52 46.3 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.901 0.381 . . . . 0.0 110.928 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -96.34 158.89 15.23 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 179.34 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.16 133.14 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.823 0.344 . . . . 0.0 110.562 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 65.6 t60 -160.24 117.53 2.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.173 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.474 ' ND1' ' O ' ' L' ' 13' ' ' HIS . 80.1 m-70 -151.51 174.55 13.27 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.441 HE21 HD12 ' K' ' 17' ' ' LEU . 54.8 tt0 -146.08 170.59 16.36 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.336 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 16' ' ' LYS . . . . . 0.427 ' N ' ' HG2' ' L' ' 15' ' ' GLN . 99.0 mttt -148.89 117.85 6.72 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.662 0.268 . . . . 0.0 110.303 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.538 HD23 ' C ' ' L' ' 17' ' ' LEU . 7.2 tt -126.48 115.89 20.26 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.215 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 m -136.62 137.2 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-O 121.005 0.431 . . . . 0.0 110.426 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -134.28 133.81 41.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.237 0.541 . . . . 0.0 111.275 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -135.56 124.74 24.51 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.722 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -150.37 146.45 26.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.329 -0.548 . . . . 0.0 111.594 -179.253 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -104.17 102.15 11.88 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.322 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -91.87 113.64 25.96 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.562 ' O ' ' N ' ' L' ' 26' ' ' SER . 85.2 t -65.95 131.26 31.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.439 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -54.53 84.51 0.01 OUTLIER Glycine 0 CA--C 1.528 0.892 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.271 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.562 ' N ' ' O ' ' L' ' 24' ' ' VAL . 1.4 p 159.82 178.88 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.473 ' O ' ' O ' ' L' ' 26' ' ' SER . 21.2 p30 -41.92 177.64 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.053 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.551 ' NZ ' ' O ' ' L' ' 30' ' ' ALA . 8.6 tptp -75.2 110.57 9.64 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.708 -1.133 . . . . 0.0 112.31 178.548 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -51.29 -99.87 0.01 OUTLIER Glycine 0 C--N 1.317 -0.513 0 CA-C-O 119.054 -0.859 . . . . 0.0 111.607 179.714 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.551 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . . . -80.48 163.91 23.41 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 104.75 -2.315 . . . . 0.0 104.75 -178.505 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.411 HD13 HG21 ' L' ' 31' ' ' ILE . 0.2 OUTLIER -135.28 128.85 49.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 116.487 -2.085 . . . . 0.0 113.038 -174.155 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.57 ' HB ' HD13 ' L' ' 34' ' ' LEU . 2.0 pt -117.52 114.94 47.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.232 178.819 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 33' ' ' GLY . . . . . 0.731 ' C ' HD12 ' L' ' 34' ' ' LEU . . . -112.8 90.64 0.56 Allowed Glycine 0 N--CA 1.463 0.47 0 N-CA-C 106.029 -2.828 . . . . 0.0 106.029 176.492 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.731 HD12 ' C ' ' L' ' 33' ' ' GLY . 9.1 mp -116.16 134.59 54.76 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.747 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 77.7 mmm -119.62 119.47 33.84 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.683 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' L' ' 37' ' ' GLY . 1.2 m -125.64 76.54 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 115.043 -0.981 . . . . 0.0 108.657 178.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -37.12 105.71 0.04 OUTLIER Glycine 0 C--N 1.356 1.646 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.86 172.15 6.81 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.933 -0.467 . . . . 0.0 111.933 -177.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 14.9 p -133.57 144.07 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 115.457 -0.371 . . . . 0.0 110.362 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.558 179.797 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.465 0.284 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -107.24 119.41 39.33 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.687 0.28 . . . . 0.0 111.032 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -100.27 165.88 11.25 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -156.23 174.14 15.83 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.887 178.006 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttp -175.8 115.76 0.14 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.377 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 97.0 mt -124.89 115.69 21.03 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.119 0.485 . . . . 0.0 110.439 179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.2 m -122.14 126.92 75.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.355 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.935 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 0.6 OUTLIER -117.85 113.52 21.9 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.418 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 t80 -122.87 116.42 23.61 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.092 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.79 119.87 38.11 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.22 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -174.79 108.57 0.11 Allowed 'General case' 0 CA--C 1.528 0.098 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -74.09 114.6 12.61 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.98 -0.688 . . . . 0.0 109.782 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.56 ' O ' HG23 ' A' ' 24' ' ' VAL . 27.9 m -121.46 123.54 69.85 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.769 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.4 82.09 0.01 OUTLIER Glycine 0 CA--C 1.53 0.971 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.259 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.616 ' O ' ' O ' ' A' ' 27' ' ' ASN . 58.4 m -140.5 170.68 15.34 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 117.923 0.862 . . . . 0.0 108.942 177.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.616 ' O ' ' O ' ' A' ' 26' ' ' SER . 70.9 m-80 -30.94 174.4 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.707 0 O-C-N 124.29 0.994 . . . . 0.0 113.261 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.61 110.84 21.67 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.592 176.416 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 52.09 91.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.719 0 C-N-CA 119.922 -1.132 . . . . 0.0 110.436 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.65 166.77 10.22 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 118.906 1.353 . . . . 0.0 110.518 179.512 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.467 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -141.05 107.32 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.389 -178.137 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 93.6 mt -128.21 130.09 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 121.442 0.639 . . . . 0.0 112.291 -177.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.433 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -128.13 110.88 1.2 Allowed Glycine 0 CA--C 1.521 0.439 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.03 124.55 52.88 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 120.908 0.385 . . . . 0.0 110.395 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.55 ' SD ' ' CA ' ' G' ' 33' ' ' GLY . 25.7 ttt -130.73 126.32 36.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.893 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.1 t -98.12 65.39 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 112.983 0.735 . . . . 0.0 112.983 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.2 -106.19 0.06 OUTLIER Glycine 0 N--CA 1.44 -1.075 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.247 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -95.44 178.16 35.26 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.468 0.438 0 CA-C-O 120.92 0.39 . . . . 0.0 110.275 179.739 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 N--CA 1.466 0.367 0 CA-C-O 121.165 0.507 . . . . 0.0 111.344 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.585 ' CG ' ' H ' ' B' ' 14' ' ' HIS . 15.3 t-80 -122.86 -164.26 1.18 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.036 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.586 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 19.9 t-80 -71.59 168.05 18.46 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.586 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 79.0 mt-30 -152.3 177.47 10.53 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.156 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -158.43 128.63 6.02 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 120.554 -0.458 . . . . 0.0 111.672 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.44 119.55 29.51 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -129.21 131.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 121.068 0.461 . . . . 0.0 111.52 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.635 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 7.9 t80 -122.64 115.55 22.3 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 53.3 t80 -125.59 122.33 36.17 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 110.4 -0.222 . . . . 0.0 110.4 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.52 125.77 45.49 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.121 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -163.48 130.23 3.34 Favored 'General case' 0 C--O 1.222 -0.364 0 CA-C-N 115.018 -0.992 . . . . 0.0 108.472 178.489 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' NZ ' ' D' ' 28' ' ' LYS . 66.1 t0 -142.6 113.14 7.31 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.404 ' H ' HG22 ' B' ' 24' ' ' VAL . 6.0 m -59.32 131.59 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.13 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 176.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.413 ' HA3' ' O ' ' C' ' 26' ' ' SER . . . -66.36 84.33 0.1 Allowed Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.357 -0.925 . . . . 0.0 113.313 -178.688 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 6.3 p -87.77 180.0 6.38 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.757 0.789 . . . . 0.0 109.438 176.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.487 ' O ' ' O ' ' B' ' 28' ' ' LYS . 51.1 p30 -76.69 179.22 6.17 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.342 -1.299 . . . . 0.0 109.578 175.57 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 27' ' ' ASN . 68.4 mttm 43.93 110.53 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 115.019 1.489 . . . . 0.0 115.019 175.773 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' C' ' 29' ' ' GLY . . . -78.76 97.79 1.51 Allowed Glycine 0 CA--C 1.485 -1.827 0 CA-C-N 113.562 -1.654 . . . . 0.0 110.866 -176.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.4 ' C ' HG12 ' B' ' 31' ' ' ILE . . . -75.62 164.75 25.99 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 122.462 1.125 . . . . 0.0 109.658 -175.229 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.549 HG23 ' CG1' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -137.57 114.04 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 CA-C-N 112.63 -2.077 . . . . 0.0 110.504 -170.157 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' I' ' 35' ' ' MET . 96.4 mt -132.83 128.12 56.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 CA-C-O 121.64 0.733 . . . . 0.0 112.805 -177.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.491 ' CA ' ' SD ' ' I' ' 35' ' ' MET . . . -129.74 128.8 5.79 Favored Glycine 0 N--CA 1.471 0.999 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 179.304 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.403 HD21 HG23 ' B' ' 36' ' ' VAL . 2.9 tt -129.25 126.13 38.4 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.149 0.5 . . . . 0.0 111.761 -178.855 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 7.2 tpp -120.86 117.81 28.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.428 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.403 HG23 HD21 ' B' ' 34' ' ' LEU . 59.0 t -125.37 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -179.434 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.66 104.63 2.1 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.505 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.44 -171.81 0.65 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.106 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.2 m -133.77 163.06 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.896 0.379 . . . . 0.0 110.47 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.342 179.727 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.439 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -116.2 138.53 51.2 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.767 0.318 . . . . 0.0 110.644 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -120.72 128.49 52.99 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.34 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -130.04 134.63 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.249 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.496 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.0 t-80 -136.62 127.36 27.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.843 0.354 . . . . 0.0 110.61 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.496 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 79.9 m-70 -152.16 164.74 36.69 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -156.83 171.01 21.16 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.092 178.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.482 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.9 mttt -158.13 113.95 2.74 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.518 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.482 HD12 ' C ' ' C' ' 16' ' ' LYS . 11.0 mp -114.46 122.38 46.43 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.27 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.45 124.52 62.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.658 -0.246 . . . . 0.0 110.431 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.629 ' CZ ' HD11 ' E' ' 34' ' ' LEU . 1.1 t80 -120.46 111.98 18.39 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.054 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.4 t80 -119.84 121.92 40.15 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.681 0.277 . . . . 0.0 110.828 -178.598 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.74 128.92 49.51 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 121.331 0.586 . . . . 0.0 112.065 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -150.37 149.8 30.56 Favored 'General case' 0 C--O 1.226 -0.157 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.959 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -163.77 121.23 1.8 Allowed 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.63 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.479 HG23 ' H ' ' C' ' 25' ' ' GLY . 4.2 m -128.02 -112.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.803 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.479 ' H ' HG23 ' C' ' 24' ' ' VAL . . . 34.26 -90.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 115.725 -0.671 . . . . 0.0 112.315 -178.271 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.619 ' O ' ' O ' ' C' ' 27' ' ' ASN . 0.3 OUTLIER 172.0 -170.82 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.6 179.65 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.619 ' O ' ' O ' ' C' ' 26' ' ' SER . 76.8 m-20 -20.31 -175.2 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 117.327 2.343 . . . . 0.0 117.327 177.665 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 82.6 tttt 111.64 110.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 CA-C-N 111.81 -2.45 . . . . 0.0 114.477 176.061 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.412 ' O ' ' HA3' ' B' ' 29' ' ' GLY . . . -61.74 92.48 0.07 OUTLIER Glycine 0 C--O 1.218 -0.87 0 CA-C-N 112.305 -2.225 . . . . 0.0 112.714 171.739 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.67 156.8 40.47 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 122.902 3.351 . . . . 0.0 107.984 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.598 HD13 ' N ' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -138.73 129.07 33.51 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.189 -176.021 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.488 HG12 HD21 ' C' ' 34' ' ' LEU . 13.0 tt -133.84 122.97 43.96 Favored 'Isoleucine or valine' 0 C--N 1.348 0.525 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.523 177.175 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.52 115.36 3.61 Favored Glycine 0 CA--C 1.499 -0.936 0 N-CA-C 107.602 -2.199 . . . . 0.0 107.602 178.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.935 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 52.6 mt -116.26 111.4 20.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.117 0.484 . . . . 0.0 111.56 -176.607 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.405 ' HE2' ' H ' ' J' ' 33' ' ' GLY . 24.6 tpp -109.48 103.16 12.01 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 177.126 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -121.35 70.74 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.727 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.239 -178.734 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -38.2 -100.79 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 178.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.85 -163.79 31.73 Favored Glycine 0 CA--C 1.521 0.456 0 N-CA-C 110.535 -1.026 . . . . 0.0 110.535 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 68.5 t -119.19 134.06 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.005 -0.997 . . . . 0.0 110.632 -179.641 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.477 ' C ' ' ND1' ' D' ' 13' ' ' HIS . 9.8 p . . . . . 0 N--CA 1.467 0.385 0 CA-C-O 121.142 0.496 . . . . 0.0 110.702 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' C ' ' D' ' 12' ' ' VAL . 14.7 m80 -142.56 108.99 5.3 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.555 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.44 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 31.6 m-70 -126.55 167.08 16.13 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -151.39 171.86 16.83 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.581 179.05 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.594 ' C ' HD12 ' D' ' 17' ' ' LEU . 63.3 mttp -155.24 121.16 5.11 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.139 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.594 HD12 ' C ' ' D' ' 16' ' ' LYS . 11.0 mp -119.92 122.83 42.11 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.33 125.1 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.016 0.436 . . . . 0.0 110.678 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.908 ' CE1' HD22 ' F' ' 34' ' ' LEU . 1.3 t80 -118.73 117.55 29.22 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.446 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -128.26 122.3 31.38 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 112.059 0.392 . . . . 0.0 112.059 -177.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.79 121.3 29.84 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-O 121.112 0.482 . . . . 0.0 109.978 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -97.85 175.29 6.21 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.212 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -72.63 122.08 20.83 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.26 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.451 ' O ' HG23 ' D' ' 24' ' ' VAL . 28.7 m -87.56 123.33 40.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.914 179.107 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -42.88 -86.09 0.01 OUTLIER Glycine 0 CA--C 1.532 1.152 0 C-N-CA 121.393 -0.432 . . . . 0.0 112.443 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.738 ' O ' ' O ' ' D' ' 27' ' ' ASN . 13.2 p -152.84 -171.61 3.99 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -178.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.738 ' O ' ' O ' ' D' ' 26' ' ' SER . 81.5 m-20 -20.15 172.24 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 114.783 1.401 . . . . 0.0 114.783 -179.05 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.556 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 83.2 tttt 132.02 105.65 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 124.95 1.3 . . . . 0.0 107.701 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -49.89 -97.72 0.01 OUTLIER Glycine 0 N--CA 1.473 1.135 0 C-N-CA 118.112 -1.994 . . . . 0.0 110.269 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.451 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . 72.54 145.01 0.07 Allowed 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.687 HG23 ' CG1' ' E' ' 31' ' ' ILE . 0.3 OUTLIER -149.42 116.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.202 -175.026 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.513 HG22 ' O ' ' D' ' 32' ' ' ILE . 1.0 OUTLIER -111.57 111.41 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.741 -179.661 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.91 97.53 1.61 Allowed Glycine 0 CA--C 1.509 -0.289 0 N-CA-C 105.024 -3.23 . . . . 0.0 105.024 175.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.635 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 62.8 tp -110.94 118.67 36.71 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -175.149 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -122.16 108.84 13.78 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 176.135 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.434 HG22 HD11 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -124.43 70.04 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.847 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -49.41 -100.6 0.01 OUTLIER Glycine 0 C--N 1.347 1.142 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.266 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 111.23 159.19 15.67 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -124.15 136.34 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.972 0.415 . . . . 0.0 110.664 -179.558 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 91.6 t . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.058 -0.973 . . . . 0.0 110.414 179.63 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -104.87 134.95 47.14 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -140.8 146.57 37.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.997 0.427 . . . . 0.0 110.956 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 4.2 m -131.55 155.84 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.748 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -156.75 162.37 39.77 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 121.312 0.577 . . . . 0.0 112.302 -179.025 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.59 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 36.4 t60 -154.96 164.75 38.45 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-O 121.411 0.624 . . . . 0.0 110.635 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.59 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 82.6 mt-30 -149.85 170.03 19.72 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.465 0.65 . . . . 0.0 110.892 178.608 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.19 128.79 3.17 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.096 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 52.5 tp -125.36 124.36 41.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.2 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.73 123.61 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -124.54 120.24 31.39 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.239 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -129.13 120.53 26.02 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 120.31 16.94 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.213 0.53 . . . . 0.0 110.948 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -143.09 128.3 18.71 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.476 179.538 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -154.14 120.4 5.4 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.455 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 14.1 t -107.5 -112.76 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.007 0.432 . . . . 0.0 110.327 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.7 -90.63 0.01 OUTLIER Glycine 0 N--CA 1.469 0.878 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.397 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.602 ' O ' ' O ' ' E' ' 27' ' ' ASN . 2.7 t 171.34 170.1 0.08 Allowed 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.502 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.602 ' O ' ' O ' ' E' ' 26' ' ' SER . 60.3 t30 -17.67 158.34 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.861 ' O ' ' HB2' ' F' ' 30' ' ' ALA . 75.2 tttt -161.73 111.41 1.57 Allowed 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.406 175.456 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.77 92.29 0.23 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-O 119.156 -0.802 . . . . 0.0 113.178 176.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.537 ' HB2' ' O ' ' D' ' 28' ' ' LYS . . . -160.24 154.08 22.82 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.512 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.687 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -141.47 126.05 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 117.49 -1.684 . . . . 0.0 114.123 -175.926 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.522 ' O ' ' SD ' ' L' ' 35' ' ' MET . 0.8 OUTLIER -114.39 116.39 52.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 114.731 -1.122 . . . . 0.0 108.202 176.505 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.95 102.13 2.76 Favored Glycine 0 CA--C 1.501 -0.811 0 N-CA-C 104.192 -3.563 . . . . 0.0 104.192 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.629 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 6.7 tt -107.14 105.54 15.59 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 121.045 0.45 . . . . 0.0 111.366 -174.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.9 ttt -123.82 112.51 17.38 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.5 80.38 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.01 102.76 0.26 Allowed Glycine 0 C--N 1.351 1.397 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.54 -151.55 23.62 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.0 p -130.84 140.82 47.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 43.1 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.755 -179.828 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p . . . . . 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.753 . . . . 0.0 111.507 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.444 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 33.0 p-80 -161.64 157.08 24.02 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.188 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 97.0 m-70 -156.4 168.29 27.8 Favored 'General case' 0 CA--C 1.511 -0.537 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.101 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -151.01 173.26 14.52 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 119.951 -0.7 . . . . 0.0 110.716 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -147.66 129.09 14.89 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.447 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 50.8 mt -120.33 115.48 23.63 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.306 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -127.31 129.5 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.82 0.343 . . . . 0.0 110.129 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.524 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.3 p90 -143.34 126.23 16.2 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.069 0.462 . . . . 0.0 111.543 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -127.29 128.11 45.44 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.18 149.64 28.22 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 119.89 -0.724 . . . . 0.0 112.286 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -80.09 126.56 31.23 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.194 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 57.8 t0 . . . . . 0 N--CA 1.471 0.601 0 CA-C-O 121.868 0.842 . . . . 0.0 113.266 -177.483 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.461 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 80.1 tttt . . . . . 0 CA--C 1.542 0.664 0 CA-C-O 123.537 1.637 . . . . 0.0 111.859 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.461 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -114.33 -100.45 2.36 Favored Glycine 0 CA--C 1.483 -1.944 0 CA-C-N 111.218 -2.719 . . . . 0.0 113.305 -179.664 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.861 ' HB2' ' O ' ' E' ' 28' ' ' LYS . . . -60.41 177.04 0.3 Allowed 'General case' 0 CA--C 1.474 -1.957 0 CA-C-N 110.82 -2.69 . . . . 0.0 104.933 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 tp -158.41 144.76 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 C-N-CA 114.998 -2.681 . . . . 0.0 114.638 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 pt -102.14 112.34 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-N 112.807 -1.997 . . . . 0.0 107.965 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -80.38 97.12 1.67 Allowed Glycine 0 CA--C 1.497 -1.061 0 N-CA-C 103.496 -3.842 . . . . 0.0 103.496 175.408 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.908 HD22 ' CE1' ' D' ' 19' ' ' PHE . 0.3 OUTLIER -100.01 111.09 23.39 Favored 'General case' 0 CA--C 1.497 -1.089 0 CA-C-N 117.412 0.606 . . . . 0.0 111.445 -176.676 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.622 ' SD ' ' O ' ' L' ' 32' ' ' ILE . 24.2 mtp -135.33 114.94 12.71 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-O 122.754 1.264 . . . . 0.0 107.766 176.463 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.74 HG13 ' O ' ' F' ' 36' ' ' VAL . 5.5 p -133.0 78.63 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 CA-C-N 112.566 -2.106 . . . . 0.0 108.373 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.646 ' HA2' HD13 ' L' ' 31' ' ' ILE . . . 51.87 -104.08 0.14 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -175.13 46.7 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 66.6 t -131.42 137.72 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 120.814 0.34 . . . . 0.0 111.16 -179.005 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 61.5 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.119 -0.943 . . . . 0.0 110.335 179.289 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.457 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -98.71 130.29 45.19 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.859 0.361 . . . . 0.0 110.345 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -71.02 147.61 48.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.744 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 t -124.95 134.03 67.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.8 t60 -144.27 136.9 26.85 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.382 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 27.6 m170 -112.78 178.69 4.2 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -102.33 178.11 4.68 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.407 -179.445 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -97.02 137.63 35.81 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.655 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -123.97 128.14 48.96 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.375 0.607 . . . . 0.0 111.378 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.49 128.85 61.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.562 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.45 ' CE2' HD23 ' J' ' 34' ' ' LEU . 3.8 m-85 -108.85 113.27 26.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 176.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 52.7 p90 -124.99 123.96 40.98 Favored 'General case' 0 CA--C 1.521 -0.14 0 CA-C-O 120.892 0.377 . . . . 0.0 110.932 -178.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.09 120.84 40.37 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -159.27 141.63 13.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -66.29 112.12 3.83 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' G' ' 26' ' ' SER . 54.2 t -111.86 130.85 64.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.96 81.85 0.0 OUTLIER Glycine 0 CA--C 1.532 1.126 0 CA-C-N 114.97 -1.014 . . . . 0.0 113.376 177.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.516 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.6 m -131.41 179.46 6.02 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 119.172 1.486 . . . . 0.0 109.562 178.168 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.465 ' O ' ' O ' ' G' ' 26' ' ' SER . 79.1 m-20 -40.18 174.37 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.186 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -77.41 110.64 12.34 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.381 175.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.457 ' H ' ' HE2' ' H' ' 28' ' ' LYS . . . 65.36 94.39 0.03 OUTLIER Glycine 0 N--CA 1.466 0.648 0 C-N-CA 118.292 -1.909 . . . . 0.0 110.361 177.312 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 161.37 13.65 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 120.18 1.99 . . . . 0.0 109.386 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.404 HG22 HD12 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -150.98 112.77 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.758 -172.957 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' A' ' 35' ' ' MET . 94.8 mt -121.45 117.26 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-O 120.662 0.268 . . . . 0.0 110.89 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.55 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -125.7 116.39 2.62 Favored Glycine 0 N--CA 1.47 0.911 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 179.401 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 56.4 tp -144.15 140.57 29.45 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-O 121.384 0.611 . . . . 0.0 112.198 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.433 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 40.0 ttp -130.64 137.73 49.75 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.466 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' G' ' 37' ' ' GLY . 4.8 t -125.82 69.77 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 CA-C-N 116.328 -0.396 . . . . 0.0 112.038 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -43.77 -101.68 0.01 OUTLIER Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.12 174.28 40.21 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 13.3 p -145.03 149.56 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.183 0.516 . . . . 0.0 111.329 -179.493 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.969 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -82.44 130.11 35.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.012 0.434 . . . . 0.0 110.392 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -115.34 163.51 15.59 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.761 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.504 HG12 ' N ' ' H' ' 13' ' ' HIS . 71.5 t -118.66 158.78 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.869 0.842 . . . . 0.0 110.902 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.504 ' N ' HG12 ' H' ' 12' ' ' VAL . 32.5 p-80 -98.65 154.24 18.09 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -178.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.566 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 58.4 t60 -87.93 167.4 13.77 Favored 'General case' 0 N--CA 1.442 -0.862 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 178.139 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.566 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 26.7 mt-30 -150.66 167.2 28.05 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 119.906 -0.717 . . . . 0.0 111.381 178.782 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -153.11 115.26 4.37 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.389 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 24.6 tp -122.64 121.86 37.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.737 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.09 123.43 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-O 121.106 0.479 . . . . 0.0 112.146 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.897 ' CZ ' HD22 ' K' ' 34' ' ' LEU . 3.3 m-85 -110.2 114.31 27.69 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 177.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.597 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 48.4 t80 -127.63 123.74 36.33 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 118.473 0.579 . . . . 0.0 110.407 -178.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.59 128.67 44.68 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 120.924 0.392 . . . . 0.0 111.918 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -144.87 153.22 41.36 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -105.28 103.7 13.29 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.66 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' H' ' 26' ' ' SER . 22.5 t -90.23 153.68 3.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 48.71 -80.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.75 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.7 OUTLIER 171.46 -170.71 0.03 OUTLIER 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 117.371 0.586 . . . . 0.0 109.578 -179.787 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.75 ' O ' ' O ' ' H' ' 26' ' ' SER . 18.1 m-20 -18.67 -172.42 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 116.322 1.971 . . . . 0.0 116.322 -178.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.546 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 62.9 tttm 127.02 104.51 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.984 0 CA-C-N 113.644 -1.617 . . . . 0.0 111.307 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.98 96.86 0.07 OUTLIER Glycine 0 N--CA 1.47 0.954 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.153 176.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.99 148.12 43.94 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.514 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -146.1 124.92 5.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.263 -173.41 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -122.81 117.53 52.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.83 179.268 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.02 122.72 5.09 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 178.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 7.8 tt -151.44 140.38 21.01 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.557 -0.966 . . . . 0.0 111.582 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 43.0 ttp -131.74 130.17 41.58 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.298 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' H' ' 37' ' ' GLY . 11.6 t -123.77 73.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -48.2 -95.07 0.01 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 177.166 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.76 177.42 16.71 Favored Glycine 0 C--N 1.336 0.571 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.56 134.57 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.402 HG22 ' H ' ' H' ' 40' ' ' VAL . 15.6 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.641 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m . . . . . 0 N--CA 1.463 0.195 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.458 ' ND1' ' O ' ' H' ' 12' ' ' VAL . 2.0 m80 -107.06 -172.56 2.1 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.958 0.409 . . . . 0.0 110.884 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.598 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 20.9 p-80 -135.91 176.53 8.6 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -133.18 177.73 7.44 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.588 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -138.69 115.9 11.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.039 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 39.0 mt -114.27 117.38 30.95 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -126.62 125.8 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.208 0.528 . . . . 0.0 111.614 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.974 ' CZ ' HD22 ' L' ' 34' ' ' LEU . 6.9 m-85 -113.25 115.09 27.65 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 177.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.597 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 25.8 t80 -129.27 122.96 30.71 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.482 0.583 . . . . 0.0 110.237 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.15 131.31 34.53 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.539 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -137.9 132.49 32.53 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -96.69 101.38 12.98 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.59 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.615 ' O ' ' N ' ' I' ' 26' ' ' SER . 53.6 t -91.27 158.46 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.333 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 48.9 -80.46 0.01 OUTLIER Glycine 0 CA--C 1.527 0.805 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.427 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.615 ' N ' ' O ' ' I' ' 24' ' ' VAL . 2.4 p 171.16 171.21 0.08 Allowed 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.397 0.618 . . . . 0.0 110.052 -179.481 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.589 ' O ' ' O ' ' I' ' 26' ' ' SER . 23.0 p30 -16.13 158.41 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.335 -1.757 . . . . 0.0 115.5 -176.658 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.556 ' O ' ' O ' ' J' ' 29' ' ' GLY . 63.5 tttp -161.17 111.03 1.66 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.497 176.391 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.73 92.8 0.2 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 150.71 52.03 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.56 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.514 HD12 ' CG2' ' H' ' 31' ' ' ILE . 0.0 OUTLIER -151.57 123.43 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 C-N-CA 118.711 -1.196 . . . . 0.0 110.943 -174.989 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.534 ' CG2' HD11 ' J' ' 34' ' ' LEU . 97.3 mt -116.69 116.21 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.279 178.362 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.65 98.03 1.03 Allowed Glycine 0 N--CA 1.462 0.381 0 N-CA-C 105.888 -2.885 . . . . 0.0 105.888 175.283 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -122.61 129.07 51.48 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.68 0.752 . . . . 0.0 112.334 -176.015 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 78.9 mtp -108.91 112.78 25.19 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.434 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.502 ' H ' ' HG2' ' J' ' 35' ' ' MET . 0.2 OUTLIER -123.54 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 177.454 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.6 111.2 3.22 Favored Glycine 0 C--N 1.364 2.107 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.0 179.38 1.56 Allowed Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.39 156.24 41.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.365 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.571 -179.701 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -82.54 140.84 33.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.659 0.266 . . . . 0.0 110.314 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -141.74 159.92 41.23 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.931 0.396 . . . . 0.0 110.874 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' J' ' 13' ' ' HIS . 25.8 t -120.57 161.22 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.469 ' N ' ' CG1' ' J' ' 12' ' ' VAL . 28.9 p-80 -71.48 150.54 44.77 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -176.533 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.598 ' NE2' ' CG ' ' I' ' 14' ' ' HIS . 43.8 p-80 -152.86 172.87 16.09 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 113.918 -1.492 . . . . 0.0 107.167 179.326 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -144.36 174.12 11.19 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.59 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.654 ' C ' HD12 ' J' ' 17' ' ' LEU . 99.2 mttt -148.73 112.47 5.09 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.333 -0.849 . . . . 0.0 109.974 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.654 HD12 ' C ' ' J' ' 16' ' ' LYS . 10.5 mp -117.52 121.21 40.38 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.91 123.28 58.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.937 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.643 ' CE1' ' CE2' ' K' ' 19' ' ' PHE . 94.9 m-85 -115.87 117.09 29.24 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -123.22 111.24 16.23 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.54 132.93 46.97 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -120.84 87.89 2.84 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.216 -0.902 . . . . 0.0 108.862 177.49 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.577 ' C ' ' HZ2' ' K' ' 28' ' ' LYS . 20.9 m-20 -68.33 -102.42 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 114.602 -1.181 . . . . 0.0 108.53 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.552 HG12 ' N ' ' J' ' 25' ' ' GLY . 34.5 t 46.43 157.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 122.661 1.22 . . . . 0.0 114.254 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.552 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 91.67 -80.25 1.26 Allowed Glycine 0 CA--C 1.527 0.843 0 CA-C-N 113.219 -1.809 . . . . 0.0 110.46 -176.786 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.606 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.8 p 170.28 170.48 0.06 Allowed 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 118.092 0.946 . . . . 0.0 109.729 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.606 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.8 t-20 -17.66 157.75 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.699 0 O-C-N 124.953 1.408 . . . . 0.0 114.02 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.583 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 61.3 tttt -161.6 110.55 1.53 Allowed 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 173.505 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.556 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -68.13 93.06 0.27 Allowed Glycine 0 C--O 1.216 -1.0 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.75 177.049 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.472 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -143.28 143.25 31.64 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 103.061 -2.94 . . . . 0.0 103.061 173.404 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.505 HD12 ' CG2' ' I' ' 31' ' ' ILE . 0.2 OUTLIER -152.37 111.76 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 118.424 -1.31 . . . . 0.0 108.929 -171.546 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.485 HG22 ' H ' ' K' ' 33' ' ' GLY . 0.1 OUTLIER -111.6 111.92 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.046 0.451 . . . . 0.0 109.86 -179.491 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.593 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -112.16 94.56 0.75 Allowed Glycine 0 C--O 1.239 0.447 0 N-CA-C 107.398 -2.281 . . . . 0.0 107.398 176.739 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.593 HD12 ' C ' ' J' ' 33' ' ' GLY . 9.7 mp -117.33 127.15 53.77 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 122.279 1.038 . . . . 0.0 111.307 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.502 ' HG2' ' H ' ' I' ' 36' ' ' VAL . 0.1 OUTLIER -101.57 118.59 37.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.521 178.315 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 98.2 t -133.9 76.55 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.49 104.58 2.07 Favored Glycine 0 C--N 1.352 1.443 0 CA-C-N 115.353 -0.839 . . . . 0.0 111.849 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.61 -176.76 40.0 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.6 m -134.4 162.5 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.682 0.277 . . . . 0.0 110.509 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 95.0 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.886 -179.76 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -111.53 145.79 38.46 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.706 0.288 . . . . 0.0 110.655 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -53.78 148.85 9.39 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.879 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -134.04 156.59 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 121.891 0.853 . . . . 0.0 111.996 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -170.17 83.42 0.11 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.074 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -154.98 169.0 25.1 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 65.5 mt-30 -149.9 178.31 9.03 Favored 'General case' 0 C--N 1.312 -1.047 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.004 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -126.66 109.45 12.1 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.717 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 55.8 mt -111.23 113.04 25.25 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.9 t -126.24 114.13 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 O-C-N 122.015 -0.428 . . . . 0.0 111.091 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.718 ' O ' ' C ' ' L' ' 19' ' ' PHE . 76.0 m-85 -116.86 105.31 12.22 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 177.139 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.448 ' HA ' ' O ' ' L' ' 19' ' ' PHE . 91.0 t80 -128.3 125.99 39.91 Favored 'General case' 0 N--CA 1.482 1.151 0 O-C-N 124.287 0.992 . . . . 0.0 112.219 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.492 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -147.36 156.32 42.79 Favored 'General case' 0 C--N 1.353 0.732 0 C-N-CA 118.502 -1.279 . . . . 0.0 114.236 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -127.3 137.27 52.79 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.42 ' O ' HG11 ' L' ' 24' ' ' VAL . 11.4 p-10 -165.5 135.43 3.55 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 118.868 -1.133 . . . . 0.0 113.725 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.592 HG13 ' O ' ' K' ' 24' ' ' VAL . 13.1 p -70.83 112.74 5.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -50.59 92.47 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.526 -1.215 . . . . 0.0 114.546 -175.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.451 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.5 t 162.35 160.5 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.766 0 CA-C-O 121.801 0.81 . . . . 0.0 110.134 176.45 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.451 ' O ' ' O ' ' K' ' 26' ' ' SER . 74.9 m-20 -29.7 159.8 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 113.785 -1.552 . . . . 0.0 113.207 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.577 ' HZ2' ' C ' ' J' ' 23' ' ' ASP . 75.6 tttt 179.48 104.01 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.228 175.154 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -65.62 94.7 0.2 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.923 -0.932 . . . . 0.0 113.781 177.624 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.638 ' O ' HG23 ' K' ' 31' ' ' ILE . . . -168.01 147.08 4.67 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.638 HG23 ' O ' ' K' ' 30' ' ' ALA . 0.1 OUTLIER -160.37 130.02 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.54 0 C-N-CA 118.283 -1.367 . . . . 0.0 113.575 -176.311 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.422 ' O ' HG23 ' K' ' 32' ' ' ILE . 12.8 tt -108.51 113.85 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 175.327 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.485 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -121.35 121.69 4.88 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.613 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.897 HD22 ' CZ ' ' H' ' 19' ' ' PHE . 20.1 tp -140.66 136.99 33.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.781 0.801 . . . . 0.0 110.214 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.545 ' H ' HD12 ' K' ' 34' ' ' LEU . 1.7 ttm -112.03 124.09 51.67 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.664 HG22 HD11 ' L' ' 34' ' ' LEU . 5.4 m -124.06 79.38 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.111 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -69.4 103.3 1.07 Allowed Glycine 0 C--N 1.35 1.308 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.48 146.9 17.38 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -127.12 136.78 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 120.734 0.302 . . . . 0.0 110.223 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 40' ' ' VAL . . . . . 0.418 ' H ' HG22 ' K' ' 40' ' ' VAL . 16.0 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.422 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -90.22 128.05 36.29 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.754 0.312 . . . . 0.0 110.81 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -140.06 160.83 39.06 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 109.935 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.438 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 49.6 t -118.63 130.17 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.553 0.692 . . . . 0.0 110.372 179.779 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.438 ' CD2' ' O ' ' L' ' 12' ' ' VAL . 88.6 m-70 -156.86 110.44 2.63 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.583 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.509 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 35.3 t-80 -156.85 175.67 13.77 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.039 0.447 . . . . 0.0 109.881 -179.054 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.509 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 77.8 mt-30 -142.4 -179.97 6.59 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.216 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -164.66 114.48 1.16 Allowed 'General case' 0 C--O 1.234 0.261 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.7 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 17.5 mt -116.02 121.25 41.68 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -112.36 133.1 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 118.802 0.728 . . . . 0.0 110.966 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.718 ' C ' ' O ' ' K' ' 19' ' ' PHE . 63.6 m-85 -42.37 141.56 0.95 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 -172.549 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.567 ' N ' ' O ' ' K' ' 19' ' ' PHE . 50.5 p90 -99.93 -169.47 1.74 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-N 108.638 -3.892 . . . . 0.0 110.363 179.298 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -23.47 135.24 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -173.282 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -70.46 159.38 34.35 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 113.04 -1.891 . . . . 0.0 109.239 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -50.52 114.05 1.04 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.106 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 25' ' ' GLY . 3.5 m -127.82 121.22 55.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.812 -178.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -27.84 -87.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.956 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -67.2 -173.01 0.24 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-O 121.222 0.534 . . . . 0.0 109.992 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 10.3 m120 -78.73 175.88 10.04 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.025 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 32.2 tttm -49.12 111.21 0.45 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 114.219 -1.355 . . . . 0.0 113.967 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.47 -97.86 0.05 OUTLIER Glycine 0 C--O 1.223 -0.593 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.535 ' HB2' ' HD3' ' K' ' 28' ' ' LYS . . . -60.95 172.23 1.03 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 120.265 2.033 . . . . 0.0 106.544 -179.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.646 HD13 ' HA2' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -146.9 141.26 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 117.236 -1.786 . . . . 0.0 114.375 -173.586 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.622 ' O ' ' SD ' ' F' ' 35' ' ' MET . 88.4 mt -109.14 114.66 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 CA-C-N 114.061 -1.427 . . . . 0.0 110.131 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.92 91.25 0.56 Allowed Glycine 0 CA--C 1.517 0.179 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 177.343 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.974 HD22 ' CZ ' ' I' ' 19' ' ' PHE . 18.9 tp -117.72 120.65 38.61 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.205 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 42.2 ttp -97.08 119.19 35.11 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.084 179.067 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' L' ' 37' ' ' GLY . 1.4 m -130.25 71.01 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -29.8 -102.67 0.01 OUTLIER Glycine 0 C--N 1.358 1.802 0 O-C-N 122.935 0.147 . . . . 0.0 112.892 -178.729 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.61 163.07 35.86 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -136.81 162.64 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.913 0.387 . . . . 0.0 110.661 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.635 -179.414 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.465 0.302 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -131.25 138.83 49.49 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.161 0.505 . . . . 0.0 111.295 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.583 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 10.5 t-80 -156.85 165.85 35.04 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.025 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.583 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 51.2 tt0 -169.52 169.93 8.52 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.537 179.265 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.407 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 65.5 mttm -152.27 115.12 4.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.983 178.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 35.3 tp -121.37 121.6 37.99 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 109.945 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 18' ' ' VAL . 35.5 m -122.85 122.68 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 CA-C-O 121.351 0.596 . . . . 0.0 111.246 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.461 ' CD1' ' CE1' ' B' ' 19' ' ' PHE . 15.6 t80 -123.64 106.41 10.52 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 178.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -134.39 145.94 49.4 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.01 117.76 13.16 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.122 -0.945 . . . . 0.0 108.512 177.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -130.76 157.65 42.27 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.408 ' OD1' ' C ' ' A' ' 23' ' ' ASP . 47.5 t0 -98.42 112.69 24.62 Favored 'General case' 0 N--CA 1.462 0.158 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.089 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.518 ' O ' ' C ' ' A' ' 25' ' ' GLY . 2.1 p -147.72 113.49 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 103.595 -2.742 . . . . 0.0 103.595 172.771 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.518 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -19.87 87.17 0.01 OUTLIER Glycine 0 N--CA 1.476 1.303 0 CA-C-O 119.282 -0.732 . . . . 0.0 112.522 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.483 ' N ' ' O ' ' A' ' 24' ' ' VAL . 40.9 t -67.97 -179.72 1.28 Allowed 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 119.219 1.509 . . . . 0.0 108.046 178.044 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 53.2 p30 -87.31 174.93 8.26 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt 35.85 -108.45 0.05 OUTLIER 'General case' 0 CA--C 1.538 0.514 0 CA-C-O 122.28 1.038 . . . . 0.0 113.574 173.193 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 30' ' ' ALA . . . 90.59 -102.04 2.87 Favored Glycine 1 CA--C 1.427 -5.457 0 CA-C-N 113.157 -1.838 . . . . 0.0 108.635 -177.384 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 29' ' ' GLY . . . 56.63 -146.95 0.54 Allowed 'General case' 0 N--CA 1.405 -2.7 0 C-N-CA 113.497 -3.281 . . . . 0.0 109.7 173.251 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.68 ' H ' ' CD1' ' A' ' 31' ' ' ILE 0.252 0.0 OUTLIER -89.89 113.65 26.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 CA-C-N 113.259 -1.791 . . . . 0.0 113.688 -179.788 . . . . . . . . 4 4 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' G' ' 35' ' ' MET . 87.1 mt -130.03 120.17 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 O-C-N 120.103 -1.623 . . . . 0.0 109.922 178.395 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.609 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.68 113.63 1.53 Allowed Glycine 0 CA--C 1.52 0.375 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -133.29 134.9 44.47 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.99 0.424 . . . . 0.0 110.72 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 5.9 ttm -125.44 129.62 50.21 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.738 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.92 70.8 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 120.656 -0.417 . . . . 0.0 111.473 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -114.66 100.65 1.02 Allowed Glycine 0 C--N 1.341 0.811 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 177.647 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.65 41.6 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.554 -1.018 . . . . 0.0 110.554 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 120.76 0.314 . . . . 0.0 110.383 -179.893 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.483 HG12 ' N ' ' B' ' 13' ' ' HIS . 33.5 t . . . . . 0 N--CA 1.465 0.304 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.483 ' N ' HG12 ' B' ' 12' ' ' VAL . 86.0 t60 -157.87 101.47 1.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.628 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 55.7 m170 -110.2 167.44 10.19 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -152.43 176.7 11.38 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.231 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -171.46 111.95 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.638 178.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 64.1 mt -120.98 120.33 35.11 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.5 t -120.79 121.6 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 120.889 -0.325 . . . . 0.0 111.432 -179.053 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.485 ' CZ ' HD23 ' D' ' 34' ' ' LEU . 12.0 t80 -120.7 110.54 16.51 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -119.32 117.11 27.67 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.22 119.92 34.61 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -177.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' B' ' 23' ' ' ASP . 95.3 mt-10 -153.05 89.82 1.4 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 115.162 -0.926 . . . . 0.0 108.754 176.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.532 ' OD2' ' HB2' ' D' ' 30' ' ' ALA . 49.5 t0 8.2 113.63 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 114.039 1.125 . . . . 0.0 114.039 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 85.4 t -58.56 131.2 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.205 0.526 . . . . 0.0 110.367 178.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.34 84.67 0.13 Allowed Glycine 0 CA--C 1.529 0.927 0 CA-C-N 115.415 -0.811 . . . . 0.0 113.768 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.517 ' O ' ' O ' ' B' ' 27' ' ' ASN . 39.0 m -132.24 162.67 30.38 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 118.284 1.042 . . . . 0.0 110.003 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.517 ' O ' ' O ' ' B' ' 26' ' ' SER . 65.5 t30 -38.44 177.72 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.632 179.384 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.44 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 98.7 mttt -73.31 111.87 8.84 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.527 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' C' ' 29' ' ' GLY . . . 71.22 92.5 0.08 OUTLIER Glycine 0 N--CA 1.464 0.567 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 -178.092 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.58 152.66 49.72 Favored 'General case' 0 CA--C 1.487 -1.465 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 174.284 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.603 ' N ' HD12 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -139.89 117.44 10.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -173.989 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.524 ' O ' ' SD ' ' I' ' 35' ' ' MET . 81.6 mt -122.13 126.63 74.62 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.733 -177.014 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.1 118.53 3.59 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 42.3 tp -126.53 118.45 24.92 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.292 0.568 . . . . 0.0 110.557 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.8 tpt -106.4 115.52 30.35 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.487 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' B' ' 37' ' ' GLY . 8.8 t -112.65 74.16 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.782 -0.19 . . . . 0.0 110.823 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.594 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -40.07 -95.84 0.01 OUTLIER Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -170.68 40.02 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m -135.72 161.9 37.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.896 0.379 . . . . 0.0 110.344 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.572 179.969 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -86.88 144.87 26.8 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.379 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 11' ' ' GLU . . . . . 0.424 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 84.6 tt0 -142.32 136.25 29.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.957 0.408 . . . . 0.0 110.55 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 5.6 m -126.23 131.56 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.008 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.424 ' NE2' ' OE2' ' C' ' 11' ' ' GLU . 82.1 m-70 -114.75 127.18 55.6 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.162 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.427 ' CE1' ' CB ' ' D' ' 13' ' ' HIS . 1.3 m80 -119.04 164.08 16.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 79.7 mt-30 -156.68 170.42 22.46 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 121.234 0.54 . . . . 0.0 110.818 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -168.0 113.83 0.68 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.362 178.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 tp -128.15 123.64 34.89 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 35.6 m -124.87 126.68 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.524 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 47.3 t80 -123.78 111.04 15.65 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.929 -178.562 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -114.56 119.35 36.5 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 120.428 0.156 . . . . 0.0 110.767 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.82 115.97 27.85 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.8 mt-10 -150.7 169.4 21.69 Favored 'General case' 0 C--N 1.347 0.473 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.707 -179.201 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.5 ' HB2' ' HZ3' ' E' ' 28' ' ' LYS . 74.8 m-20 -155.45 121.2 5.03 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.794 HG22 ' N ' ' C' ' 25' ' ' GLY . 3.5 p -136.73 -112.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.311 -177.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.794 ' N ' HG22 ' C' ' 24' ' ' VAL . . . 30.38 -89.21 0.01 OUTLIER Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.434 -177.166 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.4 t 171.54 177.73 0.07 Allowed 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 117.817 0.808 . . . . 0.0 109.687 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' C' ' 26' ' ' SER . 42.4 t30 -28.46 178.07 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.722 0 O-C-N 124.766 1.291 . . . . 0.0 113.818 -179.189 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.506 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 88.8 mttt 127.66 104.91 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 C-N-CA 125.564 1.545 . . . . 0.0 111.616 175.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.42 ' O ' ' HA2' ' B' ' 29' ' ' GLY . . . -58.37 96.64 0.07 OUTLIER Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 174.345 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -122.54 145.69 48.1 Favored 'General case' 0 CA--C 1.479 -1.77 0 N-CA-C 104.519 -2.4 . . . . 0.0 104.519 176.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.559 HD12 HG23 ' B' ' 31' ' ' ILE . 2.0 mt -142.8 108.4 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.548 0 CA-C-N 113.851 -1.522 . . . . 0.0 108.801 -172.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.541 HG12 HD11 ' C' ' 34' ' ' LEU . 14.9 tt -120.17 128.06 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 CA-C-O 121.054 0.454 . . . . 0.0 110.176 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.407 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -133.67 122.6 3.1 Favored Glycine 0 CA--C 1.508 -0.387 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.694 HD12 ' N ' ' C' ' 34' ' ' LEU . 0.0 OUTLIER -136.96 147.44 46.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 122.085 0.945 . . . . 0.0 111.837 -179.084 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.509 ' SD ' ' O ' ' I' ' 32' ' ' ILE . 5.1 tpt -111.56 117.42 32.92 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.54 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 26.2 t -130.96 66.33 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 -179.172 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.451 ' O ' HD13 ' I' ' 31' ' ' ILE . . . -123.83 102.48 0.73 Allowed Glycine 0 C--N 1.358 1.772 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.83 -170.31 12.66 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 -179.333 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.2 t -119.47 135.03 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.703 -179.475 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 121.008 0.432 . . . . 0.0 110.485 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.676 ' CG ' ' H ' ' D' ' 14' ' ' HIS . 21.7 t-80 -93.14 -169.93 2.28 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.572 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.676 ' H ' ' CG ' ' D' ' 13' ' ' HIS . 52.9 m80 -73.85 170.61 14.99 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.353 0.597 . . . . 0.0 110.146 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -148.93 173.58 13.17 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.177 179.141 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -147.26 114.63 6.29 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 120.898 0.38 . . . . 0.0 111.409 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -122.36 116.16 23.55 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.04 131.13 72.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.38 0.609 . . . . 0.0 110.654 -179.513 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.524 ' CE2' ' CD1' ' C' ' 19' ' ' PHE . 28.1 t80 -131.62 110.75 11.16 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -118.71 126.45 51.93 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.817 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 21' ' ' ALA . . . . . 0.59 ' HB1' ' CD1' ' F' ' 32' ' ' ILE . . . -124.3 126.25 45.73 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.602 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -149.52 111.56 4.61 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.496 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -90.35 134.04 34.59 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.591 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.09 112.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.278 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.49 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -46.53 91.77 0.01 OUTLIER Glycine 0 CA--C 1.536 1.367 0 CA-C-O 119.125 -0.819 . . . . 0.0 114.276 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 1.4 t 161.98 161.08 0.02 OUTLIER 'General case' 0 C--O 1.212 -0.89 0 CA-C-N 118.472 1.136 . . . . 0.0 112.303 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.49 ' O ' ' HB3' ' D' ' 28' ' ' LYS . 73.7 m-80 -33.48 -179.26 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 112.998 -1.91 . . . . 0.0 116.118 178.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.49 ' HB3' ' O ' ' D' ' 27' ' ' ASN . 87.1 tttt 99.64 113.8 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 128.398 2.679 . . . . 0.0 115.73 177.015 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.29 92.53 0.58 Allowed Glycine 0 C--N 1.348 1.238 0 CA-C-N 111.868 -2.423 . . . . 0.0 114.474 173.58 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.532 ' HB2' ' OD2' ' B' ' 23' ' ' ASP . . . -127.99 151.54 49.02 Favored 'General case' 0 CA--C 1.501 -0.911 0 CA-C-N 121.369 2.584 . . . . 0.0 106.725 173.614 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.488 HD12 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -146.03 116.84 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.56 -173.582 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.25 124.92 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.81 99.19 0.53 Allowed Glycine 0 N--CA 1.464 0.534 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 177.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.636 HD12 ' O ' ' C' ' 34' ' ' LEU . 40.7 tp -126.3 130.23 50.43 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 122.75 1.262 . . . . 0.0 112.69 -179.07 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.415 ' N ' HD12 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -104.54 110.92 23.4 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 113.688 -1.596 . . . . 0.0 107.302 176.372 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.485 HG23 ' O ' ' E' ' 35' ' ' MET . 0.1 OUTLIER -126.68 71.38 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.758 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -34.27 -100.46 0.01 OUTLIER Glycine 0 C--N 1.357 1.696 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.33 -168.06 40.65 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.2 160.58 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.955 0.407 . . . . 0.0 110.933 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.711 -179.978 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -114.47 139.17 49.75 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -113.67 141.26 47.45 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.941 0.4 . . . . 0.0 110.802 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.438 HG22 ' ND1' ' F' ' 13' ' ' HIS . 19.1 m -134.29 158.07 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.95 179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.49 ' ND1' ' CE1' ' D' ' 14' ' ' HIS . 12.1 m170 -86.75 178.31 7.05 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.633 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.1 OUTLIER -77.08 172.23 13.55 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -179.359 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.493 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 44.2 tt0 -148.2 170.17 18.44 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.113 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.493 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 99.1 mttt -144.16 117.28 8.92 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.123 0.487 . . . . 0.0 111.165 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.2 tt -119.21 114.95 23.23 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.358 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 t -124.06 120.46 59.53 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.601 0.715 . . . . 0.0 111.743 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.569 ' O ' ' N ' ' F' ' 20' ' ' PHE . 10.2 m-85 -126.39 104.54 8.23 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 48.1 t80 -121.97 129.6 52.63 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 122.975 0.172 . . . . 0.0 111.092 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.721 ' O ' ' HB3' ' F' ' 21' ' ' ALA . . . -133.82 135.39 43.75 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-O 123.362 1.553 . . . . 0.0 113.332 178.75 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -145.14 105.37 4.06 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.976 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.431 ' O ' ' OD2' ' F' ' 23' ' ' ASP . 4.2 t0 -83.04 122.63 28.58 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.49 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 63.4 t -72.8 120.42 21.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.353 0.597 . . . . 0.0 111.863 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.9 -90.25 0.04 OUTLIER Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.016 -0.993 . . . . 0.0 114.633 176.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.638 ' O ' ' O ' ' E' ' 27' ' ' ASN . 9.7 p -171.14 -178.61 2.47 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-O 121.153 0.502 . . . . 0.0 110.992 -176.423 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.638 ' O ' ' O ' ' E' ' 26' ' ' SER . 92.1 m-20 20.62 -179.81 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 117.12 2.267 . . . . 0.0 117.12 178.751 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.512 ' CB ' ' O ' ' E' ' 27' ' ' ASN . 78.2 tttt 128.68 106.13 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 112.381 -2.19 . . . . 0.0 110.002 -177.115 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -55.32 93.6 0.02 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.054 176.464 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.73 144.64 18.07 Favored 'General case' 0 CA--C 1.477 -1.843 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 174.426 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.434 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -154.55 125.66 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 117.946 -1.502 . . . . 0.0 111.177 -173.029 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -109.51 117.42 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.768 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 33' ' ' GLY . . . . . 0.458 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -109.63 97.86 1.07 Allowed Glycine 0 C--O 1.231 -0.074 0 N-CA-C 106.28 -2.728 . . . . 0.0 106.28 176.537 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.444 ' O ' ' HA ' ' F' ' 34' ' ' LEU . 6.9 tt -138.87 128.68 24.95 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-O 123.01 1.386 . . . . 0.0 113.427 -176.059 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.485 ' O ' HG23 ' D' ' 36' ' ' VAL . 97.3 mmm -106.98 120.27 41.62 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 114.097 -1.41 . . . . 0.0 110.489 179.141 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.1 OUTLIER -116.39 72.31 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 176.968 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -27.71 -101.03 0.01 OUTLIER Glycine 0 C--N 1.366 2.218 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.32 -176.71 25.67 Favored Glycine 0 N--CA 1.461 0.365 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.44 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -129.22 160.18 40.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.28 -0.46 . . . . 0.0 109.995 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.903 -1.046 . . . . 0.0 110.565 179.859 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.506 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.7 p . . . . . 0 CA--C 1.53 0.187 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.506 ' N ' HG22 ' F' ' 12' ' ' VAL . 17.5 m-70 -95.02 97.99 10.35 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.586 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.569 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 82.9 t60 -156.36 167.74 29.49 Favored 'General case' 0 N--CA 1.446 -0.672 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.569 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 12.0 pt20 -167.33 177.83 5.86 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.104 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -121.55 123.97 43.26 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.664 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 mt -122.94 121.21 35.59 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 111.653 0.242 . . . . 0.0 111.653 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.89 133.11 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 177.354 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.54 ' O ' ' O ' ' F' ' 20' ' ' PHE . 98.0 m-85 -114.24 136.58 52.8 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -177.632 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.605 ' O ' ' HB2' ' F' ' 21' ' ' ALA . 42.0 p90 -20.58 -157.29 0.0 OUTLIER 'General case' 0 C--O 1.195 -1.792 0 N-CA-C 118.991 2.96 . . . . 0.0 118.991 -175.807 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.721 ' HB3' ' O ' ' E' ' 21' ' ' ALA . . . 175.54 -168.56 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 122.213 1.006 . . . . 0.0 111.54 -173.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -170.97 167.27 7.35 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 114.473 -1.24 . . . . 0.0 107.964 -177.671 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.431 ' OD2' ' O ' ' E' ' 23' ' ' ASP . 23.6 m-20 . . . . . 0 N--CA 1.475 0.803 0 CA-C-N 119.05 0.841 . . . . 0.0 111.823 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 44.6 tttm . . . . . 0 N--CA 1.473 0.68 0 CA-C-O 121.224 0.535 . . . . 0.0 111.531 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -50.27 -99.42 0.01 OUTLIER Glycine 0 CA--C 1.506 -0.488 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.553 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.76 173.39 12.65 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.7 118.41 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 116.302 -2.159 . . . . 0.0 114.101 -170.38 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.59 ' CD1' ' HB1' ' D' ' 21' ' ' ALA . 59.4 mt -98.83 112.1 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.054 177.229 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -109.72 89.68 0.56 Allowed Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 105.831 -2.907 . . . . 0.0 105.831 177.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.75 HD23 ' C ' ' F' ' 34' ' ' LEU . 0.8 OUTLIER -141.29 147.65 38.53 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 120.714 -0.394 . . . . 0.0 109.952 -177.894 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.543 ' CE ' HG22 ' L' ' 31' ' ' ILE . 3.6 ttp -137.05 133.95 36.0 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.943 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.666 HG13 HD21 ' F' ' 34' ' ' LEU . 1.9 m -114.28 80.32 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.909 -179.025 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.409 ' HA2' HG21 ' L' ' 31' ' ' ILE . . . 50.82 -102.66 0.07 OUTLIER Glycine 0 C--N 1.342 0.862 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.763 178.723 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.44 -156.49 15.49 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 90.9 t -122.96 136.22 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.833 0.349 . . . . 0.0 110.959 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 m . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.482 179.683 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -100.93 127.56 47.36 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -88.68 156.89 18.75 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.488 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 3.4 m -132.85 154.69 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.164 0.507 . . . . 0.0 110.601 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 69.7 m80 -158.2 167.11 30.71 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.153 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -122.53 179.1 4.71 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 98.7 mt-30 -96.85 176.6 5.92 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.376 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -113.96 144.04 43.73 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.098 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.3 mt -119.07 126.83 52.6 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.048 0.452 . . . . 0.0 110.786 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.548 ' O ' HG23 ' G' ' 18' ' ' VAL . 25.9 m -133.44 119.96 36.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 121.18 0.514 . . . . 0.0 110.658 179.65 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.879 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 2.4 m-85 -113.07 119.63 38.51 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.26 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.528 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 48.5 p90 -122.2 121.78 37.65 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.071 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.94 122.47 42.31 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 120.55 -0.46 . . . . 0.0 111.812 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -166.73 89.17 0.36 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.698 ' H ' ' NZ ' ' I' ' 28' ' ' LYS . 90.8 m-20 -85.71 102.78 13.91 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.993 0.425 . . . . 0.0 112.131 -177.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.412 ' O ' ' O ' ' G' ' 23' ' ' ASP . 18.3 m -56.78 -160.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.489 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -77.59 80.51 1.3 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-O 119.524 -0.598 . . . . 0.0 112.947 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.416 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 30.9 t -94.4 176.55 6.26 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 118.76 1.28 . . . . 0.0 107.879 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -60.14 178.24 0.2 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 119.166 -1.013 . . . . 0.0 111.096 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -60.77 110.71 1.39 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.064 -0.517 . . . . 0.0 112.318 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.87 94.25 0.08 OUTLIER Glycine 0 N--CA 1.465 0.61 0 C-N-CA 118.381 -1.866 . . . . 0.0 112.601 174.774 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.43 158.72 16.46 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-N 119.935 1.867 . . . . 0.0 106.464 177.364 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.831 HD12 ' H ' ' G' ' 31' ' ' ILE . 0.2 OUTLIER -150.31 114.72 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.382 -174.427 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 97.3 mt -125.27 124.98 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.224 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.02 123.12 3.92 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 tp -131.03 133.7 45.99 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 117.211 0.505 . . . . 0.0 111.32 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.609 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 63.4 ttp -130.82 134.91 47.25 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.421 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.52 79.78 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.79 104.64 1.27 Allowed Glycine 0 C--N 1.342 0.905 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 44.05 -167.2 0.02 OUTLIER Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.24 160.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 120.855 0.36 . . . . 0.0 110.65 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.515 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -80.91 136.12 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.781 0.324 . . . . 0.0 110.624 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -52.64 137.63 30.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.466 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.403 HG23 ' O ' ' I' ' 12' ' ' VAL . 2.3 p -127.41 132.87 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.159 0.504 . . . . 0.0 110.744 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.51 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 34.5 m170 -126.99 111.38 14.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.106 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.448 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 84.0 t60 -114.05 162.15 16.82 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.442 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.448 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 83.3 mt-30 -156.72 177.9 10.96 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.136 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -167.73 111.23 0.65 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.824 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.498 ' HB2' HD22 ' I' ' 17' ' ' LEU . 5.3 mp -116.96 120.92 39.91 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.551 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 66.7 t -124.0 123.34 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 121.343 0.592 . . . . 0.0 110.786 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.776 ' CE1' HD13 ' J' ' 34' ' ' LEU . 11.5 m-85 -117.02 115.49 25.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.132 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -143.13 132.2 23.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.967 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 138.84 41.06 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.105 0.955 . . . . 0.0 112.777 -178.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -131.01 105.91 8.04 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 105.861 -1.903 . . . . 0.0 105.861 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -77.95 117.25 19.1 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -175.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.556 ' O ' ' N ' ' H' ' 26' ' ' SER . 55.0 t -102.46 125.94 56.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.6 83.05 0.0 OUTLIER Glycine 0 CA--C 1.537 1.443 0 CA-C-O 119.536 -0.591 . . . . 0.0 113.291 178.408 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.556 ' N ' ' O ' ' H' ' 24' ' ' VAL . 17.4 p -94.15 176.8 6.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 177.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' O ' ' G' ' 26' ' ' SER . 28.1 m120 -60.11 178.22 0.2 Allowed 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.247 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -60.63 110.66 1.35 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.03 94.17 0.08 OUTLIER Glycine 0 N--CA 1.469 0.869 0 C-N-CA 118.741 -1.695 . . . . 0.0 114.815 173.1 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.19 157.57 17.47 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 102.659 -3.089 . . . . 0.0 102.659 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.705 HG23 HG13 ' I' ' 31' ' ' ILE . 0.1 OUTLIER -145.86 121.61 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 118.146 -1.421 . . . . 0.0 112.207 -171.552 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 93.0 mt -132.57 127.47 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.381 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.74 128.6 5.55 Favored Glycine 0 N--CA 1.472 1.097 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.786 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 mp -132.6 130.66 40.53 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.284 0.564 . . . . 0.0 111.458 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.3 tmm? -129.67 127.32 40.29 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.454 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' H' ' 37' ' ' GLY . 66.9 t -107.41 86.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -179.009 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.493 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -15.48 -93.38 0.01 OUTLIER Glycine 0 C--N 1.346 1.084 0 O-C-N 123.859 0.724 . . . . 0.0 112.288 177.812 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.44 -176.13 42.32 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.62 162.23 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 120.715 0.293 . . . . 0.0 110.501 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.403 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.361 179.791 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.48 HG23 ' CD2' ' I' ' 14' ' ' HIS . 35.7 m . . . . . 0 N--CA 1.469 0.514 0 N-CA-C 111.541 0.2 . . . . 0.0 111.541 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.533 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 53.3 m-70 -68.43 145.1 54.4 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -177.545 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.48 ' CD2' HG23 ' I' ' 12' ' ' VAL . 47.8 m-70 -154.66 169.28 24.25 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.382 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.403 ' HG2' ' N ' ' I' ' 16' ' ' LYS . 54.8 tt0 -159.99 168.3 25.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.033 178.786 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.403 ' N ' ' HG2' ' I' ' 15' ' ' GLN . 99.2 mttt -154.64 131.54 10.83 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.51 0.195 . . . . 0.0 110.539 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.509 HD12 ' CE2' ' I' ' 19' ' ' PHE . 0.0 OUTLIER -127.72 119.91 26.82 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.68 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 70.7 t -126.24 129.53 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 120.629 -0.428 . . . . 0.0 112.151 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.702 ' CE1' HD22 ' K' ' 34' ' ' LEU . 61.2 m-85 -123.22 121.75 36.68 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.924 179.169 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.419 ' CE2' ' CG ' ' J' ' 20' ' ' PHE . 7.5 m-85 -131.67 130.69 42.37 Favored 'General case' 0 N--CA 1.476 0.867 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 135.17 39.23 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -137.76 150.28 47.12 Favored 'General case' 0 C--N 1.352 0.692 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.247 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.435 ' OD2' ' O ' ' J' ' 26' ' ' SER . 13.4 t70 -116.95 114.53 23.96 Favored 'General case' 0 N--CA 1.481 1.115 0 O-C-N 122.21 -0.306 . . . . 0.0 111.36 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.458 ' O ' ' N ' ' I' ' 26' ' ' SER . 14.7 t -81.59 130.93 34.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.708 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.8 -85.8 0.01 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.529 ' O ' ' O ' ' I' ' 27' ' ' ASN . 26.1 p -153.62 -172.86 4.37 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-O 121.639 0.733 . . . . 0.0 111.224 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.686 ' H ' ' NZ ' ' K' ' 28' ' ' LYS . 64.8 t30 -19.71 159.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 113.303 -1.771 . . . . 0.0 115.156 178.502 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.698 ' NZ ' ' H ' ' G' ' 23' ' ' ASP . 74.1 tttt -161.21 110.83 1.64 Allowed 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 114.744 -1.116 . . . . 0.0 109.376 175.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.33 93.23 0.23 Allowed Glycine 0 CA--C 1.508 -0.369 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 177.313 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.73 147.05 51.3 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 176.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.705 HG13 HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -146.68 113.97 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.942 -175.583 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.509 ' O ' ' SD ' ' C' ' 35' ' ' MET . 0.1 OUTLIER -110.76 124.56 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.522 179.471 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.35 102.84 1.39 Allowed Glycine 0 N--CA 1.46 0.292 0 N-CA-C 108.446 -1.862 . . . . 0.0 108.446 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.879 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 23.1 tp -119.0 126.68 52.29 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 117.277 0.538 . . . . 0.0 111.817 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.524 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 12.2 ptm -131.9 110.87 11.1 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 174.52 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.599 HG13 HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -121.18 72.02 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.652 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.57 179.554 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.61 102.81 2.33 Favored Glycine 0 C--N 1.36 1.869 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.62 157.36 22.07 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.4 t -124.28 136.56 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.913 0.387 . . . . 0.0 110.53 -179.582 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.377 179.78 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.426 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -83.38 138.48 33.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.797 0.332 . . . . 0.0 110.478 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 11' ' ' GLU . . . . . 0.461 ' O ' HG12 ' K' ' 12' ' ' VAL . 79.9 tt0 -152.34 137.54 17.43 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.408 -179.745 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.435 ' HB ' ' H ' ' K' ' 13' ' ' HIS . 0.2 OUTLIER -93.03 126.93 45.4 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.694 0 CA-C-O 121.319 0.58 . . . . 0.0 109.847 -179.932 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.533 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 18.3 t60 -164.92 111.76 0.99 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.233 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.757 ' CE1' ' O ' ' K' ' 13' ' ' HIS . 77.3 m80 -154.55 177.23 11.43 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -133.82 177.58 7.61 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.731 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -137.54 131.77 32.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 mt -117.89 121.7 41.41 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.673 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 67.8 t -122.47 121.21 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-O 120.948 0.404 . . . . 0.0 110.961 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.862 ' CE1' HD22 ' L' ' 34' ' ' LEU . 96.9 m-85 -113.39 114.49 26.68 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 178.83 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 19.2 t80 -129.03 123.34 32.09 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.988 0.423 . . . . 0.0 111.634 -177.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.94 124.12 32.31 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.05 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.4 tt0 -103.52 156.81 17.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.131 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.456 ' CG ' ' N ' ' J' ' 24' ' ' VAL . 35.2 t70 -78.13 -113.89 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.341 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' J' ' 26' ' ' SER . 4.1 t 73.45 124.45 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.57 -87.09 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -177.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.678 ' O ' ' O ' ' J' ' 27' ' ' ASN . 0.5 OUTLIER 170.79 176.17 0.06 Allowed 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.702 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.678 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.4 m120 -28.3 170.42 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.13 0 O-C-N 124.319 1.012 . . . . 0.0 112.074 177.446 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.561 ' O ' ' N ' ' J' ' 30' ' ' ALA . 37.4 pttt -148.73 111.55 4.82 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.161 -0.962 . . . . 0.0 112.208 177.604 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.44 91.35 0.01 OUTLIER Glycine 0 CA--C 1.505 -0.566 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 176.23 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -137.85 153.71 49.56 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 103.328 -2.842 . . . . 0.0 103.328 177.576 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.417 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -144.41 111.67 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 C-N-CA 118.265 -1.374 . . . . 0.0 109.968 -174.096 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.484 HD13 HD11 ' J' ' 34' ' ' LEU . 6.7 tt -112.71 116.63 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.293 -0.867 . . . . 0.0 108.731 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.07 103.69 2.33 Favored Glycine 0 N--CA 1.46 0.284 0 N-CA-C 107.596 -2.202 . . . . 0.0 107.596 178.467 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.776 HD13 ' CE1' ' H' ' 19' ' ' PHE . 24.2 mt -114.39 114.0 25.28 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 121.606 0.717 . . . . 0.0 110.247 -177.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -116.59 118.65 33.21 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.506 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.44 ' O ' ' C ' ' J' ' 37' ' ' GLY . 1.1 t -131.15 75.95 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.025 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.2 -97.56 0.01 OUTLIER Glycine 0 C--N 1.362 2.025 0 N-CA-C 112.097 -0.401 . . . . 0.0 112.097 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.97 -163.85 30.23 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 82.9 t -121.95 135.32 62.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.039 -0.982 . . . . 0.0 110.554 -179.649 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.1 137.88 50.77 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 120.89 0.376 . . . . 0.0 110.514 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.77 162.28 35.12 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.4 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.461 HG12 ' O ' ' J' ' 11' ' ' GLU . 6.0 m -110.7 133.22 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.757 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 0.4 OUTLIER -76.12 -166.01 0.55 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.259 -178.546 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 7.6 p-80 -138.23 178.45 7.12 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.607 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -99.27 175.1 5.99 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.486 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -147.42 124.95 11.69 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -117.55 124.05 47.74 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 44.9 t -127.94 126.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-O 120.832 0.349 . . . . 0.0 111.575 -179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -115.62 116.09 27.53 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.594 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.7 t80 -125.19 122.73 37.88 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.68 26.4 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.159 1.17 . . . . 0.0 114.159 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' L' ' 22' ' ' GLU . 70.3 mm-40 -90.46 152.41 20.97 Favored 'General case' 0 C--O 1.232 0.158 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 177.667 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.561 ' OD2' ' N ' ' L' ' 28' ' ' LYS . 28.0 t0 -148.43 116.29 6.36 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.028 0.442 . . . . 0.0 111.739 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 2.5 p -146.81 112.14 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.044 -179.194 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.32 91.32 0.01 OUTLIER Glycine 0 N--CA 1.472 1.064 0 CA-C-O 121.509 0.505 . . . . 0.0 112.63 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -45.15 153.86 0.18 Allowed 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 122.597 1.189 . . . . 0.0 112.511 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.514 ' O ' ' C ' ' K' ' 28' ' ' LYS . 33.9 m120 -156.85 178.58 10.19 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 112.631 -2.077 . . . . 0.0 108.483 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.686 ' NZ ' ' H ' ' I' ' 27' ' ' ASN . 0.1 OUTLIER 2.91 -104.33 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.411 0 C-N-CA 123.562 0.745 . . . . 0.0 112.05 179.816 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.436 ' H ' ' HB2' ' K' ' 28' ' ' LYS . . . 141.09 95.33 0.25 Allowed Glycine 0 N--CA 1.48 1.602 0 CA-C-N 118.986 0.812 . . . . 0.0 111.924 178.051 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.4 169.85 0.41 Allowed 'General case' 0 C--N 1.345 0.399 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.036 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.417 HD12 ' CG2' ' J' ' 31' ' ' ILE . 0.0 OUTLIER -148.53 111.97 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 118.996 -1.082 . . . . 0.0 109.035 -179.028 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.541 HG12 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -111.99 122.08 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.465 -177.998 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.45 108.99 2.54 Favored Glycine 0 N--CA 1.468 0.829 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.702 HD22 ' CE1' ' I' ' 19' ' ' PHE . 5.1 mt -122.09 114.96 21.63 Favored 'General case' 0 CA--C 1.501 -0.913 0 CA-C-N 117.332 0.566 . . . . 0.0 110.821 -177.261 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.458 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 33.6 ttp -120.86 114.31 21.41 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 176.984 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.479 HG23 HG12 ' L' ' 36' ' ' VAL . 0.0 OUTLIER -130.19 73.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 107.672 -1.232 . . . . 0.0 107.672 178.632 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.35 -101.6 0.01 OUTLIER Glycine 0 C--N 1.364 2.121 0 O-C-N 123.59 0.556 . . . . 0.0 112.482 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.35 -170.97 38.11 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -125.13 137.19 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.848 -179.788 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -100.77 132.7 46.04 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -151.32 147.39 26.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.965 0.412 . . . . 0.0 111.055 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.5 t -123.13 129.32 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.471 ' O ' ' CG ' ' L' ' 13' ' ' HIS . 56.5 p-80 -170.74 111.88 0.39 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.053 0.454 . . . . 0.0 110.973 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 72.9 m80 -155.8 177.81 10.98 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -115.58 173.8 6.35 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.302 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 50.3 mtpt -151.25 109.54 3.76 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.959 0.409 . . . . 0.0 110.455 179.136 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 57.6 tp -123.66 118.51 27.44 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -130.26 133.06 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.875 0.369 . . . . 0.0 110.086 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.469 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -136.86 129.73 30.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.271 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -138.8 132.05 30.0 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.496 0.665 . . . . 0.0 110.455 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.83 138.88 42.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.498 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 95.0 mt-10 -98.4 114.73 27.19 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -102.68 121.64 42.83 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.26 0.552 . . . . 0.0 111.838 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 25.3 t -104.91 -111.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.34 -91.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' L' ' 27' ' ' ASN . 45.9 m -141.01 170.68 15.28 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' L' ' 26' ' ' SER . 93.8 m-20 -29.0 170.13 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.828 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.561 ' N ' ' OD2' ' K' ' 23' ' ' ASP . 87.8 tttt -148.35 109.99 4.46 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 176.08 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -50.84 -95.8 0.01 OUTLIER Glycine 0 C--N 1.334 0.445 0 C-N-CA 118.549 -1.786 . . . . 0.0 112.545 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.599 ' HB2' HD21 ' J' ' 27' ' ' ASN . . . 72.57 156.11 0.17 Allowed 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 100.409 -3.923 . . . . 0.0 100.409 -176.749 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.543 HG22 ' CE ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -144.77 107.67 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 CA-C-N 124.081 3.128 . . . . 0.0 109.237 179.781 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.648 HG23 HD23 ' L' ' 34' ' ' LEU . 1.4 tt -102.53 112.46 35.93 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 CA-C-N 113.956 -1.475 . . . . 0.0 109.975 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.1 96.69 1.0 Allowed Glycine 0 N--CA 1.46 0.286 0 N-CA-C 107.296 -2.321 . . . . 0.0 107.296 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.862 HD22 ' CE1' ' J' ' 19' ' ' PHE . 3.4 pp -120.62 125.88 48.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.91 0.386 . . . . 0.0 110.948 -177.745 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 65.6 ttp -125.6 121.77 34.52 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-O 121.431 0.634 . . . . 0.0 109.877 179.112 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.479 HG12 HG23 ' K' ' 36' ' ' VAL . 2.8 m -124.26 77.05 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.65 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -35.64 104.81 0.03 OUTLIER Glycine 0 C--N 1.349 1.289 0 N-CA-C 111.751 -0.539 . . . . 0.0 111.751 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.05 -177.28 42.51 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 8.5 p -140.86 151.12 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 121.081 0.467 . . . . 0.0 111.066 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 47.3 t . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.292 179.7 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 99.5 m-85 -114.81 144.69 43.1 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.834 0.35 . . . . 0.0 110.502 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -55.83 140.59 41.83 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.0 t -118.55 131.54 71.04 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.426 0.632 . . . . 0.0 111.591 -179.003 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -106.5 -172.35 2.07 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.96 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 48.5 p-80 -146.8 170.92 16.02 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -147.69 178.75 8.22 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.603 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -138.7 129.45 26.36 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.801 0.334 . . . . 0.0 110.467 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.4 mt -112.48 114.61 27.39 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.592 HG23 ' O ' ' A' ' 18' ' ' VAL . 6.2 m -127.55 121.16 56.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.119 0 CA-C-O 121.345 0.593 . . . . 0.0 111.433 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.501 ' CE1' HD21 ' D' ' 34' ' ' LEU . 0.9 OUTLIER -116.88 107.9 15.17 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 177.283 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.4 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.8 p90 -126.68 126.81 44.15 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.94 125.62 53.84 Favored 'General case' 0 C--O 1.24 0.577 0 CA-C-O 121.275 0.56 . . . . 0.0 111.624 -178.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -155.47 82.0 1.04 Allowed 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.162 -2.162 . . . . 0.0 105.162 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -34.84 120.64 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 114.922 -1.035 . . . . 0.0 113.612 -176.315 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 26' ' ' SER . 60.7 t -100.94 125.13 54.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 177.56 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -31.71 83.27 0.0 OUTLIER Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.324 0.39 . . . . 0.0 113.033 -177.28 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.599 ' N ' ' O ' ' A' ' 24' ' ' VAL . 69.5 m -87.02 -179.23 6.45 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 28' ' ' LYS . 87.7 m-20 -75.71 178.53 6.03 Favored 'General case' 0 C--N 1.314 -0.966 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.094 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.507 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.1 mttt -45.34 -110.77 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.879 0.847 . . . . 0.0 112.066 178.689 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.32 93.71 1.65 Allowed Glycine 0 N--CA 1.467 0.734 0 CA-C-O 118.428 -1.206 . . . . 0.0 110.181 178.104 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.57 160.11 14.73 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 116.688 -2.005 . . . . 0.0 108.699 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.648 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.4 OUTLIER -155.39 117.81 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 113.986 -1.461 . . . . 0.0 109.464 -173.987 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.453 ' C ' ' SD ' ' G' ' 35' ' ' MET . 96.9 mt -126.33 129.37 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-O 120.812 0.339 . . . . 0.0 110.686 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.49 121.67 2.73 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.9 mt -138.96 139.07 37.84 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.938 0.875 . . . . 0.0 111.463 179.284 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.438 ' C ' ' SD ' ' A' ' 35' ' ' MET . 6.8 tmm? -136.15 131.42 34.66 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.288 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.0 t -121.52 73.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.415 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -105.5 100.7 1.75 Allowed Glycine 0 N--CA 1.442 -0.933 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 178.315 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -177.66 170.44 42.84 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m -134.33 161.46 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.889 0.376 . . . . 0.0 110.795 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.407 179.728 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -111.59 136.95 50.08 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.701 0.286 . . . . 0.0 110.672 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -111.72 129.65 56.04 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.021 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t -142.19 138.39 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.799 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -132.41 104.95 6.98 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.585 0.231 . . . . 0.0 110.793 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' B' ' 15' ' ' GLN . 52.7 m170 -126.33 167.08 15.99 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.6 mm-40 -155.27 178.39 10.27 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.663 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -171.08 115.72 0.43 Allowed 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.113 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.679 HD23 ' C ' ' B' ' 17' ' ' LEU . 8.2 tt -128.42 122.62 31.77 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.127 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.41 ' N ' HD23 ' B' ' 17' ' ' LEU . 28.6 m -137.76 131.98 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 N-CA-C 113.129 0.788 . . . . 0.0 113.129 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.548 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 2.8 m-85 -110.09 115.68 30.19 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.198 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.598 ' CE1' ' CD1' ' C' ' 20' ' ' PHE . 74.2 t80 -121.76 123.5 41.97 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.56 124.76 36.77 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 113.04 0.756 . . . . 0.0 113.04 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.451 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 42.8 tp10 -153.99 129.49 9.91 Favored 'General case' 0 C--O 1.221 -0.415 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.344 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.529 ' OD2' ' NZ ' ' C' ' 28' ' ' LYS . 8.8 t0 -152.41 134.99 15.31 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.055 -178.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' B' ' 25' ' ' GLY . 2.1 p -110.73 111.68 37.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.898 -1.047 . . . . 0.0 108.928 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 32.74 90.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.349 0 C-N-CA 121.586 -0.34 . . . . 0.0 113.328 177.524 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.51 ' OG ' ' CE ' ' C' ' 28' ' ' LYS . 54.8 p -100.31 150.52 22.49 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 117.626 0.713 . . . . 0.0 109.083 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.491 ' CG ' ' H ' ' B' ' 28' ' ' LYS . 25.6 t-20 -42.02 173.94 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.852 0.834 . . . . 0.0 113.207 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.491 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 57.7 tttt -76.3 111.15 11.43 Favored 'General case' 0 CA--C 1.548 0.893 0 N-CA-C 115.563 1.69 . . . . 0.0 115.563 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.36 93.41 0.03 OUTLIER Glycine 0 N--CA 1.478 1.454 0 C-N-CA 119.123 -1.513 . . . . 0.0 115.695 171.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.442 ' C ' ' CG1' ' B' ' 31' ' ' ILE . . . -123.3 152.47 41.38 Favored 'General case' 0 C--O 1.245 0.836 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 173.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.648 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.2 OUTLIER -152.8 135.31 6.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 C-N-CA 118.215 -1.394 . . . . 0.0 111.899 -171.762 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 16.5 tt -146.29 137.44 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.332 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.48 128.89 6.48 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.441 ' HB2' HD22 ' C' ' 34' ' ' LEU . 48.9 mt -139.33 128.98 24.55 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 122.227 -0.573 . . . . 0.0 111.94 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.43 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 61.8 ttp -130.93 127.33 38.23 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.247 177.467 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' B' ' 37' ' ' GLY . 15.4 m -133.83 76.4 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 119.936 -0.706 . . . . 0.0 112.779 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.437 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -33.6 -95.67 0.01 OUTLIER Glycine 0 CA--C 1.53 1.0 0 N-CA-C 111.521 -0.632 . . . . 0.0 111.521 178.11 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.47 -168.75 35.43 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.64 134.78 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 120.985 0.421 . . . . 0.0 110.412 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.668 179.837 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -108.44 132.09 54.13 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.551 0.215 . . . . 0.0 110.457 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -95.92 134.77 38.52 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 121.014 0.435 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -127.71 136.15 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.11 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -130.16 125.48 35.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.792 0.33 . . . . 0.0 111.013 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.497 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 45.1 t-80 -145.2 166.79 24.44 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.464 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.497 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 99.7 mm-40 -153.16 176.83 11.49 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.807 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.66 ' C ' HD12 ' C' ' 17' ' ' LEU . 69.0 tttt -170.17 104.31 0.3 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.598 178.389 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.66 HD12 ' C ' ' C' ' 16' ' ' LYS . 11.2 mp -118.5 118.59 32.12 Favored 'General case' 0 C--O 1.237 0.432 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.321 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -131.73 131.5 62.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.895 ' CZ ' HD23 ' E' ' 34' ' ' LEU . 52.3 m-85 -113.69 116.51 29.55 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.382 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE1' ' B' ' 20' ' ' PHE . 51.9 t80 -125.94 122.14 35.12 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 118.625 0.648 . . . . 0.0 109.548 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 21' ' ' ALA . . . . . 0.527 ' HB1' ' HB3' ' D' ' 27' ' ' ASN . . . -137.29 130.12 30.37 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 113.769 1.025 . . . . 0.0 113.769 -178.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.451 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 71.3 mt-10 -155.17 114.98 3.72 Favored 'General case' 0 C--N 1.352 0.682 0 CA-C-N 113.661 -1.608 . . . . 0.0 108.806 178.104 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.423 ' O ' ' O ' ' D' ' 26' ' ' SER . 65.6 t0 -147.54 122.51 10.05 Favored 'General case' 0 N--CA 1.476 0.862 0 O-C-N 121.739 -0.6 . . . . 0.0 111.419 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 14.5 t -98.53 -112.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.056 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 39.68 -90.94 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.103 -179.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.631 ' O ' ' O ' ' C' ' 27' ' ' ASN . 2.0 m 171.15 170.11 0.08 Allowed 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.436 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.631 ' O ' ' O ' ' C' ' 26' ' ' SER . 65.8 t30 -17.56 158.61 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 O-C-N 124.616 1.198 . . . . 0.0 113.696 177.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.529 ' NZ ' ' OD2' ' B' ' 23' ' ' ASP . 50.5 tttt -161.26 110.63 1.61 Allowed 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.521 174.491 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.69 92.64 0.29 Allowed Glycine 0 C--O 1.224 -0.488 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 173.421 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.16 150.5 47.98 Favored 'General case' 0 CA--C 1.476 -1.885 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 174.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.42 HD13 HG21 ' C' ' 31' ' ' ILE . 0.1 OUTLIER -147.36 114.49 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 C-N-CA 117.672 -1.611 . . . . 0.0 110.996 -173.931 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 9.2 mt -108.84 124.04 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.147 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.859 ' O ' HD23 ' C' ' 34' ' ' LEU . . . -125.43 100.62 0.6 Allowed Glycine 0 N--CA 1.474 1.186 0 N-CA-C 108.521 -1.831 . . . . 0.0 108.521 177.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.859 HD23 ' O ' ' C' ' 33' ' ' GLY . 1.6 mt -134.32 142.27 47.19 Favored 'General case' 0 C--O 1.243 0.722 0 CA-C-O 122.886 1.327 . . . . 0.0 113.859 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.544 ' SD ' ' CE ' ' D' ' 35' ' ' MET . 41.9 ttp -127.51 118.8 24.7 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 112.771 -2.013 . . . . 0.0 108.127 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.448 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.1 OUTLIER -116.33 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-N 114.173 -1.376 . . . . 0.0 107.864 179.067 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -39.86 -101.48 0.01 OUTLIER Glycine 0 C--N 1.366 2.238 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.88 -145.83 11.32 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.4 m -128.32 158.85 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 120.664 0.269 . . . . 0.0 110.306 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.467 179.984 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -83.37 137.61 33.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.799 0.333 . . . . 0.0 110.522 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -120.9 133.65 55.29 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.426 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 33.7 m -129.03 133.13 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 121.348 0.594 . . . . 0.0 110.757 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -132.97 134.85 45.05 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.666 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 73.3 m80 -149.04 167.03 26.93 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 121.266 0.555 . . . . 0.0 110.039 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -155.76 171.23 20.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.326 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -158.62 114.1 2.62 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.926 -0.31 . . . . 0.0 111.107 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mt -118.55 119.13 33.59 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.444 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -131.31 129.54 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.603 ' CZ ' ' CD1' ' C' ' 19' ' ' PHE . 19.8 m-85 -118.97 123.63 45.04 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -131.26 119.83 22.35 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.747 0.308 . . . . 0.0 111.633 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.08 122.45 28.35 Favored 'General case' 0 N--CA 1.476 0.835 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.136 178.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -84.9 157.01 20.99 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.416 ' HA ' ' NZ ' ' F' ' 28' ' ' LYS . 1.2 t0 -88.72 -174.12 4.4 Favored 'General case' 0 C--N 1.348 0.525 0 CA-C-O 121.213 0.53 . . . . 0.0 110.897 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.413 ' O ' ' O ' ' D' ' 25' ' ' GLY . 20.7 t 62.64 104.45 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' D' ' 24' ' ' VAL . . . 64.71 100.0 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 117.618 -2.23 . . . . 0.0 107.686 -178.664 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.423 ' O ' ' O ' ' C' ' 23' ' ' ASP . 78.6 p -52.44 171.93 0.05 OUTLIER 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 118.037 0.918 . . . . 0.0 108.617 -176.024 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.527 ' HB3' ' HB1' ' C' ' 21' ' ' ALA . 6.8 m120 -81.84 178.51 8.27 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.694 -0.802 . . . . 0.0 112.115 -175.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' D' ' 27' ' ' ASN . 44.2 tttp -38.6 -106.51 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.294 -1.321 . . . . 0.0 112.533 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.673 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . 86.29 -100.04 2.48 Favored Glycine 0 CA--C 1.456 -3.637 0 N-CA-C 106.218 -2.753 . . . . 0.0 106.218 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.918 ' C ' HD13 ' D' ' 31' ' ' ILE . . . 67.55 -163.86 0.21 Allowed 'General case' 0 N--CA 1.419 -2.001 1 N-CA-C 98.449 -4.648 . . . . 0.0 98.449 -176.36 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.918 HD13 ' C ' ' D' ' 30' ' ' ALA . 0.0 OUTLIER -115.79 110.94 33.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 CA-C-N 123.941 3.064 . . . . 0.0 110.397 177.258 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.446 ' C ' ' SD ' ' J' ' 35' ' ' MET . 13.7 tt -122.57 127.56 75.04 Favored 'Isoleucine or valine' 0 C--N 1.353 0.744 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.96 179.351 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.544 ' O ' HD12 ' D' ' 34' ' ' LEU . . . -121.36 101.22 0.77 Allowed Glycine 0 N--CA 1.457 0.092 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.544 HD12 ' O ' ' D' ' 33' ' ' GLY . 5.0 mp -120.34 125.81 48.96 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 122.32 1.057 . . . . 0.0 110.923 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.617 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 37.3 ttp -120.29 119.26 32.63 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 113.928 -1.487 . . . . 0.0 107.839 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.51 74.06 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.698 -178.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . -48.35 111.45 0.89 Allowed Glycine 0 C--N 1.351 1.392 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 37' ' ' GLY . . . -59.77 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 74.7 t -120.95 133.73 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.688 -179.93 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -109.23 132.86 53.72 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.58 151.0 42.79 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.684 0.278 . . . . 0.0 110.629 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 66.2 t -125.86 131.2 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.947 0.403 . . . . 0.0 110.609 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 16.9 t60 -138.93 130.75 27.69 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.532 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 27.1 m80 -148.15 168.24 22.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.751 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 32.7 mt-30 -154.83 165.97 34.97 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.427 178.051 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -148.6 117.73 6.81 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.192 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.27 122.72 34.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.238 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -127.56 125.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.074 0.464 . . . . 0.0 111.0 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -117.74 113.81 22.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.542 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 55.0 t80 -123.46 116.72 23.69 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 134.74 15.52 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 118.974 -1.09 . . . . 0.0 113.664 -178.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -102.6 117.28 34.33 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 176.275 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.498 ' OD1' ' N ' ' E' ' 23' ' ' ASP . 7.1 p-10 -131.06 113.26 13.72 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 114.395 1.257 . . . . 0.0 114.395 -177.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.631 ' O ' ' N ' ' E' ' 26' ' ' SER . 40.3 t -127.23 122.29 59.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 175.35 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.467 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . -28.97 83.8 0.0 OUTLIER Glycine 0 N--CA 1.484 1.883 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.631 ' N ' ' O ' ' E' ' 24' ' ' VAL . 6.3 p -88.24 -179.75 6.2 Favored 'General case' 0 N--CA 1.441 -0.885 0 CA-C-O 123.102 1.43 . . . . 0.0 113.734 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -77.04 179.35 6.31 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-N 111.446 -2.616 . . . . 0.0 110.836 176.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.478 ' HE2' ' HB2' ' E' ' 30' ' ' ALA . 82.9 tttt 42.88 110.98 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 114.697 1.369 . . . . 0.0 114.697 176.444 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.43 93.99 1.68 Allowed Glycine 0 N--CA 1.47 0.905 0 N-CA-C 108.035 -2.026 . . . . 0.0 108.035 174.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.659 ' HB1' ' H ' ' D' ' 30' ' ' ALA . . . -100.5 166.79 10.75 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.475 HG22 ' HE1' ' L' ' 35' ' ' MET . 0.0 OUTLIER -156.44 121.79 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.051 0 C-N-CA 117.916 -1.514 . . . . 0.0 112.306 -173.087 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -111.15 123.74 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.877 178.188 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.8 109.78 1.7 Allowed Glycine 0 CA--C 1.512 -0.139 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.895 HD23 ' CZ ' ' C' ' 19' ' ' PHE . 41.5 tp -133.24 126.74 32.2 Favored 'General case' 0 C--O 1.243 0.745 0 CA-C-O 121.848 0.832 . . . . 0.0 111.454 -179.64 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.541 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 57.9 ttp -115.62 124.3 50.58 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.059 177.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -129.68 71.58 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.332 -179.885 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -32.46 -101.0 0.01 OUTLIER Glycine 0 C--N 1.364 2.106 0 N-CA-C 111.678 -0.569 . . . . 0.0 111.678 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.18 159.2 30.21 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.94 161.38 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.697 0.284 . . . . 0.0 110.424 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.509 179.501 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -109.28 140.11 43.35 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.685 0.278 . . . . 0.0 110.623 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -54.87 142.28 30.06 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 77.0 t -100.56 130.44 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-O 121.144 0.497 . . . . 0.0 110.72 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -161.11 109.84 1.58 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.243 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -153.63 174.58 14.29 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 -145.56 172.89 12.59 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.326 -0.549 . . . . 0.0 110.605 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.79 112.32 7.83 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.012 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.583 HD23 ' C ' ' F' ' 17' ' ' LEU . 8.4 tt -125.2 122.4 36.9 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.418 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 18' ' ' VAL . . . . . 0.415 ' N ' HD23 ' F' ' 17' ' ' LEU . 69.2 t -129.32 130.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.536 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 53.0 p90 -131.5 127.47 37.36 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.816 0.341 . . . . 0.0 110.292 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -142.04 126.87 18.16 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.422 0.629 . . . . 0.0 110.057 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -161.3 161.9 30.77 Favored 'General case' 0 C--N 1.32 -0.683 0 C-N-CA 120.08 -0.648 . . . . 0.0 111.082 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 95.6 mt-10 -116.82 107.99 15.3 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.275 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 49.1 t0 -108.73 114.14 27.69 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.265 0.555 . . . . 0.0 111.951 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.588 ' O ' ' N ' ' F' ' 26' ' ' SER . 83.1 t -96.11 130.97 44.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 177.387 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.88 -85.5 0.01 OUTLIER Glycine 0 CA--C 1.529 0.915 0 N-CA-C 109.604 -1.399 . . . . 0.0 109.604 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.588 ' N ' ' O ' ' F' ' 24' ' ' VAL . 58.3 p -132.35 162.84 30.07 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 117.946 0.873 . . . . 0.0 109.258 177.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.449 ' O ' ' O ' ' F' ' 26' ' ' SER . 53.1 p30 -38.6 174.88 0.0 OUTLIER 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.683 -1.144 . . . . 0.0 113.387 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.546 ' O ' ' N ' ' F' ' 30' ' ' ALA . 22.6 tttt -74.63 112.47 10.85 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.807 175.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.88 91.65 0.08 OUTLIER Glycine 0 N--CA 1.467 0.761 0 C-N-CA 117.056 -2.497 . . . . 0.0 109.034 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.546 ' N ' ' O ' ' F' ' 28' ' ' LYS . . . -171.53 162.01 6.4 Favored 'General case' 0 C--N 1.295 -1.786 1 N-CA-C 98.752 -4.536 . . . . 0.0 98.752 178.569 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.463 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.0 OUTLIER -152.11 131.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 115.778 -2.369 . . . . 0.0 113.243 -175.262 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.55 HG22 HD23 ' F' ' 34' ' ' LEU . 76.0 mt -106.12 113.49 42.99 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 114.13 -1.395 . . . . 0.0 109.615 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.08 96.46 1.53 Allowed Glycine 0 CA--C 1.502 -0.75 0 N-CA-C 106.217 -2.753 . . . . 0.0 106.217 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.55 HD23 HG22 ' F' ' 32' ' ' ILE . 1.4 pp -118.39 122.2 42.23 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 111.478 0.177 . . . . 0.0 111.478 -177.141 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.784 ' SD ' HG23 ' L' ' 31' ' ' ILE . 58.1 ttp -118.71 115.71 25.07 Favored 'General case' 0 CA--C 1.5 -0.96 0 C-N-CA 119.094 -1.042 . . . . 0.0 108.64 176.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' F' ' 37' ' ' GLY . 3.1 m -123.34 71.44 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.469 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -24.97 -103.29 0.0 OUTLIER Glycine 0 C--N 1.36 1.863 0 O-C-N 123.515 0.509 . . . . 0.0 112.432 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.04 163.27 7.45 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -144.34 143.32 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.79 0.328 . . . . 0.0 110.612 179.303 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.428 179.921 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -118.64 138.27 52.72 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.801 0.334 . . . . 0.0 110.496 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -76.2 158.62 31.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.289 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 56.8 t -118.27 132.93 66.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.147 0.499 . . . . 0.0 110.225 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -104.77 -168.78 1.52 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.395 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.45 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 3.4 m80 -76.57 165.28 25.0 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.449 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 34.8 tp60 -161.67 175.18 12.3 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.449 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 64.2 tttp -161.63 131.82 4.91 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.102 179.522 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -123.54 125.66 45.28 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.397 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 63.2 t -125.19 126.45 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.857 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.853 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 5.7 t80 -114.49 109.08 17.73 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -118.34 115.66 25.15 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.94 121.38 44.49 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.96 0.41 . . . . 0.0 110.632 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -154.81 118.34 4.54 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -58.23 121.27 10.33 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.279 -178.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.2 m -88.25 124.15 41.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.99 84.53 0.01 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 121.461 -0.4 . . . . 0.0 112.192 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' G' ' 24' ' ' VAL . 60.7 m -93.52 178.6 5.65 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.03 178.73 0.17 Allowed 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.127 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.95 110.94 1.3 Allowed 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.101 -0.64 . . . . 0.0 111.009 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.848 ' H ' HD22 ' H' ' 27' ' ' ASN . . . 71.16 93.11 0.08 OUTLIER Glycine 0 N--CA 1.463 0.485 0 C-N-CA 119.501 -1.333 . . . . 0.0 112.21 176.186 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.67 160.27 17.42 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 119.784 1.792 . . . . 0.0 109.195 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.426 HG22 HD12 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -145.04 123.67 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.017 -177.107 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -133.96 128.29 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 O-C-N 121.942 -0.474 . . . . 0.0 111.249 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.04 121.59 3.43 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 54.6 tp -142.5 135.13 28.05 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.384 0.611 . . . . 0.0 112.254 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.453 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 66.3 ttp -127.3 139.01 53.18 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.502 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' G' ' 37' ' ' GLY . 22.5 t -133.55 78.36 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -179.31 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.433 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -33.85 -94.11 0.01 OUTLIER Glycine 0 C--N 1.345 1.045 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 177.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.99 -164.32 37.87 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -126.53 158.1 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.482 -179.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.613 -179.197 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -104.53 131.66 51.67 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -141.3 144.47 34.64 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.608 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.449 ' O ' HG23 ' H' ' 12' ' ' VAL . 18.9 m -125.62 131.84 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.501 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -127.1 115.71 19.56 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-O 120.854 0.359 . . . . 0.0 110.956 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 16.5 p-80 -158.99 171.42 20.06 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.39 0.614 . . . . 0.0 110.587 179.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mm-40 -150.35 173.89 13.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.417 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -148.17 121.26 8.86 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -123.0 127.61 49.06 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.81 0.338 . . . . 0.0 111.851 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -122.05 125.64 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.502 ' HZ ' HD13 ' J' ' 34' ' ' LEU . 2.7 t80 -122.27 115.17 21.87 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -126.86 121.66 32.47 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.49 127.13 51.92 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.613 -0.435 . . . . 0.0 112.001 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.461 ' HG3' ' H ' ' I' ' 24' ' ' VAL . 43.0 tt0 -158.29 103.34 1.8 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.918 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.464 ' HB3' ' HZ1' ' J' ' 28' ' ' LYS . 78.4 m-20 -80.17 134.7 36.17 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-O 120.952 0.406 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.403 ' O ' ' N ' ' H' ' 26' ' ' SER . 88.9 t -103.68 113.73 41.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -178.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -30.6 88.64 0.01 OUTLIER Glycine 0 CA--C 1.537 1.459 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.775 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' H' ' 27' ' ' ASN . 11.7 p -129.78 -178.54 4.75 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.739 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.848 HD22 ' H ' ' G' ' 29' ' ' GLY . 1.4 p-10 -40.16 174.82 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 113.486 0.921 . . . . 0.0 113.486 -174.245 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -74.8 111.15 9.71 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 116.18 1.919 . . . . 0.0 116.18 -178.065 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.472 ' H ' ' HG3' ' I' ' 28' ' ' LYS . . . 70.32 93.54 0.07 OUTLIER Glycine 0 N--CA 1.467 0.733 0 C-N-CA 119.893 -1.146 . . . . 0.0 115.484 171.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.76 157.68 18.9 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 103.348 -2.834 . . . . 0.0 103.348 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.437 HD13 ' HA3' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -144.44 119.46 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.714 -174.545 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.403 ' C ' ' SD ' ' B' ' 35' ' ' MET . 27.7 mm -124.55 124.26 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.414 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.1 126.65 5.49 Favored Glycine 0 N--CA 1.469 0.873 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.4 tt -147.76 134.59 20.1 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.929 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.1 tmm? -128.62 127.09 41.55 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.851 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.436 ' O ' ' O ' ' H' ' 37' ' ' GLY . 10.5 t -122.92 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.294 0.85 . . . . 0.0 113.294 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -35.6 -93.8 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 177.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.1 -171.03 33.88 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.47 141.9 36.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 110.122 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.676 -179.995 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -87.1 135.01 33.45 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.593 0.235 . . . . 0.0 110.404 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -80.22 149.39 30.46 Favored 'General case' 0 C--N 1.332 -0.153 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.443 HG12 ' N ' ' I' ' 13' ' ' HIS . 15.4 t -132.11 162.42 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.056 -178.446 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.443 ' N ' HG12 ' I' ' 12' ' ' VAL . 0.5 OUTLIER -116.22 170.19 8.71 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.93 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -72.89 169.81 16.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -137.36 172.77 12.49 Favored 'General case' 0 C--N 1.318 -0.768 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.415 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -150.19 128.96 12.42 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.1 0.476 . . . . 0.0 111.663 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.6 tt -133.62 124.47 26.87 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -123.71 128.83 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.862 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.648 ' CD2' HD22 ' L' ' 34' ' ' LEU . 10.3 t80 -122.39 118.99 29.73 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.912 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -135.16 121.63 20.53 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.802 0.334 . . . . 0.0 111.062 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.18 123.49 38.35 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -162.6 126.52 3.02 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 115.354 -0.839 . . . . 0.0 108.815 178.195 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -102.27 114.03 27.84 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.461 ' H ' ' HG3' ' H' ' 22' ' ' GLU . 4.0 p -79.86 131.63 33.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.754 177.453 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.63 82.62 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 C-N-CA 119.725 -1.226 . . . . 0.0 112.392 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' I' ' 27' ' ' ASN . 75.1 m -60.04 -174.11 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 115.194 -0.503 . . . . 0.0 109.858 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' I' ' 26' ' ' SER . 17.9 m-20 98.53 -175.3 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 O-C-N 124.218 0.949 . . . . 0.0 109.975 -176.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' I' ' 27' ' ' ASN . 82.4 tttt 38.71 110.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -177.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 95.85 1.74 Allowed Glycine 0 CA--C 1.484 -1.885 0 N-CA-C 107.98 -2.048 . . . . 0.0 107.98 176.292 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 164.89 16.92 Favored 'General case' 0 N--CA 1.426 -1.662 0 C-N-CA 118.001 -1.48 . . . . 0.0 107.272 -179.024 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.719 HG23 ' CG1' ' J' ' 31' ' ' ILE . 0.2 OUTLIER -142.56 117.31 4.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 119.376 -0.929 . . . . 0.0 108.827 -174.497 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 tt -125.51 124.16 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.834 178.18 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.33 96.62 0.73 Allowed Glycine 0 C--N 1.331 0.275 0 N-CA-C 107.72 -2.152 . . . . 0.0 107.72 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.513 HD21 HG13 ' I' ' 36' ' ' VAL . 8.7 tt -130.32 134.1 46.94 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 122.392 1.092 . . . . 0.0 112.183 -178.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 tmm? -128.26 125.74 39.49 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.618 -1.174 . . . . 0.0 110.344 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.513 HG13 HD21 ' I' ' 34' ' ' LEU . 0.1 OUTLIER -130.69 76.95 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.34 179.678 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 38' ' ' GLY . . . -71.9 106.36 1.9 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -49.27 179.38 0.01 OUTLIER Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 -179.29 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -124.58 138.78 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.938 -1.03 . . . . 0.0 110.365 179.688 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -110.06 138.58 46.24 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.692 0.282 . . . . 0.0 110.298 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -127.56 145.19 50.94 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.952 0.406 . . . . 0.0 110.768 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.86 152.71 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.778 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 31.0 m80 -132.57 146.98 52.33 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.52 ' CE1' ' O ' ' J' ' 15' ' ' GLN . 5.9 t-80 -154.52 157.84 38.95 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.52 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 82.3 mt-30 -148.97 178.06 9.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-O 121.538 0.685 . . . . 0.0 111.653 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -165.34 114.03 1.02 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.151 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -120.86 122.29 39.95 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.155 0.502 . . . . 0.0 111.04 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -114.02 121.82 66.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.677 ' CZ ' HD23 ' L' ' 34' ' ' LEU . 1.0 OUTLIER -125.04 108.37 11.76 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.9 0.381 . . . . 0.0 110.236 -177.124 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -130.17 127.83 40.51 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.629 0.728 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.67 128.57 31.28 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.842 178.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -142.39 111.24 6.3 Favored 'General case' 0 N--CA 1.462 0.142 0 C-N-CA 119.621 -0.831 . . . . 0.0 111.249 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -85.73 105.02 15.96 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.671 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.759 HG12 ' H ' ' J' ' 25' ' ' GLY . 10.5 t -110.12 -131.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.123 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.759 ' H ' HG12 ' J' ' 24' ' ' VAL . . . 29.03 -82.24 0.0 OUTLIER Glycine 0 CA--C 1.529 0.914 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.869 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.636 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.2 p 169.65 177.76 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.34 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.636 ' O ' ' O ' ' J' ' 26' ' ' SER . 77.6 m-20 -28.08 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 114.183 -1.371 . . . . 0.0 112.838 173.611 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.535 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 29.5 tttt 144.63 104.31 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 123.02 1.39 . . . . 0.0 112.005 177.347 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.16 93.54 0.01 OUTLIER Glycine 0 C--O 1.219 -0.825 0 CA-C-N 112.248 -2.251 . . . . 0.0 111.373 174.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.2 152.81 47.68 Favored 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 120.78 2.29 . . . . 0.0 106.526 176.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.719 ' CG1' HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -137.97 121.86 21.61 Favored 'Isoleucine or valine' 0 C--O 1.248 1.022 0 C-N-CA 119.218 -0.993 . . . . 0.0 112.384 -174.895 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -104.42 109.44 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.406 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.617 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -109.72 102.46 1.59 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 106.37 -2.692 . . . . 0.0 106.37 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.853 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 5.1 tt -144.35 140.51 29.13 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 122.406 1.098 . . . . 0.0 111.775 -175.388 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.525 ' N ' HD23 ' J' ' 34' ' ' LEU . 61.0 ttp -133.69 130.21 37.85 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.08 -179.142 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.471 HG13 HG23 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -122.78 79.47 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.78 -178.336 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.19 104.54 0.48 Allowed Glycine 0 C--N 1.342 0.907 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.74 167.06 54.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -139.28 160.66 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.727 0.299 . . . . 0.0 110.584 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.442 HG23 ' H ' ' J' ' 40' ' ' VAL . 15.9 t . . . . . 0 C--O 1.221 -0.419 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.846 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -84.33 138.07 33.09 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.867 0.365 . . . . 0.0 111.068 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' L' ' 11' ' ' GLU . 72.3 mm-40 -137.6 131.98 32.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.628 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 m -138.09 135.56 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.906 0.384 . . . . 0.0 111.123 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 9.7 m80 -134.28 127.51 31.96 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.571 ' NE2' ' CG ' ' L' ' 13' ' ' HIS . 80.5 m80 -116.43 163.17 16.44 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.646 0.736 . . . . 0.0 110.36 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.52 ' N ' ' OE1' ' L' ' 15' ' ' GLN . 50.9 tt0 -163.27 172.31 14.89 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.412 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' K' ' 15' ' ' GLN . 55.4 tttp -164.81 114.88 1.14 Allowed 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 28.6 tp -118.8 121.65 40.54 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.76 127.83 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -131.0 125.7 34.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.23 0.538 . . . . 0.0 112.262 -178.361 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -133.06 125.79 30.39 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.993 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 127.43 35.36 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.182 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -149.29 137.73 20.88 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.048 -0.661 . . . . 0.0 112.023 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.45 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 20.6 p-10 -123.23 120.53 33.42 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 120.986 0.422 . . . . 0.0 110.029 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.554 HG21 HG13 ' J' ' 24' ' ' VAL . 84.3 t -60.62 121.1 7.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.519 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.31 -90.97 0.53 Allowed Glycine 0 CA--C 1.527 0.817 0 C-N-CA 121.368 -0.444 . . . . 0.0 112.464 177.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.587 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.8 p -141.37 171.22 14.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 121.196 0.522 . . . . 0.0 110.348 -178.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.587 ' O ' ' O ' ' K' ' 26' ' ' SER . 3.3 p30 -29.01 170.5 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.179 -1.373 . . . . 0.0 113.983 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.662 ' O ' ' HB3' ' L' ' 30' ' ' ALA . 80.0 tttt -148.35 111.3 4.84 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.141 178.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.514 ' HA2' ' HB2' ' L' ' 30' ' ' ALA . . . -54.53 91.58 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 121.244 -0.503 . . . . 0.0 112.211 179.208 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.746 ' H ' ' HB1' ' L' ' 30' ' ' ALA . . . -166.38 158.17 13.56 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.504 ' CG1' HG22 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -145.8 123.61 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 118.721 -1.192 . . . . 0.0 111.829 -179.209 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.448 ' C ' ' SD ' ' E' ' 35' ' ' MET . 1.0 OUTLIER -102.09 118.41 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.077 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.541 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -112.74 94.88 0.75 Allowed Glycine 0 CA--C 1.51 -0.26 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 179.181 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.636 HD12 ' O ' ' J' ' 34' ' ' LEU . 41.0 tp -129.38 130.77 46.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-O 122.218 1.009 . . . . 0.0 111.968 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.48 ' H ' HD12 ' K' ' 34' ' ' LEU . 7.9 tmm? -116.71 114.73 24.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.893 175.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.405 HG12 ' CG2' ' J' ' 36' ' ' VAL . 2.2 m -116.56 79.86 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.419 ' HA3' HD13 ' E' ' 31' ' ' ILE . . . -66.8 103.24 0.87 Allowed Glycine 0 C--N 1.35 1.36 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -87.39 -178.55 48.38 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.48 142.9 30.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.951 0.405 . . . . 0.0 110.29 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.761 -179.768 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -101.7 130.06 48.0 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.5 tt0 -123.52 138.75 54.5 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 120.96 0.41 . . . . 0.0 110.748 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.413 HG22 ' O ' ' L' ' 13' ' ' HIS . 2.4 p -139.53 156.04 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.187 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.661 ' CG ' ' H ' ' L' ' 14' ' ' HIS . 41.8 t-80 -91.29 -177.5 4.88 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 120.784 0.326 . . . . 0.0 110.727 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.661 ' H ' ' CG ' ' L' ' 13' ' ' HIS . 99.2 m-70 -75.52 171.73 13.77 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.53 ' NE2' ' O ' ' L' ' 14' ' ' HIS . 51.5 mm-40 -139.2 -179.78 6.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.62 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.95 124.38 15.72 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.685 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 58.0 tp -125.44 121.22 33.19 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.381 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -129.41 129.35 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.461 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 54.7 p90 -139.45 130.85 26.92 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.785 0.326 . . . . 0.0 111.123 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 84.8 t80 -142.55 131.99 23.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.019 179.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.16 146.43 35.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.814 0.34 . . . . 0.0 110.58 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' K' ' 23' ' ' ASP . 84.6 tt0 -78.52 142.76 37.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.145 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -76.73 121.72 23.7 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 121.225 0.536 . . . . 0.0 110.766 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' L' ' 25' ' ' GLY . 19.5 t -102.75 122.88 55.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.115 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.452 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -30.56 -86.47 0.01 OUTLIER Glycine 0 N--CA 1.478 1.442 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 30.7 t -90.21 -179.97 5.77 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 177.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -58.8 162.89 3.7 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 117.866 -1.534 . . . . 0.0 110.456 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.565 ' HB3' HD12 ' L' ' 31' ' ' ILE . 59.6 tttt -58.3 111.64 1.28 Allowed 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 179.11 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.85 -98.28 0.01 OUTLIER Glycine 0 C--N 1.319 -0.416 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.746 ' HB1' ' H ' ' K' ' 30' ' ' ALA . . . -72.72 174.57 7.45 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 178.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.784 HG23 ' SD ' ' F' ' 35' ' ' MET . 7.5 tt -171.17 165.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 C-N-CA 115.033 -2.667 . . . . 0.0 115.448 -172.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.544 ' O ' HG23 ' L' ' 32' ' ' ILE . 16.3 tt -99.31 122.02 50.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.761 0 CA-C-N 113.284 -1.78 . . . . 0.0 108.154 177.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 33' ' ' GLY . . . . . 0.501 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -110.52 94.37 0.79 Allowed Glycine 0 CA--C 1.507 -0.436 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.677 HD23 ' CZ ' ' J' ' 19' ' ' PHE . 51.3 tp -119.03 118.76 32.33 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.475 ' HE1' HG22 ' E' ' 31' ' ' ILE . 11.3 tmm? -105.16 119.22 38.5 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.202 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.497 ' O ' ' C ' ' L' ' 37' ' ' GLY . 2.7 m -129.03 75.04 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.927 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.497 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -16.95 -101.76 0.0 OUTLIER Glycine 0 C--N 1.359 1.856 0 O-C-N 123.158 0.286 . . . . 0.0 112.707 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.0 173.87 37.68 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.271 -0.731 . . . . 0.0 111.271 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -122.65 138.45 52.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.885 0.374 . . . . 0.0 110.51 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.813 -179.659 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -109.86 141.64 42.27 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.924 0.393 . . . . 0.0 110.937 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.52 ' CD ' ' H ' ' A' ' 11' ' ' GLU . 2.0 pm0 -117.58 147.99 42.31 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.074 179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m -113.8 133.79 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 110.613 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 18.5 p-80 -143.71 164.44 30.44 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.934 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.1 p-80 -87.78 169.98 11.61 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-O 121.395 0.617 . . . . 0.0 110.375 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HG2' ' N ' ' A' ' 16' ' ' LYS . 51.5 tt0 -153.28 175.32 13.21 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.301 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.442 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 99.5 mttt -137.68 133.65 34.48 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.819 0.343 . . . . 0.0 110.831 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -129.16 121.52 27.91 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -132.74 131.3 59.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.75 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 14.7 m-85 -111.21 116.79 31.66 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.535 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 55.5 p90 -129.84 125.92 36.81 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.75 126.3 32.15 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.083 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' A' ' 22' ' ' GLU . 55.4 mp0 -141.32 163.94 31.59 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 33.7 t70 -79.2 113.67 17.52 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -178.538 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.502 ' O ' ' N ' ' A' ' 26' ' ' SER . 3.5 p -127.11 121.66 58.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 176.359 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -29.31 84.04 0.0 OUTLIER Glycine 0 CA--C 1.537 1.412 0 CA-C-O 118.833 -0.982 . . . . 0.0 113.834 178.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 24' ' ' VAL . 10.0 p -97.62 171.82 8.11 Favored 'General case' 0 C--N 1.347 0.468 0 CA-C-N 119.686 1.743 . . . . 0.0 107.311 177.002 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 p30 -60.13 177.53 0.25 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 118.418 -1.313 . . . . 0.0 110.227 178.461 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -61.76 110.61 1.57 Allowed 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.505 174.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.655 ' H ' ' CB ' ' B' ' 27' ' ' ASN . . . 70.86 93.82 0.07 OUTLIER Glycine 0 N--CA 1.467 0.714 0 C-N-CA 117.541 -2.266 . . . . 0.0 111.716 174.284 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.52 158.57 17.43 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 121.283 2.542 . . . . 0.0 111.225 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.603 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -143.98 120.38 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 113.433 -1.712 . . . . 0.0 110.566 -175.532 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.7 mt -130.6 125.3 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 O-C-N 121.52 -0.738 . . . . 0.0 110.438 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.575 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -132.15 119.12 2.43 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 80.8 mt -122.23 129.97 52.74 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.071 0.462 . . . . 0.0 110.895 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.53 120.49 29.78 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.18 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -104.94 77.74 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 120.22 -0.592 . . . . 0.0 112.239 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.542 ' CA ' HG21 ' G' ' 31' ' ' ILE . . . -92.27 101.0 2.73 Favored Glycine 0 C--N 1.342 0.893 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.14 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.64 155.87 27.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 28.4 m -136.93 161.51 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.415 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.6 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.616 -179.909 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 72.0 t80 -138.81 159.05 43.07 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -60.39 132.17 53.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.121 0.486 . . . . 0.0 110.965 -179.431 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 26.5 m -139.56 162.88 26.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.631 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.437 ' C ' ' CG ' ' B' ' 14' ' ' HIS . 80.6 t60 -138.7 138.9 38.16 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.644 0.259 . . . . 0.0 110.533 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.437 ' CG ' ' C ' ' B' ' 13' ' ' HIS . 19.6 m-70 -150.76 170.24 19.71 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.278 0.561 . . . . 0.0 109.983 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -153.14 173.04 16.01 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.49 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -153.9 118.66 4.97 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -116.31 120.95 40.54 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 45.5 t -126.07 121.79 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.157 0.504 . . . . 0.0 110.641 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.906 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 6.4 m-85 -113.52 113.16 24.73 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.709 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -118.17 106.17 12.57 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 175.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.99 125.93 52.12 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.523 ' N ' ' OE1' ' B' ' 22' ' ' GLU . 57.0 mp0 -142.41 178.88 7.29 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 177.208 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.499 ' OD1' ' NZ ' ' D' ' 28' ' ' LYS . 14.1 m-20 -38.09 121.92 0.99 Allowed 'General case' 0 N--CA 1.475 0.811 0 CA-C-N 119.244 0.929 . . . . 0.0 110.644 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.805 HG12 ' H ' ' B' ' 25' ' ' GLY . 97.3 t -58.55 -120.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.648 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.021 -178.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.805 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -79.67 -90.28 0.45 Allowed Glycine 0 CA--C 1.523 0.577 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.996 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.419 ' HB3' ' H ' ' A' ' 26' ' ' SER . 77.6 p -155.01 -172.07 4.06 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.835 0.826 . . . . 0.0 110.403 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.655 ' CB ' ' H ' ' A' ' 29' ' ' GLY . 8.9 t-20 57.72 -171.72 0.1 Allowed 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 114.201 -1.363 . . . . 0.0 111.671 178.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.566 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 72.2 mmtt -56.96 -111.3 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.709 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.92 94.47 1.57 Allowed Glycine 0 N--CA 1.461 0.314 0 CA-C-N 115.265 -0.88 . . . . 0.0 114.39 -177.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.33 163.97 15.79 Favored 'General case' 0 C--N 1.35 0.605 0 C-N-CA 116.821 -1.952 . . . . 0.0 106.673 177.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.46 HD13 ' HA3' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -150.26 128.76 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 C-N-CA 119.111 -1.036 . . . . 0.0 111.739 -172.779 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 99.0 mt -133.23 133.61 58.02 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.325 0.583 . . . . 0.0 110.922 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.01 127.11 4.63 Favored Glycine 0 N--CA 1.47 0.952 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.238 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.41 HD21 ' CG2' ' B' ' 36' ' ' VAL . 7.9 tt -133.79 127.87 33.59 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.294 0.547 . . . . 0.0 111.038 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.548 ' SD ' ' CA ' ' H' ' 33' ' ' GLY . 20.7 ttt -130.24 123.82 31.04 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.421 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.41 ' CG2' HD21 ' B' ' 34' ' ' LEU . 2.6 t -124.33 76.02 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.801 178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.32 101.54 2.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -134.72 163.54 24.72 Favored Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.86 136.97 56.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.506 -179.813 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -106.9 135.97 47.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.921 0.391 . . . . 0.0 110.644 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -67.77 135.63 52.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.795 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.572 HG13 ' O ' ' D' ' 12' ' ' VAL . 58.5 t -124.89 133.65 68.92 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.05 0.452 . . . . 0.0 111.075 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 p-80 -147.52 145.51 29.12 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.574 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 17.4 p80 -153.76 168.05 27.58 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.361 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -148.75 176.85 10.02 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.248 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -147.23 127.74 14.11 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.296 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.7 mp -130.51 127.28 38.83 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-O 121.1 0.476 . . . . 0.0 111.372 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.8 t -127.4 126.01 66.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.089 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.403 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 57.2 m-85 -111.45 116.11 30.36 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.198 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 50.4 t80 -127.88 117.68 22.24 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.6 130.67 49.43 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.326 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -155.57 101.1 2.15 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.979 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -68.7 133.98 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.977 0.418 . . . . 0.0 110.206 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.34 113.02 20.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.621 0.724 . . . . 0.0 111.178 -179.07 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.431 ' O ' HG11 ' D' ' 24' ' ' VAL . . . 52.97 -91.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.473 -1.24 . . . . 0.0 115.288 177.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.515 ' OG ' ' N ' ' C' ' 27' ' ' ASN . 47.3 t -153.78 -175.57 5.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 122.678 1.228 . . . . 0.0 113.102 -175.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.515 ' N ' ' OG ' ' C' ' 26' ' ' SER . 24.7 m120 52.73 179.93 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 112.433 -2.167 . . . . 0.0 115.129 178.716 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 75.2 mttt 53.4 110.6 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 CA-C-N 112.536 -2.12 . . . . 0.0 113.967 -177.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.77 95.97 1.85 Allowed Glycine 0 N--CA 1.488 2.127 0 CA-C-O 117.828 -1.54 . . . . 0.0 110.366 175.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.52 ' HB1' HG21 ' B' ' 24' ' ' VAL . . . -91.54 160.09 15.59 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 121.354 2.577 . . . . 0.0 109.833 -179.044 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.592 ' CG2' HD12 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -148.53 124.97 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.102 -176.421 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.44 ' O ' ' SD ' ' J' ' 35' ' ' MET . 14.3 tt -130.18 128.92 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 121.195 0.522 . . . . 0.0 110.459 177.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.445 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -112.77 117.62 4.36 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.75 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 29.3 mt -124.69 119.66 29.61 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -176.211 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.461 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 5.3 ttm -122.4 117.58 26.35 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 177.312 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.52 74.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.998 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.313 -178.375 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 38' ' ' GLY . . . -61.0 110.98 3.4 Favored Glycine 0 C--N 1.354 1.535 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . -53.9 -167.47 0.02 OUTLIER Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.71 161.82 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.068 0.461 . . . . 0.0 111.221 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 68.6 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.889 -1.053 . . . . 0.0 110.594 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -82.31 145.78 29.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.994 0.426 . . . . 0.0 110.547 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.495 ' HB3' HG11 ' C' ' 12' ' ' VAL . 94.2 mt-10 -65.49 167.17 9.18 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.378 -179.62 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.572 ' O ' HG13 ' C' ' 12' ' ' VAL . 30.9 m -131.18 171.44 17.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -177.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CB ' ' E' ' 13' ' ' HIS . 5.7 t60 -89.21 122.38 32.44 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.013 178.567 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 47.5 p-80 -156.15 169.04 25.43 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.056 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -145.04 177.97 8.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -152.59 119.77 5.88 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.185 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -119.68 120.35 36.37 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.855 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -125.7 125.87 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.802 0.334 . . . . 0.0 110.962 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.403 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 72.3 m-85 -115.75 115.82 26.97 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.069 179.011 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 53.9 t80 -127.5 121.15 29.96 Favored 'General case' 0 C--O 1.239 0.5 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 178.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.15 135.58 37.49 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.298 0.571 . . . . 0.0 112.297 -179.026 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -136.92 96.48 3.31 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.048 178.379 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.425 ' O ' ' CG2' ' E' ' 24' ' ' VAL . 89.8 m-20 -85.89 134.89 33.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.416 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.5 ' O ' HG13 ' D' ' 24' ' ' VAL . 8.1 p -88.27 112.75 24.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.457 0.646 . . . . 0.0 109.403 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.472 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -45.45 92.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.597 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.346 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.472 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 163.92 -169.6 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.641 0 CA-C-O 121.727 0.775 . . . . 0.0 110.163 -178.562 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -50.64 179.77 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.314 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.727 ' HE2' ' HB2' ' D' ' 30' ' ' ALA . 67.2 tttt 60.49 112.38 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 112.248 -2.251 . . . . 0.0 115.881 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.0 96.16 2.18 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.091 -2.804 . . . . 0.0 106.091 170.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.727 ' HB2' ' HE2' ' D' ' 28' ' ' LYS . . . -79.31 162.77 25.4 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 123.47 3.635 . . . . 0.0 105.805 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.592 HD12 ' CG2' ' C' ' 31' ' ' ILE . 1.1 mt -147.21 126.47 4.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 C-N-CA 117.679 -1.608 . . . . 0.0 111.348 -174.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 52.6 mt -123.91 116.95 49.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 177.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.28 103.59 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 105.878 -2.889 . . . . 0.0 105.878 176.028 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.906 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 12.7 tp -116.54 124.36 49.68 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 114.077 1.139 . . . . 0.0 114.077 -175.172 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.437 ' N ' HD12 ' D' ' 34' ' ' LEU . 8.0 ttm -126.54 110.47 13.28 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 174.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.596 HG13 HD11 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -126.25 79.89 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.151 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.02 103.13 1.32 Allowed Glycine 0 C--N 1.349 1.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 112.506 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.59 178.93 38.46 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 178.584 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.51 HG12 ' N ' ' D' ' 40' ' ' VAL . 60.7 t -141.88 157.95 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.946 0.403 . . . . 0.0 111.011 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.51 ' N ' HG12 ' D' ' 39' ' ' VAL . 19.4 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.52 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 77.1 t80 -85.28 138.96 31.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.883 0.373 . . . . 0.0 110.528 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -55.4 143.05 30.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.689 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.64 135.75 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.487 ' CB ' ' O ' ' D' ' 13' ' ' HIS . 12.0 p-80 -155.66 162.07 40.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.041 0.448 . . . . 0.0 111.296 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 69.0 m80 -139.82 168.19 20.39 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.854 0.835 . . . . 0.0 110.287 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.412 ' HG2' ' N ' ' E' ' 16' ' ' LYS . 51.8 tt0 -153.17 165.34 35.97 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 114.678 -1.146 . . . . 0.0 108.826 178.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.412 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 98.0 mttt -157.24 116.88 3.4 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.627 0.251 . . . . 0.0 110.334 179.392 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 32.6 tp -117.14 113.79 22.77 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.47 128.7 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' E' ' 21' ' ' ALA . 41.1 t80 -127.27 120.49 28.77 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.924 -179.786 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -127.84 118.49 23.77 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.422 ' HB2' ' CZ ' ' E' ' 19' ' ' PHE . . . -128.68 130.04 46.65 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.129 0.49 . . . . 0.0 111.326 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -113.27 102.62 10.53 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 64.4 t0 -79.9 123.17 27.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.174 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.437 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 93.0 t -96.5 121.65 47.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.195 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 42.7 -87.03 0.01 OUTLIER Glycine 0 CA--C 1.533 1.17 0 CA-C-N 115.127 -0.942 . . . . 0.0 114.688 178.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 11.1 p -165.38 -178.36 4.95 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-O 122.235 1.017 . . . . 0.0 112.044 -175.524 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.6 ' CG ' ' H ' ' E' ' 28' ' ' LYS . 7.0 t-20 51.36 -179.13 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 116.105 1.891 . . . . 0.0 116.105 177.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.6 ' H ' ' CG ' ' E' ' 27' ' ' ASN . 27.2 tttt 53.76 110.97 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 112.178 -2.283 . . . . 0.0 114.223 -175.648 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.456 ' HA2' ' H ' ' F' ' 30' ' ' ALA . . . -87.13 96.44 2.17 Favored Glycine 0 C--N 1.337 0.6 0 CA-C-N 111.973 -2.376 . . . . 0.0 110.909 175.04 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.412 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -78.83 166.24 22.65 Favored 'General case' 0 C--O 1.241 0.624 0 CA-C-N 122.765 3.282 . . . . 0.0 103.553 177.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.435 HG21 HD13 ' E' ' 31' ' ' ILE . 1.1 mt -147.57 127.39 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 116.687 -2.005 . . . . 0.0 112.903 -172.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.49 ' O ' HG23 ' E' ' 32' ' ' ILE . 15.7 tt -135.4 119.88 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-O 121.472 0.653 . . . . 0.0 109.49 176.141 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.68 110.3 2.78 Favored Glycine 0 CA--C 1.508 -0.356 0 N-CA-C 107.492 -2.243 . . . . 0.0 107.492 178.356 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.57 123.24 43.44 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 122.259 1.028 . . . . 0.0 111.775 -178.2 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.432 ' HE2' ' N ' ' K' ' 32' ' ' ILE . 9.5 tpt -111.47 110.77 21.38 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 113.709 -1.587 . . . . 0.0 107.467 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.404 HG13 HG23 ' D' ' 36' ' ' VAL . 0.2 OUTLIER -119.66 80.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-O 121.035 0.445 . . . . 0.0 109.94 -178.043 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.08 102.17 0.08 OUTLIER Glycine 0 C--N 1.341 0.833 0 CA-C-N 116.247 -0.433 . . . . 0.0 112.044 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.96 150.61 22.7 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.6 t -126.56 136.71 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 88.8 t . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.374 179.819 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 31.5 p90 -147.72 159.48 43.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.686 0.279 . . . . 0.0 110.415 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -153.78 147.21 24.94 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.198 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m -140.23 -172.01 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 120.99 0.424 . . . . 0.0 110.785 -179.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.414 ' HB3' ' CE1' ' E' ' 13' ' ' HIS . 44.4 p-80 -87.68 163.21 16.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.312 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 53.2 m80 -147.33 172.15 14.33 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -144.12 178.06 8.15 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.847 -179.482 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.9 121.9 0.57 Allowed 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.738 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.69 125.19 35.4 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.401 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 86.9 t -134.1 129.4 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.923 0.392 . . . . 0.0 111.237 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -122.55 125.66 46.17 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.049 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -136.07 132.63 36.42 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.13 0.491 . . . . 0.0 110.024 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.27 149.46 31.91 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.099 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -74.17 152.74 39.75 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.729 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 t0 78.13 -141.02 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.137 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.121 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 59.4 t -108.02 106.85 21.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.74 -95.27 0.01 OUTLIER Glycine 0 CA--C 1.528 0.893 0 CA-C-N 114.672 -1.149 . . . . 0.0 111.848 -179.041 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 41.6 t -48.08 150.61 1.14 Allowed 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 178.475 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.622 ' O ' ' O ' ' F' ' 28' ' ' LYS . 94.0 m-20 -127.4 179.74 5.32 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 175.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.622 ' O ' ' O ' ' F' ' 27' ' ' ASN . 28.6 pttt -28.87 -103.95 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.85 177.016 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.618 ' O ' ' O ' ' F' ' 30' ' ' ALA . . . -120.01 -100.1 1.81 Allowed Glycine 0 C--N 1.343 0.943 0 N-CA-C 108.299 -1.921 . . . . 0.0 108.299 173.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.618 ' O ' ' O ' ' F' ' 29' ' ' GLY . . . 54.83 151.97 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 105.412 -2.07 . . . . 0.0 105.412 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.447 ' HB ' ' O ' ' F' ' 30' ' ' ALA . 2.7 tp -165.8 132.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 C-N-CA 115.002 -2.679 . . . . 0.0 114.192 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 97.0 mt -111.69 112.98 42.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 113.631 -1.622 . . . . 0.0 108.418 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 33' ' ' GLY . . . . . 0.437 ' H ' ' HE2' ' L' ' 35' ' ' MET . . . -97.13 101.74 2.63 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 105.382 -3.087 . . . . 0.0 105.382 176.045 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.473 HD12 ' O ' ' F' ' 34' ' ' LEU . 0.4 OUTLIER -104.73 108.69 20.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -176.189 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.47 ' SD ' ' C ' ' L' ' 32' ' ' ILE . 0.9 OUTLIER -109.42 107.34 17.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 176.102 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -136.01 80.59 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.984 -179.329 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.49 -101.66 0.09 OUTLIER Glycine 0 C--N 1.344 1.004 0 C-N-CA 120.976 -0.631 . . . . 0.0 111.99 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.74 -159.71 31.64 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.1 m -135.19 161.72 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 120.626 0.251 . . . . 0.0 110.529 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.204 179.612 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -126.77 142.69 51.47 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.37 143.72 42.11 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.057 0.456 . . . . 0.0 111.019 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.413 ' O ' HG13 ' G' ' 12' ' ' VAL . 12.4 p -130.49 134.99 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.187 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -122.79 127.25 48.88 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 120.95 0.405 . . . . 0.0 110.445 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 70.8 t60 -157.62 165.41 35.58 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-O 121.16 0.505 . . . . 0.0 110.183 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 83.6 mt-30 -151.28 174.76 12.91 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.018 178.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -171.57 114.04 0.36 Allowed 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.082 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 64.7 mt -131.16 124.1 29.97 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.331 0.586 . . . . 0.0 110.306 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.46 ' O ' HG23 ' G' ' 18' ' ' VAL . 30.9 m -128.12 129.83 69.53 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.135 -179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.551 ' CE2' HD21 ' J' ' 34' ' ' LEU . 15.4 m-85 -110.53 113.03 25.34 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.466 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 45.6 p90 -123.95 124.13 41.93 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.27 131.13 38.07 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -145.6 167.22 23.59 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 177.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 58.6 t0 -90.14 111.78 23.03 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.015 -0.674 . . . . 0.0 112.186 -178.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.611 ' O ' ' N ' ' G' ' 26' ' ' SER . 3.6 p -113.17 131.04 65.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.127 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.29 81.96 0.0 OUTLIER Glycine 0 CA--C 1.532 1.11 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.782 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.611 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.1 m -96.58 176.2 6.11 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.504 ' O ' ' O ' ' G' ' 28' ' ' LYS . 53.3 p30 -62.2 -177.73 0.14 Allowed 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.137 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.504 ' O ' ' O ' ' G' ' 27' ' ' ASN . 98.4 mttt -48.85 -109.2 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-O 121.682 0.753 . . . . 0.0 110.64 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.65 96.53 2.1 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.42 161.32 23.77 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 115.49 -2.484 . . . . 0.0 109.609 -177.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.627 ' CG2' HD12 ' H' ' 31' ' ' ILE . 0.1 OUTLIER -154.33 116.27 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.868 -175.066 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -143.09 137.76 26.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.502 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -158.8 164.33 33.6 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.466 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 3.3 tp -169.57 163.28 10.21 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.13 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.575 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 53.5 ttp -131.93 134.12 45.3 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.601 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.406 ' HB ' HG23 ' H' ' 36' ' ' VAL . 21.1 t -117.48 65.03 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.514 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.603 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -55.12 -106.76 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.25 -166.12 13.97 Favored Glycine 0 N--CA 1.465 0.629 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -132.58 159.22 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.025 0.44 . . . . 0.0 110.852 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.669 -179.805 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -107.41 128.95 54.93 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.869 0.366 . . . . 0.0 110.354 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -145.76 135.4 23.29 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.612 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -140.44 134.93 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 77.6 m80 -118.69 118.74 32.44 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.416 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.528 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 5.8 m-70 -135.56 164.29 28.17 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.507 0.67 . . . . 0.0 109.856 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.43 HE21 ' HB2' ' H' ' 15' ' ' GLN . 6.4 tt0 -161.86 170.51 19.34 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.437 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 16' ' ' LYS . . . . . 0.416 ' N ' ' CG ' ' H' ' 15' ' ' GLN . 68.7 mttm -155.94 115.79 3.64 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.722 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.687 HD12 HD22 ' I' ' 17' ' ' LEU . 76.6 mt -114.76 115.27 26.77 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -125.09 124.6 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.396 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -113.01 108.76 17.79 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.522 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 24.6 t80 -127.06 129.52 48.16 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.164 0.438 . . . . 0.0 110.635 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.47 150.4 26.57 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 118.346 -1.342 . . . . 0.0 114.56 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -132.53 173.04 11.73 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 114.367 -1.288 . . . . 0.0 109.582 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.406 ' OD1' ' C ' ' H' ' 23' ' ' ASP . 64.5 t0 -148.51 116.53 6.4 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 113.253 0.835 . . . . 0.0 113.253 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 3.2 p -121.49 122.33 66.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 177.412 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.24 83.79 0.01 OUTLIER Glycine 0 N--CA 1.472 1.052 0 CA-C-O 121.588 0.549 . . . . 0.0 112.245 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -45.35 170.28 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 113.864 1.061 . . . . 0.0 113.864 179.197 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.472 ' O ' ' O ' ' H' ' 28' ' ' LYS . 19.5 m120 -135.61 177.04 8.13 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 113.444 -1.707 . . . . 0.0 107.738 173.773 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.472 ' O ' ' O ' ' H' ' 27' ' ' ASN . 65.2 mttm -21.28 -102.86 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . -158.85 100.27 0.19 Allowed Glycine 0 C--N 1.349 1.256 0 CA-C-O 118.365 -1.241 . . . . 0.0 110.788 177.042 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.82 157.14 31.19 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-N 120.869 2.334 . . . . 0.0 109.125 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.637 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.5 OUTLIER -142.91 118.5 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.473 -176.547 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.53 ' O ' ' SD ' ' B' ' 35' ' ' MET . 86.1 mt -127.7 126.17 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.406 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.548 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -131.88 110.33 0.95 Allowed Glycine 0 N--CA 1.477 1.398 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.76 137.96 31.97 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 121.582 -0.952 . . . . 0.0 112.476 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 40.8 ttp -127.3 139.33 52.96 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.835 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.614 ' O ' HG22 ' H' ' 36' ' ' VAL . 2.5 p -153.48 75.15 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.943 178.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.46 ' HA3' HD13 ' B' ' 31' ' ' ILE . . . -37.25 -95.5 0.01 OUTLIER Glycine 0 C--N 1.343 0.928 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 178.376 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -165.22 38.58 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 t -90.44 134.67 28.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.969 0.414 . . . . 0.0 110.764 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.218 -0.587 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.312 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -136.67 149.41 47.92 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.656 0.265 . . . . 0.0 110.299 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -56.37 133.18 52.74 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 120.96 0.41 . . . . 0.0 110.961 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.488 HG21 ' NE2' ' I' ' 14' ' ' HIS . 2.5 p -150.32 151.02 13.06 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.001 -179.528 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.519 ' CD2' ' HB2' ' H' ' 13' ' ' HIS . 27.3 m80 -119.87 138.92 53.11 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.605 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.488 ' NE2' HG21 ' I' ' 12' ' ' VAL . 25.8 m-70 -144.74 168.79 19.37 Favored 'General case' 0 CA--C 1.511 -0.552 0 CA-C-O 121.499 0.666 . . . . 0.0 110.483 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -149.42 177.99 9.2 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.84 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -171.36 107.01 0.24 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.862 179.191 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.687 HD22 HD12 ' H' ' 17' ' ' LEU . 9.2 mt -120.07 115.54 23.91 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.407 ' O ' HG23 ' I' ' 18' ' ' VAL . 2.2 m -134.43 127.61 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.23 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.42 ' CD2' ' CE2' ' J' ' 19' ' ' PHE . 12.6 m-30 -110.35 118.8 37.27 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.251 178.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.522 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 53.3 t80 -125.65 118.05 24.83 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.664 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.454 ' HB1' ' O ' ' I' ' 25' ' ' GLY . . . -139.43 135.49 33.66 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -177.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.548 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 82.9 tt0 -115.92 100.18 7.8 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.155 -1.794 . . . . 0.0 106.155 176.05 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.548 ' CB ' ' O ' ' I' ' 22' ' ' GLU . 53.2 t0 121.61 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 O-C-N 124.817 1.323 . . . . 0.0 108.246 -176.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.586 HG13 ' NZ ' ' K' ' 28' ' ' LYS . 19.8 m -106.14 112.02 37.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.798 0.809 . . . . 0.0 108.929 -178.501 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.454 ' O ' ' HB1' ' I' ' 21' ' ' ALA . . . 33.65 -92.16 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -177.206 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.64 ' O ' ' O ' ' I' ' 27' ' ' ASN . 41.4 t -130.46 168.24 17.33 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.64 ' O ' ' O ' ' I' ' 26' ' ' SER . 98.2 m-20 38.43 179.13 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 O-C-N 124.096 0.873 . . . . 0.0 111.628 176.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.619 ' H ' ' HD2' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -92.65 -120.75 0.08 Allowed 'General case' 0 N--CA 1.471 0.585 0 O-C-N 120.906 -1.121 . . . . 0.0 109.134 178.919 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.461 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -69.08 88.11 0.23 Allowed Glycine 0 CA--C 1.484 -1.903 0 N-CA-C 104.824 -3.31 . . . . 0.0 104.824 171.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.47 162.79 35.65 Favored 'General case' 0 CA--C 1.464 -2.331 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.91 -175.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.637 ' CG1' HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -137.74 113.21 10.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.004 -179.404 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.601 ' CG2' HD11 ' J' ' 34' ' ' LEU . 1.6 tt -107.03 114.1 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 179.179 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.427 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -116.65 97.52 0.76 Allowed Glycine 0 CA--C 1.508 -0.377 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -123.17 131.55 53.72 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-O 122.379 1.085 . . . . 0.0 110.579 179.576 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 25.6 ttt -116.19 117.38 29.88 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.577 -1.647 . . . . 0.0 110.29 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.7 71.3 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.51 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.19 105.58 3.21 Favored Glycine 0 C--N 1.365 2.157 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 176.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.08 165.17 53.27 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.745 -0.741 . . . . 0.0 111.694 -178.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t -143.75 136.9 24.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.68 0.276 . . . . 0.0 110.351 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.098 -0.953 . . . . 0.0 110.324 179.699 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -81.92 142.81 32.13 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.957 0.408 . . . . 0.0 110.926 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -63.04 142.12 58.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.705 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -134.85 144.29 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 3.5 m80 -139.13 138.55 37.11 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.377 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.475 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 79.6 t60 -139.73 166.92 23.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.475 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 85.5 mt-30 -148.61 172.0 15.25 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.612 179.655 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 47.6 mtpt -156.93 112.07 2.83 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.603 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' J' ' 17' ' ' LEU . 5.3 mp -123.82 120.53 32.89 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.437 0.16 . . . . 0.0 110.661 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -137.31 130.86 44.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 119.921 -0.712 . . . . 0.0 112.014 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.42 ' CE2' ' CD2' ' I' ' 19' ' ' PHE . 18.0 m-85 -111.04 119.78 40.18 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 114.741 -1.118 . . . . 0.0 108.75 178.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -131.31 122.08 25.79 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.67 145.04 31.54 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -131.41 160.31 35.46 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.911 -1.041 . . . . 0.0 108.897 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -121.77 120.63 35.17 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.524 HG12 ' N ' ' J' ' 25' ' ' GLY . 14.3 t -62.87 -120.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.94 177.794 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.524 ' N ' HG12 ' J' ' 24' ' ' VAL . . . -75.3 -90.26 0.21 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.203 -177.494 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 53.4 m -140.97 171.23 14.36 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 122.067 0.937 . . . . 0.0 111.024 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' J' ' 28' ' ' LYS . 38.8 t-20 -28.66 151.1 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 113.627 -1.624 . . . . 0.0 115.168 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.533 ' N ' ' OD1' ' J' ' 27' ' ' ASN . 97.9 mttt -163.75 110.7 1.13 Allowed 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 112.594 -2.094 . . . . 0.0 107.594 177.231 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.65 93.82 0.32 Allowed Glycine 0 N--CA 1.476 1.303 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.538 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.507 ' HB2' ' O ' ' I' ' 28' ' ' LYS . . . -112.16 157.73 20.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 105.85 -1.907 . . . . 0.0 105.85 177.122 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.646 HG23 ' CG1' ' K' ' 31' ' ' ILE . 0.0 OUTLIER -146.55 111.24 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 119.715 -0.794 . . . . 0.0 110.329 -173.729 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.437 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.2 tt -104.54 118.57 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.113 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.773 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.61 106.51 0.89 Allowed Glycine 0 C--O 1.241 0.567 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.601 HD11 ' CG2' ' I' ' 32' ' ' ILE . 5.3 mp -129.71 132.06 46.52 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-O 122.15 0.976 . . . . 0.0 111.217 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.44 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 23.2 ttt -102.04 114.91 29.44 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 113.383 -1.735 . . . . 0.0 108.143 178.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -136.46 70.45 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.446 -177.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.72 -101.12 1.99 Allowed Glycine 0 C--N 1.358 1.756 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 177.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.61 154.71 26.21 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -142.79 139.17 28.11 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-O 121.128 0.489 . . . . 0.0 110.726 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.589 179.641 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.62 139.03 45.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.76 0.314 . . . . 0.0 110.913 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.542 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 95.0 mt-10 -139.47 153.53 47.55 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.619 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.454 HG22 ' H ' ' L' ' 12' ' ' VAL . 54.6 t -121.71 131.16 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 116.312 -0.403 . . . . 0.0 109.968 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -161.51 162.63 30.4 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.716 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -152.45 168.01 26.89 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.947 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 -158.04 178.83 9.77 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.11 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.1 tttt -160.14 126.58 4.27 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.123 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -116.86 119.11 34.37 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.043 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.38 125.69 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.866 0.365 . . . . 0.0 111.395 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -116.91 119.69 36.14 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.116 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.405 ' CE1' ' OE2' ' K' ' 22' ' ' GLU . 37.8 t80 -127.92 119.72 26.16 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.367 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.43 132.98 34.21 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.47 ' OE1' ' OE2' ' L' ' 22' ' ' GLU . 57.7 mm-40 -102.83 167.86 9.6 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.763 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' K' ' 23' ' ' ASP . 2.9 p30 -152.35 133.7 14.44 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 119.11 -1.036 . . . . 0.0 113.788 -178.524 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.555 ' O ' HG13 ' K' ' 24' ' ' VAL . 7.7 p -88.69 113.29 25.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 104.222 -2.51 . . . . 0.0 104.222 174.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.46 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -45.39 91.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.621 0 C-N-CA 119.722 -1.228 . . . . 0.0 113.503 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.6 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.6 t 161.17 160.69 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.127 0.489 . . . . 0.0 110.159 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' K' ' 28' ' ' LYS . 82.3 m-20 -29.76 175.91 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.245 173.227 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.66 ' HB2' ' O ' ' K' ' 27' ' ' ASN . 2.9 tptm 147.56 100.85 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 C-N-CA 127.032 2.133 . . . . 0.0 110.299 176.02 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -51.22 -100.17 0.01 OUTLIER Glycine 0 C--O 1.21 -1.397 0 CA-C-O 124.465 2.147 . . . . 0.0 114.385 175.133 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.81 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 70.74 143.87 0.06 Allowed 'General case' 0 C--O 1.245 0.826 0 CA-C-N 111.354 -2.423 . . . . 0.0 107.203 177.407 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.81 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -147.88 123.09 2.35 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.795 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.493 ' O ' ' CG2' ' K' ' 32' ' ' ILE . 0.8 OUTLIER -108.97 115.12 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.692 178.816 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 91.35 0.58 Allowed Glycine 0 C--O 1.24 0.485 0 N-CA-C 107.333 -2.307 . . . . 0.0 107.333 176.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.4 HD12 ' CE2' ' I' ' 19' ' ' PHE . 92.2 mt -114.75 118.75 34.47 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.331 0.586 . . . . 0.0 109.862 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 2.5 ttt -107.7 115.04 29.43 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.742 -178.788 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.11 68.35 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.763 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.415 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -62.03 -100.99 0.01 OUTLIER Glycine 0 C--N 1.349 1.262 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.86 160.2 14.39 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.9 m -136.76 159.74 37.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.794 0.33 . . . . 0.0 110.219 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.325 -0.457 0 CA-C-O 118.089 -0.958 . . . . 0.0 110.765 -179.77 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.351 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -104.38 132.33 50.75 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -71.9 132.42 44.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.354 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.454 ' H ' HG22 ' K' ' 12' ' ' VAL . 21.8 m -143.13 156.2 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 122.011 0.91 . . . . 0.0 112.543 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.542 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 3.9 m80 -151.16 118.33 5.94 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.729 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -153.88 172.82 16.8 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.273 0.559 . . . . 0.0 110.418 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -145.67 173.86 11.7 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.728 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -159.82 120.92 3.14 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.93 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 tt -122.51 119.73 31.77 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -129.07 132.89 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -135.64 130.32 34.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.935 0.398 . . . . 0.0 110.715 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.2 t80 -137.31 127.62 26.38 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.568 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.0 148.21 36.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.265 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.47 ' OE2' ' OE1' ' K' ' 22' ' ' GLU . 78.1 mt-10 -81.73 149.17 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.464 0.649 . . . . 0.0 110.722 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.411 ' O ' ' O ' ' L' ' 22' ' ' GLU . 99.3 m-20 54.17 114.42 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.869 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 67.3 t -95.12 130.61 43.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 CA-C-N 114.519 -1.219 . . . . 0.0 109.879 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 49.56 82.74 0.03 OUTLIER Glycine 0 CA--C 1.525 0.698 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.183 178.151 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' L' ' 27' ' ' ASN . 5.8 p 176.96 -167.52 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' L' ' 26' ' ' SER . 90.4 m-20 -38.92 179.91 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -175.485 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.468 ' NZ ' ' O ' ' K' ' 22' ' ' GLU . 85.1 tttt 77.42 -111.42 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.668 -1.151 . . . . 0.0 112.128 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.646 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 83.93 -94.59 1.83 Allowed Glycine 0 CA--C 1.503 -0.682 0 N-CA-C 107.892 -2.083 . . . . 0.0 107.892 -174.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.646 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 77.17 169.77 0.23 Allowed 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.617 HD13 ' C ' ' L' ' 30' ' ' ALA . 0.0 OUTLIER -138.83 109.19 4.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 116.81 -1.956 . . . . 0.0 111.224 179.23 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' L' ' 32' ' ' ILE . 7.4 tt -102.7 115.88 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-N 113.34 -1.755 . . . . 0.0 107.961 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 110.18 2.24 Favored Glycine 0 C--N 1.334 0.464 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 -179.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.38 111.8 22.03 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.582 -0.809 . . . . 0.0 110.086 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.437 ' HE2' ' H ' ' F' ' 33' ' ' GLY . 2.7 tpp -93.65 104.97 17.05 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' L' ' 37' ' ' GLY . 0.7 OUTLIER -131.09 71.36 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.954 0 O-C-N 122.051 -0.405 . . . . 0.0 109.922 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -35.49 -100.66 0.01 OUTLIER Glycine 0 C--N 1.346 1.085 0 C-N-CA 121.815 -0.231 . . . . 0.0 112.717 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.27 174.91 19.16 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 159.2 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.979 0.419 . . . . 0.0 110.709 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.184 179.897 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -81.86 137.03 35.32 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.828 0.346 . . . . 0.0 110.547 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -122.48 143.02 49.97 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.94 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t -121.48 132.35 70.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 121.307 0.575 . . . . 0.0 110.859 -179.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.491 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 69.7 m80 -116.44 172.5 7.17 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.813 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.51 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 34.9 t60 -80.45 165.55 22.09 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 109.622 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.51 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 0.1 OUTLIER -161.01 179.03 8.78 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.315 179.428 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -144.24 128.22 17.48 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.713 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 78.5 mt -124.03 124.19 42.01 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.24 131.45 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.333 0.587 . . . . 0.0 111.852 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.912 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 0.2 OUTLIER -118.44 112.11 19.53 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.937 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.533 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 51.1 p90 -125.44 128.27 47.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -177.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.27 115.85 28.06 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.219 0.533 . . . . 0.0 110.166 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.465 ' O ' ' C ' ' A' ' 23' ' ' ASP . 84.7 tt0 -163.89 96.52 0.82 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.465 ' C ' ' O ' ' A' ' 22' ' ' GLU . 0.1 OUTLIER -25.89 115.46 0.06 Allowed 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 -177.097 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' A' ' 26' ' ' SER . 2.1 p -87.27 130.64 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.75 82.29 0.0 OUTLIER Glycine 0 CA--C 1.525 0.712 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.618 -177.249 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' A' ' 24' ' ' VAL . 80.2 p -98.47 174.95 6.21 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.123 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.07 178.89 0.16 Allowed 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 119.396 -0.922 . . . . 0.0 108.635 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.68 110.78 1.22 Allowed 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.73 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 94.2 0.11 Allowed Glycine 0 N--CA 1.469 0.843 0 C-N-CA 119.702 -1.237 . . . . 0.0 111.284 177.516 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.402 ' HB2' ' OG ' ' A' ' 26' ' ' SER . . . -103.32 160.23 14.87 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-N 119.707 1.753 . . . . 0.0 107.497 177.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.579 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.2 OUTLIER -152.6 113.03 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.175 -175.308 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.47 ' O ' ' SD ' ' G' ' 35' ' ' MET . 97.6 mt -128.86 128.04 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-O 121.435 0.636 . . . . 0.0 111.671 -179.362 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' G' ' 35' ' ' MET . . . -123.5 127.03 6.43 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.043 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -130.18 130.05 44.21 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.799 0.3 . . . . 0.0 111.021 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.674 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 19.8 ttp -130.63 128.08 40.24 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.096 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.449 HG12 ' O ' ' A' ' 36' ' ' VAL . 54.4 t -115.64 72.15 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.88 98.82 0.81 Allowed Glycine 0 CA--C 1.529 0.924 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 176.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.76 172.45 40.48 Favored Glycine 0 CA--C 1.523 0.547 0 C-N-CA 120.485 -0.864 . . . . 0.0 111.564 -179.272 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m -132.47 161.24 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-O 120.781 0.324 . . . . 0.0 110.765 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 N--CA 1.467 0.385 0 CA-C-O 118.073 -0.965 . . . . 0.0 110.217 179.369 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -104.83 139.17 39.98 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.123 0.487 . . . . 0.0 110.597 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' C' ' 11' ' ' GLU . 18.6 pt-20 -64.19 142.97 58.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.181 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -132.88 137.36 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.16 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.464 ' O ' ' CB ' ' C' ' 13' ' ' HIS . 4.8 m-70 -105.67 117.76 34.84 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.789 0.328 . . . . 0.0 110.909 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.437 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 52.5 t-80 -157.21 159.51 37.76 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.437 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 74.4 mt-30 -159.98 179.07 9.09 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.832 179.342 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -157.71 126.12 5.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.754 0.311 . . . . 0.0 110.762 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 tp -120.76 123.25 42.21 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.312 0.577 . . . . 0.0 110.297 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.48 HG22 ' CG1' ' C' ' 18' ' ' VAL . 56.0 t -117.93 121.37 67.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.601 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.901 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 13.5 t80 -128.05 116.26 19.73 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 -178.908 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.543 ' CG ' ' CZ ' ' C' ' 20' ' ' PHE . 38.8 p90 -150.2 160.22 43.85 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.41 138.85 38.59 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.896 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -125.4 175.1 7.72 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.487 ' CG ' ' H ' ' C' ' 27' ' ' ASN . 50.5 t0 -142.98 99.33 3.44 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.139 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.656 HG12 ' H ' ' B' ' 25' ' ' GLY . 1.6 t -118.21 -151.17 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.656 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -38.9 -75.88 0.09 OUTLIER Glycine 0 N--CA 1.47 0.937 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.601 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.592 ' HG ' ' H ' ' B' ' 27' ' ' ASN . 31.1 t 60.15 173.13 0.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.73 -1.235 . . . . 0.0 113.568 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.592 ' H ' ' HG ' ' B' ' 26' ' ' SER . 18.9 p30 -101.38 -178.98 3.89 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 113.395 -1.73 . . . . 0.0 112.567 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.494 ' O ' ' O ' ' B' ' 27' ' ' ASN . 87.3 tttt -34.15 -102.66 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.118 177.115 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -137.13 100.8 0.32 Allowed Glycine 0 CA--C 1.485 -1.829 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.5 157.72 31.45 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.349 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.754 HG23 HG13 ' C' ' 31' ' ' ILE . 0.6 OUTLIER -148.58 120.87 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.583 -178.796 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.501 ' O ' ' SD ' ' H' ' 35' ' ' MET . 86.8 mt -133.98 128.68 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.362 -178.065 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.505 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -120.81 109.5 1.56 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.976 -1.65 . . . . 0.0 108.976 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 8.7 tt -117.08 123.32 46.53 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 117.072 0.436 . . . . 0.0 111.099 -179.051 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.599 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 32.1 ttp -124.79 117.37 24.01 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.299 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 37' ' ' GLY . 34.5 m -136.54 73.01 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -47.4 -95.35 0.01 OUTLIER Glycine 0 C--N 1.337 0.604 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 175.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.13 176.67 40.45 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -140.96 144.48 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-O 121.031 0.443 . . . . 0.0 111.215 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 85.0 t . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.309 179.842 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.156 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -105.73 131.56 52.94 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.709 0.29 . . . . 0.0 110.595 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 11' ' ' GLU . 97.5 mt-10 -74.3 133.14 42.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.068 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.16 166.68 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 CA-C-O 120.832 0.349 . . . . 0.0 110.887 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.493 ' ND1' ' OE1' ' D' ' 11' ' ' GLU . 0.0 OUTLIER -169.28 164.76 10.92 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.271 178.749 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.495 ' CG ' ' OE1' ' D' ' 15' ' ' GLN . 54.1 m80 -105.52 -179.91 4.08 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' C' ' 16' ' ' LYS . 13.6 tt0 -88.69 169.19 11.88 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.433 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' C' ' 15' ' ' GLN . 99.2 mttt -123.5 133.92 53.95 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 29.1 mt -122.3 119.35 30.86 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.026 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 18' ' ' VAL . . . . . 0.48 ' CG1' HG22 ' B' ' 18' ' ' VAL . 6.2 p -124.77 123.23 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.067 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.707 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 3.6 t80 -123.41 119.17 29.25 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.571 -176.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.543 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 49.7 p90 -142.86 130.26 21.11 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-O 122.574 1.178 . . . . 0.0 112.953 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.94 121.74 38.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.397 179.683 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.496 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 97.2 mt-10 -99.01 101.08 12.35 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.498 ' OD1' ' NZ ' ' E' ' 28' ' ' LYS . 15.7 t0 83.68 133.56 0.05 Allowed 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.508 ' O ' ' N ' ' C' ' 26' ' ' SER . 34.8 t -83.41 -110.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.718 ' HA2' ' HB3' ' D' ' 30' ' ' ALA . . . -42.85 92.19 0.01 OUTLIER Glycine 0 C--N 1.317 -0.473 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.527 ' O ' ' O ' ' C' ' 27' ' ' ASN . 42.3 p -101.11 165.22 11.42 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 122.49 1.138 . . . . 0.0 110.784 -176.33 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.646 ' CG ' ' HZ2' ' C' ' 28' ' ' LYS . 0.1 OUTLIER 49.05 169.15 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 112.009 -2.36 . . . . 0.0 109.114 -176.235 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.787 ' CE ' ' H ' ' C' ' 28' ' ' LYS . 0.0 OUTLIER -79.08 110.7 14.57 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.641 -0.824 . . . . 0.0 108.824 175.634 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 57.25 91.51 0.01 OUTLIER Glycine 0 C--O 1.219 -0.829 0 C-N-CA 118.342 -1.885 . . . . 0.0 109.877 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.421 ' HB2' ' OD1' ' C' ' 27' ' ' ASN . . . -136.66 152.22 50.16 Favored 'General case' 0 CA--C 1.476 -1.903 0 CA-C-N 121.428 2.614 . . . . 0.0 105.016 175.673 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.754 HG13 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -144.48 109.66 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.185 -173.028 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.488 HG12 HD21 ' C' ' 34' ' ' LEU . 0.8 OUTLIER -114.9 118.44 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.05 -178.918 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.21 108.51 2.48 Favored Glycine 0 N--CA 1.46 0.298 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.912 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 5.8 mt -114.76 112.72 23.25 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 120.916 0.388 . . . . 0.0 110.331 -178.428 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.5 ttt -112.42 104.06 12.18 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.59 72.24 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.994 -177.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -42.97 -97.43 0.01 OUTLIER Glycine 0 C--N 1.349 1.27 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.12 -173.12 42.95 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -141.52 154.22 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.019 0.438 . . . . 0.0 111.133 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.087 -0.959 . . . . 0.0 110.218 179.56 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.129 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 10' ' ' TYR . . . . . 0.528 ' CD2' ' N ' ' E' ' 9' ' ' GLY . 96.5 m-85 -109.2 133.39 53.08 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.954 0.407 . . . . 0.0 110.336 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.493 ' OE1' ' ND1' ' C' ' 13' ' ' HIS . 80.9 mm-40 -77.17 133.91 38.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.415 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.439 ' HB ' ' H ' ' E' ' 12' ' ' VAL . 23.0 m -142.19 174.86 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.126 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 96.5 m-70 -82.15 112.95 19.65 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.168 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.624 ' CE1' HG23 ' E' ' 12' ' ' VAL . 3.4 m-70 -145.72 159.94 42.44 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG ' ' C' ' 14' ' ' HIS . 0.0 OUTLIER -159.23 174.18 15.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.26 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -153.32 129.09 10.14 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.886 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 36.7 tp -123.28 118.33 27.32 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -122.39 126.19 73.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.941 0.4 . . . . 0.0 110.687 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -123.25 112.33 17.52 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.369 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -131.57 133.42 45.0 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.79 131.79 29.59 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.886 0.374 . . . . 0.0 111.725 179.29 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -127.88 143.52 51.11 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.991 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -131.3 111.97 12.35 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.969 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.494 ' O ' ' N ' ' D' ' 26' ' ' SER . 12.6 m -138.01 -122.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 120.424 -0.51 . . . . 0.0 109.915 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.418 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . 28.37 -84.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.536 -0.756 . . . . 0.0 113.097 -178.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.3 m 170.28 178.77 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.518 0.675 . . . . 0.0 110.574 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' D' ' 26' ' ' SER . 12.4 m120 -28.73 -179.21 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 113.041 -1.891 . . . . 0.0 114.248 176.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 85.4 mttt 128.26 105.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 125.867 1.667 . . . . 0.0 112.137 176.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.6 94.87 0.05 OUTLIER Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.718 ' HB3' ' HA2' ' C' ' 25' ' ' GLY . . . -122.43 154.25 38.0 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 176.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.504 HD12 ' CG2' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.04 112.29 2.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.732 -171.629 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.41 ' O ' HG22 ' D' ' 32' ' ' ILE . 2.1 mt -107.93 114.01 45.3 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.409 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.408 ' CA ' ' HG3' ' J' ' 35' ' ' MET . . . -106.38 100.65 1.66 Allowed Glycine 0 CA--C 1.498 -1.007 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 176.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.901 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 13.6 tp -112.99 121.08 43.56 Favored 'General case' 0 CA--C 1.503 -0.852 0 CA-C-N 115.298 -0.451 . . . . 0.0 110.934 -177.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 43.3 ttp -128.97 107.25 9.46 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -123.61 72.14 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.675 -179.927 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.15 -100.52 0.01 OUTLIER Glycine 0 C--N 1.36 1.892 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.891 179.144 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 157.13 -157.24 27.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -132.36 147.95 31.99 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.462 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.32 -179.731 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' E' E ' 9' ' ' GLY . . . . . 0.528 ' N ' ' CD2' ' D' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -114.76 134.31 55.21 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.768 0.318 . . . . 0.0 110.491 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -98.37 137.47 37.04 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.28 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.624 HG23 ' CE1' ' D' ' 14' ' ' HIS . 22.6 m -131.74 160.34 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 121.332 0.587 . . . . 0.0 111.141 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 27.6 m80 -124.01 120.51 32.65 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.606 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.467 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -150.66 162.91 39.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.927 0.87 . . . . 0.0 111.473 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.467 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 50.2 tt0 -157.99 168.6 26.67 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.375 -1.284 . . . . 0.0 110.063 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -143.57 126.79 16.59 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.837 179.126 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 tt -118.98 115.68 24.86 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -120.23 125.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.734 0.302 . . . . 0.0 110.36 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -124.16 113.4 18.28 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.482 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -125.72 125.13 42.51 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.212 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.434 ' HB3' ' CB ' ' F' ' 21' ' ' ALA . . . -134.23 119.63 19.01 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.232 0.539 . . . . 0.0 110.327 179.096 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.402 ' C ' ' OD1' ' E' ' 23' ' ' ASP . 97.8 mt-10 -129.16 128.35 43.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.459 ' HB3' ' HZ2' ' F' ' 28' ' ' LYS . 1.2 m-20 -141.89 112.1 6.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.264 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' E' ' 26' ' ' SER . 13.2 m -103.24 -122.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 C-N-CA 120.326 -0.55 . . . . 0.0 111.057 -178.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.05 -84.92 0.01 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.834 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' E' ' 27' ' ' ASN . 3.0 p 170.88 170.54 0.07 Allowed 'General case' 0 CA--C 1.511 -0.55 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' E' ' 26' ' ' SER . 27.6 t-20 -18.17 157.47 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.975 0 O-C-N 124.792 1.308 . . . . 0.0 113.475 179.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.722 ' O ' ' HB2' ' F' ' 30' ' ' ALA . 84.8 tttt -162.55 111.35 1.38 Allowed 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.552 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.17 92.36 0.25 Allowed Glycine 0 N--CA 1.479 1.528 0 O-C-N 121.931 -0.481 . . . . 0.0 113.194 177.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.5 161.97 21.58 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 175.623 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.466 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.68 132.21 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 118.903 -1.119 . . . . 0.0 113.647 -175.561 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.571 HG23 HD21 ' E' ' 34' ' ' LEU . 0.2 OUTLIER -109.71 116.48 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.306 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.67 105.36 2.23 Favored Glycine 0 N--CA 1.466 0.669 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.707 HD13 ' CZ ' ' C' ' 19' ' ' PHE . 16.4 mt -115.83 115.0 25.49 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 117.561 0.68 . . . . 0.0 112.155 -177.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.717 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 11.4 ttp -114.07 106.66 14.66 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 176.074 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.91 73.81 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.331 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.17 111.57 2.66 Favored Glycine 0 C--N 1.354 1.577 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 178.603 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.5 -157.08 0.04 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.15 142.81 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.975 0.417 . . . . 0.0 110.49 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.772 179.827 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.464 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -107.02 134.91 49.46 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.566 0.222 . . . . 0.0 110.622 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 11' ' ' GLU . . . . . 0.525 ' N ' ' OE1' ' F' ' 11' ' ' GLU . 56.7 mp0 -105.12 143.38 33.38 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.209 -0.45 . . . . 0.0 109.903 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t -120.76 135.26 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-O 121.115 0.483 . . . . 0.0 110.397 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -130.02 128.53 42.18 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.923 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.448 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 78.8 t60 -151.99 168.5 25.02 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.448 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 33.8 mt-30 -150.52 173.47 14.05 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.41 179.454 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.41 127.01 14.21 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.39 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -128.73 127.57 42.33 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.554 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -127.56 128.3 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -123.36 120.74 33.92 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.678 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 78.8 t80 -141.13 121.88 14.35 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.434 ' CB ' ' HB3' ' E' ' 21' ' ' ALA . . . -159.59 154.71 25.04 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 119.785 -0.766 . . . . 0.0 112.578 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -96.94 124.16 40.84 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.558 ' OD1' ' N ' ' F' ' 24' ' ' VAL . 60.3 t0 -169.66 139.0 1.95 Allowed 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 119.652 -0.819 . . . . 0.0 113.033 -178.198 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.572 ' O ' ' O ' ' F' ' 26' ' ' SER . 24.2 t -108.07 111.7 37.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.513 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.23 -92.04 0.01 OUTLIER Glycine 0 CA--C 1.539 1.535 0 CA-C-O 119.026 -0.874 . . . . 0.0 111.732 -177.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.572 ' O ' ' O ' ' F' ' 24' ' ' VAL . 13.7 p -63.79 -177.56 0.25 Allowed 'General case' 0 CA--C 1.503 -0.848 0 N-CA-C 104.403 -2.443 . . . . 0.0 104.403 177.404 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.439 ' O ' ' O ' ' F' ' 28' ' ' LYS . 64.3 t30 -80.59 174.13 11.91 Favored 'General case' 0 C--N 1.318 -0.798 0 C-N-CA 114.894 -2.722 . . . . 0.0 108.25 178.18 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.509 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 75.1 tttt -43.7 -105.91 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 124.085 1.897 . . . . 0.0 112.226 174.243 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.509 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -109.29 -100.33 2.63 Favored Glycine 0 CA--C 1.484 -1.881 0 C-N-CA 130.168 3.747 . . . . 0.0 109.753 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.722 ' HB2' ' O ' ' E' ' 28' ' ' LYS . . . -58.11 172.85 0.39 Allowed 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 -178.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.448 HD13 ' HA3' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -140.39 134.42 34.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.147 -1.421 . . . . 0.0 111.479 -172.131 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.495 ' CG2' ' O ' ' F' ' 32' ' ' ILE . 5.2 tt -110.12 117.24 54.29 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 114.001 -1.454 . . . . 0.0 108.452 -179.266 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.77 102.87 2.42 Favored Glycine 0 C--N 1.322 -0.249 0 N-CA-C 108.027 -2.029 . . . . 0.0 108.027 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.504 ' O ' HD12 ' F' ' 34' ' ' LEU . 2.2 pp -107.44 115.73 30.67 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 117.039 0.42 . . . . 0.0 110.518 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 18.3 ttp -119.46 110.5 16.99 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 m -132.87 79.92 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.16 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -64.65 103.5 0.77 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.0 -146.15 19.15 Favored Glycine 0 N--CA 1.465 0.61 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -113.86 133.58 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 32.9 m . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.761 -179.67 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -121.92 147.84 45.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.745 0.307 . . . . 0.0 110.707 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -68.51 156.96 36.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.069 179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 78.0 t -115.63 131.6 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.061 0.458 . . . . 0.0 110.315 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -89.15 179.45 6.13 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.972 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -74.69 164.45 26.57 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 91.7 mt-30 -155.63 -179.84 8.5 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.442 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.414 ' NZ ' ' CG2' ' G' ' 18' ' ' VAL . 65.2 tttm -161.32 119.26 2.35 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.682 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 35.7 tp -118.83 126.12 51.11 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 121.299 0.571 . . . . 0.0 110.478 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.414 ' CG2' ' NZ ' ' G' ' 16' ' ' LYS . 47.9 t -125.72 125.9 69.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.901 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.923 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 0.1 OUTLIER -114.76 119.47 36.77 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.937 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -142.92 147.96 36.14 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 119.674 -0.81 . . . . 0.0 112.369 -178.041 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.32 132.22 35.37 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.285 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -135.48 167.33 21.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.53 ' OD2' ' N ' ' H' ' 24' ' ' VAL . 34.8 m-20 -85.94 -151.19 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.168 -178.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' G' ' 23' ' ' ASP . 14.0 t 27.09 103.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.77 -94.69 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.827 177.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -64.03 -178.81 0.36 Allowed 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -80.95 173.49 12.56 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.12 0.486 . . . . 0.0 111.302 177.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -44.91 110.79 0.26 Allowed 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.947 176.365 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.26 94.73 0.52 Allowed Glycine 0 N--CA 1.472 1.084 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.324 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -118.34 151.61 37.39 Favored 'General case' 0 CA--C 1.504 -0.808 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.196 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.19 108.81 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 CA-C-N 113.182 -1.826 . . . . 0.0 109.594 -171.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.76 123.46 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.89 0.376 . . . . 0.0 111.237 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.674 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -130.33 111.23 1.11 Allowed Glycine 0 N--CA 1.465 0.573 0 N-CA-C 108.794 -1.723 . . . . 0.0 108.794 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.89 130.41 52.82 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.916 0.388 . . . . 0.0 111.656 -178.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' A' ' 33' ' ' GLY . 28.1 ttt -130.46 128.52 41.43 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' G' ' 37' ' ' GLY . 3.7 t -111.42 65.9 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -178.209 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.509 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -55.25 -105.55 0.01 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 178.151 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -105.06 174.59 21.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 30.0 m -135.23 158.13 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.11 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -86.65 131.01 34.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.918 0.389 . . . . 0.0 110.103 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -136.06 142.81 44.41 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.908 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -126.06 134.31 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.456 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 75.4 m80 -87.08 175.35 8.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.124 0.488 . . . . 0.0 110.792 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.547 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 25.4 m-70 -77.9 173.28 12.32 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.45 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -142.75 175.44 9.82 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.128 179.623 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -151.58 125.87 9.36 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.151 -179.184 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 58.1 mt -121.17 120.51 35.43 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -127.8 130.52 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -178.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.744 ' CZ ' HD22 ' J' ' 34' ' ' LEU . 5.9 m-85 -117.73 120.06 36.81 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.615 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 29.0 t80 -130.78 122.6 27.46 Favored 'General case' 0 N--CA 1.476 0.834 0 O-C-N 122.231 -0.293 . . . . 0.0 110.626 -179.129 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.77 130.0 48.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -137.94 106.74 5.93 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -114.51 114.11 25.34 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.53 ' N ' ' OD2' ' G' ' 23' ' ' ASP . 1.2 p -128.79 122.26 56.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.051 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 30.49 82.79 0.01 OUTLIER Glycine 0 CA--C 1.537 1.442 0 CA-C-O 119.473 -0.626 . . . . 0.0 114.593 175.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.542 ' O ' ' O ' ' H' ' 27' ' ' ASN . 1.0 OUTLIER -140.14 170.62 15.49 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 118.71 1.255 . . . . 0.0 111.108 179.107 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' H' ' 26' ' ' SER . 5.5 m-20 -31.04 173.14 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 113.671 -1.604 . . . . 0.0 114.812 -177.206 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -87.84 111.41 21.38 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.267 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . 69.61 93.6 0.06 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 118.124 -1.989 . . . . 0.0 115.526 172.442 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.42 155.51 22.09 Favored 'General case' 0 C--O 1.248 0.985 0 CA-C-N 120.627 2.214 . . . . 0.0 106.698 175.327 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.759 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -148.31 119.27 1.37 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 118.921 -1.112 . . . . 0.0 111.684 -173.055 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.9 mt -129.87 128.32 64.98 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.034 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.599 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -132.23 127.54 4.94 Favored Glycine 0 N--CA 1.465 0.63 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.454 ' O ' HD12 ' I' ' 34' ' ' LEU . 8.4 tt -135.08 130.96 36.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.565 0.698 . . . . 0.0 110.736 -179.48 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 19.3 ttt -130.37 128.99 42.53 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.652 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.52 79.54 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.549 ' CA ' HG21 ' B' ' 31' ' ' ILE . . . -65.77 105.12 1.15 Allowed Glycine 0 C--N 1.339 0.707 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.74 -171.27 50.34 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -132.37 161.78 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-O 120.993 0.425 . . . . 0.0 110.909 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 34.3 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.658 179.766 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -109.94 132.15 54.42 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.8 0.333 . . . . 0.0 110.72 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -73.79 131.92 42.06 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.563 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.61 131.17 47.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.075 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.513 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 16.5 p-80 -164.27 161.08 21.72 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.554 -0.459 . . . . 0.0 111.229 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.547 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 0.8 OUTLIER -122.92 166.76 14.52 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.951 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 26.6 mt-30 -142.25 175.64 9.6 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.65 179.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.528 ' C ' HD12 ' I' ' 17' ' ' LEU . 87.4 tttt -166.49 113.7 0.86 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.771 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.528 HD12 ' C ' ' I' ' 16' ' ' LYS . 8.0 mp -112.56 124.24 52.09 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.162 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -127.91 128.75 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-O 121.17 0.51 . . . . 0.0 112.095 -179.382 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.834 ' CZ ' HD13 ' K' ' 34' ' ' LEU . 32.1 m-85 -118.75 118.98 33.07 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.573 178.251 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.615 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 58.8 t80 -126.57 116.95 21.85 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.48 129.63 52.21 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.18 0.514 . . . . 0.0 111.771 -179.108 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -143.83 144.29 31.71 Favored 'General case' 0 C--N 1.34 0.193 0 CA-C-N 115.366 -0.833 . . . . 0.0 109.036 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.605 ' O ' ' O ' ' I' ' 24' ' ' VAL . 0.9 OUTLIER -175.04 129.55 0.3 Allowed 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.062 -0.655 . . . . 0.0 110.773 179.724 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.757 HG12 ' N ' ' I' ' 25' ' ' GLY . 61.6 t -29.34 -113.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 O-C-N 124.425 1.078 . . . . 0.0 112.66 178.156 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.757 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -170.77 90.55 0.09 OUTLIER Glycine 0 CA--C 1.53 0.981 0 CA-C-N 115.272 -0.877 . . . . 0.0 112.117 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.525 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t 161.99 160.45 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.921 0.867 . . . . 0.0 111.128 176.729 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.525 ' O ' ' O ' ' I' ' 26' ' ' SER . 81.8 m-20 -30.16 179.07 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 113.084 -1.871 . . . . 0.0 116.027 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.508 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 86.4 tttt 127.81 103.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 112.2 -2.273 . . . . 0.0 111.203 174.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.514 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -59.86 99.54 0.16 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.248 -1.307 . . . . 0.0 110.735 174.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.439 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -118.08 141.4 48.51 Favored 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 102.529 -3.137 . . . . 0.0 102.529 174.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.759 HD12 ' CG2' ' H' ' 31' ' ' ILE . 2.1 mt -146.06 114.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 C-N-CA 118.181 -1.408 . . . . 0.0 112.515 -169.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 1.3 mt -114.62 119.74 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.16 106.56 1.44 Allowed Glycine 0 N--CA 1.461 0.311 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.923 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 54.4 tp -116.23 120.93 40.53 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 5.6 tpp -117.1 102.02 8.96 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 174.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.705 ' O ' HG13 ' I' ' 36' ' ' VAL . 4.2 p -131.81 74.89 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.114 -177.298 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.28 -96.92 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.995 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 163.31 -167.76 37.72 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.65 150.58 3.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.768 0.318 . . . . 0.0 110.387 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.854 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -83.64 141.89 31.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.955 0.407 . . . . 0.0 110.065 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -66.35 135.63 54.64 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.477 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.814 HG12 ' H ' ' J' ' 13' ' ' HIS . 27.4 t -145.77 178.8 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.119 179.434 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.814 ' H ' HG12 ' J' ' 12' ' ' VAL . 92.2 m-70 -50.82 125.28 12.96 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.069 0.461 . . . . 0.0 112.146 -177.422 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.499 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 18.0 t-80 -145.38 163.43 34.6 Favored 'General case' 0 C--N 1.341 0.239 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.499 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 89.6 mt-30 -148.54 177.6 9.34 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.088 0.47 . . . . 0.0 111.364 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.419 ' C ' HD22 ' J' ' 17' ' ' LEU . 88.9 tttt -170.26 116.28 0.51 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.819 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.419 HD22 ' C ' ' J' ' 16' ' ' LYS . 1.4 mm? -114.23 125.27 53.72 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.495 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -126.78 121.05 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 120.78 0.324 . . . . 0.0 111.241 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.673 ' CZ ' HD22 ' L' ' 34' ' ' LEU . 95.4 m-85 -118.43 116.22 26.26 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.416 ' CZ ' ' CD1' ' K' ' 20' ' ' PHE . 1.1 t80 -131.38 129.66 41.62 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 120.922 0.391 . . . . 0.0 110.553 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.41 134.65 41.88 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.458 0.647 . . . . 0.0 112.421 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 mt-10 -144.3 102.87 3.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.029 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -152.22 177.3 10.68 Favored 'General case' 0 CA--C 1.515 -0.394 0 O-C-N 122.096 -0.378 . . . . 0.0 110.392 -178.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -91.96 102.99 14.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 122.176 0.989 . . . . 0.0 108.379 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' K' ' 26' ' ' SER . . . -35.9 95.59 0.01 OUTLIER Glycine 0 CA--C 1.526 0.763 0 CA-C-N 113.269 -1.787 . . . . 0.0 115.653 -179.087 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.4 t 170.24 176.18 0.05 Allowed 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 121.627 0.727 . . . . 0.0 110.678 175.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' J' ' 26' ' ' SER . 52.2 t30 -28.96 179.5 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 115.886 1.81 . . . . 0.0 115.886 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.505 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 61.8 tttp 128.26 105.11 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 112.715 -2.039 . . . . 0.0 112.719 175.329 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.02 95.07 0.05 OUTLIER Glycine 0 N--CA 1.465 0.59 0 CA-C-N 113.934 -1.484 . . . . 0.0 113.031 174.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.51 142.33 46.99 Favored 'General case' 0 CA--C 1.496 -1.117 0 CA-C-N 119.884 1.842 . . . . 0.0 106.201 174.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.46 HG23 ' CG1' ' K' ' 31' ' ' ILE . 0.0 OUTLIER -143.11 110.93 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 CA-C-N 114.454 -1.248 . . . . 0.0 111.837 -171.41 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.529 ' O ' ' SD ' ' E' ' 35' ' ' MET . 0.2 OUTLIER -114.68 118.9 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 177.783 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -114.15 106.68 1.75 Allowed Glycine 0 CA--C 1.496 -1.115 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 177.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.744 HD22 ' CZ ' ' H' ' 19' ' ' PHE . 37.1 tp -115.37 118.87 34.44 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 113.292 0.849 . . . . 0.0 113.292 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.408 ' HG3' ' CA ' ' D' ' 33' ' ' GLY . 0.0 OUTLIER -117.29 107.63 14.63 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.639 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.524 HG22 HD11 ' J' ' 34' ' ' LEU . 0.0 OUTLIER -119.37 80.29 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.3 -94.42 0.01 OUTLIER Glycine 0 C--N 1.352 1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.714 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.62 -178.14 18.74 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 111.031 -0.827 . . . . 0.0 111.031 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -114.63 134.93 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.444 179.95 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -103.96 135.44 45.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.655 0.264 . . . . 0.0 110.377 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.471 ' N ' ' OE1' ' L' ' 11' ' ' GLU . 94.9 mt-10 -137.48 156.52 48.06 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.607 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.6 m -134.48 163.2 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.657 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 t60 -159.37 128.37 5.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.314 -179.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -152.67 167.52 28.65 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.688 0.756 . . . . 0.0 110.002 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -156.51 175.92 13.39 Favored 'General case' 0 C--N 1.307 -1.239 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.762 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -148.73 120.37 8.03 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 23.1 mt -112.51 116.05 29.63 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.6 p -133.31 134.47 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 CA-C-O 121.42 0.629 . . . . 0.0 112.308 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -125.76 126.94 45.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.227 179.087 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.416 ' CD1' ' CZ ' ' J' ' 20' ' ' PHE . 8.2 t80 -136.51 128.96 30.26 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.171 0.51 . . . . 0.0 111.818 -179.315 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.78 129.53 47.19 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.772 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.446 ' HG2' ' N ' ' K' ' 23' ' ' ASP . 75.7 tt0 -88.44 170.1 11.2 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.453 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.503 ' OD1' HG21 ' L' ' 24' ' ' VAL . 48.0 t0 -39.33 115.46 0.5 Allowed 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 121.007 0.432 . . . . 0.0 110.821 -178.601 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.556 HG13 ' O ' ' K' ' 24' ' ' VAL . 10.4 p -129.84 117.16 40.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.867 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . -27.92 -90.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.381 0 CA-C-O 121.524 0.513 . . . . 0.0 111.825 178.161 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.637 ' O ' ' O ' ' K' ' 27' ' ' ASN . 26.7 p -140.97 170.73 15.18 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.121 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.637 ' O ' ' O ' ' K' ' 26' ' ' SER . 56.8 p30 -28.29 169.75 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -149.4 111.45 4.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.685 178.068 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.71 91.6 0.02 OUTLIER Glycine 0 N--CA 1.464 0.521 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.59 151.69 43.37 Favored 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 106.314 -1.735 . . . . 0.0 106.314 176.685 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.46 ' CG1' HG23 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -135.83 115.44 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.579 -178.724 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.545 HG23 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -115.59 116.91 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 178.362 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.717 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -109.56 106.0 2.13 Favored Glycine 0 N--CA 1.464 0.547 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 178.581 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.834 HD13 ' CZ ' ' I' ' 19' ' ' PHE . 21.5 mt -110.44 111.98 23.6 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 117.047 0.423 . . . . 0.0 111.659 -177.55 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.46 ' CE ' ' O ' ' E' ' 32' ' ' ILE . 11.4 tpt -107.59 103.1 12.32 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 176.624 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -129.58 73.83 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.146 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.445 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.38 -101.5 0.01 OUTLIER Glycine 0 C--N 1.359 1.828 0 CA-C-N 116.388 -0.369 . . . . 0.0 112.844 -179.215 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.92 -155.69 26.57 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 30.0 m -126.54 160.54 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.762 0.315 . . . . 0.0 110.548 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.501 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -148.22 160.68 42.69 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.655 0.264 . . . . 0.0 110.334 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 11' ' ' GLU . . . . . 0.471 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 78.5 mm-40 -75.78 157.0 34.02 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.733 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 96.1 t -92.86 131.06 40.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.123 0 CA-C-O 121.061 0.458 . . . . 0.0 110.216 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.5 ' NE2' ' OXT' ' L' ' 40' ' ' VAL . 45.1 t-80 -144.25 134.21 23.98 Favored 'General case' 0 N--CA 1.461 0.113 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.954 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 46.8 t-80 -154.99 170.83 20.84 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.466 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.478 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 96.2 mt-30 -148.3 178.56 8.47 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.646 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -164.3 122.48 1.79 Allowed 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.11 0.481 . . . . 0.0 111.204 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 59.1 tp -120.75 121.57 38.5 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.977 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.91 131.65 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.156 0.503 . . . . 0.0 110.501 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.534 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 41.1 p90 -135.14 125.63 26.72 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.217 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -140.08 142.57 36.1 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 121.776 0.798 . . . . 0.0 110.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.39 143.63 24.06 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.343 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.405 ' O ' ' O ' ' L' ' 23' ' ' ASP . 78.5 tt0 -76.12 153.1 36.52 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.585 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.535 ' C ' HG23 ' L' ' 24' ' ' VAL . 59.4 m-20 -58.62 -134.4 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -177.09 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.535 HG23 ' C ' ' L' ' 23' ' ' ASP . 3.8 t 84.69 110.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.6 -92.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.807 ' O ' ' O ' ' L' ' 27' ' ' ASN . 34.1 p -161.18 163.98 30.82 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.698 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.807 ' O ' ' O ' ' L' ' 26' ' ' SER . 83.2 m-20 -9.98 -178.62 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 177.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' L' ' 29' ' ' GLY . 82.6 tttt -128.08 110.41 12.46 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.052 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' L' ' 28' ' ' LYS . . . -54.15 -95.26 0.01 OUTLIER Glycine 0 C--N 1.334 0.451 0 C-N-CA 117.113 -2.47 . . . . 0.0 111.305 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.793 ' C ' HD13 ' L' ' 31' ' ' ILE . . . 71.65 163.32 0.26 Allowed 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 103.663 -2.717 . . . . 0.0 103.663 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.798 HD13 ' N ' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -138.2 100.6 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 122.957 2.617 . . . . 0.0 108.838 175.181 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.501 ' CG2' ' O ' ' L' ' 32' ' ' ILE . 4.6 tt -102.01 112.67 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 CA-C-N 113.356 -1.747 . . . . 0.0 106.628 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -99.97 102.39 2.5 Favored Glycine 0 CA--C 1.5 -0.889 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.673 HD22 ' CZ ' ' J' ' 19' ' ' PHE . 43.6 tp -107.23 115.93 31.04 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.912 -0.315 . . . . 0.0 111.233 -178.369 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 17.6 tpp -112.64 104.22 12.28 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 176.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.426 ' CG1' HG23 ' K' ' 36' ' ' VAL . 10.5 m -135.84 79.59 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.448 ' HA3' HD13 ' F' ' 31' ' ' ILE . . . -66.1 103.68 0.9 Allowed Glycine 0 C--N 1.344 0.986 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.398 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 -162.04 38.0 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -125.58 153.12 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 121.044 0.449 . . . . 0.0 110.839 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.5 ' OXT' ' NE2' ' L' ' 13' ' ' HIS . 31.3 m . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.73 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -90.95 138.35 31.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.806 0.336 . . . . 0.0 110.504 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -122.83 136.34 54.83 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.344 0.592 . . . . 0.0 111.273 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.501 ' O ' ' CG ' ' A' ' 13' ' ' HIS . 48.9 t -142.55 158.96 19.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.182 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 12' ' ' VAL . 97.3 m-70 -155.57 110.4 2.95 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.218 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 6.1 p-80 -151.12 166.33 31.13 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 97.9 mm-40 -152.51 179.22 8.78 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.394 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -149.48 110.9 4.45 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.918 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 77.3 mt -138.12 127.8 25.15 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 121.575 0.702 . . . . 0.0 112.076 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 18' ' ' VAL . 17.4 m -129.16 127.78 66.08 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.233 178.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.515 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 11.2 t80 -121.18 121.8 38.6 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.502 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.2 p90 -137.1 128.19 27.74 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.407 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.66 126.67 52.44 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.979 0.418 . . . . 0.0 111.122 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -153.21 108.81 3.27 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.41 ' HB3' ' HZ1' ' C' ' 28' ' ' LYS . 1.6 m-20 -57.21 121.55 10.35 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.489 -177.727 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 26' ' ' SER . 26.9 m -88.63 124.03 41.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.413 ' HA2' ' H ' ' B' ' 27' ' ' ASN . . . -44.84 84.71 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 CA-C-N 116.08 -0.509 . . . . 0.0 112.388 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.524 ' N ' ' O ' ' A' ' 24' ' ' VAL . 11.8 p -91.85 179.16 5.69 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 m120 -60.31 178.97 0.17 Allowed 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 120.166 -0.613 . . . . 0.0 111.258 -179.424 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.4 110.89 1.2 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.718 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.934 ' H ' HD21 ' B' ' 27' ' ' ASN . . . 71.93 94.09 0.08 OUTLIER Glycine 0 N--CA 1.465 0.587 0 CA-C-O 118.511 -1.161 . . . . 0.0 111.783 177.332 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 153.78 25.87 Favored 'General case' 0 C--O 1.241 0.646 0 C-N-CA 117.607 -1.637 . . . . 0.0 107.602 177.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.481 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.2 OUTLIER -148.2 109.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 CA-C-N 113.783 -1.553 . . . . 0.0 110.023 -171.945 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -131.07 126.96 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.245 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.47 119.57 2.12 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 mt -136.15 150.31 49.01 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-O 121.398 0.618 . . . . 0.0 111.762 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 18.6 ttt -149.53 139.8 22.25 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.992 -0.443 . . . . 0.0 111.865 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 36' ' ' VAL . 5.6 p -152.28 79.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.385 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.64 ' HA3' HD12 ' H' ' 31' ' ' ILE . . . -73.69 104.78 1.67 Allowed Glycine 0 CA--C 1.527 0.814 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.138 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.38 176.17 23.84 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.88 -0.488 . . . . 0.0 111.88 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.7 t -131.95 138.25 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 63.9 t . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.473 -179.92 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -113.29 143.71 43.97 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 121.015 0.436 . . . . 0.0 110.764 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -119.24 131.65 55.82 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.114 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 34.4 m -136.33 158.65 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.903 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -135.69 137.55 41.88 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 111.262 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 72.7 t60 -155.44 169.88 23.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.549 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 47.1 tt0 -163.4 169.74 18.51 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.251 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.43 ' N ' ' HG2' ' B' ' 15' ' ' GLN . 98.0 mttt -151.3 108.69 3.61 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 178.97 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.5 mt -126.08 120.77 31.08 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.119 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -123.26 130.35 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.567 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 2.0 t80 -129.39 122.88 30.34 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.305 -178.837 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -131.88 133.29 44.44 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 120.892 0.377 . . . . 0.0 110.453 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.48 126.19 32.41 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.882 0.372 . . . . 0.0 110.779 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -155.03 158.9 39.83 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -147.43 112.68 5.54 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 65.4 t -123.73 124.94 70.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.498 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.55 82.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 114.63 0.612 . . . . 0.0 114.63 174.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.551 ' O ' ' O ' ' B' ' 27' ' ' ASN . 32.2 p -140.06 170.71 15.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 118.338 1.069 . . . . 0.0 109.615 179.372 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.934 HD21 ' H ' ' A' ' 29' ' ' GLY . 48.1 t30 -30.88 173.25 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -175.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.494 ' N ' ' CG ' ' B' ' 27' ' ' ASN . 88.3 tttt -88.95 111.16 21.79 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.167 -0.924 . . . . 0.0 112.079 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.512 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 60.31 92.96 0.01 OUTLIER Glycine 0 N--CA 1.465 0.583 0 C-N-CA 118.66 -1.733 . . . . 0.0 112.631 174.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.17 155.06 36.58 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 119.486 1.643 . . . . 0.0 110.172 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.411 HG21 ' CA ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -141.85 120.17 9.04 Favored 'Isoleucine or valine' 0 C--O 1.244 0.774 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.622 -176.731 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 14.9 mm -131.87 133.11 61.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.189 -177.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.584 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -143.43 146.23 16.74 Favored Glycine 0 N--CA 1.468 0.802 0 C-N-CA 120.349 -0.929 . . . . 0.0 111.726 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.455 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 3.3 tt -156.45 135.62 12.05 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 119.781 -0.767 . . . . 0.0 112.235 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.8 ' SD ' HG22 ' H' ' 31' ' ' ILE . 11.4 ttm -119.54 126.56 51.55 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.932 179.41 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.515 ' O ' ' C ' ' B' ' 37' ' ' GLY . 11.6 t -129.08 83.55 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.593 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' B' ' 36' ' ' VAL . . . -12.42 -95.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.068 0 O-C-N 123.642 0.589 . . . . 0.0 113.041 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.06 -179.14 40.38 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -138.5 162.41 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 120.826 0.346 . . . . 0.0 110.818 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 117.908 -1.044 . . . . 0.0 110.319 179.849 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -108.04 143.12 37.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.932 0.396 . . . . 0.0 110.587 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -64.77 153.55 39.55 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -131.46 157.3 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.144 0.497 . . . . 0.0 111.5 -179.028 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -138.78 127.73 23.79 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.12 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.579 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 38.6 t60 -148.2 168.08 23.43 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 121.375 0.607 . . . . 0.0 110.322 -178.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.579 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 47.1 tt0 -160.42 165.65 30.69 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.997 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -153.95 115.62 4.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.111 0.482 . . . . 0.0 110.71 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 49.9 tp -129.23 122.31 29.42 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -121.92 128.71 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.015 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.447 ' HE2' HD22 ' E' ' 34' ' ' LEU . 1.7 t80 -125.15 121.32 33.87 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.414 ' C ' ' CD1' ' C' ' 20' ' ' PHE . 25.3 t80 -131.96 126.97 35.34 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.5 136.34 39.32 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.292 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -140.5 146.32 38.01 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.094 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -129.09 111.95 13.49 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.676 179.293 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.842 HG22 ' H ' ' C' ' 25' ' ' GLY . 7.0 p -137.68 -122.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.169 -178.317 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.842 ' H ' HG22 ' C' ' 24' ' ' VAL . . . 28.72 -84.31 0.0 OUTLIER Glycine 0 N--CA 1.47 0.907 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.822 -177.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.5 t 170.54 176.88 0.06 Allowed 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 117.484 0.642 . . . . 0.0 110.332 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' C' ' 26' ' ' SER . 59.8 t30 -28.53 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.536 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 86.2 tttt 128.23 104.75 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 113.847 -1.524 . . . . 0.0 112.115 176.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.29 96.68 0.08 OUTLIER Glycine 0 CA--C 1.501 -0.827 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 173.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -117.19 150.67 38.35 Favored 'General case' 0 CA--C 1.481 -1.686 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.436 HG23 HD12 ' D' ' 31' ' ' ILE . 0.2 OUTLIER -145.62 116.23 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 C-N-CA 118.938 -1.105 . . . . 0.0 109.634 -172.716 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -109.78 117.12 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.79 98.26 0.73 Allowed Glycine 0 N--CA 1.469 0.891 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.562 ' HB2' HD12 ' D' ' 34' ' ' LEU . 4.6 mp -132.49 148.37 52.39 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 122.853 1.311 . . . . 0.0 113.192 -178.613 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.405 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 15.8 ttm -135.15 120.31 18.84 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.484 -1.234 . . . . 0.0 108.352 177.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.484 ' O ' ' C ' ' C' ' 37' ' ' GLY . 0.2 OUTLIER -129.95 75.13 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.206 -179.527 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.484 ' C ' ' O ' ' C' ' 36' ' ' VAL . . . -16.88 -101.43 0.0 OUTLIER Glycine 0 C--N 1.367 2.299 0 O-C-N 123.418 0.448 . . . . 0.0 112.366 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.46 -158.69 31.71 Favored Glycine 0 CA--C 1.522 0.479 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 54.8 t -120.01 135.46 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.555 -179.96 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 10' ' ' TYR . . . . . 0.625 ' CD2' ' CE1' ' E' ' 10' ' ' TYR . 96.6 m-85 -106.59 135.25 48.44 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.789 0.328 . . . . 0.0 110.373 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -146.26 161.43 40.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.577 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 m -100.89 131.54 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.115 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' E' ' 13' ' ' HIS . 73.9 m80 -106.53 136.52 46.16 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 120.883 0.373 . . . . 0.0 111.589 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.568 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 44.5 t-80 -149.77 167.54 26.23 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.191 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.568 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 51.6 tt0 -169.73 165.74 9.9 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.409 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.442 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.0 mttt -146.39 112.59 5.82 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.677 177.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -124.54 125.43 44.18 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.779 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 96.1 t -123.95 124.82 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.306 0.574 . . . . 0.0 111.378 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.405 ' CZ ' HD23 ' F' ' 34' ' ' LEU . 0.2 OUTLIER -109.83 107.72 17.79 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 178.985 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 8.8 t80 -129.07 122.81 30.75 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 119.643 1.111 . . . . 0.0 111.263 -178.384 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.62 132.51 33.14 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -130.02 106.27 8.52 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.004 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.79 112.0 24.04 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' D' ' 26' ' ' SER . 4.7 t -131.83 -122.16 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.634 . . . . 0.0 110.251 -178.142 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.418 ' N ' HG12 ' D' ' 24' ' ' VAL . . . 30.16 -84.33 0.0 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.757 -177.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.684 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.8 p 170.56 178.85 0.05 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.684 ' O ' ' O ' ' D' ' 26' ' ' SER . 70.2 m-80 -28.2 171.13 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 O-C-N 124.731 1.269 . . . . 0.0 112.57 178.018 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 79.0 tttt 141.42 103.31 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 124.145 0.978 . . . . 0.0 108.468 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.552 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . -43.69 -98.25 0.01 OUTLIER Glycine 0 C--N 1.344 0.994 0 C-N-CA 118.816 -1.659 . . . . 0.0 111.313 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' D' ' 29' ' ' GLY . . . 83.56 142.21 0.06 Allowed 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 101.928 -3.36 . . . . 0.0 101.928 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.704 HG22 ' SD ' ' J' ' 35' ' ' MET . 0.3 OUTLIER -146.98 116.24 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 117.904 -1.518 . . . . 0.0 108.974 -177.071 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.453 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.1 OUTLIER -106.95 112.41 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -179.704 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.59 101.24 0.96 Allowed Glycine 0 C--O 1.236 0.249 0 N-CA-C 108.139 -1.984 . . . . 0.0 108.139 179.255 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.581 HD23 ' N ' ' D' ' 35' ' ' MET . 8.8 tt -143.51 144.02 31.8 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 122.411 1.1 . . . . 0.0 113.329 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.581 ' N ' HD23 ' D' ' 34' ' ' LEU . 14.5 ttm -125.19 125.47 43.7 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-N 114.669 -1.15 . . . . 0.0 109.017 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.421 HG22 ' O ' ' D' ' 36' ' ' VAL . 2.2 p -137.5 71.89 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.042 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.391 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.64 111.74 3.48 Favored Glycine 0 C--N 1.366 2.212 0 N-CA-C 111.837 -0.505 . . . . 0.0 111.837 -179.04 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' E' ' 38' ' ' GLY . . . -101.48 146.22 17.15 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.556 HG12 ' N ' ' D' ' 40' ' ' VAL . 21.3 t -137.51 165.51 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.564 0.221 . . . . 0.0 110.674 -179.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.556 ' N ' HG12 ' D' ' 39' ' ' VAL . 98.4 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.974 -1.012 . . . . 0.0 111.585 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' E' E ' 10' ' ' TYR . . . . . 0.625 ' CE1' ' CD2' ' D' ' 10' ' ' TYR . 74.2 m-85 -83.98 140.04 32.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.633 0.254 . . . . 0.0 110.436 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -142.38 153.74 44.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.87 0.366 . . . . 0.0 110.744 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -121.93 134.64 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' D' ' 13' ' ' HIS . 0.2 OUTLIER -76.74 156.98 32.03 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.083 0.468 . . . . 0.0 110.694 -179.214 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.494 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 3.6 m170 -88.42 174.71 7.97 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.521 ' OE1' ' NE2' ' F' ' 15' ' ' GLN . 89.1 mt-30 -124.83 173.64 8.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.352 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -136.81 115.16 11.77 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.254 0.55 . . . . 0.0 111.814 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 35.2 mt -119.55 119.6 34.27 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -127.25 126.29 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-O 120.76 0.314 . . . . 0.0 111.198 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -121.14 122.37 39.86 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 79.8 t80 -134.51 121.61 21.24 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.813 0.34 . . . . 0.0 111.115 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.05 127.78 23.36 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 121.07 0.462 . . . . 0.0 111.032 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.403 ' O ' ' HB3' ' E' ' 23' ' ' ASP . 16.7 pt-20 -135.32 139.68 44.5 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.444 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' C ' ' E' ' 24' ' ' VAL . 18.9 p-10 159.47 113.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 O-C-N 124.204 0.94 . . . . 0.0 108.997 -178.073 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.476 ' C ' ' O ' ' E' ' 23' ' ' ASP . 70.7 t -37.46 132.4 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -178.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.49 85.64 1.48 Allowed Glycine 0 CA--C 1.523 0.531 0 N-CA-C 116.756 1.462 . . . . 0.0 116.756 -173.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.532 ' O ' ' O ' ' E' ' 27' ' ' ASN . 92.8 p -145.75 151.97 38.82 Favored 'General case' 0 CA--C 1.508 -0.665 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 172.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.532 ' O ' ' O ' ' E' ' 26' ' ' SER . 37.8 t30 -21.49 155.86 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.453 ' HD3' ' HB2' ' F' ' 30' ' ' ALA . 86.1 tttt -164.45 110.97 1.03 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 170.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.41 ' O ' ' HA2' ' D' ' 29' ' ' GLY . . . -67.55 92.57 0.23 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 120.106 -1.045 . . . . 0.0 113.734 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' D' ' 29' ' ' GLY . . . -168.39 150.09 5.07 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.699 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.1 OUTLIER -146.42 125.28 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 118.05 -1.46 . . . . 0.0 113.434 -177.562 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.432 ' C ' ' SD ' ' K' ' 35' ' ' MET . 2.0 mt -107.65 116.44 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.477 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -116.18 100.01 0.9 Allowed Glycine 0 C--O 1.234 0.146 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.639 HD23 ' N ' ' E' ' 35' ' ' MET . 7.7 tt -143.91 137.14 27.64 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 122.26 1.029 . . . . 0.0 112.951 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.736 ' SD ' HG22 ' K' ' 31' ' ' ILE . 23.3 ttm -117.6 128.37 54.87 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.495 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -124.81 74.28 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.387 179.834 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.464 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -20.98 -101.38 0.0 OUTLIER Glycine 0 C--N 1.355 1.637 0 O-C-N 123.208 0.317 . . . . 0.0 112.817 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . 140.9 -174.95 22.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 56.3 t -121.24 135.63 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.4 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.433 -179.934 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 87.5 m-85 -117.68 136.71 53.15 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.088 0.47 . . . . 0.0 110.946 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -109.84 128.46 55.34 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.063 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t -128.13 133.81 66.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.893 0.378 . . . . 0.0 110.753 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -150.35 102.38 3.06 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -151.19 174.42 13.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.521 ' NE2' ' OE1' ' E' ' 15' ' ' GLN . 88.3 mt-30 -141.36 175.0 10.01 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.979 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -130.13 114.84 16.22 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.943 0.402 . . . . 0.0 110.135 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -120.03 116.92 26.69 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.259 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 49.7 t -129.95 131.39 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.459 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 55.2 p90 -142.63 133.09 24.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.266 0.555 . . . . 0.0 111.659 -179.391 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -138.1 120.39 15.83 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.14 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.34 144.83 31.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.167 0.508 . . . . 0.0 111.376 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -101.1 106.22 17.47 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.988 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.424 ' OD1' ' O ' ' F' ' 26' ' ' SER . 61.8 t0 -146.66 118.57 8.17 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.388 0.613 . . . . 0.0 112.029 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' F' ' 26' ' ' SER . 3.1 m -97.74 125.36 50.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.173 -0.922 . . . . 0.0 111.051 178.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.8 -86.41 0.01 OUTLIER Glycine 0 N--CA 1.473 1.161 0 C-N-CA 121.521 -0.371 . . . . 0.0 113.503 177.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.455 ' N ' ' O ' ' F' ' 24' ' ' VAL . 72.9 m -63.8 -173.72 0.08 Allowed 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 -177.498 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.544 ' O ' ' O ' ' F' ' 28' ' ' LYS . 88.2 m-20 -78.89 177.87 8.41 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 118.038 -1.465 . . . . 0.0 108.763 -176.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.544 ' O ' ' O ' ' F' ' 27' ' ' ASN . 88.2 tttt -38.04 -103.51 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.619 0.723 . . . . 0.0 112.775 -176.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.444 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -139.9 -100.57 0.46 Allowed Glycine 0 CA--C 1.482 -2.018 0 CA-C-O 123.622 1.679 . . . . 0.0 111.48 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.453 ' HB2' ' HD3' ' E' ' 28' ' ' LYS . . . -58.33 175.73 0.22 Allowed 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 110.164 -3.018 . . . . 0.0 103.358 173.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.5 mt -131.43 116.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 116.538 -2.065 . . . . 0.0 109.774 -177.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.655 ' O ' HG23 ' F' ' 32' ' ' ILE . 16.5 tt -103.33 116.96 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 CA-C-N 113.084 -1.871 . . . . 0.0 110.074 -177.539 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -105.71 86.34 0.48 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 106.7 -2.56 . . . . 0.0 106.7 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.452 HD11 ' CG2' ' E' ' 36' ' ' VAL . 35.2 tp -116.72 119.02 34.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 35.2 mmm -123.04 135.44 54.44 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.057 -0.657 . . . . 0.0 112.28 -177.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 m -124.99 81.14 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.515 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.58 102.07 0.35 Allowed Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -153.52 178.09 30.7 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -124.94 137.16 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.247 0.546 . . . . 0.0 110.192 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.43 ' HB ' HE22 ' F' ' 15' ' ' GLN . 27.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.819 -1.086 . . . . 0.0 110.398 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -106.39 131.79 53.18 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.921 0.391 . . . . 0.0 110.617 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -89.22 158.15 17.98 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.431 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -122.43 133.85 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.134 0.493 . . . . 0.0 110.705 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -134.44 -178.49 5.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.623 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -77.56 167.62 21.32 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -157.49 169.59 24.36 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.995 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.27 130.08 10.1 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.676 0.274 . . . . 0.0 110.732 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 90.2 mt -125.05 115.59 20.77 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.659 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.482 ' O ' HG23 ' G' ' 18' ' ' VAL . 14.3 m -133.87 129.14 54.42 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 121.45 0.643 . . . . 0.0 112.134 -178.712 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.521 ' CE2' HD11 ' J' ' 34' ' ' LEU . 8.8 m-85 -111.79 116.77 31.25 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.445 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.494 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 55.1 p90 -133.96 130.72 38.08 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.775 -179.236 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.429 ' O ' ' OD1' ' H' ' 23' ' ' ASP . . . -121.35 125.43 46.97 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-O 121.122 0.487 . . . . 0.0 110.985 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.499 ' CA ' ' OD2' ' H' ' 23' ' ' ASP . 96.0 mt-10 -146.64 150.31 35.19 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 106.43 -1.693 . . . . 0.0 106.43 178.336 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' NZ ' ' I' ' 28' ' ' LYS . 78.2 m-20 -78.11 111.61 14.21 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 112.754 -177.491 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.577 ' O ' ' N ' ' G' ' 26' ' ' SER . 52.9 t -114.06 130.85 67.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 176.464 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.48 81.94 0.0 OUTLIER Glycine 0 CA--C 1.535 1.308 0 CA-C-O 119.561 -0.577 . . . . 0.0 113.532 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.577 ' N ' ' O ' ' G' ' 24' ' ' VAL . 4.7 t -98.62 172.36 7.54 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 176.744 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 76.3 m-20 -58.73 162.4 4.02 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 118.567 -1.253 . . . . 0.0 109.726 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -58.68 111.3 1.21 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 118.789 -0.624 . . . . 0.0 111.562 175.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.24 93.29 0.08 OUTLIER Glycine 0 N--CA 1.471 0.976 0 C-N-CA 118.311 -1.9 . . . . 0.0 111.947 175.185 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.75 159.2 17.85 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 120.319 2.06 . . . . 0.0 111.556 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.01 123.2 1.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.154 -178.292 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' A' ' 35' ' ' MET . 96.8 mt -133.5 128.71 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.952 -0.468 . . . . 0.0 111.308 -179.319 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.445 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -132.85 117.56 1.99 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.434 -1.067 . . . . 0.0 110.434 179.295 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 84.1 mt -134.86 142.54 46.64 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.95 0.405 . . . . 0.0 110.576 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -141.09 137.55 32.91 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.212 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.3 t -119.03 82.72 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.481 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -87.68 97.99 2.34 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.12 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.95 165.03 38.61 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.23 159.08 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.738 0.304 . . . . 0.0 110.226 179.381 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.542 -179.924 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -117.21 139.5 50.71 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.642 0.258 . . . . 0.0 110.596 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.48 ' CD ' ' N ' ' H' ' 11' ' ' GLU . 0.9 OUTLIER -128.02 132.24 49.13 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -140.02 157.21 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -139.5 105.61 5.23 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.929 0.395 . . . . 0.0 111.34 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.416 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 17.2 m-70 -118.86 166.46 12.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -151.14 176.68 10.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.996 178.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -170.97 113.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.164 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -113.41 119.81 38.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.98 127.16 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 121.061 0.458 . . . . 0.0 111.683 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.558 ' CZ ' HD11 ' K' ' 34' ' ' LEU . 18.1 m-85 -117.24 118.28 31.85 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.056 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -126.44 119.59 27.6 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.82 119.58 33.11 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.145 0.498 . . . . 0.0 111.626 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -163.48 89.27 0.6 Allowed 'General case' 0 C--N 1.341 0.234 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.41 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.711 ' H ' ' HZ2' ' J' ' 28' ' ' LYS . 5.0 m-20 -128.2 119.28 24.91 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -177.21 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.637 ' O ' ' O ' ' H' ' 23' ' ' ASP . 3.1 t -38.04 -124.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 124.105 0.878 . . . . 0.0 112.021 176.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.401 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -130.38 83.93 0.31 Allowed Glycine 0 CA--C 1.533 1.187 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 12.5 p -67.37 -173.06 0.26 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -78.92 169.69 17.82 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 118.332 -1.347 . . . . 0.0 110.506 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -47.09 110.21 0.28 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.95 95.61 0.28 Allowed Glycine 0 N--CA 1.468 0.827 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.582 171.701 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.455 ' C ' ' CG1' ' H' ' 31' ' ' ILE . . . -119.29 147.45 44.27 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 101.117 -3.661 . . . . 0.0 101.117 171.548 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.8 HG22 ' SD ' ' B' ' 35' ' ' MET . 1.2 mt -149.01 126.12 2.51 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 C-N-CA 117.918 -1.513 . . . . 0.0 111.752 -170.82 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 44.2 mm -121.3 123.36 69.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.73 123.58 5.11 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.518 ' CB ' HD22 ' I' ' 34' ' ' LEU . 29.0 tp -135.12 128.75 32.74 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 122.286 -0.538 . . . . 0.0 110.453 -179.252 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.584 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 2.6 ttp -123.34 116.94 24.13 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.031 -178.782 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' H' ' 37' ' ' GLY . 14.2 t -133.42 83.19 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -22.75 -94.05 0.01 OUTLIER Glycine 0 C--N 1.349 1.273 0 N-CA-C 112.159 -0.376 . . . . 0.0 112.159 177.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.65 -177.23 42.12 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 50.4 t -127.58 136.12 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-O 120.962 0.411 . . . . 0.0 110.245 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 34.8 t . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.451 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 9' ' ' GLY . . . . . 0.421 ' O ' ' N ' ' J' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -95.34 128.36 42.12 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.472 ' O ' ' CB ' ' J' ' 11' ' ' GLU . 22.4 pt-20 -164.32 146.93 9.01 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.222 -0.591 . . . . 0.0 111.5 -179.627 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 m -133.07 162.85 39.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.359 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.434 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 34.0 m80 -141.79 145.13 34.38 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.752 0.311 . . . . 0.0 111.413 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.434 ' ND1' ' C ' ' I' ' 13' ' ' HIS . 42.6 m80 -148.18 159.18 44.22 Favored 'General case' 0 CA--C 1.514 -0.427 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.372 178.665 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -153.94 166.06 34.15 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.283 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.504 ' C ' HD12 ' I' ' 17' ' ' LEU . 96.2 mttt -162.53 123.86 2.59 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 123.023 0.202 . . . . 0.0 110.566 179.12 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.504 HD12 ' C ' ' I' ' 16' ' ' LYS . 10.6 mp -115.22 115.63 27.02 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -126.56 123.68 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 CA-C-O 120.983 0.421 . . . . 0.0 111.307 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.754 ' CZ ' HD12 ' L' ' 34' ' ' LEU . 9.8 m-85 -119.21 116.43 26.27 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 115.815 -0.629 . . . . 0.0 109.742 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -128.59 126.85 41.12 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.76 135.33 26.11 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.382 0.61 . . . . 0.0 111.961 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -141.57 142.58 33.49 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.081 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.442 ' O ' ' CG2' ' J' ' 24' ' ' VAL . 64.9 t0 -85.78 123.35 31.05 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 121.47 0.652 . . . . 0.0 111.69 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' I' ' 26' ' ' SER . 2.9 t -93.2 121.81 44.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.06 -88.22 0.01 OUTLIER Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.891 -1.283 . . . . 0.0 109.891 -177.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' I' ' 24' ' ' VAL . 52.9 p -141.0 170.28 16.03 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 118.127 0.964 . . . . 0.0 109.477 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -29.17 169.44 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 114.138 -1.392 . . . . 0.0 114.027 -179.252 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.609 ' NZ ' ' OD1' ' G' ' 23' ' ' ASP . 35.8 tttt -150.27 111.18 4.32 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 114.372 -1.286 . . . . 0.0 108.936 172.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.96 92.07 0.02 OUTLIER Glycine 0 N--CA 1.464 0.535 0 C-N-CA 118.913 -1.613 . . . . 0.0 109.082 176.619 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -138.32 148.07 44.22 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.407 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.693 HG13 HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -146.9 116.18 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-N 114.057 -1.429 . . . . 0.0 110.387 -174.125 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.412 HD13 HG21 ' I' ' 32' ' ' ILE . 0.3 OUTLIER -106.99 114.76 46.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.542 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.533 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -118.68 93.87 0.57 Allowed Glycine 0 N--CA 1.462 0.415 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 179.304 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.533 HD23 ' O ' ' I' ' 33' ' ' GLY . 7.4 mt -127.61 135.26 50.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 122.484 1.135 . . . . 0.0 111.554 -178.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 42.9 ttp -125.62 120.7 31.47 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.402 177.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.99 73.57 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.784 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -21.1 -101.72 0.0 OUTLIER Glycine 0 C--N 1.367 2.301 0 O-C-N 123.508 0.505 . . . . 0.0 112.378 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.66 -153.71 23.65 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.655 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 5.0 p -134.59 141.43 43.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-O 120.879 0.371 . . . . 0.0 110.105 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' H' ' 40' ' ' VAL . 2.6 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.062 -0.97 . . . . 0.0 110.218 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 9' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' K' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.489 2.197 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -142.22 163.14 33.66 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-O 120.778 0.323 . . . . 0.0 110.289 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.472 ' CB ' ' O ' ' I' ' 11' ' ' GLU . 17.3 pt-20 -153.3 154.21 34.14 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.162 0.506 . . . . 0.0 111.212 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.431 HG23 HG23 ' K' ' 12' ' ' VAL . 2.4 p -140.56 151.37 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.799 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.43 ' ND1' ' C ' ' J' ' 12' ' ' VAL . 1.6 m80 -127.34 130.79 50.09 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.479 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -126.6 156.57 40.7 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-O 121.494 0.664 . . . . 0.0 109.529 178.444 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mt-30 -150.68 173.79 13.76 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.775 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -175.25 123.92 0.23 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.842 179.133 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.456 HD13 HE21 ' K' ' 15' ' ' GLN . 4.7 mp -125.48 122.25 36.08 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.753 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.43 137.22 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.197 0.522 . . . . 0.0 112.135 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.493 ' CZ ' HD13 ' L' ' 34' ' ' LEU . 73.7 m-85 -121.62 129.65 52.96 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.863 179.106 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -129.65 122.19 28.5 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.136 0.426 . . . . 0.0 110.245 178.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.96 126.87 35.09 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 121.382 0.61 . . . . 0.0 111.427 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -126.77 109.33 11.9 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.229 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.562 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 0.0 OUTLIER -104.68 112.3 25.33 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 120.068 -0.653 . . . . 0.0 112.127 -178.607 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.571 ' O ' ' N ' ' J' ' 26' ' ' SER . 2.7 m -82.37 132.87 30.42 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.381 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.254 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.26 -85.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.415 0 N-CA-C 107.484 -2.246 . . . . 0.0 107.484 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.571 ' N ' ' O ' ' J' ' 24' ' ' VAL . 10.9 t -140.98 169.62 17.26 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 118.373 1.086 . . . . 0.0 110.298 174.251 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' N ' ' L' ' 30' ' ' ALA . 1.0 OUTLIER -30.27 172.81 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 N-CA-C 115.165 1.542 . . . . 0.0 115.165 178.394 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.718 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 87.0 tttt -97.54 112.25 24.18 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 117.671 -1.157 . . . . 0.0 110.197 171.176 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.494 ' H ' ' HB2' ' I' ' 27' ' ' ASN . . . -61.42 91.49 0.06 OUTLIER Glycine 0 N--CA 1.49 2.271 0 CA-C-N 123.453 2.842 . . . . 0.0 108.343 175.052 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.555 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -148.85 153.42 38.04 Favored 'General case' 0 CA--C 1.482 -1.655 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.546 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -142.35 115.95 4.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 C-N-CA 118.716 -1.194 . . . . 0.0 109.439 -174.632 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.438 HG22 ' O ' ' J' ' 32' ' ' ILE . 1.7 mt -105.52 117.01 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.563 -178.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 101.1 1.02 Allowed Glycine 0 CA--C 1.503 -0.71 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.521 HD11 ' CE2' ' G' ' 19' ' ' PHE . 5.1 tt -142.02 135.4 29.22 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 118.932 -1.107 . . . . 0.0 112.788 -177.039 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.704 ' SD ' HG22 ' D' ' 31' ' ' ILE . 60.9 ttp -127.82 124.0 36.54 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.807 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.464 HG23 HG13 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -124.3 75.36 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.751 0 CA-C-N 114.52 -1.218 . . . . 0.0 107.734 178.415 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -89.75 103.17 2.98 Favored Glycine 0 C--N 1.356 1.665 0 N-CA-C 111.784 -0.526 . . . . 0.0 111.784 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.82 152.14 20.9 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 30.6 m -135.08 157.38 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 8.3 p . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.176 -0.916 . . . . 0.0 110.5 -179.63 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' K' K ' 9' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' J' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -135.48 154.84 51.29 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 121.159 0.504 . . . . 0.0 111.179 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -137.3 131.77 32.73 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.34 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.431 HG23 HG23 ' J' ' 12' ' ' VAL . 11.2 m -145.0 136.63 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.348 179.339 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -118.4 127.15 53.4 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.742 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -124.02 158.27 32.53 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.556 0.693 . . . . 0.0 110.179 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.481 ' O ' ' O ' ' L' ' 15' ' ' GLN . 50.9 tt0 -166.17 170.23 13.55 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.776 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.406 ' CG ' ' O ' ' K' ' 15' ' ' GLN . 66.3 mttm -163.82 125.5 2.37 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.556 179.356 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.929 ' O ' ' C ' ' L' ' 17' ' ' LEU . 17.9 tp -118.05 118.39 31.8 Favored 'General case' 0 N--CA 1.503 2.224 0 CA-C-O 123.339 1.543 . . . . 0.0 112.124 178.479 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.517 HG13 ' O ' ' K' ' 18' ' ' VAL . 5.3 p -134.07 123.96 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.352 -179.466 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -109.23 127.17 54.03 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.464 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -117.36 114.3 23.35 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 178.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 131.31 47.51 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.208 0.528 . . . . 0.0 111.569 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.406 ' O ' ' O ' ' K' ' 23' ' ' ASP . 74.5 mm-40 -83.33 158.26 22.25 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.257 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.55 ' O ' ' O ' ' K' ' 24' ' ' VAL . 48.8 p-10 -60.99 -133.88 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.201 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.55 ' O ' ' O ' ' K' ' 23' ' ' ASP . 24.7 t 26.72 111.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 123.942 0.776 . . . . 0.0 112.356 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.43 82.74 0.14 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 120.206 -0.997 . . . . 0.0 113.183 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 30.2 p -139.05 170.2 16.41 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-N 117.759 0.779 . . . . 0.0 109.334 177.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 50.62 -178.75 0.02 OUTLIER 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.765 179.078 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt 55.37 -106.61 0.33 Allowed 'General case' 0 C--O 1.233 0.208 0 CA-C-O 121.204 0.526 . . . . 0.0 111.918 177.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.433 ' H ' ' HB2' ' J' ' 27' ' ' ASN . . . 96.6 91.54 1.83 Allowed Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -177.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' J' ' 28' ' ' LYS . . . -82.19 174.2 11.4 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 104.707 -2.331 . . . . 0.0 104.707 177.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.736 HG22 ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -156.4 119.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 116.768 -1.973 . . . . 0.0 111.224 -175.431 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.453 HG22 ' O ' ' K' ' 32' ' ' ILE . 0.9 OUTLIER -103.72 113.09 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 176.687 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.1 88.98 0.52 Allowed Glycine 0 CA--C 1.504 -0.603 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 177.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.58 HD23 ' N ' ' K' ' 35' ' ' MET . 9.3 tt -127.66 134.54 49.62 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 122.004 0.907 . . . . 0.0 111.834 -177.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.58 ' N ' HD23 ' K' ' 34' ' ' LEU . 65.8 ttp -123.34 127.56 48.68 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 115.079 -0.964 . . . . 0.0 112.593 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.464 HG13 HG23 ' J' ' 36' ' ' VAL . 0.0 OUTLIER -132.5 72.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 114.427 -1.26 . . . . 0.0 107.887 177.703 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.03 101.86 2.33 Favored Glycine 0 C--N 1.353 1.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -145.16 163.52 28.08 Favored Glycine 0 N--CA 1.46 0.242 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -124.06 135.58 63.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.905 0.383 . . . . 0.0 110.125 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.466 179.967 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -112.95 152.92 28.81 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.507 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.51 136.8 49.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.856 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.97 132.77 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.999 0.428 . . . . 0.0 110.503 -179.485 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 23.3 p-80 -160.91 147.71 15.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.487 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -95.16 177.54 5.83 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.497 ' HG3' ' H ' ' L' ' 16' ' ' LYS . 45.6 tp60 -114.84 174.98 5.7 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.932 -179.564 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 16' ' ' LYS . . . . . 0.497 ' H ' ' HG3' ' L' ' 15' ' ' GLN . 88.9 mttt -88.9 -174.96 4.7 Favored 'General case' 0 C--O 1.176 -2.765 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.929 ' C ' ' O ' ' K' ' 17' ' ' LEU . 38.3 mt -141.48 161.28 38.29 Favored 'General case' 0 C--N 1.31 -1.12 0 O-C-N 119.922 -1.736 . . . . 0.0 110.289 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 18' ' ' VAL . . . . . 0.452 HG23 ' N ' ' L' ' 19' ' ' PHE . 10.8 m -84.54 -144.05 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 117.723 2.49 . . . . 0.0 117.723 -171.208 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.492 ' CD1' ' N ' ' L' ' 19' ' ' PHE . 9.6 m-85 -124.22 147.62 47.91 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 113.506 -1.679 . . . . 0.0 111.143 -178.066 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -137.48 132.19 32.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.263 -0.881 . . . . 0.0 108.945 178.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.3 159.37 38.78 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.277 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -85.7 157.97 20.17 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -53.16 122.88 10.34 Favored 'General case' 0 CA--C 1.52 -0.185 0 C-N-CA 119.899 -0.721 . . . . 0.0 109.243 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 3.5 t -92.68 121.79 43.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.575 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.16 -87.01 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.093 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 79.4 p -89.07 -177.7 5.5 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 63.9 t30 -60.27 179.55 0.14 Allowed 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.713 -177.334 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 11.6 tptt -57.26 110.72 0.89 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 122.005 0.907 . . . . 0.0 112.998 -176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.27 -98.14 0.04 OUTLIER Glycine 0 CA--C 1.496 -1.149 0 CA-C-N 113.801 -1.545 . . . . 0.0 111.155 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.683 ' N ' ' ND2' ' J' ' 27' ' ' ASN . . . -61.2 165.16 4.64 Favored 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 -178.612 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.504 HD12 ' O ' ' K' ' 30' ' ' ALA . 0.8 OUTLIER -141.51 125.32 16.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 117.692 -1.603 . . . . 0.0 112.441 -176.238 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 4.3 mt -101.16 117.66 46.74 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.632 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 177.81 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.55 98.19 0.61 Allowed Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.97 HD21 HG13 ' L' ' 36' ' ' VAL . 1.0 OUTLIER -128.82 139.58 52.1 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.557 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 66.4 ttp -118.33 124.15 47.08 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.588 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.97 HG13 HD21 ' L' ' 34' ' ' LEU . 0.9 OUTLIER -123.42 80.07 0.67 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.648 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.93 102.48 0.12 Allowed Glycine 0 C--N 1.349 1.295 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.247 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.68 -173.21 29.37 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.56 142.87 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.842 0.353 . . . . 0.0 110.599 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.995 -1.002 . . . . 0.0 111.015 -179.795 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -84.03 140.09 32.09 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.813 0.339 . . . . 0.0 110.212 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -65.76 145.32 56.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.013 -179.326 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -139.35 141.11 36.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.09 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 77.7 m80 -142.98 165.13 28.2 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.344 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m80 -135.69 178.55 6.96 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 109.61 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -98.12 179.18 4.85 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.022 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -104.56 140.95 37.24 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.195 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -124.12 120.12 31.42 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.079 0.466 . . . . 0.0 110.726 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 18' ' ' VAL . 5.6 m -134.06 128.19 52.53 Favored 'Isoleucine or valine' 0 C--O 1.231 0.098 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.11 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.623 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 11.7 m-85 -112.88 118.83 35.98 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.07 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.549 ' CE2' ' CD1' ' B' ' 20' ' ' PHE . 55.7 t80 -127.71 113.08 15.56 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.51 129.26 56.41 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.118 0.485 . . . . 0.0 110.98 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 tt0 -156.72 158.69 37.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 179.284 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -81.11 111.29 17.42 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.718 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.628 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.0 t -114.27 131.18 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.839 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 177.639 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.83 81.94 0.0 OUTLIER Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.576 -0.345 . . . . 0.0 112.409 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.628 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.1 p -94.64 177.31 5.96 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.686 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' A' ' 28' ' ' LYS . 98.5 m-20 -61.58 179.6 0.23 Allowed 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.584 -0.846 . . . . 0.0 108.763 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.8 mttm -52.12 -111.87 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.761 0.791 . . . . 0.0 111.406 178.668 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.41 93.33 1.63 Allowed Glycine 0 N--CA 1.467 0.707 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 177.113 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.55 160.9 14.05 Favored 'General case' 0 CA--C 1.509 -0.605 0 C-N-CA 116.582 -2.047 . . . . 0.0 111.627 -177.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.0 OUTLIER -152.51 117.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.112 0 CA-C-N 111.819 -2.446 . . . . 0.0 109.184 -174.334 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.87 118.54 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.709 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.64 108.71 0.98 Allowed Glycine 0 N--CA 1.464 0.56 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 48.5 tp -131.69 133.01 44.4 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 117.194 0.497 . . . . 0.0 111.07 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 13.4 ttt -139.38 134.66 32.77 Favored 'General case' 0 C--N 1.328 -0.36 0 O-C-N 122.234 -0.291 . . . . 0.0 110.788 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.7 t -146.06 81.29 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.487 ' HA3' HD12 ' H' ' 31' ' ' ILE . . . -85.51 100.22 2.43 Favored Glycine 0 C--N 1.338 0.66 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.226 178.315 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.24 176.48 47.86 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m -131.72 158.57 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 120.82 0.343 . . . . 0.0 110.356 179.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.3 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.636 -179.706 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 10' ' ' TYR . . . . . 0.563 ' CE1' ' CD1' ' D' ' 10' ' ' TYR . 95.7 m-85 -83.06 144.1 30.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.736 0.303 . . . . 0.0 110.489 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -133.99 156.33 48.37 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.68 -179.613 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.509 HG12 ' N ' ' B' ' 13' ' ' HIS . 93.4 t -133.17 159.94 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.894 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.509 ' N ' HG12 ' B' ' 12' ' ' VAL . 28.3 t60 -166.77 104.78 0.59 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.218 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.9 m-70 -120.0 165.77 14.25 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.605 HE21 HD21 ' B' ' 17' ' ' LEU . 50.6 tt0 -162.85 173.23 14.01 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.331 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.41 ' N ' ' HG2' ' B' ' 15' ' ' GLN . 97.6 mttt -149.85 116.29 5.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.939 0.399 . . . . 0.0 110.742 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.605 HD21 HE21 ' B' ' 15' ' ' GLN . 60.6 mt -116.57 114.42 24.11 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.302 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.52 123.66 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-O 121.214 0.531 . . . . 0.0 110.945 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.646 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 4.4 m-85 -117.47 118.52 32.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.963 179.197 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.549 ' CD1' ' CE2' ' A' ' 20' ' ' PHE . 33.1 t80 -138.37 125.67 21.69 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 122.22 -0.3 . . . . 0.0 110.326 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 131.32 46.89 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.155 0.503 . . . . 0.0 111.965 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -157.67 91.3 1.13 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.619 ' H ' ' CG ' ' C' ' 23' ' ' ASP . 10.7 t0 -121.6 113.1 19.3 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -176.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' B' ' 26' ' ' SER . 12.0 p -60.41 132.37 25.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.252 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.94 83.72 0.04 OUTLIER Glycine 0 CA--C 1.526 0.751 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.694 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.425 ' N ' ' O ' ' B' ' 24' ' ' VAL . 11.8 p -87.62 -179.1 6.25 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.583 0.706 . . . . 0.0 109.627 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.425 ' O ' ' O ' ' B' ' 28' ' ' LYS . 28.3 t-20 -75.63 175.96 8.1 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.544 177.203 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' B' ' 27' ' ' ASN . 97.6 mttt 42.49 107.9 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 114.9 1.445 . . . . 0.0 114.9 176.121 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.2 100.04 1.98 Allowed Glycine 0 N--CA 1.479 1.565 0 CA-C-N 114.273 -1.33 . . . . 0.0 110.717 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 161.35 31.15 Favored 'General case' 0 C--O 1.248 1.016 0 CA-C-O 122.772 1.272 . . . . 0.0 110.772 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.514 ' CG2' HD12 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.02 122.74 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 112.939 -1.937 . . . . 0.0 110.378 -172.929 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.452 ' C ' ' SD ' ' H' ' 35' ' ' MET . 44.3 pt -136.08 135.29 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-O 121.847 0.832 . . . . 0.0 112.129 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -141.11 137.88 8.46 Favored Glycine 0 CA--C 1.531 1.033 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.142 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 tt -146.93 139.74 25.12 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 120.196 -0.601 . . . . 0.0 111.158 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 24.1 ttm -128.32 126.19 40.27 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-O 121.397 0.618 . . . . 0.0 112.133 -179.346 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.43 79.6 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.021 177.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.533 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -50.91 104.13 0.12 Allowed Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.769 -179.045 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 44.99 179.74 0.01 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 p -148.36 149.77 14.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.439 ' OXT' HG22 ' B' ' 40' ' ' VAL . 6.0 p . . . . . 0 C--O 1.218 -0.559 0 CA-C-O 118.176 -0.916 . . . . 0.0 111.078 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 141.44 47.83 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.417 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -142.58 159.34 42.43 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.418 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.463 HG13 ' CD2' ' D' ' 13' ' ' HIS . 55.3 t -121.27 133.56 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.489 ' H ' ' H ' ' D' ' 13' ' ' HIS . 97.6 m-70 -148.08 123.63 10.42 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.822 0.344 . . . . 0.0 111.179 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.529 ' ND1' ' O ' ' D' ' 14' ' ' HIS . 26.1 t60 -141.45 164.65 29.66 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.437 ' HG2' ' N ' ' C' ' 16' ' ' LYS . 51.8 tt0 -169.39 170.36 8.45 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.845 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.437 ' N ' ' HG2' ' C' ' 15' ' ' GLN . 68.2 mttm -142.59 118.79 10.77 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.238 178.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -120.11 121.39 38.73 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.06 123.25 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.048 0.452 . . . . 0.0 111.739 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.953 ' CZ ' HD22 ' F' ' 34' ' ' LEU . 6.6 m-85 -113.65 116.78 30.0 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.408 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.544 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 33.6 t80 -132.24 118.65 19.78 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 118.227 0.467 . . . . 0.0 110.203 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.9 37.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 120.857 0.361 . . . . 0.0 110.884 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -173.2 102.97 0.13 Allowed 'General case' 0 CA--C 1.522 -0.134 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.912 ' H ' ' HZ2' ' E' ' 28' ' ' LYS . 1.1 m-20 -115.15 113.66 24.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 121.095 0.474 . . . . 0.0 111.417 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 91.4 t -64.76 131.5 30.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.84 84.02 0.31 Allowed Glycine 0 CA--C 1.525 0.696 0 C-N-CA 119.195 -1.479 . . . . 0.0 110.726 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.536 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 1.7 m -59.87 -174.27 0.02 OUTLIER 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.536 ' CB ' ' O ' ' C' ' 26' ' ' SER . 6.1 t-20 99.85 -174.62 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.928 0 O-C-N 124.342 1.026 . . . . 0.0 111.202 -177.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.52 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 81.9 tttt 37.44 108.93 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.987 -177.077 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.426 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -85.79 96.84 2.13 Favored Glycine 0 CA--C 1.504 -0.622 0 CA-C-N 114.325 -1.307 . . . . 0.0 112.056 177.387 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.8 164.7 19.36 Favored 'General case' 0 C--O 1.244 0.808 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.689 HG23 HG13 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.83 121.3 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 117.961 -1.496 . . . . 0.0 111.702 -174.804 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 1.1 mt -114.54 120.63 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.898 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.98 98.88 0.65 Allowed Glycine 0 N--CA 1.472 1.04 0 N-CA-C 106.939 -2.464 . . . . 0.0 106.939 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.467 HD21 HG13 ' C' ' 36' ' ' VAL . 5.1 tt -129.93 129.28 43.64 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 119.05 -1.06 . . . . 0.0 113.749 -175.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.435 ' CG ' ' HA3' ' I' ' 33' ' ' GLY . 96.6 mmm -107.39 118.08 35.77 Favored 'General case' 0 CA--C 1.503 -0.859 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.267 179.261 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.467 HG13 HD21 ' C' ' 34' ' ' LEU . 0.0 OUTLIER -131.02 72.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.723 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 175.83 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.14 112.31 4.6 Favored Glycine 0 C--N 1.36 1.882 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.47 157.39 51.88 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -138.72 161.51 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.103 -0.951 . . . . 0.0 110.508 179.968 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 10' ' ' TYR . . . . . 0.563 ' CD1' ' CE1' ' B' ' 10' ' ' TYR . 87.3 m-85 -108.42 142.12 39.27 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.736 0.303 . . . . 0.0 110.322 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' D' ' 11' ' ' GLU . 2.1 pm0 -143.92 169.42 17.84 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.646 -179.479 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t -83.12 130.68 35.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.489 ' H ' ' H ' ' C' ' 13' ' ' HIS . 3.4 m-70 -87.31 161.48 17.92 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.336 0.589 . . . . 0.0 111.354 -178.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.529 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.8 p-80 -93.93 178.83 5.54 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.327 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -127.7 179.04 5.74 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.502 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -137.23 127.1 25.66 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.248 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.3 mp -126.43 129.17 48.21 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.223 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -126.81 125.01 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.027 0.441 . . . . 0.0 111.488 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.756 ' CZ ' HD23 ' F' ' 34' ' ' LEU . 4.9 m-85 -110.57 112.57 24.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.039 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.51 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 27.5 t80 -126.72 123.32 37.21 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 118.542 0.61 . . . . 0.0 109.947 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.17 142.63 28.63 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -142.97 145.17 32.72 Favored 'General case' 0 C--N 1.343 0.302 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.653 178.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.515 ' O ' ' O ' ' E' ' 24' ' ' VAL . 14.0 m-20 -112.64 124.67 53.07 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.898 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' E' ' 26' ' ' SER . 5.7 t -95.34 -112.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 113.124 0.787 . . . . 0.0 113.124 -176.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.94 -91.12 0.01 OUTLIER Glycine 0 N--CA 1.469 0.864 0 N-CA-C 112.386 -0.286 . . . . 0.0 112.386 -176.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.609 ' O ' ' O ' ' D' ' 27' ' ' ASN . 21.5 p -151.54 171.87 16.91 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.692 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 90.6 m-20 -19.29 156.7 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 O-C-N 124.253 0.971 . . . . 0.0 113.164 -178.313 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.497 ' H ' ' H ' ' E' ' 29' ' ' GLY . 56.5 tttt -162.45 110.68 1.36 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 121.406 -0.809 . . . . 0.0 110.461 173.548 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.426 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -68.62 92.83 0.29 Allowed Glycine 0 C--O 1.215 -1.036 0 CA-C-O 117.861 -1.522 . . . . 0.0 110.77 175.425 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.463 ' O ' HG13 ' E' ' 31' ' ' ILE . . . -129.04 151.61 49.54 Favored 'General case' 0 CA--C 1.482 -1.652 0 N-CA-C 103.028 -2.953 . . . . 0.0 103.028 173.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.689 HG13 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -147.75 118.25 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.339 -172.909 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.532 ' O ' HG23 ' D' ' 32' ' ' ILE . 18.5 tt -119.0 113.42 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.483 178.459 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.705 ' C ' HD12 ' D' ' 34' ' ' LEU . . . -130.07 128.22 5.57 Favored Glycine 0 C--O 1.241 0.536 0 C-N-CA 121.09 -0.576 . . . . 0.0 111.811 -178.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.705 HD12 ' C ' ' D' ' 33' ' ' GLY . 4.0 mp -141.5 142.57 33.58 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-O 122.249 1.023 . . . . 0.0 111.277 178.659 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.46 ' SD ' ' HB ' ' J' ' 31' ' ' ILE . 29.3 tpp -100.87 113.6 26.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 113.574 -1.648 . . . . 0.0 108.448 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.617 ' CG2' HD11 ' E' ' 34' ' ' LEU . 0.0 OUTLIER -126.55 74.0 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.302 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.113 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.96 111.21 1.82 Allowed Glycine 0 C--N 1.358 1.793 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.17 -170.28 0.15 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m -133.85 160.62 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.815 0.34 . . . . 0.0 110.791 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.562 179.845 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -101.47 129.12 47.46 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.993 0.425 . . . . 0.0 110.539 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.88 138.86 28.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.84 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.1 t -126.36 132.77 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.904 0.383 . . . . 0.0 110.329 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 t-80 -143.95 112.57 6.55 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.564 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -128.81 173.01 10.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -151.1 175.93 11.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.709 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -167.85 108.25 0.57 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.05 0.452 . . . . 0.0 110.686 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.0 tt -124.84 127.35 47.02 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.707 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.13 128.84 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -119.61 119.97 35.33 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -128.18 121.96 30.73 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-O 120.909 0.385 . . . . 0.0 110.273 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.5 133.33 43.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.994 0.426 . . . . 0.0 111.52 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -137.74 123.78 20.28 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.554 -0.458 . . . . 0.0 109.831 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -84.77 114.82 22.34 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.062 0.458 . . . . 0.0 111.181 -178.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' E' ' 26' ' ' SER . 53.8 t -95.78 130.81 43.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.68 -85.07 0.01 OUTLIER Glycine 0 CA--C 1.535 1.289 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' E' ' 24' ' ' VAL . 12.6 t -153.0 174.29 14.35 Favored 'General case' 0 C--N 1.347 0.46 0 CA-C-N 118.897 1.348 . . . . 0.0 112.995 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.692 ' ND2' ' H ' ' D' ' 27' ' ' ASN . 12.9 p-10 -19.01 160.24 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 116.761 2.134 . . . . 0.0 116.761 178.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.912 ' HZ2' ' H ' ' C' ' 23' ' ' ASP . 80.9 tttt -170.14 105.55 0.31 Allowed 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 174.676 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.677 ' O ' ' HA ' ' F' ' 30' ' ' ALA . . . -49.99 -97.84 0.01 OUTLIER Glycine 0 N--CA 1.469 0.9 0 C-N-CA 118.664 -1.731 . . . . 0.0 111.299 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.561 ' HB3' ' O ' ' E' ' 29' ' ' GLY . . . 74.07 143.71 0.07 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.599 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -150.78 118.11 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.08 -178.471 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 4.5 tt -117.44 128.31 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 CA-C-O 121.329 0.585 . . . . 0.0 111.255 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 99.7 0.7 Allowed Glycine 0 N--CA 1.451 -0.331 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 178.405 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.646 HD13 ' CZ ' ' B' ' 19' ' ' PHE . 37.6 tp -115.58 116.39 28.06 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.551 ' CE ' ' SD ' ' F' ' 35' ' ' MET . 0.4 OUTLIER -91.76 111.63 23.24 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.976 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.71 ' O ' HG12 ' E' ' 36' ' ' VAL . 2.0 t -138.4 66.56 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -54.84 -103.53 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.44 169.01 34.51 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -140.67 140.85 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.064 -0.969 . . . . 0.0 110.357 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -84.3 139.92 31.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.04 0.448 . . . . 0.0 110.887 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -60.7 149.85 34.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.911 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.14 131.44 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.851 179.501 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.508 ' ND1' ' N ' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -151.26 130.05 12.4 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.417 -179.868 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.402 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 80.6 m80 -155.82 178.29 10.43 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -139.72 177.87 7.64 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.248 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -155.12 115.9 3.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.336 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.44 128.01 42.07 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.17 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 99.8 t -129.63 130.94 67.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.7 p90 -132.32 128.52 37.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.887 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.6 t80 -138.82 125.37 20.63 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.46 146.3 30.51 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.681 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -124.15 95.68 4.64 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 178.173 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -108.3 114.57 28.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.909 -178.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' F' ' 26' ' ' SER . 43.9 t -63.49 130.92 28.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 107.141 -1.429 . . . . 0.0 107.141 178.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.32 84.37 0.01 OUTLIER Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.352 -0.928 . . . . 0.0 112.866 -176.049 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.559 ' O ' ' O ' ' F' ' 27' ' ' ASN . 2.8 p 170.68 175.59 0.06 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 114.902 -0.649 . . . . 0.0 109.486 176.304 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.559 ' O ' ' O ' ' F' ' 26' ' ' SER . 65.0 t30 -29.15 179.29 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 115.587 1.699 . . . . 0.0 115.587 178.695 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.547 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 33.1 tttm 129.07 102.33 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.937 0 C-N-CA 128.826 2.85 . . . . 0.0 108.455 174.697 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.64 -99.88 0.01 OUTLIER Glycine 0 C--N 1.348 1.214 0 CA-C-O 124.622 2.235 . . . . 0.0 114.143 174.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.677 ' HA ' ' O ' ' E' ' 29' ' ' GLY . . . 70.18 143.36 0.05 Allowed 'General case' 0 CA--C 1.503 -0.839 0 CA-C-N 108.575 -3.812 . . . . 0.0 107.208 177.062 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.513 HG13 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -160.06 125.05 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 122.538 2.427 . . . . 0.0 113.399 -179.711 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 87.7 mt -107.78 117.74 54.05 Favored 'Isoleucine or valine' 0 C--N 1.355 0.83 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.951 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.53 91.06 0.55 Allowed Glycine 0 N--CA 1.452 -0.245 0 N-CA-C 109.061 -1.615 . . . . 0.0 109.061 177.261 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.953 HD22 ' CZ ' ' C' ' 19' ' ' PHE . 3.1 tp -114.22 116.18 28.63 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.628 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 2.2 mtp -88.34 114.26 24.78 Favored 'General case' 0 CA--C 1.48 -1.735 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.407 HG22 ' O ' ' F' ' 36' ' ' VAL . 2.2 p -139.63 74.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 105.775 -1.935 . . . . 0.0 105.775 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.32 104.85 2.64 Favored Glycine 0 C--N 1.356 1.667 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.03 -179.43 26.37 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -134.76 138.07 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.692 0.282 . . . . 0.0 111.03 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 N--CA 1.469 0.52 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.538 179.584 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -119.51 142.59 48.16 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -152.43 123.56 7.59 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.416 0.626 . . . . 0.0 111.578 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -150.21 146.29 16.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.498 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -151.93 140.97 21.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.077 0.465 . . . . 0.0 110.815 179.596 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -134.64 163.74 29.07 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -150.53 171.34 17.24 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.528 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -156.2 128.98 7.84 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.46 HD13 HE21 ' H' ' 15' ' ' GLN . 5.8 mp -122.15 124.6 44.26 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 110.218 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.436 ' O ' HG13 ' G' ' 18' ' ' VAL . 5.4 p -121.67 120.46 61.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.189 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.586 ' CZ ' HD13 ' I' ' 34' ' ' LEU . 3.9 t80 -117.12 103.16 9.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -122.37 121.5 36.84 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.93 123.75 48.86 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.862 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -158.3 155.53 28.99 Favored 'General case' 0 CA--C 1.528 0.122 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -88.25 120.9 30.05 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.116 0.484 . . . . 0.0 112.289 -178.54 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.569 ' O ' ' N ' ' G' ' 26' ' ' SER . 88.1 t -100.97 124.03 54.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.63 83.49 0.0 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-O 120.052 -0.305 . . . . 0.0 112.985 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.569 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.1 m -97.46 174.78 6.5 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.269 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 22.8 p30 -59.22 164.38 3.21 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.196 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -57.23 111.53 1.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.779 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.462 ' H ' ' HE3' ' H' ' 28' ' ' LYS . . . 72.38 93.49 0.09 OUTLIER Glycine 0 N--CA 1.466 0.681 0 C-N-CA 119.678 -1.249 . . . . 0.0 111.315 177.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.55 157.51 19.56 Favored 'General case' 0 CA--C 1.51 -0.595 0 C-N-CA 118.426 -1.31 . . . . 0.0 108.847 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.514 HG22 HD12 ' H' ' 31' ' ' ILE . 0.1 OUTLIER -153.04 117.35 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.776 -173.434 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.485 ' O ' ' SD ' ' A' ' 35' ' ' MET . 18.0 tt -135.58 129.47 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.064 179.543 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.88 116.9 1.96 Allowed Glycine 0 N--CA 1.466 0.639 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 76.5 mt -137.33 148.77 46.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 121.681 0.753 . . . . 0.0 112.289 -178.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 ttt -139.3 135.8 34.19 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.196 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' G' ' 37' ' ' GLY . 9.5 t -141.53 81.27 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' G' ' 36' ' ' VAL . . . -26.89 -94.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 O-C-N 123.337 0.398 . . . . 0.0 112.773 178.551 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.13 -157.84 30.5 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 71.8 t -98.86 133.49 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.847 0.356 . . . . 0.0 110.24 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.731 -179.395 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -145.0 159.5 42.84 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.788 0.327 . . . . 0.0 110.522 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.481 ' CD ' ' NE2' ' H' ' 13' ' ' HIS . 82.5 tt0 -134.73 145.54 48.56 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.835 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.48 133.17 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 116.793 -0.185 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.481 ' NE2' ' CD ' ' H' ' 11' ' ' GLU . 80.9 m-70 -137.31 143.58 42.18 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.837 0.351 . . . . 0.0 111.307 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.506 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 86.3 t60 -146.92 162.08 39.43 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.448 0.642 . . . . 0.0 110.307 178.709 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.506 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 42.4 tt0 -156.72 174.62 15.21 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -162.71 125.47 2.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.892 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.561 HD23 ' C ' ' H' ' 17' ' ' LEU . 6.6 tt -125.62 121.79 34.55 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.982 0.42 . . . . 0.0 110.533 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.498 ' N ' HD23 ' H' ' 17' ' ' LEU . 56.6 t -120.36 126.16 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.876 179.206 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 29.5 t80 -121.93 111.91 17.66 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -130.38 126.23 36.55 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.34 128.64 51.27 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.238 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.24 149.1 40.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.643 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.51 ' O ' ' NZ ' ' J' ' 28' ' ' LYS . 53.2 t0 -155.79 121.1 4.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.849 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.802 HG22 ' N ' ' H' ' 25' ' ' GLY . 2.6 p -133.87 -112.01 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.587 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.802 ' N ' HG22 ' H' ' 24' ' ' VAL . . . 32.86 -90.26 0.01 OUTLIER Glycine 0 CA--C 1.53 1.016 0 CA-C-N 115.97 -0.559 . . . . 0.0 112.362 -178.085 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.661 ' O ' ' O ' ' H' ' 27' ' ' ASN . 1.6 t 171.61 178.72 0.07 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 117.622 0.711 . . . . 0.0 109.984 -179.519 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.661 ' O ' ' O ' ' H' ' 26' ' ' SER . 9.4 t-20 -28.57 179.59 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 O-C-N 125.07 1.481 . . . . 0.0 114.259 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.555 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 87.0 tttt 128.43 105.18 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 124.359 1.064 . . . . 0.0 111.763 178.356 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.86 96.27 0.05 OUTLIER Glycine 0 N--CA 1.47 0.948 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.08 146.6 47.04 Favored 'General case' 0 C--O 1.253 1.288 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 177.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.599 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.1 OUTLIER -140.04 119.61 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.281 0 CA-C-N 113.02 -1.9 . . . . 0.0 110.697 -171.855 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -126.96 122.73 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.767 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.17 118.64 2.18 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -137.3 129.97 30.1 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.456 0.646 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.452 ' SD ' ' C ' ' B' ' 32' ' ' ILE . 13.2 ttt -124.47 124.91 43.33 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.247 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.556 ' O ' HG23 ' H' ' 36' ' ' VAL . 34.5 m -136.08 81.24 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -29.14 -93.47 0.01 OUTLIER Glycine 0 CA--C 1.529 0.925 0 CA-C-N 116.488 -0.324 . . . . 0.0 112.489 178.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.09 -161.86 28.66 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.407 ' O ' HG23 ' I' ' 39' ' ' VAL . 27.7 m -120.51 134.79 62.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 120.657 0.265 . . . . 0.0 110.39 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.442 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' I' I ' 10' ' ' TYR . . . . . 0.52 ' CD1' ' OE2' ' J' ' 11' ' ' GLU . 89.5 m-85 -108.41 145.21 34.93 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.69 0.281 . . . . 0.0 110.322 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -122.63 147.12 46.8 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.905 0.383 . . . . 0.0 110.694 -179.535 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m -119.03 133.13 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.98 -0.554 . . . . 0.0 109.647 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.54 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 49.3 p-80 -155.86 161.62 40.57 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.147 -0.621 . . . . 0.0 112.303 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 7.2 m-70 -141.37 162.78 34.66 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.45 179.097 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -150.54 175.36 11.97 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.858 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -155.26 130.53 9.61 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.989 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.4 mt -124.39 118.74 27.39 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -123.62 128.44 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.56 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.648 ' CD2' ' CZ ' ' J' ' 19' ' ' PHE . 27.7 t80 -128.01 116.23 19.72 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -127.89 130.32 48.33 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-O 120.703 0.287 . . . . 0.0 110.941 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.14 125.78 32.09 Favored 'General case' 0 C--O 1.243 0.718 0 CA-C-O 121.444 0.64 . . . . 0.0 112.067 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -145.08 158.34 43.85 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.553 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.545 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.9 p-10 -173.96 121.88 0.31 Allowed 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 -179.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' I' ' 26' ' ' SER . 11.5 t -124.0 -111.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.222 -178.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.18 -90.75 0.01 OUTLIER Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -177.227 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.563 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.7 p 171.39 169.37 0.09 Allowed 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 177.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.563 ' O ' ' O ' ' I' ' 26' ' ' SER . 21.3 t-20 -19.49 155.8 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 179.552 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.542 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 73.5 tttt -170.69 106.57 0.28 Allowed 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.676 173.718 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.66 93.16 0.01 OUTLIER Glycine 0 C--O 1.227 -0.335 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 174.577 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -142.04 145.38 34.32 Favored 'General case' 0 CA--C 1.486 -1.504 0 CA-C-N 119.167 1.483 . . . . 0.0 107.889 177.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.599 ' CG1' HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -139.8 117.28 10.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.349 -177.964 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' I' ' 32' ' ' ILE . 0.4 OUTLIER -107.82 116.63 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.435 ' HA3' ' CG ' ' C' ' 35' ' ' MET . . . -119.68 100.61 0.8 Allowed Glycine 0 CA--C 1.496 -1.133 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.057 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.586 HD13 ' CZ ' ' G' ' 19' ' ' PHE . 5.3 tt -130.49 125.33 34.09 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 118.824 -1.151 . . . . 0.0 110.252 -179.449 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.679 ' SD ' HG22 ' C' ' 31' ' ' ILE . 28.3 ttm -115.56 117.11 29.42 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.176 -1.375 . . . . 0.0 109.01 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.97 75.29 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.681 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.431 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -29.63 -97.29 0.01 OUTLIER Glycine 0 C--N 1.354 1.543 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.843 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.75 -164.54 28.5 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.407 HG23 ' O ' ' H' ' 39' ' ' VAL . 2.6 p -133.82 146.91 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 110.027 -0.361 . . . . 0.0 110.027 179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.73 -179.79 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.173 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -105.21 129.45 53.58 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 120.901 0.382 . . . . 0.0 110.615 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.52 ' OE2' ' CD1' ' I' ' 10' ' ' TYR . 97.6 mt-10 -127.95 127.14 42.77 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.228 179.6 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 t -141.64 134.18 28.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -149.61 133.54 17.04 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.479 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 1.5 t-80 -151.64 159.2 44.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.455 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.633 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 49.6 tt0 -160.58 169.5 22.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.419 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -151.08 128.79 11.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 14.2 tp -126.33 114.55 18.39 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 64.6 t -119.51 126.76 75.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.981 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.648 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 1.5 t80 -120.19 119.35 32.97 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.51 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 56.4 t80 -132.84 126.36 32.08 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.611 0.243 . . . . 0.0 110.849 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.84 26.58 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 119.848 -0.741 . . . . 0.0 112.47 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -125.58 143.89 50.82 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.151 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -130.04 110.85 11.96 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 177.391 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.584 HG12 ' N ' ' J' ' 25' ' ' GLY . 14.0 t -139.39 -123.51 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.589 -178.551 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.584 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 27.5 -83.92 0.0 OUTLIER Glycine 0 C--N 1.342 0.879 0 CA-C-N 114.947 -1.024 . . . . 0.0 112.406 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.635 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.2 p 170.48 170.42 0.07 Allowed 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 178.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.635 ' O ' ' O ' ' J' ' 26' ' ' SER . 76.3 m-20 -18.37 157.58 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 O-C-N 124.375 1.047 . . . . 0.0 113.064 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.576 ' HB3' ' HB2' ' K' ' 30' ' ' ALA . 81.0 tttt -161.79 110.9 1.52 Allowed 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.573 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.471 ' H ' ' CG ' ' I' ' 27' ' ' ASN . . . -67.45 92.49 0.22 Allowed Glycine 0 C--N 1.32 -0.333 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.609 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -157.06 149.17 22.84 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 177.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.658 HD13 ' N ' ' J' ' 31' ' ' ILE . 0.0 OUTLIER -144.81 122.56 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 C-N-CA 119.201 -1.0 . . . . 0.0 111.505 -176.946 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 4.2 mt -108.94 119.56 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-N 114.975 -1.012 . . . . 0.0 109.826 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.42 112.91 2.48 Favored Glycine 0 C--N 1.336 0.567 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 177.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.435 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 0.1 OUTLIER -143.72 135.0 25.85 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.126 0.965 . . . . 0.0 113.015 -177.586 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.586 ' CE ' HG22 ' D' ' 31' ' ' ILE . 98.7 mmm -112.63 111.19 21.82 Favored 'General case' 0 CA--C 1.504 -0.79 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.032 177.15 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.25 62.39 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.34 -111.49 0.13 Allowed Glycine 0 C--N 1.356 1.642 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.771 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.35 142.83 7.04 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 11.6 p -142.08 151.82 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 m . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.402 179.806 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -113.48 132.28 55.72 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.718 0.294 . . . . 0.0 110.442 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -129.9 127.71 40.72 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.918 0.389 . . . . 0.0 110.936 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.55 132.74 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.729 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -150.64 131.84 14.48 Favored 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.054 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' CE1' ' J' ' 14' ' ' HIS . 50.3 t-80 -152.93 165.01 36.85 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.174 0.511 . . . . 0.0 109.842 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 80.8 mt-30 -156.88 179.85 8.89 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.325 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -170.3 120.08 0.59 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.327 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 31.4 tp -119.98 123.99 44.85 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.549 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 65.0 t -130.03 121.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.551 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -118.67 120.62 37.96 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.51 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 48.6 t80 -129.01 121.26 27.56 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.998 0.428 . . . . 0.0 111.592 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.19 129.36 41.61 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.494 178.577 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -124.49 143.2 50.79 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 121.417 0.627 . . . . 0.0 112.323 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -131.55 123.7 28.51 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.974 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.64 HG12 ' N ' ' K' ' 25' ' ' GLY . 57.7 t -96.15 -112.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.667 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.64 ' N ' HG12 ' K' ' 24' ' ' VAL . . . -46.96 -91.04 0.01 OUTLIER Glycine 0 CA--C 1.526 0.765 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.456 -176.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.605 ' O ' ' O ' ' K' ' 27' ' ' ASN . 34.9 p -152.98 -172.63 4.31 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 117.611 0.705 . . . . 0.0 110.444 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.605 ' O ' ' O ' ' K' ' 26' ' ' SER . 54.7 t30 -19.86 158.05 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.65 0 O-C-N 124.997 1.436 . . . . 0.0 113.724 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' L' ' 30' ' ' ALA . 87.1 tttt -161.6 111.08 1.57 Allowed 'General case' 0 C--O 1.213 -0.823 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.839 176.112 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.574 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -67.92 92.39 0.24 Allowed Glycine 0 N--CA 1.475 1.276 0 CA-C-O 119.376 -0.68 . . . . 0.0 113.553 177.004 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.576 ' HB2' ' HB3' ' J' ' 28' ' ' LYS . . . -156.87 152.82 27.28 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 103.523 -2.769 . . . . 0.0 103.523 174.289 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.496 ' HB ' ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -149.62 116.16 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.857 0 C-N-CA 116.714 -1.994 . . . . 0.0 113.407 -171.844 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.428 ' C ' ' CE ' ' E' ' 35' ' ' MET . 62.7 mt -104.55 118.3 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.91 177.445 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.413 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.06 104.19 1.32 Allowed Glycine 0 C--O 1.237 0.319 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 177.537 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.578 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 8.4 tt -139.54 132.7 29.71 Favored 'General case' 0 C--O 1.243 0.734 0 CA-C-O 122.835 1.302 . . . . 0.0 112.876 -177.487 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CG ' ' L' ' 35' ' ' MET . 95.9 mmm -107.17 118.43 36.69 Favored 'General case' 0 CA--C 1.505 -0.767 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.53 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.569 HG13 HD21 ' K' ' 34' ' ' LEU . 0.0 OUTLIER -124.24 74.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.911 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.46 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -17.43 -101.93 0.0 OUTLIER Glycine 0 C--N 1.359 1.855 0 O-C-N 123.868 0.73 . . . . 0.0 113.031 -179.249 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.17 -161.9 30.28 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 74.4 t -124.08 138.39 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-O 120.751 0.31 . . . . 0.0 110.611 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.413 ' O ' HG13 ' K' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.436 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -82.23 134.68 35.3 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.856 0.36 . . . . 0.0 110.48 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.42 143.68 33.83 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.519 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 50.4 t -121.68 132.92 69.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.063 0.459 . . . . 0.0 110.222 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 21.3 p-80 -164.12 110.43 1.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.479 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -144.85 169.04 18.8 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -151.72 175.64 12.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.126 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -153.34 123.89 7.18 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.346 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 64.4 mt -120.6 114.8 22.25 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -128.5 130.39 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.966 0.412 . . . . 0.0 110.54 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.506 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 55.4 p90 -138.19 127.69 24.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -134.28 127.3 31.53 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.217 0.532 . . . . 0.0 110.746 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.61 134.48 32.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.771 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -110.19 109.77 20.38 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.644 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 42.7 t0 -99.16 133.84 42.87 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.188 0.518 . . . . 0.0 109.961 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' L' ' 26' ' ' SER . 90.5 t -107.02 112.97 42.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.394 -179.393 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 35.3 -91.22 0.01 OUTLIER Glycine 0 CA--C 1.528 0.88 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.873 -179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.448 ' N ' ' O ' ' L' ' 24' ' ' VAL . 13.4 p -62.49 -177.83 0.16 Allowed 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 117.571 0.685 . . . . 0.0 110.342 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 90.2 m-20 -79.52 176.63 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.855 -1.066 . . . . 0.0 113.697 -177.166 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 35.7 tttp -48.51 111.1 0.41 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 113.835 -1.53 . . . . 0.0 112.947 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.41 -97.91 0.04 OUTLIER Glycine 0 CA--C 1.501 -0.808 0 CA-C-N 114.542 -1.208 . . . . 0.0 110.606 -178.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' K' ' 28' ' ' LYS . . . -60.84 170.87 1.34 Allowed 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 119.882 1.841 . . . . 0.0 106.135 -178.121 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -139.87 118.88 12.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 117.799 -1.56 . . . . 0.0 110.629 -172.71 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.541 ' C ' ' SD ' ' F' ' 35' ' ' MET . 67.2 mt -108.92 123.74 65.01 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 CA-C-N 114.398 -1.274 . . . . 0.0 109.09 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 33' ' ' GLY . . . . . 0.628 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -101.66 89.26 0.76 Allowed Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 105.477 -3.049 . . . . 0.0 105.477 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -108.57 112.89 25.48 Favored 'General case' 0 CA--C 1.502 -0.897 0 CA-C-O 120.684 0.278 . . . . 0.0 110.27 -177.835 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.505 ' CG ' ' SD ' ' K' ' 35' ' ' MET . 93.9 mmm -105.48 110.4 22.73 Favored 'General case' 0 CA--C 1.503 -0.846 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.169 179.428 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.487 HG13 HG23 ' K' ' 36' ' ' VAL . 2.9 m -128.7 79.42 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.263 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.5 103.68 0.52 Allowed Glycine 0 C--N 1.346 1.098 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.6 -161.06 36.9 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.7 m -133.15 160.91 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 120.966 0.412 . . . . 0.0 110.607 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 14.1 m . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.37 179.794 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -100.4 133.7 44.44 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.495 ' N ' ' OE1' ' A' ' 11' ' ' GLU . 54.6 mp0 -95.18 164.0 13.05 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.034 0.445 . . . . 0.0 110.643 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.31 131.6 56.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -93.6 135.5 34.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.761 0.315 . . . . 0.0 110.648 -179.043 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.554 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 75.2 t60 -152.21 164.09 38.08 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 44.9 tt0 -169.04 168.75 9.92 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.419 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.429 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 66.5 mttm -153.75 123.72 6.86 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -119.59 114.12 21.75 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.179 0.514 . . . . 0.0 110.466 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 70.5 t -120.34 115.44 47.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.147 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.961 ' CZ ' HD22 ' C' ' 34' ' ' LEU . 23.7 t80 -115.65 110.45 19.19 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.252 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.513 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 50.0 p90 -125.74 124.29 40.71 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.43 120.68 43.1 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.817 0.341 . . . . 0.0 110.357 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -159.65 115.32 2.46 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -74.89 121.85 22.5 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.96 0.409 . . . . 0.0 111.697 -178.553 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 26' ' ' SER . 13.9 t -84.48 124.6 39.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.06 84.3 0.01 OUTLIER Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.989 -178.109 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 24' ' ' VAL . 20.7 p -91.41 -179.76 5.47 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 178.175 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.43 179.13 0.17 Allowed 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 119.656 -0.817 . . . . 0.0 110.722 -179.087 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -59.5 111.11 1.28 Allowed 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.66 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.23 93.81 0.09 OUTLIER Glycine 0 N--CA 1.464 0.501 0 C-N-CA 120.169 -1.015 . . . . 0.0 112.214 177.602 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.24 156.14 21.92 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 176.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.609 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.2 OUTLIER -151.86 119.67 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.0 -173.248 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.455 ' C ' ' SD ' ' G' ' 35' ' ' MET . 5.9 tp -149.59 131.58 5.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.154 179.416 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.415 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.67 128.86 5.82 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -129.65 129.63 44.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.314 0.578 . . . . 0.0 110.606 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.517 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 27.9 ttt -130.81 129.23 42.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.552 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.6 t -84.46 75.99 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.979 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.412 ' CA ' HG21 ' G' ' 31' ' ' ILE . . . -90.51 103.36 3.02 Favored Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 178.731 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.45 179.95 52.43 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.57 163.7 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.492 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 46.9 t . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.488 179.798 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -98.14 127.17 43.93 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -67.33 127.4 32.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.267 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 70.8 t -134.06 136.67 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.039 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.487 ' H ' ' HA ' ' C' ' 12' ' ' VAL . 61.7 t-80 -122.46 118.73 29.02 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.861 0.363 . . . . 0.0 110.198 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.489 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 80.8 t60 -132.8 163.83 28.18 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.489 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 1.6 pt20 -169.93 177.6 4.3 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.981 179.174 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -156.28 125.96 6.33 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.438 ' N ' HD12 ' B' ' 17' ' ' LEU . 5.0 mp -122.23 121.2 36.27 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.162 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 7.1 p -134.18 130.79 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.916 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 18.2 t80 -115.29 117.58 30.85 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -129.14 129.22 44.86 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.716 0.293 . . . . 0.0 111.423 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.8 123.37 37.21 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 120.616 -0.433 . . . . 0.0 111.652 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 41.0 tp10 -164.74 105.1 0.82 Allowed 'General case' 0 C--N 1.343 0.283 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.553 ' O ' ' O ' ' B' ' 24' ' ' VAL . 42.6 t0 -104.67 112.1 25.06 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.553 ' O ' ' O ' ' B' ' 23' ' ' ASP . 2.1 t -50.27 -133.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.745 178.042 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -95.35 -84.95 1.68 Allowed Glycine 0 CA--C 1.536 1.403 0 CA-C-N 115.933 -0.576 . . . . 0.0 113.276 -178.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 35.0 t 68.51 178.83 0.24 Allowed 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -177.538 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -89.88 168.27 12.18 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 118.456 -1.298 . . . . 0.0 112.513 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 45.9 pttt -40.92 110.57 0.16 Allowed 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 177.101 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.546 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 80.0 94.54 0.37 Allowed Glycine 0 N--CA 1.476 1.329 0 N-CA-C 116.892 1.517 . . . . 0.0 116.892 171.156 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.25 152.91 37.08 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 171.611 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.609 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.0 OUTLIER -145.36 117.72 2.27 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.721 -174.308 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -127.05 131.57 70.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.029 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.31 119.59 3.45 Favored Glycine 0 N--CA 1.475 1.239 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 59.3 tp -127.45 126.24 41.97 Favored 'General case' 0 N--CA 1.47 0.527 0 O-C-N 122.287 -0.537 . . . . 0.0 110.885 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.518 ' SD ' ' O ' ' H' ' 32' ' ' ILE . 11.9 ttt -139.6 137.75 35.59 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.348 0.594 . . . . 0.0 111.481 179.525 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 24.4 t -122.51 73.88 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.845 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.657 ' CA ' HG21 ' H' ' 31' ' ' ILE . . . -62.85 111.95 4.52 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 178.351 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -26.66 148.53 0.01 OUTLIER Glycine 0 N--CA 1.469 0.871 0 CA-C-O 121.107 0.282 . . . . 0.0 112.676 -178.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 68.1 t -115.29 135.58 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 m . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.381 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -114.22 138.59 50.27 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.781 0.324 . . . . 0.0 110.592 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.448 ' OE2' ' O ' ' D' ' 10' ' ' TYR . 80.0 mm-40 -110.75 131.28 55.18 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.146 0.498 . . . . 0.0 110.538 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.487 ' HA ' ' H ' ' B' ' 13' ' ' HIS . 28.3 m -136.11 164.17 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.473 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.699 ' CG ' ' H ' ' C' ' 14' ' ' HIS . 24.2 t-80 -103.15 -173.48 2.32 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.699 ' H ' ' CG ' ' C' ' 13' ' ' HIS . 2.3 m170 -77.2 174.13 11.08 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.89 174.83 10.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.414 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -151.51 133.37 14.98 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.937 0.398 . . . . 0.0 111.731 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.63 HD23 ' C ' ' C' ' 17' ' ' LEU . 6.6 tt -127.62 123.2 35.06 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.578 178.752 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 18' ' ' VAL . . . . . 0.607 ' N ' HD23 ' C' ' 17' ' ' LEU . 57.5 t -128.04 129.52 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 CA-C-O 120.912 0.387 . . . . 0.0 111.648 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.737 ' CE1' HD13 ' E' ' 34' ' ' LEU . 2.5 t80 -121.7 115.21 22.3 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -127.45 125.79 41.18 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.92 0.39 . . . . 0.0 111.083 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.2 129.52 46.58 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.87 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 80.5 tt0 -155.97 158.39 37.82 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.938 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -142.8 120.65 11.97 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.57 0.224 . . . . 0.0 110.624 179.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -129.88 -112.19 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-O 121.308 0.575 . . . . 0.0 110.13 -179.235 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 35.07 -90.68 0.01 OUTLIER Glycine 0 CA--C 1.531 1.054 0 CA-C-N 115.337 -0.847 . . . . 0.0 114.084 -178.159 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.0 OUTLIER 175.28 -167.21 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 118.396 1.098 . . . . 0.0 110.793 -178.582 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' C' ' 26' ' ' SER . 51.4 p-10 -36.47 -179.62 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.164 -1.38 . . . . 0.0 113.641 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.546 ' HG3' ' H ' ' B' ' 29' ' ' GLY . 74.8 tttt 98.55 113.88 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.958 1.703 . . . . 0.0 113.182 179.047 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.88 93.64 0.49 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 172.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.2 163.07 12.88 Favored 'General case' 0 CA--C 1.498 -1.047 0 CA-C-N 120.74 2.27 . . . . 0.0 106.461 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.579 HD12 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -149.72 117.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 118.337 -1.345 . . . . 0.0 110.417 -174.113 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.485 ' C ' ' SD ' ' I' ' 35' ' ' MET . 13.5 tt -129.13 132.84 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 CA-C-O 121.736 0.779 . . . . 0.0 110.747 178.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -119.71 119.34 4.22 Favored Glycine 0 N--CA 1.465 0.612 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.961 HD22 ' CZ ' ' A' ' 19' ' ' PHE . 32.6 tp -118.67 121.86 41.14 Favored 'General case' 0 CA--C 1.512 -0.516 0 C-N-CA 120.986 -0.285 . . . . 0.0 111.743 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.522 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 7.9 ttm -122.05 108.98 14.0 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 173.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 m -128.75 72.37 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 120.543 -0.463 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.0 110.81 3.11 Favored Glycine 0 C--N 1.362 1.993 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.13 160.07 53.93 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -139.06 161.43 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.871 0.367 . . . . 0.0 111.051 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.414 ' O ' HG22 ' C' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.398 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 10' ' ' TYR . . . . . 0.448 ' O ' ' OE2' ' C' ' 11' ' ' GLU . 95.7 m-85 -106.83 129.66 54.64 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.499 ' OE2' ' NE2' ' D' ' 13' ' ' HIS . 9.9 pt-20 -155.06 159.23 40.12 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 70.0 t -114.52 131.7 65.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.026 0.441 . . . . 0.0 110.935 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.499 ' NE2' ' OE2' ' D' ' 11' ' ' GLU . 32.5 m-70 -138.39 97.83 3.46 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.167 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 m170 -119.98 161.93 20.07 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.41 0.624 . . . . 0.0 109.583 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.429 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 43.9 tt0 -154.32 170.33 21.56 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.804 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.429 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.3 mttt -152.95 129.33 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.364 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -123.23 124.24 42.57 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.715 0.293 . . . . 0.0 110.643 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -123.63 126.77 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.085 0.469 . . . . 0.0 110.508 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.854 ' CZ ' HD22 ' F' ' 34' ' ' LEU . 7.7 t80 -124.69 110.55 14.51 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -123.13 129.85 51.99 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.522 0.677 . . . . 0.0 111.778 -178.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.93 122.19 26.5 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.497 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 79.6 mm-40 -115.86 120.33 38.87 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -151.51 112.0 4.17 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 -179.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.695 ' O ' ' N ' ' D' ' 26' ' ' SER . 52.1 t -111.96 131.07 64.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 102.572 -3.121 . . . . 0.0 102.572 174.125 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.624 ' H ' ' HZ1' ' F' ' 28' ' ' LYS . . . -37.59 81.67 0.0 OUTLIER Glycine 0 CA--C 1.534 1.256 0 C-N-CA 120.172 -1.014 . . . . 0.0 112.569 -176.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.695 ' N ' ' O ' ' D' ' 24' ' ' VAL . 26.8 m -88.48 -179.58 6.1 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-O 122.566 1.174 . . . . 0.0 111.612 178.356 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -76.61 -177.13 4.07 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.921 175.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 35.1 tttt 44.96 111.62 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 117.959 2.577 . . . . 0.0 117.959 177.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.483 ' HA2' ' HB2' ' E' ' 30' ' ' ALA . . . -82.64 94.66 1.74 Allowed Glycine 0 CA--C 1.499 -0.957 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 173.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.24 167.36 12.38 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.721 HG23 HG13 ' E' ' 31' ' ' ILE . 0.2 OUTLIER -146.42 118.29 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.623 -174.976 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.422 HD12 ' CG2' ' C' ' 32' ' ' ILE . 14.4 tt -130.13 130.88 66.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-O 121.828 0.823 . . . . 0.0 111.942 179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.8 104.27 2.35 Favored Glycine 0 CA--C 1.509 -0.338 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 177.544 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.916 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 16.6 tp -111.33 117.85 34.26 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 117.376 0.588 . . . . 0.0 111.945 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.55 ' SD ' HG22 ' J' ' 31' ' ' ILE . 17.7 tpp -121.08 108.01 13.31 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 176.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.6 HG22 HD11 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -121.04 76.51 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.951 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.778 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.04 103.31 2.85 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.16 174.33 41.96 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -135.4 160.62 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 121.047 0.451 . . . . 0.0 110.755 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.177 -0.916 . . . . 0.0 110.366 179.578 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -120.26 143.78 48.12 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.815 0.34 . . . . 0.0 110.332 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.523 ' OE1' ' CE1' ' F' ' 10' ' ' TYR . 82.5 tt0 -73.23 135.15 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.84 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 8.4 t -146.74 135.62 16.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.108 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -132.54 131.7 41.83 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.638 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 24.2 t60 -152.08 163.6 38.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 121.922 0.868 . . . . 0.0 110.446 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.638 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 53.5 tt0 -159.55 167.11 29.35 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.496 178.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.401 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 99.2 mttt -151.44 130.11 12.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 179.432 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.5 HD12 ' CD2' ' F' ' 17' ' ' LEU . 12.5 mt -115.52 116.18 27.74 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.425 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.52 115.34 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.099 -179.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -117.03 124.43 49.29 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 116.78 -0.191 . . . . 0.0 110.756 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -129.94 119.09 22.68 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.65 121.13 22.7 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.231 0.539 . . . . 0.0 111.425 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 35.0 tt0 -88.52 165.63 14.73 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.7 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.563 ' O ' ' O ' ' E' ' 24' ' ' VAL . 46.0 t0 -145.4 -122.27 0.08 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.002 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.563 ' O ' ' O ' ' E' ' 23' ' ' ASP . 2.9 t 22.22 121.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 -178.707 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.08 -85.0 0.09 OUTLIER Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 177.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.509 ' H ' ' CE ' ' F' ' 28' ' ' LYS . 1.7 p 162.39 160.8 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 177.353 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.455 ' O ' ' O ' ' E' ' 26' ' ' SER . 69.6 m-80 -29.78 159.42 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.694 178.087 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.476 ' HD2' ' H ' ' D' ' 26' ' ' SER . 76.1 tttt -179.73 105.84 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 174.528 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.465 ' O ' ' CA ' ' D' ' 29' ' ' GLY . . . -58.65 93.54 0.05 OUTLIER Glycine 0 C--O 1.211 -1.323 0 CA-C-O 118.16 -1.356 . . . . 0.0 111.708 173.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.483 ' HB2' ' HA2' ' D' ' 29' ' ' GLY . . . -155.9 149.37 24.82 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 103.1 -2.926 . . . . 0.0 103.1 173.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.721 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.05 124.3 6.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 C-N-CA 117.984 -1.486 . . . . 0.0 112.133 -168.983 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.461 HG12 HD21 ' E' ' 34' ' ' LEU . 0.7 OUTLIER -120.91 111.29 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 CA-C-N 114.529 -1.214 . . . . 0.0 107.761 179.541 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.57 110.24 3.62 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.737 HD13 ' CE1' ' C' ' 19' ' ' PHE . 2.9 mt -117.97 112.76 20.72 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -176.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' K' ' 32' ' ' ILE . 6.2 ttm -115.29 107.91 15.87 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 175.419 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.16 80.97 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.23 102.64 0.5 Allowed Glycine 0 C--N 1.346 1.116 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -86.67 -160.22 34.35 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.31 160.47 33.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.185 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.5 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.689 -179.993 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.43 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' F' F ' 10' ' ' TYR . . . . . 0.523 ' CE1' ' OE1' ' E' ' 11' ' ' GLU . 41.8 t80 -78.89 125.42 29.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.073 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 11' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' E' ' 11' ' ' GLU . 78.6 mm-40 -118.54 132.48 56.21 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.158 0.504 . . . . 0.0 110.988 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.408 ' CG2' ' N ' ' F' ' 13' ' ' HIS . 1.5 p -147.82 160.23 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.434 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.536 ' ND1' ' ND1' ' E' ' 14' ' ' HIS . 15.2 t-80 -125.02 155.27 39.98 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 120.912 0.387 . . . . 0.0 110.595 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.558 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 89.9 m-70 -80.42 178.28 8.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -125.93 -179.88 4.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.364 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -133.62 137.58 45.5 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.161 0.505 . . . . 0.0 110.993 -179.599 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.5 ' CD2' HD12 ' E' ' 17' ' ' LEU . 33.1 mt -122.03 115.17 22.02 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.276 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 28.5 m -134.04 127.64 51.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.341 0.591 . . . . 0.0 110.092 178.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.495 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 50.0 p90 -138.69 131.52 29.39 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.575 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -129.79 122.27 28.45 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.252 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.6 146.24 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.422 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -115.78 125.9 53.33 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.217 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -168.12 113.45 0.66 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.978 178.536 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.498 ' O ' ' N ' ' F' ' 26' ' ' SER . 95.6 t -81.1 132.44 31.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.978 178.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.16 -85.58 0.01 OUTLIER Glycine 0 CA--C 1.523 0.558 0 C-N-CA 119.338 -1.41 . . . . 0.0 111.702 178.045 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' F' ' 27' ' ' ASN . 62.3 m -140.38 171.4 14.2 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -178.332 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' F' ' 26' ' ' SER . 25.0 m120 -29.66 169.98 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 122.79 1.281 . . . . 0.0 114.23 -174.444 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.624 ' HZ1' ' H ' ' D' ' 25' ' ' GLY . 30.6 tttt -98.54 -111.17 0.17 Allowed 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 113.881 -1.509 . . . . 0.0 112.476 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.516 ' H ' ' CG ' ' F' ' 28' ' ' LYS . . . -90.6 -99.85 1.18 Allowed Glycine 0 CA--C 1.484 -1.883 0 C-N-CA 127.568 2.509 . . . . 0.0 111.76 -179.509 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.66 166.46 3.24 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 105.838 -1.912 . . . . 0.0 105.838 -177.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -132.61 135.71 57.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.34 -171.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 61.4 mt -114.87 117.24 55.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 CA-C-N 115.198 -0.91 . . . . 0.0 112.646 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.69 92.58 1.23 Allowed Glycine 0 CA--C 1.51 -0.244 0 N-CA-C 104.51 -3.436 . . . . 0.0 104.51 173.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.854 HD22 ' CZ ' ' D' ' 19' ' ' PHE . 8.4 tp -110.3 116.77 32.07 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.346 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.466 ' HG3' ' CA ' ' L' ' 33' ' ' GLY . 96.4 mmm -119.58 111.98 18.75 Favored 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 176.122 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.491 HG13 HD11 ' F' ' 34' ' ' LEU . 0.1 OUTLIER -127.36 80.22 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.075 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 34.47 -103.27 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 CA-C-N 116.436 -0.347 . . . . 0.0 112.308 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.97 -150.17 10.95 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.8 t -120.02 135.77 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.997 0.427 . . . . 0.0 110.803 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.13 -0.938 . . . . 0.0 110.281 179.559 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' G' G ' 10' ' ' TYR . . . . . 0.409 ' O ' ' OE2' ' H' ' 11' ' ' GLU . 99.1 m-85 -99.19 133.77 43.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.136 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -139.67 145.6 38.62 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.301 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 62.2 t -125.34 132.63 70.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.225 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -88.31 172.11 9.67 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.919 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.537 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 3.6 m170 -89.05 170.52 10.58 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.626 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.431 ' HG2' ' N ' ' G' ' 16' ' ' LYS . 54.8 tt0 -147.57 171.81 14.99 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.859 179.24 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.431 ' N ' ' HG2' ' G' ' 15' ' ' GLN . 98.9 mttt -150.8 125.0 9.38 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 121.227 -0.189 . . . . 0.0 111.101 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 77.9 mt -118.28 122.42 42.87 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -138.66 132.42 40.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 121.774 0.797 . . . . 0.0 113.101 -178.437 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.637 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 6.9 m-85 -113.14 111.72 22.59 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 175.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -130.62 121.06 24.92 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 131.03 41.07 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-O 121.373 0.606 . . . . 0.0 112.038 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' G' ' 23' ' ' ASP . 83.8 tt0 -156.05 152.95 28.68 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 177.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.475 ' O ' ' C ' ' G' ' 24' ' ' VAL . 22.2 t70 -59.48 -120.41 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.534 -178.612 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.475 ' C ' ' O ' ' G' ' 23' ' ' ASP . 22.7 m -27.2 121.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 122.179 0.192 . . . . 0.0 111.001 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.15 -85.6 0.1 Allowed Glycine 0 CA--C 1.526 0.775 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.225 -177.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.697 ' O ' ' O ' ' G' ' 27' ' ' ASN . 62.5 m -152.73 -170.81 3.74 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -175.591 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.697 ' O ' ' O ' ' G' ' 26' ' ' SER . 12.7 t-20 -19.34 159.59 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.103 0 O-C-N 124.629 1.206 . . . . 0.0 114.016 -176.35 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -159.82 110.64 1.94 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.236 -176.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 1.058 ' O ' ' HB1' ' H' ' 30' ' ' ALA . . . -69.51 96.09 0.48 Allowed Glycine 0 CA--C 1.455 -3.683 0 CA-C-O 123.686 1.715 . . . . 0.0 110.511 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.522 ' O ' ' C ' ' G' ' 29' ' ' GLY . . . -81.6 -139.99 0.04 OUTLIER 'General case' 0 N--CA 1.395 -3.215 1 N-CA-C 94.424 -6.139 . . . . 0.0 94.424 171.171 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.693 ' CD1' ' N ' ' G' ' 31' ' ' ILE . 1.0 OUTLIER -85.18 111.31 20.5 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.298 0 CA-C-N 125.186 3.63 . . . . 0.0 109.443 179.928 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.517 ' O ' ' SD ' ' A' ' 35' ' ' MET . 39.1 mm -136.73 129.34 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 120.304 -0.558 . . . . 0.0 112.035 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.516 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -131.34 130.76 6.13 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.64 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 34.2 tp -156.19 135.33 12.09 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.801 0.81 . . . . 0.0 112.99 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.455 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 63.7 ttp -121.93 143.94 49.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.363 178.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 25.5 t -120.03 75.86 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.482 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -96.5 101.12 2.58 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.6 167.33 22.13 Favored Glycine 0 N--CA 1.467 0.741 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.16 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 81.8 t -131.3 138.27 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.752 0.31 . . . . 0.0 110.301 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.9 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.347 179.472 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -118.61 140.48 49.84 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' O ' ' G' ' 10' ' ' TYR . 80.9 mm-40 -132.36 135.9 46.47 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.711 0.767 . . . . 0.0 111.978 -178.926 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 58.0 t -128.47 134.33 64.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.094 -0.957 . . . . 0.0 108.654 179.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 -137.86 101.11 4.36 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.95 -0.3 . . . . 0.0 110.754 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 11.1 m170 -115.5 154.67 28.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.725 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 80.5 mt-30 -155.91 174.31 15.51 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.468 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -156.96 112.17 2.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.712 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.507 ' N ' HD12 ' H' ' 17' ' ' LEU . 6.5 mp -111.42 111.4 22.41 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.69 125.32 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-O 121.86 0.838 . . . . 0.0 111.732 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.604 ' CG ' ' CE2' ' I' ' 19' ' ' PHE . 6.0 m-85 -113.17 116.81 30.41 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 114.182 -1.372 . . . . 0.0 108.666 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -128.67 126.56 40.38 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.434 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.13 130.24 35.14 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 121.19 0.519 . . . . 0.0 111.394 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' H' ' 23' ' ' ASP . 84.9 tt0 -149.96 91.12 1.75 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 178.057 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' H' ' 22' ' ' GLU . 1.1 m-20 62.74 115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 -176.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.598 ' C ' ' HZ3' ' I' ' 28' ' ' LYS . 48.9 t -118.84 123.75 72.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.471 -174.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.505 ' C ' ' HZ3' ' I' ' 28' ' ' LYS . . . 35.91 83.69 0.01 OUTLIER Glycine 0 N--CA 1.47 0.905 0 C-N-CA 121.482 -0.39 . . . . 0.0 113.255 177.128 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.627 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 5.4 t -58.9 170.92 0.74 Allowed 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 121.18 0.514 . . . . 0.0 110.389 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.512 ' O ' ' O ' ' H' ' 28' ' ' LYS . 19.6 m120 103.26 177.43 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 113.259 -1.791 . . . . 0.0 107.298 -177.334 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' H' ' 27' ' ' ASN . 98.7 mttt -23.69 -102.87 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 O-C-N 123.567 0.542 . . . . 0.0 111.981 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -141.25 100.46 0.26 Allowed Glycine 0 N--CA 1.472 1.059 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 177.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 1.058 ' HB1' ' O ' ' G' ' 29' ' ' GLY . . . -66.59 158.48 29.72 Favored 'General case' 0 C--O 1.248 1.013 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.016 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.657 HG21 ' CA ' ' B' ' 37' ' ' GLY . 0.1 OUTLIER -154.55 132.15 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.544 -175.796 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' B' ' 35' ' ' MET . 41.5 pt -130.42 127.07 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.499 0.666 . . . . 0.0 112.226 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.53 97.89 0.66 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.507 ' O ' HD12 ' I' ' 34' ' ' LEU . 4.4 mp -129.44 149.8 51.07 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.924 0.868 . . . . 0.0 111.974 -178.31 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.406 ' CE ' ' SD ' ' G' ' 35' ' ' MET . 20.7 ttp -141.03 134.69 30.17 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.482 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 4.1 t -126.42 79.01 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' B' ' 31' ' ' ILE . . . -61.53 105.07 0.8 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 177.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.94 173.05 0.64 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.99 161.88 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.965 0.412 . . . . 0.0 110.66 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.9 m . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.831 179.951 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -110.2 151.74 26.93 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.692 0.282 . . . . 0.0 110.337 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.478 ' O ' ' O ' ' J' ' 11' ' ' GLU . 83.1 tt0 -50.0 134.95 21.05 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.27 151.01 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.97 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -135.75 132.31 36.65 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.505 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.625 ' NE2' ' CG ' ' J' ' 13' ' ' HIS . 75.7 m80 -122.91 159.69 27.71 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 178.37 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -157.51 177.52 11.32 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.629 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -170.05 114.16 0.49 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.462 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 tt -117.67 118.49 32.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.071 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -141.72 136.76 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 119.967 -0.693 . . . . 0.0 111.896 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.604 ' CE2' ' CG ' ' H' ' 19' ' ' PHE . 26.8 m-85 -123.92 128.5 49.52 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 115.393 -0.822 . . . . 0.0 110.224 179.473 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.587 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.2 t80 -133.26 124.86 28.12 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.09 133.21 44.07 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.488 0.921 . . . . 0.0 113.488 -178.524 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -143.35 167.75 21.42 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' I' ' 24' ' ' VAL . 3.6 m-20 -142.32 -102.14 0.13 Allowed 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.519 ' O ' ' O ' ' I' ' 23' ' ' ASP . 10.9 t 46.98 159.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 122.263 1.03 . . . . 0.0 112.655 -176.402 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.497 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 107.88 -76.35 0.22 Allowed Glycine 0 CA--C 1.541 1.712 0 CA-C-N 114.139 -1.391 . . . . 0.0 112.529 -175.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.9 ' O ' ' O ' ' I' ' 27' ' ' ASN . 0.4 OUTLIER 170.89 -169.48 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.403 0 CA-C-N 119.502 1.651 . . . . 0.0 109.354 -176.43 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.9 ' O ' ' O ' ' I' ' 26' ' ' SER . 62.1 t30 -17.01 -179.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.06 0 O-C-N 125.287 1.617 . . . . 0.0 113.537 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.659 ' CG ' ' O ' ' I' ' 27' ' ' ASN . 26.8 mmtt 139.89 -110.52 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -175.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.42 ' CA ' ' O ' ' J' ' 29' ' ' GLY . . . 49.27 91.28 0.01 OUTLIER Glycine 0 CA--C 1.482 -2.022 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -171.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.447 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -103.06 170.75 7.78 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 111.509 -2.346 . . . . 0.0 106.63 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.481 HD12 ' CG2' ' H' ' 31' ' ' ILE . 0.3 OUTLIER -145.78 110.03 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 C-N-CA 118.299 -1.361 . . . . 0.0 109.423 -175.899 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.517 HG12 HD11 ' H' ' 32' ' ' ILE . 58.7 mt -103.6 115.72 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.516 -178.654 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.522 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.61 92.65 0.54 Allowed Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 107.509 -2.237 . . . . 0.0 107.509 176.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.61 HD23 ' HZ ' ' G' ' 19' ' ' PHE . 22.6 tp -129.22 122.4 29.63 Favored 'General case' 0 C--O 1.244 0.785 0 CA-C-O 123.276 1.512 . . . . 0.0 110.798 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 24.7 ttp -106.61 120.42 41.91 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 112.596 -2.093 . . . . 0.0 108.548 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -135.49 72.23 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.392 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -104.13 101.62 2.01 Favored Glycine 0 C--N 1.36 1.914 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 178.272 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.35 178.91 24.56 Favored Glycine 0 N--CA 1.463 0.485 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 8.4 p -141.43 152.34 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.878 0.371 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.5 179.856 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.452 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' J' J ' 10' ' ' TYR . . . . . 0.471 ' CD1' ' OE1' ' I' ' 11' ' ' GLU . 66.8 m-85 -120.45 147.2 45.41 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.478 ' O ' ' O ' ' I' ' 11' ' ' GLU . 95.6 mt-10 -122.95 161.65 23.78 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.185 0.517 . . . . 0.0 110.441 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -143.77 151.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.591 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.625 ' CG ' ' NE2' ' I' ' 14' ' ' HIS . 25.2 t-80 -92.45 -173.92 3.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.853 0.359 . . . . 0.0 110.219 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.621 ' H ' ' CG ' ' J' ' 13' ' ' HIS . 0.5 OUTLIER -86.01 175.19 8.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.336 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.408 ' HG2' ' N ' ' J' ' 16' ' ' LYS . 48.3 tt0 -126.16 166.26 17.38 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.408 ' N ' ' HG2' ' J' ' 15' ' ' GLN . 99.5 mttt -148.57 122.89 9.63 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.756 0.312 . . . . 0.0 111.591 -179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 3.4 mp -123.9 121.14 34.54 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.32 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 94.5 t -129.72 128.66 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-O 121.149 0.499 . . . . 0.0 112.086 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.453 ' CZ ' HD13 ' L' ' 34' ' ' LEU . 46.5 m-85 -115.53 119.83 37.48 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 178.106 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.587 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 29.0 t80 -130.99 120.35 23.37 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.616 0.644 . . . . 0.0 109.727 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.34 134.44 34.24 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -110.45 122.96 48.98 Favored 'General case' 0 C--N 1.346 0.43 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.311 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.549 ' HB3' ' H ' ' K' ' 24' ' ' VAL . 8.8 t70 -84.28 122.66 29.2 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.017 0.437 . . . . 0.0 110.911 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' J' ' 26' ' ' SER . 72.1 t -99.66 122.52 51.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.748 -179.06 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 39.17 -86.06 0.01 OUTLIER Glycine 0 C--N 1.337 0.619 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.301 177.08 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.653 ' O ' ' O ' ' J' ' 27' ' ' ASN . 87.9 p -161.25 174.17 13.98 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.653 ' O ' ' O ' ' J' ' 26' ' ' SER . 74.9 m-20 -9.39 159.4 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 116.369 1.989 . . . . 0.0 116.369 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt 179.86 104.83 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 112.566 -2.106 . . . . 0.0 106.618 175.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.42 ' O ' ' CA ' ' I' ' 29' ' ' GLY . . . -60.51 95.03 0.08 OUTLIER Glycine 0 C--O 1.22 -0.722 0 CA-C-O 118.724 -1.042 . . . . 0.0 113.924 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.401 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -127.37 149.01 50.25 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 102.215 -3.254 . . . . 0.0 102.215 172.414 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.55 HG22 ' SD ' ' D' ' 35' ' ' MET . 0.2 OUTLIER -148.48 118.64 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 C-N-CA 118.011 -1.476 . . . . 0.0 111.222 -172.296 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.649 ' CG2' HD21 ' K' ' 34' ' ' LEU . 2.0 mt -108.12 112.48 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.384 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.07 101.94 1.32 Allowed Glycine 0 C--O 1.239 0.455 0 N-CA-C 106.579 -2.608 . . . . 0.0 106.579 176.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.637 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 0.2 OUTLIER -142.16 135.17 28.73 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 122.205 1.002 . . . . 0.0 112.391 -176.634 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 49.0 ttp -123.3 127.61 48.79 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.979 179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.86 69.08 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.306 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.725 178.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.2 -100.83 0.01 OUTLIER Glycine 0 C--N 1.36 1.89 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.07 150.91 20.43 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 75.6 t -134.52 137.31 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 p . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.401 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -109.51 142.54 40.4 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.58 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -130.59 144.13 51.21 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.671 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.05 133.79 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.803 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -134.4 124.27 25.43 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.019 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.553 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 62.4 t-80 -156.48 166.87 32.17 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-O 121.409 0.623 . . . . 0.0 109.921 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.553 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 79.6 mt-30 -153.91 173.49 15.88 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.359 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 79.1 tttt -153.78 113.3 3.8 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.125 178.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 tt -116.01 121.74 43.15 Favored 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -126.61 129.37 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -125.05 123.82 40.62 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -134.39 122.54 22.71 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.676 0.274 . . . . 0.0 111.266 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.49 131.42 31.81 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 121.246 0.546 . . . . 0.0 111.85 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -110.27 128.17 55.39 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.748 179.378 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.462 ' H ' ' HB2' ' L' ' 22' ' ' GLU . 89.0 m-20 -100.48 115.65 30.57 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.552 ' O ' ' N ' ' K' ' 26' ' ' SER . 53.3 t -95.37 130.29 44.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.03 -85.31 0.01 OUTLIER Glycine 0 CA--C 1.529 0.917 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.552 ' N ' ' O ' ' K' ' 24' ' ' VAL . 29.4 p -141.16 170.76 15.12 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.945 0.878 . . . . 0.0 111.516 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.515 ' O ' ' O ' ' K' ' 26' ' ' SER . 2.3 p30 -28.83 169.72 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.184 -1.825 . . . . 0.0 114.294 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.541 ' O ' ' HB2' ' L' ' 30' ' ' ALA . 88.6 tttt -149.85 111.38 4.48 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.101 175.579 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.11 91.91 0.05 OUTLIER Glycine 0 N--CA 1.476 1.337 0 CA-C-O 119.603 -0.554 . . . . 0.0 113.643 176.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.12 153.97 51.02 Favored 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 102.961 -2.977 . . . . 0.0 102.961 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.504 HG23 ' CG1' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -142.09 111.68 2.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 C-N-CA 118.221 -1.392 . . . . 0.0 111.713 -172.965 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.49 HG22 ' O ' ' K' ' 32' ' ' ILE . 0.1 OUTLIER -106.83 111.12 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.661 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.79 97.64 1.05 Allowed Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.649 HD21 ' CG2' ' J' ' 32' ' ' ILE . 94.2 mt -130.24 142.3 50.57 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 122.024 0.916 . . . . 0.0 113.196 -176.451 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 40.7 ttp -129.67 117.91 21.08 Favored 'General case' 0 CA--C 1.501 -0.939 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.266 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' K' ' 37' ' ' GLY . 0.2 OUTLIER -115.19 65.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.666 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -36.69 -106.87 0.01 OUTLIER Glycine 0 C--N 1.352 1.471 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.569 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.73 144.98 0.07 OUTLIER Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -178.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -146.38 143.57 20.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.782 -179.579 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -111.87 137.2 50.15 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.703 0.287 . . . . 0.0 110.271 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -53.98 152.48 5.72 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.18 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 28.5 m -113.77 133.27 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.549 0.69 . . . . 0.0 111.663 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -150.07 138.59 20.66 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.804 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.517 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 18.8 t-80 -157.31 175.5 13.93 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.517 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 87.9 mt-30 -142.86 176.44 9.07 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.952 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -166.23 113.47 0.88 Allowed 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.268 0.556 . . . . 0.0 111.024 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -121.56 125.97 48.02 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.607 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.6 t -134.43 133.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -141.78 133.4 26.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.124 0.488 . . . . 0.0 111.41 -179.575 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -134.49 128.56 33.64 Favored 'General case' 0 C--O 1.231 0.088 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.243 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.74 148.5 25.48 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.566 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.462 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 98.5 mt-10 -91.26 152.57 20.45 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.484 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -141.55 123.32 15.24 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.459 0.647 . . . . 0.0 112.036 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.533 ' O ' ' N ' ' L' ' 26' ' ' SER . 94.7 t -94.58 121.04 44.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.0 -88.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.082 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.533 ' N ' ' O ' ' L' ' 24' ' ' VAL . 11.9 p -90.97 179.72 5.68 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 88.0 m-20 -61.1 170.44 1.63 Allowed 'General case' 0 C--N 1.314 -0.945 0 C-N-CA 118.491 -1.284 . . . . 0.0 109.612 -179.448 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -53.88 111.94 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.198 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.474 ' H ' ' HB3' ' K' ' 27' ' ' ASN . . . -71.45 92.23 0.5 Allowed Glycine 0 N--CA 1.47 0.923 0 C-N-CA 118.64 -1.743 . . . . 0.0 110.058 176.028 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.541 ' HB2' ' O ' ' K' ' 28' ' ' LYS . . . -174.83 163.29 3.35 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 102.386 -3.19 . . . . 0.0 102.386 178.103 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.504 ' CG1' HG23 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -143.86 120.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 116.927 -1.909 . . . . 0.0 113.207 -177.464 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.435 HG22 ' O ' ' L' ' 32' ' ' ILE . 3.4 mt -102.78 111.72 33.57 Favored 'Isoleucine or valine' 0 C--N 1.343 0.325 0 CA-C-N 113.466 -1.697 . . . . 0.0 107.372 177.437 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 33' ' ' GLY . . . . . 0.466 ' CA ' ' HG3' ' F' ' 35' ' ' MET . . . -110.06 83.94 0.35 Allowed Glycine 0 CA--C 1.493 -1.318 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 177.305 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.692 HD21 HG13 ' L' ' 36' ' ' VAL . 7.3 tt -122.27 117.08 25.28 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.499 ' N ' HD23 ' L' ' 34' ' ' LEU . 65.4 ttp -106.05 130.27 53.99 Favored 'General case' 0 CA--C 1.505 -0.784 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.333 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.692 HG13 HD21 ' L' ' 34' ' ' LEU . 0.0 OUTLIER -132.2 79.97 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.629 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.18 103.24 0.76 Allowed Glycine 0 C--N 1.348 1.224 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.96 152.98 21.24 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -132.14 157.81 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.751 -179.599 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.396 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -112.69 147.02 37.67 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.756 0.312 . . . . 0.0 110.433 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.0 mt-10 -113.33 143.54 44.27 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.981 0.419 . . . . 0.0 110.748 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.2 m -130.65 154.91 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.778 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -138.24 163.19 32.38 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.944 0.402 . . . . 0.0 110.866 -178.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.629 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -82.11 170.82 15.05 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.551 -179.844 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -148.89 174.76 11.9 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.01 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -153.4 124.54 7.46 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.074 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.0 mt -121.12 114.26 21.19 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.1 t -131.26 129.34 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 CA-C-O 121.403 0.621 . . . . 0.0 112.354 -178.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.595 ' CG ' ' CE1' ' B' ' 19' ' ' PHE . 3.5 m-85 -108.85 111.63 23.45 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 50.1 p90 -131.59 126.32 34.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 118.797 0.726 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.12 133.14 42.51 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-O 121.461 0.648 . . . . 0.0 112.405 -178.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.496 ' N ' ' OE1' ' A' ' 22' ' ' GLU . 36.5 mp0 -142.97 156.52 44.88 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.457 ' O ' ' CG1' ' B' ' 24' ' ' VAL . 34.5 t70 -87.89 111.72 21.74 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 120.165 -0.614 . . . . 0.0 112.387 -178.445 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.598 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.5 t -113.8 131.2 66.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.093 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.96 81.97 0.0 OUTLIER Glycine 0 CA--C 1.53 1.022 0 O-C-N 123.315 0.384 . . . . 0.0 112.427 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.598 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.4 p -91.19 -179.3 5.39 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.538 ' O ' ' O ' ' A' ' 28' ' ' LYS . 58.8 t30 -62.64 -178.03 0.18 Allowed 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.538 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.2 mttt -48.48 -110.51 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.746 0.784 . . . . 0.0 110.604 -179.355 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -84.2 94.97 1.88 Allowed Glycine 0 N--CA 1.459 0.23 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 176.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.07 161.32 16.61 Favored 'General case' 0 C--N 1.351 0.636 0 C-N-CA 115.473 -2.491 . . . . 0.0 110.776 -177.105 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.458 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.7 OUTLIER -153.4 121.7 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 CA-C-N 112.545 -2.116 . . . . 0.0 110.667 -172.596 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' G' ' 35' ' ' MET . 78.6 mt -129.2 120.16 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 120.381 -0.527 . . . . 0.0 110.72 178.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.62 122.31 3.54 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 16.0 tp -127.75 141.96 51.44 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 117.241 0.52 . . . . 0.0 111.355 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.57 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 13.3 ttt -131.32 129.29 41.25 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.315 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 16.4 t -131.4 71.66 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 N-CA-C 112.315 0.487 . . . . 0.0 112.315 178.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.549 ' O ' HD12 ' G' ' 31' ' ' ILE . . . -125.75 96.51 0.49 Allowed Glycine 0 C--N 1.344 1.024 0 N-CA-C 108.799 -1.72 . . . . 0.0 108.799 177.386 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.86 172.25 42.56 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -133.99 159.22 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 110.761 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.923 -1.037 . . . . 0.0 110.297 179.769 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.177 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -109.53 134.69 51.6 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.693 0.282 . . . . 0.0 110.47 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.527 ' N ' ' OE1' ' B' ' 11' ' ' GLU . 56.9 mp0 -121.09 128.08 52.25 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.44 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p -144.46 138.42 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.971 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 -142.18 105.98 4.71 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.659 0.266 . . . . 0.0 110.923 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -160.45 178.77 9.22 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-O 121.109 0.481 . . . . 0.0 110.283 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -133.44 -179.14 5.33 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.97 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -146.74 132.38 18.84 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.879 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.9 tp -125.39 115.9 21.02 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 120.701 -0.4 . . . . 0.0 112.01 -177.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 74.9 t -125.39 123.8 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 120.866 0.365 . . . . 0.0 110.912 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.595 ' CE1' ' CG ' ' A' ' 19' ' ' PHE . 13.3 m-85 -116.83 118.98 33.97 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.73 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.7 t80 -134.11 125.4 27.91 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.99 133.71 33.98 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -178.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -153.15 176.76 11.57 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.46 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -153.35 134.69 14.22 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.913 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.457 ' CG1' ' O ' ' A' ' 23' ' ' ASP . 2.8 p -109.09 112.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.005 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 33.09 88.57 0.01 OUTLIER Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -177.288 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -46.96 170.86 0.01 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.17 -1.015 . . . . 0.0 113.232 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.559 ' H ' ' HD2' ' C' ' 28' ' ' LYS . 78.3 m-20 -129.67 -179.94 5.47 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 114.316 -1.311 . . . . 0.0 108.62 176.546 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.498 ' O ' ' O ' ' B' ' 27' ' ' ASN . 98.1 mttt -26.71 -103.3 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 179.42 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.85 98.43 0.18 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.091 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.42 ' H ' ' HE3' ' C' ' 28' ' ' LYS . . . -74.82 158.72 32.96 Favored 'General case' 0 C--O 1.25 1.088 0 C-N-CA 117.086 -1.846 . . . . 0.0 111.26 177.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.458 ' O ' ' HA ' ' A' ' 31' ' ' ILE . 0.1 OUTLIER -153.68 112.99 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.556 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.491 ' O ' ' SD ' ' H' ' 35' ' ' MET . 42.7 pt -136.02 150.36 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.255 -177.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.506 ' O ' HD23 ' B' ' 34' ' ' LEU . . . -166.18 150.29 17.4 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 119.835 -1.174 . . . . 0.0 112.332 -179.641 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.628 HD12 HD11 ' C' ' 34' ' ' LEU . 6.0 mt -139.17 143.43 38.14 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 120.9 0.381 . . . . 0.0 110.586 179.81 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.63 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 5.2 ttt -120.22 122.09 40.16 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.2 t -138.14 71.83 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.814 ' O ' HG21 ' H' ' 31' ' ' ILE . . . -128.12 95.85 0.41 Allowed Glycine 0 C--N 1.343 0.969 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 177.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.33 179.44 18.69 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -179.039 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -123.75 136.12 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.982 0.42 . . . . 0.0 110.284 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.186 179.812 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -147.79 163.82 35.56 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.515 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 56.7 mp0 -127.04 150.25 49.53 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.663 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.49 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 32.6 m -131.27 156.16 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.949 179.661 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 10.0 m-70 -150.98 150.43 30.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.995 -178.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 2.4 t60 -154.55 158.14 39.35 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.508 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 78.2 mt-30 -152.08 179.27 8.63 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 120.289 -0.565 . . . . 0.0 111.432 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -165.45 117.53 1.14 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.836 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.3 mt -115.81 114.78 25.22 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.79 140.92 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 119.426 -0.91 . . . . 0.0 113.163 -178.546 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.552 ' CE1' ' CD1' ' F' ' 34' ' ' LEU . 65.1 m-85 -124.28 125.11 43.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.541 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.0 t80 -130.61 117.21 19.19 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.027 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.24 136.15 46.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 120.559 -0.456 . . . . 0.0 111.641 -178.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -125.97 121.04 31.93 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.418 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' D' ' 24' ' ' VAL . 41.0 t0 -90.63 123.05 33.95 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.127 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.3 t -142.32 -111.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' C' ' 26' ' ' SER . . . -29.8 91.56 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 CA-C-N 116.145 -0.479 . . . . 0.0 112.747 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.545 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 12.8 p -61.18 179.15 0.21 Allowed 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 105.596 -2.001 . . . . 0.0 105.596 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.545 ' CB ' ' O ' ' C' ' 26' ' ' SER . 3.1 m120 91.17 -170.81 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -177.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.559 ' HD2' ' H ' ' B' ' 27' ' ' ASN . 84.3 tttt 40.59 -106.29 0.06 Allowed 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 114.803 1.408 . . . . 0.0 114.803 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.6 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . 92.95 91.91 1.51 Allowed Glycine 0 CA--C 1.497 -1.07 0 N-CA-C 107.483 -2.247 . . . . 0.0 107.483 -171.691 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.475 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -83.5 172.47 12.37 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.512 -176.48 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.475 ' CG1' ' C ' ' C' ' 30' ' ' ALA . 0.1 OUTLIER -152.72 124.19 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 C-N-CA 117.7 -1.6 . . . . 0.0 110.157 -175.909 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.7 tt -122.42 131.73 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.462 ' O ' ' CA ' ' B' ' 33' ' ' GLY . . . -122.44 109.13 1.36 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 179.131 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.764 ' H ' HD23 ' D' ' 34' ' ' LEU . 1.0 OUTLIER -137.07 126.57 25.12 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.45 -1.029 . . . . 0.0 112.258 -178.402 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.666 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 14.2 ttp -110.58 121.8 46.2 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 114.388 -1.278 . . . . 0.0 109.945 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.463 HG13 ' CD2' ' C' ' 34' ' ' LEU . 0.2 OUTLIER -139.87 70.46 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.732 179.847 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.53 -100.48 0.62 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.44 155.27 25.49 Favored Glycine 0 CA--C 1.521 0.434 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -136.06 162.09 36.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.761 0.315 . . . . 0.0 110.213 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.8 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.721 -179.699 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -116.09 138.64 51.06 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 120.837 0.351 . . . . 0.0 110.407 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -64.09 128.86 37.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.197 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m -137.84 137.42 44.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.787 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 73.9 m-70 -128.62 102.04 6.42 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 m170 -95.23 158.15 15.59 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 121.904 0.859 . . . . 0.0 111.162 -179.179 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 29.6 mm100 -152.61 171.34 18.31 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 114.023 -1.444 . . . . 0.0 107.905 178.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -174.1 128.67 0.37 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 121.014 -0.275 . . . . 0.0 110.275 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.474 HD21 HG11 ' F' ' 36' ' ' VAL . 8.8 mt -120.74 119.46 32.83 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 120.451 -0.5 . . . . 0.0 111.103 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -128.99 119.47 49.43 Favored 'Isoleucine or valine' 0 C--N 1.341 0.201 0 C-N-CA 120.636 -0.426 . . . . 0.0 111.359 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -113.03 116.66 30.28 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' OE2' ' D' ' 22' ' ' GLU . 9.0 t80 -129.5 119.4 23.66 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.13 0.423 . . . . 0.0 110.152 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.76 127.58 43.84 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 78.6 mm-40 -121.49 112.31 18.36 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 179.214 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 24' ' ' VAL . 19.9 t0 -84.35 97.34 9.41 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.622 ' O ' ' N ' ' D' ' 26' ' ' SER . 14.0 t -103.61 168.73 2.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.607 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.495 ' N ' ' CG1' ' D' ' 24' ' ' VAL . . . 39.36 -78.31 0.0 OUTLIER Glycine 0 CA--C 1.527 0.783 0 CA-C-O 119.448 -0.64 . . . . 0.0 112.631 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.622 ' N ' ' O ' ' D' ' 24' ' ' VAL . 1.4 p 170.98 -170.83 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 117.895 0.848 . . . . 0.0 111.552 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.592 ' O ' ' O ' ' D' ' 26' ' ' SER . 20.5 m-80 -18.68 -172.11 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -179.126 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.554 ' H ' ' HD3' ' E' ' 28' ' ' LYS . 86.0 tttt 127.2 104.46 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 111.217 -2.719 . . . . 0.0 110.48 177.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.6 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -59.9 96.28 0.08 OUTLIER Glycine 0 CA--C 1.491 -1.438 0 CA-C-O 118.337 -1.257 . . . . 0.0 110.559 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.464 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . -117.61 150.36 39.15 Favored 'General case' 0 CA--C 1.467 -2.224 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 174.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.464 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 0.3 OUTLIER -150.51 122.03 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 118.049 -1.461 . . . . 0.0 110.278 -171.973 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.415 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.1 OUTLIER -105.87 119.01 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 114.187 -1.369 . . . . 0.0 110.375 -179.091 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.623 ' O ' HD23 ' D' ' 34' ' ' LEU . . . -123.86 101.55 0.69 Allowed Glycine 0 N--CA 1.464 0.554 0 N-CA-C 108.093 -2.003 . . . . 0.0 108.093 178.598 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.764 HD23 ' H ' ' C' ' 34' ' ' LEU . 16.8 mt -139.09 152.03 47.19 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.378 -0.929 . . . . 0.0 112.326 -176.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.591 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 35.2 ttp -126.36 118.16 24.46 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 176.639 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 40.1 t -127.06 70.22 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.57 -102.62 2.75 Favored Glycine 0 C--N 1.36 1.884 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.422 ' H ' HG21 ' J' ' 31' ' ' ILE . . . 77.73 170.21 34.72 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -140.29 140.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.854 0.359 . . . . 0.0 110.232 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.43 -179.824 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.434 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -146.26 162.09 38.86 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.897 0.379 . . . . 0.0 110.458 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.533 ' N ' ' OE1' ' E' ' 11' ' ' GLU . 56.1 mp0 -130.91 144.16 51.26 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.587 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.52 HG13 ' H ' ' D' ' 13' ' ' HIS . 46.9 t -115.65 131.63 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 179.524 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' D' ' 13' ' ' HIS . 85.9 m-70 -109.99 160.56 16.32 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 118.532 0.605 . . . . 0.0 111.949 -178.634 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.539 ' CE1' ' O ' ' D' ' 13' ' ' HIS . 98.0 m-70 -152.14 174.44 13.72 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.279 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mm-40 -119.75 -171.02 2.05 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -97.77 175.72 6.07 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 122.504 1.145 . . . . 0.0 113.945 -176.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.1 tt -120.81 121.47 38.24 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 113.407 -1.724 . . . . 0.0 106.986 178.001 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.57 138.66 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-O 121.524 0.678 . . . . 0.0 112.616 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -124.21 124.51 42.62 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.578 -1.192 . . . . 0.0 109.007 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -131.2 122.55 26.77 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.86 127.87 42.72 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 120.861 0.362 . . . . 0.0 111.025 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 80.1 tt0 -92.91 144.48 25.23 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.814 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.612 ' O ' ' O ' ' E' ' 24' ' ' VAL . 41.5 p-10 -71.21 -122.34 0.0 OUTLIER 'General case' 0 C--O 1.218 -0.562 0 CA-C-N 116.304 -0.407 . . . . 0.0 109.982 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.612 ' O ' ' O ' ' E' ' 23' ' ' ASP . 87.3 t 19.84 122.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.58 -84.19 0.09 OUTLIER Glycine 0 CA--C 1.522 0.514 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.69 177.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.529 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.4 p 154.18 -179.23 0.0 OUTLIER 'General case' 0 C--N 1.345 0.382 0 CA-C-O 122.58 1.181 . . . . 0.0 111.006 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.426 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 1.8 m-20 -52.63 -178.94 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 112.44 -2.163 . . . . 0.0 112.643 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.554 ' HD3' ' H ' ' D' ' 28' ' ' LYS . 0.0 OUTLIER 60.66 113.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 123.017 1.389 . . . . 0.0 114.385 -179.521 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -88.26 96.22 2.17 Favored Glycine 0 C--O 1.224 -0.522 0 CA-C-N 111.687 -2.506 . . . . 0.0 112.727 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -63.95 175.44 1.19 Allowed 'General case' 0 C--O 1.24 0.596 0 CA-C-N 119.882 1.841 . . . . 0.0 107.461 -178.548 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.428 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.1 OUTLIER -152.39 129.65 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.421 0 C-N-CA 116.736 -1.986 . . . . 0.0 114.606 -172.451 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mt -107.67 121.04 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.072 177.237 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.3 104.59 0.82 Allowed Glycine 0 C--N 1.332 0.332 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.775 HD12 ' N ' ' E' ' 35' ' ' MET . 3.4 tp -150.31 135.3 17.73 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.461 1.124 . . . . 0.0 112.584 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.775 ' N ' HD12 ' E' ' 34' ' ' LEU . 33.8 ttp -102.26 126.3 49.22 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.762 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.39 70.94 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.9 114.08 5.88 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.05 -139.49 0.14 Allowed Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -119.01 136.7 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 120.755 0.312 . . . . 0.0 110.527 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 20.6 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.408 179.824 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -111.33 133.2 53.83 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-O 120.856 0.36 . . . . 0.0 110.401 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -121.8 138.58 54.32 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.365 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.52 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 58.3 t -123.73 131.32 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.44 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.52 ' CG ' ' O ' ' F' ' 12' ' ' VAL . 78.9 m80 -161.28 99.39 1.18 Allowed 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.817 179.59 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -153.74 163.99 39.08 Favored 'General case' 0 N--CA 1.447 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 109.9 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -158.27 177.43 11.28 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.792 179.022 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -142.53 139.83 31.58 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 121.16 0.505 . . . . 0.0 110.574 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 39.5 mt -113.33 127.94 56.3 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.17 138.26 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.535 0.683 . . . . 0.0 111.694 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.0 p90 -132.47 131.03 41.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.765 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -136.44 130.15 32.22 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.99 144.31 25.75 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.633 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.467 ' HB2' ' H ' ' E' ' 23' ' ' ASP . 73.0 mm-40 -99.27 161.27 13.71 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.491 ' O ' ' O ' ' F' ' 24' ' ' VAL . 59.9 m-20 -145.29 -132.32 0.08 Allowed 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.531 -179.213 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' F' ' 23' ' ' ASP . 2.8 t 25.81 112.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -178.835 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.17 -91.57 0.1 OUTLIER Glycine 0 CA--C 1.525 0.695 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 177.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.495 ' O ' ' O ' ' F' ' 27' ' ' ASN . 50.4 m -141.3 170.26 16.05 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.444 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.542 ' OD1' ' N ' ' F' ' 28' ' ' LYS . 56.8 t-20 -29.19 155.89 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.744 0 O-C-N 123.73 0.643 . . . . 0.0 111.727 179.012 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.542 ' N ' ' OD1' ' F' ' 27' ' ' ASN . 23.8 tttm -151.67 -110.45 0.05 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.588 0.708 . . . . 0.0 111.89 176.126 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 45.82 91.36 0.01 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 114.632 -1.167 . . . . 0.0 114.577 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.429 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -103.15 176.41 5.16 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 100.204 -3.998 . . . . 0.0 100.204 172.2 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.459 HG22 ' SD ' ' L' ' 35' ' ' MET . 0.1 OUTLIER -149.76 122.38 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 C-N-CA 115.986 -2.285 . . . . 0.0 112.566 -175.053 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -104.81 111.38 34.1 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.441 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.304 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.01 89.98 0.56 Allowed Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 107.102 -2.399 . . . . 0.0 107.102 175.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.659 HD21 HG13 ' F' ' 36' ' ' VAL . 9.2 tt -126.86 127.84 45.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 39.5 ttp -106.04 129.47 54.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.59 -178.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.659 HG13 HD21 ' F' ' 34' ' ' LEU . 0.0 OUTLIER -132.55 78.48 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.08 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.05 104.35 1.32 Allowed Glycine 0 C--N 1.344 1.019 0 N-CA-C 111.269 -0.732 . . . . 0.0 111.269 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.64 -164.84 33.99 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 63.1 t -120.54 135.65 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.887 0.375 . . . . 0.0 110.178 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 37.9 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.574 179.952 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.83 138.84 49.73 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.719 0.295 . . . . 0.0 110.564 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 11' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' G' ' 11' ' ' GLU . 57.8 mp0 -76.92 134.1 39.04 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.493 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 21.9 m -137.7 165.82 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.857 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 64.6 m80 -154.99 135.14 13.09 Favored 'General case' 0 C--O 1.222 -0.371 0 C-N-CA 120.241 -0.584 . . . . 0.0 111.169 179.133 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -156.74 165.7 35.48 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 96.3 mm-40 -150.59 177.47 10.0 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.865 179.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -158.61 129.68 6.32 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.056 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -133.86 128.93 35.66 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 121.097 0.475 . . . . 0.0 110.421 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.17 130.76 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.38 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.435 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 2.6 t80 -116.65 114.31 23.89 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.532 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 54.5 p90 -124.19 121.14 34.3 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.68 125.3 50.44 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.112 0.482 . . . . 0.0 111.222 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -161.44 166.51 27.14 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' ND2' ' H' ' 27' ' ' ASN . 63.3 t0 -79.0 114.84 18.28 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.075 -0.65 . . . . 0.0 111.077 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.0 p -88.57 130.83 37.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.82 82.43 0.0 OUTLIER Glycine 0 CA--C 1.531 1.058 0 CA-C-N 116.055 -0.52 . . . . 0.0 112.803 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.535 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.3 m -132.23 162.47 30.88 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 178.23 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.531 ' O ' ' O ' ' G' ' 26' ' ' SER . 80.6 m-20 -38.74 175.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.241 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -73.62 111.15 8.49 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.38 93.97 0.19 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.31 162.06 13.2 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.045 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -146.72 104.02 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -174.631 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.508 ' O ' ' SD ' ' B' ' 35' ' ' MET . 85.5 mt -126.89 127.93 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.242 0.544 . . . . 0.0 111.126 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.57 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -133.15 113.22 1.2 Allowed Glycine 0 CA--C 1.517 0.158 0 N-CA-C 108.934 -1.666 . . . . 0.0 108.934 178.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -136.69 147.87 47.05 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 122.221 1.01 . . . . 0.0 112.726 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 49.4 ttp -131.24 132.04 44.35 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.734 -1.575 . . . . 0.0 109.591 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.1 t -99.86 72.01 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.22 -96.45 0.01 OUTLIER Glycine 0 N--CA 1.438 -1.17 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.26 -172.11 33.47 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.43 ' O ' ' OXT' ' G' ' 40' ' ' VAL . 2.7 p -139.2 142.92 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.47 ' O ' HG12 ' G' ' 40' ' ' VAL . 53.7 t . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.014 -0.993 . . . . 0.0 110.069 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.49 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -115.21 140.62 48.94 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.671 0.272 . . . . 0.0 110.476 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -81.23 142.33 33.27 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.452 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.421 ' O ' HG23 ' H' ' 12' ' ' VAL . 6.2 m -121.76 131.82 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.415 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -118.93 140.62 49.69 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.733 0.301 . . . . 0.0 111.599 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.47 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 45.1 m-70 -142.31 160.61 39.92 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.345 0.593 . . . . 0.0 109.812 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.47 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 98.5 mm-40 -149.1 172.45 14.78 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.128 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -159.48 117.37 2.74 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.062 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -119.26 119.91 35.45 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -125.5 126.73 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.837 0.351 . . . . 0.0 110.534 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.647 ' CE1' HD11 ' K' ' 34' ' ' LEU . 1.4 t80 -123.06 118.77 28.5 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 72.1 t80 -131.23 127.91 38.83 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.756 0.312 . . . . 0.0 111.288 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.7 123.96 30.47 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-O 120.886 0.374 . . . . 0.0 111.557 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -165.64 140.87 4.95 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 45.4 p30 -100.13 140.53 34.23 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.453 0.644 . . . . 0.0 112.509 -178.435 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.408 ' O ' ' C ' ' H' ' 25' ' ' GLY . 92.5 t -108.4 111.12 34.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' H' ' 24' ' ' VAL . . . 33.63 90.97 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 -177.532 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -46.45 152.74 0.42 Allowed 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.169 -1.015 . . . . 0.0 113.538 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.537 ' O ' ' O ' ' H' ' 28' ' ' LYS . 16.8 p30 -128.19 -179.97 5.29 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 114.189 -1.369 . . . . 0.0 107.823 174.54 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.537 ' O ' ' O ' ' H' ' 27' ' ' ASN . 84.4 tttt -27.51 -102.71 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.727 0.694 . . . . 0.0 111.885 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.413 ' CA ' ' O ' ' I' ' 29' ' ' GLY . . . -149.96 100.36 0.21 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 175.271 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.415 ' H ' ' CE ' ' I' ' 28' ' ' LYS . . . -65.56 155.45 35.7 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 117.064 -1.854 . . . . 0.0 108.336 177.063 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.814 HG21 ' O ' ' B' ' 37' ' ' GLY . 2.2 mt -144.45 108.17 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -128.35 129.71 69.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.419 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.63 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.68 119.5 3.68 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 108.314 -1.915 . . . . 0.0 108.314 177.645 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.752 ' HB2' HD12 ' I' ' 34' ' ' LEU . 95.1 mt -135.31 129.45 33.51 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -177.083 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.491 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 24.0 ttp -129.55 131.87 46.69 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.338 178.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.631 ' CG1' HG12 ' I' ' 36' ' ' VAL . 2.4 p -149.47 75.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 119.999 -0.68 . . . . 0.0 112.325 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.74 -95.56 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 178.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -165.08 37.72 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.77 141.78 41.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.893 0.377 . . . . 0.0 110.353 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 27.9 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.645 -179.996 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -113.96 139.5 49.18 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -86.47 163.81 17.33 Favored 'General case' 0 N--CA 1.463 0.177 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -99.3 132.79 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.574 ' CE1' ' HD1' ' J' ' 13' ' ' HIS . 32.9 p80 -156.24 156.19 33.67 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.767 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' I' ' 15' ' ' GLN . 16.2 m-70 -133.37 161.19 35.2 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.696 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' I' ' 14' ' ' HIS . 43.6 mm-40 -142.59 171.71 13.68 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.521 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -159.51 120.49 3.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.103 178.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 tt -125.3 124.38 41.5 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 120.803 0.335 . . . . 0.0 110.48 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.59 125.32 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.408 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.541 ' CZ ' HD13 ' K' ' 34' ' ' LEU . 12.2 t80 -118.97 113.24 20.68 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.552 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 47.6 t80 -126.45 116.82 21.73 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 121.076 0.465 . . . . 0.0 111.058 -178.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.71 126.71 47.02 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.244 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -146.65 103.86 3.69 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.077 0.465 . . . . 0.0 110.818 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.434 ' O ' HG12 ' J' ' 24' ' ' VAL . 99.4 m-20 -95.31 122.82 38.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.496 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.48 HG23 ' H ' ' I' ' 25' ' ' GLY . 3.6 m -143.5 -111.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.854 -178.699 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.48 ' H ' HG23 ' I' ' 24' ' ' VAL . . . 27.39 -90.2 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.433 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.826 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.1 p 171.54 171.0 0.09 Allowed 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.826 ' O ' ' O ' ' I' ' 26' ' ' SER . 44.5 p-10 -9.51 179.27 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 O-C-N 125.869 1.981 . . . . 0.0 115.745 178.09 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.564 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 85.8 tttt 129.64 104.69 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 114.052 1.13 . . . . 0.0 114.052 175.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.413 ' O ' ' CA ' ' H' ' 29' ' ' GLY . . . -58.46 96.81 0.07 OUTLIER Glycine 0 C--O 1.225 -0.422 0 N-CA-C 106.711 -2.556 . . . . 0.0 106.711 171.133 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.891 ' C ' HD13 ' I' ' 31' ' ' ILE . . . -120.88 146.04 47.01 Favored 'General case' 0 CA--C 1.48 -1.729 0 N-CA-C 105.112 -2.181 . . . . 0.0 105.112 178.144 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.891 HD13 ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -137.84 108.04 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 C-N-CA 119.343 -0.943 . . . . 0.0 111.088 -173.854 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -111.65 112.5 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 175.779 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.666 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.05 108.74 1.69 Allowed Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 177.029 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.752 HD12 ' HB2' ' H' ' 34' ' ' LEU . 0.9 OUTLIER -142.39 144.0 32.94 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-O 122.673 1.225 . . . . 0.0 113.352 -177.082 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.445 ' N ' ' HG ' ' I' ' 34' ' ' LEU . 12.7 tmm? -127.42 117.95 23.14 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 113.196 -1.82 . . . . 0.0 109.626 177.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.747 HG13 HD21 ' I' ' 34' ' ' LEU . 15.7 m -121.91 73.94 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.822 179.235 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.36 103.48 2.99 Favored Glycine 0 C--N 1.36 1.883 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 175.88 43.96 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -144.94 151.45 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 120.891 0.376 . . . . 0.0 110.774 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.412 ' O ' HG13 ' I' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.567 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.447 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -111.1 132.55 54.18 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.781 0.324 . . . . 0.0 110.266 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' K' ' 11' ' ' GLU . 17.1 pt-20 -158.56 138.26 11.93 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.053 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -150.23 153.4 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.574 ' HD1' ' CE1' ' I' ' 13' ' ' HIS . 50.5 m-70 -144.21 116.05 8.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 118.966 0.803 . . . . 0.0 110.966 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.64 ' NE2' ' CG ' ' K' ' 13' ' ' HIS . 44.3 m80 -122.0 159.88 26.06 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.386 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.408 HE21 ' HG3' ' I' ' 15' ' ' GLN . 63.2 mt-30 -158.12 177.06 11.72 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.412 178.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 43.5 tttp -169.43 123.32 0.79 Allowed 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.427 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 8.8 tt -121.21 121.87 38.73 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.634 0.254 . . . . 0.0 110.328 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 79.2 t -124.28 127.48 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.493 ' CZ ' ' CD1' ' I' ' 19' ' ' PHE . 5.4 t80 -126.53 121.35 32.04 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.907 0.384 . . . . 0.0 110.72 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.552 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 50.7 t80 -128.93 127.18 41.24 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.003 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.34 137.53 30.61 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -142.58 106.0 4.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.131 -0.941 . . . . 0.0 109.272 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.448 ' OD1' HD11 ' L' ' 32' ' ' ILE . 10.3 m-20 -96.59 108.91 21.59 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.049 -179.075 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.434 HG12 ' O ' ' I' ' 23' ' ' ASP . 2.1 p -46.1 140.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.256 178.633 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.626 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -86.12 84.85 1.56 Allowed Glycine 0 CA--C 1.531 1.091 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.423 -178.631 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.59 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.3 t 162.36 160.41 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 CA-C-O 121.212 0.53 . . . . 0.0 110.12 176.203 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.59 ' O ' ' O ' ' J' ' 26' ' ' SER . 7.2 t-20 -29.99 178.99 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.517 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 42.6 tttp 128.45 104.85 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 113.052 -1.886 . . . . 0.0 112.899 175.189 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.84 95.43 0.05 OUTLIER Glycine 0 N--CA 1.462 0.429 0 CA-C-N 113.057 -1.883 . . . . 0.0 112.782 173.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.739 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -140.21 141.06 35.97 Favored 'General case' 0 CA--C 1.49 -1.364 0 CA-C-N 120.751 2.275 . . . . 0.0 107.353 174.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.739 HD13 ' C ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -137.73 106.94 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.894 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.468 HG22 ' O ' ' J' ' 32' ' ' ILE . 0.1 OUTLIER -109.75 110.84 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.018 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.591 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -123.78 98.82 0.6 Allowed Glycine 0 N--CA 1.463 0.436 0 N-CA-C 107.312 -2.315 . . . . 0.0 107.312 178.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.667 HD23 HD22 ' I' ' 34' ' ' LEU . 5.5 mp -131.07 140.75 50.09 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-O 122.134 0.969 . . . . 0.0 111.786 -177.706 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.416 ' SD ' HG22 ' D' ' 31' ' ' ILE . 11.5 tmm? -124.18 121.44 35.11 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.513 179.172 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' J' ' 37' ' ' GLY . 0.1 OUTLIER -110.43 73.74 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.178 -178.75 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -24.9 -101.18 0.01 OUTLIER Glycine 0 C--N 1.355 1.62 0 CA-C-N 116.198 -0.456 . . . . 0.0 112.851 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 131.24 -174.54 19.94 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -133.7 160.44 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 110.357 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.548 -179.934 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.74 133.35 51.55 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 110.267 -0.271 . . . . 0.0 110.267 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' J' ' 11' ' ' GLU . 81.4 tt0 -156.18 141.18 17.27 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-O 120.944 0.402 . . . . 0.0 110.711 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.34 154.57 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.64 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 22.3 m-70 -125.64 144.56 50.54 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 118.608 0.64 . . . . 0.0 110.725 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.522 ' CG ' ' H ' ' K' ' 15' ' ' GLN . 30.9 t-80 -86.71 -178.25 6.31 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.499 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.522 ' H ' ' CG ' ' K' ' 14' ' ' HIS . 86.5 mt-30 -84.85 172.69 11.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.148 -178.522 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -146.25 133.01 19.99 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 114.825 -1.08 . . . . 0.0 108.575 179.023 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -131.42 131.57 43.7 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.225 0.536 . . . . 0.0 112.274 -178.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.6 t -126.77 127.7 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.836 178.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -128.86 128.2 43.39 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.561 0.22 . . . . 0.0 110.795 -178.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.435 ' CE2' ' CD2' ' L' ' 20' ' ' PHE . 8.8 t80 -135.76 123.43 22.33 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-O 120.906 0.384 . . . . 0.0 110.517 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.51 129.33 44.39 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.113 0.483 . . . . 0.0 111.312 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.094 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.492 ' H ' ' HB3' ' L' ' 22' ' ' GLU . 26.3 t70 -91.85 134.25 34.93 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.429 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.626 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 44.0 t -109.19 112.46 40.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.27 -91.29 0.01 OUTLIER Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.21 -0.905 . . . . 0.0 112.783 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.504 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.8 m -162.86 -161.11 0.68 Allowed 'General case' 0 N--CA 1.447 -0.615 0 CA-C-O 122.579 1.181 . . . . 0.0 112.867 -179.406 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.572 ' CG ' ' H ' ' K' ' 28' ' ' LYS . 4.4 t-20 30.08 -173.28 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 111.874 -2.421 . . . . 0.0 115.401 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.572 ' H ' ' CG ' ' K' ' 27' ' ' ASN . 82.3 tttt 103.56 110.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 127.136 2.174 . . . . 0.0 109.184 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -60.16 -95.16 0.01 OUTLIER Glycine 0 CA--C 1.535 1.3 0 C-N-CA 115.212 -3.375 . . . . 0.0 110.535 175.519 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.521 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 69.63 151.21 0.09 Allowed 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 174.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.521 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -149.25 117.88 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-N 120.974 1.716 . . . . 0.0 111.508 178.075 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.413 ' N ' ' HE1' ' F' ' 35' ' ' MET . 4.6 mt -105.38 111.85 36.44 Favored 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 175.691 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.585 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.84 96.77 0.75 Allowed Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 106.315 -2.714 . . . . 0.0 106.315 177.242 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.647 HD11 ' CE1' ' H' ' 19' ' ' PHE . 0.3 OUTLIER -120.93 120.37 35.29 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-O 122.304 1.05 . . . . 0.0 110.201 -177.971 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -109.53 114.08 27.42 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.412 -1.722 . . . . 0.0 107.965 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.18 78.38 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.829 -177.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.48 105.43 0.97 Allowed Glycine 0 C--N 1.352 1.472 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.71 -144.01 4.35 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -106.79 134.7 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 20.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.021 -0.99 . . . . 0.0 111.073 -179.579 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.542 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -84.52 139.9 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.723 0.297 . . . . 0.0 110.855 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -121.52 131.03 53.91 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.971 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.98 156.79 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.179 0.514 . . . . 0.0 111.252 -179.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -158.19 163.21 37.74 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.787 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 41.9 m80 -136.74 169.8 17.13 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -148.08 176.29 10.32 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.174 0.512 . . . . 0.0 111.304 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 ttpt -170.59 111.46 0.39 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.983 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 72.0 mt -121.22 111.37 17.3 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.478 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 70.4 t -126.64 129.95 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.7 p90 -136.94 125.28 23.3 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.299 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.435 ' CD2' ' CE2' ' K' ' 20' ' ' PHE . 79.4 t80 -136.8 131.57 33.5 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 121.123 0.487 . . . . 0.0 110.297 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.74 143.75 35.15 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.393 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.492 ' HB3' ' H ' ' K' ' 23' ' ' ASP . 51.8 tp10 -78.21 140.96 38.92 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -58.86 130.46 47.05 Favored 'General case' 0 CA--C 1.518 -0.275 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.451 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.602 ' O ' HG13 ' L' ' 24' ' ' VAL . 14.7 p -116.12 114.84 47.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.279 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.443 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -28.28 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.47 0.927 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -88.45 -177.4 5.61 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 60.3 m-20 -60.29 179.62 0.14 Allowed 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.477 -176.491 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.551 ' HZ3' HG13 ' L' ' 32' ' ' ILE 0.251 69.1 tttt -57.45 111.36 1.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 -177.015 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -68.62 -97.71 0.04 OUTLIER Glycine 0 CA--C 1.499 -0.932 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.586 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -60.9 170.78 1.4 Allowed 'General case' 0 CA--C 1.511 -0.552 0 CA-C-N 120.844 2.322 . . . . 0.0 105.805 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.649 HD12 ' N ' ' L' ' 31' ' ' ILE . 0.1 OUTLIER -134.17 121.79 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 115.811 -2.356 . . . . 0.0 114.086 -174.327 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.551 HG13 ' HZ3' ' L' ' 28' ' ' LYS . 97.3 mt -106.41 116.07 49.36 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 176.261 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -106.29 96.73 1.17 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 105.71 -2.956 . . . . 0.0 105.71 176.708 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.456 HD23 HG22 ' L' ' 32' ' ' ILE . 1.2 pp -110.23 112.09 23.84 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.751 -0.725 . . . . 0.0 110.298 -177.493 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.459 ' SD ' HG22 ' F' ' 31' ' ' ILE . 8.6 tmm? -109.69 110.85 22.01 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 178.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' C ' ' L' ' 37' ' ' GLY . 3.3 m -126.93 77.42 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.681 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 22.29 -110.69 0.01 OUTLIER Glycine 0 C--N 1.356 1.654 0 O-C-N 123.106 0.254 . . . . 0.0 113.017 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.79 140.85 8.9 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -134.89 159.24 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.886 0.375 . . . . 0.0 110.46 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.128 -0.939 . . . . 0.0 110.764 -179.885 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -113.72 138.38 50.31 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.995 0.426 . . . . 0.0 110.914 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 52.4 tp10 -113.45 133.8 55.0 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 m -133.15 135.03 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 111.846 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 5.4 p80 -97.15 -175.58 3.28 Favored 'General case' 0 CA--C 1.527 0.086 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.838 178.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.5 p-80 -89.85 164.98 14.39 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.44 0.638 . . . . 0.0 110.619 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 83.0 mt-30 -155.99 -178.2 7.13 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.684 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.611 ' C ' HD22 ' A' ' 17' ' ' LEU . 99.6 mttt -135.29 111.69 9.82 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.372 -0.232 . . . . 0.0 110.372 179.269 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.611 HD22 ' C ' ' A' ' 16' ' ' LYS . 4.3 mm? -117.81 127.8 54.24 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 120.792 0.33 . . . . 0.0 110.515 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 18' ' ' VAL . 5.8 m -133.04 128.39 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-O 121.149 0.5 . . . . 0.0 111.125 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.519 ' CZ ' HD23 ' C' ' 34' ' ' LEU . 75.0 t80 -122.69 116.13 23.27 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -147.08 153.84 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.343 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.0 133.81 43.62 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.209 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -167.49 92.21 0.38 Allowed 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 62.5 t0 -70.11 121.82 18.24 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -177.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.565 ' O ' HG23 ' A' ' 24' ' ' VAL . 26.1 m -105.98 121.72 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.637 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . 30.8 82.8 0.01 OUTLIER Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.847 -0.418 . . . . 0.0 112.255 178.398 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 19.9 p -95.8 175.65 6.43 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 118.059 0.93 . . . . 0.0 109.182 178.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' LYS . 20.1 p30 -61.93 -177.67 0.13 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 176.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.548 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.6 mttm -50.41 -110.85 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.846 0.832 . . . . 0.0 109.842 178.615 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.66 94.66 1.82 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 176.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.479 ' CB ' HD21 ' A' ' 27' ' ' ASN . . . -92.54 160.65 14.94 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 115.599 -2.441 . . . . 0.0 109.703 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.537 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.3 OUTLIER -154.31 119.68 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 114.0 -1.455 . . . . 0.0 109.878 -173.729 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.51 ' O ' ' SD ' ' G' ' 35' ' ' MET . 96.5 mt -119.44 112.45 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.103 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.21 106.64 1.45 Allowed Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 178.335 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.407 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 34.7 tp -149.11 147.19 28.19 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 118.124 0.962 . . . . 0.0 113.028 -178.417 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.511 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 53.5 ttp -141.43 146.35 36.42 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.2 t -128.89 79.61 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.949 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.51 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -96.99 97.85 2.06 Favored Glycine 0 C--N 1.338 0.681 0 N-CA-C 109.599 -1.401 . . . . 0.0 109.599 177.483 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.13 167.81 39.68 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.541 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.37 137.42 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.405 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.742 -179.821 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -116.15 138.92 50.85 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.736 0.303 . . . . 0.0 110.434 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -56.37 136.14 53.71 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.899 0.38 . . . . 0.0 110.543 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -137.22 153.13 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.446 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -117.09 160.1 21.53 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.1 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 16.3 p-80 -77.34 171.94 14.08 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.432 ' H ' ' HA ' ' C' ' 15' ' ' GLN . 54.0 tt0 -149.48 176.0 11.0 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.578 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.558 ' NZ ' ' CG2' ' B' ' 18' ' ' VAL . 62.4 tttm -140.3 123.3 16.59 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.233 0.54 . . . . 0.0 111.407 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.1 mt -118.37 124.08 46.86 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.093 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.558 ' CG2' ' NZ ' ' B' ' 16' ' ' LYS . 93.7 t -119.56 121.45 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 C-N-CA 120.711 -0.395 . . . . 0.0 110.998 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 11.8 t80 -115.2 112.22 22.16 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -132.59 125.76 31.21 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.18 0.514 . . . . 0.0 112.238 -177.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.66 126.28 49.85 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -153.96 159.75 41.81 Favored 'General case' 0 C--N 1.348 0.512 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.061 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -121.46 123.06 41.15 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.535 0.607 . . . . 0.0 111.885 -178.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.17 120.88 55.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.18 84.11 0.01 OUTLIER Glycine 0 N--CA 1.471 0.986 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.445 179.328 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 4.3 p -45.88 167.61 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.499 ' O ' ' O ' ' B' ' 28' ' ' LYS . 1.3 p-10 -137.82 178.87 6.78 Favored 'General case' 0 C--O 1.203 -1.383 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 171.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.499 ' O ' ' O ' ' B' ' 27' ' ' ASN . 61.2 mttp -19.85 -103.13 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 CA-C-N 120.219 1.372 . . . . 0.0 113.338 176.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -142.62 99.94 0.24 Allowed Glycine 0 N--CA 1.485 1.962 0 N-CA-C 107.831 -2.108 . . . . 0.0 107.831 174.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.511 ' H ' ' CE ' ' C' ' 28' ' ' LYS . . . -70.6 156.55 39.3 Favored 'General case' 0 C--O 1.245 0.836 0 C-N-CA 117.064 -1.854 . . . . 0.0 109.399 177.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.537 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.2 OUTLIER -144.25 115.49 2.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.814 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.481 ' O ' ' SD ' ' H' ' 35' ' ' MET . 82.9 mt -121.13 119.62 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -177.118 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.51 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -125.37 117.15 2.87 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 177.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.72 ' O ' HD12 ' C' ' 34' ' ' LEU . 9.6 tt -148.8 154.67 39.87 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.532 -178.487 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 17.6 ttp -147.83 141.57 25.66 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 120.16 -0.616 . . . . 0.0 112.458 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' B' ' 37' ' ' GLY . 38.2 t -131.78 83.28 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.307 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.682 ' HA2' HG21 ' H' ' 31' ' ' ILE . . . -23.45 -93.71 0.01 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.818 -0.513 . . . . 0.0 111.818 177.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.88 179.16 40.33 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.404 HG22 ' N ' ' B' ' 40' ' ' VAL . 8.3 p -143.95 153.09 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.937 0.398 . . . . 0.0 110.821 -179.266 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.404 ' N ' HG22 ' B' ' 39' ' ' VAL . 7.2 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.46 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -111.51 146.95 36.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 110.378 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -55.84 146.19 22.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.16 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.513 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 32.9 m -129.28 156.31 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.513 ' CD2' ' O ' ' C' ' 12' ' ' VAL . 48.2 m80 -158.01 151.71 23.75 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.405 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -87.39 -179.67 6.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.432 ' HA ' ' H ' ' B' ' 15' ' ' GLN . 13.1 pt20 -88.2 174.91 7.94 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.958 -179.374 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -123.85 138.77 54.44 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -141.62 131.65 24.62 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 120.422 -0.511 . . . . 0.0 111.764 -179.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -126.55 130.42 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.307 0.575 . . . . 0.0 109.706 178.362 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.523 ' CE2' HD12 ' F' ' 34' ' ' LEU . 21.2 t80 -117.34 118.52 32.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.135 -178.579 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -130.35 114.9 16.18 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 118.147 0.43 . . . . 0.0 110.017 179.2 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.03 126.74 51.54 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.645 -0.422 . . . . 0.0 111.549 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -157.73 155.7 30.36 Favored 'General case' 0 C--O 1.226 -0.158 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.524 ' O ' ' NZ ' ' E' ' 28' ' ' LYS . 7.2 t0 -175.21 108.58 0.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 119.794 -0.762 . . . . 0.0 112.251 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 m -46.46 141.05 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 176.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -86.34 82.82 1.63 Allowed Glycine 0 N--CA 1.463 0.468 0 C-N-CA 118.471 -1.823 . . . . 0.0 110.159 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 50.7 p -100.48 -163.97 1.07 Allowed 'General case' 0 N--CA 1.439 -0.991 0 CA-C-O 122.432 1.11 . . . . 0.0 110.077 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.433 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 61.8 t30 -63.31 179.5 0.42 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.266 -1.788 . . . . 0.0 109.344 175.282 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.511 ' CE ' ' H ' ' B' ' 30' ' ' ALA . 41.5 tttt 55.35 111.08 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 118.424 2.75 . . . . 0.0 118.424 178.075 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -81.63 96.43 1.77 Allowed Glycine 0 CA--C 1.497 -1.088 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 171.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 163.67 22.1 Favored 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 116.22 -2.192 . . . . 0.0 108.278 -177.092 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.622 HG23 ' CG1' ' D' ' 31' ' ' ILE . 0.0 OUTLIER -139.86 108.06 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.013 -174.85 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.484 ' C ' ' SD ' ' I' ' 35' ' ' MET . 2.0 mt -106.78 117.9 53.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.406 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -122.96 94.25 0.51 Allowed Glycine 0 CA--C 1.523 0.577 0 N-CA-C 107.912 -2.075 . . . . 0.0 107.912 177.522 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.72 HD12 ' O ' ' B' ' 34' ' ' LEU . 22.7 tp -124.77 137.03 54.34 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.345 1.069 . . . . 0.0 112.048 -178.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' D' ' 35' ' ' MET . 11.3 mmm -110.97 116.38 31.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.835 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.498 HG13 HD11 ' C' ' 34' ' ' LEU . 2.6 m -142.88 63.45 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 C-N-CA 121.11 -0.236 . . . . 0.0 110.507 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.09 -110.31 0.79 Allowed Glycine 0 C--N 1.363 2.053 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.56 -175.2 34.03 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.92 158.69 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.602 -179.728 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -111.39 130.12 55.8 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.771 0.32 . . . . 0.0 110.307 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.455 ' OE2' HG22 ' C' ' 12' ' ' VAL . 34.6 tp10 -136.98 135.91 38.05 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.398 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -141.76 148.22 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 121.04 0.448 . . . . 0.0 111.54 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.448 ' NE2' ' OE2' ' E' ' 11' ' ' GLU . 86.8 m-70 -123.66 125.19 44.36 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.801 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.58 ' CG ' ' N ' ' D' ' 15' ' ' GLN . 82.5 t60 -136.94 166.84 22.71 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.163 0.506 . . . . 0.0 110.144 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.58 ' N ' ' CG ' ' D' ' 14' ' ' HIS . 51.9 tt0 -161.61 173.23 15.04 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.438 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.408 ' N ' ' HG2' ' D' ' 15' ' ' GLN . 65.1 tttp -160.92 110.12 1.65 Allowed 'General case' 0 C--O 1.235 0.307 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.95 179.136 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -122.0 115.82 23.21 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.911 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.4 t -114.35 115.61 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.572 ' CE1' HD13 ' F' ' 34' ' ' LEU . 0.8 OUTLIER -114.27 109.05 17.77 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -178.164 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -136.47 130.89 33.28 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.444 0.64 . . . . 0.0 111.621 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.427 ' CB ' ' CD1' ' F' ' 32' ' ' ILE . . . -144.83 145.09 31.47 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.352 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -132.67 102.96 5.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.751 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -79.26 112.54 16.59 Favored 'General case' 0 C--O 1.231 0.119 0 C-N-CA 118.099 -1.44 . . . . 0.0 107.631 179.228 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 89.6 t -60.92 130.38 24.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.694 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -68.74 86.35 0.21 Allowed Glycine 0 CA--C 1.538 1.489 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.618 177.517 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.4 OUTLIER 162.18 161.3 0.02 OUTLIER 'General case' 0 C--N 1.345 0.393 0 CA-C-N 119.267 1.533 . . . . 0.0 112.786 176.801 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.462 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 87.1 m-20 -34.07 -179.65 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 112.056 -2.338 . . . . 0.0 116.25 179.119 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' E' ' 29' ' ' GLY . 86.7 tttt 98.92 114.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 128.095 2.558 . . . . 0.0 113.576 176.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.447 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -73.39 92.1 0.66 Allowed Glycine 0 N--CA 1.473 1.132 0 CA-C-O 116.284 -2.398 . . . . 0.0 113.159 173.478 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.87 157.09 35.01 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 123.271 3.536 . . . . 0.0 109.197 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.622 ' CG1' HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -145.01 126.1 8.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.892 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.725 -177.216 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.518 ' C ' ' SD ' ' J' ' 35' ' ' MET . 2.1 mt -110.49 110.48 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.408 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -109.21 95.57 0.91 Allowed Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 178.35 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.49 HD13 ' O ' ' C' ' 34' ' ' LEU . 0.0 OUTLIER -122.07 120.97 35.87 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-O 121.578 0.704 . . . . 0.0 110.461 -178.395 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' C' ' 35' ' ' MET . 26.9 ttt -102.02 114.04 27.8 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 176.725 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.475 HG22 HD12 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -126.51 80.64 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.247 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.437 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.22 102.46 0.86 Allowed Glycine 0 C--N 1.353 1.475 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.88 -167.06 38.9 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 40' ' ' VAL . 53.9 t -123.07 136.89 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 39' ' ' VAL . 18.0 m . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.47 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -111.61 133.13 54.07 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.855 0.359 . . . . 0.0 110.95 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.496 ' O ' ' O ' ' F' ' 11' ' ' GLU . 39.1 tp10 -120.51 127.39 52.14 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.8 t -134.13 134.36 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 O-C-N 123.322 0.389 . . . . 0.0 110.466 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 83.6 m-70 -119.47 133.64 55.59 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 120.884 0.373 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.474 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 85.2 t60 -143.3 165.41 27.55 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 178.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.474 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 81.8 mt-30 -154.94 179.16 9.39 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.359 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.35 108.13 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.692 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -126.99 121.93 33.06 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.025 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 77.4 t -125.88 127.53 71.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.746 0.307 . . . . 0.0 110.881 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -126.47 120.53 29.94 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.514 179.369 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -133.9 127.36 32.34 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.027 0.442 . . . . 0.0 110.263 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.29 128.42 41.51 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.341 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -110.56 167.69 10.02 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.345 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' E' ' 24' ' ' VAL . 14.3 t0 -173.11 -125.28 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.389 -177.144 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.519 ' N ' ' OD1' ' E' ' 23' ' ' ASP . 7.9 t 31.61 115.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -90.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 106.001 -2.84 . . . . 0.0 106.001 179.266 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.544 ' O ' ' O ' ' E' ' 27' ' ' ASN . 27.9 p -152.03 155.0 37.1 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 119.224 1.512 . . . . 0.0 109.067 172.687 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.544 ' O ' ' O ' ' E' ' 26' ' ' SER . 88.7 m-20 -20.01 157.83 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 176.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.663 ' HB3' ' HB2' ' F' ' 30' ' ' ALA . 75.4 tttt -162.88 110.89 1.28 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.09 170.41 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.595 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -68.53 92.12 0.27 Allowed Glycine 0 C--O 1.218 -0.852 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 174.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.41 150.56 33.73 Favored 'General case' 0 CA--C 1.464 -2.345 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 175.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.426 ' HA ' ' O ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -151.24 117.24 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 C-N-CA 118.679 -1.208 . . . . 0.0 110.042 -172.948 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.56 112.99 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.44 ' H ' ' HE1' ' J' ' 35' ' ' MET . . . -109.28 85.9 0.42 Allowed Glycine 0 CA--C 1.499 -0.963 0 N-CA-C 104.884 -3.286 . . . . 0.0 104.884 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.549 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 6.4 tt -130.31 134.05 46.91 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.787 0.803 . . . . 0.0 111.717 -177.496 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.7 ttm -122.91 125.34 45.15 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.484 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.58 ' CG2' HD21 ' F' ' 34' ' ' LEU . 0.0 OUTLIER -124.32 81.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.687 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.497 ' HA2' HD13 ' K' ' 31' ' ' ILE . . . 34.42 -101.66 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.681 -0.567 . . . . 0.0 111.681 178.231 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.94 -172.21 33.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.784 -0.927 . . . . 0.0 110.784 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.06 161.2 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.893 0.378 . . . . 0.0 110.595 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 8.8 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.362 179.788 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -82.23 139.25 34.35 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 11' ' ' GLU . . . . . 0.496 ' O ' ' O ' ' E' ' 11' ' ' GLU . 97.6 mt-10 -124.88 167.03 15.23 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-O 121.302 0.572 . . . . 0.0 110.79 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.401 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.3 p -147.3 156.72 10.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.719 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.645 ' CG ' ' N ' ' F' ' 14' ' ' HIS . 46.4 t-80 -111.62 175.18 5.53 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.645 ' N ' ' CG ' ' F' ' 13' ' ' HIS . 98.1 m-70 -70.2 177.05 3.47 Favored 'General case' 0 N--CA 1.44 -0.936 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' E' ' 15' ' ' GLN . 57.7 mm-40 -133.26 179.19 6.35 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.278 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -151.29 106.06 3.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.21 0.528 . . . . 0.0 110.695 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 tt -127.81 121.58 30.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.182 179.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.51 129.93 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.532 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -120.1 128.1 53.15 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.577 179.133 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -142.37 130.14 21.62 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.973 0.416 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.53 141.02 26.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.474 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 74.4 tt0 -92.51 115.46 28.11 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -73.87 134.32 43.25 Favored 'General case' 0 N--CA 1.462 0.126 0 CA-C-O 121.169 0.509 . . . . 0.0 111.317 -178.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.514 ' O ' ' N ' ' F' ' 26' ' ' SER . 62.4 t -89.4 112.75 24.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.223 179.391 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.538 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . -46.05 92.16 0.01 OUTLIER Glycine 0 CA--C 1.533 1.213 0 N-CA-C 110.209 -1.157 . . . . 0.0 110.209 177.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' F' ' 27' ' ' ASN . 68.0 m 121.04 172.43 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 -178.76 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' F' ' 26' ' ' SER . 1.2 p-10 -41.21 176.37 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 121.127 0.489 . . . . 0.0 111.476 -179.006 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 43.9 tttm -75.33 110.44 9.68 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.79 -99.33 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 177.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' E' ' 28' ' ' LYS . . . -80.37 170.95 15.69 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 103.356 -2.831 . . . . 0.0 103.356 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' E' ' 31' ' ' ILE . 0.0 OUTLIER -138.94 117.13 12.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 118.043 -1.463 . . . . 0.0 111.398 -172.473 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.476 ' O ' HG23 ' F' ' 32' ' ' ILE . 12.9 tt -103.86 123.2 57.41 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.261 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.19 102.75 1.04 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.58 HD21 ' CG2' ' E' ' 36' ' ' VAL . 3.4 tt -122.95 113.36 18.99 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.351 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.473 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.3 ttt -95.39 121.88 37.53 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.606 -178.735 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.561 HG13 ' CD2' ' F' ' 34' ' ' LEU . 0.5 OUTLIER -138.3 80.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.614 -178.749 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 40.57 -103.25 0.03 OUTLIER Glycine 0 C--N 1.346 1.11 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.214 177.154 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -147.84 7.77 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 40' ' ' VAL . 55.9 t -121.41 136.39 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.874 0.368 . . . . 0.0 110.766 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 39' ' ' VAL . 2.3 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.592 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -108.15 137.93 45.29 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.482 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -125.33 145.67 49.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.077 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 7.4 m -119.78 134.79 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.134 0.492 . . . . 0.0 110.851 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -142.63 140.26 31.56 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.01 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -88.74 169.13 11.9 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.332 0.587 . . . . 0.0 110.532 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -151.4 177.67 10.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.486 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -137.58 129.11 28.27 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.665 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.5 tp -123.8 125.84 45.41 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -131.39 127.71 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.601 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 9.5 m-85 -113.58 117.5 31.81 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 176.595 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.518 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 39.9 p90 -130.37 118.02 20.61 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 121.034 -0.266 . . . . 0.0 111.558 -179.138 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.484 ' O ' ' OE1' ' H' ' 22' ' ' GLU . . . -117.96 117.4 29.13 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.432 ' HG2' ' H ' ' G' ' 23' ' ' ASP . 68.4 tt0 -144.75 175.0 10.5 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 123.729 0.643 . . . . 0.0 109.815 -179.536 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.432 ' H ' ' HG2' ' G' ' 22' ' ' GLU . 15.8 t0 -64.85 113.55 3.9 Favored 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 112.025 0.379 . . . . 0.0 112.025 -178.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.442 ' H ' ' HA2' ' H' ' 25' ' ' GLY . 60.1 t -127.22 121.54 57.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.506 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' G' ' 24' ' ' VAL . . . -29.22 -85.87 0.01 OUTLIER Glycine 0 CA--C 1.535 1.317 0 CA-C-O 121.607 0.559 . . . . 0.0 113.481 179.044 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.6 t 65.7 176.2 0.22 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 -178.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -88.06 177.31 6.96 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.98 176.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -56.73 110.41 0.79 Allowed 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 118.612 -0.709 . . . . 0.0 111.895 175.209 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.507 ' H ' ' CB ' ' H' ' 27' ' ' ASN . . . 72.12 94.51 0.08 OUTLIER Glycine 0 N--CA 1.469 0.897 0 C-N-CA 118.165 -1.969 . . . . 0.0 112.391 174.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.87 156.13 19.02 Favored 'General case' 0 CA--C 1.507 -0.679 0 CA-C-N 120.004 1.902 . . . . 0.0 107.885 178.066 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.51 HG21 ' HA3' ' A' ' 37' ' ' GLY . 0.4 OUTLIER -152.53 106.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.347 -0.842 . . . . 0.0 108.835 -173.187 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.447 ' C ' ' SD ' ' A' ' 35' ' ' MET . 50.3 mm -124.56 130.57 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.103 -178.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.511 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -135.57 125.5 3.65 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 179.247 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.4 tp -144.82 136.85 25.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.258 0.529 . . . . 0.0 111.857 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.51 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 11.4 ttt -133.66 144.71 49.36 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.401 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.4 t -102.51 72.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.463 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -109.46 100.71 1.38 Allowed Glycine 0 C--N 1.341 0.837 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 177.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.93 170.96 41.62 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.423 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.449 HG22 HG23 ' G' ' 40' ' ' VAL . 5.6 p -135.8 143.33 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.52 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.449 HG23 HG22 ' G' ' 39' ' ' VAL . 80.5 t . . . . . 0 C--O 1.218 -0.565 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.565 -179.372 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -82.46 145.46 29.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.732 0.301 . . . . 0.0 110.593 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.03 137.09 47.69 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-O 121.194 0.521 . . . . 0.0 110.751 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.1 t -121.75 134.03 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.546 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 t-80 -142.49 103.46 4.25 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.197 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.434 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 33.4 p-80 -152.23 168.7 24.5 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.484 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -150.58 171.96 16.27 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.151 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -134.45 118.39 17.32 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.245 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -118.57 121.33 39.96 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 62.3 t -124.43 126.28 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.976 0.417 . . . . 0.0 110.421 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.511 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 2.5 m-85 -119.16 108.91 15.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -117.17 115.62 25.68 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 177.372 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.607 ' HB2' HD12 ' J' ' 32' ' ' ILE . . . -129.1 130.09 46.04 Favored 'General case' 0 C--O 1.242 0.671 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -177.519 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.566 ' O ' ' O ' ' H' ' 23' ' ' ASP . 52.4 mp0 -142.29 141.9 32.48 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.825 -1.534 . . . . 0.0 107.194 176.79 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.566 ' O ' ' O ' ' H' ' 22' ' ' GLU . 7.6 t0 -54.79 -130.63 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' H' ' 23' ' ' ASP . 32.7 m 28.49 111.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 178.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.442 ' HA2' ' H ' ' G' ' 24' ' ' VAL . . . -160.86 -91.24 0.08 OUTLIER Glycine 0 CA--C 1.521 0.428 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 177.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.473 ' HB2' ' HB2' ' H' ' 30' ' ' ALA . 0.1 OUTLIER -101.81 -163.2 0.99 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 119.551 1.676 . . . . 0.0 109.487 176.603 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.507 ' CB ' ' H ' ' G' ' 29' ' ' GLY . 66.5 t30 -61.8 177.62 0.41 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.777 177.566 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.489 ' H ' ' CG ' ' H' ' 27' ' ' ASN . 60.1 tttm -47.51 111.06 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.291 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 92.43 -95.71 2.05 Favored Glycine 0 C--O 1.207 -1.591 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.217 -176.649 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.605 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . 70.44 145.37 0.06 Allowed 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 103.141 -2.911 . . . . 0.0 103.141 -176.411 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.682 HG21 ' HA2' ' B' ' 37' ' ' GLY . 5.2 tt -163.34 124.61 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 115.783 -2.367 . . . . 0.0 112.266 -177.206 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.9 mt -120.22 122.94 69.61 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 113.947 -1.478 . . . . 0.0 109.951 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.28 117.08 2.46 Favored Glycine 0 N--CA 1.47 0.9 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.73 141.97 51.74 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.277 0.561 . . . . 0.0 111.127 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.51 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 23.2 ttt -140.39 126.58 19.8 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.127 0.489 . . . . 0.0 111.303 -178.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 11.8 t -122.68 74.06 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.024 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.42 101.49 2.32 Favored Glycine 0 C--N 1.344 1.023 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.65 159.13 31.78 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 120.245 -0.979 . . . . 0.0 111.722 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -125.9 134.64 66.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.885 -1.055 . . . . 0.0 110.552 -179.903 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -113.4 135.94 53.32 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.958 0.408 . . . . 0.0 110.644 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 81.1 mm-40 -122.0 129.49 52.5 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.066 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m -143.5 140.22 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-O 120.884 0.373 . . . . 0.0 110.721 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 48.2 m-70 -144.07 104.43 4.13 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.855 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.434 ' O ' ' CB ' ' H' ' 14' ' ' HIS . 7.2 m-70 -130.82 169.03 16.27 Favored 'General case' 0 C--O 1.221 -0.442 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 81.2 mt-30 -155.31 172.14 18.69 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 178.342 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -145.09 125.1 13.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.717 0.294 . . . . 0.0 111.279 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 37.9 tp -125.82 117.46 23.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 120.806 0.336 . . . . 0.0 110.35 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -122.59 127.96 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.934 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.478 ' CD2' HD23 ' L' ' 34' ' ' LEU . 1.1 m-85 -121.91 117.25 26.0 Favored 'General case' 0 N--CA 1.47 0.575 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.357 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.411 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 42.0 t80 -126.24 123.76 38.88 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.32 132.07 42.59 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.813 0.339 . . . . 0.0 111.412 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -155.93 157.33 36.09 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.767 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.505 ' HB2' ' HZ1' ' K' ' 28' ' ' LYS . 7.1 t70 -111.6 101.83 10.2 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 121.415 0.626 . . . . 0.0 110.655 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.9 p -90.01 159.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.068 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 49.64 -80.28 0.01 OUTLIER Glycine 0 CA--C 1.531 1.073 0 CA-C-O 119.382 -0.677 . . . . 0.0 112.955 -179.126 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.621 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.4 p 170.84 -179.53 0.05 OUTLIER 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 118.445 1.122 . . . . 0.0 110.577 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.621 ' O ' ' O ' ' I' ' 26' ' ' SER . 42.0 p-10 -28.31 -179.82 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 -177.596 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.445 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 83.9 mttt 128.77 103.38 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 111.828 -2.442 . . . . 0.0 108.571 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -59.25 100.32 0.18 Allowed Glycine 0 CA--C 1.486 -1.756 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.665 177.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' H' ' 29' ' ' GLY . . . -112.47 144.67 41.54 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 103.869 -2.641 . . . . 0.0 103.869 177.717 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.555 HD12 HD12 ' H' ' 31' ' ' ILE . 1.1 mt -137.98 107.21 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 C-N-CA 118.251 -1.38 . . . . 0.0 110.472 -174.137 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -117.66 130.75 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 120.981 0.42 . . . . 0.0 110.115 179.094 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -134.18 134.01 7.17 Favored Glycine 0 CA--C 1.503 -0.673 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 177.78 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.496 ' H ' ' HG ' ' J' ' 34' ' ' LEU . 3.8 tt -145.89 131.21 18.56 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.799 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.484 ' SD ' ' C ' ' C' ' 32' ' ' ILE . 8.7 ttt -112.91 119.75 39.04 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.263 -1.335 . . . . 0.0 108.395 179.117 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.1 OUTLIER -118.53 72.38 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.645 -179.504 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -31.15 -100.25 0.01 OUTLIER Glycine 0 C--N 1.369 2.373 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -175.89 40.73 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.1 t -134.37 152.48 33.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.497 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' J' J ' 9' ' ' GLY . . . . . 0.436 ' O ' ' CE2' ' K' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.367 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -123.15 119.37 30.05 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -137.36 134.2 35.71 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.589 0.233 . . . . 0.0 110.388 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.449 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -126.01 132.81 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.953 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' K' ' 13' ' ' HIS . 66.4 m80 -119.64 140.65 50.29 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.418 -0.216 . . . . 0.0 110.418 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 59.5 t60 -151.83 167.78 27.2 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 121.204 0.526 . . . . 0.0 109.77 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.6 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 66.7 tp60 -158.32 164.31 36.51 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.613 178.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.415 ' N ' ' HG3' ' J' ' 15' ' ' GLN . 50.3 tttp -157.99 116.29 3.08 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.977 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.657 HD23 ' C ' ' J' ' 17' ' ' LEU . 7.2 tt -131.35 123.26 27.89 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 18' ' ' VAL . . . . . 0.545 ' N ' HD23 ' J' ' 17' ' ' LEU . 2.7 p -132.51 127.91 57.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.33 0.586 . . . . 0.0 111.636 179.327 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.6 ' CE1' HD21 ' J' ' 17' ' ' LEU . 6.1 m-30 -109.17 119.2 38.8 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 115.079 -0.964 . . . . 0.0 108.648 178.113 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD2' ' K' ' 20' ' ' PHE . 34.6 t80 -124.58 113.7 18.41 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 134.23 47.81 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.491 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -134.75 105.99 6.71 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.676 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -85.41 114.24 22.31 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' J' ' 25' ' ' GLY . 4.6 p -122.56 122.9 67.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 24' ' ' VAL . . . 34.61 84.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.141 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -177.634 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.461 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 6.0 m -46.2 152.05 0.45 Allowed 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 113.722 -1.239 . . . . 0.0 114.066 -177.508 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' J' ' 28' ' ' LYS . 65.9 m-80 -138.02 178.0 7.45 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.881 172.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.888 ' HZ3' ' H ' ' J' ' 29' ' ' GLY . 0.9 OUTLIER -20.43 -104.12 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.413 1.264 . . . . 0.0 114.413 177.668 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.888 ' H ' ' HZ3' ' J' ' 28' ' ' LYS . . . -167.45 96.88 0.13 Allowed Glycine 0 C--N 1.361 1.919 0 CA-C-O 117.472 -1.738 . . . . 0.0 110.745 176.179 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.562 ' HB2' ' OD1' ' H' ' 23' ' ' ASP . . . -68.2 167.44 14.25 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 123.128 3.464 . . . . 0.0 106.884 177.164 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.55 HD12 HG23 ' I' ' 31' ' ' ILE . 0.3 OUTLIER -145.14 123.79 5.53 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.328 0 CA-C-N 121.128 1.786 . . . . 0.0 111.943 -176.924 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.607 HD12 ' HB2' ' H' ' 21' ' ' ALA . 0.1 OUTLIER -122.33 122.52 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.891 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.565 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -131.17 100.97 0.47 Allowed Glycine 0 N--CA 1.476 1.302 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.601 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 6.0 mp -131.78 138.54 48.61 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-O 122.696 1.236 . . . . 0.0 113.906 -176.763 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.518 ' SD ' ' C ' ' D' ' 32' ' ' ILE . 4.9 ttm -116.66 119.57 35.91 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 113.799 -1.546 . . . . 0.0 109.66 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.61 77.03 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.074 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.738 -179.169 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -84.57 103.97 2.69 Favored Glycine 0 C--N 1.355 1.596 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 179.295 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.46 170.9 55.14 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 65.6 t -131.47 136.02 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.947 0.403 . . . . 0.0 110.536 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.517 179.817 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' K' K ' 10' ' ' TYR . . . . . 0.436 ' CE2' ' O ' ' J' ' 9' ' ' GLY . 93.3 m-85 -112.68 133.95 54.45 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' L' ' 10' ' ' TYR . 79.7 mm-40 -137.43 139.23 40.53 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.96 0.409 . . . . 0.0 110.792 -179.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 58.1 t -127.63 132.54 69.02 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' J' ' 13' ' ' HIS . 22.1 m170 -79.26 149.1 31.95 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.86 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 24.5 p-80 -78.84 178.08 8.21 Favored 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -117.87 175.88 5.46 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.574 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -145.14 118.52 9.01 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 120.911 0.386 . . . . 0.0 111.205 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.441 HD12 HE21 ' L' ' 15' ' ' GLN . 34.1 mt -124.77 118.8 27.21 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.37 138.15 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.644 0.735 . . . . 0.0 112.633 -178.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -124.21 127.67 48.06 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.288 179.236 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.418 ' CD2' ' CE2' ' J' ' 20' ' ' PHE . 71.5 t80 -133.09 121.07 22.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.56 133.69 31.14 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.476 0.655 . . . . 0.0 112.665 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 96.4 mt-10 -117.69 124.66 49.07 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.211 178.327 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' K' ' 22' ' ' GLU . 14.5 m-20 -140.15 111.89 7.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' K' ' 26' ' ' SER . 6.3 m -129.55 -122.48 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 31.63 -84.25 0.0 OUTLIER Glycine 0 N--CA 1.474 1.183 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 -179.737 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.623 ' O ' ' O ' ' K' ' 27' ' ' ASN . 3.9 p 170.93 170.64 0.07 Allowed 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.209 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.623 ' O ' ' O ' ' K' ' 26' ' ' SER . 93.6 m-20 -18.75 157.48 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.554 1.159 . . . . 0.0 113.849 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' K' ' 29' ' ' GLY . 88.1 tttt -170.47 104.95 0.28 Allowed 'General case' 0 C--O 1.215 -0.729 0 CA-C-O 117.709 -1.139 . . . . 0.0 109.01 176.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -50.65 -99.08 0.01 OUTLIER Glycine 0 C--O 1.214 -1.126 0 C-N-CA 116.6 -2.714 . . . . 0.0 110.994 178.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 70.74 141.91 0.05 Allowed 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 102.616 -3.105 . . . . 0.0 102.616 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.497 HD13 ' HA2' ' E' ' 37' ' ' GLY . 0.2 OUTLIER -147.95 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 122.298 2.317 . . . . 0.0 111.214 -176.903 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.57 HG22 HD11 ' L' ' 34' ' ' LEU . 10.6 mt -106.61 113.4 43.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 175.762 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.7 115.2 2.29 Favored Glycine 0 C--N 1.317 -0.519 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 1.037 HD21 HG13 ' K' ' 36' ' ' VAL . 0.8 OUTLIER -150.42 143.27 24.69 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 122.732 1.253 . . . . 0.0 112.631 -178.526 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 29.4 ttm -117.67 122.21 42.93 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 113.664 -1.607 . . . . 0.0 109.308 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 1.037 HG13 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -116.2 79.76 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.131 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.23 103.91 0.4 Allowed Glycine 0 C--N 1.351 1.377 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.48 -163.11 15.38 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.1 136.27 54.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 120.833 0.349 . . . . 0.0 110.623 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 86.6 t . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.455 179.868 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' L' L ' 10' ' ' TYR . . . . . 0.402 ' O ' ' OE2' ' K' ' 11' ' ' GLU . 94.9 m-85 -108.48 137.52 46.3 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.901 0.381 . . . . 0.0 110.928 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -96.34 158.89 15.23 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 179.34 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.16 133.14 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.823 0.344 . . . . 0.0 110.562 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 65.6 t60 -160.24 117.53 2.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.173 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.474 ' ND1' ' O ' ' L' ' 13' ' ' HIS . 80.1 m-70 -151.51 174.55 13.27 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.441 HE21 HD12 ' K' ' 17' ' ' LEU . 54.8 tt0 -146.08 170.59 16.36 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.336 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 16' ' ' LYS . . . . . 0.427 ' N ' ' HG2' ' L' ' 15' ' ' GLN . 99.0 mttt -148.89 117.85 6.72 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.662 0.268 . . . . 0.0 110.303 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.538 HD23 ' C ' ' L' ' 17' ' ' LEU . 7.2 tt -126.48 115.89 20.26 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.215 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 m -136.62 137.2 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-O 121.005 0.431 . . . . 0.0 110.426 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -134.28 133.81 41.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.237 0.541 . . . . 0.0 111.275 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -135.56 124.74 24.51 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.722 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -150.37 146.45 26.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.329 -0.548 . . . . 0.0 111.594 -179.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -104.17 102.15 11.88 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.322 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -91.87 113.64 25.96 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.562 ' O ' ' N ' ' L' ' 26' ' ' SER . 85.2 t -65.95 131.26 31.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.439 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -54.53 84.51 0.01 OUTLIER Glycine 0 CA--C 1.528 0.892 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.271 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.562 ' N ' ' O ' ' L' ' 24' ' ' VAL . 1.4 p 159.82 178.88 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.473 ' O ' ' O ' ' L' ' 26' ' ' SER . 21.2 p30 -41.92 177.64 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.053 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.551 ' NZ ' ' O ' ' L' ' 30' ' ' ALA . 8.6 tptp -75.2 110.57 9.64 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.708 -1.133 . . . . 0.0 112.31 178.548 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -51.29 -99.87 0.01 OUTLIER Glycine 0 C--N 1.317 -0.513 0 CA-C-O 119.054 -0.859 . . . . 0.0 111.607 179.714 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.551 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . . . -80.48 163.91 23.41 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 104.75 -2.315 . . . . 0.0 104.75 -178.505 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.411 HD13 HG21 ' L' ' 31' ' ' ILE . 0.2 OUTLIER -135.28 128.85 49.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 116.487 -2.085 . . . . 0.0 113.038 -174.155 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.57 ' HB ' HD13 ' L' ' 34' ' ' LEU . 2.0 pt -117.52 114.94 47.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.232 178.819 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 33' ' ' GLY . . . . . 0.731 ' C ' HD12 ' L' ' 34' ' ' LEU . . . -112.8 90.64 0.56 Allowed Glycine 0 N--CA 1.463 0.47 0 N-CA-C 106.029 -2.828 . . . . 0.0 106.029 176.492 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.731 HD12 ' C ' ' L' ' 33' ' ' GLY . 9.1 mp -116.16 134.59 54.76 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.747 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 77.7 mmm -119.62 119.47 33.84 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.683 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' L' ' 37' ' ' GLY . 1.2 m -125.64 76.54 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 115.043 -0.981 . . . . 0.0 108.657 178.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -37.12 105.71 0.04 OUTLIER Glycine 0 C--N 1.356 1.646 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.86 172.15 6.81 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.933 -0.467 . . . . 0.0 111.933 -177.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 14.9 p -133.57 144.07 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 115.457 -0.371 . . . . 0.0 110.362 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.558 179.797 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -148.36 159.47 43.98 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.757 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.8 tp10 -134.52 127.32 31.13 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 121.242 0.544 . . . . 0.0 110.866 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m -139.3 163.78 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -107.24 119.41 39.33 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.687 0.28 . . . . 0.0 111.032 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -100.27 165.88 11.25 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -156.23 174.14 15.83 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.887 178.006 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttp -175.8 115.76 0.14 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.377 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 97.0 mt -124.89 115.69 21.03 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.119 0.485 . . . . 0.0 110.439 179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.2 m -122.14 126.92 75.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.355 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.935 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 0.6 OUTLIER -117.85 113.52 21.9 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.418 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 t80 -122.87 116.42 23.61 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.092 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.79 119.87 38.11 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.22 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -174.79 108.57 0.11 Allowed 'General case' 0 CA--C 1.528 0.098 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.277 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -74.09 114.6 12.61 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.98 -0.688 . . . . 0.0 109.782 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.56 ' O ' HG23 ' A' ' 24' ' ' VAL . 27.9 m -121.46 123.54 69.85 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.769 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.4 82.09 0.01 OUTLIER Glycine 0 CA--C 1.53 0.971 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.259 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.616 ' O ' ' O ' ' A' ' 27' ' ' ASN . 58.4 m -140.5 170.68 15.34 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 117.923 0.862 . . . . 0.0 108.942 177.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.616 ' O ' ' O ' ' A' ' 26' ' ' SER . 70.9 m-80 -30.94 174.4 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.707 0 O-C-N 124.29 0.994 . . . . 0.0 113.261 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.61 110.84 21.67 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.592 176.416 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 52.09 91.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.719 0 C-N-CA 119.922 -1.132 . . . . 0.0 110.436 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.65 166.77 10.22 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 118.906 1.353 . . . . 0.0 110.518 179.512 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.467 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -141.05 107.32 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.389 -178.137 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 93.6 mt -128.21 130.09 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 121.442 0.639 . . . . 0.0 112.291 -177.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.433 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -128.13 110.88 1.2 Allowed Glycine 0 CA--C 1.521 0.439 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.03 124.55 52.88 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 120.908 0.385 . . . . 0.0 110.395 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.55 ' SD ' ' CA ' ' G' ' 33' ' ' GLY . 25.7 ttt -130.73 126.32 36.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.893 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.1 t -98.12 65.39 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 112.983 0.735 . . . . 0.0 112.983 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.2 -106.19 0.06 OUTLIER Glycine 0 N--CA 1.44 -1.075 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.247 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -95.44 178.16 35.26 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -135.14 140.53 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 120.92 0.39 . . . . 0.0 110.275 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.935 -179.401 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -103.49 130.17 50.81 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.652 0.263 . . . . 0.0 110.481 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -76.85 136.08 38.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.559 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m -135.53 166.04 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 121.165 0.507 . . . . 0.0 111.344 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.585 ' CG ' ' H ' ' B' ' 14' ' ' HIS . 15.3 t-80 -122.86 -164.26 1.18 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.036 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.586 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 19.9 t-80 -71.59 168.05 18.46 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.586 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 79.0 mt-30 -152.3 177.47 10.53 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.156 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -158.43 128.63 6.02 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 120.554 -0.458 . . . . 0.0 111.672 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.44 119.55 29.51 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -129.21 131.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 121.068 0.461 . . . . 0.0 111.52 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.635 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 7.9 t80 -122.64 115.55 22.3 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 53.3 t80 -125.59 122.33 36.17 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 110.4 -0.222 . . . . 0.0 110.4 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.52 125.77 45.49 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.121 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -163.48 130.23 3.34 Favored 'General case' 0 C--O 1.222 -0.364 0 CA-C-N 115.018 -0.992 . . . . 0.0 108.472 178.489 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' NZ ' ' D' ' 28' ' ' LYS . 66.1 t0 -142.6 113.14 7.31 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.404 ' H ' HG22 ' B' ' 24' ' ' VAL . 6.0 m -59.32 131.59 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.13 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 176.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.413 ' HA3' ' O ' ' C' ' 26' ' ' SER . . . -66.36 84.33 0.1 Allowed Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.357 -0.925 . . . . 0.0 113.313 -178.688 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 6.3 p -87.77 180.0 6.38 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.757 0.789 . . . . 0.0 109.438 176.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.487 ' O ' ' O ' ' B' ' 28' ' ' LYS . 51.1 p30 -76.69 179.22 6.17 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.342 -1.299 . . . . 0.0 109.578 175.57 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 27' ' ' ASN . 68.4 mttm 43.93 110.53 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 115.019 1.489 . . . . 0.0 115.019 175.773 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' C' ' 29' ' ' GLY . . . -78.76 97.79 1.51 Allowed Glycine 0 CA--C 1.485 -1.827 0 CA-C-N 113.562 -1.654 . . . . 0.0 110.866 -176.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.4 ' C ' HG12 ' B' ' 31' ' ' ILE . . . -75.62 164.75 25.99 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 122.462 1.125 . . . . 0.0 109.658 -175.229 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.549 HG23 ' CG1' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -137.57 114.04 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 CA-C-N 112.63 -2.077 . . . . 0.0 110.504 -170.157 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' I' ' 35' ' ' MET . 96.4 mt -132.83 128.12 56.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 CA-C-O 121.64 0.733 . . . . 0.0 112.805 -177.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.491 ' CA ' ' SD ' ' I' ' 35' ' ' MET . . . -129.74 128.8 5.79 Favored Glycine 0 N--CA 1.471 0.999 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 179.304 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.403 HD21 HG23 ' B' ' 36' ' ' VAL . 2.9 tt -129.25 126.13 38.4 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.149 0.5 . . . . 0.0 111.761 -178.855 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 7.2 tpp -120.86 117.81 28.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.428 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.403 HG23 HD21 ' B' ' 34' ' ' LEU . 59.0 t -125.37 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -179.434 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.66 104.63 2.1 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.505 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.44 -171.81 0.65 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.106 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.2 m -133.77 163.06 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.896 0.379 . . . . 0.0 110.47 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.342 179.727 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.439 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -116.2 138.53 51.2 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.767 0.318 . . . . 0.0 110.644 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -120.72 128.49 52.99 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.34 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -130.04 134.63 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.249 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.496 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.0 t-80 -136.62 127.36 27.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.843 0.354 . . . . 0.0 110.61 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.496 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 79.9 m-70 -152.16 164.74 36.69 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -156.83 171.01 21.16 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.092 178.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.482 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.9 mttt -158.13 113.95 2.74 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.518 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.482 HD12 ' C ' ' C' ' 16' ' ' LYS . 11.0 mp -114.46 122.38 46.43 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.27 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.45 124.52 62.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.658 -0.246 . . . . 0.0 110.431 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.629 ' CZ ' HD11 ' E' ' 34' ' ' LEU . 1.1 t80 -120.46 111.98 18.39 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.054 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.4 t80 -119.84 121.92 40.15 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.681 0.277 . . . . 0.0 110.828 -178.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.74 128.92 49.51 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 121.331 0.586 . . . . 0.0 112.065 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -150.37 149.8 30.56 Favored 'General case' 0 C--O 1.226 -0.157 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.959 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -163.77 121.23 1.8 Allowed 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.63 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.479 HG23 ' H ' ' C' ' 25' ' ' GLY . 4.2 m -128.02 -112.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.803 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.479 ' H ' HG23 ' C' ' 24' ' ' VAL . . . 34.26 -90.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 115.725 -0.671 . . . . 0.0 112.315 -178.271 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.619 ' O ' ' O ' ' C' ' 27' ' ' ASN . 0.3 OUTLIER 172.0 -170.82 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.6 179.65 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.619 ' O ' ' O ' ' C' ' 26' ' ' SER . 76.8 m-20 -20.31 -175.2 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 117.327 2.343 . . . . 0.0 117.327 177.665 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 82.6 tttt 111.64 110.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 CA-C-N 111.81 -2.45 . . . . 0.0 114.477 176.061 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.412 ' O ' ' HA3' ' B' ' 29' ' ' GLY . . . -61.74 92.48 0.07 OUTLIER Glycine 0 C--O 1.218 -0.87 0 CA-C-N 112.305 -2.225 . . . . 0.0 112.714 171.739 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.67 156.8 40.47 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 122.902 3.351 . . . . 0.0 107.984 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.598 HD13 ' N ' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -138.73 129.07 33.51 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.189 -176.021 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.488 HG12 HD21 ' C' ' 34' ' ' LEU . 13.0 tt -133.84 122.97 43.96 Favored 'Isoleucine or valine' 0 C--N 1.348 0.525 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.523 177.175 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.52 115.36 3.61 Favored Glycine 0 CA--C 1.499 -0.936 0 N-CA-C 107.602 -2.199 . . . . 0.0 107.602 178.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.935 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 52.6 mt -116.26 111.4 20.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.117 0.484 . . . . 0.0 111.56 -176.607 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.405 ' HE2' ' H ' ' J' ' 33' ' ' GLY . 24.6 tpp -109.48 103.16 12.01 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 177.126 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -121.35 70.74 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.727 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.239 -178.734 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -38.2 -100.79 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 178.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.85 -163.79 31.73 Favored Glycine 0 CA--C 1.521 0.456 0 N-CA-C 110.535 -1.026 . . . . 0.0 110.535 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 68.5 t -119.19 134.06 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.005 -0.997 . . . . 0.0 110.632 -179.641 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -82.55 137.69 34.5 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.734 0.302 . . . . 0.0 110.461 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -115.75 141.28 48.3 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.392 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.477 ' C ' ' ND1' ' D' ' 13' ' ' HIS . 9.8 p -130.17 135.59 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-O 121.142 0.496 . . . . 0.0 110.702 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' C ' ' D' ' 12' ' ' VAL . 14.7 m80 -142.56 108.99 5.3 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.555 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.44 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 31.6 m-70 -126.55 167.08 16.13 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -151.39 171.86 16.83 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.581 179.05 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.594 ' C ' HD12 ' D' ' 17' ' ' LEU . 63.3 mttp -155.24 121.16 5.11 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.139 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.594 HD12 ' C ' ' D' ' 16' ' ' LYS . 11.0 mp -119.92 122.83 42.11 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.33 125.1 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.016 0.436 . . . . 0.0 110.678 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.908 ' CE1' HD22 ' F' ' 34' ' ' LEU . 1.3 t80 -118.73 117.55 29.22 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.446 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -128.26 122.3 31.38 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 112.059 0.392 . . . . 0.0 112.059 -177.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.79 121.3 29.84 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-O 121.112 0.482 . . . . 0.0 109.978 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -97.85 175.29 6.21 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.212 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -72.63 122.08 20.83 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.26 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.451 ' O ' HG23 ' D' ' 24' ' ' VAL . 28.7 m -87.56 123.33 40.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.914 179.107 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -42.88 -86.09 0.01 OUTLIER Glycine 0 CA--C 1.532 1.152 0 C-N-CA 121.393 -0.432 . . . . 0.0 112.443 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.738 ' O ' ' O ' ' D' ' 27' ' ' ASN . 13.2 p -152.84 -171.61 3.99 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -178.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.738 ' O ' ' O ' ' D' ' 26' ' ' SER . 81.5 m-20 -20.15 172.24 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 114.783 1.401 . . . . 0.0 114.783 -179.05 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.556 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 83.2 tttt 132.02 105.65 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 124.95 1.3 . . . . 0.0 107.701 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -49.89 -97.72 0.01 OUTLIER Glycine 0 N--CA 1.473 1.135 0 C-N-CA 118.112 -1.994 . . . . 0.0 110.269 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.451 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . 72.54 145.01 0.07 Allowed 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.687 HG23 ' CG1' ' E' ' 31' ' ' ILE . 0.3 OUTLIER -149.42 116.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.202 -175.026 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.513 HG22 ' O ' ' D' ' 32' ' ' ILE . 1.0 OUTLIER -111.57 111.41 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.741 -179.661 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.91 97.53 1.61 Allowed Glycine 0 CA--C 1.509 -0.289 0 N-CA-C 105.024 -3.23 . . . . 0.0 105.024 175.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.635 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 62.8 tp -110.94 118.67 36.71 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -175.149 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -122.16 108.84 13.78 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 176.135 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.434 HG22 HD11 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -124.43 70.04 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.847 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -49.41 -100.6 0.01 OUTLIER Glycine 0 C--N 1.347 1.142 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.266 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 111.23 159.19 15.67 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -124.15 136.34 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.972 0.415 . . . . 0.0 110.664 -179.558 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 91.6 t . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.058 -0.973 . . . . 0.0 110.414 179.63 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -104.87 134.95 47.14 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.448 ' H ' ' HG2' ' F' ' 11' ' ' GLU . 22.3 pt-20 -140.8 146.57 37.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.997 0.427 . . . . 0.0 110.956 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 4.2 m -131.55 155.84 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.748 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -156.75 162.37 39.77 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 121.312 0.577 . . . . 0.0 112.302 -179.025 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.59 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 36.4 t60 -154.96 164.75 38.45 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-O 121.411 0.624 . . . . 0.0 110.635 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.59 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 82.6 mt-30 -149.85 170.03 19.72 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.465 0.65 . . . . 0.0 110.892 178.608 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.19 128.79 3.17 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.096 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 52.5 tp -125.36 124.36 41.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.2 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.73 123.61 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -124.54 120.24 31.39 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.239 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -129.13 120.53 26.02 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 120.31 16.94 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.213 0.53 . . . . 0.0 110.948 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -143.09 128.3 18.71 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.476 179.538 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -154.14 120.4 5.4 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.455 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 14.1 t -107.5 -112.76 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.007 0.432 . . . . 0.0 110.327 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.7 -90.63 0.01 OUTLIER Glycine 0 N--CA 1.469 0.878 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.397 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.602 ' O ' ' O ' ' E' ' 27' ' ' ASN . 2.7 t 171.34 170.1 0.08 Allowed 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.502 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.602 ' O ' ' O ' ' E' ' 26' ' ' SER . 60.3 t30 -17.67 158.34 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.861 ' O ' ' HB2' ' F' ' 30' ' ' ALA . 75.2 tttt -161.73 111.41 1.57 Allowed 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.406 175.456 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.77 92.29 0.23 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-O 119.156 -0.802 . . . . 0.0 113.178 176.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.537 ' HB2' ' O ' ' D' ' 28' ' ' LYS . . . -160.24 154.08 22.82 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.512 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.687 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -141.47 126.05 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 117.49 -1.684 . . . . 0.0 114.123 -175.926 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.522 ' O ' ' SD ' ' L' ' 35' ' ' MET . 0.8 OUTLIER -114.39 116.39 52.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 114.731 -1.122 . . . . 0.0 108.202 176.505 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.95 102.13 2.76 Favored Glycine 0 CA--C 1.501 -0.811 0 N-CA-C 104.192 -3.563 . . . . 0.0 104.192 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.629 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 6.7 tt -107.14 105.54 15.59 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 121.045 0.45 . . . . 0.0 111.366 -174.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.9 ttt -123.82 112.51 17.38 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.5 80.38 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.01 102.76 0.26 Allowed Glycine 0 C--N 1.351 1.397 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.54 -151.55 23.62 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.0 p -130.84 140.82 47.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 43.1 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.755 -179.828 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -116.19 139.34 50.45 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.74 0.305 . . . . 0.0 110.711 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 11' ' ' GLU . . . . . 0.448 ' HG2' ' H ' ' E' ' 11' ' ' GLU . 98.4 mt-10 -56.81 135.79 55.55 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.345 -0.389 . . . . 0.0 109.997 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p -141.81 148.11 21.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.753 . . . . 0.0 111.507 -178.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.444 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 33.0 p-80 -161.64 157.08 24.02 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.188 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 97.0 m-70 -156.4 168.29 27.8 Favored 'General case' 0 CA--C 1.511 -0.537 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.101 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -151.01 173.26 14.52 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 119.951 -0.7 . . . . 0.0 110.716 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -147.66 129.09 14.89 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.447 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 50.8 mt -120.33 115.48 23.63 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.306 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -127.31 129.5 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.82 0.343 . . . . 0.0 110.129 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.524 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.3 p90 -143.34 126.23 16.2 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.069 0.462 . . . . 0.0 111.543 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -127.29 128.11 45.44 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.18 149.64 28.22 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 119.89 -0.724 . . . . 0.0 112.286 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -80.09 126.56 31.23 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.194 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -91.32 113.71 26.05 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 121.868 0.842 . . . . 0.0 113.266 -177.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.571 ' O ' ' O ' ' F' ' 26' ' ' SER . 78.4 t -128.54 120.8 53.63 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 177.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.482 ' C ' ' O ' ' F' ' 24' ' ' VAL . . . -27.67 -88.95 0.01 OUTLIER Glycine 0 N--CA 1.486 2.017 0 CA-C-N 119.358 0.981 . . . . 0.0 111.65 -177.713 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.571 ' O ' ' O ' ' F' ' 24' ' ' VAL . 69.3 m -70.31 -173.55 0.72 Allowed 'General case' 0 CA--C 1.502 -0.899 0 N-CA-C 103.251 -2.87 . . . . 0.0 103.251 175.018 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.478 ' O ' ' O ' ' F' ' 28' ' ' LYS . 16.8 t-20 -79.91 176.19 9.96 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 115.677 -2.409 . . . . 0.0 107.941 175.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.478 ' O ' ' O ' ' F' ' 27' ' ' ASN . 80.1 tttt -44.45 -105.83 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.664 0 CA-C-O 123.537 1.637 . . . . 0.0 111.859 174.383 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.461 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -114.33 -100.45 2.36 Favored Glycine 0 CA--C 1.483 -1.944 0 CA-C-N 111.218 -2.719 . . . . 0.0 113.305 -179.664 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.861 ' HB2' ' O ' ' E' ' 28' ' ' LYS . . . -60.41 177.04 0.3 Allowed 'General case' 0 CA--C 1.474 -1.957 0 CA-C-N 110.82 -2.69 . . . . 0.0 104.933 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 tp -158.41 144.76 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 C-N-CA 114.998 -2.681 . . . . 0.0 114.638 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 pt -102.14 112.34 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-N 112.807 -1.997 . . . . 0.0 107.965 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -80.38 97.12 1.67 Allowed Glycine 0 CA--C 1.497 -1.061 0 N-CA-C 103.496 -3.842 . . . . 0.0 103.496 175.408 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.908 HD22 ' CE1' ' D' ' 19' ' ' PHE . 0.3 OUTLIER -100.01 111.09 23.39 Favored 'General case' 0 CA--C 1.497 -1.089 0 CA-C-N 117.412 0.606 . . . . 0.0 111.445 -176.676 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.622 ' SD ' ' O ' ' L' ' 32' ' ' ILE . 24.2 mtp -135.33 114.94 12.71 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-O 122.754 1.264 . . . . 0.0 107.766 176.463 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.74 HG13 ' O ' ' F' ' 36' ' ' VAL . 5.5 p -133.0 78.63 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 CA-C-N 112.566 -2.106 . . . . 0.0 108.373 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.646 ' HA2' HD13 ' L' ' 31' ' ' ILE . . . 51.87 -104.08 0.14 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -175.13 46.7 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 66.6 t -131.42 137.72 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 120.814 0.34 . . . . 0.0 111.16 -179.005 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 61.5 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.119 -0.943 . . . . 0.0 110.335 179.289 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.457 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -98.71 130.29 45.19 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.859 0.361 . . . . 0.0 110.345 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -71.02 147.61 48.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.744 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 t -124.95 134.03 67.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.8 t60 -144.27 136.9 26.85 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.382 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 27.6 m170 -112.78 178.69 4.2 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -102.33 178.11 4.68 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.407 -179.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -97.02 137.63 35.81 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.655 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -123.97 128.14 48.96 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.375 0.607 . . . . 0.0 111.378 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.49 128.85 61.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.562 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.45 ' CE2' HD23 ' J' ' 34' ' ' LEU . 3.8 m-85 -108.85 113.27 26.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 176.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 52.7 p90 -124.99 123.96 40.98 Favored 'General case' 0 CA--C 1.521 -0.14 0 CA-C-O 120.892 0.377 . . . . 0.0 110.932 -178.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.09 120.84 40.37 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -159.27 141.63 13.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -66.29 112.12 3.83 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' G' ' 26' ' ' SER . 54.2 t -111.86 130.85 64.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.96 81.85 0.0 OUTLIER Glycine 0 CA--C 1.532 1.126 0 CA-C-N 114.97 -1.014 . . . . 0.0 113.376 177.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.516 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.6 m -131.41 179.46 6.02 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 119.172 1.486 . . . . 0.0 109.562 178.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.465 ' O ' ' O ' ' G' ' 26' ' ' SER . 79.1 m-20 -40.18 174.37 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.186 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -77.41 110.64 12.34 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.381 175.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.457 ' H ' ' HE2' ' H' ' 28' ' ' LYS . . . 65.36 94.39 0.03 OUTLIER Glycine 0 N--CA 1.466 0.648 0 C-N-CA 118.292 -1.909 . . . . 0.0 110.361 177.312 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 161.37 13.65 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 120.18 1.99 . . . . 0.0 109.386 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.404 HG22 HD12 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -150.98 112.77 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.758 -172.957 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' A' ' 35' ' ' MET . 94.8 mt -121.45 117.26 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-O 120.662 0.268 . . . . 0.0 110.89 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.55 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -125.7 116.39 2.62 Favored Glycine 0 N--CA 1.47 0.911 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 179.401 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 56.4 tp -144.15 140.57 29.45 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-O 121.384 0.611 . . . . 0.0 112.198 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.433 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 40.0 ttp -130.64 137.73 49.75 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.466 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' G' ' 37' ' ' GLY . 4.8 t -125.82 69.77 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 CA-C-N 116.328 -0.396 . . . . 0.0 112.038 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -43.77 -101.68 0.01 OUTLIER Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.12 174.28 40.21 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 13.3 p -145.03 149.56 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.183 0.516 . . . . 0.0 111.329 -179.493 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.969 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -82.44 130.11 35.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.012 0.434 . . . . 0.0 110.392 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -115.34 163.51 15.59 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.761 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.504 HG12 ' N ' ' H' ' 13' ' ' HIS . 71.5 t -118.66 158.78 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.869 0.842 . . . . 0.0 110.902 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.504 ' N ' HG12 ' H' ' 12' ' ' VAL . 32.5 p-80 -98.65 154.24 18.09 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -178.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.566 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 58.4 t60 -87.93 167.4 13.77 Favored 'General case' 0 N--CA 1.442 -0.862 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 178.139 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.566 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 26.7 mt-30 -150.66 167.2 28.05 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 119.906 -0.717 . . . . 0.0 111.381 178.782 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -153.11 115.26 4.37 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.389 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 24.6 tp -122.64 121.86 37.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.737 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.09 123.43 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-O 121.106 0.479 . . . . 0.0 112.146 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.897 ' CZ ' HD22 ' K' ' 34' ' ' LEU . 3.3 m-85 -110.2 114.31 27.69 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 177.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.597 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 48.4 t80 -127.63 123.74 36.33 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 118.473 0.579 . . . . 0.0 110.407 -178.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.59 128.67 44.68 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 120.924 0.392 . . . . 0.0 111.918 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -144.87 153.22 41.36 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -105.28 103.7 13.29 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.66 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' H' ' 26' ' ' SER . 22.5 t -90.23 153.68 3.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 48.71 -80.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.75 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.7 OUTLIER 171.46 -170.71 0.03 OUTLIER 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 117.371 0.586 . . . . 0.0 109.578 -179.787 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.75 ' O ' ' O ' ' H' ' 26' ' ' SER . 18.1 m-20 -18.67 -172.42 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 116.322 1.971 . . . . 0.0 116.322 -178.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.546 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 62.9 tttm 127.02 104.51 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.984 0 CA-C-N 113.644 -1.617 . . . . 0.0 111.307 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.98 96.86 0.07 OUTLIER Glycine 0 N--CA 1.47 0.954 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.153 176.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.99 148.12 43.94 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.514 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -146.1 124.92 5.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.263 -173.41 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -122.81 117.53 52.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.83 179.268 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.02 122.72 5.09 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 178.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 7.8 tt -151.44 140.38 21.01 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.557 -0.966 . . . . 0.0 111.582 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 43.0 ttp -131.74 130.17 41.58 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.298 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' H' ' 37' ' ' GLY . 11.6 t -123.77 73.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -48.2 -95.07 0.01 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 177.166 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.76 177.42 16.71 Favored Glycine 0 C--N 1.336 0.571 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.56 134.57 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.402 HG22 ' H ' ' H' ' 40' ' ' VAL . 15.6 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.641 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -102.6 132.4 48.72 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -94.17 132.54 38.6 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 121.0 0.429 . . . . 0.0 110.437 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m -138.95 159.28 29.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.267 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.458 ' ND1' ' O ' ' H' ' 12' ' ' VAL . 2.0 m80 -107.06 -172.56 2.1 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.958 0.409 . . . . 0.0 110.884 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.598 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 20.9 p-80 -135.91 176.53 8.6 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -133.18 177.73 7.44 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.588 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -138.69 115.9 11.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.039 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 39.0 mt -114.27 117.38 30.95 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -126.62 125.8 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.208 0.528 . . . . 0.0 111.614 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.974 ' CZ ' HD22 ' L' ' 34' ' ' LEU . 6.9 m-85 -113.25 115.09 27.65 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 177.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.597 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 25.8 t80 -129.27 122.96 30.71 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.482 0.583 . . . . 0.0 110.237 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.15 131.31 34.53 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.539 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -137.9 132.49 32.53 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -96.69 101.38 12.98 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.59 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.615 ' O ' ' N ' ' I' ' 26' ' ' SER . 53.6 t -91.27 158.46 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.333 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 48.9 -80.46 0.01 OUTLIER Glycine 0 CA--C 1.527 0.805 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.427 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.615 ' N ' ' O ' ' I' ' 24' ' ' VAL . 2.4 p 171.16 171.21 0.08 Allowed 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.397 0.618 . . . . 0.0 110.052 -179.481 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.589 ' O ' ' O ' ' I' ' 26' ' ' SER . 23.0 p30 -16.13 158.41 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.335 -1.757 . . . . 0.0 115.5 -176.658 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.556 ' O ' ' O ' ' J' ' 29' ' ' GLY . 63.5 tttp -161.17 111.03 1.66 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.497 176.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.73 92.8 0.2 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 150.71 52.03 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.56 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.514 HD12 ' CG2' ' H' ' 31' ' ' ILE . 0.0 OUTLIER -151.57 123.43 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 C-N-CA 118.711 -1.196 . . . . 0.0 110.943 -174.989 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.534 ' CG2' HD11 ' J' ' 34' ' ' LEU . 97.3 mt -116.69 116.21 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.279 178.362 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.65 98.03 1.03 Allowed Glycine 0 N--CA 1.462 0.381 0 N-CA-C 105.888 -2.885 . . . . 0.0 105.888 175.283 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -122.61 129.07 51.48 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.68 0.752 . . . . 0.0 112.334 -176.015 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 78.9 mtp -108.91 112.78 25.19 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.434 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.502 ' H ' ' HG2' ' J' ' 35' ' ' MET . 0.2 OUTLIER -123.54 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 177.454 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.6 111.2 3.22 Favored Glycine 0 C--N 1.364 2.107 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.0 179.38 1.56 Allowed Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.39 156.24 41.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.365 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.571 -179.701 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -82.54 140.84 33.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.659 0.266 . . . . 0.0 110.314 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -141.74 159.92 41.23 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.931 0.396 . . . . 0.0 110.874 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' J' ' 13' ' ' HIS . 25.8 t -120.57 161.22 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.469 ' N ' ' CG1' ' J' ' 12' ' ' VAL . 28.9 p-80 -71.48 150.54 44.77 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -176.533 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.598 ' NE2' ' CG ' ' I' ' 14' ' ' HIS . 43.8 p-80 -152.86 172.87 16.09 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 113.918 -1.492 . . . . 0.0 107.167 179.326 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -144.36 174.12 11.19 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.59 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.654 ' C ' HD12 ' J' ' 17' ' ' LEU . 99.2 mttt -148.73 112.47 5.09 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.333 -0.849 . . . . 0.0 109.974 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.654 HD12 ' C ' ' J' ' 16' ' ' LYS . 10.5 mp -117.52 121.21 40.38 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.91 123.28 58.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.937 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.643 ' CE1' ' CE2' ' K' ' 19' ' ' PHE . 94.9 m-85 -115.87 117.09 29.24 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -123.22 111.24 16.23 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.54 132.93 46.97 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -120.84 87.89 2.84 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.216 -0.902 . . . . 0.0 108.862 177.49 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.577 ' C ' ' HZ2' ' K' ' 28' ' ' LYS . 20.9 m-20 -68.33 -102.42 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 114.602 -1.181 . . . . 0.0 108.53 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.552 HG12 ' N ' ' J' ' 25' ' ' GLY . 34.5 t 46.43 157.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 122.661 1.22 . . . . 0.0 114.254 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.552 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 91.67 -80.25 1.26 Allowed Glycine 0 CA--C 1.527 0.843 0 CA-C-N 113.219 -1.809 . . . . 0.0 110.46 -176.786 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.606 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.8 p 170.28 170.48 0.06 Allowed 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 118.092 0.946 . . . . 0.0 109.729 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.606 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.8 t-20 -17.66 157.75 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.699 0 O-C-N 124.953 1.408 . . . . 0.0 114.02 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.583 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 61.3 tttt -161.6 110.55 1.53 Allowed 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 173.505 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.556 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -68.13 93.06 0.27 Allowed Glycine 0 C--O 1.216 -1.0 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.75 177.049 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.472 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -143.28 143.25 31.64 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 103.061 -2.94 . . . . 0.0 103.061 173.404 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.505 HD12 ' CG2' ' I' ' 31' ' ' ILE . 0.2 OUTLIER -152.37 111.76 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 118.424 -1.31 . . . . 0.0 108.929 -171.546 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.485 HG22 ' H ' ' K' ' 33' ' ' GLY . 0.1 OUTLIER -111.6 111.92 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.046 0.451 . . . . 0.0 109.86 -179.491 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.593 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -112.16 94.56 0.75 Allowed Glycine 0 C--O 1.239 0.447 0 N-CA-C 107.398 -2.281 . . . . 0.0 107.398 176.739 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.593 HD12 ' C ' ' J' ' 33' ' ' GLY . 9.7 mp -117.33 127.15 53.77 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 122.279 1.038 . . . . 0.0 111.307 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.502 ' HG2' ' H ' ' I' ' 36' ' ' VAL . 0.1 OUTLIER -101.57 118.59 37.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.521 178.315 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 98.2 t -133.9 76.55 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.49 104.58 2.07 Favored Glycine 0 C--N 1.352 1.443 0 CA-C-N 115.353 -0.839 . . . . 0.0 111.849 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.61 -176.76 40.0 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.6 m -134.4 162.5 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.682 0.277 . . . . 0.0 110.509 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 95.0 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.886 -179.76 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -111.53 145.79 38.46 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.706 0.288 . . . . 0.0 110.655 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -53.78 148.85 9.39 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.879 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -134.04 156.59 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 121.891 0.853 . . . . 0.0 111.996 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -170.17 83.42 0.11 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.074 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -154.98 169.0 25.1 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 65.5 mt-30 -149.9 178.31 9.03 Favored 'General case' 0 C--N 1.312 -1.047 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.004 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -126.66 109.45 12.1 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.717 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 55.8 mt -111.23 113.04 25.25 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.9 t -126.24 114.13 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 O-C-N 122.015 -0.428 . . . . 0.0 111.091 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.718 ' O ' ' C ' ' L' ' 19' ' ' PHE . 76.0 m-85 -116.86 105.31 12.22 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 177.139 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.448 ' HA ' ' O ' ' L' ' 19' ' ' PHE . 91.0 t80 -128.3 125.99 39.91 Favored 'General case' 0 N--CA 1.482 1.151 0 O-C-N 124.287 0.992 . . . . 0.0 112.219 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.492 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -147.36 156.32 42.79 Favored 'General case' 0 C--N 1.353 0.732 0 C-N-CA 118.502 -1.279 . . . . 0.0 114.236 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -127.3 137.27 52.79 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.42 ' O ' HG11 ' L' ' 24' ' ' VAL . 11.4 p-10 -165.5 135.43 3.55 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 118.868 -1.133 . . . . 0.0 113.725 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.592 HG13 ' O ' ' K' ' 24' ' ' VAL . 13.1 p -70.83 112.74 5.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -50.59 92.47 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.526 -1.215 . . . . 0.0 114.546 -175.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.451 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.5 t 162.35 160.5 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.766 0 CA-C-O 121.801 0.81 . . . . 0.0 110.134 176.45 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.451 ' O ' ' O ' ' K' ' 26' ' ' SER . 74.9 m-20 -29.7 159.8 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 113.785 -1.552 . . . . 0.0 113.207 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.577 ' HZ2' ' C ' ' J' ' 23' ' ' ASP . 75.6 tttt 179.48 104.01 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.228 175.154 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -65.62 94.7 0.2 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.923 -0.932 . . . . 0.0 113.781 177.624 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.638 ' O ' HG23 ' K' ' 31' ' ' ILE . . . -168.01 147.08 4.67 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.638 HG23 ' O ' ' K' ' 30' ' ' ALA . 0.1 OUTLIER -160.37 130.02 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.54 0 C-N-CA 118.283 -1.367 . . . . 0.0 113.575 -176.311 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.422 ' O ' HG23 ' K' ' 32' ' ' ILE . 12.8 tt -108.51 113.85 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 175.327 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.485 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -121.35 121.69 4.88 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.613 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.897 HD22 ' CZ ' ' H' ' 19' ' ' PHE . 20.1 tp -140.66 136.99 33.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.781 0.801 . . . . 0.0 110.214 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.545 ' H ' HD12 ' K' ' 34' ' ' LEU . 1.7 ttm -112.03 124.09 51.67 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.664 HG22 HD11 ' L' ' 34' ' ' LEU . 5.4 m -124.06 79.38 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.111 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -69.4 103.3 1.07 Allowed Glycine 0 C--N 1.35 1.308 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.48 146.9 17.38 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -127.12 136.78 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 120.734 0.302 . . . . 0.0 110.223 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.418 ' H ' HG22 ' K' ' 40' ' ' VAL . 16.0 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.422 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -90.22 128.05 36.29 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.754 0.312 . . . . 0.0 110.81 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -140.06 160.83 39.06 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 109.935 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.438 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 49.6 t -118.63 130.17 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.553 0.692 . . . . 0.0 110.372 179.779 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.438 ' CD2' ' O ' ' L' ' 12' ' ' VAL . 88.6 m-70 -156.86 110.44 2.63 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.583 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.509 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 35.3 t-80 -156.85 175.67 13.77 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.039 0.447 . . . . 0.0 109.881 -179.054 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.509 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 77.8 mt-30 -142.4 -179.97 6.59 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.216 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -164.66 114.48 1.16 Allowed 'General case' 0 C--O 1.234 0.261 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.7 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 17.5 mt -116.02 121.25 41.68 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -112.36 133.1 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 118.802 0.728 . . . . 0.0 110.966 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.718 ' C ' ' O ' ' K' ' 19' ' ' PHE . 63.6 m-85 -42.37 141.56 0.95 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 -172.549 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.567 ' N ' ' O ' ' K' ' 19' ' ' PHE . 50.5 p90 -99.93 -169.47 1.74 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-N 108.638 -3.892 . . . . 0.0 110.363 179.298 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -23.47 135.24 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -173.282 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -70.46 159.38 34.35 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 113.04 -1.891 . . . . 0.0 109.239 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -50.52 114.05 1.04 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.106 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 25' ' ' GLY . 3.5 m -127.82 121.22 55.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.812 -178.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -27.84 -87.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.956 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -67.2 -173.01 0.24 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-O 121.222 0.534 . . . . 0.0 109.992 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 10.3 m120 -78.73 175.88 10.04 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.025 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 32.2 tttm -49.12 111.21 0.45 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 114.219 -1.355 . . . . 0.0 113.967 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.47 -97.86 0.05 OUTLIER Glycine 0 C--O 1.223 -0.593 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.535 ' HB2' ' HD3' ' K' ' 28' ' ' LYS . . . -60.95 172.23 1.03 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 120.265 2.033 . . . . 0.0 106.544 -179.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.646 HD13 ' HA2' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -146.9 141.26 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 117.236 -1.786 . . . . 0.0 114.375 -173.586 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.622 ' O ' ' SD ' ' F' ' 35' ' ' MET . 88.4 mt -109.14 114.66 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 CA-C-N 114.061 -1.427 . . . . 0.0 110.131 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.92 91.25 0.56 Allowed Glycine 0 CA--C 1.517 0.179 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 177.343 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.974 HD22 ' CZ ' ' I' ' 19' ' ' PHE . 18.9 tp -117.72 120.65 38.61 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.205 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 42.2 ttp -97.08 119.19 35.11 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.084 179.067 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' L' ' 37' ' ' GLY . 1.4 m -130.25 71.01 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -29.8 -102.67 0.01 OUTLIER Glycine 0 C--N 1.358 1.802 0 O-C-N 122.935 0.147 . . . . 0.0 112.892 -178.729 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.61 163.07 35.86 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -136.81 162.64 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.913 0.387 . . . . 0.0 110.661 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.635 -179.414 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.58 128.89 49.05 Favored 'General case' 0 N--CA 1.463 0.194 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.484 ' OE2' ' NE2' ' A' ' 13' ' ' HIS . 81.6 tt0 -156.09 143.23 19.07 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.529 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p -136.49 143.29 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.663 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.484 ' NE2' ' OE2' ' A' ' 11' ' ' GLU . 98.7 m-70 -131.25 138.83 49.49 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.161 0.505 . . . . 0.0 111.295 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.583 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 10.5 t-80 -156.85 165.85 35.04 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.025 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.583 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 51.2 tt0 -169.52 169.93 8.52 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.537 179.265 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.407 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 65.5 mttm -152.27 115.12 4.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.983 178.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 35.3 tp -121.37 121.6 37.99 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 109.945 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 18' ' ' VAL . 35.5 m -122.85 122.68 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 CA-C-O 121.351 0.596 . . . . 0.0 111.246 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.461 ' CD1' ' CE1' ' B' ' 19' ' ' PHE . 15.6 t80 -123.64 106.41 10.52 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 178.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -134.39 145.94 49.4 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.01 117.76 13.16 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.122 -0.945 . . . . 0.0 108.512 177.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -130.76 157.65 42.27 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.408 ' OD1' ' C ' ' A' ' 23' ' ' ASP . 47.5 t0 -98.42 112.69 24.62 Favored 'General case' 0 N--CA 1.462 0.158 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.089 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.518 ' O ' ' C ' ' A' ' 25' ' ' GLY . 2.1 p -147.72 113.49 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 103.595 -2.742 . . . . 0.0 103.595 172.771 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -19.87 87.17 0.01 OUTLIER Glycine 0 N--CA 1.476 1.303 0 CA-C-O 119.282 -0.732 . . . . 0.0 112.522 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.483 ' N ' ' O ' ' A' ' 24' ' ' VAL . 40.9 t -67.97 -179.72 1.28 Allowed 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 119.219 1.509 . . . . 0.0 108.046 178.044 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 53.2 p30 -87.31 174.93 8.26 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt 35.85 -108.45 0.05 OUTLIER 'General case' 0 CA--C 1.538 0.514 0 CA-C-O 122.28 1.038 . . . . 0.0 113.574 173.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 30' ' ' ALA . . . 90.59 -102.04 2.87 Favored Glycine 1 CA--C 1.427 -5.457 0 CA-C-N 113.157 -1.838 . . . . 0.0 108.635 -177.384 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 29' ' ' GLY . . . 56.63 -146.95 0.54 Allowed 'General case' 0 N--CA 1.405 -2.7 0 C-N-CA 113.497 -3.281 . . . . 0.0 109.7 173.251 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.68 ' H ' ' CD1' ' A' ' 31' ' ' ILE 0.252 0.0 OUTLIER -89.89 113.65 26.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 CA-C-N 113.259 -1.791 . . . . 0.0 113.688 -179.788 . . . . . . . . 4 4 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' G' ' 35' ' ' MET . 87.1 mt -130.03 120.17 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 O-C-N 120.103 -1.623 . . . . 0.0 109.922 178.395 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.609 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.68 113.63 1.53 Allowed Glycine 0 CA--C 1.52 0.375 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -133.29 134.9 44.47 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.99 0.424 . . . . 0.0 110.72 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 5.9 ttm -125.44 129.62 50.21 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.738 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.92 70.8 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 120.656 -0.417 . . . . 0.0 111.473 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -114.66 100.65 1.02 Allowed Glycine 0 C--N 1.341 0.811 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 177.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.65 41.6 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.554 -1.018 . . . . 0.0 110.554 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -120.04 136.21 57.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.76 0.314 . . . . 0.0 110.383 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.7 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.139 -0.934 . . . . 0.0 110.663 -179.895 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 56.3 p90 -143.08 157.41 44.55 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.874 0.369 . . . . 0.0 110.653 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -144.45 150.41 37.61 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.252 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.483 HG12 ' N ' ' B' ' 13' ' ' HIS . 33.5 t -130.77 159.78 42.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.039 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.483 ' N ' HG12 ' B' ' 12' ' ' VAL . 86.0 t60 -157.87 101.47 1.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.628 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 55.7 m170 -110.2 167.44 10.19 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 27.7 mt-30 -152.43 176.7 11.38 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.231 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -171.46 111.95 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.638 178.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 64.1 mt -120.98 120.33 35.11 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.5 t -120.79 121.6 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 120.889 -0.325 . . . . 0.0 111.432 -179.053 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.485 ' CZ ' HD23 ' D' ' 34' ' ' LEU . 12.0 t80 -120.7 110.54 16.51 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -119.32 117.11 27.67 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.22 119.92 34.61 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -177.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' B' ' 23' ' ' ASP . 95.3 mt-10 -153.05 89.82 1.4 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 115.162 -0.926 . . . . 0.0 108.754 176.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.532 ' OD2' ' HB2' ' D' ' 30' ' ' ALA . 49.5 t0 8.2 113.63 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 114.039 1.125 . . . . 0.0 114.039 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 85.4 t -58.56 131.2 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.205 0.526 . . . . 0.0 110.367 178.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.34 84.67 0.13 Allowed Glycine 0 CA--C 1.529 0.927 0 CA-C-N 115.415 -0.811 . . . . 0.0 113.768 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.517 ' O ' ' O ' ' B' ' 27' ' ' ASN . 39.0 m -132.24 162.67 30.38 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 118.284 1.042 . . . . 0.0 110.003 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.517 ' O ' ' O ' ' B' ' 26' ' ' SER . 65.5 t30 -38.44 177.72 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.632 179.384 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.44 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 98.7 mttt -73.31 111.87 8.84 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.527 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' C' ' 29' ' ' GLY . . . 71.22 92.5 0.08 OUTLIER Glycine 0 N--CA 1.464 0.567 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 -178.092 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.58 152.66 49.72 Favored 'General case' 0 CA--C 1.487 -1.465 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 174.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.603 ' N ' HD12 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -139.89 117.44 10.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -173.989 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.524 ' O ' ' SD ' ' I' ' 35' ' ' MET . 81.6 mt -122.13 126.63 74.62 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.733 -177.014 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.1 118.53 3.59 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 42.3 tp -126.53 118.45 24.92 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.292 0.568 . . . . 0.0 110.557 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.8 tpt -106.4 115.52 30.35 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.487 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' B' ' 37' ' ' GLY . 8.8 t -112.65 74.16 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.782 -0.19 . . . . 0.0 110.823 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.594 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -40.07 -95.84 0.01 OUTLIER Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -170.68 40.02 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m -135.72 161.9 37.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.896 0.379 . . . . 0.0 110.344 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.572 179.969 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -86.88 144.87 26.8 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.379 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' D' ' 11' ' ' GLU . 84.6 tt0 -142.32 136.25 29.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.957 0.408 . . . . 0.0 110.55 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 5.6 m -126.23 131.56 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.008 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.424 ' NE2' ' OE2' ' C' ' 11' ' ' GLU . 82.1 m-70 -114.75 127.18 55.6 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.162 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.427 ' CE1' ' CB ' ' D' ' 13' ' ' HIS . 1.3 m80 -119.04 164.08 16.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 79.7 mt-30 -156.68 170.42 22.46 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 121.234 0.54 . . . . 0.0 110.818 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -168.0 113.83 0.68 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.362 178.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 tp -128.15 123.64 34.89 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 35.6 m -124.87 126.68 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.524 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 47.3 t80 -123.78 111.04 15.65 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.929 -178.562 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -114.56 119.35 36.5 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 120.428 0.156 . . . . 0.0 110.767 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.82 115.97 27.85 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.8 mt-10 -150.7 169.4 21.69 Favored 'General case' 0 C--N 1.347 0.473 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.707 -179.201 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.5 ' HB2' ' HZ3' ' E' ' 28' ' ' LYS . 74.8 m-20 -155.45 121.2 5.03 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.794 HG22 ' N ' ' C' ' 25' ' ' GLY . 3.5 p -136.73 -112.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.311 -177.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.794 ' N ' HG22 ' C' ' 24' ' ' VAL . . . 30.38 -89.21 0.01 OUTLIER Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.434 -177.166 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.4 t 171.54 177.73 0.07 Allowed 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 117.817 0.808 . . . . 0.0 109.687 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' C' ' 26' ' ' SER . 42.4 t30 -28.46 178.07 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.722 0 O-C-N 124.766 1.291 . . . . 0.0 113.818 -179.189 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.506 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 88.8 mttt 127.66 104.91 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 C-N-CA 125.564 1.545 . . . . 0.0 111.616 175.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.42 ' O ' ' HA2' ' B' ' 29' ' ' GLY . . . -58.37 96.64 0.07 OUTLIER Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 174.345 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -122.54 145.69 48.1 Favored 'General case' 0 CA--C 1.479 -1.77 0 N-CA-C 104.519 -2.4 . . . . 0.0 104.519 176.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.559 HD12 HG23 ' B' ' 31' ' ' ILE . 2.0 mt -142.8 108.4 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.548 0 CA-C-N 113.851 -1.522 . . . . 0.0 108.801 -172.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.541 HG12 HD11 ' C' ' 34' ' ' LEU . 14.9 tt -120.17 128.06 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 CA-C-O 121.054 0.454 . . . . 0.0 110.176 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.407 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -133.67 122.6 3.1 Favored Glycine 0 CA--C 1.508 -0.387 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.694 HD12 ' N ' ' C' ' 34' ' ' LEU . 0.0 OUTLIER -136.96 147.44 46.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 122.085 0.945 . . . . 0.0 111.837 -179.084 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.509 ' SD ' ' O ' ' I' ' 32' ' ' ILE . 5.1 tpt -111.56 117.42 32.92 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.54 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 26.2 t -130.96 66.33 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 -179.172 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.451 ' O ' HD13 ' I' ' 31' ' ' ILE . . . -123.83 102.48 0.73 Allowed Glycine 0 C--N 1.358 1.772 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.83 -170.31 12.66 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 -179.333 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.2 t -119.47 135.03 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.703 -179.475 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -125.68 143.66 50.94 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.889 0.376 . . . . 0.0 110.557 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' C' ' 11' ' ' GLU . 95.0 mt-10 -63.41 152.46 38.16 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.683 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 32.5 m -134.36 156.87 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 121.008 0.432 . . . . 0.0 110.485 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.676 ' CG ' ' H ' ' D' ' 14' ' ' HIS . 21.7 t-80 -93.14 -169.93 2.28 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.572 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.676 ' H ' ' CG ' ' D' ' 13' ' ' HIS . 52.9 m80 -73.85 170.61 14.99 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.353 0.597 . . . . 0.0 110.146 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -148.93 173.58 13.17 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.177 179.141 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -147.26 114.63 6.29 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 120.898 0.38 . . . . 0.0 111.409 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -122.36 116.16 23.55 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.04 131.13 72.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.38 0.609 . . . . 0.0 110.654 -179.513 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.524 ' CE2' ' CD1' ' C' ' 19' ' ' PHE . 28.1 t80 -131.62 110.75 11.16 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -118.71 126.45 51.93 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.817 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.59 ' HB1' ' CD1' ' F' ' 32' ' ' ILE . . . -124.3 126.25 45.73 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.602 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -149.52 111.56 4.61 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.496 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -90.35 134.04 34.59 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.591 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.09 112.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.278 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.49 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -46.53 91.77 0.01 OUTLIER Glycine 0 CA--C 1.536 1.367 0 CA-C-O 119.125 -0.819 . . . . 0.0 114.276 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 1.4 t 161.98 161.08 0.02 OUTLIER 'General case' 0 C--O 1.212 -0.89 0 CA-C-N 118.472 1.136 . . . . 0.0 112.303 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.49 ' O ' ' HB3' ' D' ' 28' ' ' LYS . 73.7 m-80 -33.48 -179.26 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 112.998 -1.91 . . . . 0.0 116.118 178.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.49 ' HB3' ' O ' ' D' ' 27' ' ' ASN . 87.1 tttt 99.64 113.8 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 128.398 2.679 . . . . 0.0 115.73 177.015 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.29 92.53 0.58 Allowed Glycine 0 C--N 1.348 1.238 0 CA-C-N 111.868 -2.423 . . . . 0.0 114.474 173.58 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.532 ' HB2' ' OD2' ' B' ' 23' ' ' ASP . . . -127.99 151.54 49.02 Favored 'General case' 0 CA--C 1.501 -0.911 0 CA-C-N 121.369 2.584 . . . . 0.0 106.725 173.614 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.488 HD12 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -146.03 116.84 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.56 -173.582 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.25 124.92 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.81 99.19 0.53 Allowed Glycine 0 N--CA 1.464 0.534 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 177.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.636 HD12 ' O ' ' C' ' 34' ' ' LEU . 40.7 tp -126.3 130.23 50.43 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 122.75 1.262 . . . . 0.0 112.69 -179.07 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.415 ' N ' HD12 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -104.54 110.92 23.4 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 113.688 -1.596 . . . . 0.0 107.302 176.372 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.485 HG23 ' O ' ' E' ' 35' ' ' MET . 0.1 OUTLIER -126.68 71.38 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.758 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -34.27 -100.46 0.01 OUTLIER Glycine 0 C--N 1.357 1.696 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.33 -168.06 40.65 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.2 160.58 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.955 0.407 . . . . 0.0 110.933 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.711 -179.978 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -114.47 139.17 49.75 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -113.67 141.26 47.45 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.941 0.4 . . . . 0.0 110.802 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.438 HG22 ' ND1' ' F' ' 13' ' ' HIS . 19.1 m -134.29 158.07 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.95 179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.49 ' ND1' ' CE1' ' D' ' 14' ' ' HIS . 12.1 m170 -86.75 178.31 7.05 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.633 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.1 OUTLIER -77.08 172.23 13.55 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -179.359 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.493 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 44.2 tt0 -148.2 170.17 18.44 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.113 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.493 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 99.1 mttt -144.16 117.28 8.92 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.123 0.487 . . . . 0.0 111.165 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.2 tt -119.21 114.95 23.23 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.358 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 t -124.06 120.46 59.53 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.601 0.715 . . . . 0.0 111.743 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.569 ' O ' ' N ' ' F' ' 20' ' ' PHE . 10.2 m-85 -126.39 104.54 8.23 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 48.1 t80 -121.97 129.6 52.63 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 122.975 0.172 . . . . 0.0 111.092 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.721 ' O ' ' HB3' ' F' ' 21' ' ' ALA . . . -133.82 135.39 43.75 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-O 123.362 1.553 . . . . 0.0 113.332 178.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -145.14 105.37 4.06 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.976 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.431 ' O ' ' OD2' ' F' ' 23' ' ' ASP . 4.2 t0 -83.04 122.63 28.58 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.49 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 63.4 t -72.8 120.42 21.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.353 0.597 . . . . 0.0 111.863 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.9 -90.25 0.04 OUTLIER Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.016 -0.993 . . . . 0.0 114.633 176.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.638 ' O ' ' O ' ' E' ' 27' ' ' ASN . 9.7 p -171.14 -178.61 2.47 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-O 121.153 0.502 . . . . 0.0 110.992 -176.423 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.638 ' O ' ' O ' ' E' ' 26' ' ' SER . 92.1 m-20 20.62 -179.81 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 117.12 2.267 . . . . 0.0 117.12 178.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.512 ' CB ' ' O ' ' E' ' 27' ' ' ASN . 78.2 tttt 128.68 106.13 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 112.381 -2.19 . . . . 0.0 110.002 -177.115 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -55.32 93.6 0.02 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.054 176.464 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.73 144.64 18.07 Favored 'General case' 0 CA--C 1.477 -1.843 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 174.426 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.434 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -154.55 125.66 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 117.946 -1.502 . . . . 0.0 111.177 -173.029 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -109.51 117.42 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.768 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.458 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -109.63 97.86 1.07 Allowed Glycine 0 C--O 1.231 -0.074 0 N-CA-C 106.28 -2.728 . . . . 0.0 106.28 176.537 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.444 ' O ' ' HA ' ' F' ' 34' ' ' LEU . 6.9 tt -138.87 128.68 24.95 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-O 123.01 1.386 . . . . 0.0 113.427 -176.059 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.485 ' O ' HG23 ' D' ' 36' ' ' VAL . 97.3 mmm -106.98 120.27 41.62 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 114.097 -1.41 . . . . 0.0 110.489 179.141 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.1 OUTLIER -116.39 72.31 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 176.968 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -27.71 -101.03 0.01 OUTLIER Glycine 0 C--N 1.366 2.218 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.32 -176.71 25.67 Favored Glycine 0 N--CA 1.461 0.365 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.44 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -129.22 160.18 40.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.28 -0.46 . . . . 0.0 109.995 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.903 -1.046 . . . . 0.0 110.565 179.859 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -96.19 134.65 39.01 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.824 0.345 . . . . 0.0 110.465 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -85.34 136.11 33.61 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.336 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.506 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.7 p -143.28 161.52 17.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.964 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.506 ' N ' HG22 ' F' ' 12' ' ' VAL . 17.5 m-70 -95.02 97.99 10.35 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.586 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.569 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 82.9 t60 -156.36 167.74 29.49 Favored 'General case' 0 N--CA 1.446 -0.672 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.569 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 12.0 pt20 -167.33 177.83 5.86 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.104 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -121.55 123.97 43.26 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.664 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 mt -122.94 121.21 35.59 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 111.653 0.242 . . . . 0.0 111.653 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.89 133.11 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 177.354 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.54 ' O ' ' O ' ' F' ' 20' ' ' PHE . 98.0 m-85 -114.24 136.58 52.8 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -177.632 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.605 ' O ' ' HB2' ' F' ' 21' ' ' ALA . 42.0 p90 -20.58 -157.29 0.0 OUTLIER 'General case' 0 C--O 1.195 -1.792 0 N-CA-C 118.991 2.96 . . . . 0.0 118.991 -175.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.721 ' HB3' ' O ' ' E' ' 21' ' ' ALA . . . 175.54 -168.56 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 122.213 1.006 . . . . 0.0 111.54 -173.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -170.97 167.27 7.35 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 114.473 -1.24 . . . . 0.0 107.964 -177.671 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.431 ' OD2' ' O ' ' E' ' 23' ' ' ASP . 23.6 m-20 -92.84 113.98 26.41 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 119.05 0.841 . . . . 0.0 111.823 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.517 ' O ' HG13 ' F' ' 24' ' ' VAL . 11.7 p -31.2 123.9 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-N 115.194 -0.912 . . . . 0.0 112.743 177.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.87 -85.1 0.1 OUTLIER Glycine 0 CA--C 1.526 0.738 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.79 177.314 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.775 ' O ' ' O ' ' F' ' 27' ' ' ASN . 10.5 m -172.11 173.7 4.25 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 178.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.775 ' O ' ' O ' ' F' ' 26' ' ' SER . 9.0 t-20 19.8 -178.34 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.071 0 O-C-N 125.374 1.671 . . . . 0.0 114.982 178.549 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.505 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 44.6 tttm -108.49 110.36 21.84 Favored 'General case' 0 N--CA 1.473 0.68 0 CA-C-O 121.224 0.535 . . . . 0.0 111.531 179.018 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -50.27 -99.42 0.01 OUTLIER Glycine 0 CA--C 1.506 -0.488 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.553 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.76 173.39 12.65 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.7 118.41 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 116.302 -2.159 . . . . 0.0 114.101 -170.38 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.59 ' CD1' ' HB1' ' D' ' 21' ' ' ALA . 59.4 mt -98.83 112.1 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.054 177.229 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -109.72 89.68 0.56 Allowed Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 105.831 -2.907 . . . . 0.0 105.831 177.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.75 HD23 ' C ' ' F' ' 34' ' ' LEU . 0.8 OUTLIER -141.29 147.65 38.53 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 120.714 -0.394 . . . . 0.0 109.952 -177.894 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.543 ' CE ' HG22 ' L' ' 31' ' ' ILE . 3.6 ttp -137.05 133.95 36.0 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.943 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.666 HG13 HD21 ' F' ' 34' ' ' LEU . 1.9 m -114.28 80.32 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.909 -179.025 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.409 ' HA2' HG21 ' L' ' 31' ' ' ILE . . . 50.82 -102.66 0.07 OUTLIER Glycine 0 C--N 1.342 0.862 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.763 178.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.44 -156.49 15.49 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 90.9 t -122.96 136.22 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.833 0.349 . . . . 0.0 110.959 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 m . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.482 179.683 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -100.93 127.56 47.36 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -88.68 156.89 18.75 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.488 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 3.4 m -132.85 154.69 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.164 0.507 . . . . 0.0 110.601 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 69.7 m80 -158.2 167.11 30.71 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.153 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -122.53 179.1 4.71 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 98.7 mt-30 -96.85 176.6 5.92 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.376 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -113.96 144.04 43.73 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.098 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.3 mt -119.07 126.83 52.6 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.048 0.452 . . . . 0.0 110.786 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.548 ' O ' HG23 ' G' ' 18' ' ' VAL . 25.9 m -133.44 119.96 36.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 121.18 0.514 . . . . 0.0 110.658 179.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.879 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 2.4 m-85 -113.07 119.63 38.51 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.26 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.528 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 48.5 p90 -122.2 121.78 37.65 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.071 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.94 122.47 42.31 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 120.55 -0.46 . . . . 0.0 111.812 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -166.73 89.17 0.36 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.698 ' H ' ' NZ ' ' I' ' 28' ' ' LYS . 90.8 m-20 -85.71 102.78 13.91 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.993 0.425 . . . . 0.0 112.131 -177.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.412 ' O ' ' O ' ' G' ' 23' ' ' ASP . 18.3 m -56.78 -160.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.489 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -77.59 80.51 1.3 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-O 119.524 -0.598 . . . . 0.0 112.947 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.416 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 30.9 t -94.4 176.55 6.26 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 118.76 1.28 . . . . 0.0 107.879 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -60.14 178.24 0.2 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 119.166 -1.013 . . . . 0.0 111.096 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -60.77 110.71 1.39 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.064 -0.517 . . . . 0.0 112.318 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.87 94.25 0.08 OUTLIER Glycine 0 N--CA 1.465 0.61 0 C-N-CA 118.381 -1.866 . . . . 0.0 112.601 174.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.43 158.72 16.46 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-N 119.935 1.867 . . . . 0.0 106.464 177.364 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.831 HD12 ' H ' ' G' ' 31' ' ' ILE . 0.2 OUTLIER -150.31 114.72 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.382 -174.427 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 97.3 mt -125.27 124.98 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.224 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.02 123.12 3.92 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 tp -131.03 133.7 45.99 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 117.211 0.505 . . . . 0.0 111.32 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.609 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 63.4 ttp -130.82 134.91 47.25 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.421 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.52 79.78 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.79 104.64 1.27 Allowed Glycine 0 C--N 1.342 0.905 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 44.05 -167.2 0.02 OUTLIER Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.24 160.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 120.855 0.36 . . . . 0.0 110.65 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.515 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -80.91 136.12 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.781 0.324 . . . . 0.0 110.624 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -52.64 137.63 30.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.466 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.403 HG23 ' O ' ' I' ' 12' ' ' VAL . 2.3 p -127.41 132.87 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.159 0.504 . . . . 0.0 110.744 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.51 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 34.5 m170 -126.99 111.38 14.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.106 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.448 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 84.0 t60 -114.05 162.15 16.82 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.442 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.448 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 83.3 mt-30 -156.72 177.9 10.96 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.136 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -167.73 111.23 0.65 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.824 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.498 ' HB2' HD22 ' I' ' 17' ' ' LEU . 5.3 mp -116.96 120.92 39.91 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.551 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 66.7 t -124.0 123.34 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 121.343 0.592 . . . . 0.0 110.786 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.776 ' CE1' HD13 ' J' ' 34' ' ' LEU . 11.5 m-85 -117.02 115.49 25.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.132 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -143.13 132.2 23.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.967 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 138.84 41.06 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.105 0.955 . . . . 0.0 112.777 -178.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -131.01 105.91 8.04 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 105.861 -1.903 . . . . 0.0 105.861 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -77.95 117.25 19.1 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -175.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.556 ' O ' ' N ' ' H' ' 26' ' ' SER . 55.0 t -102.46 125.94 56.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.6 83.05 0.0 OUTLIER Glycine 0 CA--C 1.537 1.443 0 CA-C-O 119.536 -0.591 . . . . 0.0 113.291 178.408 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.556 ' N ' ' O ' ' H' ' 24' ' ' VAL . 17.4 p -94.15 176.8 6.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 177.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' O ' ' G' ' 26' ' ' SER . 28.1 m120 -60.11 178.22 0.2 Allowed 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.247 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -60.63 110.66 1.35 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.03 94.17 0.08 OUTLIER Glycine 0 N--CA 1.469 0.869 0 C-N-CA 118.741 -1.695 . . . . 0.0 114.815 173.1 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.19 157.57 17.47 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 102.659 -3.089 . . . . 0.0 102.659 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.705 HG23 HG13 ' I' ' 31' ' ' ILE . 0.1 OUTLIER -145.86 121.61 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 118.146 -1.421 . . . . 0.0 112.207 -171.552 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 93.0 mt -132.57 127.47 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.381 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.74 128.6 5.55 Favored Glycine 0 N--CA 1.472 1.097 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.786 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 mp -132.6 130.66 40.53 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.284 0.564 . . . . 0.0 111.458 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.3 tmm? -129.67 127.32 40.29 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.454 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' H' ' 37' ' ' GLY . 66.9 t -107.41 86.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -179.009 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.493 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -15.48 -93.38 0.01 OUTLIER Glycine 0 C--N 1.346 1.084 0 O-C-N 123.859 0.724 . . . . 0.0 112.288 177.812 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.44 -176.13 42.32 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.62 162.23 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 120.715 0.293 . . . . 0.0 110.501 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.403 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.361 179.791 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 46.0 p90 -143.09 147.99 35.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.913 0.387 . . . . 0.0 110.571 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -143.35 131.02 21.3 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.48 HG23 ' CD2' ' I' ' 14' ' ' HIS . 35.7 m -145.18 164.52 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.541 -177.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.533 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 53.3 m-70 -68.43 145.1 54.4 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -177.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.48 ' CD2' HG23 ' I' ' 12' ' ' VAL . 47.8 m-70 -154.66 169.28 24.25 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.382 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.403 ' HG2' ' N ' ' I' ' 16' ' ' LYS . 54.8 tt0 -159.99 168.3 25.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.033 178.786 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.403 ' N ' ' HG2' ' I' ' 15' ' ' GLN . 99.2 mttt -154.64 131.54 10.83 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.51 0.195 . . . . 0.0 110.539 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.509 HD12 ' CE2' ' I' ' 19' ' ' PHE . 0.0 OUTLIER -127.72 119.91 26.82 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.68 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 70.7 t -126.24 129.53 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 120.629 -0.428 . . . . 0.0 112.151 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.702 ' CE1' HD22 ' K' ' 34' ' ' LEU . 61.2 m-85 -123.22 121.75 36.68 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.924 179.169 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.419 ' CE2' ' CG ' ' J' ' 20' ' ' PHE . 7.5 m-85 -131.67 130.69 42.37 Favored 'General case' 0 N--CA 1.476 0.867 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 135.17 39.23 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -137.76 150.28 47.12 Favored 'General case' 0 C--N 1.352 0.692 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.247 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.435 ' OD2' ' O ' ' J' ' 26' ' ' SER . 13.4 t70 -116.95 114.53 23.96 Favored 'General case' 0 N--CA 1.481 1.115 0 O-C-N 122.21 -0.306 . . . . 0.0 111.36 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.458 ' O ' ' N ' ' I' ' 26' ' ' SER . 14.7 t -81.59 130.93 34.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.708 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.8 -85.8 0.01 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.529 ' O ' ' O ' ' I' ' 27' ' ' ASN . 26.1 p -153.62 -172.86 4.37 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-O 121.639 0.733 . . . . 0.0 111.224 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.686 ' H ' ' NZ ' ' K' ' 28' ' ' LYS . 64.8 t30 -19.71 159.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 113.303 -1.771 . . . . 0.0 115.156 178.502 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.698 ' NZ ' ' H ' ' G' ' 23' ' ' ASP . 74.1 tttt -161.21 110.83 1.64 Allowed 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 114.744 -1.116 . . . . 0.0 109.376 175.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.33 93.23 0.23 Allowed Glycine 0 CA--C 1.508 -0.369 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 177.313 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.73 147.05 51.3 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 176.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.705 HG13 HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -146.68 113.97 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.942 -175.583 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.509 ' O ' ' SD ' ' C' ' 35' ' ' MET . 0.1 OUTLIER -110.76 124.56 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.522 179.471 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.35 102.84 1.39 Allowed Glycine 0 N--CA 1.46 0.292 0 N-CA-C 108.446 -1.862 . . . . 0.0 108.446 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.879 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 23.1 tp -119.0 126.68 52.29 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 117.277 0.538 . . . . 0.0 111.817 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.524 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 12.2 ptm -131.9 110.87 11.1 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 174.52 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.599 HG13 HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -121.18 72.02 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.652 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.57 179.554 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.61 102.81 2.33 Favored Glycine 0 C--N 1.36 1.869 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.62 157.36 22.07 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.4 t -124.28 136.56 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.913 0.387 . . . . 0.0 110.53 -179.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.377 179.78 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.426 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -83.38 138.48 33.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.797 0.332 . . . . 0.0 110.478 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.461 ' O ' HG12 ' K' ' 12' ' ' VAL . 79.9 tt0 -152.34 137.54 17.43 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.408 -179.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.435 ' HB ' ' H ' ' K' ' 13' ' ' HIS . 0.2 OUTLIER -93.03 126.93 45.4 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.694 0 CA-C-O 121.319 0.58 . . . . 0.0 109.847 -179.932 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.533 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 18.3 t60 -164.92 111.76 0.99 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.233 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.757 ' CE1' ' O ' ' K' ' 13' ' ' HIS . 77.3 m80 -154.55 177.23 11.43 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -133.82 177.58 7.61 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.731 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -137.54 131.77 32.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 mt -117.89 121.7 41.41 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.673 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 67.8 t -122.47 121.21 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-O 120.948 0.404 . . . . 0.0 110.961 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.862 ' CE1' HD22 ' L' ' 34' ' ' LEU . 96.9 m-85 -113.39 114.49 26.68 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 178.83 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 19.2 t80 -129.03 123.34 32.09 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.988 0.423 . . . . 0.0 111.634 -177.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.94 124.12 32.31 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.05 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.4 tt0 -103.52 156.81 17.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.131 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.456 ' CG ' ' N ' ' J' ' 24' ' ' VAL . 35.2 t70 -78.13 -113.89 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.341 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' J' ' 26' ' ' SER . 4.1 t 73.45 124.45 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.57 -87.09 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -177.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.678 ' O ' ' O ' ' J' ' 27' ' ' ASN . 0.5 OUTLIER 170.79 176.17 0.06 Allowed 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.702 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.678 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.4 m120 -28.3 170.42 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.13 0 O-C-N 124.319 1.012 . . . . 0.0 112.074 177.446 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.561 ' O ' ' N ' ' J' ' 30' ' ' ALA . 37.4 pttt -148.73 111.55 4.82 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.161 -0.962 . . . . 0.0 112.208 177.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.44 91.35 0.01 OUTLIER Glycine 0 CA--C 1.505 -0.566 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 176.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -137.85 153.71 49.56 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 103.328 -2.842 . . . . 0.0 103.328 177.576 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.417 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -144.41 111.67 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 C-N-CA 118.265 -1.374 . . . . 0.0 109.968 -174.096 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.484 HD13 HD11 ' J' ' 34' ' ' LEU . 6.7 tt -112.71 116.63 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.293 -0.867 . . . . 0.0 108.731 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.07 103.69 2.33 Favored Glycine 0 N--CA 1.46 0.284 0 N-CA-C 107.596 -2.202 . . . . 0.0 107.596 178.467 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.776 HD13 ' CE1' ' H' ' 19' ' ' PHE . 24.2 mt -114.39 114.0 25.28 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 121.606 0.717 . . . . 0.0 110.247 -177.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -116.59 118.65 33.21 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.506 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.44 ' O ' ' C ' ' J' ' 37' ' ' GLY . 1.1 t -131.15 75.95 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.025 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.2 -97.56 0.01 OUTLIER Glycine 0 C--N 1.362 2.025 0 N-CA-C 112.097 -0.401 . . . . 0.0 112.097 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.97 -163.85 30.23 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 82.9 t -121.95 135.32 62.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.039 -0.982 . . . . 0.0 110.554 -179.649 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.1 137.88 50.77 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 120.89 0.376 . . . . 0.0 110.514 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.77 162.28 35.12 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.4 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.461 HG12 ' O ' ' J' ' 11' ' ' GLU . 6.0 m -110.7 133.22 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.757 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 0.4 OUTLIER -76.12 -166.01 0.55 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.259 -178.546 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 7.6 p-80 -138.23 178.45 7.12 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.607 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -99.27 175.1 5.99 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.486 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -147.42 124.95 11.69 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -117.55 124.05 47.74 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 44.9 t -127.94 126.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-O 120.832 0.349 . . . . 0.0 111.575 -179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -115.62 116.09 27.53 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.594 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.7 t80 -125.19 122.73 37.88 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.68 26.4 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.159 1.17 . . . . 0.0 114.159 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' L' ' 22' ' ' GLU . 70.3 mm-40 -90.46 152.41 20.97 Favored 'General case' 0 C--O 1.232 0.158 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 177.667 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.561 ' OD2' ' N ' ' L' ' 28' ' ' LYS . 28.0 t0 -148.43 116.29 6.36 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.028 0.442 . . . . 0.0 111.739 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 2.5 p -146.81 112.14 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.044 -179.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.32 91.32 0.01 OUTLIER Glycine 0 N--CA 1.472 1.064 0 CA-C-O 121.509 0.505 . . . . 0.0 112.63 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -45.15 153.86 0.18 Allowed 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 122.597 1.189 . . . . 0.0 112.511 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.514 ' O ' ' C ' ' K' ' 28' ' ' LYS . 33.9 m120 -156.85 178.58 10.19 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 112.631 -2.077 . . . . 0.0 108.483 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.686 ' NZ ' ' H ' ' I' ' 27' ' ' ASN . 0.1 OUTLIER 2.91 -104.33 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.411 0 C-N-CA 123.562 0.745 . . . . 0.0 112.05 179.816 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.436 ' H ' ' HB2' ' K' ' 28' ' ' LYS . . . 141.09 95.33 0.25 Allowed Glycine 0 N--CA 1.48 1.602 0 CA-C-N 118.986 0.812 . . . . 0.0 111.924 178.051 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.4 169.85 0.41 Allowed 'General case' 0 C--N 1.345 0.399 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.036 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.417 HD12 ' CG2' ' J' ' 31' ' ' ILE . 0.0 OUTLIER -148.53 111.97 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 118.996 -1.082 . . . . 0.0 109.035 -179.028 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.541 HG12 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -111.99 122.08 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.465 -177.998 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.45 108.99 2.54 Favored Glycine 0 N--CA 1.468 0.829 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.702 HD22 ' CE1' ' I' ' 19' ' ' PHE . 5.1 mt -122.09 114.96 21.63 Favored 'General case' 0 CA--C 1.501 -0.913 0 CA-C-N 117.332 0.566 . . . . 0.0 110.821 -177.261 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.458 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 33.6 ttp -120.86 114.31 21.41 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 176.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.479 HG23 HG12 ' L' ' 36' ' ' VAL . 0.0 OUTLIER -130.19 73.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 107.672 -1.232 . . . . 0.0 107.672 178.632 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.35 -101.6 0.01 OUTLIER Glycine 0 C--N 1.364 2.121 0 O-C-N 123.59 0.556 . . . . 0.0 112.482 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.35 -170.97 38.11 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -125.13 137.19 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.848 -179.788 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -100.77 132.7 46.04 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -151.32 147.39 26.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.965 0.412 . . . . 0.0 111.055 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.5 t -123.13 129.32 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.471 ' O ' ' CG ' ' L' ' 13' ' ' HIS . 56.5 p-80 -170.74 111.88 0.39 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.053 0.454 . . . . 0.0 110.973 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 72.9 m80 -155.8 177.81 10.98 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -115.58 173.8 6.35 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.302 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 50.3 mtpt -151.25 109.54 3.76 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.959 0.409 . . . . 0.0 110.455 179.136 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 57.6 tp -123.66 118.51 27.44 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -130.26 133.06 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.875 0.369 . . . . 0.0 110.086 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.469 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -136.86 129.73 30.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.271 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -138.8 132.05 30.0 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.496 0.665 . . . . 0.0 110.455 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.83 138.88 42.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.498 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 95.0 mt-10 -98.4 114.73 27.19 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -102.68 121.64 42.83 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.26 0.552 . . . . 0.0 111.838 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 25.3 t -104.91 -111.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.34 -91.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' L' ' 27' ' ' ASN . 45.9 m -141.01 170.68 15.28 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' L' ' 26' ' ' SER . 93.8 m-20 -29.0 170.13 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.828 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.561 ' N ' ' OD2' ' K' ' 23' ' ' ASP . 87.8 tttt -148.35 109.99 4.46 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 176.08 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -50.84 -95.8 0.01 OUTLIER Glycine 0 C--N 1.334 0.445 0 C-N-CA 118.549 -1.786 . . . . 0.0 112.545 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.599 ' HB2' HD21 ' J' ' 27' ' ' ASN . . . 72.57 156.11 0.17 Allowed 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 100.409 -3.923 . . . . 0.0 100.409 -176.749 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.543 HG22 ' CE ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -144.77 107.67 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 CA-C-N 124.081 3.128 . . . . 0.0 109.237 179.781 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.648 HG23 HD23 ' L' ' 34' ' ' LEU . 1.4 tt -102.53 112.46 35.93 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 CA-C-N 113.956 -1.475 . . . . 0.0 109.975 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.1 96.69 1.0 Allowed Glycine 0 N--CA 1.46 0.286 0 N-CA-C 107.296 -2.321 . . . . 0.0 107.296 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.862 HD22 ' CE1' ' J' ' 19' ' ' PHE . 3.4 pp -120.62 125.88 48.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.91 0.386 . . . . 0.0 110.948 -177.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 65.6 ttp -125.6 121.77 34.52 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-O 121.431 0.634 . . . . 0.0 109.877 179.112 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.479 HG12 HG23 ' K' ' 36' ' ' VAL . 2.8 m -124.26 77.05 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.65 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -35.64 104.81 0.03 OUTLIER Glycine 0 C--N 1.349 1.289 0 N-CA-C 111.751 -0.539 . . . . 0.0 111.751 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.05 -177.28 42.51 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 8.5 p -140.86 151.12 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 121.081 0.467 . . . . 0.0 111.066 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 47.3 t . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.292 179.7 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.0 t . . . . . 0 N--CA 1.465 0.283 0 CA-C-O 121.426 0.632 . . . . 0.0 111.591 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -106.5 -172.35 2.07 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.96 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 48.5 p-80 -146.8 170.92 16.02 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -147.69 178.75 8.22 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.603 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -138.7 129.45 26.36 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.801 0.334 . . . . 0.0 110.467 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.4 mt -112.48 114.61 27.39 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.592 HG23 ' O ' ' A' ' 18' ' ' VAL . 6.2 m -127.55 121.16 56.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.119 0 CA-C-O 121.345 0.593 . . . . 0.0 111.433 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.501 ' CE1' HD21 ' D' ' 34' ' ' LEU . 0.9 OUTLIER -116.88 107.9 15.17 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 177.283 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.4 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.8 p90 -126.68 126.81 44.15 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.94 125.62 53.84 Favored 'General case' 0 C--O 1.24 0.577 0 CA-C-O 121.275 0.56 . . . . 0.0 111.624 -178.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -155.47 82.0 1.04 Allowed 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.162 -2.162 . . . . 0.0 105.162 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -34.84 120.64 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 114.922 -1.035 . . . . 0.0 113.612 -176.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 26' ' ' SER . 60.7 t -100.94 125.13 54.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 177.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -31.71 83.27 0.0 OUTLIER Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.324 0.39 . . . . 0.0 113.033 -177.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.599 ' N ' ' O ' ' A' ' 24' ' ' VAL . 69.5 m -87.02 -179.23 6.45 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 28' ' ' LYS . 11.8 m120 -75.71 178.53 6.03 Favored 'General case' 0 C--N 1.314 -0.966 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.094 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.519 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 99.1 mttt -45.34 -110.77 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.879 0.847 . . . . 0.0 112.066 178.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.32 93.71 1.65 Allowed Glycine 0 N--CA 1.467 0.734 0 CA-C-O 118.428 -1.206 . . . . 0.0 110.181 178.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.57 160.11 14.73 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 116.688 -2.005 . . . . 0.0 108.699 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.648 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.4 OUTLIER -155.39 117.81 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 113.986 -1.461 . . . . 0.0 109.464 -173.987 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.453 ' C ' ' SD ' ' G' ' 35' ' ' MET . 96.9 mt -126.33 129.37 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-O 120.812 0.339 . . . . 0.0 110.686 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.49 121.67 2.73 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.9 mt -138.96 139.07 37.84 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.938 0.875 . . . . 0.0 111.463 179.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.438 ' C ' ' SD ' ' A' ' 35' ' ' MET . 6.8 tmm? -136.15 131.42 34.66 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.288 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.0 t -121.52 73.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.415 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -105.5 100.7 1.75 Allowed Glycine 0 N--CA 1.442 -0.933 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 178.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -177.66 170.44 42.84 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 N--CA 1.468 0.428 0 CA-C-O 120.889 0.376 . . . . 0.0 110.795 179.981 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.461 0.172 . . . . 0.0 110.799 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -132.41 104.95 6.98 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.585 0.231 . . . . 0.0 110.793 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' B' ' 15' ' ' GLN . 52.7 m170 -126.33 167.08 15.99 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.6 mm-40 -155.27 178.39 10.27 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.663 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -171.08 115.72 0.43 Allowed 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.113 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.679 HD23 ' C ' ' B' ' 17' ' ' LEU . 8.2 tt -128.42 122.62 31.77 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.127 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.41 ' N ' HD23 ' B' ' 17' ' ' LEU . 28.6 m -137.76 131.98 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 N-CA-C 113.129 0.788 . . . . 0.0 113.129 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.548 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 2.8 m-85 -110.09 115.68 30.19 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.198 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.598 ' CE1' ' CD1' ' C' ' 20' ' ' PHE . 74.2 t80 -121.76 123.5 41.97 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.56 124.76 36.77 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 113.04 0.756 . . . . 0.0 113.04 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.451 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 42.8 tp10 -153.99 129.49 9.91 Favored 'General case' 0 C--O 1.221 -0.415 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.344 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.529 ' OD2' ' NZ ' ' C' ' 28' ' ' LYS . 8.8 t0 -152.41 134.99 15.31 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.055 -178.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' B' ' 25' ' ' GLY . 2.1 p -110.73 111.68 37.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.898 -1.047 . . . . 0.0 108.928 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 32.74 90.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.349 0 C-N-CA 121.586 -0.34 . . . . 0.0 113.328 177.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.51 ' OG ' ' CE ' ' C' ' 28' ' ' LYS . 54.8 p -100.31 150.52 22.49 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 117.626 0.713 . . . . 0.0 109.083 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 28' ' ' LYS . 11.6 t30 -42.02 173.94 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.852 0.834 . . . . 0.0 113.207 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.514 ' N ' ' ND2' ' B' ' 27' ' ' ASN . 57.7 tttt -76.3 111.15 11.43 Favored 'General case' 0 CA--C 1.548 0.893 0 N-CA-C 115.563 1.69 . . . . 0.0 115.563 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.36 93.41 0.03 OUTLIER Glycine 0 N--CA 1.478 1.454 0 C-N-CA 119.123 -1.513 . . . . 0.0 115.695 171.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.442 ' C ' ' CG1' ' B' ' 31' ' ' ILE . . . -123.3 152.47 41.38 Favored 'General case' 0 C--O 1.245 0.836 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 173.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.648 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.2 OUTLIER -152.8 135.31 6.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 C-N-CA 118.215 -1.394 . . . . 0.0 111.899 -171.762 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 16.5 tt -146.29 137.44 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.332 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.48 128.89 6.48 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.441 ' HB2' HD22 ' C' ' 34' ' ' LEU . 48.9 mt -139.33 128.98 24.55 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 122.227 -0.573 . . . . 0.0 111.94 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.43 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 61.8 ttp -130.93 127.33 38.23 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.247 177.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' B' ' 37' ' ' GLY . 15.4 m -133.83 76.4 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 119.936 -0.706 . . . . 0.0 112.779 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.437 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -33.6 -95.67 0.01 OUTLIER Glycine 0 CA--C 1.53 1.0 0 N-CA-C 111.521 -0.632 . . . . 0.0 111.521 178.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.47 -168.75 35.43 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.64 134.78 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 120.985 0.421 . . . . 0.0 110.412 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.668 179.837 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -108.44 132.09 54.13 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.551 0.215 . . . . 0.0 110.457 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -95.92 134.77 38.52 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 121.014 0.435 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -127.71 136.15 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.11 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -130.16 125.48 35.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.792 0.33 . . . . 0.0 111.013 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.497 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 45.1 t-80 -145.2 166.79 24.44 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.497 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 99.7 mm-40 -153.16 176.83 11.49 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.807 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.66 ' C ' HD12 ' C' ' 17' ' ' LEU . 69.0 tttt -170.17 104.31 0.3 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.598 178.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.66 HD12 ' C ' ' C' ' 16' ' ' LYS . 11.2 mp -118.5 118.59 32.12 Favored 'General case' 0 C--O 1.237 0.432 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -131.73 131.5 62.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.895 ' CZ ' HD23 ' E' ' 34' ' ' LEU . 52.3 m-85 -113.69 116.51 29.55 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.382 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE1' ' B' ' 20' ' ' PHE . 51.9 t80 -125.94 122.14 35.12 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 118.625 0.648 . . . . 0.0 109.548 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . 0.527 ' HB1' ' HB3' ' D' ' 27' ' ' ASN . . . -137.29 130.12 30.37 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 113.769 1.025 . . . . 0.0 113.769 -178.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.451 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 71.3 mt-10 -155.17 114.98 3.72 Favored 'General case' 0 C--N 1.352 0.682 0 CA-C-N 113.661 -1.608 . . . . 0.0 108.806 178.104 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.423 ' O ' ' O ' ' D' ' 26' ' ' SER . 65.6 t0 -147.54 122.51 10.05 Favored 'General case' 0 N--CA 1.476 0.862 0 O-C-N 121.739 -0.6 . . . . 0.0 111.419 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 14.5 t -98.53 -112.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.056 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 39.68 -90.94 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.103 -179.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.631 ' O ' ' O ' ' C' ' 27' ' ' ASN . 2.0 m 171.15 170.11 0.08 Allowed 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.631 ' O ' ' O ' ' C' ' 26' ' ' SER . 65.8 t30 -17.56 158.61 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 O-C-N 124.616 1.198 . . . . 0.0 113.696 177.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.529 ' NZ ' ' OD2' ' B' ' 23' ' ' ASP . 50.5 tttt -161.26 110.63 1.61 Allowed 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.521 174.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.69 92.64 0.29 Allowed Glycine 0 C--O 1.224 -0.488 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 173.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.16 150.5 47.98 Favored 'General case' 0 CA--C 1.476 -1.885 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 174.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.42 HD13 HG21 ' C' ' 31' ' ' ILE . 0.1 OUTLIER -147.36 114.49 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 C-N-CA 117.672 -1.611 . . . . 0.0 110.996 -173.931 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 9.2 mt -108.84 124.04 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.147 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.859 ' O ' HD23 ' C' ' 34' ' ' LEU . . . -125.43 100.62 0.6 Allowed Glycine 0 N--CA 1.474 1.186 0 N-CA-C 108.521 -1.831 . . . . 0.0 108.521 177.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.859 HD23 ' O ' ' C' ' 33' ' ' GLY . 1.6 mt -134.32 142.27 47.19 Favored 'General case' 0 C--O 1.243 0.722 0 CA-C-O 122.886 1.327 . . . . 0.0 113.859 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.544 ' SD ' ' CE ' ' D' ' 35' ' ' MET . 41.9 ttp -127.51 118.8 24.7 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 112.771 -2.013 . . . . 0.0 108.127 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.448 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.1 OUTLIER -116.33 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-N 114.173 -1.376 . . . . 0.0 107.864 179.067 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -39.86 -101.48 0.01 OUTLIER Glycine 0 C--N 1.366 2.238 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.88 -145.83 11.32 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.4 m -128.32 158.85 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 120.664 0.269 . . . . 0.0 110.306 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.467 179.984 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 N--CA 1.465 0.281 0 CA-C-O 121.348 0.594 . . . . 0.0 110.757 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -132.97 134.85 45.05 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.666 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 73.3 m80 -149.04 167.03 26.93 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 121.266 0.555 . . . . 0.0 110.039 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -155.76 171.23 20.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.326 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -158.62 114.1 2.62 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.926 -0.31 . . . . 0.0 111.107 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mt -118.55 119.13 33.59 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -131.31 129.54 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.603 ' CZ ' ' CD1' ' C' ' 19' ' ' PHE . 19.8 m-85 -118.97 123.63 45.04 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -131.26 119.83 22.35 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.747 0.308 . . . . 0.0 111.633 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.47 ' HB1' HD21 ' D' ' 27' ' ' ASN . . . -130.08 122.45 28.35 Favored 'General case' 0 N--CA 1.476 0.835 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.136 178.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -84.9 157.01 20.99 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.416 ' HA ' ' NZ ' ' F' ' 28' ' ' LYS . 1.2 t0 -88.72 -174.12 4.4 Favored 'General case' 0 C--N 1.348 0.525 0 CA-C-O 121.213 0.53 . . . . 0.0 110.897 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.413 ' O ' ' O ' ' D' ' 25' ' ' GLY . 20.7 t 62.64 104.45 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' D' ' 24' ' ' VAL . . . 64.71 100.0 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 117.618 -2.23 . . . . 0.0 107.686 -178.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.423 ' O ' ' O ' ' C' ' 23' ' ' ASP . 78.6 p -52.44 171.93 0.05 OUTLIER 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 118.037 0.918 . . . . 0.0 108.617 -176.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.527 ' HB3' ' HB1' ' C' ' 21' ' ' ALA . 27.4 m-20 -81.84 178.51 8.27 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.694 -0.802 . . . . 0.0 112.115 -175.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' D' ' 27' ' ' ASN . 44.2 tttp -38.6 -106.51 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.294 -1.321 . . . . 0.0 112.533 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.673 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . 86.29 -100.04 2.48 Favored Glycine 0 CA--C 1.456 -3.637 0 N-CA-C 106.218 -2.753 . . . . 0.0 106.218 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.918 ' C ' HD13 ' D' ' 31' ' ' ILE . . . 67.55 -163.86 0.21 Allowed 'General case' 0 N--CA 1.419 -2.001 1 N-CA-C 98.449 -4.648 . . . . 0.0 98.449 -176.36 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.918 HD13 ' C ' ' D' ' 30' ' ' ALA . 0.0 OUTLIER -115.79 110.94 33.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 CA-C-N 123.941 3.064 . . . . 0.0 110.397 177.258 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.446 ' C ' ' SD ' ' J' ' 35' ' ' MET . 13.7 tt -122.57 127.56 75.04 Favored 'Isoleucine or valine' 0 C--N 1.353 0.744 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.96 179.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.544 ' O ' HD12 ' D' ' 34' ' ' LEU . . . -121.36 101.22 0.77 Allowed Glycine 0 N--CA 1.457 0.092 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.544 HD12 ' O ' ' D' ' 33' ' ' GLY . 5.0 mp -120.34 125.81 48.96 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 122.32 1.057 . . . . 0.0 110.923 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.617 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 37.3 ttp -120.29 119.26 32.63 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 113.928 -1.487 . . . . 0.0 107.839 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.51 74.06 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.698 -178.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . -48.35 111.45 0.89 Allowed Glycine 0 C--N 1.351 1.392 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 37' ' ' GLY . . . -59.77 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 74.7 t -120.95 133.73 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.688 -179.93 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -109.23 132.86 53.72 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.58 151.0 42.79 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.684 0.278 . . . . 0.0 110.629 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 66.2 t -125.86 131.2 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.947 0.403 . . . . 0.0 110.609 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 16.9 t60 -138.93 130.75 27.69 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.532 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 27.1 m80 -148.15 168.24 22.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.751 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.633 ' NE2' HE21 ' F' ' 15' ' ' GLN . 75.1 mt-30 -154.83 165.97 34.97 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.427 178.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -148.6 117.73 6.81 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.192 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.27 122.72 34.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.238 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -127.56 125.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.074 0.464 . . . . 0.0 111.0 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -117.74 113.81 22.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.542 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 55.0 t80 -123.46 116.72 23.69 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 134.74 15.52 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 118.974 -1.09 . . . . 0.0 113.664 -178.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -102.6 117.28 34.33 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 176.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.498 ' OD1' ' N ' ' E' ' 23' ' ' ASP . 7.1 p-10 -131.06 113.26 13.72 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 114.395 1.257 . . . . 0.0 114.395 -177.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.631 ' O ' ' N ' ' E' ' 26' ' ' SER . 40.3 t -127.23 122.29 59.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 175.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.467 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . -28.97 83.8 0.0 OUTLIER Glycine 0 N--CA 1.484 1.883 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.631 ' N ' ' O ' ' E' ' 24' ' ' VAL . 6.3 p -88.24 -179.75 6.2 Favored 'General case' 0 N--CA 1.441 -0.885 0 CA-C-O 123.102 1.43 . . . . 0.0 113.734 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -77.04 179.35 6.31 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-N 111.446 -2.616 . . . . 0.0 110.836 176.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.478 ' HE2' ' HB2' ' E' ' 30' ' ' ALA . 82.9 tttt 42.88 110.98 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 114.697 1.369 . . . . 0.0 114.697 176.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.43 93.99 1.68 Allowed Glycine 0 N--CA 1.47 0.905 0 N-CA-C 108.035 -2.026 . . . . 0.0 108.035 174.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.659 ' HB1' ' H ' ' D' ' 30' ' ' ALA . . . -100.5 166.79 10.75 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.475 HG22 ' HE1' ' L' ' 35' ' ' MET . 0.0 OUTLIER -156.44 121.79 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.051 0 C-N-CA 117.916 -1.514 . . . . 0.0 112.306 -173.087 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -111.15 123.74 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.877 178.188 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.8 109.78 1.7 Allowed Glycine 0 CA--C 1.512 -0.139 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.895 HD23 ' CZ ' ' C' ' 19' ' ' PHE . 41.5 tp -133.24 126.74 32.2 Favored 'General case' 0 C--O 1.243 0.745 0 CA-C-O 121.848 0.832 . . . . 0.0 111.454 -179.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.541 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 57.9 ttp -115.62 124.3 50.58 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.059 177.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -129.68 71.58 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.332 -179.885 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -32.46 -101.0 0.01 OUTLIER Glycine 0 C--N 1.364 2.106 0 N-CA-C 111.678 -0.569 . . . . 0.0 111.678 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.18 159.2 30.21 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.94 161.38 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.697 0.284 . . . . 0.0 110.424 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.509 179.501 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 77.0 t . . . . . 0 N--CA 1.464 0.27 0 CA-C-O 121.144 0.497 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -161.11 109.84 1.58 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.243 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -153.63 174.58 14.29 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.633 HE21 ' NE2' ' E' ' 15' ' ' GLN . 95.0 mt-30 -145.56 172.89 12.59 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.326 -0.549 . . . . 0.0 110.605 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.79 112.32 7.83 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.012 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.583 HD23 ' C ' ' F' ' 17' ' ' LEU . 8.4 tt -125.2 122.4 36.9 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.418 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . 0.415 ' N ' HD23 ' F' ' 17' ' ' LEU . 69.2 t -129.32 130.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.536 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 53.0 p90 -131.5 127.47 37.36 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.816 0.341 . . . . 0.0 110.292 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -142.04 126.87 18.16 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.422 0.629 . . . . 0.0 110.057 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -161.3 161.9 30.77 Favored 'General case' 0 C--N 1.32 -0.683 0 C-N-CA 120.08 -0.648 . . . . 0.0 111.082 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 95.6 mt-10 -116.82 107.99 15.3 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.275 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 49.1 t0 . . . . . 0 N--CA 1.467 0.401 0 CA-C-O 121.265 0.555 . . . . 0.0 111.951 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.546 ' O ' ' N ' ' F' ' 30' ' ' ALA . 22.6 tttt . . . . . 0 CA--C 1.527 0.086 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.88 91.65 0.08 OUTLIER Glycine 0 N--CA 1.467 0.761 0 C-N-CA 117.056 -2.497 . . . . 0.0 109.034 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.546 ' N ' ' O ' ' F' ' 28' ' ' LYS . . . -171.53 162.01 6.4 Favored 'General case' 0 C--N 1.295 -1.786 1 N-CA-C 98.752 -4.536 . . . . 0.0 98.752 178.569 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.463 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.0 OUTLIER -152.11 131.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 115.778 -2.369 . . . . 0.0 113.243 -175.262 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.55 HG22 HD23 ' F' ' 34' ' ' LEU . 76.0 mt -106.12 113.49 42.99 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 114.13 -1.395 . . . . 0.0 109.615 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.08 96.46 1.53 Allowed Glycine 0 CA--C 1.502 -0.75 0 N-CA-C 106.217 -2.753 . . . . 0.0 106.217 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.55 HD23 HG22 ' F' ' 32' ' ' ILE . 1.4 pp -118.39 122.2 42.23 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 111.478 0.177 . . . . 0.0 111.478 -177.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.784 ' SD ' HG23 ' L' ' 31' ' ' ILE . 58.1 ttp -118.71 115.71 25.07 Favored 'General case' 0 CA--C 1.5 -0.96 0 C-N-CA 119.094 -1.042 . . . . 0.0 108.64 176.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' F' ' 37' ' ' GLY . 3.1 m -123.34 71.44 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -24.97 -103.29 0.0 OUTLIER Glycine 0 C--N 1.36 1.863 0 O-C-N 123.515 0.509 . . . . 0.0 112.432 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.04 163.27 7.45 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -144.34 143.32 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.79 0.328 . . . . 0.0 110.612 179.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.428 179.921 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -118.64 138.27 52.72 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.801 0.334 . . . . 0.0 110.496 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -76.2 158.62 31.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.289 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 56.8 t -118.27 132.93 66.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.147 0.499 . . . . 0.0 110.225 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -104.77 -168.78 1.52 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.395 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.45 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 3.4 m80 -76.57 165.28 25.0 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.449 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 6.3 tp-100 -161.67 175.18 12.3 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.449 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 64.2 tttp -161.63 131.82 4.91 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.102 179.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -123.54 125.66 45.28 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.397 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 63.2 t -125.19 126.45 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.857 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.853 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 5.7 t80 -114.49 109.08 17.73 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -118.34 115.66 25.15 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.94 121.38 44.49 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.96 0.41 . . . . 0.0 110.632 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -154.81 118.34 4.54 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -58.23 121.27 10.33 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.279 -178.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.2 m -88.25 124.15 41.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.99 84.53 0.01 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 121.461 -0.4 . . . . 0.0 112.192 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' G' ' 24' ' ' VAL . 60.7 m -93.52 178.6 5.65 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.03 178.73 0.17 Allowed 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.127 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.95 110.94 1.3 Allowed 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.101 -0.64 . . . . 0.0 111.009 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.848 ' H ' HD22 ' H' ' 27' ' ' ASN . . . 71.16 93.11 0.08 OUTLIER Glycine 0 N--CA 1.463 0.485 0 C-N-CA 119.501 -1.333 . . . . 0.0 112.21 176.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.67 160.27 17.42 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 119.784 1.792 . . . . 0.0 109.195 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.426 HG22 HD12 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -145.04 123.67 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.017 -177.107 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -133.96 128.29 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 O-C-N 121.942 -0.474 . . . . 0.0 111.249 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.04 121.59 3.43 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 54.6 tp -142.5 135.13 28.05 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.384 0.611 . . . . 0.0 112.254 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.453 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 66.3 ttp -127.3 139.01 53.18 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' G' ' 37' ' ' GLY . 22.5 t -133.55 78.36 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -179.31 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.433 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -33.85 -94.11 0.01 OUTLIER Glycine 0 C--N 1.345 1.045 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 177.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.99 -164.32 37.87 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -126.53 158.1 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.482 -179.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.613 -179.197 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -104.53 131.66 51.67 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -141.3 144.47 34.64 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.608 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.449 ' O ' HG23 ' H' ' 12' ' ' VAL . 18.9 m -125.62 131.84 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -127.1 115.71 19.56 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-O 120.854 0.359 . . . . 0.0 110.956 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.405 ' CD2' ' N ' ' H' ' 14' ' ' HIS . 5.1 p80 -158.99 171.42 20.06 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.39 0.614 . . . . 0.0 110.587 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mm-40 -150.35 173.89 13.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.417 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -148.17 121.26 8.86 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -123.0 127.61 49.06 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.81 0.338 . . . . 0.0 111.851 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -122.05 125.64 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.502 ' HZ ' HD13 ' J' ' 34' ' ' LEU . 2.7 t80 -122.27 115.17 21.87 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -126.86 121.66 32.47 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.49 127.13 51.92 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.613 -0.435 . . . . 0.0 112.001 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.461 ' HG3' ' H ' ' I' ' 24' ' ' VAL . 43.0 tt0 -158.29 103.34 1.8 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.918 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.464 ' HB3' ' HZ1' ' J' ' 28' ' ' LYS . 78.4 m-20 -80.17 134.7 36.17 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-O 120.952 0.406 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.403 ' O ' ' N ' ' H' ' 26' ' ' SER . 88.9 t -103.68 113.73 41.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -178.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -30.6 88.64 0.01 OUTLIER Glycine 0 CA--C 1.537 1.459 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.775 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' H' ' 27' ' ' ASN . 11.7 p -129.78 -178.54 4.75 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.848 HD22 ' H ' ' G' ' 29' ' ' GLY . 1.4 p-10 -40.16 174.82 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 113.486 0.921 . . . . 0.0 113.486 -174.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -74.8 111.15 9.71 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 116.18 1.919 . . . . 0.0 116.18 -178.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.472 ' H ' ' HG3' ' I' ' 28' ' ' LYS . . . 70.32 93.54 0.07 OUTLIER Glycine 0 N--CA 1.467 0.733 0 C-N-CA 119.893 -1.146 . . . . 0.0 115.484 171.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.76 157.68 18.9 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 103.348 -2.834 . . . . 0.0 103.348 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.437 HD13 ' HA3' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -144.44 119.46 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.714 -174.545 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.403 ' C ' ' SD ' ' B' ' 35' ' ' MET . 27.7 mm -124.55 124.26 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.414 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.1 126.65 5.49 Favored Glycine 0 N--CA 1.469 0.873 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.4 tt -147.76 134.59 20.1 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.929 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.1 tmm? -128.62 127.09 41.55 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.851 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.436 ' O ' ' O ' ' H' ' 37' ' ' GLY . 10.5 t -122.92 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.294 0.85 . . . . 0.0 113.294 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -35.6 -93.8 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 177.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.1 -171.03 33.88 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.47 141.9 36.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 110.122 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.676 -179.995 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.443 HG12 ' N ' ' I' ' 13' ' ' HIS . 15.4 t . . . . . 0 N--CA 1.465 0.283 0 CA-C-O 120.675 0.274 . . . . 0.0 111.056 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.443 ' N ' HG12 ' I' ' 12' ' ' VAL . 0.5 OUTLIER -116.22 170.19 8.71 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.93 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -72.89 169.81 16.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -137.36 172.77 12.49 Favored 'General case' 0 C--N 1.318 -0.768 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.415 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -150.19 128.96 12.42 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.1 0.476 . . . . 0.0 111.663 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.6 tt -133.62 124.47 26.87 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -123.71 128.83 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.862 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.648 ' CD2' HD22 ' L' ' 34' ' ' LEU . 10.3 t80 -122.39 118.99 29.73 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.912 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -135.16 121.63 20.53 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.802 0.334 . . . . 0.0 111.062 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.18 123.49 38.35 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -162.6 126.52 3.02 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 115.354 -0.839 . . . . 0.0 108.815 178.195 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -102.27 114.03 27.84 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.461 ' H ' ' HG3' ' H' ' 22' ' ' GLU . 4.0 p -79.86 131.63 33.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.754 177.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.63 82.62 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 C-N-CA 119.725 -1.226 . . . . 0.0 112.392 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' I' ' 27' ' ' ASN . 75.1 m -60.04 -174.11 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 115.194 -0.503 . . . . 0.0 109.858 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' I' ' 26' ' ' SER . 17.9 m-20 98.53 -175.3 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 O-C-N 124.218 0.949 . . . . 0.0 109.975 -176.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' I' ' 27' ' ' ASN . 82.4 tttt 38.71 110.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -177.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 95.85 1.74 Allowed Glycine 0 CA--C 1.484 -1.885 0 N-CA-C 107.98 -2.048 . . . . 0.0 107.98 176.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 164.89 16.92 Favored 'General case' 0 N--CA 1.426 -1.662 0 C-N-CA 118.001 -1.48 . . . . 0.0 107.272 -179.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.719 HG23 ' CG1' ' J' ' 31' ' ' ILE . 0.2 OUTLIER -142.56 117.31 4.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 119.376 -0.929 . . . . 0.0 108.827 -174.497 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 tt -125.51 124.16 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.834 178.18 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.33 96.62 0.73 Allowed Glycine 0 C--N 1.331 0.275 0 N-CA-C 107.72 -2.152 . . . . 0.0 107.72 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.513 HD21 HG13 ' I' ' 36' ' ' VAL . 8.7 tt -130.32 134.1 46.94 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 122.392 1.092 . . . . 0.0 112.183 -178.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 tmm? -128.26 125.74 39.49 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.618 -1.174 . . . . 0.0 110.344 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.513 HG13 HD21 ' I' ' 34' ' ' LEU . 0.1 OUTLIER -130.69 76.95 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.34 179.678 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 38' ' ' GLY . . . -71.9 106.36 1.9 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -49.27 179.38 0.01 OUTLIER Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 -179.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -124.58 138.78 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.938 -1.03 . . . . 0.0 110.365 179.688 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -110.06 138.58 46.24 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.692 0.282 . . . . 0.0 110.298 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -127.56 145.19 50.94 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.952 0.406 . . . . 0.0 110.768 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.86 152.71 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.778 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 31.0 m80 -132.57 146.98 52.33 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.52 ' CE1' ' O ' ' J' ' 15' ' ' GLN . 5.9 t-80 -154.52 157.84 38.95 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.52 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 82.3 mt-30 -148.97 178.06 9.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-O 121.538 0.685 . . . . 0.0 111.653 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -165.34 114.03 1.02 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.151 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -120.86 122.29 39.95 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.155 0.502 . . . . 0.0 111.04 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -114.02 121.82 66.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.677 ' CZ ' HD23 ' L' ' 34' ' ' LEU . 1.0 OUTLIER -125.04 108.37 11.76 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.9 0.381 . . . . 0.0 110.236 -177.124 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -130.17 127.83 40.51 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.629 0.728 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.67 128.57 31.28 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.842 178.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -142.39 111.24 6.3 Favored 'General case' 0 N--CA 1.462 0.142 0 C-N-CA 119.621 -0.831 . . . . 0.0 111.249 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -85.73 105.02 15.96 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.671 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.759 HG12 ' H ' ' J' ' 25' ' ' GLY . 10.5 t -110.12 -131.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.123 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.759 ' H ' HG12 ' J' ' 24' ' ' VAL . . . 29.03 -82.24 0.0 OUTLIER Glycine 0 CA--C 1.529 0.914 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.869 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.636 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.2 p 169.65 177.76 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.34 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.769 HD22 ' H ' ' K' ' 29' ' ' GLY . 31.7 m120 -28.08 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 114.183 -1.371 . . . . 0.0 112.838 173.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.535 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 29.5 tttt 144.63 104.31 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 123.02 1.39 . . . . 0.0 112.005 177.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.16 93.54 0.01 OUTLIER Glycine 0 C--O 1.219 -0.825 0 CA-C-N 112.248 -2.251 . . . . 0.0 111.373 174.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.2 152.81 47.68 Favored 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 120.78 2.29 . . . . 0.0 106.526 176.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.719 ' CG1' HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -137.97 121.86 21.61 Favored 'Isoleucine or valine' 0 C--O 1.248 1.022 0 C-N-CA 119.218 -0.993 . . . . 0.0 112.384 -174.895 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -104.42 109.44 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.406 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.617 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -109.72 102.46 1.59 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 106.37 -2.692 . . . . 0.0 106.37 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.853 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 5.1 tt -144.35 140.51 29.13 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 122.406 1.098 . . . . 0.0 111.775 -175.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.525 ' N ' HD23 ' J' ' 34' ' ' LEU . 61.0 ttp -133.69 130.21 37.85 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.08 -179.142 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.471 HG13 HG23 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -122.78 79.47 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.78 -178.336 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.19 104.54 0.48 Allowed Glycine 0 C--N 1.342 0.907 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.74 167.06 54.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -139.28 160.66 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.727 0.299 . . . . 0.0 110.584 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.442 HG23 ' H ' ' J' ' 40' ' ' VAL . 15.9 t . . . . . 0 C--O 1.221 -0.419 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.846 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -84.33 138.07 33.09 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.867 0.365 . . . . 0.0 111.068 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' L' ' 11' ' ' GLU . 72.3 mm-40 -137.6 131.98 32.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.628 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 m -138.09 135.56 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.906 0.384 . . . . 0.0 111.123 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 9.7 m80 -134.28 127.51 31.96 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.571 ' NE2' ' CG ' ' L' ' 13' ' ' HIS . 80.5 m80 -116.43 163.17 16.44 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.646 0.736 . . . . 0.0 110.36 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.52 ' N ' ' OE1' ' L' ' 15' ' ' GLN . 50.9 tt0 -163.27 172.31 14.89 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.412 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' K' ' 15' ' ' GLN . 55.4 tttp -164.81 114.88 1.14 Allowed 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 28.6 tp -118.8 121.65 40.54 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.76 127.83 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -131.0 125.7 34.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.23 0.538 . . . . 0.0 112.262 -178.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -133.06 125.79 30.39 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.993 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 127.43 35.36 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.182 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -149.29 137.73 20.88 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.048 -0.661 . . . . 0.0 112.023 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.45 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 20.6 p-10 -123.23 120.53 33.42 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 120.986 0.422 . . . . 0.0 110.029 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.554 HG21 HG13 ' J' ' 24' ' ' VAL . 84.3 t -60.62 121.1 7.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.519 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.31 -90.97 0.53 Allowed Glycine 0 CA--C 1.527 0.817 0 C-N-CA 121.368 -0.444 . . . . 0.0 112.464 177.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.587 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.8 p -141.37 171.22 14.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 121.196 0.522 . . . . 0.0 110.348 -178.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.587 ' O ' ' O ' ' K' ' 26' ' ' SER . 3.3 p30 -29.01 170.5 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.179 -1.373 . . . . 0.0 113.983 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.662 ' O ' ' HB3' ' L' ' 30' ' ' ALA . 80.0 tttt -148.35 111.3 4.84 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.141 178.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.769 ' H ' HD22 ' J' ' 27' ' ' ASN . . . -54.53 91.58 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 121.244 -0.503 . . . . 0.0 112.211 179.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.746 ' H ' ' HB1' ' L' ' 30' ' ' ALA . . . -166.38 158.17 13.56 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.504 ' CG1' HG22 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -145.8 123.61 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 118.721 -1.192 . . . . 0.0 111.829 -179.209 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.448 ' C ' ' SD ' ' E' ' 35' ' ' MET . 1.0 OUTLIER -102.09 118.41 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.077 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.541 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -112.74 94.88 0.75 Allowed Glycine 0 CA--C 1.51 -0.26 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 179.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.636 HD12 ' O ' ' J' ' 34' ' ' LEU . 41.0 tp -129.38 130.77 46.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-O 122.218 1.009 . . . . 0.0 111.968 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.48 ' H ' HD12 ' K' ' 34' ' ' LEU . 7.9 tmm? -116.71 114.73 24.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.893 175.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.405 HG12 ' CG2' ' J' ' 36' ' ' VAL . 2.2 m -116.56 79.86 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.419 ' HA3' HD13 ' E' ' 31' ' ' ILE . . . -66.8 103.24 0.87 Allowed Glycine 0 C--N 1.35 1.36 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -87.39 -178.55 48.38 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.48 142.9 30.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.951 0.405 . . . . 0.0 110.29 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.761 -179.768 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -101.7 130.06 48.0 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.5 tt0 -123.52 138.75 54.5 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 120.96 0.41 . . . . 0.0 110.748 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.413 HG22 ' O ' ' L' ' 13' ' ' HIS . 2.4 p -139.53 156.04 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.187 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.661 ' CG ' ' H ' ' L' ' 14' ' ' HIS . 41.8 t-80 -91.29 -177.5 4.88 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 120.784 0.326 . . . . 0.0 110.727 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.661 ' H ' ' CG ' ' L' ' 13' ' ' HIS . 99.2 m-70 -75.52 171.73 13.77 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.53 ' NE2' ' O ' ' L' ' 14' ' ' HIS . 51.5 mm-40 -139.2 -179.78 6.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.62 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.95 124.38 15.72 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.685 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 58.0 tp -125.44 121.22 33.19 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.381 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -129.41 129.35 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.461 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 54.7 p90 -139.45 130.85 26.92 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.785 0.326 . . . . 0.0 111.123 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 84.8 t80 -142.55 131.99 23.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.019 179.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.16 146.43 35.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.814 0.34 . . . . 0.0 110.58 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' K' ' 23' ' ' ASP . 84.6 tt0 -78.52 142.76 37.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.145 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -76.73 121.72 23.7 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 121.225 0.536 . . . . 0.0 110.766 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' L' ' 25' ' ' GLY . 19.5 t -102.75 122.88 55.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.115 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.452 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -30.56 -86.47 0.01 OUTLIER Glycine 0 N--CA 1.478 1.442 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 30.7 t -90.21 -179.97 5.77 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 177.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -58.8 162.89 3.7 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 117.866 -1.534 . . . . 0.0 110.456 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.565 ' HB3' HD12 ' L' ' 31' ' ' ILE . 59.6 tttt -58.3 111.64 1.28 Allowed 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 179.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.85 -98.28 0.01 OUTLIER Glycine 0 C--N 1.319 -0.416 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.746 ' HB1' ' H ' ' K' ' 30' ' ' ALA . . . -72.72 174.57 7.45 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 178.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.784 HG23 ' SD ' ' F' ' 35' ' ' MET . 7.5 tt -171.17 165.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 C-N-CA 115.033 -2.667 . . . . 0.0 115.448 -172.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.544 ' O ' HG23 ' L' ' 32' ' ' ILE . 16.3 tt -99.31 122.02 50.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.761 0 CA-C-N 113.284 -1.78 . . . . 0.0 108.154 177.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . 0.501 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -110.52 94.37 0.79 Allowed Glycine 0 CA--C 1.507 -0.436 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.677 HD23 ' CZ ' ' J' ' 19' ' ' PHE . 51.3 tp -119.03 118.76 32.33 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.475 ' HE1' HG22 ' E' ' 31' ' ' ILE . 11.3 tmm? -105.16 119.22 38.5 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.202 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.497 ' O ' ' C ' ' L' ' 37' ' ' GLY . 2.7 m -129.03 75.04 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.927 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.497 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -16.95 -101.76 0.0 OUTLIER Glycine 0 C--N 1.359 1.856 0 O-C-N 123.158 0.286 . . . . 0.0 112.707 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.0 173.87 37.68 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.271 -0.731 . . . . 0.0 111.271 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -122.65 138.45 52.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.885 0.374 . . . . 0.0 110.51 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.813 -179.659 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 18.5 p-80 -143.71 164.44 30.44 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.934 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.1 p-80 -87.78 169.98 11.61 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-O 121.395 0.617 . . . . 0.0 110.375 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HG2' ' N ' ' A' ' 16' ' ' LYS . 51.5 tt0 -153.28 175.32 13.21 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.301 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.442 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 99.5 mttt -137.68 133.65 34.48 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.819 0.343 . . . . 0.0 110.831 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -129.16 121.52 27.91 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -132.74 131.3 59.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.75 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 14.7 m-85 -111.21 116.79 31.66 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.535 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 55.5 p90 -129.84 125.92 36.81 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.75 126.3 32.15 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.083 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' A' ' 22' ' ' GLU . 55.4 mp0 -141.32 163.94 31.59 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 33.7 t70 -79.2 113.67 17.52 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -178.538 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.502 ' O ' ' N ' ' A' ' 26' ' ' SER . 3.5 p -127.11 121.66 58.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 176.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -29.31 84.04 0.0 OUTLIER Glycine 0 CA--C 1.537 1.412 0 CA-C-O 118.833 -0.982 . . . . 0.0 113.834 178.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 24' ' ' VAL . 10.0 p -97.62 171.82 8.11 Favored 'General case' 0 C--N 1.347 0.468 0 CA-C-N 119.686 1.743 . . . . 0.0 107.311 177.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 p30 -60.13 177.53 0.25 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 118.418 -1.313 . . . . 0.0 110.227 178.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -61.76 110.61 1.57 Allowed 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.505 174.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.655 ' H ' ' CB ' ' B' ' 27' ' ' ASN . . . 70.86 93.82 0.07 OUTLIER Glycine 0 N--CA 1.467 0.714 0 C-N-CA 117.541 -2.266 . . . . 0.0 111.716 174.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.52 158.57 17.43 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 121.283 2.542 . . . . 0.0 111.225 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.603 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -143.98 120.38 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 113.433 -1.712 . . . . 0.0 110.566 -175.532 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.7 mt -130.6 125.3 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 O-C-N 121.52 -0.738 . . . . 0.0 110.438 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.575 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -132.15 119.12 2.43 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 80.8 mt -122.23 129.97 52.74 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.071 0.462 . . . . 0.0 110.895 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.53 120.49 29.78 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.18 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -104.94 77.74 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 120.22 -0.592 . . . . 0.0 112.239 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.542 ' CA ' HG21 ' G' ' 31' ' ' ILE . . . -92.27 101.0 2.73 Favored Glycine 0 C--N 1.342 0.893 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.14 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.64 155.87 27.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 28.4 m . . . . . 0 N--CA 1.464 0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.415 179.701 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 26.5 m . . . . . 0 N--CA 1.464 0.239 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.437 ' C ' ' CG ' ' B' ' 14' ' ' HIS . 80.6 t60 -138.7 138.9 38.16 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.644 0.259 . . . . 0.0 110.533 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.587 ' CE1' ' CE1' ' C' ' 14' ' ' HIS . 19.6 m-70 -150.76 170.24 19.71 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.278 0.561 . . . . 0.0 109.983 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -153.14 173.04 16.01 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.49 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -153.9 118.66 4.97 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -116.31 120.95 40.54 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 45.5 t -126.07 121.79 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.157 0.504 . . . . 0.0 110.641 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.906 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 6.4 m-85 -113.52 113.16 24.73 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.709 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -118.17 106.17 12.57 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 175.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.99 125.93 52.12 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.523 ' N ' ' OE1' ' B' ' 22' ' ' GLU . 57.0 mp0 -142.41 178.88 7.29 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 177.208 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.499 ' OD1' ' NZ ' ' D' ' 28' ' ' LYS . 14.1 m-20 -38.09 121.92 0.99 Allowed 'General case' 0 N--CA 1.475 0.811 0 CA-C-N 119.244 0.929 . . . . 0.0 110.644 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.805 HG12 ' H ' ' B' ' 25' ' ' GLY . 97.3 t -58.55 -120.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.648 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.021 -178.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.805 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -79.67 -90.28 0.45 Allowed Glycine 0 CA--C 1.523 0.577 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.996 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.419 ' HB3' ' H ' ' A' ' 26' ' ' SER . 77.6 p -155.01 -172.07 4.06 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.835 0.826 . . . . 0.0 110.403 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.655 ' CB ' ' H ' ' A' ' 29' ' ' GLY . 8.9 t-20 57.72 -171.72 0.1 Allowed 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 114.201 -1.363 . . . . 0.0 111.671 178.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.566 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 72.2 mmtt -56.96 -111.3 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.709 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.92 94.47 1.57 Allowed Glycine 0 N--CA 1.461 0.314 0 CA-C-N 115.265 -0.88 . . . . 0.0 114.39 -177.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.33 163.97 15.79 Favored 'General case' 0 C--N 1.35 0.605 0 C-N-CA 116.821 -1.952 . . . . 0.0 106.673 177.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.46 HD13 ' HA3' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -150.26 128.76 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 C-N-CA 119.111 -1.036 . . . . 0.0 111.739 -172.779 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 99.0 mt -133.23 133.61 58.02 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.325 0.583 . . . . 0.0 110.922 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.01 127.11 4.63 Favored Glycine 0 N--CA 1.47 0.952 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.238 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.41 HD21 ' CG2' ' B' ' 36' ' ' VAL . 7.9 tt -133.79 127.87 33.59 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.294 0.547 . . . . 0.0 111.038 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.548 ' SD ' ' CA ' ' H' ' 33' ' ' GLY . 20.7 ttt -130.24 123.82 31.04 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.421 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.41 ' CG2' HD21 ' B' ' 34' ' ' LEU . 2.6 t -124.33 76.02 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.801 178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.32 101.54 2.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -134.72 163.54 24.72 Favored Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.86 136.97 56.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.506 -179.813 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -106.9 135.97 47.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.921 0.391 . . . . 0.0 110.644 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -67.77 135.63 52.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.795 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.572 HG13 ' O ' ' D' ' 12' ' ' VAL . 58.5 t -124.89 133.65 68.92 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.05 0.452 . . . . 0.0 111.075 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 p-80 -147.52 145.51 29.12 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.574 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.587 ' CE1' ' CE1' ' B' ' 14' ' ' HIS . 10.2 p-80 -153.76 168.05 27.58 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.361 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -148.75 176.85 10.02 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.248 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -147.23 127.74 14.11 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.296 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.7 mp -130.51 127.28 38.83 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-O 121.1 0.476 . . . . 0.0 111.372 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.8 t -127.4 126.01 66.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.089 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.403 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 57.2 m-85 -111.45 116.11 30.36 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 50.4 t80 -127.88 117.68 22.24 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.6 130.67 49.43 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.326 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -155.57 101.1 2.15 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.979 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -68.7 133.98 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.977 0.418 . . . . 0.0 110.206 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.34 113.02 20.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.621 0.724 . . . . 0.0 111.178 -179.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.431 ' O ' HG11 ' D' ' 24' ' ' VAL . . . 52.97 -91.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.473 -1.24 . . . . 0.0 115.288 177.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.515 ' OG ' ' N ' ' C' ' 27' ' ' ASN . 47.3 t -153.78 -175.57 5.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 122.678 1.228 . . . . 0.0 113.102 -175.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.515 ' N ' ' OG ' ' C' ' 26' ' ' SER . 24.7 m120 52.73 179.93 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 112.433 -2.167 . . . . 0.0 115.129 178.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 75.2 mttt 53.4 110.6 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 CA-C-N 112.536 -2.12 . . . . 0.0 113.967 -177.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.77 95.97 1.85 Allowed Glycine 0 N--CA 1.488 2.127 0 CA-C-O 117.828 -1.54 . . . . 0.0 110.366 175.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.52 ' HB1' HG21 ' B' ' 24' ' ' VAL . . . -91.54 160.09 15.59 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 121.354 2.577 . . . . 0.0 109.833 -179.044 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.592 ' CG2' HD12 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -148.53 124.97 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.102 -176.421 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.44 ' O ' ' SD ' ' J' ' 35' ' ' MET . 14.3 tt -130.18 128.92 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 121.195 0.522 . . . . 0.0 110.459 177.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.445 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -112.77 117.62 4.36 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.75 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 29.3 mt -124.69 119.66 29.61 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -176.211 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.461 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 5.3 ttm -122.4 117.58 26.35 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 177.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.52 74.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.998 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.313 -178.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 38' ' ' GLY . . . -61.0 110.98 3.4 Favored Glycine 0 C--N 1.354 1.535 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . -53.9 -167.47 0.02 OUTLIER Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.71 161.82 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.068 0.461 . . . . 0.0 111.221 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 68.6 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.889 -1.053 . . . . 0.0 110.594 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.572 ' O ' HG13 ' C' ' 12' ' ' VAL . 30.9 m . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CB ' ' E' ' 13' ' ' HIS . 5.7 t60 -89.21 122.38 32.44 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.013 178.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 47.5 p-80 -156.15 169.04 25.43 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.056 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -145.04 177.97 8.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -152.59 119.77 5.88 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.185 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -119.68 120.35 36.37 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.855 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -125.7 125.87 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.802 0.334 . . . . 0.0 110.962 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.403 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 72.3 m-85 -115.75 115.82 26.97 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.069 179.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 53.9 t80 -127.5 121.15 29.96 Favored 'General case' 0 C--O 1.239 0.5 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 178.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.15 135.58 37.49 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.298 0.571 . . . . 0.0 112.297 -179.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -136.92 96.48 3.31 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.048 178.379 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.425 ' O ' ' CG2' ' E' ' 24' ' ' VAL . 89.8 m-20 -85.89 134.89 33.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.416 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.5 ' O ' HG13 ' D' ' 24' ' ' VAL . 8.1 p -88.27 112.75 24.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.457 0.646 . . . . 0.0 109.403 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.472 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -45.45 92.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.597 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.346 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.472 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 163.92 -169.6 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.641 0 CA-C-O 121.727 0.775 . . . . 0.0 110.163 -178.562 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -50.64 179.77 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.727 ' HE2' ' HB2' ' D' ' 30' ' ' ALA . 67.2 tttt 60.49 112.38 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 112.248 -2.251 . . . . 0.0 115.881 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.0 96.16 2.18 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.091 -2.804 . . . . 0.0 106.091 170.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.727 ' HB2' ' HE2' ' D' ' 28' ' ' LYS . . . -79.31 162.77 25.4 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 123.47 3.635 . . . . 0.0 105.805 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.592 HD12 ' CG2' ' C' ' 31' ' ' ILE . 1.1 mt -147.21 126.47 4.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 C-N-CA 117.679 -1.608 . . . . 0.0 111.348 -174.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 52.6 mt -123.91 116.95 49.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 177.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.28 103.59 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 105.878 -2.889 . . . . 0.0 105.878 176.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.906 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 12.7 tp -116.54 124.36 49.68 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 114.077 1.139 . . . . 0.0 114.077 -175.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.437 ' N ' HD12 ' D' ' 34' ' ' LEU . 8.0 ttm -126.54 110.47 13.28 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 174.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.596 HG13 HD11 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -126.25 79.89 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.151 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.02 103.13 1.32 Allowed Glycine 0 C--N 1.349 1.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 112.506 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.59 178.93 38.46 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 178.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.51 HG12 ' N ' ' D' ' 40' ' ' VAL . 60.7 t -141.88 157.95 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.946 0.403 . . . . 0.0 111.011 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.51 ' N ' HG12 ' D' ' 39' ' ' VAL . 19.4 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.52 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 77.1 t80 -85.28 138.96 31.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.883 0.373 . . . . 0.0 110.528 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -55.4 143.05 30.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.689 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.64 135.75 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.487 ' CB ' ' O ' ' D' ' 13' ' ' HIS . 6.4 p80 -155.66 162.07 40.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.041 0.448 . . . . 0.0 111.296 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 69.0 m80 -139.82 168.19 20.39 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.854 0.835 . . . . 0.0 110.287 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.412 ' HG2' ' N ' ' E' ' 16' ' ' LYS . 51.8 tt0 -153.17 165.34 35.97 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 114.678 -1.146 . . . . 0.0 108.826 178.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.412 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 98.0 mttt -157.24 116.88 3.4 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.627 0.251 . . . . 0.0 110.334 179.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 32.6 tp -117.14 113.79 22.77 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.47 128.7 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' E' ' 21' ' ' ALA . 41.1 t80 -127.27 120.49 28.77 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.924 -179.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -127.84 118.49 23.77 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.422 ' HB2' ' CZ ' ' E' ' 19' ' ' PHE . . . -128.68 130.04 46.65 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.129 0.49 . . . . 0.0 111.326 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -113.27 102.62 10.53 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 64.4 t0 -79.9 123.17 27.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.174 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.437 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 93.0 t -96.5 121.65 47.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 42.7 -87.03 0.01 OUTLIER Glycine 0 CA--C 1.533 1.17 0 CA-C-N 115.127 -0.942 . . . . 0.0 114.688 178.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 11.1 p -165.38 -178.36 4.95 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-O 122.235 1.017 . . . . 0.0 112.044 -175.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.6 ' CG ' ' H ' ' E' ' 28' ' ' LYS . 7.0 t-20 51.36 -179.13 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 116.105 1.891 . . . . 0.0 116.105 177.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.6 ' H ' ' CG ' ' E' ' 27' ' ' ASN . 27.2 tttt 53.76 110.97 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 112.178 -2.283 . . . . 0.0 114.223 -175.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.456 ' HA2' ' H ' ' F' ' 30' ' ' ALA . . . -87.13 96.44 2.17 Favored Glycine 0 C--N 1.337 0.6 0 CA-C-N 111.973 -2.376 . . . . 0.0 110.909 175.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.412 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -78.83 166.24 22.65 Favored 'General case' 0 C--O 1.241 0.624 0 CA-C-N 122.765 3.282 . . . . 0.0 103.553 177.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.435 HG21 HD13 ' E' ' 31' ' ' ILE . 1.1 mt -147.57 127.39 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 116.687 -2.005 . . . . 0.0 112.903 -172.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.49 ' O ' HG23 ' E' ' 32' ' ' ILE . 15.7 tt -135.4 119.88 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-O 121.472 0.653 . . . . 0.0 109.49 176.141 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.68 110.3 2.78 Favored Glycine 0 CA--C 1.508 -0.356 0 N-CA-C 107.492 -2.243 . . . . 0.0 107.492 178.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.57 123.24 43.44 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 122.259 1.028 . . . . 0.0 111.775 -178.2 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.432 ' HE2' ' N ' ' K' ' 32' ' ' ILE . 9.5 tpt -111.47 110.77 21.38 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 113.709 -1.587 . . . . 0.0 107.467 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.404 HG13 HG23 ' D' ' 36' ' ' VAL . 0.2 OUTLIER -119.66 80.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-O 121.035 0.445 . . . . 0.0 109.94 -178.043 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.08 102.17 0.08 OUTLIER Glycine 0 C--N 1.341 0.833 0 CA-C-N 116.247 -0.433 . . . . 0.0 112.044 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.96 150.61 22.7 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.6 t -126.56 136.71 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 88.8 t . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.374 179.819 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m . . . . . 0 N--CA 1.467 0.379 0 CA-C-O 120.99 0.424 . . . . 0.0 110.785 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.468 ' CB ' ' CE1' ' E' ' 13' ' ' HIS . 44.4 p-80 -87.68 163.21 16.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.312 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 53.2 m80 -147.33 172.15 14.33 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -144.12 178.06 8.15 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.847 -179.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.9 121.9 0.57 Allowed 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.738 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.69 125.19 35.4 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.401 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 86.9 t -134.1 129.4 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.923 0.392 . . . . 0.0 111.237 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -122.55 125.66 46.17 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.049 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -136.07 132.63 36.42 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.13 0.491 . . . . 0.0 110.024 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.27 149.46 31.91 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.099 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -74.17 152.74 39.75 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.729 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 t0 . . . . . 0 N--CA 1.462 0.137 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.121 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 28.6 pttt . . . . . 0 N--CA 1.487 1.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.85 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.618 ' O ' ' O ' ' F' ' 30' ' ' ALA . . . -120.01 -100.1 1.81 Allowed Glycine 0 C--N 1.343 0.943 0 N-CA-C 108.299 -1.921 . . . . 0.0 108.299 173.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.618 ' O ' ' O ' ' F' ' 29' ' ' GLY . . . 54.83 151.97 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 105.412 -2.07 . . . . 0.0 105.412 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.447 ' HB ' ' O ' ' F' ' 30' ' ' ALA . 2.7 tp -165.8 132.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 C-N-CA 115.002 -2.679 . . . . 0.0 114.192 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 97.0 mt -111.69 112.98 42.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 113.631 -1.622 . . . . 0.0 108.418 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . 0.437 ' H ' ' HE2' ' L' ' 35' ' ' MET . . . -97.13 101.74 2.63 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 105.382 -3.087 . . . . 0.0 105.382 176.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.473 HD12 ' O ' ' F' ' 34' ' ' LEU . 0.4 OUTLIER -104.73 108.69 20.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -176.189 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.47 ' SD ' ' C ' ' L' ' 32' ' ' ILE . 0.9 OUTLIER -109.42 107.34 17.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 176.102 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -136.01 80.59 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.984 -179.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.49 -101.66 0.09 OUTLIER Glycine 0 C--N 1.344 1.004 0 C-N-CA 120.976 -0.631 . . . . 0.0 111.99 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.74 -159.71 31.64 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.1 m -135.19 161.72 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 120.626 0.251 . . . . 0.0 110.529 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.204 179.612 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -126.77 142.69 51.47 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.37 143.72 42.11 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.057 0.456 . . . . 0.0 111.019 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.413 ' O ' HG13 ' G' ' 12' ' ' VAL . 12.4 p -130.49 134.99 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.187 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -122.79 127.25 48.88 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 120.95 0.405 . . . . 0.0 110.445 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 70.8 t60 -157.62 165.41 35.58 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-O 121.16 0.505 . . . . 0.0 110.183 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 83.6 mt-30 -151.28 174.76 12.91 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.018 178.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -171.57 114.04 0.36 Allowed 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.082 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 64.7 mt -131.16 124.1 29.97 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.331 0.586 . . . . 0.0 110.306 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.46 ' O ' HG23 ' G' ' 18' ' ' VAL . 30.9 m -128.12 129.83 69.53 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.135 -179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.551 ' CE2' HD21 ' J' ' 34' ' ' LEU . 15.4 m-85 -110.53 113.03 25.34 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.466 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 45.6 p90 -123.95 124.13 41.93 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.27 131.13 38.07 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -145.6 167.22 23.59 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 177.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 58.6 t0 -90.14 111.78 23.03 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.015 -0.674 . . . . 0.0 112.186 -178.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.611 ' O ' ' N ' ' G' ' 26' ' ' SER . 3.6 p -113.17 131.04 65.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.127 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.29 81.96 0.0 OUTLIER Glycine 0 CA--C 1.532 1.11 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.782 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.611 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.1 m -96.58 176.2 6.11 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.504 ' O ' ' O ' ' G' ' 28' ' ' LYS . 53.3 p30 -62.2 -177.73 0.14 Allowed 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.504 ' O ' ' O ' ' G' ' 27' ' ' ASN . 98.4 mttt -48.85 -109.2 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-O 121.682 0.753 . . . . 0.0 110.64 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.65 96.53 2.1 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.42 161.32 23.77 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 115.49 -2.484 . . . . 0.0 109.609 -177.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.627 ' CG2' HD12 ' H' ' 31' ' ' ILE . 0.1 OUTLIER -154.33 116.27 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.868 -175.066 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -143.09 137.76 26.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.502 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -158.8 164.33 33.6 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.466 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 3.3 tp -169.57 163.28 10.21 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.13 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.575 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 53.5 ttp -131.93 134.12 45.3 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.601 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.406 ' HB ' HG23 ' H' ' 36' ' ' VAL . 21.1 t -117.48 65.03 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.514 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.603 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -55.12 -106.76 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.25 -166.12 13.97 Favored Glycine 0 N--CA 1.465 0.629 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -132.58 159.22 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.025 0.44 . . . . 0.0 110.852 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.669 -179.805 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -107.41 128.95 54.93 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.869 0.366 . . . . 0.0 110.354 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -145.76 135.4 23.29 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.612 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -140.44 134.93 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 77.6 m80 -118.69 118.74 32.44 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.416 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.528 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 5.8 m-70 -135.56 164.29 28.17 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.507 0.67 . . . . 0.0 109.856 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.693 HE21 HD21 ' H' ' 17' ' ' LEU . 52.5 tt0 -161.86 170.51 19.34 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.437 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . 0.416 ' N ' ' CG ' ' H' ' 15' ' ' GLN . 68.7 mttm -155.94 115.79 3.64 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.722 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.693 HD21 HE21 ' H' ' 15' ' ' GLN . 76.6 mt -114.76 115.27 26.77 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -125.09 124.6 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -113.01 108.76 17.79 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.522 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 24.6 t80 -127.06 129.52 48.16 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.164 0.438 . . . . 0.0 110.635 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.47 150.4 26.57 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 118.346 -1.342 . . . . 0.0 114.56 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -132.53 173.04 11.73 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 114.367 -1.288 . . . . 0.0 109.582 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.406 ' OD1' ' C ' ' H' ' 23' ' ' ASP . 64.5 t0 -148.51 116.53 6.4 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 113.253 0.835 . . . . 0.0 113.253 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 3.2 p -121.49 122.33 66.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 177.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.24 83.79 0.01 OUTLIER Glycine 0 N--CA 1.472 1.052 0 CA-C-O 121.588 0.549 . . . . 0.0 112.245 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -45.35 170.28 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 113.864 1.061 . . . . 0.0 113.864 179.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.472 ' O ' ' O ' ' H' ' 28' ' ' LYS . 19.5 m120 -135.61 177.04 8.13 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 113.444 -1.707 . . . . 0.0 107.738 173.773 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.472 ' O ' ' O ' ' H' ' 27' ' ' ASN . 65.2 mttm -21.28 -102.86 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . -158.85 100.27 0.19 Allowed Glycine 0 C--N 1.349 1.256 0 CA-C-O 118.365 -1.241 . . . . 0.0 110.788 177.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.82 157.14 31.19 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-N 120.869 2.334 . . . . 0.0 109.125 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.637 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.5 OUTLIER -142.91 118.5 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.473 -176.547 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.53 ' O ' ' SD ' ' B' ' 35' ' ' MET . 86.1 mt -127.7 126.17 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.406 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.548 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -131.88 110.33 0.95 Allowed Glycine 0 N--CA 1.477 1.398 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.76 137.96 31.97 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 121.582 -0.952 . . . . 0.0 112.476 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 40.8 ttp -127.3 139.33 52.96 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.835 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.614 ' O ' HG22 ' H' ' 36' ' ' VAL . 2.5 p -153.48 75.15 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.943 178.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.46 ' HA3' HD13 ' B' ' 31' ' ' ILE . . . -37.25 -95.5 0.01 OUTLIER Glycine 0 C--N 1.343 0.928 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 178.376 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -165.22 38.58 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 t -90.44 134.67 28.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.969 0.414 . . . . 0.0 110.764 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.218 -0.587 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.312 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.488 HG21 ' NE2' ' I' ' 14' ' ' HIS . 2.5 p . . . . . 0 CA--C 1.531 0.237 0 CA-C-O 120.873 0.368 . . . . 0.0 111.001 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.449 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 25.0 m-70 -119.87 138.92 53.11 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.605 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.488 ' NE2' HG21 ' I' ' 12' ' ' VAL . 25.8 m-70 -144.74 168.79 19.37 Favored 'General case' 0 CA--C 1.511 -0.552 0 CA-C-O 121.499 0.666 . . . . 0.0 110.483 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -149.42 177.99 9.2 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.84 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -171.36 107.01 0.24 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.862 179.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.687 HD22 HD12 ' H' ' 17' ' ' LEU . 9.2 mt -120.07 115.54 23.91 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.407 ' O ' HG23 ' I' ' 18' ' ' VAL . 2.2 m -134.43 127.61 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.23 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.42 ' CD2' ' CE2' ' J' ' 19' ' ' PHE . 12.6 m-30 -110.35 118.8 37.27 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.251 178.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.522 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 53.3 t80 -125.65 118.05 24.83 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 0.454 ' HB1' ' O ' ' I' ' 25' ' ' GLY . . . -139.43 135.49 33.66 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -177.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.548 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 82.9 tt0 -115.92 100.18 7.8 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.155 -1.794 . . . . 0.0 106.155 176.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.548 ' CB ' ' O ' ' I' ' 22' ' ' GLU . 53.2 t0 121.61 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 O-C-N 124.817 1.323 . . . . 0.0 108.246 -176.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.586 HG13 ' NZ ' ' K' ' 28' ' ' LYS . 19.8 m -106.14 112.02 37.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.798 0.809 . . . . 0.0 108.929 -178.501 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.454 ' O ' ' HB1' ' I' ' 21' ' ' ALA . . . 33.65 -92.16 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -177.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.64 ' O ' ' O ' ' I' ' 27' ' ' ASN . 41.4 t -130.46 168.24 17.33 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.64 ' O ' ' O ' ' I' ' 26' ' ' SER . 98.2 m-20 38.43 179.13 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 O-C-N 124.096 0.873 . . . . 0.0 111.628 176.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.619 ' H ' ' HD2' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -92.65 -120.75 0.08 Allowed 'General case' 0 N--CA 1.471 0.585 0 O-C-N 120.906 -1.121 . . . . 0.0 109.134 178.919 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.461 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -69.08 88.11 0.23 Allowed Glycine 0 CA--C 1.484 -1.903 0 N-CA-C 104.824 -3.31 . . . . 0.0 104.824 171.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.47 162.79 35.65 Favored 'General case' 0 CA--C 1.464 -2.331 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.91 -175.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.637 ' CG1' HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -137.74 113.21 10.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.004 -179.404 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.601 ' CG2' HD11 ' J' ' 34' ' ' LEU . 1.6 tt -107.03 114.1 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 179.179 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.427 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -116.65 97.52 0.76 Allowed Glycine 0 CA--C 1.508 -0.377 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -123.17 131.55 53.72 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-O 122.379 1.085 . . . . 0.0 110.579 179.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 25.6 ttt -116.19 117.38 29.88 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.577 -1.647 . . . . 0.0 110.29 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.7 71.3 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.51 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.19 105.58 3.21 Favored Glycine 0 C--N 1.365 2.157 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 176.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.08 165.17 53.27 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.745 -0.741 . . . . 0.0 111.694 -178.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t -143.75 136.9 24.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.68 0.276 . . . . 0.0 110.351 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.098 -0.953 . . . . 0.0 110.324 179.699 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -81.92 142.81 32.13 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.957 0.408 . . . . 0.0 110.926 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -63.04 142.12 58.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.705 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -134.85 144.29 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 3.5 m80 -139.13 138.55 37.11 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.377 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.475 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 79.6 t60 -139.73 166.92 23.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.475 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 85.5 mt-30 -148.61 172.0 15.25 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.612 179.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 47.6 mtpt -156.93 112.07 2.83 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.603 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' J' ' 17' ' ' LEU . 5.3 mp -123.82 120.53 32.89 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.437 0.16 . . . . 0.0 110.661 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -137.31 130.86 44.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 119.921 -0.712 . . . . 0.0 112.014 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.42 ' CE2' ' CD2' ' I' ' 19' ' ' PHE . 18.0 m-85 -111.04 119.78 40.18 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 114.741 -1.118 . . . . 0.0 108.75 178.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -131.31 122.08 25.79 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.67 145.04 31.54 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -131.41 160.31 35.46 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.911 -1.041 . . . . 0.0 108.897 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -121.77 120.63 35.17 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.524 HG12 ' N ' ' J' ' 25' ' ' GLY . 14.3 t -62.87 -120.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.94 177.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.524 ' N ' HG12 ' J' ' 24' ' ' VAL . . . -75.3 -90.26 0.21 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.203 -177.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 53.4 m -140.97 171.23 14.36 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 122.067 0.937 . . . . 0.0 111.024 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' J' ' 28' ' ' LYS . 38.8 t-20 -28.66 151.1 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 113.627 -1.624 . . . . 0.0 115.168 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.533 ' N ' ' OD1' ' J' ' 27' ' ' ASN . 97.9 mttt -163.75 110.7 1.13 Allowed 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 112.594 -2.094 . . . . 0.0 107.594 177.231 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.65 93.82 0.32 Allowed Glycine 0 N--CA 1.476 1.303 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.538 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.507 ' HB2' ' O ' ' I' ' 28' ' ' LYS . . . -112.16 157.73 20.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 105.85 -1.907 . . . . 0.0 105.85 177.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.646 HG23 ' CG1' ' K' ' 31' ' ' ILE . 0.0 OUTLIER -146.55 111.24 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 119.715 -0.794 . . . . 0.0 110.329 -173.729 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.437 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.2 tt -104.54 118.57 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.113 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.773 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.61 106.51 0.89 Allowed Glycine 0 C--O 1.241 0.567 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.601 HD11 ' CG2' ' I' ' 32' ' ' ILE . 5.3 mp -129.71 132.06 46.52 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-O 122.15 0.976 . . . . 0.0 111.217 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.44 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 23.2 ttt -102.04 114.91 29.44 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 113.383 -1.735 . . . . 0.0 108.143 178.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -136.46 70.45 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.446 -177.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.72 -101.12 1.99 Allowed Glycine 0 C--N 1.358 1.756 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 177.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.61 154.71 26.21 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -142.79 139.17 28.11 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-O 121.128 0.489 . . . . 0.0 110.726 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.589 179.641 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.62 139.03 45.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.76 0.314 . . . . 0.0 110.913 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.542 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 95.0 mt-10 -139.47 153.53 47.55 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.619 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.454 HG22 ' H ' ' L' ' 12' ' ' VAL . 54.6 t -121.71 131.16 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 116.312 -0.403 . . . . 0.0 109.968 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -161.51 162.63 30.4 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.716 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -152.45 168.01 26.89 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.947 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 -158.04 178.83 9.77 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.11 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.1 tttt -160.14 126.58 4.27 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.123 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -116.86 119.11 34.37 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.38 125.69 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.866 0.365 . . . . 0.0 111.395 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -116.91 119.69 36.14 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.116 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.405 ' CE1' ' OE2' ' K' ' 22' ' ' GLU . 37.8 t80 -127.92 119.72 26.16 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.43 132.98 34.21 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.47 ' OE1' ' OE2' ' L' ' 22' ' ' GLU . 57.7 mm-40 -102.83 167.86 9.6 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' K' ' 23' ' ' ASP . 2.9 p30 -152.35 133.7 14.44 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 119.11 -1.036 . . . . 0.0 113.788 -178.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.555 ' O ' HG13 ' K' ' 24' ' ' VAL . 7.7 p -88.69 113.29 25.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 104.222 -2.51 . . . . 0.0 104.222 174.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.46 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -45.39 91.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.621 0 C-N-CA 119.722 -1.228 . . . . 0.0 113.503 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.6 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.6 t 161.17 160.69 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.127 0.489 . . . . 0.0 110.159 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' K' ' 28' ' ' LYS . 82.3 m-20 -29.76 175.91 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.245 173.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.66 ' HB2' ' O ' ' K' ' 27' ' ' ASN . 2.9 tptm 147.56 100.85 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 C-N-CA 127.032 2.133 . . . . 0.0 110.299 176.02 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -51.22 -100.17 0.01 OUTLIER Glycine 0 C--O 1.21 -1.397 0 CA-C-O 124.465 2.147 . . . . 0.0 114.385 175.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.81 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 70.74 143.87 0.06 Allowed 'General case' 0 C--O 1.245 0.826 0 CA-C-N 111.354 -2.423 . . . . 0.0 107.203 177.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.81 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -147.88 123.09 2.35 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.795 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.493 ' O ' ' CG2' ' K' ' 32' ' ' ILE . 0.8 OUTLIER -108.97 115.12 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.692 178.816 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 91.35 0.58 Allowed Glycine 0 C--O 1.24 0.485 0 N-CA-C 107.333 -2.307 . . . . 0.0 107.333 176.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.4 HD12 ' CE2' ' I' ' 19' ' ' PHE . 92.2 mt -114.75 118.75 34.47 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.331 0.586 . . . . 0.0 109.862 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 2.5 ttt -107.7 115.04 29.43 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.742 -178.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.11 68.35 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.763 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.415 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -62.03 -100.99 0.01 OUTLIER Glycine 0 C--N 1.349 1.262 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.86 160.2 14.39 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.9 m -136.76 159.74 37.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.794 0.33 . . . . 0.0 110.219 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.325 -0.457 0 CA-C-O 118.089 -0.958 . . . . 0.0 110.765 -179.77 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.351 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -104.38 132.33 50.75 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -71.9 132.42 44.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.354 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.454 ' H ' HG22 ' K' ' 12' ' ' VAL . 21.8 m -143.13 156.2 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 122.011 0.91 . . . . 0.0 112.543 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.542 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 3.9 m80 -151.16 118.33 5.94 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.729 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -153.88 172.82 16.8 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.273 0.559 . . . . 0.0 110.418 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -145.67 173.86 11.7 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.728 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -159.82 120.92 3.14 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.93 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 tt -122.51 119.73 31.77 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -129.07 132.89 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -135.64 130.32 34.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.935 0.398 . . . . 0.0 110.715 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.2 t80 -137.31 127.62 26.38 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.0 148.21 36.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.265 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.47 ' OE2' ' OE1' ' K' ' 22' ' ' GLU . 78.1 mt-10 -81.73 149.17 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.464 0.649 . . . . 0.0 110.722 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.411 ' O ' ' O ' ' L' ' 22' ' ' GLU . 99.3 m-20 54.17 114.42 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.869 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 67.3 t -95.12 130.61 43.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 CA-C-N 114.519 -1.219 . . . . 0.0 109.879 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 49.56 82.74 0.03 OUTLIER Glycine 0 CA--C 1.525 0.698 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.183 178.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' L' ' 27' ' ' ASN . 5.8 p 176.96 -167.52 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' L' ' 26' ' ' SER . 14.5 m120 -38.92 179.91 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -175.485 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.468 ' NZ ' ' O ' ' K' ' 22' ' ' GLU . 85.1 tttt 77.42 -111.42 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.668 -1.151 . . . . 0.0 112.128 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.646 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 83.93 -94.59 1.83 Allowed Glycine 0 CA--C 1.503 -0.682 0 N-CA-C 107.892 -2.083 . . . . 0.0 107.892 -174.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.646 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 77.17 169.77 0.23 Allowed 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.617 HD13 ' C ' ' L' ' 30' ' ' ALA . 0.0 OUTLIER -138.83 109.19 4.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 116.81 -1.956 . . . . 0.0 111.224 179.23 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' L' ' 32' ' ' ILE . 7.4 tt -102.7 115.88 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-N 113.34 -1.755 . . . . 0.0 107.961 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 110.18 2.24 Favored Glycine 0 C--N 1.334 0.464 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 -179.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.38 111.8 22.03 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.582 -0.809 . . . . 0.0 110.086 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.437 ' HE2' ' H ' ' F' ' 33' ' ' GLY . 2.7 tpp -93.65 104.97 17.05 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' L' ' 37' ' ' GLY . 0.7 OUTLIER -131.09 71.36 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.954 0 O-C-N 122.051 -0.405 . . . . 0.0 109.922 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -35.49 -100.66 0.01 OUTLIER Glycine 0 C--N 1.346 1.085 0 C-N-CA 121.815 -0.231 . . . . 0.0 112.717 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.27 174.91 19.16 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 159.2 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.979 0.419 . . . . 0.0 110.709 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.184 179.897 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 121.307 0.575 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.488 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 69.7 m80 -116.44 172.5 7.17 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.813 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.682 ' CD2' ' H ' ' A' ' 15' ' ' GLN . 12.3 t-80 -80.45 165.55 22.09 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 109.622 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.682 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 1.2 pm0 -161.01 179.03 8.78 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.315 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -144.24 128.22 17.48 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.713 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 78.5 mt -124.03 124.19 42.01 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.24 131.45 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.333 0.587 . . . . 0.0 111.852 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.912 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 0.2 OUTLIER -118.44 112.11 19.53 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.937 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.533 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 51.1 p90 -125.44 128.27 47.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -177.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.27 115.85 28.06 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.219 0.533 . . . . 0.0 110.166 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.465 ' O ' ' C ' ' A' ' 23' ' ' ASP . 84.7 tt0 -163.89 96.52 0.82 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.465 ' C ' ' O ' ' A' ' 22' ' ' GLU . 0.1 OUTLIER -25.89 115.46 0.06 Allowed 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 -177.097 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' A' ' 26' ' ' SER . 2.1 p -87.27 130.64 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.75 82.29 0.0 OUTLIER Glycine 0 CA--C 1.525 0.712 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.618 -177.249 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' A' ' 24' ' ' VAL . 80.2 p -98.47 174.95 6.21 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.07 178.89 0.16 Allowed 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 119.396 -0.922 . . . . 0.0 108.635 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.68 110.78 1.22 Allowed 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.73 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 94.2 0.11 Allowed Glycine 0 N--CA 1.469 0.843 0 C-N-CA 119.702 -1.237 . . . . 0.0 111.284 177.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.402 ' HB2' ' OG ' ' A' ' 26' ' ' SER . . . -103.32 160.23 14.87 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-N 119.707 1.753 . . . . 0.0 107.497 177.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.579 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.2 OUTLIER -152.6 113.03 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.175 -175.308 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.47 ' O ' ' SD ' ' G' ' 35' ' ' MET . 97.6 mt -128.86 128.04 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-O 121.435 0.636 . . . . 0.0 111.671 -179.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' G' ' 35' ' ' MET . . . -123.5 127.03 6.43 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.043 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -130.18 130.05 44.21 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.799 0.3 . . . . 0.0 111.021 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.674 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 19.8 ttp -130.63 128.08 40.24 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.096 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.449 HG12 ' O ' ' A' ' 36' ' ' VAL . 54.4 t -115.64 72.15 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.88 98.82 0.81 Allowed Glycine 0 CA--C 1.529 0.924 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 176.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.76 172.45 40.48 Favored Glycine 0 CA--C 1.523 0.547 0 C-N-CA 120.485 -0.864 . . . . 0.0 111.564 -179.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m . . . . . 0 N--CA 1.471 0.587 0 CA-C-O 120.781 0.324 . . . . 0.0 110.765 179.986 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.466 0.366 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.464 ' O ' ' CB ' ' C' ' 13' ' ' HIS . 4.8 m-70 -105.67 117.76 34.84 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.789 0.328 . . . . 0.0 110.909 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.476 ' ND1' ' CD2' ' A' ' 14' ' ' HIS . 52.5 t-80 -157.21 159.51 37.76 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.437 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 74.4 mt-30 -159.98 179.07 9.09 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.832 179.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -157.71 126.12 5.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.754 0.311 . . . . 0.0 110.762 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 tp -120.76 123.25 42.21 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.312 0.577 . . . . 0.0 110.297 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.48 HG22 ' CG1' ' C' ' 18' ' ' VAL . 56.0 t -117.93 121.37 67.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.601 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.901 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 13.5 t80 -128.05 116.26 19.73 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 -178.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.543 ' CG ' ' CZ ' ' C' ' 20' ' ' PHE . 38.8 p90 -150.2 160.22 43.85 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.41 138.85 38.59 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.896 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -125.4 175.1 7.72 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.487 ' CG ' ' H ' ' C' ' 27' ' ' ASN . 50.5 t0 -142.98 99.33 3.44 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.139 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.656 HG12 ' H ' ' B' ' 25' ' ' GLY . 1.6 t -118.21 -151.17 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.656 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -38.9 -75.88 0.09 OUTLIER Glycine 0 N--CA 1.47 0.937 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.601 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.592 ' HG ' ' H ' ' B' ' 27' ' ' ASN . 31.1 t 60.15 173.13 0.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.73 -1.235 . . . . 0.0 113.568 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.592 ' H ' ' HG ' ' B' ' 26' ' ' SER . 18.9 p30 -101.38 -178.98 3.89 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 113.395 -1.73 . . . . 0.0 112.567 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.494 ' O ' ' O ' ' B' ' 27' ' ' ASN . 87.3 tttt -34.15 -102.66 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.118 177.115 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -137.13 100.8 0.32 Allowed Glycine 0 CA--C 1.485 -1.829 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.5 157.72 31.45 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.349 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.754 HG23 HG13 ' C' ' 31' ' ' ILE . 0.6 OUTLIER -148.58 120.87 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.583 -178.796 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.501 ' O ' ' SD ' ' H' ' 35' ' ' MET . 86.8 mt -133.98 128.68 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.362 -178.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.505 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -120.81 109.5 1.56 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.976 -1.65 . . . . 0.0 108.976 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 8.7 tt -117.08 123.32 46.53 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 117.072 0.436 . . . . 0.0 111.099 -179.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.599 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 32.1 ttp -124.79 117.37 24.01 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.299 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 37' ' ' GLY . 34.5 m -136.54 73.01 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -47.4 -95.35 0.01 OUTLIER Glycine 0 C--N 1.337 0.604 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 175.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.13 176.67 40.45 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -140.96 144.48 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-O 121.031 0.443 . . . . 0.0 111.215 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 85.0 t . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.309 179.842 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.156 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -105.73 131.56 52.94 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.709 0.29 . . . . 0.0 110.595 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -74.3 133.14 42.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.068 179.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.16 166.68 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 CA-C-O 120.832 0.349 . . . . 0.0 110.887 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.464 ' CB ' ' O ' ' B' ' 13' ' ' HIS . 0.0 OUTLIER -169.28 164.76 10.92 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.271 178.749 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.495 ' CG ' ' OE1' ' D' ' 15' ' ' GLN . 88.6 m-70 -105.52 -179.91 4.08 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' C' ' 16' ' ' LYS . 44.9 tt0 -88.69 169.19 11.88 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.433 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' C' ' 15' ' ' GLN . 99.2 mttt -123.5 133.92 53.95 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 29.1 mt -122.3 119.35 30.86 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.026 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . 0.48 ' CG1' HG22 ' B' ' 18' ' ' VAL . 6.2 p -124.77 123.23 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.067 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.707 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 3.6 t80 -123.41 119.17 29.25 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.571 -176.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.543 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 49.7 p90 -142.86 130.26 21.11 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-O 122.574 1.178 . . . . 0.0 112.953 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.94 121.74 38.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.397 179.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.496 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 97.2 mt-10 -99.01 101.08 12.35 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.498 ' OD1' ' NZ ' ' E' ' 28' ' ' LYS . 15.7 t0 83.68 133.56 0.05 Allowed 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.508 ' O ' ' N ' ' C' ' 26' ' ' SER . 34.8 t -83.41 -110.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.718 ' HA2' ' HB3' ' D' ' 30' ' ' ALA . . . -42.85 92.19 0.01 OUTLIER Glycine 0 C--N 1.317 -0.473 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.527 ' O ' ' O ' ' C' ' 27' ' ' ASN . 42.3 p -101.11 165.22 11.42 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 122.49 1.138 . . . . 0.0 110.784 -176.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.646 ' CG ' ' HZ2' ' C' ' 28' ' ' LYS . 0.1 OUTLIER 49.05 169.15 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 112.009 -2.36 . . . . 0.0 109.114 -176.235 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.787 ' CE ' ' H ' ' C' ' 28' ' ' LYS . 0.0 OUTLIER -79.08 110.7 14.57 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.641 -0.824 . . . . 0.0 108.824 175.634 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 57.25 91.51 0.01 OUTLIER Glycine 0 C--O 1.219 -0.829 0 C-N-CA 118.342 -1.885 . . . . 0.0 109.877 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.421 ' HB2' ' OD1' ' C' ' 27' ' ' ASN . . . -136.66 152.22 50.16 Favored 'General case' 0 CA--C 1.476 -1.903 0 CA-C-N 121.428 2.614 . . . . 0.0 105.016 175.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.754 HG13 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -144.48 109.66 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.185 -173.028 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.488 HG12 HD21 ' C' ' 34' ' ' LEU . 0.8 OUTLIER -114.9 118.44 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.05 -178.918 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.21 108.51 2.48 Favored Glycine 0 N--CA 1.46 0.298 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.912 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 5.8 mt -114.76 112.72 23.25 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 120.916 0.388 . . . . 0.0 110.331 -178.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.5 ttt -112.42 104.06 12.18 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.59 72.24 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.994 -177.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -42.97 -97.43 0.01 OUTLIER Glycine 0 C--N 1.349 1.27 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.12 -173.12 42.95 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -141.52 154.22 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.019 0.438 . . . . 0.0 111.133 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.087 -0.959 . . . . 0.0 110.218 179.56 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.439 ' HB ' ' H ' ' E' ' 12' ' ' VAL . 23.0 m . . . . . 0 N--CA 1.465 0.28 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 70.0 m80 -82.15 112.95 19.65 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.168 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.624 ' CE1' HG23 ' E' ' 12' ' ' VAL . 3.4 m-70 -145.72 159.94 42.44 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG ' ' C' ' 14' ' ' HIS . 0.0 OUTLIER -159.23 174.18 15.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.26 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -153.32 129.09 10.14 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.886 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 36.7 tp -123.28 118.33 27.32 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -122.39 126.19 73.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.941 0.4 . . . . 0.0 110.687 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -123.25 112.33 17.52 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -131.57 133.42 45.0 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.79 131.79 29.59 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.886 0.374 . . . . 0.0 111.725 179.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -127.88 143.52 51.11 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.991 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -131.3 111.97 12.35 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.969 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.494 ' O ' ' N ' ' D' ' 26' ' ' SER . 12.6 m -138.01 -122.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 120.424 -0.51 . . . . 0.0 109.915 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.418 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . 28.37 -84.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.536 -0.756 . . . . 0.0 113.097 -178.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.3 m 170.28 178.77 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.518 0.675 . . . . 0.0 110.574 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' D' ' 26' ' ' SER . 12.4 m120 -28.73 -179.21 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 113.041 -1.891 . . . . 0.0 114.248 176.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 85.4 mttt 128.26 105.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 125.867 1.667 . . . . 0.0 112.137 176.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.6 94.87 0.05 OUTLIER Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.718 ' HB3' ' HA2' ' C' ' 25' ' ' GLY . . . -122.43 154.25 38.0 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 176.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.504 HD12 ' CG2' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.04 112.29 2.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.732 -171.629 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.41 ' O ' HG22 ' D' ' 32' ' ' ILE . 2.1 mt -107.93 114.01 45.3 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.409 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.408 ' CA ' ' HG3' ' J' ' 35' ' ' MET . . . -106.38 100.65 1.66 Allowed Glycine 0 CA--C 1.498 -1.007 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 176.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.901 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 13.6 tp -112.99 121.08 43.56 Favored 'General case' 0 CA--C 1.503 -0.852 0 CA-C-N 115.298 -0.451 . . . . 0.0 110.934 -177.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 43.3 ttp -128.97 107.25 9.46 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -123.61 72.14 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.675 -179.927 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.15 -100.52 0.01 OUTLIER Glycine 0 C--N 1.36 1.892 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.891 179.144 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 157.13 -157.24 27.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -132.36 147.95 31.99 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.462 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.32 -179.731 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -114.76 134.31 55.21 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.768 0.318 . . . . 0.0 110.491 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -98.37 137.47 37.04 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.28 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.624 HG23 ' CE1' ' D' ' 14' ' ' HIS . 22.6 m -131.74 160.34 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 121.332 0.587 . . . . 0.0 111.141 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 27.6 m80 -124.01 120.51 32.65 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.606 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.467 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -150.66 162.91 39.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.927 0.87 . . . . 0.0 111.473 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.467 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 50.2 tt0 -157.99 168.6 26.67 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.375 -1.284 . . . . 0.0 110.063 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -143.57 126.79 16.59 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.837 179.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 tt -118.98 115.68 24.86 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -120.23 125.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.734 0.302 . . . . 0.0 110.36 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -124.16 113.4 18.28 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.482 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -125.72 125.13 42.51 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.212 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.434 ' HB3' ' CB ' ' F' ' 21' ' ' ALA . . . -134.23 119.63 19.01 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.232 0.539 . . . . 0.0 110.327 179.096 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.402 ' C ' ' OD1' ' E' ' 23' ' ' ASP . 97.8 mt-10 -129.16 128.35 43.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.459 ' HB3' ' HZ2' ' F' ' 28' ' ' LYS . 1.2 m-20 -141.89 112.1 6.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.264 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' E' ' 26' ' ' SER . 13.2 m -103.24 -122.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 C-N-CA 120.326 -0.55 . . . . 0.0 111.057 -178.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.05 -84.92 0.01 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.834 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' E' ' 27' ' ' ASN . 3.0 p 170.88 170.54 0.07 Allowed 'General case' 0 CA--C 1.511 -0.55 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' E' ' 26' ' ' SER . 27.6 t-20 -18.17 157.47 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.975 0 O-C-N 124.792 1.308 . . . . 0.0 113.475 179.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.722 ' O ' ' HB2' ' F' ' 30' ' ' ALA . 84.8 tttt -162.55 111.35 1.38 Allowed 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.552 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.17 92.36 0.25 Allowed Glycine 0 N--CA 1.479 1.528 0 O-C-N 121.931 -0.481 . . . . 0.0 113.194 177.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.5 161.97 21.58 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 175.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.466 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.68 132.21 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 118.903 -1.119 . . . . 0.0 113.647 -175.561 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.571 HG23 HD21 ' E' ' 34' ' ' LEU . 0.2 OUTLIER -109.71 116.48 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.306 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.67 105.36 2.23 Favored Glycine 0 N--CA 1.466 0.669 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.707 HD13 ' CZ ' ' C' ' 19' ' ' PHE . 16.4 mt -115.83 115.0 25.49 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 117.561 0.68 . . . . 0.0 112.155 -177.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.717 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 11.4 ttp -114.07 106.66 14.66 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 176.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.91 73.81 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.331 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.17 111.57 2.66 Favored Glycine 0 C--N 1.354 1.577 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 178.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.5 -157.08 0.04 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.15 142.81 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.975 0.417 . . . . 0.0 110.49 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.772 179.827 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t . . . . . 0 N--CA 1.468 0.43 0 CA-C-O 121.115 0.483 . . . . 0.0 110.397 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -130.02 128.53 42.18 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.923 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.519 ' CE1' ' O ' ' F' ' 15' ' ' GLN . 56.9 t-80 -151.99 168.5 25.02 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.519 ' O ' ' CE1' ' F' ' 14' ' ' HIS . 84.7 mt-30 -150.52 173.47 14.05 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.41 179.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.41 127.01 14.21 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.39 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -128.73 127.57 42.33 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.554 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -127.56 128.3 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -123.36 120.74 33.92 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.678 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 78.8 t80 -141.13 121.88 14.35 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.434 ' CB ' ' HB3' ' E' ' 21' ' ' ALA . . . -159.59 154.71 25.04 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 119.785 -0.766 . . . . 0.0 112.578 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -96.94 124.16 40.84 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 60.3 t0 . . . . . 0 CA--C 1.536 0.407 0 C-N-CA 119.652 -0.819 . . . . 0.0 113.033 -178.198 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.509 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 75.1 tttt . . . . . 0 CA--C 1.544 0.717 0 CA-C-O 124.085 1.897 . . . . 0.0 112.226 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.509 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -109.29 -100.33 2.63 Favored Glycine 0 CA--C 1.484 -1.881 0 C-N-CA 130.168 3.747 . . . . 0.0 109.753 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.722 ' HB2' ' O ' ' E' ' 28' ' ' LYS . . . -58.11 172.85 0.39 Allowed 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 -178.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.448 HD13 ' HA3' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -140.39 134.42 34.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.147 -1.421 . . . . 0.0 111.479 -172.131 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.495 ' CG2' ' O ' ' F' ' 32' ' ' ILE . 5.2 tt -110.12 117.24 54.29 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 114.001 -1.454 . . . . 0.0 108.452 -179.266 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.77 102.87 2.42 Favored Glycine 0 C--N 1.322 -0.249 0 N-CA-C 108.027 -2.029 . . . . 0.0 108.027 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.504 ' O ' HD12 ' F' ' 34' ' ' LEU . 2.2 pp -107.44 115.73 30.67 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 117.039 0.42 . . . . 0.0 110.518 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 18.3 ttp -119.46 110.5 16.99 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 m -132.87 79.92 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.16 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -64.65 103.5 0.77 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.0 -146.15 19.15 Favored Glycine 0 N--CA 1.465 0.61 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -113.86 133.58 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 32.9 m . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.761 -179.67 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -121.92 147.84 45.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.745 0.307 . . . . 0.0 110.707 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -68.51 156.96 36.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.069 179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 78.0 t -115.63 131.6 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.061 0.458 . . . . 0.0 110.315 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.448 ' CD2' ' H ' ' G' ' 13' ' ' HIS . 0.5 OUTLIER -89.15 179.45 6.13 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.972 179.679 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -74.69 164.45 26.57 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 91.7 mt-30 -155.63 -179.84 8.5 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.442 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.414 ' NZ ' ' CG2' ' G' ' 18' ' ' VAL . 65.2 tttm -161.32 119.26 2.35 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.682 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 35.7 tp -118.83 126.12 51.11 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 121.299 0.571 . . . . 0.0 110.478 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.414 ' CG2' ' NZ ' ' G' ' 16' ' ' LYS . 47.9 t -125.72 125.9 69.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.901 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.923 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 0.1 OUTLIER -114.76 119.47 36.77 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.937 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -142.92 147.96 36.14 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 119.674 -0.81 . . . . 0.0 112.369 -178.041 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.32 132.22 35.37 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.285 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -135.48 167.33 21.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.53 ' OD2' ' N ' ' H' ' 24' ' ' VAL . 34.8 m-20 -85.94 -151.19 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.168 -178.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' G' ' 23' ' ' ASP . 14.0 t 27.09 103.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.77 -94.69 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.827 177.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -64.03 -178.81 0.36 Allowed 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -80.95 173.49 12.56 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.12 0.486 . . . . 0.0 111.302 177.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -44.91 110.79 0.26 Allowed 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.947 176.365 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.26 94.73 0.52 Allowed Glycine 0 N--CA 1.472 1.084 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.324 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -118.34 151.61 37.39 Favored 'General case' 0 CA--C 1.504 -0.808 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.196 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.19 108.81 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 CA-C-N 113.182 -1.826 . . . . 0.0 109.594 -171.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.76 123.46 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.89 0.376 . . . . 0.0 111.237 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.674 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -130.33 111.23 1.11 Allowed Glycine 0 N--CA 1.465 0.573 0 N-CA-C 108.794 -1.723 . . . . 0.0 108.794 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.89 130.41 52.82 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.916 0.388 . . . . 0.0 111.656 -178.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' A' ' 33' ' ' GLY . 28.1 ttt -130.46 128.52 41.43 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' G' ' 37' ' ' GLY . 3.7 t -111.42 65.9 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -178.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.509 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -55.25 -105.55 0.01 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 178.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -105.06 174.59 21.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 30.0 m -135.23 158.13 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.11 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -86.65 131.01 34.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.918 0.389 . . . . 0.0 110.103 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -136.06 142.81 44.41 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.908 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -126.06 134.31 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.456 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 75.4 m80 -87.08 175.35 8.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.124 0.488 . . . . 0.0 110.792 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.547 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 25.4 m-70 -77.9 173.28 12.32 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.45 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -142.75 175.44 9.82 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.128 179.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -151.58 125.87 9.36 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.151 -179.184 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 58.1 mt -121.17 120.51 35.43 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -127.8 130.52 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -178.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.744 ' CZ ' HD22 ' J' ' 34' ' ' LEU . 5.9 m-85 -117.73 120.06 36.81 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.615 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 29.0 t80 -130.78 122.6 27.46 Favored 'General case' 0 N--CA 1.476 0.834 0 O-C-N 122.231 -0.293 . . . . 0.0 110.626 -179.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.77 130.0 48.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -137.94 106.74 5.93 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -114.51 114.11 25.34 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.53 ' N ' ' OD2' ' G' ' 23' ' ' ASP . 1.2 p -128.79 122.26 56.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.051 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 30.49 82.79 0.01 OUTLIER Glycine 0 CA--C 1.537 1.442 0 CA-C-O 119.473 -0.626 . . . . 0.0 114.593 175.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.542 ' O ' ' O ' ' H' ' 27' ' ' ASN . 1.0 OUTLIER -140.14 170.62 15.49 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 118.71 1.255 . . . . 0.0 111.108 179.107 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' H' ' 26' ' ' SER . 5.5 m-20 -31.04 173.14 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 113.671 -1.604 . . . . 0.0 114.812 -177.206 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -87.84 111.41 21.38 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.267 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . 69.61 93.6 0.06 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 118.124 -1.989 . . . . 0.0 115.526 172.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.42 155.51 22.09 Favored 'General case' 0 C--O 1.248 0.985 0 CA-C-N 120.627 2.214 . . . . 0.0 106.698 175.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.759 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -148.31 119.27 1.37 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 118.921 -1.112 . . . . 0.0 111.684 -173.055 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.9 mt -129.87 128.32 64.98 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.034 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.599 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -132.23 127.54 4.94 Favored Glycine 0 N--CA 1.465 0.63 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.454 ' O ' HD12 ' I' ' 34' ' ' LEU . 8.4 tt -135.08 130.96 36.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.565 0.698 . . . . 0.0 110.736 -179.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 19.3 ttt -130.37 128.99 42.53 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.652 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.52 79.54 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.549 ' CA ' HG21 ' B' ' 31' ' ' ILE . . . -65.77 105.12 1.15 Allowed Glycine 0 C--N 1.339 0.707 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.74 -171.27 50.34 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -132.37 161.78 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-O 120.993 0.425 . . . . 0.0 110.909 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 34.3 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.658 179.766 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.464 0.25 0 N-CA-C 110.075 -0.342 . . . . 0.0 110.075 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.513 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 16.5 p-80 -164.27 161.08 21.72 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.554 -0.459 . . . . 0.0 111.229 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.547 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 0.8 OUTLIER -122.92 166.76 14.52 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.951 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.476 HE22 HG13 ' K' ' 39' ' ' VAL . 86.6 mt-30 -142.25 175.64 9.6 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.65 179.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.528 ' C ' HD12 ' I' ' 17' ' ' LEU . 87.4 tttt -166.49 113.7 0.86 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.771 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.528 HD12 ' C ' ' I' ' 16' ' ' LYS . 8.0 mp -112.56 124.24 52.09 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -127.91 128.75 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-O 121.17 0.51 . . . . 0.0 112.095 -179.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.834 ' CZ ' HD13 ' K' ' 34' ' ' LEU . 32.1 m-85 -118.75 118.98 33.07 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.573 178.251 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.615 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 58.8 t80 -126.57 116.95 21.85 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.48 129.63 52.21 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.18 0.514 . . . . 0.0 111.771 -179.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -143.83 144.29 31.71 Favored 'General case' 0 C--N 1.34 0.193 0 CA-C-N 115.366 -0.833 . . . . 0.0 109.036 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.605 ' O ' ' O ' ' I' ' 24' ' ' VAL . 0.9 OUTLIER -175.04 129.55 0.3 Allowed 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.062 -0.655 . . . . 0.0 110.773 179.724 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.757 HG12 ' N ' ' I' ' 25' ' ' GLY . 61.6 t -29.34 -113.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 O-C-N 124.425 1.078 . . . . 0.0 112.66 178.156 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.757 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -170.77 90.55 0.09 OUTLIER Glycine 0 CA--C 1.53 0.981 0 CA-C-N 115.272 -0.877 . . . . 0.0 112.117 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.525 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t 161.99 160.45 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.921 0.867 . . . . 0.0 111.128 176.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.525 ' O ' ' O ' ' I' ' 26' ' ' SER . 29.2 m120 -30.16 179.07 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 113.084 -1.871 . . . . 0.0 116.027 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.508 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 86.4 tttt 127.81 103.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 112.2 -2.273 . . . . 0.0 111.203 174.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.514 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -59.86 99.54 0.16 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.248 -1.307 . . . . 0.0 110.735 174.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.439 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -118.08 141.4 48.51 Favored 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 102.529 -3.137 . . . . 0.0 102.529 174.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.759 HD12 ' CG2' ' H' ' 31' ' ' ILE . 2.1 mt -146.06 114.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 C-N-CA 118.181 -1.408 . . . . 0.0 112.515 -169.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 1.3 mt -114.62 119.74 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.16 106.56 1.44 Allowed Glycine 0 N--CA 1.461 0.311 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.923 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 54.4 tp -116.23 120.93 40.53 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 5.6 tpp -117.1 102.02 8.96 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 174.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.705 ' O ' HG13 ' I' ' 36' ' ' VAL . 4.2 p -131.81 74.89 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.114 -177.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.28 -96.92 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.995 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 163.31 -167.76 37.72 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.65 150.58 3.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.768 0.318 . . . . 0.0 110.387 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.854 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -83.64 141.89 31.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.955 0.407 . . . . 0.0 110.065 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -66.35 135.63 54.64 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.477 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.814 HG12 ' H ' ' J' ' 13' ' ' HIS . 27.4 t -145.77 178.8 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.119 179.434 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.814 ' H ' HG12 ' J' ' 12' ' ' VAL . 92.2 m-70 -50.82 125.28 12.96 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.069 0.461 . . . . 0.0 112.146 -177.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.499 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 18.0 t-80 -145.38 163.43 34.6 Favored 'General case' 0 C--N 1.341 0.239 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.499 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 89.6 mt-30 -148.54 177.6 9.34 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.088 0.47 . . . . 0.0 111.364 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.419 ' C ' HD22 ' J' ' 17' ' ' LEU . 88.9 tttt -170.26 116.28 0.51 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.819 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.419 HD22 ' C ' ' J' ' 16' ' ' LYS . 1.4 mm? -114.23 125.27 53.72 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.495 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -126.78 121.05 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 120.78 0.324 . . . . 0.0 111.241 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.673 ' CZ ' HD22 ' L' ' 34' ' ' LEU . 95.4 m-85 -118.43 116.22 26.26 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.416 ' CZ ' ' CD1' ' K' ' 20' ' ' PHE . 1.1 t80 -131.38 129.66 41.62 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 120.922 0.391 . . . . 0.0 110.553 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.41 134.65 41.88 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.458 0.647 . . . . 0.0 112.421 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 mt-10 -144.3 102.87 3.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.029 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -152.22 177.3 10.68 Favored 'General case' 0 CA--C 1.515 -0.394 0 O-C-N 122.096 -0.378 . . . . 0.0 110.392 -178.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -91.96 102.99 14.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 122.176 0.989 . . . . 0.0 108.379 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' K' ' 26' ' ' SER . . . -35.9 95.59 0.01 OUTLIER Glycine 0 CA--C 1.526 0.763 0 CA-C-N 113.269 -1.787 . . . . 0.0 115.653 -179.087 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.4 t 170.24 176.18 0.05 Allowed 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 121.627 0.727 . . . . 0.0 110.678 175.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' J' ' 26' ' ' SER . 52.2 t30 -28.96 179.5 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 115.886 1.81 . . . . 0.0 115.886 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.505 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 61.8 tttp 128.26 105.11 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 112.715 -2.039 . . . . 0.0 112.719 175.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.02 95.07 0.05 OUTLIER Glycine 0 N--CA 1.465 0.59 0 CA-C-N 113.934 -1.484 . . . . 0.0 113.031 174.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.51 142.33 46.99 Favored 'General case' 0 CA--C 1.496 -1.117 0 CA-C-N 119.884 1.842 . . . . 0.0 106.201 174.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.46 HG23 ' CG1' ' K' ' 31' ' ' ILE . 0.0 OUTLIER -143.11 110.93 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 CA-C-N 114.454 -1.248 . . . . 0.0 111.837 -171.41 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.529 ' O ' ' SD ' ' E' ' 35' ' ' MET . 0.2 OUTLIER -114.68 118.9 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 177.783 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -114.15 106.68 1.75 Allowed Glycine 0 CA--C 1.496 -1.115 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 177.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.744 HD22 ' CZ ' ' H' ' 19' ' ' PHE . 37.1 tp -115.37 118.87 34.44 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 113.292 0.849 . . . . 0.0 113.292 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.408 ' HG3' ' CA ' ' D' ' 33' ' ' GLY . 0.0 OUTLIER -117.29 107.63 14.63 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.639 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.524 HG22 HD11 ' J' ' 34' ' ' LEU . 0.0 OUTLIER -119.37 80.29 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.3 -94.42 0.01 OUTLIER Glycine 0 C--N 1.352 1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.714 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.62 -178.14 18.74 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 111.031 -0.827 . . . . 0.0 111.031 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -114.63 134.93 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.444 179.95 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -103.96 135.44 45.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.655 0.264 . . . . 0.0 110.377 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.471 ' N ' ' OE1' ' L' ' 11' ' ' GLU . 94.9 mt-10 -137.48 156.52 48.06 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.607 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.6 m -134.48 163.2 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.657 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 t60 -159.37 128.37 5.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.314 -179.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -152.67 167.52 28.65 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.688 0.756 . . . . 0.0 110.002 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -156.51 175.92 13.39 Favored 'General case' 0 C--N 1.307 -1.239 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.762 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -148.73 120.37 8.03 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 23.1 mt -112.51 116.05 29.63 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.6 p -133.31 134.47 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 CA-C-O 121.42 0.629 . . . . 0.0 112.308 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -125.76 126.94 45.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.227 179.087 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.416 ' CD1' ' CZ ' ' J' ' 20' ' ' PHE . 8.2 t80 -136.51 128.96 30.26 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.171 0.51 . . . . 0.0 111.818 -179.315 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.78 129.53 47.19 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.772 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.446 ' HG2' ' N ' ' K' ' 23' ' ' ASP . 75.7 tt0 -88.44 170.1 11.2 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.453 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.503 ' OD1' HG21 ' L' ' 24' ' ' VAL . 48.0 t0 -39.33 115.46 0.5 Allowed 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 121.007 0.432 . . . . 0.0 110.821 -178.601 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.556 HG13 ' O ' ' K' ' 24' ' ' VAL . 10.4 p -129.84 117.16 40.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . -27.92 -90.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.381 0 CA-C-O 121.524 0.513 . . . . 0.0 111.825 178.161 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.637 ' O ' ' O ' ' K' ' 27' ' ' ASN . 26.7 p -140.97 170.73 15.18 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.121 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.637 ' O ' ' O ' ' K' ' 26' ' ' SER . 56.8 p30 -28.29 169.75 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -149.4 111.45 4.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.685 178.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.71 91.6 0.02 OUTLIER Glycine 0 N--CA 1.464 0.521 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.59 151.69 43.37 Favored 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 106.314 -1.735 . . . . 0.0 106.314 176.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.46 ' CG1' HG23 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -135.83 115.44 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.579 -178.724 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.545 HG23 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -115.59 116.91 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 178.362 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.717 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -109.56 106.0 2.13 Favored Glycine 0 N--CA 1.464 0.547 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 178.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.834 HD13 ' CZ ' ' I' ' 19' ' ' PHE . 21.5 mt -110.44 111.98 23.6 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 117.047 0.423 . . . . 0.0 111.659 -177.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.46 ' CE ' ' O ' ' E' ' 32' ' ' ILE . 11.4 tpt -107.59 103.1 12.32 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 176.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -129.58 73.83 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.146 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.445 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.38 -101.5 0.01 OUTLIER Glycine 0 C--N 1.359 1.828 0 CA-C-N 116.388 -0.369 . . . . 0.0 112.844 -179.215 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.92 -155.69 26.57 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.476 HG13 HE22 ' I' ' 15' ' ' GLN . 30.0 m -126.54 160.54 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.762 0.315 . . . . 0.0 110.548 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.501 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -148.22 160.68 42.69 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.655 0.264 . . . . 0.0 110.334 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . 0.471 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 78.5 mm-40 -75.78 157.0 34.02 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.733 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 96.1 t -92.86 131.06 40.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.123 0 CA-C-O 121.061 0.458 . . . . 0.0 110.216 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.5 ' NE2' ' OXT' ' L' ' 40' ' ' VAL . 45.1 t-80 -144.25 134.21 23.98 Favored 'General case' 0 N--CA 1.461 0.113 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.954 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 46.8 t-80 -154.99 170.83 20.84 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.478 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 96.2 mt-30 -148.3 178.56 8.47 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.646 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -164.3 122.48 1.79 Allowed 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.11 0.481 . . . . 0.0 111.204 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 59.1 tp -120.75 121.57 38.5 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.977 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.91 131.65 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.156 0.503 . . . . 0.0 110.501 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.534 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 41.1 p90 -135.14 125.63 26.72 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.217 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -140.08 142.57 36.1 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 121.776 0.798 . . . . 0.0 110.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.39 143.63 24.06 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.343 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.405 ' O ' ' O ' ' L' ' 23' ' ' ASP . 78.5 tt0 -76.12 153.1 36.52 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.585 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.535 ' C ' HG23 ' L' ' 24' ' ' VAL . 59.4 m-20 -58.62 -134.4 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -177.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.535 HG23 ' C ' ' L' ' 23' ' ' ASP . 3.8 t 84.69 110.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.6 -92.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.807 ' O ' ' O ' ' L' ' 27' ' ' ASN . 34.1 p -161.18 163.98 30.82 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.807 ' O ' ' O ' ' L' ' 26' ' ' SER . 83.2 m-20 -9.98 -178.62 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 177.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' L' ' 29' ' ' GLY . 82.6 tttt -128.08 110.41 12.46 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.052 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' L' ' 28' ' ' LYS . . . -54.15 -95.26 0.01 OUTLIER Glycine 0 C--N 1.334 0.451 0 C-N-CA 117.113 -2.47 . . . . 0.0 111.305 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.793 ' C ' HD13 ' L' ' 31' ' ' ILE . . . 71.65 163.32 0.26 Allowed 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 103.663 -2.717 . . . . 0.0 103.663 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.798 HD13 ' N ' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -138.2 100.6 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 122.957 2.617 . . . . 0.0 108.838 175.181 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.501 ' CG2' ' O ' ' L' ' 32' ' ' ILE . 4.6 tt -102.01 112.67 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 CA-C-N 113.356 -1.747 . . . . 0.0 106.628 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -99.97 102.39 2.5 Favored Glycine 0 CA--C 1.5 -0.889 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.673 HD22 ' CZ ' ' J' ' 19' ' ' PHE . 43.6 tp -107.23 115.93 31.04 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.912 -0.315 . . . . 0.0 111.233 -178.369 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 17.6 tpp -112.64 104.22 12.28 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 176.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.426 ' CG1' HG23 ' K' ' 36' ' ' VAL . 10.5 m -135.84 79.59 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.448 ' HA3' HD13 ' F' ' 31' ' ' ILE . . . -66.1 103.68 0.9 Allowed Glycine 0 C--N 1.344 0.986 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 -162.04 38.0 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -125.58 153.12 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 121.044 0.449 . . . . 0.0 110.839 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . 0.5 ' OXT' ' NE2' ' L' ' 13' ' ' HIS . 31.3 m . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.73 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.501 ' O ' ' CG ' ' A' ' 13' ' ' HIS . 48.9 t . . . . . 0 C--O 1.231 0.13 0 N-CA-C 109.182 -0.674 . . . . 0.0 109.182 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 12' ' ' VAL . 97.3 m-70 -155.57 110.4 2.95 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.218 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 6.1 p-80 -151.12 166.33 31.13 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 97.9 mm-40 -152.51 179.22 8.78 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.394 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -149.48 110.9 4.45 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.918 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 77.3 mt -138.12 127.8 25.15 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 121.575 0.702 . . . . 0.0 112.076 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 18' ' ' VAL . 17.4 m -129.16 127.78 66.08 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.233 178.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.515 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 11.2 t80 -121.18 121.8 38.6 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.502 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.2 p90 -137.1 128.19 27.74 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.407 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.66 126.67 52.44 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.979 0.418 . . . . 0.0 111.122 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -153.21 108.81 3.27 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.41 ' HB3' ' HZ1' ' C' ' 28' ' ' LYS . 1.6 m-20 -57.21 121.55 10.35 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.489 -177.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 26' ' ' SER . 26.9 m -88.63 124.03 41.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.413 ' HA2' ' H ' ' B' ' 27' ' ' ASN . . . -44.84 84.71 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 CA-C-N 116.08 -0.509 . . . . 0.0 112.388 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.524 ' N ' ' O ' ' A' ' 24' ' ' VAL . 11.8 p -91.85 179.16 5.69 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 m120 -60.31 178.97 0.17 Allowed 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 120.166 -0.613 . . . . 0.0 111.258 -179.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.4 110.89 1.2 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.718 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.934 ' H ' HD21 ' B' ' 27' ' ' ASN . . . 71.93 94.09 0.08 OUTLIER Glycine 0 N--CA 1.465 0.587 0 CA-C-O 118.511 -1.161 . . . . 0.0 111.783 177.332 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 153.78 25.87 Favored 'General case' 0 C--O 1.241 0.646 0 C-N-CA 117.607 -1.637 . . . . 0.0 107.602 177.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.481 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.2 OUTLIER -148.2 109.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 CA-C-N 113.783 -1.553 . . . . 0.0 110.023 -171.945 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -131.07 126.96 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.245 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.47 119.57 2.12 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 mt -136.15 150.31 49.01 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-O 121.398 0.618 . . . . 0.0 111.762 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 18.6 ttt -149.53 139.8 22.25 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.992 -0.443 . . . . 0.0 111.865 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 36' ' ' VAL . 5.6 p -152.28 79.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.385 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.64 ' HA3' HD12 ' H' ' 31' ' ' ILE . . . -73.69 104.78 1.67 Allowed Glycine 0 CA--C 1.527 0.814 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.138 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.38 176.17 23.84 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.88 -0.488 . . . . 0.0 111.88 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.7 t . . . . . 0 N--CA 1.465 0.316 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.931 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 N--CA 1.464 0.259 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -135.69 137.55 41.88 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 111.262 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 72.7 t60 -155.44 169.88 23.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.549 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 47.1 tt0 -163.4 169.74 18.51 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.251 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.43 ' N ' ' HG2' ' B' ' 15' ' ' GLN . 98.0 mttt -151.3 108.69 3.61 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 178.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.5 mt -126.08 120.77 31.08 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.119 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -123.26 130.35 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.567 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 2.0 t80 -129.39 122.88 30.34 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.305 -178.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -131.88 133.29 44.44 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 120.892 0.377 . . . . 0.0 110.453 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.48 126.19 32.41 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.882 0.372 . . . . 0.0 110.779 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -155.03 158.9 39.83 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -147.43 112.68 5.54 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 65.4 t -123.73 124.94 70.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.498 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.55 82.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 114.63 0.612 . . . . 0.0 114.63 174.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.551 ' O ' ' O ' ' B' ' 27' ' ' ASN . 32.2 p -140.06 170.71 15.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 118.338 1.069 . . . . 0.0 109.615 179.372 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.934 HD21 ' H ' ' A' ' 29' ' ' GLY . 48.1 t30 -30.88 173.25 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -175.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.494 ' N ' ' CG ' ' B' ' 27' ' ' ASN . 88.3 tttt -88.95 111.16 21.79 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.167 -0.924 . . . . 0.0 112.079 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.512 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 60.31 92.96 0.01 OUTLIER Glycine 0 N--CA 1.465 0.583 0 C-N-CA 118.66 -1.733 . . . . 0.0 112.631 174.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.17 155.06 36.58 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 119.486 1.643 . . . . 0.0 110.172 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.411 HG21 ' CA ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -141.85 120.17 9.04 Favored 'Isoleucine or valine' 0 C--O 1.244 0.774 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.622 -176.731 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 14.9 mm -131.87 133.11 61.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.189 -177.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.584 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -143.43 146.23 16.74 Favored Glycine 0 N--CA 1.468 0.802 0 C-N-CA 120.349 -0.929 . . . . 0.0 111.726 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.455 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 3.3 tt -156.45 135.62 12.05 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 119.781 -0.767 . . . . 0.0 112.235 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.8 ' SD ' HG22 ' H' ' 31' ' ' ILE . 11.4 ttm -119.54 126.56 51.55 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.932 179.41 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.515 ' O ' ' C ' ' B' ' 37' ' ' GLY . 11.6 t -129.08 83.55 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.593 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' B' ' 36' ' ' VAL . . . -12.42 -95.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.068 0 O-C-N 123.642 0.589 . . . . 0.0 113.041 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.06 -179.14 40.38 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -138.5 162.41 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 120.826 0.346 . . . . 0.0 110.818 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 117.908 -1.044 . . . . 0.0 110.319 179.849 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -108.04 143.12 37.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.932 0.396 . . . . 0.0 110.587 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -64.77 153.55 39.55 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -131.46 157.3 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.144 0.497 . . . . 0.0 111.5 -179.028 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -138.78 127.73 23.79 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.12 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.579 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 38.6 t60 -148.2 168.08 23.43 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 121.375 0.607 . . . . 0.0 110.322 -178.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.579 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 47.1 tt0 -160.42 165.65 30.69 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.997 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -153.95 115.62 4.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.111 0.482 . . . . 0.0 110.71 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 49.9 tp -129.23 122.31 29.42 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -121.92 128.71 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.015 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.447 ' HE2' HD22 ' E' ' 34' ' ' LEU . 1.7 t80 -125.15 121.32 33.87 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.414 ' C ' ' CD1' ' C' ' 20' ' ' PHE . 25.3 t80 -131.96 126.97 35.34 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.5 136.34 39.32 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.292 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -140.5 146.32 38.01 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.094 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -129.09 111.95 13.49 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.676 179.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.842 HG22 ' H ' ' C' ' 25' ' ' GLY . 7.0 p -137.68 -122.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.169 -178.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.842 ' H ' HG22 ' C' ' 24' ' ' VAL . . . 28.72 -84.31 0.0 OUTLIER Glycine 0 N--CA 1.47 0.907 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.822 -177.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.5 t 170.54 176.88 0.06 Allowed 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 117.484 0.642 . . . . 0.0 110.332 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' C' ' 26' ' ' SER . 59.8 t30 -28.53 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.536 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 86.2 tttt 128.23 104.75 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 113.847 -1.524 . . . . 0.0 112.115 176.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.29 96.68 0.08 OUTLIER Glycine 0 CA--C 1.501 -0.827 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 173.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -117.19 150.67 38.35 Favored 'General case' 0 CA--C 1.481 -1.686 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.436 HG23 HD12 ' D' ' 31' ' ' ILE . 0.2 OUTLIER -145.62 116.23 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 C-N-CA 118.938 -1.105 . . . . 0.0 109.634 -172.716 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -109.78 117.12 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.79 98.26 0.73 Allowed Glycine 0 N--CA 1.469 0.891 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.562 ' HB2' HD12 ' D' ' 34' ' ' LEU . 4.6 mp -132.49 148.37 52.39 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 122.853 1.311 . . . . 0.0 113.192 -178.613 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.405 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 15.8 ttm -135.15 120.31 18.84 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.484 -1.234 . . . . 0.0 108.352 177.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.484 ' O ' ' C ' ' C' ' 37' ' ' GLY . 0.2 OUTLIER -129.95 75.13 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.206 -179.527 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.484 ' C ' ' O ' ' C' ' 36' ' ' VAL . . . -16.88 -101.43 0.0 OUTLIER Glycine 0 C--N 1.367 2.299 0 O-C-N 123.418 0.448 . . . . 0.0 112.366 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.46 -158.69 31.71 Favored Glycine 0 CA--C 1.522 0.479 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 54.8 t -120.01 135.46 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.555 -179.96 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 m . . . . . 0 N--CA 1.467 0.406 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' E' ' 13' ' ' HIS . 73.9 m80 -106.53 136.52 46.16 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 120.883 0.373 . . . . 0.0 111.589 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.568 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 44.5 t-80 -149.77 167.54 26.23 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.191 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.568 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 51.6 tt0 -169.73 165.74 9.9 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.409 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.442 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.0 mttt -146.39 112.59 5.82 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.677 177.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -124.54 125.43 44.18 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.779 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 96.1 t -123.95 124.82 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.306 0.574 . . . . 0.0 111.378 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.405 ' CZ ' HD23 ' F' ' 34' ' ' LEU . 0.2 OUTLIER -109.83 107.72 17.79 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 178.985 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 8.8 t80 -129.07 122.81 30.75 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 119.643 1.111 . . . . 0.0 111.263 -178.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.62 132.51 33.14 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -130.02 106.27 8.52 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.004 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.79 112.0 24.04 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' D' ' 26' ' ' SER . 4.7 t -131.83 -122.16 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.634 . . . . 0.0 110.251 -178.142 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.418 ' N ' HG12 ' D' ' 24' ' ' VAL . . . 30.16 -84.33 0.0 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.757 -177.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.684 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.8 p 170.56 178.85 0.05 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.684 ' O ' ' O ' ' D' ' 26' ' ' SER . 70.2 m-80 -28.2 171.13 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 O-C-N 124.731 1.269 . . . . 0.0 112.57 178.018 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 79.0 tttt 141.42 103.31 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 124.145 0.978 . . . . 0.0 108.468 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.552 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . -43.69 -98.25 0.01 OUTLIER Glycine 0 C--N 1.344 0.994 0 C-N-CA 118.816 -1.659 . . . . 0.0 111.313 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' D' ' 29' ' ' GLY . . . 83.56 142.21 0.06 Allowed 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 101.928 -3.36 . . . . 0.0 101.928 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.704 HG22 ' SD ' ' J' ' 35' ' ' MET . 0.3 OUTLIER -146.98 116.24 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 117.904 -1.518 . . . . 0.0 108.974 -177.071 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.453 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.1 OUTLIER -106.95 112.41 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -179.704 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.59 101.24 0.96 Allowed Glycine 0 C--O 1.236 0.249 0 N-CA-C 108.139 -1.984 . . . . 0.0 108.139 179.255 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.581 HD23 ' N ' ' D' ' 35' ' ' MET . 8.8 tt -143.51 144.02 31.8 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 122.411 1.1 . . . . 0.0 113.329 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.581 ' N ' HD23 ' D' ' 34' ' ' LEU . 14.5 ttm -125.19 125.47 43.7 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-N 114.669 -1.15 . . . . 0.0 109.017 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.421 HG22 ' O ' ' D' ' 36' ' ' VAL . 2.2 p -137.5 71.89 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.042 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.64 111.74 3.48 Favored Glycine 0 C--N 1.366 2.212 0 N-CA-C 111.837 -0.505 . . . . 0.0 111.837 -179.04 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' E' ' 38' ' ' GLY . . . -101.48 146.22 17.15 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.556 HG12 ' N ' ' D' ' 40' ' ' VAL . 21.3 t -137.51 165.51 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.564 0.221 . . . . 0.0 110.674 -179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.556 ' N ' HG12 ' D' ' 39' ' ' VAL . 98.4 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.974 -1.012 . . . . 0.0 111.585 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -83.98 140.04 32.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.633 0.254 . . . . 0.0 110.436 -179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -142.38 153.74 44.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.87 0.366 . . . . 0.0 110.744 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -121.93 134.64 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' D' ' 13' ' ' HIS . 0.2 OUTLIER -76.74 156.98 32.03 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.083 0.468 . . . . 0.0 110.694 -179.214 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.494 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 3.6 m170 -88.42 174.71 7.97 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.521 ' OE1' ' NE2' ' F' ' 15' ' ' GLN . 89.1 mt-30 -124.83 173.64 8.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -136.81 115.16 11.77 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.254 0.55 . . . . 0.0 111.814 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 35.2 mt -119.55 119.6 34.27 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -127.25 126.29 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-O 120.76 0.314 . . . . 0.0 111.198 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -121.14 122.37 39.86 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 79.8 t80 -134.51 121.61 21.24 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.813 0.34 . . . . 0.0 111.115 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.05 127.78 23.36 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 121.07 0.462 . . . . 0.0 111.032 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.403 ' O ' ' HB3' ' E' ' 23' ' ' ASP . 16.7 pt-20 -135.32 139.68 44.5 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.444 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' C ' ' E' ' 24' ' ' VAL . 18.9 p-10 159.47 113.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 O-C-N 124.204 0.94 . . . . 0.0 108.997 -178.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.476 ' C ' ' O ' ' E' ' 23' ' ' ASP . 70.7 t -37.46 132.4 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -178.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.49 85.64 1.48 Allowed Glycine 0 CA--C 1.523 0.531 0 N-CA-C 116.756 1.462 . . . . 0.0 116.756 -173.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.532 ' O ' ' O ' ' E' ' 27' ' ' ASN . 92.8 p -145.75 151.97 38.82 Favored 'General case' 0 CA--C 1.508 -0.665 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 172.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.532 ' O ' ' O ' ' E' ' 26' ' ' SER . 9.1 t-20 -21.49 155.86 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.453 ' HD3' ' HB2' ' F' ' 30' ' ' ALA . 86.1 tttt -164.45 110.97 1.03 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 170.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.41 ' O ' ' HA2' ' D' ' 29' ' ' GLY . . . -67.55 92.57 0.23 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 120.106 -1.045 . . . . 0.0 113.734 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' D' ' 29' ' ' GLY . . . -168.39 150.09 5.07 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.699 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.1 OUTLIER -146.42 125.28 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 118.05 -1.46 . . . . 0.0 113.434 -177.562 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.432 ' C ' ' SD ' ' K' ' 35' ' ' MET . 2.0 mt -107.65 116.44 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . 0.477 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -116.18 100.01 0.9 Allowed Glycine 0 C--O 1.234 0.146 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.639 HD23 ' N ' ' E' ' 35' ' ' MET . 7.7 tt -143.91 137.14 27.64 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 122.26 1.029 . . . . 0.0 112.951 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.736 ' SD ' HG22 ' K' ' 31' ' ' ILE . 23.3 ttm -117.6 128.37 54.87 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.495 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -124.81 74.28 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.387 179.834 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.464 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -20.98 -101.38 0.0 OUTLIER Glycine 0 C--N 1.355 1.637 0 O-C-N 123.208 0.317 . . . . 0.0 112.817 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . 140.9 -174.95 22.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 56.3 t -121.24 135.63 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.4 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.433 -179.934 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.893 0.378 . . . . 0.0 110.753 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -150.35 102.38 3.06 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -151.19 174.42 13.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.521 ' NE2' ' OE1' ' E' ' 15' ' ' GLN . 88.3 mt-30 -141.36 175.0 10.01 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.979 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -130.13 114.84 16.22 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.943 0.402 . . . . 0.0 110.135 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -120.03 116.92 26.69 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.259 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 49.7 t -129.95 131.39 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.459 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 55.2 p90 -142.63 133.09 24.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.266 0.555 . . . . 0.0 111.659 -179.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -138.1 120.39 15.83 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.34 144.83 31.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.167 0.508 . . . . 0.0 111.376 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -101.1 106.22 17.47 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.988 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 61.8 t0 . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 121.388 0.613 . . . . 0.0 112.029 -179.76 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.444 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 88.2 tttt . . . . . 0 CA--C 1.538 0.495 0 CA-C-O 121.619 0.723 . . . . 0.0 112.775 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.444 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -139.9 -100.57 0.46 Allowed Glycine 0 CA--C 1.482 -2.018 0 CA-C-O 123.622 1.679 . . . . 0.0 111.48 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.453 ' HB2' ' HD3' ' E' ' 28' ' ' LYS . . . -58.33 175.73 0.22 Allowed 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 110.164 -3.018 . . . . 0.0 103.358 173.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.5 mt -131.43 116.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 116.538 -2.065 . . . . 0.0 109.774 -177.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.655 ' O ' HG23 ' F' ' 32' ' ' ILE . 16.5 tt -103.33 116.96 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 CA-C-N 113.084 -1.871 . . . . 0.0 110.074 -177.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -105.71 86.34 0.48 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 106.7 -2.56 . . . . 0.0 106.7 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.452 HD11 ' CG2' ' E' ' 36' ' ' VAL . 35.2 tp -116.72 119.02 34.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 35.2 mmm -123.04 135.44 54.44 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.057 -0.657 . . . . 0.0 112.28 -177.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 m -124.99 81.14 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.515 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.58 102.07 0.35 Allowed Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -153.52 178.09 30.7 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -124.94 137.16 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.247 0.546 . . . . 0.0 110.192 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.43 ' HB ' HE22 ' F' ' 15' ' ' GLN . 27.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.819 -1.086 . . . . 0.0 110.398 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -106.39 131.79 53.18 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.921 0.391 . . . . 0.0 110.617 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -89.22 158.15 17.98 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.431 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -122.43 133.85 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.134 0.493 . . . . 0.0 110.705 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -134.44 -178.49 5.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.623 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -77.56 167.62 21.32 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -157.49 169.59 24.36 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.995 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.27 130.08 10.1 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.676 0.274 . . . . 0.0 110.732 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 90.2 mt -125.05 115.59 20.77 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.659 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.482 ' O ' HG23 ' G' ' 18' ' ' VAL . 14.3 m -133.87 129.14 54.42 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 121.45 0.643 . . . . 0.0 112.134 -178.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.521 ' CE2' HD11 ' J' ' 34' ' ' LEU . 8.8 m-85 -111.79 116.77 31.25 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.445 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.494 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 55.1 p90 -133.96 130.72 38.08 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.775 -179.236 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . 0.429 ' O ' ' OD1' ' H' ' 23' ' ' ASP . . . -121.35 125.43 46.97 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-O 121.122 0.487 . . . . 0.0 110.985 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.499 ' CA ' ' OD2' ' H' ' 23' ' ' ASP . 96.0 mt-10 -146.64 150.31 35.19 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 106.43 -1.693 . . . . 0.0 106.43 178.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' NZ ' ' I' ' 28' ' ' LYS . 78.2 m-20 -78.11 111.61 14.21 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 112.754 -177.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.577 ' O ' ' N ' ' G' ' 26' ' ' SER . 52.9 t -114.06 130.85 67.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 176.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.48 81.94 0.0 OUTLIER Glycine 0 CA--C 1.535 1.308 0 CA-C-O 119.561 -0.577 . . . . 0.0 113.532 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.577 ' N ' ' O ' ' G' ' 24' ' ' VAL . 4.7 t -98.62 172.36 7.54 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 176.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -58.73 162.4 4.02 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 118.567 -1.253 . . . . 0.0 109.726 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -58.68 111.3 1.21 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 118.789 -0.624 . . . . 0.0 111.562 175.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.24 93.29 0.08 OUTLIER Glycine 0 N--CA 1.471 0.976 0 C-N-CA 118.311 -1.9 . . . . 0.0 111.947 175.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.75 159.2 17.85 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 120.319 2.06 . . . . 0.0 111.556 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.01 123.2 1.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.154 -178.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' A' ' 35' ' ' MET . 96.8 mt -133.5 128.71 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.952 -0.468 . . . . 0.0 111.308 -179.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.445 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -132.85 117.56 1.99 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.434 -1.067 . . . . 0.0 110.434 179.295 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 84.1 mt -134.86 142.54 46.64 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.95 0.405 . . . . 0.0 110.576 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -141.09 137.55 32.91 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.212 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.3 t -119.03 82.72 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.481 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -87.68 97.99 2.34 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.12 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.95 165.03 38.61 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.23 159.08 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.738 0.304 . . . . 0.0 110.226 179.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.542 -179.924 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -117.21 139.5 50.71 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.642 0.258 . . . . 0.0 110.596 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . 0.48 ' CD ' ' N ' ' H' ' 11' ' ' GLU . 0.9 OUTLIER -128.02 132.24 49.13 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -140.02 157.21 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -139.5 105.61 5.23 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.929 0.395 . . . . 0.0 111.34 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.416 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 17.2 m-70 -118.86 166.46 12.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -151.14 176.68 10.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.996 178.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -170.97 113.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.164 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -113.41 119.81 38.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.98 127.16 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 121.061 0.458 . . . . 0.0 111.683 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.558 ' CZ ' HD11 ' K' ' 34' ' ' LEU . 18.1 m-85 -117.24 118.28 31.85 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.056 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -126.44 119.59 27.6 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.82 119.58 33.11 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.145 0.498 . . . . 0.0 111.626 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -163.48 89.27 0.6 Allowed 'General case' 0 C--N 1.341 0.234 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.711 ' H ' ' HZ2' ' J' ' 28' ' ' LYS . 5.0 m-20 -128.2 119.28 24.91 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -177.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.637 ' O ' ' O ' ' H' ' 23' ' ' ASP . 3.1 t -38.04 -124.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 124.105 0.878 . . . . 0.0 112.021 176.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.401 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -130.38 83.93 0.31 Allowed Glycine 0 CA--C 1.533 1.187 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 12.5 p -67.37 -173.06 0.26 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -78.92 169.69 17.82 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 118.332 -1.347 . . . . 0.0 110.506 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -47.09 110.21 0.28 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.95 95.61 0.28 Allowed Glycine 0 N--CA 1.468 0.827 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.582 171.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.455 ' C ' ' CG1' ' H' ' 31' ' ' ILE . . . -119.29 147.45 44.27 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 101.117 -3.661 . . . . 0.0 101.117 171.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.8 HG22 ' SD ' ' B' ' 35' ' ' MET . 1.2 mt -149.01 126.12 2.51 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 C-N-CA 117.918 -1.513 . . . . 0.0 111.752 -170.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 44.2 mm -121.3 123.36 69.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.73 123.58 5.11 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.518 ' CB ' HD22 ' I' ' 34' ' ' LEU . 29.0 tp -135.12 128.75 32.74 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 122.286 -0.538 . . . . 0.0 110.453 -179.252 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.584 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 2.6 ttp -123.34 116.94 24.13 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.031 -178.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' H' ' 37' ' ' GLY . 14.2 t -133.42 83.19 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -22.75 -94.05 0.01 OUTLIER Glycine 0 C--N 1.349 1.273 0 N-CA-C 112.159 -0.376 . . . . 0.0 112.159 177.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.65 -177.23 42.12 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 50.4 t -127.58 136.12 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-O 120.962 0.411 . . . . 0.0 110.245 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 34.8 t . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.451 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.401 ' C ' ' CD2' ' I' ' 13' ' ' HIS . 3.8 m . . . . . 0 N--CA 1.466 0.363 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.434 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 30.9 m-70 -141.79 145.13 34.38 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.752 0.311 . . . . 0.0 111.413 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.434 ' ND1' ' C ' ' I' ' 13' ' ' HIS . 42.6 m80 -148.18 159.18 44.22 Favored 'General case' 0 CA--C 1.514 -0.427 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.372 178.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -153.94 166.06 34.15 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.283 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.504 ' C ' HD12 ' I' ' 17' ' ' LEU . 96.2 mttt -162.53 123.86 2.59 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 123.023 0.202 . . . . 0.0 110.566 179.12 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.504 HD12 ' C ' ' I' ' 16' ' ' LYS . 10.6 mp -115.22 115.63 27.02 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -126.56 123.68 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 CA-C-O 120.983 0.421 . . . . 0.0 111.307 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.754 ' CZ ' HD12 ' L' ' 34' ' ' LEU . 9.8 m-85 -119.21 116.43 26.27 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 115.815 -0.629 . . . . 0.0 109.742 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -128.59 126.85 41.12 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.76 135.33 26.11 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.382 0.61 . . . . 0.0 111.961 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -141.57 142.58 33.49 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.081 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.442 ' O ' ' CG2' ' J' ' 24' ' ' VAL . 64.9 t0 -85.78 123.35 31.05 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 121.47 0.652 . . . . 0.0 111.69 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' I' ' 26' ' ' SER . 2.9 t -93.2 121.81 44.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.06 -88.22 0.01 OUTLIER Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.891 -1.283 . . . . 0.0 109.891 -177.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' I' ' 24' ' ' VAL . 52.9 p -141.0 170.28 16.03 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 118.127 0.964 . . . . 0.0 109.477 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -29.17 169.44 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 114.138 -1.392 . . . . 0.0 114.027 -179.252 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.609 ' NZ ' ' OD1' ' G' ' 23' ' ' ASP . 35.8 tttt -150.27 111.18 4.32 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 114.372 -1.286 . . . . 0.0 108.936 172.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.96 92.07 0.02 OUTLIER Glycine 0 N--CA 1.464 0.535 0 C-N-CA 118.913 -1.613 . . . . 0.0 109.082 176.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -138.32 148.07 44.22 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.693 HG13 HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -146.9 116.18 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-N 114.057 -1.429 . . . . 0.0 110.387 -174.125 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.412 HD13 HG21 ' I' ' 32' ' ' ILE . 0.3 OUTLIER -106.99 114.76 46.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.542 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.533 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -118.68 93.87 0.57 Allowed Glycine 0 N--CA 1.462 0.415 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 179.304 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.533 HD23 ' O ' ' I' ' 33' ' ' GLY . 7.4 mt -127.61 135.26 50.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 122.484 1.135 . . . . 0.0 111.554 -178.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 42.9 ttp -125.62 120.7 31.47 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.402 177.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.99 73.57 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.784 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -21.1 -101.72 0.0 OUTLIER Glycine 0 C--N 1.367 2.301 0 O-C-N 123.508 0.505 . . . . 0.0 112.378 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.66 -153.71 23.65 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.655 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 5.0 p -134.59 141.43 43.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-O 120.879 0.371 . . . . 0.0 110.105 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' H' ' 40' ' ' VAL . 2.6 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.062 -0.97 . . . . 0.0 110.218 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' K' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.489 2.197 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -142.22 163.14 33.66 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-O 120.778 0.323 . . . . 0.0 110.289 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 17.3 pt-20 -153.3 154.21 34.14 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.162 0.506 . . . . 0.0 111.212 -179.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.431 HG23 HG23 ' K' ' 12' ' ' VAL . 2.4 p -140.56 151.37 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.799 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.43 ' ND1' ' C ' ' J' ' 12' ' ' VAL . 1.6 m80 -127.34 130.79 50.09 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.479 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -126.6 156.57 40.7 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-O 121.494 0.664 . . . . 0.0 109.529 178.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mt-30 -150.68 173.79 13.76 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.775 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -175.25 123.92 0.23 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.842 179.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.456 HD13 HE21 ' K' ' 15' ' ' GLN . 4.7 mp -125.48 122.25 36.08 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.43 137.22 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.197 0.522 . . . . 0.0 112.135 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.493 ' CZ ' HD13 ' L' ' 34' ' ' LEU . 73.7 m-85 -121.62 129.65 52.96 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.863 179.106 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -129.65 122.19 28.5 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.136 0.426 . . . . 0.0 110.245 178.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.96 126.87 35.09 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 121.382 0.61 . . . . 0.0 111.427 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -126.77 109.33 11.9 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.229 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.562 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 0.0 OUTLIER -104.68 112.3 25.33 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 120.068 -0.653 . . . . 0.0 112.127 -178.607 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.571 ' O ' ' N ' ' J' ' 26' ' ' SER . 2.7 m -82.37 132.87 30.42 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.381 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.26 -85.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.415 0 N-CA-C 107.484 -2.246 . . . . 0.0 107.484 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.571 ' N ' ' O ' ' J' ' 24' ' ' VAL . 10.9 t -140.98 169.62 17.26 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 118.373 1.086 . . . . 0.0 110.298 174.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' N ' ' L' ' 30' ' ' ALA . 1.0 OUTLIER -30.27 172.81 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 N-CA-C 115.165 1.542 . . . . 0.0 115.165 178.394 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.718 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 87.0 tttt -97.54 112.25 24.18 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 117.671 -1.157 . . . . 0.0 110.197 171.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.494 ' H ' ' HB2' ' I' ' 27' ' ' ASN . . . -61.42 91.49 0.06 OUTLIER Glycine 0 N--CA 1.49 2.271 0 CA-C-N 123.453 2.842 . . . . 0.0 108.343 175.052 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.555 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -148.85 153.42 38.04 Favored 'General case' 0 CA--C 1.482 -1.655 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.546 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -142.35 115.95 4.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 C-N-CA 118.716 -1.194 . . . . 0.0 109.439 -174.632 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.438 HG22 ' O ' ' J' ' 32' ' ' ILE . 1.7 mt -105.52 117.01 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.563 -178.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 101.1 1.02 Allowed Glycine 0 CA--C 1.503 -0.71 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.521 HD11 ' CE2' ' G' ' 19' ' ' PHE . 5.1 tt -142.02 135.4 29.22 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 118.932 -1.107 . . . . 0.0 112.788 -177.039 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.704 ' SD ' HG22 ' D' ' 31' ' ' ILE . 60.9 ttp -127.82 124.0 36.54 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.807 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.464 HG23 HG13 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -124.3 75.36 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.751 0 CA-C-N 114.52 -1.218 . . . . 0.0 107.734 178.415 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -89.75 103.17 2.98 Favored Glycine 0 C--N 1.356 1.665 0 N-CA-C 111.784 -0.526 . . . . 0.0 111.784 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.82 152.14 20.9 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 30.6 m -135.08 157.38 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 8.3 p . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.176 -0.916 . . . . 0.0 110.5 -179.63 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' J' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -135.48 154.84 51.29 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 121.159 0.504 . . . . 0.0 111.179 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -137.3 131.77 32.73 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.34 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.431 HG23 HG23 ' J' ' 12' ' ' VAL . 11.2 m -145.0 136.63 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.348 179.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -118.4 127.15 53.4 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.742 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -124.02 158.27 32.53 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.556 0.693 . . . . 0.0 110.179 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.481 ' O ' ' O ' ' L' ' 15' ' ' GLN . 50.9 tt0 -166.17 170.23 13.55 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.776 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.406 ' CG ' ' O ' ' K' ' 15' ' ' GLN . 66.3 mttm -163.82 125.5 2.37 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.556 179.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.929 ' O ' ' C ' ' L' ' 17' ' ' LEU . 17.9 tp -118.05 118.39 31.8 Favored 'General case' 0 N--CA 1.503 2.224 0 CA-C-O 123.339 1.543 . . . . 0.0 112.124 178.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.517 HG13 ' O ' ' K' ' 18' ' ' VAL . 5.3 p -134.07 123.96 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.352 -179.466 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -109.23 127.17 54.03 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.464 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -117.36 114.3 23.35 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 178.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 131.31 47.51 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.208 0.528 . . . . 0.0 111.569 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.406 ' O ' ' O ' ' K' ' 23' ' ' ASP . 74.5 mm-40 -83.33 158.26 22.25 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.257 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.55 ' O ' ' O ' ' K' ' 24' ' ' VAL . 48.8 p-10 -60.99 -133.88 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.201 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.55 ' O ' ' O ' ' K' ' 23' ' ' ASP . 24.7 t 26.72 111.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 123.942 0.776 . . . . 0.0 112.356 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.43 82.74 0.14 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 120.206 -0.997 . . . . 0.0 113.183 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 30.2 p -139.05 170.2 16.41 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-N 117.759 0.779 . . . . 0.0 109.334 177.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 50.62 -178.75 0.02 OUTLIER 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.765 179.078 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt 55.37 -106.61 0.33 Allowed 'General case' 0 C--O 1.233 0.208 0 CA-C-O 121.204 0.526 . . . . 0.0 111.918 177.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.433 ' H ' ' HB2' ' J' ' 27' ' ' ASN . . . 96.6 91.54 1.83 Allowed Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -177.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' J' ' 28' ' ' LYS . . . -82.19 174.2 11.4 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 104.707 -2.331 . . . . 0.0 104.707 177.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.736 HG22 ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -156.4 119.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 116.768 -1.973 . . . . 0.0 111.224 -175.431 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.453 HG22 ' O ' ' K' ' 32' ' ' ILE . 0.9 OUTLIER -103.72 113.09 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 176.687 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.1 88.98 0.52 Allowed Glycine 0 CA--C 1.504 -0.603 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 177.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.58 HD23 ' N ' ' K' ' 35' ' ' MET . 9.3 tt -127.66 134.54 49.62 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 122.004 0.907 . . . . 0.0 111.834 -177.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.58 ' N ' HD23 ' K' ' 34' ' ' LEU . 65.8 ttp -123.34 127.56 48.68 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 115.079 -0.964 . . . . 0.0 112.593 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.464 HG13 HG23 ' J' ' 36' ' ' VAL . 0.0 OUTLIER -132.5 72.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 114.427 -1.26 . . . . 0.0 107.887 177.703 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.03 101.86 2.33 Favored Glycine 0 C--N 1.353 1.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -145.16 163.52 28.08 Favored Glycine 0 N--CA 1.46 0.242 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -124.06 135.58 63.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.905 0.383 . . . . 0.0 110.125 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.466 179.967 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -112.95 152.92 28.81 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.507 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.51 136.8 49.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.856 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.97 132.77 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.999 0.428 . . . . 0.0 110.503 -179.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 23.3 p-80 -160.91 147.71 15.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.487 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -95.16 177.54 5.83 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.497 ' HG3' ' H ' ' L' ' 16' ' ' LYS . 45.6 tp60 -114.84 174.98 5.7 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.932 -179.564 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . 0.497 ' H ' ' HG3' ' L' ' 15' ' ' GLN . 88.9 mttt -88.9 -174.96 4.7 Favored 'General case' 0 C--O 1.176 -2.765 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.929 ' C ' ' O ' ' K' ' 17' ' ' LEU . 38.3 mt -141.48 161.28 38.29 Favored 'General case' 0 C--N 1.31 -1.12 0 O-C-N 119.922 -1.736 . . . . 0.0 110.289 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . 0.452 HG23 ' N ' ' L' ' 19' ' ' PHE . 10.8 m -84.54 -144.05 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 117.723 2.49 . . . . 0.0 117.723 -171.208 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.492 ' CD1' ' N ' ' L' ' 19' ' ' PHE . 9.6 m-85 -124.22 147.62 47.91 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 113.506 -1.679 . . . . 0.0 111.143 -178.066 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -137.48 132.19 32.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.263 -0.881 . . . . 0.0 108.945 178.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.3 159.37 38.78 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.277 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -85.7 157.97 20.17 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -53.16 122.88 10.34 Favored 'General case' 0 CA--C 1.52 -0.185 0 C-N-CA 119.899 -0.721 . . . . 0.0 109.243 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 3.5 t -92.68 121.79 43.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.575 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.16 -87.01 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 79.4 p -89.07 -177.7 5.5 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 63.9 t30 -60.27 179.55 0.14 Allowed 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.713 -177.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 11.6 tptt -57.26 110.72 0.89 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 122.005 0.907 . . . . 0.0 112.998 -176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.27 -98.14 0.04 OUTLIER Glycine 0 CA--C 1.496 -1.149 0 CA-C-N 113.801 -1.545 . . . . 0.0 111.155 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.683 ' N ' ' ND2' ' J' ' 27' ' ' ASN . . . -61.2 165.16 4.64 Favored 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 -178.612 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.504 HD12 ' O ' ' K' ' 30' ' ' ALA . 0.8 OUTLIER -141.51 125.32 16.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 117.692 -1.603 . . . . 0.0 112.441 -176.238 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 4.3 mt -101.16 117.66 46.74 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.632 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 177.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.55 98.19 0.61 Allowed Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.97 HD21 HG13 ' L' ' 36' ' ' VAL . 1.0 OUTLIER -128.82 139.58 52.1 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.557 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 66.4 ttp -118.33 124.15 47.08 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.588 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.97 HG13 HD21 ' L' ' 34' ' ' LEU . 0.9 OUTLIER -123.42 80.07 0.67 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.648 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.93 102.48 0.12 Allowed Glycine 0 C--N 1.349 1.295 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.68 -173.21 29.37 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.56 142.87 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.842 0.353 . . . . 0.0 110.599 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.995 -1.002 . . . . 0.0 111.015 -179.795 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.466 0.355 0 CA-C-O 120.868 0.366 . . . . 0.0 111.09 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 77.7 m80 -142.98 165.13 28.2 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.344 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m80 -135.69 178.55 6.96 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 109.61 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -98.12 179.18 4.85 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.022 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -104.56 140.95 37.24 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.195 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -124.12 120.12 31.42 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.079 0.466 . . . . 0.0 110.726 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 18' ' ' VAL . 5.6 m -134.06 128.19 52.53 Favored 'Isoleucine or valine' 0 C--O 1.231 0.098 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.11 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.623 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 11.7 m-85 -112.88 118.83 35.98 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.549 ' CE2' ' CD1' ' B' ' 20' ' ' PHE . 55.7 t80 -127.71 113.08 15.56 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.51 129.26 56.41 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.118 0.485 . . . . 0.0 110.98 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 tt0 -156.72 158.69 37.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 179.284 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -81.11 111.29 17.42 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.718 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.628 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.0 t -114.27 131.18 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.839 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 177.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.83 81.94 0.0 OUTLIER Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.576 -0.345 . . . . 0.0 112.409 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.628 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.1 p -94.64 177.31 5.96 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' A' ' 28' ' ' LYS . 98.5 m-20 -61.58 179.6 0.23 Allowed 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.584 -0.846 . . . . 0.0 108.763 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.8 mttm -52.12 -111.87 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.761 0.791 . . . . 0.0 111.406 178.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.41 93.33 1.63 Allowed Glycine 0 N--CA 1.467 0.707 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 177.113 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.55 160.9 14.05 Favored 'General case' 0 CA--C 1.509 -0.605 0 C-N-CA 116.582 -2.047 . . . . 0.0 111.627 -177.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.0 OUTLIER -152.51 117.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.112 0 CA-C-N 111.819 -2.446 . . . . 0.0 109.184 -174.334 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.87 118.54 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.709 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.64 108.71 0.98 Allowed Glycine 0 N--CA 1.464 0.56 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 48.5 tp -131.69 133.01 44.4 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 117.194 0.497 . . . . 0.0 111.07 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 13.4 ttt -139.38 134.66 32.77 Favored 'General case' 0 C--N 1.328 -0.36 0 O-C-N 122.234 -0.291 . . . . 0.0 110.788 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.7 t -146.06 81.29 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.487 ' HA3' HD12 ' H' ' 31' ' ' ILE . . . -85.51 100.22 2.43 Favored Glycine 0 C--N 1.338 0.66 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.226 178.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.24 176.48 47.86 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 N--CA 1.466 0.369 0 CA-C-O 120.82 0.343 . . . . 0.0 110.356 179.214 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.509 HG12 ' N ' ' B' ' 13' ' ' HIS . 93.4 t . . . . . 0 N--CA 1.469 0.478 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.509 ' N ' HG12 ' B' ' 12' ' ' VAL . 28.3 t60 -166.77 104.78 0.59 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.218 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 47.6 m170 -120.0 165.77 14.25 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.605 HE21 HD21 ' B' ' 17' ' ' LEU . 50.6 tt0 -162.85 173.23 14.01 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.331 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.41 ' N ' ' HG2' ' B' ' 15' ' ' GLN . 97.6 mttt -149.85 116.29 5.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.939 0.399 . . . . 0.0 110.742 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.605 HD21 HE21 ' B' ' 15' ' ' GLN . 60.6 mt -116.57 114.42 24.11 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.302 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.52 123.66 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-O 121.214 0.531 . . . . 0.0 110.945 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.646 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 4.4 m-85 -117.47 118.52 32.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.963 179.197 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.549 ' CD1' ' CE2' ' A' ' 20' ' ' PHE . 33.1 t80 -138.37 125.67 21.69 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 122.22 -0.3 . . . . 0.0 110.326 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 131.32 46.89 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.155 0.503 . . . . 0.0 111.965 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -157.67 91.3 1.13 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.619 ' H ' ' CG ' ' C' ' 23' ' ' ASP . 10.7 t0 -121.6 113.1 19.3 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -176.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' B' ' 26' ' ' SER . 12.0 p -60.41 132.37 25.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.252 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.94 83.72 0.04 OUTLIER Glycine 0 CA--C 1.526 0.751 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.694 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.425 ' N ' ' O ' ' B' ' 24' ' ' VAL . 11.8 p -87.62 -179.1 6.25 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.583 0.706 . . . . 0.0 109.627 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.425 ' O ' ' O ' ' B' ' 28' ' ' LYS . 28.3 t-20 -75.63 175.96 8.1 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.544 177.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' B' ' 27' ' ' ASN . 97.6 mttt 42.49 107.9 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 114.9 1.445 . . . . 0.0 114.9 176.121 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.2 100.04 1.98 Allowed Glycine 0 N--CA 1.479 1.565 0 CA-C-N 114.273 -1.33 . . . . 0.0 110.717 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 161.35 31.15 Favored 'General case' 0 C--O 1.248 1.016 0 CA-C-O 122.772 1.272 . . . . 0.0 110.772 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.514 ' CG2' HD12 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.02 122.74 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 112.939 -1.937 . . . . 0.0 110.378 -172.929 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.452 ' C ' ' SD ' ' H' ' 35' ' ' MET . 44.3 pt -136.08 135.29 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-O 121.847 0.832 . . . . 0.0 112.129 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -141.11 137.88 8.46 Favored Glycine 0 CA--C 1.531 1.033 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.142 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 tt -146.93 139.74 25.12 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 120.196 -0.601 . . . . 0.0 111.158 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 24.1 ttm -128.32 126.19 40.27 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-O 121.397 0.618 . . . . 0.0 112.133 -179.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.43 79.6 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.021 177.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.533 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -50.91 104.13 0.12 Allowed Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.769 -179.045 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 44.99 179.74 0.01 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 p -148.36 149.77 14.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.439 ' OXT' HG22 ' B' ' 40' ' ' VAL . 6.0 p . . . . . 0 C--O 1.218 -0.559 0 CA-C-O 118.176 -0.916 . . . . 0.0 111.078 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 141.44 47.83 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.417 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -142.58 159.34 42.43 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.418 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.463 HG13 ' CD2' ' D' ' 13' ' ' HIS . 55.3 t -121.27 133.56 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.489 ' H ' ' H ' ' D' ' 13' ' ' HIS . 97.6 m-70 -148.08 123.63 10.42 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.822 0.344 . . . . 0.0 111.179 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.529 ' ND1' ' O ' ' D' ' 14' ' ' HIS . 26.1 t60 -141.45 164.65 29.66 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.437 ' HG2' ' N ' ' C' ' 16' ' ' LYS . 51.8 tt0 -169.39 170.36 8.45 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.845 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.437 ' N ' ' HG2' ' C' ' 15' ' ' GLN . 68.2 mttm -142.59 118.79 10.77 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.238 178.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -120.11 121.39 38.73 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.06 123.25 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.048 0.452 . . . . 0.0 111.739 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.953 ' CZ ' HD22 ' F' ' 34' ' ' LEU . 6.6 m-85 -113.65 116.78 30.0 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.544 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 33.6 t80 -132.24 118.65 19.78 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 118.227 0.467 . . . . 0.0 110.203 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.9 37.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 120.857 0.361 . . . . 0.0 110.884 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -173.2 102.97 0.13 Allowed 'General case' 0 CA--C 1.522 -0.134 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.912 ' H ' ' HZ2' ' E' ' 28' ' ' LYS . 1.1 m-20 -115.15 113.66 24.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 121.095 0.474 . . . . 0.0 111.417 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 91.4 t -64.76 131.5 30.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.84 84.02 0.31 Allowed Glycine 0 CA--C 1.525 0.696 0 C-N-CA 119.195 -1.479 . . . . 0.0 110.726 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.536 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 1.7 m -59.87 -174.27 0.02 OUTLIER 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.536 ' CB ' ' O ' ' C' ' 26' ' ' SER . 6.1 t-20 99.85 -174.62 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.928 0 O-C-N 124.342 1.026 . . . . 0.0 111.202 -177.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.52 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 81.9 tttt 37.44 108.93 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.987 -177.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.426 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -85.79 96.84 2.13 Favored Glycine 0 CA--C 1.504 -0.622 0 CA-C-N 114.325 -1.307 . . . . 0.0 112.056 177.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.8 164.7 19.36 Favored 'General case' 0 C--O 1.244 0.808 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.689 HG23 HG13 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.83 121.3 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 117.961 -1.496 . . . . 0.0 111.702 -174.804 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 1.1 mt -114.54 120.63 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.898 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.98 98.88 0.65 Allowed Glycine 0 N--CA 1.472 1.04 0 N-CA-C 106.939 -2.464 . . . . 0.0 106.939 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.467 HD21 HG13 ' C' ' 36' ' ' VAL . 5.1 tt -129.93 129.28 43.64 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 119.05 -1.06 . . . . 0.0 113.749 -175.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.435 ' CG ' ' HA3' ' I' ' 33' ' ' GLY . 96.6 mmm -107.39 118.08 35.77 Favored 'General case' 0 CA--C 1.503 -0.859 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.267 179.261 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.467 HG13 HD21 ' C' ' 34' ' ' LEU . 0.0 OUTLIER -131.02 72.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.723 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 175.83 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.14 112.31 4.6 Favored Glycine 0 C--N 1.36 1.882 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.47 157.39 51.88 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -138.72 161.51 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.103 -0.951 . . . . 0.0 110.508 179.968 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t . . . . . 0 C--O 1.232 0.173 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.489 ' H ' ' H ' ' C' ' 13' ' ' HIS . 3.4 m-70 -87.31 161.48 17.92 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.336 0.589 . . . . 0.0 111.354 -178.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.529 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.8 p-80 -93.93 178.83 5.54 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.327 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -127.7 179.04 5.74 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.502 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -137.23 127.1 25.66 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.248 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.3 mp -126.43 129.17 48.21 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.223 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -126.81 125.01 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.027 0.441 . . . . 0.0 111.488 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.756 ' CZ ' HD23 ' F' ' 34' ' ' LEU . 4.9 m-85 -110.57 112.57 24.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.039 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.51 ' CE1' ' CE2' ' C' ' 20' ' ' PHE . 27.5 t80 -126.72 123.32 37.21 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 118.542 0.61 . . . . 0.0 109.947 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.17 142.63 28.63 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -142.97 145.17 32.72 Favored 'General case' 0 C--N 1.343 0.302 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.653 178.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.515 ' O ' ' O ' ' E' ' 24' ' ' VAL . 14.0 m-20 -112.64 124.67 53.07 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.898 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' E' ' 26' ' ' SER . 5.7 t -95.34 -112.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 113.124 0.787 . . . . 0.0 113.124 -176.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.94 -91.12 0.01 OUTLIER Glycine 0 N--CA 1.469 0.864 0 N-CA-C 112.386 -0.286 . . . . 0.0 112.386 -176.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.609 ' O ' ' O ' ' D' ' 27' ' ' ASN . 21.5 p -151.54 171.87 16.91 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.692 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 18.6 m120 -19.29 156.7 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 O-C-N 124.253 0.971 . . . . 0.0 113.164 -178.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.497 ' H ' ' H ' ' E' ' 29' ' ' GLY . 56.5 tttt -162.45 110.68 1.36 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 121.406 -0.809 . . . . 0.0 110.461 173.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.426 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -68.62 92.83 0.29 Allowed Glycine 0 C--O 1.215 -1.036 0 CA-C-O 117.861 -1.522 . . . . 0.0 110.77 175.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.463 ' O ' HG13 ' E' ' 31' ' ' ILE . . . -129.04 151.61 49.54 Favored 'General case' 0 CA--C 1.482 -1.652 0 N-CA-C 103.028 -2.953 . . . . 0.0 103.028 173.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.689 HG13 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -147.75 118.25 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.339 -172.909 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.532 ' O ' HG23 ' D' ' 32' ' ' ILE . 18.5 tt -119.0 113.42 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.483 178.459 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.705 ' C ' HD12 ' D' ' 34' ' ' LEU . . . -130.07 128.22 5.57 Favored Glycine 0 C--O 1.241 0.536 0 C-N-CA 121.09 -0.576 . . . . 0.0 111.811 -178.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.705 HD12 ' C ' ' D' ' 33' ' ' GLY . 4.0 mp -141.5 142.57 33.58 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-O 122.249 1.023 . . . . 0.0 111.277 178.659 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.46 ' SD ' ' HB ' ' J' ' 31' ' ' ILE . 29.3 tpp -100.87 113.6 26.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 113.574 -1.648 . . . . 0.0 108.448 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.617 ' CG2' HD11 ' E' ' 34' ' ' LEU . 0.0 OUTLIER -126.55 74.0 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.302 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.113 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.96 111.21 1.82 Allowed Glycine 0 C--N 1.358 1.793 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.17 -170.28 0.15 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m -133.85 160.62 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.815 0.34 . . . . 0.0 110.791 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.562 179.845 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -101.47 129.12 47.46 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.993 0.425 . . . . 0.0 110.539 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.88 138.86 28.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.84 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.1 t -126.36 132.77 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.904 0.383 . . . . 0.0 110.329 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 t-80 -143.95 112.57 6.55 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.564 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -128.81 173.01 10.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -151.1 175.93 11.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.709 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -167.85 108.25 0.57 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.05 0.452 . . . . 0.0 110.686 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.0 tt -124.84 127.35 47.02 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.707 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.13 128.84 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -119.61 119.97 35.33 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -128.18 121.96 30.73 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-O 120.909 0.385 . . . . 0.0 110.273 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.5 133.33 43.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.994 0.426 . . . . 0.0 111.52 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -137.74 123.78 20.28 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.554 -0.458 . . . . 0.0 109.831 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -84.77 114.82 22.34 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.062 0.458 . . . . 0.0 111.181 -178.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' E' ' 26' ' ' SER . 53.8 t -95.78 130.81 43.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.68 -85.07 0.01 OUTLIER Glycine 0 CA--C 1.535 1.289 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' E' ' 24' ' ' VAL . 12.6 t -153.0 174.29 14.35 Favored 'General case' 0 C--N 1.347 0.46 0 CA-C-N 118.897 1.348 . . . . 0.0 112.995 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.692 ' ND2' ' H ' ' D' ' 27' ' ' ASN . 12.9 p-10 -19.01 160.24 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 116.761 2.134 . . . . 0.0 116.761 178.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.912 ' HZ2' ' H ' ' C' ' 23' ' ' ASP . 80.9 tttt -170.14 105.55 0.31 Allowed 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 174.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.677 ' O ' ' HA ' ' F' ' 30' ' ' ALA . . . -49.99 -97.84 0.01 OUTLIER Glycine 0 N--CA 1.469 0.9 0 C-N-CA 118.664 -1.731 . . . . 0.0 111.299 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.561 ' HB3' ' O ' ' E' ' 29' ' ' GLY . . . 74.07 143.71 0.07 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.599 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -150.78 118.11 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.08 -178.471 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 4.5 tt -117.44 128.31 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 CA-C-O 121.329 0.585 . . . . 0.0 111.255 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 99.7 0.7 Allowed Glycine 0 N--CA 1.451 -0.331 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 178.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.646 HD13 ' CZ ' ' B' ' 19' ' ' PHE . 37.6 tp -115.58 116.39 28.06 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.551 ' CE ' ' SD ' ' F' ' 35' ' ' MET . 0.4 OUTLIER -91.76 111.63 23.24 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.976 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.71 ' O ' HG12 ' E' ' 36' ' ' VAL . 2.0 t -138.4 66.56 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -54.84 -103.53 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.44 169.01 34.51 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -140.67 140.85 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.064 -0.969 . . . . 0.0 110.357 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.463 0.211 0 CA-C-O 121.199 0.523 . . . . 0.0 109.851 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.508 ' ND1' ' N ' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -151.26 130.05 12.4 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.417 -179.868 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.402 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 80.6 m80 -155.82 178.29 10.43 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -139.72 177.87 7.64 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.248 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -155.12 115.9 3.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.336 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.44 128.01 42.07 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.17 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 99.8 t -129.63 130.94 67.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.508 ' O ' ' CD2' ' F' ' 19' ' ' PHE . 54.7 p90 -132.32 128.52 37.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.887 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.6 t80 -138.82 125.37 20.63 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.46 146.3 30.51 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.681 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -124.15 95.68 4.64 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 178.173 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 5.8 t70 . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.909 -178.673 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 33.1 tttm . . . . . 0 N--CA 1.498 1.937 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.64 -99.88 0.01 OUTLIER Glycine 0 C--N 1.348 1.214 0 CA-C-O 124.622 2.235 . . . . 0.0 114.143 174.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.677 ' HA ' ' O ' ' E' ' 29' ' ' GLY . . . 70.18 143.36 0.05 Allowed 'General case' 0 CA--C 1.503 -0.839 0 CA-C-N 108.575 -3.812 . . . . 0.0 107.208 177.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.513 HG13 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -160.06 125.05 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 122.538 2.427 . . . . 0.0 113.399 -179.711 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 87.7 mt -107.78 117.74 54.05 Favored 'Isoleucine or valine' 0 C--N 1.355 0.83 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.951 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.53 91.06 0.55 Allowed Glycine 0 N--CA 1.452 -0.245 0 N-CA-C 109.061 -1.615 . . . . 0.0 109.061 177.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.953 HD22 ' CZ ' ' C' ' 19' ' ' PHE . 3.1 tp -114.22 116.18 28.63 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.628 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 2.2 mtp -88.34 114.26 24.78 Favored 'General case' 0 CA--C 1.48 -1.735 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.407 HG22 ' O ' ' F' ' 36' ' ' VAL . 2.2 p -139.63 74.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 105.775 -1.935 . . . . 0.0 105.775 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.32 104.85 2.64 Favored Glycine 0 C--N 1.356 1.667 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.03 -179.43 26.37 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -134.76 138.07 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.692 0.282 . . . . 0.0 111.03 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 N--CA 1.469 0.52 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.538 179.584 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -119.51 142.59 48.16 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -152.43 123.56 7.59 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.416 0.626 . . . . 0.0 111.578 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -150.21 146.29 16.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.498 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -151.93 140.97 21.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.077 0.465 . . . . 0.0 110.815 179.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -134.64 163.74 29.07 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -150.53 171.34 17.24 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.528 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -156.2 128.98 7.84 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.46 HD13 HE21 ' H' ' 15' ' ' GLN . 5.8 mp -122.15 124.6 44.26 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 110.218 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.436 HG13 ' O ' ' G' ' 18' ' ' VAL . 5.4 p -121.67 120.46 61.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.189 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.586 ' CZ ' HD13 ' I' ' 34' ' ' LEU . 3.9 t80 -117.12 103.16 9.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -122.37 121.5 36.84 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.93 123.75 48.86 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.862 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -158.3 155.53 28.99 Favored 'General case' 0 CA--C 1.528 0.122 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -88.25 120.9 30.05 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.116 0.484 . . . . 0.0 112.289 -178.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.569 ' O ' ' N ' ' G' ' 26' ' ' SER . 88.1 t -100.97 124.03 54.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.63 83.49 0.0 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-O 120.052 -0.305 . . . . 0.0 112.985 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.569 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.1 m -97.46 174.78 6.5 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 22.8 p30 -59.22 164.38 3.21 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.196 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -57.23 111.53 1.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.779 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.462 ' H ' ' HE3' ' H' ' 28' ' ' LYS . . . 72.38 93.49 0.09 OUTLIER Glycine 0 N--CA 1.466 0.681 0 C-N-CA 119.678 -1.249 . . . . 0.0 111.315 177.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.55 157.51 19.56 Favored 'General case' 0 CA--C 1.51 -0.595 0 C-N-CA 118.426 -1.31 . . . . 0.0 108.847 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.514 HG22 HD12 ' H' ' 31' ' ' ILE . 0.1 OUTLIER -153.04 117.35 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.776 -173.434 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.485 ' O ' ' SD ' ' A' ' 35' ' ' MET . 18.0 tt -135.58 129.47 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.064 179.543 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.88 116.9 1.96 Allowed Glycine 0 N--CA 1.466 0.639 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 76.5 mt -137.33 148.77 46.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 121.681 0.753 . . . . 0.0 112.289 -178.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 ttt -139.3 135.8 34.19 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.196 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' G' ' 37' ' ' GLY . 9.5 t -141.53 81.27 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' G' ' 36' ' ' VAL . . . -26.89 -94.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 O-C-N 123.337 0.398 . . . . 0.0 112.773 178.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.13 -157.84 30.5 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 71.8 t -98.86 133.49 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.847 0.356 . . . . 0.0 110.24 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.731 -179.395 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -145.0 159.5 42.84 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.788 0.327 . . . . 0.0 110.522 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . 0.481 ' CD ' ' NE2' ' H' ' 13' ' ' HIS . 82.5 tt0 -134.73 145.54 48.56 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.835 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.48 133.17 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 116.793 -0.185 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.481 ' NE2' ' CD ' ' H' ' 11' ' ' GLU . 80.9 m-70 -137.31 143.58 42.18 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.837 0.351 . . . . 0.0 111.307 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.506 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 86.3 t60 -146.92 162.08 39.43 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.448 0.642 . . . . 0.0 110.307 178.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.506 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 42.4 tt0 -156.72 174.62 15.21 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -162.71 125.47 2.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.892 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.561 ' C ' HD23 ' H' ' 17' ' ' LEU . 6.6 tt -125.62 121.79 34.55 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.982 0.42 . . . . 0.0 110.533 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.498 ' N ' HD23 ' H' ' 17' ' ' LEU . 56.6 t -120.36 126.16 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.876 179.206 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 29.5 t80 -121.93 111.91 17.66 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -130.38 126.23 36.55 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.34 128.64 51.27 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.238 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.24 149.1 40.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.643 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.51 ' O ' ' NZ ' ' J' ' 28' ' ' LYS . 53.2 t0 -155.79 121.1 4.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.802 HG22 ' N ' ' H' ' 25' ' ' GLY . 2.6 p -133.87 -112.01 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.802 ' N ' HG22 ' H' ' 24' ' ' VAL . . . 32.86 -90.26 0.01 OUTLIER Glycine 0 CA--C 1.53 1.016 0 CA-C-N 115.97 -0.559 . . . . 0.0 112.362 -178.085 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.661 ' O ' ' O ' ' H' ' 27' ' ' ASN . 1.6 t 171.61 178.72 0.07 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 117.622 0.711 . . . . 0.0 109.984 -179.519 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.661 ' O ' ' O ' ' H' ' 26' ' ' SER . 9.4 t-20 -28.57 179.59 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 O-C-N 125.07 1.481 . . . . 0.0 114.259 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.555 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 87.0 tttt 128.43 105.18 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 124.359 1.064 . . . . 0.0 111.763 178.356 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.86 96.27 0.05 OUTLIER Glycine 0 N--CA 1.47 0.948 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.08 146.6 47.04 Favored 'General case' 0 C--O 1.253 1.288 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 177.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.599 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.1 OUTLIER -140.04 119.61 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.281 0 CA-C-N 113.02 -1.9 . . . . 0.0 110.697 -171.855 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -126.96 122.73 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.767 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.17 118.64 2.18 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -137.3 129.97 30.1 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.456 0.646 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.452 ' SD ' ' C ' ' B' ' 32' ' ' ILE . 13.2 ttt -124.47 124.91 43.33 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.247 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.556 HG23 ' O ' ' H' ' 36' ' ' VAL . 34.5 m -136.08 81.24 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -29.14 -93.47 0.01 OUTLIER Glycine 0 CA--C 1.529 0.925 0 CA-C-N 116.488 -0.324 . . . . 0.0 112.489 178.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.09 -161.86 28.66 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.407 ' O ' HG23 ' I' ' 39' ' ' VAL . 27.7 m -120.51 134.79 62.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 120.657 0.265 . . . . 0.0 110.39 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.442 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.468 0.473 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.54 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 49.3 p-80 -155.86 161.62 40.57 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.147 -0.621 . . . . 0.0 112.303 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 7.2 m-70 -141.37 162.78 34.66 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.45 179.097 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -150.54 175.36 11.97 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.858 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -155.26 130.53 9.61 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.989 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.4 mt -124.39 118.74 27.39 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -123.62 128.44 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.56 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.648 ' CD2' ' CZ ' ' J' ' 19' ' ' PHE . 27.7 t80 -128.01 116.23 19.72 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -127.89 130.32 48.33 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-O 120.703 0.287 . . . . 0.0 110.941 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.14 125.78 32.09 Favored 'General case' 0 C--O 1.243 0.718 0 CA-C-O 121.444 0.64 . . . . 0.0 112.067 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -145.08 158.34 43.85 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.553 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.545 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.9 p-10 -173.96 121.88 0.31 Allowed 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 -179.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' I' ' 26' ' ' SER . 11.5 t -124.0 -111.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.222 -178.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.18 -90.75 0.01 OUTLIER Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -177.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.563 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.7 p 171.39 169.37 0.09 Allowed 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 177.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.563 ' O ' ' O ' ' I' ' 26' ' ' SER . 21.3 t-20 -19.49 155.8 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 179.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.542 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 73.5 tttt -170.69 106.57 0.28 Allowed 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.676 173.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.66 93.16 0.01 OUTLIER Glycine 0 C--O 1.227 -0.335 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 174.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -142.04 145.38 34.32 Favored 'General case' 0 CA--C 1.486 -1.504 0 CA-C-N 119.167 1.483 . . . . 0.0 107.889 177.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.599 ' CG1' HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -139.8 117.28 10.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.349 -177.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' I' ' 32' ' ' ILE . 0.4 OUTLIER -107.82 116.63 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.435 ' HA3' ' CG ' ' C' ' 35' ' ' MET . . . -119.68 100.61 0.8 Allowed Glycine 0 CA--C 1.496 -1.133 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.057 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.586 HD13 ' CZ ' ' G' ' 19' ' ' PHE . 5.3 tt -130.49 125.33 34.09 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 118.824 -1.151 . . . . 0.0 110.252 -179.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.679 ' SD ' HG22 ' C' ' 31' ' ' ILE . 28.3 ttm -115.56 117.11 29.42 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.176 -1.375 . . . . 0.0 109.01 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.97 75.29 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.681 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.431 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -29.63 -97.29 0.01 OUTLIER Glycine 0 C--N 1.354 1.543 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.843 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.75 -164.54 28.5 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.407 HG23 ' O ' ' H' ' 39' ' ' VAL . 2.6 p -133.82 146.91 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 110.027 -0.361 . . . . 0.0 110.027 179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.73 -179.79 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.173 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -105.21 129.45 53.58 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 120.901 0.382 . . . . 0.0 110.615 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -127.95 127.14 42.77 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.228 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 t -141.64 134.18 28.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -149.61 133.54 17.04 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.479 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 1.5 t-80 -151.64 159.2 44.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.633 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 49.6 tt0 -160.58 169.5 22.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.419 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -151.08 128.79 11.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 14.2 tp -126.33 114.55 18.39 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 64.6 t -119.51 126.76 75.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.981 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.648 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 1.5 t80 -120.19 119.35 32.97 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.51 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 56.4 t80 -132.84 126.36 32.08 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.611 0.243 . . . . 0.0 110.849 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.84 26.58 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 119.848 -0.741 . . . . 0.0 112.47 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -125.58 143.89 50.82 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.151 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -130.04 110.85 11.96 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 177.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.584 HG12 ' N ' ' J' ' 25' ' ' GLY . 14.0 t -139.39 -123.51 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.589 -178.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.584 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 27.5 -83.92 0.0 OUTLIER Glycine 0 C--N 1.342 0.879 0 CA-C-N 114.947 -1.024 . . . . 0.0 112.406 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.635 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.2 p 170.48 170.42 0.07 Allowed 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 178.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.635 ' O ' ' O ' ' J' ' 26' ' ' SER . 76.3 m-20 -18.37 157.58 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 O-C-N 124.375 1.047 . . . . 0.0 113.064 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.576 ' HB3' ' HB2' ' K' ' 30' ' ' ALA . 81.0 tttt -161.79 110.9 1.52 Allowed 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.573 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.471 ' H ' ' CG ' ' I' ' 27' ' ' ASN . . . -67.45 92.49 0.22 Allowed Glycine 0 C--N 1.32 -0.333 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.609 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -157.06 149.17 22.84 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 177.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.658 ' N ' HD13 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -144.81 122.56 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 C-N-CA 119.201 -1.0 . . . . 0.0 111.505 -176.946 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 4.2 mt -108.94 119.56 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-N 114.975 -1.012 . . . . 0.0 109.826 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.42 112.91 2.48 Favored Glycine 0 C--N 1.336 0.567 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 177.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.435 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 0.1 OUTLIER -143.72 135.0 25.85 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.126 0.965 . . . . 0.0 113.015 -177.586 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.586 ' CE ' HG22 ' D' ' 31' ' ' ILE . 98.7 mmm -112.63 111.19 21.82 Favored 'General case' 0 CA--C 1.504 -0.79 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.032 177.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.25 62.39 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.34 -111.49 0.13 Allowed Glycine 0 C--N 1.356 1.642 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.771 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.35 142.83 7.04 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 11.6 p -142.08 151.82 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 m . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.402 179.806 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -113.48 132.28 55.72 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.718 0.294 . . . . 0.0 110.442 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -129.9 127.71 40.72 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.918 0.389 . . . . 0.0 110.936 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.55 132.74 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -150.64 131.84 14.48 Favored 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.054 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' CE1' ' J' ' 14' ' ' HIS . 50.3 t-80 -152.93 165.01 36.85 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.174 0.511 . . . . 0.0 109.842 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 80.8 mt-30 -156.88 179.85 8.89 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.325 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -170.3 120.08 0.59 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.327 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 31.4 tp -119.98 123.99 44.85 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.549 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 65.0 t -130.03 121.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.551 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -118.67 120.62 37.96 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.51 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 48.6 t80 -129.01 121.26 27.56 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.998 0.428 . . . . 0.0 111.592 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.19 129.36 41.61 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.494 178.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -124.49 143.2 50.79 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 121.417 0.627 . . . . 0.0 112.323 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -131.55 123.7 28.51 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.974 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.64 HG12 ' N ' ' K' ' 25' ' ' GLY . 57.7 t -96.15 -112.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.667 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.64 ' N ' HG12 ' K' ' 24' ' ' VAL . . . -46.96 -91.04 0.01 OUTLIER Glycine 0 CA--C 1.526 0.765 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.456 -176.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.605 ' O ' ' O ' ' K' ' 27' ' ' ASN . 34.9 p -152.98 -172.63 4.31 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 117.611 0.705 . . . . 0.0 110.444 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.605 ' O ' ' O ' ' K' ' 26' ' ' SER . 54.7 t30 -19.86 158.05 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.65 0 O-C-N 124.997 1.436 . . . . 0.0 113.724 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' L' ' 30' ' ' ALA . 87.1 tttt -161.6 111.08 1.57 Allowed 'General case' 0 C--O 1.213 -0.823 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.839 176.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.574 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -67.92 92.39 0.24 Allowed Glycine 0 N--CA 1.475 1.276 0 CA-C-O 119.376 -0.68 . . . . 0.0 113.553 177.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.576 ' HB2' ' HB3' ' J' ' 28' ' ' LYS . . . -156.87 152.82 27.28 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 103.523 -2.769 . . . . 0.0 103.523 174.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.496 ' HB ' ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -149.62 116.16 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.857 0 C-N-CA 116.714 -1.994 . . . . 0.0 113.407 -171.844 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.428 ' C ' ' CE ' ' E' ' 35' ' ' MET . 62.7 mt -104.55 118.3 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.91 177.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.413 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.06 104.19 1.32 Allowed Glycine 0 C--O 1.237 0.319 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 177.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.578 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 8.4 tt -139.54 132.7 29.71 Favored 'General case' 0 C--O 1.243 0.734 0 CA-C-O 122.835 1.302 . . . . 0.0 112.876 -177.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CG ' ' L' ' 35' ' ' MET . 95.9 mmm -107.17 118.43 36.69 Favored 'General case' 0 CA--C 1.505 -0.767 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.53 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.569 HG13 HD21 ' K' ' 34' ' ' LEU . 0.0 OUTLIER -124.24 74.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.911 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.46 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -17.43 -101.93 0.0 OUTLIER Glycine 0 C--N 1.359 1.855 0 O-C-N 123.868 0.73 . . . . 0.0 113.031 -179.249 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.17 -161.9 30.28 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 74.4 t -124.08 138.39 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-O 120.751 0.31 . . . . 0.0 110.611 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . 0.413 ' O ' HG13 ' K' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.436 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -82.23 134.68 35.3 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.856 0.36 . . . . 0.0 110.48 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.42 143.68 33.83 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.519 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 50.4 t -121.68 132.92 69.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.063 0.459 . . . . 0.0 110.222 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 21.3 p-80 -164.12 110.43 1.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.479 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -144.85 169.04 18.8 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -151.72 175.64 12.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.126 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -153.34 123.89 7.18 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.346 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 64.4 mt -120.6 114.8 22.25 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -128.5 130.39 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.966 0.412 . . . . 0.0 110.54 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.506 ' CD1' ' O ' ' L' ' 19' ' ' PHE . 55.4 p90 -138.19 127.69 24.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -134.28 127.3 31.53 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.217 0.532 . . . . 0.0 110.746 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.61 134.48 32.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.771 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -110.19 109.77 20.38 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.644 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 42.7 t0 -99.16 133.84 42.87 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.188 0.518 . . . . 0.0 109.961 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' L' ' 26' ' ' SER . 90.5 t -107.02 112.97 42.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.394 -179.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 35.3 -91.22 0.01 OUTLIER Glycine 0 CA--C 1.528 0.88 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.873 -179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.448 ' N ' ' O ' ' L' ' 24' ' ' VAL . 13.4 p -62.49 -177.83 0.16 Allowed 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 117.571 0.685 . . . . 0.0 110.342 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -79.52 176.63 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.855 -1.066 . . . . 0.0 113.697 -177.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 35.7 tttp -48.51 111.1 0.41 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 113.835 -1.53 . . . . 0.0 112.947 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.41 -97.91 0.04 OUTLIER Glycine 0 CA--C 1.501 -0.808 0 CA-C-N 114.542 -1.208 . . . . 0.0 110.606 -178.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' K' ' 28' ' ' LYS . . . -60.84 170.87 1.34 Allowed 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 119.882 1.841 . . . . 0.0 106.135 -178.121 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -139.87 118.88 12.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 117.799 -1.56 . . . . 0.0 110.629 -172.71 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.541 ' C ' ' SD ' ' F' ' 35' ' ' MET . 67.2 mt -108.92 123.74 65.01 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 CA-C-N 114.398 -1.274 . . . . 0.0 109.09 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . 0.628 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -101.66 89.26 0.76 Allowed Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 105.477 -3.049 . . . . 0.0 105.477 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -108.57 112.89 25.48 Favored 'General case' 0 CA--C 1.502 -0.897 0 CA-C-O 120.684 0.278 . . . . 0.0 110.27 -177.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.505 ' CG ' ' SD ' ' K' ' 35' ' ' MET . 93.9 mmm -105.48 110.4 22.73 Favored 'General case' 0 CA--C 1.503 -0.846 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.169 179.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.487 HG13 HG23 ' K' ' 36' ' ' VAL . 2.9 m -128.7 79.42 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.263 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.5 103.68 0.52 Allowed Glycine 0 C--N 1.346 1.098 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.6 -161.06 36.9 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.7 m -133.15 160.91 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 120.966 0.412 . . . . 0.0 110.607 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 14.1 m . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.37 179.794 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 N--CA 1.464 0.264 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -93.6 135.5 34.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.761 0.315 . . . . 0.0 110.648 -179.043 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.554 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 75.2 t60 -152.21 164.09 38.08 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 44.9 tt0 -169.04 168.75 9.92 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.419 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.429 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 66.5 mttm -153.75 123.72 6.86 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -119.59 114.12 21.75 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.179 0.514 . . . . 0.0 110.466 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 70.5 t -120.34 115.44 47.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.147 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.961 ' CZ ' HD22 ' C' ' 34' ' ' LEU . 23.7 t80 -115.65 110.45 19.19 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.513 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 50.0 p90 -125.74 124.29 40.71 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.43 120.68 43.1 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.817 0.341 . . . . 0.0 110.357 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -159.65 115.32 2.46 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -74.89 121.85 22.5 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.96 0.409 . . . . 0.0 111.697 -178.553 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 26' ' ' SER . 13.9 t -84.48 124.6 39.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.06 84.3 0.01 OUTLIER Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.989 -178.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 24' ' ' VAL . 20.7 p -91.41 -179.76 5.47 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 178.175 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.43 179.13 0.17 Allowed 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 119.656 -0.817 . . . . 0.0 110.722 -179.087 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -59.5 111.11 1.28 Allowed 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.66 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.23 93.81 0.09 OUTLIER Glycine 0 N--CA 1.464 0.501 0 C-N-CA 120.169 -1.015 . . . . 0.0 112.214 177.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.24 156.14 21.92 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 176.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.609 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.2 OUTLIER -151.86 119.67 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.0 -173.248 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.455 ' C ' ' SD ' ' G' ' 35' ' ' MET . 5.9 tp -149.59 131.58 5.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.154 179.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.415 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.67 128.86 5.82 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -129.65 129.63 44.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.314 0.578 . . . . 0.0 110.606 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.517 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 27.9 ttt -130.81 129.23 42.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.552 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.6 t -84.46 75.99 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.979 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.412 ' CA ' HG21 ' G' ' 31' ' ' ILE . . . -90.51 103.36 3.02 Favored Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 178.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.45 179.95 52.43 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 N--CA 1.467 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.492 -179.886 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 N--CA 1.465 0.303 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.487 ' H ' ' HA ' ' C' ' 12' ' ' VAL . 61.7 t-80 -122.46 118.73 29.02 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.861 0.363 . . . . 0.0 110.198 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.489 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 80.8 t60 -132.8 163.83 28.18 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.489 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 1.6 pt20 -169.93 177.6 4.3 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.981 179.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -156.28 125.96 6.33 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.438 ' N ' HD12 ' B' ' 17' ' ' LEU . 5.0 mp -122.23 121.2 36.27 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.162 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 7.1 p -134.18 130.79 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.916 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 18.2 t80 -115.29 117.58 30.85 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -129.14 129.22 44.86 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.716 0.293 . . . . 0.0 111.423 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.8 123.37 37.21 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 120.616 -0.433 . . . . 0.0 111.652 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 41.0 tp10 -164.74 105.1 0.82 Allowed 'General case' 0 C--N 1.343 0.283 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.553 ' O ' ' O ' ' B' ' 24' ' ' VAL . 42.6 t0 -104.67 112.1 25.06 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.553 ' O ' ' O ' ' B' ' 23' ' ' ASP . 2.1 t -50.27 -133.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.745 178.042 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -95.35 -84.95 1.68 Allowed Glycine 0 CA--C 1.536 1.403 0 CA-C-N 115.933 -0.576 . . . . 0.0 113.276 -178.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 35.0 t 68.51 178.83 0.24 Allowed 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -177.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -89.88 168.27 12.18 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 118.456 -1.298 . . . . 0.0 112.513 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 45.9 pttt -40.92 110.57 0.16 Allowed 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 177.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.546 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 80.0 94.54 0.37 Allowed Glycine 0 N--CA 1.476 1.329 0 N-CA-C 116.892 1.517 . . . . 0.0 116.892 171.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.25 152.91 37.08 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 171.611 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.609 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.0 OUTLIER -145.36 117.72 2.27 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.721 -174.308 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -127.05 131.57 70.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.029 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.31 119.59 3.45 Favored Glycine 0 N--CA 1.475 1.239 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 59.3 tp -127.45 126.24 41.97 Favored 'General case' 0 N--CA 1.47 0.527 0 O-C-N 122.287 -0.537 . . . . 0.0 110.885 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.518 ' SD ' ' O ' ' H' ' 32' ' ' ILE . 11.9 ttt -139.6 137.75 35.59 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.348 0.594 . . . . 0.0 111.481 179.525 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 24.4 t -122.51 73.88 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.845 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.657 ' CA ' HG21 ' H' ' 31' ' ' ILE . . . -62.85 111.95 4.52 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 178.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -26.66 148.53 0.01 OUTLIER Glycine 0 N--CA 1.469 0.871 0 CA-C-O 121.107 0.282 . . . . 0.0 112.676 -178.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 68.1 t -115.29 135.58 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 m . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.381 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -114.22 138.59 50.27 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.781 0.324 . . . . 0.0 110.592 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -110.75 131.28 55.18 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.146 0.498 . . . . 0.0 110.538 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.487 ' HA ' ' H ' ' B' ' 13' ' ' HIS . 28.3 m -136.11 164.17 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.473 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.699 ' CG ' ' H ' ' C' ' 14' ' ' HIS . 76.0 t60 -103.15 -173.48 2.32 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.699 ' H ' ' CG ' ' C' ' 13' ' ' HIS . 2.3 m170 -77.2 174.13 11.08 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.89 174.83 10.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.414 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -151.51 133.37 14.98 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.937 0.398 . . . . 0.0 111.731 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.63 HD23 ' C ' ' C' ' 17' ' ' LEU . 6.6 tt -127.62 123.2 35.06 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.578 178.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . 0.607 ' N ' HD23 ' C' ' 17' ' ' LEU . 57.5 t -128.04 129.52 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 CA-C-O 120.912 0.387 . . . . 0.0 111.648 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.737 ' CE1' HD13 ' E' ' 34' ' ' LEU . 2.5 t80 -121.7 115.21 22.3 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -127.45 125.79 41.18 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.92 0.39 . . . . 0.0 111.083 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.2 129.52 46.58 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.87 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 80.5 tt0 -155.97 158.39 37.82 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.938 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -142.8 120.65 11.97 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.57 0.224 . . . . 0.0 110.624 179.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -129.88 -112.19 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-O 121.308 0.575 . . . . 0.0 110.13 -179.235 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 35.07 -90.68 0.01 OUTLIER Glycine 0 CA--C 1.531 1.054 0 CA-C-N 115.337 -0.847 . . . . 0.0 114.084 -178.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.0 OUTLIER 175.28 -167.21 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 118.396 1.098 . . . . 0.0 110.793 -178.582 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' C' ' 26' ' ' SER . 51.4 p-10 -36.47 -179.62 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.164 -1.38 . . . . 0.0 113.641 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.546 ' HG3' ' H ' ' B' ' 29' ' ' GLY . 74.8 tttt 98.55 113.88 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.958 1.703 . . . . 0.0 113.182 179.047 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.88 93.64 0.49 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 172.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.2 163.07 12.88 Favored 'General case' 0 CA--C 1.498 -1.047 0 CA-C-N 120.74 2.27 . . . . 0.0 106.461 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.579 HD12 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -149.72 117.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 118.337 -1.345 . . . . 0.0 110.417 -174.113 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.485 ' C ' ' SD ' ' I' ' 35' ' ' MET . 13.5 tt -129.13 132.84 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 CA-C-O 121.736 0.779 . . . . 0.0 110.747 178.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -119.71 119.34 4.22 Favored Glycine 0 N--CA 1.465 0.612 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.961 HD22 ' CZ ' ' A' ' 19' ' ' PHE . 32.6 tp -118.67 121.86 41.14 Favored 'General case' 0 CA--C 1.512 -0.516 0 C-N-CA 120.986 -0.285 . . . . 0.0 111.743 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.522 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 7.9 ttm -122.05 108.98 14.0 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 173.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 m -128.75 72.37 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 120.543 -0.463 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.0 110.81 3.11 Favored Glycine 0 C--N 1.362 1.993 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.13 160.07 53.93 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -139.06 161.43 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.871 0.367 . . . . 0.0 111.051 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.414 ' O ' HG22 ' C' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.398 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 70.0 t . . . . . 0 N--CA 1.468 0.459 0 CA-C-O 121.026 0.441 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.447 ' CE1' ' CG2' ' C' ' 12' ' ' VAL . 32.5 m-70 -138.39 97.83 3.46 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.167 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 m170 -119.98 161.93 20.07 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.41 0.624 . . . . 0.0 109.583 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.429 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 43.9 tt0 -154.32 170.33 21.56 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.804 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.429 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.3 mttt -152.95 129.33 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -123.23 124.24 42.57 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.715 0.293 . . . . 0.0 110.643 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -123.63 126.77 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.085 0.469 . . . . 0.0 110.508 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.854 ' CZ ' HD22 ' F' ' 34' ' ' LEU . 7.7 t80 -124.69 110.55 14.51 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -123.13 129.85 51.99 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.522 0.677 . . . . 0.0 111.778 -178.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.93 122.19 26.5 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.497 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 79.6 mm-40 -115.86 120.33 38.87 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -151.51 112.0 4.17 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 -179.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.695 ' O ' ' N ' ' D' ' 26' ' ' SER . 52.1 t -111.96 131.07 64.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 102.572 -3.121 . . . . 0.0 102.572 174.125 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.624 ' H ' ' HZ1' ' F' ' 28' ' ' LYS . . . -37.59 81.67 0.0 OUTLIER Glycine 0 CA--C 1.534 1.256 0 C-N-CA 120.172 -1.014 . . . . 0.0 112.569 -176.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.695 ' N ' ' O ' ' D' ' 24' ' ' VAL . 26.8 m -88.48 -179.58 6.1 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-O 122.566 1.174 . . . . 0.0 111.612 178.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -76.61 -177.13 4.07 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.921 175.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 35.1 tttt 44.96 111.62 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 117.959 2.577 . . . . 0.0 117.959 177.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.483 ' HA2' ' HB2' ' E' ' 30' ' ' ALA . . . -82.64 94.66 1.74 Allowed Glycine 0 CA--C 1.499 -0.957 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 173.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.24 167.36 12.38 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.721 HG23 HG13 ' E' ' 31' ' ' ILE . 0.2 OUTLIER -146.42 118.29 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.623 -174.976 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.422 HD12 ' CG2' ' C' ' 32' ' ' ILE . 14.4 tt -130.13 130.88 66.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-O 121.828 0.823 . . . . 0.0 111.942 179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.8 104.27 2.35 Favored Glycine 0 CA--C 1.509 -0.338 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 177.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.916 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 16.6 tp -111.33 117.85 34.26 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 117.376 0.588 . . . . 0.0 111.945 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.55 ' SD ' HG22 ' J' ' 31' ' ' ILE . 17.7 tpp -121.08 108.01 13.31 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 176.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.6 HG22 HD11 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -121.04 76.51 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.951 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.778 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.04 103.31 2.85 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.16 174.33 41.96 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -135.4 160.62 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 121.047 0.451 . . . . 0.0 110.755 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.177 -0.916 . . . . 0.0 110.366 179.578 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -120.26 143.78 48.12 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.815 0.34 . . . . 0.0 110.332 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -73.23 135.15 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.84 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 8.4 t -146.74 135.62 16.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.108 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -132.54 131.7 41.83 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.638 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 24.2 t60 -152.08 163.6 38.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 121.922 0.868 . . . . 0.0 110.446 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.638 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 53.5 tt0 -159.55 167.11 29.35 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.496 178.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.401 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 99.2 mttt -151.44 130.11 12.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 179.432 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.5 HD12 ' CD2' ' F' ' 17' ' ' LEU . 12.5 mt -115.52 116.18 27.74 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.425 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.52 115.34 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.099 -179.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -117.03 124.43 49.29 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 116.78 -0.191 . . . . 0.0 110.756 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -129.94 119.09 22.68 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.65 121.13 22.7 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.231 0.539 . . . . 0.0 111.425 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 35.0 tt0 -88.52 165.63 14.73 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.7 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.563 ' O ' ' O ' ' E' ' 24' ' ' VAL . 46.0 t0 -145.4 -122.27 0.08 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.002 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.563 ' O ' ' O ' ' E' ' 23' ' ' ASP . 2.9 t 22.22 121.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 -178.707 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.08 -85.0 0.09 OUTLIER Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 177.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.509 ' H ' ' CE ' ' F' ' 28' ' ' LYS . 1.7 p 162.39 160.8 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 177.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.455 ' O ' ' O ' ' E' ' 26' ' ' SER . 69.6 m-80 -29.78 159.42 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.694 178.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.476 ' HD2' ' H ' ' D' ' 26' ' ' SER . 76.1 tttt -179.73 105.84 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 174.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.465 ' O ' ' CA ' ' D' ' 29' ' ' GLY . . . -58.65 93.54 0.05 OUTLIER Glycine 0 C--O 1.211 -1.323 0 CA-C-O 118.16 -1.356 . . . . 0.0 111.708 173.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.483 ' HB2' ' HA2' ' D' ' 29' ' ' GLY . . . -155.9 149.37 24.82 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 103.1 -2.926 . . . . 0.0 103.1 173.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.721 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.05 124.3 6.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 C-N-CA 117.984 -1.486 . . . . 0.0 112.133 -168.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.461 HG12 HD21 ' E' ' 34' ' ' LEU . 0.7 OUTLIER -120.91 111.29 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 CA-C-N 114.529 -1.214 . . . . 0.0 107.761 179.541 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.57 110.24 3.62 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.737 HD13 ' CE1' ' C' ' 19' ' ' PHE . 2.9 mt -117.97 112.76 20.72 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -176.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' K' ' 32' ' ' ILE . 6.2 ttm -115.29 107.91 15.87 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 175.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.16 80.97 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.23 102.64 0.5 Allowed Glycine 0 C--N 1.346 1.116 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -86.67 -160.22 34.35 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.31 160.47 33.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.185 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.5 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.689 -179.993 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.408 ' CG2' ' N ' ' F' ' 13' ' ' HIS . 1.5 p . . . . . 0 N--CA 1.464 0.27 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.536 ' ND1' ' ND1' ' E' ' 14' ' ' HIS . 15.2 t-80 -125.02 155.27 39.98 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 120.912 0.387 . . . . 0.0 110.595 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.558 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 89.9 m-70 -80.42 178.28 8.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -125.93 -179.88 4.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.364 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -133.62 137.58 45.5 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.161 0.505 . . . . 0.0 110.993 -179.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.5 ' CD2' HD12 ' E' ' 17' ' ' LEU . 33.1 mt -122.03 115.17 22.02 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.276 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 28.5 m -134.04 127.64 51.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.341 0.591 . . . . 0.0 110.092 178.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.495 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 50.0 p90 -138.69 131.52 29.39 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.575 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -129.79 122.27 28.45 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.6 146.24 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.422 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -115.78 125.9 53.33 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.217 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 . . . . . 0 CA--C 1.532 0.286 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.978 178.536 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.624 ' HZ1' ' H ' ' D' ' 25' ' ' GLY . 30.6 tttt . . . . . 0 CA--C 1.544 0.723 0 CA-C-O 122.882 1.325 . . . . 0.0 112.476 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.516 ' H ' ' CG ' ' F' ' 28' ' ' LYS . . . -90.6 -99.85 1.18 Allowed Glycine 0 CA--C 1.484 -1.883 0 C-N-CA 127.568 2.509 . . . . 0.0 111.76 -179.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.66 166.46 3.24 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 105.838 -1.912 . . . . 0.0 105.838 -177.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -132.61 135.71 57.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.34 -171.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 61.4 mt -114.87 117.24 55.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 CA-C-N 115.198 -0.91 . . . . 0.0 112.646 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.69 92.58 1.23 Allowed Glycine 0 CA--C 1.51 -0.244 0 N-CA-C 104.51 -3.436 . . . . 0.0 104.51 173.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.854 HD22 ' CZ ' ' D' ' 19' ' ' PHE . 8.4 tp -110.3 116.77 32.07 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.466 ' HG3' ' CA ' ' L' ' 33' ' ' GLY . 96.4 mmm -119.58 111.98 18.75 Favored 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 176.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.491 HG13 HD11 ' F' ' 34' ' ' LEU . 0.1 OUTLIER -127.36 80.22 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.075 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 34.47 -103.27 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 CA-C-N 116.436 -0.347 . . . . 0.0 112.308 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.97 -150.17 10.95 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.8 t -120.02 135.77 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.997 0.427 . . . . 0.0 110.803 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.13 -0.938 . . . . 0.0 110.281 179.559 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . 0.409 ' O ' ' OE2' ' H' ' 11' ' ' GLU . 99.1 m-85 -99.19 133.77 43.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.136 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -139.67 145.6 38.62 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.301 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 62.2 t -125.34 132.63 70.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.225 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -88.31 172.11 9.67 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.919 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.537 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 3.6 m170 -89.05 170.52 10.58 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.626 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.431 ' HG2' ' N ' ' G' ' 16' ' ' LYS . 54.8 tt0 -147.57 171.81 14.99 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.859 179.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.431 ' N ' ' HG2' ' G' ' 15' ' ' GLN . 98.9 mttt -150.8 125.0 9.38 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 121.227 -0.189 . . . . 0.0 111.101 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 77.9 mt -118.28 122.42 42.87 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -138.66 132.42 40.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 121.774 0.797 . . . . 0.0 113.101 -178.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.637 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 6.9 m-85 -113.14 111.72 22.59 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 175.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -130.62 121.06 24.92 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 131.03 41.07 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-O 121.373 0.606 . . . . 0.0 112.038 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' G' ' 23' ' ' ASP . 83.8 tt0 -156.05 152.95 28.68 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 177.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.475 ' O ' ' C ' ' G' ' 24' ' ' VAL . 22.2 t70 -59.48 -120.41 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.534 -178.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.475 ' C ' ' O ' ' G' ' 23' ' ' ASP . 22.7 m -27.2 121.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 122.179 0.192 . . . . 0.0 111.001 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.15 -85.6 0.1 Allowed Glycine 0 CA--C 1.526 0.775 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.225 -177.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.697 ' O ' ' O ' ' G' ' 27' ' ' ASN . 62.5 m -152.73 -170.81 3.74 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -175.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.697 ' O ' ' O ' ' G' ' 26' ' ' SER . 12.7 t-20 -19.34 159.59 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.103 0 O-C-N 124.629 1.206 . . . . 0.0 114.016 -176.35 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -159.82 110.64 1.94 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.236 -176.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 1.058 ' O ' ' HB1' ' H' ' 30' ' ' ALA . . . -69.51 96.09 0.48 Allowed Glycine 0 CA--C 1.455 -3.683 0 CA-C-O 123.686 1.715 . . . . 0.0 110.511 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.522 ' O ' ' C ' ' G' ' 29' ' ' GLY . . . -81.6 -139.99 0.04 OUTLIER 'General case' 0 N--CA 1.395 -3.215 1 N-CA-C 94.424 -6.139 . . . . 0.0 94.424 171.171 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.693 ' CD1' ' N ' ' G' ' 31' ' ' ILE . 1.0 OUTLIER -85.18 111.31 20.5 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.298 0 CA-C-N 125.186 3.63 . . . . 0.0 109.443 179.928 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.517 ' O ' ' SD ' ' A' ' 35' ' ' MET . 39.1 mm -136.73 129.34 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 120.304 -0.558 . . . . 0.0 112.035 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.516 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -131.34 130.76 6.13 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 34.2 tp -156.19 135.33 12.09 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.801 0.81 . . . . 0.0 112.99 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.455 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 63.7 ttp -121.93 143.94 49.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.363 178.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 25.5 t -120.03 75.86 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.482 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -96.5 101.12 2.58 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.6 167.33 22.13 Favored Glycine 0 N--CA 1.467 0.741 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 81.8 t -131.3 138.27 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.752 0.31 . . . . 0.0 110.301 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.9 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.347 179.472 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -118.61 140.48 49.84 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' O ' ' G' ' 10' ' ' TYR . 80.9 mm-40 -132.36 135.9 46.47 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.711 0.767 . . . . 0.0 111.978 -178.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 58.0 t -128.47 134.33 64.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.094 -0.957 . . . . 0.0 108.654 179.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 -137.86 101.11 4.36 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.95 -0.3 . . . . 0.0 110.754 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 11.1 m170 -115.5 154.67 28.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 80.5 mt-30 -155.91 174.31 15.51 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.468 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -156.96 112.17 2.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.712 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.507 ' N ' HD12 ' H' ' 17' ' ' LEU . 6.5 mp -111.42 111.4 22.41 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.69 125.32 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-O 121.86 0.838 . . . . 0.0 111.732 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.604 ' CG ' ' CE2' ' I' ' 19' ' ' PHE . 6.0 m-85 -113.17 116.81 30.41 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 114.182 -1.372 . . . . 0.0 108.666 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -128.67 126.56 40.38 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.13 130.24 35.14 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 121.19 0.519 . . . . 0.0 111.394 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' H' ' 23' ' ' ASP . 84.9 tt0 -149.96 91.12 1.75 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 178.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' H' ' 22' ' ' GLU . 1.1 m-20 62.74 115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 -176.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.598 ' C ' ' HZ3' ' I' ' 28' ' ' LYS . 48.9 t -118.84 123.75 72.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.471 -174.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.505 ' C ' ' HZ3' ' I' ' 28' ' ' LYS . . . 35.91 83.69 0.01 OUTLIER Glycine 0 N--CA 1.47 0.905 0 C-N-CA 121.482 -0.39 . . . . 0.0 113.255 177.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.627 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 5.4 t -58.9 170.92 0.74 Allowed 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 121.18 0.514 . . . . 0.0 110.389 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.527 ' ND2' ' O ' ' H' ' 26' ' ' SER . 68.7 m-20 103.26 177.43 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 113.259 -1.791 . . . . 0.0 107.298 -177.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' H' ' 27' ' ' ASN . 98.7 mttt -23.69 -102.87 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 O-C-N 123.567 0.542 . . . . 0.0 111.981 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -141.25 100.46 0.26 Allowed Glycine 0 N--CA 1.472 1.059 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 177.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 1.058 ' HB1' ' O ' ' G' ' 29' ' ' GLY . . . -66.59 158.48 29.72 Favored 'General case' 0 C--O 1.248 1.013 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.016 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.657 HG21 ' CA ' ' B' ' 37' ' ' GLY . 0.1 OUTLIER -154.55 132.15 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.544 -175.796 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' B' ' 35' ' ' MET . 41.5 pt -130.42 127.07 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.499 0.666 . . . . 0.0 112.226 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.53 97.89 0.66 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.507 ' O ' HD12 ' I' ' 34' ' ' LEU . 4.4 mp -129.44 149.8 51.07 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.924 0.868 . . . . 0.0 111.974 -178.31 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.406 ' CE ' ' SD ' ' G' ' 35' ' ' MET . 20.7 ttp -141.03 134.69 30.17 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.482 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 4.1 t -126.42 79.01 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' B' ' 31' ' ' ILE . . . -61.53 105.07 0.8 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 177.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.94 173.05 0.64 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.99 161.88 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.965 0.412 . . . . 0.0 110.66 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.9 m . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.831 179.951 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 N--CA 1.468 0.452 0 CA-C-O 120.188 0.042 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -135.75 132.31 36.65 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.505 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.625 ' NE2' ' CG ' ' J' ' 13' ' ' HIS . 75.7 m80 -122.91 159.69 27.71 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 178.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -157.51 177.52 11.32 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.629 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -170.05 114.16 0.49 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 tt -117.67 118.49 32.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.071 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -141.72 136.76 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 119.967 -0.693 . . . . 0.0 111.896 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.604 ' CE2' ' CG ' ' H' ' 19' ' ' PHE . 26.8 m-85 -123.92 128.5 49.52 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 115.393 -0.822 . . . . 0.0 110.224 179.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.587 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.2 t80 -133.26 124.86 28.12 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.09 133.21 44.07 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.488 0.921 . . . . 0.0 113.488 -178.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -143.35 167.75 21.42 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' I' ' 24' ' ' VAL . 3.6 m-20 -142.32 -102.14 0.13 Allowed 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.519 ' O ' ' O ' ' I' ' 23' ' ' ASP . 10.9 t 46.98 159.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 122.263 1.03 . . . . 0.0 112.655 -176.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.497 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 107.88 -76.35 0.22 Allowed Glycine 0 CA--C 1.541 1.712 0 CA-C-N 114.139 -1.391 . . . . 0.0 112.529 -175.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.9 ' O ' ' O ' ' I' ' 27' ' ' ASN . 0.4 OUTLIER 170.89 -169.48 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.403 0 CA-C-N 119.502 1.651 . . . . 0.0 109.354 -176.43 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.9 ' O ' ' O ' ' I' ' 26' ' ' SER . 62.1 t30 -17.01 -179.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.06 0 O-C-N 125.287 1.617 . . . . 0.0 113.537 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.659 ' CG ' ' O ' ' I' ' 27' ' ' ASN . 26.8 mmtt 139.89 -110.52 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -175.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.42 ' CA ' ' O ' ' J' ' 29' ' ' GLY . . . 49.27 91.28 0.01 OUTLIER Glycine 0 CA--C 1.482 -2.022 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -171.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.447 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -103.06 170.75 7.78 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 111.509 -2.346 . . . . 0.0 106.63 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.481 HD12 ' CG2' ' H' ' 31' ' ' ILE . 0.3 OUTLIER -145.78 110.03 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 C-N-CA 118.299 -1.361 . . . . 0.0 109.423 -175.899 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.517 HG12 HD11 ' H' ' 32' ' ' ILE . 58.7 mt -103.6 115.72 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.516 -178.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.522 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.61 92.65 0.54 Allowed Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 107.509 -2.237 . . . . 0.0 107.509 176.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.61 HD23 ' HZ ' ' G' ' 19' ' ' PHE . 22.6 tp -129.22 122.4 29.63 Favored 'General case' 0 C--O 1.244 0.785 0 CA-C-O 123.276 1.512 . . . . 0.0 110.798 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 24.7 ttp -106.61 120.42 41.91 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 112.596 -2.093 . . . . 0.0 108.548 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -135.49 72.23 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.392 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -104.13 101.62 2.01 Favored Glycine 0 C--N 1.36 1.914 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 178.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.35 178.91 24.56 Favored Glycine 0 N--CA 1.463 0.485 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 8.4 p -141.43 152.34 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.878 0.371 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.5 179.856 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.452 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 66.8 m-85 -120.45 147.2 45.41 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -122.95 161.65 23.78 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.185 0.517 . . . . 0.0 110.441 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -143.77 151.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.591 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.625 ' CG ' ' NE2' ' I' ' 14' ' ' HIS . 25.2 t-80 -92.45 -173.92 3.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.853 0.359 . . . . 0.0 110.219 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.621 ' H ' ' CG ' ' J' ' 13' ' ' HIS . 0.5 OUTLIER -86.01 175.19 8.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.336 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.408 ' HG2' ' N ' ' J' ' 16' ' ' LYS . 48.3 tt0 -126.16 166.26 17.38 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.408 ' N ' ' HG2' ' J' ' 15' ' ' GLN . 99.5 mttt -148.57 122.89 9.63 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.756 0.312 . . . . 0.0 111.591 -179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 3.4 mp -123.9 121.14 34.54 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 94.5 t -129.72 128.66 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-O 121.149 0.499 . . . . 0.0 112.086 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.453 ' CZ ' HD13 ' L' ' 34' ' ' LEU . 46.5 m-85 -115.53 119.83 37.48 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 178.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.587 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 29.0 t80 -130.99 120.35 23.37 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.616 0.644 . . . . 0.0 109.727 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.34 134.44 34.24 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -110.45 122.96 48.98 Favored 'General case' 0 C--N 1.346 0.43 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.311 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.549 ' HB3' ' H ' ' K' ' 24' ' ' VAL . 8.8 t70 -84.28 122.66 29.2 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.017 0.437 . . . . 0.0 110.911 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' J' ' 26' ' ' SER . 72.1 t -99.66 122.52 51.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.748 -179.06 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 39.17 -86.06 0.01 OUTLIER Glycine 0 C--N 1.337 0.619 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.301 177.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.653 ' O ' ' O ' ' J' ' 27' ' ' ASN . 87.9 p -161.25 174.17 13.98 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.653 ' O ' ' O ' ' J' ' 26' ' ' SER . 74.9 m-20 -9.39 159.4 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 116.369 1.989 . . . . 0.0 116.369 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt 179.86 104.83 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 112.566 -2.106 . . . . 0.0 106.618 175.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.42 ' O ' ' CA ' ' I' ' 29' ' ' GLY . . . -60.51 95.03 0.08 OUTLIER Glycine 0 C--O 1.22 -0.722 0 CA-C-O 118.724 -1.042 . . . . 0.0 113.924 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.401 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -127.37 149.01 50.25 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 102.215 -3.254 . . . . 0.0 102.215 172.414 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.55 HG22 ' SD ' ' D' ' 35' ' ' MET . 0.2 OUTLIER -148.48 118.64 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 C-N-CA 118.011 -1.476 . . . . 0.0 111.222 -172.296 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.649 ' CG2' HD21 ' K' ' 34' ' ' LEU . 2.0 mt -108.12 112.48 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.384 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.07 101.94 1.32 Allowed Glycine 0 C--O 1.239 0.455 0 N-CA-C 106.579 -2.608 . . . . 0.0 106.579 176.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.637 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 0.2 OUTLIER -142.16 135.17 28.73 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 122.205 1.002 . . . . 0.0 112.391 -176.634 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 49.0 ttp -123.3 127.61 48.79 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.979 179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.86 69.08 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.306 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.725 178.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.2 -100.83 0.01 OUTLIER Glycine 0 C--N 1.36 1.89 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.07 150.91 20.43 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 75.6 t -134.52 137.31 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 p . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.401 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -109.51 142.54 40.4 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.58 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -130.59 144.13 51.21 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.671 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.05 133.79 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.803 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -134.4 124.27 25.43 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.019 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.578 ' CD2' ' N ' ' K' ' 15' ' ' GLN . 33.0 t60 -156.48 166.87 32.17 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-O 121.409 0.623 . . . . 0.0 109.921 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.578 ' N ' ' CD2' ' K' ' 14' ' ' HIS . 79.6 mt-30 -153.91 173.49 15.88 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.359 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 79.1 tttt -153.78 113.3 3.8 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.125 178.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 tt -116.01 121.74 43.15 Favored 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -126.61 129.37 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -125.05 123.82 40.62 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -134.39 122.54 22.71 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.676 0.274 . . . . 0.0 111.266 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.49 131.42 31.81 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 121.246 0.546 . . . . 0.0 111.85 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -110.27 128.17 55.39 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.748 179.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.462 ' H ' ' HB2' ' L' ' 22' ' ' GLU . 89.0 m-20 -100.48 115.65 30.57 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.552 ' O ' ' N ' ' K' ' 26' ' ' SER . 53.3 t -95.37 130.29 44.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.03 -85.31 0.01 OUTLIER Glycine 0 CA--C 1.529 0.917 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.552 ' N ' ' O ' ' K' ' 24' ' ' VAL . 29.4 p -141.16 170.76 15.12 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.945 0.878 . . . . 0.0 111.516 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.515 ' O ' ' O ' ' K' ' 26' ' ' SER . 2.3 p30 -28.83 169.72 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.184 -1.825 . . . . 0.0 114.294 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.541 ' O ' ' HB2' ' L' ' 30' ' ' ALA . 88.6 tttt -149.85 111.38 4.48 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.101 175.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.11 91.91 0.05 OUTLIER Glycine 0 N--CA 1.476 1.337 0 CA-C-O 119.603 -0.554 . . . . 0.0 113.643 176.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.12 153.97 51.02 Favored 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 102.961 -2.977 . . . . 0.0 102.961 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.504 HG23 ' CG1' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -142.09 111.68 2.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 C-N-CA 118.221 -1.392 . . . . 0.0 111.713 -172.965 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.49 HG22 ' O ' ' K' ' 32' ' ' ILE . 0.1 OUTLIER -106.83 111.12 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.79 97.64 1.05 Allowed Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.649 HD21 ' CG2' ' J' ' 32' ' ' ILE . 94.2 mt -130.24 142.3 50.57 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 122.024 0.916 . . . . 0.0 113.196 -176.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 40.7 ttp -129.67 117.91 21.08 Favored 'General case' 0 CA--C 1.501 -0.939 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.266 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' K' ' 37' ' ' GLY . 0.2 OUTLIER -115.19 65.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.666 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -36.69 -106.87 0.01 OUTLIER Glycine 0 C--N 1.352 1.471 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.569 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.73 144.98 0.07 OUTLIER Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -178.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -146.38 143.57 20.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.782 -179.579 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -111.87 137.2 50.15 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.703 0.287 . . . . 0.0 110.271 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -53.98 152.48 5.72 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.18 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 28.5 m -113.77 133.27 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.549 0.69 . . . . 0.0 111.663 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -150.07 138.59 20.66 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.804 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.517 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 68.0 t60 -157.31 175.5 13.93 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.517 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 87.9 mt-30 -142.86 176.44 9.07 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.952 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -166.23 113.47 0.88 Allowed 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.268 0.556 . . . . 0.0 111.024 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -121.56 125.97 48.02 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.607 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.6 t -134.43 133.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -141.78 133.4 26.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.124 0.488 . . . . 0.0 111.41 -179.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -134.49 128.56 33.64 Favored 'General case' 0 C--O 1.231 0.088 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.74 148.5 25.48 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.566 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.462 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 98.5 mt-10 -91.26 152.57 20.45 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.484 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -141.55 123.32 15.24 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.459 0.647 . . . . 0.0 112.036 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.533 ' O ' ' N ' ' L' ' 26' ' ' SER . 94.7 t -94.58 121.04 44.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.0 -88.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.082 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.533 ' N ' ' O ' ' L' ' 24' ' ' VAL . 11.9 p -90.97 179.72 5.68 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -61.1 170.44 1.63 Allowed 'General case' 0 C--N 1.314 -0.945 0 C-N-CA 118.491 -1.284 . . . . 0.0 109.612 -179.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -53.88 111.94 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.198 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.474 ' H ' ' HB3' ' K' ' 27' ' ' ASN . . . -71.45 92.23 0.5 Allowed Glycine 0 N--CA 1.47 0.923 0 C-N-CA 118.64 -1.743 . . . . 0.0 110.058 176.028 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.541 ' HB2' ' O ' ' K' ' 28' ' ' LYS . . . -174.83 163.29 3.35 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 102.386 -3.19 . . . . 0.0 102.386 178.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.504 ' CG1' HG23 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -143.86 120.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 116.927 -1.909 . . . . 0.0 113.207 -177.464 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.435 HG22 ' O ' ' L' ' 32' ' ' ILE . 3.4 mt -102.78 111.72 33.57 Favored 'Isoleucine or valine' 0 C--N 1.343 0.325 0 CA-C-N 113.466 -1.697 . . . . 0.0 107.372 177.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . 0.466 ' CA ' ' HG3' ' F' ' 35' ' ' MET . . . -110.06 83.94 0.35 Allowed Glycine 0 CA--C 1.493 -1.318 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 177.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.692 HD21 HG13 ' L' ' 36' ' ' VAL . 7.3 tt -122.27 117.08 25.28 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.499 ' N ' HD23 ' L' ' 34' ' ' LEU . 65.4 ttp -106.05 130.27 53.99 Favored 'General case' 0 CA--C 1.505 -0.784 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.333 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.692 HG13 HD21 ' L' ' 34' ' ' LEU . 0.0 OUTLIER -132.2 79.97 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.629 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.18 103.24 0.76 Allowed Glycine 0 C--N 1.348 1.224 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.96 152.98 21.24 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -132.14 157.81 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.751 -179.599 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.2 m . . . . . 0 N--CA 1.466 0.347 0 N-CA-C 109.778 -0.452 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -138.24 163.19 32.38 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.944 0.402 . . . . 0.0 110.866 -178.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.629 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -82.11 170.82 15.05 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.551 -179.844 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -148.89 174.76 11.9 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.01 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -153.4 124.54 7.46 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.074 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.0 mt -121.12 114.26 21.19 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.1 t -131.26 129.34 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 CA-C-O 121.403 0.621 . . . . 0.0 112.354 -178.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.595 ' CG ' ' CE1' ' B' ' 19' ' ' PHE . 3.5 m-85 -108.85 111.63 23.45 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 50.1 p90 -131.59 126.32 34.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 118.797 0.726 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.12 133.14 42.51 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-O 121.461 0.648 . . . . 0.0 112.405 -178.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.496 ' N ' ' OE1' ' A' ' 22' ' ' GLU . 36.5 mp0 -142.97 156.52 44.88 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.457 ' O ' ' CG1' ' B' ' 24' ' ' VAL . 34.5 t70 -87.89 111.72 21.74 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 120.165 -0.614 . . . . 0.0 112.387 -178.445 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.598 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.5 t -113.8 131.2 66.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.093 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.96 81.97 0.0 OUTLIER Glycine 0 CA--C 1.53 1.022 0 O-C-N 123.315 0.384 . . . . 0.0 112.427 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.598 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.4 p -91.19 -179.3 5.39 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.538 ' O ' ' O ' ' A' ' 28' ' ' LYS . 58.8 t30 -62.64 -178.03 0.18 Allowed 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.538 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.2 mttt -48.48 -110.51 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.746 0.784 . . . . 0.0 110.604 -179.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -84.2 94.97 1.88 Allowed Glycine 0 N--CA 1.459 0.23 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 176.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.07 161.32 16.61 Favored 'General case' 0 C--N 1.351 0.636 0 C-N-CA 115.473 -2.491 . . . . 0.0 110.776 -177.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.458 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.7 OUTLIER -153.4 121.7 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 CA-C-N 112.545 -2.116 . . . . 0.0 110.667 -172.596 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' G' ' 35' ' ' MET . 78.6 mt -129.2 120.16 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 120.381 -0.527 . . . . 0.0 110.72 178.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.62 122.31 3.54 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 16.0 tp -127.75 141.96 51.44 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 117.241 0.52 . . . . 0.0 111.355 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.57 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 13.3 ttt -131.32 129.29 41.25 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.315 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 16.4 t -131.4 71.66 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 N-CA-C 112.315 0.487 . . . . 0.0 112.315 178.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.549 ' O ' HD12 ' G' ' 31' ' ' ILE . . . -125.75 96.51 0.49 Allowed Glycine 0 C--N 1.344 1.024 0 N-CA-C 108.799 -1.72 . . . . 0.0 108.799 177.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.86 172.25 42.56 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.466 0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 110.761 179.834 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p . . . . . 0 N--CA 1.464 0.239 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 -142.18 105.98 4.71 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.659 0.266 . . . . 0.0 110.923 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -160.45 178.77 9.22 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-O 121.109 0.481 . . . . 0.0 110.283 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -133.44 -179.14 5.33 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.97 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -146.74 132.38 18.84 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.879 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.9 tp -125.39 115.9 21.02 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 120.701 -0.4 . . . . 0.0 112.01 -177.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 74.9 t -125.39 123.8 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 120.866 0.365 . . . . 0.0 110.912 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.595 ' CE1' ' CG ' ' A' ' 19' ' ' PHE . 13.3 m-85 -116.83 118.98 33.97 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.73 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.7 t80 -134.11 125.4 27.91 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.99 133.71 33.98 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -178.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -153.15 176.76 11.57 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -153.35 134.69 14.22 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.913 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.457 ' CG1' ' O ' ' A' ' 23' ' ' ASP . 2.8 p -109.09 112.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 33.09 88.57 0.01 OUTLIER Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -177.288 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -46.96 170.86 0.01 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.17 -1.015 . . . . 0.0 113.232 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.559 ' H ' ' HD2' ' C' ' 28' ' ' LYS . 78.3 m-20 -129.67 -179.94 5.47 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 114.316 -1.311 . . . . 0.0 108.62 176.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.498 ' O ' ' O ' ' B' ' 27' ' ' ASN . 98.1 mttt -26.71 -103.3 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 179.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.85 98.43 0.18 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.091 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.42 ' H ' ' HE3' ' C' ' 28' ' ' LYS . . . -74.82 158.72 32.96 Favored 'General case' 0 C--O 1.25 1.088 0 C-N-CA 117.086 -1.846 . . . . 0.0 111.26 177.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.458 ' O ' ' HA ' ' A' ' 31' ' ' ILE . 0.1 OUTLIER -153.68 112.99 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.556 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.491 ' O ' ' SD ' ' H' ' 35' ' ' MET . 42.7 pt -136.02 150.36 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.255 -177.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.506 ' O ' HD23 ' B' ' 34' ' ' LEU . . . -166.18 150.29 17.4 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 119.835 -1.174 . . . . 0.0 112.332 -179.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.628 HD12 HD11 ' C' ' 34' ' ' LEU . 6.0 mt -139.17 143.43 38.14 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 120.9 0.381 . . . . 0.0 110.586 179.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.63 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 5.2 ttt -120.22 122.09 40.16 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.2 t -138.14 71.83 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.814 ' O ' HG21 ' H' ' 31' ' ' ILE . . . -128.12 95.85 0.41 Allowed Glycine 0 C--N 1.343 0.969 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 177.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.33 179.44 18.69 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -179.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -123.75 136.12 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.982 0.42 . . . . 0.0 110.284 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.186 179.812 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -147.79 163.82 35.56 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . 0.515 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 56.7 mp0 -127.04 150.25 49.53 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.663 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.49 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 32.6 m -131.27 156.16 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.949 179.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 10.0 m-70 -150.98 150.43 30.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.995 -178.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 2.4 t60 -154.55 158.14 39.35 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 78.2 mt-30 -152.08 179.27 8.63 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 120.289 -0.565 . . . . 0.0 111.432 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -165.45 117.53 1.14 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.836 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.3 mt -115.81 114.78 25.22 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.79 140.92 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 119.426 -0.91 . . . . 0.0 113.163 -178.546 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.552 ' CE1' ' CD1' ' F' ' 34' ' ' LEU . 65.1 m-85 -124.28 125.11 43.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.541 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.0 t80 -130.61 117.21 19.19 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.24 136.15 46.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 120.559 -0.456 . . . . 0.0 111.641 -178.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -125.97 121.04 31.93 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.418 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' D' ' 24' ' ' VAL . 41.0 t0 -90.63 123.05 33.95 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.127 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.3 t -142.32 -111.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' C' ' 26' ' ' SER . . . -29.8 91.56 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 CA-C-N 116.145 -0.479 . . . . 0.0 112.747 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.545 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 12.8 p -61.18 179.15 0.21 Allowed 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 105.596 -2.001 . . . . 0.0 105.596 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.545 ' CB ' ' O ' ' C' ' 26' ' ' SER . 3.1 m120 91.17 -170.81 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -177.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.559 ' HD2' ' H ' ' B' ' 27' ' ' ASN . 84.3 tttt 40.59 -106.29 0.06 Allowed 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 114.803 1.408 . . . . 0.0 114.803 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.6 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . 92.95 91.91 1.51 Allowed Glycine 0 CA--C 1.497 -1.07 0 N-CA-C 107.483 -2.247 . . . . 0.0 107.483 -171.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.475 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -83.5 172.47 12.37 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.512 -176.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.475 ' CG1' ' C ' ' C' ' 30' ' ' ALA . 0.1 OUTLIER -152.72 124.19 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 C-N-CA 117.7 -1.6 . . . . 0.0 110.157 -175.909 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.7 tt -122.42 131.73 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.462 ' O ' ' CA ' ' B' ' 33' ' ' GLY . . . -122.44 109.13 1.36 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 179.131 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.764 ' H ' HD23 ' D' ' 34' ' ' LEU . 1.0 OUTLIER -137.07 126.57 25.12 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.45 -1.029 . . . . 0.0 112.258 -178.402 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.666 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 14.2 ttp -110.58 121.8 46.2 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 114.388 -1.278 . . . . 0.0 109.945 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.463 HG13 ' CD2' ' C' ' 34' ' ' LEU . 0.2 OUTLIER -139.87 70.46 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.732 179.847 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.53 -100.48 0.62 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.44 155.27 25.49 Favored Glycine 0 CA--C 1.521 0.434 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -136.06 162.09 36.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.761 0.315 . . . . 0.0 110.213 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.8 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.721 -179.699 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.467 0.385 0 N-CA-C 110.787 -0.079 . . . . 0.0 110.787 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 73.9 m-70 -128.62 102.04 6.42 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.534 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 6.7 m170 -95.23 158.15 15.59 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 121.904 0.859 . . . . 0.0 111.162 -179.179 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.554 HE22 ' NE2' ' C' ' 15' ' ' GLN . 99.7 mm-40 -152.61 171.34 18.31 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 114.023 -1.444 . . . . 0.0 107.905 178.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -174.1 128.67 0.37 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 121.014 -0.275 . . . . 0.0 110.275 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.474 HD21 HG11 ' F' ' 36' ' ' VAL . 8.8 mt -120.74 119.46 32.83 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 120.451 -0.5 . . . . 0.0 111.103 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -128.99 119.47 49.43 Favored 'Isoleucine or valine' 0 C--N 1.341 0.201 0 C-N-CA 120.636 -0.426 . . . . 0.0 111.359 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -113.03 116.66 30.28 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' OE2' ' D' ' 22' ' ' GLU . 9.0 t80 -129.5 119.4 23.66 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.13 0.423 . . . . 0.0 110.152 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.76 127.58 43.84 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 78.6 mm-40 -121.49 112.31 18.36 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 179.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 24' ' ' VAL . 19.9 t0 -84.35 97.34 9.41 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.622 ' O ' ' N ' ' D' ' 26' ' ' SER . 14.0 t -103.61 168.73 2.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.607 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.495 ' N ' ' CG1' ' D' ' 24' ' ' VAL . . . 39.36 -78.31 0.0 OUTLIER Glycine 0 CA--C 1.527 0.783 0 CA-C-O 119.448 -0.64 . . . . 0.0 112.631 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.622 ' N ' ' O ' ' D' ' 24' ' ' VAL . 1.4 p 170.98 -170.83 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 117.895 0.848 . . . . 0.0 111.552 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.592 ' O ' ' O ' ' D' ' 26' ' ' SER . 20.5 m-80 -18.68 -172.11 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -179.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.554 ' H ' ' HD3' ' E' ' 28' ' ' LYS . 86.0 tttt 127.2 104.46 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 111.217 -2.719 . . . . 0.0 110.48 177.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.6 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -59.9 96.28 0.08 OUTLIER Glycine 0 CA--C 1.491 -1.438 0 CA-C-O 118.337 -1.257 . . . . 0.0 110.559 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.464 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . -117.61 150.36 39.15 Favored 'General case' 0 CA--C 1.467 -2.224 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 174.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.464 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 0.3 OUTLIER -150.51 122.03 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 118.049 -1.461 . . . . 0.0 110.278 -171.973 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.415 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.1 OUTLIER -105.87 119.01 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 114.187 -1.369 . . . . 0.0 110.375 -179.091 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.623 ' O ' HD23 ' D' ' 34' ' ' LEU . . . -123.86 101.55 0.69 Allowed Glycine 0 N--CA 1.464 0.554 0 N-CA-C 108.093 -2.003 . . . . 0.0 108.093 178.598 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.764 HD23 ' H ' ' C' ' 34' ' ' LEU . 16.8 mt -139.09 152.03 47.19 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.378 -0.929 . . . . 0.0 112.326 -176.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.591 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 35.2 ttp -126.36 118.16 24.46 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 176.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 40.1 t -127.06 70.22 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.57 -102.62 2.75 Favored Glycine 0 C--N 1.36 1.884 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.422 ' H ' HG21 ' J' ' 31' ' ' ILE . . . 77.73 170.21 34.72 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -140.29 140.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.854 0.359 . . . . 0.0 110.232 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.43 -179.824 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.434 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -146.26 162.09 38.86 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.897 0.379 . . . . 0.0 110.458 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.533 ' N ' ' OE1' ' E' ' 11' ' ' GLU . 56.1 mp0 -130.91 144.16 51.26 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.587 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.52 HG13 ' H ' ' D' ' 13' ' ' HIS . 46.9 t -115.65 131.63 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 179.524 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' D' ' 13' ' ' HIS . 85.9 m-70 -109.99 160.56 16.32 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 118.532 0.605 . . . . 0.0 111.949 -178.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.539 ' CE1' ' O ' ' D' ' 13' ' ' HIS . 98.0 m-70 -152.14 174.44 13.72 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.279 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mm-40 -119.75 -171.02 2.05 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -97.77 175.72 6.07 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 122.504 1.145 . . . . 0.0 113.945 -176.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.1 tt -120.81 121.47 38.24 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 113.407 -1.724 . . . . 0.0 106.986 178.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.57 138.66 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-O 121.524 0.678 . . . . 0.0 112.616 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -124.21 124.51 42.62 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.578 -1.192 . . . . 0.0 109.007 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -131.2 122.55 26.77 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.86 127.87 42.72 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 120.861 0.362 . . . . 0.0 111.025 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 80.1 tt0 -92.91 144.48 25.23 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.814 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.612 ' O ' ' O ' ' E' ' 24' ' ' VAL . 41.5 p-10 -71.21 -122.34 0.0 OUTLIER 'General case' 0 C--O 1.218 -0.562 0 CA-C-N 116.304 -0.407 . . . . 0.0 109.982 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.612 ' O ' ' O ' ' E' ' 23' ' ' ASP . 87.3 t 19.84 122.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.58 -84.19 0.09 OUTLIER Glycine 0 CA--C 1.522 0.514 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.69 177.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.529 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.4 p 154.18 -179.23 0.0 OUTLIER 'General case' 0 C--N 1.345 0.382 0 CA-C-O 122.58 1.181 . . . . 0.0 111.006 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.426 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 1.8 m-20 -52.63 -178.94 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 112.44 -2.163 . . . . 0.0 112.643 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.554 ' HD3' ' H ' ' D' ' 28' ' ' LYS . 0.0 OUTLIER 60.66 113.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 123.017 1.389 . . . . 0.0 114.385 -179.521 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -88.26 96.22 2.17 Favored Glycine 0 C--O 1.224 -0.522 0 CA-C-N 111.687 -2.506 . . . . 0.0 112.727 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -63.95 175.44 1.19 Allowed 'General case' 0 C--O 1.24 0.596 0 CA-C-N 119.882 1.841 . . . . 0.0 107.461 -178.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.428 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.1 OUTLIER -152.39 129.65 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.421 0 C-N-CA 116.736 -1.986 . . . . 0.0 114.606 -172.451 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mt -107.67 121.04 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.072 177.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.3 104.59 0.82 Allowed Glycine 0 C--N 1.332 0.332 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.775 HD12 ' N ' ' E' ' 35' ' ' MET . 3.4 tp -150.31 135.3 17.73 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.461 1.124 . . . . 0.0 112.584 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.775 ' N ' HD12 ' E' ' 34' ' ' LEU . 33.8 ttp -102.26 126.3 49.22 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.762 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.39 70.94 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.9 114.08 5.88 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.05 -139.49 0.14 Allowed Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -119.01 136.7 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 120.755 0.312 . . . . 0.0 110.527 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 20.6 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.408 179.824 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.52 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 58.3 t . . . . . 0 N--CA 1.468 0.466 0 CA-C-O 120.841 0.353 . . . . 0.0 110.44 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.52 ' CG ' ' O ' ' F' ' 12' ' ' VAL . 78.9 m80 -161.28 99.39 1.18 Allowed 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.817 179.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 92.1 m-70 -153.74 163.99 39.08 Favored 'General case' 0 N--CA 1.447 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 109.9 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -158.27 177.43 11.28 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.792 179.022 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -142.53 139.83 31.58 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 121.16 0.505 . . . . 0.0 110.574 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 39.5 mt -113.33 127.94 56.3 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.17 138.26 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.535 0.683 . . . . 0.0 111.694 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.0 p90 -132.47 131.03 41.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.765 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -136.44 130.15 32.22 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.99 144.31 25.75 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.633 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.467 ' HB2' ' H ' ' E' ' 23' ' ' ASP . 73.0 mm-40 -99.27 161.27 13.71 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 59.9 m-20 . . . . . 0 N--CA 1.465 0.292 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.531 -179.213 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 23.8 tttm . . . . . 0 CA--C 1.536 0.418 0 CA-C-O 121.588 0.708 . . . . 0.0 111.89 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 45.82 91.36 0.01 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 114.632 -1.167 . . . . 0.0 114.577 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.429 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -103.15 176.41 5.16 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 100.204 -3.998 . . . . 0.0 100.204 172.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.459 HG22 ' SD ' ' L' ' 35' ' ' MET . 0.1 OUTLIER -149.76 122.38 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 C-N-CA 115.986 -2.285 . . . . 0.0 112.566 -175.053 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -104.81 111.38 34.1 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.441 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.304 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.01 89.98 0.56 Allowed Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 107.102 -2.399 . . . . 0.0 107.102 175.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.659 HD21 HG13 ' F' ' 36' ' ' VAL . 9.2 tt -126.86 127.84 45.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 39.5 ttp -106.04 129.47 54.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.59 -178.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.659 HG13 HD21 ' F' ' 34' ' ' LEU . 0.0 OUTLIER -132.55 78.48 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.08 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.05 104.35 1.32 Allowed Glycine 0 C--N 1.344 1.019 0 N-CA-C 111.269 -0.732 . . . . 0.0 111.269 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.64 -164.84 33.99 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 63.1 t -120.54 135.65 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.887 0.375 . . . . 0.0 110.178 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 37.9 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.574 179.952 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.83 138.84 49.73 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.719 0.295 . . . . 0.0 110.564 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' G' ' 11' ' ' GLU . 57.8 mp0 -76.92 134.1 39.04 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.493 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 21.9 m -137.7 165.82 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.857 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 64.6 m80 -154.99 135.14 13.09 Favored 'General case' 0 C--O 1.222 -0.371 0 C-N-CA 120.241 -0.584 . . . . 0.0 111.169 179.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -156.74 165.7 35.48 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 96.3 mm-40 -150.59 177.47 10.0 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.865 179.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -158.61 129.68 6.32 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.056 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -133.86 128.93 35.66 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 121.097 0.475 . . . . 0.0 110.421 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.17 130.76 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.38 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.435 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 2.6 t80 -116.65 114.31 23.89 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.532 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 54.5 p90 -124.19 121.14 34.3 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.68 125.3 50.44 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.112 0.482 . . . . 0.0 111.222 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -161.44 166.51 27.14 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' ND2' ' H' ' 27' ' ' ASN . 63.3 t0 -79.0 114.84 18.28 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.075 -0.65 . . . . 0.0 111.077 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.0 p -88.57 130.83 37.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.82 82.43 0.0 OUTLIER Glycine 0 CA--C 1.531 1.058 0 CA-C-N 116.055 -0.52 . . . . 0.0 112.803 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.535 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.3 m -132.23 162.47 30.88 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 178.23 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.531 ' O ' ' O ' ' G' ' 26' ' ' SER . 80.6 m-20 -38.74 175.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.241 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -73.62 111.15 8.49 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.38 93.97 0.19 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.31 162.06 13.2 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -146.72 104.02 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -174.631 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.508 ' O ' ' SD ' ' B' ' 35' ' ' MET . 85.5 mt -126.89 127.93 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.242 0.544 . . . . 0.0 111.126 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.57 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -133.15 113.22 1.2 Allowed Glycine 0 CA--C 1.517 0.158 0 N-CA-C 108.934 -1.666 . . . . 0.0 108.934 178.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -136.69 147.87 47.05 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 122.221 1.01 . . . . 0.0 112.726 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 49.4 ttp -131.24 132.04 44.35 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.734 -1.575 . . . . 0.0 109.591 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.1 t -99.86 72.01 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.22 -96.45 0.01 OUTLIER Glycine 0 N--CA 1.438 -1.17 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.26 -172.11 33.47 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.43 ' O ' ' OXT' ' G' ' 40' ' ' VAL . 2.7 p -139.2 142.92 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . 0.47 ' O ' HG12 ' G' ' 40' ' ' VAL . 53.7 t . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.014 -0.993 . . . . 0.0 110.069 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.49 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -115.21 140.62 48.94 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.671 0.272 . . . . 0.0 110.476 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -81.23 142.33 33.27 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.452 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.421 ' O ' HG23 ' H' ' 12' ' ' VAL . 6.2 m -121.76 131.82 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -118.93 140.62 49.69 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.733 0.301 . . . . 0.0 111.599 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.47 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 45.1 m-70 -142.31 160.61 39.92 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.345 0.593 . . . . 0.0 109.812 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.47 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 98.5 mm-40 -149.1 172.45 14.78 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.128 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -159.48 117.37 2.74 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.062 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -119.26 119.91 35.45 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -125.5 126.73 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.837 0.351 . . . . 0.0 110.534 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.647 ' CE1' HD11 ' K' ' 34' ' ' LEU . 1.4 t80 -123.06 118.77 28.5 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 72.1 t80 -131.23 127.91 38.83 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.756 0.312 . . . . 0.0 111.288 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.7 123.96 30.47 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-O 120.886 0.374 . . . . 0.0 111.557 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -165.64 140.87 4.95 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 45.4 p30 -100.13 140.53 34.23 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.453 0.644 . . . . 0.0 112.509 -178.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.408 ' O ' ' C ' ' H' ' 25' ' ' GLY . 92.5 t -108.4 111.12 34.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' H' ' 24' ' ' VAL . . . 33.63 90.97 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 -177.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -46.45 152.74 0.42 Allowed 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.169 -1.015 . . . . 0.0 113.538 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.537 ' O ' ' O ' ' H' ' 28' ' ' LYS . 16.8 p30 -128.19 -179.97 5.29 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 114.189 -1.369 . . . . 0.0 107.823 174.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.537 ' O ' ' O ' ' H' ' 27' ' ' ASN . 84.4 tttt -27.51 -102.71 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.727 0.694 . . . . 0.0 111.885 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.413 ' CA ' ' O ' ' I' ' 29' ' ' GLY . . . -149.96 100.36 0.21 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 175.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.415 ' H ' ' CE ' ' I' ' 28' ' ' LYS . . . -65.56 155.45 35.7 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 117.064 -1.854 . . . . 0.0 108.336 177.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.814 HG21 ' O ' ' B' ' 37' ' ' GLY . 2.2 mt -144.45 108.17 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -128.35 129.71 69.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.63 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.68 119.5 3.68 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 108.314 -1.915 . . . . 0.0 108.314 177.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.752 ' HB2' HD12 ' I' ' 34' ' ' LEU . 95.1 mt -135.31 129.45 33.51 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -177.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.491 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 24.0 ttp -129.55 131.87 46.69 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.338 178.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.631 ' CG1' HG12 ' I' ' 36' ' ' VAL . 2.4 p -149.47 75.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 119.999 -0.68 . . . . 0.0 112.325 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.74 -95.56 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 178.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -165.08 37.72 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.77 141.78 41.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.893 0.377 . . . . 0.0 110.353 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 27.9 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.645 -179.996 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.636 ' CE1' ' ND1' ' J' ' 13' ' ' HIS . 14.9 p-80 -156.24 156.19 33.67 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.767 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' I' ' 15' ' ' GLN . 11.1 m170 -133.37 161.19 35.2 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.696 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' I' ' 14' ' ' HIS . 43.6 mm-40 -142.59 171.71 13.68 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.521 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -159.51 120.49 3.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.103 178.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 tt -125.3 124.38 41.5 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 120.803 0.335 . . . . 0.0 110.48 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.59 125.32 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.408 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.541 ' CZ ' HD13 ' K' ' 34' ' ' LEU . 12.2 t80 -118.97 113.24 20.68 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.552 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 47.6 t80 -126.45 116.82 21.73 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 121.076 0.465 . . . . 0.0 111.058 -178.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.71 126.71 47.02 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.244 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -146.65 103.86 3.69 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.077 0.465 . . . . 0.0 110.818 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.434 ' O ' HG12 ' J' ' 24' ' ' VAL . 99.4 m-20 -95.31 122.82 38.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.496 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.48 HG23 ' H ' ' I' ' 25' ' ' GLY . 3.6 m -143.5 -111.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.854 -178.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.48 ' H ' HG23 ' I' ' 24' ' ' VAL . . . 27.39 -90.2 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.433 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.826 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.1 p 171.54 171.0 0.09 Allowed 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.826 ' O ' ' O ' ' I' ' 26' ' ' SER . 44.5 p-10 -9.51 179.27 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 O-C-N 125.869 1.981 . . . . 0.0 115.745 178.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.564 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 85.8 tttt 129.64 104.69 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 114.052 1.13 . . . . 0.0 114.052 175.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.413 ' O ' ' CA ' ' H' ' 29' ' ' GLY . . . -58.46 96.81 0.07 OUTLIER Glycine 0 C--O 1.225 -0.422 0 N-CA-C 106.711 -2.556 . . . . 0.0 106.711 171.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.891 ' C ' HD13 ' I' ' 31' ' ' ILE . . . -120.88 146.04 47.01 Favored 'General case' 0 CA--C 1.48 -1.729 0 N-CA-C 105.112 -2.181 . . . . 0.0 105.112 178.144 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.891 HD13 ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -137.84 108.04 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 C-N-CA 119.343 -0.943 . . . . 0.0 111.088 -173.854 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -111.65 112.5 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 175.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.666 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.05 108.74 1.69 Allowed Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 177.029 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.752 HD12 ' HB2' ' H' ' 34' ' ' LEU . 0.9 OUTLIER -142.39 144.0 32.94 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-O 122.673 1.225 . . . . 0.0 113.352 -177.082 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.445 ' N ' ' HG ' ' I' ' 34' ' ' LEU . 12.7 tmm? -127.42 117.95 23.14 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 113.196 -1.82 . . . . 0.0 109.626 177.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.747 HG13 HD21 ' I' ' 34' ' ' LEU . 15.7 m -121.91 73.94 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.822 179.235 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.36 103.48 2.99 Favored Glycine 0 C--N 1.36 1.883 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 175.88 43.96 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -144.94 151.45 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 120.891 0.376 . . . . 0.0 110.774 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.412 ' O ' HG13 ' I' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.567 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.447 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -111.1 132.55 54.18 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.781 0.324 . . . . 0.0 110.266 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' K' ' 11' ' ' GLU . 17.1 pt-20 -158.56 138.26 11.93 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.053 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -150.23 153.4 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.636 ' ND1' ' CE1' ' I' ' 13' ' ' HIS . 50.5 m-70 -144.21 116.05 8.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 118.966 0.803 . . . . 0.0 110.966 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.64 ' NE2' ' CG ' ' K' ' 13' ' ' HIS . 44.3 m80 -122.0 159.88 26.06 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.408 HE21 ' HG3' ' I' ' 15' ' ' GLN . 63.2 mt-30 -158.12 177.06 11.72 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.412 178.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 43.5 tttp -169.43 123.32 0.79 Allowed 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.427 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 8.8 tt -121.21 121.87 38.73 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.634 0.254 . . . . 0.0 110.328 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 79.2 t -124.28 127.48 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.493 ' CZ ' ' CD1' ' I' ' 19' ' ' PHE . 5.4 t80 -126.53 121.35 32.04 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.907 0.384 . . . . 0.0 110.72 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.552 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 50.7 t80 -128.93 127.18 41.24 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.003 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.34 137.53 30.61 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -142.58 106.0 4.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.131 -0.941 . . . . 0.0 109.272 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.448 ' OD1' HD11 ' L' ' 32' ' ' ILE . 10.3 m-20 -96.59 108.91 21.59 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.049 -179.075 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.434 HG12 ' O ' ' I' ' 23' ' ' ASP . 2.1 p -46.1 140.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.256 178.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.626 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -86.12 84.85 1.56 Allowed Glycine 0 CA--C 1.531 1.091 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.423 -178.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.59 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.3 t 162.36 160.41 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 CA-C-O 121.212 0.53 . . . . 0.0 110.12 176.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.59 ' O ' ' O ' ' J' ' 26' ' ' SER . 7.2 t-20 -29.99 178.99 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.517 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 42.6 tttp 128.45 104.85 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 113.052 -1.886 . . . . 0.0 112.899 175.189 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.84 95.43 0.05 OUTLIER Glycine 0 N--CA 1.462 0.429 0 CA-C-N 113.057 -1.883 . . . . 0.0 112.782 173.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.739 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -140.21 141.06 35.97 Favored 'General case' 0 CA--C 1.49 -1.364 0 CA-C-N 120.751 2.275 . . . . 0.0 107.353 174.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.739 HD13 ' C ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -137.73 106.94 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.894 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.468 HG22 ' O ' ' J' ' 32' ' ' ILE . 0.1 OUTLIER -109.75 110.84 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.018 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.591 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -123.78 98.82 0.6 Allowed Glycine 0 N--CA 1.463 0.436 0 N-CA-C 107.312 -2.315 . . . . 0.0 107.312 178.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.667 HD23 HD22 ' I' ' 34' ' ' LEU . 5.5 mp -131.07 140.75 50.09 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-O 122.134 0.969 . . . . 0.0 111.786 -177.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.416 ' SD ' HG22 ' D' ' 31' ' ' ILE . 11.5 tmm? -124.18 121.44 35.11 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.513 179.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' J' ' 37' ' ' GLY . 0.1 OUTLIER -110.43 73.74 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.178 -178.75 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -24.9 -101.18 0.01 OUTLIER Glycine 0 C--N 1.355 1.62 0 CA-C-N 116.198 -0.456 . . . . 0.0 112.851 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 131.24 -174.54 19.94 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -133.7 160.44 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 110.357 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.548 -179.934 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.74 133.35 51.55 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 110.267 -0.271 . . . . 0.0 110.267 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' J' ' 11' ' ' GLU . 81.4 tt0 -156.18 141.18 17.27 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-O 120.944 0.402 . . . . 0.0 110.711 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.34 154.57 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.64 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 22.3 m-70 -125.64 144.56 50.54 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 118.608 0.64 . . . . 0.0 110.725 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.522 ' CG ' ' H ' ' K' ' 15' ' ' GLN . 30.9 t-80 -86.71 -178.25 6.31 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.499 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.522 ' H ' ' CG ' ' K' ' 14' ' ' HIS . 86.5 mt-30 -84.85 172.69 11.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.148 -178.522 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -146.25 133.01 19.99 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 114.825 -1.08 . . . . 0.0 108.575 179.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -131.42 131.57 43.7 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.225 0.536 . . . . 0.0 112.274 -178.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.6 t -126.77 127.7 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.836 178.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -128.86 128.2 43.39 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.561 0.22 . . . . 0.0 110.795 -178.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.435 ' CE2' ' CD2' ' L' ' 20' ' ' PHE . 8.8 t80 -135.76 123.43 22.33 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-O 120.906 0.384 . . . . 0.0 110.517 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.51 129.33 44.39 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.113 0.483 . . . . 0.0 111.312 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.094 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.492 ' H ' ' HB3' ' L' ' 22' ' ' GLU . 26.3 t70 -91.85 134.25 34.93 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.429 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.626 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 44.0 t -109.19 112.46 40.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.27 -91.29 0.01 OUTLIER Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.21 -0.905 . . . . 0.0 112.783 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.504 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.8 m -162.86 -161.11 0.68 Allowed 'General case' 0 N--CA 1.447 -0.615 0 CA-C-O 122.579 1.181 . . . . 0.0 112.867 -179.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.572 ' CG ' ' H ' ' K' ' 28' ' ' LYS . 4.4 t-20 30.08 -173.28 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 111.874 -2.421 . . . . 0.0 115.401 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.572 ' H ' ' CG ' ' K' ' 27' ' ' ASN . 82.3 tttt 103.56 110.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 127.136 2.174 . . . . 0.0 109.184 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -60.16 -95.16 0.01 OUTLIER Glycine 0 CA--C 1.535 1.3 0 C-N-CA 115.212 -3.375 . . . . 0.0 110.535 175.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.521 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 69.63 151.21 0.09 Allowed 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 174.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.521 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -149.25 117.88 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-N 120.974 1.716 . . . . 0.0 111.508 178.075 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.413 ' N ' ' HE1' ' F' ' 35' ' ' MET . 4.6 mt -105.38 111.85 36.44 Favored 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 175.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.585 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.84 96.77 0.75 Allowed Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 106.315 -2.714 . . . . 0.0 106.315 177.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.647 HD11 ' CE1' ' H' ' 19' ' ' PHE . 0.3 OUTLIER -120.93 120.37 35.29 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-O 122.304 1.05 . . . . 0.0 110.201 -177.971 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -109.53 114.08 27.42 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.412 -1.722 . . . . 0.0 107.965 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.18 78.38 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.829 -177.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.48 105.43 0.97 Allowed Glycine 0 C--N 1.352 1.472 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.71 -144.01 4.35 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -106.79 134.7 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 20.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.021 -0.99 . . . . 0.0 111.073 -179.579 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.542 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -84.52 139.9 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.723 0.297 . . . . 0.0 110.855 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -121.52 131.03 53.91 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.971 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.98 156.79 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.179 0.514 . . . . 0.0 111.252 -179.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -158.19 163.21 37.74 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.787 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 41.9 m80 -136.74 169.8 17.13 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -148.08 176.29 10.32 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.174 0.512 . . . . 0.0 111.304 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 ttpt -170.59 111.46 0.39 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.983 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 72.0 mt -121.22 111.37 17.3 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 70.4 t -126.64 129.95 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.7 p90 -136.94 125.28 23.3 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.299 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.435 ' CD2' ' CE2' ' K' ' 20' ' ' PHE . 79.4 t80 -136.8 131.57 33.5 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 121.123 0.487 . . . . 0.0 110.297 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.74 143.75 35.15 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.393 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.492 ' HB3' ' H ' ' K' ' 23' ' ' ASP . 51.8 tp10 -78.21 140.96 38.92 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -58.86 130.46 47.05 Favored 'General case' 0 CA--C 1.518 -0.275 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.451 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.602 ' O ' HG13 ' L' ' 24' ' ' VAL . 14.7 p -116.12 114.84 47.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.279 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.443 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -28.28 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.47 0.927 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -88.45 -177.4 5.61 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 60.3 m-20 -60.29 179.62 0.14 Allowed 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.477 -176.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.551 ' HZ3' HG13 ' L' ' 32' ' ' ILE 0.251 69.1 tttt -57.45 111.36 1.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 -177.015 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -68.62 -97.71 0.04 OUTLIER Glycine 0 CA--C 1.499 -0.932 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.586 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -60.9 170.78 1.4 Allowed 'General case' 0 CA--C 1.511 -0.552 0 CA-C-N 120.844 2.322 . . . . 0.0 105.805 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.649 HD12 ' N ' ' L' ' 31' ' ' ILE . 0.1 OUTLIER -134.17 121.79 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 115.811 -2.356 . . . . 0.0 114.086 -174.327 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.551 HG13 ' HZ3' ' L' ' 28' ' ' LYS . 97.3 mt -106.41 116.07 49.36 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 176.261 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -106.29 96.73 1.17 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 105.71 -2.956 . . . . 0.0 105.71 176.708 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.456 HD23 HG22 ' L' ' 32' ' ' ILE . 1.2 pp -110.23 112.09 23.84 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.751 -0.725 . . . . 0.0 110.298 -177.493 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.459 ' SD ' HG22 ' F' ' 31' ' ' ILE . 8.6 tmm? -109.69 110.85 22.01 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 178.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' C ' ' L' ' 37' ' ' GLY . 3.3 m -126.93 77.42 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.681 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 22.29 -110.69 0.01 OUTLIER Glycine 0 C--N 1.356 1.654 0 O-C-N 123.106 0.254 . . . . 0.0 113.017 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.79 140.85 8.9 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -134.89 159.24 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.886 0.375 . . . . 0.0 110.46 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.128 -0.939 . . . . 0.0 110.764 -179.885 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 m . . . . . 0 N--CA 1.465 0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 111.846 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 5.4 p80 -97.15 -175.58 3.28 Favored 'General case' 0 CA--C 1.527 0.086 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.838 178.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.5 p-80 -89.85 164.98 14.39 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.44 0.638 . . . . 0.0 110.619 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 83.0 mt-30 -155.99 -178.2 7.13 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.684 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.611 ' C ' HD22 ' A' ' 17' ' ' LEU . 99.6 mttt -135.29 111.69 9.82 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.372 -0.232 . . . . 0.0 110.372 179.269 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.611 HD22 ' C ' ' A' ' 16' ' ' LYS . 4.3 mm? -117.81 127.8 54.24 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 120.792 0.33 . . . . 0.0 110.515 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 18' ' ' VAL . 5.8 m -133.04 128.39 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-O 121.149 0.5 . . . . 0.0 111.125 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.519 ' CZ ' HD23 ' C' ' 34' ' ' LEU . 75.0 t80 -122.69 116.13 23.27 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -147.08 153.84 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.343 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.0 133.81 43.62 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.209 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -167.49 92.21 0.38 Allowed 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 62.5 t0 -70.11 121.82 18.24 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -177.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.565 ' O ' HG23 ' A' ' 24' ' ' VAL . 26.1 m -105.98 121.72 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . 30.8 82.8 0.01 OUTLIER Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.847 -0.418 . . . . 0.0 112.255 178.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.519 ' OG ' ' ND2' ' B' ' 27' ' ' ASN . 19.9 p -95.8 175.65 6.43 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 118.059 0.93 . . . . 0.0 109.182 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' LYS . 20.1 p30 -61.93 -177.67 0.13 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 176.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.548 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.6 mttm -50.41 -110.85 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.846 0.832 . . . . 0.0 109.842 178.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.66 94.66 1.82 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 176.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.479 ' CB ' HD21 ' A' ' 27' ' ' ASN . . . -92.54 160.65 14.94 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 115.599 -2.441 . . . . 0.0 109.703 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.537 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.3 OUTLIER -154.31 119.68 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 114.0 -1.455 . . . . 0.0 109.878 -173.729 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.51 ' O ' ' SD ' ' G' ' 35' ' ' MET . 96.5 mt -119.44 112.45 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.103 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.21 106.64 1.45 Allowed Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 178.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.407 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 34.7 tp -149.11 147.19 28.19 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 118.124 0.962 . . . . 0.0 113.028 -178.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.511 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 53.5 ttp -141.43 146.35 36.42 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.2 t -128.89 79.61 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.949 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.51 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -96.99 97.85 2.06 Favored Glycine 0 C--N 1.338 0.681 0 N-CA-C 109.599 -1.401 . . . . 0.0 109.599 177.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.13 167.81 39.68 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.541 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m . . . . . 0 N--CA 1.465 0.293 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.405 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p . . . . . 0 N--CA 1.465 0.28 0 CA-C-O 120.747 0.308 . . . . 0.0 110.446 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -117.09 160.1 21.53 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.1 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 16.3 p-80 -77.34 171.94 14.08 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.432 ' H ' ' HA ' ' C' ' 15' ' ' GLN . 54.0 tt0 -149.48 176.0 11.0 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.558 ' NZ ' ' CG2' ' B' ' 18' ' ' VAL . 62.4 tttm -140.3 123.3 16.59 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.233 0.54 . . . . 0.0 111.407 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.1 mt -118.37 124.08 46.86 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.093 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.558 ' CG2' ' NZ ' ' B' ' 16' ' ' LYS . 93.7 t -119.56 121.45 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 C-N-CA 120.711 -0.395 . . . . 0.0 110.998 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 11.8 t80 -115.2 112.22 22.16 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -132.59 125.76 31.21 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.18 0.514 . . . . 0.0 112.238 -177.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.66 126.28 49.85 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -153.96 159.75 41.81 Favored 'General case' 0 C--N 1.348 0.512 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -121.46 123.06 41.15 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.535 0.607 . . . . 0.0 111.885 -178.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.17 120.88 55.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.18 84.11 0.01 OUTLIER Glycine 0 N--CA 1.471 0.986 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.445 179.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 4.3 p -45.88 167.61 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.519 ' ND2' ' OG ' ' A' ' 26' ' ' SER . 2.2 p30 -137.82 178.87 6.78 Favored 'General case' 0 C--O 1.203 -1.383 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 171.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.499 ' O ' ' O ' ' B' ' 27' ' ' ASN . 61.2 mttp -19.85 -103.13 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 CA-C-N 120.219 1.372 . . . . 0.0 113.338 176.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -142.62 99.94 0.24 Allowed Glycine 0 N--CA 1.485 1.962 0 N-CA-C 107.831 -2.108 . . . . 0.0 107.831 174.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.511 ' H ' ' CE ' ' C' ' 28' ' ' LYS . . . -70.6 156.55 39.3 Favored 'General case' 0 C--O 1.245 0.836 0 C-N-CA 117.064 -1.854 . . . . 0.0 109.399 177.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.537 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.2 OUTLIER -144.25 115.49 2.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.814 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.481 ' O ' ' SD ' ' H' ' 35' ' ' MET . 82.9 mt -121.13 119.62 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -177.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.51 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -125.37 117.15 2.87 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 177.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.72 ' O ' HD12 ' C' ' 34' ' ' LEU . 9.6 tt -148.8 154.67 39.87 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.532 -178.487 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 17.6 ttp -147.83 141.57 25.66 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 120.16 -0.616 . . . . 0.0 112.458 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' B' ' 37' ' ' GLY . 38.2 t -131.78 83.28 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.307 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.682 ' HA2' HG21 ' H' ' 31' ' ' ILE . . . -23.45 -93.71 0.01 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.818 -0.513 . . . . 0.0 111.818 177.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.88 179.16 40.33 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.404 HG22 ' N ' ' B' ' 40' ' ' VAL . 8.3 p -143.95 153.09 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.937 0.398 . . . . 0.0 110.821 -179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.404 ' N ' HG22 ' B' ' 39' ' ' VAL . 7.2 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.46 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -111.51 146.95 36.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 110.378 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -55.84 146.19 22.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.16 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.513 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 32.9 m -129.28 156.31 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.513 ' CD2' ' O ' ' C' ' 12' ' ' VAL . 48.2 m80 -158.01 151.71 23.75 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.405 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -87.39 -179.67 6.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.432 ' HA ' ' H ' ' B' ' 15' ' ' GLN . 13.1 pt20 -88.2 174.91 7.94 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.958 -179.374 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -123.85 138.77 54.44 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -141.62 131.65 24.62 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 120.422 -0.511 . . . . 0.0 111.764 -179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -126.55 130.42 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.307 0.575 . . . . 0.0 109.706 178.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.523 ' CE2' HD12 ' F' ' 34' ' ' LEU . 21.2 t80 -117.34 118.52 32.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.135 -178.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -130.35 114.9 16.18 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 118.147 0.43 . . . . 0.0 110.017 179.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.03 126.74 51.54 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.645 -0.422 . . . . 0.0 111.549 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -157.73 155.7 30.36 Favored 'General case' 0 C--O 1.226 -0.158 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.524 ' O ' ' NZ ' ' E' ' 28' ' ' LYS . 7.2 t0 -175.21 108.58 0.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 119.794 -0.762 . . . . 0.0 112.251 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 m -46.46 141.05 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 176.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -86.34 82.82 1.63 Allowed Glycine 0 N--CA 1.463 0.468 0 C-N-CA 118.471 -1.823 . . . . 0.0 110.159 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 50.7 p -100.48 -163.97 1.07 Allowed 'General case' 0 N--CA 1.439 -0.991 0 CA-C-O 122.432 1.11 . . . . 0.0 110.077 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.433 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 61.8 t30 -63.31 179.5 0.42 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.266 -1.788 . . . . 0.0 109.344 175.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.511 ' CE ' ' H ' ' B' ' 30' ' ' ALA . 41.5 tttt 55.35 111.08 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 118.424 2.75 . . . . 0.0 118.424 178.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -81.63 96.43 1.77 Allowed Glycine 0 CA--C 1.497 -1.088 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 171.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 163.67 22.1 Favored 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 116.22 -2.192 . . . . 0.0 108.278 -177.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.622 HG23 ' CG1' ' D' ' 31' ' ' ILE . 0.0 OUTLIER -139.86 108.06 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.013 -174.85 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.484 ' C ' ' SD ' ' I' ' 35' ' ' MET . 2.0 mt -106.78 117.9 53.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.406 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -122.96 94.25 0.51 Allowed Glycine 0 CA--C 1.523 0.577 0 N-CA-C 107.912 -2.075 . . . . 0.0 107.912 177.522 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.72 HD12 ' O ' ' B' ' 34' ' ' LEU . 22.7 tp -124.77 137.03 54.34 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.345 1.069 . . . . 0.0 112.048 -178.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' D' ' 35' ' ' MET . 11.3 mmm -110.97 116.38 31.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.835 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.498 HG13 HD11 ' C' ' 34' ' ' LEU . 2.6 m -142.88 63.45 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 C-N-CA 121.11 -0.236 . . . . 0.0 110.507 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.09 -110.31 0.79 Allowed Glycine 0 C--N 1.363 2.053 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.56 -175.2 34.03 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.92 158.69 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.602 -179.728 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p . . . . . 0 N--CA 1.466 0.365 0 CA-C-O 121.04 0.448 . . . . 0.0 111.54 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.448 ' NE2' ' OE2' ' E' ' 11' ' ' GLU . 86.8 m-70 -123.66 125.19 44.36 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.801 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.58 ' CG ' ' N ' ' D' ' 15' ' ' GLN . 82.5 t60 -136.94 166.84 22.71 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.163 0.506 . . . . 0.0 110.144 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.58 ' N ' ' CG ' ' D' ' 14' ' ' HIS . 51.9 tt0 -161.61 173.23 15.04 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.438 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.408 ' N ' ' HG2' ' D' ' 15' ' ' GLN . 65.1 tttp -160.92 110.12 1.65 Allowed 'General case' 0 C--O 1.235 0.307 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.95 179.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -122.0 115.82 23.21 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.911 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.4 t -114.35 115.61 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.572 ' CE1' HD13 ' F' ' 34' ' ' LEU . 0.8 OUTLIER -114.27 109.05 17.77 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -178.164 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -136.47 130.89 33.28 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.444 0.64 . . . . 0.0 111.621 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.427 ' CB ' ' CD1' ' F' ' 32' ' ' ILE . . . -144.83 145.09 31.47 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.352 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -132.67 102.96 5.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.751 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -79.26 112.54 16.59 Favored 'General case' 0 C--O 1.231 0.119 0 C-N-CA 118.099 -1.44 . . . . 0.0 107.631 179.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 89.6 t -60.92 130.38 24.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.694 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -68.74 86.35 0.21 Allowed Glycine 0 CA--C 1.538 1.489 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.618 177.517 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.4 OUTLIER 162.18 161.3 0.02 OUTLIER 'General case' 0 C--N 1.345 0.393 0 CA-C-N 119.267 1.533 . . . . 0.0 112.786 176.801 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.462 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 87.1 m-20 -34.07 -179.65 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 112.056 -2.338 . . . . 0.0 116.25 179.119 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' E' ' 29' ' ' GLY . 86.7 tttt 98.92 114.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 128.095 2.558 . . . . 0.0 113.576 176.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.447 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -73.39 92.1 0.66 Allowed Glycine 0 N--CA 1.473 1.132 0 CA-C-O 116.284 -2.398 . . . . 0.0 113.159 173.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.87 157.09 35.01 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 123.271 3.536 . . . . 0.0 109.197 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.622 ' CG1' HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -145.01 126.1 8.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.892 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.725 -177.216 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.518 ' C ' ' SD ' ' J' ' 35' ' ' MET . 2.1 mt -110.49 110.48 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.408 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -109.21 95.57 0.91 Allowed Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 178.35 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.49 HD13 ' O ' ' C' ' 34' ' ' LEU . 0.0 OUTLIER -122.07 120.97 35.87 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-O 121.578 0.704 . . . . 0.0 110.461 -178.395 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' C' ' 35' ' ' MET . 26.9 ttt -102.02 114.04 27.8 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 176.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.475 HG22 HD12 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -126.51 80.64 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.247 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.437 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.22 102.46 0.86 Allowed Glycine 0 C--N 1.353 1.475 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.88 -167.06 38.9 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 40' ' ' VAL . 53.9 t -123.07 136.89 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 39' ' ' VAL . 18.0 m . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.47 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -111.61 133.13 54.07 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.855 0.359 . . . . 0.0 110.95 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.448 ' OE2' ' NE2' ' D' ' 13' ' ' HIS . 39.1 tp10 -120.51 127.39 52.14 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.8 t -134.13 134.36 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 O-C-N 123.322 0.389 . . . . 0.0 110.466 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 58.0 m80 -119.47 133.64 55.59 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 120.884 0.373 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.474 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 85.2 t60 -143.3 165.41 27.55 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 178.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.474 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 81.8 mt-30 -154.94 179.16 9.39 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.359 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.35 108.13 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.692 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -126.99 121.93 33.06 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.025 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 77.4 t -125.88 127.53 71.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.746 0.307 . . . . 0.0 110.881 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -126.47 120.53 29.94 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.514 179.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -133.9 127.36 32.34 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.027 0.442 . . . . 0.0 110.263 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.29 128.42 41.51 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.341 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -110.56 167.69 10.02 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.345 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' E' ' 24' ' ' VAL . 14.3 t0 -173.11 -125.28 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.389 -177.144 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.519 ' N ' ' OD1' ' E' ' 23' ' ' ASP . 7.9 t 31.61 115.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -90.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 106.001 -2.84 . . . . 0.0 106.001 179.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.544 ' O ' ' O ' ' E' ' 27' ' ' ASN . 27.9 p -152.03 155.0 37.1 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 119.224 1.512 . . . . 0.0 109.067 172.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.544 ' O ' ' O ' ' E' ' 26' ' ' SER . 17.0 m120 -20.01 157.83 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 176.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.663 ' HB3' ' HB2' ' F' ' 30' ' ' ALA . 75.4 tttt -162.88 110.89 1.28 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.09 170.41 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.595 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -68.53 92.12 0.27 Allowed Glycine 0 C--O 1.218 -0.852 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 174.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.41 150.56 33.73 Favored 'General case' 0 CA--C 1.464 -2.345 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 175.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.426 ' HA ' ' O ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -151.24 117.24 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 C-N-CA 118.679 -1.208 . . . . 0.0 110.042 -172.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.56 112.99 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . 0.44 ' H ' ' HE1' ' J' ' 35' ' ' MET . . . -109.28 85.9 0.42 Allowed Glycine 0 CA--C 1.499 -0.963 0 N-CA-C 104.884 -3.286 . . . . 0.0 104.884 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.549 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 6.4 tt -130.31 134.05 46.91 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.787 0.803 . . . . 0.0 111.717 -177.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.7 ttm -122.91 125.34 45.15 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.484 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.58 ' CG2' HD21 ' F' ' 34' ' ' LEU . 0.0 OUTLIER -124.32 81.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.687 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.497 ' HA2' HD13 ' K' ' 31' ' ' ILE . . . 34.42 -101.66 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.681 -0.567 . . . . 0.0 111.681 178.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.94 -172.21 33.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.784 -0.927 . . . . 0.0 110.784 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.06 161.2 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.893 0.378 . . . . 0.0 110.595 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 8.8 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.362 179.788 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.401 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.3 p . . . . . 0 CA--C 1.52 -0.183 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.645 ' CG ' ' N ' ' F' ' 14' ' ' HIS . 46.4 t-80 -111.62 175.18 5.53 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.645 ' N ' ' CG ' ' F' ' 13' ' ' HIS . 98.1 m-70 -70.2 177.05 3.47 Favored 'General case' 0 N--CA 1.44 -0.936 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' E' ' 15' ' ' GLN . 57.7 mm-40 -133.26 179.19 6.35 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.278 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -151.29 106.06 3.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.21 0.528 . . . . 0.0 110.695 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 tt -127.81 121.58 30.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.182 179.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.51 129.93 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.532 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -120.1 128.1 53.15 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.577 179.133 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -142.37 130.14 21.62 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.973 0.416 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.53 141.02 26.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.474 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 74.4 tt0 -92.51 115.46 28.11 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 . . . . . 0 N--CA 1.462 0.126 0 CA-C-O 121.169 0.509 . . . . 0.0 111.317 -178.801 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 43.9 tttm . . . . . 0 N--CA 1.463 0.178 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.79 -99.33 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 177.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' E' ' 28' ' ' LYS . . . -80.37 170.95 15.69 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 103.356 -2.831 . . . . 0.0 103.356 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' E' ' 31' ' ' ILE . 0.0 OUTLIER -138.94 117.13 12.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 118.043 -1.463 . . . . 0.0 111.398 -172.473 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.476 ' O ' HG23 ' F' ' 32' ' ' ILE . 12.9 tt -103.86 123.2 57.41 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.261 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.19 102.75 1.04 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.58 HD21 ' CG2' ' E' ' 36' ' ' VAL . 3.4 tt -122.95 113.36 18.99 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.473 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.3 ttt -95.39 121.88 37.53 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.606 -178.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.561 HG13 ' CD2' ' F' ' 34' ' ' LEU . 0.5 OUTLIER -138.3 80.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.614 -178.749 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 40.57 -103.25 0.03 OUTLIER Glycine 0 C--N 1.346 1.11 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.214 177.154 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -147.84 7.77 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 40' ' ' VAL . 55.9 t -121.41 136.39 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.874 0.368 . . . . 0.0 110.766 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 39' ' ' VAL . 2.3 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.592 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -108.15 137.93 45.29 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.482 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -125.33 145.67 49.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.077 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 7.4 m -119.78 134.79 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.134 0.492 . . . . 0.0 110.851 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -142.63 140.26 31.56 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.01 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -88.74 169.13 11.9 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.332 0.587 . . . . 0.0 110.532 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -151.4 177.67 10.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.486 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -137.58 129.11 28.27 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.665 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.5 tp -123.8 125.84 45.41 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -131.39 127.71 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.601 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 9.5 m-85 -113.58 117.5 31.81 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 176.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.518 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 39.9 p90 -130.37 118.02 20.61 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 121.034 -0.266 . . . . 0.0 111.558 -179.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . 0.484 ' O ' ' OE1' ' H' ' 22' ' ' GLU . . . -117.96 117.4 29.13 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.432 ' HG2' ' H ' ' G' ' 23' ' ' ASP . 68.4 tt0 -144.75 175.0 10.5 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 123.729 0.643 . . . . 0.0 109.815 -179.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.432 ' H ' ' HG2' ' G' ' 22' ' ' GLU . 15.8 t0 -64.85 113.55 3.9 Favored 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 112.025 0.379 . . . . 0.0 112.025 -178.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.442 ' H ' ' HA2' ' H' ' 25' ' ' GLY . 60.1 t -127.22 121.54 57.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' G' ' 24' ' ' VAL . . . -29.22 -85.87 0.01 OUTLIER Glycine 0 CA--C 1.535 1.317 0 CA-C-O 121.607 0.559 . . . . 0.0 113.481 179.044 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.6 t 65.7 176.2 0.22 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 -178.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -88.06 177.31 6.96 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.98 176.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -56.73 110.41 0.79 Allowed 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 118.612 -0.709 . . . . 0.0 111.895 175.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.507 ' H ' ' CB ' ' H' ' 27' ' ' ASN . . . 72.12 94.51 0.08 OUTLIER Glycine 0 N--CA 1.469 0.897 0 C-N-CA 118.165 -1.969 . . . . 0.0 112.391 174.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.87 156.13 19.02 Favored 'General case' 0 CA--C 1.507 -0.679 0 CA-C-N 120.004 1.902 . . . . 0.0 107.885 178.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.51 HG21 ' HA3' ' A' ' 37' ' ' GLY . 0.4 OUTLIER -152.53 106.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.347 -0.842 . . . . 0.0 108.835 -173.187 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.447 ' C ' ' SD ' ' A' ' 35' ' ' MET . 50.3 mm -124.56 130.57 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.103 -178.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.511 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -135.57 125.5 3.65 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 179.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.4 tp -144.82 136.85 25.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.258 0.529 . . . . 0.0 111.857 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.51 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 11.4 ttt -133.66 144.71 49.36 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.401 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.4 t -102.51 72.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.463 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -109.46 100.71 1.38 Allowed Glycine 0 C--N 1.341 0.837 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 177.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.93 170.96 41.62 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.423 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.449 HG22 HG23 ' G' ' 40' ' ' VAL . 5.6 p -135.8 143.33 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.52 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . 0.449 HG23 HG22 ' G' ' 39' ' ' VAL . 80.5 t . . . . . 0 C--O 1.218 -0.565 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.565 -179.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -82.46 145.46 29.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.732 0.301 . . . . 0.0 110.593 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.03 137.09 47.69 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-O 121.194 0.521 . . . . 0.0 110.751 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.1 t -121.75 134.03 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.546 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 t-80 -142.49 103.46 4.25 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.197 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.434 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 33.4 p-80 -152.23 168.7 24.5 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -150.58 171.96 16.27 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.151 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -134.45 118.39 17.32 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.245 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -118.57 121.33 39.96 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 62.3 t -124.43 126.28 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.976 0.417 . . . . 0.0 110.421 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.511 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 2.5 m-85 -119.16 108.91 15.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -117.17 115.62 25.68 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 177.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . 0.607 ' HB2' HD12 ' J' ' 32' ' ' ILE . . . -129.1 130.09 46.04 Favored 'General case' 0 C--O 1.242 0.671 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -177.519 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.566 ' O ' ' O ' ' H' ' 23' ' ' ASP . 52.4 mp0 -142.29 141.9 32.48 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.825 -1.534 . . . . 0.0 107.194 176.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.566 ' O ' ' O ' ' H' ' 22' ' ' GLU . 7.6 t0 -54.79 -130.63 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' H' ' 23' ' ' ASP . 32.7 m 28.49 111.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 178.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.442 ' HA2' ' H ' ' G' ' 24' ' ' VAL . . . -160.86 -91.24 0.08 OUTLIER Glycine 0 CA--C 1.521 0.428 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 177.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.473 ' HB2' ' HB2' ' H' ' 30' ' ' ALA . 0.1 OUTLIER -101.81 -163.2 0.99 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 119.551 1.676 . . . . 0.0 109.487 176.603 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.507 ' CB ' ' H ' ' G' ' 29' ' ' GLY . 66.5 t30 -61.8 177.62 0.41 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.777 177.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.489 ' H ' ' CG ' ' H' ' 27' ' ' ASN . 60.1 tttm -47.51 111.06 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.291 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 92.43 -95.71 2.05 Favored Glycine 0 C--O 1.207 -1.591 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.217 -176.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.605 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . 70.44 145.37 0.06 Allowed 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 103.141 -2.911 . . . . 0.0 103.141 -176.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.682 HG21 ' HA2' ' B' ' 37' ' ' GLY . 5.2 tt -163.34 124.61 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 115.783 -2.367 . . . . 0.0 112.266 -177.206 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.9 mt -120.22 122.94 69.61 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 113.947 -1.478 . . . . 0.0 109.951 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.28 117.08 2.46 Favored Glycine 0 N--CA 1.47 0.9 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.73 141.97 51.74 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.277 0.561 . . . . 0.0 111.127 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.51 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 23.2 ttt -140.39 126.58 19.8 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.127 0.489 . . . . 0.0 111.303 -178.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 11.8 t -122.68 74.06 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.024 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.42 101.49 2.32 Favored Glycine 0 C--N 1.344 1.023 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.65 159.13 31.78 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 120.245 -0.979 . . . . 0.0 111.722 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -125.9 134.64 66.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.885 -1.055 . . . . 0.0 110.552 -179.903 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.466 0.374 0 CA-C-O 120.884 0.373 . . . . 0.0 110.721 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 48.2 m-70 -144.07 104.43 4.13 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.855 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.434 ' O ' ' CB ' ' H' ' 14' ' ' HIS . 5.3 m170 -130.82 169.03 16.27 Favored 'General case' 0 C--O 1.221 -0.442 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 81.2 mt-30 -155.31 172.14 18.69 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 178.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -145.09 125.1 13.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.717 0.294 . . . . 0.0 111.279 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 37.9 tp -125.82 117.46 23.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 120.806 0.336 . . . . 0.0 110.35 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -122.59 127.96 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.934 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.478 ' CD2' HD23 ' L' ' 34' ' ' LEU . 1.1 m-85 -121.91 117.25 26.0 Favored 'General case' 0 N--CA 1.47 0.575 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.357 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.411 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 42.0 t80 -126.24 123.76 38.88 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.32 132.07 42.59 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.813 0.339 . . . . 0.0 111.412 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -155.93 157.33 36.09 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.767 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.505 ' HB2' ' HZ1' ' K' ' 28' ' ' LYS . 7.1 t70 -111.6 101.83 10.2 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 121.415 0.626 . . . . 0.0 110.655 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.9 p -90.01 159.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.068 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 49.64 -80.28 0.01 OUTLIER Glycine 0 CA--C 1.531 1.073 0 CA-C-O 119.382 -0.677 . . . . 0.0 112.955 -179.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.621 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.4 p 170.84 -179.53 0.05 OUTLIER 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 118.445 1.122 . . . . 0.0 110.577 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.621 ' O ' ' O ' ' I' ' 26' ' ' SER . 42.0 p-10 -28.31 -179.82 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 -177.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.445 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 83.9 mttt 128.77 103.38 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 111.828 -2.442 . . . . 0.0 108.571 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -59.25 100.32 0.18 Allowed Glycine 0 CA--C 1.486 -1.756 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.665 177.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' H' ' 29' ' ' GLY . . . -112.47 144.67 41.54 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 103.869 -2.641 . . . . 0.0 103.869 177.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.555 HD12 HD12 ' H' ' 31' ' ' ILE . 1.1 mt -137.98 107.21 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 C-N-CA 118.251 -1.38 . . . . 0.0 110.472 -174.137 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -117.66 130.75 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 120.981 0.42 . . . . 0.0 110.115 179.094 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -134.18 134.01 7.17 Favored Glycine 0 CA--C 1.503 -0.673 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 177.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.496 ' H ' ' HG ' ' J' ' 34' ' ' LEU . 3.8 tt -145.89 131.21 18.56 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.799 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.484 ' SD ' ' C ' ' C' ' 32' ' ' ILE . 8.7 ttt -112.91 119.75 39.04 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.263 -1.335 . . . . 0.0 108.395 179.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.1 OUTLIER -118.53 72.38 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.645 -179.504 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -31.15 -100.25 0.01 OUTLIER Glycine 0 C--N 1.369 2.373 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -175.89 40.73 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.1 t -134.37 152.48 33.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.497 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . 0.436 ' O ' ' CE2' ' K' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.367 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -123.15 119.37 30.05 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -137.36 134.2 35.71 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.589 0.233 . . . . 0.0 110.388 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.449 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -126.01 132.81 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.953 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' K' ' 13' ' ' HIS . 66.4 m80 -119.64 140.65 50.29 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.418 -0.216 . . . . 0.0 110.418 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 59.5 t60 -151.83 167.78 27.2 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 121.204 0.526 . . . . 0.0 109.77 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.6 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 66.7 tp60 -158.32 164.31 36.51 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.613 178.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.415 ' N ' ' HG3' ' J' ' 15' ' ' GLN . 50.3 tttp -157.99 116.29 3.08 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.977 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.657 HD23 ' C ' ' J' ' 17' ' ' LEU . 7.2 tt -131.35 123.26 27.89 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . 0.545 ' N ' HD23 ' J' ' 17' ' ' LEU . 2.7 p -132.51 127.91 57.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.33 0.586 . . . . 0.0 111.636 179.327 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.6 ' CE1' HD21 ' J' ' 17' ' ' LEU . 6.1 m-30 -109.17 119.2 38.8 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 115.079 -0.964 . . . . 0.0 108.648 178.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD2' ' K' ' 20' ' ' PHE . 34.6 t80 -124.58 113.7 18.41 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 134.23 47.81 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.491 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -134.75 105.99 6.71 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.676 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -85.41 114.24 22.31 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' J' ' 25' ' ' GLY . 4.6 p -122.56 122.9 67.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 24' ' ' VAL . . . 34.61 84.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.141 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -177.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.461 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 6.0 m -46.2 152.05 0.45 Allowed 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 113.722 -1.239 . . . . 0.0 114.066 -177.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' J' ' 28' ' ' LYS . 65.9 m-80 -138.02 178.0 7.45 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.881 172.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.888 ' HZ3' ' H ' ' J' ' 29' ' ' GLY . 0.9 OUTLIER -20.43 -104.12 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.413 1.264 . . . . 0.0 114.413 177.668 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.888 ' H ' ' HZ3' ' J' ' 28' ' ' LYS . . . -167.45 96.88 0.13 Allowed Glycine 0 C--N 1.361 1.919 0 CA-C-O 117.472 -1.738 . . . . 0.0 110.745 176.179 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.562 ' HB2' ' OD1' ' H' ' 23' ' ' ASP . . . -68.2 167.44 14.25 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 123.128 3.464 . . . . 0.0 106.884 177.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.55 HD12 HG23 ' I' ' 31' ' ' ILE . 0.3 OUTLIER -145.14 123.79 5.53 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.328 0 CA-C-N 121.128 1.786 . . . . 0.0 111.943 -176.924 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.607 HD12 ' HB2' ' H' ' 21' ' ' ALA . 0.1 OUTLIER -122.33 122.52 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.891 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.565 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -131.17 100.97 0.47 Allowed Glycine 0 N--CA 1.476 1.302 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.601 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 6.0 mp -131.78 138.54 48.61 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-O 122.696 1.236 . . . . 0.0 113.906 -176.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.518 ' SD ' ' C ' ' D' ' 32' ' ' ILE . 4.9 ttm -116.66 119.57 35.91 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 113.799 -1.546 . . . . 0.0 109.66 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.61 77.03 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.074 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.738 -179.169 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -84.57 103.97 2.69 Favored Glycine 0 C--N 1.355 1.596 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 179.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.46 170.9 55.14 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 65.6 t -131.47 136.02 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.947 0.403 . . . . 0.0 110.536 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.517 179.817 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . 0.436 ' CE2' ' O ' ' J' ' 9' ' ' GLY . 93.3 m-85 -112.68 133.95 54.45 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' L' ' 10' ' ' TYR . 79.7 mm-40 -137.43 139.23 40.53 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.96 0.409 . . . . 0.0 110.792 -179.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 58.1 t -127.63 132.54 69.02 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' J' ' 13' ' ' HIS . 22.1 m170 -79.26 149.1 31.95 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.86 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 24.5 p-80 -78.84 178.08 8.21 Favored 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -117.87 175.88 5.46 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.574 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -145.14 118.52 9.01 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 120.911 0.386 . . . . 0.0 111.205 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.441 HD12 HE21 ' L' ' 15' ' ' GLN . 34.1 mt -124.77 118.8 27.21 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.37 138.15 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.644 0.735 . . . . 0.0 112.633 -178.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -124.21 127.67 48.06 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.288 179.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.418 ' CD2' ' CE2' ' J' ' 20' ' ' PHE . 71.5 t80 -133.09 121.07 22.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.56 133.69 31.14 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.476 0.655 . . . . 0.0 112.665 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 96.4 mt-10 -117.69 124.66 49.07 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.211 178.327 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' K' ' 22' ' ' GLU . 14.5 m-20 -140.15 111.89 7.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' K' ' 26' ' ' SER . 6.3 m -129.55 -122.48 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 31.63 -84.25 0.0 OUTLIER Glycine 0 N--CA 1.474 1.183 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 -179.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.623 ' O ' ' O ' ' K' ' 27' ' ' ASN . 3.9 p 170.93 170.64 0.07 Allowed 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.209 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.623 ' O ' ' O ' ' K' ' 26' ' ' SER . 93.6 m-20 -18.75 157.48 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.554 1.159 . . . . 0.0 113.849 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' K' ' 29' ' ' GLY . 88.1 tttt -170.47 104.95 0.28 Allowed 'General case' 0 C--O 1.215 -0.729 0 CA-C-O 117.709 -1.139 . . . . 0.0 109.01 176.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -50.65 -99.08 0.01 OUTLIER Glycine 0 C--O 1.214 -1.126 0 C-N-CA 116.6 -2.714 . . . . 0.0 110.994 178.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 70.74 141.91 0.05 Allowed 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 102.616 -3.105 . . . . 0.0 102.616 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.497 HD13 ' HA2' ' E' ' 37' ' ' GLY . 0.2 OUTLIER -147.95 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 122.298 2.317 . . . . 0.0 111.214 -176.903 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.57 HG22 HD11 ' L' ' 34' ' ' LEU . 10.6 mt -106.61 113.4 43.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 175.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.7 115.2 2.29 Favored Glycine 0 C--N 1.317 -0.519 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 1.037 HD21 HG13 ' K' ' 36' ' ' VAL . 0.8 OUTLIER -150.42 143.27 24.69 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 122.732 1.253 . . . . 0.0 112.631 -178.526 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 29.4 ttm -117.67 122.21 42.93 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 113.664 -1.607 . . . . 0.0 109.308 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 1.037 HG13 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -116.2 79.76 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.131 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.23 103.91 0.4 Allowed Glycine 0 C--N 1.351 1.377 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.48 -163.11 15.38 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.1 136.27 54.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 120.833 0.349 . . . . 0.0 110.623 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 86.6 t . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.455 179.868 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' L' L ' 10' ' ' TYR . . . . . 0.402 ' O ' ' OE2' ' K' ' 11' ' ' GLU . 94.9 m-85 -108.48 137.52 46.3 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.901 0.381 . . . . 0.0 110.928 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -96.34 158.89 15.23 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 179.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.16 133.14 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.823 0.344 . . . . 0.0 110.562 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 65.6 t60 -160.24 117.53 2.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.173 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.474 ' ND1' ' O ' ' L' ' 13' ' ' HIS . 80.1 m-70 -151.51 174.55 13.27 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.441 HE21 HD12 ' K' ' 17' ' ' LEU . 54.8 tt0 -146.08 170.59 16.36 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . 0.427 ' N ' ' HG2' ' L' ' 15' ' ' GLN . 99.0 mttt -148.89 117.85 6.72 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.662 0.268 . . . . 0.0 110.303 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.538 HD23 ' C ' ' L' ' 17' ' ' LEU . 7.2 tt -126.48 115.89 20.26 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.215 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 m -136.62 137.2 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-O 121.005 0.431 . . . . 0.0 110.426 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -134.28 133.81 41.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.237 0.541 . . . . 0.0 111.275 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -135.56 124.74 24.51 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.722 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -150.37 146.45 26.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.329 -0.548 . . . . 0.0 111.594 -179.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -104.17 102.15 11.88 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -91.87 113.64 25.96 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.562 ' O ' ' N ' ' L' ' 26' ' ' SER . 85.2 t -65.95 131.26 31.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.439 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -54.53 84.51 0.01 OUTLIER Glycine 0 CA--C 1.528 0.892 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.562 ' N ' ' O ' ' L' ' 24' ' ' VAL . 1.4 p 159.82 178.88 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.473 ' O ' ' O ' ' L' ' 26' ' ' SER . 21.2 p30 -41.92 177.64 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.053 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.551 ' NZ ' ' O ' ' L' ' 30' ' ' ALA . 8.6 tptp -75.2 110.57 9.64 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.708 -1.133 . . . . 0.0 112.31 178.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -51.29 -99.87 0.01 OUTLIER Glycine 0 C--N 1.317 -0.513 0 CA-C-O 119.054 -0.859 . . . . 0.0 111.607 179.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.551 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . . . -80.48 163.91 23.41 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 104.75 -2.315 . . . . 0.0 104.75 -178.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.411 HD13 HG21 ' L' ' 31' ' ' ILE . 0.2 OUTLIER -135.28 128.85 49.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 116.487 -2.085 . . . . 0.0 113.038 -174.155 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.57 ' HB ' HD13 ' L' ' 34' ' ' LEU . 2.0 pt -117.52 114.94 47.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.232 178.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . 0.731 ' C ' HD12 ' L' ' 34' ' ' LEU . . . -112.8 90.64 0.56 Allowed Glycine 0 N--CA 1.463 0.47 0 N-CA-C 106.029 -2.828 . . . . 0.0 106.029 176.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.731 HD12 ' C ' ' L' ' 33' ' ' GLY . 9.1 mp -116.16 134.59 54.76 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.747 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 77.7 mmm -119.62 119.47 33.84 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.683 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' L' ' 37' ' ' GLY . 1.2 m -125.64 76.54 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 115.043 -0.981 . . . . 0.0 108.657 178.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -37.12 105.71 0.04 OUTLIER Glycine 0 C--N 1.356 1.646 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.86 172.15 6.81 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.933 -0.467 . . . . 0.0 111.933 -177.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 14.9 p -133.57 144.07 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 115.457 -0.371 . . . . 0.0 110.362 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 m . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.558 179.797 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m . . . . . 0 N--CA 1.465 0.284 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -107.24 119.41 39.33 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.687 0.28 . . . . 0.0 111.032 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -100.27 165.88 11.25 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -156.23 174.14 15.83 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.887 178.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttp -175.8 115.76 0.14 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.377 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 97.0 mt -124.89 115.69 21.03 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.119 0.485 . . . . 0.0 110.439 179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.2 m -122.14 126.92 75.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.355 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.935 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 0.6 OUTLIER -117.85 113.52 21.9 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.418 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 t80 -122.87 116.42 23.61 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.79 119.87 38.11 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.22 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -174.79 108.57 0.11 Allowed 'General case' 0 CA--C 1.528 0.098 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -74.09 114.6 12.61 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.98 -0.688 . . . . 0.0 109.782 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.56 ' O ' HG23 ' A' ' 24' ' ' VAL . 27.9 m -121.46 123.54 69.85 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.769 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.4 82.09 0.01 OUTLIER Glycine 0 CA--C 1.53 0.971 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.259 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.616 ' O ' ' O ' ' A' ' 27' ' ' ASN . 58.4 m -140.5 170.68 15.34 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 117.923 0.862 . . . . 0.0 108.942 177.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.616 ' O ' ' O ' ' A' ' 26' ' ' SER . 70.9 m-80 -30.94 174.4 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.707 0 O-C-N 124.29 0.994 . . . . 0.0 113.261 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.61 110.84 21.67 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.592 176.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 52.09 91.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.719 0 C-N-CA 119.922 -1.132 . . . . 0.0 110.436 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.65 166.77 10.22 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 118.906 1.353 . . . . 0.0 110.518 179.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.467 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -141.05 107.32 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.389 -178.137 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 93.6 mt -128.21 130.09 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 121.442 0.639 . . . . 0.0 112.291 -177.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.433 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -128.13 110.88 1.2 Allowed Glycine 0 CA--C 1.521 0.439 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.03 124.55 52.88 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 120.908 0.385 . . . . 0.0 110.395 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.55 ' SD ' ' CA ' ' G' ' 33' ' ' GLY . 25.7 ttt -130.73 126.32 36.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.893 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.1 t -98.12 65.39 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 112.983 0.735 . . . . 0.0 112.983 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.2 -106.19 0.06 OUTLIER Glycine 0 N--CA 1.44 -1.075 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -95.44 178.16 35.26 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.468 0.438 0 CA-C-O 120.92 0.39 . . . . 0.0 110.275 179.739 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 N--CA 1.466 0.367 0 CA-C-O 121.165 0.507 . . . . 0.0 111.344 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.585 ' CG ' ' H ' ' B' ' 14' ' ' HIS . 15.3 t-80 -122.86 -164.26 1.18 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.036 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.586 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 19.9 t-80 -71.59 168.05 18.46 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.586 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 79.0 mt-30 -152.3 177.47 10.53 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.156 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -158.43 128.63 6.02 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 120.554 -0.458 . . . . 0.0 111.672 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.44 119.55 29.51 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -129.21 131.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 121.068 0.461 . . . . 0.0 111.52 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.635 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 7.9 t80 -122.64 115.55 22.3 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 53.3 t80 -125.59 122.33 36.17 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 110.4 -0.222 . . . . 0.0 110.4 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.52 125.77 45.49 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -163.48 130.23 3.34 Favored 'General case' 0 C--O 1.222 -0.364 0 CA-C-N 115.018 -0.992 . . . . 0.0 108.472 178.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' NZ ' ' D' ' 28' ' ' LYS . 66.1 t0 -142.6 113.14 7.31 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.404 ' H ' HG22 ' B' ' 24' ' ' VAL . 6.0 m -59.32 131.59 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.13 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 176.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.413 ' HA3' ' O ' ' C' ' 26' ' ' SER . . . -66.36 84.33 0.1 Allowed Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.357 -0.925 . . . . 0.0 113.313 -178.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 6.3 p -87.77 180.0 6.38 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.757 0.789 . . . . 0.0 109.438 176.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.487 ' O ' ' O ' ' B' ' 28' ' ' LYS . 51.1 p30 -76.69 179.22 6.17 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.342 -1.299 . . . . 0.0 109.578 175.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 27' ' ' ASN . 68.4 mttm 43.93 110.53 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 115.019 1.489 . . . . 0.0 115.019 175.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' C' ' 29' ' ' GLY . . . -78.76 97.79 1.51 Allowed Glycine 0 CA--C 1.485 -1.827 0 CA-C-N 113.562 -1.654 . . . . 0.0 110.866 -176.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.4 ' C ' HG12 ' B' ' 31' ' ' ILE . . . -75.62 164.75 25.99 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 122.462 1.125 . . . . 0.0 109.658 -175.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.549 HG23 ' CG1' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -137.57 114.04 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 CA-C-N 112.63 -2.077 . . . . 0.0 110.504 -170.157 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' I' ' 35' ' ' MET . 96.4 mt -132.83 128.12 56.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 CA-C-O 121.64 0.733 . . . . 0.0 112.805 -177.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.491 ' CA ' ' SD ' ' I' ' 35' ' ' MET . . . -129.74 128.8 5.79 Favored Glycine 0 N--CA 1.471 0.999 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 179.304 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.403 HD21 HG23 ' B' ' 36' ' ' VAL . 2.9 tt -129.25 126.13 38.4 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.149 0.5 . . . . 0.0 111.761 -178.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 7.2 tpp -120.86 117.81 28.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.428 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.403 HG23 HD21 ' B' ' 34' ' ' LEU . 59.0 t -125.37 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -179.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.66 104.63 2.1 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.505 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.44 -171.81 0.65 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.106 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.2 m -133.77 163.06 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.896 0.379 . . . . 0.0 110.47 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.342 179.727 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.439 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -116.2 138.53 51.2 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.767 0.318 . . . . 0.0 110.644 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -120.72 128.49 52.99 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.34 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -130.04 134.63 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.496 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.0 t-80 -136.62 127.36 27.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.843 0.354 . . . . 0.0 110.61 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.496 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 79.9 m-70 -152.16 164.74 36.69 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -156.83 171.01 21.16 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.092 178.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.482 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.9 mttt -158.13 113.95 2.74 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.482 HD12 ' C ' ' C' ' 16' ' ' LYS . 11.0 mp -114.46 122.38 46.43 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.45 124.52 62.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.658 -0.246 . . . . 0.0 110.431 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.629 ' CZ ' HD11 ' E' ' 34' ' ' LEU . 1.1 t80 -120.46 111.98 18.39 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.054 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.4 t80 -119.84 121.92 40.15 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.681 0.277 . . . . 0.0 110.828 -178.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.74 128.92 49.51 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 121.331 0.586 . . . . 0.0 112.065 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -150.37 149.8 30.56 Favored 'General case' 0 C--O 1.226 -0.157 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.959 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -163.77 121.23 1.8 Allowed 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.63 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.479 HG23 ' H ' ' C' ' 25' ' ' GLY . 4.2 m -128.02 -112.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.803 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.479 ' H ' HG23 ' C' ' 24' ' ' VAL . . . 34.26 -90.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 115.725 -0.671 . . . . 0.0 112.315 -178.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.619 ' O ' ' O ' ' C' ' 27' ' ' ASN . 0.3 OUTLIER 172.0 -170.82 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.6 179.65 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.619 ' O ' ' O ' ' C' ' 26' ' ' SER . 14.3 m120 -20.31 -175.2 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 117.327 2.343 . . . . 0.0 117.327 177.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 82.6 tttt 111.64 110.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 CA-C-N 111.81 -2.45 . . . . 0.0 114.477 176.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.412 ' O ' ' HA3' ' B' ' 29' ' ' GLY . . . -61.74 92.48 0.07 OUTLIER Glycine 0 C--O 1.218 -0.87 0 CA-C-N 112.305 -2.225 . . . . 0.0 112.714 171.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.67 156.8 40.47 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 122.902 3.351 . . . . 0.0 107.984 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.598 HD13 ' N ' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -138.73 129.07 33.51 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.189 -176.021 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.488 HG12 HD21 ' C' ' 34' ' ' LEU . 13.0 tt -133.84 122.97 43.96 Favored 'Isoleucine or valine' 0 C--N 1.348 0.525 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.523 177.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.52 115.36 3.61 Favored Glycine 0 CA--C 1.499 -0.936 0 N-CA-C 107.602 -2.199 . . . . 0.0 107.602 178.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.935 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 52.6 mt -116.26 111.4 20.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.117 0.484 . . . . 0.0 111.56 -176.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.405 ' HE2' ' H ' ' J' ' 33' ' ' GLY . 24.6 tpp -109.48 103.16 12.01 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 177.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -121.35 70.74 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.727 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.239 -178.734 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -38.2 -100.79 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 178.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.85 -163.79 31.73 Favored Glycine 0 CA--C 1.521 0.456 0 N-CA-C 110.535 -1.026 . . . . 0.0 110.535 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 68.5 t -119.19 134.06 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.005 -0.997 . . . . 0.0 110.632 -179.641 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.477 ' C ' ' ND1' ' D' ' 13' ' ' HIS . 9.8 p . . . . . 0 N--CA 1.467 0.385 0 CA-C-O 121.142 0.496 . . . . 0.0 110.702 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' C ' ' D' ' 12' ' ' VAL . 14.7 m80 -142.56 108.99 5.3 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.555 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.44 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 31.6 m-70 -126.55 167.08 16.13 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -151.39 171.86 16.83 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.581 179.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.594 ' C ' HD12 ' D' ' 17' ' ' LEU . 63.3 mttp -155.24 121.16 5.11 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.139 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.594 HD12 ' C ' ' D' ' 16' ' ' LYS . 11.0 mp -119.92 122.83 42.11 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.33 125.1 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.016 0.436 . . . . 0.0 110.678 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.908 ' CE1' HD22 ' F' ' 34' ' ' LEU . 1.3 t80 -118.73 117.55 29.22 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -128.26 122.3 31.38 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 112.059 0.392 . . . . 0.0 112.059 -177.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.79 121.3 29.84 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-O 121.112 0.482 . . . . 0.0 109.978 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -97.85 175.29 6.21 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.212 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -72.63 122.08 20.83 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.26 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.451 ' O ' HG23 ' D' ' 24' ' ' VAL . 28.7 m -87.56 123.33 40.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.914 179.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -42.88 -86.09 0.01 OUTLIER Glycine 0 CA--C 1.532 1.152 0 C-N-CA 121.393 -0.432 . . . . 0.0 112.443 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.738 ' O ' ' O ' ' D' ' 27' ' ' ASN . 13.2 p -152.84 -171.61 3.99 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -178.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.738 ' O ' ' O ' ' D' ' 26' ' ' SER . 81.5 m-20 -20.15 172.24 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 114.783 1.401 . . . . 0.0 114.783 -179.05 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.556 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 83.2 tttt 132.02 105.65 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 124.95 1.3 . . . . 0.0 107.701 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -49.89 -97.72 0.01 OUTLIER Glycine 0 N--CA 1.473 1.135 0 C-N-CA 118.112 -1.994 . . . . 0.0 110.269 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.451 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . 72.54 145.01 0.07 Allowed 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.687 HG23 ' CG1' ' E' ' 31' ' ' ILE . 0.3 OUTLIER -149.42 116.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.202 -175.026 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.513 HG22 ' O ' ' D' ' 32' ' ' ILE . 1.0 OUTLIER -111.57 111.41 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.741 -179.661 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.91 97.53 1.61 Allowed Glycine 0 CA--C 1.509 -0.289 0 N-CA-C 105.024 -3.23 . . . . 0.0 105.024 175.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.635 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 62.8 tp -110.94 118.67 36.71 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -175.149 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -122.16 108.84 13.78 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 176.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.434 HG22 HD11 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -124.43 70.04 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.847 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -49.41 -100.6 0.01 OUTLIER Glycine 0 C--N 1.347 1.142 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.266 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 111.23 159.19 15.67 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -124.15 136.34 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.972 0.415 . . . . 0.0 110.664 -179.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 91.6 t . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.058 -0.973 . . . . 0.0 110.414 179.63 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -104.87 134.95 47.14 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -140.8 146.57 37.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.997 0.427 . . . . 0.0 110.956 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 4.2 m -131.55 155.84 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.748 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -156.75 162.37 39.77 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 121.312 0.577 . . . . 0.0 112.302 -179.025 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.59 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 36.4 t60 -154.96 164.75 38.45 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-O 121.411 0.624 . . . . 0.0 110.635 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.59 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 82.6 mt-30 -149.85 170.03 19.72 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.465 0.65 . . . . 0.0 110.892 178.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.19 128.79 3.17 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.096 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 52.5 tp -125.36 124.36 41.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.2 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.73 123.61 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -124.54 120.24 31.39 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.239 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -129.13 120.53 26.02 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 120.31 16.94 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.213 0.53 . . . . 0.0 110.948 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -143.09 128.3 18.71 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.476 179.538 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -154.14 120.4 5.4 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.455 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 14.1 t -107.5 -112.76 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.007 0.432 . . . . 0.0 110.327 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.7 -90.63 0.01 OUTLIER Glycine 0 N--CA 1.469 0.878 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.397 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.602 ' O ' ' O ' ' E' ' 27' ' ' ASN . 2.7 t 171.34 170.1 0.08 Allowed 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.602 ' O ' ' O ' ' E' ' 26' ' ' SER . 60.3 t30 -17.67 158.34 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.861 ' O ' ' HB2' ' F' ' 30' ' ' ALA . 75.2 tttt -161.73 111.41 1.57 Allowed 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.406 175.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.77 92.29 0.23 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-O 119.156 -0.802 . . . . 0.0 113.178 176.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.537 ' HB2' ' O ' ' D' ' 28' ' ' LYS . . . -160.24 154.08 22.82 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.687 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -141.47 126.05 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 117.49 -1.684 . . . . 0.0 114.123 -175.926 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.522 ' O ' ' SD ' ' L' ' 35' ' ' MET . 0.8 OUTLIER -114.39 116.39 52.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 114.731 -1.122 . . . . 0.0 108.202 176.505 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.95 102.13 2.76 Favored Glycine 0 CA--C 1.501 -0.811 0 N-CA-C 104.192 -3.563 . . . . 0.0 104.192 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.629 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 6.7 tt -107.14 105.54 15.59 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 121.045 0.45 . . . . 0.0 111.366 -174.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.9 ttt -123.82 112.51 17.38 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.5 80.38 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.01 102.76 0.26 Allowed Glycine 0 C--N 1.351 1.397 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.54 -151.55 23.62 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.0 p -130.84 140.82 47.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 43.1 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.755 -179.828 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p . . . . . 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.753 . . . . 0.0 111.507 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.444 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 33.0 p-80 -161.64 157.08 24.02 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.188 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 97.0 m-70 -156.4 168.29 27.8 Favored 'General case' 0 CA--C 1.511 -0.537 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.101 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -151.01 173.26 14.52 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 119.951 -0.7 . . . . 0.0 110.716 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -147.66 129.09 14.89 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.447 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 50.8 mt -120.33 115.48 23.63 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -127.31 129.5 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.82 0.343 . . . . 0.0 110.129 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.524 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.3 p90 -143.34 126.23 16.2 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.069 0.462 . . . . 0.0 111.543 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -127.29 128.11 45.44 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.18 149.64 28.22 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 119.89 -0.724 . . . . 0.0 112.286 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -80.09 126.56 31.23 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 57.8 t0 . . . . . 0 N--CA 1.471 0.601 0 CA-C-O 121.868 0.842 . . . . 0.0 113.266 -177.483 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.461 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 80.1 tttt . . . . . 0 CA--C 1.542 0.664 0 CA-C-O 123.537 1.637 . . . . 0.0 111.859 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.461 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -114.33 -100.45 2.36 Favored Glycine 0 CA--C 1.483 -1.944 0 CA-C-N 111.218 -2.719 . . . . 0.0 113.305 -179.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.861 ' HB2' ' O ' ' E' ' 28' ' ' LYS . . . -60.41 177.04 0.3 Allowed 'General case' 0 CA--C 1.474 -1.957 0 CA-C-N 110.82 -2.69 . . . . 0.0 104.933 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 tp -158.41 144.76 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 C-N-CA 114.998 -2.681 . . . . 0.0 114.638 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 pt -102.14 112.34 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-N 112.807 -1.997 . . . . 0.0 107.965 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -80.38 97.12 1.67 Allowed Glycine 0 CA--C 1.497 -1.061 0 N-CA-C 103.496 -3.842 . . . . 0.0 103.496 175.408 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.908 HD22 ' CE1' ' D' ' 19' ' ' PHE . 0.3 OUTLIER -100.01 111.09 23.39 Favored 'General case' 0 CA--C 1.497 -1.089 0 CA-C-N 117.412 0.606 . . . . 0.0 111.445 -176.676 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.622 ' SD ' ' O ' ' L' ' 32' ' ' ILE . 24.2 mtp -135.33 114.94 12.71 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-O 122.754 1.264 . . . . 0.0 107.766 176.463 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.74 HG13 ' O ' ' F' ' 36' ' ' VAL . 5.5 p -133.0 78.63 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 CA-C-N 112.566 -2.106 . . . . 0.0 108.373 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.646 ' HA2' HD13 ' L' ' 31' ' ' ILE . . . 51.87 -104.08 0.14 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -175.13 46.7 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.551 ' C ' HD21 ' L' ' 27' ' ' ASN . 66.6 t -131.42 137.72 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 120.814 0.34 . . . . 0.0 111.16 -179.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.414 ' HA ' HD21 ' L' ' 27' ' ' ASN . 61.5 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.119 -0.943 . . . . 0.0 110.335 179.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.457 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -98.71 130.29 45.19 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.859 0.361 . . . . 0.0 110.345 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -71.02 147.61 48.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.744 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 t -124.95 134.03 67.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.8 t60 -144.27 136.9 26.85 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.382 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 27.6 m170 -112.78 178.69 4.2 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -102.33 178.11 4.68 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.407 -179.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -97.02 137.63 35.81 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.655 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -123.97 128.14 48.96 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.375 0.607 . . . . 0.0 111.378 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.49 128.85 61.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.562 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.45 ' CE2' HD23 ' J' ' 34' ' ' LEU . 3.8 m-85 -108.85 113.27 26.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 176.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 52.7 p90 -124.99 123.96 40.98 Favored 'General case' 0 CA--C 1.521 -0.14 0 CA-C-O 120.892 0.377 . . . . 0.0 110.932 -178.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.09 120.84 40.37 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -159.27 141.63 13.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -66.29 112.12 3.83 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' G' ' 26' ' ' SER . 54.2 t -111.86 130.85 64.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.96 81.85 0.0 OUTLIER Glycine 0 CA--C 1.532 1.126 0 CA-C-N 114.97 -1.014 . . . . 0.0 113.376 177.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.516 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.6 m -131.41 179.46 6.02 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 119.172 1.486 . . . . 0.0 109.562 178.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.465 ' O ' ' O ' ' G' ' 26' ' ' SER . 15.0 m120 -40.18 174.37 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.186 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -77.41 110.64 12.34 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.381 175.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.457 ' H ' ' HE2' ' H' ' 28' ' ' LYS . . . 65.36 94.39 0.03 OUTLIER Glycine 0 N--CA 1.466 0.648 0 C-N-CA 118.292 -1.909 . . . . 0.0 110.361 177.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 161.37 13.65 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 120.18 1.99 . . . . 0.0 109.386 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.404 HG22 HD12 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -150.98 112.77 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.758 -172.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' A' ' 35' ' ' MET . 94.8 mt -121.45 117.26 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-O 120.662 0.268 . . . . 0.0 110.89 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.55 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -125.7 116.39 2.62 Favored Glycine 0 N--CA 1.47 0.911 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 179.401 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 56.4 tp -144.15 140.57 29.45 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-O 121.384 0.611 . . . . 0.0 112.198 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.433 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 40.0 ttp -130.64 137.73 49.75 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.466 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' G' ' 37' ' ' GLY . 4.8 t -125.82 69.77 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 CA-C-N 116.328 -0.396 . . . . 0.0 112.038 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -43.77 -101.68 0.01 OUTLIER Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.12 174.28 40.21 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 13.3 p -145.03 149.56 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.183 0.516 . . . . 0.0 111.329 -179.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.969 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -82.44 130.11 35.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.012 0.434 . . . . 0.0 110.392 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -115.34 163.51 15.59 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.761 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.504 HG12 ' N ' ' H' ' 13' ' ' HIS . 71.5 t -118.66 158.78 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.869 0.842 . . . . 0.0 110.902 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.668 ' CD2' HE21 ' H' ' 15' ' ' GLN . 32.5 p-80 -98.65 154.24 18.09 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -178.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.566 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 58.4 t60 -87.93 167.4 13.77 Favored 'General case' 0 N--CA 1.442 -0.862 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 178.139 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.668 HE21 ' CD2' ' H' ' 13' ' ' HIS . 84.5 mt-30 -150.66 167.2 28.05 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 119.906 -0.717 . . . . 0.0 111.381 178.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -153.11 115.26 4.37 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.389 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 24.6 tp -122.64 121.86 37.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.737 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.09 123.43 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-O 121.106 0.479 . . . . 0.0 112.146 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.897 ' CZ ' HD22 ' K' ' 34' ' ' LEU . 3.3 m-85 -110.2 114.31 27.69 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 177.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.597 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 48.4 t80 -127.63 123.74 36.33 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 118.473 0.579 . . . . 0.0 110.407 -178.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.59 128.67 44.68 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 120.924 0.392 . . . . 0.0 111.918 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -144.87 153.22 41.36 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -105.28 103.7 13.29 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' H' ' 26' ' ' SER . 22.5 t -90.23 153.68 3.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 48.71 -80.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.75 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.7 OUTLIER 171.46 -170.71 0.03 OUTLIER 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 117.371 0.586 . . . . 0.0 109.578 -179.787 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.75 ' O ' ' O ' ' H' ' 26' ' ' SER . 4.9 m120 -18.67 -172.42 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 116.322 1.971 . . . . 0.0 116.322 -178.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.546 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 62.9 tttm 127.02 104.51 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.984 0 CA-C-N 113.644 -1.617 . . . . 0.0 111.307 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.98 96.86 0.07 OUTLIER Glycine 0 N--CA 1.47 0.954 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.153 176.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.99 148.12 43.94 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.514 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -146.1 124.92 5.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.263 -173.41 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -122.81 117.53 52.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.83 179.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.02 122.72 5.09 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 178.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 7.8 tt -151.44 140.38 21.01 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.557 -0.966 . . . . 0.0 111.582 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 43.0 ttp -131.74 130.17 41.58 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.298 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' H' ' 37' ' ' GLY . 11.6 t -123.77 73.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -48.2 -95.07 0.01 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 177.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.76 177.42 16.71 Favored Glycine 0 C--N 1.336 0.571 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.56 134.57 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.402 HG22 ' H ' ' H' ' 40' ' ' VAL . 15.6 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.641 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m . . . . . 0 N--CA 1.463 0.195 0 N-CA-C 110.267 -0.272 . . . . 0.0 110.267 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.458 ' ND1' ' O ' ' H' ' 12' ' ' VAL . 2.0 m80 -107.06 -172.56 2.1 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.958 0.409 . . . . 0.0 110.884 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.598 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 20.9 p-80 -135.91 176.53 8.6 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -133.18 177.73 7.44 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.588 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -138.69 115.9 11.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.039 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 39.0 mt -114.27 117.38 30.95 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -126.62 125.8 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.208 0.528 . . . . 0.0 111.614 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.974 ' CZ ' HD22 ' L' ' 34' ' ' LEU . 6.9 m-85 -113.25 115.09 27.65 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 177.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.597 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 25.8 t80 -129.27 122.96 30.71 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.482 0.583 . . . . 0.0 110.237 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.15 131.31 34.53 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.539 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -137.9 132.49 32.53 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -96.69 101.38 12.98 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.59 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.615 ' O ' ' N ' ' I' ' 26' ' ' SER . 53.6 t -91.27 158.46 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 48.9 -80.46 0.01 OUTLIER Glycine 0 CA--C 1.527 0.805 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.427 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.615 ' N ' ' O ' ' I' ' 24' ' ' VAL . 2.4 p 171.16 171.21 0.08 Allowed 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.397 0.618 . . . . 0.0 110.052 -179.481 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.589 ' O ' ' O ' ' I' ' 26' ' ' SER . 23.0 p30 -16.13 158.41 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.335 -1.757 . . . . 0.0 115.5 -176.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.556 ' O ' ' O ' ' J' ' 29' ' ' GLY . 63.5 tttp -161.17 111.03 1.66 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.497 176.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.73 92.8 0.2 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 150.71 52.03 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.514 HD12 ' CG2' ' H' ' 31' ' ' ILE . 0.0 OUTLIER -151.57 123.43 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 C-N-CA 118.711 -1.196 . . . . 0.0 110.943 -174.989 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.534 ' CG2' HD11 ' J' ' 34' ' ' LEU . 97.3 mt -116.69 116.21 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.279 178.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.65 98.03 1.03 Allowed Glycine 0 N--CA 1.462 0.381 0 N-CA-C 105.888 -2.885 . . . . 0.0 105.888 175.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -122.61 129.07 51.48 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.68 0.752 . . . . 0.0 112.334 -176.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 78.9 mtp -108.91 112.78 25.19 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.434 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.502 ' H ' ' HG2' ' J' ' 35' ' ' MET . 0.2 OUTLIER -123.54 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 177.454 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.6 111.2 3.22 Favored Glycine 0 C--N 1.364 2.107 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.0 179.38 1.56 Allowed Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.39 156.24 41.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.365 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.571 -179.701 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -82.54 140.84 33.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.659 0.266 . . . . 0.0 110.314 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -141.74 159.92 41.23 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.931 0.396 . . . . 0.0 110.874 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' J' ' 13' ' ' HIS . 25.8 t -120.57 161.22 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.469 ' N ' ' CG1' ' J' ' 12' ' ' VAL . 28.9 p-80 -71.48 150.54 44.77 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -176.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.598 ' NE2' ' CG ' ' I' ' 14' ' ' HIS . 43.8 p-80 -152.86 172.87 16.09 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 113.918 -1.492 . . . . 0.0 107.167 179.326 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -144.36 174.12 11.19 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.59 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.654 ' C ' HD12 ' J' ' 17' ' ' LEU . 99.2 mttt -148.73 112.47 5.09 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.333 -0.849 . . . . 0.0 109.974 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.654 HD12 ' C ' ' J' ' 16' ' ' LYS . 10.5 mp -117.52 121.21 40.38 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.91 123.28 58.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.937 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.643 ' CE1' ' CE2' ' K' ' 19' ' ' PHE . 94.9 m-85 -115.87 117.09 29.24 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -123.22 111.24 16.23 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.54 132.93 46.97 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -120.84 87.89 2.84 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.216 -0.902 . . . . 0.0 108.862 177.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.577 ' C ' ' HZ2' ' K' ' 28' ' ' LYS . 20.9 m-20 -68.33 -102.42 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 114.602 -1.181 . . . . 0.0 108.53 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.552 HG12 ' N ' ' J' ' 25' ' ' GLY . 34.5 t 46.43 157.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 122.661 1.22 . . . . 0.0 114.254 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.552 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 91.67 -80.25 1.26 Allowed Glycine 0 CA--C 1.527 0.843 0 CA-C-N 113.219 -1.809 . . . . 0.0 110.46 -176.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.606 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.8 p 170.28 170.48 0.06 Allowed 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 118.092 0.946 . . . . 0.0 109.729 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.606 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.8 t-20 -17.66 157.75 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.699 0 O-C-N 124.953 1.408 . . . . 0.0 114.02 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.583 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 61.3 tttt -161.6 110.55 1.53 Allowed 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 173.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.556 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -68.13 93.06 0.27 Allowed Glycine 0 C--O 1.216 -1.0 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.75 177.049 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.472 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -143.28 143.25 31.64 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 103.061 -2.94 . . . . 0.0 103.061 173.404 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.505 HD12 ' CG2' ' I' ' 31' ' ' ILE . 0.2 OUTLIER -152.37 111.76 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 118.424 -1.31 . . . . 0.0 108.929 -171.546 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.485 HG22 ' H ' ' K' ' 33' ' ' GLY . 0.1 OUTLIER -111.6 111.92 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.046 0.451 . . . . 0.0 109.86 -179.491 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.593 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -112.16 94.56 0.75 Allowed Glycine 0 C--O 1.239 0.447 0 N-CA-C 107.398 -2.281 . . . . 0.0 107.398 176.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.593 HD12 ' C ' ' J' ' 33' ' ' GLY . 9.7 mp -117.33 127.15 53.77 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 122.279 1.038 . . . . 0.0 111.307 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.502 ' HG2' ' H ' ' I' ' 36' ' ' VAL . 0.1 OUTLIER -101.57 118.59 37.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.521 178.315 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 98.2 t -133.9 76.55 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.49 104.58 2.07 Favored Glycine 0 C--N 1.352 1.443 0 CA-C-N 115.353 -0.839 . . . . 0.0 111.849 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.61 -176.76 40.0 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.6 m -134.4 162.5 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.682 0.277 . . . . 0.0 110.509 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 95.0 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.886 -179.76 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -111.53 145.79 38.46 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.706 0.288 . . . . 0.0 110.655 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -53.78 148.85 9.39 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.879 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -134.04 156.59 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 121.891 0.853 . . . . 0.0 111.996 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -170.17 83.42 0.11 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.074 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -154.98 169.0 25.1 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 65.5 mt-30 -149.9 178.31 9.03 Favored 'General case' 0 C--N 1.312 -1.047 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.004 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -126.66 109.45 12.1 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.717 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 55.8 mt -111.23 113.04 25.25 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.9 t -126.24 114.13 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 O-C-N 122.015 -0.428 . . . . 0.0 111.091 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.718 ' O ' ' C ' ' L' ' 19' ' ' PHE . 76.0 m-85 -116.86 105.31 12.22 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 177.139 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.448 ' HA ' ' O ' ' L' ' 19' ' ' PHE . 91.0 t80 -128.3 125.99 39.91 Favored 'General case' 0 N--CA 1.482 1.151 0 O-C-N 124.287 0.992 . . . . 0.0 112.219 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.492 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -147.36 156.32 42.79 Favored 'General case' 0 C--N 1.353 0.732 0 C-N-CA 118.502 -1.279 . . . . 0.0 114.236 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -127.3 137.27 52.79 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.42 ' O ' HG11 ' L' ' 24' ' ' VAL . 11.4 p-10 -165.5 135.43 3.55 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 118.868 -1.133 . . . . 0.0 113.725 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.592 HG13 ' O ' ' K' ' 24' ' ' VAL . 13.1 p -70.83 112.74 5.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -50.59 92.47 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.526 -1.215 . . . . 0.0 114.546 -175.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.451 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.5 t 162.35 160.5 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.766 0 CA-C-O 121.801 0.81 . . . . 0.0 110.134 176.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.451 ' O ' ' O ' ' K' ' 26' ' ' SER . 31.4 m120 -29.7 159.8 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 113.785 -1.552 . . . . 0.0 113.207 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.577 ' HZ2' ' C ' ' J' ' 23' ' ' ASP . 75.6 tttt 179.48 104.01 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.228 175.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -65.62 94.7 0.2 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.923 -0.932 . . . . 0.0 113.781 177.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.638 ' O ' HG23 ' K' ' 31' ' ' ILE . . . -168.01 147.08 4.67 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.638 HG23 ' O ' ' K' ' 30' ' ' ALA . 0.1 OUTLIER -160.37 130.02 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.54 0 C-N-CA 118.283 -1.367 . . . . 0.0 113.575 -176.311 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.422 ' O ' HG23 ' K' ' 32' ' ' ILE . 12.8 tt -108.51 113.85 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 175.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.485 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -121.35 121.69 4.88 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.897 HD22 ' CZ ' ' H' ' 19' ' ' PHE . 20.1 tp -140.66 136.99 33.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.781 0.801 . . . . 0.0 110.214 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.545 ' H ' HD12 ' K' ' 34' ' ' LEU . 1.7 ttm -112.03 124.09 51.67 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.664 HG22 HD11 ' L' ' 34' ' ' LEU . 5.4 m -124.06 79.38 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -69.4 103.3 1.07 Allowed Glycine 0 C--N 1.35 1.308 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.48 146.9 17.38 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -127.12 136.78 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 120.734 0.302 . . . . 0.0 110.223 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . 0.418 ' H ' HG22 ' K' ' 40' ' ' VAL . 16.0 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.422 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -90.22 128.05 36.29 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.754 0.312 . . . . 0.0 110.81 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -140.06 160.83 39.06 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 109.935 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.438 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 49.6 t -118.63 130.17 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.553 0.692 . . . . 0.0 110.372 179.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.438 ' CD2' ' O ' ' L' ' 12' ' ' VAL . 88.6 m-70 -156.86 110.44 2.63 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.583 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.509 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 35.3 t-80 -156.85 175.67 13.77 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.039 0.447 . . . . 0.0 109.881 -179.054 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.509 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 77.8 mt-30 -142.4 -179.97 6.59 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.216 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -164.66 114.48 1.16 Allowed 'General case' 0 C--O 1.234 0.261 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.7 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 17.5 mt -116.02 121.25 41.68 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -112.36 133.1 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 118.802 0.728 . . . . 0.0 110.966 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.718 ' C ' ' O ' ' K' ' 19' ' ' PHE . 63.6 m-85 -42.37 141.56 0.95 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 -172.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.567 ' N ' ' O ' ' K' ' 19' ' ' PHE . 50.5 p90 -99.93 -169.47 1.74 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-N 108.638 -3.892 . . . . 0.0 110.363 179.298 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -23.47 135.24 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -173.282 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -70.46 159.38 34.35 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 113.04 -1.891 . . . . 0.0 109.239 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -50.52 114.05 1.04 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.106 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 25' ' ' GLY . 3.5 m -127.82 121.22 55.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.812 -178.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -27.84 -87.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.956 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -67.2 -173.01 0.24 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-O 121.222 0.534 . . . . 0.0 109.992 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.551 HD21 ' C ' ' F' ' 39' ' ' VAL . 72.4 m-20 -78.73 175.88 10.04 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.025 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 32.2 tttm -49.12 111.21 0.45 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 114.219 -1.355 . . . . 0.0 113.967 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.47 -97.86 0.05 OUTLIER Glycine 0 C--O 1.223 -0.593 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.535 ' HB2' ' HD3' ' K' ' 28' ' ' LYS . . . -60.95 172.23 1.03 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 120.265 2.033 . . . . 0.0 106.544 -179.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.646 HD13 ' HA2' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -146.9 141.26 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 117.236 -1.786 . . . . 0.0 114.375 -173.586 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.622 ' O ' ' SD ' ' F' ' 35' ' ' MET . 88.4 mt -109.14 114.66 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 CA-C-N 114.061 -1.427 . . . . 0.0 110.131 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.92 91.25 0.56 Allowed Glycine 0 CA--C 1.517 0.179 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 177.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.974 HD22 ' CZ ' ' I' ' 19' ' ' PHE . 18.9 tp -117.72 120.65 38.61 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.205 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 42.2 ttp -97.08 119.19 35.11 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.084 179.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' L' ' 37' ' ' GLY . 1.4 m -130.25 71.01 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -29.8 -102.67 0.01 OUTLIER Glycine 0 C--N 1.358 1.802 0 O-C-N 122.935 0.147 . . . . 0.0 112.892 -178.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.61 163.07 35.86 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -136.81 162.64 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.913 0.387 . . . . 0.0 110.661 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.635 -179.414 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p . . . . . 0 N--CA 1.465 0.302 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.757 ' HB2' ' HD1' ' B' ' 13' ' ' HIS . 98.7 m-70 -131.25 138.83 49.49 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.161 0.505 . . . . 0.0 111.295 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.583 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 10.5 t-80 -156.85 165.85 35.04 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.583 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 51.2 tt0 -169.52 169.93 8.52 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.537 179.265 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.407 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 65.5 mttm -152.27 115.12 4.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.983 178.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 35.3 tp -121.37 121.6 37.99 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 109.945 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 18' ' ' VAL . 35.5 m -122.85 122.68 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 CA-C-O 121.351 0.596 . . . . 0.0 111.246 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.461 ' CD1' ' CE1' ' B' ' 19' ' ' PHE . 15.6 t80 -123.64 106.41 10.52 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 178.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -134.39 145.94 49.4 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.01 117.76 13.16 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.122 -0.945 . . . . 0.0 108.512 177.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -130.76 157.65 42.27 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.408 ' OD1' ' C ' ' A' ' 23' ' ' ASP . 47.5 t0 -98.42 112.69 24.62 Favored 'General case' 0 N--CA 1.462 0.158 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.518 ' O ' ' C ' ' A' ' 25' ' ' GLY . 2.1 p -147.72 113.49 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 103.595 -2.742 . . . . 0.0 103.595 172.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.518 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -19.87 87.17 0.01 OUTLIER Glycine 0 N--CA 1.476 1.303 0 CA-C-O 119.282 -0.732 . . . . 0.0 112.522 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.483 ' N ' ' O ' ' A' ' 24' ' ' VAL . 40.9 t -67.97 -179.72 1.28 Allowed 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 119.219 1.509 . . . . 0.0 108.046 178.044 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 53.2 p30 -87.31 174.93 8.26 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt 35.85 -108.45 0.05 OUTLIER 'General case' 0 CA--C 1.538 0.514 0 CA-C-O 122.28 1.038 . . . . 0.0 113.574 173.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 30' ' ' ALA . . . 90.59 -102.04 2.87 Favored Glycine 1 CA--C 1.427 -5.457 0 CA-C-N 113.157 -1.838 . . . . 0.0 108.635 -177.384 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 29' ' ' GLY . . . 56.63 -146.95 0.54 Allowed 'General case' 0 N--CA 1.405 -2.7 0 C-N-CA 113.497 -3.281 . . . . 0.0 109.7 173.251 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.68 ' H ' ' CD1' ' A' ' 31' ' ' ILE 0.252 0.0 OUTLIER -89.89 113.65 26.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 CA-C-N 113.259 -1.791 . . . . 0.0 113.688 -179.788 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' G' ' 35' ' ' MET . 87.1 mt -130.03 120.17 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 O-C-N 120.103 -1.623 . . . . 0.0 109.922 178.395 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.609 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.68 113.63 1.53 Allowed Glycine 0 CA--C 1.52 0.375 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -133.29 134.9 44.47 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.99 0.424 . . . . 0.0 110.72 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 5.9 ttm -125.44 129.62 50.21 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.738 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.92 70.8 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 120.656 -0.417 . . . . 0.0 111.473 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -114.66 100.65 1.02 Allowed Glycine 0 C--N 1.341 0.811 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 177.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.65 41.6 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.554 -1.018 . . . . 0.0 110.554 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m . . . . . 0 C--N 1.33 -0.267 0 CA-C-O 120.76 0.314 . . . . 0.0 110.383 -179.893 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.483 HG12 ' N ' ' B' ' 13' ' ' HIS . 33.5 t . . . . . 0 N--CA 1.465 0.304 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.757 ' HD1' ' HB2' ' A' ' 13' ' ' HIS . 86.0 t60 -157.87 101.47 1.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.628 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 55.7 m170 -110.2 167.44 10.19 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -152.43 176.7 11.38 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.231 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -171.46 111.95 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.638 178.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 64.1 mt -120.98 120.33 35.11 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.5 t -120.79 121.6 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 120.889 -0.325 . . . . 0.0 111.432 -179.053 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.485 ' CZ ' HD23 ' D' ' 34' ' ' LEU . 12.0 t80 -120.7 110.54 16.51 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -119.32 117.11 27.67 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.22 119.92 34.61 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -177.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' B' ' 23' ' ' ASP . 95.3 mt-10 -153.05 89.82 1.4 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 115.162 -0.926 . . . . 0.0 108.754 176.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.532 ' OD2' ' HB2' ' D' ' 30' ' ' ALA . 49.5 t0 8.2 113.63 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 114.039 1.125 . . . . 0.0 114.039 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 85.4 t -58.56 131.2 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.205 0.526 . . . . 0.0 110.367 178.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.34 84.67 0.13 Allowed Glycine 0 CA--C 1.529 0.927 0 CA-C-N 115.415 -0.811 . . . . 0.0 113.768 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.517 ' O ' ' O ' ' B' ' 27' ' ' ASN . 39.0 m -132.24 162.67 30.38 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 118.284 1.042 . . . . 0.0 110.003 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.517 ' O ' ' O ' ' B' ' 26' ' ' SER . 65.5 t30 -38.44 177.72 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.632 179.384 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.44 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 98.7 mttt -73.31 111.87 8.84 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' C' ' 29' ' ' GLY . . . 71.22 92.5 0.08 OUTLIER Glycine 0 N--CA 1.464 0.567 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 -178.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.58 152.66 49.72 Favored 'General case' 0 CA--C 1.487 -1.465 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 174.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.603 ' N ' HD12 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -139.89 117.44 10.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -173.989 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.524 ' O ' ' SD ' ' I' ' 35' ' ' MET . 81.6 mt -122.13 126.63 74.62 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.733 -177.014 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.1 118.53 3.59 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 42.3 tp -126.53 118.45 24.92 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.292 0.568 . . . . 0.0 110.557 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.8 tpt -106.4 115.52 30.35 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' B' ' 37' ' ' GLY . 8.8 t -112.65 74.16 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.782 -0.19 . . . . 0.0 110.823 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.594 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -40.07 -95.84 0.01 OUTLIER Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -170.68 40.02 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m -135.72 161.9 37.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.896 0.379 . . . . 0.0 110.344 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.572 179.969 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -86.88 144.87 26.8 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.379 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . 0.424 ' OE2' ' NE2' ' C' ' 13' ' ' HIS . 84.6 tt0 -142.32 136.25 29.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.957 0.408 . . . . 0.0 110.55 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 5.6 m -126.23 131.56 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.008 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.424 ' NE2' ' OE2' ' C' ' 11' ' ' GLU . 82.1 m-70 -114.75 127.18 55.6 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.162 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CG ' ' D' ' 13' ' ' HIS . 4.0 m-70 -119.04 164.08 16.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 79.7 mt-30 -156.68 170.42 22.46 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 121.234 0.54 . . . . 0.0 110.818 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -168.0 113.83 0.68 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.362 178.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 tp -128.15 123.64 34.89 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 35.6 m -124.87 126.68 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.524 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 47.3 t80 -123.78 111.04 15.65 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.929 -178.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -114.56 119.35 36.5 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 120.428 0.156 . . . . 0.0 110.767 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.82 115.97 27.85 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.8 mt-10 -150.7 169.4 21.69 Favored 'General case' 0 C--N 1.347 0.473 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.707 -179.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.5 ' HB2' ' HZ3' ' E' ' 28' ' ' LYS . 74.8 m-20 -155.45 121.2 5.03 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.794 HG22 ' N ' ' C' ' 25' ' ' GLY . 3.5 p -136.73 -112.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.311 -177.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.794 ' N ' HG22 ' C' ' 24' ' ' VAL . . . 30.38 -89.21 0.01 OUTLIER Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.434 -177.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.4 t 171.54 177.73 0.07 Allowed 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 117.817 0.808 . . . . 0.0 109.687 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' C' ' 26' ' ' SER . 42.4 t30 -28.46 178.07 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.722 0 O-C-N 124.766 1.291 . . . . 0.0 113.818 -179.189 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.506 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 88.8 mttt 127.66 104.91 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 C-N-CA 125.564 1.545 . . . . 0.0 111.616 175.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.42 ' O ' ' HA2' ' B' ' 29' ' ' GLY . . . -58.37 96.64 0.07 OUTLIER Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 174.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -122.54 145.69 48.1 Favored 'General case' 0 CA--C 1.479 -1.77 0 N-CA-C 104.519 -2.4 . . . . 0.0 104.519 176.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.559 HD12 HG23 ' B' ' 31' ' ' ILE . 2.0 mt -142.8 108.4 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.548 0 CA-C-N 113.851 -1.522 . . . . 0.0 108.801 -172.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.541 HG12 HD11 ' C' ' 34' ' ' LEU . 14.9 tt -120.17 128.06 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 CA-C-O 121.054 0.454 . . . . 0.0 110.176 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.407 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -133.67 122.6 3.1 Favored Glycine 0 CA--C 1.508 -0.387 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.694 HD12 ' N ' ' C' ' 34' ' ' LEU . 0.0 OUTLIER -136.96 147.44 46.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 122.085 0.945 . . . . 0.0 111.837 -179.084 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.509 ' SD ' ' O ' ' I' ' 32' ' ' ILE . 5.1 tpt -111.56 117.42 32.92 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 26.2 t -130.96 66.33 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 -179.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.451 ' O ' HD13 ' I' ' 31' ' ' ILE . . . -123.83 102.48 0.73 Allowed Glycine 0 C--N 1.358 1.772 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.83 -170.31 12.66 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 -179.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.2 t -119.47 135.03 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.703 -179.475 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 121.008 0.432 . . . . 0.0 110.485 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.708 ' CD2' ' H ' ' D' ' 14' ' ' HIS . 51.6 t60 -93.14 -169.93 2.28 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.572 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.708 ' H ' ' CD2' ' D' ' 13' ' ' HIS . 52.9 m80 -73.85 170.61 14.99 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.353 0.597 . . . . 0.0 110.146 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -148.93 173.58 13.17 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.177 179.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -147.26 114.63 6.29 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 120.898 0.38 . . . . 0.0 111.409 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -122.36 116.16 23.55 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.04 131.13 72.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.38 0.609 . . . . 0.0 110.654 -179.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.524 ' CE2' ' CD1' ' C' ' 19' ' ' PHE . 28.1 t80 -131.62 110.75 11.16 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -118.71 126.45 51.93 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.817 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.59 ' HB1' ' CD1' ' F' ' 32' ' ' ILE . . . -124.3 126.25 45.73 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.602 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -149.52 111.56 4.61 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.496 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -90.35 134.04 34.59 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.591 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.09 112.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.278 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.49 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -46.53 91.77 0.01 OUTLIER Glycine 0 CA--C 1.536 1.367 0 CA-C-O 119.125 -0.819 . . . . 0.0 114.276 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 1.4 t 161.98 161.08 0.02 OUTLIER 'General case' 0 C--O 1.212 -0.89 0 CA-C-N 118.472 1.136 . . . . 0.0 112.303 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.49 ' O ' ' HB3' ' D' ' 28' ' ' LYS . 73.7 m-80 -33.48 -179.26 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 112.998 -1.91 . . . . 0.0 116.118 178.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.49 ' HB3' ' O ' ' D' ' 27' ' ' ASN . 87.1 tttt 99.64 113.8 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 128.398 2.679 . . . . 0.0 115.73 177.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.29 92.53 0.58 Allowed Glycine 0 C--N 1.348 1.238 0 CA-C-N 111.868 -2.423 . . . . 0.0 114.474 173.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.532 ' HB2' ' OD2' ' B' ' 23' ' ' ASP . . . -127.99 151.54 49.02 Favored 'General case' 0 CA--C 1.501 -0.911 0 CA-C-N 121.369 2.584 . . . . 0.0 106.725 173.614 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.488 HD12 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -146.03 116.84 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.56 -173.582 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.25 124.92 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.81 99.19 0.53 Allowed Glycine 0 N--CA 1.464 0.534 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 177.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.636 HD12 ' O ' ' C' ' 34' ' ' LEU . 40.7 tp -126.3 130.23 50.43 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 122.75 1.262 . . . . 0.0 112.69 -179.07 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.415 ' N ' HD12 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -104.54 110.92 23.4 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 113.688 -1.596 . . . . 0.0 107.302 176.372 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.485 HG23 ' O ' ' E' ' 35' ' ' MET . 0.1 OUTLIER -126.68 71.38 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.758 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -34.27 -100.46 0.01 OUTLIER Glycine 0 C--N 1.357 1.696 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.33 -168.06 40.65 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.2 160.58 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.955 0.407 . . . . 0.0 110.933 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.711 -179.978 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -114.47 139.17 49.75 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -113.67 141.26 47.45 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.941 0.4 . . . . 0.0 110.802 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.438 HG22 ' ND1' ' F' ' 13' ' ' HIS . 19.1 m -134.29 158.07 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.95 179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.49 ' ND1' ' CE1' ' D' ' 14' ' ' HIS . 12.1 m170 -86.75 178.31 7.05 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.633 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.1 OUTLIER -77.08 172.23 13.55 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -179.359 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.493 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 44.2 tt0 -148.2 170.17 18.44 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.113 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.493 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 99.1 mttt -144.16 117.28 8.92 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.123 0.487 . . . . 0.0 111.165 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.2 tt -119.21 114.95 23.23 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 t -124.06 120.46 59.53 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.601 0.715 . . . . 0.0 111.743 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.569 ' O ' ' N ' ' F' ' 20' ' ' PHE . 10.2 m-85 -126.39 104.54 8.23 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 48.1 t80 -121.97 129.6 52.63 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 122.975 0.172 . . . . 0.0 111.092 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.721 ' O ' ' HB3' ' F' ' 21' ' ' ALA . . . -133.82 135.39 43.75 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-O 123.362 1.553 . . . . 0.0 113.332 178.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -145.14 105.37 4.06 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.976 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.431 ' O ' ' OD2' ' F' ' 23' ' ' ASP . 4.2 t0 -83.04 122.63 28.58 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.49 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 63.4 t -72.8 120.42 21.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.353 0.597 . . . . 0.0 111.863 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.9 -90.25 0.04 OUTLIER Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.016 -0.993 . . . . 0.0 114.633 176.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.638 ' O ' ' O ' ' E' ' 27' ' ' ASN . 9.7 p -171.14 -178.61 2.47 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-O 121.153 0.502 . . . . 0.0 110.992 -176.423 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.638 ' O ' ' O ' ' E' ' 26' ' ' SER . 92.1 m-20 20.62 -179.81 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 117.12 2.267 . . . . 0.0 117.12 178.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.512 ' CB ' ' O ' ' E' ' 27' ' ' ASN . 78.2 tttt 128.68 106.13 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 112.381 -2.19 . . . . 0.0 110.002 -177.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -55.32 93.6 0.02 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.054 176.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.73 144.64 18.07 Favored 'General case' 0 CA--C 1.477 -1.843 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 174.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.434 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -154.55 125.66 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 117.946 -1.502 . . . . 0.0 111.177 -173.029 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -109.51 117.42 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.768 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . 0.458 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -109.63 97.86 1.07 Allowed Glycine 0 C--O 1.231 -0.074 0 N-CA-C 106.28 -2.728 . . . . 0.0 106.28 176.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.444 ' O ' ' HA ' ' F' ' 34' ' ' LEU . 6.9 tt -138.87 128.68 24.95 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-O 123.01 1.386 . . . . 0.0 113.427 -176.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.485 ' O ' HG23 ' D' ' 36' ' ' VAL . 97.3 mmm -106.98 120.27 41.62 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 114.097 -1.41 . . . . 0.0 110.489 179.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.1 OUTLIER -116.39 72.31 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 176.968 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -27.71 -101.03 0.01 OUTLIER Glycine 0 C--N 1.366 2.218 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.32 -176.71 25.67 Favored Glycine 0 N--CA 1.461 0.365 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -129.22 160.18 40.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.28 -0.46 . . . . 0.0 109.995 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.903 -1.046 . . . . 0.0 110.565 179.859 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.506 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.7 p . . . . . 0 CA--C 1.53 0.187 0 N-CA-C 109.964 -0.384 . . . . 0.0 109.964 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.506 ' N ' HG22 ' F' ' 12' ' ' VAL . 17.5 m-70 -95.02 97.99 10.35 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.586 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.569 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 82.9 t60 -156.36 167.74 29.49 Favored 'General case' 0 N--CA 1.446 -0.672 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.569 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 12.0 pt20 -167.33 177.83 5.86 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.104 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -121.55 123.97 43.26 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.664 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 mt -122.94 121.21 35.59 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 111.653 0.242 . . . . 0.0 111.653 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.89 133.11 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 177.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.54 ' O ' ' O ' ' F' ' 20' ' ' PHE . 98.0 m-85 -114.24 136.58 52.8 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -177.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.605 ' O ' ' HB2' ' F' ' 21' ' ' ALA . 42.0 p90 -20.58 -157.29 0.0 OUTLIER 'General case' 0 C--O 1.195 -1.792 0 N-CA-C 118.991 2.96 . . . . 0.0 118.991 -175.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.721 ' HB3' ' O ' ' E' ' 21' ' ' ALA . . . 175.54 -168.56 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 122.213 1.006 . . . . 0.0 111.54 -173.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -170.97 167.27 7.35 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 114.473 -1.24 . . . . 0.0 107.964 -177.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.431 ' OD2' ' O ' ' E' ' 23' ' ' ASP . 23.6 m-20 . . . . . 0 N--CA 1.475 0.803 0 CA-C-N 119.05 0.841 . . . . 0.0 111.823 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 44.6 tttm . . . . . 0 N--CA 1.473 0.68 0 CA-C-O 121.224 0.535 . . . . 0.0 111.531 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -50.27 -99.42 0.01 OUTLIER Glycine 0 CA--C 1.506 -0.488 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.553 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.76 173.39 12.65 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.7 118.41 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 116.302 -2.159 . . . . 0.0 114.101 -170.38 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.59 ' CD1' ' HB1' ' D' ' 21' ' ' ALA . 59.4 mt -98.83 112.1 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.054 177.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -109.72 89.68 0.56 Allowed Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 105.831 -2.907 . . . . 0.0 105.831 177.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.75 HD23 ' C ' ' F' ' 34' ' ' LEU . 0.8 OUTLIER -141.29 147.65 38.53 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 120.714 -0.394 . . . . 0.0 109.952 -177.894 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.543 ' CE ' HG22 ' L' ' 31' ' ' ILE . 3.6 ttp -137.05 133.95 36.0 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.943 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.666 HG13 HD21 ' F' ' 34' ' ' LEU . 1.9 m -114.28 80.32 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.909 -179.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.409 ' HA2' HG21 ' L' ' 31' ' ' ILE . . . 50.82 -102.66 0.07 OUTLIER Glycine 0 C--N 1.342 0.862 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.763 178.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.44 -156.49 15.49 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 90.9 t -122.96 136.22 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.833 0.349 . . . . 0.0 110.959 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 m . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.482 179.683 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -100.93 127.56 47.36 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -88.68 156.89 18.75 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.488 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 3.4 m -132.85 154.69 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.164 0.507 . . . . 0.0 110.601 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 96.2 m-70 -158.2 167.11 30.71 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.153 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -122.53 179.1 4.71 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 98.7 mt-30 -96.85 176.6 5.92 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.376 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -113.96 144.04 43.73 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.098 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.3 mt -119.07 126.83 52.6 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.048 0.452 . . . . 0.0 110.786 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.548 ' O ' HG23 ' G' ' 18' ' ' VAL . 25.9 m -133.44 119.96 36.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 121.18 0.514 . . . . 0.0 110.658 179.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.879 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 2.4 m-85 -113.07 119.63 38.51 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.26 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.528 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 48.5 p90 -122.2 121.78 37.65 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.071 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.94 122.47 42.31 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 120.55 -0.46 . . . . 0.0 111.812 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -166.73 89.17 0.36 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.698 ' H ' ' NZ ' ' I' ' 28' ' ' LYS . 90.8 m-20 -85.71 102.78 13.91 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.993 0.425 . . . . 0.0 112.131 -177.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.412 ' O ' ' O ' ' G' ' 23' ' ' ASP . 18.3 m -56.78 -160.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.489 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -77.59 80.51 1.3 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-O 119.524 -0.598 . . . . 0.0 112.947 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.416 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 30.9 t -94.4 176.55 6.26 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 118.76 1.28 . . . . 0.0 107.879 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -60.14 178.24 0.2 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 119.166 -1.013 . . . . 0.0 111.096 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -60.77 110.71 1.39 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.064 -0.517 . . . . 0.0 112.318 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.87 94.25 0.08 OUTLIER Glycine 0 N--CA 1.465 0.61 0 C-N-CA 118.381 -1.866 . . . . 0.0 112.601 174.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.43 158.72 16.46 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-N 119.935 1.867 . . . . 0.0 106.464 177.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.831 HD12 ' H ' ' G' ' 31' ' ' ILE . 0.2 OUTLIER -150.31 114.72 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.382 -174.427 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 97.3 mt -125.27 124.98 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.224 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.02 123.12 3.92 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 tp -131.03 133.7 45.99 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 117.211 0.505 . . . . 0.0 111.32 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.609 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 63.4 ttp -130.82 134.91 47.25 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.421 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.52 79.78 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.79 104.64 1.27 Allowed Glycine 0 C--N 1.342 0.905 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 44.05 -167.2 0.02 OUTLIER Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.24 160.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 120.855 0.36 . . . . 0.0 110.65 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.515 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -80.91 136.12 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.781 0.324 . . . . 0.0 110.624 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -52.64 137.63 30.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.466 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.403 HG23 ' O ' ' I' ' 12' ' ' VAL . 2.3 p -127.41 132.87 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.159 0.504 . . . . 0.0 110.744 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.51 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 34.5 m170 -126.99 111.38 14.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.106 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.448 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 84.0 t60 -114.05 162.15 16.82 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.448 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 83.3 mt-30 -156.72 177.9 10.96 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.136 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -167.73 111.23 0.65 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.824 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.498 ' HB2' HD22 ' I' ' 17' ' ' LEU . 5.3 mp -116.96 120.92 39.91 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 66.7 t -124.0 123.34 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 121.343 0.592 . . . . 0.0 110.786 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.776 ' CE1' HD13 ' J' ' 34' ' ' LEU . 11.5 m-85 -117.02 115.49 25.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.132 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -143.13 132.2 23.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.967 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 138.84 41.06 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.105 0.955 . . . . 0.0 112.777 -178.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -131.01 105.91 8.04 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 105.861 -1.903 . . . . 0.0 105.861 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -77.95 117.25 19.1 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -175.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.556 ' O ' ' N ' ' H' ' 26' ' ' SER . 55.0 t -102.46 125.94 56.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.6 83.05 0.0 OUTLIER Glycine 0 CA--C 1.537 1.443 0 CA-C-O 119.536 -0.591 . . . . 0.0 113.291 178.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.556 ' N ' ' O ' ' H' ' 24' ' ' VAL . 17.4 p -94.15 176.8 6.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 177.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' O ' ' G' ' 26' ' ' SER . 28.1 m120 -60.11 178.22 0.2 Allowed 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.247 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -60.63 110.66 1.35 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.03 94.17 0.08 OUTLIER Glycine 0 N--CA 1.469 0.869 0 C-N-CA 118.741 -1.695 . . . . 0.0 114.815 173.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.19 157.57 17.47 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 102.659 -3.089 . . . . 0.0 102.659 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.705 HG23 HG13 ' I' ' 31' ' ' ILE . 0.1 OUTLIER -145.86 121.61 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 118.146 -1.421 . . . . 0.0 112.207 -171.552 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 93.0 mt -132.57 127.47 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.381 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.74 128.6 5.55 Favored Glycine 0 N--CA 1.472 1.097 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.786 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 mp -132.6 130.66 40.53 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.284 0.564 . . . . 0.0 111.458 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.3 tmm? -129.67 127.32 40.29 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.454 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' H' ' 37' ' ' GLY . 66.9 t -107.41 86.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -179.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.493 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -15.48 -93.38 0.01 OUTLIER Glycine 0 C--N 1.346 1.084 0 O-C-N 123.859 0.724 . . . . 0.0 112.288 177.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.44 -176.13 42.32 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.62 162.23 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 120.715 0.293 . . . . 0.0 110.501 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.403 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.361 179.791 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.48 HG23 ' CD2' ' I' ' 14' ' ' HIS . 35.7 m . . . . . 0 N--CA 1.469 0.514 0 N-CA-C 111.541 0.2 . . . . 0.0 111.541 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.533 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 53.3 m-70 -68.43 145.1 54.4 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -177.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.48 ' CD2' HG23 ' I' ' 12' ' ' VAL . 47.8 m-70 -154.66 169.28 24.25 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.382 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.403 ' HG2' ' N ' ' I' ' 16' ' ' LYS . 54.8 tt0 -159.99 168.3 25.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.033 178.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.403 ' N ' ' HG2' ' I' ' 15' ' ' GLN . 99.2 mttt -154.64 131.54 10.83 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.51 0.195 . . . . 0.0 110.539 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.509 HD12 ' CE2' ' I' ' 19' ' ' PHE . 0.0 OUTLIER -127.72 119.91 26.82 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.68 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 70.7 t -126.24 129.53 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 120.629 -0.428 . . . . 0.0 112.151 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.702 ' CE1' HD22 ' K' ' 34' ' ' LEU . 61.2 m-85 -123.22 121.75 36.68 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.924 179.169 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.419 ' CE2' ' CG ' ' J' ' 20' ' ' PHE . 7.5 m-85 -131.67 130.69 42.37 Favored 'General case' 0 N--CA 1.476 0.867 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 135.17 39.23 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -137.76 150.28 47.12 Favored 'General case' 0 C--N 1.352 0.692 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.247 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.435 ' OD2' ' O ' ' J' ' 26' ' ' SER . 13.4 t70 -116.95 114.53 23.96 Favored 'General case' 0 N--CA 1.481 1.115 0 O-C-N 122.21 -0.306 . . . . 0.0 111.36 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.458 ' O ' ' N ' ' I' ' 26' ' ' SER . 14.7 t -81.59 130.93 34.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.8 -85.8 0.01 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.529 ' O ' ' O ' ' I' ' 27' ' ' ASN . 26.1 p -153.62 -172.86 4.37 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-O 121.639 0.733 . . . . 0.0 111.224 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.686 ' H ' ' NZ ' ' K' ' 28' ' ' LYS . 64.8 t30 -19.71 159.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 113.303 -1.771 . . . . 0.0 115.156 178.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.698 ' NZ ' ' H ' ' G' ' 23' ' ' ASP . 74.1 tttt -161.21 110.83 1.64 Allowed 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 114.744 -1.116 . . . . 0.0 109.376 175.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.33 93.23 0.23 Allowed Glycine 0 CA--C 1.508 -0.369 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 177.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.73 147.05 51.3 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 176.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.705 HG13 HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -146.68 113.97 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.942 -175.583 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.509 ' O ' ' SD ' ' C' ' 35' ' ' MET . 0.1 OUTLIER -110.76 124.56 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.522 179.471 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.35 102.84 1.39 Allowed Glycine 0 N--CA 1.46 0.292 0 N-CA-C 108.446 -1.862 . . . . 0.0 108.446 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.879 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 23.1 tp -119.0 126.68 52.29 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 117.277 0.538 . . . . 0.0 111.817 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.524 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 12.2 ptm -131.9 110.87 11.1 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 174.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.599 HG13 HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -121.18 72.02 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.652 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.57 179.554 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.61 102.81 2.33 Favored Glycine 0 C--N 1.36 1.869 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.62 157.36 22.07 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.4 t -124.28 136.56 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.913 0.387 . . . . 0.0 110.53 -179.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.377 179.78 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.426 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -83.38 138.48 33.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.797 0.332 . . . . 0.0 110.478 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . 0.461 ' O ' HG12 ' K' ' 12' ' ' VAL . 79.9 tt0 -152.34 137.54 17.43 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.408 -179.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.435 ' HB ' ' H ' ' K' ' 13' ' ' HIS . 0.2 OUTLIER -93.03 126.93 45.4 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.694 0 CA-C-O 121.319 0.58 . . . . 0.0 109.847 -179.932 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.545 ' O ' ' CD2' ' J' ' 14' ' ' HIS . 18.3 t60 -164.92 111.76 0.99 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.233 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' K' ' 13' ' ' HIS . 86.2 m-70 -154.55 177.23 11.43 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -133.82 177.58 7.61 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.731 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -137.54 131.77 32.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 mt -117.89 121.7 41.41 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.673 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 67.8 t -122.47 121.21 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-O 120.948 0.404 . . . . 0.0 110.961 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.862 ' CE1' HD22 ' L' ' 34' ' ' LEU . 96.9 m-85 -113.39 114.49 26.68 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 178.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 19.2 t80 -129.03 123.34 32.09 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.988 0.423 . . . . 0.0 111.634 -177.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.94 124.12 32.31 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.05 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.4 tt0 -103.52 156.81 17.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.131 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.456 ' CG ' ' N ' ' J' ' 24' ' ' VAL . 35.2 t70 -78.13 -113.89 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.341 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' J' ' 26' ' ' SER . 4.1 t 73.45 124.45 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.57 -87.09 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -177.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.678 ' O ' ' O ' ' J' ' 27' ' ' ASN . 0.5 OUTLIER 170.79 176.17 0.06 Allowed 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.702 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.678 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.4 m120 -28.3 170.42 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.13 0 O-C-N 124.319 1.012 . . . . 0.0 112.074 177.446 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.561 ' O ' ' N ' ' J' ' 30' ' ' ALA . 37.4 pttt -148.73 111.55 4.82 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.161 -0.962 . . . . 0.0 112.208 177.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.44 91.35 0.01 OUTLIER Glycine 0 CA--C 1.505 -0.566 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 176.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -137.85 153.71 49.56 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 103.328 -2.842 . . . . 0.0 103.328 177.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.417 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -144.41 111.67 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 C-N-CA 118.265 -1.374 . . . . 0.0 109.968 -174.096 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.484 HD13 HD11 ' J' ' 34' ' ' LEU . 6.7 tt -112.71 116.63 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.293 -0.867 . . . . 0.0 108.731 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.07 103.69 2.33 Favored Glycine 0 N--CA 1.46 0.284 0 N-CA-C 107.596 -2.202 . . . . 0.0 107.596 178.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.776 HD13 ' CE1' ' H' ' 19' ' ' PHE . 24.2 mt -114.39 114.0 25.28 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 121.606 0.717 . . . . 0.0 110.247 -177.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -116.59 118.65 33.21 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.506 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.44 ' O ' ' C ' ' J' ' 37' ' ' GLY . 1.1 t -131.15 75.95 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.025 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.2 -97.56 0.01 OUTLIER Glycine 0 C--N 1.362 2.025 0 N-CA-C 112.097 -0.401 . . . . 0.0 112.097 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.97 -163.85 30.23 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 82.9 t -121.95 135.32 62.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.039 -0.982 . . . . 0.0 110.554 -179.649 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.1 137.88 50.77 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 120.89 0.376 . . . . 0.0 110.514 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.77 162.28 35.12 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.4 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.461 HG12 ' O ' ' J' ' 11' ' ' GLU . 6.0 m -110.7 133.22 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.557 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 0.4 OUTLIER -76.12 -166.01 0.55 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.259 -178.546 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 7.6 p-80 -138.23 178.45 7.12 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.607 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -99.27 175.1 5.99 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.486 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -147.42 124.95 11.69 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -117.55 124.05 47.74 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 44.9 t -127.94 126.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-O 120.832 0.349 . . . . 0.0 111.575 -179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -115.62 116.09 27.53 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.594 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.7 t80 -125.19 122.73 37.88 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.68 26.4 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.159 1.17 . . . . 0.0 114.159 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' L' ' 22' ' ' GLU . 70.3 mm-40 -90.46 152.41 20.97 Favored 'General case' 0 C--O 1.232 0.158 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 177.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.561 ' OD2' ' N ' ' L' ' 28' ' ' LYS . 28.0 t0 -148.43 116.29 6.36 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.028 0.442 . . . . 0.0 111.739 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 2.5 p -146.81 112.14 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.044 -179.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.32 91.32 0.01 OUTLIER Glycine 0 N--CA 1.472 1.064 0 CA-C-O 121.509 0.505 . . . . 0.0 112.63 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -45.15 153.86 0.18 Allowed 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 122.597 1.189 . . . . 0.0 112.511 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.514 ' O ' ' C ' ' K' ' 28' ' ' LYS . 33.9 m120 -156.85 178.58 10.19 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 112.631 -2.077 . . . . 0.0 108.483 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.686 ' NZ ' ' H ' ' I' ' 27' ' ' ASN . 0.1 OUTLIER 2.91 -104.33 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.411 0 C-N-CA 123.562 0.745 . . . . 0.0 112.05 179.816 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.436 ' H ' ' HB2' ' K' ' 28' ' ' LYS . . . 141.09 95.33 0.25 Allowed Glycine 0 N--CA 1.48 1.602 0 CA-C-N 118.986 0.812 . . . . 0.0 111.924 178.051 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.4 169.85 0.41 Allowed 'General case' 0 C--N 1.345 0.399 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.036 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.417 HD12 ' CG2' ' J' ' 31' ' ' ILE . 0.0 OUTLIER -148.53 111.97 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 118.996 -1.082 . . . . 0.0 109.035 -179.028 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.541 HG12 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -111.99 122.08 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.465 -177.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.45 108.99 2.54 Favored Glycine 0 N--CA 1.468 0.829 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.702 HD22 ' CE1' ' I' ' 19' ' ' PHE . 5.1 mt -122.09 114.96 21.63 Favored 'General case' 0 CA--C 1.501 -0.913 0 CA-C-N 117.332 0.566 . . . . 0.0 110.821 -177.261 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.458 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 33.6 ttp -120.86 114.31 21.41 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 176.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.479 HG23 HG12 ' L' ' 36' ' ' VAL . 0.0 OUTLIER -130.19 73.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 107.672 -1.232 . . . . 0.0 107.672 178.632 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.35 -101.6 0.01 OUTLIER Glycine 0 C--N 1.364 2.121 0 O-C-N 123.59 0.556 . . . . 0.0 112.482 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.35 -170.97 38.11 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -125.13 137.19 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.848 -179.788 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -100.77 132.7 46.04 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -151.32 147.39 26.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.965 0.412 . . . . 0.0 111.055 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.5 t -123.13 129.32 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.471 ' O ' ' CG ' ' L' ' 13' ' ' HIS . 56.5 p-80 -170.74 111.88 0.39 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.053 0.454 . . . . 0.0 110.973 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 96.6 m-70 -155.8 177.81 10.98 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -115.58 173.8 6.35 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.302 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 50.3 mtpt -151.25 109.54 3.76 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.959 0.409 . . . . 0.0 110.455 179.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 57.6 tp -123.66 118.51 27.44 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -130.26 133.06 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.875 0.369 . . . . 0.0 110.086 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.469 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -136.86 129.73 30.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.271 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -138.8 132.05 30.0 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.496 0.665 . . . . 0.0 110.455 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.83 138.88 42.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.498 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 95.0 mt-10 -98.4 114.73 27.19 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -102.68 121.64 42.83 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.26 0.552 . . . . 0.0 111.838 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 25.3 t -104.91 -111.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.34 -91.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' L' ' 27' ' ' ASN . 45.9 m -141.01 170.68 15.28 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' L' ' 26' ' ' SER . 93.8 m-20 -29.0 170.13 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.828 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.561 ' N ' ' OD2' ' K' ' 23' ' ' ASP . 87.8 tttt -148.35 109.99 4.46 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 176.08 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -50.84 -95.8 0.01 OUTLIER Glycine 0 C--N 1.334 0.445 0 C-N-CA 118.549 -1.786 . . . . 0.0 112.545 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.599 ' HB2' HD21 ' J' ' 27' ' ' ASN . . . 72.57 156.11 0.17 Allowed 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 100.409 -3.923 . . . . 0.0 100.409 -176.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.543 HG22 ' CE ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -144.77 107.67 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 CA-C-N 124.081 3.128 . . . . 0.0 109.237 179.781 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.648 HG23 HD23 ' L' ' 34' ' ' LEU . 1.4 tt -102.53 112.46 35.93 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 CA-C-N 113.956 -1.475 . . . . 0.0 109.975 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.1 96.69 1.0 Allowed Glycine 0 N--CA 1.46 0.286 0 N-CA-C 107.296 -2.321 . . . . 0.0 107.296 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.862 HD22 ' CE1' ' J' ' 19' ' ' PHE . 3.4 pp -120.62 125.88 48.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.91 0.386 . . . . 0.0 110.948 -177.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 65.6 ttp -125.6 121.77 34.52 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-O 121.431 0.634 . . . . 0.0 109.877 179.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.479 HG12 HG23 ' K' ' 36' ' ' VAL . 2.8 m -124.26 77.05 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.65 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -35.64 104.81 0.03 OUTLIER Glycine 0 C--N 1.349 1.289 0 N-CA-C 111.751 -0.539 . . . . 0.0 111.751 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.05 -177.28 42.51 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 8.5 p -140.86 151.12 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 121.081 0.467 . . . . 0.0 111.066 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 47.3 t . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.292 179.7 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 99.5 m-85 -114.81 144.69 43.1 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.834 0.35 . . . . 0.0 110.502 -179.761 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -55.83 140.59 41.83 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 67.0 t -118.55 131.54 71.04 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-O 121.426 0.632 . . . . 0.0 111.591 -179.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 m80 -106.5 -172.35 2.07 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.96 179.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 48.5 p-80 -146.8 170.92 16.02 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -147.69 178.75 8.22 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.603 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 53.1 mtmt -138.7 129.45 26.36 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.801 0.334 . . . . 0.0 110.467 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.4 mt -112.48 114.61 27.39 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.592 HG23 ' O ' ' A' ' 18' ' ' VAL . 6.2 m -127.55 121.16 56.36 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.119 0 CA-C-O 121.345 0.593 . . . . 0.0 111.433 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.501 ' CE1' HD21 ' D' ' 34' ' ' LEU . 0.9 OUTLIER -116.88 107.9 15.17 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 106.188 -1.782 . . . . 0.0 106.188 177.283 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.4 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.8 p90 -126.68 126.81 44.15 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.94 125.62 53.84 Favored 'General case' 0 C--O 1.24 0.577 0 CA-C-O 121.275 0.56 . . . . 0.0 111.624 -178.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -155.47 82.0 1.04 Allowed 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 105.162 -2.162 . . . . 0.0 105.162 177.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -34.84 120.64 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 114.922 -1.035 . . . . 0.0 113.612 -176.315 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.599 ' O ' ' N ' ' A' ' 26' ' ' SER . 60.7 t -100.94 125.13 54.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 177.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -31.71 83.27 0.0 OUTLIER Glycine 0 CA--C 1.531 1.044 0 O-C-N 123.324 0.39 . . . . 0.0 113.033 -177.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.599 ' N ' ' O ' ' A' ' 24' ' ' VAL . 69.5 m -87.02 -179.23 6.45 Favored 'General case' 0 N--CA 1.444 -0.772 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 28' ' ' LYS . 11.8 m120 -75.71 178.53 6.03 Favored 'General case' 0 C--N 1.314 -0.966 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.094 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.519 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 99.1 mttt -45.34 -110.77 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.534 0 CA-C-O 121.879 0.847 . . . . 0.0 112.066 178.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.32 93.71 1.65 Allowed Glycine 0 N--CA 1.467 0.734 0 CA-C-O 118.428 -1.206 . . . . 0.0 110.181 178.104 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.57 160.11 14.73 Favored 'General case' 0 CA--C 1.502 -0.885 0 C-N-CA 116.688 -2.005 . . . . 0.0 108.699 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.648 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.4 OUTLIER -155.39 117.81 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 113.986 -1.461 . . . . 0.0 109.464 -173.987 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.453 ' C ' ' SD ' ' G' ' 35' ' ' MET . 96.9 mt -126.33 129.37 71.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-O 120.812 0.339 . . . . 0.0 110.686 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.49 121.67 2.73 Favored Glycine 0 N--CA 1.466 0.663 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.9 mt -138.96 139.07 37.84 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.938 0.875 . . . . 0.0 111.463 179.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.438 ' C ' ' SD ' ' A' ' 35' ' ' MET . 6.8 tmm? -136.15 131.42 34.66 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.085 -0.961 . . . . 0.0 109.288 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 8.0 t -121.52 73.33 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.415 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -105.5 100.7 1.75 Allowed Glycine 0 N--CA 1.442 -0.933 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 178.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -177.66 170.44 42.84 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 111.101 -0.799 . . . . 0.0 111.101 -179.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m -134.33 161.46 40.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.889 0.376 . . . . 0.0 110.795 179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.407 179.728 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -111.59 136.95 50.08 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.701 0.286 . . . . 0.0 110.672 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -111.72 129.65 56.04 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.021 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t -142.19 138.39 30.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.799 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 23.1 t-160 -132.41 104.95 6.98 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.585 0.231 . . . . 0.0 110.793 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' B' ' 15' ' ' GLN . 52.7 m170 -126.33 167.08 15.99 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.6 mm-40 -155.27 178.39 10.27 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.663 179.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -171.08 115.72 0.43 Allowed 'General case' 0 C--N 1.331 -0.213 0 C-N-CA 120.739 -0.385 . . . . 0.0 111.113 178.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.679 HD23 ' C ' ' B' ' 17' ' ' LEU . 8.2 tt -128.42 122.62 31.77 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.127 179.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.41 ' N ' HD23 ' B' ' 17' ' ' LEU . 28.6 m -137.76 131.98 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 N-CA-C 113.129 0.788 . . . . 0.0 113.129 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.548 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 2.8 m-85 -110.09 115.68 30.19 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.198 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.598 ' CE1' ' CD1' ' C' ' 20' ' ' PHE . 74.2 t80 -121.76 123.5 41.97 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -179.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.56 124.76 36.77 Favored 'General case' 0 C--O 1.243 0.726 0 N-CA-C 113.04 0.756 . . . . 0.0 113.04 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.451 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 42.8 tp10 -153.99 129.49 9.91 Favored 'General case' 0 C--O 1.221 -0.415 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.344 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.529 ' OD2' ' NZ ' ' C' ' 28' ' ' LYS . 8.8 t0 -152.41 134.99 15.31 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.055 -178.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.409 ' O ' ' C ' ' B' ' 25' ' ' GLY . 2.1 p -110.73 111.68 37.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 114.898 -1.047 . . . . 0.0 108.928 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 32.74 90.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.349 0 C-N-CA 121.586 -0.34 . . . . 0.0 113.328 177.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.51 ' OG ' ' CE ' ' C' ' 28' ' ' LYS . 54.8 p -100.31 150.52 22.49 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-N 117.626 0.713 . . . . 0.0 109.083 179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 28' ' ' LYS . 11.6 t30 -42.02 173.94 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.852 0.834 . . . . 0.0 113.207 -178.154 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.514 ' N ' ' ND2' ' B' ' 27' ' ' ASN . 57.7 tttt -76.3 111.15 11.43 Favored 'General case' 0 CA--C 1.548 0.893 0 N-CA-C 115.563 1.69 . . . . 0.0 115.563 178.699 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 65.36 93.41 0.03 OUTLIER Glycine 0 N--CA 1.478 1.454 0 C-N-CA 119.123 -1.513 . . . . 0.0 115.695 171.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.442 ' C ' ' CG1' ' B' ' 31' ' ' ILE . . . -123.3 152.47 41.38 Favored 'General case' 0 C--O 1.245 0.836 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 173.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.648 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.2 OUTLIER -152.8 135.31 6.47 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 C-N-CA 118.215 -1.394 . . . . 0.0 111.899 -171.762 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 16.5 tt -146.29 137.44 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.332 179.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.48 128.89 6.48 Favored Glycine 0 CA--C 1.53 1.012 0 N-CA-C 110.159 -1.176 . . . . 0.0 110.159 179.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.441 ' HB2' HD22 ' C' ' 34' ' ' LEU . 48.9 mt -139.33 128.98 24.55 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 122.227 -0.573 . . . . 0.0 111.94 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.43 ' SD ' ' CE ' ' C' ' 35' ' ' MET . 61.8 ttp -130.93 127.33 38.23 Favored 'General case' 0 N--CA 1.469 0.486 0 C-N-CA 120.695 -0.402 . . . . 0.0 110.247 177.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' B' ' 37' ' ' GLY . 15.4 m -133.83 76.4 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 C-N-CA 119.936 -0.706 . . . . 0.0 112.779 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.437 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -33.6 -95.67 0.01 OUTLIER Glycine 0 CA--C 1.53 1.0 0 N-CA-C 111.521 -0.632 . . . . 0.0 111.521 178.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.47 -168.75 35.43 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.64 134.78 64.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 120.985 0.421 . . . . 0.0 110.412 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.7 p . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.668 179.837 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -108.44 132.09 54.13 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.551 0.215 . . . . 0.0 110.457 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -95.92 134.77 38.52 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 121.014 0.435 . . . . 0.0 110.578 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -127.71 136.15 61.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.11 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -130.16 125.48 35.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-O 120.792 0.33 . . . . 0.0 111.013 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.497 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 45.1 t-80 -145.2 166.79 24.44 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.497 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 99.7 mm-40 -153.16 176.83 11.49 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.807 179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.66 ' C ' HD12 ' C' ' 17' ' ' LEU . 69.0 tttt -170.17 104.31 0.3 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.598 178.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.66 HD12 ' C ' ' C' ' 16' ' ' LYS . 11.2 mp -118.5 118.59 32.12 Favored 'General case' 0 C--O 1.237 0.432 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.2 t -131.73 131.5 62.19 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -178.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.895 ' CZ ' HD23 ' E' ' 34' ' ' LEU . 52.3 m-85 -113.69 116.51 29.55 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 177.382 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE1' ' B' ' 20' ' ' PHE . 51.9 t80 -125.94 122.14 35.12 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 118.625 0.648 . . . . 0.0 109.548 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . 0.527 ' HB1' ' HB3' ' D' ' 27' ' ' ASN . . . -137.29 130.12 30.37 Favored 'General case' 0 C--O 1.248 0.997 0 N-CA-C 113.769 1.025 . . . . 0.0 113.769 -178.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.451 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 71.3 mt-10 -155.17 114.98 3.72 Favored 'General case' 0 C--N 1.352 0.682 0 CA-C-N 113.661 -1.608 . . . . 0.0 108.806 178.104 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.423 ' O ' ' O ' ' D' ' 26' ' ' SER . 65.6 t0 -147.54 122.51 10.05 Favored 'General case' 0 N--CA 1.476 0.862 0 O-C-N 121.739 -0.6 . . . . 0.0 111.419 -179.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 14.5 t -98.53 -112.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.056 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 39.68 -90.94 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.935 -0.575 . . . . 0.0 112.103 -179.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.631 ' O ' ' O ' ' C' ' 27' ' ' ASN . 2.0 m 171.15 170.11 0.08 Allowed 'General case' 0 N--CA 1.444 -0.748 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.631 ' O ' ' O ' ' C' ' 26' ' ' SER . 65.8 t30 -17.56 158.61 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 O-C-N 124.616 1.198 . . . . 0.0 113.696 177.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.529 ' NZ ' ' OD2' ' B' ' 23' ' ' ASP . 50.5 tttt -161.26 110.63 1.61 Allowed 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.521 174.491 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.69 92.64 0.29 Allowed Glycine 0 C--O 1.224 -0.488 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 173.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.16 150.5 47.98 Favored 'General case' 0 CA--C 1.476 -1.885 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 174.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.42 HD13 HG21 ' C' ' 31' ' ' ILE . 0.1 OUTLIER -147.36 114.49 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 C-N-CA 117.672 -1.611 . . . . 0.0 110.996 -173.931 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 9.2 mt -108.84 124.04 65.13 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.147 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.859 ' O ' HD23 ' C' ' 34' ' ' LEU . . . -125.43 100.62 0.6 Allowed Glycine 0 N--CA 1.474 1.186 0 N-CA-C 108.521 -1.831 . . . . 0.0 108.521 177.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.859 HD23 ' O ' ' C' ' 33' ' ' GLY . 1.6 mt -134.32 142.27 47.19 Favored 'General case' 0 C--O 1.243 0.722 0 CA-C-O 122.886 1.327 . . . . 0.0 113.859 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.544 ' SD ' ' CE ' ' D' ' 35' ' ' MET . 41.9 ttp -127.51 118.8 24.7 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 112.771 -2.013 . . . . 0.0 108.127 176.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.448 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.1 OUTLIER -116.33 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.053 0 CA-C-N 114.173 -1.376 . . . . 0.0 107.864 179.067 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -39.86 -101.48 0.01 OUTLIER Glycine 0 C--N 1.366 2.238 0 N-CA-C 111.748 -0.541 . . . . 0.0 111.748 -179.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.88 -145.83 11.32 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.4 m -128.32 158.85 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 120.664 0.269 . . . . 0.0 110.306 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.467 179.984 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -83.37 137.61 33.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.799 0.333 . . . . 0.0 110.522 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 71.4 mm-40 -120.9 133.65 55.29 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.426 -179.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 33.7 m -129.03 133.13 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 121.348 0.594 . . . . 0.0 110.757 179.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 69.1 m-70 -132.97 134.85 45.05 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.666 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 73.3 m80 -149.04 167.03 26.93 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-O 121.266 0.555 . . . . 0.0 110.039 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -155.76 171.23 20.36 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.326 179.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -158.62 114.1 2.62 Favored 'General case' 0 N--CA 1.466 0.367 0 C-N-CA 120.926 -0.31 . . . . 0.0 111.107 179.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mt -118.55 119.13 33.59 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.444 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -131.31 129.54 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -179.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.603 ' CZ ' ' CD1' ' C' ' 19' ' ' PHE . 19.8 m-85 -118.97 123.63 45.04 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 29.9 t80 -131.26 119.83 22.35 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 120.747 0.308 . . . . 0.0 111.633 -179.287 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.47 ' HB1' HD21 ' D' ' 27' ' ' ASN . . . -130.08 122.45 28.35 Favored 'General case' 0 N--CA 1.476 0.835 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.136 178.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -84.9 157.01 20.99 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -178.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.416 ' HA ' ' NZ ' ' F' ' 28' ' ' LYS . 1.2 t0 -88.72 -174.12 4.4 Favored 'General case' 0 C--N 1.348 0.525 0 CA-C-O 121.213 0.53 . . . . 0.0 110.897 -179.629 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.413 ' O ' ' O ' ' D' ' 25' ' ' GLY . 20.7 t 62.64 104.45 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' D' ' 24' ' ' VAL . . . 64.71 100.0 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 117.618 -2.23 . . . . 0.0 107.686 -178.664 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.423 ' O ' ' O ' ' C' ' 23' ' ' ASP . 78.6 p -52.44 171.93 0.05 OUTLIER 'General case' 0 CA--C 1.499 -0.991 0 CA-C-N 118.037 0.918 . . . . 0.0 108.617 -176.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.527 ' HB3' ' HB1' ' C' ' 21' ' ' ALA . 27.4 m-20 -81.84 178.51 8.27 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.694 -0.802 . . . . 0.0 112.115 -175.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' D' ' 27' ' ' ASN . 44.2 tttp -38.6 -106.51 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.294 -1.321 . . . . 0.0 112.533 -178.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.673 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . 86.29 -100.04 2.48 Favored Glycine 0 CA--C 1.456 -3.637 0 N-CA-C 106.218 -2.753 . . . . 0.0 106.218 -175.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.918 ' C ' HD13 ' D' ' 31' ' ' ILE . . . 67.55 -163.86 0.21 Allowed 'General case' 0 N--CA 1.419 -2.001 1 N-CA-C 98.449 -4.648 . . . . 0.0 98.449 -176.36 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.918 HD13 ' C ' ' D' ' 30' ' ' ALA . 0.0 OUTLIER -115.79 110.94 33.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.662 0 CA-C-N 123.941 3.064 . . . . 0.0 110.397 177.258 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.446 ' C ' ' SD ' ' J' ' 35' ' ' MET . 13.7 tt -122.57 127.56 75.04 Favored 'Isoleucine or valine' 0 C--N 1.353 0.744 0 CA-C-N 114.813 -1.085 . . . . 0.0 109.96 179.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.544 ' O ' HD12 ' D' ' 34' ' ' LEU . . . -121.36 101.22 0.77 Allowed Glycine 0 N--CA 1.457 0.092 0 N-CA-C 108.589 -1.804 . . . . 0.0 108.589 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.544 HD12 ' O ' ' D' ' 33' ' ' GLY . 5.0 mp -120.34 125.81 48.96 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 122.32 1.057 . . . . 0.0 110.923 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.617 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 37.3 ttp -120.29 119.26 32.63 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 113.928 -1.487 . . . . 0.0 107.839 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -118.51 74.06 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.698 -178.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . -48.35 111.45 0.89 Allowed Glycine 0 C--N 1.351 1.392 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 179.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.419 ' O ' ' O ' ' D' ' 37' ' ' GLY . . . -59.77 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.524 0.612 0 N-CA-C 110.44 -1.064 . . . . 0.0 110.44 179.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 74.7 t -120.95 133.73 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.5 m . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.688 -179.93 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -109.23 132.86 53.72 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 92.9 mt-10 -141.58 151.0 42.79 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.684 0.278 . . . . 0.0 110.629 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 66.2 t -125.86 131.2 72.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 120.947 0.403 . . . . 0.0 110.609 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 16.9 t60 -138.93 130.75 27.69 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.532 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 27.1 m80 -148.15 168.24 22.95 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.751 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.633 ' NE2' HE21 ' F' ' 15' ' ' GLN . 75.1 mt-30 -154.83 165.97 34.97 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.427 178.051 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -148.6 117.73 6.81 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.192 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.27 122.72 34.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.238 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -127.56 125.74 66.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-O 121.074 0.464 . . . . 0.0 111.0 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -117.74 113.81 22.4 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.542 179.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 55.0 t80 -123.46 116.72 23.69 Favored 'General case' 0 C--O 1.235 0.333 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 179.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.0 134.74 15.52 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 118.974 -1.09 . . . . 0.0 113.664 -178.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 mm-40 -102.6 117.28 34.33 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 176.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.498 ' OD1' ' N ' ' E' ' 23' ' ' ASP . 7.1 p-10 -131.06 113.26 13.72 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 114.395 1.257 . . . . 0.0 114.395 -177.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.631 ' O ' ' N ' ' E' ' 26' ' ' SER . 40.3 t -127.23 122.29 59.53 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.955 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 175.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.467 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . -28.97 83.8 0.0 OUTLIER Glycine 0 N--CA 1.484 1.883 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.631 ' N ' ' O ' ' E' ' 24' ' ' VAL . 6.3 p -88.24 -179.75 6.2 Favored 'General case' 0 N--CA 1.441 -0.885 0 CA-C-O 123.102 1.43 . . . . 0.0 113.734 -177.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 60.3 t30 -77.04 179.35 6.31 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-N 111.446 -2.616 . . . . 0.0 110.836 176.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.478 ' HE2' ' HB2' ' E' ' 30' ' ' ALA . 82.9 tttt 42.88 110.98 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 114.697 1.369 . . . . 0.0 114.697 176.444 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.43 93.99 1.68 Allowed Glycine 0 N--CA 1.47 0.905 0 N-CA-C 108.035 -2.026 . . . . 0.0 108.035 174.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.659 ' HB1' ' H ' ' D' ' 30' ' ' ALA . . . -100.5 166.79 10.75 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 -179.532 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.475 HG22 ' HE1' ' L' ' 35' ' ' MET . 0.0 OUTLIER -156.44 121.79 0.5 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.051 0 C-N-CA 117.916 -1.514 . . . . 0.0 112.306 -173.087 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -111.15 123.74 67.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.877 178.188 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.8 109.78 1.7 Allowed Glycine 0 CA--C 1.512 -0.139 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 -179.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.895 HD23 ' CZ ' ' C' ' 19' ' ' PHE . 41.5 tp -133.24 126.74 32.2 Favored 'General case' 0 C--O 1.243 0.745 0 CA-C-O 121.848 0.832 . . . . 0.0 111.454 -179.64 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.541 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 57.9 ttp -115.62 124.3 50.58 Favored 'General case' 0 CA--C 1.506 -0.713 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.059 177.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -129.68 71.58 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.832 0 CA-C-N 114.727 -1.124 . . . . 0.0 109.332 -179.885 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -32.46 -101.0 0.01 OUTLIER Glycine 0 C--N 1.364 2.106 0 N-CA-C 111.678 -0.569 . . . . 0.0 111.678 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.18 159.2 30.21 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.974 -0.851 . . . . 0.0 110.974 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -136.94 161.38 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.697 0.284 . . . . 0.0 110.424 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 3.7 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.509 179.501 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -109.28 140.11 43.35 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.685 0.278 . . . . 0.0 110.623 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -54.87 142.28 30.06 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 77.0 t -100.56 130.44 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-O 121.144 0.497 . . . . 0.0 110.72 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 8.8 t-160 -161.11 109.84 1.58 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.485 -0.779 . . . . 0.0 110.243 -179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -153.63 174.58 14.29 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.633 HE21 ' NE2' ' E' ' 15' ' ' GLN . 95.0 mt-30 -145.56 172.89 12.59 Favored 'General case' 0 C--N 1.313 -1.02 0 C-N-CA 120.326 -0.549 . . . . 0.0 110.605 179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.79 112.32 7.83 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.012 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.583 HD23 ' C ' ' F' ' 17' ' ' LEU . 8.4 tt -125.2 122.4 36.9 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.418 179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . 0.415 ' N ' HD23 ' F' ' 17' ' ' LEU . 69.2 t -129.32 130.88 67.78 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 179.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.536 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 53.0 p90 -131.5 127.47 37.36 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.816 0.341 . . . . 0.0 110.292 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -142.04 126.87 18.16 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.422 0.629 . . . . 0.0 110.057 179.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -161.3 161.9 30.77 Favored 'General case' 0 C--N 1.32 -0.683 0 C-N-CA 120.08 -0.648 . . . . 0.0 111.082 179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.426 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 95.6 mt-10 -116.82 107.99 15.3 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.275 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 49.1 t0 -108.73 114.14 27.69 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.265 0.555 . . . . 0.0 111.951 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.588 ' O ' ' N ' ' F' ' 26' ' ' SER . 83.1 t -96.11 130.97 44.05 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 N-CA-C 106.641 -1.615 . . . . 0.0 106.641 177.387 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.88 -85.5 0.01 OUTLIER Glycine 0 CA--C 1.529 0.915 0 N-CA-C 109.604 -1.399 . . . . 0.0 109.604 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.588 ' N ' ' O ' ' F' ' 24' ' ' VAL . 58.3 p -132.35 162.84 30.07 Favored 'General case' 0 CA--C 1.513 -0.466 0 CA-C-N 117.946 0.873 . . . . 0.0 109.258 177.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.449 ' O ' ' O ' ' F' ' 26' ' ' SER . 53.1 p30 -38.6 174.88 0.0 OUTLIER 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 114.683 -1.144 . . . . 0.0 113.387 -179.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.546 ' O ' ' N ' ' F' ' 30' ' ' ALA . 22.6 tttt -74.63 112.47 10.85 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.807 175.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.88 91.65 0.08 OUTLIER Glycine 0 N--CA 1.467 0.761 0 C-N-CA 117.056 -2.497 . . . . 0.0 109.034 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.546 ' N ' ' O ' ' F' ' 28' ' ' LYS . . . -171.53 162.01 6.4 Favored 'General case' 0 C--N 1.295 -1.786 1 N-CA-C 98.752 -4.536 . . . . 0.0 98.752 178.569 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.463 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.0 OUTLIER -152.11 131.92 3.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 115.778 -2.369 . . . . 0.0 113.243 -175.262 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.55 HG22 HD23 ' F' ' 34' ' ' LEU . 76.0 mt -106.12 113.49 42.99 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 114.13 -1.395 . . . . 0.0 109.615 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.08 96.46 1.53 Allowed Glycine 0 CA--C 1.502 -0.75 0 N-CA-C 106.217 -2.753 . . . . 0.0 106.217 175.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.55 HD23 HG22 ' F' ' 32' ' ' ILE . 1.4 pp -118.39 122.2 42.23 Favored 'General case' 0 CA--C 1.508 -0.661 0 N-CA-C 111.478 0.177 . . . . 0.0 111.478 -177.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.784 ' SD ' HG23 ' L' ' 31' ' ' ILE . 58.1 ttp -118.71 115.71 25.07 Favored 'General case' 0 CA--C 1.5 -0.96 0 C-N-CA 119.094 -1.042 . . . . 0.0 108.64 176.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' F' ' 37' ' ' GLY . 3.1 m -123.34 71.44 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.561 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.469 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -24.97 -103.29 0.0 OUTLIER Glycine 0 C--N 1.36 1.863 0 O-C-N 123.515 0.509 . . . . 0.0 112.432 -179.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 73.04 163.27 7.45 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 179.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -144.34 143.32 23.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.79 0.328 . . . . 0.0 110.612 179.303 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.089 -0.957 . . . . 0.0 110.428 179.921 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -118.64 138.27 52.72 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.801 0.334 . . . . 0.0 110.496 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 21.2 pt-20 -76.2 158.62 31.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.289 179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 56.8 t -118.27 132.93 66.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.147 0.499 . . . . 0.0 110.225 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 77.4 m80 -104.77 -168.78 1.52 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.395 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.45 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 3.4 m80 -76.57 165.28 25.0 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.449 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 6.3 tp-100 -161.67 175.18 12.3 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.449 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 64.2 tttp -161.63 131.82 4.91 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.102 179.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -123.54 125.66 45.28 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.397 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 63.2 t -125.19 126.45 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.857 179.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.853 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 5.7 t80 -114.49 109.08 17.73 Favored 'General case' 0 C--O 1.234 0.245 0 N-CA-C 107.604 -1.258 . . . . 0.0 107.604 178.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 84.0 t80 -118.34 115.66 25.15 Favored 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 -178.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.94 121.38 44.49 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-O 120.96 0.41 . . . . 0.0 110.632 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -154.81 118.34 4.54 Favored 'General case' 0 N--CA 1.45 -0.473 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -58.23 121.27 10.33 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.527 -0.469 . . . . 0.0 111.279 -178.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.2 m -88.25 124.15 41.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.99 84.53 0.01 OUTLIER Glycine 0 CA--C 1.529 0.93 0 C-N-CA 121.461 -0.4 . . . . 0.0 112.192 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' G' ' 24' ' ' VAL . 60.7 m -93.52 178.6 5.65 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -60.03 178.73 0.17 Allowed 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 119.255 -0.978 . . . . 0.0 109.127 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.95 110.94 1.3 Allowed 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.101 -0.64 . . . . 0.0 111.009 178.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.848 ' H ' HD22 ' H' ' 27' ' ' ASN . . . 71.16 93.11 0.08 OUTLIER Glycine 0 N--CA 1.463 0.485 0 C-N-CA 119.501 -1.333 . . . . 0.0 112.21 176.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.67 160.27 17.42 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 119.784 1.792 . . . . 0.0 109.195 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.426 HG22 HD12 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -145.04 123.67 5.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.017 -177.107 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -133.96 128.29 53.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 O-C-N 121.942 -0.474 . . . . 0.0 111.249 179.582 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.04 121.59 3.43 Favored Glycine 0 CA--C 1.527 0.799 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 179.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 54.6 tp -142.5 135.13 28.05 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.384 0.611 . . . . 0.0 112.254 -178.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.453 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 66.3 ttp -127.3 139.01 53.18 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 178.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' G' ' 37' ' ' GLY . 22.5 t -133.55 78.36 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 113.022 0.749 . . . . 0.0 113.022 -179.31 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.433 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -33.85 -94.11 0.01 OUTLIER Glycine 0 C--N 1.345 1.045 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 177.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.99 -164.32 37.87 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -126.53 158.1 36.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.482 -179.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.613 -179.197 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -104.53 131.66 51.67 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -141.3 144.47 34.64 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.608 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.449 ' O ' HG23 ' H' ' 12' ' ' VAL . 18.9 m -125.62 131.84 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 179.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -127.1 115.71 19.56 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-O 120.854 0.359 . . . . 0.0 110.956 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.405 ' CD2' ' N ' ' H' ' 14' ' ' HIS . 5.1 p80 -158.99 171.42 20.06 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.39 0.614 . . . . 0.0 110.587 179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mm-40 -150.35 173.89 13.49 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.417 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -148.17 121.26 8.86 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -123.0 127.61 49.06 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 120.81 0.338 . . . . 0.0 111.851 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -122.05 125.64 73.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.13 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.502 ' HZ ' HD13 ' J' ' 34' ' ' LEU . 2.7 t80 -122.27 115.17 21.87 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 70.5 t80 -126.86 121.66 32.47 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.49 127.13 51.92 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.613 -0.435 . . . . 0.0 112.001 -179.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.461 ' HG3' ' H ' ' I' ' 24' ' ' VAL . 43.0 tt0 -158.29 103.34 1.8 Allowed 'General case' 0 CA--C 1.539 0.548 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.918 179.698 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.464 ' HB3' ' HZ1' ' J' ' 28' ' ' LYS . 78.4 m-20 -80.17 134.7 36.17 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-O 120.952 0.406 . . . . 0.0 110.825 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.403 ' O ' ' N ' ' H' ' 26' ' ' SER . 88.9 t -103.68 113.73 41.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 N-CA-C 112.764 0.653 . . . . 0.0 112.764 -178.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -30.6 88.64 0.01 OUTLIER Glycine 0 CA--C 1.537 1.459 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.775 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' H' ' 27' ' ' ASN . 11.7 p -129.78 -178.54 4.75 Favored 'General case' 0 CA--C 1.519 -0.226 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 -177.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.848 HD22 ' H ' ' G' ' 29' ' ' GLY . 1.4 p-10 -40.16 174.82 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 113.486 0.921 . . . . 0.0 113.486 -174.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 69.0 mttm -74.8 111.15 9.71 Favored 'General case' 0 CA--C 1.537 0.458 0 N-CA-C 116.18 1.919 . . . . 0.0 116.18 -178.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.472 ' H ' ' HG3' ' I' ' 28' ' ' LYS . . . 70.32 93.54 0.07 OUTLIER Glycine 0 N--CA 1.467 0.733 0 C-N-CA 119.893 -1.146 . . . . 0.0 115.484 171.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.76 157.68 18.9 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 103.348 -2.834 . . . . 0.0 103.348 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.437 HD13 ' HA3' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -144.44 119.46 3.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.714 -174.545 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.403 ' C ' ' SD ' ' B' ' 35' ' ' MET . 27.7 mm -124.55 124.26 67.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.414 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.1 126.65 5.49 Favored Glycine 0 N--CA 1.469 0.873 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.4 tt -147.76 134.59 20.1 Favored 'General case' 0 CA--C 1.536 0.442 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.929 -178.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.1 tmm? -128.62 127.09 41.55 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.851 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.436 ' O ' ' O ' ' H' ' 37' ' ' GLY . 10.5 t -122.92 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 113.294 0.85 . . . . 0.0 113.294 -178.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -35.6 -93.8 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 111.135 -0.786 . . . . 0.0 111.135 177.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.1 -171.03 33.88 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 179.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.47 141.9 36.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.825 0.345 . . . . 0.0 110.122 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.676 -179.995 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -87.1 135.01 33.45 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.593 0.235 . . . . 0.0 110.404 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -80.22 149.39 30.46 Favored 'General case' 0 C--N 1.332 -0.153 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.443 HG12 ' N ' ' I' ' 13' ' ' HIS . 15.4 t -132.11 162.42 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.283 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.056 -178.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.443 ' N ' HG12 ' I' ' 12' ' ' VAL . 0.5 OUTLIER -116.22 170.19 8.71 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 178.93 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 54.3 p-80 -72.89 169.81 16.06 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -179.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.6 mt-30 -137.36 172.77 12.49 Favored 'General case' 0 C--N 1.318 -0.768 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.415 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -150.19 128.96 12.42 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 121.1 0.476 . . . . 0.0 111.663 -179.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.6 tt -133.62 124.47 26.87 Favored 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 178.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 64.5 t -123.71 128.83 74.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.862 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.648 ' CD2' HD22 ' L' ' 34' ' ' LEU . 10.3 t80 -122.39 118.99 29.73 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 116.293 -0.412 . . . . 0.0 109.912 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -135.16 121.63 20.53 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.802 0.334 . . . . 0.0 111.062 -179.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.18 123.49 38.35 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 112.154 0.428 . . . . 0.0 112.154 179.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -162.6 126.52 3.02 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 115.354 -0.839 . . . . 0.0 108.815 178.195 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -102.27 114.03 27.84 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.461 ' H ' ' HG3' ' H' ' 22' ' ' GLU . 4.0 p -79.86 131.63 33.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.754 177.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.63 82.62 0.06 OUTLIER Glycine 0 CA--C 1.527 0.819 0 C-N-CA 119.725 -1.226 . . . . 0.0 112.392 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.498 ' O ' ' CB ' ' I' ' 27' ' ' ASN . 75.1 m -60.04 -174.11 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 115.194 -0.503 . . . . 0.0 109.858 -179.213 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' I' ' 26' ' ' SER . 17.9 m-20 98.53 -175.3 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 O-C-N 124.218 0.949 . . . . 0.0 109.975 -176.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.477 ' O ' ' O ' ' I' ' 27' ' ' ASN . 82.4 tttt 38.71 110.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 113.49 0.922 . . . . 0.0 113.49 -177.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.77 95.85 1.74 Allowed Glycine 0 CA--C 1.484 -1.885 0 N-CA-C 107.98 -2.048 . . . . 0.0 107.98 176.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 164.89 16.92 Favored 'General case' 0 N--CA 1.426 -1.662 0 C-N-CA 118.001 -1.48 . . . . 0.0 107.272 -179.024 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.719 HG23 ' CG1' ' J' ' 31' ' ' ILE . 0.2 OUTLIER -142.56 117.31 4.73 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 119.376 -0.929 . . . . 0.0 108.827 -174.497 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 20.1 tt -125.51 124.16 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.834 178.18 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.33 96.62 0.73 Allowed Glycine 0 C--N 1.331 0.275 0 N-CA-C 107.72 -2.152 . . . . 0.0 107.72 178.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.513 HD21 HG13 ' I' ' 36' ' ' VAL . 8.7 tt -130.32 134.1 46.94 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 122.392 1.092 . . . . 0.0 112.183 -178.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 tmm? -128.26 125.74 39.49 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 114.618 -1.174 . . . . 0.0 110.344 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.513 HG13 HD21 ' I' ' 34' ' ' LEU . 0.1 OUTLIER -130.69 76.95 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.34 179.678 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 38' ' ' GLY . . . -71.9 106.36 1.9 Allowed Glycine 0 C--N 1.354 1.578 0 N-CA-C 110.213 -1.155 . . . . 0.0 110.213 178.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -49.27 179.38 0.01 OUTLIER Glycine 0 CA--C 1.523 0.558 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 -179.29 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -124.58 138.78 52.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.877 0.37 . . . . 0.0 110.591 -179.694 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.938 -1.03 . . . . 0.0 110.365 179.688 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -110.06 138.58 46.24 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.692 0.282 . . . . 0.0 110.298 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -127.56 145.19 50.94 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.952 0.406 . . . . 0.0 110.768 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -137.86 152.71 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.778 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 31.0 m80 -132.57 146.98 52.33 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.52 ' CE1' ' O ' ' J' ' 15' ' ' GLN . 5.9 t-80 -154.52 157.84 38.95 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.52 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 82.3 mt-30 -148.97 178.06 9.03 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-O 121.538 0.685 . . . . 0.0 111.653 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -165.34 114.03 1.02 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.824 -1.08 . . . . 0.0 109.151 179.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -120.86 122.29 39.95 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.155 0.502 . . . . 0.0 111.04 -179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -114.02 121.82 66.92 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.161 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 178.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.677 ' CZ ' HD23 ' L' ' 34' ' ' LEU . 1.0 OUTLIER -125.04 108.37 11.76 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.9 0.381 . . . . 0.0 110.236 -177.124 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 m-85 -130.17 127.83 40.51 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.629 0.728 . . . . 0.0 111.518 -179.069 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.67 128.57 31.28 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.842 178.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -142.39 111.24 6.3 Favored 'General case' 0 N--CA 1.462 0.142 0 C-N-CA 119.621 -0.831 . . . . 0.0 111.249 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -85.73 105.02 15.96 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.133 -0.939 . . . . 0.0 109.671 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.759 HG12 ' H ' ' J' ' 25' ' ' GLY . 10.5 t -110.12 -131.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 C-N-CA 119.806 -0.758 . . . . 0.0 111.123 -179.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.759 ' H ' HG12 ' J' ' 24' ' ' VAL . . . 29.03 -82.24 0.0 OUTLIER Glycine 0 CA--C 1.529 0.914 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.869 -178.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.636 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.2 p 169.65 177.76 0.04 OUTLIER 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.34 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.769 HD22 ' H ' ' K' ' 29' ' ' GLY . 31.7 m120 -28.08 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 CA-C-N 114.183 -1.371 . . . . 0.0 112.838 173.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.535 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 29.5 tttt 144.63 104.31 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 123.02 1.39 . . . . 0.0 112.005 177.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.16 93.54 0.01 OUTLIER Glycine 0 C--O 1.219 -0.825 0 CA-C-N 112.248 -2.251 . . . . 0.0 111.373 174.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.2 152.81 47.68 Favored 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 120.78 2.29 . . . . 0.0 106.526 176.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.719 ' CG1' HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -137.97 121.86 21.61 Favored 'Isoleucine or valine' 0 C--O 1.248 1.022 0 C-N-CA 119.218 -0.993 . . . . 0.0 112.384 -174.895 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -104.42 109.44 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 177.406 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.617 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -109.72 102.46 1.59 Allowed Glycine 0 CA--C 1.502 -0.738 0 N-CA-C 106.37 -2.692 . . . . 0.0 106.37 178.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.853 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 5.1 tt -144.35 140.51 29.13 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 122.406 1.098 . . . . 0.0 111.775 -175.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.525 ' N ' HD23 ' J' ' 34' ' ' LEU . 61.0 ttp -133.69 130.21 37.85 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.08 -179.142 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.471 HG13 HG23 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -122.78 79.47 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.78 -178.336 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.19 104.54 0.48 Allowed Glycine 0 C--N 1.342 0.907 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 178.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.74 167.06 54.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -139.28 160.66 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.727 0.299 . . . . 0.0 110.584 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.442 HG23 ' H ' ' J' ' 40' ' ' VAL . 15.9 t . . . . . 0 C--O 1.221 -0.419 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.846 179.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 -84.33 138.07 33.09 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.867 0.365 . . . . 0.0 111.068 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' L' ' 11' ' ' GLU . 72.3 mm-40 -137.6 131.98 32.4 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.98 -0.555 . . . . 0.0 109.628 179.253 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 m -138.09 135.56 44.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.906 0.384 . . . . 0.0 111.123 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 9.7 m80 -134.28 127.51 31.96 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.571 ' NE2' ' CG ' ' L' ' 13' ' ' HIS . 80.5 m80 -116.43 163.17 16.44 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.646 0.736 . . . . 0.0 110.36 -179.348 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.52 ' N ' ' OE1' ' L' ' 15' ' ' GLN . 50.9 tt0 -163.27 172.31 14.89 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.412 179.427 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.456 ' N ' ' CG ' ' K' ' 15' ' ' GLN . 55.4 tttp -164.81 114.88 1.14 Allowed 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 28.6 tp -118.8 121.65 40.54 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.76 127.83 75.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -131.0 125.7 34.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.23 0.538 . . . . 0.0 112.262 -178.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -133.06 125.79 30.39 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 115.368 -0.833 . . . . 0.0 109.993 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 127.43 35.36 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.182 179.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -149.29 137.73 20.88 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.048 -0.661 . . . . 0.0 112.023 -179.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.45 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 20.6 p-10 -123.23 120.53 33.42 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 120.986 0.422 . . . . 0.0 110.029 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.554 HG21 HG13 ' J' ' 24' ' ' VAL . 84.3 t -60.62 121.1 7.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.519 179.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.31 -90.97 0.53 Allowed Glycine 0 CA--C 1.527 0.817 0 C-N-CA 121.368 -0.444 . . . . 0.0 112.464 177.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.587 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.8 p -141.37 171.22 14.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 121.196 0.522 . . . . 0.0 110.348 -178.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.587 ' O ' ' O ' ' K' ' 26' ' ' SER . 3.3 p30 -29.01 170.5 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 114.179 -1.373 . . . . 0.0 113.983 179.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.662 ' O ' ' HB3' ' L' ' 30' ' ' ALA . 80.0 tttt -148.35 111.3 4.84 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-N 114.969 -1.014 . . . . 0.0 109.141 178.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.769 ' H ' HD22 ' J' ' 27' ' ' ASN . . . -54.53 91.58 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 121.244 -0.503 . . . . 0.0 112.211 179.208 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.746 ' H ' ' HB1' ' L' ' 30' ' ' ALA . . . -166.38 158.17 13.56 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.504 ' CG1' HG22 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -145.8 123.61 4.55 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 C-N-CA 118.721 -1.192 . . . . 0.0 111.829 -179.209 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.448 ' C ' ' SD ' ' E' ' 35' ' ' MET . 1.0 OUTLIER -102.09 118.41 48.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.077 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.541 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -112.74 94.88 0.75 Allowed Glycine 0 CA--C 1.51 -0.26 0 N-CA-C 109.098 -1.601 . . . . 0.0 109.098 179.181 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.636 HD12 ' O ' ' J' ' 34' ' ' LEU . 41.0 tp -129.38 130.77 46.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-O 122.218 1.009 . . . . 0.0 111.968 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.48 ' H ' HD12 ' K' ' 34' ' ' LEU . 7.9 tmm? -116.71 114.73 24.42 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.893 175.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.405 HG12 ' CG2' ' J' ' 36' ' ' VAL . 2.2 m -116.56 79.86 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.419 ' HA3' HD13 ' E' ' 31' ' ' ILE . . . -66.8 103.24 0.87 Allowed Glycine 0 C--N 1.35 1.36 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -87.39 -178.55 48.38 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.241 -1.143 . . . . 0.0 110.241 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.48 142.9 30.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.951 0.405 . . . . 0.0 110.29 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.761 -179.768 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -101.7 130.06 48.0 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . 0.404 ' O ' ' O ' ' K' ' 11' ' ' GLU . 84.5 tt0 -123.52 138.75 54.5 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 120.96 0.41 . . . . 0.0 110.748 -179.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.413 HG22 ' O ' ' L' ' 13' ' ' HIS . 2.4 p -139.53 156.04 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.187 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.661 ' CG ' ' H ' ' L' ' 14' ' ' HIS . 41.8 t-80 -91.29 -177.5 4.88 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 120.784 0.326 . . . . 0.0 110.727 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.661 ' H ' ' CG ' ' L' ' 13' ' ' HIS . 99.2 m-70 -75.52 171.73 13.77 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.53 ' NE2' ' O ' ' L' ' 14' ' ' HIS . 51.5 mm-40 -139.2 -179.78 6.06 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.62 -179.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.95 124.38 15.72 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.685 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 58.0 tp -125.44 121.22 33.19 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.381 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -129.41 129.35 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.461 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 54.7 p90 -139.45 130.85 26.92 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 120.785 0.326 . . . . 0.0 111.123 -179.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 84.8 t80 -142.55 131.99 23.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.019 179.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.16 146.43 35.28 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.814 0.34 . . . . 0.0 110.58 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' K' ' 23' ' ' ASP . 84.6 tt0 -78.52 142.76 37.15 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.145 179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -76.73 121.72 23.7 Favored 'General case' 0 C--O 1.231 0.113 0 CA-C-O 121.225 0.536 . . . . 0.0 110.766 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' L' ' 25' ' ' GLY . 19.5 t -102.75 122.88 55.66 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.115 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.452 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -30.56 -86.47 0.01 OUTLIER Glycine 0 N--CA 1.478 1.442 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 178.271 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 30.7 t -90.21 -179.97 5.77 Favored 'General case' 0 N--CA 1.444 -0.735 0 N-CA-C 105.042 -2.207 . . . . 0.0 105.042 177.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 69.5 m-80 -58.8 162.89 3.7 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 117.866 -1.534 . . . . 0.0 110.456 -177.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.565 ' HB3' HD12 ' L' ' 31' ' ' ILE . 59.6 tttt -58.3 111.64 1.28 Allowed 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.74 0.644 . . . . 0.0 112.74 179.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.85 -98.28 0.01 OUTLIER Glycine 0 C--N 1.319 -0.416 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.746 ' HB1' ' H ' ' K' ' 30' ' ' ALA . . . -72.72 174.57 7.45 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 102.725 -3.065 . . . . 0.0 102.725 178.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.784 HG23 ' SD ' ' F' ' 35' ' ' MET . 7.5 tt -171.17 165.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 C-N-CA 115.033 -2.667 . . . . 0.0 115.448 -172.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.544 ' O ' HG23 ' L' ' 32' ' ' ILE . 16.3 tt -99.31 122.02 50.6 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.761 0 CA-C-N 113.284 -1.78 . . . . 0.0 108.154 177.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . 0.501 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -110.52 94.37 0.79 Allowed Glycine 0 CA--C 1.507 -0.436 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.677 HD23 ' CZ ' ' J' ' 19' ' ' PHE . 51.3 tp -119.03 118.76 32.33 Favored 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.475 ' HE1' HG22 ' E' ' 31' ' ' ILE . 11.3 tmm? -105.16 119.22 38.5 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 178.202 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.497 ' O ' ' C ' ' L' ' 37' ' ' GLY . 2.7 m -129.03 75.04 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.606 0 CA-C-N 115.745 -0.661 . . . . 0.0 109.927 -179.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.497 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -16.95 -101.76 0.0 OUTLIER Glycine 0 C--N 1.359 1.856 0 O-C-N 123.158 0.286 . . . . 0.0 112.707 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.0 173.87 37.68 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.271 -0.731 . . . . 0.0 111.271 179.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -122.65 138.45 52.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 120.885 0.374 . . . . 0.0 110.51 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.813 -179.659 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -109.86 141.64 42.27 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.924 0.393 . . . . 0.0 110.937 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.52 ' CD ' ' H ' ' A' ' 11' ' ' GLU . 2.0 pm0 -117.58 147.99 42.31 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.074 179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m -113.8 133.79 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 121.072 0.463 . . . . 0.0 110.613 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 18.5 p-80 -143.71 164.44 30.44 Favored 'General case' 0 N--CA 1.462 0.165 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.934 -179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.1 p-80 -87.78 169.98 11.61 Favored 'General case' 0 N--CA 1.446 -0.675 0 CA-C-O 121.395 0.617 . . . . 0.0 110.375 -179.144 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.442 ' HG2' ' N ' ' A' ' 16' ' ' LYS . 51.5 tt0 -153.28 175.32 13.21 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.301 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.442 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 99.5 mttt -137.68 133.65 34.48 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.819 0.343 . . . . 0.0 110.831 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -129.16 121.52 27.91 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -132.74 131.3 59.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.154 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.75 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 14.7 m-85 -111.21 116.79 31.66 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.535 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 55.5 p90 -129.84 125.92 36.81 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.682 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.75 126.3 32.15 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 121.095 -0.242 . . . . 0.0 111.083 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' A' ' 22' ' ' GLU . 55.4 mp0 -141.32 163.94 31.59 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' B' ' 25' ' ' GLY . 33.7 t70 -79.2 113.67 17.52 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.74 0.645 . . . . 0.0 112.74 -178.538 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.502 ' O ' ' N ' ' A' ' 26' ' ' SER . 3.5 p -127.11 121.66 58.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 176.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -29.31 84.04 0.0 OUTLIER Glycine 0 CA--C 1.537 1.412 0 CA-C-O 118.833 -0.982 . . . . 0.0 113.834 178.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.502 ' N ' ' O ' ' A' ' 24' ' ' VAL . 10.0 p -97.62 171.82 8.11 Favored 'General case' 0 C--N 1.347 0.468 0 CA-C-N 119.686 1.743 . . . . 0.0 107.311 177.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 p30 -60.13 177.53 0.25 Allowed 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 118.418 -1.313 . . . . 0.0 110.227 178.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -61.76 110.61 1.57 Allowed 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.505 174.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.655 ' H ' ' CB ' ' B' ' 27' ' ' ASN . . . 70.86 93.82 0.07 OUTLIER Glycine 0 N--CA 1.467 0.714 0 C-N-CA 117.541 -2.266 . . . . 0.0 111.716 174.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.52 158.57 17.43 Favored 'General case' 0 C--O 1.242 0.693 0 CA-C-N 121.283 2.542 . . . . 0.0 111.225 -179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.603 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -143.98 120.38 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 CA-C-N 113.433 -1.712 . . . . 0.0 110.566 -175.532 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 79.7 mt -130.6 125.3 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 O-C-N 121.52 -0.738 . . . . 0.0 110.438 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.575 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -132.15 119.12 2.43 Favored Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 80.8 mt -122.23 129.97 52.74 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.071 0.462 . . . . 0.0 110.895 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.53 120.49 29.78 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.18 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -104.94 77.74 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 C-N-CA 120.22 -0.592 . . . . 0.0 112.239 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.542 ' CA ' HG21 ' G' ' 31' ' ' ILE . . . -92.27 101.0 2.73 Favored Glycine 0 C--N 1.342 0.893 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.14 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.64 155.87 27.45 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 28.4 m -136.93 161.51 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.415 179.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.6 m . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.616 -179.909 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 72.0 t80 -138.81 159.05 43.07 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 110.206 -0.294 . . . . 0.0 110.206 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -60.39 132.17 53.05 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.121 0.486 . . . . 0.0 110.965 -179.431 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 26.5 m -139.56 162.88 26.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.631 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.437 ' C ' ' CG ' ' B' ' 14' ' ' HIS . 80.6 t60 -138.7 138.9 38.16 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.644 0.259 . . . . 0.0 110.533 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.587 ' CE1' ' CE1' ' C' ' 14' ' ' HIS . 19.6 m-70 -150.76 170.24 19.71 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-O 121.278 0.561 . . . . 0.0 109.983 -179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 74.9 mt-30 -153.14 173.04 16.01 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.49 178.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -153.9 118.66 4.97 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -116.31 120.95 40.54 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 45.5 t -126.07 121.79 60.22 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-O 121.157 0.504 . . . . 0.0 110.641 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.906 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 6.4 m-85 -113.52 113.16 24.73 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.709 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -118.17 106.17 12.57 Favored 'General case' 0 CA--C 1.52 -0.208 0 N-CA-C 106.168 -1.79 . . . . 0.0 106.168 175.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.99 125.93 52.12 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -177.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.523 ' N ' ' OE1' ' B' ' 22' ' ' GLU . 57.0 mp0 -142.41 178.88 7.29 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 177.208 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.499 ' OD1' ' NZ ' ' D' ' 28' ' ' LYS . 14.1 m-20 -38.09 121.92 0.99 Allowed 'General case' 0 N--CA 1.475 0.811 0 CA-C-N 119.244 0.929 . . . . 0.0 110.644 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.805 HG12 ' H ' ' B' ' 25' ' ' GLY . 97.3 t -58.55 -120.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.217 -0.648 0 C-N-CA 120.819 -0.353 . . . . 0.0 111.021 -178.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.805 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -79.67 -90.28 0.45 Allowed Glycine 0 CA--C 1.523 0.577 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.996 -178.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.419 ' HB3' ' H ' ' A' ' 26' ' ' SER . 77.6 p -155.01 -172.07 4.06 Favored 'General case' 0 N--CA 1.443 -0.824 0 CA-C-O 121.835 0.826 . . . . 0.0 110.403 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.655 ' CB ' ' H ' ' A' ' 29' ' ' GLY . 8.9 t-20 57.72 -171.72 0.1 Allowed 'General case' 0 C--N 1.307 -1.269 0 CA-C-N 114.201 -1.363 . . . . 0.0 111.671 178.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.566 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 72.2 mmtt -56.96 -111.3 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 CA-C-N 115.575 -0.739 . . . . 0.0 112.709 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.92 94.47 1.57 Allowed Glycine 0 N--CA 1.461 0.314 0 CA-C-N 115.265 -0.88 . . . . 0.0 114.39 -177.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.33 163.97 15.79 Favored 'General case' 0 C--N 1.35 0.605 0 C-N-CA 116.821 -1.952 . . . . 0.0 106.673 177.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.46 HD13 ' HA3' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -150.26 128.76 2.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 C-N-CA 119.111 -1.036 . . . . 0.0 111.739 -172.779 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 99.0 mt -133.23 133.61 58.02 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.573 0 CA-C-O 121.325 0.583 . . . . 0.0 110.922 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.01 127.11 4.63 Favored Glycine 0 N--CA 1.47 0.952 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.238 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.41 HD21 ' CG2' ' B' ' 36' ' ' VAL . 7.9 tt -133.79 127.87 33.59 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.294 0.547 . . . . 0.0 111.038 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.548 ' SD ' ' CA ' ' H' ' 33' ' ' GLY . 20.7 ttt -130.24 123.82 31.04 Favored 'General case' 0 C--O 1.239 0.524 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.421 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.41 ' CG2' HD21 ' B' ' 34' ' ' LEU . 2.6 t -124.33 76.02 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.801 178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.32 101.54 2.71 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 179.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -134.72 163.54 24.72 Favored Glycine 0 N--CA 1.467 0.721 0 N-CA-C 110.825 -0.91 . . . . 0.0 110.825 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.86 136.97 56.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.1 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.506 -179.813 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -106.9 135.97 47.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.921 0.391 . . . . 0.0 110.644 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -67.77 135.63 52.95 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.795 179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.572 HG13 ' O ' ' D' ' 12' ' ' VAL . 58.5 t -124.89 133.65 68.92 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 121.05 0.452 . . . . 0.0 111.075 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 p-80 -147.52 145.51 29.12 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.648 -0.706 . . . . 0.0 110.574 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.587 ' CE1' ' CE1' ' B' ' 14' ' ' HIS . 10.2 p-80 -153.76 168.05 27.58 Favored 'General case' 0 N--CA 1.437 -1.084 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.361 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 83.7 mt-30 -148.75 176.85 10.02 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.248 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -147.23 127.74 14.11 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.296 179.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.7 mp -130.51 127.28 38.83 Favored 'General case' 0 C--O 1.238 0.448 0 CA-C-O 121.1 0.476 . . . . 0.0 111.372 -179.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 77.8 t -127.4 126.01 66.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.179 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.089 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.403 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 57.2 m-85 -111.45 116.11 30.36 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 178.198 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 50.4 t80 -127.88 117.68 22.24 Favored 'General case' 0 N--CA 1.465 0.281 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.6 130.67 49.43 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.855 -0.338 . . . . 0.0 111.326 -179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -155.57 101.1 2.15 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 116.273 -0.421 . . . . 0.0 109.979 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 77.8 m-20 -68.7 133.98 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.977 0.418 . . . . 0.0 110.206 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 99.3 t -81.34 113.02 20.09 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-O 121.621 0.724 . . . . 0.0 111.178 -179.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.431 ' O ' HG11 ' D' ' 24' ' ' VAL . . . 52.97 -91.99 0.01 OUTLIER Glycine 0 CA--C 1.531 1.052 0 CA-C-N 114.473 -1.24 . . . . 0.0 115.288 177.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.515 ' OG ' ' N ' ' C' ' 27' ' ' ASN . 47.3 t -153.78 -175.57 5.43 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 122.678 1.228 . . . . 0.0 113.102 -175.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.515 ' N ' ' OG ' ' C' ' 26' ' ' SER . 24.7 m120 52.73 179.93 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 112.433 -2.167 . . . . 0.0 115.129 178.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 75.2 mttt 53.4 110.6 0.01 OUTLIER 'General case' 0 CA--C 1.548 0.878 0 CA-C-N 112.536 -2.12 . . . . 0.0 113.967 -177.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.77 95.97 1.85 Allowed Glycine 0 N--CA 1.488 2.127 0 CA-C-O 117.828 -1.54 . . . . 0.0 110.366 175.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.52 ' HB1' HG21 ' B' ' 24' ' ' VAL . . . -91.54 160.09 15.59 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-N 121.354 2.577 . . . . 0.0 109.833 -179.044 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.592 ' CG2' HD12 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -148.53 124.97 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.767 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.102 -176.421 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.44 ' O ' ' SD ' ' J' ' 35' ' ' MET . 14.3 tt -130.18 128.92 64.99 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 CA-C-O 121.195 0.522 . . . . 0.0 110.459 177.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.445 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -112.77 117.62 4.36 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.75 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 29.3 mt -124.69 119.66 29.61 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -176.211 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.461 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 5.3 ttm -122.4 117.58 26.35 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 177.312 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -131.52 74.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.998 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.313 -178.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 38' ' ' GLY . . . -61.0 110.98 3.4 Favored Glycine 0 C--N 1.354 1.535 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 179.403 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' C' ' 37' ' ' GLY . . . -53.9 -167.47 0.02 OUTLIER Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.71 161.82 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.068 0.461 . . . . 0.0 111.221 -179.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 68.6 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.889 -1.053 . . . . 0.0 110.594 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -82.31 145.78 29.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.994 0.426 . . . . 0.0 110.547 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.495 ' HB3' HG11 ' C' ' 12' ' ' VAL . 94.2 mt-10 -65.49 167.17 9.18 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.378 -179.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.572 ' O ' HG13 ' C' ' 12' ' ' VAL . 30.9 m -131.18 171.44 17.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -177.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.487 ' O ' ' CB ' ' E' ' 13' ' ' HIS . 5.7 t60 -89.21 122.38 32.44 Favored 'General case' 0 N--CA 1.472 0.654 0 C-N-CA 120.757 -0.377 . . . . 0.0 110.013 178.567 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 47.5 p-80 -156.15 169.04 25.43 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.519 -0.872 . . . . 0.0 112.056 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 88.6 mt-30 -145.04 177.97 8.39 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -152.59 119.77 5.88 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.185 -179.849 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -119.68 120.35 36.37 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.744 -0.207 . . . . 0.0 110.855 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -125.7 125.87 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.802 0.334 . . . . 0.0 110.962 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.403 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 72.3 m-85 -115.75 115.82 26.97 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.069 179.011 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 53.9 t80 -127.5 121.15 29.96 Favored 'General case' 0 C--O 1.239 0.5 0 N-CA-C 109.52 -0.548 . . . . 0.0 109.52 178.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.15 135.58 37.49 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 121.298 0.571 . . . . 0.0 112.297 -179.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -136.92 96.48 3.31 Favored 'General case' 0 N--CA 1.462 0.141 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.048 178.379 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.425 ' O ' ' CG2' ' E' ' 24' ' ' VAL . 89.8 m-20 -85.89 134.89 33.87 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.416 -179.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.5 ' O ' HG13 ' D' ' 24' ' ' VAL . 8.1 p -88.27 112.75 24.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 121.457 0.646 . . . . 0.0 109.403 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.472 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -45.45 92.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.597 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.346 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.472 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.9 OUTLIER 163.92 -169.6 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.641 0 CA-C-O 121.727 0.775 . . . . 0.0 110.163 -178.562 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 76.6 m-20 -50.64 179.77 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.727 ' HE2' ' HB2' ' D' ' 30' ' ' ALA . 67.2 tttt 60.49 112.38 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 112.248 -2.251 . . . . 0.0 115.881 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.0 96.16 2.18 Favored Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.091 -2.804 . . . . 0.0 106.091 170.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.727 ' HB2' ' HE2' ' D' ' 28' ' ' LYS . . . -79.31 162.77 25.4 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 123.47 3.635 . . . . 0.0 105.805 -178.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.592 HD12 ' CG2' ' C' ' 31' ' ' ILE . 1.1 mt -147.21 126.47 4.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 C-N-CA 117.679 -1.608 . . . . 0.0 111.348 -174.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 52.6 mt -123.91 116.95 49.52 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 177.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.28 103.59 2.1 Favored Glycine 0 N--CA 1.465 0.574 0 N-CA-C 105.878 -2.889 . . . . 0.0 105.878 176.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.906 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 12.7 tp -116.54 124.36 49.68 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 114.077 1.139 . . . . 0.0 114.077 -175.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.437 ' N ' HD12 ' D' ' 34' ' ' LEU . 8.0 ttm -126.54 110.47 13.28 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 174.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.596 HG13 HD11 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -126.25 79.89 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.7 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.151 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.02 103.13 1.32 Allowed Glycine 0 C--N 1.349 1.283 0 CA-C-N 116.371 -0.377 . . . . 0.0 112.506 -178.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.59 178.93 38.46 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 178.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.51 HG12 ' N ' ' D' ' 40' ' ' VAL . 60.7 t -141.88 157.95 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.946 0.403 . . . . 0.0 111.011 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.51 ' N ' HG12 ' D' ' 39' ' ' VAL . 19.4 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.52 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 77.1 t80 -85.28 138.96 31.99 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 120.883 0.373 . . . . 0.0 110.528 -179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 16.2 pt-20 -55.4 143.05 30.14 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.689 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 71.1 t -123.64 135.75 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.487 ' CB ' ' O ' ' D' ' 13' ' ' HIS . 6.4 p80 -155.66 162.07 40.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.041 0.448 . . . . 0.0 111.296 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 69.0 m80 -139.82 168.19 20.39 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.854 0.835 . . . . 0.0 110.287 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.412 ' HG2' ' N ' ' E' ' 16' ' ' LYS . 51.8 tt0 -153.17 165.34 35.97 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 114.678 -1.146 . . . . 0.0 108.826 178.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.412 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 98.0 mttt -157.24 116.88 3.4 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.627 0.251 . . . . 0.0 110.334 179.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 32.6 tp -117.14 113.79 22.77 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -124.47 128.7 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.422 ' CZ ' ' HB2' ' E' ' 21' ' ' ALA . 41.1 t80 -127.27 120.49 28.77 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.413 -0.358 . . . . 0.0 110.924 -179.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -127.84 118.49 23.77 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.422 ' HB2' ' CZ ' ' E' ' 19' ' ' PHE . . . -128.68 130.04 46.65 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.129 0.49 . . . . 0.0 111.326 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -113.27 102.62 10.53 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 64.4 t0 -79.9 123.17 27.53 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.174 -179.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.437 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 93.0 t -96.5 121.65 47.23 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.195 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 42.7 -87.03 0.01 OUTLIER Glycine 0 CA--C 1.533 1.17 0 CA-C-N 115.127 -0.942 . . . . 0.0 114.688 178.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 11.1 p -165.38 -178.36 4.95 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-O 122.235 1.017 . . . . 0.0 112.044 -175.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.6 ' CG ' ' H ' ' E' ' 28' ' ' LYS . 7.0 t-20 51.36 -179.13 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 116.105 1.891 . . . . 0.0 116.105 177.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.6 ' H ' ' CG ' ' E' ' 27' ' ' ASN . 27.2 tttt 53.76 110.97 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 112.178 -2.283 . . . . 0.0 114.223 -175.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.456 ' HA2' ' H ' ' F' ' 30' ' ' ALA . . . -87.13 96.44 2.17 Favored Glycine 0 C--N 1.337 0.6 0 CA-C-N 111.973 -2.376 . . . . 0.0 110.909 175.04 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.412 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -78.83 166.24 22.65 Favored 'General case' 0 C--O 1.241 0.624 0 CA-C-N 122.765 3.282 . . . . 0.0 103.553 177.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.435 HG21 HD13 ' E' ' 31' ' ' ILE . 1.1 mt -147.57 127.39 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 C-N-CA 116.687 -2.005 . . . . 0.0 112.903 -172.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.49 ' O ' HG23 ' E' ' 32' ' ' ILE . 15.7 tt -135.4 119.88 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-O 121.472 0.653 . . . . 0.0 109.49 176.141 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.68 110.3 2.78 Favored Glycine 0 CA--C 1.508 -0.356 0 N-CA-C 107.492 -2.243 . . . . 0.0 107.492 178.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -119.57 123.24 43.44 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 122.259 1.028 . . . . 0.0 111.775 -178.2 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.432 ' HE2' ' N ' ' K' ' 32' ' ' ILE . 9.5 tpt -111.47 110.77 21.38 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 113.709 -1.587 . . . . 0.0 107.467 178.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.404 HG13 HG23 ' D' ' 36' ' ' VAL . 0.2 OUTLIER -119.66 80.86 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-O 121.035 0.445 . . . . 0.0 109.94 -178.043 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.08 102.17 0.08 OUTLIER Glycine 0 C--N 1.341 0.833 0 CA-C-N 116.247 -0.433 . . . . 0.0 112.044 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.96 150.61 22.7 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 109.534 -1.427 . . . . 0.0 109.534 178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.6 t -126.56 136.71 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 88.8 t . . . . . 0 C--O 1.221 -0.398 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.374 179.819 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 31.5 p90 -147.72 159.48 43.76 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.686 0.279 . . . . 0.0 110.415 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -153.78 147.21 24.94 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.198 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 12.4 m -140.23 -172.01 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-O 120.99 0.424 . . . . 0.0 110.785 -179.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.468 ' CB ' ' CE1' ' E' ' 13' ' ' HIS . 44.4 p-80 -87.68 163.21 16.66 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.312 179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 53.2 m80 -147.33 172.15 14.33 Favored 'General case' 0 N--CA 1.447 -0.587 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 179.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -144.12 178.06 8.15 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.396 -0.366 . . . . 0.0 110.847 -179.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.9 121.9 0.57 Allowed 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.738 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.69 125.19 35.4 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.401 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 86.9 t -134.1 129.4 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.923 0.392 . . . . 0.0 111.237 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -122.55 125.66 46.17 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.049 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -136.07 132.63 36.42 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.13 0.491 . . . . 0.0 110.024 179.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.27 149.46 31.91 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.099 -179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -74.17 152.74 39.75 Favored 'General case' 0 C--N 1.33 -0.244 0 C-N-CA 120.475 -0.49 . . . . 0.0 109.729 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 t0 78.13 -141.02 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.137 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 -178.121 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 59.4 t -108.02 106.85 21.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.74 -95.27 0.01 OUTLIER Glycine 0 CA--C 1.528 0.893 0 CA-C-N 114.672 -1.149 . . . . 0.0 111.848 -179.041 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 41.6 t -48.08 150.61 1.14 Allowed 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 178.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.622 ' O ' ' O ' ' F' ' 28' ' ' LYS . 94.0 m-20 -127.4 179.74 5.32 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 175.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.622 ' O ' ' O ' ' F' ' 27' ' ' ASN . 28.6 pttt -28.87 -103.95 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.375 0 CA-C-O 121.419 0.628 . . . . 0.0 110.85 177.016 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.618 ' O ' ' O ' ' F' ' 30' ' ' ALA . . . -120.01 -100.1 1.81 Allowed Glycine 0 C--N 1.343 0.943 0 N-CA-C 108.299 -1.921 . . . . 0.0 108.299 173.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.618 ' O ' ' O ' ' F' ' 29' ' ' GLY . . . 54.83 151.97 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 105.412 -2.07 . . . . 0.0 105.412 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.447 ' HB ' ' O ' ' F' ' 30' ' ' ALA . 2.7 tp -165.8 132.87 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.214 0 C-N-CA 115.002 -2.679 . . . . 0.0 114.192 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 97.0 mt -111.69 112.98 42.87 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.35 0 CA-C-N 113.631 -1.622 . . . . 0.0 108.418 178.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . 0.437 ' H ' ' HE2' ' L' ' 35' ' ' MET . . . -97.13 101.74 2.63 Favored Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 105.382 -3.087 . . . . 0.0 105.382 176.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.473 HD12 ' O ' ' F' ' 34' ' ' LEU . 0.4 OUTLIER -104.73 108.69 20.29 Favored 'General case' 0 CA--C 1.515 -0.374 0 N-CA-C 112.537 0.569 . . . . 0.0 112.537 -176.189 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.47 ' SD ' ' C ' ' L' ' 32' ' ' ILE . 0.9 OUTLIER -109.42 107.34 17.47 Favored 'General case' 0 CA--C 1.512 -0.517 0 N-CA-C 107.224 -1.399 . . . . 0.0 107.224 176.102 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -136.01 80.59 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.523 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.984 -179.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.49 -101.66 0.09 OUTLIER Glycine 0 C--N 1.344 1.004 0 C-N-CA 120.976 -0.631 . . . . 0.0 111.99 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.74 -159.71 31.64 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 -179.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.1 m -135.19 161.72 39.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 CA-C-O 120.626 0.251 . . . . 0.0 110.529 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.204 179.612 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 7.0 m-85 -126.77 142.69 51.47 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -137.37 143.72 42.11 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.057 0.456 . . . . 0.0 111.019 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.413 ' O ' HG13 ' G' ' 12' ' ' VAL . 12.4 p -130.49 134.99 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.335 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.187 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -122.79 127.25 48.88 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 120.95 0.405 . . . . 0.0 110.445 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 70.8 t60 -157.62 165.41 35.58 Favored 'General case' 0 N--CA 1.442 -0.832 0 CA-C-O 121.16 0.505 . . . . 0.0 110.183 179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 83.6 mt-30 -151.28 174.76 12.91 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.018 178.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -171.57 114.04 0.36 Allowed 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.082 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 64.7 mt -131.16 124.1 29.97 Favored 'General case' 0 C--O 1.24 0.558 0 CA-C-O 121.331 0.586 . . . . 0.0 110.306 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.46 ' O ' HG23 ' G' ' 18' ' ' VAL . 30.9 m -128.12 129.83 69.53 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.632 -0.713 . . . . 0.0 111.135 -179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.551 ' CE2' HD21 ' J' ' 34' ' ' LEU . 15.4 m-85 -110.53 113.03 25.34 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.466 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 45.6 p90 -123.95 124.13 41.93 Favored 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.27 131.13 38.07 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -145.6 167.22 23.59 Favored 'General case' 0 CA--C 1.53 0.175 0 N-CA-C 107.127 -1.434 . . . . 0.0 107.127 177.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 58.6 t0 -90.14 111.78 23.03 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.015 -0.674 . . . . 0.0 112.186 -178.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.611 ' O ' ' N ' ' G' ' 26' ' ' SER . 3.6 p -113.17 131.04 65.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 N-CA-C 106.669 -1.604 . . . . 0.0 106.669 177.127 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.29 81.96 0.0 OUTLIER Glycine 0 CA--C 1.532 1.11 0 C-N-CA 121.562 -0.351 . . . . 0.0 112.782 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.611 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.1 m -96.58 176.2 6.11 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.504 ' O ' ' O ' ' G' ' 28' ' ' LYS . 53.3 p30 -62.2 -177.73 0.14 Allowed 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 177.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.504 ' O ' ' O ' ' G' ' 27' ' ' ASN . 98.4 mttt -48.85 -109.2 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.646 0 CA-C-O 121.682 0.753 . . . . 0.0 110.64 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -85.65 96.53 2.1 Favored Glycine 0 N--CA 1.466 0.66 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 177.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.42 161.32 23.77 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 115.49 -2.484 . . . . 0.0 109.609 -177.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.627 ' CG2' HD12 ' H' ' 31' ' ' ILE . 0.1 OUTLIER -154.33 116.27 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.868 -175.066 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -143.09 137.76 26.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.502 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.45 ' CA ' ' O ' ' H' ' 33' ' ' GLY . . . -158.8 164.33 33.6 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.466 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 3.3 tp -169.57 163.28 10.21 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.13 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.575 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 53.5 ttp -131.93 134.12 45.3 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.601 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.406 ' HB ' HG23 ' H' ' 36' ' ' VAL . 21.1 t -117.48 65.03 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 116.255 -0.429 . . . . 0.0 111.514 179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.603 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -55.12 -106.76 0.01 OUTLIER Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.25 -166.12 13.97 Favored Glycine 0 N--CA 1.465 0.629 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -132.58 159.22 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 121.025 0.44 . . . . 0.0 110.852 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 p . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.669 -179.805 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -107.41 128.95 54.93 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-O 120.869 0.366 . . . . 0.0 110.354 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -145.76 135.4 23.29 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.612 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -140.44 134.93 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 77.6 m80 -118.69 118.74 32.44 Favored 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.416 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.528 ' ND1' ' O ' ' H' ' 13' ' ' HIS . 5.8 m-70 -135.56 164.29 28.17 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-O 121.507 0.67 . . . . 0.0 109.856 179.216 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.693 HE21 HD21 ' H' ' 17' ' ' LEU . 52.5 tt0 -161.86 170.51 19.34 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.437 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . 0.416 ' N ' ' CG ' ' H' ' 15' ' ' GLN . 68.7 mttm -155.94 115.79 3.64 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.722 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.693 HD21 HE21 ' H' ' 15' ' ' GLN . 76.6 mt -114.76 115.27 26.77 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 177.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -125.09 124.6 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 63.6 m-85 -113.01 108.76 17.79 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 106.979 -1.489 . . . . 0.0 106.979 176.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.522 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 24.6 t80 -127.06 129.52 48.16 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-N 118.164 0.438 . . . . 0.0 110.635 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.47 150.4 26.57 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 118.346 -1.342 . . . . 0.0 114.56 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -132.53 173.04 11.73 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 114.367 -1.288 . . . . 0.0 109.582 179.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.406 ' OD1' ' C ' ' H' ' 23' ' ' ASP . 64.5 t0 -148.51 116.53 6.4 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 113.253 0.835 . . . . 0.0 113.253 -179.006 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 3.2 p -121.49 122.33 66.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 177.412 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.24 83.79 0.01 OUTLIER Glycine 0 N--CA 1.472 1.052 0 CA-C-O 121.588 0.549 . . . . 0.0 112.245 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 9.3 p -45.35 170.28 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 113.864 1.061 . . . . 0.0 113.864 179.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.472 ' O ' ' O ' ' H' ' 28' ' ' LYS . 19.5 m120 -135.61 177.04 8.13 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 113.444 -1.707 . . . . 0.0 107.738 173.773 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.472 ' O ' ' O ' ' H' ' 27' ' ' ASN . 65.2 mttm -21.28 -102.86 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.272 0 N-CA-C 113.693 0.998 . . . . 0.0 113.693 178.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . -158.85 100.27 0.19 Allowed Glycine 0 C--N 1.349 1.256 0 CA-C-O 118.365 -1.241 . . . . 0.0 110.788 177.042 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.82 157.14 31.19 Favored 'General case' 0 C--O 1.253 1.262 0 CA-C-N 120.869 2.334 . . . . 0.0 109.125 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.637 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.5 OUTLIER -142.91 118.5 4.9 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.473 -176.547 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.53 ' O ' ' SD ' ' B' ' 35' ' ' MET . 86.1 mt -127.7 126.17 66.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.184 0 C-N-CA 120.303 -0.559 . . . . 0.0 112.406 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.548 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -131.88 110.33 0.95 Allowed Glycine 0 N--CA 1.477 1.398 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 8.1 tt -141.76 137.96 31.97 Favored 'General case' 0 N--CA 1.474 0.746 0 O-C-N 121.582 -0.952 . . . . 0.0 112.476 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 40.8 ttp -127.3 139.33 52.96 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.835 179.292 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.614 ' O ' HG22 ' H' ' 36' ' ' VAL . 2.5 p -153.48 75.15 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.943 178.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.46 ' HA3' HD13 ' B' ' 31' ' ' ILE . . . -37.25 -95.5 0.01 OUTLIER Glycine 0 C--N 1.343 0.928 0 N-CA-C 111.201 -0.759 . . . . 0.0 111.201 178.376 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -165.22 38.58 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 t -90.44 134.67 28.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.969 0.414 . . . . 0.0 110.764 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.218 -0.587 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.312 -179.964 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -136.67 149.41 47.92 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.656 0.265 . . . . 0.0 110.299 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -56.37 133.18 52.74 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-O 120.96 0.41 . . . . 0.0 110.961 -179.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.488 HG21 ' NE2' ' I' ' 14' ' ' HIS . 2.5 p -150.32 151.02 13.06 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.237 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.001 -179.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.449 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 25.0 m-70 -119.87 138.92 53.11 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.044 -0.525 . . . . 0.0 109.605 178.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.488 ' NE2' HG21 ' I' ' 12' ' ' VAL . 25.8 m-70 -144.74 168.79 19.37 Favored 'General case' 0 CA--C 1.511 -0.552 0 CA-C-O 121.499 0.666 . . . . 0.0 110.483 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.3 mm-40 -149.42 177.99 9.2 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.84 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 tttm -171.36 107.01 0.24 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.862 179.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.687 HD22 HD12 ' H' ' 17' ' ' LEU . 9.2 mt -120.07 115.54 23.91 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.407 ' O ' HG23 ' I' ' 18' ' ' VAL . 2.2 m -134.43 127.61 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.23 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.42 ' CD2' ' CE2' ' J' ' 19' ' ' PHE . 12.6 m-30 -110.35 118.8 37.27 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.346 -0.843 . . . . 0.0 109.251 178.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.522 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 53.3 t80 -125.65 118.05 24.83 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.454 ' HB1' ' O ' ' I' ' 25' ' ' GLY . . . -139.43 135.49 33.66 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 113.226 0.824 . . . . 0.0 113.226 -177.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.548 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 82.9 tt0 -115.92 100.18 7.8 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.155 -1.794 . . . . 0.0 106.155 176.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.548 ' CB ' ' O ' ' I' ' 22' ' ' GLU . 53.2 t0 121.61 -130.3 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.632 0 O-C-N 124.817 1.323 . . . . 0.0 108.246 -176.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.586 HG13 ' NZ ' ' K' ' 28' ' ' LYS . 19.8 m -106.14 112.02 37.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.798 0.809 . . . . 0.0 108.929 -178.501 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.454 ' O ' ' HB1' ' I' ' 21' ' ' ALA . . . 33.65 -92.16 0.01 OUTLIER Glycine 0 N--CA 1.471 1.013 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -177.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.64 ' O ' ' O ' ' I' ' 27' ' ' ASN . 41.4 t -130.46 168.24 17.33 Favored 'General case' 0 CA--C 1.499 -1.004 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 174.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.64 ' O ' ' O ' ' I' ' 26' ' ' SER . 98.2 m-20 38.43 179.13 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 O-C-N 124.096 0.873 . . . . 0.0 111.628 176.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.619 ' H ' ' HD2' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -92.65 -120.75 0.08 Allowed 'General case' 0 N--CA 1.471 0.585 0 O-C-N 120.906 -1.121 . . . . 0.0 109.134 178.919 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.461 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -69.08 88.11 0.23 Allowed Glycine 0 CA--C 1.484 -1.903 0 N-CA-C 104.824 -3.31 . . . . 0.0 104.824 171.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.47 162.79 35.65 Favored 'General case' 0 CA--C 1.464 -2.331 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.91 -175.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.637 ' CG1' HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -137.74 113.21 10.44 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.004 -179.404 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.601 ' CG2' HD11 ' J' ' 34' ' ' LEU . 1.6 tt -107.03 114.1 45.21 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 179.179 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.427 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -116.65 97.52 0.76 Allowed Glycine 0 CA--C 1.508 -0.377 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -123.17 131.55 53.72 Favored 'General case' 0 CA--C 1.509 -0.619 0 CA-C-O 122.379 1.085 . . . . 0.0 110.579 179.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.564 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 25.6 ttt -116.19 117.38 29.88 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.577 -1.647 . . . . 0.0 110.29 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.3 m -134.7 71.3 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.172 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.51 -179.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.19 105.58 3.21 Favored Glycine 0 C--N 1.365 2.157 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 176.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.08 165.17 53.27 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.745 -0.741 . . . . 0.0 111.694 -178.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t -143.75 136.9 24.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.68 0.276 . . . . 0.0 110.351 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.098 -0.953 . . . . 0.0 110.324 179.699 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.784 -1.326 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -81.92 142.81 32.13 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.957 0.408 . . . . 0.0 110.926 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -63.04 142.12 58.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.705 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -134.85 144.29 35.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 3.5 m80 -139.13 138.55 37.11 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.377 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.475 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 79.6 t60 -139.73 166.92 23.33 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.475 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 85.5 mt-30 -148.61 172.0 15.25 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.612 179.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 47.6 mtpt -156.93 112.07 2.83 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.603 178.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' J' ' 17' ' ' LEU . 5.3 mp -123.82 120.53 32.89 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.437 0.16 . . . . 0.0 110.661 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 4.9 m -137.31 130.86 44.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 119.921 -0.712 . . . . 0.0 112.014 179.473 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.42 ' CE2' ' CD2' ' I' ' 19' ' ' PHE . 18.0 m-85 -111.04 119.78 40.18 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 114.741 -1.118 . . . . 0.0 108.75 178.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -131.31 122.08 25.79 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 -179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.67 145.04 31.54 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -131.41 160.31 35.46 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 114.911 -1.041 . . . . 0.0 108.897 178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -121.77 120.63 35.17 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.524 HG12 ' N ' ' J' ' 25' ' ' GLY . 14.3 t -62.87 -120.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.94 177.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.524 ' N ' HG12 ' J' ' 24' ' ' VAL . . . -75.3 -90.26 0.21 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.227 -0.897 . . . . 0.0 113.203 -177.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 53.4 m -140.97 171.23 14.36 Favored 'General case' 0 CA--C 1.513 -0.473 0 CA-C-O 122.067 0.937 . . . . 0.0 111.024 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.533 ' OD1' ' N ' ' J' ' 28' ' ' LYS . 38.8 t-20 -28.66 151.1 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.154 0 CA-C-N 113.627 -1.624 . . . . 0.0 115.168 -175.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.533 ' N ' ' OD1' ' J' ' 27' ' ' ASN . 97.9 mttt -163.75 110.7 1.13 Allowed 'General case' 0 CA--C 1.541 0.632 0 CA-C-N 112.594 -2.094 . . . . 0.0 107.594 177.231 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.65 93.82 0.32 Allowed Glycine 0 N--CA 1.476 1.303 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.538 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.507 ' HB2' ' O ' ' I' ' 28' ' ' LYS . . . -112.16 157.73 20.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 105.85 -1.907 . . . . 0.0 105.85 177.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.646 HG23 ' CG1' ' K' ' 31' ' ' ILE . 0.0 OUTLIER -146.55 111.24 0.9 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 119.715 -0.794 . . . . 0.0 110.329 -173.729 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.437 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.2 tt -104.54 118.57 52.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.113 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.773 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.61 106.51 0.89 Allowed Glycine 0 C--O 1.241 0.567 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.601 HD11 ' CG2' ' I' ' 32' ' ' ILE . 5.3 mp -129.71 132.06 46.52 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-O 122.15 0.976 . . . . 0.0 111.217 179.137 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.44 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 23.2 ttt -102.04 114.91 29.44 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 113.383 -1.735 . . . . 0.0 108.143 178.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -136.46 70.45 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.837 0 C-N-CA 120.398 -0.521 . . . . 0.0 111.446 -177.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.72 -101.12 1.99 Allowed Glycine 0 C--N 1.358 1.756 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 177.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.61 154.71 26.21 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -142.79 139.17 28.11 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 CA-C-O 121.128 0.489 . . . . 0.0 110.726 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.589 179.641 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.62 139.03 45.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.76 0.314 . . . . 0.0 110.913 -179.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.542 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 95.0 mt-10 -139.47 153.53 47.55 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.619 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.454 HG22 ' H ' ' L' ' 12' ' ' VAL . 54.6 t -121.71 131.16 73.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-N 116.312 -0.403 . . . . 0.0 109.968 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -161.51 162.63 30.4 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.716 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 89.4 m-70 -152.45 168.01 26.89 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.947 179.389 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 -158.04 178.83 9.77 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.11 179.452 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.1 tttt -160.14 126.58 4.27 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 120.608 -0.437 . . . . 0.0 111.123 179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -116.86 119.11 34.37 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 179.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.38 125.69 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.866 0.365 . . . . 0.0 111.395 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -116.91 119.69 36.14 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.116 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.405 ' CE1' ' OE2' ' K' ' 22' ' ' GLU . 37.8 t80 -127.92 119.72 26.16 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.367 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.43 132.98 34.21 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.47 ' OE1' ' OE2' ' L' ' 22' ' ' GLU . 57.7 mm-40 -102.83 167.86 9.6 Favored 'General case' 0 N--CA 1.464 0.257 0 N-CA-C 107.464 -1.309 . . . . 0.0 107.464 177.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' K' ' 23' ' ' ASP . 2.9 p30 -152.35 133.7 14.44 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 119.11 -1.036 . . . . 0.0 113.788 -178.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.555 ' O ' HG13 ' K' ' 24' ' ' VAL . 7.7 p -88.69 113.29 25.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 104.222 -2.51 . . . . 0.0 104.222 174.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.46 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -45.39 91.13 0.01 OUTLIER Glycine 0 CA--C 1.524 0.621 0 C-N-CA 119.722 -1.228 . . . . 0.0 113.503 -174.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.6 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.6 t 161.17 160.69 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.127 0.489 . . . . 0.0 110.159 175.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' K' ' 28' ' ' LYS . 82.3 m-20 -29.76 175.91 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 113.637 -1.62 . . . . 0.0 113.245 173.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.66 ' HB2' ' O ' ' K' ' 27' ' ' ASN . 2.9 tptm 147.56 100.85 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.862 0 C-N-CA 127.032 2.133 . . . . 0.0 110.299 176.02 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.584 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -51.22 -100.17 0.01 OUTLIER Glycine 0 C--O 1.21 -1.397 0 CA-C-O 124.465 2.147 . . . . 0.0 114.385 175.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.81 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 70.74 143.87 0.06 Allowed 'General case' 0 C--O 1.245 0.826 0 CA-C-N 111.354 -2.423 . . . . 0.0 107.203 177.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.81 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -147.88 123.09 2.35 Favored 'Isoleucine or valine' 0 C--O 1.24 0.591 0 C-N-CA 118.595 -1.242 . . . . 0.0 110.795 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.493 ' O ' ' CG2' ' K' ' 32' ' ' ILE . 0.8 OUTLIER -108.97 115.12 48.69 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.692 178.816 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 91.35 0.58 Allowed Glycine 0 C--O 1.24 0.485 0 N-CA-C 107.333 -2.307 . . . . 0.0 107.333 176.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.4 HD12 ' CE2' ' I' ' 19' ' ' PHE . 92.2 mt -114.75 118.75 34.47 Favored 'General case' 0 CA--C 1.509 -0.611 0 CA-C-O 121.331 0.586 . . . . 0.0 109.862 -179.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 2.5 ttt -107.7 115.04 29.43 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.742 -178.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.11 68.35 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.763 179.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.415 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -62.03 -100.99 0.01 OUTLIER Glycine 0 C--N 1.349 1.262 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.86 160.2 14.39 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.422 -1.071 . . . . 0.0 110.422 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.9 m -136.76 159.74 37.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.794 0.33 . . . . 0.0 110.219 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 m . . . . . 0 C--N 1.325 -0.457 0 CA-C-O 118.089 -0.958 . . . . 0.0 110.765 -179.77 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.351 0 N-CA-C 109.471 -1.452 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -104.38 132.33 50.75 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 19.7 pt-20 -71.9 132.42 44.34 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.708 -0.397 . . . . 0.0 110.354 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.454 ' H ' HG22 ' K' ' 12' ' ' VAL . 21.8 m -143.13 156.2 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 122.011 0.91 . . . . 0.0 112.543 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.542 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 3.9 m80 -151.16 118.33 5.94 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 113.849 -1.523 . . . . 0.0 108.729 179.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -153.88 172.82 16.8 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-O 121.273 0.559 . . . . 0.0 110.418 -179.055 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 86.4 mt-30 -145.67 173.86 11.7 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.099 -0.955 . . . . 0.0 109.728 179.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 52.1 mtmt -159.82 120.92 3.14 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.93 179.087 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 tt -122.51 119.73 31.77 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -129.07 132.89 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 43.1 p90 -135.64 130.32 34.17 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.935 0.398 . . . . 0.0 110.715 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.2 t80 -137.31 127.62 26.38 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 179.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.0 148.21 36.41 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.265 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.47 ' OE2' ' OE1' ' K' ' 22' ' ' GLU . 78.1 mt-10 -81.73 149.17 28.58 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.464 0.649 . . . . 0.0 110.722 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.411 ' O ' ' O ' ' L' ' 22' ' ' GLU . 99.3 m-20 54.17 114.42 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.869 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 67.3 t -95.12 130.61 43.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.969 0 CA-C-N 114.519 -1.219 . . . . 0.0 109.879 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 49.56 82.74 0.03 OUTLIER Glycine 0 CA--C 1.525 0.698 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.183 178.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' L' ' 27' ' ' ASN . 5.8 p 176.96 -167.52 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -177.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' L' ' 26' ' ' SER . 14.5 m120 -38.92 179.91 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 113.95 1.093 . . . . 0.0 113.95 -175.485 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.468 ' NZ ' ' O ' ' K' ' 22' ' ' GLU . 85.1 tttt 77.42 -111.42 0.02 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.668 -1.151 . . . . 0.0 112.128 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.646 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 83.93 -94.59 1.83 Allowed Glycine 0 CA--C 1.503 -0.682 0 N-CA-C 107.892 -2.083 . . . . 0.0 107.892 -174.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.646 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 77.17 169.77 0.23 Allowed 'General case' 0 CA--C 1.498 -1.043 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 179.805 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.617 HD13 ' C ' ' L' ' 30' ' ' ALA . 0.0 OUTLIER -138.83 109.19 4.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 116.81 -1.956 . . . . 0.0 111.224 179.23 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' L' ' 32' ' ' ILE . 7.4 tt -102.7 115.88 45.41 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.507 0 CA-C-N 113.34 -1.755 . . . . 0.0 107.961 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 110.18 2.24 Favored Glycine 0 C--N 1.334 0.464 0 N-CA-C 110.544 -1.022 . . . . 0.0 110.544 -179.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -114.38 111.8 22.03 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 114.582 -0.809 . . . . 0.0 110.086 -179.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.437 ' HE2' ' H ' ' F' ' 33' ' ' GLY . 2.7 tpp -93.65 104.97 17.05 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 104.841 -2.281 . . . . 0.0 104.841 176.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' L' ' 37' ' ' GLY . 0.7 OUTLIER -131.09 71.36 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.954 0 O-C-N 122.051 -0.405 . . . . 0.0 109.922 -176.334 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -35.49 -100.66 0.01 OUTLIER Glycine 0 C--N 1.346 1.085 0 C-N-CA 121.815 -0.231 . . . . 0.0 112.717 -179.297 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.27 174.91 19.16 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.2 m -130.69 159.2 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.979 0.419 . . . . 0.0 110.709 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.184 179.897 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -81.86 137.03 35.32 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.828 0.346 . . . . 0.0 110.547 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 73.2 mm-40 -122.48 143.02 49.97 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.94 179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t -121.48 132.35 70.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 121.307 0.575 . . . . 0.0 110.859 -179.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.488 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 69.7 m80 -116.44 172.5 7.17 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 115.329 -0.85 . . . . 0.0 109.813 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.682 ' CD2' ' H ' ' A' ' 15' ' ' GLN . 12.3 t-80 -80.45 165.55 22.09 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-O 121.253 0.549 . . . . 0.0 109.622 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.682 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 1.2 pm0 -161.01 179.03 8.78 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.315 179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -144.24 128.22 17.48 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.713 179.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 78.5 mt -124.03 124.19 42.01 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 109.544 -0.539 . . . . 0.0 109.544 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.24 131.45 60.87 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.333 0.587 . . . . 0.0 111.852 -179.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.912 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 0.2 OUTLIER -118.44 112.11 19.53 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 178.937 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.533 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 51.1 p90 -125.44 128.27 47.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -177.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.27 115.85 28.06 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-O 121.219 0.533 . . . . 0.0 110.166 178.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.465 ' O ' ' C ' ' A' ' 23' ' ' ASP . 84.7 tt0 -163.89 96.52 0.82 Allowed 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.465 ' C ' ' O ' ' A' ' 22' ' ' GLU . 0.1 OUTLIER -25.89 115.46 0.06 Allowed 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 -177.097 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' A' ' 26' ' ' SER . 2.1 p -87.27 130.64 36.77 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.75 82.29 0.0 OUTLIER Glycine 0 CA--C 1.525 0.712 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.618 -177.249 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' A' ' 24' ' ' VAL . 80.2 p -98.47 174.95 6.21 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.07 178.89 0.16 Allowed 'General case' 0 C--N 1.313 -0.996 0 C-N-CA 119.396 -0.922 . . . . 0.0 108.635 177.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -59.68 110.78 1.22 Allowed 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 120.596 -0.442 . . . . 0.0 110.73 178.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.69 94.2 0.11 Allowed Glycine 0 N--CA 1.469 0.843 0 C-N-CA 119.702 -1.237 . . . . 0.0 111.284 177.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.402 ' HB2' ' OG ' ' A' ' 26' ' ' SER . . . -103.32 160.23 14.87 Favored 'General case' 0 CA--C 1.506 -0.716 0 CA-C-N 119.707 1.753 . . . . 0.0 107.497 177.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.579 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.2 OUTLIER -152.6 113.03 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.175 -175.308 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.47 ' O ' ' SD ' ' G' ' 35' ' ' MET . 97.6 mt -128.86 128.04 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-O 121.435 0.636 . . . . 0.0 111.671 -179.362 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' G' ' 35' ' ' MET . . . -123.5 127.03 6.43 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.043 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 57.4 tp -130.18 130.05 44.21 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.799 0.3 . . . . 0.0 111.021 -179.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.674 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 19.8 ttp -130.63 128.08 40.24 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.096 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.449 HG12 ' O ' ' A' ' 36' ' ' VAL . 54.4 t -115.64 72.15 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.11 0 N-CA-C 113.225 0.824 . . . . 0.0 113.225 -179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.88 98.82 0.81 Allowed Glycine 0 CA--C 1.529 0.924 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 176.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.76 172.45 40.48 Favored Glycine 0 CA--C 1.523 0.547 0 C-N-CA 120.485 -0.864 . . . . 0.0 111.564 -179.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m -132.47 161.24 41.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 CA-C-O 120.781 0.324 . . . . 0.0 110.765 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 p . . . . . 0 N--CA 1.467 0.385 0 CA-C-O 118.073 -0.965 . . . . 0.0 110.217 179.369 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 -104.83 139.17 39.98 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.123 0.487 . . . . 0.0 110.597 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' C' ' 11' ' ' GLU . 18.6 pt-20 -64.19 142.97 58.22 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.181 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -132.88 137.36 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.16 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.464 ' O ' ' CB ' ' C' ' 13' ' ' HIS . 4.8 m-70 -105.67 117.76 34.84 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.789 0.328 . . . . 0.0 110.909 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.476 ' ND1' ' CD2' ' A' ' 14' ' ' HIS . 52.5 t-80 -157.21 159.51 37.76 Favored 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.437 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 74.4 mt-30 -159.98 179.07 9.09 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.832 179.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -157.71 126.12 5.54 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.754 0.311 . . . . 0.0 110.762 179.231 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 tp -120.76 123.25 42.21 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.312 0.577 . . . . 0.0 110.297 179.651 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.48 HG22 ' CG1' ' C' ' 18' ' ' VAL . 56.0 t -117.93 121.37 67.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.601 -179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.901 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 13.5 t80 -128.05 116.26 19.73 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 -178.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.543 ' CG ' ' CZ ' ' C' ' 20' ' ' PHE . 38.8 p90 -150.2 160.22 43.85 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 179.379 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.41 138.85 38.59 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 114.772 -1.104 . . . . 0.0 112.896 -179.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -125.4 175.1 7.72 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 -179.466 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.487 ' CG ' ' H ' ' C' ' 27' ' ' ASN . 50.5 t0 -142.98 99.33 3.44 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.139 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.656 HG12 ' H ' ' B' ' 25' ' ' GLY . 1.6 t -118.21 -151.17 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 177.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.656 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -38.9 -75.88 0.09 OUTLIER Glycine 0 N--CA 1.47 0.937 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.601 178.285 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.592 ' HG ' ' H ' ' B' ' 27' ' ' ASN . 31.1 t 60.15 173.13 0.09 Allowed 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.73 -1.235 . . . . 0.0 113.568 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.592 ' H ' ' HG ' ' B' ' 26' ' ' SER . 18.9 p30 -101.38 -178.98 3.89 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 113.395 -1.73 . . . . 0.0 112.567 179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.494 ' O ' ' O ' ' B' ' 27' ' ' ASN . 87.3 tttt -34.15 -102.66 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 115.497 -0.774 . . . . 0.0 111.118 177.115 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -137.13 100.8 0.32 Allowed Glycine 0 CA--C 1.485 -1.829 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -66.5 157.72 31.45 Favored 'General case' 0 N--CA 1.43 -1.447 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.349 178.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.754 HG23 HG13 ' C' ' 31' ' ' ILE . 0.6 OUTLIER -148.58 120.87 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.174 0 C-N-CA 119.384 -0.926 . . . . 0.0 108.583 -178.796 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.501 ' O ' ' SD ' ' H' ' 35' ' ' MET . 86.8 mt -133.98 128.68 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 119.739 -0.784 . . . . 0.0 112.362 -178.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.505 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -120.81 109.5 1.56 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 108.976 -1.65 . . . . 0.0 108.976 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 8.7 tt -117.08 123.32 46.53 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 117.072 0.436 . . . . 0.0 111.099 -179.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.599 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 32.1 ttp -124.79 117.37 24.01 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.299 179.201 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.428 ' O ' ' O ' ' B' ' 37' ' ' GLY . 34.5 m -136.54 73.01 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.428 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -47.4 -95.35 0.01 OUTLIER Glycine 0 C--N 1.337 0.604 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 175.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.13 176.67 40.45 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 110.106 -1.198 . . . . 0.0 110.106 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -140.96 144.48 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-O 121.031 0.443 . . . . 0.0 111.215 -178.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 85.0 t . . . . . 0 C--O 1.218 -0.554 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.309 179.842 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.156 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -105.73 131.56 52.94 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-O 120.709 0.29 . . . . 0.0 110.595 -179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' B' ' 11' ' ' GLU . 97.5 mt-10 -74.3 133.14 42.59 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.312 -0.403 . . . . 0.0 110.068 179.575 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 35.5 m -151.16 166.68 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.1 0 CA-C-O 120.832 0.349 . . . . 0.0 110.887 -179.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.493 ' ND1' ' OE1' ' D' ' 11' ' ' GLU . 0.0 OUTLIER -169.28 164.76 10.92 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.271 178.749 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.495 ' CG ' ' OE1' ' D' ' 15' ' ' GLN . 88.6 m-70 -105.52 -179.91 4.08 Favored 'General case' 0 CA--C 1.509 -0.597 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.261 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' C' ' 16' ' ' LYS . 44.9 tt0 -88.69 169.19 11.88 Favored 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.433 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' C' ' 15' ' ' GLN . 99.2 mttt -123.5 133.92 53.95 Favored 'General case' 0 N--CA 1.466 0.325 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 29.1 mt -122.3 119.35 30.86 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.026 -178.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . 0.48 ' CG1' HG22 ' B' ' 18' ' ' VAL . 6.2 p -124.77 123.23 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.067 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.707 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 3.6 t80 -123.41 119.17 29.25 Favored 'General case' 0 CA--C 1.535 0.384 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.571 -176.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.543 ' CZ ' ' CG ' ' B' ' 20' ' ' PHE . 49.7 p90 -142.86 130.26 21.11 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-O 122.574 1.178 . . . . 0.0 112.953 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.94 121.74 38.69 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.397 179.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.496 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 97.2 mt-10 -99.01 101.08 12.35 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 106.649 -1.612 . . . . 0.0 106.649 177.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.498 ' OD1' ' NZ ' ' E' ' 28' ' ' LYS . 15.7 t0 83.68 133.56 0.05 Allowed 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.508 ' O ' ' N ' ' C' ' 26' ' ' SER . 34.8 t -83.41 -110.8 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.992 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.718 ' HA2' ' HB3' ' D' ' 30' ' ' ALA . . . -42.85 92.19 0.01 OUTLIER Glycine 0 C--N 1.317 -0.473 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.527 ' O ' ' O ' ' C' ' 27' ' ' ASN . 42.3 p -101.11 165.22 11.42 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 122.49 1.138 . . . . 0.0 110.784 -176.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.646 ' CG ' ' HZ2' ' C' ' 28' ' ' LYS . 0.1 OUTLIER 49.05 169.15 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.149 0 CA-C-N 112.009 -2.36 . . . . 0.0 109.114 -176.235 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.787 ' CE ' ' H ' ' C' ' 28' ' ' LYS . 0.0 OUTLIER -79.08 110.7 14.57 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 119.641 -0.824 . . . . 0.0 108.824 175.634 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 57.25 91.51 0.01 OUTLIER Glycine 0 C--O 1.219 -0.829 0 C-N-CA 118.342 -1.885 . . . . 0.0 109.877 175.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.421 ' HB2' ' OD1' ' C' ' 27' ' ' ASN . . . -136.66 152.22 50.16 Favored 'General case' 0 CA--C 1.476 -1.903 0 CA-C-N 121.428 2.614 . . . . 0.0 105.016 175.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.754 HG13 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -144.48 109.66 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 C-N-CA 118.953 -1.099 . . . . 0.0 109.185 -173.028 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.488 HG12 HD21 ' C' ' 34' ' ' LEU . 0.8 OUTLIER -114.9 118.44 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.05 -178.918 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.21 108.51 2.48 Favored Glycine 0 N--CA 1.46 0.298 0 N-CA-C 108.705 -1.758 . . . . 0.0 108.705 178.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.912 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 5.8 mt -114.76 112.72 23.25 Favored 'General case' 0 CA--C 1.509 -0.607 0 CA-C-O 120.916 0.388 . . . . 0.0 110.331 -178.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.5 ttt -112.42 104.06 12.18 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.59 72.24 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.994 -177.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -42.97 -97.43 0.01 OUTLIER Glycine 0 C--N 1.349 1.27 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.12 -173.12 42.95 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -141.52 154.22 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.446 0 CA-C-O 121.019 0.438 . . . . 0.0 111.133 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 48.4 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.087 -0.959 . . . . 0.0 110.218 179.56 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.129 0 N-CA-C 109.609 -1.396 . . . . 0.0 109.609 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . 0.528 ' CD2' ' N ' ' E' ' 9' ' ' GLY . 96.5 m-85 -109.2 133.39 53.08 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-O 120.954 0.407 . . . . 0.0 110.336 -179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.493 ' OE1' ' ND1' ' C' ' 13' ' ' HIS . 80.9 mm-40 -77.17 133.91 38.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.059 -0.518 . . . . 0.0 110.415 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.439 ' HB ' ' H ' ' E' ' 12' ' ' VAL . 23.0 m -142.19 174.86 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.126 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 70.0 m80 -82.15 112.95 19.65 Favored 'General case' 0 C--N 1.318 -0.766 0 C-N-CA 120.364 -0.534 . . . . 0.0 110.168 179.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.624 ' CE1' HG23 ' E' ' 12' ' ' VAL . 3.4 m-70 -145.72 159.94 42.44 Favored 'General case' 0 CA--C 1.514 -0.431 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 178.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG ' ' C' ' 14' ' ' HIS . 0.0 OUTLIER -159.23 174.18 15.21 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.26 178.942 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -153.32 129.09 10.14 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.886 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 36.7 tp -123.28 118.33 27.32 Favored 'General case' 0 C--O 1.237 0.437 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -122.39 126.19 73.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 CA-C-O 120.941 0.4 . . . . 0.0 110.687 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -123.25 112.33 17.52 Favored 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -178.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -131.57 133.42 45.0 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.79 131.79 29.59 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.886 0.374 . . . . 0.0 111.725 179.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -127.88 143.52 51.11 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.991 179.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -131.3 111.97 12.35 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.969 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.494 ' O ' ' N ' ' D' ' 26' ' ' SER . 12.6 m -138.01 -122.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.008 0 C-N-CA 120.424 -0.51 . . . . 0.0 109.915 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.418 ' O ' ' OG ' ' D' ' 26' ' ' SER . . . 28.37 -84.18 0.0 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 115.536 -0.756 . . . . 0.0 113.097 -178.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.3 m 170.28 178.77 0.05 OUTLIER 'General case' 0 N--CA 1.443 -0.8 0 CA-C-O 121.518 0.675 . . . . 0.0 110.574 179.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' D' ' 26' ' ' SER . 12.4 m120 -28.73 -179.21 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 113.041 -1.891 . . . . 0.0 114.248 176.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.493 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 85.4 mttt 128.26 105.45 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.53 0 C-N-CA 125.867 1.667 . . . . 0.0 112.137 176.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.6 94.87 0.05 OUTLIER Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.718 ' HB3' ' HA2' ' C' ' 25' ' ' GLY . . . -122.43 154.25 38.0 Favored 'General case' 0 CA--C 1.497 -1.063 0 N-CA-C 104.848 -2.278 . . . . 0.0 104.848 176.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.504 HD12 ' CG2' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.04 112.29 2.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 114.731 -1.122 . . . . 0.0 110.732 -171.629 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.41 ' O ' HG22 ' D' ' 32' ' ' ILE . 2.1 mt -107.93 114.01 45.3 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.409 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.408 ' CA ' ' HG3' ' J' ' 35' ' ' MET . . . -106.38 100.65 1.66 Allowed Glycine 0 CA--C 1.498 -1.007 0 N-CA-C 107.308 -2.317 . . . . 0.0 107.308 176.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.901 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 13.6 tp -112.99 121.08 43.56 Favored 'General case' 0 CA--C 1.503 -0.852 0 CA-C-N 115.298 -0.451 . . . . 0.0 110.934 -177.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 43.3 ttp -128.97 107.25 9.46 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 107.79 -1.189 . . . . 0.0 107.79 176.11 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.453 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -123.61 72.14 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.675 -179.927 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.15 -100.52 0.01 OUTLIER Glycine 0 C--N 1.36 1.892 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.891 179.144 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 157.13 -157.24 27.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.3 p -132.36 147.95 31.99 Favored 'Isoleucine or valine' 0 C--O 1.235 0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.462 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 p . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.32 -179.731 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . 0.528 ' N ' ' CD2' ' D' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -114.76 134.31 55.21 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.768 0.318 . . . . 0.0 110.491 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -98.37 137.47 37.04 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.28 179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.624 HG23 ' CE1' ' D' ' 14' ' ' HIS . 22.6 m -131.74 160.34 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 121.332 0.587 . . . . 0.0 111.141 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 27.6 m80 -124.01 120.51 32.65 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.07 -0.968 . . . . 0.0 109.606 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.467 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -150.66 162.91 39.77 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.927 0.87 . . . . 0.0 111.473 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.467 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 50.2 tt0 -157.99 168.6 26.67 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.375 -1.284 . . . . 0.0 110.063 179.308 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -143.57 126.79 16.59 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.837 179.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.0 tt -118.98 115.68 24.86 Favored 'General case' 0 C--N 1.329 -0.317 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -120.23 125.47 74.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.734 0.302 . . . . 0.0 110.36 -179.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 38.6 t80 -124.16 113.4 18.28 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.482 -179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -125.72 125.13 42.51 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.212 179.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.434 ' HB3' ' CB ' ' F' ' 21' ' ' ALA . . . -134.23 119.63 19.01 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.232 0.539 . . . . 0.0 110.327 179.096 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.402 ' C ' ' OD1' ' E' ' 23' ' ' ASP . 97.8 mt-10 -129.16 128.35 43.22 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.497 179.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.459 ' HB3' ' HZ2' ' F' ' 28' ' ' LYS . 1.2 m-20 -141.89 112.1 6.95 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.264 -179.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' E' ' 26' ' ' SER . 13.2 m -103.24 -122.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 C-N-CA 120.326 -0.55 . . . . 0.0 111.057 -178.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.05 -84.92 0.01 OUTLIER Glycine 0 CA--C 1.531 1.08 0 CA-C-N 115.551 -0.75 . . . . 0.0 112.834 -178.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.625 ' O ' ' O ' ' E' ' 27' ' ' ASN . 3.0 p 170.88 170.54 0.07 Allowed 'General case' 0 CA--C 1.511 -0.55 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.625 ' O ' ' O ' ' E' ' 26' ' ' SER . 27.6 t-20 -18.17 157.47 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.975 0 O-C-N 124.792 1.308 . . . . 0.0 113.475 179.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.722 ' O ' ' HB2' ' F' ' 30' ' ' ALA . 84.8 tttt -162.55 111.35 1.38 Allowed 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 119.356 -0.938 . . . . 0.0 112.552 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.17 92.36 0.25 Allowed Glycine 0 N--CA 1.479 1.528 0 O-C-N 121.931 -0.481 . . . . 0.0 113.194 177.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -164.5 161.97 21.58 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 175.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.466 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.68 132.21 14.41 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 C-N-CA 118.903 -1.119 . . . . 0.0 113.647 -175.561 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.571 HG23 HD21 ' E' ' 34' ' ' LEU . 0.2 OUTLIER -109.71 116.48 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.306 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.67 105.36 2.23 Favored Glycine 0 N--CA 1.466 0.669 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 179.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.707 HD13 ' CZ ' ' C' ' 19' ' ' PHE . 16.4 mt -115.83 115.0 25.49 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 117.561 0.68 . . . . 0.0 112.155 -177.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.717 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 11.4 ttp -114.07 106.66 14.66 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 176.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.91 73.81 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.331 -178.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.17 111.57 2.66 Favored Glycine 0 C--N 1.354 1.577 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 178.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.5 -157.08 0.04 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -132.15 142.81 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.975 0.417 . . . . 0.0 110.49 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--O 1.222 -0.377 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.772 179.827 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.464 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 50.7 m-85 -107.02 134.91 49.46 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.566 0.222 . . . . 0.0 110.622 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.525 ' N ' ' OE1' ' F' ' 11' ' ' GLU . 56.7 mp0 -105.12 143.38 33.38 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.209 -0.45 . . . . 0.0 109.903 179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 72.7 t -120.76 135.26 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-O 121.115 0.483 . . . . 0.0 110.397 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -130.02 128.53 42.18 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.923 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.519 ' CE1' ' O ' ' F' ' 15' ' ' GLN . 56.9 t-80 -151.99 168.5 25.02 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.519 ' O ' ' CE1' ' F' ' 14' ' ' HIS . 84.7 mt-30 -150.52 173.47 14.05 Favored 'General case' 0 C--N 1.317 -0.812 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.41 179.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -146.41 127.01 14.21 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.39 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -128.73 127.57 42.33 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.554 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -127.56 128.3 69.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.9 m-85 -123.36 120.74 33.92 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 116.596 -0.275 . . . . 0.0 110.678 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 78.8 t80 -141.13 121.88 14.35 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.434 ' CB ' ' HB3' ' E' ' 21' ' ' ALA . . . -159.59 154.71 25.04 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 119.785 -0.766 . . . . 0.0 112.578 -179.476 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -96.94 124.16 40.84 Favored 'General case' 0 N--CA 1.471 0.592 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 177.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.558 ' OD1' ' N ' ' F' ' 24' ' ' VAL . 60.3 t0 -169.66 139.0 1.95 Allowed 'General case' 0 CA--C 1.536 0.407 0 C-N-CA 119.652 -0.819 . . . . 0.0 113.033 -178.198 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.572 ' O ' ' O ' ' F' ' 26' ' ' SER . 24.2 t -108.07 111.7 37.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.23 -92.04 0.01 OUTLIER Glycine 0 CA--C 1.539 1.535 0 CA-C-O 119.026 -0.874 . . . . 0.0 111.732 -177.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.572 ' O ' ' O ' ' F' ' 24' ' ' VAL . 13.7 p -63.79 -177.56 0.25 Allowed 'General case' 0 CA--C 1.503 -0.848 0 N-CA-C 104.403 -2.443 . . . . 0.0 104.403 177.404 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.439 ' O ' ' O ' ' F' ' 28' ' ' LYS . 64.3 t30 -80.59 174.13 11.91 Favored 'General case' 0 C--N 1.318 -0.798 0 C-N-CA 114.894 -2.722 . . . . 0.0 108.25 178.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.509 ' HG2' ' N ' ' F' ' 29' ' ' GLY . 75.1 tttt -43.7 -105.91 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.717 0 CA-C-O 124.085 1.897 . . . . 0.0 112.226 174.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.509 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -109.29 -100.33 2.63 Favored Glycine 0 CA--C 1.484 -1.881 0 C-N-CA 130.168 3.747 . . . . 0.0 109.753 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.722 ' HB2' ' O ' ' E' ' 28' ' ' LYS . . . -58.11 172.85 0.39 Allowed 'General case' 0 CA--C 1.501 -0.936 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 -178.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.448 HD13 ' HA3' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -140.39 134.42 34.79 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 C-N-CA 118.147 -1.421 . . . . 0.0 111.479 -172.131 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.495 ' CG2' ' O ' ' F' ' 32' ' ' ILE . 5.2 tt -110.12 117.24 54.29 Favored 'Isoleucine or valine' 0 C--N 1.341 0.196 0 CA-C-N 114.001 -1.454 . . . . 0.0 108.452 -179.266 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.77 102.87 2.42 Favored Glycine 0 C--N 1.322 -0.249 0 N-CA-C 108.027 -2.029 . . . . 0.0 108.027 179.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.504 ' O ' HD12 ' F' ' 34' ' ' LEU . 2.2 pp -107.44 115.73 30.67 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 117.039 0.42 . . . . 0.0 110.518 -179.192 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 18.3 ttp -119.46 110.5 16.99 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.8 m -132.87 79.92 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.16 -179.144 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -64.65 103.5 0.77 Allowed Glycine 0 CA--C 1.527 0.829 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 178.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.0 -146.15 19.15 Favored Glycine 0 N--CA 1.465 0.61 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -113.86 133.58 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.754 -0.461 . . . . 0.0 109.754 179.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 32.9 m . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.929 -1.034 . . . . 0.0 110.761 -179.67 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -121.92 147.84 45.52 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 120.745 0.307 . . . . 0.0 110.707 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -68.51 156.96 36.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.069 179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 78.0 t -115.63 131.6 67.51 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.061 0.458 . . . . 0.0 110.315 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.448 ' CD2' ' H ' ' G' ' 13' ' ' HIS . 0.5 OUTLIER -89.15 179.45 6.13 Favored 'General case' 0 CA--C 1.52 -0.174 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.972 179.679 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 50.8 t-80 -74.69 164.45 26.57 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.906 -0.775 . . . . 0.0 108.906 -179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 91.7 mt-30 -155.63 -179.84 8.5 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.442 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.414 ' NZ ' ' CG2' ' G' ' 18' ' ' VAL . 65.2 tttm -161.32 119.26 2.35 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.682 179.093 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 35.7 tp -118.83 126.12 51.11 Favored 'General case' 0 C--O 1.241 0.609 0 CA-C-O 121.299 0.571 . . . . 0.0 110.478 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.414 ' CG2' ' NZ ' ' G' ' 16' ' ' LYS . 47.9 t -125.72 125.9 69.24 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.143 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.901 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.923 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 0.1 OUTLIER -114.76 119.47 36.77 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.937 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 p90 -142.92 147.96 36.14 Favored 'General case' 0 N--CA 1.464 0.253 0 C-N-CA 119.674 -0.81 . . . . 0.0 112.369 -178.041 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.32 132.22 35.37 Favored 'General case' 0 C--O 1.236 0.359 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.285 179.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -135.48 167.33 21.27 Favored 'General case' 0 N--CA 1.455 -0.222 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.53 ' OD2' ' N ' ' H' ' 24' ' ' VAL . 34.8 m-20 -85.94 -151.19 0.15 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.168 -178.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' G' ' 23' ' ' ASP . 14.0 t 27.09 103.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -174.77 -94.69 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 C-N-CA 120.407 -0.902 . . . . 0.0 111.827 177.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -64.03 -178.81 0.36 Allowed 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.7 p30 -80.95 173.49 12.56 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.12 0.486 . . . . 0.0 111.302 177.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -44.91 110.79 0.26 Allowed 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.947 176.365 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.26 94.73 0.52 Allowed Glycine 0 N--CA 1.472 1.084 0 C-N-CA 118.815 -1.66 . . . . 0.0 111.324 177.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -118.34 151.61 37.39 Favored 'General case' 0 CA--C 1.504 -0.808 0 C-N-CA 118.381 -1.328 . . . . 0.0 108.196 178.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.19 108.81 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.933 0 CA-C-N 113.182 -1.826 . . . . 0.0 109.594 -171.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -125.76 123.46 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.89 0.376 . . . . 0.0 111.237 -179.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.674 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -130.33 111.23 1.11 Allowed Glycine 0 N--CA 1.465 0.573 0 N-CA-C 108.794 -1.723 . . . . 0.0 108.794 178.543 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.89 130.41 52.82 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.916 0.388 . . . . 0.0 111.656 -178.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' A' ' 33' ' ' GLY . 28.1 ttt -130.46 128.52 41.43 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' G' ' 37' ' ' GLY . 3.7 t -111.42 65.9 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 -178.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.509 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -55.25 -105.55 0.01 OUTLIER Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.269 -1.132 . . . . 0.0 110.269 178.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -105.06 174.59 21.55 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.041 -0.823 . . . . 0.0 111.041 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 30.0 m -135.23 158.13 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.95 -1.024 . . . . 0.0 110.11 -179.98 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.351 -1.5 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -86.65 131.01 34.27 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.918 0.389 . . . . 0.0 110.103 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -136.06 142.81 44.41 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.908 -179.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -126.06 134.31 66.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 115.683 -0.689 . . . . 0.0 109.456 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 75.4 m80 -87.08 175.35 8.14 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.124 0.488 . . . . 0.0 110.792 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.547 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 25.4 m-70 -77.9 173.28 12.32 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.736 -0.665 . . . . 0.0 109.45 -179.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -142.75 175.44 9.82 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.128 179.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -151.58 125.87 9.36 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.389 -0.369 . . . . 0.0 111.151 -179.184 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 58.1 mt -121.17 120.51 35.43 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -127.8 130.52 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -178.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.744 ' CZ ' HD22 ' J' ' 34' ' ' LEU . 5.9 m-85 -117.73 120.06 36.81 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.615 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 29.0 t80 -130.78 122.6 27.46 Favored 'General case' 0 N--CA 1.476 0.834 0 O-C-N 122.231 -0.293 . . . . 0.0 110.626 -179.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.77 130.0 48.0 Favored 'General case' 0 N--CA 1.476 0.838 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.934 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -137.94 106.74 5.93 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -114.51 114.11 25.34 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.53 ' N ' ' OD2' ' G' ' 23' ' ' ASP . 1.2 p -128.79 122.26 56.57 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.051 179.124 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 30.49 82.79 0.01 OUTLIER Glycine 0 CA--C 1.537 1.442 0 CA-C-O 119.473 -0.626 . . . . 0.0 114.593 175.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.542 ' O ' ' O ' ' H' ' 27' ' ' ASN . 1.0 OUTLIER -140.14 170.62 15.49 Favored 'General case' 0 C--N 1.345 0.378 0 CA-C-N 118.71 1.255 . . . . 0.0 111.108 179.107 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.542 ' O ' ' O ' ' H' ' 26' ' ' SER . 5.5 m-20 -31.04 173.14 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 113.671 -1.604 . . . . 0.0 114.812 -177.206 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -87.84 111.41 21.38 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 114.374 -1.285 . . . . 0.0 113.267 177.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.514 ' HA2' ' O ' ' I' ' 29' ' ' GLY . . . 69.61 93.6 0.06 OUTLIER Glycine 0 CA--C 1.526 0.757 0 C-N-CA 118.124 -1.989 . . . . 0.0 115.526 172.442 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.42 155.51 22.09 Favored 'General case' 0 C--O 1.248 0.985 0 CA-C-N 120.627 2.214 . . . . 0.0 106.698 175.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.759 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -148.31 119.27 1.37 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.313 0 C-N-CA 118.921 -1.112 . . . . 0.0 111.684 -173.055 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 90.9 mt -129.87 128.32 64.98 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.034 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.599 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -132.23 127.54 4.94 Favored Glycine 0 N--CA 1.465 0.63 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 178.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.454 ' O ' HD12 ' I' ' 34' ' ' LEU . 8.4 tt -135.08 130.96 36.37 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.565 0.698 . . . . 0.0 110.736 -179.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 19.3 ttt -130.37 128.99 42.53 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.652 -179.228 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 22.0 t -112.52 79.54 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 N-CA-C 112.768 0.655 . . . . 0.0 112.768 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.549 ' CA ' HG21 ' B' ' 31' ' ' ILE . . . -65.77 105.12 1.15 Allowed Glycine 0 C--N 1.339 0.707 0 N-CA-C 111.547 -0.621 . . . . 0.0 111.547 178.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.74 -171.27 50.34 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.246 -0.742 . . . . 0.0 111.246 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -132.37 161.78 40.87 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-O 120.993 0.425 . . . . 0.0 110.909 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 34.3 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.096 -0.954 . . . . 0.0 110.658 179.766 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -109.94 132.15 54.42 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.8 0.333 . . . . 0.0 110.72 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -73.79 131.92 42.06 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.563 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.5 m -136.61 131.17 47.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.075 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.513 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 16.5 p-80 -164.27 161.08 21.72 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 120.554 -0.459 . . . . 0.0 111.229 -179.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.547 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 0.8 OUTLIER -122.92 166.76 14.52 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 178.951 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.476 HE22 HG13 ' K' ' 39' ' ' VAL . 86.6 mt-30 -142.25 175.64 9.6 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.65 179.459 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.528 ' C ' HD12 ' I' ' 17' ' ' LEU . 87.4 tttt -166.49 113.7 0.86 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.771 -179.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.528 HD12 ' C ' ' I' ' 16' ' ' LYS . 8.0 mp -112.56 124.24 52.09 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.0 t -127.91 128.75 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 CA-C-O 121.17 0.51 . . . . 0.0 112.095 -179.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.834 ' CZ ' HD13 ' K' ' 34' ' ' LEU . 32.1 m-85 -118.75 118.98 33.07 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.573 178.251 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.615 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 58.8 t80 -126.57 116.95 21.85 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.48 129.63 52.21 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.18 0.514 . . . . 0.0 111.771 -179.108 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -143.83 144.29 31.71 Favored 'General case' 0 C--N 1.34 0.193 0 CA-C-N 115.366 -0.833 . . . . 0.0 109.036 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.605 ' O ' ' O ' ' I' ' 24' ' ' VAL . 0.9 OUTLIER -175.04 129.55 0.3 Allowed 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.062 -0.655 . . . . 0.0 110.773 179.724 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.757 HG12 ' N ' ' I' ' 25' ' ' GLY . 61.6 t -29.34 -113.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.725 0 O-C-N 124.425 1.078 . . . . 0.0 112.66 178.156 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.757 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -170.77 90.55 0.09 OUTLIER Glycine 0 CA--C 1.53 0.981 0 CA-C-N 115.272 -0.877 . . . . 0.0 112.117 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.525 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.2 t 161.99 160.45 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.338 0 CA-C-O 121.921 0.867 . . . . 0.0 111.128 176.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.525 ' O ' ' O ' ' I' ' 26' ' ' SER . 29.2 m120 -30.16 179.07 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 113.084 -1.871 . . . . 0.0 116.027 179.445 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.508 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 86.4 tttt 127.81 103.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 112.2 -2.273 . . . . 0.0 111.203 174.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.514 ' O ' ' HA2' ' H' ' 29' ' ' GLY . . . -59.86 99.54 0.16 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.248 -1.307 . . . . 0.0 110.735 174.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.439 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -118.08 141.4 48.51 Favored 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 102.529 -3.137 . . . . 0.0 102.529 174.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.759 HD12 ' CG2' ' H' ' 31' ' ' ILE . 2.1 mt -146.06 114.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 C-N-CA 118.181 -1.408 . . . . 0.0 112.515 -169.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 1.3 mt -114.62 119.74 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 177.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.16 106.56 1.44 Allowed Glycine 0 N--CA 1.461 0.311 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.923 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 54.4 tp -116.23 120.93 40.53 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 112.57 0.582 . . . . 0.0 112.57 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 5.6 tpp -117.1 102.02 8.96 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 104.904 -2.258 . . . . 0.0 104.904 174.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.705 ' O ' HG13 ' I' ' 36' ' ' VAL . 4.2 p -131.81 74.89 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.715 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.114 -177.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.28 -96.92 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.995 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 163.31 -167.76 37.72 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 93.0 t -93.65 150.58 3.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.768 0.318 . . . . 0.0 110.387 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.0 p . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.854 -179.926 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -83.64 141.89 31.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.955 0.407 . . . . 0.0 110.065 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -66.35 135.63 54.64 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.477 -179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.814 HG12 ' H ' ' J' ' 13' ' ' HIS . 27.4 t -145.77 178.8 1.2 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.119 179.434 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.814 ' H ' HG12 ' J' ' 12' ' ' VAL . 92.2 m-70 -50.82 125.28 12.96 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 121.069 0.461 . . . . 0.0 112.146 -177.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.499 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 18.0 t-80 -145.38 163.43 34.6 Favored 'General case' 0 C--N 1.341 0.239 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 179.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.499 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 89.6 mt-30 -148.54 177.6 9.34 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.088 0.47 . . . . 0.0 111.364 -179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.419 ' C ' HD22 ' J' ' 17' ' ' LEU . 88.9 tttt -170.26 116.28 0.51 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.738 -0.665 . . . . 0.0 110.819 179.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.419 HD22 ' C ' ' J' ' 16' ' ' LYS . 1.4 mm? -114.23 125.27 53.72 Favored 'General case' 0 N--CA 1.472 0.645 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.495 -179.87 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -126.78 121.05 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-O 120.78 0.324 . . . . 0.0 111.241 179.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.673 ' CZ ' HD22 ' L' ' 34' ' ' LEU . 95.4 m-85 -118.43 116.22 26.26 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 178.245 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.416 ' CZ ' ' CD1' ' K' ' 20' ' ' PHE . 1.1 t80 -131.38 129.66 41.62 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 120.922 0.391 . . . . 0.0 110.553 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.41 134.65 41.88 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.458 0.647 . . . . 0.0 112.421 -178.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 mt-10 -144.3 102.87 3.91 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.029 179.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 20.9 p30 -152.22 177.3 10.68 Favored 'General case' 0 CA--C 1.515 -0.394 0 O-C-N 122.096 -0.378 . . . . 0.0 110.392 -178.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -91.96 102.99 14.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 122.176 0.989 . . . . 0.0 108.379 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.458 ' CA ' ' O ' ' K' ' 26' ' ' SER . . . -35.9 95.59 0.01 OUTLIER Glycine 0 CA--C 1.526 0.763 0 CA-C-N 113.269 -1.787 . . . . 0.0 115.653 -179.087 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.4 t 170.24 176.18 0.05 Allowed 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 121.627 0.727 . . . . 0.0 110.678 175.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' J' ' 26' ' ' SER . 52.2 t30 -28.96 179.5 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 115.886 1.81 . . . . 0.0 115.886 179.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.505 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 61.8 tttp 128.26 105.11 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 112.715 -2.039 . . . . 0.0 112.719 175.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -58.02 95.07 0.05 OUTLIER Glycine 0 N--CA 1.465 0.59 0 CA-C-N 113.934 -1.484 . . . . 0.0 113.031 174.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.51 142.33 46.99 Favored 'General case' 0 CA--C 1.496 -1.117 0 CA-C-N 119.884 1.842 . . . . 0.0 106.201 174.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.46 HG23 ' CG1' ' K' ' 31' ' ' ILE . 0.0 OUTLIER -143.11 110.93 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 CA-C-N 114.454 -1.248 . . . . 0.0 111.837 -171.41 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.529 ' O ' ' SD ' ' E' ' 35' ' ' MET . 0.2 OUTLIER -114.68 118.9 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 177.783 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -114.15 106.68 1.75 Allowed Glycine 0 CA--C 1.496 -1.115 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 177.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.744 HD22 ' CZ ' ' H' ' 19' ' ' PHE . 37.1 tp -115.37 118.87 34.44 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 113.292 0.849 . . . . 0.0 113.292 -175.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.408 ' HG3' ' CA ' ' D' ' 33' ' ' GLY . 0.0 OUTLIER -117.29 107.63 14.63 Favored 'General case' 0 C--O 1.234 0.248 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 176.639 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.524 HG22 HD11 ' J' ' 34' ' ' LEU . 0.0 OUTLIER -119.37 80.29 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.785 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.21 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.3 -94.42 0.01 OUTLIER Glycine 0 C--N 1.352 1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 111.714 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 112.62 -178.14 18.74 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 111.031 -0.827 . . . . 0.0 111.031 179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -114.63 134.93 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.4 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.444 179.95 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.304 -1.518 . . . . 0.0 109.304 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -103.96 135.44 45.48 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.655 0.264 . . . . 0.0 110.377 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.471 ' N ' ' OE1' ' L' ' 11' ' ' GLU . 94.9 mt-10 -137.48 156.52 48.06 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.607 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.6 m -134.48 163.2 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.657 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 t60 -159.37 128.37 5.28 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.314 -179.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -152.67 167.52 28.65 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.688 0.756 . . . . 0.0 110.002 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -156.51 175.92 13.39 Favored 'General case' 0 C--N 1.307 -1.239 0 CA-C-N 114.73 -1.123 . . . . 0.0 109.762 179.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -148.73 120.37 8.03 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 23.1 mt -112.51 116.05 29.63 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.6 p -133.31 134.47 57.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 CA-C-O 121.42 0.629 . . . . 0.0 112.308 -179.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 36.4 t80 -125.76 126.94 45.38 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 114.914 -1.039 . . . . 0.0 109.227 179.087 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.416 ' CD1' ' CZ ' ' J' ' 20' ' ' PHE . 8.2 t80 -136.51 128.96 30.26 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.171 0.51 . . . . 0.0 111.818 -179.315 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.78 129.53 47.19 Favored 'General case' 0 N--CA 1.475 0.818 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.772 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.446 ' HG2' ' N ' ' K' ' 23' ' ' ASP . 75.7 tt0 -88.44 170.1 11.2 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.453 -179.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.503 ' OD1' HG21 ' L' ' 24' ' ' VAL . 48.0 t0 -39.33 115.46 0.5 Allowed 'General case' 0 CA--C 1.517 -0.298 0 CA-C-O 121.007 0.432 . . . . 0.0 110.821 -178.601 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.556 HG13 ' O ' ' K' ' 24' ' ' VAL . 10.4 p -129.84 117.16 40.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.282 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 178.867 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . -27.92 -90.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.381 0 CA-C-O 121.524 0.513 . . . . 0.0 111.825 178.161 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.637 ' O ' ' O ' ' K' ' 27' ' ' ASN . 26.7 p -140.97 170.73 15.18 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 179.121 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.637 ' O ' ' O ' ' K' ' 26' ' ' SER . 56.8 p30 -28.29 169.75 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 -178.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 70.4 tttt -149.4 111.45 4.62 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.685 178.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.71 91.6 0.02 OUTLIER Glycine 0 N--CA 1.464 0.521 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 178.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.59 151.69 43.37 Favored 'General case' 0 CA--C 1.494 -1.193 0 N-CA-C 106.314 -1.735 . . . . 0.0 106.314 176.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.46 ' CG1' HG23 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -135.83 115.44 16.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.579 -178.724 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.545 HG23 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -115.59 116.91 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 178.362 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.717 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -109.56 106.0 2.13 Favored Glycine 0 N--CA 1.464 0.547 0 N-CA-C 108.444 -1.862 . . . . 0.0 108.444 178.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.834 HD13 ' CZ ' ' I' ' 19' ' ' PHE . 21.5 mt -110.44 111.98 23.6 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 117.047 0.423 . . . . 0.0 111.659 -177.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.46 ' CE ' ' O ' ' E' ' 32' ' ' ILE . 11.4 tpt -107.59 103.1 12.32 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 176.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -129.58 73.83 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.888 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 -178.146 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.445 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.38 -101.5 0.01 OUTLIER Glycine 0 C--N 1.359 1.828 0 CA-C-N 116.388 -0.369 . . . . 0.0 112.844 -179.215 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.92 -155.69 26.57 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.476 HG13 HE22 ' I' ' 15' ' ' GLN . 30.0 m -126.54 160.54 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.762 0.315 . . . . 0.0 110.548 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.501 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -148.22 160.68 42.69 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.655 0.264 . . . . 0.0 110.334 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . 0.471 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 78.5 mm-40 -75.78 157.0 34.02 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.733 -179.15 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 96.1 t -92.86 131.06 40.94 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.123 0 CA-C-O 121.061 0.458 . . . . 0.0 110.216 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.5 ' NE2' ' OXT' ' L' ' 40' ' ' VAL . 45.1 t-80 -144.25 134.21 23.98 Favored 'General case' 0 N--CA 1.461 0.113 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.954 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.478 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 46.8 t-80 -154.99 170.83 20.84 Favored 'General case' 0 N--CA 1.446 -0.653 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.478 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 96.2 mt-30 -148.3 178.56 8.47 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.646 -179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -164.3 122.48 1.79 Allowed 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.11 0.481 . . . . 0.0 111.204 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 59.1 tp -120.75 121.57 38.5 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.977 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.91 131.65 66.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.156 0.503 . . . . 0.0 110.501 179.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.534 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 41.1 p90 -135.14 125.63 26.72 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.217 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 37.8 m-85 -140.08 142.57 36.1 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 121.776 0.798 . . . . 0.0 110.887 179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.39 143.63 24.06 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.52 -0.764 . . . . 0.0 109.343 179.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.405 ' O ' ' O ' ' L' ' 23' ' ' ASP . 78.5 tt0 -76.12 153.1 36.52 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.602 -0.839 . . . . 0.0 109.585 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.535 ' C ' HG23 ' L' ' 24' ' ' VAL . 59.4 m-20 -58.62 -134.4 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.295 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -177.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.535 HG23 ' C ' ' L' ' 23' ' ' ASP . 3.8 t 84.69 110.69 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 N-CA-C 108.165 -1.05 . . . . 0.0 108.165 -178.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.6 -92.76 0.01 OUTLIER Glycine 0 CA--C 1.528 0.845 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.807 ' O ' ' O ' ' L' ' 27' ' ' ASN . 34.1 p -161.18 163.98 30.82 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.807 ' O ' ' O ' ' L' ' 26' ' ' SER . 83.2 m-20 -9.98 -178.62 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 116.213 1.931 . . . . 0.0 116.213 177.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.448 ' O ' ' O ' ' L' ' 29' ' ' GLY . 82.6 tttt -128.08 110.41 12.46 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 107.111 -1.44 . . . . 0.0 107.111 176.052 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' L' ' 28' ' ' LYS . . . -54.15 -95.26 0.01 OUTLIER Glycine 0 C--N 1.334 0.451 0 C-N-CA 117.113 -2.47 . . . . 0.0 111.305 -179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.793 ' C ' HD13 ' L' ' 31' ' ' ILE . . . 71.65 163.32 0.26 Allowed 'General case' 0 CA--C 1.503 -0.838 0 N-CA-C 103.663 -2.717 . . . . 0.0 103.663 178.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.798 HD13 ' N ' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -138.2 100.6 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 122.957 2.617 . . . . 0.0 108.838 175.181 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.501 ' CG2' ' O ' ' L' ' 32' ' ' ILE . 4.6 tt -102.01 112.67 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.346 0 CA-C-N 113.356 -1.747 . . . . 0.0 106.628 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -99.97 102.39 2.5 Favored Glycine 0 CA--C 1.5 -0.889 0 N-CA-C 107.813 -2.115 . . . . 0.0 107.813 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.673 HD22 ' CZ ' ' J' ' 19' ' ' PHE . 43.6 tp -107.23 115.93 31.04 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 120.912 -0.315 . . . . 0.0 111.233 -178.369 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 17.6 tpp -112.64 104.22 12.28 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 176.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.426 ' CG1' HG23 ' K' ' 36' ' ' VAL . 10.5 m -135.84 79.59 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.448 ' HA3' HD13 ' F' ' 31' ' ' ILE . . . -66.1 103.68 0.9 Allowed Glycine 0 C--N 1.344 0.986 0 N-CA-C 111.325 -0.71 . . . . 0.0 111.325 -179.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 -162.04 38.0 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -125.58 153.12 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 121.044 0.449 . . . . 0.0 110.839 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.5 ' OXT' ' NE2' ' L' ' 13' ' ' HIS . 31.3 m . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.105 -0.95 . . . . 0.0 110.73 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -90.95 138.35 31.66 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.806 0.336 . . . . 0.0 110.504 179.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -122.83 136.34 54.83 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.344 0.592 . . . . 0.0 111.273 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.501 ' O ' ' CG ' ' A' ' 13' ' ' HIS . 48.9 t -142.55 158.96 19.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.182 179.55 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.501 ' CG ' ' O ' ' A' ' 12' ' ' VAL . 97.3 m-70 -155.57 110.4 2.95 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.097 -0.641 . . . . 0.0 111.218 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.472 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 6.1 p-80 -151.12 166.33 31.13 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.472 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 97.9 mm-40 -152.51 179.22 8.78 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.394 -179.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -149.48 110.9 4.45 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.068 -0.514 . . . . 0.0 109.918 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 77.3 mt -138.12 127.8 25.15 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 121.575 0.702 . . . . 0.0 112.076 -179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 18' ' ' VAL . 17.4 m -129.16 127.78 66.08 Favored 'Isoleucine or valine' 0 C--O 1.231 0.127 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.233 178.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.515 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 11.2 t80 -121.18 121.8 38.6 Favored 'General case' 0 N--CA 1.469 0.475 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.502 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.2 p90 -137.1 128.19 27.74 Favored 'General case' 0 N--CA 1.466 0.372 0 C-N-CA 120.897 -0.321 . . . . 0.0 110.407 -179.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.66 126.67 52.44 Favored 'General case' 0 C--O 1.239 0.552 0 CA-C-O 120.979 0.418 . . . . 0.0 111.122 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -153.21 108.81 3.27 Favored 'General case' 0 N--CA 1.456 -0.16 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.41 ' HB3' ' HZ1' ' C' ' 28' ' ' LYS . 1.6 m-20 -57.21 121.55 10.35 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.489 -177.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.524 ' O ' ' N ' ' A' ' 26' ' ' SER . 26.9 m -88.63 124.03 41.31 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.413 ' HA2' ' H ' ' B' ' 27' ' ' ASN . . . -44.84 84.71 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 CA-C-N 116.08 -0.509 . . . . 0.0 112.388 179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.524 ' N ' ' O ' ' A' ' 24' ' ' VAL . 11.8 p -91.85 179.16 5.69 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 178.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 m120 -60.31 178.97 0.17 Allowed 'General case' 0 C--N 1.312 -1.06 0 C-N-CA 120.166 -0.613 . . . . 0.0 111.258 -179.424 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.4 110.89 1.2 Allowed 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.718 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.934 ' H ' HD21 ' B' ' 27' ' ' ASN . . . 71.93 94.09 0.08 OUTLIER Glycine 0 N--CA 1.465 0.587 0 CA-C-O 118.511 -1.161 . . . . 0.0 111.783 177.332 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.64 153.78 25.87 Favored 'General case' 0 C--O 1.241 0.646 0 C-N-CA 117.607 -1.637 . . . . 0.0 107.602 177.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.481 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.2 OUTLIER -148.2 109.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 CA-C-N 113.783 -1.553 . . . . 0.0 110.023 -171.945 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -131.07 126.96 60.3 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.245 179.479 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.47 119.57 2.12 Favored Glycine 0 C--N 1.336 0.529 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 mt -136.15 150.31 49.01 Favored 'General case' 0 N--CA 1.478 0.958 0 CA-C-O 121.398 0.618 . . . . 0.0 111.762 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 18.6 ttt -149.53 139.8 22.25 Favored 'General case' 0 N--CA 1.465 0.28 0 O-C-N 121.992 -0.443 . . . . 0.0 111.865 -179.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 36' ' ' VAL . 5.6 p -152.28 79.14 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.385 179.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.64 ' HA3' HD12 ' H' ' 31' ' ' ILE . . . -73.69 104.78 1.67 Allowed Glycine 0 CA--C 1.527 0.814 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.138 -179.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.38 176.17 23.84 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 111.88 -0.488 . . . . 0.0 111.88 178.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 69.7 t -131.95 138.25 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 63.9 t . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.473 -179.92 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -113.29 143.71 43.97 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 121.015 0.436 . . . . 0.0 110.764 -179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -119.24 131.65 55.82 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.114 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 34.4 m -136.33 158.65 38.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.903 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -135.69 137.55 41.88 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 121.078 0.466 . . . . 0.0 111.262 -179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.549 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 72.7 t60 -155.44 169.88 23.23 Favored 'General case' 0 N--CA 1.446 -0.671 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.549 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 47.1 tt0 -163.4 169.74 18.51 Favored 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.251 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.43 ' N ' ' HG2' ' B' ' 15' ' ' GLN . 98.0 mttt -151.3 108.69 3.61 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 178.97 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.5 mt -126.08 120.77 31.08 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.119 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -123.26 130.35 74.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.567 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 2.0 t80 -129.39 122.88 30.34 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.516 -0.311 . . . . 0.0 110.305 -178.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 m-85 -131.88 133.29 44.44 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 120.892 0.377 . . . . 0.0 110.453 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.48 126.19 32.41 Favored 'General case' 0 C--O 1.238 0.474 0 CA-C-O 120.882 0.372 . . . . 0.0 110.779 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -155.03 158.9 39.83 Favored 'General case' 0 C--O 1.223 -0.329 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.181 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -147.43 112.68 5.54 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 65.4 t -123.73 124.94 70.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.498 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.55 82.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 114.63 0.612 . . . . 0.0 114.63 174.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.551 ' O ' ' O ' ' B' ' 27' ' ' ASN . 32.2 p -140.06 170.71 15.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 118.338 1.069 . . . . 0.0 109.615 179.372 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.934 HD21 ' H ' ' A' ' 29' ' ' GLY . 48.1 t30 -30.88 173.25 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -175.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.494 ' N ' ' CG ' ' B' ' 27' ' ' ASN . 88.3 tttt -88.95 111.16 21.79 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 115.167 -0.924 . . . . 0.0 112.079 176.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.512 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 60.31 92.96 0.01 OUTLIER Glycine 0 N--CA 1.465 0.583 0 C-N-CA 118.66 -1.733 . . . . 0.0 112.631 174.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.17 155.06 36.58 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-N 119.486 1.643 . . . . 0.0 110.172 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.411 HG21 ' CA ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -141.85 120.17 9.04 Favored 'Isoleucine or valine' 0 C--O 1.244 0.774 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.622 -176.731 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 14.9 mm -131.87 133.11 61.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 115.145 -0.934 . . . . 0.0 111.189 -177.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.584 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -143.43 146.23 16.74 Favored Glycine 0 N--CA 1.468 0.802 0 C-N-CA 120.349 -0.929 . . . . 0.0 111.726 178.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.455 ' H ' ' HG ' ' C' ' 34' ' ' LEU . 3.3 tt -156.45 135.62 12.05 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 119.781 -0.767 . . . . 0.0 112.235 -178.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.8 ' SD ' HG22 ' H' ' 31' ' ' ILE . 11.4 ttm -119.54 126.56 51.55 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.932 179.41 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.515 ' O ' ' C ' ' B' ' 37' ' ' GLY . 11.6 t -129.08 83.55 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.593 179.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' B' ' 36' ' ' VAL . . . -12.42 -95.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.068 0 O-C-N 123.642 0.589 . . . . 0.0 113.041 178.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.06 -179.14 40.38 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.944 -0.863 . . . . 0.0 110.944 179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -138.5 162.41 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 120.826 0.346 . . . . 0.0 110.818 -179.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.469 0.482 0 CA-C-O 117.908 -1.044 . . . . 0.0 110.319 179.849 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 78.9 m-85 -108.04 143.12 37.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-O 120.932 0.396 . . . . 0.0 110.587 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -64.77 153.55 39.55 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.536 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -131.46 157.3 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.144 0.497 . . . . 0.0 111.5 -179.028 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 67.9 t60 -138.78 127.73 23.79 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.12 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.579 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 38.6 t60 -148.2 168.08 23.43 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 121.375 0.607 . . . . 0.0 110.322 -178.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.579 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 47.1 tt0 -160.42 165.65 30.69 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.997 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -153.95 115.62 4.21 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.111 0.482 . . . . 0.0 110.71 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 49.9 tp -129.23 122.31 29.42 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 179.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -121.92 128.71 75.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.015 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.447 ' HE2' HD22 ' E' ' 34' ' ' LEU . 1.7 t80 -125.15 121.32 33.87 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.414 ' C ' ' CD1' ' C' ' 20' ' ' PHE . 25.3 t80 -131.96 126.97 35.34 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 -179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.5 136.34 39.32 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.292 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -140.5 146.32 38.01 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.094 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 65.4 t0 -129.09 111.95 13.49 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.008 -0.542 . . . . 0.0 109.676 179.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.842 HG22 ' H ' ' C' ' 25' ' ' GLY . 7.0 p -137.68 -122.12 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.169 -178.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.842 ' H ' HG22 ' C' ' 24' ' ' VAL . . . 28.72 -84.31 0.0 OUTLIER Glycine 0 N--CA 1.47 0.907 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.822 -177.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.5 t 170.54 176.88 0.06 Allowed 'General case' 0 N--CA 1.445 -0.701 0 CA-C-N 117.484 0.642 . . . . 0.0 110.332 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' C' ' 26' ' ' SER . 59.8 t30 -28.53 178.92 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.536 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 86.2 tttt 128.23 104.75 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 113.847 -1.524 . . . . 0.0 112.115 176.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -59.29 96.68 0.08 OUTLIER Glycine 0 CA--C 1.501 -0.827 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 173.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -117.19 150.67 38.35 Favored 'General case' 0 CA--C 1.481 -1.686 0 N-CA-C 104.98 -2.23 . . . . 0.0 104.98 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.436 HG23 HD12 ' D' ' 31' ' ' ILE . 0.2 OUTLIER -145.62 116.23 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 C-N-CA 118.938 -1.105 . . . . 0.0 109.634 -172.716 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -109.78 117.12 53.9 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 -179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.79 98.26 0.73 Allowed Glycine 0 N--CA 1.469 0.891 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.562 ' HB2' HD12 ' D' ' 34' ' ' LEU . 4.6 mp -132.49 148.37 52.39 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 122.853 1.311 . . . . 0.0 113.192 -178.613 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.405 ' SD ' ' CE ' ' B' ' 35' ' ' MET . 15.8 ttm -135.15 120.31 18.84 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.484 -1.234 . . . . 0.0 108.352 177.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.484 ' O ' ' C ' ' C' ' 37' ' ' GLY . 0.2 OUTLIER -129.95 75.13 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.731 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.206 -179.527 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.484 ' C ' ' O ' ' C' ' 36' ' ' VAL . . . -16.88 -101.43 0.0 OUTLIER Glycine 0 C--N 1.367 2.299 0 O-C-N 123.418 0.448 . . . . 0.0 112.366 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.46 -158.69 31.71 Favored Glycine 0 CA--C 1.522 0.479 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 54.8 t -120.01 135.46 60.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.555 -179.96 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . 0.625 ' CD2' ' CE1' ' E' ' 10' ' ' TYR . 96.6 m-85 -106.59 135.25 48.44 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.789 0.328 . . . . 0.0 110.373 179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -146.26 161.43 40.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.577 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 m -100.89 131.54 48.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.115 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' E' ' 13' ' ' HIS . 73.9 m80 -106.53 136.52 46.16 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 120.883 0.373 . . . . 0.0 111.589 -178.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.568 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 44.5 t-80 -149.77 167.54 26.23 Favored 'General case' 0 N--CA 1.447 -0.594 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.191 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.568 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 51.6 tt0 -169.73 165.74 9.9 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 120.384 -0.527 . . . . 0.0 111.409 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.442 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.0 mttt -146.39 112.59 5.82 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.677 177.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -124.54 125.43 44.18 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.779 179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 96.1 t -123.95 124.82 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.306 0.574 . . . . 0.0 111.378 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.405 ' CZ ' HD23 ' F' ' 34' ' ' LEU . 0.2 OUTLIER -109.83 107.72 17.79 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 178.985 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD2' ' E' ' 20' ' ' PHE . 8.8 t80 -129.07 122.81 30.75 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 119.643 1.111 . . . . 0.0 111.263 -178.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.62 132.51 33.14 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 112.61 0.596 . . . . 0.0 112.61 -179.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -130.02 106.27 8.52 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.004 178.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -108.79 112.0 24.04 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' D' ' 26' ' ' SER . 4.7 t -131.83 -122.16 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.634 . . . . 0.0 110.251 -178.142 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.418 ' N ' HG12 ' D' ' 24' ' ' VAL . . . 30.16 -84.33 0.0 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.757 -177.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.684 ' O ' ' O ' ' D' ' 27' ' ' ASN . 1.8 p 170.56 178.85 0.05 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.684 ' O ' ' O ' ' D' ' 26' ' ' SER . 70.2 m-80 -28.2 171.13 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 O-C-N 124.731 1.269 . . . . 0.0 112.57 178.018 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.524 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 79.0 tttt 141.42 103.31 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 124.145 0.978 . . . . 0.0 108.468 179.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.552 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . -43.69 -98.25 0.01 OUTLIER Glycine 0 C--N 1.344 0.994 0 C-N-CA 118.816 -1.659 . . . . 0.0 111.313 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' D' ' 29' ' ' GLY . . . 83.56 142.21 0.06 Allowed 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 101.928 -3.36 . . . . 0.0 101.928 179.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.704 HG22 ' SD ' ' J' ' 35' ' ' MET . 0.3 OUTLIER -146.98 116.24 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 117.904 -1.518 . . . . 0.0 108.974 -177.071 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.453 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.1 OUTLIER -106.95 112.41 39.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -179.704 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.59 101.24 0.96 Allowed Glycine 0 C--O 1.236 0.249 0 N-CA-C 108.139 -1.984 . . . . 0.0 108.139 179.255 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.581 HD23 ' N ' ' D' ' 35' ' ' MET . 8.8 tt -143.51 144.02 31.8 Favored 'General case' 0 C--O 1.231 0.085 0 CA-C-O 122.411 1.1 . . . . 0.0 113.329 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.581 ' N ' HD23 ' D' ' 34' ' ' LEU . 14.5 ttm -125.19 125.47 43.7 Favored 'General case' 0 CA--C 1.508 -0.672 0 CA-C-N 114.669 -1.15 . . . . 0.0 109.017 177.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.421 HG22 ' O ' ' D' ' 36' ' ' VAL . 2.2 p -137.5 71.89 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.042 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 -179.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.64 111.74 3.48 Favored Glycine 0 C--N 1.366 2.212 0 N-CA-C 111.837 -0.505 . . . . 0.0 111.837 -179.04 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' E' ' 38' ' ' GLY . . . -101.48 146.22 17.15 Favored Glycine 0 CA--C 1.524 0.634 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.556 HG12 ' N ' ' D' ' 40' ' ' VAL . 21.3 t -137.51 165.51 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.564 0.221 . . . . 0.0 110.674 -179.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.556 ' N ' HG12 ' D' ' 39' ' ' VAL . 98.4 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.974 -1.012 . . . . 0.0 111.585 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . 0.625 ' CE1' ' CD2' ' D' ' 10' ' ' TYR . 74.2 m-85 -83.98 140.04 32.16 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.633 0.254 . . . . 0.0 110.436 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -142.38 153.74 44.04 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.87 0.366 . . . . 0.0 110.744 -179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -121.93 134.64 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.449 ' O ' ' O ' ' D' ' 13' ' ' HIS . 0.2 OUTLIER -76.74 156.98 32.03 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.083 0.468 . . . . 0.0 110.694 -179.214 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.494 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 3.6 m170 -88.42 174.71 7.97 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.521 ' OE1' ' NE2' ' F' ' 15' ' ' GLN . 89.1 mt-30 -124.83 173.64 8.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 80.9 tttt -136.81 115.16 11.77 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-O 121.254 0.55 . . . . 0.0 111.814 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 35.2 mt -119.55 119.6 34.27 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 178.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 53.4 t -127.25 126.29 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-O 120.76 0.314 . . . . 0.0 111.198 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -121.14 122.37 39.86 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 178.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD2' ' CE2' ' D' ' 20' ' ' PHE . 79.8 t80 -134.51 121.61 21.24 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.813 0.34 . . . . 0.0 111.115 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.05 127.78 23.36 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-O 121.07 0.462 . . . . 0.0 111.032 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.403 ' O ' ' HB3' ' E' ' 23' ' ' ASP . 16.7 pt-20 -135.32 139.68 44.5 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.444 179.211 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' C ' ' E' ' 24' ' ' VAL . 18.9 p-10 159.47 113.01 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.67 0 O-C-N 124.204 0.94 . . . . 0.0 108.997 -178.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.476 ' C ' ' O ' ' E' ' 23' ' ' ASP . 70.7 t -37.46 132.4 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 -178.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.49 85.64 1.48 Allowed Glycine 0 CA--C 1.523 0.531 0 N-CA-C 116.756 1.462 . . . . 0.0 116.756 -173.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.532 ' O ' ' O ' ' E' ' 27' ' ' ASN . 92.8 p -145.75 151.97 38.82 Favored 'General case' 0 CA--C 1.508 -0.665 0 N-CA-C 105.554 -2.017 . . . . 0.0 105.554 172.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.532 ' O ' ' O ' ' E' ' 26' ' ' SER . 9.1 t-20 -21.49 155.86 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 179.529 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.453 ' HD3' ' HB2' ' F' ' 30' ' ' ALA . 86.1 tttt -164.45 110.97 1.03 Allowed 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 170.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.41 ' O ' ' HA2' ' D' ' 29' ' ' GLY . . . -67.55 92.57 0.23 Allowed Glycine 0 CA--C 1.527 0.787 0 C-N-CA 120.106 -1.045 . . . . 0.0 113.734 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' D' ' 29' ' ' GLY . . . -168.39 150.09 5.07 Favored 'General case' 0 CA--C 1.493 -1.212 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.699 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.1 OUTLIER -146.42 125.28 4.82 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.848 0 C-N-CA 118.05 -1.46 . . . . 0.0 113.434 -177.562 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.432 ' C ' ' SD ' ' K' ' 35' ' ' MET . 2.0 mt -107.65 116.44 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 176.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.477 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -116.18 100.01 0.9 Allowed Glycine 0 C--O 1.234 0.146 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.639 HD23 ' N ' ' E' ' 35' ' ' MET . 7.7 tt -143.91 137.14 27.64 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 122.26 1.029 . . . . 0.0 112.951 -179.035 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.736 ' SD ' HG22 ' K' ' 31' ' ' ILE . 23.3 ttm -117.6 128.37 54.87 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 114.81 -1.086 . . . . 0.0 111.495 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -124.81 74.28 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.84 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.387 179.834 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.464 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -20.98 -101.38 0.0 OUTLIER Glycine 0 C--N 1.355 1.637 0 O-C-N 123.208 0.317 . . . . 0.0 112.817 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' D' ' 38' ' ' GLY . . . 140.9 -174.95 22.43 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 56.3 t -121.24 135.63 60.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.4 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.433 -179.934 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 87.5 m-85 -117.68 136.71 53.15 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.088 0.47 . . . . 0.0 110.946 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -109.84 128.46 55.34 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.063 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 42.1 t -128.13 133.81 66.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.893 0.378 . . . . 0.0 110.753 -179.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -150.35 102.38 3.06 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.23 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -151.19 174.42 13.27 Favored 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.731 -0.841 . . . . 0.0 108.731 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.521 ' NE2' ' OE1' ' E' ' 15' ' ' GLN . 88.3 mt-30 -141.36 175.0 10.01 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.979 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -130.13 114.84 16.22 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.943 0.402 . . . . 0.0 110.135 179.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 58.9 tp -120.03 116.92 26.69 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 115.765 -0.652 . . . . 0.0 109.259 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 49.7 t -129.95 131.39 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.459 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 55.2 p90 -142.63 133.09 24.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.266 0.555 . . . . 0.0 111.659 -179.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.5 m-85 -138.1 120.39 15.83 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.34 144.83 31.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.167 0.508 . . . . 0.0 111.376 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -101.1 106.22 17.47 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.873 -0.603 . . . . 0.0 109.988 178.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.424 ' OD1' ' O ' ' F' ' 26' ' ' SER . 61.8 t0 -146.66 118.57 8.17 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.388 0.613 . . . . 0.0 112.029 -179.76 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' F' ' 26' ' ' SER . 3.1 m -97.74 125.36 50.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.717 0 CA-C-N 115.173 -0.922 . . . . 0.0 111.051 178.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.8 -86.41 0.01 OUTLIER Glycine 0 N--CA 1.473 1.161 0 C-N-CA 121.521 -0.371 . . . . 0.0 113.503 177.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.455 ' N ' ' O ' ' F' ' 24' ' ' VAL . 72.9 m -63.8 -173.72 0.08 Allowed 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 -177.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.544 ' O ' ' O ' ' F' ' 28' ' ' LYS . 88.2 m-20 -78.89 177.87 8.41 Favored 'General case' 0 C--N 1.317 -0.834 0 C-N-CA 118.038 -1.465 . . . . 0.0 108.763 -176.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.544 ' O ' ' O ' ' F' ' 27' ' ' ASN . 88.2 tttt -38.04 -103.51 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.619 0.723 . . . . 0.0 112.775 -176.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.444 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -139.9 -100.57 0.46 Allowed Glycine 0 CA--C 1.482 -2.018 0 CA-C-O 123.622 1.679 . . . . 0.0 111.48 177.573 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.453 ' HB2' ' HD3' ' E' ' 28' ' ' LYS . . . -58.33 175.73 0.22 Allowed 'General case' 0 CA--C 1.487 -1.478 0 CA-C-N 110.164 -3.018 . . . . 0.0 103.358 173.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.5 mt -131.43 116.11 31.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 116.538 -2.065 . . . . 0.0 109.774 -177.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.655 ' O ' HG23 ' F' ' 32' ' ' ILE . 16.5 tt -103.33 116.96 48.02 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 CA-C-N 113.084 -1.871 . . . . 0.0 110.074 -177.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -105.71 86.34 0.48 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 106.7 -2.56 . . . . 0.0 106.7 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.452 HD11 ' CG2' ' E' ' 36' ' ' VAL . 35.2 tp -116.72 119.02 34.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 35.2 mmm -123.04 135.44 54.44 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 120.057 -0.657 . . . . 0.0 112.28 -177.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.7 m -124.99 81.14 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.591 0 CA-C-N 115.385 -0.825 . . . . 0.0 110.515 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.58 102.07 0.35 Allowed Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.281 -0.728 . . . . 0.0 111.281 179.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -153.52 178.09 30.7 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -124.94 137.16 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.247 0.546 . . . . 0.0 110.192 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.43 ' HB ' HE22 ' F' ' 15' ' ' GLN . 27.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.819 -1.086 . . . . 0.0 110.398 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.365 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -106.39 131.79 53.18 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.921 0.391 . . . . 0.0 110.617 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -89.22 158.15 17.98 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.431 179.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 16.5 m -122.43 133.85 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.134 0.493 . . . . 0.0 110.705 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -134.44 -178.49 5.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.623 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -77.56 167.62 21.32 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.62 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 52.9 tt0 -157.49 169.59 24.36 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.995 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.27 130.08 10.1 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.676 0.274 . . . . 0.0 110.732 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 90.2 mt -125.05 115.59 20.77 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.659 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.482 ' O ' HG23 ' G' ' 18' ' ' VAL . 14.3 m -133.87 129.14 54.42 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-O 121.45 0.643 . . . . 0.0 112.134 -178.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.521 ' CE2' HD11 ' J' ' 34' ' ' LEU . 8.8 m-85 -111.79 116.77 31.25 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.445 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.494 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 55.1 p90 -133.96 130.72 38.08 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.983 -0.287 . . . . 0.0 110.775 -179.236 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.429 ' O ' ' OD1' ' H' ' 23' ' ' ASP . . . -121.35 125.43 46.97 Favored 'General case' 0 C--O 1.239 0.519 0 CA-C-O 121.122 0.487 . . . . 0.0 110.985 179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.499 ' CA ' ' OD2' ' H' ' 23' ' ' ASP . 96.0 mt-10 -146.64 150.31 35.19 Favored 'General case' 0 N--CA 1.455 -0.189 0 N-CA-C 106.43 -1.693 . . . . 0.0 106.43 178.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.609 ' OD1' ' NZ ' ' I' ' 28' ' ' LYS . 78.2 m-20 -78.11 111.61 14.21 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 112.754 -177.491 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.577 ' O ' ' N ' ' G' ' 26' ' ' SER . 52.9 t -114.06 130.85 67.54 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 N-CA-C 106.117 -1.809 . . . . 0.0 106.117 176.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.48 81.94 0.0 OUTLIER Glycine 0 CA--C 1.535 1.308 0 CA-C-O 119.561 -0.577 . . . . 0.0 113.532 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.577 ' N ' ' O ' ' G' ' 24' ' ' VAL . 4.7 t -98.62 172.36 7.54 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 176.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -58.73 162.4 4.02 Favored 'General case' 0 C--N 1.315 -0.93 0 C-N-CA 118.567 -1.253 . . . . 0.0 109.726 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -58.68 111.3 1.21 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 118.789 -0.624 . . . . 0.0 111.562 175.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.24 93.29 0.08 OUTLIER Glycine 0 N--CA 1.471 0.976 0 C-N-CA 118.311 -1.9 . . . . 0.0 111.947 175.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.75 159.2 17.85 Favored 'General case' 0 C--O 1.237 0.443 0 CA-C-N 120.319 2.06 . . . . 0.0 111.556 -179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.01 123.2 1.45 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.154 -178.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' A' ' 35' ' ' MET . 96.8 mt -133.5 128.71 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 O-C-N 121.952 -0.468 . . . . 0.0 111.308 -179.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.445 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -132.85 117.56 1.99 Allowed Glycine 0 CA--C 1.527 0.812 0 N-CA-C 110.434 -1.067 . . . . 0.0 110.434 179.295 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 84.1 mt -134.86 142.54 46.64 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 120.95 0.405 . . . . 0.0 110.576 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -141.09 137.55 32.91 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.212 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.3 t -119.03 82.72 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.481 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -87.68 97.99 2.34 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.12 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.95 165.03 38.61 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -136.23 159.08 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-O 120.738 0.304 . . . . 0.0 110.226 179.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 t . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.542 -179.924 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -117.21 139.5 50.71 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.642 0.258 . . . . 0.0 110.596 -179.549 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.48 ' CD ' ' N ' ' H' ' 11' ' ' GLU . 0.9 OUTLIER -128.02 132.24 49.13 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 34.3 m -140.02 157.21 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -139.5 105.61 5.23 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.929 0.395 . . . . 0.0 111.34 -179.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.416 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 17.2 m-70 -118.86 166.46 12.79 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.7 mt-30 -151.14 176.68 10.94 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.996 178.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -170.97 113.48 0.4 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.164 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -113.41 119.81 38.92 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -128.98 127.16 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 121.061 0.458 . . . . 0.0 111.683 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.558 ' CZ ' HD11 ' K' ' 34' ' ' LEU . 18.1 m-85 -117.24 118.28 31.85 Favored 'General case' 0 N--CA 1.468 0.439 0 N-CA-C 108.723 -0.843 . . . . 0.0 108.723 178.056 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -126.44 119.59 27.6 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 110.193 -0.299 . . . . 0.0 110.193 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.82 119.58 33.11 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.145 0.498 . . . . 0.0 111.626 -179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -163.48 89.27 0.6 Allowed 'General case' 0 C--N 1.341 0.234 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.711 ' H ' ' HZ2' ' J' ' 28' ' ' LYS . 5.0 m-20 -128.2 119.28 24.91 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.728 0.64 . . . . 0.0 112.728 -177.21 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.637 ' O ' ' O ' ' H' ' 23' ' ' ASP . 3.1 t -38.04 -124.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 O-C-N 124.105 0.878 . . . . 0.0 112.021 176.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.401 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -130.38 83.93 0.31 Allowed Glycine 0 CA--C 1.533 1.187 0 N-CA-C 111.44 -0.664 . . . . 0.0 111.44 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 12.5 p -67.37 -173.06 0.26 Allowed 'General case' 0 CA--C 1.508 -0.667 0 N-CA-C 107.05 -1.463 . . . . 0.0 107.05 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -78.92 169.69 17.82 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 118.332 -1.347 . . . . 0.0 110.506 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -47.09 110.21 0.28 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.95 95.61 0.28 Allowed Glycine 0 N--CA 1.468 0.827 0 C-N-CA 118.437 -1.84 . . . . 0.0 115.582 171.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.455 ' C ' ' CG1' ' H' ' 31' ' ' ILE . . . -119.29 147.45 44.27 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 101.117 -3.661 . . . . 0.0 101.117 171.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.8 HG22 ' SD ' ' B' ' 35' ' ' MET . 1.2 mt -149.01 126.12 2.51 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 C-N-CA 117.918 -1.513 . . . . 0.0 111.752 -170.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 44.2 mm -121.3 123.36 69.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.73 123.58 5.11 Favored Glycine 0 CA--C 1.53 1.026 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.518 ' CB ' HD22 ' I' ' 34' ' ' LEU . 29.0 tp -135.12 128.75 32.74 Favored 'General case' 0 N--CA 1.47 0.565 0 O-C-N 122.286 -0.538 . . . . 0.0 110.453 -179.252 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.584 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 2.6 ttp -123.34 116.94 24.13 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.088 -0.506 . . . . 0.0 111.031 -178.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' H' ' 37' ' ' GLY . 14.2 t -133.42 83.19 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -22.75 -94.05 0.01 OUTLIER Glycine 0 C--N 1.349 1.273 0 N-CA-C 112.159 -0.376 . . . . 0.0 112.159 177.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.65 -177.23 42.12 Favored Glycine 0 CA--C 1.525 0.662 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 50.4 t -127.58 136.12 61.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-O 120.962 0.411 . . . . 0.0 110.245 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.401 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 34.8 t . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.451 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . 0.421 ' O ' ' N ' ' J' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -95.34 128.36 42.12 Favored 'General case' 0 C--N 1.331 -0.23 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.472 ' O ' ' CB ' ' J' ' 11' ' ' GLU . 22.4 pt-20 -164.32 146.93 9.01 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.222 -0.591 . . . . 0.0 111.5 -179.627 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.401 ' C ' ' CD2' ' I' ' 13' ' ' HIS . 3.8 m -133.07 162.85 39.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 179.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.434 ' C ' ' ND1' ' I' ' 14' ' ' HIS . 30.9 m-70 -141.79 145.13 34.38 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.752 0.311 . . . . 0.0 111.413 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.434 ' ND1' ' C ' ' I' ' 13' ' ' HIS . 42.6 m80 -148.18 159.18 44.22 Favored 'General case' 0 CA--C 1.514 -0.427 0 C-N-CA 120.325 -0.55 . . . . 0.0 110.372 178.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -153.94 166.06 34.15 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.283 177.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.504 ' C ' HD12 ' I' ' 17' ' ' LEU . 96.2 mttt -162.53 123.86 2.59 Favored 'General case' 0 N--CA 1.471 0.581 0 O-C-N 123.023 0.202 . . . . 0.0 110.566 179.12 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.504 HD12 ' C ' ' I' ' 16' ' ' LYS . 10.6 mp -115.22 115.63 27.02 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 78.8 t -126.56 123.68 63.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 CA-C-O 120.983 0.421 . . . . 0.0 111.307 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.754 ' CZ ' HD12 ' L' ' 34' ' ' LEU . 9.8 m-85 -119.21 116.43 26.27 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 115.815 -0.629 . . . . 0.0 109.742 179.144 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -128.59 126.85 41.12 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.76 135.33 26.11 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.382 0.61 . . . . 0.0 111.961 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -141.57 142.58 33.49 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.081 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.442 ' O ' ' CG2' ' J' ' 24' ' ' VAL . 64.9 t0 -85.78 123.35 31.05 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-O 121.47 0.652 . . . . 0.0 111.69 -179.273 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' I' ' 26' ' ' SER . 2.9 t -93.2 121.81 44.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.874 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.06 -88.22 0.01 OUTLIER Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.891 -1.283 . . . . 0.0 109.891 -177.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' I' ' 24' ' ' VAL . 52.9 p -141.0 170.28 16.03 Favored 'General case' 0 CA--C 1.51 -0.59 0 CA-C-N 118.127 0.964 . . . . 0.0 109.477 177.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.546 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 0.1 OUTLIER -29.17 169.44 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 114.138 -1.392 . . . . 0.0 114.027 -179.252 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.609 ' NZ ' ' OD1' ' G' ' 23' ' ' ASP . 35.8 tttt -150.27 111.18 4.32 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 114.372 -1.286 . . . . 0.0 108.936 172.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.96 92.07 0.02 OUTLIER Glycine 0 N--CA 1.464 0.535 0 C-N-CA 118.913 -1.613 . . . . 0.0 109.082 176.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.486 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -138.32 148.07 44.22 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 177.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.693 HG13 HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -146.9 116.18 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 CA-C-N 114.057 -1.429 . . . . 0.0 110.387 -174.125 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.412 HD13 HG21 ' I' ' 32' ' ' ILE . 0.3 OUTLIER -106.99 114.76 46.88 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.542 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.533 ' O ' HD23 ' I' ' 34' ' ' LEU . . . -118.68 93.87 0.57 Allowed Glycine 0 N--CA 1.462 0.415 0 N-CA-C 108.553 -1.819 . . . . 0.0 108.553 179.304 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.533 HD23 ' O ' ' I' ' 33' ' ' GLY . 7.4 mt -127.61 135.26 50.03 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 122.484 1.135 . . . . 0.0 111.554 -178.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 42.9 ttp -125.62 120.7 31.47 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.402 177.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.99 73.57 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.784 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -21.1 -101.72 0.0 OUTLIER Glycine 0 C--N 1.367 2.301 0 O-C-N 123.508 0.505 . . . . 0.0 112.378 -179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.66 -153.71 23.65 Favored Glycine 0 CA--C 1.525 0.696 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.655 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 5.0 p -134.59 141.43 43.38 Favored 'Isoleucine or valine' 0 C--O 1.232 0.173 0 CA-C-O 120.879 0.371 . . . . 0.0 110.105 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' H' ' 40' ' ' VAL . 2.6 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.062 -0.97 . . . . 0.0 110.218 -179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' K' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.489 2.197 0 N-CA-C 109.672 -1.371 . . . . 0.0 109.672 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -142.22 163.14 33.66 Favored 'General case' 0 C--O 1.238 0.468 0 CA-C-O 120.778 0.323 . . . . 0.0 110.289 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.472 ' CB ' ' O ' ' I' ' 11' ' ' GLU . 17.3 pt-20 -153.3 154.21 34.14 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-O 121.162 0.506 . . . . 0.0 111.212 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.431 HG23 HG23 ' K' ' 12' ' ' VAL . 2.4 p -140.56 151.37 20.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.799 179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.43 ' ND1' ' C ' ' J' ' 12' ' ' VAL . 1.6 m80 -127.34 130.79 50.09 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.479 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 90.9 m-70 -126.6 156.57 40.7 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-O 121.494 0.664 . . . . 0.0 109.529 178.444 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mt-30 -150.68 173.79 13.76 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.775 179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -175.25 123.92 0.23 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.842 179.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.456 HD13 HE21 ' K' ' 15' ' ' GLN . 4.7 mp -125.48 122.25 36.08 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 -179.753 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.43 137.22 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 121.197 0.522 . . . . 0.0 112.135 -179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.493 ' CZ ' HD13 ' L' ' 34' ' ' LEU . 73.7 m-85 -121.62 129.65 52.96 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.358 -0.837 . . . . 0.0 109.863 179.106 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -129.65 122.19 28.5 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 118.136 0.426 . . . . 0.0 110.245 178.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.96 126.87 35.09 Favored 'General case' 0 C--O 1.239 0.535 0 CA-C-O 121.382 0.61 . . . . 0.0 111.427 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 78.7 tt0 -126.77 109.33 11.9 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.229 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.562 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 0.0 OUTLIER -104.68 112.3 25.33 Favored 'General case' 0 CA--C 1.544 0.73 0 C-N-CA 120.068 -0.653 . . . . 0.0 112.127 -178.607 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.571 ' O ' ' N ' ' J' ' 26' ' ' SER . 2.7 m -82.37 132.87 30.42 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.381 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.26 -85.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.415 0 N-CA-C 107.484 -2.246 . . . . 0.0 107.484 -177.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.571 ' N ' ' O ' ' J' ' 24' ' ' VAL . 10.9 t -140.98 169.62 17.26 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 118.373 1.086 . . . . 0.0 110.298 174.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' N ' ' L' ' 30' ' ' ALA . 1.0 OUTLIER -30.27 172.81 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 N-CA-C 115.165 1.542 . . . . 0.0 115.165 178.394 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.718 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 87.0 tttt -97.54 112.25 24.18 Favored 'General case' 0 CA--C 1.548 0.904 0 CA-C-O 117.671 -1.157 . . . . 0.0 110.197 171.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.494 ' H ' ' HB2' ' I' ' 27' ' ' ASN . . . -61.42 91.49 0.06 OUTLIER Glycine 0 N--CA 1.49 2.271 0 CA-C-N 123.453 2.842 . . . . 0.0 108.343 175.052 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.555 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -148.85 153.42 38.04 Favored 'General case' 0 CA--C 1.482 -1.655 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 177.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.546 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -142.35 115.95 4.23 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 C-N-CA 118.716 -1.194 . . . . 0.0 109.439 -174.632 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.438 HG22 ' O ' ' J' ' 32' ' ' ILE . 1.7 mt -105.52 117.01 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.563 -178.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.16 101.1 1.02 Allowed Glycine 0 CA--C 1.503 -0.71 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.521 HD11 ' CE2' ' G' ' 19' ' ' PHE . 5.1 tt -142.02 135.4 29.22 Favored 'General case' 0 CA--C 1.51 -0.567 0 C-N-CA 118.932 -1.107 . . . . 0.0 112.788 -177.039 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.704 ' SD ' HG22 ' D' ' 31' ' ' ILE . 60.9 ttp -127.82 124.0 36.54 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.807 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.464 HG23 HG13 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -124.3 75.36 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.751 0 CA-C-N 114.52 -1.218 . . . . 0.0 107.734 178.415 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -89.75 103.17 2.98 Favored Glycine 0 C--N 1.356 1.665 0 N-CA-C 111.784 -0.526 . . . . 0.0 111.784 -178.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.82 152.14 20.9 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 30.6 m -135.08 157.38 40.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 8.3 p . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.176 -0.916 . . . . 0.0 110.5 -179.63 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' J' ' 9' ' ' GLY . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -135.48 154.84 51.29 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 121.159 0.504 . . . . 0.0 111.179 -179.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -137.3 131.77 32.73 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.34 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.431 HG23 HG23 ' J' ' 12' ' ' VAL . 11.2 m -145.0 136.63 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.348 179.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 28.6 m80 -118.4 127.15 53.4 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.742 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 61.4 m-70 -124.02 158.27 32.53 Favored 'General case' 0 CA--C 1.518 -0.288 0 CA-C-O 121.556 0.693 . . . . 0.0 110.179 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.481 ' O ' ' O ' ' L' ' 15' ' ' GLN . 50.9 tt0 -166.17 170.23 13.55 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.776 179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.406 ' CG ' ' O ' ' K' ' 15' ' ' GLN . 66.3 mttm -163.82 125.5 2.37 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 118.905 -0.569 . . . . 0.0 109.556 179.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.929 ' O ' ' C ' ' L' ' 17' ' ' LEU . 17.9 tp -118.05 118.39 31.8 Favored 'General case' 0 N--CA 1.503 2.224 0 CA-C-O 123.339 1.543 . . . . 0.0 112.124 178.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.517 HG13 ' O ' ' K' ' 18' ' ' VAL . 5.3 p -134.07 123.96 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 115.166 -0.925 . . . . 0.0 112.352 -179.466 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 2.6 t80 -109.23 127.17 54.03 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.464 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -117.36 114.3 23.35 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 178.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.94 131.31 47.51 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.208 0.528 . . . . 0.0 111.569 -179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.406 ' O ' ' O ' ' K' ' 23' ' ' ASP . 74.5 mm-40 -83.33 158.26 22.25 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.257 179.265 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.55 ' O ' ' O ' ' K' ' 24' ' ' VAL . 48.8 p-10 -60.99 -133.88 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.201 -178.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.55 ' O ' ' O ' ' K' ' 23' ' ' ASP . 24.7 t 26.72 111.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 O-C-N 123.942 0.776 . . . . 0.0 112.356 -179.533 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.43 82.74 0.14 Allowed Glycine 0 CA--C 1.532 1.102 0 C-N-CA 120.206 -0.997 . . . . 0.0 113.183 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 30.2 p -139.05 170.2 16.41 Favored 'General case' 0 CA--C 1.514 -0.42 0 CA-C-N 117.759 0.779 . . . . 0.0 109.334 177.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 50.62 -178.75 0.02 OUTLIER 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.765 179.078 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt 55.37 -106.61 0.33 Allowed 'General case' 0 C--O 1.233 0.208 0 CA-C-O 121.204 0.526 . . . . 0.0 111.918 177.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.433 ' H ' ' HB2' ' J' ' 27' ' ' ASN . . . 96.6 91.54 1.83 Allowed Glycine 0 N--CA 1.467 0.712 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -177.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' J' ' 28' ' ' LYS . . . -82.19 174.2 11.4 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 104.707 -2.331 . . . . 0.0 104.707 177.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.736 HG22 ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -156.4 119.18 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 C-N-CA 116.768 -1.973 . . . . 0.0 111.224 -175.431 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.453 HG22 ' O ' ' K' ' 32' ' ' ILE . 0.9 OUTLIER -103.72 113.09 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 176.687 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.1 88.98 0.52 Allowed Glycine 0 CA--C 1.504 -0.603 0 N-CA-C 106.026 -2.83 . . . . 0.0 106.026 177.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.58 HD23 ' N ' ' K' ' 35' ' ' MET . 9.3 tt -127.66 134.54 49.62 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 122.004 0.907 . . . . 0.0 111.834 -177.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.58 ' N ' HD23 ' K' ' 34' ' ' LEU . 65.8 ttp -123.34 127.56 48.68 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 115.079 -0.964 . . . . 0.0 112.593 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.464 HG13 HG23 ' J' ' 36' ' ' VAL . 0.0 OUTLIER -132.5 72.9 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.642 0 CA-C-N 114.427 -1.26 . . . . 0.0 107.887 177.703 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.03 101.86 2.33 Favored Glycine 0 C--N 1.353 1.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -145.16 163.52 28.08 Favored Glycine 0 N--CA 1.46 0.242 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t -124.06 135.58 63.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.905 0.383 . . . . 0.0 110.125 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 9.2 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.466 179.967 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -112.95 152.92 28.81 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.856 0.36 . . . . 0.0 110.507 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -55.51 136.8 49.68 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.856 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.97 132.77 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 120.999 0.428 . . . . 0.0 110.503 -179.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 23.3 p-80 -160.91 147.71 15.19 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.487 179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 11.0 t60 -95.16 177.54 5.83 Favored 'General case' 0 N--CA 1.45 -0.438 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.497 ' HG3' ' H ' ' L' ' 16' ' ' LYS . 45.6 tp60 -114.84 174.98 5.7 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.932 -179.564 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . 0.497 ' H ' ' HG3' ' L' ' 15' ' ' GLN . 88.9 mttt -88.9 -174.96 4.7 Favored 'General case' 0 C--O 1.176 -2.765 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.929 ' C ' ' O ' ' K' ' 17' ' ' LEU . 38.3 mt -141.48 161.28 38.29 Favored 'General case' 0 C--N 1.31 -1.12 0 O-C-N 119.922 -1.736 . . . . 0.0 110.289 -179.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . 0.452 HG23 ' N ' ' L' ' 19' ' ' PHE . 10.8 m -84.54 -144.05 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 117.723 2.49 . . . . 0.0 117.723 -171.208 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.492 ' CD1' ' N ' ' L' ' 19' ' ' PHE . 9.6 m-85 -124.22 147.62 47.91 Favored 'General case' 0 N--CA 1.45 -0.458 0 CA-C-N 113.506 -1.679 . . . . 0.0 111.143 -178.066 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -137.48 132.19 32.95 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-N 115.263 -0.881 . . . . 0.0 108.945 178.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -156.3 159.37 38.78 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.277 -179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.4 mm-40 -85.7 157.97 20.17 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -53.16 122.88 10.34 Favored 'General case' 0 CA--C 1.52 -0.185 0 C-N-CA 119.899 -0.721 . . . . 0.0 109.243 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 3.5 t -92.68 121.79 43.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.748 0 C-N-CA 120.628 -0.429 . . . . 0.0 110.575 -178.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.16 -87.01 0.01 OUTLIER Glycine 0 CA--C 1.522 0.494 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 177.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 79.4 p -89.07 -177.7 5.5 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 106.545 -1.65 . . . . 0.0 106.545 179.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 63.9 t30 -60.27 179.55 0.14 Allowed 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.713 -177.334 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 11.6 tptt -57.26 110.72 0.89 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 122.005 0.907 . . . . 0.0 112.998 -176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.27 -98.14 0.04 OUTLIER Glycine 0 CA--C 1.496 -1.149 0 CA-C-N 113.801 -1.545 . . . . 0.0 111.155 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.683 ' N ' ' ND2' ' J' ' 27' ' ' ASN . . . -61.2 165.16 4.64 Favored 'General case' 0 CA--C 1.51 -0.575 0 N-CA-C 105.05 -2.204 . . . . 0.0 105.05 -178.612 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.504 HD12 ' O ' ' K' ' 30' ' ' ALA . 0.8 OUTLIER -141.51 125.32 16.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 C-N-CA 117.692 -1.603 . . . . 0.0 112.441 -176.238 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 4.3 mt -101.16 117.66 46.74 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.632 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 177.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.55 98.19 0.61 Allowed Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 178.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.97 HD21 HG13 ' L' ' 36' ' ' VAL . 1.0 OUTLIER -128.82 139.58 52.1 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 179.557 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 66.4 ttp -118.33 124.15 47.08 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 120.505 -0.478 . . . . 0.0 110.588 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.97 HG13 HD21 ' L' ' 34' ' ' LEU . 0.9 OUTLIER -123.42 80.07 0.67 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 178.648 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.93 102.48 0.12 Allowed Glycine 0 C--N 1.349 1.295 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 179.247 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -100.68 -173.21 29.37 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 7.3 p -141.56 142.87 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.842 0.353 . . . . 0.0 110.599 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.995 -1.002 . . . . 0.0 111.015 -179.795 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -84.03 140.09 32.09 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.813 0.339 . . . . 0.0 110.212 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -65.76 145.32 56.13 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.013 -179.326 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -139.35 141.11 36.3 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.09 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 77.7 m80 -142.98 165.13 28.2 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.344 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m80 -135.69 178.55 6.96 Favored 'General case' 0 CA--C 1.517 -0.31 0 CA-C-O 121.232 0.539 . . . . 0.0 109.61 -179.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -98.12 179.18 4.85 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.329 -0.851 . . . . 0.0 111.022 -179.626 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -104.56 140.95 37.24 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.195 -179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -124.12 120.12 31.42 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 121.079 0.466 . . . . 0.0 110.726 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 18' ' ' VAL . 5.6 m -134.06 128.19 52.53 Favored 'Isoleucine or valine' 0 C--O 1.231 0.098 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.11 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.623 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 11.7 m-85 -112.88 118.83 35.98 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 178.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.549 ' CE2' ' CD1' ' B' ' 20' ' ' PHE . 55.7 t80 -127.71 113.08 15.56 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -112.51 129.26 56.41 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.118 0.485 . . . . 0.0 110.98 -178.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 73.2 tt0 -156.72 158.69 37.39 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 179.284 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -81.11 111.29 17.42 Favored 'General case' 0 C--N 1.324 -0.521 0 C-N-CA 119.719 -0.793 . . . . 0.0 111.718 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.628 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.0 t -114.27 131.18 67.04 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.839 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 177.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.83 81.94 0.0 OUTLIER Glycine 0 CA--C 1.53 0.984 0 C-N-CA 121.576 -0.345 . . . . 0.0 112.409 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.628 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.1 p -94.64 177.31 5.96 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 178.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.485 ' O ' ' O ' ' A' ' 28' ' ' LYS . 98.5 m-20 -61.58 179.6 0.23 Allowed 'General case' 0 C--N 1.31 -1.149 0 C-N-CA 119.584 -0.846 . . . . 0.0 108.763 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.485 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.8 mttm -52.12 -111.87 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.761 0.791 . . . . 0.0 111.406 178.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.41 93.33 1.63 Allowed Glycine 0 N--CA 1.467 0.707 0 N-CA-C 109.379 -1.488 . . . . 0.0 109.379 177.113 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.55 160.9 14.05 Favored 'General case' 0 CA--C 1.509 -0.605 0 C-N-CA 116.582 -2.047 . . . . 0.0 111.627 -177.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.492 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.0 OUTLIER -152.51 117.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.112 0 CA-C-N 111.819 -2.446 . . . . 0.0 109.184 -174.334 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -117.87 118.54 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 C-N-CA 120.621 -0.432 . . . . 0.0 110.709 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.64 108.71 0.98 Allowed Glycine 0 N--CA 1.464 0.56 0 N-CA-C 109.35 -1.5 . . . . 0.0 109.35 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 48.5 tp -131.69 133.01 44.4 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 117.194 0.497 . . . . 0.0 111.07 -179.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 13.4 ttt -139.38 134.66 32.77 Favored 'General case' 0 C--N 1.328 -0.36 0 O-C-N 122.234 -0.291 . . . . 0.0 110.788 -179.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.7 t -146.06 81.29 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.487 ' HA3' HD12 ' H' ' 31' ' ' ILE . . . -85.51 100.22 2.43 Favored Glycine 0 C--N 1.338 0.66 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.226 178.315 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -179.24 176.48 47.86 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m -131.72 158.57 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 120.82 0.343 . . . . 0.0 110.356 179.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.3 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.636 -179.706 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . 0.563 ' CE1' ' CD1' ' D' ' 10' ' ' TYR . 95.7 m-85 -83.06 144.1 30.14 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.736 0.303 . . . . 0.0 110.489 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -133.99 156.33 48.37 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.68 -179.613 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.509 HG12 ' N ' ' B' ' 13' ' ' HIS . 93.4 t -133.17 159.94 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.894 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.509 ' N ' HG12 ' B' ' 12' ' ' VAL . 28.3 t60 -166.77 104.78 0.59 Allowed 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.218 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 47.6 m170 -120.0 165.77 14.25 Favored 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 178.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.605 HE21 HD21 ' B' ' 17' ' ' LEU . 50.6 tt0 -162.85 173.23 14.01 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.331 179.141 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.41 ' N ' ' HG2' ' B' ' 15' ' ' GLN . 97.6 mttt -149.85 116.29 5.79 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.939 0.399 . . . . 0.0 110.742 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.605 HD21 HE21 ' B' ' 15' ' ' GLN . 60.6 mt -116.57 114.42 24.11 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.302 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.52 123.66 66.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-O 121.214 0.531 . . . . 0.0 110.945 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.646 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 4.4 m-85 -117.47 118.52 32.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.963 179.197 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.549 ' CD1' ' CE2' ' A' ' 20' ' ' PHE . 33.1 t80 -138.37 125.67 21.69 Favored 'General case' 0 N--CA 1.467 0.386 0 O-C-N 122.22 -0.3 . . . . 0.0 110.326 -179.398 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 131.32 46.89 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 121.155 0.503 . . . . 0.0 111.965 -179.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 45.1 tt0 -157.67 91.3 1.13 Allowed 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 177.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.619 ' H ' ' CG ' ' C' ' 23' ' ' ASP . 10.7 t0 -121.6 113.1 19.3 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -176.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.425 ' O ' ' N ' ' B' ' 26' ' ' SER . 12.0 p -60.41 132.37 25.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 177.252 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.94 83.72 0.04 OUTLIER Glycine 0 CA--C 1.526 0.751 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.694 -178.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.425 ' N ' ' O ' ' B' ' 24' ' ' VAL . 11.8 p -87.62 -179.1 6.25 Favored 'General case' 0 N--CA 1.443 -0.786 0 CA-C-O 121.583 0.706 . . . . 0.0 109.627 178.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.425 ' O ' ' O ' ' B' ' 28' ' ' LYS . 28.3 t-20 -75.63 175.96 8.1 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.544 177.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.425 ' O ' ' O ' ' B' ' 27' ' ' ASN . 97.6 mttt 42.49 107.9 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.656 0 N-CA-C 114.9 1.445 . . . . 0.0 114.9 176.121 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.2 100.04 1.98 Allowed Glycine 0 N--CA 1.479 1.565 0 CA-C-N 114.273 -1.33 . . . . 0.0 110.717 -179.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 161.35 31.15 Favored 'General case' 0 C--O 1.248 1.016 0 CA-C-O 122.772 1.272 . . . . 0.0 110.772 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.514 ' CG2' HD12 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.02 122.74 9.21 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 112.939 -1.937 . . . . 0.0 110.378 -172.929 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.452 ' C ' ' SD ' ' H' ' 35' ' ' MET . 44.3 pt -136.08 135.29 50.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-O 121.847 0.832 . . . . 0.0 112.129 -179.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -141.11 137.88 8.46 Favored Glycine 0 CA--C 1.531 1.033 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.142 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 tt -146.93 139.74 25.12 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 120.196 -0.601 . . . . 0.0 111.158 -179.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.509 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 24.1 ttm -128.32 126.19 40.27 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-O 121.397 0.618 . . . . 0.0 112.133 -179.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.43 79.6 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.021 177.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.533 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -50.91 104.13 0.12 Allowed Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.769 -179.045 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . 44.99 179.74 0.01 OUTLIER Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 p -148.36 149.77 14.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.439 ' OXT' HG22 ' B' ' 40' ' ' VAL . 6.0 p . . . . . 0 C--O 1.218 -0.559 0 CA-C-O 118.176 -0.916 . . . . 0.0 111.078 -179.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.526 -1.429 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -114.72 141.44 47.83 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.417 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -142.58 159.34 42.43 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.418 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.463 HG13 ' CD2' ' D' ' 13' ' ' HIS . 55.3 t -121.27 133.56 67.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.489 ' H ' ' H ' ' D' ' 13' ' ' HIS . 97.6 m-70 -148.08 123.63 10.42 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.822 0.344 . . . . 0.0 111.179 -179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.529 ' ND1' ' O ' ' D' ' 14' ' ' HIS . 26.1 t60 -141.45 164.65 29.66 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.437 ' HG2' ' N ' ' C' ' 16' ' ' LYS . 51.8 tt0 -169.39 170.36 8.45 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 120.387 -0.525 . . . . 0.0 110.845 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.437 ' N ' ' HG2' ' C' ' 15' ' ' GLN . 68.2 mttm -142.59 118.79 10.77 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.238 178.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -120.11 121.39 38.73 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.06 123.25 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.048 0.452 . . . . 0.0 111.739 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.953 ' CZ ' HD22 ' F' ' 34' ' ' LEU . 6.6 m-85 -113.65 116.78 30.0 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 178.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.544 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 33.6 t80 -132.24 118.65 19.78 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 118.227 0.467 . . . . 0.0 110.203 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.9 37.92 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 120.857 0.361 . . . . 0.0 110.884 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -173.2 102.97 0.13 Allowed 'General case' 0 CA--C 1.522 -0.134 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.912 ' H ' ' HZ2' ' E' ' 28' ' ' LYS . 1.1 m-20 -115.15 113.66 24.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 121.095 0.474 . . . . 0.0 111.417 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 91.4 t -64.76 131.5 30.53 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 178.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.84 84.02 0.31 Allowed Glycine 0 CA--C 1.525 0.696 0 C-N-CA 119.195 -1.479 . . . . 0.0 110.726 -179.027 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.536 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 1.7 m -59.87 -174.27 0.02 OUTLIER 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.536 ' CB ' ' O ' ' C' ' 26' ' ' SER . 6.1 t-20 99.85 -174.62 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.928 0 O-C-N 124.342 1.026 . . . . 0.0 111.202 -177.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.52 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 81.9 tttt 37.44 108.93 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.987 -177.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.426 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -85.79 96.84 2.13 Favored Glycine 0 CA--C 1.504 -0.622 0 CA-C-N 114.325 -1.307 . . . . 0.0 112.056 177.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.8 164.7 19.36 Favored 'General case' 0 C--O 1.244 0.808 0 N-CA-C 106.063 -1.828 . . . . 0.0 106.063 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.689 HG23 HG13 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.83 121.3 3.26 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 C-N-CA 117.961 -1.496 . . . . 0.0 111.702 -174.804 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 1.1 mt -114.54 120.63 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.898 178.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.98 98.88 0.65 Allowed Glycine 0 N--CA 1.472 1.04 0 N-CA-C 106.939 -2.464 . . . . 0.0 106.939 176.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.467 HD21 HG13 ' C' ' 36' ' ' VAL . 5.1 tt -129.93 129.28 43.64 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 119.05 -1.06 . . . . 0.0 113.749 -175.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.435 ' CG ' ' HA3' ' I' ' 33' ' ' GLY . 96.6 mmm -107.39 118.08 35.77 Favored 'General case' 0 CA--C 1.503 -0.859 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.267 179.261 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.467 HG13 HD21 ' C' ' 34' ' ' LEU . 0.0 OUTLIER -131.02 72.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.723 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 175.83 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.14 112.31 4.6 Favored Glycine 0 C--N 1.36 1.882 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.47 157.39 51.88 Favored Glycine 0 CA--C 1.523 0.588 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 -179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -138.72 161.51 29.95 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 110.26 -0.274 . . . . 0.0 110.26 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.103 -0.951 . . . . 0.0 110.508 179.968 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.329 -1.509 . . . . 0.0 109.329 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . 0.563 ' CD1' ' CE1' ' B' ' 10' ' ' TYR . 87.3 m-85 -108.42 142.12 39.27 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.736 0.303 . . . . 0.0 110.322 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' D' ' 11' ' ' GLU . 2.1 pm0 -143.92 169.42 17.84 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.646 -179.479 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 86.1 t -83.12 130.68 35.33 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.18 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.489 ' H ' ' H ' ' C' ' 13' ' ' HIS . 3.4 m-70 -87.31 161.48 17.92 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.336 0.589 . . . . 0.0 111.354 -178.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.529 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.8 p-80 -93.93 178.83 5.54 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 115.253 -0.885 . . . . 0.0 109.327 179.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -127.7 179.04 5.74 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.502 -179.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -137.23 127.1 25.66 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.248 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.3 mp -126.43 129.17 48.21 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.223 -179.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -126.81 125.01 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.027 0.441 . . . . 0.0 111.488 -179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.756 ' CZ ' HD23 ' F' ' 34' ' ' LEU . 4.9 m-85 -110.57 112.57 24.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.039 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.51 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 27.5 t80 -126.72 123.32 37.21 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 118.542 0.61 . . . . 0.0 109.947 -179.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.17 142.63 28.63 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 88.8 mt-10 -142.97 145.17 32.72 Favored 'General case' 0 C--N 1.343 0.302 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.653 178.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.515 ' O ' ' O ' ' E' ' 24' ' ' VAL . 14.0 m-20 -112.64 124.67 53.07 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.898 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' E' ' 26' ' ' SER . 5.7 t -95.34 -112.08 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 N-CA-C 113.124 0.787 . . . . 0.0 113.124 -176.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.94 -91.12 0.01 OUTLIER Glycine 0 N--CA 1.469 0.864 0 N-CA-C 112.386 -0.286 . . . . 0.0 112.386 -176.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.609 ' O ' ' O ' ' D' ' 27' ' ' ASN . 21.5 p -151.54 171.87 16.91 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -179.535 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.692 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 18.6 m120 -19.29 156.7 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.077 0 O-C-N 124.253 0.971 . . . . 0.0 113.164 -178.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.497 ' H ' ' H ' ' E' ' 29' ' ' GLY . 56.5 tttt -162.45 110.68 1.36 Allowed 'General case' 0 C--N 1.331 -0.223 0 O-C-N 121.406 -0.809 . . . . 0.0 110.461 173.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.426 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -68.62 92.83 0.29 Allowed Glycine 0 C--O 1.215 -1.036 0 CA-C-O 117.861 -1.522 . . . . 0.0 110.77 175.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.463 ' O ' HG13 ' E' ' 31' ' ' ILE . . . -129.04 151.61 49.54 Favored 'General case' 0 CA--C 1.482 -1.652 0 N-CA-C 103.028 -2.953 . . . . 0.0 103.028 173.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.689 HG13 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -147.75 118.25 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 C-N-CA 117.681 -1.608 . . . . 0.0 111.339 -172.909 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.532 ' O ' HG23 ' D' ' 32' ' ' ILE . 18.5 tt -119.0 113.42 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 115.064 -0.971 . . . . 0.0 108.483 178.459 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.705 ' C ' HD12 ' D' ' 34' ' ' LEU . . . -130.07 128.22 5.57 Favored Glycine 0 C--O 1.241 0.536 0 C-N-CA 121.09 -0.576 . . . . 0.0 111.811 -178.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.705 HD12 ' C ' ' D' ' 33' ' ' GLY . 4.0 mp -141.5 142.57 33.58 Favored 'General case' 0 CA--C 1.505 -0.763 0 CA-C-O 122.249 1.023 . . . . 0.0 111.277 178.659 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.46 ' SD ' ' HB ' ' J' ' 31' ' ' ILE . 29.3 tpp -100.87 113.6 26.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 113.574 -1.648 . . . . 0.0 108.448 178.937 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.617 ' CG2' HD11 ' E' ' 34' ' ' LEU . 0.0 OUTLIER -126.55 74.0 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.302 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 179.113 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.96 111.21 1.82 Allowed Glycine 0 C--N 1.358 1.793 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.17 -170.28 0.15 Allowed Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 27.1 m -133.85 160.62 41.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-O 120.815 0.34 . . . . 0.0 110.791 -179.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.926 -1.035 . . . . 0.0 110.562 179.845 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.6 m-85 -101.47 129.12 47.46 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.993 0.425 . . . . 0.0 110.539 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -143.88 138.86 28.89 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.84 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.1 t -126.36 132.77 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.904 0.383 . . . . 0.0 110.329 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 t-80 -143.95 112.57 6.55 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.564 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 62.4 m-70 -128.81 173.01 10.74 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -151.1 175.93 11.65 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.709 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -167.85 108.25 0.57 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.05 0.452 . . . . 0.0 110.686 178.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.0 tt -124.84 127.35 47.02 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.707 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.13 128.84 72.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.345 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -119.61 119.97 35.33 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.7 t80 -128.18 121.96 30.73 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-O 120.909 0.385 . . . . 0.0 110.273 -179.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.5 133.33 43.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.994 0.426 . . . . 0.0 111.52 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 59.7 mm-40 -137.74 123.78 20.28 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.554 -0.458 . . . . 0.0 109.831 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 68.2 t0 -84.77 114.82 22.34 Favored 'General case' 0 C--O 1.233 0.2 0 CA-C-O 121.062 0.458 . . . . 0.0 111.181 -178.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' E' ' 26' ' ' SER . 53.8 t -95.78 130.81 43.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.68 -85.07 0.01 OUTLIER Glycine 0 CA--C 1.535 1.289 0 N-CA-C 111.3 -0.72 . . . . 0.0 111.3 -177.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.528 ' N ' ' O ' ' E' ' 24' ' ' VAL . 12.6 t -153.0 174.29 14.35 Favored 'General case' 0 C--N 1.347 0.46 0 CA-C-N 118.897 1.348 . . . . 0.0 112.995 179.391 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.692 ' ND2' ' H ' ' D' ' 27' ' ' ASN . 12.9 p-10 -19.01 160.24 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 116.761 2.134 . . . . 0.0 116.761 178.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.912 ' HZ2' ' H ' ' C' ' 23' ' ' ASP . 80.9 tttt -170.14 105.55 0.31 Allowed 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 174.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.677 ' O ' ' HA ' ' F' ' 30' ' ' ALA . . . -49.99 -97.84 0.01 OUTLIER Glycine 0 N--CA 1.469 0.9 0 C-N-CA 118.664 -1.731 . . . . 0.0 111.299 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.561 ' HB3' ' O ' ' E' ' 29' ' ' GLY . . . 74.07 143.71 0.07 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.599 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -150.78 118.11 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 C-N-CA 119.097 -1.041 . . . . 0.0 109.08 -178.471 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 4.5 tt -117.44 128.31 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 CA-C-O 121.329 0.585 . . . . 0.0 111.255 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.44 99.7 0.7 Allowed Glycine 0 N--CA 1.451 -0.331 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 178.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.646 HD13 ' CZ ' ' B' ' 19' ' ' PHE . 37.6 tp -115.58 116.39 28.06 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.551 ' CE ' ' SD ' ' F' ' 35' ' ' MET . 0.4 OUTLIER -91.76 111.63 23.24 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.976 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.71 ' O ' HG12 ' E' ' 36' ' ' VAL . 2.0 t -138.4 66.56 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 107.857 -1.164 . . . . 0.0 107.857 -179.418 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -54.84 -103.53 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 N-CA-C 110.101 -1.199 . . . . 0.0 110.101 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.44 169.01 34.51 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 13.2 p -140.67 140.85 33.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.434 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.064 -0.969 . . . . 0.0 110.357 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -84.3 139.92 31.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.04 0.448 . . . . 0.0 110.887 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -60.7 149.85 34.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.911 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.3 t -119.14 131.44 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.851 179.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.508 ' ND1' ' N ' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -151.26 130.05 12.4 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.58 -0.737 . . . . 0.0 110.417 -179.868 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.402 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 80.6 m80 -155.82 178.29 10.43 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -139.72 177.87 7.64 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.248 179.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 65.4 tttm -155.12 115.9 3.91 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.336 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.44 128.01 42.07 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.751 -0.658 . . . . 0.0 110.17 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 99.8 t -129.63 130.94 67.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.7 p90 -132.32 128.52 37.89 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.927 0.394 . . . . 0.0 110.887 -179.224 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.6 t80 -138.82 125.37 20.63 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 178.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.46 146.3 30.51 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.229 -0.588 . . . . 0.0 111.681 -178.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -124.15 95.68 4.64 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 178.173 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 5.8 t70 -108.3 114.57 28.54 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.909 -178.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' F' ' 26' ' ' SER . 43.9 t -63.49 130.92 28.83 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 N-CA-C 107.141 -1.429 . . . . 0.0 107.141 178.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.32 84.37 0.01 OUTLIER Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.352 -0.928 . . . . 0.0 112.866 -176.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.559 ' O ' ' O ' ' F' ' 27' ' ' ASN . 2.8 p 170.68 175.59 0.06 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 114.902 -0.649 . . . . 0.0 109.486 176.304 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.559 ' O ' ' O ' ' F' ' 26' ' ' SER . 65.0 t30 -29.15 179.29 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 115.587 1.699 . . . . 0.0 115.587 178.695 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.547 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 33.1 tttm 129.07 102.33 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.937 0 C-N-CA 128.826 2.85 . . . . 0.0 108.455 174.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.64 -99.88 0.01 OUTLIER Glycine 0 C--N 1.348 1.214 0 CA-C-O 124.622 2.235 . . . . 0.0 114.143 174.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.677 ' HA ' ' O ' ' E' ' 29' ' ' GLY . . . 70.18 143.36 0.05 Allowed 'General case' 0 CA--C 1.503 -0.839 0 CA-C-N 108.575 -3.812 . . . . 0.0 107.208 177.062 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.513 HG13 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -160.06 125.05 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 122.538 2.427 . . . . 0.0 113.399 -179.711 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 87.7 mt -107.78 117.74 54.05 Favored 'Isoleucine or valine' 0 C--N 1.355 0.83 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.951 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.53 91.06 0.55 Allowed Glycine 0 N--CA 1.452 -0.245 0 N-CA-C 109.061 -1.615 . . . . 0.0 109.061 177.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.953 HD22 ' CZ ' ' C' ' 19' ' ' PHE . 3.1 tp -114.22 116.18 28.63 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.628 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 2.2 mtp -88.34 114.26 24.78 Favored 'General case' 0 CA--C 1.48 -1.735 0 N-CA-C 107.688 -1.226 . . . . 0.0 107.688 178.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.407 HG22 ' O ' ' F' ' 36' ' ' VAL . 2.2 p -139.63 74.55 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 105.775 -1.935 . . . . 0.0 105.775 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.32 104.85 2.64 Favored Glycine 0 C--N 1.356 1.667 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 -178.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.03 -179.43 26.37 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -134.76 138.07 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.692 0.282 . . . . 0.0 111.03 -179.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 N--CA 1.469 0.52 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.538 179.584 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -119.51 142.59 48.16 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -152.43 123.56 7.59 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.416 0.626 . . . . 0.0 111.578 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -150.21 146.29 16.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.498 178.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -151.93 140.97 21.2 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.077 0.465 . . . . 0.0 110.815 179.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -134.64 163.74 29.07 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -150.53 171.34 17.24 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.528 178.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -156.2 128.98 7.84 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.46 HD13 HE21 ' H' ' 15' ' ' GLN . 5.8 mp -122.15 124.6 44.26 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 110.218 179.095 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.436 ' O ' HG13 ' G' ' 18' ' ' VAL . 5.4 p -121.67 120.46 61.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 179.189 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.586 ' CZ ' HD13 ' I' ' 34' ' ' LEU . 3.9 t80 -117.12 103.16 9.94 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -122.37 121.5 36.84 Favored 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.592 -0.521 . . . . 0.0 109.592 -178.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.93 123.75 48.86 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.862 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -158.3 155.53 28.99 Favored 'General case' 0 CA--C 1.528 0.122 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 178.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 36.5 t0 -88.25 120.9 30.05 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 121.116 0.484 . . . . 0.0 112.289 -178.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.569 ' O ' ' N ' ' G' ' 26' ' ' SER . 88.1 t -100.97 124.03 54.36 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.63 83.49 0.0 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-O 120.052 -0.305 . . . . 0.0 112.985 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.569 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.1 m -97.46 174.78 6.5 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.269 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 22.8 p30 -59.22 164.38 3.21 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.196 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -57.23 111.53 1.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.486 -0.324 . . . . 0.0 111.779 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.462 ' H ' ' HE3' ' H' ' 28' ' ' LYS . . . 72.38 93.49 0.09 OUTLIER Glycine 0 N--CA 1.466 0.681 0 C-N-CA 119.678 -1.249 . . . . 0.0 111.315 177.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.55 157.51 19.56 Favored 'General case' 0 CA--C 1.51 -0.595 0 C-N-CA 118.426 -1.31 . . . . 0.0 108.847 178.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.514 HG22 HD12 ' H' ' 31' ' ' ILE . 0.1 OUTLIER -153.04 117.35 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.832 0 CA-C-N 114.651 -1.159 . . . . 0.0 109.776 -173.434 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.485 ' O ' ' SD ' ' A' ' 35' ' ' MET . 18.0 tt -135.58 129.47 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 120.233 -0.587 . . . . 0.0 111.064 179.543 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.88 116.9 1.96 Allowed Glycine 0 N--CA 1.466 0.639 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 76.5 mt -137.33 148.77 46.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 121.681 0.753 . . . . 0.0 112.289 -178.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 ttt -139.3 135.8 34.19 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.196 -179.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' G' ' 37' ' ' GLY . 9.5 t -141.53 81.27 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' G' ' 36' ' ' VAL . . . -26.89 -94.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 O-C-N 123.337 0.398 . . . . 0.0 112.773 178.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.13 -157.84 30.5 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 71.8 t -98.86 133.49 41.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.847 0.356 . . . . 0.0 110.24 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.731 -179.395 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -145.0 159.5 42.84 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.788 0.327 . . . . 0.0 110.522 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.481 ' CD ' ' NE2' ' H' ' 13' ' ' HIS . 82.5 tt0 -134.73 145.54 48.56 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.176 -0.465 . . . . 0.0 109.835 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.48 133.17 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 CA-C-N 116.793 -0.185 . . . . 0.0 111.08 -178.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.481 ' NE2' ' CD ' ' H' ' 11' ' ' GLU . 80.9 m-70 -137.31 143.58 42.18 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.837 0.351 . . . . 0.0 111.307 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.506 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 86.3 t60 -146.92 162.08 39.43 Favored 'General case' 0 CA--C 1.514 -0.441 0 CA-C-O 121.448 0.642 . . . . 0.0 110.307 178.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.506 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 42.4 tt0 -156.72 174.62 15.21 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -162.71 125.47 2.78 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.892 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.561 HD23 ' C ' ' H' ' 17' ' ' LEU . 6.6 tt -125.62 121.79 34.55 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.982 0.42 . . . . 0.0 110.533 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.498 ' N ' HD23 ' H' ' 17' ' ' LEU . 56.6 t -120.36 126.16 74.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 115.93 -0.577 . . . . 0.0 109.876 179.206 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 29.5 t80 -121.93 111.91 17.66 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -130.38 126.23 36.55 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 -179.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.34 128.64 51.27 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.238 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -141.24 149.1 40.9 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.643 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.51 ' O ' ' NZ ' ' J' ' 28' ' ' LYS . 53.2 t0 -155.79 121.1 4.85 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 178.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.802 HG22 ' N ' ' H' ' 25' ' ' GLY . 2.6 p -133.87 -112.01 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.802 ' N ' HG22 ' H' ' 24' ' ' VAL . . . 32.86 -90.26 0.01 OUTLIER Glycine 0 CA--C 1.53 1.016 0 CA-C-N 115.97 -0.559 . . . . 0.0 112.362 -178.085 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.661 ' O ' ' O ' ' H' ' 27' ' ' ASN . 1.6 t 171.61 178.72 0.07 Allowed 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 117.622 0.711 . . . . 0.0 109.984 -179.519 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.661 ' O ' ' O ' ' H' ' 26' ' ' SER . 9.4 t-20 -28.57 179.59 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 O-C-N 125.07 1.481 . . . . 0.0 114.259 179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.555 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 87.0 tttt 128.43 105.18 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 124.359 1.064 . . . . 0.0 111.763 178.356 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -56.86 96.27 0.05 OUTLIER Glycine 0 N--CA 1.47 0.948 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -122.08 146.6 47.04 Favored 'General case' 0 C--O 1.253 1.288 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 177.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.599 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.1 OUTLIER -140.04 119.61 12.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.281 0 CA-C-N 113.02 -1.9 . . . . 0.0 110.697 -171.855 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 86.0 mt -126.96 122.73 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.767 -179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.17 118.64 2.18 Favored Glycine 0 CA--C 1.529 0.963 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -137.3 129.97 30.1 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.456 0.646 . . . . 0.0 111.1 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.452 ' SD ' ' C ' ' B' ' 32' ' ' ILE . 13.2 ttt -124.47 124.91 43.33 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.247 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.556 ' O ' HG23 ' H' ' 36' ' ' VAL . 34.5 m -136.08 81.24 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 N-CA-C 112.823 0.675 . . . . 0.0 112.823 -179.072 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -29.14 -93.47 0.01 OUTLIER Glycine 0 CA--C 1.529 0.925 0 CA-C-N 116.488 -0.324 . . . . 0.0 112.489 178.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.09 -161.86 28.66 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 -179.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.407 ' O ' HG23 ' I' ' 39' ' ' VAL . 27.7 m -120.51 134.79 62.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 120.657 0.265 . . . . 0.0 110.39 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.442 179.908 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . 0.52 ' CD1' ' OE2' ' J' ' 11' ' ' GLU . 89.5 m-85 -108.41 145.21 34.93 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.69 0.281 . . . . 0.0 110.322 179.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -122.63 147.12 46.8 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.905 0.383 . . . . 0.0 110.694 -179.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m -119.03 133.13 66.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-N 115.98 -0.554 . . . . 0.0 109.647 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.54 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 49.3 p-80 -155.86 161.62 40.57 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.147 -0.621 . . . . 0.0 112.303 -178.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.54 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 7.2 m-70 -141.37 162.78 34.66 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.45 179.097 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 90.5 mt-30 -150.54 175.36 11.97 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.858 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -155.26 130.53 9.61 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.976 -0.556 . . . . 0.0 109.989 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.4 mt -124.39 118.74 27.39 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -123.62 128.44 74.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.56 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.648 ' CD2' ' CZ ' ' J' ' 19' ' ' PHE . 27.7 t80 -128.01 116.23 19.72 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -127.89 130.32 48.33 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-O 120.703 0.287 . . . . 0.0 110.941 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.14 125.78 32.09 Favored 'General case' 0 C--O 1.243 0.718 0 CA-C-O 121.444 0.64 . . . . 0.0 112.067 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -145.08 158.34 43.85 Favored 'General case' 0 CA--C 1.535 0.369 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.553 179.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.545 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.9 p-10 -173.96 121.88 0.31 Allowed 'General case' 0 N--CA 1.467 0.419 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 -179.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.455 ' O ' ' N ' ' I' ' 26' ' ' SER . 11.5 t -124.0 -111.6 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.222 -178.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.18 -90.75 0.01 OUTLIER Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 -177.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.563 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.7 p 171.39 169.37 0.09 Allowed 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 177.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.563 ' O ' ' O ' ' I' ' 26' ' ' SER . 21.3 t-20 -19.49 155.8 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 113.866 1.061 . . . . 0.0 113.866 179.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.542 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 73.5 tttt -170.69 106.57 0.28 Allowed 'General case' 0 N--CA 1.445 -0.686 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.676 173.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.66 93.16 0.01 OUTLIER Glycine 0 C--O 1.227 -0.335 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 174.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -142.04 145.38 34.32 Favored 'General case' 0 CA--C 1.486 -1.504 0 CA-C-N 119.167 1.483 . . . . 0.0 107.889 177.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.599 ' CG1' HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -139.8 117.28 10.46 Favored 'Isoleucine or valine' 0 C--O 1.244 0.805 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.349 -177.964 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' I' ' 32' ' ' ILE . 0.4 OUTLIER -107.82 116.63 51.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.435 ' HA3' ' CG ' ' C' ' 35' ' ' MET . . . -119.68 100.61 0.8 Allowed Glycine 0 CA--C 1.496 -1.133 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.057 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.586 HD13 ' CZ ' ' G' ' 19' ' ' PHE . 5.3 tt -130.49 125.33 34.09 Favored 'General case' 0 C--N 1.322 -0.603 0 C-N-CA 118.824 -1.151 . . . . 0.0 110.252 -179.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.679 ' SD ' HG22 ' C' ' 31' ' ' ILE . 28.3 ttm -115.56 117.11 29.42 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 114.176 -1.375 . . . . 0.0 109.01 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.97 75.29 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.385 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.681 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.431 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -29.63 -97.29 0.01 OUTLIER Glycine 0 C--N 1.354 1.543 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.843 179.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.75 -164.54 28.5 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.407 HG23 ' O ' ' H' ' 39' ' ' VAL . 2.6 p -133.82 146.91 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 110.027 -0.361 . . . . 0.0 110.027 179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.73 -179.79 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.173 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 87.6 m-85 -105.21 129.45 53.58 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-O 120.901 0.382 . . . . 0.0 110.615 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.52 ' OE2' ' CD1' ' I' ' 10' ' ' TYR . 97.6 mt-10 -127.95 127.14 42.77 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.228 179.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 t -141.64 134.18 28.81 Favored 'Isoleucine or valine' 0 C--O 1.232 0.179 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.12 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 82.7 t60 -149.61 133.54 17.04 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.479 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' J' ' 15' ' ' GLN . 1.5 t-80 -151.64 159.2 44.13 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.633 ' N ' ' ND1' ' J' ' 14' ' ' HIS . 49.6 tt0 -160.58 169.5 22.79 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.419 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 50.7 mtpt -151.08 128.79 11.55 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 179.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 14.2 tp -126.33 114.55 18.39 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 64.6 t -119.51 126.76 75.63 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-N 115.875 -0.602 . . . . 0.0 109.981 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.648 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 1.5 t80 -120.19 119.35 32.97 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.51 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 56.4 t80 -132.84 126.36 32.08 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.611 0.243 . . . . 0.0 110.849 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.84 26.58 Favored 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 119.848 -0.741 . . . . 0.0 112.47 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -125.58 143.89 50.82 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-N 115.183 -0.917 . . . . 0.0 112.151 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -130.04 110.85 11.96 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 177.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.584 HG12 ' N ' ' J' ' 25' ' ' GLY . 14.0 t -139.39 -123.51 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.589 -178.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.584 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 27.5 -83.92 0.0 OUTLIER Glycine 0 C--N 1.342 0.879 0 CA-C-N 114.947 -1.024 . . . . 0.0 112.406 -178.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.635 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.2 p 170.48 170.42 0.07 Allowed 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 106.829 -1.545 . . . . 0.0 106.829 178.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.635 ' O ' ' O ' ' J' ' 26' ' ' SER . 76.3 m-20 -18.37 157.58 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 O-C-N 124.375 1.047 . . . . 0.0 113.064 178.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.576 ' HB3' ' HB2' ' K' ' 30' ' ' ALA . 81.0 tttt -161.79 110.9 1.52 Allowed 'General case' 0 C--N 1.326 -0.422 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.573 173.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.471 ' H ' ' CG ' ' I' ' 27' ' ' ASN . . . -67.45 92.49 0.22 Allowed Glycine 0 C--N 1.32 -0.333 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 176.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.609 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -157.06 149.17 22.84 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 107.391 -1.337 . . . . 0.0 107.391 177.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.658 HD13 ' N ' ' J' ' 31' ' ' ILE . 0.0 OUTLIER -144.81 122.56 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.102 0 C-N-CA 119.201 -1.0 . . . . 0.0 111.505 -176.946 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 4.2 mt -108.94 119.56 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-N 114.975 -1.012 . . . . 0.0 109.826 179.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.42 112.91 2.48 Favored Glycine 0 C--N 1.336 0.567 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 177.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.435 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 0.1 OUTLIER -143.72 135.0 25.85 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.126 0.965 . . . . 0.0 113.015 -177.586 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.586 ' CE ' HG22 ' D' ' 31' ' ' ILE . 98.7 mmm -112.63 111.19 21.82 Favored 'General case' 0 CA--C 1.504 -0.79 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.032 177.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.25 62.39 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.34 -111.49 0.13 Allowed Glycine 0 C--N 1.356 1.642 0 C-N-CA 120.764 -0.731 . . . . 0.0 111.771 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.35 142.83 7.04 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 11.6 p -142.08 151.82 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 m . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.402 179.806 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -113.48 132.28 55.72 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.718 0.294 . . . . 0.0 110.442 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -129.9 127.71 40.72 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 120.918 0.389 . . . . 0.0 110.936 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -129.55 132.74 66.1 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 178.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 94.5 m-70 -150.64 131.84 14.48 Favored 'General case' 0 N--CA 1.463 0.212 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.054 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' CE1' ' J' ' 14' ' ' HIS . 50.3 t-80 -152.93 165.01 36.85 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.174 0.511 . . . . 0.0 109.842 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 80.8 mt-30 -156.88 179.85 8.89 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.325 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -170.3 120.08 0.59 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.327 178.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 31.4 tp -119.98 123.99 44.85 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.549 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 65.0 t -130.03 121.44 51.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.551 179.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -118.67 120.62 37.96 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.884 -0.414 . . . . 0.0 109.884 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.51 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 48.6 t80 -129.01 121.26 27.56 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 120.998 0.428 . . . . 0.0 111.592 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.19 129.36 41.61 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.494 178.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -124.49 143.2 50.79 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 121.417 0.627 . . . . 0.0 112.323 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -131.55 123.7 28.51 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 114.957 -1.02 . . . . 0.0 108.974 178.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.64 HG12 ' N ' ' K' ' 25' ' ' GLY . 57.7 t -96.15 -112.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 C-N-CA 120.758 -0.377 . . . . 0.0 111.667 -177.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.64 ' N ' HG12 ' K' ' 24' ' ' VAL . . . -46.96 -91.04 0.01 OUTLIER Glycine 0 CA--C 1.526 0.765 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.456 -176.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.605 ' O ' ' O ' ' K' ' 27' ' ' ASN . 34.9 p -152.98 -172.63 4.31 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 117.611 0.705 . . . . 0.0 110.444 -179.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.605 ' O ' ' O ' ' K' ' 26' ' ' SER . 54.7 t30 -19.86 158.05 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.65 0 O-C-N 124.997 1.436 . . . . 0.0 113.724 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' L' ' 30' ' ' ALA . 87.1 tttt -161.6 111.08 1.57 Allowed 'General case' 0 C--O 1.213 -0.823 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.839 176.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.574 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -67.92 92.39 0.24 Allowed Glycine 0 N--CA 1.475 1.276 0 CA-C-O 119.376 -0.68 . . . . 0.0 113.553 177.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.576 ' HB2' ' HB3' ' J' ' 28' ' ' LYS . . . -156.87 152.82 27.28 Favored 'General case' 0 CA--C 1.492 -1.259 0 N-CA-C 103.523 -2.769 . . . . 0.0 103.523 174.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.496 ' HB ' ' SD ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -149.62 116.16 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.857 0 C-N-CA 116.714 -1.994 . . . . 0.0 113.407 -171.844 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.428 ' C ' ' CE ' ' E' ' 35' ' ' MET . 62.7 mt -104.55 118.3 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-N 114.485 -1.234 . . . . 0.0 108.91 177.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.413 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.06 104.19 1.32 Allowed Glycine 0 C--O 1.237 0.319 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 177.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.578 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 8.4 tt -139.54 132.7 29.71 Favored 'General case' 0 C--O 1.243 0.734 0 CA-C-O 122.835 1.302 . . . . 0.0 112.876 -177.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.505 ' SD ' ' CG ' ' L' ' 35' ' ' MET . 95.9 mmm -107.17 118.43 36.69 Favored 'General case' 0 CA--C 1.505 -0.767 0 CA-C-N 113.505 -1.68 . . . . 0.0 110.53 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.569 HG13 HD21 ' K' ' 34' ' ' LEU . 0.0 OUTLIER -124.24 74.11 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.911 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.46 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -17.43 -101.93 0.0 OUTLIER Glycine 0 C--N 1.359 1.855 0 O-C-N 123.868 0.73 . . . . 0.0 113.031 -179.249 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 154.17 -161.9 30.28 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 74.4 t -124.08 138.39 53.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-O 120.751 0.31 . . . . 0.0 110.611 -179.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.413 ' O ' HG13 ' K' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.436 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.996 -1.241 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 59.7 t80 -82.23 134.68 35.3 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 120.856 0.36 . . . . 0.0 110.48 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -56.42 143.68 33.83 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.519 179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 50.4 t -121.68 132.92 69.69 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.063 0.459 . . . . 0.0 110.222 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 21.3 p-80 -164.12 110.43 1.06 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.479 -179.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 91.6 m-70 -144.85 169.04 18.8 Favored 'General case' 0 CA--C 1.513 -0.445 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 -151.72 175.64 12.19 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.126 179.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -153.34 123.89 7.18 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.346 179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 64.4 mt -120.6 114.8 22.25 Favored 'General case' 0 N--CA 1.468 0.445 0 N-CA-C 109.686 -0.487 . . . . 0.0 109.686 179.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -128.5 130.39 69.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.966 0.412 . . . . 0.0 110.54 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.506 ' O ' ' CD1' ' L' ' 19' ' ' PHE . 55.4 p90 -138.19 127.69 24.84 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 -179.797 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 t80 -134.28 127.3 31.53 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.217 0.532 . . . . 0.0 110.746 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.61 134.48 32.13 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.771 179.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 49.0 tp10 -110.19 109.77 20.38 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.644 -179.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 42.7 t0 -99.16 133.84 42.87 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.188 0.518 . . . . 0.0 109.961 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.448 ' O ' ' N ' ' L' ' 26' ' ' SER . 90.5 t -107.02 112.97 42.22 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.109 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.394 -179.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 35.3 -91.22 0.01 OUTLIER Glycine 0 CA--C 1.528 0.88 0 CA-C-N 116.063 -0.517 . . . . 0.0 112.873 -179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.448 ' N ' ' O ' ' L' ' 24' ' ' VAL . 13.4 p -62.49 -177.83 0.16 Allowed 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 117.571 0.685 . . . . 0.0 110.342 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 14.0 m120 -79.52 176.63 9.53 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.855 -1.066 . . . . 0.0 113.697 -177.166 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 35.7 tttp -48.51 111.1 0.41 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 113.835 -1.53 . . . . 0.0 112.947 179.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.41 -97.91 0.04 OUTLIER Glycine 0 CA--C 1.501 -0.808 0 CA-C-N 114.542 -1.208 . . . . 0.0 110.606 -178.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.499 ' HA ' ' O ' ' K' ' 28' ' ' LYS . . . -60.84 170.87 1.34 Allowed 'General case' 0 CA--C 1.499 -0.99 0 CA-C-N 119.882 1.841 . . . . 0.0 106.135 -178.121 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -139.87 118.88 12.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 C-N-CA 117.799 -1.56 . . . . 0.0 110.629 -172.71 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.541 ' C ' ' SD ' ' F' ' 35' ' ' MET . 67.2 mt -108.92 123.74 65.01 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.348 0 CA-C-N 114.398 -1.274 . . . . 0.0 109.09 179.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . 0.628 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -101.66 89.26 0.76 Allowed Glycine 0 CA--C 1.501 -0.837 0 N-CA-C 105.477 -3.049 . . . . 0.0 105.477 176.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -108.57 112.89 25.48 Favored 'General case' 0 CA--C 1.502 -0.897 0 CA-C-O 120.684 0.278 . . . . 0.0 110.27 -177.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.505 ' CG ' ' SD ' ' K' ' 35' ' ' MET . 93.9 mmm -105.48 110.4 22.73 Favored 'General case' 0 CA--C 1.503 -0.846 0 C-N-CA 119.287 -0.965 . . . . 0.0 110.169 179.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.487 HG13 HG23 ' K' ' 36' ' ' VAL . 2.9 m -128.7 79.42 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.72 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.263 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.5 103.68 0.52 Allowed Glycine 0 C--N 1.346 1.098 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -178.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.6 -161.06 36.9 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.7 m -133.15 160.91 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 120.966 0.412 . . . . 0.0 110.607 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 14.1 m . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.37 179.794 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -100.4 133.7 44.44 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.495 ' N ' ' OE1' ' A' ' 11' ' ' GLU . 54.6 mp0 -95.18 164.0 13.05 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.034 0.445 . . . . 0.0 110.643 -179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 44.9 t -107.31 131.6 56.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -93.6 135.5 34.81 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.761 0.315 . . . . 0.0 110.648 -179.043 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.554 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 75.2 t60 -152.21 164.09 38.08 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 179.66 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 44.9 tt0 -169.04 168.75 9.92 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.419 179.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.429 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 66.5 mttm -153.75 123.72 6.86 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.7 mt -119.59 114.12 21.75 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.179 0.514 . . . . 0.0 110.466 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 70.5 t -120.34 115.44 47.2 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.147 179.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.961 ' CZ ' HD22 ' C' ' 34' ' ' LEU . 23.7 t80 -115.65 110.45 19.19 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 179.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.513 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 50.0 p90 -125.74 124.29 40.71 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -108.43 120.68 43.1 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.817 0.341 . . . . 0.0 110.357 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 79.5 tt0 -159.65 115.32 2.46 Favored 'General case' 0 CA--C 1.535 0.375 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 83.2 m-20 -74.89 121.85 22.5 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.96 0.409 . . . . 0.0 111.697 -178.553 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 26' ' ' SER . 13.9 t -84.48 124.6 39.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -43.06 84.3 0.01 OUTLIER Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.572 -0.74 . . . . 0.0 112.989 -178.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.52 ' N ' ' O ' ' A' ' 24' ' ' VAL . 20.7 p -91.41 -179.76 5.47 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 107.378 -1.342 . . . . 0.0 107.378 178.175 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -60.43 179.13 0.17 Allowed 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 119.656 -0.817 . . . . 0.0 110.722 -179.087 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -59.5 111.11 1.28 Allowed 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.66 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.23 93.81 0.09 OUTLIER Glycine 0 N--CA 1.464 0.501 0 C-N-CA 120.169 -1.015 . . . . 0.0 112.214 177.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.24 156.14 21.92 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 176.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.609 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.2 OUTLIER -151.86 119.67 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.807 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.0 -173.248 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.455 ' C ' ' SD ' ' G' ' 35' ' ' MET . 5.9 tp -149.59 131.58 5.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 119.985 -0.686 . . . . 0.0 111.154 179.416 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.415 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.67 128.86 5.82 Favored Glycine 0 CA--C 1.521 0.425 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -129.65 129.63 44.54 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.314 0.578 . . . . 0.0 110.606 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.517 ' SD ' ' O ' ' G' ' 32' ' ' ILE . 27.9 ttt -130.81 129.23 42.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.552 179.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 13.6 t -84.46 75.99 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.979 -179.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.412 ' CA ' HG21 ' G' ' 31' ' ' ILE . . . -90.51 103.36 3.02 Favored Glycine 0 N--CA 1.442 -0.953 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 178.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.45 179.95 52.43 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 111.18 -0.768 . . . . 0.0 111.18 -179.245 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.57 163.7 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 CA-C-O 120.949 0.404 . . . . 0.0 110.492 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 46.9 t . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.488 179.798 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -98.14 127.17 43.93 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 110.131 -0.322 . . . . 0.0 110.131 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -67.33 127.4 32.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.267 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 70.8 t -134.06 136.67 53.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.039 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.487 ' H ' ' HA ' ' C' ' 12' ' ' VAL . 61.7 t-80 -122.46 118.73 29.02 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 120.861 0.363 . . . . 0.0 110.198 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.489 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 80.8 t60 -132.8 163.83 28.18 Favored 'General case' 0 CA--C 1.511 -0.543 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.489 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 1.6 pt20 -169.93 177.6 4.3 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.981 179.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -156.28 125.96 6.33 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.438 ' N ' HD12 ' B' ' 17' ' ' LEU . 5.0 mp -122.23 121.2 36.27 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -179.162 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 7.1 p -134.18 130.79 54.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 C-N-CA 120.251 -0.58 . . . . 0.0 111.551 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.916 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 18.2 t80 -115.29 117.58 30.85 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 179.018 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 40.4 t80 -129.14 129.22 44.86 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.716 0.293 . . . . 0.0 111.423 -177.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.8 123.37 37.21 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 120.616 -0.433 . . . . 0.0 111.652 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.428 ' OE1' ' O ' ' C' ' 22' ' ' GLU . 41.0 tp10 -164.74 105.1 0.82 Allowed 'General case' 0 C--N 1.343 0.283 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 179.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.553 ' O ' ' O ' ' B' ' 24' ' ' VAL . 42.6 t0 -104.67 112.1 25.06 Favored 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.553 ' O ' ' O ' ' B' ' 23' ' ' ASP . 2.1 t -50.27 -133.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.745 178.042 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -95.35 -84.95 1.68 Allowed Glycine 0 CA--C 1.536 1.403 0 CA-C-N 115.933 -0.576 . . . . 0.0 113.276 -178.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 35.0 t 68.51 178.83 0.24 Allowed 'General case' 0 CA--C 1.519 -0.219 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -177.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 74.2 m-20 -89.88 168.27 12.18 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 118.456 -1.298 . . . . 0.0 112.513 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 45.9 pttt -40.92 110.57 0.16 Allowed 'General case' 0 CA--C 1.545 0.788 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 177.101 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.546 ' H ' ' HG3' ' C' ' 28' ' ' LYS . . . 80.0 94.54 0.37 Allowed Glycine 0 N--CA 1.476 1.329 0 N-CA-C 116.892 1.517 . . . . 0.0 116.892 171.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.25 152.91 37.08 Favored 'General case' 0 CA--C 1.506 -0.731 0 N-CA-C 103.404 -2.813 . . . . 0.0 103.404 171.611 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.609 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.0 OUTLIER -145.36 117.72 2.27 Favored 'Isoleucine or valine' 0 C--O 1.239 0.514 0 C-N-CA 118.513 -1.275 . . . . 0.0 110.721 -174.308 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 91.4 mt -127.05 131.57 70.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.029 -177.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.31 119.59 3.45 Favored Glycine 0 N--CA 1.475 1.239 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 59.3 tp -127.45 126.24 41.97 Favored 'General case' 0 N--CA 1.47 0.527 0 O-C-N 122.287 -0.537 . . . . 0.0 110.885 -179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.518 ' SD ' ' O ' ' H' ' 32' ' ' ILE . 11.9 ttt -139.6 137.75 35.59 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.348 0.594 . . . . 0.0 111.481 179.525 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 24.4 t -122.51 73.88 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.845 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.657 ' CA ' HG21 ' H' ' 31' ' ' ILE . . . -62.85 111.95 4.52 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 178.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -26.66 148.53 0.01 OUTLIER Glycine 0 N--CA 1.469 0.871 0 CA-C-O 121.107 0.282 . . . . 0.0 112.676 -178.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 68.1 t -115.29 135.58 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.904 0.383 . . . . 0.0 110.513 -179.586 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 m . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.381 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -114.22 138.59 50.27 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.781 0.324 . . . . 0.0 110.592 179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.448 ' OE2' ' O ' ' D' ' 10' ' ' TYR . 80.0 mm-40 -110.75 131.28 55.18 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.146 0.498 . . . . 0.0 110.538 179.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.487 ' HA ' ' H ' ' B' ' 13' ' ' HIS . 28.3 m -136.11 164.17 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.473 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.699 ' CG ' ' H ' ' C' ' 14' ' ' HIS . 76.0 t60 -103.15 -173.48 2.32 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 110.165 -0.309 . . . . 0.0 110.165 179.347 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.699 ' H ' ' CG ' ' C' ' 13' ' ' HIS . 2.3 m170 -77.2 174.13 11.08 Favored 'General case' 0 N--CA 1.446 -0.656 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -138.89 174.83 10.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.414 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -151.51 133.37 14.98 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-O 120.937 0.398 . . . . 0.0 111.731 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.63 HD23 ' C ' ' C' ' 17' ' ' LEU . 6.6 tt -127.62 123.2 35.06 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 116.02 -0.536 . . . . 0.0 109.578 178.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . 0.607 ' N ' HD23 ' C' ' 17' ' ' LEU . 57.5 t -128.04 129.52 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 CA-C-O 120.912 0.387 . . . . 0.0 111.648 -179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.737 ' CE1' HD13 ' E' ' 34' ' ' LEU . 2.5 t80 -121.7 115.21 22.3 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.2 t80 -127.45 125.79 41.18 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 120.92 0.39 . . . . 0.0 111.083 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.2 129.52 46.58 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.87 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OE1' ' B' ' 22' ' ' GLU . 80.5 tt0 -155.97 158.39 37.82 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 116.01 -0.541 . . . . 0.0 109.938 179.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 t0 -142.8 120.65 11.97 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.57 0.224 . . . . 0.0 110.624 179.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -129.88 -112.19 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.993 0 CA-C-O 121.308 0.575 . . . . 0.0 110.13 -179.235 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 35.07 -90.68 0.01 OUTLIER Glycine 0 CA--C 1.531 1.054 0 CA-C-N 115.337 -0.847 . . . . 0.0 114.084 -178.159 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.546 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.0 OUTLIER 175.28 -167.21 0.04 OUTLIER 'General case' 0 N--CA 1.445 -0.704 0 CA-C-N 118.396 1.098 . . . . 0.0 110.793 -178.582 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' C' ' 26' ' ' SER . 51.4 p-10 -36.47 -179.62 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 114.164 -1.38 . . . . 0.0 113.641 -179.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.546 ' HG3' ' H ' ' B' ' 29' ' ' GLY . 74.8 tttt 98.55 113.88 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.958 1.703 . . . . 0.0 113.182 179.047 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.88 93.64 0.49 Allowed Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.963 -1.655 . . . . 0.0 108.963 172.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.2 163.07 12.88 Favored 'General case' 0 CA--C 1.498 -1.047 0 CA-C-N 120.74 2.27 . . . . 0.0 106.461 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.579 HD12 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -149.72 117.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.859 0 C-N-CA 118.337 -1.345 . . . . 0.0 110.417 -174.113 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.485 ' C ' ' SD ' ' I' ' 35' ' ' MET . 13.5 tt -129.13 132.84 66.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 CA-C-O 121.736 0.779 . . . . 0.0 110.747 178.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.697 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -119.71 119.34 4.22 Favored Glycine 0 N--CA 1.465 0.612 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -178.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.961 HD22 ' CZ ' ' A' ' 19' ' ' PHE . 32.6 tp -118.67 121.86 41.14 Favored 'General case' 0 CA--C 1.512 -0.516 0 C-N-CA 120.986 -0.285 . . . . 0.0 111.743 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.522 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 7.9 ttm -122.05 108.98 14.0 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 173.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 m -128.75 72.37 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.638 0 C-N-CA 120.543 -0.463 . . . . 0.0 109.825 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.0 110.81 3.11 Favored Glycine 0 C--N 1.362 1.993 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.13 160.07 53.93 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -139.06 161.43 28.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-O 120.871 0.367 . . . . 0.0 111.051 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.414 ' O ' HG22 ' C' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.398 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . 0.448 ' O ' ' OE2' ' C' ' 11' ' ' GLU . 95.7 m-85 -106.83 129.66 54.64 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.499 ' OE2' ' NE2' ' D' ' 13' ' ' HIS . 9.9 pt-20 -155.06 159.23 40.12 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 70.0 t -114.52 131.7 65.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.026 0.441 . . . . 0.0 110.935 -179.051 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.499 ' NE2' ' OE2' ' D' ' 11' ' ' GLU . 32.5 m-70 -138.39 97.83 3.46 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.167 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 m170 -119.98 161.93 20.07 Favored 'General case' 0 CA--C 1.516 -0.336 0 CA-C-O 121.41 0.624 . . . . 0.0 109.583 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.429 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 43.9 tt0 -154.32 170.33 21.56 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.804 179.529 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.429 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 98.3 mttt -152.95 129.33 10.6 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -123.23 124.24 42.57 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.715 0.293 . . . . 0.0 110.643 -179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 80.9 t -123.63 126.77 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 121.085 0.469 . . . . 0.0 110.508 179.506 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.854 ' CZ ' HD22 ' F' ' 34' ' ' LEU . 7.7 t80 -124.69 110.55 14.51 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -123.13 129.85 51.99 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.522 0.677 . . . . 0.0 111.778 -178.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.93 122.19 26.5 Favored 'General case' 0 C--O 1.237 0.442 0 CA-C-N 115.34 -0.845 . . . . 0.0 109.497 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 79.6 mm-40 -115.86 120.33 38.87 Favored 'General case' 0 CA--C 1.518 -0.276 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -151.51 112.0 4.17 Favored 'General case' 0 C--O 1.232 0.184 0 N-CA-C 113.72 1.007 . . . . 0.0 113.72 -179.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.695 ' O ' ' N ' ' D' ' 26' ' ' SER . 52.1 t -111.96 131.07 64.38 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.884 0 N-CA-C 102.572 -3.121 . . . . 0.0 102.572 174.125 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.624 ' H ' ' HZ1' ' F' ' 28' ' ' LYS . . . -37.59 81.67 0.0 OUTLIER Glycine 0 CA--C 1.534 1.256 0 C-N-CA 120.172 -1.014 . . . . 0.0 112.569 -176.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.695 ' N ' ' O ' ' D' ' 24' ' ' VAL . 26.8 m -88.48 -179.58 6.1 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-O 122.566 1.174 . . . . 0.0 111.612 178.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 48.6 t30 -76.61 -177.13 4.07 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 112.383 -2.19 . . . . 0.0 110.921 175.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 35.1 tttt 44.96 111.62 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 117.959 2.577 . . . . 0.0 117.959 177.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.483 ' HA2' ' HB2' ' E' ' 30' ' ' ALA . . . -82.64 94.66 1.74 Allowed Glycine 0 CA--C 1.499 -0.957 0 N-CA-C 108.014 -2.034 . . . . 0.0 108.014 173.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -91.24 167.36 12.38 Favored 'General case' 0 CA--C 1.494 -1.196 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.721 HG23 HG13 ' E' ' 31' ' ' ILE . 0.2 OUTLIER -146.42 118.29 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.859 0 C-N-CA 118.555 -1.258 . . . . 0.0 109.623 -174.976 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.422 HD12 ' CG2' ' C' ' 32' ' ' ILE . 14.4 tt -130.13 130.88 66.05 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.175 0 CA-C-O 121.828 0.823 . . . . 0.0 111.942 179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.8 104.27 2.35 Favored Glycine 0 CA--C 1.509 -0.338 0 N-CA-C 107.851 -2.1 . . . . 0.0 107.851 177.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.916 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 16.6 tp -111.33 117.85 34.26 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-N 117.376 0.588 . . . . 0.0 111.945 -178.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.55 ' SD ' HG22 ' J' ' 31' ' ' ILE . 17.7 tpp -121.08 108.01 13.31 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 176.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.6 HG22 HD11 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -121.04 76.51 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.951 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 179.778 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.04 103.31 2.85 Favored Glycine 0 C--N 1.352 1.431 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.16 174.33 41.96 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.648 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -135.4 160.62 40.09 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 CA-C-O 121.047 0.451 . . . . 0.0 110.755 -179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 118.177 -0.916 . . . . 0.0 110.366 179.578 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -120.26 143.78 48.12 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.815 0.34 . . . . 0.0 110.332 179.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.523 ' OE1' ' CE1' ' F' ' 10' ' ' TYR . 82.5 tt0 -73.23 135.15 44.5 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.84 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 8.4 t -146.74 135.62 16.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.108 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 82.2 m-70 -132.54 131.7 41.83 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.638 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 24.2 t60 -152.08 163.6 38.99 Favored 'General case' 0 N--CA 1.449 -0.495 0 CA-C-O 121.922 0.868 . . . . 0.0 110.446 -179.615 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.638 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 53.5 tt0 -159.55 167.11 29.35 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.595 -1.184 . . . . 0.0 109.496 178.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.401 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 99.2 mttt -151.44 130.11 12.32 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 179.432 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.5 HD12 ' CD2' ' F' ' 17' ' ' LEU . 12.5 mt -115.52 116.18 27.74 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 179.425 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -120.52 115.34 46.78 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.099 -179.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -117.03 124.43 49.29 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 116.78 -0.191 . . . . 0.0 110.756 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 56.1 t80 -129.94 119.09 22.68 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.65 121.13 22.7 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.231 0.539 . . . . 0.0 111.425 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.413 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 35.0 tt0 -88.52 165.63 14.73 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.7 179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.563 ' O ' ' O ' ' E' ' 24' ' ' VAL . 46.0 t0 -145.4 -122.27 0.08 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.002 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.563 ' O ' ' O ' ' E' ' 23' ' ' ASP . 2.9 t 22.22 121.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 114.144 1.164 . . . . 0.0 114.144 -178.707 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.08 -85.0 0.09 OUTLIER Glycine 0 CA--C 1.523 0.587 0 N-CA-C 109.113 -1.595 . . . . 0.0 109.113 177.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.509 ' H ' ' CE ' ' F' ' 28' ' ' LYS . 1.7 p 162.39 160.8 0.02 OUTLIER 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 177.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.455 ' O ' ' O ' ' E' ' 26' ' ' SER . 69.6 m-80 -29.78 159.42 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.691 -1.14 . . . . 0.0 112.694 178.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.476 ' HD2' ' H ' ' D' ' 26' ' ' SER . 76.1 tttt -179.73 105.84 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.908 174.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.465 ' O ' ' CA ' ' D' ' 29' ' ' GLY . . . -58.65 93.54 0.05 OUTLIER Glycine 0 C--O 1.211 -1.323 0 CA-C-O 118.16 -1.356 . . . . 0.0 111.708 173.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.483 ' HB2' ' HA2' ' D' ' 29' ' ' GLY . . . -155.9 149.37 24.82 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 103.1 -2.926 . . . . 0.0 103.1 173.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.721 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -145.05 124.3 6.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 C-N-CA 117.984 -1.486 . . . . 0.0 112.133 -168.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.461 HG12 HD21 ' E' ' 34' ' ' LEU . 0.7 OUTLIER -120.91 111.29 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 CA-C-N 114.529 -1.214 . . . . 0.0 107.761 179.541 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.57 110.24 3.62 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 108.626 -1.79 . . . . 0.0 108.626 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.737 HD13 ' CE1' ' C' ' 19' ' ' PHE . 2.9 mt -117.97 112.76 20.72 Favored 'General case' 0 C--O 1.236 0.385 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -176.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.481 ' SD ' ' C ' ' K' ' 32' ' ' ILE . 6.2 ttm -115.29 107.91 15.87 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 175.419 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.16 80.97 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.539 0 N-CA-C 108.879 -0.785 . . . . 0.0 108.879 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.23 102.64 0.5 Allowed Glycine 0 C--N 1.346 1.116 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -86.67 -160.22 34.35 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 27.6 m -126.31 160.47 33.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.792 0.33 . . . . 0.0 110.185 -179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.5 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.689 -179.993 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.43 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . 0.523 ' CE1' ' OE1' ' E' ' 11' ' ' GLU . 41.8 t80 -78.89 125.42 29.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.844 0.354 . . . . 0.0 110.073 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' E' ' 11' ' ' GLU . 78.6 mm-40 -118.54 132.48 56.21 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.158 0.504 . . . . 0.0 110.988 -179.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.408 ' CG2' ' N ' ' F' ' 13' ' ' HIS . 1.5 p -147.82 160.23 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.434 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.536 ' ND1' ' ND1' ' E' ' 14' ' ' HIS . 15.2 t-80 -125.02 155.27 39.98 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 120.912 0.387 . . . . 0.0 110.595 179.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.558 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 89.9 m-70 -80.42 178.28 8.42 Favored 'General case' 0 N--CA 1.446 -0.65 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 17.9 pt20 -125.93 -179.88 4.89 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.364 -179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -133.62 137.58 45.5 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-O 121.161 0.505 . . . . 0.0 110.993 -179.599 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.5 ' CD2' HD12 ' E' ' 17' ' ' LEU . 33.1 mt -122.03 115.17 22.02 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.276 -179.628 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 28.5 m -134.04 127.64 51.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 121.341 0.591 . . . . 0.0 110.092 178.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.495 ' O ' ' CD1' ' F' ' 19' ' ' PHE . 50.0 p90 -138.69 131.52 29.39 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.575 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -129.79 122.27 28.45 Favored 'General case' 0 C--N 1.331 -0.231 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.252 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.6 146.24 25.7 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 120.43 -0.508 . . . . 0.0 110.422 -179.214 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -115.78 125.9 53.33 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 111.217 179.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -168.12 113.45 0.66 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.978 178.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.498 ' O ' ' N ' ' F' ' 26' ' ' SER . 95.6 t -81.1 132.44 31.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.978 178.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.16 -85.58 0.01 OUTLIER Glycine 0 CA--C 1.523 0.558 0 C-N-CA 119.338 -1.41 . . . . 0.0 111.702 178.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' F' ' 27' ' ' ASN . 62.3 m -140.38 171.4 14.2 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 107.124 -1.436 . . . . 0.0 107.124 -178.332 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' F' ' 26' ' ' SER . 25.0 m120 -29.66 169.98 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 122.79 1.281 . . . . 0.0 114.23 -174.444 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.624 ' HZ1' ' H ' ' D' ' 25' ' ' GLY . 30.6 tttt -98.54 -111.17 0.17 Allowed 'General case' 0 CA--C 1.544 0.723 0 CA-C-N 113.881 -1.509 . . . . 0.0 112.476 179.109 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.516 ' H ' ' CG ' ' F' ' 28' ' ' LYS . . . -90.6 -99.85 1.18 Allowed Glycine 0 CA--C 1.484 -1.883 0 C-N-CA 127.568 2.509 . . . . 0.0 111.76 -179.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.66 166.46 3.24 Favored 'General case' 0 CA--C 1.494 -1.182 0 N-CA-C 105.838 -1.912 . . . . 0.0 105.838 -177.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -132.61 135.71 57.12 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 C-N-CA 118.532 -1.267 . . . . 0.0 111.34 -171.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 61.4 mt -114.87 117.24 55.02 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 CA-C-N 115.198 -0.91 . . . . 0.0 112.646 -177.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -98.69 92.58 1.23 Allowed Glycine 0 CA--C 1.51 -0.244 0 N-CA-C 104.51 -3.436 . . . . 0.0 104.51 173.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.854 HD22 ' CZ ' ' D' ' 19' ' ' PHE . 8.4 tp -110.3 116.77 32.07 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 113.036 0.754 . . . . 0.0 113.036 -175.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.466 ' HG3' ' CA ' ' L' ' 33' ' ' GLY . 96.4 mmm -119.58 111.98 18.75 Favored 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 176.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.491 HG13 HD11 ' F' ' 34' ' ' LEU . 0.1 OUTLIER -127.36 80.22 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 178.075 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 34.47 -103.27 0.01 OUTLIER Glycine 0 C--N 1.35 1.33 0 CA-C-N 116.436 -0.347 . . . . 0.0 112.308 179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.97 -150.17 10.95 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 111.096 -0.802 . . . . 0.0 111.096 -179.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.8 t -120.02 135.77 59.24 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.997 0.427 . . . . 0.0 110.803 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.13 -0.938 . . . . 0.0 110.281 179.559 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . 0.409 ' O ' ' OE2' ' H' ' 11' ' ' GLU . 99.1 m-85 -99.19 133.77 43.01 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.79 0.329 . . . . 0.0 110.136 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -139.67 145.6 38.62 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.301 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 62.2 t -125.34 132.63 70.84 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.225 -179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -88.31 172.11 9.67 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.919 -179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.537 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 3.6 m170 -89.05 170.52 10.58 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.626 -179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.431 ' HG2' ' N ' ' G' ' 16' ' ' LYS . 54.8 tt0 -147.57 171.81 14.99 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.094 -0.503 . . . . 0.0 109.859 179.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.431 ' N ' ' HG2' ' G' ' 15' ' ' GLN . 98.9 mttt -150.8 125.0 9.38 Favored 'General case' 0 N--CA 1.469 0.483 0 C-N-CA 121.227 -0.189 . . . . 0.0 111.101 -179.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 77.9 mt -118.28 122.42 42.87 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 178.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 p -138.66 132.42 40.68 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.149 0 CA-C-O 121.774 0.797 . . . . 0.0 113.101 -178.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.637 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 6.9 m-85 -113.14 111.72 22.59 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 105.989 -1.856 . . . . 0.0 105.989 175.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -130.62 121.06 24.92 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 -178.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 131.03 41.07 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-O 121.373 0.606 . . . . 0.0 112.038 -178.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.473 ' O ' ' O ' ' G' ' 23' ' ' ASP . 83.8 tt0 -156.05 152.95 28.68 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 107.138 -1.43 . . . . 0.0 107.138 177.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.475 ' O ' ' C ' ' G' ' 24' ' ' VAL . 22.2 t70 -59.48 -120.41 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.534 -178.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.475 ' C ' ' O ' ' G' ' 23' ' ' ASP . 22.7 m -27.2 121.12 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.946 0 C-N-CA 122.179 0.192 . . . . 0.0 111.001 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 164.15 -85.6 0.1 Allowed Glycine 0 CA--C 1.526 0.775 0 C-N-CA 119.333 -1.413 . . . . 0.0 113.225 -177.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.697 ' O ' ' O ' ' G' ' 27' ' ' ASN . 62.5 m -152.73 -170.81 3.74 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -175.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.697 ' O ' ' O ' ' G' ' 26' ' ' SER . 12.7 t-20 -19.34 159.59 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.103 0 O-C-N 124.629 1.206 . . . . 0.0 114.016 -176.35 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -159.82 110.64 1.94 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.236 -176.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 1.058 ' O ' ' HB1' ' H' ' 30' ' ' ALA . . . -69.51 96.09 0.48 Allowed Glycine 0 CA--C 1.455 -3.683 0 CA-C-O 123.686 1.715 . . . . 0.0 110.511 -179.035 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.522 ' O ' ' C ' ' G' ' 29' ' ' GLY . . . -81.6 -139.99 0.04 OUTLIER 'General case' 0 N--CA 1.395 -3.215 1 N-CA-C 94.424 -6.139 . . . . 0.0 94.424 171.171 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.693 ' CD1' ' N ' ' G' ' 31' ' ' ILE . 1.0 OUTLIER -85.18 111.31 20.5 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.298 0 CA-C-N 125.186 3.63 . . . . 0.0 109.443 179.928 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.517 ' O ' ' SD ' ' A' ' 35' ' ' MET . 39.1 mm -136.73 129.34 44.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 120.304 -0.558 . . . . 0.0 112.035 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.516 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -131.34 130.76 6.13 Favored Glycine 0 CA--C 1.531 1.074 0 N-CA-C 110.549 -1.02 . . . . 0.0 110.549 178.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 34.2 tp -156.19 135.33 12.09 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.801 0.81 . . . . 0.0 112.99 -179.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.455 ' SD ' ' C ' ' A' ' 32' ' ' ILE . 63.7 ttp -121.93 143.94 49.16 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.363 178.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 25.5 t -120.03 75.86 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 111.937 0.347 . . . . 0.0 111.937 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.482 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -96.5 101.12 2.58 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.6 167.33 22.13 Favored Glycine 0 N--CA 1.467 0.741 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 81.8 t -131.3 138.27 53.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.752 0.31 . . . . 0.0 110.301 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.9 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.347 179.472 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -118.61 140.48 49.84 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' O ' ' G' ' 10' ' ' TYR . 80.9 mm-40 -132.36 135.9 46.47 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 121.711 0.767 . . . . 0.0 111.978 -178.926 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 58.0 t -128.47 134.33 64.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.094 -0.957 . . . . 0.0 108.654 179.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 24.1 m-70 -137.86 101.11 4.36 Favored 'General case' 0 N--CA 1.469 0.489 0 C-N-CA 120.95 -0.3 . . . . 0.0 110.754 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' ND1' ' I' ' 14' ' ' HIS . 11.1 m170 -115.5 154.67 28.91 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 80.5 mt-30 -155.91 174.31 15.51 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.468 178.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 mttm -156.96 112.17 2.83 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.712 178.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.507 ' N ' HD12 ' H' ' 17' ' ' LEU . 6.5 mp -111.42 111.4 22.41 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.326 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.69 125.32 52.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-O 121.86 0.838 . . . . 0.0 111.732 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.604 ' CG ' ' CE2' ' I' ' 19' ' ' PHE . 6.0 m-85 -113.17 116.81 30.41 Favored 'General case' 0 CA--C 1.538 0.515 0 CA-C-N 114.182 -1.372 . . . . 0.0 108.666 178.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -128.67 126.56 40.38 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.13 130.24 35.14 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-O 121.19 0.519 . . . . 0.0 111.394 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' H' ' 23' ' ' ASP . 84.9 tt0 -149.96 91.12 1.75 Allowed 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 178.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.443 ' O ' ' O ' ' H' ' 22' ' ' GLU . 1.1 m-20 62.74 115.75 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 -176.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.598 ' C ' ' HZ3' ' I' ' 28' ' ' LYS . 48.9 t -118.84 123.75 72.03 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 CA-C-N 115.737 -0.665 . . . . 0.0 112.471 -174.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.505 ' C ' ' HZ3' ' I' ' 28' ' ' LYS . . . 35.91 83.69 0.01 OUTLIER Glycine 0 N--CA 1.47 0.905 0 C-N-CA 121.482 -0.39 . . . . 0.0 113.255 177.128 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.627 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 5.4 t -58.9 170.92 0.74 Allowed 'General case' 0 N--CA 1.443 -0.806 0 CA-C-O 121.18 0.514 . . . . 0.0 110.389 -178.658 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.527 ' ND2' ' O ' ' H' ' 26' ' ' SER . 68.7 m-20 103.26 177.43 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 113.259 -1.791 . . . . 0.0 107.298 -177.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.512 ' O ' ' O ' ' H' ' 27' ' ' ASN . 98.7 mttt -23.69 -102.87 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.029 0 O-C-N 123.567 0.542 . . . . 0.0 111.981 179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -141.25 100.46 0.26 Allowed Glycine 0 N--CA 1.472 1.059 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 177.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 1.058 ' HB1' ' O ' ' G' ' 29' ' ' GLY . . . -66.59 158.48 29.72 Favored 'General case' 0 C--O 1.248 1.013 0 C-N-CA 118.877 -1.129 . . . . 0.0 110.016 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.657 HG21 ' CA ' ' B' ' 37' ' ' GLY . 0.1 OUTLIER -154.55 132.15 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.544 -175.796 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' B' ' 35' ' ' MET . 41.5 pt -130.42 127.07 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 CA-C-O 121.499 0.666 . . . . 0.0 112.226 178.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.53 97.89 0.66 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 178.094 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.507 ' O ' HD12 ' I' ' 34' ' ' LEU . 4.4 mp -129.44 149.8 51.07 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-O 121.924 0.868 . . . . 0.0 111.974 -178.31 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.406 ' CE ' ' SD ' ' G' ' 35' ' ' MET . 20.7 ttp -141.03 134.69 30.17 Favored 'General case' 0 C--O 1.236 0.349 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.482 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 4.1 t -126.42 79.01 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.476 ' HA3' HD13 ' B' ' 31' ' ' ILE . . . -61.53 105.07 0.8 Allowed Glycine 0 N--CA 1.444 -0.789 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 177.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -53.94 173.05 0.64 Allowed Glycine 0 CA--C 1.523 0.553 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -132.99 161.88 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 CA-C-O 120.965 0.412 . . . . 0.0 110.66 -179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.9 m . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.831 179.951 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -110.2 151.74 26.93 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-O 120.692 0.282 . . . . 0.0 110.337 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.478 ' O ' ' O ' ' J' ' 11' ' ' GLU . 83.1 tt0 -50.0 134.95 21.05 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.27 151.01 13.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.97 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -135.75 132.31 36.65 Favored 'General case' 0 N--CA 1.468 0.472 0 C-N-CA 120.858 -0.337 . . . . 0.0 110.505 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.625 ' NE2' ' CG ' ' J' ' 13' ' ' HIS . 75.7 m80 -122.91 159.69 27.71 Favored 'General case' 0 CA--C 1.518 -0.253 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 178.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -157.51 177.52 11.32 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.629 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -170.05 114.16 0.49 Allowed 'General case' 0 C--N 1.325 -0.489 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 tt -117.67 118.49 32.24 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.071 -179.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -141.72 136.76 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.659 0 C-N-CA 119.967 -0.693 . . . . 0.0 111.896 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.604 ' CE2' ' CG ' ' H' ' 19' ' ' PHE . 26.8 m-85 -123.92 128.5 49.52 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 115.393 -0.822 . . . . 0.0 110.224 179.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.587 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 21.2 t80 -133.26 124.86 28.12 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.09 133.21 44.07 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 113.488 0.921 . . . . 0.0 113.488 -178.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -143.35 167.75 21.42 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' I' ' 24' ' ' VAL . 3.6 m-20 -142.32 -102.14 0.13 Allowed 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -177.228 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.519 ' O ' ' O ' ' I' ' 23' ' ' ASP . 10.9 t 46.98 159.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.672 0 CA-C-O 122.263 1.03 . . . . 0.0 112.655 -176.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.497 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 107.88 -76.35 0.22 Allowed Glycine 0 CA--C 1.541 1.712 0 CA-C-N 114.139 -1.391 . . . . 0.0 112.529 -175.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.9 ' O ' ' O ' ' I' ' 27' ' ' ASN . 0.4 OUTLIER 170.89 -169.48 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.403 0 CA-C-N 119.502 1.651 . . . . 0.0 109.354 -176.43 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.9 ' O ' ' O ' ' I' ' 26' ' ' SER . 62.1 t30 -17.01 -179.74 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.06 0 O-C-N 125.287 1.617 . . . . 0.0 113.537 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.659 ' CG ' ' O ' ' I' ' 27' ' ' ASN . 26.8 mmtt 139.89 -110.52 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 112.308 0.484 . . . . 0.0 112.308 -175.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.42 ' CA ' ' O ' ' J' ' 29' ' ' GLY . . . 49.27 91.28 0.01 OUTLIER Glycine 0 CA--C 1.482 -2.022 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 -171.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.447 ' C ' ' CG1' ' I' ' 31' ' ' ILE . . . -103.06 170.75 7.78 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 111.509 -2.346 . . . . 0.0 106.63 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.481 HD12 ' CG2' ' H' ' 31' ' ' ILE . 0.3 OUTLIER -145.78 110.03 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.144 0 C-N-CA 118.299 -1.361 . . . . 0.0 109.423 -175.899 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.517 HG12 HD11 ' H' ' 32' ' ' ILE . 58.7 mt -103.6 115.72 46.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 CA-C-N 115.226 -0.897 . . . . 0.0 111.516 -178.654 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.522 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.61 92.65 0.54 Allowed Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 107.509 -2.237 . . . . 0.0 107.509 176.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.61 HD23 ' HZ ' ' G' ' 19' ' ' PHE . 22.6 tp -129.22 122.4 29.63 Favored 'General case' 0 C--O 1.244 0.785 0 CA-C-O 123.276 1.512 . . . . 0.0 110.798 179.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.697 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 24.7 ttp -106.61 120.42 41.91 Favored 'General case' 0 N--CA 1.44 -0.973 0 CA-C-N 112.596 -2.093 . . . . 0.0 108.548 179.65 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 m -135.49 72.23 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.805 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.392 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -104.13 101.62 2.01 Favored Glycine 0 C--N 1.36 1.914 0 N-CA-C 109.556 -1.417 . . . . 0.0 109.556 178.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.35 178.91 24.56 Favored Glycine 0 N--CA 1.463 0.485 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 -179.029 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 8.4 p -141.43 152.34 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-O 120.878 0.371 . . . . 0.0 110.31 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.92 -1.038 . . . . 0.0 110.5 179.856 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.452 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . 0.471 ' CD1' ' OE1' ' I' ' 11' ' ' GLU . 66.8 m-85 -120.45 147.2 45.41 Favored 'General case' 0 N--CA 1.468 0.471 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.478 ' O ' ' O ' ' I' ' 11' ' ' GLU . 95.6 mt-10 -122.95 161.65 23.78 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.185 0.517 . . . . 0.0 110.441 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 10.0 p -143.77 151.59 16.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.591 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.625 ' CG ' ' NE2' ' I' ' 14' ' ' HIS . 25.2 t-80 -92.45 -173.92 3.53 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.853 0.359 . . . . 0.0 110.219 179.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.621 ' H ' ' CG ' ' J' ' 13' ' ' HIS . 0.5 OUTLIER -86.01 175.19 8.72 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -179.336 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.408 ' HG2' ' N ' ' J' ' 16' ' ' LYS . 48.3 tt0 -126.16 166.26 17.38 Favored 'General case' 0 N--CA 1.472 0.657 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.408 ' N ' ' HG2' ' J' ' 15' ' ' GLN . 99.5 mttt -148.57 122.89 9.63 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 120.756 0.312 . . . . 0.0 111.591 -179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 3.4 mp -123.9 121.14 34.54 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 94.5 t -129.72 128.66 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-O 121.149 0.499 . . . . 0.0 112.086 -178.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.453 ' CZ ' HD13 ' L' ' 34' ' ' LEU . 46.5 m-85 -115.53 119.83 37.48 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 178.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.587 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 29.0 t80 -130.99 120.35 23.37 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 118.616 0.644 . . . . 0.0 109.727 179.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.34 134.44 34.24 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -110.45 122.96 48.98 Favored 'General case' 0 C--N 1.346 0.43 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.311 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.549 ' HB3' ' H ' ' K' ' 24' ' ' VAL . 8.8 t70 -84.28 122.66 29.2 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 121.017 0.437 . . . . 0.0 110.911 -178.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' J' ' 26' ' ' SER . 72.1 t -99.66 122.52 51.58 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.748 -179.06 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 39.17 -86.06 0.01 OUTLIER Glycine 0 C--N 1.337 0.619 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.301 177.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.653 ' O ' ' O ' ' J' ' 27' ' ' ASN . 87.9 p -161.25 174.17 13.98 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 108.809 -0.811 . . . . 0.0 108.809 -178.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.653 ' O ' ' O ' ' J' ' 26' ' ' SER . 74.9 m-20 -9.39 159.4 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 116.369 1.989 . . . . 0.0 116.369 -175.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 88.4 tttt 179.86 104.83 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 112.566 -2.106 . . . . 0.0 106.618 175.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.42 ' O ' ' CA ' ' I' ' 29' ' ' GLY . . . -60.51 95.03 0.08 OUTLIER Glycine 0 C--O 1.22 -0.722 0 CA-C-O 118.724 -1.042 . . . . 0.0 113.924 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.401 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -127.37 149.01 50.25 Favored 'General case' 0 CA--C 1.489 -1.382 0 N-CA-C 102.215 -3.254 . . . . 0.0 102.215 172.414 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.55 HG22 ' SD ' ' D' ' 35' ' ' MET . 0.2 OUTLIER -148.48 118.64 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.919 0 C-N-CA 118.011 -1.476 . . . . 0.0 111.222 -172.296 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.649 ' CG2' HD21 ' K' ' 34' ' ' LEU . 2.0 mt -108.12 112.48 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.384 179.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.07 101.94 1.32 Allowed Glycine 0 C--O 1.239 0.455 0 N-CA-C 106.579 -2.608 . . . . 0.0 106.579 176.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.637 HD11 ' CZ ' ' G' ' 19' ' ' PHE . 0.2 OUTLIER -142.16 135.17 28.73 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 122.205 1.002 . . . . 0.0 112.391 -176.634 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 49.0 ttp -123.3 127.61 48.79 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 114.159 -1.382 . . . . 0.0 110.979 179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.86 69.08 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.306 0 CA-C-N 114.681 -1.145 . . . . 0.0 108.725 178.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.2 -100.83 0.01 OUTLIER Glycine 0 C--N 1.36 1.89 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.07 150.91 20.43 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.375 -0.69 . . . . 0.0 111.375 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 75.6 t -134.52 137.31 51.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 p . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.401 179.752 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -109.51 142.54 40.4 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.872 0.368 . . . . 0.0 110.58 -179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -130.59 144.13 51.21 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.671 -179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 97.8 t -127.05 133.79 67.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.803 -179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 61.7 m80 -134.4 124.27 25.43 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.019 179.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.578 ' CD2' ' N ' ' K' ' 15' ' ' GLN . 33.0 t60 -156.48 166.87 32.17 Favored 'General case' 0 N--CA 1.445 -0.679 0 CA-C-O 121.409 0.623 . . . . 0.0 109.921 179.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.578 ' N ' ' CD2' ' K' ' 14' ' ' HIS . 79.6 mt-30 -153.91 173.49 15.88 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.359 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 79.1 tttt -153.78 113.3 3.8 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 120.734 -0.387 . . . . 0.0 110.125 178.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 tt -116.01 121.74 43.15 Favored 'General case' 0 N--CA 1.466 0.35 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -126.61 129.37 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 t80 -125.05 123.82 40.62 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -134.39 122.54 22.71 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 120.676 0.274 . . . . 0.0 111.266 -179.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.49 131.42 31.81 Favored 'General case' 0 N--CA 1.477 0.886 0 CA-C-O 121.246 0.546 . . . . 0.0 111.85 179.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -110.27 128.17 55.39 Favored 'General case' 0 N--CA 1.479 0.999 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.748 179.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.462 ' H ' ' HB2' ' L' ' 22' ' ' GLU . 89.0 m-20 -100.48 115.65 30.57 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 112.482 0.549 . . . . 0.0 112.482 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.552 ' O ' ' N ' ' K' ' 26' ' ' SER . 53.3 t -95.37 130.29 44.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 47.03 -85.31 0.01 OUTLIER Glycine 0 CA--C 1.529 0.917 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.552 ' N ' ' O ' ' K' ' 24' ' ' VAL . 29.4 p -141.16 170.76 15.12 Favored 'General case' 0 CA--C 1.516 -0.361 0 CA-C-O 121.945 0.878 . . . . 0.0 111.516 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.515 ' O ' ' O ' ' K' ' 26' ' ' SER . 2.3 p30 -28.83 169.72 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.184 -1.825 . . . . 0.0 114.294 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.541 ' O ' ' HB2' ' L' ' 30' ' ' ALA . 88.6 tttt -149.85 111.38 4.48 Favored 'General case' 0 CA--C 1.546 0.792 0 CA-C-N 115.493 -0.776 . . . . 0.0 112.101 175.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.11 91.91 0.05 OUTLIER Glycine 0 N--CA 1.476 1.337 0 CA-C-O 119.603 -0.554 . . . . 0.0 113.643 176.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.12 153.97 51.02 Favored 'General case' 0 CA--C 1.493 -1.242 0 N-CA-C 102.961 -2.977 . . . . 0.0 102.961 172.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.504 HG23 ' CG1' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -142.09 111.68 2.67 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.69 0 C-N-CA 118.221 -1.392 . . . . 0.0 111.713 -172.965 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.49 HG22 ' O ' ' K' ' 32' ' ' ILE . 0.1 OUTLIER -106.83 111.12 34.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 178.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.79 97.64 1.05 Allowed Glycine 0 CA--C 1.505 -0.577 0 N-CA-C 106.431 -2.668 . . . . 0.0 106.431 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.649 HD21 ' CG2' ' J' ' 32' ' ' ILE . 94.2 mt -130.24 142.3 50.57 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 122.024 0.916 . . . . 0.0 113.196 -176.451 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 40.7 ttp -129.67 117.91 21.08 Favored 'General case' 0 CA--C 1.501 -0.939 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.266 176.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' K' ' 37' ' ' GLY . 0.2 OUTLIER -115.19 65.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.666 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 -179.879 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -36.69 -106.87 0.01 OUTLIER Glycine 0 C--N 1.352 1.471 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.569 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 66.73 144.98 0.07 OUTLIER Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -178.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -146.38 143.57 20.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.401 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.782 -179.579 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -111.87 137.2 50.15 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.703 0.287 . . . . 0.0 110.271 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -53.98 152.48 5.72 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 120.894 -0.322 . . . . 0.0 110.18 179.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 28.5 m -113.77 133.27 60.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-O 121.549 0.69 . . . . 0.0 111.663 -178.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -150.07 138.59 20.66 Favored 'General case' 0 N--CA 1.454 -0.231 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.804 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.517 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 68.0 t60 -157.31 175.5 13.93 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.517 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 87.9 mt-30 -142.86 176.44 9.07 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.203 -0.453 . . . . 0.0 109.952 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -166.23 113.47 0.88 Allowed 'General case' 0 C--O 1.235 0.292 0 CA-C-O 121.268 0.556 . . . . 0.0 111.024 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -121.56 125.97 48.02 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.529 -0.759 . . . . 0.0 109.607 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 54.6 t -134.43 133.36 55.05 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -141.78 133.4 26.93 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.124 0.488 . . . . 0.0 111.41 -179.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.5 m-85 -134.49 128.56 33.64 Favored 'General case' 0 C--O 1.231 0.088 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.243 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.74 148.5 25.48 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 119.766 -0.774 . . . . 0.0 111.566 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.462 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 98.5 mt-10 -91.26 152.57 20.45 Favored 'General case' 0 C--N 1.33 -0.248 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 177.484 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 35.6 p-10 -141.55 123.32 15.24 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.459 0.647 . . . . 0.0 112.036 -179.48 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.533 ' O ' ' N ' ' L' ' 26' ' ' SER . 94.7 t -94.58 121.04 44.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 46.0 -88.79 0.01 OUTLIER Glycine 0 CA--C 1.531 1.082 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 -178.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.533 ' N ' ' O ' ' L' ' 24' ' ' VAL . 11.9 p -90.97 179.72 5.68 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -61.1 170.44 1.63 Allowed 'General case' 0 C--N 1.314 -0.945 0 C-N-CA 118.491 -1.284 . . . . 0.0 109.612 -179.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -53.88 111.94 0.84 Allowed 'General case' 0 C--N 1.326 -0.414 0 C-N-CA 120.726 -0.389 . . . . 0.0 111.198 178.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.474 ' H ' ' HB3' ' K' ' 27' ' ' ASN . . . -71.45 92.23 0.5 Allowed Glycine 0 N--CA 1.47 0.923 0 C-N-CA 118.64 -1.743 . . . . 0.0 110.058 176.028 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.541 ' HB2' ' O ' ' K' ' 28' ' ' LYS . . . -174.83 163.29 3.35 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 102.386 -3.19 . . . . 0.0 102.386 178.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.504 ' CG1' HG23 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -143.86 120.4 5.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 116.927 -1.909 . . . . 0.0 113.207 -177.464 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.435 HG22 ' O ' ' L' ' 32' ' ' ILE . 3.4 mt -102.78 111.72 33.57 Favored 'Isoleucine or valine' 0 C--N 1.343 0.325 0 CA-C-N 113.466 -1.697 . . . . 0.0 107.372 177.437 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . 0.466 ' CA ' ' HG3' ' F' ' 35' ' ' MET . . . -110.06 83.94 0.35 Allowed Glycine 0 CA--C 1.493 -1.318 0 N-CA-C 108.071 -2.012 . . . . 0.0 108.071 177.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.692 HD21 HG13 ' L' ' 36' ' ' VAL . 7.3 tt -122.27 117.08 25.28 Favored 'General case' 0 CA--C 1.501 -0.92 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.499 ' N ' HD23 ' L' ' 34' ' ' LEU . 65.4 ttp -106.05 130.27 53.99 Favored 'General case' 0 CA--C 1.505 -0.784 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.333 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.692 HG13 HD21 ' L' ' 34' ' ' LEU . 0.0 OUTLIER -132.2 79.97 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.684 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.629 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.18 103.24 0.76 Allowed Glycine 0 C--N 1.348 1.224 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -135.96 152.98 21.24 Favored Glycine 0 N--CA 1.466 0.648 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -132.14 157.81 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 p . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.751 -179.599 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.396 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -112.69 147.02 37.67 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.756 0.312 . . . . 0.0 110.433 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 76.0 mt-10 -113.33 143.54 44.27 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 120.981 0.419 . . . . 0.0 110.748 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 18.2 m -130.65 154.91 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.778 179.401 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -138.24 163.19 32.38 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.944 0.402 . . . . 0.0 110.866 -178.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.629 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -82.11 170.82 15.05 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.551 -179.844 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -148.89 174.76 11.9 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.322 -0.854 . . . . 0.0 109.01 178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -153.4 124.54 7.46 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.074 -179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.0 mt -121.12 114.26 21.19 Favored 'General case' 0 C--O 1.237 0.399 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 51.1 t -131.26 129.34 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 CA-C-O 121.403 0.621 . . . . 0.0 112.354 -178.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.595 ' CG ' ' CE1' ' B' ' 19' ' ' PHE . 3.5 m-85 -108.85 111.63 23.45 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 106.643 -1.614 . . . . 0.0 106.643 176.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.537 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 50.1 p90 -131.59 126.32 34.48 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 118.797 0.726 . . . . 0.0 109.188 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.12 133.14 42.51 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-O 121.461 0.648 . . . . 0.0 112.405 -178.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.496 ' N ' ' OE1' ' A' ' 22' ' ' GLU . 36.5 mp0 -142.97 156.52 44.88 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 178.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.457 ' O ' ' CG1' ' B' ' 24' ' ' VAL . 34.5 t70 -87.89 111.72 21.74 Favored 'General case' 0 N--CA 1.47 0.57 0 C-N-CA 120.165 -0.614 . . . . 0.0 112.387 -178.445 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.598 ' O ' ' N ' ' A' ' 26' ' ' SER . 54.5 t -113.8 131.2 66.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.093 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -36.96 81.97 0.0 OUTLIER Glycine 0 CA--C 1.53 1.022 0 O-C-N 123.315 0.384 . . . . 0.0 112.427 179.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.598 ' N ' ' O ' ' A' ' 24' ' ' VAL . 5.4 p -91.19 -179.3 5.39 Favored 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.538 ' O ' ' O ' ' A' ' 28' ' ' LYS . 58.8 t30 -62.64 -178.03 0.18 Allowed 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 178.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.538 ' O ' ' O ' ' A' ' 27' ' ' ASN . 99.2 mttt -48.48 -110.51 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.746 0.784 . . . . 0.0 110.604 -179.355 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -84.2 94.97 1.88 Allowed Glycine 0 N--CA 1.459 0.23 0 N-CA-C 108.332 -1.907 . . . . 0.0 108.332 176.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.07 161.32 16.61 Favored 'General case' 0 C--N 1.351 0.636 0 C-N-CA 115.473 -2.491 . . . . 0.0 110.776 -177.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.458 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.7 OUTLIER -153.4 121.7 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 CA-C-N 112.545 -2.116 . . . . 0.0 110.667 -172.596 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.512 ' O ' ' SD ' ' G' ' 35' ' ' MET . 78.6 mt -129.2 120.16 50.68 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 C-N-CA 120.381 -0.527 . . . . 0.0 110.72 178.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.62 122.31 3.54 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 16.0 tp -127.75 141.96 51.44 Favored 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 117.241 0.52 . . . . 0.0 111.355 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.57 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 13.3 ttt -131.32 129.29 41.25 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.315 -179.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 16.4 t -131.4 71.66 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.783 0 N-CA-C 112.315 0.487 . . . . 0.0 112.315 178.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.549 ' O ' HD12 ' G' ' 31' ' ' ILE . . . -125.75 96.51 0.49 Allowed Glycine 0 C--N 1.344 1.024 0 N-CA-C 108.799 -1.72 . . . . 0.0 108.799 177.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.86 172.25 42.56 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 -178.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -133.99 159.22 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.762 0.315 . . . . 0.0 110.761 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.923 -1.037 . . . . 0.0 110.297 179.769 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.177 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -109.53 134.69 51.6 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 120.693 0.282 . . . . 0.0 110.47 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.527 ' N ' ' OE1' ' B' ' 11' ' ' GLU . 56.9 mp0 -121.09 128.08 52.25 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.44 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p -144.46 138.42 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.971 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 47.1 t-80 -142.18 105.98 4.71 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.659 0.266 . . . . 0.0 110.923 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 43.8 p-80 -160.45 178.77 9.22 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-O 121.109 0.481 . . . . 0.0 110.283 -179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 79.0 mt-30 -133.44 -179.14 5.33 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.531 -0.759 . . . . 0.0 110.97 -179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -146.74 132.38 18.84 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.879 -179.364 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 18.9 tp -125.39 115.9 21.02 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 120.701 -0.4 . . . . 0.0 112.01 -177.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 74.9 t -125.39 123.8 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-O 120.866 0.365 . . . . 0.0 110.912 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.595 ' CE1' ' CG ' ' A' ' 19' ' ' PHE . 13.3 m-85 -116.83 118.98 33.97 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.1 -0.5 . . . . 0.0 109.73 178.96 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.7 t80 -134.11 125.4 27.91 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.99 133.71 33.98 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -178.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 14.2 pt-20 -153.15 176.76 11.57 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 178.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -153.35 134.69 14.22 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.833 -0.747 . . . . 0.0 112.913 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.457 ' CG1' ' O ' ' A' ' 23' ' ' ASP . 2.8 p -109.09 112.64 41.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 178.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' B' ' 24' ' ' VAL . . . 33.09 88.57 0.01 OUTLIER Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.828 -0.909 . . . . 0.0 110.828 -177.288 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -46.96 170.86 0.01 OUTLIER 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.17 -1.015 . . . . 0.0 113.232 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.559 ' H ' ' HD2' ' C' ' 28' ' ' LYS . 78.3 m-20 -129.67 -179.94 5.47 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 114.316 -1.311 . . . . 0.0 108.62 176.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.498 ' O ' ' O ' ' B' ' 27' ' ' ASN . 98.1 mttt -26.71 -103.3 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 179.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.85 98.43 0.18 Allowed Glycine 0 N--CA 1.487 2.041 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.091 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.42 ' H ' ' HE3' ' C' ' 28' ' ' LYS . . . -74.82 158.72 32.96 Favored 'General case' 0 C--O 1.25 1.088 0 C-N-CA 117.086 -1.846 . . . . 0.0 111.26 177.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.458 ' O ' ' HA ' ' A' ' 31' ' ' ILE . 0.1 OUTLIER -153.68 112.99 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.556 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.491 ' O ' ' SD ' ' H' ' 35' ' ' MET . 42.7 pt -136.02 150.36 28.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 C-N-CA 119.777 -0.769 . . . . 0.0 112.255 -177.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.506 ' O ' HD23 ' B' ' 34' ' ' LEU . . . -166.18 150.29 17.4 Favored Glycine 0 CA--C 1.525 0.667 0 C-N-CA 119.835 -1.174 . . . . 0.0 112.332 -179.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.628 HD12 HD11 ' C' ' 34' ' ' LEU . 6.0 mt -139.17 143.43 38.14 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 120.9 0.381 . . . . 0.0 110.586 179.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.63 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 5.2 ttt -120.22 122.09 40.16 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.107 179.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 5.2 t -138.14 71.83 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.814 ' O ' HG21 ' H' ' 31' ' ' ILE . . . -128.12 95.85 0.41 Allowed Glycine 0 C--N 1.343 0.969 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 177.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.33 179.44 18.69 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 -179.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -123.75 136.12 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.982 0.42 . . . . 0.0 110.284 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.186 179.812 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 53.9 p90 -147.79 163.82 35.56 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.515 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 56.7 mp0 -127.04 150.25 49.53 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.663 -179.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.49 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 32.6 m -131.27 156.16 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.949 179.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.551 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 10.0 m-70 -150.98 150.43 30.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.97 0.414 . . . . 0.0 110.995 -178.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.62 ' CD2' ' N ' ' C' ' 15' ' ' GLN . 2.4 t60 -154.55 158.14 39.35 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 178.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 78.2 mt-30 -152.08 179.27 8.63 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 120.289 -0.565 . . . . 0.0 111.432 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -165.45 117.53 1.14 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.836 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.3 mt -115.81 114.78 25.22 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.79 140.92 35.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 119.426 -0.91 . . . . 0.0 113.163 -178.546 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.552 ' CE1' ' CD1' ' F' ' 34' ' ' LEU . 65.1 m-85 -124.28 125.11 43.83 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 114.742 -1.117 . . . . 0.0 110.541 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.0 t80 -130.61 117.21 19.19 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.24 136.15 46.79 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 120.559 -0.456 . . . . 0.0 111.641 -178.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -125.97 121.04 31.93 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.418 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.505 ' O ' ' O ' ' D' ' 24' ' ' VAL . 41.0 t0 -90.63 123.05 33.95 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.127 179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.3 t -142.32 -111.72 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.087 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' C' ' 26' ' ' SER . . . -29.8 91.56 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 CA-C-N 116.145 -0.479 . . . . 0.0 112.747 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.545 ' O ' ' CB ' ' C' ' 27' ' ' ASN . 12.8 p -61.18 179.15 0.21 Allowed 'General case' 0 CA--C 1.505 -0.774 0 N-CA-C 105.596 -2.001 . . . . 0.0 105.596 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.545 ' CB ' ' O ' ' C' ' 26' ' ' SER . 3.1 m120 91.17 -170.81 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 -177.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.559 ' HD2' ' H ' ' B' ' 27' ' ' ASN . 84.3 tttt 40.59 -106.29 0.06 Allowed 'General case' 0 C--N 1.319 -0.717 0 N-CA-C 114.803 1.408 . . . . 0.0 114.803 179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.6 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . 92.95 91.91 1.51 Allowed Glycine 0 CA--C 1.497 -1.07 0 N-CA-C 107.483 -2.247 . . . . 0.0 107.483 -171.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.475 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -83.5 172.47 12.37 Favored 'General case' 0 N--CA 1.434 -1.242 0 C-N-CA 119.09 -1.044 . . . . 0.0 109.512 -176.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.475 ' CG1' ' C ' ' C' ' 30' ' ' ALA . 0.1 OUTLIER -152.72 124.19 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 C-N-CA 117.7 -1.6 . . . . 0.0 110.157 -175.909 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.7 tt -122.42 131.73 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 N-CA-C 112.632 0.605 . . . . 0.0 112.632 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.462 ' O ' ' CA ' ' B' ' 33' ' ' GLY . . . -122.44 109.13 1.36 Allowed Glycine 0 CA--C 1.53 0.984 0 N-CA-C 109.138 -1.585 . . . . 0.0 109.138 179.131 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.764 ' H ' HD23 ' D' ' 34' ' ' LEU . 1.0 OUTLIER -137.07 126.57 25.12 Favored 'General case' 0 N--CA 1.474 0.758 0 O-C-N 121.45 -1.029 . . . . 0.0 112.258 -178.402 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.666 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 14.2 ttp -110.58 121.8 46.2 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 114.388 -1.278 . . . . 0.0 109.945 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.463 HG13 ' CD2' ' C' ' 34' ' ' LEU . 0.2 OUTLIER -139.87 70.46 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.683 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.732 179.847 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.53 -100.48 0.62 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.44 155.27 25.49 Favored Glycine 0 CA--C 1.521 0.434 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -136.06 162.09 36.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 120.761 0.315 . . . . 0.0 110.213 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.8 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.721 -179.699 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 88.0 m-85 -116.09 138.64 51.06 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 120.837 0.351 . . . . 0.0 110.407 -179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -64.09 128.86 37.64 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.197 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m -137.84 137.42 44.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.787 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 73.9 m-70 -128.62 102.04 6.42 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.534 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 6.7 m170 -95.23 158.15 15.59 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-O 121.904 0.859 . . . . 0.0 111.162 -179.179 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.554 HE22 ' NE2' ' C' ' 15' ' ' GLN . 99.7 mm-40 -152.61 171.34 18.31 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 114.023 -1.444 . . . . 0.0 107.905 178.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -174.1 128.67 0.37 Allowed 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 121.014 -0.275 . . . . 0.0 110.275 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.474 HD21 HG11 ' F' ' 36' ' ' VAL . 8.8 mt -120.74 119.46 32.83 Favored 'General case' 0 N--CA 1.477 0.892 0 C-N-CA 120.451 -0.5 . . . . 0.0 111.103 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 93.3 t -128.99 119.47 49.43 Favored 'Isoleucine or valine' 0 C--N 1.341 0.201 0 C-N-CA 120.636 -0.426 . . . . 0.0 111.359 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -113.03 116.66 30.28 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' OE2' ' D' ' 22' ' ' GLU . 9.0 t80 -129.5 119.4 23.66 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.13 0.423 . . . . 0.0 110.152 -179.021 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.76 127.58 43.84 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 78.6 mm-40 -121.49 112.31 18.36 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 179.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.478 ' O ' ' O ' ' E' ' 24' ' ' VAL . 19.9 t0 -84.35 97.34 9.41 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.622 ' O ' ' N ' ' D' ' 26' ' ' SER . 14.0 t -103.61 168.73 2.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.033 -0.985 . . . . 0.0 108.607 -179.285 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.495 ' N ' ' CG1' ' D' ' 24' ' ' VAL . . . 39.36 -78.31 0.0 OUTLIER Glycine 0 CA--C 1.527 0.783 0 CA-C-O 119.448 -0.64 . . . . 0.0 112.631 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.622 ' N ' ' O ' ' D' ' 24' ' ' VAL . 1.4 p 170.98 -170.83 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 117.895 0.848 . . . . 0.0 111.552 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.592 ' O ' ' O ' ' D' ' 26' ' ' SER . 20.5 m-80 -18.68 -172.11 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.948 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -179.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.554 ' H ' ' HD3' ' E' ' 28' ' ' LYS . 86.0 tttt 127.2 104.46 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.743 0 CA-C-N 111.217 -2.719 . . . . 0.0 110.48 177.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.6 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -59.9 96.28 0.08 OUTLIER Glycine 0 CA--C 1.491 -1.438 0 CA-C-O 118.337 -1.257 . . . . 0.0 110.559 175.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.464 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . -117.61 150.36 39.15 Favored 'General case' 0 CA--C 1.467 -2.224 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 174.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.464 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 0.3 OUTLIER -150.51 122.03 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 118.049 -1.461 . . . . 0.0 110.278 -171.973 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.415 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.1 OUTLIER -105.87 119.01 54.47 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 114.187 -1.369 . . . . 0.0 110.375 -179.091 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.623 ' O ' HD23 ' D' ' 34' ' ' LEU . . . -123.86 101.55 0.69 Allowed Glycine 0 N--CA 1.464 0.554 0 N-CA-C 108.093 -2.003 . . . . 0.0 108.093 178.598 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.764 HD23 ' H ' ' C' ' 34' ' ' LEU . 16.8 mt -139.09 152.03 47.19 Favored 'General case' 0 C--N 1.322 -0.605 0 C-N-CA 119.378 -0.929 . . . . 0.0 112.326 -176.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.591 ' SD ' ' N ' ' J' ' 33' ' ' GLY . 35.2 ttp -126.36 118.16 24.46 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 176.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 40.1 t -127.06 70.22 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -109.57 -102.62 2.75 Favored Glycine 0 C--N 1.36 1.884 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.422 ' H ' HG21 ' J' ' 31' ' ' ILE . . . 77.73 170.21 34.72 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.015 -1.234 . . . . 0.0 110.015 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.7 p -140.29 140.54 34.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.854 0.359 . . . . 0.0 110.232 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 m . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 117.906 -1.045 . . . . 0.0 110.43 -179.824 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.434 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -146.26 162.09 38.86 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.897 0.379 . . . . 0.0 110.458 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.533 ' N ' ' OE1' ' E' ' 11' ' ' GLU . 56.1 mp0 -130.91 144.16 51.26 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.587 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.52 HG13 ' H ' ' D' ' 13' ' ' HIS . 46.9 t -115.65 131.63 67.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 179.524 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.459 ' O ' ' O ' ' D' ' 13' ' ' HIS . 85.9 m-70 -109.99 160.56 16.32 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-N 118.532 0.605 . . . . 0.0 111.949 -178.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.539 ' CE1' ' O ' ' D' ' 13' ' ' HIS . 98.0 m-70 -152.14 174.44 13.72 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.279 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 83.4 mm-40 -119.75 -171.02 2.05 Favored 'General case' 0 C--N 1.322 -0.596 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -97.77 175.72 6.07 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 122.504 1.145 . . . . 0.0 113.945 -176.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.1 tt -120.81 121.47 38.24 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 113.407 -1.724 . . . . 0.0 106.986 178.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.57 138.66 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 CA-C-O 121.524 0.678 . . . . 0.0 112.616 -178.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 t80 -124.21 124.51 42.62 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 114.578 -1.192 . . . . 0.0 109.007 178.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 50.0 t80 -131.2 122.55 26.77 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 110.438 -0.208 . . . . 0.0 110.438 -179.525 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.86 127.87 42.72 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-O 120.861 0.362 . . . . 0.0 111.025 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.458 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 80.1 tt0 -92.91 144.48 25.23 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 120.182 -0.607 . . . . 0.0 110.814 179.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.612 ' O ' ' O ' ' E' ' 24' ' ' VAL . 41.5 p-10 -71.21 -122.34 0.0 OUTLIER 'General case' 0 C--O 1.218 -0.562 0 CA-C-N 116.304 -0.407 . . . . 0.0 109.982 179.687 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.612 ' O ' ' O ' ' E' ' 23' ' ' ASP . 87.3 t 19.84 122.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.529 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 169.58 -84.19 0.09 OUTLIER Glycine 0 CA--C 1.522 0.514 0 C-N-CA 120.409 -0.901 . . . . 0.0 111.69 177.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.529 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.4 p 154.18 -179.23 0.0 OUTLIER 'General case' 0 C--N 1.345 0.382 0 CA-C-O 122.58 1.181 . . . . 0.0 111.006 179.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.426 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 1.8 m-20 -52.63 -178.94 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 112.44 -2.163 . . . . 0.0 112.643 178.613 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.554 ' HD3' ' H ' ' D' ' 28' ' ' LYS . 0.0 OUTLIER 60.66 113.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 123.017 1.389 . . . . 0.0 114.385 -179.521 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -88.26 96.22 2.17 Favored Glycine 0 C--O 1.224 -0.522 0 CA-C-N 111.687 -2.506 . . . . 0.0 112.727 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -63.95 175.44 1.19 Allowed 'General case' 0 C--O 1.24 0.596 0 CA-C-N 119.882 1.841 . . . . 0.0 107.461 -178.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.428 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.1 OUTLIER -152.39 129.65 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.421 0 C-N-CA 116.736 -1.986 . . . . 0.0 114.606 -172.451 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mt -107.67 121.04 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.072 177.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.3 104.59 0.82 Allowed Glycine 0 C--N 1.332 0.332 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 177.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.775 HD12 ' N ' ' E' ' 35' ' ' MET . 3.4 tp -150.31 135.3 17.73 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 122.461 1.124 . . . . 0.0 112.584 -178.656 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.775 ' N ' HD12 ' E' ' 34' ' ' LEU . 33.8 ttp -102.26 126.3 49.22 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.762 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.39 70.94 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.128 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.9 114.08 5.88 Favored Glycine 0 C--N 1.352 1.47 0 N-CA-C 111.244 -0.742 . . . . 0.0 111.244 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -70.05 -139.49 0.14 Allowed Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -119.01 136.7 55.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 120.755 0.312 . . . . 0.0 110.527 -179.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 20.6 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.408 179.824 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -111.33 133.2 53.83 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-O 120.856 0.36 . . . . 0.0 110.401 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -121.8 138.58 54.32 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.365 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.52 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 58.3 t -123.73 131.32 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.44 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.52 ' CG ' ' O ' ' F' ' 12' ' ' VAL . 78.9 m80 -161.28 99.39 1.18 Allowed 'General case' 0 C--O 1.232 0.156 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.817 179.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 92.1 m-70 -153.74 163.99 39.08 Favored 'General case' 0 N--CA 1.447 -0.624 0 CA-C-O 121.224 0.535 . . . . 0.0 109.9 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 78.9 mt-30 -158.27 177.43 11.28 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.792 179.022 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -142.53 139.83 31.58 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 121.16 0.505 . . . . 0.0 110.574 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 39.5 mt -113.33 127.94 56.3 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 13.1 p -141.17 138.26 33.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.535 0.683 . . . . 0.0 111.694 -179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.424 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.0 p90 -132.47 131.03 41.26 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.765 179.552 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 44.7 t80 -136.44 130.15 32.22 Favored 'General case' 0 N--CA 1.463 0.186 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.99 144.31 25.75 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.303 -0.559 . . . . 0.0 111.633 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.467 ' HB2' ' H ' ' E' ' 23' ' ' ASP . 73.0 mm-40 -99.27 161.27 13.71 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.491 ' O ' ' O ' ' F' ' 24' ' ' VAL . 59.9 m-20 -145.29 -132.32 0.08 Allowed 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 120.7 -0.4 . . . . 0.0 111.531 -179.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' F' ' 23' ' ' ASP . 2.8 t 25.81 112.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -178.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.17 -91.57 0.1 OUTLIER Glycine 0 CA--C 1.525 0.695 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 177.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.495 ' O ' ' O ' ' F' ' 27' ' ' ASN . 50.4 m -141.3 170.26 16.05 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.444 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.542 ' OD1' ' N ' ' F' ' 28' ' ' LYS . 56.8 t-20 -29.19 155.89 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.744 0 O-C-N 123.73 0.643 . . . . 0.0 111.727 179.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.542 ' N ' ' OD1' ' F' ' 27' ' ' ASN . 23.8 tttm -151.67 -110.45 0.05 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.588 0.708 . . . . 0.0 111.89 176.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 45.82 91.36 0.01 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 114.632 -1.167 . . . . 0.0 114.577 -179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.429 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -103.15 176.41 5.16 Favored 'General case' 0 CA--C 1.496 -1.122 0 N-CA-C 100.204 -3.998 . . . . 0.0 100.204 172.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.459 HG22 ' SD ' ' L' ' 35' ' ' MET . 0.1 OUTLIER -149.76 122.38 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 C-N-CA 115.986 -2.285 . . . . 0.0 112.566 -175.053 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -104.81 111.38 34.1 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.441 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.304 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.01 89.98 0.56 Allowed Glycine 0 N--CA 1.451 -0.356 0 N-CA-C 107.102 -2.399 . . . . 0.0 107.102 175.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.659 HD21 HG13 ' F' ' 36' ' ' VAL . 9.2 tt -126.86 127.84 45.58 Favored 'General case' 0 CA--C 1.508 -0.671 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 39.5 ttp -106.04 129.47 54.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 C-N-CA 119.904 -0.718 . . . . 0.0 111.59 -178.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.659 HG13 HD21 ' F' ' 34' ' ' LEU . 0.0 OUTLIER -132.55 78.48 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.743 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.08 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.05 104.35 1.32 Allowed Glycine 0 C--N 1.344 1.019 0 N-CA-C 111.269 -0.732 . . . . 0.0 111.269 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.64 -164.84 33.99 Favored Glycine 0 CA--C 1.522 0.483 0 N-CA-C 110.309 -1.117 . . . . 0.0 110.309 179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 63.1 t -120.54 135.65 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-O 120.887 0.375 . . . . 0.0 110.178 -179.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 37.9 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.974 -1.012 . . . . 0.0 110.574 179.952 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.735 -1.346 . . . . 0.0 109.735 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.83 138.84 49.73 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.719 0.295 . . . . 0.0 110.564 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . 0.521 ' OE1' ' N ' ' G' ' 11' ' ' GLU . 57.8 mp0 -76.92 134.1 39.04 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 179.824 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.493 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 21.9 m -137.7 165.82 25.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.857 -179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.493 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 64.6 m80 -154.99 135.14 13.09 Favored 'General case' 0 C--O 1.222 -0.371 0 C-N-CA 120.241 -0.584 . . . . 0.0 111.169 179.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 56.0 p-80 -156.74 165.7 35.48 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 96.3 mm-40 -150.59 177.47 10.0 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.865 179.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -158.61 129.68 6.32 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.056 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -133.86 128.93 35.66 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 121.097 0.475 . . . . 0.0 110.421 179.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -128.17 130.76 69.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.38 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.435 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 2.6 t80 -116.65 114.31 23.89 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.532 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 54.5 p90 -124.19 121.14 34.3 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.358 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.68 125.3 50.44 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 121.112 0.482 . . . . 0.0 111.222 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -161.44 166.51 27.14 Favored 'General case' 0 N--CA 1.455 -0.202 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' ND2' ' H' ' 27' ' ' ASN . 63.3 t0 -79.0 114.84 18.28 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 120.075 -0.65 . . . . 0.0 111.077 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.535 ' O ' ' N ' ' G' ' 26' ' ' SER . 15.0 p -88.57 130.83 37.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -44.82 82.43 0.0 OUTLIER Glycine 0 CA--C 1.531 1.058 0 CA-C-N 116.055 -0.52 . . . . 0.0 112.803 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.535 ' N ' ' O ' ' G' ' 24' ' ' VAL . 75.3 m -132.23 162.47 30.88 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 178.23 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.531 ' O ' ' O ' ' G' ' 26' ' ' SER . 80.6 m-20 -38.74 175.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.799 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.241 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -73.62 111.15 8.49 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.101 177.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.38 93.97 0.19 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.31 162.06 13.2 Favored 'General case' 0 CA--C 1.496 -1.103 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 177.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.549 HD12 ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -146.72 104.02 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.072 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 -174.631 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.508 ' O ' ' SD ' ' B' ' 35' ' ' MET . 85.5 mt -126.89 127.93 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.242 0.544 . . . . 0.0 111.126 -178.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.57 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -133.15 113.22 1.2 Allowed Glycine 0 CA--C 1.517 0.158 0 N-CA-C 108.934 -1.666 . . . . 0.0 108.934 178.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -136.69 147.87 47.05 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 122.221 1.01 . . . . 0.0 112.726 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.512 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 49.4 ttp -131.24 132.04 44.35 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.734 -1.575 . . . . 0.0 109.591 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.1 t -99.86 72.01 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.22 -96.45 0.01 OUTLIER Glycine 0 N--CA 1.438 -1.17 0 N-CA-C 111.02 -0.832 . . . . 0.0 111.02 178.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.26 -172.11 33.47 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.43 ' O ' ' OXT' ' G' ' 40' ' ' VAL . 2.7 p -139.2 142.92 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.47 ' O ' HG12 ' G' ' 40' ' ' VAL . 53.7 t . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 118.014 -0.993 . . . . 0.0 110.069 -179.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.49 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 84.6 m-85 -115.21 140.62 48.94 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 120.671 0.272 . . . . 0.0 110.476 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -81.23 142.33 33.27 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.452 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.421 ' O ' HG23 ' H' ' 12' ' ' VAL . 6.2 m -121.76 131.82 72.24 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 179.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -118.93 140.62 49.69 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.733 0.301 . . . . 0.0 111.599 -179.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.47 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 45.1 m-70 -142.31 160.61 39.92 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-O 121.345 0.593 . . . . 0.0 109.812 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.47 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 98.5 mm-40 -149.1 172.45 14.78 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.128 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.7 mttt -159.48 117.37 2.74 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.062 177.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -119.26 119.91 35.45 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -125.5 126.73 70.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 CA-C-O 120.837 0.351 . . . . 0.0 110.534 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.647 ' CE1' HD11 ' K' ' 34' ' ' LEU . 1.4 t80 -123.06 118.77 28.5 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 -179.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 72.1 t80 -131.23 127.91 38.83 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 120.756 0.312 . . . . 0.0 111.288 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.7 123.96 30.47 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-O 120.886 0.374 . . . . 0.0 111.557 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 78.8 tt0 -165.64 140.87 4.95 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 45.4 p30 -100.13 140.53 34.23 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.453 0.644 . . . . 0.0 112.509 -178.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.408 ' O ' ' C ' ' H' ' 25' ' ' GLY . 92.5 t -108.4 111.12 34.59 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 179.072 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' H' ' 24' ' ' VAL . . . 33.63 90.97 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 -177.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -46.45 152.74 0.42 Allowed 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 114.169 -1.015 . . . . 0.0 113.538 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.537 ' O ' ' O ' ' H' ' 28' ' ' LYS . 16.8 p30 -128.19 -179.97 5.29 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 114.189 -1.369 . . . . 0.0 107.823 174.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.537 ' O ' ' O ' ' H' ' 27' ' ' ASN . 84.4 tttt -27.51 -102.71 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.727 0.694 . . . . 0.0 111.885 178.216 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.413 ' CA ' ' O ' ' I' ' 29' ' ' GLY . . . -149.96 100.36 0.21 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 175.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.415 ' H ' ' CE ' ' I' ' 28' ' ' LYS . . . -65.56 155.45 35.7 Favored 'General case' 0 C--O 1.245 0.861 0 C-N-CA 117.064 -1.854 . . . . 0.0 108.336 177.063 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.814 HG21 ' O ' ' B' ' 37' ' ' GLY . 2.2 mt -144.45 108.17 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.819 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -128.35 129.71 69.14 Favored 'Isoleucine or valine' 0 C--O 1.237 0.408 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.63 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.68 119.5 3.68 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 108.314 -1.915 . . . . 0.0 108.314 177.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.752 ' HB2' HD12 ' I' ' 34' ' ' LEU . 95.1 mt -135.31 129.45 33.51 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 -177.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.491 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 24.0 ttp -129.55 131.87 46.69 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.338 178.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.631 ' CG1' HG12 ' I' ' 36' ' ' VAL . 2.4 p -149.47 75.36 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 119.999 -0.68 . . . . 0.0 112.325 179.888 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.43 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.74 -95.56 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 178.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -165.08 37.72 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.277 -1.129 . . . . 0.0 110.277 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.77 141.78 41.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.893 0.377 . . . . 0.0 110.353 -179.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 27.9 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.645 -179.996 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -113.96 139.5 49.18 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 110.202 -0.296 . . . . 0.0 110.202 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -86.47 163.81 17.33 Favored 'General case' 0 N--CA 1.463 0.177 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -99.3 132.79 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 -179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.636 ' CE1' ' ND1' ' J' ' 13' ' ' HIS . 14.9 p-80 -156.24 156.19 33.67 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.767 -179.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' I' ' 15' ' ' GLN . 11.1 m170 -133.37 161.19 35.2 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.696 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.545 ' NE2' ' O ' ' I' ' 14' ' ' HIS . 43.6 mm-40 -142.59 171.71 13.68 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.521 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -159.51 120.49 3.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.103 178.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 tt -125.3 124.38 41.5 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 120.803 0.335 . . . . 0.0 110.48 -179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 90.2 t -125.59 125.32 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.408 179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.541 ' CZ ' HD13 ' K' ' 34' ' ' LEU . 12.2 t80 -118.97 113.24 20.68 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.552 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 47.6 t80 -126.45 116.82 21.73 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 121.076 0.465 . . . . 0.0 111.058 -178.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.71 126.71 47.02 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.244 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -146.65 103.86 3.69 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-O 121.077 0.465 . . . . 0.0 110.818 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.434 ' O ' HG12 ' J' ' 24' ' ' VAL . 99.4 m-20 -95.31 122.82 38.41 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.496 179.093 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.48 HG23 ' H ' ' I' ' 25' ' ' GLY . 3.6 m -143.5 -111.54 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 C-N-CA 120.193 -0.603 . . . . 0.0 109.854 -178.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.48 ' H ' HG23 ' I' ' 24' ' ' VAL . . . 27.39 -90.2 0.01 OUTLIER Glycine 0 CA--C 1.529 0.911 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.433 -178.052 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.826 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.1 p 171.54 171.0 0.09 Allowed 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 178.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.826 ' O ' ' O ' ' I' ' 26' ' ' SER . 44.5 p-10 -9.51 179.27 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 O-C-N 125.869 1.981 . . . . 0.0 115.745 178.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.564 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 85.8 tttt 129.64 104.69 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 114.052 1.13 . . . . 0.0 114.052 175.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.413 ' O ' ' CA ' ' H' ' 29' ' ' GLY . . . -58.46 96.81 0.07 OUTLIER Glycine 0 C--O 1.225 -0.422 0 N-CA-C 106.711 -2.556 . . . . 0.0 106.711 171.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.891 ' C ' HD13 ' I' ' 31' ' ' ILE . . . -120.88 146.04 47.01 Favored 'General case' 0 CA--C 1.48 -1.729 0 N-CA-C 105.112 -2.181 . . . . 0.0 105.112 178.144 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.891 HD13 ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -137.84 108.04 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.672 0 C-N-CA 119.343 -0.943 . . . . 0.0 111.088 -173.854 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -111.65 112.5 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 175.779 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.666 ' N ' ' SD ' ' C' ' 35' ' ' MET . . . -118.05 108.74 1.69 Allowed Glycine 0 CA--C 1.511 -0.157 0 N-CA-C 106.693 -2.563 . . . . 0.0 106.693 177.029 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.752 HD12 ' HB2' ' H' ' 34' ' ' LEU . 0.9 OUTLIER -142.39 144.0 32.94 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-O 122.673 1.225 . . . . 0.0 113.352 -177.082 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.445 ' N ' ' HG ' ' I' ' 34' ' ' LEU . 12.7 tmm? -127.42 117.95 23.14 Favored 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 113.196 -1.82 . . . . 0.0 109.626 177.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.747 HG13 HD21 ' I' ' 34' ' ' LEU . 15.7 m -121.91 73.94 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.797 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.822 179.235 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.36 103.48 2.99 Favored Glycine 0 C--N 1.36 1.883 0 N-CA-C 111.707 -0.557 . . . . 0.0 111.707 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -88.77 175.88 43.96 Favored Glycine 0 CA--C 1.525 0.702 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 3.9 p -144.94 151.45 15.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 120.891 0.376 . . . . 0.0 110.774 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.412 ' O ' HG13 ' I' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.567 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.447 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 t80 -111.1 132.55 54.18 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 120.781 0.324 . . . . 0.0 110.266 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' K' ' 11' ' ' GLU . 17.1 pt-20 -158.56 138.26 11.93 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.387 -0.37 . . . . 0.0 111.053 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -150.23 153.4 10.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.636 ' ND1' ' CE1' ' I' ' 13' ' ' HIS . 50.5 m-70 -144.21 116.05 8.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 118.966 0.803 . . . . 0.0 110.966 179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.64 ' NE2' ' CG ' ' K' ' 13' ' ' HIS . 44.3 m80 -122.0 159.88 26.06 Favored 'General case' 0 CA--C 1.517 -0.308 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 178.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.408 HE21 ' HG3' ' I' ' 15' ' ' GLN . 63.2 mt-30 -158.12 177.06 11.72 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.412 178.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 43.5 tttp -169.43 123.32 0.79 Allowed 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.865 -0.334 . . . . 0.0 110.427 179.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 8.8 tt -121.21 121.87 38.73 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.634 0.254 . . . . 0.0 110.328 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 79.2 t -124.28 127.48 73.27 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.493 ' CZ ' ' CD1' ' I' ' 19' ' ' PHE . 5.4 t80 -126.53 121.35 32.04 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.907 0.384 . . . . 0.0 110.72 -179.261 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.552 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 50.7 t80 -128.93 127.18 41.24 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.003 -179.909 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.34 137.53 30.61 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -142.58 106.0 4.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 115.131 -0.941 . . . . 0.0 109.272 178.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.448 ' OD1' HD11 ' L' ' 32' ' ' ILE . 10.3 m-20 -96.59 108.91 21.59 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 121.203 -0.199 . . . . 0.0 111.049 -179.075 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.434 HG12 ' O ' ' I' ' 23' ' ' ASP . 2.1 p -46.1 140.0 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.256 178.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.626 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . -86.12 84.85 1.56 Allowed Glycine 0 CA--C 1.531 1.091 0 C-N-CA 121.124 -0.56 . . . . 0.0 113.423 -178.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.59 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.3 t 162.36 160.41 0.02 OUTLIER 'General case' 0 C--O 1.221 -0.414 0 CA-C-O 121.212 0.53 . . . . 0.0 110.12 176.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.59 ' O ' ' O ' ' J' ' 26' ' ' SER . 7.2 t-20 -29.99 178.99 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.517 ' CB ' ' O ' ' J' ' 27' ' ' ASN . 42.6 tttp 128.45 104.85 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 113.052 -1.886 . . . . 0.0 112.899 175.189 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.84 95.43 0.05 OUTLIER Glycine 0 N--CA 1.462 0.429 0 CA-C-N 113.057 -1.883 . . . . 0.0 112.782 173.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.739 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -140.21 141.06 35.97 Favored 'General case' 0 CA--C 1.49 -1.364 0 CA-C-N 120.751 2.275 . . . . 0.0 107.353 174.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.739 HD13 ' C ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -137.73 106.94 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.918 0 CA-C-N 114.931 -1.032 . . . . 0.0 108.894 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.468 HG22 ' O ' ' J' ' 32' ' ' ILE . 0.1 OUTLIER -109.75 110.84 33.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.018 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.591 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -123.78 98.82 0.6 Allowed Glycine 0 N--CA 1.463 0.436 0 N-CA-C 107.312 -2.315 . . . . 0.0 107.312 178.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.667 HD23 HD22 ' I' ' 34' ' ' LEU . 5.5 mp -131.07 140.75 50.09 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-O 122.134 0.969 . . . . 0.0 111.786 -177.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.416 ' SD ' HG22 ' D' ' 31' ' ' ILE . 11.5 tmm? -124.18 121.44 35.11 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.513 179.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' J' ' 37' ' ' GLY . 0.1 OUTLIER -110.43 73.74 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.862 0 CA-C-N 114.874 -1.057 . . . . 0.0 110.178 -178.75 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -24.9 -101.18 0.01 OUTLIER Glycine 0 C--N 1.355 1.62 0 CA-C-N 116.198 -0.456 . . . . 0.0 112.851 -179.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 131.24 -174.54 19.94 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 -179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -133.7 160.44 42.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 110.357 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 47.1 t . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.548 -179.934 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.74 133.35 51.55 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 110.267 -0.271 . . . . 0.0 110.267 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.502 ' O ' ' O ' ' J' ' 11' ' ' GLU . 81.4 tt0 -156.18 141.18 17.27 Favored 'General case' 0 C--O 1.222 -0.35 0 CA-C-O 120.944 0.402 . . . . 0.0 110.711 179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.34 154.57 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.64 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 22.3 m-70 -125.64 144.56 50.54 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-N 118.608 0.64 . . . . 0.0 110.725 179.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.522 ' CG ' ' H ' ' K' ' 15' ' ' GLN . 30.9 t-80 -86.71 -178.25 6.31 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.499 -179.215 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.522 ' H ' ' CG ' ' K' ' 14' ' ' HIS . 86.5 mt-30 -84.85 172.69 11.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.148 -178.522 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -146.25 133.01 19.99 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 114.825 -1.08 . . . . 0.0 108.575 179.023 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -131.42 131.57 43.7 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.225 0.536 . . . . 0.0 112.274 -178.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.6 t -126.77 127.7 70.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.836 178.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 26.7 t80 -128.86 128.2 43.39 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.561 0.22 . . . . 0.0 110.795 -178.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.435 ' CE2' ' CD2' ' L' ' 20' ' ' PHE . 8.8 t80 -135.76 123.43 22.33 Favored 'General case' 0 CA--C 1.538 0.498 0 CA-C-O 120.906 0.384 . . . . 0.0 110.517 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.51 129.33 44.39 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.113 0.483 . . . . 0.0 111.312 -179.687 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -111.86 125.64 54.24 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.094 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.492 ' H ' ' HB3' ' L' ' 22' ' ' GLU . 26.3 t70 -91.85 134.25 34.93 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.429 179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.626 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 44.0 t -109.19 112.46 40.58 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.962 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.27 -91.29 0.01 OUTLIER Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.21 -0.905 . . . . 0.0 112.783 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.504 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.8 m -162.86 -161.11 0.68 Allowed 'General case' 0 N--CA 1.447 -0.615 0 CA-C-O 122.579 1.181 . . . . 0.0 112.867 -179.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.572 ' CG ' ' H ' ' K' ' 28' ' ' LYS . 4.4 t-20 30.08 -173.28 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 111.874 -2.421 . . . . 0.0 115.401 179.11 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.572 ' H ' ' CG ' ' K' ' 27' ' ' ASN . 82.3 tttt 103.56 110.73 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 127.136 2.174 . . . . 0.0 109.184 -179.73 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.586 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . -60.16 -95.16 0.01 OUTLIER Glycine 0 CA--C 1.535 1.3 0 C-N-CA 115.212 -3.375 . . . . 0.0 110.535 175.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.521 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 69.63 151.21 0.09 Allowed 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.178 -1.416 . . . . 0.0 107.178 174.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.521 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -149.25 117.88 0.97 Allowed 'Isoleucine or valine' 0 C--O 1.24 0.6 0 CA-C-N 120.974 1.716 . . . . 0.0 111.508 178.075 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.413 ' N ' ' HE1' ' F' ' 35' ' ' MET . 4.6 mt -105.38 111.85 36.44 Favored 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 175.691 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.585 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -115.84 96.77 0.75 Allowed Glycine 0 CA--C 1.504 -0.601 0 N-CA-C 106.315 -2.714 . . . . 0.0 106.315 177.242 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.647 HD11 ' CE1' ' H' ' 19' ' ' PHE . 0.3 OUTLIER -120.93 120.37 35.29 Favored 'General case' 0 C--O 1.24 0.579 0 CA-C-O 122.304 1.05 . . . . 0.0 110.201 -177.971 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 10.6 tmm? -109.53 114.08 27.42 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.412 -1.722 . . . . 0.0 107.965 179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.18 78.38 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.883 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.829 -177.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.48 105.43 0.97 Allowed Glycine 0 C--N 1.352 1.472 0 N-CA-C 110.279 -1.129 . . . . 0.0 110.279 178.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.71 -144.01 4.35 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -106.79 134.7 47.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 20.5 m . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 118.021 -0.99 . . . . 0.0 111.073 -179.579 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.542 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 90.9 m-85 -84.52 139.9 31.82 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.723 0.297 . . . . 0.0 110.855 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -121.52 131.03 53.91 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.971 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 29.8 m -139.98 156.79 25.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 121.179 0.514 . . . . 0.0 111.252 -179.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 20.9 p-80 -158.19 163.21 37.74 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.787 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 41.9 m80 -136.74 169.8 17.13 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.306 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -148.08 176.29 10.32 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.174 0.512 . . . . 0.0 111.304 -179.623 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 ttpt -170.59 111.46 0.39 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.983 178.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 72.0 mt -121.22 111.37 17.3 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 178.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 70.4 t -126.64 129.95 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 109.854 -0.425 . . . . 0.0 109.854 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.471 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 51.7 p90 -136.94 125.28 23.3 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.299 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.435 ' CD2' ' CE2' ' K' ' 20' ' ' PHE . 79.4 t80 -136.8 131.57 33.5 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 121.123 0.487 . . . . 0.0 110.297 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.74 143.75 35.15 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.393 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.492 ' HB3' ' H ' ' K' ' 23' ' ' ASP . 51.8 tp10 -78.21 140.96 38.92 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 179.549 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -58.86 130.46 47.05 Favored 'General case' 0 CA--C 1.518 -0.275 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.451 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.602 ' O ' HG13 ' L' ' 24' ' ' VAL . 14.7 p -116.12 114.84 47.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.279 -179.147 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.443 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -28.28 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.47 0.927 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 178.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -88.45 -177.4 5.61 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 -179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 60.3 m-20 -60.29 179.62 0.14 Allowed 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.477 -176.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.551 ' HZ3' HG13 ' L' ' 32' ' ' ILE 0.251 69.1 tttt -57.45 111.36 1.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.954 1.094 . . . . 0.0 113.954 -177.015 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -68.62 -97.71 0.04 OUTLIER Glycine 0 CA--C 1.499 -0.932 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.586 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -60.9 170.78 1.4 Allowed 'General case' 0 CA--C 1.511 -0.552 0 CA-C-N 120.844 2.322 . . . . 0.0 105.805 -178.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.649 HD12 ' N ' ' L' ' 31' ' ' ILE . 0.1 OUTLIER -134.17 121.79 38.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 115.811 -2.356 . . . . 0.0 114.086 -174.327 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.551 HG13 ' HZ3' ' L' ' 28' ' ' LYS . 97.3 mt -106.41 116.07 49.36 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.628 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 176.261 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -106.29 96.73 1.17 Allowed Glycine 0 CA--C 1.499 -0.942 0 N-CA-C 105.71 -2.956 . . . . 0.0 105.71 176.708 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.456 HD23 HG22 ' L' ' 32' ' ' ILE . 1.2 pp -110.23 112.09 23.84 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.751 -0.725 . . . . 0.0 110.298 -177.493 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.459 ' SD ' HG22 ' F' ' 31' ' ' ILE . 8.6 tmm? -109.69 110.85 22.01 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 178.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' C ' ' L' ' 37' ' ' GLY . 3.3 m -126.93 77.42 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.697 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.681 -178.492 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.446 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 22.29 -110.69 0.01 OUTLIER Glycine 0 C--N 1.356 1.654 0 O-C-N 123.106 0.254 . . . . 0.0 113.017 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.79 140.85 8.9 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -134.89 159.24 41.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.886 0.375 . . . . 0.0 110.46 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.128 -0.939 . . . . 0.0 110.764 -179.885 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.506 -1.437 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -113.72 138.38 50.31 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.995 0.426 . . . . 0.0 110.914 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 52.4 tp10 -113.45 133.8 55.0 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 179.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 m -133.15 135.03 57.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-O 121.658 0.742 . . . . 0.0 111.846 -179.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 5.4 p80 -97.15 -175.58 3.28 Favored 'General case' 0 CA--C 1.527 0.086 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.838 178.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.5 p-80 -89.85 164.98 14.39 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-O 121.44 0.638 . . . . 0.0 110.619 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 83.0 mt-30 -155.99 -178.2 7.13 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.787 -1.097 . . . . 0.0 109.684 179.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.611 ' C ' HD22 ' A' ' 17' ' ' LEU . 99.6 mttt -135.29 111.69 9.82 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 110.372 -0.232 . . . . 0.0 110.372 179.269 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.611 HD22 ' C ' ' A' ' 16' ' ' LYS . 4.3 mm? -117.81 127.8 54.24 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 120.792 0.33 . . . . 0.0 110.515 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.466 HG23 ' O ' ' A' ' 18' ' ' VAL . 5.8 m -133.04 128.39 56.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-O 121.149 0.5 . . . . 0.0 111.125 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.519 ' CZ ' HD23 ' C' ' 34' ' ' LEU . 75.0 t80 -122.69 116.13 23.27 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -147.08 153.84 40.44 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.343 -178.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.0 133.81 43.62 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.209 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -167.49 92.21 0.38 Allowed 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 62.5 t0 -70.11 121.82 18.24 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 -177.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.565 ' O ' HG23 ' A' ' 24' ' ' VAL . 26.1 m -105.98 121.72 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.417 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.422 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . 30.8 82.8 0.01 OUTLIER Glycine 0 CA--C 1.532 1.112 0 CA-C-O 119.847 -0.418 . . . . 0.0 112.255 178.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.519 ' OG ' ' ND2' ' B' ' 27' ' ' ASN . 19.9 p -95.8 175.65 6.43 Favored 'General case' 0 CA--C 1.509 -0.608 0 CA-C-N 118.059 0.93 . . . . 0.0 109.182 178.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' LYS . 20.1 p30 -61.93 -177.67 0.13 Allowed 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 176.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.548 ' O ' ' O ' ' A' ' 27' ' ' ASN . 68.6 mttm -50.41 -110.85 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.602 0 CA-C-O 121.846 0.832 . . . . 0.0 109.842 178.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -83.66 94.66 1.82 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 108.45 -1.86 . . . . 0.0 108.45 176.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.479 ' CB ' HD21 ' A' ' 27' ' ' ASN . . . -92.54 160.65 14.94 Favored 'General case' 0 CA--C 1.504 -0.802 0 C-N-CA 115.599 -2.441 . . . . 0.0 109.703 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.537 ' CG2' HD12 ' B' ' 31' ' ' ILE . 0.3 OUTLIER -154.31 119.68 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.852 0 CA-C-N 114.0 -1.455 . . . . 0.0 109.878 -173.729 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.51 ' O ' ' SD ' ' G' ' 35' ' ' MET . 96.5 mt -119.44 112.45 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 120.588 -0.445 . . . . 0.0 111.103 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.21 106.64 1.45 Allowed Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.988 -1.645 . . . . 0.0 108.988 178.335 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.407 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 34.7 tp -149.11 147.19 28.19 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 118.124 0.962 . . . . 0.0 113.028 -178.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.511 ' SD ' ' N ' ' G' ' 33' ' ' GLY . 53.5 ttp -141.43 146.35 36.42 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.331 179.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.2 t -128.89 79.61 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.727 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.949 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.51 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -96.99 97.85 2.06 Favored Glycine 0 C--N 1.338 0.681 0 N-CA-C 109.599 -1.401 . . . . 0.0 109.599 177.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.13 167.81 39.68 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.341 -0.933 . . . . 0.0 111.541 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.37 137.42 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.742 -179.821 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.267 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -116.15 138.92 50.85 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.736 0.303 . . . . 0.0 110.434 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -56.37 136.14 53.71 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.899 0.38 . . . . 0.0 110.543 -179.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -137.22 153.13 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.446 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 70.4 m80 -117.09 160.1 21.53 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.1 179.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 16.3 p-80 -77.34 171.94 14.08 Favored 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.432 ' H ' ' HA ' ' C' ' 15' ' ' GLN . 54.0 tt0 -149.48 176.0 11.0 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -179.578 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.558 ' NZ ' ' CG2' ' B' ' 18' ' ' VAL . 62.4 tttm -140.3 123.3 16.59 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 121.233 0.54 . . . . 0.0 111.407 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 15.1 mt -118.37 124.08 46.86 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.093 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.558 ' CG2' ' NZ ' ' B' ' 16' ' ' LYS . 93.7 t -119.56 121.45 66.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 C-N-CA 120.711 -0.395 . . . . 0.0 110.998 -179.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' E' ' 34' ' ' LEU . 11.8 t80 -115.2 112.22 22.16 Favored 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -132.59 125.76 31.21 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.18 0.514 . . . . 0.0 112.238 -177.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.66 126.28 49.85 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -153.96 159.75 41.81 Favored 'General case' 0 C--N 1.348 0.512 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -121.46 123.06 41.15 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-N 118.535 0.607 . . . . 0.0 111.885 -178.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.17 120.88 55.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 178.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.18 84.11 0.01 OUTLIER Glycine 0 N--CA 1.471 0.986 0 CA-C-N 115.923 -0.581 . . . . 0.0 112.445 179.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 4.3 p -45.88 167.61 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 113.992 1.108 . . . . 0.0 113.992 178.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.519 ' ND2' ' OG ' ' A' ' 26' ' ' SER . 2.2 p30 -137.82 178.87 6.78 Favored 'General case' 0 C--O 1.203 -1.383 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 171.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.499 ' O ' ' O ' ' B' ' 27' ' ' ASN . 61.2 mttp -19.85 -103.13 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 CA-C-N 120.219 1.372 . . . . 0.0 113.338 176.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -142.62 99.94 0.24 Allowed Glycine 0 N--CA 1.485 1.962 0 N-CA-C 107.831 -2.108 . . . . 0.0 107.831 174.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.511 ' H ' ' CE ' ' C' ' 28' ' ' LYS . . . -70.6 156.55 39.3 Favored 'General case' 0 C--O 1.245 0.836 0 C-N-CA 117.064 -1.854 . . . . 0.0 109.399 177.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.537 HD12 ' CG2' ' A' ' 31' ' ' ILE . 0.2 OUTLIER -144.25 115.49 2.35 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.814 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.481 ' O ' ' SD ' ' H' ' 35' ' ' MET . 82.9 mt -121.13 119.62 59.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 -177.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.51 ' CA ' ' SD ' ' H' ' 35' ' ' MET . . . -125.37 117.15 2.87 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 177.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.72 ' O ' HD12 ' C' ' 34' ' ' LEU . 9.6 tt -148.8 154.67 39.87 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.532 -178.487 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 17.6 ttp -147.83 141.57 25.66 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 120.16 -0.616 . . . . 0.0 112.458 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' B' ' 37' ' ' GLY . 38.2 t -131.78 83.28 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 CA-C-N 116.043 -0.526 . . . . 0.0 112.307 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.682 ' HA2' HG21 ' H' ' 31' ' ' ILE . . . -23.45 -93.71 0.01 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 111.818 -0.513 . . . . 0.0 111.818 177.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.88 179.16 40.33 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.404 HG22 ' N ' ' B' ' 40' ' ' VAL . 8.3 p -143.95 153.09 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 CA-C-O 120.937 0.398 . . . . 0.0 110.821 -179.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.404 ' N ' HG22 ' B' ' 39' ' ' VAL . 7.2 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.46 179.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -111.51 146.95 36.38 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.745 0.307 . . . . 0.0 110.378 -179.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 93.3 mt-10 -55.84 146.19 22.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.16 179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.513 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 32.9 m -129.28 156.31 41.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.513 ' CD2' ' O ' ' C' ' 12' ' ' VAL . 48.2 m80 -158.01 151.71 23.75 Favored 'General case' 0 C--N 1.331 -0.227 0 C-N-CA 120.602 -0.439 . . . . 0.0 111.405 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -87.39 -179.67 6.42 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 178.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.432 ' HA ' ' H ' ' B' ' 15' ' ' GLN . 13.1 pt20 -88.2 174.91 7.94 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.958 -179.374 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -123.85 138.77 54.44 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -141.62 131.65 24.62 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 120.422 -0.511 . . . . 0.0 111.764 -179.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.4 p -126.55 130.42 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.307 0.575 . . . . 0.0 109.706 178.362 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.523 ' CE2' HD12 ' F' ' 34' ' ' LEU . 21.2 t80 -117.34 118.52 32.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.135 -178.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -130.35 114.9 16.18 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 118.147 0.43 . . . . 0.0 110.017 179.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.03 126.74 51.54 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 120.645 -0.422 . . . . 0.0 111.549 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -157.73 155.7 30.36 Favored 'General case' 0 C--O 1.226 -0.158 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.524 ' O ' ' NZ ' ' E' ' 28' ' ' LYS . 7.2 t0 -175.21 108.58 0.1 Allowed 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 119.794 -0.762 . . . . 0.0 112.251 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 m -46.46 141.05 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 176.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -86.34 82.82 1.63 Allowed Glycine 0 N--CA 1.463 0.468 0 C-N-CA 118.471 -1.823 . . . . 0.0 110.159 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 50.7 p -100.48 -163.97 1.07 Allowed 'General case' 0 N--CA 1.439 -0.991 0 CA-C-O 122.432 1.11 . . . . 0.0 110.077 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.433 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 61.8 t30 -63.31 179.5 0.42 Allowed 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.266 -1.788 . . . . 0.0 109.344 175.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.511 ' CE ' ' H ' ' B' ' 30' ' ' ALA . 41.5 tttt 55.35 111.08 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.231 0 N-CA-C 118.424 2.75 . . . . 0.0 118.424 178.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.447 ' CA ' ' O ' ' D' ' 29' ' ' GLY . . . -81.63 96.43 1.77 Allowed Glycine 0 CA--C 1.497 -1.088 0 N-CA-C 106.736 -2.546 . . . . 0.0 106.736 171.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.89 163.67 22.1 Favored 'General case' 0 CA--C 1.501 -0.93 0 C-N-CA 116.22 -2.192 . . . . 0.0 108.278 -177.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.622 HG23 ' CG1' ' D' ' 31' ' ' ILE . 0.0 OUTLIER -139.86 108.06 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.433 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.013 -174.85 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.484 ' C ' ' SD ' ' I' ' 35' ' ' MET . 2.0 mt -106.78 117.9 53.48 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 N-CA-C 110.407 -0.22 . . . . 0.0 110.407 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.406 ' O ' ' HA2' ' B' ' 33' ' ' GLY . . . -122.96 94.25 0.51 Allowed Glycine 0 CA--C 1.523 0.577 0 N-CA-C 107.912 -2.075 . . . . 0.0 107.912 177.522 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.72 HD12 ' O ' ' B' ' 34' ' ' LEU . 22.7 tp -124.77 137.03 54.34 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.345 1.069 . . . . 0.0 112.048 -178.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' D' ' 35' ' ' MET . 11.3 mmm -110.97 116.38 31.11 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.835 179.037 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.498 HG13 HD11 ' C' ' 34' ' ' LEU . 2.6 m -142.88 63.45 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 C-N-CA 121.11 -0.236 . . . . 0.0 110.507 -179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -86.09 -110.31 0.79 Allowed Glycine 0 C--N 1.363 2.053 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 69.56 -175.2 34.03 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 179.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -133.92 158.69 42.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.602 -179.728 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.656 -1.377 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -111.39 130.12 55.8 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.771 0.32 . . . . 0.0 110.307 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.455 ' OE2' HG22 ' C' ' 12' ' ' VAL . 34.6 tp10 -136.98 135.91 38.05 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.398 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 14.5 p -141.76 148.22 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 121.04 0.448 . . . . 0.0 111.54 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.448 ' NE2' ' OE2' ' E' ' 11' ' ' GLU . 86.8 m-70 -123.66 125.19 44.36 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.801 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.58 ' CG ' ' N ' ' D' ' 15' ' ' GLN . 82.5 t60 -136.94 166.84 22.71 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-O 121.163 0.506 . . . . 0.0 110.144 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.58 ' N ' ' CG ' ' D' ' 14' ' ' HIS . 51.9 tt0 -161.61 173.23 15.04 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.438 179.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.408 ' N ' ' HG2' ' D' ' 15' ' ' GLN . 65.1 tttp -160.92 110.12 1.65 Allowed 'General case' 0 C--O 1.235 0.307 0 C-N-CA 120.652 -0.419 . . . . 0.0 110.95 179.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 45.6 tp -122.0 115.82 23.21 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.911 178.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 97.4 t -114.35 115.61 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 178.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.572 ' CE1' HD13 ' F' ' 34' ' ' LEU . 0.8 OUTLIER -114.27 109.05 17.77 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 -178.164 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -136.47 130.89 33.28 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.444 0.64 . . . . 0.0 111.621 -177.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.427 ' CB ' ' CD1' ' F' ' 32' ' ' ILE . . . -144.83 145.09 31.47 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.352 179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.4 mt-10 -132.67 102.96 5.89 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.751 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -79.26 112.54 16.59 Favored 'General case' 0 C--O 1.231 0.119 0 C-N-CA 118.099 -1.44 . . . . 0.0 107.631 179.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 89.6 t -60.92 130.38 24.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.694 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -68.74 86.35 0.21 Allowed Glycine 0 CA--C 1.538 1.489 0 CA-C-O 118.67 -1.072 . . . . 0.0 112.618 177.517 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 0.4 OUTLIER 162.18 161.3 0.02 OUTLIER 'General case' 0 C--N 1.345 0.393 0 CA-C-N 119.267 1.533 . . . . 0.0 112.786 176.801 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.462 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 87.1 m-20 -34.07 -179.65 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.032 0 CA-C-N 112.056 -2.338 . . . . 0.0 116.25 179.119 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.595 ' O ' ' O ' ' E' ' 29' ' ' GLY . 86.7 tttt 98.92 114.08 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 128.095 2.558 . . . . 0.0 113.576 176.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.447 ' O ' ' CA ' ' C' ' 29' ' ' GLY . . . -73.39 92.1 0.66 Allowed Glycine 0 N--CA 1.473 1.132 0 CA-C-O 116.284 -2.398 . . . . 0.0 113.159 173.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.87 157.09 35.01 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 123.271 3.536 . . . . 0.0 109.197 176.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.622 ' CG1' HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -145.01 126.1 8.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.892 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.725 -177.216 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.518 ' C ' ' SD ' ' J' ' 35' ' ' MET . 2.1 mt -110.49 110.48 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.277 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.408 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -109.21 95.57 0.91 Allowed Glycine 0 CA--C 1.509 -0.309 0 N-CA-C 107.67 -2.172 . . . . 0.0 107.67 178.35 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.49 HD13 ' O ' ' C' ' 34' ' ' LEU . 0.0 OUTLIER -122.07 120.97 35.87 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-O 121.578 0.704 . . . . 0.0 110.461 -178.395 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.586 ' SD ' ' SD ' ' C' ' 35' ' ' MET . 26.9 ttt -102.02 114.04 27.8 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.364 -1.347 . . . . 0.0 107.364 176.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.475 HG22 HD12 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -126.51 80.64 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.247 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 -178.437 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.22 102.46 0.86 Allowed Glycine 0 C--N 1.353 1.475 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.88 -167.06 38.9 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 40' ' ' VAL . 53.9 t -123.07 136.89 58.35 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 N-CA-C 110.067 -0.346 . . . . 0.0 110.067 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.417 ' O ' ' O ' ' D' ' 39' ' ' VAL . 18.0 m . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.47 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -111.61 133.13 54.07 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.855 0.359 . . . . 0.0 110.95 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.496 ' O ' ' O ' ' F' ' 11' ' ' GLU . 39.1 tp10 -120.51 127.39 52.14 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.508 -0.552 . . . . 0.0 109.508 179.289 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 73.8 t -134.13 134.36 55.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 O-C-N 123.322 0.389 . . . . 0.0 110.466 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 58.0 m80 -119.47 133.64 55.59 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 120.884 0.373 . . . . 0.0 110.933 -179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.474 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 85.2 t60 -143.3 165.41 27.55 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 178.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.474 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 81.8 mt-30 -154.94 179.16 9.39 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.359 179.562 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.35 108.13 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.692 179.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -126.99 121.93 33.06 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.025 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 77.4 t -125.88 127.53 71.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 120.746 0.307 . . . . 0.0 110.881 -179.718 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 26.0 t80 -126.47 120.53 29.94 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.514 179.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 7.1 m-85 -133.9 127.36 32.34 Favored 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 121.027 0.442 . . . . 0.0 110.263 179.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.29 128.42 41.51 Favored 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.341 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -110.56 167.69 10.02 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.345 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' E' ' 24' ' ' VAL . 14.3 t0 -173.11 -125.28 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.389 -177.144 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.519 ' N ' ' OD1' ' E' ' 23' ' ' ASP . 7.9 t 31.61 115.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -179.331 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -90.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 106.001 -2.84 . . . . 0.0 106.001 179.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.544 ' O ' ' O ' ' E' ' 27' ' ' ASN . 27.9 p -152.03 155.0 37.1 Favored 'General case' 0 CA--C 1.509 -0.617 0 CA-C-N 119.224 1.512 . . . . 0.0 109.067 172.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.544 ' O ' ' O ' ' E' ' 26' ' ' SER . 17.0 m120 -20.01 157.83 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 114.092 1.145 . . . . 0.0 114.092 176.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.663 ' HB3' ' HB2' ' F' ' 30' ' ' ALA . 75.4 tttt -162.88 110.89 1.28 Allowed 'General case' 0 C--N 1.329 -0.307 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.09 170.41 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.595 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -68.53 92.12 0.27 Allowed Glycine 0 C--O 1.218 -0.852 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 174.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.41 150.56 33.73 Favored 'General case' 0 CA--C 1.464 -2.345 0 N-CA-C 105.431 -2.063 . . . . 0.0 105.431 175.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.426 ' HA ' ' O ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -151.24 117.24 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.803 0 C-N-CA 118.679 -1.208 . . . . 0.0 110.042 -172.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mm -99.56 112.99 33.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.738 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.44 ' H ' ' HE1' ' J' ' 35' ' ' MET . . . -109.28 85.9 0.42 Allowed Glycine 0 CA--C 1.499 -0.963 0 N-CA-C 104.884 -3.286 . . . . 0.0 104.884 175.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.549 ' CD1' ' CZ ' ' B' ' 19' ' ' PHE . 6.4 tt -130.31 134.05 46.91 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-O 121.787 0.803 . . . . 0.0 111.717 -177.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.7 ttm -122.91 125.34 45.15 Favored 'General case' 0 CA--C 1.501 -0.914 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.484 179.453 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.58 ' CG2' HD21 ' F' ' 34' ' ' LEU . 0.0 OUTLIER -124.32 81.07 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 177.687 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.497 ' HA2' HD13 ' K' ' 31' ' ' ILE . . . 34.42 -101.66 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.681 -0.567 . . . . 0.0 111.681 178.231 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.94 -172.21 33.89 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.784 -0.927 . . . . 0.0 110.784 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -136.06 161.2 38.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.893 0.378 . . . . 0.0 110.595 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 8.8 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.362 179.788 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -82.23 139.25 34.35 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.496 ' O ' ' O ' ' E' ' 11' ' ' GLU . 97.6 mt-10 -124.88 167.03 15.23 Favored 'General case' 0 N--CA 1.463 0.182 0 CA-C-O 121.302 0.572 . . . . 0.0 110.79 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.401 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.3 p -147.3 156.72 10.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.719 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.645 ' CG ' ' N ' ' F' ' 14' ' ' HIS . 46.4 t-80 -111.62 175.18 5.53 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.645 ' N ' ' CG ' ' F' ' 13' ' ' HIS . 98.1 m-70 -70.2 177.05 3.47 Favored 'General case' 0 N--CA 1.44 -0.936 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.473 ' OE1' ' N ' ' E' ' 15' ' ' GLN . 57.7 mm-40 -133.26 179.19 6.35 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.278 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 85.8 tttt -151.29 106.06 3.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.21 0.528 . . . . 0.0 110.695 179.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 tt -127.81 121.58 30.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.182 179.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -137.51 129.93 41.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 120.192 -0.603 . . . . 0.0 111.532 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -120.1 128.1 53.15 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.577 179.133 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -142.37 130.14 21.62 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.973 0.416 . . . . 0.0 110.035 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.53 141.02 26.59 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.739 0.304 . . . . 0.0 110.474 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 74.4 tt0 -92.51 115.46 28.11 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 179.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 -73.87 134.32 43.25 Favored 'General case' 0 N--CA 1.462 0.126 0 CA-C-O 121.169 0.509 . . . . 0.0 111.317 -178.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.514 ' O ' ' N ' ' F' ' 26' ' ' SER . 62.4 t -89.4 112.75 24.8 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.223 179.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.538 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . -46.05 92.16 0.01 OUTLIER Glycine 0 CA--C 1.533 1.213 0 N-CA-C 110.209 -1.157 . . . . 0.0 110.209 177.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.548 ' O ' ' O ' ' F' ' 27' ' ' ASN . 68.0 m 121.04 172.43 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 -178.76 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.548 ' O ' ' O ' ' F' ' 26' ' ' SER . 15.4 p30 -41.21 176.37 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 121.127 0.489 . . . . 0.0 111.476 -179.006 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 43.9 tttm -75.33 110.44 9.68 Favored 'General case' 0 N--CA 1.463 0.178 0 N-CA-C 113.005 0.743 . . . . 0.0 113.005 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -51.79 -99.33 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.712 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 177.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.663 ' HB2' ' HB3' ' E' ' 28' ' ' LYS . . . -80.37 170.95 15.69 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 103.356 -2.831 . . . . 0.0 103.356 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' E' ' 31' ' ' ILE . 0.0 OUTLIER -138.94 117.13 12.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 C-N-CA 118.043 -1.463 . . . . 0.0 111.398 -172.473 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.476 ' O ' HG23 ' F' ' 32' ' ' ILE . 12.9 tt -103.86 123.2 57.41 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.261 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.19 102.75 1.04 Allowed Glycine 0 N--CA 1.448 -0.502 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.58 HD21 ' CG2' ' E' ' 36' ' ' VAL . 3.4 tt -122.95 113.36 18.99 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 178.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.473 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.3 ttt -95.39 121.88 37.53 Favored 'General case' 0 C--O 1.239 0.546 0 C-N-CA 120.551 -0.459 . . . . 0.0 110.606 -178.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.561 HG13 ' CD2' ' F' ' 34' ' ' LEU . 0.5 OUTLIER -138.3 80.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.614 -178.749 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 40.57 -103.25 0.03 OUTLIER Glycine 0 C--N 1.346 1.11 0 C-N-CA 120.613 -0.803 . . . . 0.0 112.214 177.154 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -147.84 7.77 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 40' ' ' VAL . 55.9 t -121.41 136.39 58.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-O 120.874 0.368 . . . . 0.0 110.766 -179.351 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' F' ' 39' ' ' VAL . 2.3 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.592 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 88.5 m-85 -108.15 137.93 45.29 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.846 0.355 . . . . 0.0 110.482 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -125.33 145.67 49.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.077 179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 7.4 m -119.78 134.79 62.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 121.134 0.492 . . . . 0.0 110.851 -179.738 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.8 t-80 -142.63 140.26 31.56 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.01 -179.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -88.74 169.13 11.9 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.332 0.587 . . . . 0.0 110.532 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 88.7 mt-30 -151.4 177.67 10.05 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.486 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 85.7 tttt -137.58 129.11 28.27 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.665 -179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.5 tp -123.8 125.84 45.41 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -131.39 127.71 60.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 N-CA-C 112.434 0.531 . . . . 0.0 112.434 -178.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.601 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 9.5 m-85 -113.58 117.5 31.81 Favored 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 176.595 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.518 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 39.9 p90 -130.37 118.02 20.61 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 121.034 -0.266 . . . . 0.0 111.558 -179.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.484 ' O ' ' OE1' ' H' ' 22' ' ' GLU . . . -117.96 117.4 29.13 Favored 'General case' 0 N--CA 1.478 0.929 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.432 ' HG2' ' H ' ' G' ' 23' ' ' ASP . 68.4 tt0 -144.75 175.0 10.5 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 123.729 0.643 . . . . 0.0 109.815 -179.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.432 ' H ' ' HG2' ' G' ' 22' ' ' GLU . 15.8 t0 -64.85 113.55 3.9 Favored 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 112.025 0.379 . . . . 0.0 112.025 -178.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.442 ' H ' ' HA2' ' H' ' 25' ' ' GLY . 60.1 t -127.22 121.54 57.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.725 0 N-CA-C 107.621 -1.251 . . . . 0.0 107.621 177.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' G' ' 24' ' ' VAL . . . -29.22 -85.87 0.01 OUTLIER Glycine 0 CA--C 1.535 1.317 0 CA-C-O 121.607 0.559 . . . . 0.0 113.481 179.044 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 11.6 t 65.7 176.2 0.22 Allowed 'General case' 0 N--CA 1.449 -0.514 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 -178.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 91.7 m-20 -88.06 177.31 6.96 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 119.011 -1.076 . . . . 0.0 109.98 176.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -56.73 110.41 0.79 Allowed 'General case' 0 CA--C 1.538 0.503 0 CA-C-O 118.612 -0.709 . . . . 0.0 111.895 175.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.507 ' H ' ' CB ' ' H' ' 27' ' ' ASN . . . 72.12 94.51 0.08 OUTLIER Glycine 0 N--CA 1.469 0.897 0 C-N-CA 118.165 -1.969 . . . . 0.0 112.391 174.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.87 156.13 19.02 Favored 'General case' 0 CA--C 1.507 -0.679 0 CA-C-N 120.004 1.902 . . . . 0.0 107.885 178.066 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.51 HG21 ' HA3' ' A' ' 37' ' ' GLY . 0.4 OUTLIER -152.53 106.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.722 0 CA-C-N 115.347 -0.842 . . . . 0.0 108.835 -173.187 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.447 ' C ' ' SD ' ' A' ' 35' ' ' MET . 50.3 mm -124.56 130.57 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.103 -178.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.511 ' N ' ' SD ' ' A' ' 35' ' ' MET . . . -135.57 125.5 3.65 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.586 -1.005 . . . . 0.0 110.586 179.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.4 tp -144.82 136.85 25.92 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.258 0.529 . . . . 0.0 111.857 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.51 ' SD ' ' O ' ' A' ' 32' ' ' ILE . 11.4 ttt -133.66 144.71 49.36 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.401 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 12.4 t -102.51 72.51 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.463 ' CA ' HG21 ' A' ' 31' ' ' ILE . . . -109.46 100.71 1.38 Allowed Glycine 0 C--N 1.341 0.837 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 177.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.93 170.96 41.62 Favored Glycine 0 CA--C 1.525 0.66 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.423 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.449 HG22 HG23 ' G' ' 40' ' ' VAL . 5.6 p -135.8 143.33 36.64 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 CA-C-O 120.785 0.326 . . . . 0.0 110.52 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.449 HG23 HG22 ' G' ' 39' ' ' VAL . 80.5 t . . . . . 0 C--O 1.218 -0.565 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.565 -179.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -82.46 145.46 29.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.732 0.301 . . . . 0.0 110.593 -179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -132.03 137.09 47.69 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-O 121.194 0.521 . . . . 0.0 110.751 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 69.1 t -121.75 134.03 66.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.546 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 t-80 -142.49 103.46 4.25 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 120.618 -0.433 . . . . 0.0 111.197 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.434 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 33.4 p-80 -152.23 168.7 24.5 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 84.8 mt-30 -150.58 171.96 16.27 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.151 179.02 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -134.45 118.39 17.32 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.245 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -118.57 121.33 39.96 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 62.3 t -124.43 126.28 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 120.976 0.417 . . . . 0.0 110.421 179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.511 ' CZ ' ' CD1' ' K' ' 34' ' ' LEU . 2.5 m-85 -119.16 108.91 15.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.489 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -117.17 115.62 25.68 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 177.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.607 ' HB2' HD12 ' J' ' 32' ' ' ILE . . . -129.1 130.09 46.04 Favored 'General case' 0 C--O 1.242 0.671 0 N-CA-C 113.786 1.032 . . . . 0.0 113.786 -177.519 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.566 ' O ' ' O ' ' H' ' 23' ' ' ASP . 52.4 mp0 -142.29 141.9 32.48 Favored 'General case' 0 N--CA 1.443 -0.799 0 CA-C-N 113.825 -1.534 . . . . 0.0 107.194 176.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.566 ' O ' ' O ' ' H' ' 22' ' ' GLU . 7.6 t0 -54.79 -130.63 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' H' ' 23' ' ' ASP . 32.7 m 28.49 111.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 N-CA-C 115.703 1.742 . . . . 0.0 115.703 178.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.442 ' HA2' ' H ' ' G' ' 24' ' ' VAL . . . -160.86 -91.24 0.08 OUTLIER Glycine 0 CA--C 1.521 0.428 0 N-CA-C 109.102 -1.599 . . . . 0.0 109.102 177.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.473 ' HB2' ' HB2' ' H' ' 30' ' ' ALA . 0.1 OUTLIER -101.81 -163.2 0.99 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 119.551 1.676 . . . . 0.0 109.487 176.603 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.507 ' CB ' ' H ' ' G' ' 29' ' ' GLY . 66.5 t30 -61.8 177.62 0.41 Allowed 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 113.775 -1.557 . . . . 0.0 111.777 177.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.489 ' H ' ' CG ' ' H' ' 27' ' ' ASN . 60.1 tttm -47.51 111.06 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.291 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 92.43 -95.71 2.05 Favored Glycine 0 C--O 1.207 -1.591 0 CA-C-N 114.595 -1.184 . . . . 0.0 110.217 -176.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.605 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . 70.44 145.37 0.06 Allowed 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 103.141 -2.911 . . . . 0.0 103.141 -176.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.682 HG21 ' HA2' ' B' ' 37' ' ' GLY . 5.2 tt -163.34 124.61 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 115.783 -2.367 . . . . 0.0 112.266 -177.206 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 95.9 mt -120.22 122.94 69.61 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 CA-C-N 113.947 -1.478 . . . . 0.0 109.951 -178.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.28 117.08 2.46 Favored Glycine 0 N--CA 1.47 0.9 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 4.3 mp -125.73 141.97 51.74 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 121.277 0.561 . . . . 0.0 111.127 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.51 ' SD ' ' CA ' ' B' ' 33' ' ' GLY . 23.2 ttt -140.39 126.58 19.8 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.127 0.489 . . . . 0.0 111.303 -178.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 11.8 t -122.68 74.06 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.024 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.42 101.49 2.32 Favored Glycine 0 C--N 1.344 1.023 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 178.526 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.65 159.13 31.78 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 120.245 -0.979 . . . . 0.0 111.722 -179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -125.9 134.64 66.09 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.885 -1.055 . . . . 0.0 110.552 -179.903 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -113.4 135.94 53.32 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.958 0.408 . . . . 0.0 110.644 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 81.1 mm-40 -122.0 129.49 52.5 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.892 -0.594 . . . . 0.0 110.066 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m -143.5 140.22 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-O 120.884 0.373 . . . . 0.0 110.721 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 48.2 m-70 -144.07 104.43 4.13 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.855 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.434 ' O ' ' CB ' ' H' ' 14' ' ' HIS . 5.3 m170 -130.82 169.03 16.27 Favored 'General case' 0 C--O 1.221 -0.442 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 81.2 mt-30 -155.31 172.14 18.69 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 178.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -145.09 125.1 13.56 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.717 0.294 . . . . 0.0 111.279 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 37.9 tp -125.82 117.46 23.43 Favored 'General case' 0 N--CA 1.472 0.626 0 CA-C-O 120.806 0.336 . . . . 0.0 110.35 179.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 69.7 t -122.59 127.96 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.553 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.934 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.478 ' CD2' HD23 ' L' ' 34' ' ' LEU . 1.1 m-85 -121.91 117.25 26.0 Favored 'General case' 0 N--CA 1.47 0.575 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 178.357 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.411 ' CE2' ' CD1' ' J' ' 20' ' ' PHE . 42.0 t80 -126.24 123.76 38.88 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.712 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.32 132.07 42.59 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.813 0.339 . . . . 0.0 111.412 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -155.93 157.33 36.09 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.767 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.505 ' HB2' ' HZ1' ' K' ' 28' ' ' LYS . 7.1 t70 -111.6 101.83 10.2 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 121.415 0.626 . . . . 0.0 110.655 179.558 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.492 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.9 p -90.01 159.65 2.83 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.068 179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 49.64 -80.28 0.01 OUTLIER Glycine 0 CA--C 1.531 1.073 0 CA-C-O 119.382 -0.677 . . . . 0.0 112.955 -179.126 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.621 ' O ' ' O ' ' I' ' 27' ' ' ASN . 1.4 p 170.84 -179.53 0.05 OUTLIER 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 118.445 1.122 . . . . 0.0 110.577 -177.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.621 ' O ' ' O ' ' I' ' 26' ' ' SER . 42.0 p-10 -28.31 -179.82 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 116.003 1.853 . . . . 0.0 116.003 -177.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.445 ' CB ' ' O ' ' I' ' 27' ' ' ASN . 83.9 mttt 128.77 103.38 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 111.828 -2.442 . . . . 0.0 108.571 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.647 ' O ' ' O ' ' H' ' 29' ' ' GLY . . . -59.25 100.32 0.18 Allowed Glycine 0 CA--C 1.486 -1.756 0 CA-C-N 114.984 -1.007 . . . . 0.0 110.665 177.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' H' ' 29' ' ' GLY . . . -112.47 144.67 41.54 Favored 'General case' 0 CA--C 1.494 -1.201 0 N-CA-C 103.869 -2.641 . . . . 0.0 103.869 177.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.555 HD12 HD12 ' H' ' 31' ' ' ILE . 1.1 mt -137.98 107.21 4.28 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.944 0 C-N-CA 118.251 -1.38 . . . . 0.0 110.472 -174.137 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -117.66 130.75 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 CA-C-O 120.981 0.42 . . . . 0.0 110.115 179.094 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' J' ' 33' ' ' GLY . . . -134.18 134.01 7.17 Favored Glycine 0 CA--C 1.503 -0.673 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 177.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.496 ' H ' ' HG ' ' J' ' 34' ' ' LEU . 3.8 tt -145.89 131.21 18.56 Favored 'General case' 0 C--N 1.32 -0.697 0 C-N-CA 119.003 -1.079 . . . . 0.0 110.799 -179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.484 ' SD ' ' C ' ' C' ' 32' ' ' ILE . 8.7 ttt -112.91 119.75 39.04 Favored 'General case' 0 N--CA 1.446 -0.667 0 CA-C-N 114.263 -1.335 . . . . 0.0 108.395 179.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.1 OUTLIER -118.53 72.38 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.645 -179.504 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -31.15 -100.25 0.01 OUTLIER Glycine 0 C--N 1.369 2.373 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 178.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -175.89 40.73 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.1 t -134.37 152.48 33.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 m . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.497 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . 0.436 ' O ' ' CE2' ' K' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.367 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 68.3 t80 -123.15 119.37 30.05 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -137.36 134.2 35.71 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.589 0.233 . . . . 0.0 110.388 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.449 ' CG1' ' CG ' ' K' ' 13' ' ' HIS . 61.8 t -126.01 132.81 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.953 -179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' K' ' 13' ' ' HIS . 66.4 m80 -119.64 140.65 50.29 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.418 -0.216 . . . . 0.0 110.418 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.6 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 59.5 t60 -151.83 167.78 27.2 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-O 121.204 0.526 . . . . 0.0 109.77 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.6 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 66.7 tp60 -158.32 164.31 36.51 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.613 178.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.415 ' N ' ' HG3' ' J' ' 15' ' ' GLN . 50.3 tttp -157.99 116.29 3.08 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.259 -0.428 . . . . 0.0 109.977 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.657 HD23 ' C ' ' J' ' 17' ' ' LEU . 7.2 tt -131.35 123.26 27.89 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.262 -0.273 . . . . 0.0 110.262 -179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . 0.545 ' N ' HD23 ' J' ' 17' ' ' LEU . 2.7 p -132.51 127.91 57.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.33 0.586 . . . . 0.0 111.636 179.327 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.6 ' CE1' HD21 ' J' ' 17' ' ' LEU . 6.1 m-30 -109.17 119.2 38.8 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 115.079 -0.964 . . . . 0.0 108.648 178.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.418 ' CE2' ' CD2' ' K' ' 20' ' ' PHE . 34.6 t80 -124.58 113.7 18.41 Favored 'General case' 0 C--N 1.331 -0.233 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.33 134.23 47.81 Favored 'General case' 0 N--CA 1.467 0.379 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.491 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -134.75 105.99 6.71 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 120.763 -0.375 . . . . 0.0 110.676 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -85.41 114.24 22.31 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' J' ' 25' ' ' GLY . 4.6 p -122.56 122.9 67.24 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 108.428 -0.952 . . . . 0.0 108.428 -179.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' J' ' 24' ' ' VAL . . . 34.61 84.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.141 0 N-CA-C 109.75 -1.34 . . . . 0.0 109.75 -177.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.461 ' CB ' ' O ' ' K' ' 27' ' ' ASN . 6.0 m -46.2 152.05 0.45 Allowed 'General case' 0 N--CA 1.431 -1.395 0 CA-C-N 113.722 -1.239 . . . . 0.0 114.066 -177.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.445 ' O ' ' O ' ' J' ' 28' ' ' LYS . 65.9 m-80 -138.02 178.0 7.45 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 114.454 -1.248 . . . . 0.0 109.881 172.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.888 ' HZ3' ' H ' ' J' ' 29' ' ' GLY . 0.9 OUTLIER -20.43 -104.12 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.072 0 N-CA-C 114.413 1.264 . . . . 0.0 114.413 177.668 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.888 ' H ' ' HZ3' ' J' ' 28' ' ' LYS . . . -167.45 96.88 0.13 Allowed Glycine 0 C--N 1.361 1.919 0 CA-C-O 117.472 -1.738 . . . . 0.0 110.745 176.179 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.562 ' HB2' ' OD1' ' H' ' 23' ' ' ASP . . . -68.2 167.44 14.25 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 123.128 3.464 . . . . 0.0 106.884 177.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.55 HD12 HG23 ' I' ' 31' ' ' ILE . 0.3 OUTLIER -145.14 123.79 5.53 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.328 0 CA-C-N 121.128 1.786 . . . . 0.0 111.943 -176.924 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.607 HD12 ' HB2' ' H' ' 21' ' ' ALA . 0.1 OUTLIER -122.33 122.52 66.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.268 0 N-CA-C 107.986 -1.116 . . . . 0.0 107.986 178.891 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.565 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -131.17 100.97 0.47 Allowed Glycine 0 N--CA 1.476 1.302 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 -179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.601 ' CD2' ' CZ ' ' G' ' 19' ' ' PHE . 6.0 mp -131.78 138.54 48.61 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-O 122.696 1.236 . . . . 0.0 113.906 -176.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.518 ' SD ' ' C ' ' D' ' 32' ' ' ILE . 4.9 ttm -116.66 119.57 35.91 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 113.799 -1.546 . . . . 0.0 109.66 179.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.61 77.03 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.074 0 CA-C-N 115.802 -0.635 . . . . 0.0 109.738 -179.169 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' I' ' 37' ' ' GLY . . . -84.57 103.97 2.69 Favored Glycine 0 C--N 1.355 1.596 0 N-CA-C 110.696 -0.962 . . . . 0.0 110.696 179.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.46 170.9 55.14 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 65.6 t -131.47 136.02 58.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.947 0.403 . . . . 0.0 110.536 -179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.035 -0.983 . . . . 0.0 110.517 179.817 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . 0.436 ' CE2' ' O ' ' J' ' 9' ' ' GLY . 93.3 m-85 -112.68 133.95 54.45 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.402 ' OE2' ' O ' ' L' ' 10' ' ' TYR . 79.7 mm-40 -137.43 139.23 40.53 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.96 0.409 . . . . 0.0 110.792 -179.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 58.1 t -127.63 132.54 69.02 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.238 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.476 ' O ' ' O ' ' J' ' 13' ' ' HIS . 22.1 m170 -79.26 149.1 31.95 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.86 -179.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.559 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 24.5 p-80 -78.84 178.08 8.21 Favored 'General case' 0 N--CA 1.444 -0.761 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -117.87 175.88 5.46 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.574 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 77.4 tttt -145.14 118.52 9.01 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 120.911 0.386 . . . . 0.0 111.205 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.441 HD12 HE21 ' L' ' 15' ' ' GLN . 34.1 mt -124.77 118.8 27.21 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.37 138.15 45.32 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 CA-C-O 121.644 0.735 . . . . 0.0 112.633 -178.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -124.21 127.67 48.06 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.288 179.236 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.418 ' CD2' ' CE2' ' J' ' 20' ' ' PHE . 71.5 t80 -133.09 121.07 22.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.56 133.69 31.14 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.476 0.655 . . . . 0.0 112.665 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 96.4 mt-10 -117.69 124.66 49.07 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.502 -0.772 . . . . 0.0 109.211 178.327 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' K' ' 22' ' ' GLU . 14.5 m-20 -140.15 111.89 7.42 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' K' ' 26' ' ' SER . 6.3 m -129.55 -122.48 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 108.048 -1.094 . . . . 0.0 108.048 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 31.63 -84.25 0.0 OUTLIER Glycine 0 N--CA 1.474 1.183 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 -179.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.623 ' O ' ' O ' ' K' ' 27' ' ' ASN . 3.9 p 170.93 170.64 0.07 Allowed 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.209 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.623 ' O ' ' O ' ' K' ' 26' ' ' SER . 93.6 m-20 -18.75 157.48 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 O-C-N 124.554 1.159 . . . . 0.0 113.849 -178.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.53 ' O ' ' O ' ' K' ' 29' ' ' GLY . 88.1 tttt -170.47 104.95 0.28 Allowed 'General case' 0 C--O 1.215 -0.729 0 CA-C-O 117.709 -1.139 . . . . 0.0 109.01 176.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -50.65 -99.08 0.01 OUTLIER Glycine 0 C--O 1.214 -1.126 0 C-N-CA 116.6 -2.714 . . . . 0.0 110.994 178.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . 70.74 141.91 0.05 Allowed 'General case' 0 CA--C 1.498 -1.022 0 N-CA-C 102.616 -3.105 . . . . 0.0 102.616 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.497 HD13 ' HA2' ' E' ' 37' ' ' GLY . 0.2 OUTLIER -147.95 110.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 122.298 2.317 . . . . 0.0 111.214 -176.903 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.57 HG22 HD11 ' L' ' 34' ' ' LEU . 10.6 mt -106.61 113.4 43.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.515 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 175.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.7 115.2 2.29 Favored Glycine 0 C--N 1.317 -0.519 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 1.037 HD21 HG13 ' K' ' 36' ' ' VAL . 0.8 OUTLIER -150.42 143.27 24.69 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 122.732 1.253 . . . . 0.0 112.631 -178.526 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 29.4 ttm -117.67 122.21 42.93 Favored 'General case' 0 CA--C 1.508 -0.637 0 CA-C-N 113.664 -1.607 . . . . 0.0 109.308 179.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 1.037 HG13 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -116.2 79.76 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 178.131 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.23 103.91 0.4 Allowed Glycine 0 C--N 1.351 1.377 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.48 -163.11 15.38 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -117.1 136.27 54.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 120.833 0.349 . . . . 0.0 110.623 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 86.6 t . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.455 179.868 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.428 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . 0.402 ' O ' ' OE2' ' K' ' 11' ' ' GLU . 94.9 m-85 -108.48 137.52 46.3 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 120.901 0.381 . . . . 0.0 110.928 -179.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -96.34 158.89 15.23 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 179.34 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.8 t -122.16 133.14 69.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.823 0.344 . . . . 0.0 110.562 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' L' ' 14' ' ' HIS . 65.6 t60 -160.24 117.53 2.51 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.173 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.474 ' ND1' ' O ' ' L' ' 13' ' ' HIS . 80.1 m-70 -151.51 174.55 13.27 Favored 'General case' 0 N--CA 1.444 -0.737 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 -179.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.441 HE21 HD12 ' K' ' 17' ' ' LEU . 54.8 tt0 -146.08 170.59 16.36 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . 0.427 ' N ' ' HG2' ' L' ' 15' ' ' GLN . 99.0 mttt -148.89 117.85 6.72 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.662 0.268 . . . . 0.0 110.303 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.538 HD23 ' C ' ' L' ' 17' ' ' LEU . 7.2 tt -126.48 115.89 20.26 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.215 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 m -136.62 137.2 47.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 CA-C-O 121.005 0.431 . . . . 0.0 110.426 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 p90 -134.28 133.81 41.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.237 0.541 . . . . 0.0 111.275 -179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 92.3 t80 -135.56 124.74 24.51 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-N 115.273 -0.876 . . . . 0.0 108.722 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -150.37 146.45 26.72 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.329 -0.548 . . . . 0.0 111.594 -179.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 50.4 tp10 -104.17 102.15 11.88 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 177.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -91.87 113.64 25.96 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.354 0.502 . . . . 0.0 112.354 -177.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.562 ' O ' ' N ' ' L' ' 26' ' ' SER . 85.2 t -65.95 131.26 31.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 177.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.439 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . -54.53 84.51 0.01 OUTLIER Glycine 0 CA--C 1.528 0.892 0 N-CA-C 110.478 -1.049 . . . . 0.0 110.478 -179.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.562 ' N ' ' O ' ' L' ' 24' ' ' VAL . 1.4 p 159.82 178.88 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.473 ' O ' ' O ' ' L' ' 26' ' ' SER . 21.2 p30 -41.92 177.64 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.029 0 CA-C-N 115.425 -0.807 . . . . 0.0 113.053 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.551 ' NZ ' ' O ' ' L' ' 30' ' ' ALA . 8.6 tptp -75.2 110.57 9.64 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 114.708 -1.133 . . . . 0.0 112.31 178.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.504 ' O ' ' O ' ' K' ' 28' ' ' LYS . . . -51.29 -99.87 0.01 OUTLIER Glycine 0 C--N 1.317 -0.513 0 CA-C-O 119.054 -0.859 . . . . 0.0 111.607 179.714 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.551 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . . . -80.48 163.91 23.41 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 104.75 -2.315 . . . . 0.0 104.75 -178.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.411 HD13 HG21 ' L' ' 31' ' ' ILE . 0.2 OUTLIER -135.28 128.85 49.28 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 C-N-CA 116.487 -2.085 . . . . 0.0 113.038 -174.155 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.57 ' HB ' HD13 ' L' ' 34' ' ' LEU . 2.0 pt -117.52 114.94 47.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 114.67 -1.15 . . . . 0.0 109.232 178.819 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . 0.731 ' C ' HD12 ' L' ' 34' ' ' LEU . . . -112.8 90.64 0.56 Allowed Glycine 0 N--CA 1.463 0.47 0 N-CA-C 106.029 -2.828 . . . . 0.0 106.029 176.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.731 HD12 ' C ' ' L' ' 33' ' ' GLY . 9.1 mp -116.16 134.59 54.76 Favored 'General case' 0 CA--C 1.507 -0.685 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.747 -176.412 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 77.7 mmm -119.62 119.47 33.84 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.683 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' L' ' 37' ' ' GLY . 1.2 m -125.64 76.54 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.571 0 CA-C-N 115.043 -0.981 . . . . 0.0 108.657 178.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -37.12 105.71 0.04 OUTLIER Glycine 0 C--N 1.356 1.646 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.86 172.15 6.81 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.933 -0.467 . . . . 0.0 111.933 -177.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 14.9 p -133.57 144.07 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 115.457 -0.371 . . . . 0.0 110.362 -179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.503 HG13 HD22 ' F' ' 27' ' ' ASN . 21.9 m . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.558 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -148.36 159.47 43.98 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 179.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.8 tp10 -134.52 127.32 31.13 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-O 121.242 0.544 . . . . 0.0 110.866 -179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 34.9 m -139.3 163.78 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -107.24 119.41 39.33 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.687 0.28 . . . . 0.0 111.032 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 75.3 m80 -100.27 165.88 11.25 Favored 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -156.23 174.14 15.83 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.887 178.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttp -175.8 115.76 0.14 Allowed 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.377 179.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 97.0 mt -124.89 115.69 21.03 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 121.119 0.485 . . . . 0.0 110.439 179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.2 m -122.14 126.92 75.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.355 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.935 ' CZ ' HD13 ' C' ' 34' ' ' LEU . 0.6 OUTLIER -117.85 113.52 21.9 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 -179.418 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 t80 -122.87 116.42 23.61 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -179.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.79 119.87 38.11 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 120.787 -0.365 . . . . 0.0 111.22 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -174.79 108.57 0.11 Allowed 'General case' 0 CA--C 1.528 0.098 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 179.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -74.09 114.6 12.61 Favored 'General case' 0 C--N 1.329 -0.324 0 C-N-CA 119.98 -0.688 . . . . 0.0 109.782 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.56 ' O ' HG23 ' A' ' 24' ' ' VAL . 27.9 m -121.46 123.54 69.85 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.769 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.4 82.09 0.01 OUTLIER Glycine 0 CA--C 1.53 0.971 0 CA-C-N 115.599 -0.728 . . . . 0.0 113.259 177.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.616 ' O ' ' O ' ' A' ' 27' ' ' ASN . 58.4 m -140.5 170.68 15.34 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 117.923 0.862 . . . . 0.0 108.942 177.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.616 ' O ' ' O ' ' A' ' 26' ' ' SER . 70.9 m-80 -30.94 174.4 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.707 0 O-C-N 124.29 0.994 . . . . 0.0 113.261 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -89.61 110.84 21.67 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.592 176.416 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 52.09 91.97 0.01 OUTLIER Glycine 0 N--CA 1.467 0.719 0 C-N-CA 119.922 -1.132 . . . . 0.0 110.436 178.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.65 166.77 10.22 Favored 'General case' 0 CA--C 1.512 -0.513 0 CA-C-N 118.906 1.353 . . . . 0.0 110.518 179.512 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.467 HG21 ' CA ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -141.05 107.32 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.682 0 CA-C-N 115.046 -0.979 . . . . 0.0 108.389 -178.137 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 93.6 mt -128.21 130.09 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-O 121.442 0.639 . . . . 0.0 112.291 -177.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.433 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -128.13 110.88 1.2 Allowed Glycine 0 CA--C 1.521 0.439 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 96.0 mt -113.03 124.55 52.88 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 120.908 0.385 . . . . 0.0 110.395 -179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.55 ' SD ' ' CA ' ' G' ' 33' ' ' GLY . 25.7 ttt -130.73 126.32 36.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.893 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.1 t -98.12 65.39 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 112.983 0.735 . . . . 0.0 112.983 -178.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.2 -106.19 0.06 OUTLIER Glycine 0 N--CA 1.44 -1.075 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -95.44 178.16 35.26 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -135.14 140.53 44.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 120.92 0.39 . . . . 0.0 110.275 179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.6 m . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.935 -179.401 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -103.49 130.17 50.81 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.652 0.263 . . . . 0.0 110.481 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -76.85 136.08 38.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.352 -0.386 . . . . 0.0 110.559 179.664 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 27.6 m -135.53 166.04 28.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 CA-C-O 121.165 0.507 . . . . 0.0 111.344 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.585 ' CG ' ' H ' ' B' ' 14' ' ' HIS . 15.3 t-80 -122.86 -164.26 1.18 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.036 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.586 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 19.9 t-80 -71.59 168.05 18.46 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 -179.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.586 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 79.0 mt-30 -152.3 177.47 10.53 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.156 -179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -158.43 128.63 6.02 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 120.554 -0.458 . . . . 0.0 111.672 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -124.44 119.55 29.51 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -129.21 131.84 67.39 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 CA-C-O 121.068 0.461 . . . . 0.0 111.52 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.635 ' CZ ' HD22 ' D' ' 34' ' ' LEU . 7.9 t80 -122.64 115.55 22.3 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.604 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 53.3 t80 -125.59 122.33 36.17 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 110.4 -0.222 . . . . 0.0 110.4 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.52 125.77 45.49 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -179.121 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -163.48 130.23 3.34 Favored 'General case' 0 C--O 1.222 -0.364 0 CA-C-N 115.018 -0.992 . . . . 0.0 108.472 178.489 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' NZ ' ' D' ' 28' ' ' LYS . 66.1 t0 -142.6 113.14 7.31 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -178.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.404 ' H ' HG22 ' B' ' 24' ' ' VAL . 6.0 m -59.32 131.59 23.89 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.13 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 176.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.413 ' HA3' ' O ' ' C' ' 26' ' ' SER . . . -66.36 84.33 0.1 Allowed Glycine 0 CA--C 1.521 0.444 0 C-N-CA 120.357 -0.925 . . . . 0.0 113.313 -178.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 6.3 p -87.77 180.0 6.38 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-O 121.757 0.789 . . . . 0.0 109.438 176.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.487 ' O ' ' O ' ' B' ' 28' ' ' LYS . 51.1 p30 -76.69 179.22 6.17 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 114.342 -1.299 . . . . 0.0 109.578 175.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.487 ' O ' ' O ' ' B' ' 27' ' ' ASN . 68.4 mttm 43.93 110.53 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 115.019 1.489 . . . . 0.0 115.019 175.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' C' ' 29' ' ' GLY . . . -78.76 97.79 1.51 Allowed Glycine 0 CA--C 1.485 -1.827 0 CA-C-N 113.562 -1.654 . . . . 0.0 110.866 -176.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.4 ' C ' HG12 ' B' ' 31' ' ' ILE . . . -75.62 164.75 25.99 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 122.462 1.125 . . . . 0.0 109.658 -175.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.549 HG23 ' CG1' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -137.57 114.04 11.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 CA-C-N 112.63 -2.077 . . . . 0.0 110.504 -170.157 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' I' ' 35' ' ' MET . 96.4 mt -132.83 128.12 56.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 CA-C-O 121.64 0.733 . . . . 0.0 112.805 -177.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.491 ' CA ' ' SD ' ' I' ' 35' ' ' MET . . . -129.74 128.8 5.79 Favored Glycine 0 N--CA 1.471 0.999 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 179.304 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.403 HD21 HG23 ' B' ' 36' ' ' VAL . 2.9 tt -129.25 126.13 38.4 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.149 0.5 . . . . 0.0 111.761 -178.855 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 7.2 tpp -120.86 117.81 28.33 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.428 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.403 HG23 HD21 ' B' ' 34' ' ' LEU . 59.0 t -125.37 78.75 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 N-CA-C 112.649 0.611 . . . . 0.0 112.649 -179.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.66 104.63 2.1 Favored Glycine 0 C--N 1.339 0.723 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.505 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.44 -171.81 0.65 Allowed Glycine 0 CA--C 1.524 0.607 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.106 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.2 m -133.77 163.06 38.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.896 0.379 . . . . 0.0 110.47 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 10.7 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.342 179.727 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.439 0 N-CA-C 109.864 -1.295 . . . . 0.0 109.864 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -116.2 138.53 51.2 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.767 0.318 . . . . 0.0 110.644 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -120.72 128.49 52.99 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.34 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -130.04 134.63 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 179.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.496 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 38.0 t-80 -136.62 127.36 27.25 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.843 0.354 . . . . 0.0 110.61 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.496 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 79.9 m-70 -152.16 164.74 36.69 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 178.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -156.83 171.01 21.16 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.092 178.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.482 ' C ' HD12 ' C' ' 17' ' ' LEU . 98.9 mttt -158.13 113.95 2.74 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.482 HD12 ' C ' ' C' ' 16' ' ' LYS . 11.0 mp -114.46 122.38 46.43 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.45 124.52 62.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.658 -0.246 . . . . 0.0 110.431 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.629 ' CZ ' HD11 ' E' ' 34' ' ' LEU . 1.1 t80 -120.46 111.98 18.39 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.054 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 49.4 t80 -119.84 121.92 40.15 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 120.681 0.277 . . . . 0.0 110.828 -178.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.74 128.92 49.51 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 121.331 0.586 . . . . 0.0 112.065 -179.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -150.37 149.8 30.56 Favored 'General case' 0 C--O 1.226 -0.157 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.959 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -163.77 121.23 1.8 Allowed 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.542 -0.463 . . . . 0.0 110.63 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.479 HG23 ' H ' ' C' ' 25' ' ' GLY . 4.2 m -128.02 -112.17 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.803 -179.02 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.479 ' H ' HG23 ' C' ' 24' ' ' VAL . . . 34.26 -90.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 115.725 -0.671 . . . . 0.0 112.315 -178.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.619 ' O ' ' O ' ' C' ' 27' ' ' ASN . 0.3 OUTLIER 172.0 -170.82 0.03 OUTLIER 'General case' 0 N--CA 1.445 -0.724 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.6 179.65 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.619 ' O ' ' O ' ' C' ' 26' ' ' SER . 14.3 m120 -20.31 -175.2 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 117.327 2.343 . . . . 0.0 117.327 177.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.495 ' CB ' ' O ' ' C' ' 27' ' ' ASN . 82.6 tttt 111.64 110.66 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.446 0 CA-C-N 111.81 -2.45 . . . . 0.0 114.477 176.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.412 ' O ' ' HA3' ' B' ' 29' ' ' GLY . . . -61.74 92.48 0.07 OUTLIER Glycine 0 C--O 1.218 -0.87 0 CA-C-N 112.305 -2.225 . . . . 0.0 112.714 171.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.67 156.8 40.47 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 122.902 3.351 . . . . 0.0 107.984 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.598 HD13 ' N ' ' C' ' 31' ' ' ILE . 0.0 OUTLIER -138.73 129.07 33.51 Favored 'Isoleucine or valine' 0 C--O 1.238 0.486 0 C-N-CA 119.073 -1.051 . . . . 0.0 111.189 -176.021 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.488 HG12 HD21 ' C' ' 34' ' ' LEU . 13.0 tt -133.84 122.97 43.96 Favored 'Isoleucine or valine' 0 C--N 1.348 0.525 0 C-N-CA 120.287 -0.565 . . . . 0.0 109.523 177.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.52 115.36 3.61 Favored Glycine 0 CA--C 1.499 -0.936 0 N-CA-C 107.602 -2.199 . . . . 0.0 107.602 178.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.935 HD13 ' CZ ' ' A' ' 19' ' ' PHE . 52.6 mt -116.26 111.4 20.1 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.117 0.484 . . . . 0.0 111.56 -176.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.405 ' HE2' ' H ' ' J' ' 33' ' ' GLY . 24.6 tpp -109.48 103.16 12.01 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 177.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' C' ' 37' ' ' GLY . 0.0 OUTLIER -121.35 70.74 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.727 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.239 -178.734 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.503 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -38.2 -100.79 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 178.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.85 -163.79 31.73 Favored Glycine 0 CA--C 1.521 0.456 0 N-CA-C 110.535 -1.026 . . . . 0.0 110.535 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 68.5 t -119.19 134.06 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.005 -0.997 . . . . 0.0 110.632 -179.641 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -82.55 137.69 34.5 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.734 0.302 . . . . 0.0 110.461 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -115.75 141.28 48.3 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.392 -179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.477 ' C ' ' ND1' ' D' ' 13' ' ' HIS . 9.8 p -130.17 135.59 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-O 121.142 0.496 . . . . 0.0 110.702 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' C ' ' D' ' 12' ' ' VAL . 14.7 m80 -142.56 108.99 5.3 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.562 -0.744 . . . . 0.0 110.555 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.44 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 31.6 m-70 -126.55 167.08 16.13 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.8 mt-30 -151.39 171.86 16.83 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.581 179.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.594 ' C ' HD12 ' D' ' 17' ' ' LEU . 63.3 mttp -155.24 121.16 5.11 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.139 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.594 HD12 ' C ' ' D' ' 16' ' ' LYS . 11.0 mp -119.92 122.83 42.11 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 72.0 t -127.33 125.1 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.016 0.436 . . . . 0.0 110.678 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.908 ' CE1' HD22 ' F' ' 34' ' ' LEU . 1.3 t80 -118.73 117.55 29.22 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -128.26 122.3 31.38 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 112.059 0.392 . . . . 0.0 112.059 -177.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.79 121.3 29.84 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-O 121.112 0.482 . . . . 0.0 109.978 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -97.85 175.29 6.21 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.212 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 52.5 t0 -72.63 122.08 20.83 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.26 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.451 ' O ' HG23 ' D' ' 24' ' ' VAL . 28.7 m -87.56 123.33 40.18 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.914 179.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -42.88 -86.09 0.01 OUTLIER Glycine 0 CA--C 1.532 1.152 0 C-N-CA 121.393 -0.432 . . . . 0.0 112.443 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.738 ' O ' ' O ' ' D' ' 27' ' ' ASN . 13.2 p -152.84 -171.61 3.99 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -178.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.738 ' O ' ' O ' ' D' ' 26' ' ' SER . 81.5 m-20 -20.15 172.24 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 114.783 1.401 . . . . 0.0 114.783 -179.05 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.556 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 83.2 tttt 132.02 105.65 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 124.95 1.3 . . . . 0.0 107.701 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.495 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -49.89 -97.72 0.01 OUTLIER Glycine 0 N--CA 1.473 1.135 0 C-N-CA 118.112 -1.994 . . . . 0.0 110.269 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.451 ' C ' ' CG1' ' D' ' 31' ' ' ILE . . . 72.54 145.01 0.07 Allowed 'General case' 0 C--N 1.302 -1.486 0 N-CA-C 104.462 -2.421 . . . . 0.0 104.462 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.687 HG23 ' CG1' ' E' ' 31' ' ' ILE . 0.3 OUTLIER -149.42 116.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 C-N-CA 118.268 -1.373 . . . . 0.0 109.202 -175.026 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.513 HG22 ' O ' ' D' ' 32' ' ' ILE . 1.0 OUTLIER -111.57 111.41 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.741 -179.661 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -101.91 97.53 1.61 Allowed Glycine 0 CA--C 1.509 -0.289 0 N-CA-C 105.024 -3.23 . . . . 0.0 105.024 175.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.635 HD22 ' CZ ' ' B' ' 19' ' ' PHE . 62.8 tp -110.94 118.67 36.71 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 114.241 1.2 . . . . 0.0 114.241 -175.149 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -122.16 108.84 13.78 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.018 -1.475 . . . . 0.0 107.018 176.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.434 HG22 HD11 ' D' ' 34' ' ' LEU . 0.1 OUTLIER -124.43 70.04 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.847 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -49.41 -100.6 0.01 OUTLIER Glycine 0 C--N 1.347 1.142 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.266 -178.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 111.23 159.19 15.67 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -124.15 136.34 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.972 0.415 . . . . 0.0 110.664 -179.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 91.6 t . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.058 -0.973 . . . . 0.0 110.414 179.63 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.206 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -104.87 134.95 47.14 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.448 ' H ' ' HG2' ' F' ' 11' ' ' GLU . 22.3 pt-20 -140.8 146.57 37.79 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.997 0.427 . . . . 0.0 110.956 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 4.2 m -131.55 155.84 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.748 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.8 p-80 -156.75 162.37 39.77 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 121.312 0.577 . . . . 0.0 112.302 -179.025 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.59 ' CD2' ' N ' ' E' ' 15' ' ' GLN . 36.4 t60 -154.96 164.75 38.45 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-O 121.411 0.624 . . . . 0.0 110.635 179.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.59 ' N ' ' CD2' ' E' ' 14' ' ' HIS . 82.6 mt-30 -149.85 170.03 19.72 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.465 0.65 . . . . 0.0 110.892 178.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.19 128.79 3.17 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.096 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 52.5 tp -125.36 124.36 41.36 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.2 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 47.2 t -122.73 123.61 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -124.54 120.24 31.39 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.239 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 64.5 t80 -129.13 120.53 26.02 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 120.31 16.94 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-O 121.213 0.53 . . . . 0.0 110.948 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -143.09 128.3 18.71 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 120.164 -0.614 . . . . 0.0 111.476 179.538 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -154.14 120.4 5.4 Favored 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.455 179.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 14.1 t -107.5 -112.76 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 121.007 0.432 . . . . 0.0 110.327 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.7 -90.63 0.01 OUTLIER Glycine 0 N--CA 1.469 0.878 0 CA-C-N 115.791 -0.641 . . . . 0.0 112.397 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.602 ' O ' ' O ' ' E' ' 27' ' ' ASN . 2.7 t 171.34 170.1 0.08 Allowed 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.602 ' O ' ' O ' ' E' ' 26' ' ' SER . 60.3 t30 -17.67 158.34 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 114.778 1.399 . . . . 0.0 114.778 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.861 ' O ' ' HB2' ' F' ' 30' ' ' ALA . 75.2 tttt -161.73 111.41 1.57 Allowed 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.406 175.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.77 92.29 0.23 Allowed Glycine 0 CA--C 1.535 1.282 0 CA-C-O 119.156 -0.802 . . . . 0.0 113.178 176.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.537 ' HB2' ' O ' ' D' ' 28' ' ' LYS . . . -160.24 154.08 22.82 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 175.512 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.687 ' CG1' HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -141.47 126.05 17.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 C-N-CA 117.49 -1.684 . . . . 0.0 114.123 -175.926 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.522 ' O ' ' SD ' ' L' ' 35' ' ' MET . 0.8 OUTLIER -114.39 116.39 52.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 114.731 -1.122 . . . . 0.0 108.202 176.505 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.95 102.13 2.76 Favored Glycine 0 CA--C 1.501 -0.811 0 N-CA-C 104.192 -3.563 . . . . 0.0 104.192 175.26 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.629 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 6.7 tt -107.14 105.54 15.59 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-O 121.045 0.45 . . . . 0.0 111.366 -174.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.9 ttt -123.82 112.51 17.38 Favored 'General case' 0 C--O 1.24 0.576 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 178.166 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.5 80.38 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.01 102.76 0.26 Allowed Glycine 0 C--N 1.351 1.397 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.54 -151.55 23.62 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 110.094 -1.202 . . . . 0.0 110.094 179.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.0 p -130.84 140.82 47.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 43.1 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.755 -179.828 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -116.19 139.34 50.45 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.74 0.305 . . . . 0.0 110.711 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.448 ' HG2' ' H ' ' E' ' 11' ' ' GLU . 98.4 mt-10 -56.81 135.79 55.55 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.345 -0.389 . . . . 0.0 109.997 179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p -141.81 148.11 21.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.753 . . . . 0.0 111.507 -178.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.444 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 33.0 p-80 -161.64 157.08 24.02 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-N 115.056 -0.975 . . . . 0.0 111.188 179.485 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 97.0 m-70 -156.4 168.29 27.8 Favored 'General case' 0 CA--C 1.511 -0.537 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 179.101 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 73.1 mt-30 -151.01 173.26 14.52 Favored 'General case' 0 C--N 1.312 -1.059 0 C-N-CA 119.951 -0.7 . . . . 0.0 110.716 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -147.66 129.09 14.89 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.447 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 50.8 mt -120.33 115.48 23.63 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.306 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -127.31 129.5 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-O 120.82 0.343 . . . . 0.0 110.129 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.524 ' CD2' ' O ' ' F' ' 19' ' ' PHE . 54.3 p90 -143.34 126.23 16.2 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 121.069 0.462 . . . . 0.0 111.543 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -127.29 128.11 45.44 Favored 'General case' 0 C--N 1.33 -0.249 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 177.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.18 149.64 28.22 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 119.89 -0.724 . . . . 0.0 112.286 -178.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -80.09 126.56 31.23 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 178.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -91.32 113.71 26.05 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 121.868 0.842 . . . . 0.0 113.266 -177.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.571 ' O ' ' O ' ' F' ' 26' ' ' SER . 78.4 t -128.54 120.8 53.63 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 N-CA-C 105.991 -1.855 . . . . 0.0 105.991 177.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.482 ' C ' ' O ' ' F' ' 24' ' ' VAL . . . -27.67 -88.95 0.01 OUTLIER Glycine 0 N--CA 1.486 2.017 0 CA-C-N 119.358 0.981 . . . . 0.0 111.65 -177.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.571 ' O ' ' O ' ' F' ' 24' ' ' VAL . 69.3 m -70.31 -173.55 0.72 Allowed 'General case' 0 CA--C 1.502 -0.899 0 N-CA-C 103.251 -2.87 . . . . 0.0 103.251 175.018 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.478 ' O ' ' O ' ' F' ' 28' ' ' LYS . 16.6 t30 -79.91 176.19 9.96 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 115.677 -2.409 . . . . 0.0 107.941 175.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.478 ' O ' ' O ' ' F' ' 27' ' ' ASN . 80.1 tttt -44.45 -105.83 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.664 0 CA-C-O 123.537 1.637 . . . . 0.0 111.859 174.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.461 ' N ' ' HG2' ' F' ' 28' ' ' LYS . . . -114.33 -100.45 2.36 Favored Glycine 0 CA--C 1.483 -1.944 0 CA-C-N 111.218 -2.719 . . . . 0.0 113.305 -179.664 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.861 ' HB2' ' O ' ' E' ' 28' ' ' LYS . . . -60.41 177.04 0.3 Allowed 'General case' 0 CA--C 1.474 -1.957 0 CA-C-N 110.82 -2.69 . . . . 0.0 104.933 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 1.7 tp -158.41 144.76 8.15 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 C-N-CA 114.998 -2.681 . . . . 0.0 114.638 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.4 pt -102.14 112.34 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-N 112.807 -1.997 . . . . 0.0 107.965 178.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -80.38 97.12 1.67 Allowed Glycine 0 CA--C 1.497 -1.061 0 N-CA-C 103.496 -3.842 . . . . 0.0 103.496 175.408 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.908 HD22 ' CE1' ' D' ' 19' ' ' PHE . 0.3 OUTLIER -100.01 111.09 23.39 Favored 'General case' 0 CA--C 1.497 -1.089 0 CA-C-N 117.412 0.606 . . . . 0.0 111.445 -176.676 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.622 ' SD ' ' O ' ' L' ' 32' ' ' ILE . 24.2 mtp -135.33 114.94 12.71 Favored 'General case' 0 N--CA 1.445 -0.678 0 CA-C-O 122.754 1.264 . . . . 0.0 107.766 176.463 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.74 HG13 ' O ' ' F' ' 36' ' ' VAL . 5.5 p -133.0 78.63 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 CA-C-N 112.566 -2.106 . . . . 0.0 108.373 -177.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.646 ' HA2' HD13 ' L' ' 31' ' ' ILE . . . 51.87 -104.08 0.14 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.61 -175.13 46.7 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.551 ' C ' HD21 ' L' ' 27' ' ' ASN . 66.6 t -131.42 137.72 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 120.814 0.34 . . . . 0.0 111.16 -179.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.414 ' HA ' HD21 ' L' ' 27' ' ' ASN . 61.5 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.119 -0.943 . . . . 0.0 110.335 179.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.457 0 N-CA-C 109.724 -1.351 . . . . 0.0 109.724 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -98.71 130.29 45.19 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 120.859 0.361 . . . . 0.0 110.345 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -71.02 147.61 48.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.744 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 t -124.95 134.03 67.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.247 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.8 t60 -144.27 136.9 26.85 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.382 -179.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 27.6 m170 -112.78 178.69 4.2 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -102.33 178.11 4.68 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.407 -179.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -97.02 137.63 35.81 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.655 -179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -123.97 128.14 48.96 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 121.375 0.607 . . . . 0.0 111.378 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -131.49 128.85 61.49 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.562 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.45 ' CE2' HD23 ' J' ' 34' ' ' LEU . 3.8 m-85 -108.85 113.27 26.05 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 176.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 52.7 p90 -124.99 123.96 40.98 Favored 'General case' 0 CA--C 1.521 -0.14 0 CA-C-O 120.892 0.377 . . . . 0.0 110.932 -178.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.09 120.84 40.37 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 70.2 tt0 -159.27 141.63 13.81 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 -179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -66.29 112.12 3.83 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.973 -178.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.516 ' O ' ' N ' ' G' ' 26' ' ' SER . 54.2 t -111.86 130.85 64.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.54 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -37.96 81.85 0.0 OUTLIER Glycine 0 CA--C 1.532 1.126 0 CA-C-N 114.97 -1.014 . . . . 0.0 113.376 177.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.516 ' N ' ' O ' ' G' ' 24' ' ' VAL . 74.6 m -131.41 179.46 6.02 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 119.172 1.486 . . . . 0.0 109.562 178.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.465 ' O ' ' O ' ' G' ' 26' ' ' SER . 15.0 m120 -40.18 174.37 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.616 -0.72 . . . . 0.0 112.186 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 37.5 ttmt -77.41 110.64 12.34 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.381 175.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.457 ' H ' ' HE2' ' H' ' 28' ' ' LYS . . . 65.36 94.39 0.03 OUTLIER Glycine 0 N--CA 1.466 0.648 0 C-N-CA 118.292 -1.909 . . . . 0.0 110.361 177.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 161.37 13.65 Favored 'General case' 0 CA--C 1.511 -0.534 0 CA-C-N 120.18 1.99 . . . . 0.0 109.386 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.404 HG22 HD12 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -150.98 112.77 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.62 0 CA-C-N 114.202 -1.363 . . . . 0.0 109.758 -172.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' A' ' 35' ' ' MET . 94.8 mt -121.45 117.26 52.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-O 120.662 0.268 . . . . 0.0 110.89 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.55 ' CA ' ' SD ' ' A' ' 35' ' ' MET . . . -125.7 116.39 2.62 Favored Glycine 0 N--CA 1.47 0.911 0 N-CA-C 110.681 -0.968 . . . . 0.0 110.681 179.401 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 56.4 tp -144.15 140.57 29.45 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-O 121.384 0.611 . . . . 0.0 112.198 -179.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.433 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 40.0 ttp -130.64 137.73 49.75 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.466 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.47 ' O ' ' O ' ' G' ' 37' ' ' GLY . 4.8 t -125.82 69.77 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 CA-C-N 116.328 -0.396 . . . . 0.0 112.038 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.47 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -43.77 -101.68 0.01 OUTLIER Glycine 0 CA--C 1.529 0.932 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 177.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.12 174.28 40.21 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 13.3 p -145.03 149.56 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.183 0.516 . . . . 0.0 111.329 -179.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 48.0 t . . . . . 0 C--O 1.221 -0.414 0 CA-C-O 117.931 -1.033 . . . . 0.0 110.969 -179.993 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 65.3 t80 -82.44 130.11 35.04 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.012 0.434 . . . . 0.0 110.392 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -115.34 163.51 15.59 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.837 -0.619 . . . . 0.0 109.761 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.504 HG12 ' N ' ' H' ' 13' ' ' HIS . 71.5 t -118.66 158.78 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.869 0.842 . . . . 0.0 110.902 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.668 ' CD2' HE21 ' H' ' 15' ' ' GLN . 32.5 p-80 -98.65 154.24 18.09 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-N 114.231 -1.35 . . . . 0.0 111.604 -178.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.566 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 58.4 t60 -87.93 167.4 13.77 Favored 'General case' 0 N--CA 1.442 -0.862 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 178.139 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.668 HE21 ' CD2' ' H' ' 13' ' ' HIS . 84.5 mt-30 -150.66 167.2 28.05 Favored 'General case' 0 C--N 1.317 -0.842 0 C-N-CA 119.906 -0.717 . . . . 0.0 111.381 178.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -153.11 115.26 4.37 Favored 'General case' 0 CA--C 1.53 0.2 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.389 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 24.6 tp -122.64 121.86 37.43 Favored 'General case' 0 C--O 1.238 0.496 0 CA-C-N 116.165 -0.471 . . . . 0.0 109.737 179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 23.6 t -127.09 123.43 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-O 121.106 0.479 . . . . 0.0 112.146 -179.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.897 ' CZ ' HD22 ' K' ' 34' ' ' LEU . 3.3 m-85 -110.2 114.31 27.69 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 177.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.597 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 48.4 t80 -127.63 123.74 36.33 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 118.473 0.579 . . . . 0.0 110.407 -178.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.59 128.67 44.68 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 120.924 0.392 . . . . 0.0 111.918 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 tt0 -144.87 153.22 41.36 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.403 -0.591 . . . . 0.0 109.403 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -105.28 103.7 13.29 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' H' ' 26' ' ' SER . 22.5 t -90.23 153.68 3.21 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 48.71 -80.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.808 0 N-CA-C 111.351 -0.7 . . . . 0.0 111.351 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.75 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.7 OUTLIER 171.46 -170.71 0.03 OUTLIER 'General case' 0 N--CA 1.441 -0.88 0 CA-C-N 117.371 0.586 . . . . 0.0 109.578 -179.787 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.75 ' O ' ' O ' ' H' ' 26' ' ' SER . 4.9 m120 -18.67 -172.42 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 116.322 1.971 . . . . 0.0 116.322 -178.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.546 ' CB ' ' O ' ' H' ' 27' ' ' ASN . 62.9 tttm 127.02 104.51 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.984 0 CA-C-N 113.644 -1.617 . . . . 0.0 111.307 178.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.98 96.86 0.07 OUTLIER Glycine 0 N--CA 1.47 0.954 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.153 176.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.99 148.12 43.94 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.514 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -146.1 124.92 5.03 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.263 -173.41 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 85.1 mt -122.81 117.53 52.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.23 0 CA-C-N 115.549 -0.75 . . . . 0.0 109.83 179.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.02 122.72 5.09 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 109.401 -1.48 . . . . 0.0 109.401 178.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 7.8 tt -151.44 140.38 21.01 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 121.557 -0.966 . . . . 0.0 111.582 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' I' ' 35' ' ' MET . 43.0 ttp -131.74 130.17 41.58 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.298 -179.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' H' ' 37' ' ' GLY . 11.6 t -123.77 73.54 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -48.2 -95.07 0.01 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 177.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.76 177.42 16.71 Favored Glycine 0 C--N 1.336 0.571 0 N-CA-C 110.609 -0.996 . . . . 0.0 110.609 179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 60.4 t -120.56 134.57 63.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.402 HG22 ' H ' ' H' ' 40' ' ' VAL . 15.6 m . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.641 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.203 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -102.6 132.4 48.72 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -94.17 132.54 38.6 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-O 121.0 0.429 . . . . 0.0 110.437 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 12.6 m -138.95 159.28 29.93 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.267 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.458 ' ND1' ' O ' ' H' ' 12' ' ' VAL . 2.0 m80 -107.06 -172.56 2.1 Favored 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.958 0.409 . . . . 0.0 110.884 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.598 ' CG ' ' NE2' ' J' ' 14' ' ' HIS . 20.9 p-80 -135.91 176.53 8.6 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -179.448 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -133.18 177.73 7.44 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.588 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -138.69 115.9 11.06 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.039 -179.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 39.0 mt -114.27 117.38 30.95 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -126.62 125.8 67.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 CA-C-O 121.208 0.528 . . . . 0.0 111.614 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.974 ' CZ ' HD22 ' L' ' 34' ' ' LEU . 6.9 m-85 -113.25 115.09 27.65 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 107.826 -1.175 . . . . 0.0 107.826 177.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.597 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 25.8 t80 -129.27 122.96 30.71 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 118.482 0.583 . . . . 0.0 110.237 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.15 131.31 34.53 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.539 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -137.9 132.49 32.53 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -96.69 101.38 12.98 Favored 'General case' 0 N--CA 1.468 0.459 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.59 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.615 ' O ' ' N ' ' I' ' 26' ' ' SER . 53.6 t -91.27 158.46 2.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.743 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 177.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 48.9 -80.46 0.01 OUTLIER Glycine 0 CA--C 1.527 0.805 0 C-N-CA 120.588 -0.815 . . . . 0.0 111.427 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.615 ' N ' ' O ' ' I' ' 24' ' ' VAL . 2.4 p 171.16 171.21 0.08 Allowed 'General case' 0 N--CA 1.443 -0.819 0 CA-C-O 121.397 0.618 . . . . 0.0 110.052 -179.481 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.589 ' O ' ' O ' ' I' ' 26' ' ' SER . 23.0 p30 -16.13 158.41 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 113.335 -1.757 . . . . 0.0 115.5 -176.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.556 ' O ' ' O ' ' J' ' 29' ' ' GLY . 63.5 tttp -161.17 111.03 1.66 Allowed 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.497 176.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.73 92.8 0.2 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 110.886 -0.885 . . . . 0.0 110.886 177.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 150.71 52.03 Favored 'General case' 0 CA--C 1.492 -1.284 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.514 HD12 ' CG2' ' H' ' 31' ' ' ILE . 0.0 OUTLIER -151.57 123.43 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 C-N-CA 118.711 -1.196 . . . . 0.0 110.943 -174.989 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.534 ' CG2' HD11 ' J' ' 34' ' ' LEU . 97.3 mt -116.69 116.21 51.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 C-N-CA 120.688 -0.405 . . . . 0.0 110.279 178.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.65 98.03 1.03 Allowed Glycine 0 N--CA 1.462 0.381 0 N-CA-C 105.888 -2.885 . . . . 0.0 105.888 175.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -122.61 129.07 51.48 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.68 0.752 . . . . 0.0 112.334 -176.015 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.574 ' SD ' ' SD ' ' H' ' 35' ' ' MET . 78.9 mtp -108.91 112.78 25.19 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.41 -1.268 . . . . 0.0 109.434 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.502 ' H ' ' HG2' ' J' ' 35' ' ' MET . 0.2 OUTLIER -123.54 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 177.454 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -76.6 111.2 3.22 Favored Glycine 0 C--N 1.364 2.107 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -59.0 179.38 1.56 Allowed Glycine 0 CA--C 1.52 0.394 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.39 156.24 41.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-O 120.747 0.308 . . . . 0.0 110.365 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.571 -179.701 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.317 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -82.54 140.84 33.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.659 0.266 . . . . 0.0 110.314 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -141.74 159.92 41.23 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.931 0.396 . . . . 0.0 110.874 -179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.469 ' CG1' ' N ' ' J' ' 13' ' ' HIS . 25.8 t -120.57 161.22 20.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.469 ' N ' ' CG1' ' J' ' 12' ' ' VAL . 28.9 p-80 -71.48 150.54 44.77 Favored 'General case' 0 C--N 1.33 -0.258 0 N-CA-C 113.506 0.928 . . . . 0.0 113.506 -176.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.598 ' NE2' ' CG ' ' I' ' 14' ' ' HIS . 43.8 p-80 -152.86 172.87 16.09 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-N 113.918 -1.492 . . . . 0.0 107.167 179.326 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -144.36 174.12 11.19 Favored 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 120.053 -0.659 . . . . 0.0 111.59 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.654 ' C ' HD12 ' J' ' 17' ' ' LEU . 99.2 mttt -148.73 112.47 5.09 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.333 -0.849 . . . . 0.0 109.974 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.654 HD12 ' C ' ' J' ' 16' ' ' LYS . 10.5 mp -117.52 121.21 40.38 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 44.7 t -128.91 123.28 58.63 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 120.417 -0.513 . . . . 0.0 111.937 -179.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.643 ' CE1' ' CE2' ' K' ' 19' ' ' PHE . 94.9 m-85 -115.87 117.09 29.24 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 176.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 54.6 t80 -123.22 111.24 16.23 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.54 132.93 46.97 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -177.514 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -120.84 87.89 2.84 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 115.216 -0.902 . . . . 0.0 108.862 177.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.577 ' C ' ' HZ2' ' K' ' 28' ' ' LYS . 20.9 m-20 -68.33 -102.42 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 114.602 -1.181 . . . . 0.0 108.53 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.552 HG12 ' N ' ' J' ' 25' ' ' GLY . 34.5 t 46.43 157.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 CA-C-O 122.661 1.22 . . . . 0.0 114.254 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.552 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 91.67 -80.25 1.26 Allowed Glycine 0 CA--C 1.527 0.843 0 CA-C-N 113.219 -1.809 . . . . 0.0 110.46 -176.786 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.606 ' O ' ' O ' ' J' ' 27' ' ' ASN . 1.8 p 170.28 170.48 0.06 Allowed 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 118.092 0.946 . . . . 0.0 109.729 177.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.606 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.8 t-20 -17.66 157.75 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.699 0 O-C-N 124.953 1.408 . . . . 0.0 114.02 179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.583 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 61.3 tttt -161.6 110.55 1.53 Allowed 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 173.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.556 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -68.13 93.06 0.27 Allowed Glycine 0 C--O 1.216 -1.0 0 C-N-CA 119.458 -1.353 . . . . 0.0 110.75 177.049 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.472 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -143.28 143.25 31.64 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 103.061 -2.94 . . . . 0.0 103.061 173.404 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.505 HD12 ' CG2' ' I' ' 31' ' ' ILE . 0.2 OUTLIER -152.37 111.76 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 C-N-CA 118.424 -1.31 . . . . 0.0 108.929 -171.546 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.485 HG22 ' H ' ' K' ' 33' ' ' GLY . 0.1 OUTLIER -111.6 111.92 38.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-O 121.046 0.451 . . . . 0.0 109.86 -179.491 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.593 ' C ' HD12 ' J' ' 34' ' ' LEU . . . -112.16 94.56 0.75 Allowed Glycine 0 C--O 1.239 0.447 0 N-CA-C 107.398 -2.281 . . . . 0.0 107.398 176.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.593 HD12 ' C ' ' J' ' 33' ' ' GLY . 9.7 mp -117.33 127.15 53.77 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-O 122.279 1.038 . . . . 0.0 111.307 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.502 ' HG2' ' H ' ' I' ' 36' ' ' VAL . 0.1 OUTLIER -101.57 118.59 37.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.011 -1.45 . . . . 0.0 107.521 178.315 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 98.2 t -133.9 76.55 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -78.49 104.58 2.07 Favored Glycine 0 C--N 1.352 1.443 0 CA-C-N 115.353 -0.839 . . . . 0.0 111.849 -178.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -93.61 -176.76 40.0 Favored Glycine 0 CA--C 1.524 0.639 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.6 m -134.4 162.5 38.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.682 0.277 . . . . 0.0 110.509 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 95.0 t . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.886 -179.76 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -111.53 145.79 38.46 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.706 0.288 . . . . 0.0 110.655 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -53.78 148.85 9.39 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.258 -0.428 . . . . 0.0 109.879 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -134.04 156.59 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 121.891 0.853 . . . . 0.0 111.996 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -170.17 83.42 0.11 Allowed 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.074 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -154.98 169.0 25.1 Favored 'General case' 0 N--CA 1.441 -0.882 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 179.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 65.5 mt-30 -149.9 178.31 9.03 Favored 'General case' 0 C--N 1.312 -1.047 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.004 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -126.66 109.45 12.1 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.717 179.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 55.8 mt -111.23 113.04 25.25 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 70.9 t -126.24 114.13 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 O-C-N 122.015 -0.428 . . . . 0.0 111.091 -178.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.718 ' O ' ' C ' ' L' ' 19' ' ' PHE . 76.0 m-85 -116.86 105.31 12.22 Favored 'General case' 0 C--O 1.243 0.719 0 N-CA-C 106.395 -1.705 . . . . 0.0 106.395 177.139 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.448 ' HA ' ' O ' ' L' ' 19' ' ' PHE . 91.0 t80 -128.3 125.99 39.91 Favored 'General case' 0 N--CA 1.482 1.151 0 O-C-N 124.287 0.992 . . . . 0.0 112.219 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.492 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -147.36 156.32 42.79 Favored 'General case' 0 C--N 1.353 0.732 0 C-N-CA 118.502 -1.279 . . . . 0.0 114.236 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -127.3 137.27 52.79 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.42 ' O ' HG11 ' L' ' 24' ' ' VAL . 11.4 p-10 -165.5 135.43 3.55 Favored 'General case' 0 CA--C 1.515 -0.371 0 C-N-CA 118.868 -1.133 . . . . 0.0 113.725 -176.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.592 HG13 ' O ' ' K' ' 24' ' ' VAL . 13.1 p -70.83 112.74 5.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 178.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.43 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . -50.59 92.47 0.01 OUTLIER Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.526 -1.215 . . . . 0.0 114.546 -175.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.451 ' O ' ' O ' ' K' ' 27' ' ' ASN . 1.5 t 162.35 160.5 0.02 OUTLIER 'General case' 0 N--CA 1.444 -0.766 0 CA-C-O 121.801 0.81 . . . . 0.0 110.134 176.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.451 ' O ' ' O ' ' K' ' 26' ' ' SER . 31.4 m120 -29.7 159.8 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 113.785 -1.552 . . . . 0.0 113.207 179.177 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.577 ' HZ2' ' C ' ' J' ' 23' ' ' ASP . 75.6 tttt 179.48 104.01 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.228 175.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.553 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . -65.62 94.7 0.2 Allowed Glycine 0 C--O 1.222 -0.631 0 CA-C-O 118.923 -0.932 . . . . 0.0 113.781 177.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.638 ' O ' HG23 ' K' ' 31' ' ' ILE . . . -168.01 147.08 4.67 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 173.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.638 HG23 ' O ' ' K' ' 30' ' ' ALA . 0.1 OUTLIER -160.37 130.02 0.76 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.54 0 C-N-CA 118.283 -1.367 . . . . 0.0 113.575 -176.311 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.422 ' O ' HG23 ' K' ' 32' ' ' ILE . 12.8 tt -108.51 113.85 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 175.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.485 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -121.35 121.69 4.88 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.934 -0.466 . . . . 0.0 111.934 -177.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.897 HD22 ' CZ ' ' H' ' 19' ' ' PHE . 20.1 tp -140.66 136.99 33.24 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.781 0.801 . . . . 0.0 110.214 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.545 ' H ' HD12 ' K' ' 34' ' ' LEU . 1.7 ttm -112.03 124.09 51.67 Favored 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 177.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.664 HG22 HD11 ' L' ' 34' ' ' LEU . 5.4 m -124.06 79.38 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.597 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 178.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -69.4 103.3 1.07 Allowed Glycine 0 C--N 1.35 1.308 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.48 146.9 17.38 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.0 t -127.12 136.78 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 120.734 0.302 . . . . 0.0 110.223 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.418 ' H ' HG22 ' K' ' 40' ' ' VAL . 16.0 m . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.422 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 t80 -90.22 128.05 36.29 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.754 0.312 . . . . 0.0 110.81 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -140.06 160.83 39.06 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.189 -0.459 . . . . 0.0 109.935 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.438 ' O ' ' CD2' ' L' ' 13' ' ' HIS . 49.6 t -118.63 130.17 73.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 CA-C-O 121.553 0.692 . . . . 0.0 110.372 179.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.438 ' CD2' ' O ' ' L' ' 12' ' ' VAL . 88.6 m-70 -156.86 110.44 2.63 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.831 -1.077 . . . . 0.0 109.583 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.509 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 35.3 t-80 -156.85 175.67 13.77 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.039 0.447 . . . . 0.0 109.881 -179.054 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.509 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 77.8 mt-30 -142.4 -179.97 6.59 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.216 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -164.66 114.48 1.16 Allowed 'General case' 0 C--O 1.234 0.261 0 C-N-CA 120.506 -0.478 . . . . 0.0 111.7 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 17.5 mt -116.02 121.25 41.68 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 65.2 t -112.36 133.1 59.18 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 118.802 0.728 . . . . 0.0 110.966 -179.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.718 ' C ' ' O ' ' K' ' 19' ' ' PHE . 63.6 m-85 -42.37 141.56 0.95 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 -172.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.567 ' N ' ' O ' ' K' ' 19' ' ' PHE . 50.5 p90 -99.93 -169.47 1.74 Allowed 'General case' 0 N--CA 1.494 1.743 0 CA-C-N 108.638 -3.892 . . . . 0.0 110.363 179.298 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -23.47 135.24 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 114.266 1.21 . . . . 0.0 114.266 -173.282 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -70.46 159.38 34.35 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 113.04 -1.891 . . . . 0.0 109.239 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -50.52 114.05 1.04 Allowed 'General case' 0 N--CA 1.464 0.235 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.106 -178.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 25' ' ' GLY . 3.5 m -127.82 121.22 55.99 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 CA-C-N 115.696 -0.684 . . . . 0.0 110.812 -178.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' L' ' 24' ' ' VAL . . . -27.84 -87.61 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.956 178.108 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 11.0 p -67.2 -173.01 0.24 Allowed 'General case' 0 N--CA 1.442 -0.868 0 CA-C-O 121.222 0.534 . . . . 0.0 109.992 -179.29 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.551 HD21 ' C ' ' F' ' 39' ' ' VAL . 72.4 m-20 -78.73 175.88 10.04 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 115.324 -0.853 . . . . 0.0 113.025 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 32.2 tttm -49.12 111.21 0.45 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 114.219 -1.355 . . . . 0.0 113.967 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.47 -97.86 0.05 OUTLIER Glycine 0 C--O 1.223 -0.593 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.535 ' HB2' ' HD3' ' K' ' 28' ' ' LYS . . . -60.95 172.23 1.03 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 120.265 2.033 . . . . 0.0 106.544 -179.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.646 HD13 ' HA2' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -146.9 141.26 20.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 C-N-CA 117.236 -1.786 . . . . 0.0 114.375 -173.586 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.622 ' O ' ' SD ' ' F' ' 35' ' ' MET . 88.4 mt -109.14 114.66 47.5 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 CA-C-N 114.061 -1.427 . . . . 0.0 110.131 178.772 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.92 91.25 0.56 Allowed Glycine 0 CA--C 1.517 0.179 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 177.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.974 HD22 ' CZ ' ' I' ' 19' ' ' PHE . 18.9 tp -117.72 120.65 38.61 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 177.205 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 42.2 ttp -97.08 119.19 35.11 Favored 'General case' 0 CA--C 1.51 -0.591 0 C-N-CA 119.662 -0.815 . . . . 0.0 109.084 179.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' L' ' 37' ' ' GLY . 1.4 m -130.25 71.01 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.936 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -29.8 -102.67 0.01 OUTLIER Glycine 0 C--N 1.358 1.802 0 O-C-N 122.935 0.147 . . . . 0.0 112.892 -178.729 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.61 163.07 35.86 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.274 -0.731 . . . . 0.0 111.274 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -136.81 162.64 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 120.913 0.387 . . . . 0.0 110.661 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.1 p . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.635 -179.414 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.58 128.89 49.05 Favored 'General case' 0 N--CA 1.463 0.194 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.484 ' OE2' ' NE2' ' A' ' 13' ' ' HIS . 81.6 tt0 -156.09 143.23 19.07 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.529 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.6 p -136.49 143.29 35.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.663 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.757 ' HB2' ' HD1' ' B' ' 13' ' ' HIS . 98.7 m-70 -131.25 138.83 49.49 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 121.161 0.505 . . . . 0.0 111.295 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.583 ' CG ' ' N ' ' A' ' 15' ' ' GLN . 10.5 t-80 -156.85 165.85 35.04 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.583 ' N ' ' CG ' ' A' ' 14' ' ' HIS . 51.2 tt0 -169.52 169.93 8.52 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.537 179.265 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.407 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 65.5 mttm -152.27 115.12 4.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.983 178.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 35.3 tp -121.37 121.6 37.99 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 109.945 179.389 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.481 HG23 ' O ' ' A' ' 18' ' ' VAL . 35.5 m -122.85 122.68 66.38 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 CA-C-O 121.351 0.596 . . . . 0.0 111.246 -179.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.461 ' CD1' ' CE1' ' B' ' 19' ' ' PHE . 15.6 t80 -123.64 106.41 10.52 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 178.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -134.39 145.94 49.4 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.01 117.76 13.16 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.122 -0.945 . . . . 0.0 108.512 177.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -130.76 157.65 42.27 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.408 ' OD1' ' C ' ' A' ' 23' ' ' ASP . 47.5 t0 -98.42 112.69 24.62 Favored 'General case' 0 N--CA 1.462 0.158 0 N-CA-C 113.764 1.024 . . . . 0.0 113.764 -178.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.518 ' O ' ' C ' ' A' ' 25' ' ' GLY . 2.1 p -147.72 113.49 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 N-CA-C 103.595 -2.742 . . . . 0.0 103.595 172.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.518 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -19.87 87.17 0.01 OUTLIER Glycine 0 N--CA 1.476 1.303 0 CA-C-O 119.282 -0.732 . . . . 0.0 112.522 -179.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.483 ' N ' ' O ' ' A' ' 24' ' ' VAL . 40.9 t -67.97 -179.72 1.28 Allowed 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 119.219 1.509 . . . . 0.0 108.046 178.044 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 53.2 p30 -87.31 174.93 8.26 Favored 'General case' 0 C--N 1.313 -1.018 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt 35.85 -108.45 0.05 OUTLIER 'General case' 0 CA--C 1.538 0.514 0 CA-C-O 122.28 1.038 . . . . 0.0 113.574 173.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.43 ' O ' ' HB3' ' A' ' 30' ' ' ALA . . . 90.59 -102.04 2.87 Favored Glycine 1 CA--C 1.427 -5.457 0 CA-C-N 113.157 -1.838 . . . . 0.0 108.635 -177.384 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.43 ' HB3' ' O ' ' A' ' 29' ' ' GLY . . . 56.63 -146.95 0.54 Allowed 'General case' 0 N--CA 1.405 -2.7 0 C-N-CA 113.497 -3.281 . . . . 0.0 109.7 173.251 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.68 ' H ' ' CD1' ' A' ' 31' ' ' ILE 0.252 0.0 OUTLIER -89.89 113.65 26.45 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.305 0 CA-C-N 113.259 -1.791 . . . . 0.0 113.688 -179.788 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' G' ' 35' ' ' MET . 87.1 mt -130.03 120.17 48.82 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 O-C-N 120.103 -1.623 . . . . 0.0 109.922 178.395 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.609 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -129.68 113.63 1.53 Allowed Glycine 0 CA--C 1.52 0.375 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 -179.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -133.29 134.9 44.47 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.99 0.424 . . . . 0.0 110.72 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 5.9 ttm -125.44 129.62 50.21 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.856 -0.611 . . . . 0.0 109.738 179.78 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 21.6 t -90.92 70.8 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 C-N-CA 120.656 -0.417 . . . . 0.0 111.473 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -114.66 100.65 1.02 Allowed Glycine 0 C--N 1.341 0.811 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 177.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.22 169.65 41.6 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.554 -1.018 . . . . 0.0 110.554 -179.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -120.04 136.21 57.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.76 0.314 . . . . 0.0 110.383 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.7 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.139 -0.934 . . . . 0.0 110.663 -179.895 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 56.3 p90 -143.08 157.41 44.55 Favored 'General case' 0 N--CA 1.463 0.191 0 CA-C-O 120.874 0.369 . . . . 0.0 110.653 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -144.45 150.41 37.61 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.252 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.483 HG12 ' N ' ' B' ' 13' ' ' HIS . 33.5 t -130.77 159.78 42.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.039 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.757 ' HD1' ' HB2' ' A' ' 13' ' ' HIS . 86.0 t60 -157.87 101.47 1.79 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.628 179.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 55.7 m170 -110.2 167.44 10.19 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 -179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -152.43 176.7 11.38 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.231 179.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -171.46 111.95 0.33 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.638 178.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 64.1 mt -120.98 120.33 35.11 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.5 t -120.79 121.6 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 120.889 -0.325 . . . . 0.0 111.432 -179.053 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.485 ' CZ ' HD23 ' D' ' 34' ' ' LEU . 12.0 t80 -120.7 110.54 16.51 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -119.32 117.11 27.67 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.22 119.92 34.61 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -177.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.458 ' O ' ' C ' ' B' ' 23' ' ' ASP . 95.3 mt-10 -153.05 89.82 1.4 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 115.162 -0.926 . . . . 0.0 108.754 176.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.532 ' OD2' ' HB2' ' D' ' 30' ' ' ALA . 49.5 t0 8.2 113.63 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 114.039 1.125 . . . . 0.0 114.039 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 85.4 t -58.56 131.2 22.64 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.205 0.526 . . . . 0.0 110.367 178.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.34 84.67 0.13 Allowed Glycine 0 CA--C 1.529 0.927 0 CA-C-N 115.415 -0.811 . . . . 0.0 113.768 -179.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.517 ' O ' ' O ' ' B' ' 27' ' ' ASN . 39.0 m -132.24 162.67 30.38 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 118.284 1.042 . . . . 0.0 110.003 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.517 ' O ' ' O ' ' B' ' 26' ' ' SER . 65.5 t30 -38.44 177.72 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.632 179.384 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.44 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 98.7 mttt -73.31 111.87 8.84 Favored 'General case' 0 N--CA 1.457 -0.114 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 177.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.42 ' HA2' ' O ' ' C' ' 29' ' ' GLY . . . 71.22 92.5 0.08 OUTLIER Glycine 0 N--CA 1.464 0.567 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 -178.092 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.58 152.66 49.72 Favored 'General case' 0 CA--C 1.487 -1.465 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 174.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.603 ' N ' HD12 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -139.89 117.44 10.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 -173.989 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.524 ' O ' ' SD ' ' I' ' 35' ' ' MET . 81.6 mt -122.13 126.63 74.62 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.733 -177.014 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.1 118.53 3.59 Favored Glycine 0 CA--C 1.529 0.965 0 N-CA-C 109.892 -1.283 . . . . 0.0 109.892 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 42.3 tp -126.53 118.45 24.92 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.292 0.568 . . . . 0.0 110.557 -179.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.8 tpt -106.4 115.52 30.35 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.487 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' O ' ' B' ' 37' ' ' GLY . 8.8 t -112.65 74.16 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.782 -0.19 . . . . 0.0 110.823 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.594 ' HA3' HD13 ' H' ' 31' ' ' ILE . . . -40.07 -95.84 0.01 OUTLIER Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.85 -170.68 40.02 Favored Glycine 0 CA--C 1.522 0.495 0 N-CA-C 110.969 -0.853 . . . . 0.0 110.969 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 30.2 m -135.72 161.9 37.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.896 0.379 . . . . 0.0 110.344 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.572 179.969 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 m-85 -86.88 144.87 26.8 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.823 0.344 . . . . 0.0 110.379 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' D' ' 11' ' ' GLU . 84.6 tt0 -142.32 136.25 29.51 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-O 120.957 0.408 . . . . 0.0 110.55 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 5.6 m -126.23 131.56 71.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.008 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.424 ' NE2' ' OE2' ' C' ' 11' ' ' GLU . 82.1 m-70 -114.75 127.18 55.6 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-O 120.749 0.309 . . . . 0.0 111.162 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CG ' ' D' ' 13' ' ' HIS . 4.0 m-70 -119.04 164.08 16.03 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 79.7 mt-30 -156.68 170.42 22.46 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 121.234 0.54 . . . . 0.0 110.818 178.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -168.0 113.83 0.68 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.362 178.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 tp -128.15 123.64 34.89 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 35.6 m -124.87 126.68 71.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.524 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 47.3 t80 -123.78 111.04 15.65 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 116.186 -0.461 . . . . 0.0 109.929 -178.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -114.56 119.35 36.5 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 120.428 0.156 . . . . 0.0 110.767 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.82 115.97 27.85 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 178.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.8 mt-10 -150.7 169.4 21.69 Favored 'General case' 0 C--N 1.347 0.473 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.707 -179.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.5 ' HB2' ' HZ3' ' E' ' 28' ' ' LYS . 74.8 m-20 -155.45 121.2 5.03 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 178.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.794 HG22 ' N ' ' C' ' 25' ' ' GLY . 3.5 p -136.73 -112.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 C-N-CA 120.776 -0.369 . . . . 0.0 110.311 -177.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.794 ' N ' HG22 ' C' ' 24' ' ' VAL . . . 30.38 -89.21 0.01 OUTLIER Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.434 -177.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' C' ' 27' ' ' ASN . 1.4 t 171.54 177.73 0.07 Allowed 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 117.817 0.808 . . . . 0.0 109.687 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' C' ' 26' ' ' SER . 42.4 t30 -28.46 178.07 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.722 0 O-C-N 124.766 1.291 . . . . 0.0 113.818 -179.189 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.506 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 88.8 mttt 127.66 104.91 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 C-N-CA 125.564 1.545 . . . . 0.0 111.616 175.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.42 ' O ' ' HA2' ' B' ' 29' ' ' GLY . . . -58.37 96.64 0.07 OUTLIER Glycine 0 CA--C 1.493 -1.307 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 174.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -122.54 145.69 48.1 Favored 'General case' 0 CA--C 1.479 -1.77 0 N-CA-C 104.519 -2.4 . . . . 0.0 104.519 176.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.559 HD12 HG23 ' B' ' 31' ' ' ILE . 2.0 mt -142.8 108.4 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.428 -1.548 0 CA-C-N 113.851 -1.522 . . . . 0.0 108.801 -172.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.541 HG12 HD11 ' C' ' 34' ' ' LEU . 14.9 tt -120.17 128.06 75.94 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 CA-C-O 121.054 0.454 . . . . 0.0 110.176 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.407 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -133.67 122.6 3.1 Favored Glycine 0 CA--C 1.508 -0.387 0 N-CA-C 109.204 -1.558 . . . . 0.0 109.204 178.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.694 HD12 ' N ' ' C' ' 34' ' ' LEU . 0.0 OUTLIER -136.96 147.44 46.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 122.085 0.945 . . . . 0.0 111.837 -179.084 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.509 ' SD ' ' O ' ' I' ' 32' ' ' ILE . 5.1 tpt -111.56 117.42 32.92 Favored 'General case' 0 CA--C 1.501 -0.933 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 177.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 26.2 t -130.96 66.33 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.036 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 -179.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.451 ' O ' HD13 ' I' ' 31' ' ' ILE . . . -123.83 102.48 0.73 Allowed Glycine 0 C--N 1.358 1.772 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.83 -170.31 12.66 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 111.451 -0.66 . . . . 0.0 111.451 -179.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 55.2 t -119.47 135.03 61.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 13.0 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.703 -179.475 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -125.68 143.66 50.94 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 120.889 0.376 . . . . 0.0 110.557 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' C' ' 11' ' ' GLU . 95.0 mt-10 -63.41 152.46 38.16 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.683 -179.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 32.5 m -134.36 156.87 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 121.008 0.432 . . . . 0.0 110.485 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.708 ' CD2' ' H ' ' D' ' 14' ' ' HIS . 51.6 t60 -93.14 -169.93 2.28 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.572 179.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.708 ' H ' ' CD2' ' D' ' 13' ' ' HIS . 52.9 m80 -73.85 170.61 14.99 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 121.353 0.597 . . . . 0.0 110.146 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 85.7 mt-30 -148.93 173.58 13.17 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.177 179.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -147.26 114.63 6.29 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 120.898 0.38 . . . . 0.0 111.409 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -122.36 116.16 23.55 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -125.04 131.13 72.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.38 0.609 . . . . 0.0 110.654 -179.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.524 ' CE2' ' CD1' ' C' ' 19' ' ' PHE . 28.1 t80 -131.62 110.75 11.16 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 80.2 t80 -118.71 126.45 51.93 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.817 -178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.59 ' HB1' ' CD1' ' F' ' 32' ' ' ILE . . . -124.3 126.25 45.73 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.602 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -149.52 111.56 4.61 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.197 -0.601 . . . . 0.0 111.496 179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 21.7 m-20 -90.35 134.04 34.59 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.591 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 12.0 t -89.09 112.85 24.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.278 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.49 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -46.53 91.77 0.01 OUTLIER Glycine 0 CA--C 1.536 1.367 0 CA-C-O 119.125 -0.819 . . . . 0.0 114.276 179.006 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.49 ' CB ' ' O ' ' D' ' 25' ' ' GLY . 1.4 t 161.98 161.08 0.02 OUTLIER 'General case' 0 C--O 1.212 -0.89 0 CA-C-N 118.472 1.136 . . . . 0.0 112.303 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.49 ' O ' ' HB3' ' D' ' 28' ' ' LYS . 73.7 m-80 -33.48 -179.26 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 112.998 -1.91 . . . . 0.0 116.118 178.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.49 ' HB3' ' O ' ' D' ' 27' ' ' ASN . 87.1 tttt 99.64 113.8 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 128.398 2.679 . . . . 0.0 115.73 177.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.29 92.53 0.58 Allowed Glycine 0 C--N 1.348 1.238 0 CA-C-N 111.868 -2.423 . . . . 0.0 114.474 173.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.532 ' HB2' ' OD2' ' B' ' 23' ' ' ASP . . . -127.99 151.54 49.02 Favored 'General case' 0 CA--C 1.501 -0.911 0 CA-C-N 121.369 2.584 . . . . 0.0 106.725 173.614 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.488 HD12 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -146.03 116.84 1.75 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.56 -173.582 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 1.7 mt -114.25 124.92 71.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.666 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.81 99.19 0.53 Allowed Glycine 0 N--CA 1.464 0.534 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 177.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.636 HD12 ' O ' ' C' ' 34' ' ' LEU . 40.7 tp -126.3 130.23 50.43 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 122.75 1.262 . . . . 0.0 112.69 -179.07 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.415 ' N ' HD12 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -104.54 110.92 23.4 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 113.688 -1.596 . . . . 0.0 107.302 176.372 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.485 HG23 ' O ' ' E' ' 35' ' ' MET . 0.1 OUTLIER -126.68 71.38 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 178.758 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -34.27 -100.46 0.01 OUTLIER Glycine 0 C--N 1.357 1.696 0 N-CA-C 111.627 -0.589 . . . . 0.0 111.627 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.33 -168.06 40.65 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.2 160.58 41.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.955 0.407 . . . . 0.0 110.933 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.711 -179.978 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 76.1 m-85 -114.47 139.17 49.75 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -113.67 141.26 47.45 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-O 120.941 0.4 . . . . 0.0 110.802 -179.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.438 HG22 ' ND1' ' F' ' 13' ' ' HIS . 19.1 m -134.29 158.07 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.95 179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.49 ' ND1' ' CE1' ' D' ' 14' ' ' HIS . 12.1 m170 -86.75 178.31 7.05 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.633 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.1 OUTLIER -77.08 172.23 13.55 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -179.359 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.493 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 44.2 tt0 -148.2 170.17 18.44 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.113 179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.493 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 99.1 mttt -144.16 117.28 8.92 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 121.123 0.487 . . . . 0.0 111.165 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.2 tt -119.21 114.95 23.23 Favored 'General case' 0 C--O 1.239 0.512 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 178.358 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 28.4 t -124.06 120.46 59.53 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.307 0 CA-C-O 121.601 0.715 . . . . 0.0 111.743 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.569 ' O ' ' N ' ' F' ' 20' ' ' PHE . 10.2 m-85 -126.39 104.54 8.23 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 177.858 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 48.1 t80 -121.97 129.6 52.63 Favored 'General case' 0 N--CA 1.476 0.845 0 O-C-N 122.975 0.172 . . . . 0.0 111.092 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.721 ' O ' ' HB3' ' F' ' 21' ' ' ALA . . . -133.82 135.39 43.75 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-O 123.362 1.553 . . . . 0.0 113.332 178.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -145.14 105.37 4.06 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 113.754 -1.566 . . . . 0.0 110.976 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.431 ' O ' ' OD2' ' F' ' 23' ' ' ASP . 4.2 t0 -83.04 122.63 28.58 Favored 'General case' 0 C--O 1.232 0.15 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 178.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.49 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 63.4 t -72.8 120.42 21.39 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 CA-C-O 121.353 0.597 . . . . 0.0 111.863 -178.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.9 -90.25 0.04 OUTLIER Glycine 0 CA--C 1.528 0.856 0 CA-C-N 115.016 -0.993 . . . . 0.0 114.633 176.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.638 ' O ' ' O ' ' E' ' 27' ' ' ASN . 9.7 p -171.14 -178.61 2.47 Favored 'General case' 0 N--CA 1.442 -0.838 0 CA-C-O 121.153 0.502 . . . . 0.0 110.992 -176.423 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.638 ' O ' ' O ' ' E' ' 26' ' ' SER . 92.1 m-20 20.62 -179.81 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 117.12 2.267 . . . . 0.0 117.12 178.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.512 ' CB ' ' O ' ' E' ' 27' ' ' ASN . 78.2 tttt 128.68 106.13 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 112.381 -2.19 . . . . 0.0 110.002 -177.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -55.32 93.6 0.02 OUTLIER Glycine 0 N--CA 1.453 -0.223 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.054 176.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.73 144.64 18.07 Favored 'General case' 0 CA--C 1.477 -1.843 0 N-CA-C 103.684 -2.71 . . . . 0.0 103.684 174.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.434 HG13 HG23 ' D' ' 31' ' ' ILE . 0.0 OUTLIER -154.55 125.66 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 117.946 -1.502 . . . . 0.0 111.177 -173.029 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -109.51 117.42 54.5 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.768 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.458 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -109.63 97.86 1.07 Allowed Glycine 0 C--O 1.231 -0.074 0 N-CA-C 106.28 -2.728 . . . . 0.0 106.28 176.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.444 ' O ' ' HA ' ' F' ' 34' ' ' LEU . 6.9 tt -138.87 128.68 24.95 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-O 123.01 1.386 . . . . 0.0 113.427 -176.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.485 ' O ' HG23 ' D' ' 36' ' ' VAL . 97.3 mmm -106.98 120.27 41.62 Favored 'General case' 0 CA--C 1.501 -0.919 0 CA-C-N 114.097 -1.41 . . . . 0.0 110.489 179.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . 0.1 OUTLIER -116.39 72.31 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 N-CA-C 107.319 -1.363 . . . . 0.0 107.319 176.968 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -27.71 -101.03 0.01 OUTLIER Glycine 0 C--N 1.366 2.218 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.32 -176.71 25.67 Favored Glycine 0 N--CA 1.461 0.365 0 N-CA-C 111.365 -0.694 . . . . 0.0 111.365 179.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -129.22 160.18 40.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.28 -0.46 . . . . 0.0 109.995 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.903 -1.046 . . . . 0.0 110.565 179.859 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.448 -1.461 . . . . 0.0 109.448 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 83.0 m-85 -96.19 134.65 39.01 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.824 0.345 . . . . 0.0 110.465 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -85.34 136.11 33.61 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.336 -179.418 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.506 HG22 ' N ' ' F' ' 13' ' ' HIS . 2.7 p -143.28 161.52 17.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.964 179.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.506 ' N ' HG22 ' F' ' 12' ' ' VAL . 17.5 m-70 -95.02 97.99 10.35 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.586 179.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.569 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 82.9 t60 -156.36 167.74 29.49 Favored 'General case' 0 N--CA 1.446 -0.672 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.569 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 12.0 pt20 -167.33 177.83 5.86 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.104 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -121.55 123.97 43.26 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.664 179.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 mt -122.94 121.21 35.59 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 111.653 0.242 . . . . 0.0 111.653 -179.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.89 133.11 68.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.899 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 177.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.54 ' O ' ' O ' ' F' ' 20' ' ' PHE . 98.0 m-85 -114.24 136.58 52.8 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.696 0.998 . . . . 0.0 113.696 -177.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.605 ' O ' ' HB2' ' F' ' 21' ' ' ALA . 42.0 p90 -20.58 -157.29 0.0 OUTLIER 'General case' 0 C--O 1.195 -1.792 0 N-CA-C 118.991 2.96 . . . . 0.0 118.991 -175.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.721 ' HB3' ' O ' ' E' ' 21' ' ' ALA . . . 175.54 -168.56 0.04 OUTLIER 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 122.213 1.006 . . . . 0.0 111.54 -173.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 82.5 tt0 -170.97 167.27 7.35 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-N 114.473 -1.24 . . . . 0.0 107.964 -177.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.431 ' OD2' ' O ' ' E' ' 23' ' ' ASP . 23.6 m-20 -92.84 113.98 26.41 Favored 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 119.05 0.841 . . . . 0.0 111.823 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.517 ' O ' HG13 ' F' ' 24' ' ' VAL . 11.7 p -31.2 123.9 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-N 115.194 -0.912 . . . . 0.0 112.743 177.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.87 -85.1 0.1 OUTLIER Glycine 0 CA--C 1.526 0.738 0 C-N-CA 120.629 -0.796 . . . . 0.0 111.79 177.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.775 ' O ' ' O ' ' F' ' 27' ' ' ASN . 10.5 m -172.11 173.7 4.25 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 178.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.775 ' O ' ' O ' ' F' ' 26' ' ' SER . 9.0 t-20 19.8 -178.34 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.071 0 O-C-N 125.374 1.671 . . . . 0.0 114.982 178.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.505 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 44.6 tttm -108.49 110.36 21.84 Favored 'General case' 0 N--CA 1.473 0.68 0 CA-C-O 121.224 0.535 . . . . 0.0 111.531 179.018 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -50.27 -99.42 0.01 OUTLIER Glycine 0 CA--C 1.506 -0.488 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.553 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.76 173.39 12.65 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 179.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -136.7 118.41 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 116.302 -2.159 . . . . 0.0 114.101 -170.38 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.59 ' CD1' ' HB1' ' D' ' 21' ' ' ALA . 59.4 mt -98.83 112.1 30.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.552 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.054 177.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -109.72 89.68 0.56 Allowed Glycine 0 CA--C 1.493 -1.329 0 N-CA-C 105.831 -2.907 . . . . 0.0 105.831 177.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.75 HD23 ' C ' ' F' ' 34' ' ' LEU . 0.8 OUTLIER -141.29 147.65 38.53 Favored 'General case' 0 N--CA 1.437 -1.077 0 C-N-CA 120.714 -0.394 . . . . 0.0 109.952 -177.894 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.543 ' CE ' HG22 ' L' ' 31' ' ' ILE . 3.6 ttp -137.05 133.95 36.0 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.943 178.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.666 HG13 HD21 ' F' ' 34' ' ' LEU . 1.9 m -114.28 80.32 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.669 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.909 -179.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.409 ' HA2' HG21 ' L' ' 31' ' ' ILE . . . 50.82 -102.66 0.07 OUTLIER Glycine 0 C--N 1.342 0.862 0 C-N-CA 120.743 -0.741 . . . . 0.0 111.763 178.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -176.44 -156.49 15.49 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 90.9 t -122.96 136.22 60.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 CA-C-O 120.833 0.349 . . . . 0.0 110.959 -179.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.6 m . . . . . 0 C--O 1.219 -0.505 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.482 179.683 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -100.93 127.56 47.36 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.935 0.398 . . . . 0.0 110.368 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -88.68 156.89 18.75 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.488 ' O ' ' CG ' ' G' ' 13' ' ' HIS . 3.4 m -132.85 154.69 40.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.164 0.507 . . . . 0.0 110.601 179.478 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.488 ' CG ' ' O ' ' G' ' 12' ' ' VAL . 96.2 m-70 -158.2 167.11 30.71 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.153 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -122.53 179.1 4.71 Favored 'General case' 0 N--CA 1.447 -0.588 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 98.7 mt-30 -96.85 176.6 5.92 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.852 -179.376 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -113.96 144.04 43.73 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.098 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.3 mt -119.07 126.83 52.6 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 121.048 0.452 . . . . 0.0 110.786 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.548 ' O ' HG23 ' G' ' 18' ' ' VAL . 25.9 m -133.44 119.96 36.68 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 CA-C-O 121.18 0.514 . . . . 0.0 110.658 179.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.879 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 2.4 m-85 -113.07 119.63 38.51 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.26 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.528 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 48.5 p90 -122.2 121.78 37.65 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.071 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.94 122.47 42.31 Favored 'General case' 0 N--CA 1.472 0.634 0 C-N-CA 120.55 -0.46 . . . . 0.0 111.812 -178.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -166.73 89.17 0.36 Allowed 'General case' 0 N--CA 1.453 -0.302 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.698 ' H ' ' NZ ' ' I' ' 28' ' ' LYS . 90.8 m-20 -85.71 102.78 13.91 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-O 120.993 0.425 . . . . 0.0 112.131 -177.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.412 ' O ' ' O ' ' G' ' 23' ' ' ASP . 18.3 m -56.78 -160.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.489 178.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -77.59 80.51 1.3 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-O 119.524 -0.598 . . . . 0.0 112.947 179.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.416 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 30.9 t -94.4 176.55 6.26 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 118.76 1.28 . . . . 0.0 107.879 178.603 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -60.14 178.24 0.2 Allowed 'General case' 0 C--N 1.318 -0.783 0 C-N-CA 119.166 -1.013 . . . . 0.0 111.096 -179.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -60.77 110.71 1.39 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.064 -0.517 . . . . 0.0 112.318 177.68 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.87 94.25 0.08 OUTLIER Glycine 0 N--CA 1.465 0.61 0 C-N-CA 118.381 -1.866 . . . . 0.0 112.601 174.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.43 158.72 16.46 Favored 'General case' 0 CA--C 1.508 -0.646 0 CA-C-N 119.935 1.867 . . . . 0.0 106.464 177.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.831 HD12 ' H ' ' G' ' 31' ' ' ILE . 0.2 OUTLIER -150.31 114.72 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.382 -174.427 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 97.3 mt -125.27 124.98 68.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.224 179.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.02 123.12 3.92 Favored Glycine 0 CA--C 1.529 0.933 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 50.8 tp -131.03 133.7 45.99 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 117.211 0.505 . . . . 0.0 111.32 -179.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.609 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 63.4 ttp -130.82 134.91 47.25 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.421 -179.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -114.52 79.78 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.473 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.79 104.64 1.27 Allowed Glycine 0 C--N 1.342 0.905 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 44.05 -167.2 0.02 OUTLIER Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.402 -0.679 . . . . 0.0 111.402 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 35.0 m -131.24 160.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-O 120.855 0.36 . . . . 0.0 110.65 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.0 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.515 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -80.91 136.12 36.01 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.781 0.324 . . . . 0.0 110.624 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -52.64 137.63 30.34 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.466 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.403 HG23 ' O ' ' I' ' 12' ' ' VAL . 2.3 p -127.41 132.87 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.159 0.504 . . . . 0.0 110.744 -179.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.51 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 34.5 m170 -126.99 111.38 14.02 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.106 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.448 ' CG ' ' N ' ' H' ' 15' ' ' GLN . 84.0 t60 -114.05 162.15 16.82 Favored 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.448 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 83.3 mt-30 -156.72 177.9 10.96 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.136 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -167.73 111.23 0.65 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.824 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.498 ' HB2' HD22 ' I' ' 17' ' ' LEU . 5.3 mp -116.96 120.92 39.91 Favored 'General case' 0 C--O 1.237 0.446 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 66.7 t -124.0 123.34 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.163 0 CA-C-O 121.343 0.592 . . . . 0.0 110.786 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.776 ' CE1' HD13 ' J' ' 34' ' ' LEU . 11.5 m-85 -117.02 115.49 25.53 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.132 178.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 5.8 p90 -143.13 132.2 23.04 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.967 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.93 138.84 41.06 Favored 'General case' 0 C--O 1.238 0.483 0 CA-C-O 122.105 0.955 . . . . 0.0 112.777 -178.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -131.01 105.91 8.04 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 105.861 -1.903 . . . . 0.0 105.861 176.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 20.8 m-20 -77.95 117.25 19.1 Favored 'General case' 0 C--N 1.319 -0.72 0 N-CA-C 113.192 0.812 . . . . 0.0 113.192 -175.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.556 ' O ' ' N ' ' H' ' 26' ' ' SER . 55.0 t -102.46 125.94 56.66 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.513 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 176.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -32.6 83.05 0.0 OUTLIER Glycine 0 CA--C 1.537 1.443 0 CA-C-O 119.536 -0.591 . . . . 0.0 113.291 178.408 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.556 ' N ' ' O ' ' H' ' 24' ' ' VAL . 17.4 p -94.15 176.8 6.18 Favored 'General case' 0 CA--C 1.505 -0.766 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 177.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' O ' ' G' ' 26' ' ' SER . 28.1 m120 -60.11 178.22 0.2 Allowed 'General case' 0 C--N 1.312 -1.055 0 C-N-CA 118.333 -1.347 . . . . 0.0 110.247 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 95.9 mttt -60.63 110.66 1.35 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 72.03 94.17 0.08 OUTLIER Glycine 0 N--CA 1.469 0.869 0 C-N-CA 118.741 -1.695 . . . . 0.0 114.815 173.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.19 157.57 17.47 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 102.659 -3.089 . . . . 0.0 102.659 173.521 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.705 HG23 HG13 ' I' ' 31' ' ' ILE . 0.1 OUTLIER -145.86 121.61 3.39 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 C-N-CA 118.146 -1.421 . . . . 0.0 112.207 -171.552 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 93.0 mt -132.57 127.47 56.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.785 -0.366 . . . . 0.0 110.381 179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.74 128.6 5.55 Favored Glycine 0 N--CA 1.472 1.097 0 C-N-CA 121.057 -0.592 . . . . 0.0 111.786 -179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 5.1 mp -132.6 130.66 40.53 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-O 121.284 0.564 . . . . 0.0 111.458 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.3 tmm? -129.67 127.32 40.29 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.454 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' H' ' 37' ' ' GLY . 66.9 t -107.41 86.39 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -179.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.493 ' C ' ' O ' ' H' ' 36' ' ' VAL . . . -15.48 -93.38 0.01 OUTLIER Glycine 0 C--N 1.346 1.084 0 O-C-N 123.859 0.724 . . . . 0.0 112.288 177.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.44 -176.13 42.32 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 110.355 -1.098 . . . . 0.0 110.355 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.62 162.23 35.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-O 120.715 0.293 . . . . 0.0 110.501 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.403 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.361 179.791 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 46.0 p90 -143.09 147.99 35.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.913 0.387 . . . . 0.0 110.571 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -143.35 131.02 21.3 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.48 HG23 ' CD2' ' I' ' 14' ' ' HIS . 35.7 m -145.18 164.52 12.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-N 116.567 -0.288 . . . . 0.0 111.541 -177.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.533 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 53.3 m-70 -68.43 145.1 54.4 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -177.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.48 ' CD2' HG23 ' I' ' 12' ' ' VAL . 47.8 m-70 -154.66 169.28 24.25 Favored 'General case' 0 N--CA 1.45 -0.466 0 CA-C-N 115.472 -0.785 . . . . 0.0 109.382 179.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.403 ' HG2' ' N ' ' I' ' 16' ' ' LYS . 54.8 tt0 -159.99 168.3 25.96 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.033 178.786 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.403 ' N ' ' HG2' ' I' ' 15' ' ' GLN . 99.2 mttt -154.64 131.54 10.83 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.51 0.195 . . . . 0.0 110.539 179.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.509 HD12 ' CE2' ' I' ' 19' ' ' PHE . 0.0 OUTLIER -127.72 119.91 26.82 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.68 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 70.7 t -126.24 129.53 72.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 C-N-CA 120.629 -0.428 . . . . 0.0 112.151 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.702 ' CE1' HD22 ' K' ' 34' ' ' LEU . 61.2 m-85 -123.22 121.75 36.68 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.924 179.169 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.419 ' CE2' ' CG ' ' J' ' 20' ' ' PHE . 7.5 m-85 -131.67 130.69 42.37 Favored 'General case' 0 N--CA 1.476 0.867 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 178.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.02 135.17 39.23 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 -179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 mt-10 -137.76 150.28 47.12 Favored 'General case' 0 C--N 1.352 0.692 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.247 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.435 ' OD2' ' O ' ' J' ' 26' ' ' SER . 13.4 t70 -116.95 114.53 23.96 Favored 'General case' 0 N--CA 1.481 1.115 0 O-C-N 122.21 -0.306 . . . . 0.0 111.36 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.458 ' O ' ' N ' ' I' ' 26' ' ' SER . 14.7 t -81.59 130.93 34.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.8 -85.8 0.01 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.529 ' O ' ' O ' ' I' ' 27' ' ' ASN . 26.1 p -153.62 -172.86 4.37 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-O 121.639 0.733 . . . . 0.0 111.224 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.686 ' H ' ' NZ ' ' K' ' 28' ' ' LYS . 64.8 t30 -19.71 159.3 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.773 0 CA-C-N 113.303 -1.771 . . . . 0.0 115.156 178.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.698 ' NZ ' ' H ' ' G' ' 23' ' ' ASP . 74.1 tttt -161.21 110.83 1.64 Allowed 'General case' 0 CA--C 1.52 -0.186 0 CA-C-N 114.744 -1.116 . . . . 0.0 109.376 175.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.33 93.23 0.23 Allowed Glycine 0 CA--C 1.508 -0.369 0 N-CA-C 109.986 -1.246 . . . . 0.0 109.986 177.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.73 147.05 51.3 Favored 'General case' 0 CA--C 1.494 -1.21 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 176.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.705 HG13 HG23 ' H' ' 31' ' ' ILE . 0.0 OUTLIER -146.68 113.97 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.702 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.942 -175.583 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.509 ' O ' ' SD ' ' C' ' 35' ' ' MET . 0.1 OUTLIER -110.76 124.56 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.522 179.471 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.35 102.84 1.39 Allowed Glycine 0 N--CA 1.46 0.292 0 N-CA-C 108.446 -1.862 . . . . 0.0 108.446 177.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.879 HD22 ' CZ ' ' G' ' 19' ' ' PHE . 23.1 tp -119.0 126.68 52.29 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 117.277 0.538 . . . . 0.0 111.817 -178.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.524 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 12.2 ptm -131.9 110.87 11.1 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 174.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.599 HG13 HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -121.18 72.02 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.652 0 CA-C-N 115.108 -0.951 . . . . 0.0 108.57 179.554 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.61 102.81 2.33 Favored Glycine 0 C--N 1.36 1.869 0 N-CA-C 111.169 -0.772 . . . . 0.0 111.169 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -130.62 157.36 22.07 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.4 t -124.28 136.56 60.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-O 120.913 0.387 . . . . 0.0 110.53 -179.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 12.3 p . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.377 179.78 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.426 0 N-CA-C 109.69 -1.364 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -83.38 138.48 33.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.797 0.332 . . . . 0.0 110.478 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.461 ' O ' HG12 ' K' ' 12' ' ' VAL . 79.9 tt0 -152.34 137.54 17.43 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.408 -179.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.435 ' HB ' ' H ' ' K' ' 13' ' ' HIS . 0.2 OUTLIER -93.03 126.93 45.4 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.694 0 CA-C-O 121.319 0.58 . . . . 0.0 109.847 -179.932 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.545 ' O ' ' CD2' ' J' ' 14' ' ' HIS . 18.3 t60 -164.92 111.76 0.99 Allowed 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.233 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' K' ' 13' ' ' HIS . 86.2 m-70 -154.55 177.23 11.43 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -133.82 177.58 7.61 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.731 -178.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 55.0 mtmt -137.54 131.77 32.22 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.095 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 mt -117.89 121.7 41.41 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.881 -0.599 . . . . 0.0 109.673 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 67.8 t -122.47 121.21 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-O 120.948 0.404 . . . . 0.0 110.961 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.862 ' CE1' HD22 ' L' ' 34' ' ' LEU . 96.9 m-85 -113.39 114.49 26.68 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 178.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 19.2 t80 -129.03 123.34 32.09 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.988 0.423 . . . . 0.0 111.634 -177.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.94 124.12 32.31 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.05 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 73.4 tt0 -103.52 156.81 17.49 Favored 'General case' 0 N--CA 1.467 0.394 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.131 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.456 ' CG ' ' N ' ' J' ' 24' ' ' VAL . 35.2 t70 -78.13 -113.89 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.066 -0.515 . . . . 0.0 111.341 179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.521 ' O ' ' N ' ' J' ' 26' ' ' SER . 4.1 t 73.45 124.45 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.464 0 N-CA-C 106.764 -1.569 . . . . 0.0 106.764 -177.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.57 -87.09 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -177.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.678 ' O ' ' O ' ' J' ' 27' ' ' ASN . 0.5 OUTLIER 170.79 176.17 0.06 Allowed 'General case' 0 N--CA 1.441 -0.91 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.702 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.678 ' O ' ' O ' ' J' ' 26' ' ' SER . 20.4 m120 -28.3 170.42 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.13 0 O-C-N 124.319 1.012 . . . . 0.0 112.074 177.446 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.561 ' O ' ' N ' ' J' ' 30' ' ' ALA . 37.4 pttt -148.73 111.55 4.82 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.161 -0.962 . . . . 0.0 112.208 177.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.44 91.35 0.01 OUTLIER Glycine 0 CA--C 1.505 -0.566 0 N-CA-C 108.266 -1.934 . . . . 0.0 108.266 176.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -137.85 153.71 49.56 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 103.328 -2.842 . . . . 0.0 103.328 177.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.417 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -144.41 111.67 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 C-N-CA 118.265 -1.374 . . . . 0.0 109.968 -174.096 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.484 HD13 HD11 ' J' ' 34' ' ' LEU . 6.7 tt -112.71 116.63 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.293 -0.867 . . . . 0.0 108.731 179.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.07 103.69 2.33 Favored Glycine 0 N--CA 1.46 0.284 0 N-CA-C 107.596 -2.202 . . . . 0.0 107.596 178.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.776 HD13 ' CE1' ' H' ' 19' ' ' PHE . 24.2 mt -114.39 114.0 25.28 Favored 'General case' 0 CA--C 1.509 -0.623 0 CA-C-O 121.606 0.717 . . . . 0.0 110.247 -177.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -116.59 118.65 33.21 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 114.635 -1.166 . . . . 0.0 108.506 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.44 ' O ' ' C ' ' J' ' 37' ' ' GLY . 1.1 t -131.15 75.95 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.025 -177.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' J' ' 36' ' ' VAL . . . -27.2 -97.56 0.01 OUTLIER Glycine 0 C--N 1.362 2.025 0 N-CA-C 112.097 -0.401 . . . . 0.0 112.097 179.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.97 -163.85 30.23 Favored Glycine 0 CA--C 1.522 0.478 0 N-CA-C 111.13 -0.788 . . . . 0.0 111.13 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 82.9 t -121.95 135.32 62.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 118.039 -0.982 . . . . 0.0 110.554 -179.649 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -113.1 137.88 50.77 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-O 120.89 0.376 . . . . 0.0 110.514 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.77 162.28 35.12 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.4 -179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.461 HG12 ' O ' ' J' ' 11' ' ' GLU . 6.0 m -110.7 133.22 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.557 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 0.4 OUTLIER -76.12 -166.01 0.55 Allowed 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 120.173 -0.611 . . . . 0.0 111.259 -178.546 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 7.6 p-80 -138.23 178.45 7.12 Favored 'General case' 0 N--CA 1.448 -0.544 0 CA-C-N 116.002 -0.545 . . . . 0.0 109.607 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -99.27 175.1 5.99 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.486 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -147.42 124.95 11.69 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.754 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -117.55 124.05 47.74 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.474 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 44.9 t -127.94 126.99 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-O 120.832 0.349 . . . . 0.0 111.575 -179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -115.62 116.09 27.53 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.959 -0.564 . . . . 0.0 109.594 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.7 t80 -125.19 122.73 37.88 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.26 141.68 26.4 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 114.159 1.17 . . . . 0.0 114.159 -178.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' L' ' 22' ' ' GLU . 70.3 mm-40 -90.46 152.41 20.97 Favored 'General case' 0 C--O 1.232 0.158 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 177.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.561 ' OD2' ' N ' ' L' ' 28' ' ' LYS . 28.0 t0 -148.43 116.29 6.36 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 121.028 0.442 . . . . 0.0 111.739 -178.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 2.5 p -146.81 112.14 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.044 -179.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 37.32 91.32 0.01 OUTLIER Glycine 0 N--CA 1.472 1.064 0 CA-C-O 121.509 0.505 . . . . 0.0 112.63 178.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 4.6 p -45.15 153.86 0.18 Allowed 'General case' 0 N--CA 1.445 -0.684 0 CA-C-O 122.597 1.189 . . . . 0.0 112.511 -178.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.514 ' O ' ' C ' ' K' ' 28' ' ' LYS . 33.9 m120 -156.85 178.58 10.19 Favored 'General case' 0 C--N 1.313 -0.989 0 CA-C-N 112.631 -2.077 . . . . 0.0 108.483 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.686 ' NZ ' ' H ' ' I' ' 27' ' ' ASN . 0.1 OUTLIER 2.91 -104.33 0.0 OUTLIER 'General case' 0 CA--C 1.562 1.411 0 C-N-CA 123.562 0.745 . . . . 0.0 112.05 179.816 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.436 ' H ' ' HB2' ' K' ' 28' ' ' LYS . . . 141.09 95.33 0.25 Allowed Glycine 0 N--CA 1.48 1.602 0 CA-C-N 118.986 0.812 . . . . 0.0 111.924 178.051 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.4 169.85 0.41 Allowed 'General case' 0 C--N 1.345 0.399 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.036 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.417 HD12 ' CG2' ' J' ' 31' ' ' ILE . 0.0 OUTLIER -148.53 111.97 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.094 0 C-N-CA 118.996 -1.082 . . . . 0.0 109.035 -179.028 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.541 HG12 HD21 ' K' ' 34' ' ' LEU . 0.8 OUTLIER -111.99 122.08 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.465 -177.998 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.45 108.99 2.54 Favored Glycine 0 N--CA 1.468 0.829 0 N-CA-C 109.291 -1.524 . . . . 0.0 109.291 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.702 HD22 ' CE1' ' I' ' 19' ' ' PHE . 5.1 mt -122.09 114.96 21.63 Favored 'General case' 0 CA--C 1.501 -0.913 0 CA-C-N 117.332 0.566 . . . . 0.0 110.821 -177.261 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.458 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 33.6 ttp -120.86 114.31 21.41 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 176.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.479 HG23 HG12 ' L' ' 36' ' ' VAL . 0.0 OUTLIER -130.19 73.25 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 107.672 -1.232 . . . . 0.0 107.672 178.632 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -22.35 -101.6 0.01 OUTLIER Glycine 0 C--N 1.364 2.121 0 O-C-N 123.59 0.556 . . . . 0.0 112.482 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.35 -170.97 38.11 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 53.1 t -125.13 137.19 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 5.7 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.848 -179.788 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -100.77 132.7 46.04 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -151.32 147.39 26.88 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.965 0.412 . . . . 0.0 111.055 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 54.5 t -123.13 129.32 75.06 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.471 ' O ' ' CG ' ' L' ' 13' ' ' HIS . 56.5 p-80 -170.74 111.88 0.39 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.053 0.454 . . . . 0.0 110.973 -179.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 96.6 m-70 -155.8 177.81 10.98 Favored 'General case' 0 N--CA 1.446 -0.675 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -115.58 173.8 6.35 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.302 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 50.3 mtpt -151.25 109.54 3.76 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.959 0.409 . . . . 0.0 110.455 179.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 57.6 tp -123.66 118.51 27.44 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 53.1 t -130.26 133.06 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.875 0.369 . . . . 0.0 110.086 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.469 ' CD2' ' O ' ' L' ' 19' ' ' PHE . 55.8 p90 -136.86 129.73 30.7 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.271 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -138.8 132.05 30.0 Favored 'General case' 0 C--O 1.235 0.332 0 CA-C-O 121.496 0.665 . . . . 0.0 110.455 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.83 138.88 42.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.498 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.432 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 95.0 mt-10 -98.4 114.73 27.19 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 37.8 t0 -102.68 121.64 42.83 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-O 121.26 0.552 . . . . 0.0 111.838 -179.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 25.3 t -104.91 -111.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.821 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 177.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.34 -91.23 0.01 OUTLIER Glycine 0 CA--C 1.523 0.582 0 N-CA-C 109.546 -1.421 . . . . 0.0 109.546 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' L' ' 27' ' ' ASN . 45.9 m -141.01 170.68 15.28 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 179.028 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' L' ' 26' ' ' SER . 93.8 m-20 -29.0 170.13 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 114.598 -1.183 . . . . 0.0 113.828 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.561 ' N ' ' OD2' ' K' ' 23' ' ' ASP . 87.8 tttt -148.35 109.99 4.46 Favored 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 176.08 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' L' ' 30' ' ' ALA . . . -50.84 -95.8 0.01 OUTLIER Glycine 0 C--N 1.334 0.445 0 C-N-CA 118.549 -1.786 . . . . 0.0 112.545 -178.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.599 ' HB2' HD21 ' J' ' 27' ' ' ASN . . . 72.57 156.11 0.17 Allowed 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 100.409 -3.923 . . . . 0.0 100.409 -176.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.543 HG22 ' CE ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -144.77 107.67 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 CA-C-N 124.081 3.128 . . . . 0.0 109.237 179.781 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.648 HG23 HD23 ' L' ' 34' ' ' LEU . 1.4 tt -102.53 112.46 35.93 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 CA-C-N 113.956 -1.475 . . . . 0.0 109.975 -178.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.1 96.69 1.0 Allowed Glycine 0 N--CA 1.46 0.286 0 N-CA-C 107.296 -2.321 . . . . 0.0 107.296 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.862 HD22 ' CE1' ' J' ' 19' ' ' PHE . 3.4 pp -120.62 125.88 48.87 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.91 0.386 . . . . 0.0 110.948 -177.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 65.6 ttp -125.6 121.77 34.52 Favored 'General case' 0 CA--C 1.508 -0.639 0 CA-C-O 121.431 0.634 . . . . 0.0 109.877 179.112 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.479 HG12 HG23 ' K' ' 36' ' ' VAL . 2.8 m -124.26 77.05 0.56 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.593 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.65 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -35.64 104.81 0.03 OUTLIER Glycine 0 C--N 1.349 1.289 0 N-CA-C 111.751 -0.539 . . . . 0.0 111.751 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -76.05 -177.28 42.51 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 8.5 p -140.86 151.12 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.37 0 CA-C-O 121.081 0.467 . . . . 0.0 111.066 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 47.3 t . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.292 179.7 . . . . . . . . 0 0 . 1 stop_ save_